-DOCSTART- (6794356)

METHODS	NOUN	O	O
Ten	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blinded	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
trial	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
they	PRON	O	O
received	VERB	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
,	PUNCT	O	O
remifentanil	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
alfentanil	NOUN	O	O
for	ADP	O	O
120	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
age-	NOUN	O	O
and	CCONJ	O	O
weight-adjusted	VERB	O	O
infusions	NOUN	O	O
(	PUNCT	O	O
determined	VERB	O	O
with	ADP	O	O
STANPUMP	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
computer	NOUN	O	O
modeling	PUNCT	O	O
software	NOUN	O	O
package	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
to	PART	O	O
achieve	NOUN	O	O
three	NUM	O	O
predicted	VERB	O	O
constant	ADJ	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
for	ADP	O	O
40	NUM	O	O
min	NOUN	O	O
each	ADP	O	O
of	ADP	O	O
remifentanil	NOUN	O	O
(	PUNCT	O	O
0.75	NUM	O	O
,	PUNCT	O	O
1.5	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
ng/ml	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
alfentanil	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
,	PUNCT	O	O
32	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
64	ADP	O	O
ng/ml	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mood	PUNCT	O	O
forms	NOUN	O	O
and	CCONJ	O	O
psychomotor	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
completed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
miosis	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
,	PUNCT	O	O
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
infusions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
analgesia	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
at	ADP	O	O
each	DET	O	O
dose	NOUN	O	O
level	NOUN	O	O
using	VERB	O	O
a	DET	O	O
cold-pressor	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADJ	O	O
Remifentanil	NOUN	O	O
had	PUNCT	O	O
prototypic	ADJ	O	B-MENTAL
micro-like	ADJ	O	I-MENTAL
opioid	NOUN	O	I-MENTAL
subjective	ADJ	O	I-MENTAL
effects	NOUN	O	I-MENTAL
,	PUNCT	O	O
impaired	VERB	O	B-MENTAL
psychomotor	NOUN	O	I-MENTAL
performance	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	PUNCT	O	O
produced	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
piracetam	NOUN	O	O
added	VERB	O	O
to	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
that	ADP	O	O
autism	NOUN	O	O
is	VERB	O	O
a	DET	O	O
hypoglutamatergic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
was	DET	O	O
of	ADP	O	O
interest	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
piracetam	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
positive	ADJ	O	O
modulator	NOUN	O	O
of	ADP	O	O
AMPA-sensitive	ADJ	O	O
glutamate	NOUN	O	O
receptors	NOUN	O	O
in	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

About	PUNCT	O	O
40	NUM	O	O
children	NOUN	O	O
between	ADP	O	O
the	DET	O	O
ages	NOUN	O	O
three	NUM	O	O
and	CCONJ	O	O
11	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
inclusive	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
DSM	NOUN	O	O
IV	NUM	O	O
clinical	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
who	ADP	O	O
were	ADP	O	O
outpatients	ADJ	O	O
from	ADP	O	O
a	DET	O	O
specialty	NOUN	O	O
clinic	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
children	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
a	DET	O	O
chief	ADJ	O	O
complaint	NOUN	O	O
of	ADP	O	O
severely	ADV	O	O
disruptive	ADJ	O	O
symptoms	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
piracetam	NOUN	O	O
+	SYM	O	O
risperidone	NUM	O	O
(	PUNCT	O	O
Group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
+	SYM	O	O
risperidone	NUM	O	O
(	PUNCT	O	O
Group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
10-week	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
was	VERB	O	O
titrated	VERB	O	O
up	CCONJ	O	O
to	ADP	O	O
2	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
between	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
40	NUM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
weighting	CCONJ	O	O
above	ADP	O	O
40	NUM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
piracetam	NOUN	O	O
was	VERB	O	O
titrated	VERB	O	O
up	CCONJ	O	O
to	ADP	O	O
800	NUM	O	O
mg/day	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
starting	PUNCT	O	O
medication	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
measure	NOUN	O	O
of	ADP	O	O
the	DET	O	O
outcome	NOUN	O	O
was	VERB	O	O
the	DET	O	O
Aberrant	ADJ	O	B-OTHER
Behavior	NOUN	O	I-OTHER
Checklist-Community	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
ABC-C	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
Rating	PUNCT	O	I-OTHER
Scale	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
score	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ABC-C	NOUN	O	B-OTHER
Rating	PUNCT	O	I-OTHER
Scale	NOUN	O	I-OTHER
scores	NOUN	O	O
improved	VERB	O	O
with	ADP	O	O
piracetam	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
protocols	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
as	ADP	O	O
indicated	VERB	O	O
by	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
between	ADP	O	O
subjects	ADJ	O	O
factor	NOUN	O	O
(	PUNCT	O	O
F	NOUN	O	O
=	SYM	O	O
5.85	NUM	O	O
,	PUNCT	O	O
d.f	PUNCT	O	O
.	PUNCT	O	O

=	SYM	O	O
1	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
changes	NOUN	O	O
at	ADP	O	O
the	DET	O	O
endpoint	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
baseline	NOUN	O	O
were	ADJ	O	O
:	PUNCT	O	O
-11.90	NOUN	O	O
+/-	SYM	O	O
3.79	NUM	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
-5.15	ADJ	O	O
+/-	SYM	O	O
3.04	NUM	O	O
for	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
B	NOUN	O	O
respectively	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
on	ADP	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
scores	NOUN	O	B-OTHER
in	ADP	O	I-OTHER
the	DET	O	I-OTHER
ABC-C	NOUN	O	I-OTHER
Rating	PUNCT	O	I-OTHER
Scale	NOUN	O	I-OTHER
in	ADP	O	O
week	NOUN	O	O
10	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
6.017	NUM	O	O
,	PUNCT	O	O
d.f	PUNCT	O	O
.	PUNCT	O	O

=	SYM	O	O
38	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
medications	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
glutamate	NOUN	O	O
agent	NOUN	O	O
such	PUNCT	O	O
as	ADP	O	O
piracetam	NOUN	O	O
,	PUNCT	O	O
might	VERB	O	O
have	CCONJ	O	O
increase	DET	O	O
synergistic	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
an	DET	O	O
inspiratory	ADJ	O	O
impedance	NOUN	O	O
threshold	NOUN	O	O
device	NOUN	O	O
on	ADP	O	O
a	DET	O	O
facemask	VERB	O	O
and	CCONJ	O	O
endotracheal	ADJ	O	O
tube	NOUN	O	O
to	PART	O	O
reduce	ADJ	O	O
intrathoracic	DET	O	B-PHYSICAL
pressures	NOUN	O	I-PHYSICAL
during	ADP	O	O
the	DET	O	O
decompression	NOUN	O	O
phase	NOUN	O	O
of	ADP	O	O
active	ADJ	O	O
compression-decompression	NOUN	O	B-PHYSICAL
cardiopulmonary	ADJ	O	I-PHYSICAL
resuscitation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Use	NOUN	O	O
of	ADP	O	O
an	DET	O	O
inspiratory	ADJ	O	O
impedance	NOUN	O	O
threshold	NOUN	O	O
device	NOUN	O	O
(	PUNCT	O	O
ITD	NOUN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
increases	NOUN	O	O
coronary	ADJ	O	O
perfusion	NOUN	O	O
pressures	NOUN	O	O
and	CCONJ	O	O
survival	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
ventilated	VERB	O	O
with	ADP	O	O
an	DET	O	O
endotracheal	ADJ	O	O
tube	NOUN	O	O
(	PUNCT	O	O
ETT	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
active	ADJ	O	O
compression-decompression	NOUN	O	O
cardiopulmonary	ADJ	O	O
resuscitation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
ITD	NOUN	O	O
could	PUNCT	O	O
lower	PUNCT	O	O
intratracheal	VERB	O	O
pressures	NOUN	O	O
when	ADP	O	O
attached	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
facemask	VERB	O	O
or	CCONJ	O	O
ETT	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
An	DET	O	O
active	ADJ	O	O
and	CCONJ	O	O
sham	ADJ	O	O
ITD	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
applied	VERB	O	O
first	VERB	O	O
to	ADP	O	O
a	DET	O	O
facemask	VERB	O	O
and	CCONJ	O	O
then	ADV	O	O
to	ADP	O	O
an	DET	O	O
ETT	NOUN	O	O
during	ADP	O	O
active	ADJ	O	O
compression-decompression	NOUN	O	O
cardiopulmonary	ADJ	O	O
resuscitation	NOUN	O	O
in	ADP	O	O
13	NUM	O	O
out-of-hospital	ADJ	O	O
cardiac	ADJ	O	O
arrest	ADV	O	O
patients	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blinded	VERB	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
compression-to-bag-valve	PUNCT	O	O
ventilation	NOUN	O	O
ratio	NOUN	O	O
was	ADP	O	O
15:2	PUNCT	O	O
.	PUNCT	O	O

Airway	NOUN	O	O
pressures	NOUN	O	O
(	PUNCT	O	O
surrogate	ADJ	O	O
for	ADP	O	O
intrathoracic	PUNCT	O	O
pressure	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
a	DET	O	O
pressure	NOUN	O	O
transducer	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
sham	ADJ	O	O
and	CCONJ	O	O
an	DET	O	O
active	ADJ	O	O
ITD	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
for	ADP	O	O
1	NUM	O	O
min	NOUN	O	O
each	CCONJ	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
order	NOUN	O	O
,	PUNCT	O	O
first	ADJ	O	O
on	ADP	O	O
a	DET	O	O
facemask	VERB	O	O
and	CCONJ	O	O
then	ADV	O	O
on	ADP	O	O
an	DET	O	O
ETT	NOUN	O	O
.	PUNCT	O	O

Statistical	ADJ	O	O
analyses	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
using	VERB	O	O
Friedman	NOUN	O	O
's	PUNCT	O	O
and	CCONJ	O	O
Wilcoxon	NOUN	O	O
's	PUNCT	O	O
rank-sum	NOUN	O	O
tests	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
For	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	B-PHYSICAL
sd	NOUN	O	I-PHYSICAL
maximum	NOUN	O	I-PHYSICAL
negative	ADJ	O	O
intrathoracic	PUNCT	O	B-PHYSICAL
pressures	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
decompression	NOUN	O	O
phase	NOUN	O	O
of	ADP	O	O
cardiopulmonary	ADJ	O	B-PHYSICAL
resuscitation	NOUN	O	I-PHYSICAL
were	VERB	O	O
-1.0	NUM	O	O
+/-	SYM	O	O
0.73	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
with	ADP	O	O
a	DET	O	O
sham	ADJ	O	O
vs.	CCONJ	O	O
-4.6	NUM	O	O
+/-	SYM	O	O
3.7	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
with	ADP	O	O
an	DET	O	O
active	ADJ	O	O
ITD	NOUN	O	O
on	ADP	O	O
the	DET	O	O
facemask	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.003	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
-1.3	NUM	O	O
+/-	SYM	O	O
1.3	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
with	ADP	O	O
a	DET	O	O
sham	ADJ	O	O
ITD	NOUN	O	O
vs.	CCONJ	O	O
-7.3	ADP	O	O
+/-	SYM	O	O
4.5	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
with	ADP	O	O
an	DET	O	O
active	ADJ	O	O
ITD	NOUN	O	O
on	ADP	O	O
an	DET	O	O
ETT	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.0009	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Decompression	NOUN	O	B-PHYSICAL
phase	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	O
versus	CCONJ	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
on	ADP	O	O
bladder	NOUN	O	B-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
intraabdominal	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
during	ADP	O	O
transurethral	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	O
versus	CCONJ	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
on	ADP	O	O
bladder	NOUN	O	B-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
intraabdominal	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
elderly	ADJ	O	O
males	NOUN	O	O
undergoing	VERB	O	O
elective	ADJ	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prostate	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
open-label	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	ADJ	O	O
Teaching	ADJ	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
21	NUM	O	O
ASA	NOUN	O	O
physical	ADJ	O	O
status	NOUN	O	O
I	NUM	O	O
,	PUNCT	O	O
II	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
III	NUM	O	O
patients	NOUN	O	O
at	ADP	O	O
least	ADV	O	O
18	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
undergoing	VERB	O	O
transurethral	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
According	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
computer-generated	VERB	O	O
randomization	NOUN	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
allocated	NUM	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
Spinal	ADJ	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
hyperbaric	ADJ	O	O
tetracaine	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
intrathecally	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
General	VERB	O	O
Anesthesia	NOUN	O	O
(	PUNCT	O	O
GA	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
patients	NOUN	O	O
received	VERB	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	O
intravenous	ADJ	O	O
(	PUNCT	O	O
i.v	NUM	O	O
.	PUNCT	O	O

1	NUM	O	O
to	ADP	O	O
2	NUM	O	O
micrograms/kg	NOUN	O	O
and	CCONJ	O	O
propofol	NOUN	O	O
i.v	NUM	O	O
.	PUNCT	O	O

1.0	NUM	O	O
to	ADP	O	O
2.0	NUM	O	O
mg/kg	NOUN	O	O
for	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

Thereafter	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
laryngeal	ADJ	O	O
mask	NOUN	O	O
airway	NOUN	O	O
was	NOUN	O	O
inserted	VERB	O	O
and	CCONJ	O	O
,	PUNCT	O	O
with	ADP	O	O
spontaneous	ADJ	O	O
ventilation	NOUN	O	O
,	PUNCT	O	O
anesthesia	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
by	ADP	O	O
administering	NOUN	O	O
isoflurane	NOUN	O	O
(	PUNCT	O	O
end-tidal	NOUN	O	O
0.7	NUM	O	O
%	SYM	O	O
to	ADP	O	O
1.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
70	NUM	O	O
%	SYM	O	O
nitrous	ADJ	O	O
oxide	NOUN	O	O
(	PUNCT	O	O
N2O	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
oxygen	NOUN	O	O
.	PUNCT	O	O

Intraabdominal	ADJ	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
bladder	NOUN	O	O
compliance	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
prior	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
and	CCONJ	O	O
immediately	ADV	O	O
before	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
MAIN	ADJ	O	O
RESULTS	NOUN	O	O
The	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
demographically	ADV	O	O
comparable	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
S	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
bladder	NOUN	O	O
compliance	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
higher	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
intraabdominal	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
significantly	ADV	O	O
lower	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.007	NUM	O	O
)	PUNCT	O	O
when	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
preanesthetic	ADJ	O	O
values	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
GA	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
intraabdominal	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
decreased	ADP	O	O
when	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
preanesthetic	ADJ	O	O
recordings	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
small	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
bladder	NOUN	O	B-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
was	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
reached	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
and	CCONJ	O	O
compared	VERB	O	O
using	PROPN	O	O
Student	NOUN	O	O
's	PUNCT	O	O
t-test	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
was	VERB	O	O
considered	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Both	CCONJ	O	O
spinal	ADJ	O	O
and	CCONJ	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
induced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
intraabdominal	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
both	CCONJ	O	O
techniques	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
bladder	NOUN	O	O
compliance	NOUN	O	O
,	PUNCT	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
was	VERB	O	O
demonstrated	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
anesthesia	NOUN	O	O
treatment	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
24-h	NOUN	O	O
psychological	ADJ	O	O
training	DET	O	O
program	NOUN	O	O
on	ADP	O	O
attitudes	NOUN	O	B-MENTAL
,	PUNCT	O	O
communication	NOUN	O	B-MENTAL
skills	NOUN	O	I-MENTAL
and	CCONJ	O	O
occupational	ADJ	O	B-MENTAL
stress	NOUN	O	I-MENTAL
in	ADP	O	O
oncology	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
usefulness	NOUN	O	O
of	ADP	O	O
psychological	ADJ	O	O
training	DET	O	O
programs	NOUN	O	O
(	PUNCT	O	O
P.T.P	ADP	O	O
.	PUNCT	O	O
)	PUNCT	O	O

in	ADP	O	O
health	NOUN	O	O
care	NOUN	O	O
settings	NOUN	O	O
devoted	VERB	O	O
to	ADP	O	O
cancer	PUNCT	O	O
care	NOUN	O	O
is	NOUN	O	O
beginning	ADV	O	O
to	PART	O	O
be	PUNCT	O	O
recognised	VERB	O	O
but	CCONJ	O	O
their	ADJ	O	O
content	NOUN	O	O
,	PUNCT	O	O
form	NOUN	O	O
and	CCONJ	O	O
effectiveness	NOUN	O	O
need	PART	O	O
further	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O

Seventy-two	NUM	O	O
oncology	NOUN	O	O
nurses	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
a	DET	O	O
24-h	NOUN	O	O
P.T.P	VERB	O	O
.	PUNCT	O	O

or	CCONJ	O	O
to	ADP	O	O
a	PUNCT	O	O
waiting	PUNCT	O	O
list	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Attitudes	ADV	O	B-MENTAL
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
a	DET	O	O
semantic	ADJ	O	B-MENTAL
differential	ADJ	O	I-MENTAL
questionnaire	NOUN	O	O
,	PUNCT	O	O
occupational	ADJ	O	B-MENTAL
stress	NOUN	O	I-MENTAL
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
the	DET	O	O
Nursing	PUNCT	O	B-MENTAL
Stress	NOUN	O	O
Scale	NOUN	O	B-MENTAL
and	CCONJ	O	O
communication	NOUN	O	B-MENTAL
skills	NOUN	O	I-MENTAL
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
standardised	DET	O	O
videotaped	ADJ	O	O
role-playing	ADP	O	B-MENTAL
exercises	NOUN	O	B-MENTAL
.	PUNCT	O	O

These	ADP	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
trained	VERB	O	O
(	PUNCT	O	O
T.S	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

and	CCONJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
C.S.	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
show	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
training	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
attitudes	NOUN	O	B-MENTAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
especially	ADV	O	O
on	ADP	O	O
those	ADP	O	O
related	VERB	O	O
to	PUNCT	O	O

Surgery	NOUN	O	O
of	ADP	O	O
aphakic	NOUN	O	O
retinal	ADJ	O	O
detachment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
84	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
aphakic	NOUN	O	O
retinal	ADJ	O	O
detachment	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
either	PUNCT	O	O
by	ADP	O	O
local	ADJ	O	O
scleral	ADJ	O	O
buckling	ADP	O	O
alone	ADJ	O	O
or	CCONJ	O	O
combined	VERB	O	O
with	ADP	O	O
an	DET	O	O
encirclement	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	B-PHYSICAL
surgical	ADJ	O	I-PHYSICAL
reattachment	VERB	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	PUNCT	O	I-PHYSICAL

Correlation	NOUN	O	O
between	ADP	O	O
in	PUNCT	O	O
vivo	ADJ	O	O
humoral	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
cellular	ADJ	O	O
immune	ADJ	O	O
responses	NOUN	O	O
following	VERB	O	O
immunization	NOUN	O	O
with	ADP	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
surface	NOUN	O	O
antigen	NOUN	O	O
(	PUNCT	O	O
HBsAg	NOUN	O	O
)	PUNCT	O	O
vaccines	NOUN	O	O
.	PUNCT	O	O

To	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
human	NOUN	O	O
immune	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
surface	NOUN	O	O
antigen	NOUN	O	O
(	PUNCT	O	O
HBsAg	NOUN	O	O
)	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
carefully	DET	O	O
monitored	PUNCT	O	O
the	DET	O	O
in	PUNCT	O	O
vivo	ADJ	O	O
humoral	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
cellular	ADJ	O	O
immune	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
HBsAg	NOUN	O	O
in	ADP	O	O
50	NUM	O	O
subjects	NOUN	O	O
receiving	VERB	O	O
four	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
vaccine	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
a	DET	O	O
0	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
month	NOUN	O	O
vaccination	NOUN	O	O
scheme	NOUN	O	O
.	PUNCT	O	O

Twenty-three	NUM	O	O
subjects	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
plasma-derived	VERB	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
Hevac	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
27	NUM	O	O
received	VERB	O	O
a	DET	O	O
recombinant	ADJ	O	O
HBsAg	NOUN	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
yeast-derived	PROPN	O	O
;	PUNCT	O	O
Engerix-B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
humoral	ADJ	O	O
and	CCONJ	O	O
cellular	ADJ	O	O
immune	ADJ	O	O
responses	ADV	O	O
were	VERB	O	O
measured	VERB	O	O
before	ADP	O	O
vaccination	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
0	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
6	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
second	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
36	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
6	DET	O	O
days	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
66	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
120	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
365	PUNCT	O	O
)	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
third	ADJ	O	O
dose	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
the	DET	O	O
fourth	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
395	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
the	DET	O	O
kinetics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
humoral	ADJ	O	O
immune	ADJ	O	O
responses	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
vaccinees	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
classified	VERB	O	O
into	ADP	O	O
fast	ADP	O	O
,	PUNCT	O	O
intermediate	ADJ	O	O
and	CCONJ	O	O
slow/non-responders	PUNCT	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
immune	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
anti-HBs	NOUN	O	O
titre	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
395	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
vaccinees	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
high	ADJ	O	O
(	PUNCT	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
2000	NUM	O	O
U	NOUN	O	O
l-1	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
(	PUNCT	O	O
<	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
2000	NUM	O	O
U	NOUN	O	O
l-1	NOUN	O	O
)	PUNCT	O	O
responders	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
close	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
kinetics	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
humoral	ADJ	O	B-PHYSICAL
immune	ADJ	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
in	PUNCT	O	O
vivo	PUNCT	O	B-PHYSICAL
anti-HBs	NOUN	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
using	SYM	O	O
commercially	ADV	O	O
available	ADJ	O	O
immunoradiometric	ADJ	O	O
assays	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
in	PUNCT	O	O
vitro	ADJ	O	B-PHYSICAL
cellular	ADJ	O	I-PHYSICAL
immune	ADJ	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
an	DET	O	O
HBsAg-specific	ADJ	O	O
lymphoproliferation	NOUN	O	O
assay	NOUN	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
of	ADP	O	O
interassay	NOUN	O	O
variability	NOUN	O	O
the	DET	O	O
results	CCONJ	O	O
were	VERB	O	O
considered	VERB	O	O
as	PUNCT	O	O
dichotomous	ADJ	O	B-OTHER
variables	NOUN	O	I-OTHER
(	PUNCT	O	O
proliferation	NOUN	O	O
versus	CCONJ	O	O
non-proliferation	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
further	PUNCT	O	O
data	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
the	DET	O	O
kinetics	NOUN	O	O
and	CCONJ	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
humoral	ADJ	O	O
immune	ADJ	O	O
response	NOUN	O	O
on	ADP	O	O
the	DET	O	O
one	NUM	O	O
hand	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
in	PUNCT	O	O
vitro	ADJ	O	O
anti-HBs	NOUN	O	O
response	NOUN	O	O
on	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

Salmeterol	NOUN	O	O
plus	CCONJ	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
versus	CCONJ	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
plus	CCONJ	O	O
montelukast	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
investigating	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
airway	NOUN	O	B-PHYSICAL
inflammation	NOUN	O	I-PHYSICAL
in	ADP	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Few	ADJ	O	O
studies	NOUN	O	O
have	ADP	O	O
compared	VERB	O	O
treatment	NOUN	O	O
strategies	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
asthma	NOUN	O	O
poorly	ADV	O	O
controlled	VERB	O	O
on	ADP	O	O
low	ADJ	O	O
dose	NOUN	O	O
inhaled	VERB	O	O
corticosteroids	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
little	DET	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
treatments	NOUN	O	O
on	ADP	O	O
airway	NOUN	O	O
inflammation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
group	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
compared	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
salmeterol	NOUN	O	O
plus	CCONJ	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
(	PUNCT	O	O
FP	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
Seretide	NOUN	O	O
;	PUNCT	O	O
SFC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
FP	NOUN	O	O
plus	CCONJ	O	O
montelukast	NOUN	O	O
(	PUNCT	O	O
FP/M	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
sputum	NOUN	O	B-PHYSICAL
inflammatory	ADJ	O	I-PHYSICAL
markers	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
airway	NOUN	O	B-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
lung	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
symptoms	NOUN	O	B-PHYSICAL
in	ADP	O	O
adult	NOUN	O	O
asthmatics	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty-six	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
SFC	NOUN	O	O
or	CCONJ	O	O
FP/M	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
neutrophil	NOUN	O	O
,	PUNCT	O	O
eosinophil	NOUN	O	O
,	PUNCT	O	O
macrophage	NOUN	O	O
,	PUNCT	O	O
lymphocyte	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
epithelial	ADJ	O	O
cell	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
induced	DET	O	O
sputum	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
outcomes	NOUN	O	O
included	ADP	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
other	ADJ	O	O
sputum	NOUN	O	O
markers	NOUN	O	O
of	ADP	O	O
airway	NOUN	O	B-PHYSICAL
inflammation	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
airway	NOUN	O	B-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
symptom	NOUN	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
lung	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Both	PUNCT	O	O
treatments	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
induced	VERB	O	O
sputum	NOUN	O	B-PHYSICAL
inflammatory	ADJ	O	I-PHYSICAL
cells	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
for	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
sputum	NOUN	O	B-PHYSICAL
eosinophils	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Both	CCONJ	O	O
treatments	ADJ	O	O
significantly	ADV	O	O
improved	PUNCT	O	O
airway	NOUN	O	B-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
whereas	ADP	O	O
SFC	NOUN	O	O
generally	ADV	O	O
led	PRON	O	O
to	ADP	O	O
greater	PUNCT	O	O
improvements	NOUN	O	O
in	ADP	O	O
symptom	NOUN	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
lung	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
than	PUNCT	O	O
FP/M	NOUN	O	O
.	PUNCT	O	O

FP/M	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
reductions	NOUN	O	O
in	ADP	O	O
sputum	NOUN	O	B-PHYSICAL
cysteinyl	NOUN	O	I-PHYSICAL
leukotrienes	ADJ	O	I-PHYSICAL
than	PUNCT	O	O
SFC	NOUN	O	O
(	PUNCT	O	O
treatment	NOUN	O	O
ratio	NOUN	O	O
1.80	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.09	PUNCT	O	O
,	PUNCT	O	O
2.94	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Both	PUNCT	O	O
treatments	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
similar	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
eosinophilic	ADJ	O	B-PHYSICAL
airway	NOUN	O	I-PHYSICAL
inflammation	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
although	ADP	O	O
PEF	NOUN	O	O
and	CCONJ	O	O
symptom	NOUN	O	O
control	NOUN	O	O
were	VERB	O	O
better	PUNCT	O	O
with	ADP	O	O
SFC	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
NUMBER	NOUN	O	O
:	PUNCT	O	O
SAM40030	NOUN	O	O
(	PUNCT	O	O
SOLTA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
value-congruence	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
for	ADP	O	O
emotional	ADJ	O	B-MENTAL
experiences	NOUN	O	I-MENTAL
:	PUNCT	O	O
an	DET	O	O
explanation	NOUN	O	O
for	ADP	O	O
cultural	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
emotional	ADJ	O	O
self-reports	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
3	NUM	O	O
studies	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
found	VERB	O	O
support	NOUN	O	O
for	ADP	O	O
the	DET	O	O
value-congruence	ADJ	O	O
model	NOUN	O	O
that	ADP	O	O
accounts	NOUN	O	O
for	ADP	O	O
cultural	ADJ	O	O
variations	NOUN	O	O
in	ADP	O	O
memory	NOUN	O	O
for	ADP	O	O
emotional	ADJ	O	B-MENTAL
experiences	NOUN	O	I-MENTAL
.	PUNCT	O	O

In	ADP	O	O
Study	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
found	VERB	O	O
that	ADP	O	O
in	ADP	O	O
the	DET	O	O
made-in-the-U.S.	NUM	O	O
scenario	ADJ	O	O
condition	NOUN	O	O
,	PUNCT	O	O
European	ADP	O	O
Americans	PUNCT	O	O
were	VERB	O	O
more	ADV	O	O
accurate	ADJ	O	O
than	PUNCT	O	O
were	VERB	O	O
Asian	ADJ	O	O
Americans	VERB	O	O
in	ADP	O	O
their	PUNCT	O	O
retrospective	ADJ	O	B-MENTAL
frequency	NOUN	O	O
judgments	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
emotions	NOUN	O	B-MENTAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
made-in-Japan	NUM	O	O
scenario	ADJ	O	O
condition	NOUN	O	O
,	PUNCT	O	O
European	ADP	O	O
Americans	PUNCT	O	O
were	VERB	O	O
less	ADV	O	O
accurate	ADJ	O	O
than	PUNCT	O	O
were	VERB	O	O
Asian	ADJ	O	O
Americans	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
Study	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
value	NOUN	O	O
orientation	NOUN	O	O
mediates	NOUN	O	O
the	DET	O	O
CulturexType	NOUN	O	B-MENTAL
of	ADP	O	B-MENTAL
Event	NOUN	O	O
congruence	NOUN	O	B-MENTAL
effect	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Study	NOUN	O	O
3	NUM	O	O
(	PUNCT	O	O
a	ADP	O	O
daily	ADJ	O	O
event	NOUN	O	O
sampling	PUNCT	O	O
study	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	PUNCT	O	O

Randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
comparing	VERB	O	O
laparoscopic	PUNCT	O	O
and	CCONJ	O	O
open	ADJ	O	O
surgery	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
laparoscopic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
is	VERB	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
compared	VERB	O	O
surgical	ADJ	O	O
outcomes	NOUN	O	O
after	ADP	O	O
laparoscopic	ADJ	O	O
and	CCONJ	O	O
open	ADJ	O	O
approaches	NOUN	O	O
for	ADP	O	O
mid	NOUN	O	O
and	CCONJ	O	O
low	ADJ	O	O
rectal	ADJ	O	O
cancers	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Some	PUNCT	O	O
204	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mid	NOUN	O	O
and	CCONJ	O	O
low	ADJ	O	O
rectal	ADJ	O	O
adenocarcinomas	NOUN	O	O
were	VERB	O	O
allocated	VERB	O	O
randomly	ADV	O	O
to	ADV	O	O
open	ADJ	O	O
(	PUNCT	O	O
103	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
laparoscopic	ADJ	O	O
(	PUNCT	O	O
101	NUM	O	O
)	PUNCT	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
surgical	ADJ	O	O
team	NOUN	O	O
was	ADV	O	O
the	DET	O	O
same	PUNCT	O	O
for	ADP	O	O
both	PUNCT	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Most	DET	O	O
patients	NOUN	O	O
had	PUNCT	O	O
stage	NOUN	O	O
II	NUM	O	O
or	CCONJ	O	O
III	NUM	O	O
disease	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
received	CCONJ	O	O
neoadjuvant	PUNCT	O	O
therapy	NOUN	O	O
with	ADP	O	O
oral	ADJ	O	O
capecitabine	ADJ	O	O
and	CCONJ	O	O
50-54	NUM	O	O
Gy	NOUN	O	O
external	ADJ	O	O
beam	VERB	O	O
radiotherapy	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Sphincter-preserving	PUNCT	O	O
surgery	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
78.6	NUM	O	O
and	CCONJ	O	O
76.2	NUM	O	O
per	ADP	O	O
cent	ADJ	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
open	ADJ	O	O
and	CCONJ	O	O
laparoscopic	ADJ	O	O
groups	NOUN	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-ADVERSE-EFFECTS
loss	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
for	ADP	O	O
open	PUNCT	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
operating	VERB	O	B-OTHER
time	NOUN	O	I-OTHER
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
for	ADP	O	O
laparoscopic	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.020	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
return	ADJ	O	O
to	ADP	O	O
diet	NOUN	O	O
and	CCONJ	O	O
hospital	NOUN	O	B-OTHER
stay	NOUN	O	I-OTHER
were	VERB	O	O
longer	PUNCT	O	O
for	ADP	O	O
open	PUNCT	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Complication	NOUN	O	B-ADVERSE-EFFECTS
rates	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	PUNCT	O	O

[	PUNCT	O	O
Improving	PUNCT	O	O
wound	NOUN	O	B-PHYSICAL
healing	VERB	O	I-PHYSICAL
after	ADP	O	O
nose	NOUN	O	O
surgery	NOUN	O	O
by	ADP	O	O
combined	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
xylometazoline	NOUN	O	O
and	CCONJ	O	O
dexpanthenol	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
the	DET	O	O
examination	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
an	DET	O	O
application-form	NOUN	O	O
of	ADP	O	O
the	DET	O	O
new	ADJ	O	O
combination	NOUN	O	O
of	ADP	O	O
Xylometazoline	NOUN	O	O
with	ADP	O	O
Dexpanthenol	NOUN	O	O
(	PUNCT	O	O
Nasic	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
Xylometazoline	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Randomized	PROPN	O	O
verum	ADJ	O	O
controlled	VERB	O	O
parallel-group-comparison	ADJ	O	O
of	ADP	O	O
two	NUM	O	O
weeks	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
a	DET	O	O
nasal-spray	NOUN	O	O
.	PUNCT	O	O

61	NUM	O	O
inpatients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
Rhinitis	NOUN	O	O
following	VERB	O	O
nasal	ADJ	O	O
operation	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
30	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
verum	ADJ	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
each	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
assessment	NOUN	O	O
of	ADP	O	O
nasal-breathing-resistance	NOUN	O	B-PHYSICAL
according	CCONJ	O	B-OTHER
to	ADP	O	I-OTHER
scores	NOUN	O	I-OTHER
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
target-parameter	NOUN	O	O
.	PUNCT	O	O

Confirmatory	ADJ	O	O
statistical	ADJ	O	O
analysis	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PUNCT	O	O
according	PUNCT	O	O
to	ADP	O	O
Wilcoxon-Mann-Whitney-U	ADV	O	O
two-sided	ADP	O	O
at	ADP	O	O
alpha	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.05	NUM	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURE	NOUN	O	O
The	DET	O	O
superiority	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
Xylometazoline-Dexpanthenol	NOUN	O	O
nasal-spray	NOUN	O	O
versus	CCONJ	O	O
Xylometazoline	NOUN	O	O
nasal	ADJ	O	O
spray	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
proven	VERB	O	O
for	ADP	O	O
the	DET	O	O
target-parameter	ADJ	O	O
as	PUNCT	O	O
clinically	VERB	O	O
relevant	ADJ	O	O
and	CCONJ	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
clinically	ADV	O	B-OTHER
proven	VERB	O	I-OTHER
efficacy	NOUN	O	I-OTHER
is	VERB	O	O
emphasized	PUNCT	O	O
by	ADP	O	O
good	ADJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
both	PUNCT	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Due	PUNCT	O	O
to	ADP	O	O
easy	PUNCT	O	O
handling	PROPN	O	O
of	ADP	O	O
the	DET	O	O
nasal-spray	NOUN	O	O
a	DET	O	O
good	ADJ	O	O
compliance	NOUN	O	B-OTHER
was	VERB	O	O
confirmed	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Distinct	ADJ	O	O
improvement	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
following	VERB	O	O
nasal	ADJ	O	O
operations	NOUN	O	O
underlines	PUNCT	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
medications	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
tolerability	NOUN	O	B-OTHER
therapy	NOUN	O	O
with	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
is	VERB	O	O
more	DET	O	O
beneficial	ADJ	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
the	DET	O	O
alternative	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
result	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
study	NOUN	O	O
confirms	VERB	O	O
that	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
Xylometazoline-Dexpanthenol	NOUN	O	O
is	VERB	O	O
an	DET	O	O
enlargement	NOUN	O	B-OTHER
and	CCONJ	O	O
improvement	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
effective	ADJ	O	I-OTHER
medicinal	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
rhinitis	NOUN	O	O
following	ADP	O	O
nasal	ADJ	O	O
operation	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
Xylometazoline	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

RESPECT-PTSD	NOUN	O	O
:	PUNCT	O	O
re-engineering	PUNCT	O	O
systems	NOUN	O	O
for	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
care	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
PTSD	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Although	ADP	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
for	ADP	O	O
treating	VERB	O	O
depression	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
mental	ADJ	O	O
disorders	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
have	ADP	O	O
been	PUNCT	O	O
no	DET	O	O
randomized	VERB	O	O
trials	NOUN	O	O
of	ADP	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
specifically	ADV	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Posttraumatic	ADJ	O	O
stress	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
PTSD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
a	DET	O	O
collaborative	ADJ	O	O
approach	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Three	NUM	O	O
Component	NOUN	O	O
Model	NOUN	O	O
(	PUNCT	O	O
3CM	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
usual	ADJ	O	O
care	NOUN	O	O
for	ADP	O	O
treating	VERB	O	O
PTSD	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
a	DET	O	O
two-arm	NOUN	O	O
,	PUNCT	O	O
parallel	VERB	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

PTSD	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
from	ADP	O	O
five	NUM	O	O
primary	ADJ	O	O
care	NOUN	O	O
clinics	PROPN	O	O
at	ADP	O	O
four	NUM	O	O
Veterans	PUNCT	O	O
Affairs	PUNCT	O	O
healthcare	NOUN	O	O
facilities	NOUN	O	O
and	CCONJ	O	O
randomized	ADP	O	O
to	PART	O	O
receive	NOUN	O	O
usual	ADJ	O	O
care	NOUN	O	O
or	CCONJ	O	O
usual	ADJ	O	O
care	NOUN	O	O
plus	CCONJ	O	O
3CM	NUM	O	O
.	PUNCT	O	O

Blinded	VERB	O	O
assessors	NOUN	O	O
collected	VERB	O	O
data	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
3-month	NOUN	O	O
and	CCONJ	O	O
6-month	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
Participants	NOUN	O	O
were	VERB	O	O
195	NUM	O	O
Veterans	NOUN	O	O
.	PUNCT	O	O

Their	PUNCT	O	O
average	PUNCT	O	O
age	NOUN	O	O
was	VERB	O	O
45	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
91	NUM	O	O
%	SYM	O	O
were	ADP	O	O
male	NOUN	O	O
,	PUNCT	O	O
58	NUM	O	O
%	SYM	O	O
were	VERB	O	O
white	CCONJ	O	O
,	PUNCT	O	O
40	NUM	O	O
%	SYM	O	O
served	VERB	O	O
in	ADP	O	O
Iraq	NOUN	O	O
or	CCONJ	O	O
Afghanistan	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
42	NUM	O	O
%	SYM	O	O
served	VERB	O	O
in	ADP	O	O
Vietnam	ADV	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
All	PUNCT	O	O
participants	NOUN	O	O
received	VERB	O	O
usual	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
assigned	DET	O	O
to	ADP	O	O
3CM	PUNCT	O	O
also	ADV	O	O
received	CCONJ	O	O
telephone	NOUN	O	O
care	NOUN	O	O
management	NOUN	O	O
.	PUNCT	O	O

Care	NOUN	O	O
managers	NOUN	O	O
received	VERB	O	O
supervision	NOUN	O	O
from	ADP	O	O
a	DET	O	O
psychiatrist	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
MEASURES	NOUN	O	O
PTSD	NOUN	O	B-PHYSICAL
symptom	NOUN	O	I-PHYSICAL
severity	NOUN	O	I-PHYSICAL
was	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

Depression	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
functioning	VERB	O	B-PHYSICAL
,	PUNCT	O	O
perceived	DET	O	B-PHYSICAL
quality	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
care	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
utilization	NOUN	O	B-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
costs	NOUN	O	B-OTHER
were	VERB	O	O
secondary	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

KEY	NOUN	O	O
RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
3CM	CCONJ	O	O
and	CCONJ	O	O
usual	ADJ	O	O
care	NOUN	O	O
in	ADP	O	O
symptoms	NOUN	O	O
or	CCONJ	O	O
functioning	SYM	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
assigned	DET	O	O
to	ADP	O	O
3CM	CCONJ	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
a	DET	O	O
mental	ADJ	O	B-MENTAL
health	NOUN	O	I-MENTAL
visit	NOUN	O	I-MENTAL
,	PUNCT	O	O
fill	PUNCT	O	O
an	DET	O	O
antidepressant	NOUN	O	O
prescription	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
have	PUNCT	O	O
adequate	PUNCT	O	B-OTHER
antidepressant	NOUN	O	I-OTHER
refills	NOUN	O	I-OTHER
.	PUNCT	O	O

3CM	NUM	O	O
participants	NOUN	O	O
also	ADV	O	O
had	PUNCT	O	O
more	DET	O	O
mental	ADJ	O	B-MENTAL
health	NOUN	O	I-MENTAL
visits	NOUN	O	I-MENTAL
and	CCONJ	O	O
higher	PUNCT	O	O
outpatient	ADJ	O	B-OTHER
pharmacy	NOUN	O	I-OTHER
costs	NOUN	O	I-OTHER
.	PUNCT	O	O

CONCLUSIONS	DET	O	O
Results	PUNCT	O	O
suggest	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
careful	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
way	NOUN	O	O
that	PUNCT	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
models	NOUN	O	O
are	VERB	O	O
implemented	VERB	O	O
for	ADP	O	O
treating	VERB	O	O
PTSD	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
additional	ADJ	O	O
supports	VERB	O	O
to	PUNCT	O	O
encourage	VERB	O	O
primary	ADJ	O	O
care	NOUN	O	O
providers	NOUN	O	O
to	PART	O	O
manage	NOUN	O	O
PTSD	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
non-invasive	ADJ	O	O
methods	NOUN	O	O
for	ADP	O	O
the	DET	O	O
assessment	NOUN	O	O
of	ADP	O	O
haemodynamic	ADJ	O	O
drug	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
male	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
volunteers	NOUN	O	O
:	PUNCT	O	O
sex	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
cardiovascular	ADJ	O	O
responsiveness	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
sensitivity	NOUN	O	O
and	CCONJ	O	O
short-term	NOUN	O	O
and	CCONJ	O	O
day-to-day	NOUN	O	O
variability	NOUN	O	O
of	ADP	O	O
a	DET	O	O
novel	ADJ	O	O
technique	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
laser	NOUN	O	O
interferometry	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	O
fundus	NOUN	O	O
pulsations	ADJ	O	O
and	CCONJ	O	O
of	ADP	O	O
non-invasive	ADJ	O	O
methods	NOUN	O	O
for	ADP	O	O
the	DET	O	O
quantification	NOUN	O	O
of	ADP	O	O
haemodynamic	ADJ	O	O
drug	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
additional	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
sex	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
haemodynamic	ADJ	O	O
responsiveness	NOUN	O	O
to	ADP	O	O
cardiovascular	ADJ	O	O
drugs	NOUN	O	O
in	ADP	O	O
male	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
.	PUNCT	O	O

Ten	NUM	O	O
males	NOUN	O	O
and	CCONJ	O	O
nine	NUM	O	O
females	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
range	NOUN	O	O
20-33	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Simultaneous	ADJ	O	B-PHYSICAL
measurements	NOUN	O	I-PHYSICAL
from	ADP	O	O
systemic	ADJ	O	O
haemodynamics	NOUN	O	O
,	PUNCT	O	O
laser	NOUN	O	O
interferometry	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	O
fundus	NOUN	O	O
pulsations	NOUN	O	O
,	PUNCT	O	O
systolic	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
from	ADP	O	O
mechanocardiography	NOUN	O	O
,	PUNCT	O	O
a/b	PUNCT	O	O
ratio	NOUN	O	O
from	ADP	O	O
oxymetric	ADJ	O	O
fingerplethysmography	NOUN	O	O
and	CCONJ	O	O
Doppler	NOUN	O	O
sonography	NOUN	O	O
of	ADP	O	O
the	DET	O	O
radial	ADJ	O	O
artery	NOUN	O	O
were	ADP	O	O
used	VERB	O	O
to	PART	O	O
describe	VERB	O	O
the	DET	O	O
haemodynamic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cumulative	ADJ	O	O
,	PUNCT	O	O
stepwise	DET	O	O
increasing	PUNCT	O	O
intravenous	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	O
,	PUNCT	O	O
isoprenaline	ADV	O	O
,	PUNCT	O	O
sodium	NOUN	O	O
nitroprusside	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

3	NUM	O	O
.	PUNCT	O	O

Laser	NOUN	O	O
interferometry	NOUN	O	O
detected	VERB	O	O
the	DET	O	O
isoprenaline-effects	NOUN	O	O
at	ADP	O	O
the	DET	O	O
lowest	PUNCT	O	O
dose	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
0.1	NUM	O	O
micrograms	NOUN	O	O
min-1	NOUN	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
signal-to-noise	ADJ	O	O
ratio	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
reproducibility	NOUN	O	O
of	ADP	O	O
measurements	NOUN	O	O
under	ADP	O	O
baseline	NOUN	O	O
was	VERB	O	O
high	ADJ	O	O
,	PUNCT	O	O
no	DET	O	O
changes	NOUN	O	O
were	VERB	O	O
observed	NUM	O	O
after	ADP	O	O
systemically	ADV	O	O
effective	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	O
or	CCONJ	O	O
sodium	NOUN	O	O
nitroprusside	NOUN	O	O
.	PUNCT	O	O

Systolic	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
were	VERB	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
specific	ADJ	O	O
for	ADP	O	O
isoprenaline-induced	VERB	O	O
effects	NOUN	O	O
,	PUNCT	O	O
PEP	NOUN	O	O
and	CCONJ	O	O
QS2c-measurements	NOUN	O	O
had	VERB	O	O
high	ADJ	O	O
reproducibility	NOUN	O	O
.	PUNCT	O	O

Fingerplethysmography	NOUN	O	O
proved	PROPN	O	O
a	DET	O	O
sensitive	ADJ	O	O
measurement	NOUN	O	O
for	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vasodilating	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	O
nitroprusside	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
not	ADV	O	O
specific	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
showed	VERB	O	O
low	ADJ	O	O
reproducibility	NOUN	O	O
.	PUNCT	O	O

Measurements	NOUN	O	O
from	ADP	O	O
Doppler	NOUN	O	O
sonography	NOUN	O	O
had	DET	O	O
lower	PUNCT	O	O
reproducibility	NOUN	O	O
and	CCONJ	O	O
sensitivity	NOUN	O	B-OTHER
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
other	ADJ	O	O
applied	DET	O	O
methods	NOUN	O	O
.	PUNCT	O	O

4	NUM	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
sex	NOUN	O	O
difference	NOUN	O	O
for	ADP	O	O
several	ADJ	O	O
of	ADP	O	O
the	DET	O	O
haemodynamic	ADJ	O	O
parameters	NOUN	O	O
under	ADP	O	O
baseline	NOUN	O	O
conditions	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
responsiveness	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
under	ADP	O	O
study	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
,	PUNCT	O	O
when	ADP	O	O
drug	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
expressed	VERB	O	O
as	PUNCT	O	O
%	ADV	O	O
-change	NOUN	O	O
from	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

5	NUM	O	O
.	PUNCT	O	O

Laser	NOUN	O	O
interferometry	NOUN	O	O
is	VERB	O	O
a	DET	O	O
valuable	ADJ	O	O
non-invasive	ADJ	O	O
,	PUNCT	O	O
highly	ADV	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
specific	ADJ	O	O
approach	NOUN	O	O
for	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
pulse	PUNCT	O	O
pressure	NOUN	O	O
changes	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
battery	NOUN	O	O
of	ADP	O	O
non-invasive	ADJ	O	O
tests	NOUN	O	O
appears	PART	O	O
useful	ADJ	O	O
for	ADP	O	O
the	DET	O	O
characterization	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Gender	NOUN	O	O
differences	NOUN	O	O
may	ADP	O	O
not	NOUN	O	O
pose	CCONJ	O	O
a	DET	O	O
relevant	ADJ	O	O
problem	NOUN	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
haemodynamic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Prehydration	NOUN	O	O
alone	ADJ	O	O
is	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
prevent	ADJ	O	O
contrast-induced	VERB	O	O
nephropathy	NOUN	O	O
after	ADP	O	O
day-only	ADV	O	O
angiography	NOUN	O	O
procedures	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Contrast	NOUN	O	O
agents	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
angiography	NOUN	O	O
procedures	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
are	VERB	O	O
known	VERB	O	O
to	ADP	O	O
cause	PUNCT	O	O
contrast-induced	ADP	O	O
nephropathy	NOUN	O	O
(	PUNCT	O	O
CIN	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
may	VERB	O	O
be	VERB	O	O
partially	ADV	O	O
due	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
nephrotoxic	ADJ	O	O
oxygen-free	ADP	O	O
radicals	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
uncertain	VERB	O	O
whether	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
(	PUNCT	O	O
IV	NUM	O	O
)	PUNCT	O	O
anti-oxidant	ADP	O	O
,	PUNCT	O	O
N-acetylcysteine	NOUN	O	O
(	PUNCT	O	O
NAC	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
can	VERB	O	O
prevent	VERB	O	O
reduction	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
whether	ADP	O	O
this	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
cost-effective	ADJ	O	O
approach	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty-five	ADP	O	O
day-only	PROPN	O	O
patients	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	O
impairment	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
serum	NOUN	O	O
creatinine	NOUN	O	O
concentration	NOUN	O	O
0.16+/-0.03	PUNCT	O	O
mmol/l	NOUN	O	O
)	PUNCT	O	O
due	ADJ	O	O
to	PUNCT	O	O
undergo	PUNCT	O	O
coronary	ADJ	O	O
or	CCONJ	O	O
peripheral	ADJ	O	O
angiography	NOUN	O	O
and/or	CCONJ	O	O
stenting	VERB	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
IV	PUNCT	O	O
NAC	NOUN	O	O
300	NUM	O	O
or	CCONJ	O	O
600	NUM	O	O
mg	NOUN	O	O
immediately	ADV	O	O
before	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
or	CCONJ	O	O
IV	NUM	O	O
fluid	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
60	ADV	O	O
patients	NOUN	O	O
with	ADP	O	O
complete	ADJ	O	O
data	NOUN	O	O
,	PUNCT	O	O
none	NUM	O	O
had	PUNCT	O	O
acute	ADJ	O	O
CIN	NOUN	O	O
(	PUNCT	O	O
increase	ADP	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	O
concentration	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.044	NUM	O	O
mmol/l	NOUN	O	O
,	PUNCT	O	O
48	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	O
agent	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eight	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
13	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
have	PUNCT	O	O
demonstrated	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
creatinine	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.044	PUNCT	O	O
mmol/l	NOUN	O	O
30	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	O
agent	NOUN	O	O
:	PUNCT	O	O
2/19	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
2/21	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
600	NUM	O	O
mg	NOUN	O	O
NAC	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
4/20	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
the	DET	O	O
300	NUM	O	O
mg	NOUN	O	O
NAC	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.66	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
volumes	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
contrast	NOUN	O	O
agent	NOUN	O	B-OTHER
used	ADP	O	O
and	CCONJ	O	O
prehydration	ADJ	O	O
given	ADJ	O	O
for	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
did	ADP	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.83	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	PUNCT	O	O
creatinine	PUNCT	O	B-PHYSICAL

Incidence	NOUN	O	O
of	ADP	O	O
puberty	NOUN	O	B-PHYSICAL
in	ADP	O	O
beef	NOUN	O	O
heifers	PUNCT	O	O
fed	ADJ	O	O
high-	NOUN	O	O
or	CCONJ	O	O
low-starch	NOUN	O	O
diets	NOUN	O	O
for	ADP	O	O
different	ADJ	O	O
periods	NOUN	O	O
before	ADP	O	O
breeding	VERB	O	O
.	PUNCT	O	O

Spring-born	PUNCT	O	O
Hereford	NOUN	O	O
x	ADJ	O	O
Angus	NOUN	O	O
heifers	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
206	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	ADP	O	O
effects	NOUN	O	O
of	ADP	O	O
energy	NOUN	O	O
supplementation	NOUN	O	O
programs	NOUN	O	O
and	CCONJ	O	O
amount	NOUN	O	O
of	ADP	O	O
starch	NOUN	O	O
in	ADP	O	O
the	DET	O	O
diet	NOUN	O	O
on	ADP	O	O
incidence	NOUN	O	O
of	ADP	O	O
puberty	NOUN	O	B-OTHER
.	PUNCT	O	O

In	ADP	O	O
Exp	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
,	PUNCT	O	O
heifers	ADJ	O	O
(	PUNCT	O	O
205	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
68	NUM	O	O
)	PUNCT	O	O
grazing	CCONJ	O	O
dormant	PUNCT	O	O
native	ADJ	O	O
pasture	NOUN	O	O
were	VERB	O	O
fed	VERB	O	O
0.9	NUM	O	O
kg/d	NOUN	O	O
(	PUNCT	O	O
as-fed	PUNCT	O	O
basis	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
42	NUM	O	O
%	SYM	O	O
CP	NOUN	O	O
supplement	NOUN	O	O
from	ADP	O	O
November	NOUN	O	O
until	ADP	O	O
February	PUNCT	O	O
14	NUM	O	O
.	PUNCT	O	O

Heifers	VERB	O	O
were	VERB	O	O
stratified	VERB	O	O
by	ADP	O	O
weaning	VERB	O	O
weight	NOUN	O	O
and	CCONJ	O	O
allotted	ADP	O	O
randomly	ADV	O	O
to	ADP	O	O
treatment	NOUN	O	O
before	ADP	O	O
breeding	VERB	O	O
(	PUNCT	O	O
May	NOUN	O	O
to	ADP	O	O
July	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatments	NOUN	O	O
were	VERB	O	O
1	NUM	O	O
)	PUNCT	O	O
0.9	NUM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
as-fed	PUNCT	O	O
basis	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
42	NUM	O	O
%	SYM	O	O
CP	NOUN	O	O
supplement/d	NOUN	O	O
and	CCONJ	O	O
pasture	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
high-starch	NOUN	O	O
(	PUNCT	O	O
HS	NOUN	O	O
)	PUNCT	O	O
diet	NOUN	O	O
(	PUNCT	O	O
73	NUM	O	O
%	SYM	O	O
corn	NOUN	O	O
;	PUNCT	O	O
53	NUM	O	O
%	SYM	O	O
starch	NOUN	O	O
)	PUNCT	O	O
fed	VERB	O	O
in	ADP	O	O
a	DET	O	O
drylot	NOUN	O	O
for	ADP	O	O
60	NUM	O	O
d	NOUN	O	O
(	PUNCT	O	O
HS-60	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
HS	NOUN	O	O
diet	NOUN	O	O
fed	VERB	O	O
in	ADP	O	O
drylot	NOUN	O	O
for	ADP	O	O
30	NUM	O	O
d	NOUN	O	O
(	PUNCT	O	O
HS-30	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
or	CCONJ	O	O
4	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
low-starch	NOUN	O	O
(	PUNCT	O	O
LS	NOUN	O	O
)	PUNCT	O	O
diet	NOUN	O	O
(	PUNCT	O	O
49	NUM	O	O
%	SYM	O	O
corn	NOUN	O	O
;	PUNCT	O	O
37	NUM	O	O
%	SYM	O	O
starch	NOUN	O	O
)	PUNCT	O	O
self-fed	VERB	O	O
on	ADP	O	O
pasture	NOUN	O	O
for	ADP	O	O
30	NUM	O	O
d	NOUN	O	O
(	PUNCT	O	O
LS-30	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
HS-60	NOUN	O	O
and	CCONJ	O	O
HS-30	NOUN	O	O
heifers	ADV	O	O
were	ADV	O	O
limited-fed	PUNCT	O	O
to	PUNCT	O	O
gain	NOUN	O	O
0.9	NUM	O	O
kg/d	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
LS-30	NOUN	O	O
heifers	VERB	O	O
had	PUNCT	O	O
ad	PUNCT	O	O
libitum	PUNCT	O	O
access	NOUN	O	O
to	ADP	O	O
the	DET	O	O
diet	NOUN	O	O
.	PUNCT	O	O

High-starch-60	NOUN	O	O
and	CCONJ	O	O
LS-30	NOUN	O	O
heifers	PUNCT	O	O
were	VERB	O	O
heavier	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
control	NOUN	O	O
and	CCONJ	O	O
HS-30	NOUN	O	O
heifers	VERB	O	O
at	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
breeding	ADJ	O	O
season	ADJ	O	O
.	PUNCT	O	O

Thirty-one	NUM	O	O
,	PUNCT	O	O
25	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
26	NUM	O	O
%	ADJ	O	O
more	DET	O	O
HS-60	NOUN	O	O
heifers	DET	O	O
were	PUNCT	O	O
pubertal	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
May	NOUN	O	O
1	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
LS-30	NOUN	O	O
,	PUNCT	O	O
HS-30	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
heifers	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

At	ADP	O	O
puberty	NOUN	O	O
,	PUNCT	O	O
HS-60	NOUN	O	O
heifers	NUM	O	O
were	VERB	O	O
24	NUM	O	O
and	CCONJ	O	O
22	NUM	O	O
d	NOUN	O	O
younger	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
LS-30	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
heifers	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
31	NUM	O	O
kg	NOUN	O	O
lighter	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
LS-30	NOUN	O	O
heifers	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
Exp	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
,	PUNCT	O	O
heifers	PUNCT	O	O
grazed	ADP	O	O
dormant	ADJ	O	O
pasture	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
fed	VERB	O	O
0.9	NUM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
as-fed	PUNCT	O	O
basis	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
42	NUM	O	O
%	SYM	O	O
CP	NOUN	O	O
supplement/d	NOUN	O	O
from	ADP	O	O
weaning	VERB	O	O
in	ADP	O	O
October	NOUN	O	O
to	ADP	O	O
late	ADJ	O	O
February	ADJ	O	O
;	PUNCT	O	O
then	ADV	O	O
heifers	PUNCT	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	PUNCT	O	O
treatments	ADV	O	O
for	ADP	O	O
60	NUM	O	O
d	NOUN	O	O
before	ADP	O	O
the	DET	O	O
breeding	ADJ	O	O
season	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
control	PUNCT	O	O
heifers	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
46	NUM	O	O
)	PUNCT	O	O
grazed	VERB	O	O
pasture	NOUN	O	O
and	CCONJ	O	O
received	VERB	O	O
0.9	NUM	O	O
kg	NOUN	O	O
of	ADP	O	O
SBM	NOUN	O	O
supplement/d	NOUN	O	O
;	PUNCT	O	O
LS	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
46	NUM	O	O
)	PUNCT	O	O
heifers	PUNCT	O	O
were	ADP	O	O
self-fed	VERB	O	O
a	DET	O	O
distiller	NOUN	O	O
's	PUNCT	O	O
grain	NOUN	O	O
and	CCONJ	O	O
soybean	NOUN	O	O
hull-based	NOUN	O	O
diet	NOUN	O	O
in	ADP	O	O
drylot	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
HS	NOUN	O	O
heifers	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
46	NUM	O	O
)	PUNCT	O	O
were	ADV	O	O
limited-fed	PUNCT	O	O
a	DET	O	O
corn-based	ADJ	O	O
diet	NOUN	O	O
in	ADP	O	O
drylot	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
HS	NOUN	O	O
and	CCONJ	O	O
LS	NOUN	O	O
heifers	PROPN	O	O
had	ADP	O	O
greater	PUNCT	O	O
weight	NOUN	O	O
gains	NOUN	O	B-PHYSICAL
than	PUNCT	O	O
control	NOUN	O	O
heifers	ADJ	O	O
.	PUNCT	O	O

Pubertal	PUNCT	O	B-PHYSICAL
BW	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
313	NUM	O	O
+/-	SYM	O	O
6	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
HS	NOUN	O	O
and	CCONJ	O	O
LS	NOUN	O	O
heifers	NUM	O	O
were	VERB	O	O
younger	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
control	NOUN	O	O
heifers	VERB	O	O
at	ADP	O	O
puberty	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
60-d	NOUN	O	O
breeding	ADJ	O	O
period	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
puberty	NOUN	O	B-PHYSICAL
was	VERB	O	O
greater	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
HS	NOUN	O	O
and	CCONJ	O	O
LS	NOUN	O	O
heifers	PUNCT	O	O
than	VERB	O	O
for	ADP	O	O
control	NOUN	O	O
heifers	ADJ	O	O
and	CCONJ	O	O
was	VERB	O	O
greater	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
HS	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
LS	NOUN	O	O
heifers	VERB	O	O
in	ADP	O	O
Year	NOUN	O	O
1	NUM	O	O
.	PUNCT	O	O

Feeding	ADP	O	O
a	DET	O	O
LS	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
HS	NOUN	O	O
diet	NOUN	O	O
for	ADP	O	O
30	NUM	O	O
d	NOUN	O	O
before	ADP	O	O
breeding	VERB	O	O
may	SYM	O	O
be	VERB	O	O
inadequate	ADJ	O	O
to	ADP	O	O
stimulate	ADJ	O	O
puberty	NOUN	O	B-PHYSICAL
in	ADP	O	O
beef	NOUN	O	O
heifers	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
feeding	ADP	O	O
a	DET	O	O
diet	NOUN	O	O
with	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
amount	NOUN	O	O
of	ADP	O	O
starch	NOUN	O	O
for	ADP	O	O
60	NUM	O	O
d	NOUN	O	O
before	ADP	O	O
breeding	VERB	O	O
may	SYM	O	O
increase	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
puberty	NOUN	O	B-PHYSICAL
during	ADP	O	O
breeding	VERB	O	O
of	ADP	O	O
heifers	CCONJ	O	O
that	VERB	O	O
have	PUNCT	O	O
inadequate	ADJ	O	O
yearling	PUNCT	O	O
weight	NOUN	O	O
.	PUNCT	O	O

Conduit	NOUN	O	O
artery	NOUN	O	O
structure	NOUN	O	O
and	CCONJ	O	O
function	NOUN	O	O
in	ADP	O	O
lowlanders	NOUN	O	O
and	CCONJ	O	O
native	ADJ	O	O
highlanders	NOUN	O	O
:	PUNCT	O	O
relationships	NOUN	O	O
with	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
role	NOUN	O	O
of	ADP	O	O
sympathoexcitation	NOUN	O	O
.	PUNCT	O	O

Research	NOUN	O	O
detailing	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
vascular	ADJ	O	O
adaptions	NOUN	O	O
to	ADP	O	O
high	ADJ	O	O
altitude	NOUN	O	O
is	VERB	O	O
minimal	ADJ	O	O
and	CCONJ	O	O
often	ADV	O	O
confounded	VERB	O	O
by	ADP	O	O
pathology	NOUN	O	O
(	PUNCT	O	O
e.g.	ADP	O	O
,	PUNCT	O	O
chronic	ADJ	O	O
mountain	NUM	O	O
sickness	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
methodological	ADJ	O	O
issues	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
vascular	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
structure	NOUN	O	O
in	ADP	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
healthy	ADJ	O	O
lowlanders	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
hypoxia	NOUN	O	O
and	CCONJ	O	O
prolonged	PUNCT	O	O
(	PUNCT	O	O
?2	PUNCT	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
high	ADJ	O	O
altitude	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
high-altitude	PUNCT	O	O
natives	NOUN	O	O
at	ADP	O	O
5050	NUM	O	O
m	NOUN	O	O
(	PUNCT	O	O
highlanders	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
12	NUM	O	O
healthy	ADJ	O	O
lowlanders	NOUN	O	O
(	PUNCT	O	O
aged	DET	O	O
32	NUM	O	O
?	PUNCT	O	O

7	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
highlanders	NOUN	O	O
(	PUNCT	O	O
Sherpa	ADJ	O	O
;	PUNCT	O	O
33	NUM	O	O
?	PUNCT	O	O

14	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
we	PRON	O	O
assessed	VERB	O	O
brachial	ADJ	O	O
endothelium-dependent	ADJ	O	O
flow-mediated	ADP	O	O
dilatation	NOUN	O	O
(	PUNCT	O	O
FMD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
endothelium-independent	PUNCT	O	O
dilatation	NOUN	O	O
(	PUNCT	O	O
via	ADP	O	O
glyceryl	NOUN	O	O
trinitrate	ADV	O	O
;	PUNCT	O	O
GTN	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
common	ADJ	O	O
carotid	ADJ	O	O
intima-media	ADJ	O	O
thickness	NOUN	O	O
(	PUNCT	O	O
CIMT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diameter	NOUN	O	O
(	PUNCT	O	O
ultrasound	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
arterial	ADJ	O	O
stiffness	NOUN	O	O
via	ADP	O	O
pulse	NOUN	O	O
wave	NOUN	O	O
velocity	NOUN	O	O
(	PUNCT	O	O
PWV	NOUN	O	O
;	PUNCT	O	O
applanation	NOUN	O	O
tonometry	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cephalic	ADJ	O	O
venous	ADJ	O	O
biomarkers	CCONJ	O	O
of	ADP	O	O
free	ADJ	O	O
radical-mediated	DET	O	O
lipid	NOUN	O	O
peroxidation	NOUN	O	O
(	PUNCT	O	O
lipid	NOUN	O	O
hydroperoxides	ADJ	O	O
,	PUNCT	O	O
LOOH	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nitrite	NOUN	O	O
(	PUNCT	O	O
NO2-	ADP	O	O
)	PUNCT	O	O
and	CCONJ	O	O
lipid	NOUN	O	O
soluble	ADJ	O	O
antioxidants	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
obtained	VERB	O	O
at	ADP	O	O
rest	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
lowlanders	NOUN	O	O
,	PUNCT	O	O
measurements	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
sea	NOUN	O	O
level	NOUN	O	O
(	PUNCT	O	O
334	NUM	O	O
m	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
between	ADP	O	O
days	NOUN	O	O
3-4	NUM	O	O
(	PUNCT	O	O
acute	ADJ	O	O
high	ADJ	O	O
altitude	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12-14	NUM	O	O
(	PUNCT	O	O
chronic	ADJ	O	O
high	ADJ	O	O
altitude	NOUN	O	O
)	PUNCT	O	O
following	VERB	O	O
arrival	NOUN	O	O
to	ADP	O	O
5050	NUM	O	O
m.	NOUN	O	O
Highlanders	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
once	PUNCT	O	O
at	ADP	O	O
5050	NUM	O	O
m.	ADV	O	O
Compared	ADV	O	O
with	ADP	O	O
sea	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
acute	ADJ	O	O
high	ADJ	O	O
altitude	NOUN	O	O
reduced	DET	O	O
lowlanders	NOUN	O	O
'	PUNCT	O	O
FMD	NOUN	O	O
(	PUNCT	O	O
7.9	NUM	O	O
?	PUNCT	O	O

0.4	NUM	O	O
vs.	CCONJ	O	O
6.8	NUM	O	O
?	PUNCT	O	O

0.4	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
GTN-induced	VERB	O	O
dilatation	NOUN	O	O
(	PUNCT	O	O
16.6	NUM	O	O
?	PUNCT	O	O

0.9	NUM	O	O
vs.	CCONJ	O	O
14.5	NUM	O	O
?	PUNCT	O	O

0.8	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
raised	VERB	O	O
central	ADJ	O	O
PWV	NOUN	O	O
(	PUNCT	O	O
6.0	NUM	O	O
?	PUNCT	O	O

0.2	NUM	O	O
vs.	CCONJ	O	O
6.6	NUM	O	O
?	PUNCT	O	O

0.3	NUM	O	O
m	NOUN	O	O
s	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
changes	NOUN	O	O
persisted	VERB	O	O
at	ADP	O	O
days	NOUN	O	O
12-14	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
allometrically	ADJ	O	O
scaling	PUNCT	O	O
FMD	NOUN	O	O
to	PUNCT	O	O
adjust	PUNCT	O	O
for	ADP	O	O
altered	VERB	O	O
baseline	NOUN	O	O
diameter	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
lowlanders	CCONJ	O	O
at	ADP	O	O
sea	NOUN	O	O
level	NOUN	O	O
and	CCONJ	O	O
high	ADJ	O	O
altitude	NOUN	O	O
,	PUNCT	O	O
highlanders	NOUN	O	O
had	ADP	O	O
a	DET	O	O
lower	PUNCT	O	O
carotid	ADJ	O	B-PHYSICAL
wall	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
lumen	NOUN	O	B-PHYSICAL
ratio	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
?19	PUNCT	O	O
%	ADP	O	O
,	PUNCT	O	O
P	NOUN	O	O
?	PUNCT	O	O

0.04	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
attributable	ADJ	O	O
to	ADP	O	O
a	DET	O	O
narrower	PUNCT	O	O
CIMT	NOUN	O	O
and	CCONJ	O	O
wider	PUNCT	O	O
lumen	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
both	CCONJ	O	O
LOOH	NOUN	O	B-PHYSICAL
and	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
schizophrenic	ADJ	O	O
patient	NOUN	O	O
functionality	NOUN	O	O
on	ADP	O	O
service	NOUN	O	B-OTHER
utilization	NOUN	O	I-OTHER
and	CCONJ	O	O
cost	NOUN	O	B-OTHER
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
a	DET	O	O
presentation	NOUN	O	O
by	ADP	O	O
Sandra	CCONJ	O	O
L.	ADV	O	O
Tunis	NOUN	O	O
,	PUNCT	O	O
PhD	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
the	DET	O	O
advent	NOUN	O	O
of	ADP	O	O
atypical	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
and	CCONJ	O	O
policy	NOUN	O	O
makers	NOUN	O	O
must	DET	O	O
consider	VERB	O	O
the	DET	O	O
costs	NOUN	O	O
that	ADP	O	O
may	VERB	O	O
accompany	VERB	O	O
greater	PUNCT	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

Analyses	NOUN	O	O
reveal	VERB	O	O
that	ADP	O	O
olanzapine	NOUN	O	O
shows	NOUN	O	O
a	DET	O	O
greater	PUNCT	O	O
clinical	ADJ	O	B-OTHER
cost	NOUN	O	I-OTHER
effectiveness	NOUN	O	I-OTHER
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
a	DET	O	O
greater	PUNCT	O	O
functional	ADJ	O	B-OTHER
cost	NOUN	O	I-OTHER
effectiveness	NOUN	O	I-OTHER
,	PUNCT	O	O
than	PUNCT	O	O
haloperidol	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
functional	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O
show	NUM	O	O
promise	PUNCT	O	O
as	ADP	O	O
important	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
effectiveness	NOUN	O	O
.	PUNCT	O	O

Functional	ADJ	O	O
outcomes	NOUN	O	O
can	VERB	O	O
help	ADP	O	O
differentiate	PUNCT	O	O
medications	NOUN	O	O
and	CCONJ	O	O
can	PRON	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
help	PUNCT	O	O
demonstrate	ADP	O	O
the	DET	O	O
cost	NOUN	O	B-OTHER
effectiveness	NOUN	O	I-OTHER
of	ADP	O	O
atypical	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

Mental	ADJ	O	B-MENTAL
health	NOUN	O	I-MENTAL
and	CCONJ	O	O
physical	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
functioning	VERB	O	I-PHYSICAL
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
work	NOUN	O	B-MENTAL
status	NOUN	O	I-MENTAL
,	PUNCT	O	O
are	VERB	O	O
all	DET	O	O
measures	NOUN	O	O
of	ADP	O	O
functioning	VERB	O	O
that	VERB	O	O
have	PUNCT	O	O
been	PUNCT	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
treatment	NOUN	O	O
strategies	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
comparing	ADJ	O	O
olanzapine	NOUN	O	O
with	ADP	O	O
haloperidol	NOUN	O	O
,	PUNCT	O	O
cost	NOUN	O	B-OTHER
savings	NOUN	O	I-OTHER
are	VERB	O	O
seen	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
year	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
physical	ADJ	O	B-PHYSICAL
functioning	ADP	O	I-PHYSICAL
most	ADJ	O	O
highly	ADV	O	O
affected	VERB	O	O
over	PUNCT	O	O
time	NOUN	O	O
.	PUNCT	O	O

Functional	ADJ	O	O
outcomes	NOUN	O	O
can	ADP	O	O
therefore	ADV	O	O
serve	VERB	O	O
2	NUM	O	O
purposes	NOUN	O	O
:	PUNCT	O	O
to	PART	O	O
enhance	ADJ	O	O
compliance	NOUN	O	O
by	ADP	O	O
improving	VERB	O	O
health-related	VERB	O	B-OTHER
quality	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
life	NOUN	O	I-OTHER
and	CCONJ	O	O
to	PART	O	O
assist	NOUN	O	O
in	ADP	O	O
making	VERB	O	O
both	PUNCT	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
formulary	PUNCT	O	O
decisions	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
130/0.4	ADV	O	O
versus	CCONJ	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
200/0.5	ADV	O	O
for	ADP	O	O
plasma	NOUN	O	O
volume	NOUN	O	O
expansion	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
Hydroxyethyl	NOUN	O	O
starch	NOUN	O	O
(	PUNCT	O	O
HES	NOUN	O	O
)	PUNCT	O	O
solutions	NOUN	O	O
are	PROPN	O	O
frequently	ADV	O	O
used	VERB	O	O
for	ADP	O	O
perioperative	ADJ	O	O
volume	NOUN	O	O
replacement	NOUN	O	O
.	PUNCT	O	O

Whereas	ADP	O	O
older	PUNCT	O	O
HES	NOUN	O	O
specimen	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
accumulate	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
cause	PROPN	O	O
negative	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
hemostasis	NOUN	O	O
,	PUNCT	O	O
more	ADV	O	O
recent	ADJ	O	O
products	NOUN	O	O
,	PUNCT	O	O
e.g.	ADP	O	O
,	PUNCT	O	O
HES	NOUN	O	O
130/0.4	ADV	O	O
,	PUNCT	O	O
are	VERB	O	O
characterised	VERB	O	O
by	ADP	O	O
improved	CCONJ	O	O
pharmacological	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
130/0.4	ADV	O	O
and	CCONJ	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
200/0.5	ADV	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
post-hoc	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	DET	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
multi-center	NOUN	O	O
therapeutic	ADJ	O	O
equivalence	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
76	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
elective	ADJ	O	O
on-pump	NOUN	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
received	ADP	O	O
perioperative	ADP	O	O
volume	NOUN	O	O
replacement	NOUN	O	O
using	ADP	O	O
either	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
130/0.4	ADV	O	O
(	PUNCT	O	O
N.=37	ADP	O	O
)	PUNCT	O	O
or	CCONJ	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
200/0.5	ADV	O	O
(	PUNCT	O	O
N.=39	NOUN	O	O
)	PUNCT	O	O
up	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mL	NOUN	O	O
kg-1	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADJ	O	O
Equivalent	ADJ	O	B-OTHER
volumes	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
investigational	ADJ	O	I-OTHER
medication	NOUN	O	I-OTHER
were	VERB	O	O
infused	VERB	O	O
until	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
administration	NOUN	O	O
(	PUNCT	O	O
1577	NUM	O	O
vs.	CCONJ	O	O
1540	NUM	O	O
mL	NOUN	O	O
;	PUNCT	O	O
treatment	NOUN	O	O
difference	NOUN	O	O
37	NUM	O	O
[	PUNCT	O	O
-150	ADP	O	O
;	PUNCT	O	O
223	NUM	O	O
]	PUNCT	O	O
mL	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
for	ADP	O	O
equivalence	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Whereas	ADP	O	O
standard	ADJ	O	O
laboratory	NOUN	O	O
tests	NOUN	O	O
of	ADP	O	O
coagulation	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
,	PUNCT	O	O
von	ADP	O	B-PHYSICAL
Willebrand	NOUN	O	I-PHYSICAL
factor	NOUN	O	O
activity	NOUN	O	B-PHYSICAL
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
postoperative	ADJ	O	O
morning	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
higher	PUNCT	O	O
following	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
130/0.4	ADV	O	O
as	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
10	NUM	O	O
%	SYM	O	O
HES	NOUN	O	O
200/0.5	ADV	O	O
(	PUNCT	O	O
P=0.025	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
this	DET	O	O
difference	NOUN	O	O
being	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
per-protocol	NOUN	O	O
analysis	NOUN	O	O
(	PUNCT	O	O
P=0.02	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
concerning	ADJ	O	O
other	ADJ	O	O
safety	NOUN	O	B-OTHER
parameters	NOUN	O	I-OTHER
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
drug	NOUN	O	I-ADVERSE-EFFECTS
reactions	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

In	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O

Over	ADP	O	O
time	NOUN	O	O
relationships	NOUN	O	O
between	ADP	O	O
early	ADJ	O	O
adolescent	NOUN	O	O
and	CCONJ	O	O
peer	NOUN	O	B-MENTAL
substance	NOUN	O	I-MENTAL
use	NOUN	O	O
.	PUNCT	O	O

Peer	NOUN	O	O
and	CCONJ	O	O
adolescent	NOUN	O	O
substance	NOUN	O	O
use	NOUN	O	O
are	VERB	O	O
highly	ADV	O	O
correlated	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
relationship	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
fully	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
relative	ADJ	O	O
contributions	NOUN	O	O
of	ADP	O	O
selection	NOUN	O	O
and	CCONJ	O	O
socialization	NOUN	O	O
to	ADP	O	O
substance	NOUN	O	O
use	NOUN	O	O
progression	NOUN	O	O
have	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
established	VERB	O	O
.	PUNCT	O	O

Students	NOUN	O	O
(	PUNCT	O	O
n=2453	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
seven	NUM	O	O
middle	ADJ	O	O
schools	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
school	NOUN	O	O
district	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
school	NOUN	O	O
at	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
and	CCONJ	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sixth	ADJ	O	O
,	PUNCT	O	O
seventh	NOUN	O	O
,	PUNCT	O	O
eighth	PUNCT	O	O
grade	NOUN	O	O
and	CCONJ	O	O
beginning	ADJ	O	O
of	ADP	O	O
the	DET	O	O
9th	PUNCT	O	O
grade	NOUN	O	O
.	PUNCT	O	O

Self-reported	VERB	O	B-MENTAL
smoking	VERB	O	I-MENTAL
and	CCONJ	O	I-MENTAL
drinking	PROPN	O	I-MENTAL
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
substance	NOUN	O	O
using	PROPN	O	O
friends	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
5	NUM	O	O
times	NOUN	O	O
over	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
peer	NOUN	O	B-MENTAL
and	CCONJ	O	O
adolescent	NOUN	O	B-MENTAL
substance	NOUN	O	I-MENTAL
use	NOUN	O	I-MENTAL
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
parallel	ADJ	O	O
processes	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
an	DET	O	O
autoregressive	ADJ	O	O
latent	ADJ	O	O
trajectory	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

Substance	ADJ	O	B-MENTAL
use	NOUN	O	I-MENTAL
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
substance	NOUN	O	I-MENTAL
using	VERB	O	O
friends	NOUN	O	O
increased	VERB	O	O
in	ADP	O	O
linear	ADJ	O	O
fashion	NOUN	O	O
from	ADP	O	O
T1	NOUN	O	O
to	ADP	O	O
T5	NOUN	O	O
.	PUNCT	O	O

Initial	ADJ	O	O
substance	NOUN	O	O
use	NOUN	O	O
predicted	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
substance	NOUN	O	I-MENTAL
using	VERB	O	I-MENTAL
friends	DET	O	I-MENTAL
over	PUNCT	O	I-MENTAL
time	NOUN	O	I-MENTAL
,	PUNCT	O	O
indicating	VERB	O	O
an	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
selection	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
initial	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
substance	NOUN	O	O
using	VERB	O	O
friends	NOUN	O	O
predicted	VERB	O	O
substance	NOUN	O	B-MENTAL
use	NOUN	O	I-MENTAL
progression	NOUN	O	O
,	PUNCT	O	O
providing	CCONJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
socialization	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
magnitudes	NOUN	O	O
of	ADP	O	O
these	DET	O	O
relationships	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
.	PUNCT	O	O

Bivariate	PUNCT	O	O
,	PUNCT	O	O
lagged	CCONJ	O	O
autoregressive	ADJ	O	O
analyses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
successive	ADJ	O	O
relationships	NOUN	O	O
from	ADP	O	O
one	NUM	O	O
assessment	NOUN	O	O
to	ADP	O	O
the	DET	O	O
next	PUNCT	O	O
showed	ADP	O	O
consistent	ADJ	O	O
,	PUNCT	O	O
significant	ADJ	O	O
associations	NOUN	O	O
from	ADP	O	O
peer	NOUN	O	B-MENTAL
use	ADP	O	I-MENTAL
to	ADP	O	I-MENTAL
adolescent	NOUN	O	I-MENTAL
substance	NOUN	O	I-MENTAL
use	NOUN	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
from	ADP	O	O
adolescent	NOUN	O	B-MENTAL
to	ADP	O	I-MENTAL
peer	NOUN	O	I-MENTAL
use	NOUN	O	I-MENTAL
was	VERB	O	O
significant	ADJ	O	O
only	ADV	O	O
from	ADP	O	O
7th	NOUN	O	O
to	ADP	O	O
8th	ADJ	O	O
grade	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
provide	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
reciprocal	ADJ	O	O
influences	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
socialization	NOUN	O	O
was	VERB	O	O
a	DET	O	O
more	ADV	O	O
consistent	ADJ	O	O
influence	NOUN	O	O
than	PUNCT	O	O
selection	NOUN	O	O
.	PUNCT	O	O

Why	PUNCT	O	O
the	DET	O	O
prone	ADJ	O	O
position	NOUN	O	O
is	VERB	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
sudden	ADJ	O	O
infant	NOUN	O	O
death	NOUN	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
The	DET	O	O
laryngeal	ADJ	O	O
chemoreflex	VERB	O	O
may	PART	O	O
explain	PUNCT	O	O
why	ADP	O	O
prone	ADJ	O	O
sleeping	ADV	O	O
increases	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
sudden	ADJ	O	O
infant	NOUN	O	O
death	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
SIDS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Swallowing	PUNCT	O	O
and	CCONJ	O	O
arousal	ADJ	O	O
are	ADJ	O	O
crucial	ADJ	O	O
to	PART	O	O
prevent	VERB	O	O
laryngeal	ADJ	O	O
chemoreflex	PUNCT	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

Our	PUNCT	O	O
aim	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
these	DET	O	O
reflexes	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
breathing	PROPN	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
neonates	NOUN	O	O
after	ADP	O	O
pharyngeal	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
water	NOUN	O	O
in	ADP	O	O
the	DET	O	O
supine	NOUN	O	O
versus	CCONJ	O	O
the	DET	O	O
prone	ADJ	O	O
position	NOUN	O	O
,	PUNCT	O	O
controlling	ADJ	O	O
for	ADP	O	O
sleep	NOUN	O	O
state	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
term	NOUN	O	O
infants	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
after	ADP	O	O
parental	ADJ	O	O
consent	NOUN	O	O
and	CCONJ	O	O
ethics	ADP	O	O
approval	PUNCT	O	O
.	PUNCT	O	O

Polygraphic	ADJ	O	O
recordings	NOUN	O	O
included	VERB	O	O
sleep	NOUN	O	B-PHYSICAL
state	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
active	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
quiet	NOUN	O	B-PHYSICAL
sleep	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
electroencephalogram	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
eye	NOUN	O	B-PHYSICAL
movements	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
breathing	DET	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Brief	PUNCT	O	O
Report	NOUN	O	O
:	PUNCT	O	O
Randomized	VERB	O	O
test	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
picture	NOUN	O	O
exchange	NOUN	O	O
communication	NOUN	O	O
system	NOUN	O	O
on	ADP	O	O
highly	ADV	O	O
generalized	VERB	O	B-OTHER
picture	NOUN	O	I-OTHER
exchanges	NOUN	O	I-OTHER
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
control	NOUN	O	O
trial	NOUN	O	O
comparing	VERB	O	O
two	NUM	O	O
social-communication	NOUN	O	O
interventions	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
examined	VERB	O	O
far-transfer	NOUN	O	O
of	ADP	O	B-MENTAL
the	DET	O	O
use	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
picture	NOUN	O	I-MENTAL
exchange	NOUN	O	I-MENTAL
to	ADP	O	B-MENTAL
communicate	PUNCT	O	I-MENTAL
.	PUNCT	O	O

Thirty-six	NUM	O	O
children	NOUN	O	O
were	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
treatment	NOUN	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
which	ADP	O	O
was	ADV	O	O
the	DET	O	O
Picture	NOUN	O	O
Exchange	NOUN	O	O
Communication	NOUN	O	O
System	NOUN	O	O
(	PUNCT	O	O
PECS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
children	NOUN	O	O
had	PUNCT	O	O
access	NOUN	O	O
to	ADP	O	O
picture	NOUN	O	O
symbols	ADJ	O	O
during	ADP	O	O
assessments	NOUN	O	O
.	PUNCT	O	O

Post-treatment	ADJ	O	O
measurement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
number	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
picture	NOUN	O	I-MENTAL
exchanges	ADJ	O	I-MENTAL
in	ADP	O	I-MENTAL
a	DET	O	I-MENTAL
far-transfer	NOUN	O	I-MENTAL
,	PUNCT	O	O
assessment	NOUN	O	O
context	NOUN	O	O
favored	PUNCT	O	O
the	DET	O	O
PECS	NOUN	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
were	VERB	O	O
interpreted	VERB	O	O
as	PUNCT	O	O
support	NOUN	O	O
for	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
PECS	NOUN	O	O
curriculum	NOUN	O	O
can	VERB	O	O
successfully	VERB	O	O
teach	PUNCT	O	O
a	DET	O	O
generalized	VERB	O	O
means	NOUN	O	O
of	ADP	O	O
showing	PUNCT	O	O

Women	NOUN	O	O
's	PUNCT	O	O
responses	DET	O	O
to	ADP	O	O
information	NOUN	O	O
on	ADP	O	O
mammographic	ADJ	O	O
breast	NOUN	O	O
density	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
negative	ADJ	O	O
and	CCONJ	O	O
positive	ADJ	O	O
outcomes	NOUN	O	O
of	ADP	O	O
providing	VERB	O	O
mammographic	ADJ	O	O
breast	NOUN	O	O
density	NOUN	O	O
(	PUNCT	O	O
MBD	NOUN	O	O
)	PUNCT	O	O
information	NOUN	O	O
to	ADP	O	O
participants	NOUN	O	O
of	ADP	O	O
a	DET	O	O
screening	VERB	O	O
program	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
experiment	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
with	ADP	O	O
a	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
618	NUM	O	O
women	NOUN	O	O
50	NUM	O	O
years	NOUN	O	O
or	CCONJ	O	O
older	PUNCT	O	O
with	ADP	O	O
MBD	NOUN	O	O
greater	PUNCT	O	O
than	VERB	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
breast	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
consisted	ADJ	O	O
of	ADP	O	O
reporting	SYM	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
MBD	NOUN	O	O
in	ADP	O	O
the	DET	O	O
screening	VERB	O	O
mammography	NOUN	O	O
results	PUNCT	O	O
letter	NOUN	O	O
that	PUNCT	O	O
was	VERB	O	O
sent	NOUN	O	O
along	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
information	NOUN	O	O
pamphlet	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
,	PUNCT	O	O
more	DET	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
described	VERB	O	O
the	DET	O	O
term	NOUN	O	O
breast	NOUN	O	B-PHYSICAL
density	NOUN	O	I-PHYSICAL
correctly	ADV	O	O
and	CCONJ	O	O
recognized	ADP	O	O
it	VERB	O	O
as	CCONJ	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
at	ADP	O	O
the	DET	O	O
4-week	NOUN	O	O
follow-up	NOUN	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
they	PRON	O	O
were	VERB	O	O
very	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
an	DET	O	O
annual	ADJ	O	O
clinical	ADJ	O	O
breast	NOUN	O	O
examination	NOUN	O	O
more	ADV	O	O
frequently	ADV	O	O
than	PUNCT	O	O
controls	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
on	ADP	O	O
other	ADJ	O	O
behavioural	ADJ	O	B-MENTAL
or	CCONJ	O	I-MENTAL
psychological	ADJ	O	I-MENTAL
measures	NOUN	O	I-MENTAL
,	PUNCT	O	O
although	ADP	O	O
at	ADP	O	O
the	DET	O	O
4-week	NOUN	O	O
follow-up	NOUN	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
perceived	ADP	O	O
their	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
relative	ADJ	O	O
to	ADP	O	O
other	ADJ	O	O
women	ADP	O	O
their	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
lot	NOUN	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
did	PUNCT	O	O
women	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
demonstrate	VERB	O	O
a	DET	O	O
feasible	ADJ	O	O
and	CCONJ	O	O
non-threatening	PUNCT	O	O
way	NOUN	O	O
to	ADV	O	O
provide	NOUN	O	O
women	NOUN	O	O
with	ADP	O	O
important	ADJ	O	O
personalized	DET	O	O
information	NOUN	O	O
about	PUNCT	O	O
breast	NOUN	O	B-PHYSICAL
cancer	NOUN	O	I-PHYSICAL
risk	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
6	NUM	O	O
minute	ADJ	O	O
walk	NOUN	O	O
in	ADP	O	O
idiopathic	ADJ	O	O
pulmonary	ADJ	O	O
fibrosis	NOUN	O	O
:	PUNCT	O	O
longitudinal	ADJ	O	O
changes	NOUN	O	O
and	CCONJ	O	O
minimum	NOUN	O	O
important	ADJ	O	O
difference	NOUN	O	O
.	PUNCT	O	O

RATIONALE	NOUN	O	O
The	DET	O	O
response	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
6	NUM	O	O
minute	ADJ	O	O
walk	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
6MWT	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
studies	NOUN	O	O
of	ADP	O	O
idiopathic	ADJ	O	O
pulmonary	ADJ	O	O
fibrosis	NOUN	O	O
(	PUNCT	O	O
IPF	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
only	ADV	O	O
poorly	ADV	O	O
understood	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
walk	NOUN	O	O
distance	NOUN	O	O
that	PUNCT	O	O
constitutes	NOUN	O	O
the	DET	O	O
minimum	NOUN	O	O
important	ADJ	O	O
difference	NOUN	O	O
(	PUNCT	O	O
MID	NOUN	O	O
)	PUNCT	O	O
over	PUNCT	O	O
time	NOUN	O	O
is	VERB	O	O
unknown	VERB	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
examine	NOUN	O	O
changes	NOUN	O	O
over	PUNCT	O	O
time	NOUN	O	B-MENTAL
in	ADP	O	I-MENTAL
distance	NOUN	O	O
walked	CCONJ	O	B-MENTAL
(	PUNCT	O	O
ie	ADP	O	O
,	PUNCT	O	O
6MWD	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
6MWT	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
estimate	NOUN	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
distance	NOUN	O	O
that	PUNCT	O	O
constitutes	NOUN	O	O
the	DET	O	O
MID	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
IPF	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Data	NOUN	O	O
from	ADP	O	O
a	DET	O	O
recently	ADV	O	O
completed	VERB	O	O
trial	NOUN	O	O
that	ADP	O	O
included	PUNCT	O	O
subjects	NOUN	O	O
with	ADP	O	O
IPF	NOUN	O	O
who	ADP	O	O
completed	VERB	O	O
the	DET	O	O
6MWT	NOUN	O	O
,	PUNCT	O	O
Saint	NOUN	O	O
George	NOUN	O	O
's	PUNCT	O	O
Respiratory	ADJ	O	O
Questionnaire	NOUN	O	O
(	PUNCT	O	O
SGRQ	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
forced	VERB	O	O
vital	ADJ	O	O
capacity	NOUN	O	O
(	PUNCT	O	O
FVC	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
longitudinal	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
6MWD	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
anchor-	NOUN	O	O
and	CCONJ	O	O
distribution-based	VERB	O	O
approaches	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
linear	ADJ	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
MID	NOUN	O	O
for	ADP	O	O
6MWD	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
SGRQ	NOUN	O	B-OTHER
Total	ADP	O	O
score	NOUN	O	O
and	PUNCT	O	O

Motion	NOUN	O	O
aftereffects	VERB	O	O
with	ADP	O	O
horizontally	ADJ	O	O
moving	DET	O	O
sound	ADJ	O	O
sources	NOUN	O	O
in	ADP	O	O
the	DET	O	O
free	ADJ	O	O
field	NOUN	O	O
.	PUNCT	O	O

A	PUNCT	O	O
horizontally	ADJ	O	O
moving	VERB	O	O
sound	ADJ	O	O
was	VERB	O	O
presented	VERB	O	O
to	ADP	O	O
an	DET	O	O
observer	NOUN	O	O
seated	VERB	O	O
in	ADP	O	O
the	DET	O	O
center	NOUN	O	O
of	ADP	O	O
an	DET	O	O
anechoic	PUNCT	O	O
chamber	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sound	ADJ	O	O
,	PUNCT	O	O
either	PUNCT	O	O
a	DET	O	O
500-Hz	PUNCT	O	O
low-pass	NOUN	O	O
noise	NOUN	O	O
or	CCONJ	O	O
a	PUNCT	O	O
6300-Hz	ADP	O	O
high-pass	NOUN	O	O
noise	NOUN	O	O
,	PUNCT	O	O
repeatedly	ADV	O	O
traversed	PUNCT	O	O
a	DET	O	O
semicircular	ADJ	O	O
arc	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
observer	NOUN	O	O
's	PUNCT	O	O
front	NOUN	O	O
hemifield	PUNCT	O	O
at	ADP	O	O
ear	NOUN	O	O
level	NOUN	O	O
(	PUNCT	O	O
distance	NOUN	O	O
:	PUNCT	O	O
1.5	NUM	O	O
m	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
10-sec	ADJ	O	O
intervals	NOUN	O	O
this	PUNCT	O	O
adaptor	NOUN	O	O
was	VERB	O	O
interrupted	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
750-msec	NOUN	O	O
moving	VERB	O	O
probe	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
500-Hz	PUNCT	O	O
low-pass	NOUN	O	O
noise	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
presented	VERB	O	O
from	ADP	O	O
a	DET	O	O
horizontal	ADJ	O	O
arc	PUNCT	O	O
1.6	NUM	O	O
m	NOUN	O	O
in	ADP	O	O
front	NOUN	O	O
of	ADP	O	O
the	DET	O	O
observer	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
run	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
adaptor	NOUN	O	O
was	VERB	O	O
presented	VERB	O	O
at	ADP	O	O
a	DET	O	O
constant	ADJ	O	O
velocity	NOUN	O	O
(	PUNCT	O	O
-200	ADP	O	O
degrees	NOUN	O	O
to	PUNCT	O	O
+200	PUNCT	O	O
degrees/sec	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
probes	NOUN	O	O
with	ADP	O	O
velocities	NOUN	O	O
varying	PUNCT	O	O
from	ADP	O	O
-10	NUM	O	O
degrees	NOUN	O	O
to	ADP	O	O
+10	NUM	O	O
degrees/sec	PUNCT	O	O
were	VERB	O	O
presented	VERB	O	O
in	ADP	O	O
a	DET	O	O
random	ADJ	O	O
order	NOUN	O	O
.	PUNCT	O	O

Observers	CCONJ	O	O
judged	ADP	O	O
the	DET	O	O
direction	NOUN	O	O
of	ADP	O	O
motion	NOUN	O	O
(	PUNCT	O	O
left	PUNCT	O	O
or	CCONJ	O	O
right	ADJ	O	O
)	PUNCT	O	O
of	ADP	O	O
each	DET	O	O
probe	NOUN	O	O
.	PUNCT	O	O

As	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
stimuli	NOUN	O	O
presented	VERB	O	O
over	ADP	O	O
headphones	NOUN	O	O
(	PUNCT	O	O
Grantham	PUNCT	O	O
&	CCONJ	O	O
Wightman	NOUN	O	O
,	PUNCT	O	O
1979	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
auditory	ADJ	O	B-PHYSICAL
motion	NOUN	O	I-PHYSICAL
aftereffect	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
MAE	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
occurred	VERB	O	O
:	PUNCT	O	O
subjects	NOUN	O	O
responded	VERB	O	O
left	PUNCT	O	O
to	PUNCT	O	O
probes	ADJ	O	O
more	ADV	O	O
often	ADV	O	O
when	ADP	O	O
the	DET	O	O
adaptor	ADJ	O	O
moved	PART	O	O
right	ADJ	O	O
than	ADP	O	O
when	CCONJ	O	O
it	NOUN	O	O
moved	ADV	O	O
left	ADV	O	O
.	PUNCT	O	O

When	ADP	O	O
the	DET	O	O
adaptor	ADJ	O	O
and	CCONJ	O	O
probe	NOUN	O	O
were	VERB	O	O
spectrally	ADV	O	O
the	DET	O	O
same	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
MAE	NOUN	O	B-PHYSICAL
was	VERB	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
when	CCONJ	O	O
they	PRON	O	O
were	SYM	O	O
from	ADP	O	O
different	ADJ	O	O
spectral	ADJ	O	O
regions	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
this	DET	O	O
difference	NOUN	O	O
depended	VERB	O	O
on	ADP	O	O
adaptor	PUNCT	O	O
speed	NOUN	O	O
and	CCONJ	O	O
was	ADV	O	O
subject-dependent	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
proposed	VERB	O	O
that	ADP	O	O
there	PUNCT	O	O
are	VERB	O	O
two	NUM	O	O
components	NOUN	O	O
underlying	ADV	O	O
the	DET	O	O
auditory	ADJ	O	O
MAE	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
generalized	VERB	O	O
bias	NOUN	O	O
to	PART	O	O
respond	PUNCT	O	O
that	ADP	O	O
probes	NOUN	O	O
move	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
direction	ADJ	O	O
opposite	CCONJ	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
adaptor	ADJ	O	O
,	PUNCT	O	O
independent	ADJ	O	O
of	ADP	O	O
their	DET	O	O
spectra	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
the	DET	O	O
velocity	NOUN	O	O
of	ADP	O	O
moving	PROPN	O	O
sounds	NOUN	O	O
after	ADP	O	O
prolonged	VERB	O	O
exposure	NOUN	O	O
to	PUNCT	O	O
moving	PUNCT	O	O
sounds	NOUN	O	O
having	ADJ	O	O
the	DET	O	O
same	ADJ	O	O
spectral	ADJ	O	O
content	NOUN	O	O
.	PUNCT	O	O

Dietary	ADJ	O	O
sodium	NOUN	O	O
intake	NOUN	O	O
modulates	NOUN	O	O
myocardial	ADJ	O	B-PHYSICAL
relaxation	NOUN	O	I-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
to	ADP	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
.	PUNCT	O	O

Dietary	ADJ	O	O
sodium	NOUN	O	O
alters	VERB	O	O
renovascular	ADJ	O	O
responsiveness	NOUN	O	O
to	ADP	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
Ang	NOUN	O	O
II	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Evidence	NOUN	O	O
supports	NOUN	O	O
a	DET	O	O
connection	NOUN	O	O
among	ADP	O	O
dietary	ADJ	O	O
sodium	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rennin-angiotensin	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
myocardial	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
hypothesized	VERB	O	O
that	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
relationship	NOUN	O	O
would	VERB	O	O
exist	VERB	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
responses	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
qualitatively	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
vasculature	NOUN	O	O
.	PUNCT	O	O

Thirteen	PUNCT	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
(	PUNCT	O	O
aged	DET	O	O
38.6	NUM	O	O
+/-	SYM	O	O
4	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
entered	VERB	O	O
a	DET	O	O
2	NUM	O	O
week	NOUN	O	O
crossover	NOUN	O	O
design	NOUN	O	O
study	NOUN	O	O
(	PUNCT	O	O
week	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
high	ADJ	O	O
sodium	NOUN	O	O
diet	NOUN	O	O
[	PUNCT	O	O
HS	NOUN	O	O
]	PUNCT	O	O
>	SYM	O	O
200	NUM	O	O
mmol	NOUN	O	O
Na/day	NOUN	O	O
;	PUNCT	O	O
week	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
low	ADJ	O	O
sodium	NOUN	O	O
diet	NOUN	O	O
[	PUNCT	O	O
LS	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
<	ADP	O	O
10	NUM	O	O
mmol	NOUN	O	O
Na/day	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
sodium	NOUN	O	O
and	CCONJ	O	O
Ang	NOUN	O	O
II	NUM	O	O
on	ADP	O	O
myocardial	ADJ	O	O
relaxation	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
RBF	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
each	DET	O	O
study	NOUN	O	O
week	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
assessed	VERB	O	O
diastolic	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
myocardial	ADJ	O	B-PHYSICAL
relaxation	NOUN	O	I-PHYSICAL
velocities	NOUN	O	I-PHYSICAL
[	PUNCT	O	O
E	NOUN	O	O
'	PUNCT	O	O
]	PUNCT	O	O
using	VERB	O	O
tissue	NOUN	O	O
Doppler	NOUN	O	O
imaging	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
RBF	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
para-aminohippurate	NOUN	O	O
clearance	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
Ang	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
ng/kg/min	NOUN	O	O
x	SYM	O	O
45	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
HS	NOUN	O	O
diet	NOUN	O	O
,	PUNCT	O	O
E	NOUN	O	O
'	PUNCT	O	O
and	CCONJ	O	O
RBF	NOUN	O	B-PHYSICAL
were	VERB	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
on	ADP	O	O
LS	NOUN	O	O
diet	NOUN	O	O
(	PUNCT	O	O
E	NOUN	O	O
'	PUNCT	O	O
14.0	NUM	O	O
+/-	SYM	O	O
1.2	NUM	O	O
vs	CCONJ	O	O
12.6	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
cm/s	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
;	PUNCT	O	O
RBF	NOUN	O	O
596	NUM	O	O
+/-	SYM	O	O
24	NUM	O	O
vs	CCONJ	O	O
563	NUM	O	O
+/-	SYM	O	O
26	NUM	O	O
mL/min	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Dietary	ADJ	O	O
sodium	NOUN	O	O
significantly	ADV	O	O
modulated	PUNCT	O	O
E	NOUN	O	B-PHYSICAL
'	PUNCT	O	O
and	CCONJ	O	O
RBF	NOUN	O	B-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
to	ADP	O	O
Ang	NOUN	O	O
II	NUM	O	O
infusion	NOUN	O	O
in	ADP	O	O
like	ADP	O	O
manner	NOUN	O	O
.	PUNCT	O	O

HS	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
responsiveness	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
blunted	VERB	O	O
LS	NOUN	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
HS	NOUN	O	O
DeltaE	NOUN	O	O
'	PUNCT	O	O
-1.4	NUM	O	O
+/-	SYM	O	O
0.4	NUM	O	O
cm/s	NOUN	O	O
vs	CCONJ	O	O
LS	NOUN	O	O
DeltaE	NOUN	O	O
'	PUNCT	O	O
-0.1	NUM	O	O
+/-	SYM	O	O
0.3	NUM	O	O
cm/s	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
;	PUNCT	O	O
HS	NOUN	O	O
DeltaRBF	VERB	O	O
-135.2	NUM	O	O
+/-	SYM	O	O
13.2	NUM	O	O
vs	CCONJ	O	O
LS	NOUN	O	O
DeltaRBF	NOUN	O	O
-62.5	NUM	O	O
+/-	SYM	O	O
10.1	NUM	O	O
mL/min	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
describe	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
that	ADP	O	O
dietary	ADJ	O	O
sodium	NOUN	O	O
modulates	NOUN	O	O
myocardial	ADJ	O	B-PHYSICAL
relaxation	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
to	ADP	O	O
Ang	NOUN	O	O
II	NUM	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
consider	NOUN	O	O
dietary	ADJ	O	O
sodium	NOUN	O	O
intake	NOUN	O	O
when	ADP	O	O
assessing	VERB	O	O
diastolic	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Ang	NOUN	O	O
II	NUM	O	O
may	NOUN	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
dietary	ADJ	O	O
sodium	NOUN	O	O
and	CCONJ	O	O
myocardial	ADJ	O	B-PHYSICAL
relaxation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Future	ADJ	O	O
research	NOUN	O	O
will	VERB	O	O
investigate	PUNCT	O	O
whether	ADP	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
these	DET	O	O
mechanisms	NOUN	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
disorders	NOUN	O	O
of	ADP	O	O
diastolic	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
HCG	NOUN	O	O
supplementation	NOUN	O	O
after	ADP	O	O
combined	VERB	O	O
GnRH	NOUN	O	O
agonist/HMG	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
an	DET	O	O
IVF	NOUN	O	O
programme	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
necessity	NOUN	O	O
of	ADP	O	O
luteal-phase	NOUN	O	O
supplementation	NOUN	O	O
in	ADP	O	O
an	DET	O	O
IVF	NOUN	O	O
programme	NOUN	O	O
is	ADJ	O	O
of	ADP	O	O
continuing	VERB	O	O
interest	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
ovarian	ADJ	O	O
stimulation	NOUN	O	O
with	ADP	O	O
clomiphene	NOUN	O	O
and	CCONJ	O	O
human	NOUN	O	O
menopausal	ADJ	O	O
gonadotrophin	NOUN	O	O
(	PUNCT	O	O
HMG	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
supporting	PUNCT	O	O
the	DET	O	O
luteal	ADJ	O	O
phase	NOUN	O	O
has	VERB	O	O
never	ADV	O	O
been	PUNCT	O	O
scientifically	ADV	O	O
demonstrated	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
ovarian	ADJ	O	O
stimulation	NOUN	O	O
with	ADP	O	O
GnRH	NOUN	O	O
agonist/HMG	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
luteal	ADJ	O	O
phase	NOUN	O	O
seems	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
inadequate	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
a	DET	O	O
previous	ADJ	O	O
study	NOUN	O	O
we	PROPN	O	O
did	CCONJ	O	O
not	ADV	O	O
find	VERB	O	O
evidence	NOUN	O	O
to	PART	O	O
support	NOUN	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
oral	ADJ	O	O
progesterone	NOUN	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
chorionic	ADJ	O	O
gonadotrophin	NOUN	O	O
(	PUNCT	O	O
HCG	NOUN	O	O
)	PUNCT	O	O
supplementation	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
performed	VERB	O	O
a	DET	O	O
multicentre	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
with	ADP	O	O
HCG	NOUN	O	O
(	PUNCT	O	O
193	NUM	O	O
transfers	NOUN	O	O
)	PUNCT	O	O
against	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
194	NUM	O	O
transfers	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ongoing	VERB	O	B-PHYSICAL
pregnancy	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
per	ADP	O	I-PHYSICAL
transfer	NOUN	O	I-PHYSICAL
cycle	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
with	ADP	O	O
HCG	NOUN	O	O
(	PUNCT	O	O
18.7	NUM	O	O
versus	CCONJ	O	O
9.3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
truly	ADV	O	O
objective	PUNCT	O	O
(	PUNCT	O	O
randomized	PUNCT	O	O
)	PUNCT	O	O
study	NOUN	O	O
demonstrating	VERB	O	O
the	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
supporting	PUNCT	O	O
the	DET	O	O
luteal	ADJ	O	O
phase	NOUN	O	O
in	ADP	O	O
an	DET	O	O
IVF	NOUN	O	O
programme	NOUN	O	O
.	PUNCT	O	O

Corticosteroid-induced	VERB	O	O
osteopenia	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
vitamin	NOUN	O	B-PHYSICAL
D	NOUN	O	I-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
D2	NOUN	O	O
,	PUNCT	O	O
calcium	NOUN	O	O
phosphate	NOUN	O	O
and	CCONJ	O	O
sodium	NOUN	O	O
fluoride	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Thirty-one	NUM	O	O
patients	NOUN	O	O
scheduled	DET	O	O
for	ADP	O	O
long-term	NOUN	O	O
(	PUNCT	O	O
24	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
prednisone	NOUN	O	O
in	ADP	O	O
comparatively	ADV	O	O
high	ADJ	O	O
doses	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
two	NUM	O	O
further	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
A	NOUN	O	O
received	ADP	O	O
prednisone	NOUN	O	O
plus	CCONJ	O	O
'triple-treatment	PUNCT	O	O
'	PUNCT	O	O
(	PUNCT	O	O
vitamin	NOUN	O	O
D2	NOUN	O	O
45000	NUM	O	O
iu	PUNCT	O	O
twice	ADV	O	O
weekly	ADV	O	O
,	PUNCT	O	O
sodium	NOUN	O	O
fluoride	NOUN	O	O
50	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
calcium	NOUN	O	O
phosphate	NOUN	O	O
4.5	NUM	O	O
g	ADP	O	O
daily	CCONJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
received	VERB	O	O
only	ADV	O	O
prednisone	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
prednisone-	NOUN	O	O
and	CCONJ	O	O
triple-treatment	PUNCT	O	O
upon	ADP	O	O
bone	NOUN	O	B-PHYSICAL
mineral	NOUN	O	I-PHYSICAL
content	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BMC	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
vitamin	NOUN	O	B-PHYSICAL
D	NOUN	O	I-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
groups	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
and	CCONJ	O	O
prednisone	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

BMC	NOUN	O	B-PHYSICAL
fell	ADP	O	O
rapidly	ADV	O	O
and	CCONJ	O	O
similarly	ADV	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
demonstrating	VERB	O	O
that	PUNCT	O	O
the	DET	O	O
triple-treatment	PUNCT	O	O
has	PUNCT	O	O
no	DET	O	O
preventive	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
corticosteroid	NOUN	O	O
induced	VERB	O	O
osteopenia	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
25OHD2	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
25OHD3	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
1,25	ADP	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
OH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
2D	NOUN	O	I-PHYSICAL
were	VERB	O	O
unchanged	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
without	ADP	O	O
triple-treatment	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
25OHD2	NOUN	O	B-PHYSICAL
increased	VERB	O	O
enormously	ADV	O	O
,	PUNCT	O	O
25OHD3	NOUN	O	B-PHYSICAL
was	VERB	O	O
suppressed	ADJ	O	O
possibly	ADV	O	O
by	ADP	O	O
substrate	NOUN	O	O
competition	NOUN	O	O
for	ADP	O	O
hydroxylation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
and	CCONJ	O	O
1,25	ADP	O	O
(	PUNCT	O	B-PHYSICAL
OH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
2D	NOUN	O	I-PHYSICAL
was	VERB	O	O
halved	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
suppression	NOUN	O	O
of	ADP	O	O
1,25	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
OH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
2D	NOUN	O	I-PHYSICAL
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
raised	VERB	O	O
25OHD2	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
corticosteroid	NOUN	O	O
excess	NOUN	O	O
.	PUNCT	O	O

Citalopram	NOUN	O	O
for	ADP	O	O
post-stroke	NOUN	O	O
pathological	ADJ	O	O
crying	NOUN	O	O
.	PUNCT	O	O

Post-stroke	NOUN	O	O
pathological	ADJ	O	O
crying	PUNCT	O	O
is	NOUN	O	O
a	DET	O	O
distressing	VERB	O	O
condition	NOUN	O	O
in	ADP	O	O
which	PUNCT	O	O
episodes	PUNCT	O	O
occur	VERB	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
minor	ADJ	O	O
stimuli	NOUN	O	O
without	ADP	O	O
associated	ADP	O	O
mood	PUNCT	O	O
changes	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
is	VERB	O	O
preliminary	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
disturbed	PUNCT	O	O
serotoninergic	ADJ	O	O
neurotransmission	NOUN	O	O
in	ADP	O	O
such	DET	O	O
cases	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
selective	ADJ	O	B-PHYSICAL
serotonin	NOUN	O	I-PHYSICAL
reuptake	NOUN	O	I-PHYSICAL
inhibitor	NOUN	O	I-PHYSICAL
citalopram	NOUN	O	I-PHYSICAL
on	ADP	O	O
uncontrolled	PUNCT	O	B-MENTAL
crying	NUM	O	I-MENTAL
in	ADP	O	O
stroke	NOUN	O	O
patients	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	DET	O	O
crossover	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

16	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
58.5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
range	NOUN	O	O
40-83	PUNCT	O	O
)	PUNCT	O	O
entered	VERB	O	O
the	DET	O	O
9-week	NOUN	O	O
study	PUNCT	O	O
a	DET	O	O
median	ADJ	O	O
of	ADP	O	O
168	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
6-913	ADV	O	O
)	PUNCT	O	O
post	PUNCT	O	O
stroke	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
citalopram	NOUN	O	O
10-20	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Crying	ADV	O	B-MENTAL
history	NOUN	O	I-MENTAL
was	VERB	O	O
determined	VERB	O	O
from	ADP	O	O
semistructured	DET	O	O
interviews	NOUN	O	O
and	CCONJ	O	O
from	ADP	O	O
diaries	NOUN	O	O
kept	PUNCT	O	O
by	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Psychiatric	ADJ	O	B-MENTAL
assessment	NOUN	O	I-MENTAL
was	VERB	O	O
made	VERB	O	O
with	ADP	O	O
the	DET	O	O
Hamilton	PUNCT	O	B-MENTAL
depression	NOUN	O	I-MENTAL
scale	NOUN	O	I-MENTAL
(	PUNCT	O	O
HDS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
unwanted	VERB	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
the	DET	O	O
UKU	NOUN	O	B-ADVERSE-EFFECTS
side-effect	NOUN	O	I-ADVERSE-EFFECTS
scale	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

In	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	ADP	O	O
frequency	NOUN	O	O
of	ADP	O	O
crying	NOUN	O	B-MENTAL
could	PUNCT	O	O
be	VERB	O	O
assessed	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
daily	PUNCT	O	B-MENTAL
crying	PUNCT	O	I-MENTAL
episodes	NOUN	O	I-MENTAL
decreased	VERB	O	O
by	ADP	O	O
at	ADP	O	O
least	ADV	O	O
50	NUM	O	O
%	SYM	O	O
in	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
during	ADP	O	O
citalopram	NOUN	O	O
treatment	NOUN	O	O
vs	CCONJ	O	O
2	NUM	O	O
patients	NOUN	O	O
during	ADP	O	O
placebo	NOUN	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.005	NUM	O	O
,	PUNCT	O	O
McNemar	NOUN	O	O
's	PUNCT	O	O
test	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
being	ADP	O	O
rapid	ADJ	O	O
(	PUNCT	O	O
1-3	PUNCT	O	O
days	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
pronounced	VERB	O	O
in	ADP	O	O
11	NUM	O	O
(	PUNCT	O	O
73	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
concomitant	ADJ	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
depression	NOUN	O	B-MENTAL
rating	PUNCT	O	I-MENTAL
from	ADP	O	O
HDS	NOUN	O	O
8.9	NUM	O	O
to	ADP	O	O
5.3	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.005	NUM	O	O
,	PUNCT	O	O
Wilcoxon	NOUN	O	O
's	PUNCT	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Citalopram	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
few	ADJ	O	O
side-effects	NOUN	O	O
being	VERB	O	O
mild	ADJ	O	O
and	CCONJ	O	O
transient	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
serotoninergic	ADJ	O	O
neurotransmission	NOUN	O	O
plays	NOUN	O	O
an	DET	O	O
important	ADJ	O	O
part	NOUN	O	O
in	ADP	O	O
post-stroke	NOUN	O	O
pathological	ADJ	O	O
crying	PROPN	O	O
and	CCONJ	O	O
that	ADP	O	O
citalopram	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well-tolerated	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
prolactin	NOUN	O	O
and	CCONJ	O	O
oxytocin	NOUN	O	O
responses	NOUN	O	O
and	CCONJ	O	O
milk	NOUN	O	B-PHYSICAL
yield	NOUN	O	I-PHYSICAL
to	ADP	O	O
infant	NOUN	O	O
suckling	PUNCT	O	O
and	CCONJ	O	O
artificial	ADJ	O	B-OTHER
methods	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
expression	NOUN	O	I-OTHER
in	ADP	O	O
lactating	DET	O	O
women	NOUN	O	O
.	PUNCT	O	O

Breast-feeding	ADJ	O	O
is	VERB	O	O
today	NOUN	O	O
the	DET	O	O
major	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
infant	NOUN	O	O
nutrition	NOUN	O	O
in	ADP	O	O
the	DET	O	O
immediate	ADJ	O	O
postpartum	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
this	PUNCT	O	O
,	PUNCT	O	O
recent	ADJ	O	O
trends	NOUN	O	O
in	ADP	O	O
modern	ADJ	O	O
life-styles	NOUN	O	O
have	PUNCT	O	O
raised	VERB	O	O
obstacles	ADJ	O	O
to	ADP	O	O
successful	ADJ	O	O
lactation	NOUN	O	O
.	PUNCT	O	O

These	CCONJ	O	O
include	VERB	O	O
infant	NOUN	O	O
illness	NOUN	O	O
and	CCONJ	O	O
maternal	ADJ	O	O
responsibilities	NOUN	O	O
outside	ADP	O	O
the	DET	O	O
home	NOUN	O	O
,	PUNCT	O	O
both	PUNCT	O	O
requiring	ADJ	O	O
separation	NOUN	O	O
from	ADP	O	O
the	DET	O	O
mother	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
hormonal	ADJ	O	O
dynamics	NOUN	O	O
of	ADP	O	O
infant	NOUN	O	O
suckling	PUNCT	O	O
are	VERB	O	O
understood	VERB	O	O
,	PUNCT	O	O
little	PUNCT	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
artificial	ADJ	O	O
methods	NOUN	O	O
of	ADP	O	O
milk	NOUN	O	B-OTHER
expression	NOUN	O	I-OTHER
.	PUNCT	O	O

A	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	O
pumps	NOUN	O	O
exist	VERB	O	O
in	ADP	O	O
the	DET	O	O
current	ADJ	O	O
US	PUNCT	O	O
market	NOUN	O	O
which	ADP	O	O
vary	VERB	O	O
considerably	ADV	O	O
in	ADP	O	O
price	NOUN	O	O
and	CCONJ	O	O
effectiveness	NOUN	O	O
.	PUNCT	O	O

To	ADJ	O	O
understand	ADJ	O	O
better	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
these	DET	O	O
pumps	NOUN	O	O
to	PART	O	O
assist	ADJ	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
lactation	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	ADJ	O	O
evaluate	NOUN	O	O
their	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
milk	NOUN	O	O
yield	NOUN	O	O
and	CCONJ	O	O
prolactin	NOUN	O	O
and	CCONJ	O	O
oxytocin	NOUN	O	B-OTHER
release	NOUN	O	I-OTHER
when	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
natural	ADJ	O	O
infant	NOUN	O	O
suckling	PUNCT	O	O
.	PUNCT	O	O

Twenty-three	DET	O	O
women	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
exclusively	ADV	O	O
breast-feeding	ADP	O	O
their	ADP	O	O
infants	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
serially	ADV	O	O
use	PUNCT	O	O
several	ADJ	O	O
pumping	PUNCT	O	O
methods	NOUN	O	O
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	PUNCT	O	O
infant	NOUN	O	O
suckling	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
blood	NOUN	O	O
being	ADV	O	O
taken	VERB	O	O
at	ADP	O	O
10-minute	PUNCT	O	O
intervals	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
hormonal	ADJ	O	O
responses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
reveal	VERB	O	O
variability	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prolactin	NOUN	O	B-OTHER
responses	NOUN	O	I-OTHER
to	ADP	O	O
the	DET	O	O
artificial	ADJ	O	O
pumping	PUNCT	O	O
methods	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
greatest	PUNCT	O	O
responses	NOUN	O	O
found	VERB	O	O
with	ADP	O	O
an	DET	O	O
electric	ADJ	O	O
pulsatile	ADJ	O	O
pump	NOUN	O	O
;	PUNCT	O	O
these	DET	O	O
responses	NOUN	O	O
compare	NUM	O	O
favorably	ADV	O	O
with	ADP	O	O
those	PUNCT	O	O
of	ADP	O	O
natural	ADJ	O	O
infant	NOUN	O	O
suckling	PUNCT	O	O
.	PUNCT	O	O

Other	ADJ	O	O
methods	NOUN	O	O
were	VERB	O	O
less	ADV	O	O
successful	ADJ	O	O
in	ADP	O	O
causing	VERB	O	O
prolactin	NOUN	O	B-OTHER
elevations	NOUN	O	I-OTHER
.	PUNCT	O	O

No	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
among	ADP	O	O
the	DET	O	O
methods	NOUN	O	O
in	ADP	O	O
the	DET	O	O
oxytocin	NOUN	O	B-OTHER
response	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
demonstrate	PART	O	O
striking	VERB	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
breast-pumping	VERB	O	O
methods	NOUN	O	O
to	PART	O	O
produce	NOUN	O	O
an	DET	O	O
acute	ADJ	O	B-OTHER
and	CCONJ	O	I-OTHER
sustained	VERB	O	I-OTHER
prolactin	NOUN	O	I-OTHER
rise	NOUN	O	I-OTHER
in	ADP	O	O
breast-feeding	PUNCT	O	O
mothers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
large	ADJ	O	O
discrepancies	NOUN	O	O
found	VERB	O	O
suggest	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
further	PUNCT	O	O
studies	NOUN	O	O
in	ADP	O	O
to	PUNCT	O	O
enable	NOUN	O	O
women	NOUN	O	O
and	CCONJ	O	O
health	NOUN	O	O
care	NOUN	O	O
providers	NOUN	O	O
to	ADP	O	O
choose	NOUN	O	O
the	DET	O	O
most	PUNCT	O	O
appropriate	ADJ	O	O
method	NOUN	O	O
for	ADP	O	O
milk	NOUN	O	O
expression	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

Yoga	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
mood	ADP	O	B-MENTAL
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
in	ADP	O	O
Chinese	NOUN	O	O
women	NOUN	O	O
undergoing	VERB	O	O
heroin	ADJ	O	O
detoxification	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Yoga	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
mind-body	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
improving	VERB	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
diseases	NOUN	O	O
,	PUNCT	O	O
yet	ADV	O	O
little	PUNCT	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
its	PUNCT	O	O
effectiveness	NOUN	O	O
in	ADP	O	O
female	NOUN	O	O
heroin	NOUN	O	O
addicts	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
yoga	NOUN	O	O
on	ADP	O	O
mood	PUNCT	O	O
status	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
among	ADP	O	O
women	NOUN	O	O
undergoing	VERB	O	O
detoxification	NOUN	O	O
for	ADP	O	O
heroin	ADJ	O	O
dependence	NOUN	O	O
in	ADP	O	O
China	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Seventy-five	ADJ	O	O
women	NOUN	O	O
aged	ADP	O	O
20-37	NUM	O	O
years	NOUN	O	O
undergoing	VERB	O	O
detoxification	NOUN	O	O
for	ADP	O	O
heroin	ADJ	O	O
dependence	NOUN	O	O
at	ADP	O	O
AnKang	NOUN	O	O
Hospital	NOUN	O	O
were	VERB	O	O
allocated	VERB	O	O
randomly	ADV	O	O
into	ADP	O	O
an	DET	O	O
intervention	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
a	DET	O	O
6-month	NOUN	O	O
yoga	NOUN	O	O
intervention	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
hospital	NOUN	O	O
routine	ADJ	O	O
care	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
hospital	NOUN	O	O
routine	ADJ	O	O
care	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Mood	DET	O	O
status	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
using	VERB	O	O
the	DET	O	O
Profile	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
Mood	PUNCT	O	I-MENTAL
States	NOUN	O	I-MENTAL
and	CCONJ	O	O
Medical	ADJ	O	B-MENTAL
Outcomes	NOUN	O	I-MENTAL
Study	ADP	O	I-MENTAL
36-item	NOUN	O	I-MENTAL
Short-Form	NOUN	O	I-MENTAL
Health	NOUN	O	I-MENTAL
Survey	NOUN	O	I-MENTAL
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
following	VERB	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Repeated-measures	VERB	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
mood	ADP	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
Most	PUNCT	O	O
female	NOUN	O	O
heroin	NOUN	O	O
addicts	NOUN	O	O
were	VERB	O	O
young	ADP	O	O
and	CCONJ	O	O
single	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
low	ADJ	O	O
education	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

Most	ADV	O	O
had	PUNCT	O	O
used	ADP	O	O
heroin	CCONJ	O	O
by	ADP	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Mood	PUNCT	O	O
state	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
of	ADP	O	O
female	NOUN	O	O
heroin	NOUN	O	O
addicts	NOUN	O	O
were	VERB	O	O
poor	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
mood	PUNCT	O	O
status	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
over	PUNCT	O	O
time	NOUN	O	O
compared	PRON	O	O
with	ADP	O	O
their	ADP	O	O
counterparts	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Yoga	NOUN	O	O
may	PART	O	O
improve	ADJ	O	O
mood	PUNCT	O	O
status	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
for	ADP	O	O
women	NOUN	O	O
undergoing	VERB	O	O
detoxification	NOUN	O	O
for	ADP	O	O
heroin	ADJ	O	O
dependence	NOUN	O	O
.	PUNCT	O	O

Yoga	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
auxiliary	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
traditional	ADJ	O	O
hospital	NOUN	O	O
routine	ADJ	O	O
care	NOUN	O	O
for	ADP	O	O
these	DET	O	O
women	NOUN	O	O
.	PUNCT	O	O

Assessing	ADP	O	O
drug	NOUN	O	O
use	NOUN	O	O
prevalence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
workplace	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
self-report	ADJ	O	O
methods	NOUN	O	O
and	CCONJ	O	O
urinalysis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
random	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
800	NUM	O	O
employees	NOUN	O	O
of	ADP	O	O
a	DET	O	O
steel	NOUN	O	O
manufacturing	ADP	O	O
company	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
four	NUM	O	O
self-report	ADJ	O	O
methods	NOUN	O	O
of	ADP	O	O
assessing	VERB	O	O
illicit	NOUN	O	O
drug	NOUN	O	O
use	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
Individual	ADJ	O	O
interview	NOUN	O	O
in	ADP	O	O
the	DET	O	O
workplace	CCONJ	O	O
,	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
group-administered	VERB	O	O
questionnaire	NOUN	O	O
in	ADP	O	O
the	DET	O	O
workplace	CCONJ	O	O
,	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
telephone	NOUN	O	O
interview	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
)	PUNCT	O	O
individual	ADJ	O	O
interview	NOUN	O	O
off	ADP	O	O
the	DET	O	O
worksite	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
621	NUM	O	O
subjects	NOUN	O	O
participating	VERB	O	O
in	ADP	O	O
the	DET	O	O
research	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
tested	VERB	O	O
by	ADP	O	O
urinalysis	NOUN	O	O
.	PUNCT	O	O

Rates	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	B-MENTAL
use	ADV	O	I-MENTAL
self-report	ADJ	O	I-MENTAL
were	ADV	O	O
highest	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
workplace	CCONJ	O	O
interview	NOUN	O	O
condition	NOUN	O	O
and	CCONJ	O	O
lowest	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
group	NOUN	O	O
questionnaire	NOUN	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
overall	ADJ	O	B-OTHER
prevalence	NOUN	O	O
rates	NOUN	O	B-OTHER
produced	VERB	O	O
by	ADP	O	O
self-reports	NOUN	O	O
and	CCONJ	O	O
urinalysis	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
little	DET	O	O
concordance	NOUN	O	O
between	ADP	O	O
urinalysis	NOUN	O	B-OTHER
positives	NOUN	O	O
and	CCONJ	O	O
self-report	DET	O	B-MENTAL
positives	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
self-reports	VERB	O	O
and	CCONJ	O	O
urinalysis	NOUN	O	O
are	VERB	O	O
complementary	ADJ	O	O
methods	NOUN	O	O
of	PUNCT	O	O

Hemolytic	ADJ	O	O
streptococcus	NOUN	O	O
preparation	NOUN	O	O
OK-432	NOUN	O	O
;	PUNCT	O	O
beneficial	ADJ	O	O
adjuvant	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
recurrent	ADJ	O	O
gastric	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
hemolytic	ADJ	O	O
streptococcus	NOUN	O	O
preparation	NOUN	O	O
,	PUNCT	O	O
OK-432	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
thought	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
of	ADP	O	O
therapeutic	ADJ	O	O
value	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
through	ADP	O	O
a	DET	O	O
stimulatory	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
immune	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
any	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
such	CCONJ	O	O
an	ADP	O	O
administration	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
gastric	ADJ	O	O
cancer	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
group	NOUN	O	O
was	VERB	O	O
randomly	ADV	O	O
subdivided	VERB	O	O
into	ADP	O	O
3	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
Intradermal	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
ID	NOUN	O	O
Group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
42	NUM	O	O
patients	NOUN	O	O
given	VERB	O	O
an	DET	O	O
intradermal	VERB	O	O
injections	NOUN	O	O
of	ADP	O	O
OK-432	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
)	PUNCT	O	O
Intramuscular	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
IM	NOUN	O	O
Group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
40	NUM	O	O
patients	NOUN	O	O
given	VERB	O	O
an	DET	O	O
intramuscular	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
OK-432	NOUN	O	O
.	PUNCT	O	O

3	NUM	O	O
)	PUNCT	O	O
Control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
C	NOUN	O	O
Group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
39	NUM	O	O
patients	NOUN	O	O
not	ADV	O	O
given	PUNCT	O	O
injections	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
group	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
regards	ADP	O	O
to	ADP	O	O
the	DET	O	O
length	NOUN	O	B-MORTALITY
of	ADP	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
,	PUNCT	O	O
the	DET	O	O
host	NOUN	O	B-PHYSICAL
immune	ADJ	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
side	NOUN	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

When	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
IM	NOUN	O	O
and	CCONJ	O	O
C	NOUN	O	O
Groups	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
ID	NOUN	O	O
Group	NOUN	O	O
showed	VERB	O	O
improved	VERB	O	O
survival	NOUN	O	B-MORTALITY
.	PUNCT	O	O

Accompanying	PUNCT	O	O
this	ADP	O	O
improved	PUNCT	O	O
survival	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
ID	NOUN	O	O
Group	NOUN	O	O
also	ADV	O	O
had	PUNCT	O	O
greater	PUNCT	O	O
white	ADJ	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
lymphocyte	NOUN	O	I-PHYSICAL
counts	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
greater	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
T	NOUN	O	O
cells	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
more	DET	O	O
dramatic	ADJ	O	B-PHYSICAL
skin	NOUN	O	I-PHYSICAL
reaction	NOUN	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
extracted	ADP	O	O
cell	NOUN	O	O
wall	NOUN	O	O
polysaccharide	ADP	O	O
of	ADP	O	O
hemolytic	ADJ	O	O
streptococcus	NOUN	O	O
Su-strain	NOUN	O	O
(	PUNCT	O	O
Su-PS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ID	NOUN	O	O
Group	NOUN	O	O
,	PUNCT	O	O
following	CCONJ	O	O
OK-432	NOUN	O	O
injection	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
4.8	NUM	O	O
%	SYM	O	O
incidence	NOUN	O	O
of	ADP	O	O
fever	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
a	DET	O	O
52.4	NUM	O	O
%	SYM	O	O
incidence	NOUN	O	O
of	ADP	O	O
local	ADJ	O	B-PHYSICAL
abscess	NOUN	O	I-PHYSICAL
formation	NOUN	O	I-PHYSICAL
at	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
site	NOUN	O	O
.	PUNCT	O	O

90	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
IM	NOUN	O	O
Group	NOUN	O	O
developed	VERB	O	O
fever	NOUN	O	B-PHYSICAL
but	CCONJ	O	O
abscess	ADJ	O	B-PHYSICAL
formation	NOUN	O	I-PHYSICAL
was	VERB	O	O
absent	ADJ	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
these	DET	O	O
results	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
tested	VERB	O	O
,	PUNCT	O	O
intradermal	VERB	O	O
injection	NOUN	O	O
of	ADP	O	O
OK-432	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
clinically	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
intramuscular	ADJ	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Is	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
mobile	ADJ	O	O
phone	NOUN	O	O
radiofrequency	NOUN	O	O
waves	PUNCT	O	O
on	ADP	O	O
human	NOUN	O	O
skin	NOUN	O	O
perfusion	NOUN	O	O
non-thermal	ADJ	O	O
?	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
establish	ADJ	O	O
whether	ADP	O	O
SkBF	NOUN	O	B-PHYSICAL
can	VERB	O	O
be	VERB	O	O
modified	VERB	O	O
by	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
radiofrequency	NOUN	O	O
waves	PUNCT	O	O
emitted	PRON	O	O
by	ADP	O	O
a	DET	O	O
mobile	ADJ	O	O
phone	NOUN	O	O
when	ADP	O	O
the	DET	O	O
latter	NOUN	O	O
is	VERB	O	O
held	NOUN	O	O
against	ADP	O	O
the	DET	O	O
jaw	NOUN	O	O
and	CCONJ	O	O
ear	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Variations	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
SkBF	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
Tsk	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
volunteers	NOUN	O	O
were	VERB	O	O
simultaneously	ADV	O	O
recorded	VERB	O	O
with	ADP	O	O
a	DET	O	O
thermostatic	ADJ	O	O
laser	NOUN	O	O
Doppler	NOUN	O	O
system	NOUN	O	O
during	ADP	O	O
a	DET	O	O
20-minute	NOUN	O	O
radiofrequency	NOUN	O	O
exposure	NOUN	O	O
session	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
20-minute	NOUN	O	O
sham	ADJ	O	O
session	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
skin	NOUN	O	O
microvessels	NOUN	O	O
'	PUNCT	O	O
vasodilatory	ADJ	O	O
reserve	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
a	DET	O	O
heat	NOUN	O	O
challenge	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
During	ADP	O	O
the	DET	O	O
radiofrequency	NOUN	O	O
exposure	NOUN	O	O
session	NOUN	O	O
,	PUNCT	O	O
SkBF	NOUN	O	B-PHYSICAL
increased	VERB	O	O
(	PUNCT	O	O
vs.	CCONJ	O	O
baseline	NOUN	O	O
)	PUNCT	O	O
more	ADV	O	O
than	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
sham	ADJ	O	O
exposure	NOUN	O	O
session	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sessions	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
significant	ADJ	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Tsk	PUNCT	O	B-OTHER
time-course	PUNCT	O	I-OTHER
response	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
skin	NOUN	O	B-PHYSICAL
microvessels	NOUN	O	I-PHYSICAL
'	PUNCT	O	O
vasodilatory	ADJ	O	B-PHYSICAL
ability	NOUN	O	B-PHYSICAL
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
greater	PUNCT	O	O
during	ADP	O	O
radiofrequency	NOUN	O	O
exposure	NOUN	O	O
than	PUNCT	O	O
during	ADP	O	O
sham	ADJ	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	ADP	O	O
Our	PUNCT	O	O
results	NOUN	O	O
reveal	VERB	O	O
the	DET	O	O
existence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
specific	PUNCT	O	O

Vitamin	NOUN	O	O
A	DET	O	O
supplementation	NOUN	O	O
for	ADP	O	O
extremely-low-birth-weight	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

National	ADJ	O	O
Institute	NOUN	O	O
of	ADP	O	O
Child	NOUN	O	O
Health	NOUN	O	O
and	CCONJ	O	O
Human	NOUN	O	O
Development	NOUN	O	O
Neonatal	ADJ	O	O
Research	NOUN	O	O
Network	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Vitamin	NOUN	O	O
A	DET	O	O
supplementation	NOUN	O	O
may	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
lung	NOUN	O	O
disease	NOUN	O	O
and	CCONJ	O	O
sepsis	NOUN	O	O
in	ADP	O	O
extremely-low-birth-weight	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
our	VERB	O	O
pilot	NOUN	O	O
study	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5000	NUM	O	O
IU	NOUN	O	O
administered	PUNCT	O	O
intramuscularly	ADV	O	O
three	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
for	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
than	CCONJ	O	O
the	DET	O	O
lower	PUNCT	O	O
doses	NOUN	O	O
given	VERB	O	O
in	ADP	O	O
past	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
blinded	ADP	O	O
,	PUNCT	O	O
randomized	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
this	DET	O	O
regimen	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
sham	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
807	NUM	O	O
infants	NOUN	O	O
in	ADP	O	O
need	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
support	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
birth	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
birth	NOUN	O	B-PHYSICAL
weight	NOUN	O	I-PHYSICAL
was	VERB	O	O
770	NUM	O	O
g	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vitamin	NOUN	O	O
A	DET	O	O
group	NOUN	O	O
and	CCONJ	O	O
769	NUM	O	O
g	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
respective	ADJ	O	O
gestational	ADJ	O	O
ages	NOUN	O	O
were	VERB	O	O
26.8	NUM	O	O
and	CCONJ	O	O
26.7	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
By	ADP	O	O
36	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
postmenstrual	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
59	NUM	O	O
of	ADP	O	O
the	DET	O	O
405	NUM	O	O
infants	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
vitamin	NOUN	O	O
A	DET	O	O
group	NOUN	O	O
and	CCONJ	O	O
55	NUM	O	O
of	ADP	O	O
the	DET	O	O
402	NUM	O	O
infants	NOUN	O	O
(	PUNCT	O	O
14	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
died	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
-	PUNCT	O	O
death	NOUN	O	B-MORTALITY
or	CCONJ	O	I-MORTALITY
chronic	ADJ	O	I-MORTALITY
lung	NOUN	O	I-MORTALITY
disease	NOUN	O	I-MORTALITY
at	ADP	O	O
36	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
postmenstrual	ADJ	O	O
age	NOUN	O	O
-	PUNCT	O	O
occurred	PUNCT	O	O
in	ADP	O	O
significantly	ADV	O	O
fewer	PUNCT	O	O
infants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vitamin	NOUN	O	O
A	DET	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
55	NUM	O	O
percent	NOUN	O	O
vs.	CCONJ	O	O
62	NUM	O	O
percent	NOUN	O	O
;	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
,	PUNCT	O	O
0.89	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.80	NUM	O	O
to	ADP	O	O
0.99	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
1	NUM	O	O
additional	ADJ	O	O
infant	NOUN	O	O
survived	PUNCT	O	O
without	ADP	O	O
chronic	ADJ	O	B-MORTALITY
lung	NOUN	O	I-MORTALITY
disease	NOUN	O	I-MORTALITY
for	ADP	O	O
every	DET	O	O
14	NUM	O	O
to	ADP	O	O
15	NUM	O	O
infants	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
vitamin	NOUN	O	O
A	DET	O	O
supplements	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
proportions	NOUN	O	O
of	ADP	O	O
infants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vitamin	NOUN	O	O
A	DET	O	O
group	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
who	ADP	O	O
had	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
potential	ADJ	O	B-PHYSICAL
vitamin	NOUN	O	I-PHYSICAL
A	DET	O	I-PHYSICAL
toxicity	NOUN	O	I-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
proportion	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
infants	NOUN	O	I-PHYSICAL
with	ADP	O	I-PHYSICAL
serum	NOUN	O	O
retinol	NOUN	O	O
values	NOUN	O	O
below	ADP	O	O
20	NUM	O	O
microg	NOUN	O	O
per	ADP	O	O
deciliter	VERB	O	O
(	PUNCT	O	O
0.70	NUM	O	O
micromol	NOUN	O	O
per	ADP	O	O
liter	ADJ	O	O
)	PUNCT	O	O
was	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
vitamin	NOUN	O	O
A	DET	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
percent	NOUN	O	O
vs.	CCONJ	O	O
54	NUM	O	O
percent	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Intramuscular	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
5000	NUM	O	O
IU	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
A	CCONJ	O	O
three	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
for	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
reduced	ADV	O	O
biochemical	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
A	DET	O	O
deficiency	NOUN	O	O
and	CCONJ	O	O
slightly	ADV	O	O
decreased	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-MORTALITY
lung	NOUN	O	I-MORTALITY
disease	NOUN	O	I-MORTALITY
in	ADP	O	O
extremely-low-birth-weight	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Uncomplicated	DET	O	O
moderate	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
dissections	NOUN	O	O
after	ADP	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
:	PUNCT	O	O
good	ADJ	O	O
outcome	NOUN	O	O
without	ADP	O	O
stenting	VERB	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PART	O	O
study	NOUN	O	O
the	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
moderate	ADJ	O	O
coronary	ADJ	O	O
dissections	NOUN	O	O
,	PUNCT	O	O
coronary	ADJ	O	O
flow	NOUN	O	O
velocity	NOUN	O	O
reserve	NOUN	O	O
(	PUNCT	O	O
CFVR	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
long	ADJ	O	O
term	NOUN	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
523	NUM	O	O
patients	NOUN	O	O
undergoing	PRON	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
and	CCONJ	O	O
sequential	ADJ	O	O
intracoronary	ADJ	O	O
Doppler	NOUN	O	O
measurements	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DEBATE	NOUN	O	O
II	NUM	O	O
trial	NOUN	O	O
(	PUNCT	O	O
Doppler	NOUN	O	O
endpoints	NOUN	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
trial	NOUN	O	O
Europe	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
successful	ADJ	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
stenting	VERB	O	O
or	CCONJ	O	O
no	DET	O	O
further	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Dissections	NOUN	O	O
were	VERB	O	O
graded	VERB	O	O
at	ADP	O	O
the	DET	O	O
core	NOUN	O	O
laboratory	NOUN	O	O
by	ADP	O	O
two	NUM	O	O
observers	ADJ	O	O
and	CCONJ	O	O
divided	VERB	O	O
into	ADP	O	O
four	NUM	O	O
categories	NOUN	O	O
:	PUNCT	O	O
none	NUM	O	O
,	PUNCT	O	O
mild	ADJ	O	O
(	PUNCT	O	O
type	NOUN	O	O
A-B	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
moderate	ADJ	O	O
(	PUNCT	O	O
type	NOUN	O	O
C	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
severe	ADJ	O	O
(	PUNCT	O	O
types	NOUN	O	O
D	NOUN	O	O
to	ADP	O	O
F	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
dissections	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
128	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
without	ADP	O	O
available	ADJ	O	O
reference	NOUN	O	O
vessel	NOUN	O	O
CFVR	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
139	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
remaining	VERB	O	O
256	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
45	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
absence	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
211	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
moderate	ADJ	O	O
dissection	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Following	VERB	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
CFVR	NOUN	O	B-PHYSICAL
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
follow	VERB	O	O
up	ADP	O	O
,	PUNCT	O	O
a	DET	O	O
higher	PUNCT	O	O
rate	NOUN	O	O
of	ADP	O	O
major	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
cardiac	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
observed	NUM	O	O
overall	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
A	ADJ	O	O
than	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
(	PUNCT	O	O
22	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
v	NUM	O	O
23	NUM	O	O
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.041	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
major	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
subgroups	NOUN	O	O
receiving	VERB	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
(	PUNCT	O	O
19	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
v	DET	O	O
group	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
16	NUM	O	O
(	PUNCT	O	O
16	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
NS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
group	NOUN	O	O
A	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
risk	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
those	ADP	O	O
randomised	NOUN	O	O
to	ADP	O	O
stenting	PUNCT	O	O
(	PUNCT	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
6.603	NUM	O	O
v	NUM	O	O
1.197	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.046	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
risk	NOUN	O	O
if	ADP	O	O
the	DET	O	O
group	NOUN	O	O
was	VERB	O	O
analysed	VERB	O	O
according	PUNCT	O	O
to	ADP	O	O
whether	PUNCT	O	O
the	DET	O	O
CFVR	NOUN	O	O
was	VERB	O	O
<	ADV	O	O
2.5	NUM	O	O
or	CCONJ	O	O
>	NOUN	O	O
/=	ADP	O	O
2.5	NUM	O	O
after	ADP	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Moderate	ADJ	O	O
dissections	NOUN	O	O
left	PUNCT	O	O
untreated	VERB	O	O
result	ADJ	O	O
in	ADP	O	O
no	DET	O	O
increased	ADV	O	O
risk	NOUN	O	O
of	ADP	O	O
major	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
cardiac	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Additional	ADJ	O	O
stenting	ADP	O	O
does	PUNCT	O	O
not	ADV	O	O
improve	VERB	O	O
the	DET	O	O
long	ADJ	O	O
term	NOUN	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetics	NOUN	O	B-OTHER
and	CCONJ	O	I-OTHER
relative	ADJ	O	I-OTHER
bioavailability	NOUN	O	I-OTHER
of	ADP	O	O
prajmalium	NOUN	O	O
bitartrate	ADP	O	O
after	ADP	O	O
single	ADJ	O	O
oral	ADJ	O	O
dosing	VERB	O	O
.	PUNCT	O	O

Pharmacokinetics	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
relative	ADJ	O	B-PHYSICAL
bioavailability	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
marketed	VERB	O	O
prajmalium	NOUN	O	O
bitartrate	ADP	O	O
tablet	NOUN	O	O
(	PUNCT	O	O
Neo-Gilurytmal	PUNCT	O	O
,	PUNCT	O	O
CAS	NOUN	O	O
2589-47-1	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
an	DET	O	O
oral	ADJ	O	O
solution	NOUN	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
an	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
single-dose	NOUN	O	O
two-fold	NOUN	O	O
crossover	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
20	NUM	O	O
healthy	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
subject	NOUN	O	O
was	VERB	O	O
identified	VERB	O	O
to	PUNCT	O	O
be	PUNCT	O	O
a	DET	O	O
poor	ADJ	O	B-OTHER
metabolizer	NOUN	O	I-OTHER
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
study	ADV	O	O
population	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
metabolic	ADJ	O	O
status	NOUN	O	O
the	DET	O	O
two	NUM	O	O
oral	ADJ	O	O
formulations	NOUN	O	O
proved	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
bioequivalent	ADJ	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	B-PHYSICAL
parameters	ADJ	O	I-PHYSICAL
Cmax	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
AUC	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
0-Tlast	NUM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
AUC	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
0-infinity	NUM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
Ae	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
24h	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

tmax	ADJ	O	B-PHYSICAL
was	VERB	O	O
prolonged	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tablets	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
relative	ADJ	O	B-PHYSICAL
bioavailability	NOUN	O	I-PHYSICAL
of	ADP	O	O
prajmalium	NOUN	O	O
bitartrate	ADP	O	O
from	ADP	O	O
the	DET	O	O
tablet	NOUN	O	O
amounted	VERB	O	O
to	ADP	O	O
112	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
poor	ADJ	O	O
metabolizer	NOUN	O	O
demonstrated	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
oral	ADJ	O	O
formulations	NOUN	O	O
high	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
increased	VERB	O	B-PHYSICAL
AUCs	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
prolonged	VERB	O	I-PHYSICAL
terminal	ADJ	O	I-PHYSICAL
half-lives	PUNCT	O	I-PHYSICAL
as	PUNCT	O	I-PHYSICAL
well	VERB	O	I-PHYSICAL
as	CCONJ	O	I-PHYSICAL
increased	VERB	O	I-PHYSICAL
renal	ADJ	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
prajmalium	PUNCT	O	I-PHYSICAL

Evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
acetazolamide	NOUN	O	O
on	ADP	O	O
cystoid	NOUN	O	O
macular	ADJ	O	O
oedema	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Behcet	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	NOUN	O	O
study	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
acetazolamide	NOUN	O	O
on	ADP	O	O
cystoid	NOUN	O	O
macular	ADJ	O	O
oedema	NOUN	O	O
(	PUNCT	O	O
CMO	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Behcet	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
67	NUM	O	O
eyes	NOUN	O	O
of	ADP	O	O
35	NUM	O	O
Behcet	PUNCT	O	O
's	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
well-controlled	ADJ	O	O
uveitis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
CMO	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
into	ADP	O	O
a	DET	O	O
double-masked	NOUN	O	O
,	PUNCT	O	O
crossover	ADP	O	O
trial	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
acetazolamide	NOUN	O	O
vs	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
an	DET	O	O
initial	ADJ	O	O
4-week	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
250	NUM	O	O
mg	NOUN	O	O
acetazolamide	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
(	PUNCT	O	O
b.i.d	ADP	O	O
.	PUNCT	O	O
)	PUNCT	O	O

or	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
4-week	NOUN	O	O
washout	PUNCT	O	O
period	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
then	ADV	O	O
received	VERB	O	O
a	DET	O	O
4-week	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
the	DET	O	O
reverse	ADJ	O	O
study	NOUN	O	O
medication	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
visual	ADJ	O	B-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
fundus	NOUN	O	B-PHYSICAL
fluorescein	NOUN	O	I-PHYSICAL
angiographic	ADJ	O	I-PHYSICAL
findings	NOUN	O	I-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
total	NOUN	O	O
,	PUNCT	O	O
29	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
55	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
completed	VERB	O	O
the	DET	O	O
trial	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
29	NUM	O	O
,	PUNCT	O	O
16	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
13	NUM	O	O
were	DET	O	O
women	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
age	NOUN	O	O
range	NOUN	O	O
was	ADV	O	O
13-50	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
33.6	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
on	ADP	O	O
acetazolamide	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
slightly	ADV	O	O
better	PUNCT	O	O
improvement	NOUN	O	O
of	ADP	O	O
angiographic	ADJ	O	B-PHYSICAL
signs	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
at	DET	O	O
least	ADV	O	O
by	ADP	O	O
one	NUM	O	O
grade	NOUN	O	O
improvement	NOUN	O	O
)	PUNCT	O	O
over	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
vs	CCONJ	O	O
five	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

They	PRON	O	O
also	ADV	O	O
had	PUNCT	O	O
less	DET	O	O
deterioration	NOUN	O	O
of	ADP	O	O
angiographic	ADJ	O	B-PHYSICAL
signs	NOUN	O	I-PHYSICAL
over	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
three	NUM	O	O
vs	CCONJ	O	O
seven	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
findings	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P=0.99	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Acetazolamide	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
effect	NOUN	O	O
(	PUNCT	O	O
P=0.53	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
of	ADP	O	O
patients	NOUN	O	O
over	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
13	NUM	O	O
vs	CCONJ	O	O
eight	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nor	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
deterioration	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
three	NUM	O	O
vs	CCONJ	O	O
11	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Despite	ADP	O	O
seemingly	ADV	O	O
favourable	ADJ	O	O
results	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
4-week	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
acetazolamide	NOUN	O	O
(	PUNCT	O	O
250	NUM	O	O
mg	NOUN	O	O
b.i.d	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O

has	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
visual	ADJ	O	B-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
fluorescein	NOUN	O	B-PHYSICAL
angiographic	ADJ	O	I-PHYSICAL
findings	NOUN	O	I-PHYSICAL
in	ADP	O	O
Behcet	PUNCT	O	O
's	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
CMO	NOUN	O	O
.	PUNCT	O	O

CDP571	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
humanized	VERB	O	O
monoclonal	ADJ	O	O
antibody	NOUN	O	O
to	ADP	O	O
tumour	NOUN	O	O
necrosis	NOUN	O	O
factor-alpha	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
steroid-dependent	ADJ	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
More	PUNCT	O	O
than	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
become	ADP	O	O
either	PUNCT	O	O
steroid	NOUN	O	O
resistant	ADJ	O	O
or	CCONJ	O	O
dependent	ADJ	O	O
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
development	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
treatments	NOUN	O	O
for	ADP	O	O
steroid-dependent	ADJ	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
is	VERB	O	O
a	DET	O	O
research	NOUN	O	O
priority	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
evaluate	NOUN	O	O
CDP571	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
humanized	VERB	O	O
antibody	NOUN	O	O
to	ADP	O	O
tumour	NOUN	O	O
necrosis	NOUN	O	O
factor-alpha	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
steroid-dependent	ADJ	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
steroid-dependent	ADJ	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
271	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
36-week	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Steroid	NOUN	O	O
dependence	NOUN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
prednisolone	NOUN	O	O
or	CCONJ	O	O
prednisone	NOUN	O	O
(	PUNCT	O	O
15-40	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
budesonide	NOUN	O	O
(	PUNCT	O	O
9	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
>	ADJ	O	O
or	CCONJ	O	O
=8	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
previous	ADJ	O	O
failed	VERB	O	O
attempt	PUNCT	O	O
to	ADP	O	O
decrease	ADP	O	O
or	CCONJ	O	O
discontinue	NOUN	O	O
steroids	NOUN	O	O
within	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
screening	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
Disease	NOUN	O	O
Activity	NOUN	O	O
Index	NOUN	O	O
score	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
or	CCONJ	O	O
=150	PUNCT	O	O
points	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
intravenous	ADJ	O	O
CDP571	NOUN	O	O
10	NUM	O	O
mg/kg	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
8-weekly	ADJ	O	O
through	ADP	O	O
to	PUNCT	O	O
week	NOUN	O	O
32	NUM	O	O
.	PUNCT	O	O

Steroids	NOUN	O	O
were	ADJ	O	O
then	ADV	O	O
tapered	VERB	O	O
using	VERB	O	O
a	DET	O	O
defined	VERB	O	O
schedule	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
endpoint	NOUN	O	O
was	VERB	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-PHYSICAL
with	ADP	O	I-PHYSICAL
steroid	NOUN	O	I-PHYSICAL
sparing	PROPN	O	I-PHYSICAL
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
steroid	NOUN	O	O
therapy	NOUN	O	O
without	ADP	O	O
a	DET	O	O
disease	NOUN	O	O
flare	NOUN	O	O
(	PUNCT	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
Disease	NOUN	O	O
Activity	NOUN	O	O
Index	NOUN	O	O
score	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=220	ADJ	O	O
points	ADP	O	O
)	PUNCT	O	O
at	ADP	O	O
week	NOUN	O	O
36	NUM	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Steroid	NOUN	O	B-PHYSICAL
sparing	PUNCT	O	I-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
53	NUM	O	O
of	ADP	O	O
181	NUM	O	O
(	PUNCT	O	O
29.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
CDP571	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
33	NUM	O	O
of	ADP	O	O
90	NUM	O	O
(	PUNCT	O	O
36.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
placebo	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.24	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
occurred	VERB	O	O
at	ADP	O	O
similar	ADJ	O	O
frequencies	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
CDP571	NOUN	O	O
was	VERB	O	O
ineffective	ADJ	O	O
for	ADP	O	O
sparing	PROPN	O	B-ADVERSE-EFFECTS
steroids	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
steroid-dependent	ADJ	O	O
Crohn	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

CDP571	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	O
.	PUNCT	O	O

Letrozole	NOUN	O	O
in	ADP	O	O
the	DET	O	O
neoadjuvant	ADJ	O	O
setting	VERB	O	O
:	PUNCT	O	O
the	DET	O	O
P024	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Neoadjuvant	ADV	O	O
chemotherapy	NOUN	O	O
trials	NOUN	O	O
have	ADP	O	O
consistently	ADV	O	O
reported	ADP	O	O
lower	PUNCT	O	O
response	NOUN	O	O
rates	NOUN	O	B-OTHER
in	ADP	O	O
hormone	NOUN	O	O
receptor-positive	ADJ	O	O
(	PUNCT	O	O
HR+	NOUN	O	O
)	PUNCT	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
HR-	NOUN	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Preoperative	ADJ	O	O
endocrine	ADJ	O	O
therapy	NOUN	O	O
has	PUNCT	O	O
therefore	ADV	O	O
become	VERB	O	O
a	DET	O	O
logical	ADJ	O	O
alternative	ADJ	O	O
and	CCONJ	O	O
has	PUNCT	O	O
gained	VERB	O	O
considerable	ADJ	O	O
momentum	NOUN	O	O
from	ADP	O	O
the	DET	O	O
finding	VERB	O	O
that	ADP	O	O
aromatase	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
AIs	PROPN	O	O
)	PUNCT	O	O
are	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
tamoxifen	NOUN	O	O
for	ADP	O	O
HR+	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
neoadjuvant	ADJ	O	O
and	CCONJ	O	O
adjuvant	NOUN	O	O
settings	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
convincing	VERB	O	O
neoadjuvant	PUNCT	O	O
trial	NOUN	O	O
to	PART	O	O
demonstrate	ADJ	O	O
the	DET	O	O
superiority	NOUN	O	O
of	ADP	O	O
an	DET	O	O
AI	NOUN	O	O
versus	CCONJ	O	O
tamoxifen	NOUN	O	O
was	VERB	O	O
the	DET	O	O
P024	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
large	ADJ	O	O
multinational	ADJ	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
HR+	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
ineligible	ADJ	O	O
for	ADP	O	O
breast-conserving	PUNCT	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	B-OTHER
response	NOUN	O	O
rate	NOUN	O	B-OTHER
(	PUNCT	O	I-OTHER
ORR	NOUN	O	I-OTHER
)	PUNCT	O	B-OTHER
was	VERB	O	O
55	NUM	O	O
%	SYM	O	O
for	ADP	O	O
letrozole	NOUN	O	O
and	CCONJ	O	O
36	NUM	O	O
%	SYM	O	O
for	ADP	O	O
tamoxifen	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Significantly	ADV	O	O
more	DET	O	O
letrozole-treated	ADJ	O	O
patients	NOUN	O	O
underwent	VERB	O	B-OTHER
breast-conserving	PUNCT	O	B-OTHER
surgery	NOUN	O	I-OTHER
(	PUNCT	O	O
45	NUM	O	O
vs.	CCONJ	O	O
35	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P=0.022	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
ORR	NOUN	O	B-OTHER
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
with	ADP	O	O
letrozole	NOUN	O	O
than	PUNCT	O	O
tamoxifen	NOUN	O	O
in	ADP	O	O
the	DET	O	O
human	NOUN	O	O
epidermal	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
receptor	NOUN	O	O
HER1/HER2+	NOUN	O	O
subgroup	NOUN	O	O
(	PUNCT	O	O
P=0.0004	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
of	ADP	O	O
letrozole	NOUN	O	O
in	ADP	O	O
HER2+	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
was	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
fluorescent	ADJ	O	O
in	PUNCT	O	O
situ	ADJ	O	O
hybridization	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
comparable	ADJ	O	O
to	ADP	O	O
that	ADP	O	O
of	ADP	O	O
HER2-	NOUN	O	O
cases	NOUN	O	O
(	PUNCT	O	O
ORR	NOUN	O	O
71	NUM	O	O
%	SYM	O	O
in	ADP	O	O
both	CCONJ	O	O
subsets	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Biomarker	NOUN	O	B-OTHER
studies	NOUN	O	I-OTHER
confirmed	VERB	O	O
the	DET	O	O
superiority	NOUN	O	O
of	ADP	O	O
letrozole	NOUN	O	O
in	ADP	O	O
centrally	ADJ	O	O
assessed	ADP	O	O
estrogen	NOUN	O	O
receptor-positive	ADJ	O	O
(	PUNCT	O	O
ER+	NOUN	O	O
)	PUNCT	O	O
tumors	NOUN	O	O
and	CCONJ	O	O
found	PROPN	O	O
a	DET	O	O
strong	ADJ	O	O
relationship	NOUN	O	O
with	ADP	O	O
the	DET	O	O
degree	NOUN	O	B-OTHER
of	PUNCT	O	I-OTHER

Effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
low-salt	NOUN	O	O
diet	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
acute	ADJ	O	O
salt	NOUN	O	O
loading	VERB	O	O
on	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
intralymphocytic	ADJ	O	B-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
in	ADP	O	O
young	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
borderline	NOUN	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
.	PUNCT	O	O

Three	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
young	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
borderline	NOUN	O	O
hypertension	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
a	DET	O	O
12	NUM	O	O
months	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	PUNCT	O	O
was	NOUN	O	O
on	ADP	O	O
a	DET	O	O
free	ADJ	O	O
sodium	NOUN	O	O
diet	NOUN	O	O
while	ADP	O	O
the	DET	O	O
second	ADJ	O	O
was	VERB	O	O
on	ADP	O	O
a	DET	O	O
low-salt	NOUN	O	O
diet	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
third	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
underwent	VERB	O	O
acute	ADJ	O	O
salt	NOUN	O	O
loading	VERB	O	O
.	PUNCT	O	O

2	NUM	O	O
.	PUNCT	O	O

After	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
the	DET	O	O
group	NOUN	O	O
on	ADP	O	O
free	ADJ	O	O
diet	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
intralymphocytic	ADJ	O	B-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
but	CCONJ	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
was	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
re-checked	VERB	O	O
after	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
also	ADV	O	O
had	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

3	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
low-salt	NOUN	O	O
diet	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
of	ADP	O	O
both	PUNCT	O	O
intralymphocytic	ADJ	O	B-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

4	NUM	O	O
.	PUNCT	O	O

After	ADP	O	O
acute	ADJ	O	O
salt	NOUN	O	O
loading	VERB	O	O
,	PUNCT	O	O
borderline	NOUN	O	O
subjects	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
intralymphocytic	ADJ	O	O
sodium	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
greater	PUNCT	O	O
natriuresis	NOUN	O	B-PHYSICAL
whereas	ADP	O	O
intralymphocytic	ADJ	O	B-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
increased	VERB	O	O
only	ADV	O	O
in	ADP	O	O
those	PUNCT	O	O
subjects	NOUN	O	O
in	ADP	O	O
whom	ADP	O	O
it	PRON	O	O
was	VERB	O	O
initially	ADV	O	O
normal	ADJ	O	O
.	PUNCT	O	O

Marginal	ADJ	O	O
zone	NOUN	O	O
B	NOUN	O	O
cell	NOUN	O	O
lymphoma	NOUN	O	O
of	ADP	O	O
the	DET	O	O
parotid	NOUN	O	O
glands	NOUN	O	O
:	PUNCT	O	O
results	CCONJ	O	O
of	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
trial	NOUN	O	O
comparing	PUNCT	O	O
radiotherapy	NOUN	O	O
to	ADP	O	O
combined	VERB	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

39	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
marginal	ADJ	O	O
zone	NOUN	O	O
B	NOUN	O	O
cell	NOUN	O	O
lymphoma	NOUN	O	O
(	PUNCT	O	O
MZBCL	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
parotid	NOUN	O	O
glands	NOUN	O	O
(	PUNCT	O	O
stages	NOUN	O	O
I	NUM	O	O
or	CCONJ	O	O
II	ADP	O	O
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
radiotherapy	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
extended	ADJ	O	O
fields	NOUN	O	O
,	PUNCT	O	O
4500	NUM	O	O
cGy	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
radiotherapy	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
same	ADJ	O	O
schedule	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
cyclophosphamide	NOUN	O	O
,	PUNCT	O	O
vincristine	NOUN	O	O
and	CCONJ	O	O
prednisone	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
end	NOUN	O	B-PHYSICAL
points	NOUN	O	I-PHYSICAL
were	VERB	O	O
survival	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
TTF	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	PROPN	O	O
received	CCONJ	O	O
radiotherapy	NOUN	O	O
alone	ADJ	O	O
had	PUNCT	O	O
a	DET	O	O
complete	ADJ	O	B-PHYSICAL
remission	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
100	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
the	DET	O	O
TTF	NOUN	O	B-OTHER
was	VERB	O	O
90	NUM	O	O
%	SYM	O	O
at	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
at	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
was	VERB	O	O
90	NUM	O	O
%	SYM	O	O
with	ADP	O	O
no	DET	O	O
statistical	ADJ	O	O
difference	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
combined	VERB	O	O
therapy	NOUN	O	O
[	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
and	CCONJ	O	O
95	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.5	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	B-OTHER
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
therapeutic	ADJ	O	O
approach	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
early	ADJ	O	O
stage	NOUN	O	O
MZBCL	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
offer	VERB	O	O
any	DET	O	O
advantage	NOUN	O	O
over	ADP	O	O
radiotherapy	NOUN	O	O
alone	ADJ	O	O
as	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Until	ADP	O	O
now	ADV	O	O
,	PUNCT	O	O
radiotherapy	NOUN	O	O
was	VERB	O	O
considered	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
in	ADP	O	O
this	DET	O	O
clinical	ADJ	O	O
setting	VERB	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
fixed-dose	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
aripiprazole	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
irritability	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
short-term	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
aripiprazole	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
irritability	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Two	NUM	O	O
hundred	PUNCT	O	O
eighteen	NUM	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
(	PUNCT	O	O
aged	PROPN	O	O
6-17	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
behaviors	NOUN	O	O
such	ADP	O	O
as	ADP	O	O
tantrums	ADP	O	O
,	PUNCT	O	O
aggression	NOUN	O	O
,	PUNCT	O	O
self-injurious	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
these	PUNCT	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
1:1:1:1	PUNCT	O	O
to	ADP	O	O
aripiprazole	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
15	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
this	DET	O	O
8-week	NOUN	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
the	DET	O	O
caregiver-rated	VERB	O	O
Aberrant	ADJ	O	B-MENTAL
Behavior	NOUN	O	I-MENTAL
Checklist	NOUN	O	I-MENTAL
Irritability	NOUN	O	I-MENTAL
subscale	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
primary	ADJ	O	I-MENTAL
efficacy	NOUN	O	O
measure	NOUN	O	B-MENTAL
)	PUNCT	O	B-MENTAL
and	CCONJ	O	O
the	DET	O	O
clinician-rated	VERB	O	B-MENTAL
Clinical	ADJ	O	B-MENTAL
Global	PUNCT	O	B-MENTAL
Impressions-Improvement	PUNCT	O	B-MENTAL
score	NOUN	O	O
.	PUNCT	O	O

Safety	NOUN	O	B-OTHER
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
were	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
week	NOUN	O	O
8	NUM	O	O
,	PUNCT	O	O
all	DET	O	O
aripiprazole	NOUN	O	O
doses	NOUN	O	O
produced	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
improvement	NOUN	O	B-OTHER
than	PUNCT	O	O
placebo	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
Aberrant	ADJ	O	B-MENTAL
Behavior	NOUN	O	I-MENTAL
Checklist	NOUN	O	B-MENTAL
Irritability	NOUN	O	I-MENTAL
subscale	NOUN	O	B-MENTAL
scores	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg/day	NOUN	O	O
,	PUNCT	O	O
-12.4	NUM	O	O
;	PUNCT	O	O
10	NUM	O	O
mg/day	NOUN	O	O
,	PUNCT	O	O
-13.2	ADJ	O	O
;	PUNCT	O	O
15	NUM	O	O
mg/day	NOUN	O	O
,	PUNCT	O	O
-14.4	NUM	O	O
;	PUNCT	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
-8.4	ADJ	O	O
;	PUNCT	O	O
all	DET	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
aripiprazole	NOUN	O	O
doses	NOUN	O	O
demonstrated	VERB	O	O
significantly	ADP	O	O
greater	PUNCT	O	O
improvements	NOUN	O	B-MENTAL
in	ADP	O	B-MENTAL
mean	NOUN	O	O
Clinical	ADJ	O	B-MENTAL
Global	PUNCT	O	B-MENTAL
Impressions-Improvement	ADJ	O	B-MENTAL
score	ADJ	O	O
than	PUNCT	O	O
placebo	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
8	NUM	O	O
.	PUNCT	O	O

Discontinuation	NOUN	O	O
rates	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
were	NUM	O	O
as	ADP	O	O
follows	PUNCT	O	O
:	PUNCT	O	O
placebo	NOUN	O	O
7.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
aripiprazole	NOUN	O	O
5	NUM	O	O
mg/day	NOUN	O	O
9.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
10	NUM	O	O
mg/day	NOUN	O	O
13.6	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
mg/day	NOUN	O	O
7.4	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
common	PUNCT	O	O

Haemodynamic	ADJ	O	O
profile	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
antagonism	NOUN	O	O
in	ADP	O	O
essential	ADJ	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
haemodynamic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
antagonistic	ADJ	O	O
(	PUNCT	O	O
10	NUM	O	O
microgram	NOUN	O	O
min-1	NOUN	O	O
kg-1	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
agonistic	ADJ	O	O
(	PUNCT	O	O
40	NUM	O	O
microgram	NOUN	O	O
min-1	NOUN	O	O
kg-1	NOUN	O	O
)	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
saralasin	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
young	ADJ	O	O
essential	ADJ	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
behaviour	NOUN	O	I-PHYSICAL
alone	ADJ	O	O
was	ADV	O	O
thought	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
inadequate	ADJ	O	O
to	ADP	O	O
describe	ADJ	O	O
the	DET	O	O
response	NOUN	O	O
pattern	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
.	PUNCT	O	O

Pre-saralasin	NOUN	O	O
setting	VERB	O	O
of	ADP	O	O
the	DET	O	O
renin-angiotensin	NOUN	O	O
axis	NOUN	O	O
was	VERB	O	O
varied	VERB	O	O
with	ADP	O	O
salt	NOUN	O	O
intake	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
290	NUM	O	O
mmol	NOUN	O	O
of	ADP	O	O
Na+/day	PUNCT	O	O
)	PUNCT	O	O
each	PUNCT	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
failed	VERB	O	O
to	PART	O	O
influence	ADJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
plasma	NOUN	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

3	NUM	O	O
.	PUNCT	O	O

Antagonist	NOUN	O	O
blockade	NOUN	O	O
after	ADP	O	O
low	ADJ	O	O
salt	NOUN	O	O
lowered	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
highest	PUNCT	O	O
plasma	NOUN	O	O
renin	NOUN	O	O
values	NOUN	O	O
.	PUNCT	O	O

Cardiac	ADJ	O	B-PHYSICAL
output	NOUN	O	I-PHYSICAL
rose	CCONJ	O	O
in	ADP	O	O
two	NUM	O	O
of	ADP	O	O
these	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	NOUN	O	O
dropped	VERB	O	O
in	ADP	O	O
all	DET	O	O
others	NOUN	O	O
.	PUNCT	O	O

4	NUM	O	O
.	PUNCT	O	O

Decreases	CCONJ	O	O
in	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
output	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
with	ADP	O	O
both	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
saralasin	NOUN	O	O
and	CCONJ	O	O
even	ADV	O	O
with	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin-angiotensin	NOUN	O	O
axis	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
response	NOUN	O	O
is	VERB	O	O
therefore	ADV	O	O
unlikely	ADV	O	O
to	PART	O	O
be	PUNCT	O	O
due	CCONJ	O	O
to	ADP	O	O
removal	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
venous	ADJ	O	I-PHYSICAL
angiotensin	NOUN	O	I-PHYSICAL
effects	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

5	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
renin-angiotensin	NOUN	O	O
system	NOUN	O	O
played	VERB	O	O
a	DET	O	O
part	NOUN	O	O
in	ADP	O	O
maintenance	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
only	ADV	O	O
with	ADP	O	O
severe	ADJ	O	O
salt	NOUN	O	O
restriction	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
a	DET	O	O
small	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
.	PUNCT	O	O

6	NUM	O	O
.	PUNCT	O	O

No	DET	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
effect	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
with	ADP	O	O
sarcalasin	NOUN	O	O
.	PUNCT	O	O

7	NUM	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
total	ADJ	O	O
peripheral	ADJ	O	B-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
responses	NOUN	O	B-PHYSICAL
were	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
pre-	ADJ	O	O
(	PUNCT	O	O
antagonist/agonist	NOUN	O	O
)	PUNCT	O	O
setting	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
health	NOUN	O	O
care	NOUN	O	O
program	NOUN	O	O
for	ADP	O	O
first-time	NOUN	O	O
adolescent	NOUN	O	O
mothers	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
test	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
special	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
program	NOUN	O	O
for	ADP	O	O
adolescent	NOUN	O	O
mothers	NOUN	O	O
(	PUNCT	O	O
17	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
or	CCONJ	O	O
younger	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
infants	NOUN	O	O
,	PUNCT	O	O
243	NUM	O	O
mother-infant	NOUN	O	O
pairs	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

All	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
mothers	NOUN	O	O
were	VERB	O	O
unwed	ADP	O	O
,	PUNCT	O	O
on	ADP	O	O
Medicaid	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
black	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
routine	ADJ	O	O
well-baby	NOUN	O	O
care	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
routine	ADJ	O	O
care	NOUN	O	O
and	CCONJ	O	O
services	NOUN	O	O
that	DET	O	O
included	VERB	O	O
rigorous	ADJ	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
discussions	NOUN	O	O
with	ADP	O	O
the	DET	O	O
mother	NOUN	O	O
about	ADP	O	O
her	ADP	O	O
plans	NOUN	O	O
for	ADP	O	O
return	ADP	O	O
to	ADP	O	O
school	NOUN	O	O
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
family	NOUN	O	O
planning	ADJ	O	O
methods	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
extra	ADJ	O	O
health	NOUN	O	O
teaching	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
dropout	ADP	O	O
rate	NOUN	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
60	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
after	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
than	VERB	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
82	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
the	DET	O	O
high	ADJ	O	O
dropout	ADP	O	O
rate	NOUN	O	O
,	PUNCT	O	O
91	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
mothers	NOUN	O	O
were	VERB	O	O
located	VERB	O	O
for	ADP	O	O
the	DET	O	O
18	NUM	O	O
month	NOUN	O	O
follow-up	NOUN	O	O
interview	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
repeat	NOUN	O	B-PHYSICAL
pregnancy	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
12	NUM	O	O
%	SYM	O	O
after	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
28	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
percentage	NOUN	O	B-MENTAL
returning	ADJ	O	I-MENTAL
to	ADP	O	I-MENTAL
school	NOUN	O	I-MENTAL
.	PUNCT	O	O

After	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
infants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
be	PUNCT	O	O
fully	ADV	O	B-PHYSICAL
immunized	PROPN	O	I-PHYSICAL
(	PUNCT	O	O
33	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
infants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
18	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mothers	NOUN	O	O
in	ADP	O	O
the	DET	O	O
special	ADJ	O	O
care	NOUN	O	O
program	NOUN	O	O
who	ADP	O	O
continued	VERB	O	O
to	ADP	O	O
attend	PUNCT	O	O
clinic	NOUN	O	O
used	VERB	O	O
the	DET	O	B-OTHER
emergency	NOUN	O	I-OTHER
room	NOUN	O	I-OTHER
less	ADV	O	O
than	PUNCT	O	O
the	DET	O	O
mothers	NOUN	O	O
who	ADP	O	O
continued	VERB	O	O
to	ADP	O	O
attend	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
comprehensive	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
program	NOUN	O	O
is	VERB	O	O
one	NUM	O	O
way	NOUN	O	O
to	ADP	O	O
bring	PUNCT	O	O
about	PUNCT	O	O
better	PUNCT	O	O
outcomes	NOUN	O	O
for	ADP	O	O
both	CCONJ	O	O
adolescent	NOUN	O	O
mothers	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Hypotensive	ADJ	O	O
effects	NOUN	O	O
and	CCONJ	O	O
influence	NOUN	O	O
on	ADP	O	O
serum	NOUN	O	B-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
of	ADP	O	O
SQ29,852	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
angiotensin	NOUN	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
comparison	NOUN	O	O
with	ADP	O	O
atenolol	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
SQ29,852	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
angiotensin	NOUN	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
atenolol	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
22	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
monotherapies	ADJ	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
46	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
SQ29,852	NOUN	O	O
(	PUNCT	O	O
mean	ADP	O	O
dose	NOUN	O	O
15.0	NUM	O	O
+/-	SYM	O	O
5.1	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
atenolol	NOUN	O	O
(	PUNCT	O	O
mean	ADP	O	O
dose	NOUN	O	O
37.5	NUM	O	O
+/-	SYM	O	O
18.5	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
decreased	VERB	O	O
both	CCONJ	O	O
systolic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressures	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	B-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
apolipoproteins	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
lipoproteins	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
atherosclerotic	ADJ	O	B-PHYSICAL
indices	NOUN	O	I-PHYSICAL
after	ADP	O	O
both	CCONJ	O	O
SQ29,852	NUM	O	O
and	CCONJ	O	O
atenolol	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
no	DET	O	O
significant	ADJ	O	B-OTHER
inter-group	NOUN	O	I-OTHER
differences	NOUN	O	I-OTHER
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
side	NOUN	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
or	CCONJ	O	I-ADVERSE-EFFECTS
abnormal	ADJ	O	I-ADVERSE-EFFECTS
laboratory	NOUN	O	I-ADVERSE-EFFECTS
tests	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
both	CCONJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
SQ29,852	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
antihypertensive	ADJ	O	O
drug	NOUN	O	O
without	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
effect	NOUN	O	O
on	ADP	O	O
lipid	NOUN	O	O
metabolism	NOUN	O	O
.	PUNCT	O	O

Prediction	NOUN	O	O
of	ADP	O	O
metabolic	ADJ	O	O
and	CCONJ	O	O
cardiopulmonary	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
maximum	NOUN	O	O
cycle	NOUN	O	O
ergometry	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

All	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
widely-cited	VERB	O	O
studies	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prediction	NOUN	O	O
of	ADP	O	O
maximum	NOUN	O	B-PHYSICAL
exercise	NOUN	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
have	PUNCT	O	O
utilized	VERB	O	O
either	PUNCT	O	O
volunteers	NUM	O	O
or	CCONJ	O	O
referred	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
selection	NOUN	O	O
bias	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
overestimation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
likely	ADJ	O	O
consequence	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
establish	NOUN	O	O
a	DET	O	O
set	NOUN	O	O
of	ADP	O	O
predictive	ADJ	O	O
equations	NOUN	O	O
for	ADP	O	O
the	DET	O	O
gas	NOUN	O	B-PHYSICAL
exchange	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
ventilatory	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
cardiovascular	ADJ	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	O
maximum	NOUN	O	O
ramp-incremental	ADJ	O	O
cycle	NOUN	O	O
ergometry	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
prospectively	ADV	O	O
evaluated	ADP	O	O
120	NUM	O	O
sedentary	ADJ	O	O
individuals	NOUN	O	O
(	PUNCT	O	O
60	ADP	O	O
males	PROPN	O	O
,	PUNCT	O	O
60	NUM	O	O
females	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
20-80	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
randomly-selected	PUNCT	O	O
from	ADP	O	O
>	ADP	O	O
8,000	NUM	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Regular	ADJ	O	O
physical	ADJ	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
pattern	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
questionnaire	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	B-PHYSICAL
composition	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
anthropometry	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
dual	ADJ	O	I-PHYSICAL
energy	NOUN	O	I-PHYSICAL
X-ray	NOUN	O	I-PHYSICAL
absorptiometry	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
n	NOUN	O	B-PHYSICAL
=	SYM	O	I-PHYSICAL
75	NUM	O	I-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	B-PHYSICAL
knee	NOUN	O	I-PHYSICAL
strength	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
isokinetic	ADJ	O	I-PHYSICAL
dynamometry	NOUN	O	B-PHYSICAL
were	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Previously	ADV	O	O
reported	VERB	O	O
equations	ADP	O	O
typically	ADV	O	O
overestimated	PUNCT	O	O
the	DET	O	O
subjects	NOUN	O	O
'	PUNCT	O	O
peak	ADJ	O	O
oxygen	NOUN	O	B-PHYSICAL
uptake	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Prediction	NOUN	O	O
linear	ADJ	O	O
equations	NOUN	O	O
for	ADP	O	O
the	DET	O	O
main	ADJ	O	O
variables	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
interest	NOUN	O	O
were	VERB	O	O
established	VERB	O	O
by	ADP	O	O
backward	NOUN	O	O
stepwise	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
including	ADV	O	O
:	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
knee	NOUN	O	O
extensor	NOUN	O	O
peak	ADJ	O	O
torque	NOUN	O	O
,	PUNCT	O	O
bone-free	ADP	O	O
lean	ADJ	O	O
leg	NOUN	O	O
mass	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
and	CCONJ	O	O
lean	ADJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
,	PUNCT	O	O
height	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

Reference	NOUN	O	B-PHYSICAL
intervals	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	ADP	O	O
limits	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
calculated	VERB	O	O
:	PUNCT	O	O
some	PUNCT	O	O
of	ADP	O	O
these	DET	O	O
values	NOUN	O	O
differed	VERB	O	O
markedly	ADV	O	O
from	ADP	O	O
those	PUNCT	O	O
formerly	ADV	O	O
recommended	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADP	O	O
therefore	ADV	O	O
might	CCONJ	O	O
provide	VERB	O	O
a	DET	O	O
more	ADV	O	O
appropriate	ADJ	O	O
frame	NOUN	O	O
of	ADP	O	O
reference	NOUN	O	O
for	ADP	O	O
interpretation	NOUN	O	O
of	ADP	O	O
the	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
alfentanil	NOUN	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	O
and	CCONJ	O	O
sufentanil	NOUN	O	O
for	ADP	O	O
total	ADJ	O	O
intravenous	ADJ	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
studied	VERB	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
pharmacodynamics	NOUN	O	B-PHYSICAL
of	ADP	O	O
alfentanil	NOUN	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	O
and	CCONJ	O	O
sufentanil	NOUN	O	O
together	ADV	O	O
with	ADP	O	O
propofol	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
graft	NOUN	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
CABG	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
40-73	PUNCT	O	O
yr	NOUN	O	O
,	PUNCT	O	O
56	NUM	O	O
male	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	PART	O	O
receive	NOUN	O	O
alfentanil	NOUN	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	O
or	CCONJ	O	O
sufentanil	NOUN	O	O
and	CCONJ	O	O
propofol	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
times	NOUN	O	B-OTHER
for	ADP	O	I-OTHER
the	DET	O	I-OTHER
plasma	NOUN	O	I-OTHER
concentration	NOUN	O	O
to	ADP	O	B-OTHER
decrease	VERB	O	O
by	ADP	O	B-OTHER
50	NUM	O	B-OTHER
%	SYM	O	B-OTHER
(	PUNCT	O	O
t50	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
80	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
t80	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

Times	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
to	ADP	O	O
awakening	VERB	O	O
and	CCONJ	O	O
tracheal	ADJ	O	O
extubation	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
dose	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	O
propofol	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Mean	DET	O	O
total	ADJ	O	O
doses	NOUN	O	B-OTHER
of	ADP	O	O
alfentanil	NOUN	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	O
and	CCONJ	O	O
sufentanil	NOUN	O	O
were	VERB	O	O
443	PUNCT	O	O
,	PUNCT	O	O
45	NUM	O	O
and	CCONJ	O	O
4.4	NUM	O	O
micrograms	NOUN	O	O
kg-1	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Time	NOUN	O	B-PHYSICAL
to	ADP	O	B-PHYSICAL
awakening	PROPN	O	B-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
fentanyl	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
trachea	NOUN	O	B-PHYSICAL
was	VERB	O	O
extubated	VERB	O	B-PHYSICAL
on	ADP	O	O
average	VERB	O	O
2	NUM	O	O
h	NOUN	O	O
later	ADV	O	O
than	PUNCT	O	O
in	ADP	O	O
those	PUNCT	O	O
receiving	SYM	O	O
sufentanil	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
h	NOUN	O	O
later	ADV	O	O
than	PUNCT	O	O
in	ADP	O	O
those	PUNCT	O	O
receiving	VERB	O	O
alfentanil	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
t80	NOUN	O	B-PHYSICAL
of	ADP	O	O
fentanyl	NOUN	O	O
was	VERB	O	O
longer	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
that	PUNCT	O	O
of	ADP	O	O
alfentanil	NOUN	O	O
or	CCONJ	O	O
sufentanil	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
linear	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
t80	NOUN	O	B-PHYSICAL
of	ADP	O	O
the	DET	O	O
opioid	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
tracheal	ADJ	O	I-OTHER
extubation	NOUN	O	B-OTHER
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.51	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	PUNCT	O	O

Famotidine	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
:	PUNCT	O	O
pilot	NOUN	O	O
research	NOUN	O	O
using	SYM	O	O
single	PUNCT	O	O
subject	ADJ	O	O
research	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
single	ADJ	O	O
subject	ADJ	O	O
research	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
we	NOUN	O	O
performed	PART	O	O
pilot	NOUN	O	O
research	NOUN	O	O
to	ADJ	O	O
evaluate	NOUN	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
famotidine	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
9	NUM	O	O
Caucasian	ADJ	O	O
boys	NOUN	O	O
,	PUNCT	O	O
3.8-8.1	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
DSM-IV	NOUN	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
living	CCONJ	O	O
with	ADP	O	O
their	ADP	O	O
families	NOUN	O	O
,	PUNCT	O	O
receiving	VERB	O	O
no	DET	O	O
chronic	ADJ	O	O
medications	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
without	ADP	O	O
significant	ADJ	O	O
gastrointestinal	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
famotidine	NOUN	O	O
was	VERB	O	O
2	NUM	O	O
mg/kg/day	NOUN	O	O
(	PUNCT	O	O
given	ADP	O	O
in	ADP	O	O
two	NUM	O	O
divided	VERB	O	O
doses	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
maximum	NOUN	O	O
total	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
was	VERB	O	O
100	PUNCT	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
single-subject	NOUN	O	O
research	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
medication	NOUN	O	O
given	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
of	ADP	O	O
9	NUM	O	O
children	NOUN	O	O
randomized	DET	O	O
(	PUNCT	O	O
44	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
evidence	NOUN	O	O
of	ADP	O	O
behavioral	ADJ	O	B-MENTAL
improvement	NOUN	O	I-MENTAL
.	PUNCT	O	O

Primary	ADJ	O	O
efficacy	NOUN	O	O
was	VERB	O	O
based	VERB	O	O
on	ADP	O	O
data	NOUN	O	O
kept	PUNCT	O	O
by	ADP	O	O
primary	ADJ	O	O
caregivers	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
a	DET	O	O
daily	ADJ	O	O
diary	PUNCT	O	O
;	PUNCT	O	O
daily	ADJ	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scales	NOUN	O	O
of	ADP	O	O
affection	NOUN	O	O
,	PUNCT	O	O
reciting	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
social	ADJ	O	O
interaction	NOUN	O	O
;	PUNCT	O	O
Aberrant	ADJ	O	B-PHYSICAL
Behavior	NOUN	O	I-PHYSICAL
Checklists	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
ABC	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
Aman	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
;	PUNCT	O	O
and	PUNCT	O	O

Five-year	PUNCT	O	O
outcome	NOUN	O	O
of	ADP	O	O
surgical	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-PAIN
headaches	PUNCT	O	I-PAIN
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
long-term	NOUN	O	O
efficacy	NOUN	O	O
of	ADP	O	O
surgical	ADJ	O	O
deactivation	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-PHYSICAL
headache	PUNCT	O	I-PHYSICAL
trigger	VERB	O	O
sites	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
twenty-five	PUNCT	O	O
volunteers	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
100	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
25	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
examination	NOUN	O	O
by	ADP	O	O
the	DET	O	O
team	ADJ	O	O
neurologist	NOUN	O	O
to	PART	O	O
ensure	NOUN	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-PAIN
headache	NOUN	O	I-PAIN
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
asked	ADV	O	O
to	PUNCT	O	O
complete	PUNCT	O	O
the	DET	O	O
Medical	ADJ	O	B-PHYSICAL
Outcomes	NOUN	O	I-PHYSICAL
Study	ADP	O	I-PHYSICAL
36-Item	NOUN	O	I-PHYSICAL
Short	ADJ	O	I-PHYSICAL
Form	NOUN	O	I-PHYSICAL
Health	NOUN	O	I-PHYSICAL
Survey	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
Migraine-Specific	ADJ	O	B-OTHER
Quality	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
Life	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
Migraine	NOUN	O	B-PHYSICAL
Disability	NOUN	O	I-PHYSICAL
Assessment	NOUN	O	I-PHYSICAL
questionnaires	NOUN	O	I-PHYSICAL
before	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
12-	NUM	O	O
and	CCONJ	O	O
60-month	NOUN	O	O
postoperative	ADJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
received	ADV	O	O
botulinum	NOUN	O	O
toxin	NOUN	O	O
to	PUNCT	O	O
confirm	ADJ	O	O
the	DET	O	O
trigger	VERB	O	O
sites	NOUN	O	O
;	PUNCT	O	O
controls	NOUN	O	O
received	ADP	O	O
saline	ADJ	O	O
injections	NOUN	O	O
.	PUNCT	O	O

Treated	ADJ	O	O
patients	NOUN	O	O
underwent	VERB	O	O
surgical	ADJ	O	O
deactivation	NOUN	O	O
of	ADP	O	O
trigger	PUNCT	O	O
site	NOUN	O	O
(	PUNCT	O	O
s	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
(	PUNCT	O	O
previously	ADJ	O	O
published	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
years	NOUN	O	O
postoperatively	ADV	O	O
(	PUNCT	O	O
the	DET	O	O
subject	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
report	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	ADP	O	O
Eighty-nine	NUM	O	O
of	ADP	O	O
100	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
underwent	VERB	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
79	NUM	O	O
were	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Ten	DET	O	O
patients	NOUN	O	O
underwent	VERB	O	O
deactivation	NOUN	O	O
of	ADP	O	O
additional	ADJ	O	O
(	PUNCT	O	O
different	ADJ	O	O
)	PUNCT	O	O
trigger	DET	O	O
sites	NOUN	O	O
during	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
not	ADV	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
data	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
final	ADJ	O	O
outcome	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
inclusion	NOUN	O	O
of	ADP	O	O
these	DET	O	O
10	NUM	O	O
patients	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
different	ADJ	O	O
.	PUNCT	O	O

Sixty-one	NUM	O	O
(	PUNCT	O	O
88	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
69	NUM	O	O
patients	NOUN	O	O
have	CCONJ	O	O
experienced	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
response	NOUN	O	B-PHYSICAL
to	ADP	O	O
the	DET	O	O
surgery	NOUN	O	O
after	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Twenty	PUNCT	O	O
(	PUNCT	O	O
29	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
reported	ADP	O	O
complete	ADJ	O	B-OTHER
elimination	NOUN	O	O
of	ADP	O	B-OTHER
migraine	NOUN	O	I-OTHER
headache	NOUN	O	B-OTHER
,	PUNCT	O	O
41	NUM	O	O
(	PUNCT	O	O
59	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
noticed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
eight	NUM	O	O
(	PUNCT	O	O
12	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
experienced	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
measured	PUNCT	O	O
variables	NOUN	O	O
at	ADP	O	O
60	NUM	O	O
months	NOUN	O	O
improved	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Based	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
5-year	ADJ	O	O
follow-up	NOUN	O	O
data	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
is	VERB	O	O
strong	ADJ	O	O
evidence	NOUN	O	O
that	ADP	O	O
surgical	ADJ	O	O
manipulation	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
migraine	NOUN	O	O
trigger	VERB	O	O
sites	NOUN	O	O
can	PRON	O	O
successfully	ADV	O	O
eliminate	VERB	O	B-OTHER
or	PUNCT	O	B-OTHER
reduce	PUNCT	O	I-OTHER

Neridronate	VERB	O	O
prevents	VERB	O	O
bone	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
androgen	NOUN	O	O
deprivation	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
Today	NOUN	O	O
,	PUNCT	O	O
androgen	NOUN	O	O
deprivation	NOUN	O	O
therapy	NOUN	O	O
is	VERB	O	O
a	DET	O	O
cornerstone	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
advanced	VERB	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
it	PRON	O	O
presents	NOUN	O	O
important	ADJ	O	O
complications	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
osteoporosis	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Neridronate	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
relatively	ADV	O	O
new	ADJ	O	O
bisphosphonate	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
able	ADJ	O	O
to	PART	O	O
prevent	NOUN	O	O
bone	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
during	ADP	O	O
androgen	NOUN	O	O
ablation	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Androgen-deprivation	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ADT	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
cornerstone	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
advanced	VERB	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
therapy	NOUN	O	O
has	ADP	O	O
iatrogenic	ADJ	O	O
complications	NOUN	O	O
,	PUNCT	O	O
such	CCONJ	O	O
as	ADP	O	O
osteoporosis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
our	PUNCT	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
neridronate	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
relatively	ADV	O	O
new	ADJ	O	O
bisphosphonate	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
prevent	NOUN	O	O
bone	NOUN	O	O
loss	NOUN	O	O
during	ADP	O	O
androgen	NOUN	O	O
ablation	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Forty-eight	PUNCT	O	O
osteoporotic	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
3-month	NOUN	O	O
depot	NOUN	O	O
triptorelina	ADJ	O	O
,	PUNCT	O	O
were	VERB	O	O
enrolled	VERB	O	O
and	CCONJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
daily	ADJ	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
cholecalciferol	NOUN	O	O
supplement	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
elemental	ADJ	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
400	NUM	O	O
IU	NOUN	O	O
cholecalciferol	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
same	ADJ	O	O
daily	ADJ	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
cholecalciferol	NOUN	O	O
supplement	NOUN	O	O
,	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
neridronate	VERB	O	O
given	VERB	O	O
intramuscularly	ADV	O	O
every	DET	O	O
month	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
also	ADV	O	O
received	ADP	O	O
bicalutamide	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Lumbar	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
femoral	ADJ	O	I-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
DXA	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
moreover	ADV	O	O
,	PUNCT	O	O
deoxypyridinoline	NOUN	O	O
(	PUNCT	O	O
DPD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
bone	NOUN	O	O
alkaline	ADJ	O	O
phosphatase	NOUN	O	O
(	PUNCT	O	O
BALP	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
determined	VERB	O	O
at	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
,	PUNCT	O	O
midway	NOUN	O	O
through	CCONJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
patients	NOUN	O	O
treated	PUNCT	O	O
only	ADV	O	O
with	ADP	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
cholecalciferol	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
a	DET	O	O
marked	VERB	O	B-PHYSICAL
bone	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
with	ADP	O	O
increased	VERB	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
DPD	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
BALP	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
baseline	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
treated	VERB	O	O
also	ADV	O	O
with	ADP	O	O
neridronate	VERB	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
had	PUNCT	O	O
substantially	ADV	O	O
unchanged	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
these	DET	O	O
markers	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
lumbar	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
total	ADJ	O	O
hip	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
decreased	VERB	O	I-PHYSICAL
significantly	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	PUNCT	O	O
only	ADV	O	O
with	ADP	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
cholecalciferol	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
it	DET	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	B-OTHER
significantly	ADV	O	I-OTHER
at	ADP	O	O
any	DET	O	O
skeletal	ADJ	O	O
site	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
also	ADV	O	O
with	ADP	O	O
neridronate	VERB	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
relevant	ADJ	O	B-ADVERSE-EFFECTS
side	NOUN	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
recorded	VERB	O	O
during	ADP	O	O
our	PUNCT	O	O
study	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Neridronate	ADV	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
bone	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
and	CCONJ	O	O
lumbar	ADJ	O	O
spine	NOUN	O	O
in	ADP	O	O
men	NOUN	O	O
receiving	VERB	O	O
ADT	NOUN	O	O
for	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
indobufen	NOUN	O	O
on	ADP	O	O
aortocoronary	ADJ	O	O
bypass	NOUN	O	O
patency	NOUN	O	O
after	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	O
antiaggregation	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ASA	NOUN	O	O
plus	CCONJ	O	O
dipyridamole	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
indobufen	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
after	ADP	O	O
aortocoronary	ADJ	O	O
bypass	NOUN	O	O
(	PUNCT	O	O
ACB	NOUN	O	O
)	PUNCT	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patency	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	O
ACB	NOUN	O	O
using	SYM	O	O
coronary	ADJ	O	O
DSA	NOUN	O	O
one	NUM	O	O
week	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
year	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
52	NUM	O	O
patients	NOUN	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
included	VERB	O	O
only	ADV	O	O
ACB	NOUN	O	O
's	PUNCT	O	O
with	ADP	O	O
intraoperative	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
rates	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
40	NUM	O	O
ml/min	NOUN	O	O
as	ADP	O	O
it	PRON	O	O
is	VERB	O	O
just	ADV	O	O
these	DET	O	O
ACB	NOUN	O	O
's	PUNCT	O	O
which	ADP	O	O
are	VERB	O	O
at	ADP	O	O
the	DET	O	O
highest	ADV	O	O
risk	NOUN	O	O
of	ADP	O	O
early	PUNCT	O	O
and	CCONJ	O	O
late	ADJ	O	O
occlusions	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ASA	NOUN	O	O
plus	CCONJ	O	O
dipyridamole-treated	VERB	O	O
group	NOUN	O	O
,	PUNCT	O	O
occlusions	NOUN	O	B-PHYSICAL
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
11	NUM	O	O
of	ADP	O	O
the	DET	O	O
39	NUM	O	O
reconstructions	NOUN	O	O
(	PUNCT	O	O
28.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
proportion	NOUN	O	O
was	VERB	O	O
nine	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
37	NUM	O	O
procedures	NOUN	O	O
(	PUNCT	O	O
24.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
indobufen	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
year	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
occlusion	NOUN	O	B-PHYSICAL
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
14	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
32	NUM	O	O
ACB	NOUN	O	O
's	PUNCT	O	O
(	PUNCT	O	O
43.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ASA	NOUN	O	O
plus	CCONJ	O	O
dipyridamole	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
14	NUM	O	O
occlusions	NOUN	O	O
in	ADP	O	O
31	NUM	O	O
ACB	NOUN	O	O
's	PUNCT	O	O
(	PUNCT	O	O
45.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
indobufen	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
occlusions	NOUN	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
of	ADP	O	O
some	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
indobufen	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
ASA	NOUN	O	O
(	PUNCT	O	O
shorter	VERB	O	O
time	NOUN	O	O
of	ADP	O	O
effect	NOUN	O	O
,	PUNCT	O	O
superior	ADJ	O	O
tolerance	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ulceration	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
former	ADJ	O	O
drug	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
recommended	VERB	O	O
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
some	DET	O	O
indicated	VERB	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Local	ADJ	O	B-MENTAL
contextual	ADJ	O	I-MENTAL
processing	VERB	O	I-MENTAL
in	ADP	O	O
major	ADJ	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
investigated	DET	O	O
local	ADJ	O	B-MENTAL
contextual	ADJ	O	I-MENTAL
processing	VERB	O	I-MENTAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
major	ADJ	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
MDD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
to	PART	O	O
utilize	NOUN	O	O
predictive	ADJ	O	O
contextual	ADJ	O	O
information	NOUN	O	O
to	PART	O	O
facilitate	NOUN	O	O
detection	NOUN	O	O
of	ADP	O	O
predictable	ADJ	O	O
versus	CCONJ	O	O
random	ADJ	O	O
targets	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
We	PRON	O	O
recorded	PROPN	O	O
EEG	NOUN	O	O
in	ADP	O	O
15	NUM	O	O
MDD	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
14	NUM	O	O
age-matched	VERB	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Recording	PUNCT	O	O
blocks	CCONJ	O	O
consisted	DET	O	O
of	ADP	O	O
targets	NOUN	O	O
preceded	VERB	O	O
by	ADP	O	O
randomized	VERB	O	O
sequences	NOUN	O	O
of	ADP	O	O
standards	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
sequences	NOUN	O	O
of	ADP	O	O
standards	NOUN	O	O
that	ADP	O	O
included	VERB	O	O
a	DET	O	O
predictive	ADJ	O	O
sequence	NOUN	O	O
signaling	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
subsequent	ADJ	O	O
target	NOUN	O	O
event	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Both	PUNCT	O	O
MDD	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
age-matched	VERB	O	O
controls	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
significant	ADJ	O	B-PHYSICAL
reaction	NOUN	O	O
time	NOUN	O	O
(	PUNCT	O	O
RT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
P3b	NOUN	O	B-MENTAL
latency	NOUN	O	I-MENTAL
differences	NOUN	O	B-PHYSICAL
between	ADP	O	O
predicted	ADP	O	O
and	CCONJ	O	O
random	ADJ	O	O
targets	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
patients	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
specific	ADJ	O	B-PHYSICAL
prolongation	NOUN	O	B-MENTAL
of	ADP	O	O
these	DET	O	O
measures	NOUN	O	O
during	ADP	O	O
processing	VERB	O	O
of	ADP	O	O
predicted	VERB	O	O
targets	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
an	DET	O	O
attenuation	NOUN	O	O
of	ADP	O	O
P3b	NOUN	O	B-MENTAL
amplitudes	NOUN	O	I-MENTAL
for	ADP	O	O
the	DET	O	O
predictive	ADJ	O	O
sequence	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
target	NOUN	O	O
N1	NOUN	O	B-MENTAL
amplitudes	NOUN	O	I-MENTAL
were	VERB	O	O
attenuated	VERB	O	B-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
MDD	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
able	ADJ	O	O
to	PART	O	O
utilize	NOUN	O	B-MENTAL
predictive	ADJ	O	I-MENTAL
context	NOUN	O	I-MENTAL
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
facilitate	NOUN	O	O
processing	VERB	O	O
of	ADP	O	O
deterministic	ADJ	O	O
targets	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
ability	NOUN	O	B-PHYSICAL
was	VERB	O	O
limited	ADP	O	B-ADVERSE-EFFECTS
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
demonstrated	VERB	O	O
by	ADP	O	O
context-dependent	PUNCT	O	O
P3b	NOUN	O	O
deficits	NOUN	O	O
.	PUNCT	O	O

SIGNIFICANCE	NOUN	O	O
These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
major	ADJ	O	O
depression	NOUN	O	O
have	CCONJ	O	O
altered	VERB	O	B-MENTAL
processing	VERB	O	I-MENTAL
of	ADP	O	I-MENTAL
local	ADJ	O	I-MENTAL
contextual	ADJ	O	I-MENTAL
processing	VERB	O	I-MENTAL
.	PUNCT	O	O

Low	ADJ	O	O
intensity	NOUN	O	O
physical	ADJ	O	O
training	VERB	O	O
in	ADP	O	O
older	PUNCT	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
low	ADJ	O	O
intensity	NOUN	O	O
general	ADJ	O	O
training	ADJ	O	O
program	NOUN	O	O
(	PUNCT	O	O
<	PROPN	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
reserve	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
physical	ADJ	O	O
fitness	NOUN	O	O
of	ADP	O	O
healthy	ADJ	O	O
older	PUNCT	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
comparing	DET	O	O
maximal	ADJ	O	O
and	CCONJ	O	O
submaximal	ADJ	O	O
indices	NOUN	O	O
of	ADP	O	O
training	NUM	O	O
response	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Twenty-two	NUM	O	O
volunteers	NOUN	O	O
over	ADP	O	O
60	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
participated	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sample	NOUN	O	O
was	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
in	ADP	O	O
an	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
older	PUNCT	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
10	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
63.5	NUM	O	O
+/-	SYM	O	O
3	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
9	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
64.2	NUM	O	O
+/-	SYM	O	O
4	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
served	VERB	O	O
as	ADP	O	O
inactive	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
medical	ADJ	O	O
screening	PUNCT	O	O
all	DET	O	O
participants	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
subjects	NOUN	O	O
underwent	VERB	O	O
a	DET	O	O
low	ADJ	O	O
intensity	NOUN	O	O
training	VERB	O	O
.	PUNCT	O	O

Each	DET	O	O
subjects-either	PUNCT	O	O
inactive	ADJ	O	O
or	CCONJ	O	O
active-performed	NOUN	O	O
two	NUM	O	O
treadmill	NOUN	O	O
tests	CCONJ	O	O
at	ADP	O	O
two-days	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
measure	VERB	O	O
maximal	ADJ	O	O
and	CCONJ	O	O
submaximal	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
oxygen	NOUN	O	B-PHYSICAL
uptake	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
VO2	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
pulmonary	ADJ	O	B-PHYSICAL
ventilation	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
VE	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
a	DET	O	O
telemetric	ADJ	O	O
apparatus	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
major	ADJ	O	O
finding	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	ADV	O	O
the	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
submaximal	ADJ	O	B-PHYSICAL
response	NOUN	O	O
to	ADP	O	B-PHYSICAL
exercise	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
experimental	ADJ	O	I-PHYSICAL
subjects	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
expressed	VERB	O	O
by	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
HR	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
VO2	NOUN	O	B-PHYSICAL
VE	NOUN	O	O
while	ADP	O	O
VO2	ADP	O	B-PHYSICAL
max	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	NUM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Thus	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
appears	NOUN	O	O
that	ADP	O	O
a	DET	O	O
low	ADJ	O	O
intensity	NOUN	O	O
general	ADJ	O	O
training	SYM	O	O
similar	ADJ	O	O
to	ADP	O	O
that	ADP	O	O
followed	VERB	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
may	VERB	O	O
represent	VERB	O	O
a	DET	O	O
good	ADJ	O	O
means	NOUN	O	O
to	PART	O	O
improve	PUNCT	O	O
physical	ADJ	O	B-PHYSICAL
fitness	PUNCT	O	I-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
elderly	ADJ	O	O
people	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
supports	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
evaluation	NOUN	O	O
tests	NOUN	O	O
based	VERB	O	O
on	PUNCT	O	O

Virtual	ADJ	O	O
patients	NOUN	O	O
design	NOUN	O	O
and	CCONJ	O	O
its	PUNCT	O	O
effect	NOUN	O	O
on	ADP	O	O
clinical	ADJ	O	B-MENTAL
reasoning	VERB	O	I-MENTAL
and	CCONJ	O	O
student	VERB	O	B-OTHER
experience	NOUN	O	I-OTHER
:	PUNCT	O	O
a	DET	O	O
protocol	NOUN	O	O
for	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
factorial	ADP	O	O
multi-centre	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Virtual	ADJ	O	O
Patients	NOUN	O	O
(	PUNCT	O	O
VPs	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
web-based	VERB	O	O
representations	NOUN	O	O
of	ADP	O	O
realistic	ADJ	O	O
clinical	ADJ	O	O
cases	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
are	VERB	O	O
proposed	VERB	O	O
as	VERB	O	O
being	ADV	O	O
an	DET	O	O
optimal	ADJ	O	O
method	NOUN	O	O
for	ADP	O	O
teaching	PUNCT	O	O
clinical	ADJ	O	O
reasoning	ADJ	O	O
skills	NOUN	O	O
.	PUNCT	O	O

International	ADJ	O	O
standards	NOUN	O	O
exist	ADP	O	O
which	ADP	O	O
define	VERB	O	O
precisely	NOUN	O	O
what	PUNCT	O	O
constitutes	VERB	O	O
a	DET	O	O
VP	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
are	VERB	O	O
multiple	ADJ	O	O
design	NOUN	O	O
possibilities	ADJ	O	O
for	ADP	O	O
VPs	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
there	PUNCT	O	O
is	VERB	O	O
little	DET	O	O
formal	ADJ	O	O
evidence	NOUN	O	O
to	PART	O	O
support	ADJ	O	O
individual	PUNCT	O	O
design	NOUN	O	O
features	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
potentially	ADV	O	O
important	ADJ	O	O
design	NOUN	O	O
features	NOUN	O	O
on	ADP	O	O
clinical	ADJ	O	B-MENTAL
reasoning	ADJ	O	I-MENTAL
skills	NOUN	O	I-MENTAL
and	CCONJ	O	O
the	DET	O	O
student	ADJ	O	B-OTHER
experience	NOUN	O	I-OTHER
.	PUNCT	O	O

These	PUNCT	O	O
are	ADJ	O	O
the	DET	O	O
branching	VERB	O	O
case	NOUN	O	O
pathways	NOUN	O	O
(	PUNCT	O	O
present	ADJ	O	O
or	CCONJ	O	O
absent	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
structured	VERB	O	O
clinical	ADJ	O	O
reasoning	ADJ	O	O
feedback	NOUN	O	O
(	PUNCT	O	O
present	ADJ	O	O
or	CCONJ	O	O
absent	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS/DESIGN	PUNCT	O	O
This	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
multi-centre	NOUN	O	O
randomised	VERB	O	O
2	NUM	O	O
x	SYM	O	O
2	NUM	O	O
factorial	ADJ	O	O
design	NOUN	O	O
study	NOUN	O	O
evaluating	ADP	O	O
two	NUM	O	O
independent	ADJ	O	O
variables	NOUN	O	O
of	ADP	O	O
VP	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
branching	ADP	O	O
(	PUNCT	O	O
present	ADJ	O	O
or	CCONJ	O	O
absent	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
structured	VERB	O	O
clinical	ADJ	O	O
reasoning	ADJ	O	O
feedback	NOUN	O	O
(	PUNCT	O	O
present	ADJ	O	O
or	CCONJ	O	O
absent	ADJ	O	O
)	PUNCT	O	O
.The	PUNCT	O	O
study	NOUN	O	O
will	VERB	O	O
be	DET	O	O
carried	VERB	O	O
out	ADP	O	O
in	ADP	O	O
medical	ADJ	O	O
student	ADJ	O	O
volunteers	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
group	NOUN	O	O
from	ADP	O	O
three	NUM	O	O
university	NOUN	O	O
medical	ADJ	O	O
schools	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	VERB	O	O
Kingdom	NOUN	O	O
,	PUNCT	O	O
Warwick	NOUN	O	O
,	PUNCT	O	O
Keele	ADP	O	O
and	CCONJ	O	O
Birmingham	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
are	VERB	O	O
four	NUM	O	O
core	NOUN	O	O
musculoskeletal	ADJ	O	O
topics	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
case	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
designed	VERB	O	O
in	ADP	O	O
four	NUM	O	O
different	ADJ	O	O
ways	NOUN	O	O
,	PUNCT	O	O
equating	CCONJ	O	O
to	ADP	O	O
16	NUM	O	O
VPs	PUNCT	O	O
required	VERB	O	O
for	ADP	O	O
the	DET	O	O
research	NOUN	O	O
.	PUNCT	O	O

Students	NOUN	O	O
will	ADP	O	O
be	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
completing	ADV	O	O
the	DET	O	O
four	ADV	O	O
VP	NOUN	O	O
topics	NOUN	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
order	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
each	DET	O	O
group	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
a	DET	O	O
different	ADJ	O	O
VP	NOUN	O	O
design	NOUN	O	O
sequentially	ADV	O	O
.	PUNCT	O	O

All	DET	O	O
students	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
the	DET	O	O
four	NUM	O	O
designs	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
outcomes	NOUN	O	O
are	NOUN	O	O
performance	NOUN	O	O
for	ADP	O	O
each	DET	O	O
case	NOUN	O	B-MENTAL
design	NOUN	O	I-MENTAL
in	ADP	O	I-MENTAL
a	DET	O	I-MENTAL
standardized	VERB	O	I-MENTAL
fifteen	PUNCT	O	I-MENTAL
item	NOUN	O	I-MENTAL
clinical	ADJ	O	I-MENTAL
reasoning	ADJ	O	I-MENTAL
assessment	NOUN	O	I-MENTAL
,	PUNCT	O	O
integrated	VERB	O	O
into	ADP	O	O
each	PUNCT	O	O
VP	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
identical	ADJ	O	O
for	ADP	O	O
each	DET	O	O
topic	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
a	DET	O	O
15-item	NOUN	O	B-OTHER
self-reported	VERB	O	I-OTHER
evaluation	NOUN	O	I-OTHER
is	VERB	O	O
completed	VERB	O	O
for	ADP	O	O
each	DET	O	O
VP	NOUN	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
a	DET	O	O
widely	ADV	O	O
used	PUNCT	O	O
EViP	NOUN	O	O
tool	NOUN	O	O
.	PUNCT	O	O

Student	ADJ	O	O
patterns	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
VPs	NOUN	O	O
will	NOUN	O	O
be	VERB	O	O
recorded.In	ADP	O	O
one	NUM	O	O
centre	NOUN	O	O
,	PUNCT	O	O
formative	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
examination	NOUN	O	O
performance	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
recorded	VERB	O	O
,	PUNCT	O	O
along	PUNCT	O	O
with	ADP	O	O
a	ADP	O	O
self	PUNCT	O	O
reported	VERB	O	O
pre	NOUN	O	O
and	CCONJ	O	O
post-intervention	NOUN	O	O
reasoning	PUNCT	O	O
score	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
DTI	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
power	NOUN	O	O
calculations	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
sample	NOUN	O	O
size	NOUN	O	O
of	ADP	O	O
112	NUM	O	O
is	VERB	O	O
required	VERB	O	O
for	ADP	O	O
both	CCONJ	O	O
primary	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
This	DET	O	O
trial	NOUN	O	O
will	NOUN	O	O
provide	VERB	O	O
robust	ADJ	O	O
evidence	NOUN	O	O
to	PART	O	O
support	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
designs	NOUN	O	O
of	ADP	O	O
virtual	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
student	ADJ	O	B-MENTAL
performance	NOUN	O	I-MENTAL
and	CCONJ	O	O
evaluation	NOUN	O	B-OTHER
.	PUNCT	O	O

The	DET	O	O
cases	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
learning	VERB	O	O
materials	NOUN	O	O
will	VERB	O	O
be	PUNCT	O	O
open	ADJ	O	O
access	NOUN	O	O
and	CCONJ	O	O
available	ADJ	O	O
on	ADP	O	O
a	DET	O	O
Creative	ADJ	O	O
Commons	NOUN	O	O
Attribution-Share-Alike	VERB	O	O
license	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
fatigue	NOUN	O	O
syndrome	NOUN	O	O
versus	CCONJ	O	O
neuroendocrineimmune	ADJ	O	O
dysfunction	NOUN	O	O
syndrome	NOUN	O	O
:	PUNCT	O	O
differential	ADJ	O	O
attributions	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
1988	NUM	O	O
,	PUNCT	O	O
when	ADP	O	O
the	DET	O	O
term	NOUN	O	O
chronic	ADJ	O	O
fatigue	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
CFS	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
coined	VERB	O	O
,	PUNCT	O	O
considerable	ADJ	O	O
discussion	NOUN	O	O
has	PUNCT	O	O
occurred	VERB	O	O
about	PUNCT	O	O
stigma	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
this	DET	O	O
diagnostic	ADJ	O	O
term	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
CFS	NOUN	O	O
have	PUNCT	O	O
felt	PUNCT	O	O
that	ADP	O	O
this	DET	O	O
term	NOUN	O	O
trivializes	NOUN	O	O
the	DET	O	O
serious	ADJ	O	O
nature	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
Name	PUNCT	O	O
Change	NOUN	O	O
Work	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
appointed	VERB	O	O
by	ADP	O	O
the	DET	O	O
CFS	NOUN	O	O
Coordinating	VERB	O	O
Committee	NOUN	O	O
,	PUNCT	O	O
developed	VERB	O	O
an	DET	O	O
umbrella	CCONJ	O	O
term	NOUN	O	O
:	PUNCT	O	O
chronic	ADJ	O	O
neuroendocrineimmune	CCONJ	O	O
dysfunction	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
CNDS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
proposed	VERB	O	O
that	ADP	O	O
there	PUNCT	O	O
would	VERB	O	O
be	ADP	O	O
sub-types	DET	O	O
under	ADP	O	O
this	PUNCT	O	O
term	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
being	PART	O	O
CFS	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
attributions	NOUN	O	B-OTHER
of	ADP	O	O
this	DET	O	O
new	ADJ	O	O
umbrella	NOUN	O	O
term	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
CFS	NOUN	O	O
.	PUNCT	O	O

Nurses	NOUN	O	O
and	CCONJ	O	O
physician	NOUN	O	O
assistants	NOUN	O	O
(	PUNCT	O	O
PAs	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
presented	VERB	O	O
a	DET	O	O
case	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
CFS	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
told	ADJ	O	O
that	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
had	PUNCT	O	O
either	CCONJ	O	O
chronic	ADJ	O	O
fatigue	NOUN	O	O
syndrome	NOUN	O	O
,	PUNCT	O	O
chronic	ADJ	O	O
neuroendocrineimmune	CCONJ	O	O
dysfunction	NOUN	O	O
syndrome	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
chronic	ADJ	O	O
neuroendocrineimmune	CCONJ	O	O
dysfunction	NOUN	O	O
syndrome	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
had	PUNCT	O	O
formerly	ADV	O	O
been	PUNCT	O	O
called	VERB	O	O
chronic	ADJ	O	O
fatigue	NOUN	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
different	ADJ	O	O
terms	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
different	ADJ	O	O
attributions	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
PA	NOUN	O	O
respondents	ADJ	O	O
rating	VERB	O	O
the	DET	O	O
CNDS	NOUN	O	O
label	NOUN	O	O
as	PUNCT	O	O
more	VERB	O	O
severe	ADJ	O	O
.	PUNCT	O	O

Results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
more	PUNCT	O	O
medical	ADJ	O	B-OTHER
sounding	ADJ	O	I-OTHER
term	NOUN	O	I-OTHER
(	PUNCT	O	O
CNDS	NOUN	O	O
)	PUNCT	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
attributions	NOUN	O	B-OTHER
that	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
is	VERB	O	O
a	DET	O	O
more	ADV	O	O
serious	ADJ	O	O
,	PUNCT	O	O
disabling	ADP	O	O
illness	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
policy	NOUN	O	O
implications	NOUN	O	O
of	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Detection	NOUN	O	O
of	ADP	O	O
traumatic	ADJ	O	O
arthrotomy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
using	VERB	O	O
the	DET	O	O
saline	ADJ	O	O
solution	NOUN	O	O
load	ADP	O	O
test	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
saline	ADJ	O	O
solution	NOUN	O	O
load	ADP	O	O
test	ADV	O	O
helps	PUNCT	O	O
to	CCONJ	O	O
determine	VERB	O	O
if	PUNCT	O	O
a	DET	O	O
wound	NOUN	O	O
extends	NOUN	O	O
into	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
joint	NOUN	O	O
.	PUNCT	O	O

Little	PUNCT	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
the	DET	O	O
volume	NOUN	O	O
of	ADP	O	O
injected	PUNCT	O	O
intra-articular	ADJ	O	O
saline	ADJ	O	O
solution	NOUN	O	O
that	ADP	O	O
is	VERB	O	O
needed	VERB	O	O
to	ADP	O	O
effectively	ADJ	O	O
rule	NOUN	O	O
in	ADP	O	O
or	CCONJ	O	O
rule	NOUN	O	O
out	ADP	O	O
a	DET	O	O
traumatic	ADJ	O	O
arthrotomy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
appropriate	PUNCT	O	B-OTHER
volume	NOUN	O	I-OTHER
and	CCONJ	O	O
needle	NOUN	O	B-OTHER
location	NOUN	O	I-OTHER
for	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
traumatic	ADJ	O	O
knee	NOUN	O	O
arthrotomy	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
associated	VERB	O	O
variables	NOUN	O	O
,	PUNCT	O	O
including	CCONJ	O	O
knee	NOUN	O	O
circumference	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sex	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Fifty-six	ADJ	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
scheduled	VERB	O	O
for	ADP	O	O
knee	NOUN	O	O
arthroscopy	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
standard	ADJ	O	O
inferolateral	ADJ	O	O
arthroscopic	ADJ	O	O
portal	NOUN	O	O
was	VERB	O	O
made	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
stab	NOUN	O	O
incision	NOUN	O	O
with	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
number-11	NOUN	O	O
blade	NOUN	O	O
.	PUNCT	O	O

Injection	NOUN	O	O
sites	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
superomedial	ADJ	O	O
or	CCONJ	O	O
inferomedial	ADJ	O	O
location	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
saline	ADJ	O	O
solution	NOUN	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mL/sec	NOUN	O	O
through	ADP	O	O
an	DET	O	O
18-gauge	NOUN	O	O
needle	NOUN	O	O
was	VERB	O	O
continued	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
was	VERB	O	O
moved	VERB	O	O
through	ADP	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
motion	NOUN	O	O
until	ADP	O	O
fluid	NOUN	O	O
extravasated	VERB	O	O
from	ADP	O	O
the	DET	O	O
iatrogenic	ADJ	O	O
laceration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
volume	NOUN	O	O
of	ADP	O	O
injected	ADJ	O	O
fluid	NOUN	O	O
was	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
included	VERB	O	O
thirty-one	NUM	O	O
female	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
twenty-five	ADJ	O	O
male	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
combined	VERB	O	O
average	ADP	O	O
age	NOUN	O	O
of	ADP	O	O
fifty	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
average	PUNCT	O	O
body	NOUN	O	B-PHYSICAL
mass	NOUN	O	I-PHYSICAL
index	NOUN	O	I-PHYSICAL
of	ADP	O	O
30.9	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	ADP	O	O
effectively	ADV	O	O
diagnose	PUNCT	O	B-OTHER
50	NUM	O	I-OTHER
%	SYM	O	I-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
arthrotomies	NOUN	O	I-OTHER
,	PUNCT	O	O
75	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
injected	VERB	O	O
fluid	NOUN	O	O
was	VERB	O	O
needed	VERB	O	O
;	PUNCT	O	O
the	DET	O	O
volumes	NOUN	O	O
that	DET	O	O
were	VERB	O	B-OTHER
needed	VERB	O	I-OTHER
in	ADP	O	I-OTHER
order	NOUN	O	I-OTHER
to	ADP	O	I-OTHER
effectively	ADV	O	I-OTHER
diagnose	PUNCT	O	I-OTHER
75	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
90	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
99	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
arthrotomies	NOUN	O	O
were	VERB	O	O
110	PUNCT	O	O
,	PUNCT	O	O
145	NUM	O	O
,	PUNCT	O	O
155	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
175	NUM	O	O
mL	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
volumes	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
injected	VERB	O	I-PHYSICAL
fluid	NOUN	O	I-PHYSICAL
needed	VERB	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
positive	ADJ	O	O
result	CCONJ	O	B-PHYSICAL
at	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
inferomedial	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
superomedial	ADJ	O	I-PHYSICAL
needle	NOUN	O	I-PHYSICAL
locations	NOUN	O	B-PHYSICAL
were	VERB	O	O
64.0	NUM	O	O
and	CCONJ	O	O
95.2	NUM	O	O
mL	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
this	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
necessary	ADJ	O	O
injection	NOUN	O	O
volume	NOUN	O	O
and	CCONJ	O	O
sex	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
knee	NOUN	O	O
circumference	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
detect	NOUN	O	O
95	NUM	O	O
%	SYM	O	O
of	ADP	O	O
1-cm	PUNCT	O	O
inferolateral	ADJ	O	O
arthrotomies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
with	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
saline	ADJ	O	O
solution	NOUN	O	O
load	ADP	O	O
test	NOUN	O	O
,	PUNCT	O	O
155	NUM	O	O
mL	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
injected	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
inferomedial	ADJ	O	O
injection	NOUN	O	O
location	NOUN	O	O
requires	PUNCT	O	O

Bright	PUNCT	O	O
light	VERB	O	O
therapy	NOUN	O	O
in	ADP	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Several	ADJ	O	O
observations	CCONJ	O	O
suggest	VERB	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	O
antagonism	NOUN	O	O
for	ADP	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
(	PUNCT	O	O
PD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
bright	PUNCT	O	O
light	VERB	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
BLT	NOUN	O	O
)	PUNCT	O	O
suppresses	VERB	O	O
melatonin	NOUN	O	O
release	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
an	DET	O	O
established	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
depression	NOUN	O	O
and	CCONJ	O	O
sleep	NOUN	O	O
disturbances	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
has	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
evaluated	VERB	O	O
in	ADP	O	O
PD	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
BLT	NOUN	O	O
on	ADP	O	O
motor	NOUN	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
,	PUNCT	O	O
depression	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
sleep	NOUN	O	B-MENTAL
in	ADP	O	O
PD	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
placebo-controlled	VERB	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
36	NUM	O	O
PD	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
Disease	NOUN	O	O
Rating	PUNCT	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
UPDRS	NOUN	O	O
)	PUNCT	O	O
I-IV	NOUN	O	O
,	PUNCT	O	O
Beck	NOUN	O	O
's	PUNCT	O	O
Depression	NOUN	O	O
Inventory	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Epworth	ADP	O	B-MENTAL
Sleepiness	NOUN	O	I-MENTAL
Scale	NOUN	O	I-MENTAL
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
BLT	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
the	DET	O	O
morning	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
daily	ADJ	O	O
.	PUNCT	O	O

Illuminance	NOUN	O	B-MENTAL
was	VERB	O	O
7.500	NUM	O	O
lux	NOUN	O	O
in	ADP	O	O
the	DET	O	O
active	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
950	NUM	O	O
lux	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
group	NOUN	O	O
differences	NOUN	O	O
were	VERB	O	O
small	ADJ	O	O
,	PUNCT	O	O
BLT	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
tremor	NOUN	O	B-MENTAL
,	PUNCT	O	O
UPDRS	NOUN	O	B-MENTAL
I	NUM	O	I-MENTAL
,	PUNCT	O	O
II	NUM	O	B-MENTAL
,	PUNCT	O	O
and	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
supplementation	NOUN	O	O
with	ADP	O	O
n-3	NOUN	O	O
fatty	ADJ	O	O
acids	NOUN	O	O
on	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
graft	NOUN	O	O
patency	NOUN	O	O
.	PUNCT	O	O

Epidemiologic	ADJ	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
high	ADJ	O	O
dietary	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
long-chain	NOUN	O	O
polyunsaturated	DET	O	O
n-3	NOUN	O	O
fatty	ADJ	O	O
acids	NOUN	O	O
may	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
atherothrombotic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
,	PUNCT	O	O
610	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
grafting	VERB	O	O
were	VERB	O	O
assigned	NUM	O	O
either	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
fish	NOUN	O	O
oil	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
receiving	VERB	O	O
4	NUM	O	O
g/day	PUNCT	O	O
of	ADP	O	O
fish	NOUN	O	O
oil	NOUN	O	O
concentrate	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
antithrombotic	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
either	CCONJ	O	O
aspirin	NOUN	O	O
or	CCONJ	O	O
warfarin	NOUN	O	O
.	PUNCT	O	O

Their	NOUN	O	O
diet	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
phospholipid	NOUN	O	O
fatty	ADJ	O	O
acid	NOUN	O	O
profiles	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
1-year	ADJ	O	O
graft	NOUN	O	B-PHYSICAL
patency	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
angiography	NOUN	O	O
in	ADP	O	O
95	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Vein	NOUN	O	B-PHYSICAL
graft	NOUN	O	I-PHYSICAL
occlusion	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
per	ADP	O	I-PHYSICAL
distal	ADJ	O	I-PHYSICAL
anastomoses	NOUN	O	I-PHYSICAL
were	VERB	O	O
27	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
fish	NOUN	O	O
oil	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
33	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
0.77	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.60	NUM	O	O
to	ADP	O	O
0.99	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.034	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
fish	NOUN	O	O
oil	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
43	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	PUNCT	O	O
>	SYM	O	O
or	PUNCT	O	O

Safety	NOUN	O	O
of	ADP	O	O
intravitreous	PUNCT	O	O
fomivirsen	PUNCT	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
cytomegalovirus	NOUN	O	O
retinitis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
AIDS	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADP	O	O
report	NOUN	O	O
data	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
intravitreous	PUNCT	O	O
fomivirsen	PUNCT	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
cytomegalovirus	NOUN	O	O
(	PUNCT	O	O
CMV	NOUN	O	O
)	PUNCT	O	O
retinitis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acquired	VERB	O	O
immunodeficiency	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
AIDS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Critical	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
safety	NOUN	O	O
data	NOUN	O	O
from	ADP	O	O
three	NUM	O	O
randomized	VERB	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
with	ADP	O	O
supplemental	ADJ	O	O
information	NOUN	O	O
from	ADP	O	O
an	DET	O	O
expanded	VERB	O	O
drug	NOUN	O	O
access	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Adverse	ADJ	O	O
ocular	ADJ	O	O
events	NOUN	O	O
reported	VERB	O	O
by	ADP	O	O
clinician	NOUN	O	O
investigators	NOUN	O	O
were	VERB	O	O
listed	VERB	O	O
using	PUNCT	O	O
terms	NOUN	O	O
modified	VERB	O	O
from	ADP	O	O
the	DET	O	O
COSTART	NOUN	O	O
dictionary	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
for	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
(	PUNCT	O	O
165-microg/injection	NOUN	O	O
[	PUNCT	O	O
35	PUNCT	O	O
eyes	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
patients	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
330-microg/injection	NOUN	O	O
[	PUNCT	O	O
153	PUNCT	O	O
eyes	NOUN	O	O
,	PUNCT	O	O
120	NUM	O	O
patients	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
330-microg/injection	NOUN	O	O
dose	NOUN	O	O
schedules	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
intensity	NOUN	O	O
were	VERB	O	O
pooled	VERB	O	O
to	PART	O	O
calculate	NOUN	O	O
incidence	NOUN	O	O
rates	NOUN	O	O
for	ADP	O	O
each	DET	O	O
event	NOUN	O	O
.	PUNCT	O	O

Rates	NOUN	O	O
were	VERB	O	O
calculated	VERB	O	O
as	PUNCT	O	O
events/patient-year	PUNCT	O	O
(	PUNCT	O	O
based	ADP	O	O
on	ADP	O	O
total	ADJ	O	O
cumulative	ADJ	O	O
reported	VERB	O	O
events	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
events	NOUN	O	O
that	NUM	O	O
could	VERB	O	O
recur	ADP	O	O
during	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Rates	NOUN	O	O
were	VERB	O	O
calculated	VERB	O	O
as	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
events/person-year	ADJ	O	O
for	ADP	O	O
the	DET	O	O
following	ADJ	O	O
events	NOUN	O	O
:	PUNCT	O	O
retinal	ADJ	O	O
detachment	NOUN	O	O
,	PUNCT	O	O
cataract	NOUN	O	O
,	PUNCT	O	O
visual	ADJ	O	O
field	NOUN	O	O
disturbance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
retinal	ADJ	O	O
pigment	NOUN	O	O
epitheliopathy	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	NOUN	O	O
the	DET	O	O
ability	NOUN	O	O
to	PART	O	O
manage	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
reviewed	VERB	O	O
treatments	NOUN	O	O
given	ADJ	O	O
for	ADP	O	O
two	NUM	O	O
events	NOUN	O	O
(	PUNCT	O	O
anterior	ADJ	O	O
chamber	NOUN	O	O
inflammation	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
intraocular	ADJ	O	O
pressure	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
one	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
report	VERB	O	O
an	DET	O	O
analysis	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
eyes	NOUN	O	O
that	ADP	O	O
developed	VERB	O	O
one	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
key	ADJ	O	O
events	NOUN	O	O
to	ADP	O	O
the	DET	O	O
cumulative	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
injections	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Incidence	NOUN	O	O
rates	NOUN	O	O
were	DET	O	O
dose	NOUN	O	O
and	CCONJ	O	O
schedule	NOUN	O	O
dependent	ADJ	O	O
(	PUNCT	O	O
165	NUM	O	O
microg/injection	NOUN	O	O
,	PUNCT	O	O
4.06	NUM	O	O
events/patient-year	PUNCT	O	O
;	PUNCT	O	O
330	NUM	O	O
microg/injection	NOUN	O	O
,	PUNCT	O	O
6.58	NUM	O	O
events/patient-year	PUNCT	O	O
[	PUNCT	O	O
less	ADV	O	O
intense	ADJ	O	O
regimen	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
8.35	NUM	O	O
events/patient-year	PUNCT	O	O
[	PUNCT	O	O
more	ADV	O	O
intense	ADJ	O	O
regimen	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
frequently	ADV	O	O
reported	VERB	O	O
events	NOUN	O	O
were	VERB	O	O
anterior	ADJ	O	B-ADVERSE-EFFECTS
chamber	NOUN	O	I-ADVERSE-EFFECTS
inflammation	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
increased	ADV	O	O
intraocular	ADJ	O	B-ADVERSE-EFFECTS
pressure	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-OTHER
with	ADP	O	I-OTHER
events	NOUN	O	I-OTHER
increased	NUM	O	O
as	ADP	O	O
the	DET	O	O
number	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
injections	NOUN	O	I-OTHER
increased	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Intravitreous	PUNCT	O	O
fomivirsen	PUNCT	O	O
is	VERB	O	O
well	ADP	O	B-OTHER
tolerated	VERB	O	I-OTHER
with	ADP	O	I-OTHER
an	DET	O	I-OTHER
acceptable	ADJ	O	I-OTHER
safety	NOUN	O	I-OTHER
profile	NOUN	O	I-OTHER
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
ocular	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
associated	VERB	O	O
with	ADP	O	O
doses	NOUN	O	O
and	CCONJ	O	O
schedules	NOUN	O	O
used	VERB	O	O
clinically	ADV	O	O
can	ADP	O	O
be	VERB	O	O
managed	PROPN	O	O
successfully	ADV	O	O
with	ADP	O	O
medical	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-PHYSICAL
pharmacology	NOUN	O	I-PHYSICAL
of	ADP	O	O
methadone	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	NOUN	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
methadone	NOUN	O	O
on	ADP	O	O
behaviour	NOUN	O	B-MENTAL
and	CCONJ	O	O
plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
cortisol	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
vasopressin	NOUN	O	I-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
,	PUNCT	O	O
experimental	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

ANIMALS	NOUN	O	O
Nine	NUM	O	O
adult	NOUN	O	O
dogs	NOUN	O	O
(	PUNCT	O	O
beagle	NOUN	O	O
and	CCONJ	O	O
beagle	NOUN	O	O
cross	NOUN	O	O
breeds	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
four	NUM	O	O
males	PROPN	O	O
and	CCONJ	O	O
five	NUM	O	O
females	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Methadone	NOUN	O	O
hydrochloride	NOUN	O	O
,	PUNCT	O	O
0.4	NUM	O	O
mg	NOUN	O	O
kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
intravenously	ADV	O	O
(	PUNCT	O	O
IV	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
subcutaneously	ADV	O	O
(	PUNCT	O	O
SC	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
crossover	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
and	CCONJ	O	O
hormone	NOUN	O	O
analyses	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
were	VERB	O	O
performed	VERB	O	O
using	SYM	O	O
Liquid	ADJ	O	O
Chromatography-Electrospray	NOUN	O	O
Ionization-Tandem	NOUN	O	O
Mass	NOUN	O	O
Spectrometry	NOUN	O	O
and	CCONJ	O	O
radioimmunoassay	NOUN	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Behavioural	ADJ	O	B-MENTAL
data	NOUN	O	I-MENTAL
were	VERB	O	O
collected	VERB	O	O
using	PROPN	O	O
a	DET	O	O
standardized	VERB	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
IV	NUM	O	O
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
plasma	NOUN	O	B-PHYSICAL
concentration	NOUN	O	O
of	ADP	O	B-PHYSICAL
methadone	NOUN	O	B-PHYSICAL
at	ADP	O	O
10	NUM	O	O
minutes	NOUN	O	O
was	VERB	O	O
82.1	NUM	O	O
+/-	SYM	O	O
9.2	NUM	O	O
ng	NOUN	O	O
mL	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
terminal	ADJ	O	O
half-life	NOUN	O	O
was	VERB	O	O
3.9	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
volume	NOUN	O	O
of	ADP	O	O
distribution	NOUN	O	O
9.2	NUM	O	O
+/-	SYM	O	O
3.3	NUM	O	O
L	NOUN	O	O
kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
clearance	NOUN	O	O
27.9	NUM	O	O
+/-	SYM	O	O
7.6	NUM	O	O
mL	NOUN	O	O
minute	PUNCT	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
SC	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
maximal	ADJ	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
was	VERB	O	O
1.26	NUM	O	O
+/-	SYM	O	O
1.04	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
maximal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	B-PHYSICAL
concentration	NOUN	O	O
of	ADP	O	B-PHYSICAL
methadone	NOUN	O	B-PHYSICAL
was	VERB	O	O
23.9	NUM	O	O
+/-	SYM	O	O
14.4	NUM	O	O
ng	NOUN	O	O
mL	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
terminal	ADJ	O	O
half-life	NOUN	O	O
was	VERB	O	O
10.7	NUM	O	O
+/-	SYM	O	O
4.3	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
bioavailability	NOUN	O	B-PHYSICAL
was	VERB	O	O
79	NUM	O	O
+/-	SYM	O	O
22	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

Concentrations	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
cortisol	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
vasopressin	NOUN	O	B-PHYSICAL
were	VERB	O	O
increased	VERB	O	O
for	ADP	O	O
an	DET	O	O
hour	NOUN	O	O
following	ADP	O	O
IV	NUM	O	O
methadone	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
observed	VERB	O	O
behavioural	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
methadone	NOUN	O	O
were	VERB	O	O
decreased	PUNCT	O	O
licking	PROPN	O	B-MENTAL
and	CCONJ	O	O
swallowing	VERB	O	B-MENTAL
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
whining	ADP	O	B-MENTAL
after	PUNCT	O	O
SC	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
latter	ADJ	O	O
finding	NOUN	O	O
is	VERB	O	O
notable	ADJ	O	O
as	PUNCT	O	O
it	DET	O	O
can	VERB	O	O
be	VERB	O	O
misinterpreted	VERB	O	O
as	ADP	O	O
pain	NOUN	O	B-PAIN
when	ADP	O	O
methadone	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
as	PUNCT	O	O
an	DET	O	O
analgesic	ADJ	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
AND	CCONJ	O	O
CLINICAL	ADJ	O	O
RELEVANCE	NOUN	O	O
When	ADP	O	O
methadone	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
by	ADP	O	O
the	DET	O	O
SC	NOUN	O	O
route	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
half-life	NOUN	O	O
was	VERB	O	O
longer	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
individual	ADJ	O	O
variation	NOUN	O	O
in	PUNCT	O	O

Physician-pharmacist	PUNCT	O	O
cooperation	NOUN	O	O
program	NOUN	O	O
for	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
control	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
program	NOUN	O	O
of	ADP	O	O
cooperation	NOUN	O	O
between	ADP	O	O
physician	NOUN	O	O
and	CCONJ	O	O
pharmacist	NOUN	O	O
to	PART	O	O
reduce	NOUN	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
by	ADP	O	O
promoting	VERB	O	O
better	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	NOUN	O	O
)	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
appropriate	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
antihypertensive	ADJ	O	O
medications	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
beneficial	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
lifestyle	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
132	ADJ	O	O
subjects	NOUN	O	O
in	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
the	DET	O	O
age	NOUN	O	O
range	NOUN	O	O
of	ADP	O	O
40-79	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
inclusion	NOUN	O	O
criteria	NOUN	O	O
were	ADV	O	O
:	PUNCT	O	O
systolic	ADJ	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
SBP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
ranging	CCONJ	O	O
from	ADP	O	O
140-179	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
and/or	CCONJ	O	O
diastolic	ADJ	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
DBP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
ranging	CCONJ	O	O
from	ADP	O	O
90-99	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
and	CCONJ	O	O
treatment-naive	ADJ	O	O
(	PUNCT	O	O
untreated	PROPN	O	O
for	ADP	O	O
hypertension	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
or	CCONJ	O	O
on	ADP	O	O
a	DET	O	O
regimen	NOUN	O	O
of	ADP	O	O
medication	NOUN	O	O
for	ADP	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
132	NUM	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
124	NUM	O	O
(	PUNCT	O	O
94	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
already	ADV	O	O
receiving	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
antihypertensive	ADJ	O	O
medications	NOUN	O	O
.	PUNCT	O	O

Equal	ADJ	O	O
numbers	NOUN	O	O
of	ADP	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
physician-pharmacist	NOUN	O	O
intervention	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
66	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
66	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
6-month	NOUN	O	O
follow-up	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
97	NUM	O	O
%	SYM	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
decrease	NOUN	O	O
in	ADP	O	O
SBP/DBP	ADP	O	B-PHYSICAL
,	PUNCT	O	O
as	PUNCT	O	O
measured	VERB	O	O
at	ADP	O	O
home	NOUN	O	O
in	ADP	O	O
the	DET	O	O
morning	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
2.9/3.3	PUNCT	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
for	ADP	O	O
SBP	NOUN	O	O
and	CCONJ	O	O
DBP	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
decrease	NOUN	O	O
in	ADP	O	O
home	NOUN	O	B-PHYSICAL
morning	NOUN	O	I-PHYSICAL
SBP	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
than	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
DBP	NOUN	O	B-PHYSICAL
decline	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
than	PUNCT	O	O
control	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
showed	VERB	O	O
a	DET	O	O
mean	NOUN	O	O
decrease	NOUN	O	O
of	ADP	O	O
2.8	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
(	PUNCT	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
:	PUNCT	O	O
-5.5	ADJ	O	O
to	ADP	O	O
-0.1	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
home	NOUN	O	B-PHYSICAL
morning	NOUN	O	I-PHYSICAL
BP	NOUN	O	I-PHYSICAL
was	VERB	O	O
achieved	VERB	O	O
was	VERB	O	O
53	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
47	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.40	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
higher	PUNCT	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
relative	ADJ	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
able	ADJ	O	O
to	PART	O	O
reduce	NOUN	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
antihypertensive	ADJ	O	B-OTHER
medications	NOUN	O	I-OTHER
(	PUNCT	O	O
31	NUM	O	O
vs.	CCONJ	O	O
8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fewer	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
required	VERB	O	O
additional	ADJ	O	B-PHYSICAL
medications	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
increases	NOUN	O	O
in	ADP	O	O
dosage	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
vs.	CCONJ	O	O
28	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
show	NOUN	O	O
reduction	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
and	CCONJ	O	O
sodium	NOUN	O	B-MENTAL
intake	NOUN	O	I-MENTAL
and	CCONJ	O	O
to	PART	O	O
stop	NOUN	O	B-MENTAL
smoking	VERB	O	I-MENTAL
,	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
A	DET	O	O
program	NOUN	O	O
of	ADP	O	O
cooperation	NOUN	O	O
between	ADP	O	O
physician	NOUN	O	O
and	CCONJ	O	O
pharmacist	NOUN	O	O
was	VERB	O	O
successful	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
by	ADP	O	O
promoting	VERB	O	O
better	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	NOUN	O	O
)	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
appropriate	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
antihypertensive	ADJ	O	O
medications	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
beneficial	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
lifestyle	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
instruction	NOUN	O	O
to	PUNCT	O	O
refrain	ADJ	O	O
from	ADP	O	O
blinking	ADV	O	O
affects	PART	O	O
auditory	ADJ	O	B-PHYSICAL
P3	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
N1	NOUN	O	B-PHYSICAL
amplitudes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Often	DET	O	O
subjects	NOUN	O	O
have	NOUN	O	O
been	PUNCT	O	O
instructed	VERB	O	O
to	PUNCT	O	O
refrain	ADJ	O	O
from	ADP	O	O
blinking	ADP	O	O
lest	ADP	O	O
their	PUNCT	O	O
evoked	VERB	O	O
EEG	NOUN	O	O
potentials	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
distorted	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
whether	CCONJ	O	O
these	DET	O	O
very	DET	O	O
instructions	NOUN	O	O
have	PUNCT	O	O
any	DET	O	O
impact	NOUN	O	O
on	ADP	O	O
P3	NOUN	O	B-PHYSICAL
amplitude	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
tones	NOUN	O	O
were	VERB	O	O
presented	VERB	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
to	PUNCT	O	O
count	PUNCT	O	O
the	DET	O	O
high-pitched	PUNCT	O	O
tones	NOUN	O	O
.	PUNCT	O	O

Half	PUNCT	O	O
the	DET	O	O
subjects	NOUN	O	O
were	VERB	O	O
instructed	VERB	O	O
not	ADV	O	O
to	DET	O	O
blink	PUNCT	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
this	DET	O	O
instruction	NOUN	O	O
was	VERB	O	O
omitted	VERB	O	O
for	ADP	O	O
the	DET	O	O
other	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Target	NOUN	O	O
tones	NOUN	O	O
evoked	ADV	O	O
larger	PUNCT	O	O
P3s	NOUN	O	B-PHYSICAL
than	CCONJ	O	O
non-targets	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
latter	ADJ	O	O
group	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
former	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
particular	ADJ	O	O
not	ADV	O	O
in	ADP	O	O
those	PUNCT	O	O
subjects	NOUN	O	O
that	ADP	O	O
actually	ADV	O	O
blinked	ADP	O	O
rarely	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
groups	NOUN	O	O
also	ADV	O	O
differed	VERB	O	O
in	ADP	O	O
their	ADJ	O	O
N1	NOUN	O	B-PHYSICAL
amplitudes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
relevant	ADJ	O	O
to	ADP	O	O
P3	NOUN	O	O
studies	ADP	O	O
working	CCONJ	O	O
with	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
controls	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
harder	ADJ	O	O
some	CCONJ	O	O
frequently	ADV	O	O
blinking	ADP	O	O
subjects	NOUN	O	O
try	NOUN	O	O
to	PUNCT	O	O
refrain	NOUN	O	O
from	ADP	O	O
blinking	DET	O	O
,	PUNCT	O	O
the	DET	O	O
smaller	PUNCT	O	O
might	PUNCT	O	O
become	VERB	O	O
their	ADP	O	O
P3	NOUN	O	B-PHYSICAL
amplitudes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Omitting	VERB	O	O
the	DET	O	O
instruction	NOUN	O	O
and	CCONJ	O	O
using	VERB	O	O
off-line	NOUN	O	O
blink	PUNCT	O	O
subtraction	NOUN	O	O
procedures	NOUN	O	O
seems	NOUN	O	O
a	DET	O	O
viable	ADJ	O	O
alternative	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
actually	ADV	O	O
motivated	VERB	O	O
by	ADP	O	O
discrepant	NOUN	O	O
findings	NOUN	O	O
on	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
preceding	ADJ	O	O
tone	NOUN	O	O
sequence	NOUN	O	O
on	ADP	O	O
P3	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
discrepancies	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
largely	ADV	O	O
resolved	VERB	O	O
by	ADP	O	O
the	DET	O	O
instructional	ADJ	O	O
variable	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
tone	NOUN	O	B-PHYSICAL
intensities	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
subjects	NOUN	O	O
who	ADP	O	O
are	VERB	O	O
discouraged	PRON	O	O
from	ADP	O	O
blinking	ADP	O	O
try	NOUN	O	O
to	PART	O	O
protect	ADP	O	O
themselves	PUNCT	O	O
against	ADP	O	O
the	DET	O	O
arousing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
stimuli	NOUN	O	O
.	PUNCT	O	O

Cirrhosis	NOUN	O	O
and	CCONJ	O	O
bleeding	VERB	O	O
:	PUNCT	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
very	ADV	O	O
early	ADJ	O	O
management	NOUN	O	O
.	PUNCT	O	O

BACKGROUND/AIMS	ADJ	O	O
Retrospective	ADJ	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
prognosis	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cirrhosis	NOUN	O	O
and	CCONJ	O	O
variceal	ADP	O	O
hemorrhage	NOUN	O	O
has	PUNCT	O	O
improved	VERB	O	O
in	ADP	O	O
more	DET	O	O
recent	ADJ	O	O
decades	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
cohort	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
the	DET	O	O
choice	NOUN	O	O
of	ADP	O	O
prophylactic	ADJ	O	O
therapy	NOUN	O	O
was	VERB	O	O
left	CCONJ	O	O
to	ADP	O	O
each	DET	O	O
practitioner	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
followed	VERB	O	O
cirrhotic	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
medium/large	NOUN	O	O
varices	NOUN	O	O
to	DET	O	O
determine	NOUN	O	O
factors	NOUN	O	O
predictive	ADJ	O	O
of	ADP	O	O
bleeding	VERB	O	O
and	CCONJ	O	O
death	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Three	NUM	O	O
hundred	NUM	O	O
fourteen	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
grades	NOUN	O	O
2	NUM	O	O
or	CCONJ	O	O
3	NUM	O	O
esophageal	ADJ	O	O
varices	NOUN	O	O
(	PUNCT	O	O
Child	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
B/C	NUM	O	O
:	PUNCT	O	O
218	NUM	O	O
and	CCONJ	O	O
96	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
seventy-three	ADJ	O	O
patients	NOUN	O	O
had	VERB	O	O
no	DET	O	O
previous	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
variceal	PUNCT	O	O
bleeding	VERB	O	O
.	PUNCT	O	O

Only	ADV	O	O
245	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prior	DET	O	O
variceal	PUNCT	O	O
hemorrhage	NOUN	O	O
,	PUNCT	O	O
61	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
prior	CCONJ	O	O
hemorrhage	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
receiving	ADJ	O	O
some	DET	O	O
form	NOUN	O	O
of	ADP	O	O
prophylactic	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
was	VERB	O	O
18	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
76	NUM	O	O
bleeding	VERB	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
14	NUM	O	O
related	ADJ	O	B-MORTALITY
deaths	ADV	O	I-MORTALITY
(	PUNCT	O	O
18	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
nine	NUM	O	O
of	ADP	O	O
these	DET	O	O
deaths	NOUN	O	O
occurred	VERB	O	O
within	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
of	ADP	O	O
bleeding	PUNCT	O	B-PHYSICAL
onset	NOUN	O	O
(	PUNCT	O	O
two	NUM	O	O
at	ADP	O	O
home	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
during	ADP	O	O
hospital	NOUN	O	O
transfer	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
five	NUM	O	O
in	ADP	O	O
hospital	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
2.5	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
onset	NOUN	O	O
;	PUNCT	O	O
six	NUM	O	O
involved	VERB	O	O
Child	NOUN	O	O
C	NOUN	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Twenty-five	PUNCT	O	O
deaths	NOUN	O	B-MORTALITY
were	VERB	O	O
not	ADV	O	O
due	PUNCT	O	O
to	ADP	O	O
bleeding	DET	O	O
but	CCONJ	O	O
were	VERB	O	O
closely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
cirrhosis	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
Cox	NOUN	O	O
model	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
tense	NOUN	O	O
ascites	CCONJ	O	O
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
3.4	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
CI	NOUN	O	O
2.5-5.9	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
prior	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
hemorrhage	NOUN	O	O
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
4.4	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
2.6-7.5	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
variceal	PUNCT	O	B-PHYSICAL
hemorrhage	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
a	DET	O	O
prior	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
bleeding	VERB	O	O
,	PUNCT	O	O
bleeding	ADP	O	O
risk	NOUN	O	O
was	VERB	O	O
higher	PUNCT	O	O
with	ADP	O	O
more	DET	O	O
prolonged	VERB	O	O
prothrombin	NOUN	O	O
time	NOUN	O	O
and	CCONJ	O	O
lower	PUNCT	O	O
when	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
propranolol	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Despite	ADP	O	O
the	DET	O	O
advent	NOUN	O	O
of	ADP	O	O
effective	ADJ	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
endoscopic	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
variceal	ADJ	O	O
bleeding	VERB	O	O
,	PUNCT	O	O
about	PUNCT	O	O
a	DET	O	O
quarter	NOUN	O	O
of	ADP	O	O
deaths	NOUN	O	B-MORTALITY
occur	VERB	O	O
very	ADV	O	O
early	ADJ	O	O
after	ADP	O	O
bleeding	NUM	O	O
onset	NOUN	O	O
,	PUNCT	O	O
confirming	CCONJ	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
rapid	ADJ	O	O
specific	ADJ	O	O
management	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
supplementary	ADJ	O	O
antioxidant	NOUN	O	O
vitamin	NOUN	O	O
intake	NOUN	O	O
on	ADP	O	O
carotid	ADJ	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
wall	NOUN	O	I-PHYSICAL
intima-media	NOUN	O	I-PHYSICAL
thickness	NOUN	O	I-PHYSICAL
in	ADP	O	O
a	DET	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
cholesterol	NOUN	O	O
lowering	VERB	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
There	PUNCT	O	O
is	VERB	O	O
accumulating	ADP	O	O
experimental	ADJ	O	O
,	PUNCT	O	O
epidemiological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
an	DET	O	O
association	NOUN	O	O
between	ADP	O	O
anti-oxidant	ADJ	O	O
vitamin	NOUN	O	O
intake	NOUN	O	O
and	CCONJ	O	O
reduced	ADV	O	O
risk	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Cholesterol	NOUN	O	O
Lowering	PUNCT	O	O
Atherosclerosis	NOUN	O	O
Study	NOUN	O	O
(	PUNCT	O	O
CLAS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
explored	PUNCT	O	O
the	DET	O	O
association	NOUN	O	O
of	ADP	O	O
self-selected	VERB	O	O
supplementary	ADJ	O	O
antioxidant	NOUN	O	O
vitamin	NOUN	O	O
intake	NOUN	O	O
on	ADP	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
progression	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
preintrusive	ADJ	O	O
atherosclerosis	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
CLAS	NOUN	O	O
was	VERB	O	O
an	DET	O	O
arterial	ADJ	O	O
imaging	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
nonsmoking	PUNCT	O	O
40-	ADV	O	O
to	ADP	O	O
59-year-old	PUNCT	O	O
men	NOUN	O	O
with	ADP	O	O
previous	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
graft	NOUN	O	O
surgery	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
colestipol/niacin	NOUN	O	O
plus	CCONJ	O	O
diet	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
plus	CCONJ	O	O
diet	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
progression	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
preintrusive	ADJ	O	O
atherosclerosis	NOUN	O	B-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
146	NUM	O	O
subjects	NOUN	O	O
using	VERB	O	O
high-resolution	NOUN	O	O
B-mode	NOUN	O	O
ultrasound	NOUN	O	O
quantification	NOUN	O	O
of	ADP	O	O
the	DET	O	O
distal	ADJ	O	O
common	ADJ	O	O
carotid	ADJ	O	O
artery	NOUN	O	O
far	ADV	O	O
wall	NOUN	O	O
intima-media	NOUN	O	O
thickness	NOUN	O	O
(	PUNCT	O	O
IMT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

From	ADP	O	O
the	DET	O	O
nutritional	ADJ	O	O
supplement	NOUN	O	O
database	NOUN	O	O
,	PUNCT	O	O
22	NUM	O	O
subjects	NOUN	O	O
had	VERB	O	O
an	DET	O	O
on-trial	ADJ	O	O
average	ADJ	O	O
supplementary	ADJ	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
intake	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
100	NUM	O	O
IU	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
(	PUNCT	O	O
high	ADJ	O	O
users	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
29	NUM	O	O
subjects	NOUN	O	O
had	ADP	O	O
an	DET	O	O
average	ADJ	O	O
on-trial	ADJ	O	O
supplementary	ADJ	O	O
vitamin	NOUN	O	O
C	NOUN	O	O
intake	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
250	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
(	PUNCT	O	O
high	ADJ	O	O
users	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Within	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
less	ADV	O	O
carotid	ADJ	O	B-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
progression	NOUN	O	I-PHYSICAL
was	VERB	O	O
found	VERB	O	O
for	ADP	O	O
high	ADJ	O	O
supplementary	ADJ	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
users	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
low	ADJ	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
users	NOUN	O	O
(	PUNCT	O	O
0.008	ADP	O	O
versus	CCONJ	O	O
0.023	NUM	O	O
mm/y	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-PHYSICAL
E	NOUN	O	O
within	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
C	NOUN	O	O
within	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Supplementary	ADJ	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
intake	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
progression	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
atherosclerosis	NOUN	O	I-PHYSICAL
in	ADP	O	O
subjects	NOUN	O	O
not	ADV	O	O
treated	PUNCT	O	O
with	ADP	O	O
lipid-lowering	VERB	O	O
drugs	NOUN	O	O
while	ADP	O	O
the	DET	O	O
process	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
confined	VERB	O	O
to	ADP	O	O
the	DET	O	O
arterial	ADJ	O	O
wall	NOUN	O	O
(	PUNCT	O	O
early	ADJ	O	O
preintrusive	ADJ	O	O
atherosclerosis	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Noradrenergic	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	ADP	O	O
intravenous	ADJ	O	O
yohimbine	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
depression	NOUN	O	O
and	CCONJ	O	O
comorbidity	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	O
and	CCONJ	O	O
panic	ADJ	O	O
.	PUNCT	O	O

Adrenergic	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
following	VERB	O	O
infusions	NOUN	O	O
of	ADP	O	O
yohimbine	NOUN	O	O
or	CCONJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
9	NUM	O	O
control	NOUN	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
a	DET	O	O
major	ADJ	O	O
depressive	ADJ	O	O
episode	NOUN	O	O
(	PUNCT	O	O
MDE	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
concurrent	ADJ	O	O
MDE	NOUN	O	O
and	CCONJ	O	O
panic	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
MDE	NOUN	O	O
+	SYM	O	O
P	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
was	VERB	O	O
drawn	VERB	O	O
at	ADP	O	O
-20	NUM	O	O
,	PUNCT	O	O
0	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
45	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
90	NUM	O	O
min	NOUN	O	O
following	VERB	O	O
the	DET	O	O
infusions	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
assayed	ADJ	O	O
for	ADP	O	O
norepinephrine	NOUN	O	O
(	PUNCT	O	O
NE	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
3-methoxy-4-hydroxy-phenyl	NUM	O	O
glycol	NOUN	O	O
(	PUNCT	O	O
MHPG	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
groups	NOUN	O	O
exhibited	VERB	O	O
higher	PUNCT	O	O
baseline	NOUN	O	O
NE	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
greater	PUNCT	O	O
NE	NOUN	O	B-PHYSICAL
area	NOUN	O	O
under	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
concentration	NOUN	O	O
versus	CCONJ	O	B-PHYSICAL
time	NOUN	O	B-PHYSICAL
curve	NOUN	O	O
(	PUNCT	O	O
AUC0-90	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
yohimbine	NOUN	O	O
infusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Baseline	PUNCT	O	O

Clomipramine	NOUN	O	O
versus	CCONJ	O	O
haloperidol	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

Clomipramine	NOUN	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
overall	ADJ	O	B-MENTAL
outcome	NOUN	O	I-MENTAL
,	PUNCT	O	O
specific	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
hypothesized	VERB	O	O
that	ADP	O	O
clomipramine	NOUN	O	O
would	VERB	O	O
be	ADP	O	O
better	PUNCT	O	O
tolerated	ADP	O	O
than	PUNCT	O	O
haloperidol	NOUN	O	O
and	CCONJ	O	O
prove	ADP	O	O
superior	ADJ	O	O
on	ADP	O	O
a	DET	O	O
measure	NOUN	O	O
of	ADP	O	O
stereotypy	ADJ	O	O
.	PUNCT	O	O

Individuals	NOUN	O	O
with	ADP	O	O
a	DET	O	O
DSM-IV	NOUN	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
16.3	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
10-36	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
,	PUNCT	O	O
by	ADP	O	O
using	VERB	O	O
a	DET	O	O
Latin	NOUN	O	O
square	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
following	ADP	O	O
7-week	NOUN	O	O
trials	NOUN	O	O
:	PUNCT	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
clomipramine	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
daily	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
128.4	NUM	O	O
mg	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
100-150	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
haloperidol	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
daily	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
1.3	NUM	O	O
mg	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
1-1.5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
36	NUM	O	O
subjects	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
and	CCONJ	O	O
taken	VERB	O	O
together	ADV	O	O
;	PUNCT	O	O
the	DET	O	O
results	ADP	O	O
favored	VERB	O	O
haloperidol	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
those	ADP	O	O
patients	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
able	ADJ	O	O
to	ADP	O	O
complete	ADJ	O	O
a	DET	O	O
full	ADJ	O	O
therapeutic	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
clomipramine	NOUN	O	O
proved	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
haloperidol	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
improvement	NOUN	O	B-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
significantly	ADV	O	O
fewer	PUNCT	O	O
individuals	NOUN	O	O
receiving	DET	O	O
clomipramine	NOUN	O	O
versus	CCONJ	O	O
haloperidol	NOUN	O	O
were	VERB	O	O
able	ADJ	O	O
to	ADP	O	O
complete	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
(	PUNCT	O	O
37.5	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
69.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
for	ADP	O	O
reasons	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
both	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
or	CCONJ	O	O
behavior	NOUN	O	B-MENTAL
problems	NOUN	O	I-MENTAL
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
intent-to-treat	NOUN	O	O
sample	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
perhaps	ADV	O	O
more	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
,	PUNCT	O	O
only	ADV	O	O
haloperidol	NOUN	O	O
proved	ADP	O	O
superior	ADJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
on	ADP	O	O
a	DET	O	O
global	ADJ	O	O
measure	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	B-MENTAL
symptom	NOUN	O	I-MENTAL
severity	NOUN	O	I-MENTAL
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
specific	ADJ	O	O
measures	NOUN	O	O
for	ADP	O	O
irritability	NOUN	O	B-MENTAL
and	CCONJ	O	O
hyperactivity	NOUN	O	B-MENTAL
.	PUNCT	O	O

Clomipramine	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
seem	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
on	ADP	O	O
a	DET	O	O
measure	NOUN	O	O
of	ADP	O	O
stereotypy	ADP	O	O
,	PUNCT	O	O
nor	CCONJ	O	O
was	VERB	O	O
it	PRON	O	O
better	PUNCT	O	O
tolerated	ADP	O	O
.	PUNCT	O	O

Anxiety	NOUN	O	O
disorders	NOUN	O	O
in	ADP	O	O
typically	ADV	O	O
developing	ADV	O	O
youth	NOUN	O	O
:	PUNCT	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
symptoms	ADJ	O	O
as	ADP	O	O
a	DET	O	O
predictor	NOUN	O	O
of	ADP	O	O
cognitive-behavioral	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Symptoms	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
assessed	VERB	O	O
(	PUNCT	O	O
Social	ADJ	O	O
Responsiveness	NOUN	O	O
Scale-Parent	ADJ	O	O
(	PUNCT	O	O
SRS-P	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
coded	VERB	O	O
in-session	NOUN	O	O
behavior	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
typically-developing	PUNCT	O	O
,	PUNCT	O	O
anxiety-disordered	VERB	O	O
children	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
50	NUM	O	O
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
cognitive-behavioral	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
CBT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Study	ADJ	O	O
1	NUM	O	O
:	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
autistic	ADJ	O	O
symptomology	NOUN	O	O
(	PUNCT	O	O
per	ADP	O	O
SRS-P	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
improve	VERB	O	O
from	ADP	O	O
family	NOUN	O	O
CBT	NOUN	O	O
(	PUNCT	O	O
FCBT	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
individual	ADJ	O	O
CBT	NOUN	O	O
(	PUNCT	O	O
ICBT	NOUN	O	O
;	PUNCT	O	O
OR	NOUN	O	O
=	SYM	O	O
8.67	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Coded	VERB	O	O
behavior	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
predict	VERB	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

Study	ADV	O	O
2	NUM	O	O
:	PUNCT	O	O
CBT	NOUN	O	O
components	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
by	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
ASD	NOUN	O	O
symptom	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

At-home	PUNCT	O	O
exposure	NOUN	O	O
completion	NOUN	O	O
was	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
FCBT	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
an	DET	O	O
interaction	NOUN	O	O
in	ADP	O	O
child	NOUN	O	O
involvement	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
ASD	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

Though	ADP	O	O
both	CCONJ	O	O
treatments	NOUN	O	O
reduced	VERB	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O
FCBT	NOUN	O	O
outperformed	PUNCT	O	O
ICBT	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
ASD	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
benefit	NOUN	O	O
potentially	ADV	O	O
linked	ADP	O	O
to	ADP	O	O
more	PUNCT	O	O
at-home	NOUN	O	O
exposures	NOUN	O	O
and	CCONJ	O	O
greater	PUNCT	O	O
child	NOUN	O	O
involvement	NOUN	O	O
in	ADP	O	O
FCBT	NOUN	O	O
.	PUNCT	O	O

Enhancing	ADP	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
adherence	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Suboptimal	ADJ	O	O
adherence	NOUN	O	O
to	ADP	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
(	PUNCT	O	O
AED	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
is	VERB	O	O
commonplace	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increases	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
status	NOUN	O	O
epilepticus	NOUN	O	O
and	CCONJ	O	O
sudden	PUNCT	O	O
unexplained	VERB	O	O
death	NOUN	O	O
in	ADP	O	O
epilepsy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
demonstrate	NOUN	O	O
whether	ADP	O	O
an	DET	O	O
implementation	NOUN	O	O
intention	NOUN	O	O
intervention	NOUN	O	O
involving	VERB	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
a	DET	O	O
simple	ADJ	O	O
self-administered	ADJ	O	O
questionnaire	NOUN	O	O
linking	ADJ	O	O
the	DET	O	O
intention	NOUN	O	O
of	ADP	O	O
taking	ADP	O	O
medication	NOUN	O	O
with	ADP	O	O
a	DET	O	O
particular	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
place	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
activity	NOUN	O	O
can	VERB	O	O
improve	VERB	O	O
AED	NOUN	O	O
treatment	NOUN	O	O
schedule	NOUN	O	O
adherence	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
81	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
epilepsy	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
randomized	PROPN	O	O
,	PUNCT	O	O
69	NUM	O	O
completed	DET	O	O
a	DET	O	O
1-month	NOUN	O	O
monitoring	VERB	O	O
period	NOUN	O	O
with	ADP	O	O
an	DET	O	O
objective	ADJ	O	O
measure	NOUN	O	O
of	ADP	O	O
tablet	NOUN	O	O
taking	PUNCT	O	O
(	PUNCT	O	O
electronic	ADJ	O	O
registration	NOUN	O	O
of	ADP	O	O
pill	ADJ	O	O
bottle	NOUN	O	O
openings	NOUN	O	O
,	PUNCT	O	O
Medication	NOUN	O	O
Event	NOUN	O	O
Monitoring	PUNCT	O	O
System	NOUN	O	O
[	PUNCT	O	O
MEMS	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intervention	NOUN	O	O
participants	NOUN	O	O
showed	VERB	O	O
improved	VERB	O	B-MENTAL
adherence	NOUN	O	I-MENTAL
relative	ADJ	O	I-MENTAL
to	ADP	O	I-MENTAL
controls	CCONJ	O	I-MENTAL
on	ADP	O	O
all	DET	O	O
three	NUM	O	O
outcomes	NOUN	O	O
:	PUNCT	O	O
doses	NOUN	O	B-OTHER
taken	VERB	O	I-OTHER
in	ADP	O	I-OTHER
total	ADJ	O	O
(	PUNCT	O	O
93.4	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
79.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
days	NOUN	O	O
on	ADP	O	O
which	CCONJ	O	O
correct	ADJ	O	B-OTHER
dose	NOUN	O	I-OTHER
was	VERB	O	I-OTHER
taken	VERB	O	I-OTHER
(	PUNCT	O	O
88.7	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
65.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
doses	NOUN	O	B-OTHER
taken	VERB	O	I-OTHER
on	ADP	O	I-OTHER
schedule	NOUN	O	I-OTHER
(	PUNCT	O	O
78.8	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
55.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
implementation	NOUN	O	O
intention	NOUN	O	O
intervention	NOUN	O	O
may	VERB	O	O
be	ADJ	O	O
an	DET	O	O
easy-to-administer	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
means	NOUN	O	O
of	ADP	O	O
promoting	VERB	O	O
AED	NOUN	O	O
adherence	NOUN	O	O
.	PUNCT	O	O

RAB-plate	ADJ	O	O
versus	CCONJ	O	O
sliding	ADJ	O	O
hip	NOUN	O	O
screw	PUNCT	O	O
for	ADP	O	O
unstable	ADJ	O	O
trochanteric	NOUN	O	O
hip	NOUN	O	O
fractures	NOUN	O	O
:	PUNCT	O	O
stability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fixation	NOUN	O	O
and	CCONJ	O	O
modes	NOUN	O	O
of	ADP	O	O
failure	NOUN	O	O
--	PUNCT	O	O
radiographic	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
218	NUM	O	O
fractures	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
sliding	ADJ	O	O
hip	NOUN	O	O
screw	PUNCT	O	O
has	PUNCT	O	O
gained	VERB	O	O
considerable	ADJ	O	O
acceptance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
unstable	ADJ	O	O
trochanteric	NOUN	O	O
fractures	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
new	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
120	NUM	O	O
degrees	NOUN	O	O
fixed	VERB	O	O
angle	NOUN	O	O
blade-plate	ADJ	O	O
with	ADP	O	O
a	DET	O	O
buttress	PUNCT	O	O
rod	NOUN	O	O
(	PUNCT	O	O
RAB-plate	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
encouraging	ADP	O	O
clinical	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
assess	NOUN	O	O
stability	NOUN	O	O
of	ADP	O	O
fixation	NOUN	O	O
and	CCONJ	O	O
analyze	ADP	O	O
modes	NOUN	O	O
of	ADP	O	O
failure	NOUN	O	O
in	ADP	O	O
unstable	ADJ	O	O
trochanteric	NOUN	O	O
hip	NOUN	O	O
fractures	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
these	DET	O	O
devices	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
retrospective	ADJ	O	O
radiographic	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
218	NUM	O	O
unstable	ADJ	O	O
fractures	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

Linear	ADJ	O	O
and	CCONJ	O	O
angular	ADJ	O	O
displacements	NOUN	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
fragments	NOUN	O	O
and	CCONJ	O	O
implant	NOUN	O	B-PHYSICAL
migration	NOUN	O	I-PHYSICAL
into	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
femoral	ADJ	O	I-PHYSICAL
head	NOUN	O	I-PHYSICAL
during	ADP	O	O
healing	ADP	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
adequacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
location	NOUN	O	O
of	ADP	O	O
the	DET	O	O
implant	NOUN	O	O
within	ADP	O	O
the	DET	O	O
femoral	ADJ	O	O
head	NOUN	O	O
as	ADP	O	O
predictors	NOUN	O	O
of	ADP	O	O
fixation	NOUN	O	O
failure	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
postreduction	NOUN	O	O
neck-shaft	NOUN	O	O
angle	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
in	ADP	O	O
the	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fractures	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
varus	NOUN	O	O
angulation	NOUN	O	O
by	ADP	O	O
10	NUM	O	O
degrees	NOUN	O	O
or	CCONJ	O	O
more	DET	O	O
by	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
healing	VERB	O	O
among	ADP	O	O
fractures	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
sliding	ADJ	O	O
hip	NOUN	O	O
screw	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
vertical	ADJ	O	B-PHYSICAL
migration	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
device	NOUN	O	I-PHYSICAL
into	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
femoral	ADJ	O	I-PHYSICAL
head	NOUN	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
implants	NOUN	O	O
used	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
failure	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fixation	NOUN	O	O
and	CCONJ	O	O
varus	NOUN	O	O
reduction	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
screw/neck	NOUN	O	O
angle	NOUN	O	O
deviation	NOUN	O	O
more	ADV	O	O
than	PUNCT	O	O
20	NUM	O	O
degrees	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lateral	ADJ	O	O
projection	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
if	PUNCT	O	O
the	DET	O	O
implant	NOUN	O	O
was	VERB	O	O
in	ADP	O	O
a	DET	O	O
superior	ADJ	O	O
or	CCONJ	O	O
posterior	ADJ	O	O
position	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
RAB-plate	ADJ	O	O
provided	VERB	O	O
a	DET	O	O
more	ADV	O	O
stable	ADJ	O	O
fixation	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
maintained	PUNCT	O	O
postoperative	ADJ	O	O
alignment	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
positive	ADJ	O	O
predictors	NOUN	O	O
for	ADP	O	O
fixation	NOUN	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
were	VERB	O	O
identical	ADJ	O	O
for	ADP	O	O
both	PUNCT	O	O
devices	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
screw/neck	NOUN	O	O
angle	NOUN	O	O
deviation	NOUN	O	O
has	PUNCT	O	O
had	PUNCT	O	O
the	DET	O	O
strongest	PUNCT	O	O
significance	NOUN	O	O
for	ADP	O	O
prediction	NOUN	O	O
of	ADP	O	O
fixation	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

Randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
balance-based	VERB	O	O
torso	ADP	O	O
weighting	CCONJ	O	O
for	ADP	O	O
improving	ADP	O	O
upright	PUNCT	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
in	ADP	O	O
people	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Torso	NOUN	O	O
weighting	ADP	O	O
has	PUNCT	O	O
sometimes	NOUN	O	O
been	PUNCT	O	O
effective	ADJ	O	O
for	ADP	O	O
improving	ADP	O	O
upright	PUNCT	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
in	ADP	O	O
people	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
parameters	NOUN	O	B-PHYSICAL
for	ADP	O	I-PHYSICAL
weighting	PROPN	O	I-PHYSICAL
have	DET	O	O
been	PUNCT	O	O
inconsistent	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
whether	ADP	O	O
balance-based	VERB	O	O
torso	ADP	O	O
weighting	PROPN	O	O
(	PUNCT	O	O
BBTW	PUNCT	O	O
)	PUNCT	O	O
has	PUNCT	O	O
immediate	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
upright	PUNCT	O	O
mobility	NOUN	O	O
in	ADP	O	O
people	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
2-phase	NOUN	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
phase	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
36	NUM	O	O
participants	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
experimental	ADJ	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
phase	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
subsequently	ADV	O	O
randomized	PUNCT	O	O
into	ADP	O	O
2	NUM	O	O
groups	NOUN	O	O
with	ADP	O	O
alternate	NOUN	O	O
weight-placement	ADJ	O	O
.	PUNCT	O	O

Tests	NOUN	O	O
of	ADP	O	O
upright	PUNCT	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
included	VERB	O	O
:	PUNCT	O	O
timed	PUNCT	O	B-PHYSICAL
up	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
go	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
TUG	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
sharpened	ADP	O	B-PHYSICAL
Romberg	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
360-degree	ADP	O	B-PHYSICAL
turns	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
25-foot	NOUN	O	B-PHYSICAL
walk	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
computerized	VERB	O	B-PHYSICAL
platform	NOUN	O	I-PHYSICAL
posturography	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
again	ADV	O	O
with	ADP	O	O
weights	PUNCT	O	O
placed	VERB	O	O
according	ADP	O	O
to	ADP	O	O
group	NOUN	O	O
membership	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	PUNCT	O	O
phases	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
physical	ADJ	O	O
therapist	NOUN	O	O
assessed	VERB	O	O
balance	NOUN	O	O
for	ADP	O	O
the	DET	O	O
BBTW	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
placed	VERB	O	O
weights	NOUN	O	O
to	VERB	O	O
decrease	NOUN	O	O
balance	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
phase	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
control	ADV	O	O
group	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
weights	NOUN	O	O
placed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
phase	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
alternate	NOUN	O	O
treatment	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
standard	ADJ	O	O
weight	NOUN	O	O
placement	NOUN	O	O
of	ADP	O	O
1.5	NUM	O	O
%	SYM	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
People	NUM	O	O
with	ADP	O	O
BBTW	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
25-foot	NOUN	O	B-PHYSICAL
walk	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
over	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
weight	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
TUG	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
over	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
standard	ADJ	O	O
weight	NOUN	O	O
placement	NOUN	O	O
.	PUNCT	O	O

BBTW	PUNCT	O	O
participants	NOUN	O	O
received	VERB	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
less	ADV	O	O
than	ADP	O	O
1.5	NUM	O	O
%	SYM	O	O
of	ADP	O	O
any	DET	O	O
participant	NOUN	O	O
's	PUNCT	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
BBTW	CCONJ	O	O
can	VERB	O	O
have	PUNCT	O	O
immediate	ADJ	O	O
advantages	NOUN	O	O
over	ADP	O	O
a	DET	O	O
nonweighted	ADJ	O	O
condition	NOUN	O	O
for	ADP	O	O
gait	NOUN	O	B-PHYSICAL
velocity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
over	ADP	O	O
a	DET	O	O
standardized	VERB	O	O
weighted	VERB	O	O
condition	NOUN	O	O
for	ADP	O	O
a	DET	O	O
functional	ADJ	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
in	ADP	O	O
people	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
(	PUNCT	O	O
MS	NOUN	O	O
)	PUNCT	O	O
who	DET	O	O
are	VERB	O	O
ambulatory	ADJ	O	O
but	CCONJ	O	O
have	PUNCT	O	O
balance	NOUN	O	O
and	CCONJ	O	O
mobility	NOUN	O	O
abnormalities	NOUN	O	O
.	PUNCT	O	O

Peritoneovenous	ADJ	O	O
shunting	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
alcoholic	ADJ	O	O
cirrhosis	NOUN	O	O
and	CCONJ	O	O
massive	ADJ	O	O
ascites	VERB	O	O
.	PUNCT	O	O

Veterans	PUNCT	O	O
Administration	NOUN	O	O
Cooperative	VERB	O	O
Study	NOUN	O	O
on	ADP	O	O
Treatment	NOUN	O	O
of	ADP	O	O
Alcoholic	ADJ	O	O
Cirrhosis	NOUN	O	O
with	ADP	O	O
Ascites	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
optimal	ADJ	O	O
management	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
ascites	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
alcoholic	ADJ	O	O
cirrhosis	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	PUNCT	O	O
defined	VERB	O	O
.	PUNCT	O	O

in	ADP	O	O
a	DET	O	O
5	NUM	O	O
1/2-year	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
randomly	PUNCT	O	O
assigned	PUNCT	O	O
299	NUM	O	O
men	NOUN	O	O
with	ADP	O	O
alcoholic	ADJ	O	O
cirrhosis	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
had	ADP	O	O
persistent	ADJ	O	O
or	CCONJ	O	O
recurrent	ADJ	O	O
severe	ADJ	O	O
ascites	CCONJ	O	O
despite	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
medical	ADJ	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
intensive	ADJ	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
or	CCONJ	O	O
peritoneovenous	ADJ	O	O
(	PUNCT	O	O
LeVeen	NUM	O	O
)	PUNCT	O	O
shunting	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
identified	VERB	O	O
three	NUM	O	O
risk	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
Group	NOUN	O	O
1	NUM	O	O
had	PUNCT	O	O
normal	ADJ	O	O
or	CCONJ	O	O
mildly	ADV	O	O
abnormal	ADJ	O	O
results	CCONJ	O	O
on	ADP	O	O
liver-function	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
Group	NOUN	O	O
2	NUM	O	O
had	PUNCT	O	O
more	ADV	O	O
severe	ADJ	O	O
liver	NOUN	O	O
dysfunction	NOUN	O	O
or	CCONJ	O	O
previous	ADJ	O	O
complications	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Group	NOUN	O	O
3	NUM	O	O
had	PUNCT	O	O
severe	ADJ	O	O
prerenal	ADJ	O	O
azotemia	NOUN	O	O
without	ADP	O	O
kidney	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
the	DET	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
those	ADP	O	O
who	ADP	O	O
received	VERB	O	O
the	DET	O	O
surgical	ADJ	O	O
treatment	NOUN	O	O
combined	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
survival	NOUN	O	O
times	NOUN	O	O
were	VERB	O	O
1093	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
222	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
37	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
3	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
all	DET	O	O
comparisons	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
all	DET	O	O
the	DET	O	O
groups	NOUN	O	O
combined	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
time	NOUN	O	O
to	ADP	O	O
the	DET	O	O
resolution	NOUN	O	O
of	ADP	O	O
ascites	NOUN	O	O
was	VERB	O	O
5.4	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
medical	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
3.0	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Within	ADP	O	O
each	DET	O	O
risk	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
mortality	NOUN	O	B-MORTALITY
during	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
hospitalization	NOUN	O	O
and	CCONJ	O	O
median	ADJ	O	O
long-term	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
were	VERB	O	O
similar	ADJ	O	O
among	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
either	PUNCT	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
time	NOUN	O	O
to	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
ascites	CCONJ	O	I-PHYSICAL
in	ADP	O	O
Group	NOUN	O	O
1	NUM	O	O
was	VERB	O	O
4	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
medical	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
in	ADP	O	O
Group	NOUN	O	O
2	NUM	O	O
it	PUNCT	O	O
was	VERB	O	O
3	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
medical	ADJ	O	O
patients	NOUN	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
duration	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
hospitalization	NOUN	O	I-OTHER
was	VERB	O	O
longer	PUNCT	O	O
in	ADP	O	O
medical	ADJ	O	O
patients	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
6.1	ADJ	O	O
vs.	CCONJ	O	O
2.4	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
1	NUM	O	O
[	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.001	NUM	O	O
]	PUNCT	O	O
and	CCONJ	O	O
5.0	NUM	O	O
vs.	CCONJ	O	O
3.1	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
2	NUM	O	O
[	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.01	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Group	NOUN	O	O
3	NUM	O	O
was	VERB	O	O
too	ADV	O	O
small	ADJ	O	O
to	PART	O	O
permit	PUNCT	O	O
a	DET	O	O
meaningful	ADJ	O	O
comparison	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
hospitalization	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
infections	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
gastrointestinal	ADJ	O	B-ADVERSE-EFFECTS
bleeding	VERB	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
,	PUNCT	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
and	CCONJ	O	O
myocardial	ADJ	O	O
ischaemic/reperfusion	NOUN	O	O
on	ADP	O	O
free	ADJ	O	B-PHYSICAL
radical	NOUN	O	I-PHYSICAL
generation	NOUN	O	I-PHYSICAL
in	ADP	O	O
CABG	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	NOUN	O	O
the	DET	O	O
free	ADJ	O	O
radicals	NOUN	O	O
(	PUNCT	O	O
FR	NOUN	O	O
)	PUNCT	O	O
generation	NOUN	O	O
after	ADP	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
and	CCONJ	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
reperfusion	NOUN	O	O
in	ADP	O	O
CABG	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty-three	ADP	O	O
CABG	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
into	ADP	O	O
an	DET	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
and	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
protocol	NOUN	O	O
for	ADP	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
was	VERB	O	O
two	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
2-min	NOUN	O	O
ischaemia	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
3-min	NOUN	O	O
reperfusion	NOUN	O	O
.	PUNCT	O	O

Free	ADJ	O	B-PHYSICAL
radicals	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
electron	NOUN	O	O
spin	NOUN	O	O
resonance	NOUN	O	O
spectroscopy	NOUN	O	O
.	PUNCT	O	O

Global	VERB	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
right	VERB	O	I-PHYSICAL
heart	NOUN	O	I-PHYSICAL
functions	CCONJ	O	I-PHYSICAL
were	VERB	O	O
collected	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
free	ADJ	O	B-PHYSICAL
radicals	NOUN	O	I-PHYSICAL
generation	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
coronary	ADJ	O	I-PHYSICAL
sinus	NOUN	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
ischaemic	ADJ	O	O
preconditioning	PUNCT	O	O
group	NOUN	O	O
was	VERB	O	O
9.7	NUM	O	O
and	CCONJ	O	O
16.6	NUM	O	O
%	SYM	O	O
after	ADP	O	O
the	DET	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
protocol	NOUN	O	O
and	CCONJ	O	O
10	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
declamping	ADP	O	O
,	PUNCT	O	O
6.8	NUM	O	O
and	CCONJ	O	O
13.3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
free	ADJ	O	B-PHYSICAL
radicals	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
samples	NOUN	O	I-PHYSICAL
were	VERB	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
21	NUM	O	O
,	PUNCT	O	O
14	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
%	SYM	O	O
at	ADP	O	O
10	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
reperfusion	NOUN	O	O
.	PUNCT	O	O

Cardiac	ADJ	O	B-PHYSICAL
index	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
CI	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
right	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
ejection	NOUN	O	I-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
RVEF	PUNCT	O	B-PHYSICAL
)	PUNCT	O	I-PHYSICAL
were	VERB	O	O
improved	VERB	O	O
by	ADP	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Both	CCONJ	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
and	CCONJ	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
induced	VERB	O	O
free	ADJ	O	B-PHYSICAL
radicals	NOUN	O	I-PHYSICAL
generation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Although	ADP	O	O
ischaemic	ADJ	O	O
preconditioning	VERB	O	O
had	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
on	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
short-term	NOUN	O	O
aromatase	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
letrozole	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
GnRH	NOUN	O	O
agonist	NOUN	O	O
(	PUNCT	O	O
triptorelin	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
case	NOUN	O	O
control	NOUN	O	O
on	ADP	O	O
pregnancy	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
symptom	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
sign	ADP	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
after	ADP	O	O
laparoscopic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
endometriosis	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
compare	NOUN	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
an	DET	O	O
aromatase	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
letrozole	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
GnRH	NOUN	O	O
agonist	NOUN	O	O
(	PUNCT	O	O
triptorelin	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
case	NOUN	O	O
control	NOUN	O	O
on	ADP	O	O
the	DET	O	O
pregnancy	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
recurrence	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
signs	NOUN	O	B-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
endometriosis	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
144	NUM	O	O
infertile	ADP	O	O
women	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
reproductive	ADJ	O	O
age	NOUN	O	O
by	ADP	O	O
laparoscopy	NOUN	O	O
(	PUNCT	O	O
whose	ADP	O	O
endometriosis	NOUN	O	O
was	VERB	O	O
confirmed	VERB	O	O
by	PUNCT	O	O
prior	PUNCT	O	O
laparoscopy	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
they	PUNCT	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
3	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
47	NUM	O	O
cases	NOUN	O	O
)	PUNCT	O	O
who	ADP	O	O
received	VERB	O	O
letrozole	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
40	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
who	ADP	O	O
were	VERB	O	O
prescribed	VERB	O	O
triptorelin	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
group	NOUN	O	O
3	NUM	O	O
who	ADP	O	O
were	VERB	O	O
57	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
did	DET	O	O
not	ADV	O	O
receive	VERB	O	O
any	DET	O	O
medication	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
followed	VERB	O	O
up	PUNCT	O	O
each	DET	O	O
group	NOUN	O	O
at	DET	O	O
least	DET	O	O
for	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
their	PUNCT	O	O
restoration	NOUN	O	O
of	ADP	O	O
regular	ADJ	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Pregnancy	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
23.4	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
27.5	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
28.1	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
3	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	B-OTHER
show	VERB	O	I-OTHER
significant	ADJ	O	I-OTHER
differences	NOUN	O	I-OTHER
among	ADP	O	O
the	DET	O	O
3	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Recurrence	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
endometriosis	NOUN	O	I-PHYSICAL
was	VERB	O	O
6.4	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
%	ADV	O	O
group	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
5.3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADJ	O	B-OTHER
significantly	ADV	O	I-OTHER
different	ADJ	O	I-OTHER
as	CCONJ	O	O
well	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Pregnancy	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
endometriosis	NOUN	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
are	VERB	O	O
comparable	ADJ	O	O
among	ADP	O	O
the	DET	O	O
3	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Standardized	VERB	O	O
preoperative	ADJ	O	O
corticosteroid	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
neonates	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
results	CCONJ	O	O
from	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
A	ADV	O	O
heightened	VERB	O	O
inflammatory	ADJ	O	O
response	NOUN	O	O
occurs	NOUN	O	O
after	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
perioperative	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
glucocorticoids	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
advocated	VERB	O	O
as	ADP	O	O
a	DET	O	O
method	NOUN	O	O
to	PART	O	O
improve	PUNCT	O	O
postoperative	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Randomized	VERB	O	O
prospective	ADJ	O	O
studies	NOUN	O	O
to	PART	O	O
quantify	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
methylprednisolone	NUM	O	O
on	ADP	O	O
perioperative	ADP	O	O
outcomes	NOUN	O	O
in	ADP	O	O
neonatal	ADJ	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
have	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
performed	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
preoperative	ADJ	O	O
methylprednisolone	NOUN	O	O
would	VERB	O	O
improve	VERB	O	O
postoperative	ADJ	O	O
recovery	NOUN	O	O
in	ADP	O	O
neonates	NOUN	O	O
requiring	VERB	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Neonates	PROPN	O	O
scheduled	VERB	O	O
for	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
2-dose	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
hours	NOUN	O	O
preoperatively	ADV	O	O
and	CCONJ	O	O
operatively	ADV	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
39	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
single-dose	NOUN	O	O
(	PUNCT	O	O
operatively	PROPN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
37	NUM	O	O
)	PUNCT	O	O
methylprednisolone	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
mg/kg	NOUN	O	O
per	ADP	O	O
dose	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
standardized	VERB	O	O
score	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
death	NOUN	O	O
36	NUM	O	O
hours	NOUN	O	O
postoperatively	NUM	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
outcomes	NOUN	O	O
were	VERB	O	O
death	NOUN	O	O
at	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
interleukin-6	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
inotropic	ADJ	O	O
score	NOUN	O	O
,	PUNCT	O	O
fluid	NOUN	O	O
balance	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
creatinine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
and	CCONJ	O	O
hospital	NOUN	O	O
stay	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Preoperative	ADJ	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
the	DET	O	O
inflammatory	ADJ	O	O
cytokine	NOUN	O	O
interleukin-6	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
2-fold	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
2-dose	NOUN	O	O
methylprednisolone	NUM	O	O
group	NOUN	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
anti-inflammatory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
syndrome	NOUN	O	O
was	VERB	O	O
46	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
17/37	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
single-dose	NOUN	O	O
and	CCONJ	O	O
38	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
15/39	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
2-dose	NOUN	O	O
methylprednisolone	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.51	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two-dose	ADJ	O	O
methylprednisolone	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
creatinine	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
0.61	NUM	O	O
?	PUNCT	O	O

0.18	NUM	O	O
mg/dL	NOUN	O	O
vs	CCONJ	O	O
0.53	NUM	O	O
?	PUNCT	O	O

0.12	NUM	O	O
mg/dL	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
poorer	PUNCT	O	O
postoperative	ADJ	O	O
diuresis	NOUN	O	O
(	PUNCT	O	O
-96	ADJ	O	O
?	PUNCT	O	O

49	NUM	O	O
mL	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Inotropic	ADJ	O	O
requirement	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
mechanical	ADJ	O	O
ventilation	NOUN	O	O
,	PUNCT	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hospital	NOUN	O	O
stay	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Combined	PROPN	O	O
preoperative	ADJ	O	O
and	CCONJ	O	O
intraoperative	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
glucocorticoids	NOUN	O	O
in	ADP	O	O
neonatal	ADJ	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
favorably	ADV	O	O
affect	ADV	O	O
early	ADJ	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
and	CCONJ	O	O
may	ADJ	O	O
exacerbate	CCONJ	O	O
perioperative	ADJ	O	O
renal	ADJ	O	O
dysfunction	NOUN	O	O
.	PUNCT	O	O

Temporal	ADJ	O	O
expectation	NOUN	O	O
in	ADP	O	O
focal	ADJ	O	O
hand	NOUN	O	O
dystonia	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
writer	ADJ	O	O
's	PUNCT	O	O
cramp	NOUN	O	O
present	VERB	O	O
sensory	ADJ	O	O
and	CCONJ	O	O
representational	ADJ	O	O
abnormalities	NOUN	O	O
relevant	ADJ	O	O
to	ADP	O	O
motor	NOUN	O	O
control	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	VERB	O	O
impairment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
discrimination	NOUN	O	O
between	ADP	O	O
tactile	NOUN	O	O
stimuli	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
pure	ADJ	O	O
motor	NOUN	O	O
imagery	PUNCT	O	O
tasks	NOUN	O	O
,	PUNCT	O	O
like	ADP	O	O
the	DET	O	O
mental	ADJ	O	O
rotation	NOUN	O	O
of	ADP	O	O
corporeal	ADJ	O	O
and	CCONJ	O	O
inanimate	PUNCT	O	O
objects	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
only	ADV	O	O
limited	VERB	O	O
information	NOUN	O	O
is	VERB	O	O
available	ADJ	O	O
on	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
dystonia	NOUN	O	O
to	ADP	O	O
process	NOUN	O	O
the	DET	O	O
time-dependent	ADJ	O	O
features	NOUN	O	O
(	PUNCT	O	O
e.g	NUM	O	O
.	PUNCT	O	O

speed	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
movement	NOUN	O	O
in	ADP	O	O
real	ADJ	O	O
time	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
processing	VERB	O	O
of	ADP	O	O
time-dependent	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
movement	NOUN	O	O
has	VERB	O	O
a	DET	O	O
crucial	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
predicting	VERB	O	O
whether	ADP	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
a	DET	O	O
complex	ADJ	O	O
motor	NOUN	O	O
sequence	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
handwriting	VERB	O	O
or	CCONJ	O	O
playing	VERB	O	O
a	DET	O	O
musical	ADJ	O	O
passage	NOUN	O	O
,	PUNCT	O	O
will	VERB	O	O
be	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
its	PUNCT	O	O
ultimate	ADJ	O	O
goal	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
results	ADJ	O	O
instead	PUNCT	O	O
in	ADP	O	O
an	DET	O	O
execution	NOUN	O	O
error	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
implicit	NOUN	O	O
ability	NOUN	O	O
to	ADP	O	O
perceive	CCONJ	O	O
the	DET	O	O
temporal	ADJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
movements	NOUN	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
writer	ADJ	O	O
's	PUNCT	O	O
cramp	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
patients	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
writer	ADJ	O	O
's	PUNCT	O	O
cramp	NOUN	O	O
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
hand	NOUN	O	O
and	CCONJ	O	O
17	NUM	O	O
age-	NOUN	O	O
and	CCONJ	O	O
gender-matched	NOUN	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
asked	VERB	O	O
to	PART	O	O
perform	NOUN	O	O
a	DET	O	O
temporal	ADJ	O	O
expectation	NOUN	O	O
task	NOUN	O	O
by	ADP	O	O
predicting	VERB	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
visually	ADV	O	O
perceived	VERB	O	O
human	NOUN	O	O
body	NOUN	O	O
motion	NOUN	O	O
(	PUNCT	O	O
handwriting	NUM	O	O
,	PUNCT	O	O
i.e	PUNCT	O	O
.	PUNCT	O	O

the	DET	O	O
action	NOUN	O	O
performed	VERB	O	O
by	ADP	O	O
the	DET	O	O
human	NOUN	O	O
body	NOUN	O	O
segment	PUNCT	O	O
specifically	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
writer	ADJ	O	O
's	PUNCT	O	O
cramp	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
inanimate	ADJ	O	O
object	NOUN	O	O
motion	NOUN	O	O
(	PUNCT	O	O
a	ADP	O	O
moving	ADJ	O	O
circle	NOUN	O	O
reaching	VERB	O	O
a	DET	O	O
spatial	ADJ	O	O
target	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Videos	PUNCT	O	O
representing	ADP	O	O
movements	NOUN	O	O
were	VERB	O	O
shown	VERB	O	O
in	ADP	O	O
full	ADJ	O	O
before	ADP	O	O
experimental	ADJ	O	O
trials	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
actual	ADJ	O	O
tasks	NOUN	O	O
consisted	DET	O	O
of	ADP	O	O
watching	NUM	O	O
the	DET	O	O
same	ADJ	O	O
videos	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
interrupted	VERB	O	O
after	ADP	O	O
a	DET	O	O
variable	ADJ	O	O
interval	NOUN	O	O
(	PUNCT	O	O
'pre-dark	PUNCT	O	O
'	PUNCT	O	O
)	PUNCT	O	O
from	ADP	O	O
its	PUNCT	O	O
onset	NOUN	O	O
by	ADP	O	O
a	DET	O	O
dark	ADJ	O	O
interval	NOUN	O	O
of	ADP	O	O
variable	ADJ	O	O
duration	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
'dark	PUNCT	O	O
'	PUNCT	O	O
interval	NOUN	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
were	VERB	O	O
asked	VERB	O	O
to	ADP	O	O
indicate	ADJ	O	O
when	ADP	O	O
the	DET	O	O
movement	NOUN	O	O
represented	ADJ	O	O
in	ADP	O	O
the	DET	O	O
video	ADJ	O	O
reached	VERB	O	O
its	PUNCT	O	O
end	NOUN	O	O
by	ADP	O	O
clicking	ADJ	O	O
on	ADP	O	O
the	DET	O	O
space	NOUN	O	O
bar	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
keyboard	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
included	VERB	O	O
a	DET	O	O
visual	ADJ	O	B-MENTAL
working	ADP	O	I-MENTAL
memory	NOUN	O	I-MENTAL
task	NOUN	O	I-MENTAL
.	PUNCT	O	O

Performance	NOUN	O	O
on	ADP	O	O
the	DET	O	O
timing	PUNCT	O	O
task	NOUN	O	O
was	VERB	O	O
analysed	VERB	O	O
measuring	ADP	O	O
the	DET	O	O
absolute	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
timing	VERB	O	O
error	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
coefficient	NOUN	O	O
of	ADP	O	O
variability	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
anticipation	NOUN	O	O
responses	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
writer	ADJ	O	O
's	PUNCT	O	O
cramp	NOUN	O	O
exhibited	VERB	O	O
greater	PUNCT	O	O
absolute	ADJ	O	O
timing	ADP	O	O
error	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
human	NOUN	O	O
body	NOUN	O	O
motion	NOUN	O	O
task	NOUN	O	O
(	PUNCT	O	O
whereas	ADP	O	O
no	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
inanimate	ADJ	O	O
object	NOUN	O	O
motion	NOUN	O	O
task	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
was	VERB	O	O
documented	VERB	O	O
on	ADP	O	O
the	DET	O	O
visual	ADJ	O	O
working	ADP	O	O
memory	NOUN	O	O
tasks	NOUN	O	O
.	PUNCT	O	O

Absolute	ADJ	O	B-MENTAL
timing	PART	O	I-MENTAL
error	NOUN	O	I-MENTAL
on	ADP	O	O
the	DET	O	O
human	NOUN	O	O
body	NOUN	O	O
motion	NOUN	O	O
task	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
symptom	NOUN	O	O
severity	NOUN	O	O
,	PUNCT	O	O
disease	NOUN	O	O
duration	NOUN	O	O
or	CCONJ	O	O
writing	DET	O	O
speed	NOUN	O	O
.	PUNCT	O	O

Our	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
an	DET	O	O
alteration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
writing	ADJ	O	O
movement	NOUN	O	O
representation	NOUN	O	O
at	ADP	O	O
a	DET	O	O
central	ADJ	O	O
level	NOUN	O	O
and	CCONJ	O	O
are	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
view	NOUN	O	O
that	PUNCT	O	O
dystonia	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
purely	ADV	O	O
motor	NOUN	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
also	ADP	O	O
involves	NOUN	O	O
non-motor	NOUN	O	O
(	PUNCT	O	O
sensory	ADJ	O	O
,	PUNCT	O	O
cognitive	ADJ	O	O
)	PUNCT	O	O
aspects	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
movement	NOUN	O	O
processing	VERB	O	O
and	CCONJ	O	O
planning	VERB	O	O
.	PUNCT	O	O

Stepwise	PUNCT	O	O
hook	PUNCT	O	O
extension	NOUN	O	O
technique	NOUN	O	O
for	ADP	O	O
radiofrequency	NOUN	O	O
ablation	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
hepatocellular	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Our	PUNCT	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
stepwise	PUNCT	O	O
hook	PUNCT	O	O
extension	NOUN	O	O
technique	NOUN	O	O
for	ADP	O	O
radiofrequency	NOUN	O	O
ablation	NOUN	O	O
(	PUNCT	O	O
RFA	NOUN	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
of	ADP	O	O
hepatocellular	ADJ	O	O
carcinoma	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Twenty	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatocellular	ADJ	O	O
carcinoma	NOUN	O	O
measuring	VERB	O	O
<	ADP	O	O
25	NUM	O	O
mm	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
randomly	ADV	O	O
into	ADP	O	O
two	NUM	O	O
equal	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RFA	NOUN	O	O
was	VERB	O	O
applied	VERB	O	O
using	VERB	O	O
our	PUNCT	O	O
new	ADJ	O	O
stepwise	PUNCT	O	O
hook	PUNCT	O	O
extension	NOUN	O	O
technique	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
full	ADJ	O	O
extension	NOUN	O	O
method	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
10-hook	PUNCT	O	O
electrode	NOUN	O	O
of	ADP	O	O
LeVeen	NUM	O	O
needle	NOUN	O	O
was	VERB	O	O
deployed	VERB	O	O
in	ADP	O	O
four	NUM	O	O
steps	NOUN	O	O
to	ADP	O	O
full	ADJ	O	O
extension	NOUN	O	O
during	ADP	O	O
ablation	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
full	ADJ	O	O
extension	NOUN	O	O
at	ADP	O	O
start	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Roll-off	PUNCT	O	B-PHYSICAL
was	VERB	O	O
achieved	VERB	O	O
in	ADP	O	O
all	DET	O	O
10	NUM	O	O
patients	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
indicative	ADJ	O	O
of	ADP	O	O
sufficient	ADJ	O	O
tumor	NOUN	O	O
coagulation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
in	ADP	O	O
3	NUM	O	O
of	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
completion	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
treatment	NOUN	O	I-OTHER
was	VERB	O	O
6	NUM	O	O
min	NOUN	O	O
and	CCONJ	O	O
55	NUM	O	O
s	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
3	NUM	O	O
min	NOUN	O	O
to	ADP	O	O
14	NUM	O	O
min	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
s	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
6-15	ADP	O	O
min	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
power	NOUN	O	O
output	NOUN	O	B-OTHER
used	VERB	O	O
for	ADP	O	O
RF	NOUN	O	O
was	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
than	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
median	ADJ	O	O
271	NUM	O	O
vs.	CCONJ	O	O
1,045	NUM	O	O
W.m	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
diameters	NOUN	O	O
of	ADP	O	O
RFA-induced	VERB	O	B-PHYSICAL
lesions	NOUN	O	I-PHYSICAL
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
:	PUNCT	O	O
27	NUM	O	O
,	PUNCT	O	O
range	NOUN	O	O
23-37	NUM	O	O
mm	NOUN	O	O
;	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
:	PUNCT	O	O
23	NUM	O	O
,	PUNCT	O	O
0-42	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Application	NOUN	O	O
of	ADP	O	O
RFA	NOUN	O	O
using	VERB	O	O
stepwise	PUNCT	O	O
hook	PUNCT	O	O
extension	NOUN	O	O
technique	NOUN	O	O
is	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
the	DET	O	O
full	ADJ	O	O
extension	NOUN	O	O
method	NOUN	O	O
since	ADP	O	O
it	DET	O	O
produces	NOUN	O	O
the	DET	O	O
same	ADJ	O	O
therapeutic	ADJ	O	B-OTHER
effects	NOUN	O	I-OTHER
within	ADP	O	O
a	DET	O	O
short	ADJ	O	O
period	NOUN	O	O
using	ADJ	O	O
a	DET	O	O
lower	PUNCT	O	O
energy	NOUN	O	O
.	PUNCT	O	O

Active	ADJ	O	O
warming	DET	O	O
,	PUNCT	O	O
not	ADV	O	O
passive	ADJ	O	O
heat	NOUN	O	O
retention	NOUN	O	O
,	PUNCT	O	O
maintains	NOUN	O	O
normothermia	NOUN	O	B-PHYSICAL
during	ADP	O	O
combined	VERB	O	O
epidural-general	ADJ	O	O
anesthesia	NOUN	O	O
for	ADP	O	O
hip	NOUN	O	O
and	CCONJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
passive	ADJ	O	O
heat	NOUN	O	O
retention	NOUN	O	O
by	ADP	O	O
low-flow	PUNCT	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
alone	ADJ	O	O
and	CCONJ	O	O
with	ADP	O	O
additional	ADJ	O	O
thermal	ADJ	O	O
insulation	NOUN	O	O
by	ADP	O	O
reflective	ADJ	O	O
blankets	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
forced-air	NOUN	O	O
warming	PUNCT	O	O
preventing	VERB	O	O
intraoperative	ADJ	O	O
hypothermia	NOUN	O	O
during	ADP	O	O
combined	VERB	O	O
epidural-general	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Inpatient	NOUN	O	O
anesthesia	NOUN	O	O
at	ADP	O	O
a	DET	O	O
university	NOUN	O	O
department	NOUN	O	O
of	ADP	O	O
orthopedic	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
30	NUM	O	O
ASA	NOUN	O	O
physical	ADJ	O	O
status	NOUN	O	O
I	NUM	O	O
and	CCONJ	O	O
II	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
were	VERB	O	O
scheduled	VERB	O	O
for	ADP	O	O
elective	ADJ	O	O
hip	NOUN	O	O
or	CCONJ	O	O
knee	NOUN	O	O
arthroplasty	ADJ	O	O
and	CCONJ	O	O
were	VERB	O	O
free	ADJ	O	O
from	ADP	O	O
systemic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Patients	NOUN	O	O
received	VERB	O	O
epidural	ADJ	O	O
block	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
T10	PUNCT	O	O
by	ADP	O	O
alkalinized	VERB	O	O
lidocaine	NOUN	O	O
2	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
were	ADV	O	O
administered	NUM	O	O
standard	PUNCT	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
low-flow	ADJ	O	O
rebreathing	VERB	O	O
system	NOUN	O	O
(	PUNCT	O	O
fresh	ADJ	O	O
gas	NOUN	O	O
flow	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
L/min	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
procedures	NOUN	O	O
started	VERB	O	O
between	ADP	O	O
8	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
AM	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
operating	PRON	O	O
room	NOUN	O	O
(	PUNCT	O	O
OR	CCONJ	O	O
)	PUNCT	O	O
temperature	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
between	ADP	O	O
21	NUM	O	O
degrees	NOUN	O	O
and	CCONJ	O	O
23	NUM	O	O
degrees	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
relative	ADJ	O	O
humidity	NOUN	O	O
ranging	ADJ	O	O
between	ADP	O	O
40	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
45	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

For	ADP	O	O
heat	NOUN	O	O
retention	NOUN	O	O
or	CCONJ	O	O
warming	PROPN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
received	VERB	O	O
either	PUNCT	O	O
low-flow	PUNCT	O	O
anesthesia	NOUN	O	O
only	ADV	O	O
(	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
low-flow	PUNCT	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
additional	ADJ	O	O
reflective	ADJ	O	O
blankets	NOUN	O	O
(	PUNCT	O	O
blanket	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
low-flow	ADJ	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
active	ADJ	O	O
forced-air	NOUN	O	O
warming	PROPN	O	O
(	PUNCT	O	O
forced-air	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tympanic	ADJ	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
OR	NOUN	O	O
arrival	NOUN	O	O
(	PUNCT	O	O
baseline	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
immediately	ADV	O	O
following	CCONJ	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
induction	NOUN	O	O
;	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
60	NUM	O	O
,	PUNCT	O	O
90	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
120	NUM	O	O
minutes	NOUN	O	O
from	ADP	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
induction	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
MAIN	ADJ	O	O
RESULTS	NOUN	O	O
Duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
anesthesia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
invasiveness	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
surgery	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O
baseline	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
to	PRON	O	O
assess	NOUN	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
cardiovascular	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
of	ADP	O	O
skeletal	ADJ	O	O
myoblast	NOUN	O	O
implantation	NOUN	O	O
by	ADP	O	O
catheter	NOUN	O	O
delivery	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
after	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
We	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
preliminary	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
transcatheter	CCONJ	O	O
intramyocardial	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
myoblasts	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
HF	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
MARVEL	NOUN	O	O
is	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
image-guided	ADJ	O	O
,	PUNCT	O	O
catheter-based	VERB	O	O
intramyocardial	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
myoblasts	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
or	CCONJ	O	O
800	NUM	O	O
million	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
class	NOUN	O	O
II	NUM	O	O
to	ADP	O	O
IV	NUM	O	O
HF	NOUN	O	O
and	CCONJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
<	SYM	O	O
35	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
were	VERB	O	O
frequency	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
safety	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	O
changes	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
6-minute	ADJ	O	I-PHYSICAL
walk	NOUN	O	I-PHYSICAL
test	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
Minnesota	NOUN	O	B-OTHER
Living	PUNCT	O	I-OTHER
With	ADP	O	I-OTHER
HF	NOUN	O	I-OTHER
score	NOUN	O	O
(	PUNCT	O	O
efficacy	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
330	NUM	O	O
patients	NOUN	O	O
intended	VERB	O	O
for	ADP	O	O
enrollment	NOUN	O	O
,	PUNCT	O	O
23	NUM	O	O
were	VERB	O	O
randomized	PROPN	O	O
(	PUNCT	O	O
MARVEL-1	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
stopping	ADP	O	O
the	DET	O	O
study	NOUN	O	O
for	ADP	O	O
financial	ADJ	O	O
reasons	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
similar	ADJ	O	O
numbers	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
:	PUNCT	O	O
8	NUM	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
7	NUM	O	O
(	PUNCT	O	O
low	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
8	NUM	O	O
(	PUNCT	O	O
high	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
without	ADP	O	O
deaths	NOUN	O	O
.	PUNCT	O	O

Ventricular	ADJ	O	B-PHYSICAL
tachycardia	NOUN	O	I-PHYSICAL
responsive	ADJ	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
amiodarone	NOUN	O	I-PHYSICAL
was	VERB	O	O
more	ADV	O	O
frequent	ADP	O	O
in	ADP	O	O
myoblast-treated	VERB	O	O
patients	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
3	NUM	O	O
(	PUNCT	O	O
low	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
(	PUNCT	O	O
high	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
improvement	NOUN	O	O
in	ADP	O	O
functional	ADJ	O	B-MENTAL
capacity	NOUN	O	I-MENTAL
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
myoblast-treated	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
?6-minute	PUNCT	O	O
walk	NOUN	O	O
test	NOUN	O	O
of	ADP	O	O
-3.6	NUM	O	O
vs	CCONJ	O	O
+95.6	PUNCT	O	O
vs	CCONJ	O	O
+85.5	PUNCT	O	O
m	NOUN	O	O
[	PUNCT	O	O
placebo	NOUN	O	O
vs	CCONJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
vs	CCONJ	O	O
high	ADJ	O	O
dose	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.50	PUNCT	O	O
]	PUNCT	O	O
)	PUNCT	O	O
without	ADP	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
Minnesota	NOUN	O	O
Living	PUNCT	O	O
With	ADP	O	O
HF	NOUN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
HF	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
postinfarction	NOUN	O	O
cardiomyopathy	NOUN	O	O
,	PUNCT	O	O
transcatheter	CCONJ	O	O
administration	NOUN	O	O
of	ADP	O	O
myoblasts	NOUN	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
400	NUM	O	O
to	ADP	O	O
800	NUM	O	O
million	NUM	O	O
cells	NOUN	O	O
is	VERB	O	O
feasible	ADJ	O	O
and	CCONJ	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
important	ADJ	O	O
clinical	ADJ	O	O
benefits	NOUN	O	O
.	PUNCT	O	O

Ventricular	ADJ	O	O
tachycardia	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
provoked	PROPN	O	O
by	ADP	O	O
myoblast	NOUN	O	O
injection	NOUN	O	O
but	CCONJ	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
transient	ADJ	O	O
and	CCONJ	O	O
treatable	ADJ	O	O
problem	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
large-scale	NOUN	O	O
outcome	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
myoblast	NOUN	O	O
administration	NOUN	O	O
in	ADP	O	O
HF	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
postinfarction	NOUN	O	O
cardiomyopathy	NOUN	O	O
is	VERB	O	O
feasible	ADJ	O	O
and	CCONJ	O	O
warranted	VERB	O	O
.	PUNCT	O	O

Oral	ADJ	O	B-PHYSICAL
estrogen	NOUN	O	I-PHYSICAL
antagonizes	VERB	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
metabolic	ADJ	O	I-PHYSICAL
actions	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
growth	NOUN	O	I-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
growth	NOUN	O	I-PHYSICAL
hormone-deficient	ADP	O	I-PHYSICAL
women	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
have	ADP	O	O
determined	VERB	O	O
whether	ADP	O	O
oral	ADJ	O	O
estrogen	NOUN	O	O
reduces	NOUN	O	O
the	DET	O	O
biological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
GH	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
GH-deficient	ADJ	O	O
(	PUNCT	O	O
GHD	NOUN	O	O
)	PUNCT	O	O
women	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
transdermal	ADJ	O	O
estrogen	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
separate	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
eight	NUM	O	O
GHD	NOUN	O	O
women	NOUN	O	O
randomly	ADV	O	O
received	PUNCT	O	O
either	CCONJ	O	O
oral	ADJ	O	O
or	CCONJ	O	O
transdermal	ADJ	O	O
estrogen	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
wk	NOUN	O	O
before	PUNCT	O	O
crossing	ADJ	O	O
over	PUNCT	O	O
to	PUNCT	O	O
the	DET	O	O
alternate	NOUN	O	O
route	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
incremental	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
GH	NOUN	O	O
(	PUNCT	O	O
0.5	NUM	O	O
,	PUNCT	O	O
1.0	NUM	O	O
,	PUNCT	O	O
2.0	NUM	O	O
IU/day	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
wk	NOUN	O	O
each	ADP	O	O
)	PUNCT	O	O
on	ADP	O	O
insulin-like	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
IGF-I	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
during	ADP	O	O
each	DET	O	O
estrogen	NOUN	O	O
treatment	NOUN	O	O
phase	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
GH	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
IU/day	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
lipid	NOUN	O	O
oxidation	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
protein	NOUN	O	O
metabolism	NOUN	O	O
using	VERB	O	O
the	DET	O	O
whole	ADJ	O	O
body	NOUN	O	O
leucine	NOUN	O	O
turnover	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

Mean	NOUN	O	O
IGF-I	NOUN	O	O
level	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
during	ADP	O	O
oral	ADJ	O	O
estrogen	NOUN	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
rose	PUNCT	O	B-PHYSICAL
dose	NOUN	O	I-PHYSICAL
dependently	ADV	O	I-PHYSICAL
during	ADP	O	I-PHYSICAL
GH	NOUN	O	I-PHYSICAL
administration	NOUN	O	I-PHYSICAL
by	ADP	O	O
a	DET	O	O
lesser	PUNCT	O	O
magnitude	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
transdermal	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Postprandial	ADJ	O	B-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
oxidation	NOUN	O	I-PHYSICAL
was	VERB	O	I-PHYSICAL
significantly	ADV	O	I-PHYSICAL
lower	PUNCT	O	O
with	ADP	O	B-PHYSICAL
oral	ADJ	O	I-PHYSICAL
estrogen	NOUN	O	B-PHYSICAL
treatment	NOUN	O	O
,	PUNCT	O	O
both	PUNCT	O	O
before	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
during	ADP	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
GH	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
transdermal	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Protein	NOUN	O	B-PHYSICAL
synthesis	NOUN	O	I-PHYSICAL
was	VERB	O	O
lower	PUNCT	O	O
during	ADP	O	O
oral	ADJ	O	O
estrogen	NOUN	O	O
both	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
during	ADP	O	O
GH	NOUN	O	O
administration	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
estrogen	NOUN	O	O
antagonizes	VERB	O	B-PHYSICAL
several	ADJ	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	B-PHYSICAL
metabolic	ADJ	O	I-PHYSICAL
actions	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
GH	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

It	PRON	O	O
may	PUNCT	O	O
aggravate	PUNCT	O	O

Safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
sitaxsentan	NOUN	O	O
50	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
mg	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
pulmonary	ADJ	O	O
arterial	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
sitaxsentan	NOUN	O	O
50	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
mg	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
pulmonary	ADJ	O	O
arterial	ADJ	O	O
hypertension	NOUN	O	O
(	PUNCT	O	O
PAH	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Sitaxsentan	NOUN	O	O
is	VERB	O	O
a	DET	O	O
highly	ADV	O	O
selective	ADJ	O	O
endothelin-A	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
that	ADP	O	O
was	VERB	O	O
recently	ADV	O	O
withdrawn	PUNCT	O	O
by	ADP	O	O
the	DET	O	O
manufacturer	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
idiosyncratic	ADJ	O	O
liver	NOUN	O	O
injury	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Before	PUNCT	O	O
sitaxsentan	NOUN	O	O
withdrawal	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
18-week	NOUN	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
randomized	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
PAH	NOUN	O	O
to	PROPN	O	O
receive	NOUN	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
sitaxsentan	NOUN	O	O
50	NUM	O	O
or	CCONJ	O	O
100	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
endpoint	NOUN	O	O
was	VERB	O	O
change	NUM	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
6-min	NOUN	O	O
walk	NOUN	O	O
distance	NOUN	O	O
(	PUNCT	O	O
6MWD	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
week	NOUN	O	O
18	NUM	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
World	NOUN	O	O
Health	NOUN	O	O
Organization	NOUN	O	O
(	PUNCT	O	O
WHO	NOUN	O	O
)	PUNCT	O	O
functional	ADJ	O	O
class	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
to	ADP	O	O
clinical	ADJ	O	O
worsening	ADP	O	O
(	PUNCT	O	O
TTCW	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
analysis	NOUN	O	O
was	VERB	O	O
powered	VERB	O	O
for	ADP	O	O
sitaxsentan	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
98	NUM	O	O
randomized	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
61	NUM	O	O
%	SYM	O	O
were	VERB	O	O
WHO	NOUN	O	O
functional	ADJ	O	O
class	NOUN	O	O
II	NUM	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Improvement	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	PUNCT	O	O
week	ADJ	O	O
18	NUM	O	O
in	ADP	O	O
6MWD	NOUN	O	O
occurred	VERB	O	O
with	ADP	O	O
sitaxsentan	NOUN	O	O
100	NUM	O	O
but	CCONJ	O	O
not	ADV	O	O
50	NUM	O	O
mg	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
strong	ADJ	O	O
placebo	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

At	ADP	O	O
week	NOUN	O	O
18	NUM	O	O
,	PUNCT	O	O
WHO	NOUN	O	O
functional	ADJ	O	O
class	NOUN	O	O
was	VERB	O	O
improved	ADP	O	O
or	CCONJ	O	O
maintained	VERB	O	O
in	ADP	O	O
more	DET	O	O
patients	NOUN	O	O
receiving	VERB	O	O
sitaxsentan	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
than	PUNCT	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.038	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
12	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
deteriorated	VERB	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

TTCW	NOUN	O	B-PHYSICAL
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
for	ADP	O	O
100-mg	NOUN	O	O
sitaxsentan	NOUN	O	O
patients	NOUN	O	O
than	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.090	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
events	NOUN	O	O
(	PUNCT	O	O
AEs	ADP	O	O
)	PUNCT	O	O
occurring	ADP	O	O
more	ADV	O	O
frequently	ADV	O	O
with	ADP	O	O
sitaxsentan	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
or	CCONJ	O	O
100	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
included	VERB	O	O
headache	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
peripheral	ADJ	O	B-ADVERSE-EFFECTS
edema	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
dizziness	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
extremity	NOUN	O	B-ADVERSE-EFFECTS
pain	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	PUNCT	O	O

Dual-task-related	ADP	O	O
gait	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
transitionally	ADV	O	O
frail	ADP	O	O
older	CCONJ	O	O
adults	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
the	DET	O	O
walking-associated	ADV	O	O
cognitive	ADJ	O	O
task	NOUN	O	O
matters	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Changes	PROPN	O	O
in	ADP	O	O
gait	NOUN	O	O
patterns	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
simultaneously	ADV	O	O
performed	PUNCT	O	O
cognitive	ADJ	O	O
task	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
reported	VERB	O	O
previously	ADV	O	O
and	CCONJ	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
falling	VERB	O	O
risk	NOUN	O	O
among	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Little	PUNCT	O	O
is	VERB	O	O
known	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	O
task	NOUN	O	O
performed	VERB	O	O
while	VERB	O	O
walking	VERB	O	O
is	ADV	O	O
important	ADJ	O	O
concerning	ADJ	O	O
possible	ADJ	O	O
gait	NOUN	O	O
interference	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
fall-prone	NOUN	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
quantify	NOUN	O	O
and	CCONJ	O	O
compare	ADJ	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
cognitive	ADJ	O	O
tasks	NOUN	O	O
on	ADP	O	O
gait	NOUN	O	O
in	ADP	O	O
transitionally	ADV	O	O
frail	ADP	O	O
older	CCONJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
Gait	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
30	NUM	O	O
transitionally	ADV	O	O
frail	ADJ	O	O
older	CCONJ	O	O
adults	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
82.6	NUM	O	O
+/-	SYM	O	O
7.1	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
%	SYM	O	O
female	NOUN	O	O
)	PUNCT	O	O
while	ADP	O	O
either	CCONJ	O	O
walking	PUNCT	O	B-MENTAL
alone	ADJ	O	I-MENTAL
,	PUNCT	O	O
performing	PUNCT	O	B-MENTAL
a	DET	O	I-MENTAL
simple	ADJ	O	I-MENTAL
arithmetic	ADJ	O	I-MENTAL
task	NOUN	O	I-MENTAL
,	PUNCT	O	O
or	CCONJ	O	O
performing	PUNCT	O	O
a	DET	O	O
task	NOUN	O	O
of	ADP	O	O
verbal	ADJ	O	O
fluency	NOUN	O	O
.	PUNCT	O	O

Walking	DET	O	O
time	NOUN	O	O
in	ADP	O	O
seconds	NOUN	O	O
,	PUNCT	O	O
number	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
steps	NOUN	O	I-MENTAL
,	PUNCT	O	O
frequency	NOUN	O	O
of	ADP	O	O
lateral	ADJ	O	B-MENTAL
line	NOUN	O	I-MENTAL
stepping-over	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
delay	NOUN	O	O
in	ADP	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
due	VERB	O	O
to	ADP	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
randomized	VERB	O	O
prospective	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
often	ADV	O	O
suggested	VERB	O	O
that	ADP	O	O
tumors	NOUN	O	O
will	VERB	O	O
respond	VERB	O	O
to	ADP	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
result	NOUN	O	O
in	ADP	O	O
improved	VERB	O	O
survival	NOUN	O	B-MORTALITY
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
squamous	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
of	ADP	O	O
the	DET	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
regimens	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
separate	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
trials	NOUN	O	O
over	ADP	O	O
the	DET	O	O
last	ADJ	O	O
6	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Eighty-three	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
disease	NOUN	O	O
were	VERB	O	O
entered	VERB	O	O
into	ADP	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
(	PUNCT	O	O
43/chemotherapy	NOUN	O	O
;	PUNCT	O	O
40/control	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
60	NUM	O	O
into	ADP	O	O
the	DET	O	O
second	ADJ	O	O
(	PUNCT	O	O
27/chemotherapy	NOUN	O	O
;	PUNCT	O	O
33/control	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patient	NOUN	O	O
randomization	NOUN	O	O
was	VERB	O	O
stratified	VERB	O	O
by	ADP	O	O
stage	NOUN	O	O
(	PUNCT	O	O
III/IV	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
site	NOUN	O	O
(	PUNCT	O	O
oral	ADJ	O	O
cavity	NOUN	O	O
,	PUNCT	O	O
oropharynx	ADP	O	O
,	PUNCT	O	O
nasopharynx	NOUN	O	O
,	PUNCT	O	O
hypopharynx	NOUN	O	O
,	PUNCT	O	O
larynx	NOUN	O	O
,	PUNCT	O	O
paranasal	ADJ	O	O
sinuses	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
utilized	PUNCT	O	O
bleomycin	NOUN	O	O
,	PUNCT	O	O
Cytoxan	PUNCT	O	O
,	PUNCT	O	O
methotrexate	ADJ	O	O
and	CCONJ	O	O
5-fluorouracil	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
cycles	NOUN	O	O
(	PUNCT	O	O
one	NUM	O	O
cycle	NOUN	O	O
if	PUNCT	O	O
no	DET	O	O
tumor	NOUN	O	O
response	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
which	ADP	O	O
consisted	VERB	O	O
of	ADP	O	O
combined	VERB	O	O
irradiation	NOUN	O	O
and	CCONJ	O	O
surgery	NOUN	O	O
or	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
some	DET	O	O
instances	NOUN	O	O
,	PUNCT	O	O
primary	ADJ	O	O
irradiation	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
study	NOUN	O	O
utilized	PUNCT	O	O
cisplatin	NOUN	O	O
and	CCONJ	O	O
5-fluorouracil	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
cycles	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
standard	CCONJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
objective	ADJ	O	B-OTHER
tumor	NOUN	O	I-OTHER
response	NOUN	O	I-OTHER
to	ADP	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
68	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
and	CCONJ	O	O
85	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
in	ADP	O	O
both	PUNCT	O	O
studies	NOUN	O	O
(	PUNCT	O	O
at	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADP	O	O
;	PUNCT	O	O
at	ADP	O	O
19	NUM	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
)	PUNCT	O	O
was	VERB	O	O
better	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
than	PUNCT	O	O
that	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
43	NUM	O	O
%	SYM	O	O
to	ADP	O	O
31	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
69	NUM	O	O
%	SYM	O	O
to	ADP	O	O
46	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
second	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
average	ADJ	O	O
length	NOUN	O	O
of	ADP	O	B-OTHER
delay	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
standard	ADJ	O	I-OTHER
treatment	NOUN	O	B-OTHER
was	VERB	O	O
longer	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
days	NOUN	O	O
vs.	CCONJ	O	O
66	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
combining	ADP	O	O
the	DET	O	O
P-values	NOUN	O	O
of	ADP	O	O
both	PUNCT	O	O
studies	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
having	VERB	O	O
persistent	ADJ	O	O
disease	NOUN	O	O
was	VERB	O	O
2.9	NUM	O	O
times	NOUN	O	O
greater	PUNCT	O	O
for	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

While	PUNCT	O	O

MRI	NOUN	O	O
signal	NOUN	O	O
hyperintensities	CCONJ	O	O
in	ADP	O	O
geriatric	ADJ	O	O
depression	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
authors	NOUN	O	O
rated	ADP	O	O
periventricular	PUNCT	O	O
and	CCONJ	O	O
subcortical	ADJ	O	O
signal	NOUN	O	O
hyperintensities	CCONJ	O	O
on	ADP	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	VERB	O	O
(	PUNCT	O	O
MRI	NOUN	O	O
)	PUNCT	O	O
scans	PUNCT	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
depression	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
similar	ADJ	O	O
demographic	ADJ	O	O
features	NOUN	O	O
to	PART	O	O
examine	NOUN	O	O
whether	ADP	O	O
such	ADJ	O	O
changes	DET	O	O
discriminate	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
depression	NOUN	O	O
from	ADP	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
whether	ADP	O	O
they	PRON	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
any	DET	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Two	NUM	O	O
established	VERB	O	O
hyperintensity	NOUN	O	O
rating	VERB	O	O
systems	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
MRI	NOUN	O	O
brain	NOUN	O	O
scans	ADJ	O	O
of	ADP	O	O
48	NUM	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
depression	NOUN	O	O
diagnosed	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
DSM-III-R	NOUN	O	O
with	ADP	O	O
the	DET	O	O
scans	NOUN	O	O
of	ADP	O	O
39	NUM	O	O
normal	ADJ	O	O
elderly	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Elderly	ADJ	O	O
depressed	DET	O	O
patients	NOUN	O	O
manifested	ADJ	O	O
significantly	ADV	O	O
more	ADV	O	O
severe	ADJ	O	O
hyperintensity	NOUN	O	B-PHYSICAL
ratings	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
subcortical	ADJ	O	O
gray	ADJ	O	O
matter	NOUN	O	O
than	PUNCT	O	O
age-matched	DET	O	O
comparison	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
identified	VERB	O	O
between	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
similar	ADJ	O	O
current	ADJ	O	O
ages	NOUN	O	O
and	CCONJ	O	O
cerebrovascular	ADJ	O	O
disease	NOUN	O	O
risk	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
early-onset	NOUN	O	O
or	CCONJ	O	O
late-onset	NOUN	O	O
depression	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
These	DET	O	O
findings	NOUN	O	O
support	VERB	O	O
those	PUNCT	O	O
of	ADP	O	O
neuroimaging	PUNCT	O	O
studies	NOUN	O	O
implicating	VERB	O	O
the	DET	O	O
basal	ADJ	O	O
ganglia	NOUN	O	O
in	ADP	O	O
depression	NOUN	O	O
and	CCONJ	O	O
geriatric	ADJ	O	O
depression	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
relationship	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
some	DET	O	O
reports	NOUN	O	O
between	ADP	O	O
late-onset	NOUN	O	O
depression	NOUN	O	O
and	CCONJ	O	O
MRI	NOUN	O	O
hyperintensities	CCONJ	O	O
is	VERB	O	O
most	PUNCT	O	O
likely	PUNCT	O	O
a	DET	O	O
function	NOUN	O	O
of	ADP	O	O
cerebrovascular	ADJ	O	O
disease	NOUN	O	O
risk	NOUN	O	O
and	CCONJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
pilot	NOUN	O	O
randomised	VERB	O	O
control	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
parent	NOUN	O	O
training	NUM	O	O
intervention	NOUN	O	O
for	ADP	O	O
pre-school	NOUN	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Preliminary	ADJ	O	O
findings	NOUN	O	O
and	CCONJ	O	O
methodological	ADJ	O	O
challenges	NOUN	O	O
.	PUNCT	O	O

Few	ADJ	O	O
attempts	PUNCT	O	O
have	PUNCT	O	O
been	PUNCT	O	O
made	VERB	O	O
to	PUNCT	O	O
conduct	NOUN	O	O
randomised	CCONJ	O	O
control	NOUN	O	O
trials	NOUN	O	O
(	PUNCT	O	O
RCTs	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
interventions	NOUN	O	O
for	ADP	O	O
pre-school	NOUN	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
findings	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pilot	NOUN	O	O
RCT	NOUN	O	O
for	ADP	O	O
a	DET	O	O
parent	NOUN	O	O
training	NUM	O	O
intervention	NOUN	O	O
with	ADP	O	O
a	DET	O	O
focus	NOUN	O	O
on	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
joint	NOUN	O	O
attention	NOUN	O	O
skills	NOUN	O	O
and	CCONJ	O	O
joint	NOUN	O	O
action	NOUN	O	O
routines	NOUN	O	O
.	PUNCT	O	O

Twenty-four	PUNCT	O	O
children	NOUN	O	O
meeting	PUNCT	O	O
ICD-10	NOUN	O	O
criteria	NOUN	O	O
for	ADP	O	O
childhood	NOUN	O	O
autism	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
=	SYM	O	O
23	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
identified	VERB	O	O
using	VERB	O	O
the	DET	O	O
CHAT	NOUN	O	O
screen	NOUN	O	O
and	CCONJ	O	O
randomised	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
parent	NOUN	O	O
training	ADV	O	O
group	NOUN	O	O
or	CCONJ	O	O
to	DET	O	O
local	PUNCT	O	O
services	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
follow-up	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
12	NUM	O	O
months	NOUN	O	O
later	ADJ	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
=	SYM	O	O
35	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
some	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
parent	NOUN	O	O
training	ADV	O	O
group	NOUN	O	O
made	PUNCT	O	O
more	DET	O	O
progress	CCONJ	O	O
in	ADP	O	O
language	NOUN	O	B-MENTAL
development	NOUN	O	I-MENTAL
than	PUNCT	O	O
the	DET	O	O
local	ADJ	O	O
services	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
pilot	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
compromised	VERB	O	O
by	ADP	O	O
several	ADJ	O	O
factors	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
reliance	NOUN	O	O
on	ADP	O	O
parental	ADJ	O	O
report	NOUN	O	O
to	PART	O	O
measure	ADJ	O	O
language	NOUN	O	O
,	PUNCT	O	O
non-matching	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
on	ADP	O	O
initial	ADJ	O	O
IQ	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
systematic	ADJ	O	O
checking	ADP	O	O
regarding	ADP	O	O
the	DET	O	O
implementation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
parent	NOUN	O	O
training	NUM	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
three	NUM	O	O
parents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
local	ADJ	O	O
services	NOUN	O	O
group	NOUN	O	O
commenced	VERB	O	O
intensive	ADJ	O	O
,	PUNCT	O	O
home-based	VERB	O	O
behavioural	ADJ	O	O
intervention	NOUN	O	O
during	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
difficulties	NOUN	O	O
encountered	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
conduct	NOUN	O	O
of	ADP	O	O
RCTs	NOUN	O	O
for	ADP	O	O
pre-school	NOUN	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Methodological	ADJ	O	O
challenges	NOUN	O	O
and	CCONJ	O	O
strategies	NOUN	O	O
for	ADP	O	O
future	NOUN	O	O
well-designed	VERB	O	O
RCTs	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	O
interventions	NOUN	O	O
are	PROPN	O	O
highlighted	VERB	O	O
.	PUNCT	O	O

Further	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
docosahexaenoic	ADJ	O	O
acid	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
retinitis	NOUN	O	O
pigmentosa	NOUN	O	O
receiving	DET	O	O
vitamin	NOUN	O	O
A	CCONJ	O	O
treatment	NOUN	O	O
:	PUNCT	O	O
subgroup	NOUN	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
whether	ADP	O	O
docosahexaenoic	ADJ	O	O
acid	NOUN	O	O
will	PART	O	O
slow	CCONJ	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
retinal	ADJ	O	O
degeneration	NOUN	O	O
in	ADP	O	O
subgroups	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
retinitis	NOUN	O	O
pigmentosa	NOUN	O	O
who	ADP	O	O
are	VERB	O	O
receiving	ADP	O	O
vitamin	NOUN	O	O
A	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	DET	O	O
cohort	NOUN	O	O
of	ADP	O	O
208	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
retinitis	NOUN	O	O
pigmentosa	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
18	NUM	O	O
to	ADP	O	O
55	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
1200	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
docosahexaenoic	ADJ	O	O
acid	NOUN	O	O
plus	CCONJ	O	O
15	NUM	O	O
000	NUM	O	O
IU/d	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
A	NOUN	O	O
given	VERB	O	O
as	ADP	O	O
retinyl	NOUN	O	O
palmitate	NOUN	O	O
(	PUNCT	O	O
DHA	NOUN	O	O
+	SYM	O	O
A	PUNCT	O	O
group	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
fatty	ADJ	O	O
acid	NOUN	O	O
plus	CCONJ	O	O
15	NUM	O	O
000	NUM	O	O
IU/d	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
+	ADP	O	O
A	PUNCT	O	O
group	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
followed	VERB	O	O
up	ADP	O	O
over	ADP	O	O
4	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Seventy	ADJ	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
were	VERB	O	O
taking	PUNCT	O	O
vitamin	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
15	NUM	O	O
000	NUM	O	O
IU/d	NOUN	O	O
,	PUNCT	O	O
prior	PUNCT	O	O
to	ADP	O	O
entry	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	PUNCT	O	O
rates	NOUN	O	O
of	ADP	O	O
decline	NOUN	O	O
in	ADP	O	O
ocular	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
the	DET	O	O
DHA	NOUN	O	O
+	SYM	O	O
A	NOUN	O	O
vs	CCONJ	O	O
control	NOUN	O	O
+	SYM	O	O
A	DET	O	O
groups	NOUN	O	O
among	ADP	O	O
the	DET	O	O
subgroups	NOUN	O	O
defined	VERB	O	O
by	ADP	O	O
use	NOUN	O	O
or	CCONJ	O	O
nonuse	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
A	CCONJ	O	O
prior	PUNCT	O	O
to	ADP	O	O
entry	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
determined	VERB	O	O
whether	ADP	O	O
decline	PUNCT	O	O
in	ADP	O	O
ocular	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
red	ADJ	O	O
blood	NOUN	O	O
cell	NOUN	O	O
phosphatidylethanolamine	NOUN	O	O
docosahexaenoic	ADJ	O	O
acid	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
dietary	ADJ	O	O
omega-3	NOUN	O	O
fatty	ADJ	O	O
acid	NOUN	O	O
intake	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
A	CCONJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

Main	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
were	PUNCT	O	O
Humphrey	PUNCT	O	B-PHYSICAL
Field	NOUN	O	I-PHYSICAL
Analyzer	NOUN	O	I-PHYSICAL
visual	ADJ	O	I-PHYSICAL
field	NOUN	O	I-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
30-Hz	NOUN	O	B-OTHER
electroretinogram	NOUN	O	I-OTHER
amplitude	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
visual	ADJ	O	B-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Among	ADP	O	O
patients	NOUN	O	O
not	ADV	O	O
taking	PUNCT	O	O
vitamin	NOUN	O	O
A	DET	O	O
prior	PUNCT	O	O
to	ADP	O	O
entry	NOUN	O	O
,	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
DHA	NOUN	O	O
+	SYM	O	O
A	PUNCT	O	O
group	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
slower	PUNCT	O	O
decline	NOUN	O	O
in	ADP	O	O
field	NOUN	O	B-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
electroretinogram	PUNCT	O	B-OTHER
amplitude	ADJ	O	I-OTHER
than	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
+	ADV	O	O
A	PUNCT	O	O
group	NOUN	O	O
over	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=.01	PUNCT	O	O
and	CCONJ	O	O
P	NOUN	O	O
=.03	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
;	PUNCT	O	O
these	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
years	NOUN	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
of	ADP	O	O
follow-up	NOUN	O	O
or	CCONJ	O	O
among	ADP	O	O
patients	NOUN	O	O
taking	ADP	O	O
vitamin	NOUN	O	O
A	DET	O	O
prior	PUNCT	O	O
to	ADP	O	O
entry	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
cohort	NOUN	O	O
,	PUNCT	O	O
red	ADJ	O	O
blood	NOUN	O	O
cell	NOUN	O	O
phosphatidylethanolamine	NOUN	O	O
docosahexaenoic	ADJ	O	O
acid	NOUN	O	O
level	NOUN	O	O
was	VERB	O	O
inversely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
rate	NOUN	O	O
of	ADP	O	O
decline	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
field	NOUN	O	B-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
over	ADP	O	O
4	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
test	NOUN	O	O
for	ADP	O	O
trend	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=.05	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
particularly	ADV	O	O
evident	ADJ	O	O
over	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2	NUM	O	O
years	NOUN	O	O
among	ADP	O	O
those	PUNCT	O	O
not	ADV	O	O
on	ADP	O	O
vitamin	NOUN	O	O
A	DET	O	O
prior	PUNCT	O	O
to	ADP	O	O
entry	NOUN	O	O
(	PUNCT	O	O
test	NOUN	O	O
for	ADP	O	O
trend	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=.003	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
control	NOUN	O	O
+	SYM	O	O
A	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
dietary	ADJ	O	O
omega-3	NOUN	O	O
fatty	ADJ	O	O
acid	NOUN	O	O
intake	NOUN	O	O
was	VERB	O	O
inversely	ADV	O	O
related	ADP	O	O
to	ADP	O	O
loss	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
field	NOUN	O	B-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
over	ADP	O	O
4	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
intake	NOUN	O	O
,	PUNCT	O	O
<	SYM	O	O
0.20	NUM	O	O
vs	CCONJ	O	O
>	ADJ	O	O
or	CCONJ	O	O
=0.20	NUM	O	O
g/d	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.02	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
vitamin	NOUN	O	I-PHYSICAL
A	DET	O	I-PHYSICAL
supplementation	NOUN	O	I-PHYSICAL
prior	PUNCT	O	O
to	ADP	O	O
entry	NOUN	O	O
was	VERB	O	O
inversely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
rate	NOUN	O	O
of	ADP	O	O
decline	NOUN	O	O
in	ADP	O	O
electroretinogram	PUNCT	O	O
amplitude	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=.008	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
For	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
retinitis	NOUN	O	O
pigmentosa	NOUN	O	O
beginning	ADP	O	O
vitamin	NOUN	O	O
A	CCONJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
addition	NOUN	O	O
of	ADP	O	O
docosahexaenoic	ADJ	O	O
acid	NOUN	O	O
,	PUNCT	O	O
1200	NUM	O	O
mg/d	NOUN	O	O
,	PUNCT	O	O
slowed	PUNCT	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
disease	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
vitamin	NOUN	O	O
A	NOUN	O	O
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
diet	NOUN	O	O
rich	VERB	O	O
in	ADP	O	O
omega-3	NOUN	O	O
fatty	ADJ	O	O
acids	NOUN	O	O
(	PUNCT	O	O
>	ADJ	O	O
or	CCONJ	O	O
=0.20	NUM	O	O
g/d	NOUN	O	O
)	PUNCT	O	O
slowed	PUNCT	O	O
the	DET	O	O
decline	NOUN	O	O
in	ADP	O	O
visual	ADJ	O	O
field	NOUN	O	O
sensitivity	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
acupuncture	ADP	O	O
with	ADP	O	O
advice	NOUN	O	O
and	CCONJ	O	O
exercises	NOUN	O	O
on	ADP	O	O
the	DET	O	O
symptomatic	ADJ	O	B-PHYSICAL
treatment	NOUN	O	I-PHYSICAL
of	ADP	O	O
osteoarthritis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Acupuncture	ADP	O	O
is	ADP	O	O
becoming	VERB	O	O
a	DET	O	O
common	ADJ	O	O
technique	NOUN	O	O
within	ADP	O	O
the	DET	O	O
physiotherapy	NOUN	O	O
profession	NOUN	O	O
as	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
modality	NOUN	O	O
for	ADP	O	O
pain	NOUN	O	B-PAIN
relief	NOUN	O	I-PAIN
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
few	ADJ	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trials	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
undertaken	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
acupuncture	ADP	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
osteoarthritis	NOUN	O	O
(	PUNCT	O	O
OA	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
acupuncture	ADP	O	O
with	ADP	O	O
advice	NOUN	O	O
and	CCONJ	O	O
exercises	NOUN	O	O
on	ADP	O	O
the	DET	O	O
symptomatic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
OA	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
.	PUNCT	O	O

Thirty-two	ADJ	O	O
patients	NOUN	O	O
awaiting	PUNCT	O	O
a	DET	O	O
total	ADJ	O	O
hip	NOUN	O	O
arthroplasty	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
A	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	ADP	O	O
have	PUNCT	O	O
six	NUM	O	O
sessions	NOUN	O	O
of	ADP	O	O
acupuncture	ADP	O	O
each	ADP	O	O
lasting	ADP	O	O
up	CCONJ	O	O
to	DET	O	O
25	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
B	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	PART	O	O
be	PUNCT	O	O
given	VERB	O	O
advice	NOUN	O	O
and	CCONJ	O	O
exercises	NOUN	O	O
for	ADP	O	O
their	PUNCT	O	O
hip	NOUN	O	O
over	ADP	O	O
a	DET	O	O
six	NUM	O	O
week	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
A	NOUN	O	O
consisted	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
13	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
B	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
four	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
eight	NUM	O	O
women	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
age	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
was	VERB	O	O
66	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
it	PUNCT	O	O
was	VERB	O	O
68	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
functional	ADJ	O	O
ability	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
modified	VERB	O	O
version	NOUN	O	O
of	ADP	O	O
the	DET	O	O
WOMAC	PUNCT	O	B-OTHER
questionnaire	NOUN	O	O
,	PUNCT	O	O
pre-treatment	NOUN	O	O
,	PUNCT	O	O
immediately	ADV	O	O
post-treatment	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
eight	NUM	O	O
weeks	NOUN	O	O
post-treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pre-treatment	NOUN	O	O
WOMAC	ADJ	O	B-OTHER
scores	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
(	PUNCT	O	O
p=0.85	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
WOMAC	PUNCT	O	B-OTHER
score	NOUN	O	I-OTHER
)	PUNCT	O	O
immediately	ADV	O	O
post-treatment	NOUN	O	O
(	PUNCT	O	O
p=0.002	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
this	PUNCT	O	O
was	NUM	O	O
maintained	VERB	O	O
at	ADP	O	O
the	DET	O	O
eight-week	CCONJ	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
p=0.03	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
WOMAC	ADJ	O	B-OTHER
scores	NOUN	O	I-OTHER
were	VERB	O	O
compared	VERB	O	O
between	ADP	O	O
groups	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
improvement	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
pre-treatment	NOUN	O	O
and	CCONJ	O	O
immediately	ADV	O	O
post-treatment	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
p=0.02	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
changes	NOUN	O	O
between	ADP	O	O
pre-treatment	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
eight-week	CCONJ	O	O
follow-up	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
compared	PUNCT	O	O
with	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
p=0.03	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
trial	NOUN	O	O
supports	NOUN	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
acupuncture	ADP	O	O
is	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
advice	NOUN	O	O
and	CCONJ	O	O
exercises	NOUN	O	O
in	ADP	O	O
the	DET	O	O
symptomatic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
OA	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
long-term	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
oxandrolone	ADJ	O	O
on	ADP	O	O
hepatic	ADJ	O	O
acute	ADJ	O	O
phase	NOUN	O	O
proteins	NOUN	O	O
in	ADP	O	O
severely	ADV	O	O
burned	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Acute	ADJ	O	O
phase	NOUN	O	O
protein	NOUN	O	O
production	NOUN	O	O
is	VERB	O	O
a	DET	O	O
hallmark	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
burns	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
wondered	VERB	O	O
whether	ADP	O	O
anabolic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
oxandrolone	ADJ	O	O
would	VERB	O	O
affect	VERB	O	O
these	DET	O	O
proteins	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Thirty-five	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
>	ADJ	O	O
or	CCONJ	O	O
=40	NUM	O	O
%	ADJ	O	O
total	ADJ	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
burns	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
oxandrolone	ADJ	O	O
(	PUNCT	O	O
0.1	NUM	O	O
mg/kg	NOUN	O	O
by	ADP	O	O
mouth	NOUN	O	O
twice	ADP	O	O
daily	ADP	O	O
)	PUNCT	O	O
from	ADP	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
5	NUM	O	O
to	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
postburn	ADP	O	O
.	PUNCT	O	O

Levels	NOUN	O	O
of	ADP	O	O
constitutive	DET	O	O
proteins	NOUN	O	O
and	CCONJ	O	O
acute	ADJ	O	O
phase	NOUN	O	O
proteins	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
admission	NOUN	O	O
;	PUNCT	O	O
at	ADP	O	O
discharge	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
burn	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
albumin	NOUN	O	B-PHYSICAL
supplementation	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
hepatic	ADJ	O	B-PHYSICAL
transaminases	NOUN	O	I-PHYSICAL
were	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
Constitutive	ADJ	O	B-PHYSICAL
proteins	NOUN	O	I-PHYSICAL
such	CCONJ	O	I-PHYSICAL
as	ADP	O	I-PHYSICAL
albumin	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
prealbumin	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
retinol-binding	ADP	O	I-PHYSICAL
protein	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
increased	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
acute	ADJ	O	B-PHYSICAL
phase	NOUN	O	O
proteins	NOUN	O	B-PHYSICAL
such	CCONJ	O	I-PHYSICAL
as	ADP	O	I-PHYSICAL
alpha	NOUN	O	I-PHYSICAL
1-acid	NOUN	O	I-PHYSICAL
glycoprotein	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
C3	NOUN	O	I-PHYSICAL
complement	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
alpha	NOUN	O	I-PHYSICAL
2-macroglobulin	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
fibrinogen	NOUN	O	I-PHYSICAL
levels	NOUN	O	B-PHYSICAL
significantly	ADV	O	O
decreased	NUM	O	O
in	ADP	O	O
the	DET	O	O
oxandrolone	ADJ	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Albumin	NOUN	O	B-PHYSICAL
supplementation	NOUN	O	I-PHYSICAL
during	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
acute	ADJ	O	B-PHYSICAL
hospitalization	NOUN	O	I-PHYSICAL
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
the	DET	O	O
oxandrolone	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Randomised	VERB	O	O
multicentre	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
circular	ADJ	O	O
stapling	ADP	O	O
devices	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
In	ADP	O	O
a	DET	O	O
register	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
anastomotic	ADJ	O	B-PHYSICAL
leakage	NOUN	O	I-PHYSICAL
correlated	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
choice	NOUN	O	O
of	ADP	O	O
circular	ADJ	O	O
stapling	ADP	O	O
device	NOUN	O	O
with	ADP	O	O
a	DET	O	O
4	NUM	O	O
%	ADV	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
brands	NOUN	O	O
used	VERB	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
those	PUNCT	O	O
data	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
multicentre	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
an	DET	O	O
anastomotic	ADJ	O	B-PHYSICAL
leakage	NOUN	O	I-PHYSICAL
based	VERB	O	O
upon	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
device	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
above	ADP	O	O
18	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
a	DET	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
able	ADJ	O	O
to	PART	O	O
give	VERB	O	O
informed	ADJ	O	O
consent	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
scheduled	PUNCT	O	O
for	ADP	O	O
an	DET	O	O
anterior	ADJ	O	O
resection	NOUN	O	O
were	VERB	O	O
eligible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Perioperative	PUNCT	O	O
randomisation	NOUN	O	O
was	VERB	O	O
to	ADP	O	O
Ethicon?	PUNCT	O	O
PROXIMATE?	NUM	O	O
ILS?	PUNCT	O	O
or	CCONJ	O	O
Autosuture?	ADJ	O	O
Premium	NOUN	O	O
Plus	CCONJ	O	O
CEEA?	NUM	O	O
.	PUNCT	O	O

Anastomotic	ADJ	O	O
leakage	NOUN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
clinically	ADJ	O	O
manifest	ADJ	O	O
leak	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Five	NUM	O	O
hundred	NUM	O	O
twenty-nine	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	NUM	O	O
(	PUNCT	O	O
58	NUM	O	O
%	SYM	O	O
male	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
leak	ADP	O	O
occurred	VERB	O	O
in	ADP	O	O
8.3	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
anastomoses	NOUN	O	O
created	VERB	O	O
by	ADP	O	O
PROXIMATE?	NUM	O	O
ILS?	PUNCT	O	O
leaked	PUNCT	O	O
in	ADP	O	O
25/265	NOUN	O	O
(	PUNCT	O	O
9.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
anastomoses	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Premium	NOUN	O	O
Plus	CCONJ	O	O
CEEA?	NUM	O	O
leaked	PUNCT	O	O
in	ADP	O	O
19/260	NOUN	O	O
(	PUNCT	O	O
7.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.419	NUM	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
No	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
leak	ADJ	O	O
rate	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
revealed	VERB	O	O
.	PUNCT	O	O

Several	ADJ	O	O
centres	NOUN	O	O
replaced	DET	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
staplers	NOUN	O	O
by	ADP	O	O
a	DET	O	O
new	ADJ	O	O
product	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
ended	NOUN	O	O
before	ADP	O	O
the	DET	O	O
stipulated	VERB	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
was	VERB	O	O
reached	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
future	NOUN	O	O
,	PUNCT	O	O
surgical	ADJ	O	O
devices	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
to	ADJ	O	O
prove	ADJ	O	O
superiority	NOUN	O	O
in	ADP	O	O
randomised	VERB	O	O
trials	NOUN	O	O
or	CCONJ	O	O
be	PUNCT	O	O
monitored	VERB	O	O
in	ADP	O	O
quality	NOUN	O	O
registers	NOUN	O	O
before	PUNCT	O	O
they	ADP	O	O
can	VERB	O	O
be	VERB	O	O
introduced	VERB	O	O
into	ADP	O	O
day	NOUN	O	O
to	ADP	O	O
day	NOUN	O	O
surgical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
registered	PUNCT	O	O
at	ADP	O	O
ClinicalTrials.gov	PUNCT	O	O
:	PUNCT	O	O
NCT00399009	NOUN	O	O
.	PUNCT	O	O

Laser	NOUN	O	O
therapy	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
brachytherapy	NOUN	O	O
for	ADP	O	O
the	DET	O	O
palliation	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	O
dysphagia	NOUN	O	O
.	PUNCT	O	O

BACKGROUND/AIM	NUM	O	O
OF	ADP	O	O
STUDY	NOUN	O	O
Laser	NOUN	O	O
therapy	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
relieving	ADV	O	O
malignant	ADJ	O	B-PHYSICAL
dysphagia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
repeated	VERB	O	O
treatments	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
to	ADP	O	O
6	NUM	O	O
week	NOUN	O	O
intervals	NOUN	O	O
are	VERB	O	O
usually	ADV	O	O
required	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
trial	NOUN	O	O
is	VERB	O	O
designed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
if	PUNCT	O	O
addition	NOUN	O	O
of	ADP	O	O
brachytherapy	NOUN	O	O
offers	NOUN	O	O
any	DET	O	O
advantages	NOUN	O	O
over	ADP	O	O
laser	NOUN	O	O
therapy	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
inoperable	ADJ	O	O
carcinoma	NOUN	O	O
of	ADP	O	O
the	DET	O	O
oesophagus	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	ADP	O	O
either	PUNCT	O	O
endoscopic	ADJ	O	O
Nd	NOUN	O	O
:	PUNCT	O	O
YAG	NOUN	O	O
laser	NOUN	O	O
therapy	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
laser	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
brachytherapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	ADP	O	O
developed	VERB	O	O
worsening	ADP	O	O
dysphagia	NOUN	O	O
during	ADP	O	O
follow-up	NOUN	O	O
were	VERB	O	O
offered	PUNCT	O	O
further	ADP	O	O
treatment	NOUN	O	O
as	PUNCT	O	O
appropriate	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Fourteen	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
laser	NOUN	O	O
only	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
to	PUNCT	O	O
receive	NOUN	O	O
laser	NOUN	O	O
followed	NOUN	O	O
by	ADP	O	O
brachytherapy	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
12	NUM	O	O
,	PUNCT	O	O
one	NUM	O	O
was	VERB	O	O
lost	VERB	O	O
to	ADP	O	O
follow-up	NOUN	O	O
and	CCONJ	O	O
four	NUM	O	O
did	ADP	O	O
not	ADV	O	O
receive	VERB	O	O
brachytherapy	NOUN	O	O
because	PUNCT	O	O
they	ADP	O	O
were	VERB	O	O
unfit	ADJ	O	O
,	PUNCT	O	O
had	PUNCT	O	O
extension	NOUN	O	O
into	ADP	O	O
the	DET	O	O
cardia	NOUN	O	O
or	CCONJ	O	O
had	PUNCT	O	O
mainly	ADV	O	O
extrinsic	ADJ	O	O
compression	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
4	NUM	O	O
are	VERB	O	O
included	VERB	O	O
on	ADP	O	O
an	DET	O	O
'intention-to-treat	PUNCT	O	O
'	PUNCT	O	O
basis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
therapeutic	ADJ	O	B-PHYSICAL
interval	NOUN	O	I-PHYSICAL
for	ADP	O	O
the	DET	O	O
brachytherapy	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
,	PUNCT	O	O
83	VERB	O	O
days	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
36	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
the	DET	O	O
laser	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.026	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
dysphagia	NOUN	O	B-PHYSICAL
relief	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
endoscopic	ADJ	O	B-OTHER
procedures	NOUN	O	I-OTHER
or	CCONJ	O	O
survival	NOUN	O	B-MORTALITY
times	NOUN	O	I-MORTALITY
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
preliminary	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
brachytherapy	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
laser	NOUN	O	O
therapy	NOUN	O	O
prolongs	NOUN	O	O
the	DET	O	O
first	ADJ	O	O
therapeutic	ADJ	O	B-PHYSICAL
interval	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
long-term	NOUN	O	O
advantages	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
.	PUNCT	O	O

JobTIPS	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
transition	NOUN	O	O
to	PUNCT	O	O
employment	PUNCT	O	O
program	NOUN	O	O
for	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
an	DET	O	O
internet	NOUN	O	B-OTHER
accessed	DET	O	I-OTHER
training	PROPN	O	I-OTHER
program	NOUN	O	I-OTHER
that	ADP	O	O
included	PUNCT	O	O
Theory	NOUN	O	O
of	ADP	O	O
Mind-based	VERB	O	O
guidance	NOUN	O	O
,	PUNCT	O	O
video	ADJ	O	O
models	NOUN	O	O
,	PUNCT	O	O
visual	ADJ	O	O
supports	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
virtual	ADJ	O	O
reality	NOUN	O	O
practice	NOUN	O	O
sessions	NOUN	O	O
in	ADP	O	O
teaching	PUNCT	O	O
appropriate	ADP	O	O
job	PUNCT	O	O
interview	NOUN	O	O
skills	NOUN	O	O
to	ADP	O	O
individuals	CCONJ	O	O
with	ADP	O	O
high	ADJ	O	O
functioning	VERB	O	O
Autism	NOUN	O	O
Spectrum	NOUN	O	O
Disorders	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
study	NOUN	O	O
,	PUNCT	O	O
twenty-two	PUNCT	O	O
youth	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
16-19	ADJ	O	O
,	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
during	ADP	O	O
two	NUM	O	O
employment	PUNCT	O	O
interviews	NOUN	O	O
.	PUNCT	O	O

Half	ADJ	O	O
received	VERB	O	O
a	DET	O	O
training	DET	O	O
intervention	NOUN	O	O
following	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
interview	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
half	ADJ	O	O
who	ADP	O	O
served	VERB	O	O
as	ADP	O	O
a	DET	O	O
contrast	NOUN	O	O
group	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

Their	ADJ	O	O
performance	NOUN	O	O
pre	ADP	O	O
and	CCONJ	O	O
post	PUNCT	O	O
intervention	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
four	NUM	O	O
independent	ADJ	O	O
raters	NOUN	O	O
using	VERB	O	O
a	DET	O	O
scale	NOUN	O	O
that	PUNCT	O	O
included	PUNCT	O	O
evaluation	NOUN	O	O
of	ADP	O	O
both	PUNCT	O	O
Content	NOUN	O	B-OTHER
and	CCONJ	O	O
Delivery	NOUN	O	B-OTHER
.	PUNCT	O	O

Results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
youth	NOUN	O	O
who	ADP	O	O
completed	PROPN	O	O
the	DET	O	O
JobTIPS	NOUN	O	O
employment	ADJ	O	O
program	NOUN	O	O
demonstrated	VERB	O	O
significantly	ADP	O	B-MENTAL
more	ADV	O	I-MENTAL
effective	ADJ	O	I-MENTAL
verbal	ADJ	O	I-MENTAL
content	NOUN	O	I-MENTAL
skills	NOUN	O	I-MENTAL
than	PUNCT	O	O
those	DET	O	O
who	PROPN	O	O
did	CCONJ	O	O
not	ADV	O	O
.	PUNCT	O	O

In	ADJ	O	O
vivo	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	O
on	ADP	O	O
multiple	ADJ	O	O
cytochrome	NOUN	O	O
P450s	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
in	PUNCT	O	O
vivo	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
clarithromycin	NOUN	O	O
administration	NOUN	O	O
on	ADP	O	O
the	DET	O	O
in	ADP	O	O
vivo	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
P450	NOUN	O	O
1A2	NOUN	O	O
,	PUNCT	O	O
2C9	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2D6	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
cytochrome	NOUN	O	O
P450	NOUN	O	O
probes	NOUN	O	O
caffeine	NOUN	O	O
(	PUNCT	O	O
CYP1A2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
tolbutamide	NOUN	O	O
(	PUNCT	O	O
CYP2C9	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
dextromethorphan	PUNCT	O	O
(	PUNCT	O	O
CYP2D6	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
administered	VERB	O	O
as	ADP	O	O
an	DET	O	O
oral	ADJ	O	O
cocktail	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
and	CCONJ	O	O
7	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
oral	ADJ	O	O
clarithromycin	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
)	PUNCT	O	O
administration	NOUN	O	O
to	ADP	O	O
12	NUM	O	O
healthy	ADJ	O	O
male	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
urine	NOUN	O	B-PHYSICAL
samples	NOUN	O	I-PHYSICAL
were	VERB	O	O
collected	ADV	O	O
and	CCONJ	O	O
assayed	ADJ	O	O
for	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
compounds	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
metabolites	NOUN	O	O
using	VERB	O	O
high-performance	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
CYP1A2	NOUN	O	B-PHYSICAL
indices	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
oral	ADJ	O	B-PHYSICAL
caffeine	NOUN	O	I-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
6.2	NUM	O	O
+/-	SYM	O	O
3.3	NUM	O	O
l/h	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
5.7	ADP	O	O
+/-	SYM	O	O
4.2	NUM	O	O
l/h	NOUN	O	O
after	ADP	O	O
,	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
6-h	NOUN	O	B-PHYSICAL
paraxanthine	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
caffeine	NOUN	O	I-PHYSICAL
serum	NOUN	O	I-PHYSICAL
concentration	NOUN	O	O
ratio	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
0.49	NUM	O	O
+/-	SYM	O	O
0.3	NUM	O	O
before	ADP	O	O
and	CCONJ	O	O
0.44	NUM	O	O
+/-	SYM	O	O
0.3	NUM	O	O
after	ADP	O	O
,	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
unchanged	VERB	O	O
following	VERB	O	O
clarithromycin	NOUN	O	O
dosing	VERB	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
the	DET	O	O
tolbutamide	NOUN	O	B-PHYSICAL
oral	ADJ	O	I-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
0.77	NUM	O	O
+/-	SYM	O	O
0.28	NUM	O	O
l/h	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
0.72	NUM	O	O
+/-0.24	PUNCT	O	O
l/h	ADP	O	O
after	CCONJ	O	O
,	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
nor	CCONJ	O	O
the	DET	O	O
tolbutamide	NOUN	O	B-PHYSICAL
urinary	ADJ	O	B-PHYSICAL
metabolic	ADJ	O	I-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
779	NUM	O	O
+/-	SYM	O	O
294	NUM	O	O
before	ADP	O	O
and	CCONJ	O	O
681	NUM	O	O
+/-	SYM	O	O
416	NUM	O	O
after	ADP	O	O
,	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
indices	NOUN	O	O
of	ADP	O	O
CYP2C9	NOUN	O	O
were	VERB	O	O
altered	VERB	O	O
by	ADP	O	O
clarithromycin	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
CYP2D6	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
dextromethorphan	PUNCT	O	B-PHYSICAL
to	PUNCT	O	O
dextrorphan	PUNCT	O	B-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
was	PUNCT	O	O
not	PUNCT	O	O

Simulating	PROPN	O	O
a	DET	O	O
memory	NOUN	O	O
impairment	NOUN	O	O
:	PUNCT	O	O
can	PUNCT	O	O
amnesics	PUNCT	O	O
implicitly	ADV	O	O
outperform	ADJ	O	O
simulators	NOUN	O	O
?	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
tests	NOUN	O	O
in	ADP	O	O
differentiating	VERB	O	O
simulating	PUNCT	O	B-MENTAL
test	ADV	O	I-MENTAL
performances	NOUN	O	I-MENTAL
from	ADP	O	O
genuine	ADJ	O	O
memory-impaired	NOUN	O	B-MENTAL
and	CCONJ	O	O
normal	ADJ	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
test	PUNCT	O	O
performances	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	PUNCT	O	O
simulation	ADJ	O	O
design	NOUN	O	O
was	VERB	O	O
implemented	VERB	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
an	DET	O	O
analogue	NOUN	O	O
design	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
normal	ADJ	O	O
participants	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
experimental	ADJ	O	O
instructions	NOUN	O	O
to	ADP	O	O
feign	CCONJ	O	O
a	DET	O	O
mental	ADJ	O	O
impairment	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
other	ADJ	O	O
normal	ADJ	O	O
participants	NOUN	O	O
with	ADP	O	O
instructions	NOUN	O	O
to	PART	O	O
perform	NOUN	O	O
honestly	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
a	DET	O	O
comparison	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
acquired	DET	O	O
brain-injured	ADJ	O	O
persons	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
similar	ADJ	O	O
instructions	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Forty	PUNCT	O	O
individuals	NOUN	O	O
comprised	VERB	O	O
the	DET	O	O
simulating	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
participants	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
simulating	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Twenty	VERB	O	O
memory-impaired	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
of	ADP	O	O
whom	NOUN	O	O
had	PUNCT	O	O
been	ADP	O	O
diagnosed	VERB	O	O
as	ADP	O	O
suffering	VERB	O	O
from	ADP	O	O
a	DET	O	O
memory	NOUN	O	O
impairment	NOUN	O	O
following	VERB	O	O
acquired	VERB	O	O
brain	NOUN	O	O
damage	NOUN	O	O
,	PUNCT	O	O
participated	NUM	O	O
as	ADP	O	O
the	DET	O	O
memory-impaired	VERB	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
simulation	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
directed	VERB	O	O
to	ADP	O	O
imitate	PUNCT	O	O
a	DET	O	O
person	NOUN	O	O
with	ADP	O	O
a	DET	O	O
memory	NOUN	O	O
impairment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	ADV	O	O
involved	PUNCT	O	O
identifying	VERB	O	B-MENTAL
those	ADP	O	I-MENTAL
tests	NOUN	O	I-MENTAL
,	PUNCT	O	I-MENTAL
if	VERB	O	I-MENTAL
any	DET	O	I-MENTAL
,	PUNCT	O	I-MENTAL
where	ADP	O	I-MENTAL
simulators	PUNCT	O	I-MENTAL
were	VERB	O	I-MENTAL
significantly	ADV	O	I-MENTAL
different	ADJ	O	I-MENTAL
from	ADP	O	I-MENTAL
normal	ADJ	O	I-MENTAL
and	CCONJ	O	I-MENTAL
memory-impaired	VERB	O	I-MENTAL
participants	NOUN	O	I-MENTAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
On	ADP	O	O
5	NUM	O	O
of	ADP	O	O
the	DET	O	O
15	NUM	O	O
tasks	NOUN	O	O
administered	ADP	O	O
,	PUNCT	O	O
simulators	NOUN	O	B-MENTAL
performed	VERB	O	I-MENTAL
significantly	ADV	O	I-MENTAL
differently	ADV	O	I-MENTAL
from	ADP	O	I-MENTAL
normal	ADJ	O	I-MENTAL
and	CCONJ	O	I-MENTAL
memory-impaired	VERB	O	I-MENTAL
participants	NOUN	O	I-MENTAL
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
5	NUM	O	O
tasks	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
coin-in-the-hand	CCONJ	O	O
,	PUNCT	O	O
when	ADP	O	O
administered	VERB	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
the	DET	O	O
autobiographical	ADJ	O	O
interview	NOUN	O	O
,	PUNCT	O	O
identified	ADP	O	O
95	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
of	ADP	O	O
the	DET	O	O
simulators	NOUN	O	O
without	ADP	O	O
misclassifying	NUM	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
memory-impaired	NOUN	O	O
or	CCONJ	O	O
normal	ADJ	O	O
participants	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
these	DET	O	O
two	NUM	O	O
tests	NOUN	O	O
,	PUNCT	O	O
when	ADP	O	O
administered	PUNCT	O	O
jointly	ADV	O	O
,	PUNCT	O	O
might	PROPN	O	O
be	PUNCT	O	O
of	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
settings	NOUN	O	O
to	PART	O	O
assist	NOUN	O	O
in	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
malingerers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cognitive	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
subjective	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Tramadol	PUNCT	O	O
suppository	ADJ	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
the	DET	O	O
relief	NOUN	O	O
of	ADP	O	O
perineal	NOUN	O	B-PAIN
pain	NOUN	O	I-PAIN
after	ADP	O	O
perineorrhaphy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
Thailand	CCONJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	PUNCT	O	O
randomized	VERB	O	O
double-blinded	ADV	O	O
control	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
tramodol	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
rectal	ADJ	O	O
suppository	ADJ	O	O
for	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
postpartum	NOUN	O	B-PAIN
perineal	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
after	ADP	O	O
perineorrhaphy	NOUN	O	O
.	PUNCT	O	O

MATERIAL	NOUN	O	O
AND	CCONJ	O	O
METHOD	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
women	NOUN	O	O
who	ADP	O	O
gave	VERB	O	O
birth	NOUN	O	O
vaginally	PUNCT	O	O
with	ADP	O	O
episiotomy	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
second-	ADJ	O	O
or	CCONJ	O	O
third-degree	ADP	O	O
tear	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assign	PUNCT	O	O
to	PART	O	O
receive	NOUN	O	O
two	ADJ	O	O
tablets	ADV	O	O
oftramadol	NOUN	O	O
50	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
two	NUM	O	O
tablets	ADV	O	O
ofplacebo	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pill	ADJ	O	O
were	VERB	O	O
physically	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
the	DET	O	O
real	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
ratings	NOUN	O	I-PAIN
were	VERB	O	O
recorded	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
perineorrhaphy	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
first	ADJ	O	O
dose	NOUN	O	O
on	ADP	O	O
a	DET	O	O
10-cm	ADJ	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Side	NOUN	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	I-ADVERSE-EFFECTS
overall	ADJ	O	I-ADVERSE-EFFECTS
opinion	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Tramadol	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
statistical	ADJ	O	O
significances	PUNCT	O	O
in	ADP	O	O
analgesic	ADP	O	B-PAIN
properties	NOUN	O	I-PAIN
,	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
the	DET	O	O
means	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PAIN
rating	PUNCT	O	I-PAIN
at	ADP	O	O
the	DET	O	O
different	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
reported	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
No	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
between	ADP	O	O
Tramadol	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
relief	NOUN	O	O
perineal	NOUN	O	O
pain	NOUN	O	O
after	ADP	O	O
perineorrhaphy	PUNCT	O	O

Preoperative	ADJ	O	O
lanreotide	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
acromegalic	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
macroadenomas	PUNCT	O	O
increases	PUNCT	O	O
short-term	NOUN	O	B-PHYSICAL
postoperative	ADJ	O	I-PHYSICAL
cure	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	NOUN	O	O
whether	ADP	O	O
4-month	NOUN	O	O
preoperative	ADJ	O	O
lanreotide	NOUN	O	O
treatment	NOUN	O	O
would	VERB	O	O
improve	ADJ	O	O
the	DET	O	O
surgical	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
of	ADP	O	O
newly	ADJ	O	O
diagnosed	VERB	O	O
acromegalic	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
macroadenomas	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	CCONJ	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
After	ADP	O	O
a	DET	O	O
baseline	NOUN	O	O
evaluation	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
4-month	NOUN	O	O
preoperative	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
lanreotide	NOUN	O	O
(	PUNCT	O	O
starting	ADJ	O	O
with	ADP	O	O
30	NUM	O	O
mg/2	NOUN	O	O
weeks	NOUN	O	O
i.m	NUM	O	O
.	PUNCT	O	O

and	CCONJ	O	O
increasing	VERB	O	O
to	ADP	O	O
30	NUM	O	O
mg/week	NOUN	O	O
i.m	NUM	O	O
.	PUNCT	O	O

at	ADP	O	O
week	NOUN	O	O
8	NUM	O	O
if	CCONJ	O	O
mean	PUNCT	O	O
GH	NOUN	O	O
>	SYM	O	O
2.5	NUM	O	O
microg/l	NOUN	O	O
on	ADP	O	O
GH	NOUN	O	O
day	NOUN	O	O
curves	NOUN	O	O
;	PUNCT	O	O
pretreatment	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
Group	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
to	ADP	O	O
transsphenoidal	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
direct	ADJ	O	O
surgery	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
Group	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cure	NOUN	O	B-OTHER
was	VERB	O	O
evaluated	VERB	O	O
4	NUM	O	O
months	NOUN	O	O
postoperatively	ADJ	O	O
primarily	ADV	O	O
by	ADP	O	O
fasting	DET	O	O
IGF1	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
age-adjusted	VERB	O	O
upper	ADJ	O	O
limit	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
pool	NOUN	O	O
of	ADP	O	O
108	NUM	O	O
patients	NOUN	O	O
was	ADJ	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
were	VERB	O	O
lost	VERB	O	O
to	ADP	O	O
follow-up	NOUN	O	O
during	ADP	O	O
the	DET	O	O
study	ADV	O	O
period	NOUN	O	O
,	PUNCT	O	O
so	PUNCT	O	O
49	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
were	VERB	O	O
analysed	VERB	O	O
.	PUNCT	O	O

At	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Cure	NOUN	O	B-OTHER
was	VERB	O	O
established	VERB	O	O
in	ADP	O	O
24	NUM	O	O
of	ADP	O	O
49	NUM	O	O
(	PUNCT	O	O
49.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
35.0-63.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
pretreated	DET	O	O
patients	NOUN	O	O
(	PUNCT	O	O
Group	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
9	NUM	O	O
of	ADP	O	O
49	NUM	O	O
(	PUNCT	O	O
18.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
7.6-29.2	PUNCT	O	O
%	SYM	O	O
)	PUNCT	O	O
direct	ADJ	O	O
surgery	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
Group	NOUN	O	O
2	NUM	O	O
;	PUNCT	O	O
P=0.001	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Surgical	ADJ	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
was	VERB	O	O
recorded	VERB	O	O
in	ADP	O	O
12	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
12.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
Group	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
14.3	NUM	O	O
and	CCONJ	O	O
10.2	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P=0.538	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
postoperative	ADJ	O	B-OTHER
hospital	NOUN	O	I-OTHER
stay	NOUN	O	I-OTHER
was	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
:	PUNCT	O	O
being	ADV	O	O
4.5+/-1.6	PUNCT	O	O
days	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
1	NUM	O	O
vs	CCONJ	O	O
4.8+/-1.9	PUNCT	O	O
days	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
P=0.328	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Pretreatment	NOUN	O	O
with	ADP	O	O
lanreotide	NOUN	O	O
before	ADP	O	O
transsphenoidal	ADJ	O	O
surgery	NOUN	O	O
improves	NOUN	O	O
surgical	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
rates	NOUN	O	I-OTHER
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
GH-secreting	PUNCT	O	O
pituitary	NOUN	O	O
macroadenomas	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
surgical	ADJ	O	B-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
or	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
hospital	NOUN	O	B-OTHER
stay	NOUN	O	I-OTHER
(	PUNCT	O	O
ClinicalTrials.gov	PUNCT	O	O
number	NOUN	O	O
,	PUNCT	O	O
NCT00993356	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
S-adenosylmethionine	NOUN	O	O
in	ADP	O	O
the	DET	O	O
symptomatic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
intrahepatic	ADJ	O	B-PHYSICAL
cholestasis	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

Parenteral	ADJ	O	O
S-adenosylmethionine	NOUN	O	O
proved	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
reversing	PUNCT	O	O
intrahepatic	ADJ	O	B-PHYSICAL
cholestasis	NOUN	O	I-PHYSICAL
in	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
planned	PROPN	O	O
to	ADJ	O	O
assess	NOUN	O	O
whether	ADP	O	O
oral	ADJ	O	O
S-adenosylmethionine	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
cholestatic	ADJ	O	B-PHYSICAL
patients	NOUN	O	I-PHYSICAL
with	ADP	O	O
chronic	ADJ	O	O
liver	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
220	NUM	O	O
inpatients	NOUN	O	O
(	PUNCT	O	O
26	NUM	O	O
%	SYM	O	O
chronic	ADJ	O	O
active	ADJ	O	O
hepatitis	NOUN	O	O
,	PUNCT	O	O
68	NUM	O	O
%	SYM	O	O
cirrhosis	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
primary	ADJ	O	O
biliary	ADJ	O	O
cirrhosis	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
stable	ADJ	O	O
(	PUNCT	O	O
1	NUM	O	O
month	NOUN	O	O
or	CCONJ	O	O
more	DET	O	O
)	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
twofold	NOUN	O	O
increases	CCONJ	O	O
in	ADP	O	O
serum	NOUN	O	B-PHYSICAL
total	ADJ	O	O
and	CCONJ	O	O
conjugated	VERB	O	B-PHYSICAL
bilirubin	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
alkaline	ADJ	O	I-PHYSICAL
phosphatase	NOUN	O	I-PHYSICAL
volunteered	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
markers	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
cholestasis	NOUN	O	I-PHYSICAL
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
decreased	VERB	O	O
after	PUNCT	O	O
oral	ADJ	O	O
S-adenosylmethionine	NOUN	O	O
administration	NOUN	O	O
(	PUNCT	O	O
1600	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
values	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
corresponding	ADJ	O	O
values	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

S-adenosylmethionine	NOUN	O	O
significantly	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
improved	VERB	O	O
subjective	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
such	ADP	O	I-PHYSICAL
as	ADP	O	I-PHYSICAL
pruritus	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
fatigue	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
feeling	DET	O	O
of	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
entacapone	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
peripherally	ADV	O	O
acting	ADP	O	O
catechol-O-methyltransferase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
motor	NOUN	O	B-PHYSICAL
response	NOUN	O	O
to	ADP	O	B-PHYSICAL
acute	ADJ	O	I-PHYSICAL
treatment	NOUN	O	O
with	ADP	O	B-PHYSICAL
levodopa	NOUN	O	B-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Catechol-O-methyltransferase	NOUN	O	O
(	PUNCT	O	O
COMT	NOUN	O	O
)	PUNCT	O	O
inhibitors	NOUN	O	O
may	ADP	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
by	ADP	O	O
improving	VERB	O	O
the	DET	O	O
bioavailability	NOUN	O	B-OTHER
of	ADP	O	O
levodopa	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
prolonging	VERB	O	O
its	ADP	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Entacapone	NOUN	O	O
(	PUNCT	O	O
OR-611	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
novel	ADJ	O	O
COMT	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
which	DET	O	O
does	PUNCT	O	O
not	ADV	O	O
cross	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
12	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
and	CCONJ	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
,	PUNCT	O	O
single	ADJ	O	O
dose	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
magnitude	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	NOUN	O	O
levodopa/50	NOUN	O	O
mg	NOUN	O	O
carbidopa	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
after	ADP	O	O
concomitant	ADJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
200	NUM	O	O
or	CCONJ	O	O
800	NUM	O	O
mg	NOUN	O	O
entacapone	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
motor	NOUN	O	B-PHYSICAL
response	NOUN	O	O
to	ADP	O	B-PHYSICAL
levodopa	NOUN	O	I-PHYSICAL
was	VERB	O	O
seen	VERB	O	O
when	ADP	O	O
200	NUM	O	O
mg	NOUN	O	O
entacapone	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
with	ADP	O	O
levodopa/carbidopa	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
thiopental	ADJ	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PAIN
associated	VERB	O	I-PAIN
with	ADP	O	I-PAIN
propofol	NOUN	O	I-PAIN
injection	NOUN	O	I-PAIN
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
Propofol	NOUN	O	O
causes	PUNCT	O	O
pain	NOUN	O	O
on	ADP	O	O
IV	NUM	O	B-PAIN
injection	NOUN	O	I-PAIN
in	ADP	O	O
28	NUM	O	O
%	SYM	O	O
-90	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
number	NOUN	O	O
of	ADP	O	O
techniques	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
tried	PRON	O	O
to	PART	O	O
minimize	NOUN	O	O
propofol-induced	VERB	O	O
pain	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
variable	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
thiopental	ADJ	O	O
0.25	NUM	O	O
mg/kg	NOUN	O	O
and	CCONJ	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
and	CCONJ	O	O
lidocaine	NOUN	O	O
40	NUM	O	O
mg	NOUN	O	O
after	ADP	O	O
venous	ADJ	O	O
occlusion	NOUN	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
propofol-induced	VERB	O	B-PAIN
pain	NOUN	O	I-PAIN
.	PUNCT	O	O

One-hundred-twenty-four	NOUN	O	O
adult	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
ASA	NOUN	O	O
physical	ADJ	O	O
status	NOUN	O	O
I-II	ADV	O	O
,	PUNCT	O	O
undergoing	CCONJ	O	O
elective	ADJ	O	O
surgery	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
into	ADP	O	O
4	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
31	NUM	O	O
each	ADP	O	O
.	PUNCT	O	O

Group	NOUN	O	O
I	NUM	O	O
received	VERB	O	O
normal	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
II	NUM	O	O
received	ADJ	O	O
lidocaine	NOUN	O	O
2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
40	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
groups	NOUN	O	O
III	NUM	O	O
and	CCONJ	O	O
IV	NUM	O	O
received	PUNCT	O	O
thiopental	ADJ	O	O
0.25	NUM	O	O
mg/kg	NOUN	O	O
and	CCONJ	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

All	DET	O	O
pretreatment	NOUN	O	O
drugs	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
in	ADP	O	O
2	NUM	O	O
mL	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
manual	ADJ	O	O
venous	ADJ	O	O
occlusion	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Propofol	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
after	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	O
occlusion	NOUN	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
a	DET	O	O
four-point	NOUN	O	O
scale	NOUN	O	O
:	PUNCT	O	O
0	NUM	O	O
=	SYM	O	O
no	DET	O	O
pain	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
=	SYM	O	O
mild	ADJ	O	O
pain	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
=	SYM	O	O
moderate	ADJ	O	O
pain	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
=	SYM	O	O
severe	ADJ	O	O
pain	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Twenty-four	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
77	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
complained	PUNCT	O	O
of	ADP	O	O
pain	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
as	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
12	NUM	O	O
(	PUNCT	O	O
39	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
10	NUM	O	O
(	PUNCT	O	O
32	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
lidocaine	NOUN	O	O
40	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
thiopental	ADJ	O	O
0.25	NUM	O	O
mg/kg	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thiopental	ADJ	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thiopental	ADJ	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
was	VERB	O	O
the	DET	O	O
most	ADJ	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

We	ADP	O	O
therefore	ADV	O	O
suggest	VERB	O	O
routine	ADJ	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
thiopental	ADJ	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
along	ADP	O	O
with	ADP	O	O
venous	ADJ	O	O
occlusion	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
min	NOUN	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PHYSICAL
associated	VERB	O	O
with	ADP	O	O
propofol	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

IMPLICATIONS	NOUN	O	O
Pain	NOUN	O	B-PHYSICAL
associated	VERB	O	O
with	ADP	O	O
IV	NUM	O	O
injection	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	O
is	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
28	NUM	O	O
%	SYM	O	O
-90	NUM	O	O
%	SYM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
thiopental	ADJ	O	O
0.25	NUM	O	O
mg/kg	NOUN	O	O
and	CCONJ	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
after	ADP	O	O
manual	ADJ	O	O
venous	ADJ	O	O
occlusion	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
min	NOUN	O	O
effectively	ADV	O	O
attenuated	VERB	O	O
pain	NOUN	O	B-PHYSICAL
associated	VERB	O	O
with	ADP	O	O
propofol	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Thiopental	ADJ	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
was	VERB	O	O
the	DET	O	O
most	ADJ	O	O
effective	ADJ	O	O
in	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	B-PAIN
pain	NOUN	O	I-PAIN
and	CCONJ	O	O
can	PRON	O	O
be	VERB	O	O
used	VERB	O	O
routinely	ADV	O	O
.	PUNCT	O	O

Riluzole	NUM	O	O
as	ADP	O	O
an	DET	O	O
adjunctive	ADJ	O	O
therapy	NOUN	O	O
to	ADP	O	O
risperidone	NUM	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
irritability	NOUN	O	B-MENTAL
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
A	PUNCT	O	O
hyperglutamatergic	ADJ	O	O
state	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
play	NOUN	O	O
a	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Riluzole	NOUN	O	O
is	VERB	O	O
a	DET	O	O
glutamate-modulating	VERB	O	O
agent	NOUN	O	O
with	ADP	O	O
neuroprotective	ADJ	O	O
properties	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
positive	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
many	DET	O	O
neuropsychiatric	ADJ	O	B-PHYSICAL
disorders	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
riluzole	ADJ	O	O
as	ADP	O	O
an	DET	O	O
adjunctive	ADJ	O	O
to	PUNCT	O	O
risperidone	ADP	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
irritability	NOUN	O	O
in	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
not	ADV	O	O
optimally	ADV	O	O
responding	PUNCT	O	O
to	ADP	O	O
previous	ADJ	O	O
medications	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
10-week	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
The	DET	O	O
study	NOUN	O	O
enrolled	VERB	O	O
male	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
outpatients	ADJ	O	O
aged	NOUN	O	O
5-12	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
DSM-IV-TR	NOUN	O	O
criteria	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
score	NOUN	O	O
of	ADP	O	O
?12	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
Aberrant	ADJ	O	O
Behavior	NOUN	O	O
Checklist-Community	NOUN	O	O
(	PUNCT	O	O
ABC-C	NOUN	O	O
)	PUNCT	O	O
irritability	NOUN	O	O
subscale	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
discontinued	DET	O	O
other	ADJ	O	O
medications	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	VERB	O	O
Subjects	NOUN	O	O
received	ADV	O	O
riluzole	VERB	O	O
(	PUNCT	O	O
titrated	NOUN	O	O
to	ADP	O	O
50	NUM	O	O
or	CCONJ	O	O
100	NUM	O	O
mg/day	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
bodyweight	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
risperidone	NUM	O	O
(	PUNCT	O	O
titrated	NOUN	O	O
up	ADP	O	O
to	ADP	O	O
2	NUM	O	O
or	CCONJ	O	O
3	NUM	O	O
mg/day	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
bodyweight	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
10	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

OUTCOME	NOUN	O	O
Patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
week	NOUN	O	O
5	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
week	NOUN	O	O
10	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	ADV	O	O
was	VERB	O	O
the	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ABC-C	NOUN	O	O
irritability	NOUN	O	O
subscale	NOUN	O	O
score	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	PUNCT	O	O
week	ADP	O	O
10	NUM	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
compared	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
other	ADJ	O	O
ABC-C	NOUN	O	O
subscale	NOUN	O	O
scores	NOUN	O	O
and	CCONJ	O	O
Clinical	ADJ	O	O
Global	PUNCT	O	O
Impressions-Improvement	ADJ	O	O
(	PUNCT	O	O
CGI-I	NOUN	O	O
)	PUNCT	O	O
scale	NOUN	O	O
scores	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Forty-nine	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
forty	NUM	O	O
children	NOUN	O	O
completed	VERB	O	O
the	DET	O	O
trial	NOUN	O	O
(	PUNCT	O	O
dropouts	PUNCT	O	O
:	PUNCT	O	O
placebo	NOUN	O	O
=	SYM	O	O
4	NUM	O	O
,	PUNCT	O	O
riluzole	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	PUNCT	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	ADV	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
ABC-C	NOUN	O	O
irritability	NOUN	O	O
subscale	NOUN	O	O
score	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
achieved	VERB	O	O
by	ADP	O	O
the	DET	O	O
riluzole-treated	VERB	O	O
children	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
riluzole	ADJ	O	O
group	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
significantly	ADP	O	O
greater	PUNCT	O	O
improvement	NOUN	O	O
on	ADP	O	O
the	DET	O	O
lethargy/social	ADJ	O	O
withdrawal	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
stereotypic	ADJ	O	O
behavior	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hyperactivity/non-compliance	PUNCT	O	O
subscales	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
on	ADP	O	O
the	DET	O	O
inappropriate	PUNCT	O	O
speech	NOUN	O	O
subscale	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.20	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Eleven	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
riluzole	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
five	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
responders	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
their	PUNCT	O	O
CGI-I	NOUN	O	O
scores	NOUN	O	O
[	PUNCT	O	O
?	PUNCT	O	O
(	PUNCT	O	O

2	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
=	ADP	O	O
3.750	DET	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Children	NOUN	O	O
in	ADP	O	O
the	DET	O	O
riluzole	ADJ	O	O
group	NOUN	O	O
experienced	ADP	O	O
significantly	ADV	O	O
more	DET	O	O
increases	PUNCT	O	O
in	ADP	O	O
their	PUNCT	O	O
appetite	NOUN	O	O
and	CCONJ	O	O
bodyweight	ADJ	O	O
than	ADP	O	O
children	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
by	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Riluzole	ADP	O	O
add-on	NOUN	O	O
therapy	NOUN	O	O
shows	NOUN	O	O
several	ADJ	O	O
therapeutic	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
for	ADP	O	O
improving	VERB	O	O
irritability	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
its	PUNCT	O	O
add-on	NOUN	O	O
to	ADP	O	O
risperidone	NUM	O	O
also	ADV	O	O
results	VERB	O	O
in	ADP	O	O
significantly	ADV	O	O
increased	ADJ	O	O
appetite	NOUN	O	O
and	CCONJ	O	O
weight	NOUN	O	O
gain	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
using	VERB	O	O
right	ADJ	O	O
ventricular	ADJ	O	O
myocardial	ADJ	O	O
isovolumic	ADJ	O	O
relaxation	NOUN	O	O
time	NOUN	O	O
.	PUNCT	O	O

Right	ADJ	O	O
ventricular	ADJ	O	O
(	PUNCT	O	O
RV	NOUN	O	O
)	PUNCT	O	O
blood	NOUN	O	O
pool-derived	DET	O	O
isovolumic	ADJ	O	O
relaxation	NOUN	O	O
time	NOUN	O	O
(	PUNCT	O	O
IVRT	NOUN	O	O
)	PUNCT	O	O
correlates	VERB	O	O
well	VERB	O	O
with	CCONJ	O	O
systolic	ADJ	O	O
pulmonary	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
PAP	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
complex	ADJ	O	O
parameter	NOUN	O	O
derivation	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
method	NOUN	O	O
is	VERB	O	O
rarely	ADV	O	O
used	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
validate	VERB	O	O
the	DET	O	O
measurement	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
velocity	NOUN	O	O
imaging-derived	VERB	O	O
RV	NOUN	O	O
IVRT	NOUN	O	O
(	PUNCT	O	O
IVRT	NOUN	O	O
'	PUNCT	O	O
)	PUNCT	O	O
against	ADP	O	O
invasively	PUNCT	O	O
measured	PUNCT	O	O
PAP	NOUN	O	O
.	PUNCT	O	O

Transthoracic	ADJ	O	O
echocardiography	NOUN	O	O
with	ADP	O	O
myocardial	ADJ	O	O
velocity	NOUN	O	O
imaging	VERB	O	O
and	CCONJ	O	O
right	VERB	O	O
heart	NOUN	O	O
catheterization	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
pool	NOUN	O	I-PHYSICAL
IVRT	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
myocardial	ADJ	O	B-PHYSICAL
IVRTs	NOUN	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
tricuspid	NOUN	O	I-PHYSICAL
valve	NOUN	O	I-PHYSICAL
annulus	NOUN	O	I-PHYSICAL
ring	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
basal	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
apical	ADJ	O	B-PHYSICAL
RV	NOUN	O	I-PHYSICAL
free	ADJ	O	I-PHYSICAL
wall	NOUN	O	I-PHYSICAL
segments	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
and	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
data	NOUN	O	O
from	ADP	O	O
33	NUM	O	O
age-	NOUN	O	O
and	CCONJ	O	O
sex-matched	VERB	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Measured	PUNCT	O	B-PHYSICAL
IVRTs	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
strongest	PUNCT	O	O
correlation	NOUN	O	O
(	PUNCT	O	O
R	NOUN	O	O
=	SYM	O	O
0.74	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
systolic	ADJ	O	B-PHYSICAL
PAP	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	B-PHYSICAL
heart	NOUN	O	I-PHYSICAL
rate-corrected	DET	O	I-PHYSICAL
IVRT	NOUN	O	I-PHYSICAL
'	PUNCT	O	O
derived	VERB	O	O
from	ADP	O	O
the	DET	O	O
basal	ADJ	O	O
RV	NOUN	O	O
free	ADJ	O	O
wall	NOUN	O	O
segment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
basal	ADJ	O	B-PHYSICAL
segment	NOUN	O	I-PHYSICAL
IVRT	NOUN	O	I-PHYSICAL
'	PUNCT	O	O
corrected	VERB	O	O
for	ADP	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
correlates	VERB	O	O
well	VERB	O	O
with	CCONJ	O	O
the	DET	O	O
invasive	ADJ	O	O
PAP	NOUN	O	O
measurement	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
can	PROPN	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
predict	NOUN	O	O
systolic	ADJ	O	B-PHYSICAL
PAP	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

It	PRON	O	O
can	PUNCT	O	O
even	ADV	O	O
be	ADP	O	O
considered	VERB	O	O
as	ADP	O	O
an	DET	O	O
alternative	ADJ	O	O
to	ADP	O	O
tricuspid	NOUN	O	O
regurgitation-derived	VERB	O	O
PAP	NOUN	O	O
systolic	ADJ	O	O
when	ADP	O	O
tricuspid	NOUN	O	O
regurgitation	NOUN	O	O
is	VERB	O	O
nonrecordable	ADJ	O	O
.	PUNCT	O	O

A	PUNCT	O	O
proposed	VERB	O	O
method	NOUN	O	O
to	PART	O	O
derive	NOUN	O	O
systolic	ADJ	O	O
PAP	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
while	ADP	O	O
screening	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
,	PUNCT	O	O
monitoring	VERB	O	O
the	DET	O	O
disease	NOUN	O	O
progression	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Adjvant	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
tongue	NOUN	O	O
and	CCONJ	O	O
floor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mouth	NOUN	O	O
cancers	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
January	NOUN	O	O
1974	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
anterior	ADJ	O	O
tongue	NOUN	O	O
and	CCONJ	O	O
floor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mouth	NOUN	O	O
cancers	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
stratification	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
staging	DET	O	O
and	CCONJ	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
one-third	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
methotrexate	PUNCT	O	O
400	NUM	O	O
mg	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
citrovorum	NOUN	O	O
factor	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
+	ADJ	O	O
bleomycin	NOUN	O	O
60	NUM	O	O
mg/week	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
15	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
one-third	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
immunotherapy	NOUN	O	O
with	ADP	O	O
weekly	ADV	O	O
C.	ADJ	O	O
parvum	VERB	O	O
injections	NOUN	O	O
during	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
third	PUNCT	O	O
did	PUNCT	O	O
not	ADV	O	O
receive	VERB	O	O
any	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
adjuvant	NOUN	O	O
treatment	NOUN	O	O
seems	NOUN	O	O
to	ADP	O	O
delay	ADJ	O	B-OTHER
recurrence	NOUN	O	I-OTHER
it	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
decrease	PUNCT	O	O
the	DET	O	O
recurrence	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
.	PUNCT	O	O

Survival	NOUN	O	B-MORTALITY
is	VERB	O	O
also	ADV	O	O
not	ADV	O	O
signigicantly	ADJ	O	O
modified	VERB	O	O
by	ADP	O	O
adjuvant	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
was	PROPN	O	O
better	PUNCT	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
small	ADJ	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	ADP	O	O
previously	PUNCT	O	O
received	NOUN	O	O
radiotherapy	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
benefit	NOUN	O	O
from	ADP	O	O
adjuvant	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Getting	ADP	O	O
a	DET	O	O
high	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	O
behavior	NOUN	O	O
survey	NOUN	O	O
among	ADP	O	O
the	DET	O	O
general	ADJ	O	O
population	NOUN	O	O
in	ADP	O	O
Japan	PUNCT	O	O
:	PUNCT	O	O
three	NUM	O	O
different	ADJ	O	O
methods	NOUN	O	O
of	ADP	O	O
survey	NOUN	O	O
on	ADP	O	O
sexual	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
specify	NOUN	O	O
the	DET	O	O
most	PUNCT	O	O
accurate	ADJ	O	O
,	PUNCT	O	O
reliable	ADJ	O	O
and	CCONJ	O	O
valid	PUNCT	O	O
technique	NOUN	O	O
for	ADP	O	O
a	DET	O	O
general	ADJ	O	O
sexual	ADJ	O	O
behavioral	ADJ	O	O
survey	NOUN	O	O
in	ADP	O	O
Japan	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assure	VERB	O	O
a	DET	O	O
high	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
to	PUNCT	O	O
keep	PUNCT	O	O
respondents	NOUN	O	O
'	PUNCT	O	O
privacy	NOUN	O	O
confidential	ADJ	O	O
by	ADP	O	O
using	VERB	O	O
an	DET	O	O
anonymous	ADJ	O	O
questionnaire	NOUN	O	O
survey	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sample	NOUN	O	O
(	PUNCT	O	O
360	NUM	O	O
potential	ADJ	O	O
respondents	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
selected	VERB	O	O
randomly	ADV	O	O
from	ADP	O	O
basic	ADJ	O	O
resident	ADJ	O	O
registers	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
geographically	NOUN	O	O
different	ADJ	O	O
areas	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
the	DET	O	O
registries	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
residents	NOUN	O	O
,	PUNCT	O	O
aged	ADP	O	O
20	NUM	O	O
to	ADP	O	O
49	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
,	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
selected	VERB	O	O
to	ADJ	O	O
represent	PUNCT	O	O
each	DET	O	O
sex	NOUN	O	O
from	ADP	O	O
each	DET	O	O
area	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
each	CCONJ	O	O
having	ADJ	O	O
a	DET	O	O
different	ADJ	O	O
procedure	NOUN	O	O
of	ADP	O	O
requesting	PUNCT	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
survey	NOUN	O	O
and	CCONJ	O	O
providing	VERB	O	O
the	DET	O	O
questionnaires	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
Postal	ADJ	O	O
Group	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
Telephone	NOUN	O	O
Group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
Face-to-face	NOUN	O	O
Group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
survey	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
from	ADP	O	O
October	NOUN	O	O
1995	NUM	O	O
to	ADP	O	O
February	PUNCT	O	O
1996	NUM	O	O
.	PUNCT	O	O

Effective	ADJ	O	B-OTHER
response	NOUN	O	O
rates	NOUN	O	B-OTHER
for	ADP	O	O
the	DET	O	O
above	DET	O	O
mentioned	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
69.2	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
69.2	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
55.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
difficult	ADJ	O	O
to	ADJ	O	O
determine	NOUN	O	O
the	DET	O	O
best	PUNCT	O	O
method	NOUN	O	O
when	ADP	O	O
only	ADV	O	O
considering	PUNCT	O	O
the	PUNCT	O	O

Sequential	ADJ	O	O
therapy	NOUN	O	O
versus	CCONJ	O	O
standard	ADJ	O	O
triple-drug	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
eradication	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Antimicrobial	ADJ	O	O
resistance	NOUN	O	O
has	PUNCT	O	O
decreased	PUNCT	O	O
eradication	NOUN	O	O
rates	NOUN	O	O
for	ADP	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
infection	NOUN	O	O
worldwide	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
sequential	ADJ	O	O
treatment	NOUN	O	O
schedule	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
studies	NOUN	O	O
published	VERB	O	O
to	ADP	O	O
date	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
Italy	PUNCT	O	O
.	PUNCT	O	O

We	ADP	O	O
undertook	ADJ	O	O
this	DET	O	O
study	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
these	DET	O	O
results	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
replicated	VERB	O	O
in	ADP	O	O
India	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	CCONJ	O	O
randomized	VERB	O	O
,	PUNCT	O	O
open-labeled	PUNCT	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
controlled	VERB	O	O
trial	NOUN	O	O
comparing	ADJ	O	O
sequential	ADJ	O	O
vs.	CCONJ	O	O
standard	ADJ	O	O
triple-drug	NOUN	O	O
therapy	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
at	ADP	O	O
Lokmanya	PUNCT	O	O
Tilak	NOUN	O	O
Municipal	ADJ	O	O
General	ADJ	O	O
Hospital	NOUN	O	O
,	PUNCT	O	O
Mumbai	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
thirty-one	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
dyspepsia	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
a	DET	O	O
10-day	NOUN	O	O
sequential	ADJ	O	O
regimen	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
pantoprazole	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
amoxicillin	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
administered	VERB	O	O
twice	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
5	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
40	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
pantoprazole	NOUN	O	O
,	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
500	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
tinidazole	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
administered	VERB	O	O
twice	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
5	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
to	ADP	O	O
standard	ADJ	O	O
14-day	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
pantoprazole	NOUN	O	O
,	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
amoxicillin	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
administered	VERB	O	O
twice	PUNCT	O	O
daily	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
eradication	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
achieved	VERB	O	O
with	ADP	O	O
the	DET	O	O
sequential	ADJ	O	O
regimen	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
than	CCONJ	O	O
that	PUNCT	O	O
obtained	VERB	O	O
with	ADP	O	O
the	DET	O	O
triple	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Per-protocol	ADJ	O	B-OTHER
eradication	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
of	ADP	O	O
sequential	ADJ	O	O
therapy	NOUN	O	O
was	VERB	O	O
92.4	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
85.8-96.1	ADV	O	O
%	SYM	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
81.8	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
73.9-87.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.027	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
standard	ADJ	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Intention-to-treat	NOUN	O	O
eradication	NOUN	O	O
rates	NOUN	O	O
were	VERB	O	O
88.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
80.9-93.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
79.1	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
71.1-85.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.029	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
and	CCONJ	O	O
minor	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
between	ADP	O	O
therapy	NOUN	O	O
groups	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
(	PUNCT	O	O
14.6	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
triple	ADJ	O	O
therapy	NOUN	O	O
group	NOUN	O	O
vs.	CCONJ	O	O
23.5	NUM	O	O
%	SYM	O	O
in	ADP	O	O
sequential	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Follow	PUNCT	O	O
up	ADP	O	O
was	ADP	O	O
incomplete	PUNCT	O	O
in	ADP	O	O
3.3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
4.7	NUM	O	O
%	ADV	O	O
patients	NOUN	O	O
in	ADP	O	O
standard	ADJ	O	O
and	CCONJ	O	O
sequential	ADJ	O	O
therapy	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Sequential	ADJ	O	O
therapy	NOUN	O	O
includes	NOUN	O	O
one	NUM	O	O
additional	ADJ	O	O
antibiotic	NOUN	O	O
(	PUNCT	O	O
tinidazole	NOUN	O	O
)	PUNCT	O	O
that	ADP	O	O
is	VERB	O	O
not	ADV	O	O
contained	VERB	O	O
in	ADP	O	O
standard	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Sequential	ADJ	O	O
therapy	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
than	VERB	O	O
standard	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
eradicating	VERB	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
infection	NOUN	O	O
.	PUNCT	O	O

Moisture-vapour-permeable	ADJ	O	O
film	NOUN	O	O
as	ADP	O	O
an	DET	O	O
outpatient	ADJ	O	O
burn	NOUN	O	O
dressing	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
compares	PUNCT	O	O
a	DET	O	O
moisture-vapour-permeable	ADJ	O	O
film	NOUN	O	O
(	PUNCT	O	O
MVPF	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
silver	NOUN	O	O
sulphadiazine	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
prospective	ADJ	O	O
manner	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
outpatient	ADJ	O	O
burns	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
closely	ADV	O	O
matched	PROPN	O	O
in	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
per	ADP	O	O
cent	NUM	O	O
of	ADP	O	O
BSA	NOUN	O	O
burned	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
burn	NOUN	O	O
severity	NOUN	O	O
and	CCONJ	O	O
locations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
MVPF	NOUN	O	O
group	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
39.0	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
greater	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	B-PAIN
after	ADP	O	O
application	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dressing	PUNCT	O	O
over	ADP	O	O
the	DET	O	O
silver	NOUN	O	O
sulphadiazine	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MVPF	NOUN	O	O
film	NOUN	O	O
group	NOUN	O	O
also	ADV	O	O
reported	ADJ	O	O
significantly	ADV	O	O
less	ADV	O	O
difficulty	NOUN	O	O
in	ADP	O	O
wound	NOUN	O	B-OTHER
care	NOUN	O	I-OTHER
and	CCONJ	O	O
in	ADP	O	O
dressing	PUNCT	O	B-OTHER
interference	NOUN	O	I-OTHER
with	ADP	O	I-OTHER
their	ADJ	O	I-OTHER
daily	ADJ	O	I-OTHER
functions	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	B-ADVERSE-EFFECTS
infection	NOUN	O	I-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
healing	VERB	O	I-OTHER
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
management	NOUN	O	B-OTHER
of	ADP	O	O
outpatient	ADJ	O	O
burns	NOUN	O	O
,	PUNCT	O	O
MVPF	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
superior	ADJ	O	O
to	ADP	O	O
silver	NOUN	O	O
sulphadiazine	NOUN	O	O
.	PUNCT	O	O

Specific	ADJ	O	O
immunoglobulin	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
whooping	PUNCT	O	O
cough	NOUN	O	O
.	PUNCT	O	O

Immunoglobulin	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
whooping	PROPN	O	O
cough	NOUN	O	O
(	PUNCT	O	O
pertussis	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
widely	ADV	O	O
believed	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
ineffective	ADJ	O	B-OTHER
although	ADP	O	O
there	PUNCT	O	O
are	ADJ	O	O
sound	ADJ	O	O
reasons	NOUN	O	O
for	ADP	O	O
regarding	PUNCT	O	O
the	DET	O	O
condition	NOUN	O	O
as	ADP	O	O
a	DET	O	O
toxin-induced	VERB	O	O
disease	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
wondered	VERB	O	O
whether	ADP	O	O
the	DET	O	O
lack	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
success	NOUN	O	I-OTHER
with	ADP	O	O
pertussis	NOUN	O	O
immunoglobulins	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
inadequate	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
so	PUNCT	O	O
we	ADP	O	O
designed	VERB	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
immunoglobulin	NOUN	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
at	ADP	O	O
three	NUM	O	O
Swedish	PUNCT	O	O
hospitals	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
enrolled	VERB	O	O
73	NUM	O	O
children	NOUN	O	O
aged	PROPN	O	O
less	ADV	O	O
than	ADP	O	O
36	NUM	O	O
months	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
admitted	VERB	O	O
with	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
whooping	PUNCT	O	O
cough	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
admission	NOUN	O	O
they	PUNCT	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
monocomponent	ADJ	O	O
pertussis	NOUN	O	O
toxoid	NOUN	O	O
vaccine	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
two-component	ADJ	O	O
acellular	ADJ	O	O
vaccine	NOUN	O	O
also	ADV	O	O
containing	CCONJ	O	O
filamentous	ADJ	O	O
haemagglutinin	NOUN	O	O
;	PUNCT	O	O
or	CCONJ	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
albumin	NOUN	O	O
solution	NOUN	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
immunoglobulins	NOUN	O	O
had	DET	O	O
a	DET	O	O
high	ADJ	O	O
antitoxin	NOUN	O	O
content	NOUN	O	O
and	CCONJ	O	O
had	PUNCT	O	O
been	PUNCT	O	O
raised	VERB	O	O
with	ADP	O	O
acellular	ADJ	O	O
pertussis	NOUN	O	O
vaccines	NOUN	O	O
.	PUNCT	O	O

Diagnosis	NOUN	O	O
of	ADP	O	O
pertussis	NOUN	O	O
was	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
laboratory	NOUN	O	O
tests	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
follow-up	NOUN	O	O
was	VERB	O	O
completed	VERB	O	O
in	ADP	O	O
67	NUM	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
study	ADJ	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
47	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
disease	NOUN	O	O
before	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Duration	NOUN	O	O
of	ADP	O	O
whoops	ADJ	O	B-PHYSICAL
post-treatment	NOUN	O	I-PHYSICAL
was	VERB	O	O
8.7	DET	O	O
days	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
Cl	NOUN	O	O
4.8	NUM	O	O
,	PUNCT	O	O
12.6	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
33	NUM	O	O
children	NOUN	O	O
receiving	DET	O	O
immunoglobulin	NOUN	O	O
vs	CCONJ	O	O
20.6	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
Cl	NOUN	O	O
11.9	NUM	O	O
,	PUNCT	O	O
29.3	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
14	NUM	O	O
receiving	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0041	DET	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
number	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
whoops	NOUN	O	I-PHYSICAL
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
significantly	ADV	O	O
reduced	ADP	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0196	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
early	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
important	ADJ	O	O
,	PUNCT	O	O
since	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
whoops	NOUN	O	I-PHYSICAL
was	ADJ	O	O
most	PUNCT	O	O
pronounced	NOUN	O	O
when	ADP	O	O
disease	NOUN	O	O
duration	NOUN	O	O
before	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	B-PHYSICAL
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
immunoglobulin	NOUN	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

High-dose	NOUN	O	O
specific	ADJ	O	O
pertussis	NOUN	O	O
immunoglobulin	NOUN	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
antitoxin	NOUN	O	O
concentration	NOUN	O	O
has	ADP	O	O
a	DET	O	O
beneficial	ADJ	O	B-OTHER
effect	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
whooping	PUNCT	O	O
cough	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Finnish	NOUN	O	O
Diabetes	NOUN	O	O
Prevention	NOUN	O	O
Study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Finnish	NOUN	O	O
Diabetes	NOUN	O	O
Prevention	NOUN	O	O
Study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
an	DET	O	O
intensive	ADJ	O	O
diet-exercise	ADJ	O	O
programme	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
or	CCONJ	O	O
delaying	PUNCT	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	PUNCT	O	B-PHYSICAL
in	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
impaired	VERB	O	O
glucose	NOUN	O	O
tolerance	NOUN	O	O
(	PUNCT	O	O
IGT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
to	PUNCT	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
programme	NOUN	O	O
on	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
factors	NOUN	O	O
of	ADP	O	O
atherosclerotic	ADJ	O	O
vascular	ADJ	O	O
diseases	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	PUNCT	O	O
ongoing	ADV	O	O
study	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
523	NUM	O	O
overweight	PUNCT	O	O
subjects	NOUN	O	O
with	ADP	O	O
IGT	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
two	NUM	O	O
oral	ADJ	O	O
glucose	NOUN	O	O
tolerance	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
an	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
measure	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
is	ADJ	O	O
individual	ADJ	O	B-OTHER
dietary	ADJ	O	I-OTHER
advice	NOUN	O	I-OTHER
aimed	PUNCT	O	O
at	ADP	O	O
reducing	VERB	O	O
weight	NOUN	O	O
and	CCONJ	O	O
intake	NOUN	O	O
of	ADP	O	O
saturated	VERB	O	O
fat	NOUN	O	O
and	CCONJ	O	O
increasing	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
fibre	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
subjects	NOUN	O	O
are	VERB	O	O
individually	ADV	O	O
guided	PROPN	O	O
to	PART	O	O
increase	NOUN	O	O
their	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
receives	NOUN	O	O
general	ADJ	O	O
information	NOUN	O	O
about	PUNCT	O	O
the	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
weight	NOUN	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
healthy	ADJ	O	O
diet	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
pilot	NOUN	O	O
study	VERB	O	O
began	ADV	O	O
in	ADP	O	O
1993	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
recruitment	NOUN	O	O
ended	PUNCT	O	O
in	ADP	O	O
1998	NUM	O	O
.	PUNCT	O	O

By	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
April	NOUN	O	O
1999	NUM	O	O
there	PUNCT	O	O
were	VERB	O	O
65	PUNCT	O	O
new	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	O
,	PUNCT	O	O
34	NUM	O	O
drop-outs	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
death	NOUN	O	B-MORTALITY
.	PUNCT	O	O

The	DET	O	O
weight	NOUN	O	O
reduction	NOUN	O	B-PHYSICAL
was	VERB	O	O
greater	PUNCT	O	O
(	PUNCT	O	O
-4.6	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
152	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
143	NUM	O	O
,	PUNCT	O	O
-0.9	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
sustained	VERB	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
year	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
43.4	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
at	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
41.8	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
achieved	PUNCT	O	O
a	DET	O	O
weight	NOUN	O	O
reduction	NOUN	O	B-PHYSICAL
of	ADP	O	O
at	ADP	O	O
least	ADV	O	O
5	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
corresponding	VERB	O	O
figures	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
subjects	NOUN	O	O
were	VERB	O	O
14.0	NUM	O	O
and	CCONJ	O	O
12.0	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
1	NUM	O	O
year	PUNCT	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
reductions	NOUN	O	O
in	ADP	O	O
2	NUM	O	O
h	NOUN	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
fasting	PUNCT	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
2	NUM	O	I-PHYSICAL
h	NOUN	O	I-PHYSICAL
insulin	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
systolic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
serum	NOUN	O	B-PHYSICAL
triglycerides	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
cardiovascular	ADJ	O	B-PHYSICAL
risk	NOUN	O	O
factors	NOUN	O	B-PHYSICAL
were	VERB	O	O
sustained	VERB	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
interim	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ongoing	ADV	O	O
Finnish	ADV	O	O
Diabetes	NOUN	O	O
Prevention	NOUN	O	O
Study	NOUN	O	O
demonstrate	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	PUNCT	O	O

A	DET	O	O
study	NOUN	O	O
of	ADP	O	O
a	DET	O	O
Self-Care	NOUN	O	O
Rehabilitation	NOUN	O	O
Program	NOUN	O	O
in	ADP	O	O
pediatric	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Self-Care	NOUN	O	O
Rehabilitation	NOUN	O	O
in	ADP	O	O
Pediatric	ADJ	O	O
Asthma	NOUN	O	O
(	PUNCT	O	O
SCRPA	NOUN	O	O
)	PUNCT	O	O
project	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
ascertain	NOUN	O	O
the	DET	O	O
level	NOUN	O	O
to	ADP	O	O
which	PUNCT	O	O
children	ADJ	O	O
with	ADP	O	O
asthma	NOUN	O	O
are	VERB	O	O
able	ADJ	O	O
to	PART	O	O
acquire	NOUN	O	O
the	DET	O	O
asthma	NOUN	O	O
knowledge	NOUN	O	O
and	CCONJ	O	O
skills	NOUN	O	O
presented	VERB	O	O
in	ADP	O	O
a	DET	O	O
self-management	ADJ	O	O
training	DET	O	O
program	NOUN	O	O
conducted	VERB	O	O
by	ADP	O	O
the	DET	O	O
American	ADJ	O	O
Lung	NOUN	O	O
Association	NOUN	O	O
of	ADP	O	O
Utah	CCONJ	O	O
and	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
such	CCONJ	O	O
training	ADJ	O	O
on	ADP	O	O
the	DET	O	O
asthma	NOUN	O	O
experience	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
preschool	NOUN	O	O
SCRPA	NOUN	O	O
Curriculum	NOUN	O	O
(	PUNCT	O	O
ages	NOUN	O	O
2-5	NUM	O	O
)	PUNCT	O	O
consisted	VERB	O	O
of	ADP	O	O
six	NUM	O	O
1-hour	NOUN	O	O
classes	NOUN	O	O
scheduled	DET	O	O
twice	CCONJ	O	O
a	DET	O	O
week	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
and	CCONJ	O	O
last	ADP	O	O
classes	NOUN	O	O
were	VERB	O	O
for	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
both	CCONJ	O	O
parents	NOUN	O	O
only	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
middle	ADJ	O	O
four	NUM	O	O
sessions	NOUN	O	O
were	VERB	O	O
for	ADP	O	O
the	DET	O	O
child	NOUN	O	O
and	CCONJ	O	O
parent	NOUN	O	O
(	PUNCT	O	O
s	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
school-age	NOUN	O	O
SCRPA	NOUN	O	O
curriculum	NOUN	O	O
(	PUNCT	O	O
ages	PROPN	O	O
6-14	NUM	O	O
)	PUNCT	O	O
consisted	VERB	O	O
of	ADP	O	O
eight	NUM	O	O
90-minute	NOUN	O	O
classes	NOUN	O	O
for	ADP	O	O
both	PUNCT	O	O
child	NOUN	O	O
and	CCONJ	O	O
parent	NOUN	O	O
(	PUNCT	O	O
s	NOUN	O	O
)	PUNCT	O	O
scheduled	VERB	O	O
twice	CCONJ	O	O
a	DET	O	O
week	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Private	ADJ	O	O
physicians	NOUN	O	O
referred	DET	O	O
21	NUM	O	O
preschool	NOUN	O	O
children	NOUN	O	O
and	CCONJ	O	O
38	NUM	O	O
school-age	NOUN	O	O
children	NOUN	O	O
into	ADP	O	O
the	DET	O	O
program	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
school-age	NOUN	O	O
children	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
a	DET	O	O
study	NOUN	O	O
or	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
preschool	NOUN	O	O
children	NOUN	O	O
served	VERB	O	O
as	ADP	O	O
their	PUNCT	O	O
own	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	O
episodes	NOUN	O	O
during	ADP	O	O
the	DET	O	O
3	NUM	O	O
months	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
training	VERB	O	O
showed	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	B-MENTAL
number	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
episodes	NOUN	O	I-MENTAL
but	CCONJ	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
severity	NOUN	O	B-MENTAL
in	ADP	O	O
the	DET	O	O
preschool	NOUN	O	O
,	PUNCT	O	O
school	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
school	NOUN	O	O
control	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
episodes	NOUN	O	B-MENTAL
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
groups	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
family	NOUN	O	O
record	NOUN	O	O
keeping	PUNCT	O	O
required	VERB	O	O
of	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
phenomenon	NOUN	O	O
worth	ADP	O	O
further	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
school-age	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
pre-	ADJ	O	O
and	CCONJ	O	O
posttesting	PROPN	O	O
,	PUNCT	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
SCRPA	NOUN	O	O
curriculum	NOUN	O	O
increased	VERB	O	O
knowledge	NOUN	O	B-MENTAL
and	CCONJ	O	O
skills	NOUN	O	B-MENTAL
in	ADP	O	O
the	DET	O	O
study	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
changes	NOUN	O	O
not	ADV	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Randomised	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
physiotherapy	NOUN	O	O
after	ADP	O	O
open	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
in	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	O
physiotherapy	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
reduce	NOUN	O	B-OTHER
the	DET	O	I-OTHER
incidence	NOUN	O	I-OTHER
of	ADP	O	O
postoperative	ADJ	O	O
pulmonary	ADJ	O	O
complications	NOUN	O	O
after	ADP	O	O
open	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
if	PUNCT	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
deep	ADJ	O	O
breathing	DET	O	O
exercises	NOUN	O	O
and	CCONJ	O	O
secretion	NOUN	O	O
clearing	PUNCT	O	O
techniques	NOUN	O	O
to	ADP	O	O
a	DET	O	O
standardised	VERB	O	O
physiotherapist-directed	VERB	O	O
program	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
mobilisation	NOUN	O	O
improved	PROPN	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	CCONJ	O	O
open	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Fifty-six	ADJ	O	O
patients	NOUN	O	O
undergoing	CCONJ	O	O
open	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	ADV	O	O
postoperative	ADJ	O	O
pulmonary	ADJ	O	O
complications	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomised	VERB	O	O
before	ADP	O	O
operation	NOUN	O	O
to	ADP	O	O
an	DET	O	O
early	ADJ	O	O
mobilisation-only	DET	O	O
group	NOUN	O	O
or	CCONJ	O	O
an	DET	O	O
early	ADJ	O	O
mobilisation-plus-deep	ADJ	O	O
breathing	VERB	O	O
and	CCONJ	O	O
coughing	PROPN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Mobility	NOUN	O	B-PHYSICAL
duration	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
of	ADP	O	O
breathing	PROPN	O	B-PHYSICAL
interventions	NOUN	O	I-PHYSICAL
were	VERB	O	O
quantified	VERB	O	O
for	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
outcomes	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
a	DET	O	O
blinded	ADJ	O	O
outcomes	NOUN	O	O
researcher	PUNCT	O	O
using	ADP	O	O
a	DET	O	O
standardised	VERB	O	O
outcomes	NOUN	O	O
measurement	NOUN	O	O
tool	NOUN	O	O
developed	ADP	O	O
specifically	ADV	O	O
for	ADP	O	O
this	DET	O	O
population	NOUN	O	O
.	PUNCT	O	O

Outcomes	NOUN	O	O
included	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
clinically	ADV	O	O
significant	ADJ	O	O
postoperative	ADJ	O	B-PHYSICAL
pulmonary	ADJ	O	I-PHYSICAL
complications	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
fever	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
length	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
stay	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
restoration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
anaesthetic	ADJ	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
perioperative	ADJ	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	PUNCT	O	O

[	PUNCT	O	O
Clinical	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
and	CCONJ	O	O
tolerance	NOUN	O	O
to	ADP	O	O
nimesulide	PUNCT	O	O
in	ADP	O	O
suppository	ADJ	O	O
formulation	NOUN	O	O
in	ADP	O	O
pain-inflammatory	ADJ	O	O
pathologies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ear	NOUN	O	O
,	PUNCT	O	O
nose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
throat	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
pharmaceutical	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
the	DET	O	O
non-steroid	NOUN	O	O
anti-inflammatory	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Nimesulide	PUNCT	O	O
have	PUNCT	O	O
been	PUNCT	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	PUNCT	O	O
study	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
flurbiprofen	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
98	NUM	O	O
patients	NOUN	O	O
aged	VERB	O	O
between	ADP	O	O
18	NUM	O	O
and	CCONJ	O	O
75	NUM	O	O
suffering	ADJ	O	O
from	ADP	O	O
pain-inflammatory	ADJ	O	O
pathologies	NOUN	O	O
of	ADP	O	O
ENT	NOUN	O	O
nature	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
administered	VERB	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
suppository	ADJ	O	O
twice	CCONJ	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
marked	VERB	O	O
anti-inflammatory	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
analgesic	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
antipyretic	ADJ	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
produced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
,	PUNCT	O	O
progressive	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
typical	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
inflammatory	ADJ	O	B-PHYSICAL
state	NOUN	O	I-PHYSICAL
up	PUNCT	O	O
to	ADP	O	O
their	PUNCT	O	O
complete	ADJ	O	O
remission	NOUN	O	O
.	PUNCT	O	O

Nimesulide	NOUN	O	O
evidenced	PUNCT	O	O
greater	PUNCT	O	O
speed	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
therapeutic	ADJ	O	B-PHYSICAL
action	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Assessment	NOUN	O	O
on	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
as	PUNCT	O	O
expressed	VERB	O	O
separately	ADV	O	O
by	ADP	O	O
the	DET	O	O
physician	NOUN	O	O
and	CCONJ	O	O
patient	NOUN	O	O
were	VERB	O	O
positive	ADJ	O	O
in	ADP	O	O
almost	ADV	O	O
all	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
both	PUNCT	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Superior	ADJ	O	O
visual	ADJ	O	O
search	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
studies	NOUN	O	O
have	ADP	O	O
suggested	VERB	O	O
that	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
perform	PUNCT	O	O
better	ADP	O	O
than	VERB	O	O
matched	VERB	O	O
controls	CCONJ	O	O
on	ADP	O	O
visual	ADJ	O	O
search	NOUN	O	O
tasks	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
this	ADP	O	O
stems	PUNCT	O	O
from	ADP	O	O
a	DET	O	O
superior	ADJ	O	O
visual	ADJ	O	B-MENTAL
discrimination	NOUN	O	I-MENTAL
ability	NOUN	O	I-MENTAL
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
assessed	VERB	O	O
whether	CCONJ	O	O
these	DET	O	O
findings	NOUN	O	O
generalize	PUNCT	O	O
from	ADP	O	O
children	NOUN	O	O
to	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Experiments	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
showed	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
like	ADP	O	O
children	NOUN	O	O
,	PUNCT	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
were	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
controls	CCONJ	O	O
at	ADP	O	O
searching	VERB	O	B-MENTAL
for	ADP	O	I-MENTAL
targets	NOUN	O	I-MENTAL
.	PUNCT	O	O

Experiment	NOUN	O	O
3	NUM	O	O
showed	VERB	O	O
that	ADP	O	O
increases	CCONJ	O	O
in	ADP	O	O
target-distractor	NOUN	O	B-MENTAL
similarity	NOUN	O	O
slowed	PUNCT	O	B-MENTAL
the	DET	O	I-MENTAL
visual	ADJ	O	I-MENTAL
search	NOUN	O	I-MENTAL
performance	NOUN	O	B-MENTAL
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
significantly	ADV	O	O
more	ADV	O	O
than	PUNCT	O	O
that	ADP	O	O
of	ADP	O	O
the	DET	O	O
autism	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
the	DET	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
have	PUNCT	O	O
a	DET	O	O
superior	ADJ	O	B-PHYSICAL
visual	ADJ	O	I-PHYSICAL
discrimination	PUNCT	O	I-PHYSICAL

Hepatorenal	ADJ	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	O
volume	NOUN	O	O
and	CCONJ	O	O
intraperitoneal	ADJ	O	O
pressure	NOUN	O	O
on	ADP	O	O
renal	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
hepatic	ADJ	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Eleven	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
well-documented	VERB	O	O
hepatorenal	ADJ	O	O
syndrome	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
by	ADP	O	O
measurement	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
renal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
plasma	NOUN	O	B-PHYSICAL
aldosterone	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
renin	NOUN	O	B-PHYSICAL
substrate	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
plasma	NOUN	O	B-PHYSICAL
renin	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
then	ADV	O	O
given	VERB	O	O
750	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
stored	VERB	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
750	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
fresh	ADJ	O	O
frozen	VERB	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
,	PUNCT	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
on	ADP	O	O
successive	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

Infusion	NOUN	O	O
of	ADP	O	O
fresh	ADJ	O	O
frozen	VERB	O	O
plasma	NOUN	O	O
improved	ADP	O	O
function	ADP	O	O
more	ADV	O	O
than	PUNCT	O	O
did	PUNCT	O	O
stored	PUNCT	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
addition	NOUN	O	O
returned	VERB	O	O
a	DET	O	O
very	ADJ	O	O
low	ADJ	O	O
filtration	NOUN	O	O
fraction	NOUN	O	O
toward	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

Angiotensin	NOUN	O	O
II	NUM	O	O
infusion	NOUN	O	O
increased	VERB	O	O
filtration	NOUN	O	B-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
decreased	ADV	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
renal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
urine	NOUN	O	B-PHYSICAL
flow	NOUN	O	I-PHYSICAL
sharply	ADV	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
given	VERB	O	O
a	DET	O	O
daily	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
1,000	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
fresh	ADJ	O	O
frozen	VERB	O	O
plasma	NOUN	O	O
for	ADP	O	O
seven	NUM	O	O
to	ADP	O	O
18	NUM	O	O
days	NOUN	O	O
to	PUNCT	O	O
expand	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
volume	NOUN	O	O
to	ADP	O	O
supranormal	ADJ	O	O
levels	NOUN	O	O
as	CCONJ	O	O
assayed	VERB	O	O
by	ADP	O	O
serial	ADJ	O	O
measurement	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
aldosterone	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
decreased	ADJ	O	O
to	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
range	NOUN	O	O
,	PUNCT	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
renal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
both	PUNCT	O	O
increased	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
urinary	ADJ	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
potassium	NOUN	O	B-PHYSICAL
both	PUNCT	O	O
returned	VERB	O	O
toward	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
intraperitoneal	ADJ	O	O
pressure	NOUN	O	O
was	VERB	O	O
then	ADV	O	O
studied	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
renal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
pressure	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
vena	ADP	O	I-PHYSICAL
cava	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
hepatic	ADJ	O	B-PHYSICAL
vein	NOUN	O	I-PHYSICAL
free	ADJ	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
hepatic	ADJ	O	B-PHYSICAL
vein	NOUN	O	I-PHYSICAL
wedged	ADV	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
before	ADP	O	O
,	PUNCT	O	O
during	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
paracentesis	NOUN	O	O
to	PART	O	O
reduce	ADJ	O	O
the	DET	O	O
intraperitoneal	ADJ	O	O
pressure	NOUN	O	O
from	ADP	O	O
30	NUM	O	O
to	ADP	O	O
40	NUM	O	O
cm	NOUN	O	O
H2O	NOUN	O	O
to	ADP	O	O
12	NUM	O	O
to	ADP	O	O
17	NUM	O	O
cm	NOUN	O	O
H2O	NOUN	O	O
.	PUNCT	O	O

Venous	ADJ	O	B-PHYSICAL
pressures	NOUN	O	I-PHYSICAL
moved	DET	O	O
parallel	PUNCT	O	O
to	ADP	O	O
ascitic	ADJ	O	B-PHYSICAL
fluid	NOUN	O	I-PHYSICAL
pressures	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
renal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
urine	NOUN	O	B-PHYSICAL
flow	NOUN	O	I-PHYSICAL
all	PUNCT	O	O
improved	CCONJ	O	O
sharply	ADV	O	O
;	PUNCT	O	O
then	ADV	O	O
,	PUNCT	O	O
as	PUNCT	O	O
ascitic	ADJ	O	O
fluid	NOUN	O	O
continued	VERB	O	O
to	PART	O	O
form	ADP	O	O
,	PUNCT	O	O
reducing	PUNCT	O	O
vascular	ADJ	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
urine	NOUN	O	O
flow	NOUN	O	O
,	PUNCT	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
all	PUNCT	O	O
decreased	ADP	O	O
slowly	ADV	O	O
.	PUNCT	O	O

Six	NUM	O	O
patients	NOUN	O	O
then	ADV	O	O
underwent	PUNCT	O	O
placement	NOUN	O	O
of	ADP	O	O
a	DET	O	O
LeVeen	NOUN	O	O
shunt	NOUN	O	O
.	PUNCT	O	O

Improvement	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
renal	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
clinical	ADJ	O	B-PHYSICAL
condition	NOUN	O	I-PHYSICAL
was	VERB	O	O
dramatic	VERB	O	O
.	PUNCT	O	O

During	ADP	O	O
postoperative	ADJ	O	O
observation	NOUN	O	O
of	ADP	O	O
up	PUNCT	O	O
to	ADV	O	O
two	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
progressive	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
hepatic	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
has	PUNCT	O	O
occurred	VERB	O	O
.	PUNCT	O	O

Capsular	ADJ	O	O
contracture	NOUN	O	O
around	ADP	O	O
saline-filled	ADV	O	O
fine	ADJ	O	O
textured	PUNCT	O	O
and	CCONJ	O	O
smooth	ADJ	O	O
mammary	ADJ	O	O
implants	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
7.5-year	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
previous	ADJ	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
study	NOUN	O	O
comparing	VERB	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
patient	NOUN	O	O
textured	PUNCT	O	O
and	CCONJ	O	O
smooth	ADJ	O	O
saline-filled	VERB	O	O
mammary	ADJ	O	O
implants	NOUN	O	O
(	PUNCT	O	O
Biocell	CCONJ	O	O
)	PUNCT	O	O
with	ADP	O	O
large	ADJ	O	O
pore	CCONJ	O	O
size	NOUN	O	O
(	PUNCT	O	O
300	NUM	O	O
to	ADP	O	O
600	ADV	O	O
microm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
saw	ADJ	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
capsular	ADJ	O	O
contracture	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
in	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
way	NOUN	O	O
to	PART	O	O
compare	PART	O	O
capsular	ADJ	O	O
contracture	NOUN	O	O
around	ADP	O	O
smooth	ADJ	O	O
and	CCONJ	O	O
textured	ADP	O	O
saline-filled	NOUN	O	O
prostheses	NOUN	O	O
with	ADP	O	O
pores	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
size	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
7.5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
breast	NOUN	O	O
hardness	VERB	O	O
was	VERB	O	O
followed	VERB	O	O
up	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	ADJ	O	O
patient	NOUN	O	O
satisfaction	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
healthy	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
age	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
years	NOUN	O	O
were	VERB	O	O
operated	VERB	O	O
on	ADP	O	O
for	ADP	O	O
breast	NOUN	O	O
augmentation	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
surgeons	NOUN	O	O
performed	VERB	O	O
all	DET	O	O
operations	NOUN	O	O
in	ADP	O	O
a	DET	O	O
standardized	VERB	O	O
way	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
subglandularly	PUNCT	O	O
a	DET	O	O
Siltex	NOUN	O	O
textured	PUNCT	O	O
saline-filled	VERB	O	O
prosthesis	NOUN	O	O
with	ADP	O	O
a	DET	O	O
pore	ADJ	O	O
size	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
to	ADP	O	O
70	NUM	O	O
microm	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
breast	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
smooth	ADJ	O	O
saline-filled	VERB	O	O
prosthesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
other	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
hardness	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
breasts	NOUN	O	I-PHYSICAL
was	VERB	O	O
evaluated	VERB	O	O
after	ADP	O	O
0.5	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
7.5	NUM	O	O
years	NOUN	O	O
using	VERB	O	O
Baker	ADJ	O	B-OTHER
grading	NUM	O	I-OTHER
and	CCONJ	O	I-OTHER
applanation	NOUN	O	I-OTHER
tonometry	NOUN	O	I-OTHER
.	PUNCT	O	O

Eighteen	NUM	O	O
patients	NOUN	O	O
completed	VERB	O	O
1-year	NOUN	O	O
and	CCONJ	O	O
7.5-year	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
breasts	NOUN	O	O
with	ADP	O	O
smooth	ADJ	O	O
prostheses	NOUN	O	O
were	VERB	O	O
contracted	VERB	O	O
after	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
Baker	NOUN	O	O
III	NUM	O	O
or	CCONJ	O	O
IV	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
smooth	ADJ	O	O
prostheses	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
with	ADP	O	O
a	DET	O	O
textured	VERB	O	O
prosthesis	NOUN	O	O
had	PUNCT	O	O
capsular	ADJ	O	B-PHYSICAL
contracture	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.34	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Seven	NUM	O	O
and	CCONJ	O	O
one-half	NOUN	O	O
years	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
six	NUM	O	O
patents	NOUN	O	O
with	ADP	O	O
smooth	ADJ	O	O
and	CCONJ	O	O
four	NUM	O	O
with	ADP	O	O
textured	VERB	O	O
implants	NOUN	O	O
had	PUNCT	O	O
contracture	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.66	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
smooth	ADJ	O	O
prostheses	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
textured	VERB	O	O
prosthesis	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
capsule	NOUN	O	O
around	ADP	O	O
the	DET	O	O
implant	NOUN	O	O
hardened	ADP	O	O
between	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
and	CCONJ	O	O
7.5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
breasts	NOUN	O	O
with	ADP	O	O
smooth	ADJ	O	B-OTHER
and	CCONJ	O	O
textured	DET	O	B-OTHER
implants	NOUN	O	I-OTHER
contracted	VERB	O	I-OTHER
and	CCONJ	O	O
one	NUM	O	O
with	ADP	O	O
a	DET	O	O
textured	CCONJ	O	O
implant	ADP	O	O
softened.The	PUNCT	O	O
patients	NOUN	O	O
reported	VERB	O	O
on	ADP	O	O
a	DET	O	O
Visual	ADJ	O	O
Analogue	NOUN	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
to	ADP	O	O
10	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
the	DET	O	O
augmentation	NOUN	O	O
on	ADP	O	O
their	ADJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
9	NUM	O	O
+/-	SYM	O	O
1	NUM	O	O
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
preferred	VERB	O	O
the	DET	O	O
breast	NOUN	O	O
with	ADP	O	O
the	DET	O	O
smooth	ADJ	O	O
prosthesis	NOUN	O	O
,	PUNCT	O	O
three	PUNCT	O	O
preferred	VERB	O	O
the	DET	O	O
breast	NOUN	O	O
with	ADP	O	O
the	DET	O	O
textured	VERB	O	O
prosthesis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
others	NOUN	O	O
found	VERB	O	O
both	PUNCT	O	O
breasts	DET	O	O
equal	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
significant	ADJ	O	B-OTHER
difference	NOUN	O	I-OTHER
of	ADP	O	O
contracture	NOUN	O	B-PHYSICAL
with	ADP	O	O
smooth	ADJ	O	O
versus	CCONJ	O	O
fine	ADJ	O	O
textured	ADP	O	O
implants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
preferred	VERB	O	O
the	DET	O	O
smooth	ADJ	O	O
implants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
reported	VERB	O	O
that	ADP	O	O
the	DET	O	O
breast	NOUN	O	O
augmentation	NOUN	O	O
had	PUNCT	O	O
had	PUNCT	O	O
an	DET	O	O
extremely	ADV	O	O
high	ADJ	O	O
impact	NOUN	O	O
on	ADP	O	O
their	ADJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
treatment	NOUN	O	O
study	NOUN	O	O
comparing	VERB	O	O
three	NUM	O	O
treatment	NOUN	O	O
options	NOUN	O	O
for	ADP	O	O
chalazia	ADJ	O	O
:	PUNCT	O	O
triamcinolone	ADV	O	O
acetonide	NOUN	O	O
injections	NOUN	O	O
,	PUNCT	O	O
incision	NOUN	O	O
and	CCONJ	O	O
curettage	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
hot	ADJ	O	O
compresses	CCONJ	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Three	PUNCT	O	O
methods	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
chalazia	ADP	O	O
were	ADP	O	O
compared	VERB	O	O
:	PUNCT	O	O
intralesional	ADJ	O	O
triamcinolone	NUM	O	O
acetonide	NOUN	O	O
injections	NOUN	O	O
(	PUNCT	O	O
0.2	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg/mL	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
incision	NOUN	O	O
and	CCONJ	O	O
curettage	NOUN	O	O
and	CCONJ	O	O
advice	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
application	NOUN	O	O
of	ADP	O	O
hot	ADJ	O	O
compresses	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
affected	PUNCT	O	O
eyelid	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
single	ADJ	O	O
centre	NOUN	O	O
randomized	VERB	O	O
treatment	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
chalazion	NOUN	O	O
underwent	PROPN	O	O
either	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
three	NUM	O	O
treatment	NOUN	O	O
options	NOUN	O	O
.	PUNCT	O	O

Chalazion	NOUN	O	B-OTHER
resolution	NOUN	O	I-OTHER
,	PUNCT	O	O
pain	NOUN	O	B-PAIN
,	PUNCT	O	O
satisfaction	NOUN	O	B-OTHER
and	CCONJ	O	O
inconvenience	NOUN	O	B-PAIN
experienced	ADJ	O	I-PAIN
because	PUNCT	O	I-PAIN
of	ADP	O	I-PAIN
treatments	NOUN	O	I-PAIN
were	VERB	O	O
the	DET	O	O
outcomes	NOUN	O	O
assessed	VERB	O	O
via	ADP	O	O
a	DET	O	O
telephone	NOUN	O	O
interview	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
136	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
into	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
3-week	NOUN	O	O
follow	VERB	O	O
up	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
resolution	NOUN	O	B-OTHER
rates	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
triamcinolone	ADV	O	O
acetonide	NOUN	O	O
injection	NOUN	O	O
and	CCONJ	O	O
surgical	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
each	DET	O	O
other	PUNCT	O	O
at	ADP	O	O
84	NUM	O	O
%	ADJ	O	O
(	PUNCT	O	O
47/56	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
87	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
39/45	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
conservative	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
46	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
16/35	PUNCT	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
were	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
triamcinolone	NUM	O	O
injection	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Inconvenience	NOUN	O	B-PHYSICAL
experienced	VERB	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
patients	NOUN	O	I-PHYSICAL
was	VERB	O	O
reported	VERB	O	O
as	PUNCT	O	O
significantly	ADV	O	O
less	ADV	O	O
in	ADP	O	O
the	DET	O	O
triamcinolone	NUM	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
conservative	ADJ	O	O
and	CCONJ	O	O
surgical	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
scores	NOUN	O	I-OTHER
were	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
conservative	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
each	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
two	NUM	O	O
groups	NOUN	O	O
which	DET	O	O
in	ADP	O	O
turn	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
different	ADJ	O	O
from	ADP	O	O
each	DET	O	O
other	PUNCT	O	O
regarding	ADP	O	O
this	DET	O	O
outcome	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
To	ADP	O	O
our	PUNCT	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
three	NUM	O	O
methods	NOUN	O	O
of	ADP	O	O
chalazia	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
single	ADJ	O	O
triamcinolone	NUM	O	O
acetonide	NOUN	O	O
injection	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
lid	DET	O	O
massage	NOUN	O	O
is	VERB	O	O
almost	ADV	O	O
as	PUNCT	O	O
effective	ADJ	O	O
as	CCONJ	O	O
incision	NOUN	O	O
and	CCONJ	O	O
curettage	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
chalazia	ADJ	O	O
and	CCONJ	O	O
with	ADP	O	O
similar	ADJ	O	O
patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
and	CCONJ	O	O
less	DET	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
patient	NOUN	O	B-ADVERSE-EFFECTS
inconvenience	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

[	PUNCT	O	O
Clinilal	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
medical	ADJ	O	O
ozone	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PART	O	O
study	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
medical	ADJ	O	O
ozone	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
42	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
randomly	ADV	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

22	DET	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
basic	ADJ	O	O
therapy	NOUN	O	O
were	VERB	O	O
as	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

20	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
basic	ADJ	O	O
therapy	NOUN	O	O
plus	CCONJ	O	O
ozone	NOUN	O	O
therapy	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
as	CCONJ	O	O
a	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Index	NOUN	O	O
of	ADP	O	O
biochemistry	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
virology	NOUN	O	B-PHYSICAL
were	VERB	O	O
studied	VERB	O	O
at	ADP	O	O
initial	ADJ	O	O
and	CCONJ	O	O
post-treatment	NOUN	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
liver	NOUN	O	O
function	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
more	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
complete	ADJ	O	B-OTHER
effective	ADJ	O	I-OTHER
and	CCONJ	O	O
partial	ADJ	O	B-OTHER
effective	ADJ	O	I-OTHER
were	VERB	O	O
10	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
35	NUM	O	O
%	ADV	O	O
difference	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
complete	ADJ	O	O
effective	ADJ	O	O
and	CCONJ	O	O
partial	ADJ	O	O
effective	ADJ	O	O
were	VERB	O	O
4.6	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
13.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Treatment	NOUN	O	O
of	ADP	O	O
medical	ADJ	O	O
ozone	NOUN	O	O
on	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
is	ADV	O	O
effective	ADJ	O	O
.	PUNCT	O	O

Late	ADJ	O	O
patient-reported	NOUN	O	O
toxicity	NOUN	O	O
after	ADP	O	O
preoperative	ADJ	O	O
radiotherapy	NOUN	O	O
or	CCONJ	O	O
chemoradiotherapy	NOUN	O	O
in	ADP	O	O
nonresectable	ADJ	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
results	CCONJ	O	O
from	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
Phase	NOUN	O	O
III	NUM	O	O
study	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Preoperative	ADJ	O	O
chemoradiotherapy	NOUN	O	O
(	PUNCT	O	O
CRT	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
radiotherapy	NOUN	O	O
(	PUNCT	O	O
RT	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
locally	ADV	O	O
advanced	VERB	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
survival	NOUN	O	B-MORTALITY
gain	NOUN	O	I-MORTALITY
is	VERB	O	O
limited	VERB	O	O
.	PUNCT	O	O

Late	ADJ	O	O
toxicity	NOUN	O	B-ADVERSE-EFFECTS
is	VERB	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
important	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
late	ADJ	O	B-PHYSICAL
bowel	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
sexual	ADJ	O	B-PHYSICAL
functions	NOUN	O	I-PHYSICAL
after	ADP	O	O
CRT	NOUN	O	O
or	CCONJ	O	O
RT	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
MATERIALS	NOUN	O	O
Patients	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
207	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
nonresectable	ADJ	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
preoperative	ADJ	O	O
CRT	NOUN	O	O
or	CCONJ	O	O
RT	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
Gy	NOUN	O	O
?	PUNCT	O	O

25	NUM	O	O
?	PUNCT	O	O

5-fluorouracil/leucovorin	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Extended	VERB	O	O
surgery	NOUN	O	O
was	VERB	O	O
often	ADV	O	O
required	VERB	O	O
.	PUNCT	O	O

Self-reported	VERB	O	O
late	ADJ	O	O
toxicity	NOUN	O	O
was	VERB	O	O
scored	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
LENT	NOUN	O	O
SOMA	NOUN	O	O
criteria	NOUN	O	O
in	ADP	O	O
a	DET	O	O
structured	VERB	O	O
telephone	NOUN	O	O
interview	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
questionnaires	ADJ	O	O
European	NOUN	O	O
Organisation	NOUN	O	O
for	ADP	O	O
Research	NOUN	O	O
and	CCONJ	O	O
Treatment	NOUN	O	O
of	ADP	O	O
Cancer	NOUN	O	O
(	PUNCT	O	O
EORTC	NOUN	O	O
)	PUNCT	O	O
Quality	NOUN	O	O
of	ADP	O	O
Life	NOUN	O	O
Questionnaire	NOUN	O	O
(	PUNCT	O	O
QLQ-C30	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
International	ADJ	O	O
Index	NOUN	O	O
of	ADP	O	O
Erectile	ADJ	O	O
Function	NOUN	O	O
(	PUNCT	O	O
IIEF	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sexual	ADJ	O	O
function-vaginal	ADJ	O	O
changes	NOUN	O	O
questionnaire	NOUN	O	O
(	PUNCT	O	O
SVQ	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
105	NUM	O	O
patients	NOUN	O	O
alive	ADJ	O	O
in	ADP	O	O
Norway	NOUN	O	O
and	CCONJ	O	O
Sweden	ADP	O	O
after	ADP	O	O
4	NUM	O	O
to	ADP	O	O
12	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
78	NUM	O	O
(	PUNCT	O	O
74	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
responded	VERB	O	O
.	PUNCT	O	O

More	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CRT	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
received	PUNCT	O	O
a	DET	O	O
stoma	NOUN	O	O
(	PUNCT	O	O
73	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
52	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.09	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Most	DET	O	O
patients	NOUN	O	O
without	ADP	O	O
a	DET	O	O
stoma	NOUN	O	O
(	PUNCT	O	O
7	NUM	O	O
of	ADP	O	O
12	NUM	O	O
in	ADP	O	O
CRT	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
9	NUM	O	O
of	ADP	O	O
16	NUM	O	O
in	ADP	O	O
RT	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
had	PUNCT	O	O
incontinence	NOUN	O	O
for	ADP	O	O
liquid	PUNCT	O	O
stools	NOUN	O	O
or	CCONJ	O	O
gas	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
stoma	NOUN	O	O
and	CCONJ	O	O
good	ADJ	O	O
anal	ADJ	O	O
function	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
CRT	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
11	NUM	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
RT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.046	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
44	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CRT	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
(	PUNCT	O	O
28	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
had	PUNCT	O	O
bowel	NOUN	O	O
obstruction	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
5	NUM	O	O
of	ADP	O	O
33	NUM	O	O
(	PUNCT	O	O
15	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
RT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.27	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One-quarter	ADJ	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
reported	ADP	O	O
urinary	ADJ	O	O
incontinence	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
men	NOUN	O	O
had	PUNCT	O	O
severe	ADJ	O	O
erectile	ADJ	O	O
dysfunction	NOUN	O	O
.	PUNCT	O	O

Few	DET	O	O
women	NOUN	O	O
reported	VERB	O	O
sexual	ADJ	O	O
activity	NOUN	O	O
during	ADP	O	O
the	DET	O	O
previous	ADJ	O	O
month	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
majority	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
have	PUNCT	O	O
concerns	VERB	O	O
about	CCONJ	O	O
their	PUNCT	O	O
sex	NOUN	O	O
life	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Fecal	PUNCT	O	O
incontinence	NOUN	O	O
and	CCONJ	O	O
erectile	ADJ	O	O
dysfunction	NOUN	O	O
are	VERB	O	O
frequent	ADJ	O	O
after	ADP	O	O
combined	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
locally	ADV	O	O
advanced	VERB	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
clear	ADJ	O	O
tendency	NOUN	O	O
for	ADP	O	O
the	DET	O	O
problems	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
more	ADV	O	O
common	ADJ	O	O
after	ADP	O	O
CRT	NOUN	O	O
than	PUNCT	O	O
after	ADP	O	O
RT	NOUN	O	O
.	PUNCT	O	O

Combined	VERB	O	O
delivery	NOUN	O	O
approach	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
mononuclear	ADJ	O	O
stem	NOUN	O	O
cells	NOUN	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
after	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
MYSTAR	NOUN	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Combined	PUNCT	O	O
intracoronary	ADJ	O	O
and	CCONJ	O	O
intramyocardial	ADJ	O	O
administration	NOUN	O	O
might	PART	O	O
improve	VERB	O	O
outcomes	NOUN	O	O
for	ADP	O	O
bone-marrow-derived	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
(	PUNCT	O	O
AMI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
feasibility	NOUN	O	B-OTHER
of	ADP	O	O
early	PUNCT	O	O
and	CCONJ	O	O
late	ADJ	O	O
delivery	NOUN	O	O
of	ADP	O	O
stem	NOUN	O	O
cells	NOUN	O	O
with	ADP	O	O
combined	VERB	O	O
therapy	NOUN	O	O
approaches	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
45	NUM	O	O
%	SYM	O	O
after	ADP	O	O
AMI	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	PUNCT	O	O
stem	NOUN	O	O
cell	NOUN	O	O
delivery	NOUN	O	O
via	ADP	O	O
intramyocardial	ADJ	O	O
injection	NOUN	O	O
and	CCONJ	O	O
intracoronary	ADJ	O	O
infusion	NOUN	O	O
3-6	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
3-4	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
AMI	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
were	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
infarct	NOUN	O	B-PHYSICAL
size	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
left	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
ejection	NOUN	O	I-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
3	NUM	O	I-PHYSICAL
months	NOUN	O	I-PHYSICAL
after	ADP	O	I-PHYSICAL
therapy	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
infarct	NOUN	O	B-PHYSICAL
size	NOUN	O	O
at	ADP	O	B-PHYSICAL
3	NUM	O	I-PHYSICAL
months	NOUN	O	B-PHYSICAL
were	VERB	O	O
-3.5	NUM	O	O
+/-	SYM	O	O
5.1	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
-5.5	ADJ	O	O
%	SYM	O	O
to	ADP	O	O
-1.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
-3.9	NUM	O	O
+/-	SYM	O	O
5.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
-6.1	ADP	O	O
%	SYM	O	O
to	ADP	O	O
-1.6	PUNCT	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
late	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
ejection	NOUN	O	B-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
were	VERB	O	O
3.5	NUM	O	O
+/-	SYM	O	O
5.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.3-5.6	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
3.4	ADP	O	O
+/-	SYM	O	O
7.0	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.7-6.1	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.017	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

At	ADP	O	O
9-12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
AMI	NOUN	O	O
,	PUNCT	O	O
ejection	NOUN	O	B-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
remained	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	CCONJ	O	O
at	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
200.3	NUM	O	O
+/-	SYM	O	O
68.7	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
194.8	NUM	O	O
+/-	SYM	O	O
60.4	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
stem	NOUN	O	B-PHYSICAL
cells	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
delivered	VERB	O	O
to	ADP	O	O
the	DET	O	O
myocardium	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.30	NUM	O	O
+/-	SYM	O	O
0.68	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
1.29	NUM	O	O
+/-	SYM	O	O
0.41	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
cells	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
delivered	VERB	O	O
into	ADP	O	O
the	DET	O	O
artery	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
high	ADJ	O	O
number	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
was	VERB	O	O
required	VERB	O	O
for	ADP	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Combined	PROPN	O	O
cardiac	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
delivery	NOUN	O	O
induces	NOUN	O	O
a	DET	O	O
moderate	ADJ	O	O
but	CCONJ	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
myocardial	ADJ	O	B-PHYSICAL
infarct	NOUN	O	I-PHYSICAL
size	NOUN	O	I-PHYSICAL
and	PUNCT	O	O

The	DET	O	O
Low	ADJ	O	O
Energy	NOUN	O	O
Safety	NOUN	O	O
Study	NOUN	O	O
(	PUNCT	O	O
LESS	ADP	O	O
)	PUNCT	O	O
:	PUNCT	O	O
rationale	NOUN	O	O
,	PUNCT	O	O
design	NOUN	O	O
,	PUNCT	O	O
patient	NOUN	O	O
characteristics	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
device	NOUN	O	O
utilization	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
A	DET	O	O
10-J	NOUN	O	O
energy	NOUN	O	O
safety	NOUN	O	O
margin	NOUN	O	O
has	VERB	O	O
traditionally	VERB	O	O
been	PUNCT	O	O
used	VERB	O	O
in	ADP	O	O
programming	ADP	O	O
implantable	ADJ	O	O
cardioverter	ADJ	O	O
defibrillators	NOUN	O	O
(	PUNCT	O	O
ICDs	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
Low	ADJ	O	O
Energy	NOUN	O	O
Safety	NOUN	O	O
Study	NOUN	O	O
(	PUNCT	O	O
LESS	ADP	O	O
)	PUNCT	O	O
tests	PUNCT	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
programming	DET	O	O
shocks	PUNCT	O	O
to	PUNCT	O	O
lower	PUNCT	O	O
energy	NOUN	O	O
margins	NOUN	O	O
is	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
standard	ADJ	O	O
ICD	NOUN	O	O
indications	NOUN	O	O
undergo	VERB	O	O
defibrillation	NOUN	O	O
threshold	NOUN	O	O
testing	SYM	O	O
(	PUNCT	O	O
DFT	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
ICD	NOUN	O	O
implant	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
reconfirmation	NOUN	O	O
of	ADP	O	O
lowest	PUNCT	O	O
successful	ADJ	O	O
energy	NOUN	O	O
twice	ADV	O	O
(	PUNCT	O	O
DFT++	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
are	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
2	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
first	PUNCT	O	O
has	PUNCT	O	O
the	DET	O	O
initial	ADJ	O	O
2	NUM	O	O
shocks	PUNCT	O	O
for	ADP	O	O
ventricular	ADJ	O	O
fibrillation	NOUN	O	O
conversion	NOUN	O	O
programmed	DET	O	O
at	ADP	O	O
2	NUM	O	O
energy	NOUN	O	O
steps	NOUN	O	O
above	CCONJ	O	O
DFT++	NOUN	O	O
(	PUNCT	O	O
typically	ADV	O	O
4-6	NUM	O	O
J	NOUN	O	O
,	PUNCT	O	O
maximum	NOUN	O	O
10	NUM	O	O
J	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
subsequent	ADJ	O	O
shocks	PUNCT	O	O
at	ADP	O	O
maximum	NOUN	O	O
energy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
second	ADJ	O	O
has	PUNCT	O	O
all	PUNCT	O	O
shocks	PUNCT	O	O
programmed	ADP	O	O
at	ADP	O	O
maximum	NOUN	O	O
energy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
are	VERB	O	O
followed	VERB	O	O
up	PUNCT	O	O
every	DET	O	O
3	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
shock	NOUN	O	B-PHYSICAL
conversion	NOUN	O	I-PHYSICAL
efficacy	NOUN	O	O
of	ADP	O	B-PHYSICAL
spontaneous	ADJ	O	I-PHYSICAL
arrhythmias	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
second	ADJ	O	O
randomization	NOUN	O	O
to	ADP	O	O
energy	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
4	NUM	O	O
steps	NOUN	O	O
above	CCONJ	O	O
implant	NOUN	O	O
DFT++	NOUN	O	O
for	ADP	O	O
conversion	NOUN	O	O
testing	VERB	O	O
of	ADP	O	O
3	NUM	O	O
induced	ADP	O	O
ventricular	ADJ	O	O
fibrillation	NOUN	O	O
episodes	NOUN	O	O
at	ADP	O	O
prehospital	ADJ	O	O
discharge	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
implant	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Enrollment	NOUN	O	O
is	VERB	O	O
complete	ADJ	O	O
(	PUNCT	O	O
702	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
follow-up	NOUN	O	O
results	CCONJ	O	O
are	VERB	O	O
pending	VERB	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
variations	NOUN	O	O
in	ADP	O	O
implant	NOUN	O	B-PHYSICAL
indications	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
baseline	NOUN	O	O
antiarrhythmic	ADJ	O	B-PHYSICAL
drug	NOUN	O	I-PHYSICAL
use	NOUN	O	I-PHYSICAL
over	ADP	O	O
the	DET	O	O
3-year	NOUN	O	O
enrollment	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
dual-chamber	NOUN	O	B-PHYSICAL
ICDs	NOUN	O	I-PHYSICAL
implanted	VERB	O	I-PHYSICAL
occurred	PROPN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
majority	NOUN	O	O
(	PUNCT	O	O
65	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
implanted	VERB	O	O
ICDs	NOUN	O	O
being	VERB	O	O
dual-chamber	NOUN	O	O
devices	ADP	O	O
by	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
enrollment	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
LESS	PUNCT	O	O
should	NOUN	O	O
facilitate	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
algorithms	NOUN	O	O
for	ADP	O	O
programming	NUM	O	O
ICD	PUNCT	O	O

Using	VERB	O	O
dietetic	ADJ	O	O
assistants	ADP	O	O
to	PART	O	O
improve	ADJ	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
nutritional	ADJ	O	O
support	NOUN	O	O
in	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
trauma	NOUN	O	O
ward	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
examine	NOUN	O	O
how	ADP	O	O
improved	DET	O	O
attention	NOUN	O	O
to	ADP	O	O
nutritional	ADJ	O	B-PHYSICAL
status	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
dietary	ADJ	O	B-MENTAL
intake	NOUN	O	I-MENTAL
,	PUNCT	O	O
achieved	VERB	O	O
through	ADP	O	O
the	DET	O	O
employment	NOUN	O	O
of	ADP	O	O
dietetic	ADJ	O	O
assistants	NOUN	O	O
(	PUNCT	O	O
DAs	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
will	VERB	O	O
affect	VERB	O	O
postoperative	ADJ	O	B-OTHER
clinical	ADJ	O	I-OTHER
outcome	NOUN	O	I-OTHER
among	ADP	O	O
elderly	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Open	PUNCT	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
comparing	CCONJ	O	O
conventional	ADJ	O	O
nursing	ADJ	O	O
care	NOUN	O	O
with	ADP	O	O
the	DET	O	O
additional	ADJ	O	O
nutritional	ADJ	O	O
support	NOUN	O	O
provided	VERB	O	O
by	ADP	O	O
DA	NOUN	O	O
.	PUNCT	O	O

SETTING	CCONJ	O	O
Thirty-eight	PUNCT	O	O
bedded	ADJ	O	O
acute	ADJ	O	O
trauma	NOUN	O	O
ward	ADP	O	O
in	ADP	O	O
a	DET	O	O
teaching	VERB	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
All	PUNCT	O	O
but	CCONJ	O	O
11	NUM	O	O
of	ADP	O	O
344	NUM	O	O
consecutive	ADJ	O	O
admissions	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
nonpathological	ADJ	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
were	VERB	O	O
approached	VERB	O	O
.	PUNCT	O	O

Three	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
eighteen	ADV	O	O
(	PUNCT	O	O
93	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
agreed	VERB	O	O
to	ADP	O	O
inclusion	NOUN	O	O
.	PUNCT	O	O

Sixteen	NUM	O	O
were	VERB	O	O
ineligible	ADJ	O	O
as	PUNCT	O	O
they	DET	O	O
were	VERB	O	O
immediately	ADV	O	O
transferred	VERB	O	O
to	ADP	O	O
another	CCONJ	O	O
acute	ADJ	O	O
ward	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
managed	PROPN	O	O
conservatively	ADV	O	O
or	CCONJ	O	O
died	VERB	O	O
preoperatively	ADV	O	O
.	PUNCT	O	O

PRIMARY	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURE	NOUN	O	O
Postoperative	ADJ	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
trauma	NOUN	O	O
unit	NOUN	O	O
.	PUNCT	O	O

SECONDARY	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Postoperative	PUNCT	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
at	ADP	O	I-MORTALITY
4	NUM	O	I-MORTALITY
months	NOUN	O	I-MORTALITY
after	ADP	O	I-MORTALITY
fracture	NOUN	O	I-MORTALITY
,	PUNCT	O	O
length	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
stay	NOUN	O	I-OTHER
,	PUNCT	O	O
energy	NOUN	O	B-MENTAL
intake	NOUN	O	I-MENTAL
and	CCONJ	O	O
nutritional	ADJ	O	B-PHYSICAL
status	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
DA-supported	NOUN	O	O
participants	NOUN	O	O
were	VERB	O	O
less	ADV	O	O
likely	ADJ	O	B-MORTALITY
to	PART	O	I-MORTALITY
die	ADP	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
ward	ADJ	O	O
(	PUNCT	O	O
4.1	NUM	O	O
versus	CCONJ	O	O
10.1	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.048	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
still	ADV	O	O
apparent	ADJ	O	O
at	ADP	O	O
4	NUM	O	O
month	NOUN	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
13.1	NUM	O	O
versus	CCONJ	O	O
22.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.036	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DA-supported	VERB	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
better	PUNCT	O	O
mean	NOUN	O	O
daily	ADJ	O	B-MENTAL
energy	NOUN	O	I-MENTAL
intake	NOUN	O	I-MENTAL
(	PUNCT	O	O
1,105	NUM	O	O
kcal	ADJ	O	O
versus	CCONJ	O	O
756	NUM	O	O
kcal/24	PUNCT	O	O
h	NOUN	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
259-440	NUM	O	O
kcal/24	PUNCT	O	O
h	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
significantly	ADV	O	O
smaller	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
mid-arm	NOUN	O	O
circumference	NOUN	O	O
during	ADP	O	O
their	PUNCT	O	O
inpatient	NOUN	O	O
stay	NOUN	O	O
(	PUNCT	O	O
0.39	ADP	O	O
cm	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nonsignificantly	ADV	O	O
favourable	ADJ	O	O
results	CCONJ	O	O
for	ADP	O	O
other	ADJ	O	O
anthropometric	ADJ	O	B-OTHER
and	CCONJ	O	O
laboratory	NOUN	O	B-OTHER
measurements	NOUN	O	I-OTHER
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Dietetic	ADJ	O	O
or	CCONJ	O	O
nutrition	NOUN	O	O
assistants	NOUN	O	O
are	VERB	O	O
being	VERB	O	O
introduced	VERB	O	O
in	ADP	O	O
units	NOUN	O	O
across	ADP	O	O
the	DET	O	O
UK	NOUN	O	O
.	PUNCT	O	O

This	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
largest	VERB	O	O
ever	PUNCT	O	O
study	NOUN	O	O
of	ADP	O	O
nutritional	ADJ	O	O
support	NOUN	O	O
after	ADP	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
,	PUNCT	O	O
shows	NOUN	O	O
that	ADP	O	O
their	PUNCT	O	O
employment	ADJ	O	O
significantly	ADV	O	O
reduced	VERB	O	O
patients	NOUN	O	B-MORTALITY
'	PUNCT	O	O
risk	PUNCT	O	O

Zinc	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
copper	NOUN	O	B-PHYSICAL
balances	NOUN	O	I-PHYSICAL
in	ADP	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Preterm	NOUN	O	O
infants	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
copper	NOUN	O	O
and	CCONJ	O	O
zinc	NOUN	O	O
depletion	NOUN	O	O
if	ADP	O	O
sufficient	ADJ	O	O
quantities	NOUN	O	O
of	ADP	O	O
these	DET	O	O
nutrients	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
provided	VERB	O	O
in	ADP	O	O
a	DET	O	O
bioavailable	ADJ	O	O
form	NOUN	O	O
in	ADP	O	O
postnatal	ADJ	O	O
life	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
whey-predominant	ADJ	O	O
,	PUNCT	O	O
50	NUM	O	O
%	DET	O	O
medium	ADJ	O	O
chain	NOUN	O	O
triglyceride	NOUN	O	O
formula	NOUN	O	O
with	ADP	O	O
relatively	ADV	O	O
high	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
zinc	NOUN	O	O
and	CCONJ	O	O
copper	NOUN	O	O
would	VERB	O	O
promote	VERB	O	O
the	DET	O	O
achievement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
in	PUNCT	O	O
utero	NOUN	O	B-PHYSICAL
accretion	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
zinc	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
copper	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
preterm	NOUN	O	O
infant	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
were	VERB	O	O
fed	VERB	O	O
a	DET	O	O
diet	NOUN	O	O
containing	VERB	O	O
12.5	NUM	O	O
mg/L	NOUN	O	O
of	ADP	O	O
zinc	NOUN	O	O
and	CCONJ	O	O
either	CCONJ	O	O
0.9	NUM	O	O
mg/L	NOUN	O	O
or	CCONJ	O	O
2.1	NUM	O	O
mg/L	NOUN	O	O
of	ADP	O	O
copper	NOUN	O	O
.	PUNCT	O	O

Seventy-two-hour	NUM	O	O
metabolic	ADJ	O	O
balance	NOUN	O	O
studies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
an	DET	O	O
average	ADJ	O	O
postconceptual	ADJ	O	O
age	NOUN	O	O
of	ADP	O	O
34	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
average	ADJ	O	O
weight	NOUN	O	O
of	ADP	O	O
1,549	NUM	O	O
g.	PUNCT	O	O
All	PUNCT	O	O
infants	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
positive	ADJ	O	O
zinc	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
nine	NUM	O	O
of	ADP	O	O
ten	NUM	O	O
achieved	VERB	O	O
the	DET	O	O
in	PUNCT	O	O
utero	NOUN	O	B-PHYSICAL
accretion	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
zinc	NOUN	O	I-PHYSICAL
for	ADP	O	O
a	DET	O	O
34-week	NOUN	O	O
gestation	NOUN	O	O
fetus	NOUN	O	O
(	PUNCT	O	O
greater	PUNCT	O	O
than	VERB	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
0.432	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
infants	NOUN	O	O
receiving	DET	O	O
the	DET	O	O
high	ADJ	O	O
copper	NOUN	O	O
formula	NOUN	O	O
and	CCONJ	O	O
two	NUM	O	O
receiving	VERB	O	O
the	DET	O	O
lower	PUNCT	O	O
copper	NOUN	O	O
formula	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
positive	ADJ	O	O
copper	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Two	NUM	O	O
infants	NOUN	O	O
from	ADP	O	O
each	DET	O	O
group	NOUN	O	O
achieved	VERB	O	O
the	DET	O	O
in	PUNCT	O	O
utero	NOUN	O	B-PHYSICAL
accretion	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
copper	NOUN	O	I-PHYSICAL
for	ADP	O	O
a	DET	O	O
34-week	NOUN	O	O
gestation	NOUN	O	O
fetus	NOUN	O	O
(	PUNCT	O	O
0.088	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
formula	NOUN	O	O
that	ADP	O	O
provides	NOUN	O	O
12.5	NUM	O	O
mg/L	NOUN	O	O
of	ADP	O	O
zinc	NOUN	O	O
permits	ADJ	O	O
positive	ADJ	O	O
zinc	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
zinc	NOUN	O	B-PHYSICAL
retention	NOUN	O	I-PHYSICAL
similar	ADJ	O	O
to	ADP	O	O
in	ADP	O	O
utero	ADP	O	O
rates	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
formula	NOUN	O	O
that	ADP	O	O
provides	NOUN	O	O
as	PUNCT	O	O
much	PUNCT	O	O
as	PUNCT	O	O
2.1	NUM	O	O
mg/L	NOUN	O	O
of	ADP	O	O
copper	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
may	ADP	O	O
not	ADV	O	O
always	ADV	O	O
permit	VERB	O	O
positive	ADJ	O	O
copper	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Oxidative	ADJ	O	O
DNA	NOUN	O	O
damage	NOUN	O	O
measured	PRON	O	O
in	ADP	O	O
human	NOUN	O	O
lymphocytes	NOUN	O	O
:	PUNCT	O	O
large	ADJ	O	O
differences	NOUN	O	O
between	DET	O	O
sexes	NOUN	O	O
and	CCONJ	O	O
between	ADP	O	O
countries	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
correlations	ADP	O	O
with	ADP	O	O
heart	NOUN	O	O
disease	NOUN	O	O
mortality	NOUN	O	O
rates	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
'antioxidant	PUNCT	O	O
hypothesis	NOUN	O	O
'	PUNCT	O	O
proposes	PUNCT	O	O
that	ADP	O	O
vitamin	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
,	PUNCT	O	O
carotenoids	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
antioxidants	NOUN	O	O
occurring	VERB	O	O
in	ADP	O	O
fruit	ADJ	O	O
and	CCONJ	O	O
vegetables	VERB	O	O
afford	NOUN	O	O
protection	NOUN	O	O
against	ADP	O	O
heart	NOUN	O	O
disease	NOUN	O	O
and	CCONJ	O	O
cancer	NOUN	O	O
by	ADP	O	O
preventing	VERB	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
to	ADP	O	O
lipids	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
DNA	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

To	PART	O	O
test	ADP	O	O
elements	NOUN	O	O
of	ADP	O	O
this	DET	O	O
hypothesis	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
measured	VERB	O	O
blood	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
antioxidants	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
8-oxodeoxyguanosine	NOUN	O	O
(	PUNCT	O	O
8-oxo-dG	ADV	O	O
)	PUNCT	O	O
concentrations	NOUN	O	O
in	ADP	O	O
lymphocyte	NOUN	O	O
DNA	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
healthy	ADJ	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
from	ADP	O	O
five	NUM	O	O
European	NOUN	O	O
countries	NOUN	O	O
:	PUNCT	O	O
France	NOUN	O	O
,	PUNCT	O	O
Ireland	PUNCT	O	O
,	PUNCT	O	O
The	DET	O	O
Netherlands	NOUN	O	O
,	PUNCT	O	O
Spain	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
U.K	NOUN	O	O
.	PUNCT	O	O

Volunteers	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
25	NUM	O	O
45	NUM	O	O
,	PUNCT	O	O
all	DET	O	O
nonsmokers	NOUN	O	O
,	PUNCT	O	O
gave	VERB	O	O
blood	NOUN	O	O
samples	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
a	DET	O	O
12-wk	PUNCT	O	O
carotenoid	NOUN	O	O
supplementation	NOUN	O	O
regime	NOUN	O	O
.	PUNCT	O	O

Vitamin	NOUN	O	O
C	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
and	CCONJ	O	O
carotenoids	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
serum	NOUN	O	O
by	ADP	O	O
high-performance	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
(	PUNCT	O	O
HPLC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

8-oxo-dG	ADV	O	O
was	ADP	O	O
assayed	VERB	O	O
by	ADP	O	O
HPLC	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
coulometric	ADJ	O	O
detection	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
DNA	NOUN	O	O
isolated	VERB	O	O
from	ADP	O	O
lymphocytes	NOUN	O	O
from	ADP	O	O
the	DET	O	O
same	ADJ	O	O
blood	NOUN	O	O
samples	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
values	NOUN	O	O
were	VERB	O	O
calculated	VERB	O	O
for	ADP	O	O
groups	NOUN	O	O
of	ADP	O	O
volunteers	NOUN	O	O
at	ADP	O	O
each	DET	O	O
sampling	VERB	O	O
time	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
country	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
supplementation	NOUN	O	O
(	PUNCT	O	O
between	ADP	O	O
9	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
individual	ADJ	O	O
samples	NOUN	O	O
contributing	VERB	O	O
to	ADP	O	O
each	DET	O	O
mean	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
8-oxo-dG	ADV	O	O
levels	NOUN	O	O
in	ADP	O	O
lymphocyte	NOUN	O	O
DNA	NOUN	O	O
vary	VERB	O	O
significantly	ADV	O	O
according	PUNCT	O	O
to	ADP	O	O
sex	NOUN	O	O
and	CCONJ	O	O
country	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
low	ADJ	O	O
mean	NOUN	O	O
8-oxo-dG	NUM	O	B-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
is	ADJ	O	O
seen	VERB	O	O
in	ADP	O	O
DNA	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
from	ADP	O	O
all	DET	O	O
five	NUM	O	O
countries	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
men	NOUN	O	O
from	ADP	O	O
France	NOUN	O	O
and	CCONJ	O	O
Spain	PUNCT	O	O
.	PUNCT	O	O

8-oxo-dG	ADV	O	B-PHYSICAL
is	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
up	PUNCT	O	O
to	CCONJ	O	O
about	PUNCT	O	O
threefold	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
lymphocyte	NOUN	O	O
DNA	NOUN	O	O
from	ADP	O	O
men	NOUN	O	O
in	ADP	O	O
Ireland	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
U.K.	PUNCT	O	O
Oxidative	ADJ	O	B-PHYSICAL
DNA	NOUN	O	I-PHYSICAL
damage	NOUN	O	I-PHYSICAL
is	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
carotenoid	NOUN	O	O
supplementation	NOUN	O	O
;	PUNCT	O	O
nor	CCONJ	O	O
is	VERB	O	O
there	PUNCT	O	O
any	DET	O	O
association	NOUN	O	O
with	ADP	O	O
mean	NOUN	O	O
baseline	NOUN	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
antioxidants	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
which	ADP	O	O
are	VERB	O	O
generally	ADV	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
five	NUM	O	O
countries	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
five	NUM	O	O
countries	NOUN	O	O
sampled	VERB	O	O
lie	PUNCT	O	O
on	ADP	O	O
an	DET	O	O
axis	NOUN	O	O
from	ADP	O	O
northern	NOUN	O	O
to	ADP	O	O
southern	PUNCT	O	O
Europe	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
steep	ADJ	O	O
gradient	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
premature	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
premature	ADJ	O	B-MORTALITY
coronary	ADJ	O	I-MORTALITY
heart	NOUN	O	I-MORTALITY
disease	NOUN	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
in	ADP	O	O
men	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
mean	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
8-oxo-dG	ADV	O	O
for	ADP	O	O
the	DET	O	O
five	NUM	O	O
countries	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.95	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Women	NOUN	O	O
have	PUNCT	O	O
low	ADJ	O	O
coronary	ADJ	O	B-MORTALITY
heart	NOUN	O	I-MORTALITY
disease	NOUN	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
rates	NOUN	O	I-MORTALITY
,	PUNCT	O	O
which	ADP	O	O
do	PUNCT	O	O
not	ADV	O	O
correlate	PUNCT	O	O
with	ADP	O	O
8-oxo-dG	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	O
deaths	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
in	ADP	O	O
men	NOUN	O	O
shows	ADJ	O	O
a	DET	O	O
significant	ADJ	O	B-OTHER
positive	ADJ	O	O
correlation	NOUN	O	B-OTHER
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.91	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	PUNCT	O	O

[	PUNCT	O	O
Local	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
anti-cancer	NOUN	O	O
drugs	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	O
pleural	ADP	O	O
and	CCONJ	O	O
pericardial	ADJ	O	O
effusion	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Pleural	ADJ	O	O
effusion	NOUN	O	O
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
complication	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
malignant	ADJ	O	O
neoplasm	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
of	ADP	O	O
intrapleural	PUNCT	O	O
instillation	NOUN	O	O
of	ADP	O	O
Adriamycin	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Adriamycin	NOUN	O	O
Nocardia	PUNCT	O	O
rubra	NOUN	O	O
cell	NOUN	O	O
wall	NOUN	O	O
skeleton	NOUN	O	O
(	PUNCT	O	O
N-CWS	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
26	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
tube	NOUN	O	O
thoracostomy	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
55	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
malignant	ADJ	O	O
pleural	ADJ	O	O
effusion	NOUN	O	O
due	VERB	O	O
to	ADP	O	O
primary	ADJ	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
rates	NOUN	O	O
for	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
pleural	ADJ	O	B-PHYSICAL
effusion	NOUN	O	I-PHYSICAL
were	VERB	O	O
73.4	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
N-CWS	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
46.1	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
N-CWS	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
intrapleural	PUNCT	O	O
instillation	NOUN	O	O
using	VERB	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
anti-cancer	NOUN	O	O
agent	NOUN	O	O
and	CCONJ	O	O
immunopotentiator	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
malignant	ADJ	O	O
pleurisy	NOUN	O	O
.	PUNCT	O	O

Cardiac	ADJ	O	O
tamponade	NOUN	O	O
secondary	ADJ	O	O
to	ADP	O	O
cancer	NOUN	O	O
is	VERB	O	O
a	DET	O	O
life-threatening	VERB	O	O
complication	NOUN	O	O
requiring	VERB	O	O
immediate	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Twenty-four	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
malignant	ADJ	O	O
pericardial	ADJ	O	O
effusion	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
intrapericardial	ADJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
anti-cancer	NOUN	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
Carbazilquinone	NOUN	O	O
,	PUNCT	O	O
Mitomycin-C	NOUN	O	O
or	CCONJ	O	O
ACNU	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
pericardial	ADJ	O	O
drainage	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
range	NOUN	O	O
of	ADP	O	O
survival	NOUN	O	B-MORTALITY
time	NOUN	O	I-MORTALITY
from	ADP	O	O
the	DET	O	O
instillation	NOUN	O	O
of	ADP	O	O
anti-cancer	NOUN	O	O
drug	NOUN	O	O
was	VERB	O	O
3-365	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
average	ADJ	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
only	ADV	O	O
4	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
reaccumulation	NOUN	O	O
of	ADP	O	O
pericardial	ADJ	O	B-PHYSICAL
effusion	NOUN	O	I-PHYSICAL
was	VERB	O	O
recognized	VERB	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
serious	ADJ	O	O
complications	NOUN	O	O
with	ADP	O	O
this	DET	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
considered	VERB	O	O
that	VERB	O	O
local	ADJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
anti-cancer	NOUN	O	O
agents	NOUN	O	O
with	ADP	O	O
pericardial	ADJ	O	O
drainage	NOUN	O	O
was	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
therapeutic	ADJ	O	O
modality	NOUN	O	O
for	ADP	O	O
malignant	ADJ	O	O
pericarditis	NOUN	O	O
.	PUNCT	O	O

Pregabalin	NOUN	O	O
versus	CCONJ	O	O
naltrexone	NUM	O	O
in	ADP	O	O
alcohol	NOUN	O	O
dependence	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
comparison	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Pregabalin	NOUN	O	O
(	PUNCT	O	O
PRE	NOUN	O	O
)	PUNCT	O	O
acts	NOUN	O	O
as	ADP	O	O
a	DET	O	O
presynaptic	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
excessive	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
excitatory	ADJ	O	O
neurotransmitters	NOUN	O	O
by	ADP	O	O
selectively	PRON	O	O
binding	VERB	O	O
to	ADP	O	O
the	DET	O	O
alpha	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
-delta	NOUN	O	O
subunit	NOUN	O	O
of	ADP	O	O
voltage-gated	DET	O	O
calcium	NOUN	O	O
channels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
comparison	NOUN	O	O
trial	NOUN	O	O
with	ADP	O	O
naltrexone	NUM	O	O
(	PUNCT	O	O
NAL	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PROPN	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
PRE	NOUN	O	O
on	ADP	O	O
alcohol	NOUN	O	B-MENTAL
drinking	PROPN	O	I-MENTAL
indices	NOUN	O	I-MENTAL
.	PUNCT	O	O

Craving	PUNCT	O	B-MENTAL
reduction	NOUN	O	I-MENTAL
and	CCONJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
psychiatric	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
were	VERB	O	O
the	DET	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

Seventy-one	NUM	O	O
alcohol-dependent	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
detoxified	PUNCT	O	O
and	CCONJ	O	O
subsequently	ADV	O	O
randomised	PUNCT	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
receiving	VERB	O	O
50	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
NAL	NOUN	O	O
or	CCONJ	O	O
150-450	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
PRE	NOUN	O	O
.	PUNCT	O	O

Craving	PUNCT	O	B-MENTAL
(	PUNCT	O	I-MENTAL
VAS	NOUN	O	O
;	PUNCT	O	O
OCDS	NUM	O	B-MENTAL
)	PUNCT	O	I-MENTAL
,	PUNCT	O	O
withdrawal	NOUN	O	B-OTHER
(	PUNCT	O	B-OTHER
CIWA-Ar	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
and	CCONJ	O	O
psychiatric	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
(	PUNCT	O	B-MENTAL
SCL-90-R	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
rating	ADP	O	B-MENTAL
scales	NOUN	O	O
were	VERB	O	O
applied	VERB	O	O
.	PUNCT	O	O

Alcohol	NOUN	O	B-MENTAL
drinking	PROPN	O	B-MENTAL
indices	NOUN	O	B-MENTAL
and	CCONJ	O	O
craving	ADP	O	B-MENTAL
scores	NOUN	O	I-MENTAL
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
NAL	NOUN	O	O
,	PUNCT	O	O
PRE	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
greater	PUNCT	O	O
improvement	NOUN	O	O
of	ADP	O	O
specific	ADJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
areas	NOUN	O	O
of	ADP	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O

Ceftriaxone	NOUN	O	O
versus	CCONJ	O	O
ampicillin	NOUN	O	O
and	CCONJ	O	O
chloramphenicol	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
bacterial	ADJ	O	B-PHYSICAL
meningitis	NOUN	O	I-PHYSICAL
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

78	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
bacterial	ADJ	O	O
meningitis	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
comparing	ADV	O	O
twice-daily	PUNCT	O	O
ceftriaxone	NOUN	O	O
as	PUNCT	O	O
single-drug	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
ampicillin	NOUN	O	O
and	CCONJ	O	O
chloramphenicol	NOUN	O	O
given	ADP	O	O
every	ADP	O	O
6	NUM	O	O
h.	NOUN	O	O
The	DET	O	O
groups	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
days	NOUN	O	O
of	ADP	O	O
illness	NOUN	O	O
before	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bacterial	ADJ	O	O
colony	NOUN	O	O
counts	NOUN	O	O
in	ADP	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
(	PUNCT	O	O
CSF	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
pathogens	NOUN	O	O
were	VERB	O	O
Haemophilus	NOUN	O	O
influenzae	PUNCT	O	O
type	NOUN	O	O
b	NOUN	O	O
(	PUNCT	O	O
54	NUM	O	O
cases	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
streptococci	ADJ	O	O
(	PUNCT	O	O
9	NUM	O	O
cases	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
meningococci	PUNCT	O	O
(	PUNCT	O	O
9	NUM	O	O
cases	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
unknown	VERB	O	O
(	PUNCT	O	O
6	NUM	O	O
cases	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
40	NUM	O	O
CSF	NOUN	O	O
specimens	NOUN	O	O
obtained	VERB	O	O
4-12	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
cultures	NOUN	O	B-OTHER
were	VERB	O	I-OTHER
negative	ADJ	O	O
in	ADP	O	O
57	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
ceftriaxone	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
42	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
others	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
falls	CCONJ	O	B-OTHER
in	ADP	O	I-OTHER
the	DET	O	I-OTHER
CSF	NOUN	O	I-OTHER
bacterial	ADJ	O	I-OTHER
colony	NOUN	O	I-OTHER
counts	NOUN	O	I-OTHER
were	VERB	O	O
4.7	NUM	O	O
and	CCONJ	O	O
5.0	NUM	O	O
log10	NOUN	O	O
colony-forming	VERB	O	O
units/ml	ADV	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
bactericidal	ADJ	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
CSF	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ceftriaxone	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
and	CCONJ	O	O
end	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
in	ADP	O	O
frequency	NOUN	O	O
of	ADP	O	O
complications	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
mild	ADJ	O	B-PHYSICAL
diarrhoea	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
which	ADP	O	O
occurred	VERB	O	O
in	ADP	O	O
16	NUM	O	O
ceftriaxone	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
8	NUM	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
of	ADP	O	O
dose-intensified	VERB	O	O
MEC	NOUN	O	O
(	PUNCT	O	O
methotrexate	NOUN	O	O
,	PUNCT	O	O
epirubicin	NOUN	O	O
and	CCONJ	O	O
cisplatin	NOUN	O	O
)	PUNCT	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
advanced	VERB	O	O
urothelial	ADJ	O	O
carcinoma	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
comparing	VERB	O	O
MEC	NOUN	O	O
and	CCONJ	O	O
M-VAC	NOUN	O	O
(	PUNCT	O	O
methotrexate	NOUN	O	O
,	PUNCT	O	O
vinblastine	NOUN	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	O
and	CCONJ	O	O
cisplatin	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Japanese	ADJ	O	O
Urothelial	ADJ	O	O
Cancer	NOUN	O	O
Research	NOUN	O	O
Group	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
To	ADV	O	O
evaluate	NOUN	O	O
the	DET	O	O
antitumor	NOUN	O	B-OTHER
activity	NOUN	O	I-OTHER
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
T3b	PUNCT	O	O
,	PUNCT	O	O
T4	NOUN	O	O
or	CCONJ	O	O
metastatic	ADJ	O	O
urothelial	ADJ	O	O
carcinoma	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
MEC	NOUN	O	O
or	CCONJ	O	O
M-VAC	NOUN	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
performing	ADP	O	O
a	DET	O	O
multi-center	NOUN	O	O
randomized	VERB	O	O
prospective	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
From	ADP	O	O
1991	NUM	O	O
to	ADP	O	O
1995	NUM	O	O
,	PUNCT	O	O
89	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
T3b	PUNCT	O	O
,	PUNCT	O	O
T4	NOUN	O	O
or	CCONJ	O	O
metastatic	ADJ	O	O
urothelial	ADJ	O	O
carcinoma	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
a	DET	O	O
methotrexate	NOUN	O	O
,	PUNCT	O	O
epirubicin	NOUN	O	O
and	CCONJ	O	O
cisplatin	NOUN	O	O
chemotherapy	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
arm	NOUN	O	O
1	NUM	O	O
:	PUNCT	O	O
S-MEC	NOUN	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
29	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
dose-intensified	VERB	O	O
MEC	NOUN	O	O
therapy	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
G-CSF	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
arm	NOUN	O	O
2	NUM	O	O
:	PUNCT	O	O
I-MEC	NOUN	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
methotrexate	NOUN	O	O
,	PUNCT	O	O
vinblastine	NOUN	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	O
and	CCONJ	O	O
cisplatin	NOUN	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
arm	NOUN	O	O
3	NUM	O	O
:	PUNCT	O	O
M-VAC	NOUN	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
registration	NOUN	O	O
center	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
stratified	VERB	O	O
into	ADP	O	O
previously	ADV	O	O
untreated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrence	NOUN	O	O
after	ADP	O	O
radical	ADJ	O	O
operation	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
each	DET	O	O
arm	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
courses	CCONJ	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
4-week	NOUN	O	O
cycles	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
88	NUM	O	O
eligible	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
four	NUM	O	O
treated	PRON	O	O
with	ADP	O	O
S-MEC	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
two	NUM	O	O
treated	PRON	O	O
with	ADP	O	O
I-MEC	NOUN	O	O
therapy	NOUN	O	O
showed	VERB	O	O
CR	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
rates	NOUN	O	B-OTHER
(	PUNCT	O	O
CR	NOUN	O	O
+	SYM	O	O
PR	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
52	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
15/29	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
S-MEC	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
76	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
22/29	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
I-MEC	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
47	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
14/30	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
M-VAC	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
rate	NOUN	O	O
with	ADP	O	O
I-MEC	NOUN	O	B-OTHER
therapy	NOUN	O	I-OTHER
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	VERB	O	O
that	PUNCT	O	O
with	ADP	O	O
M-VAC	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
leukopenia	NOUN	O	O
was	VERB	O	O
low	ADJ	O	O
with	ADP	O	O
I-MEC	NOUN	O	B-OTHER
therapy	NOUN	O	I-OTHER
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
thrombocytopenia	NOUN	O	B-PHYSICAL
was	VERB	O	O
high	ADJ	O	O
with	ADP	O	O
this	DET	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
MEC	NOUN	O	O
therapy	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
promising	PUNCT	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antitumor	NOUN	O	B-OTHER
effects	NOUN	O	I-OTHER
.	PUNCT	O	O

Budesonide	NOUN	O	O
and	CCONJ	O	O
beclomethasone	NOUN	O	O
dipropionate	PUNCT	O	O
in	ADP	O	O
hay	ADP	O	O
fever	NOUN	O	O
-	PUNCT	O	O
a	DET	O	O
single	ADJ	O	O
blind	ADJ	O	O
comparison	NOUN	O	O
.	PUNCT	O	O

93	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
seasonal	ADJ	O	O
allergic	ADJ	O	O
rhinitis	NOUN	O	O
took	PROPN	O	O
part	NOUN	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
blind	NOUN	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
budesonide	NOUN	O	O
and	CCONJ	O	O
beclomethasone	NOUN	O	O
dipropionate	PUNCT	O	O
(	PUNCT	O	O
Becotide	NOUN	O	O
Nasal	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
sensitive	ADJ	O	O
to	ADP	O	O
either	CCONJ	O	O
birch	NOUN	O	O
or	CCONJ	O	O
grass	NOUN	O	O
pollen	ADJ	O	O
,	PUNCT	O	O
their	ADP	O	O
sensitivity	NOUN	O	O
being	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
a	DET	O	O
skin	NOUN	O	O
prick	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
was	VERB	O	O
400	NUM	O	O
micrograms	NOUN	O	O
for	ADP	O	O
both	CCONJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Budesonide	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
twice	CCONJ	O	O
a	DET	O	O
day	NOUN	O	O
and	CCONJ	O	O
Becotide	NOUN	O	O
Nasal	ADJ	O	O
four	NUM	O	O
times	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
.	PUNCT	O	O

Symptoms	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
over	ADP	O	O
a	DET	O	O
four-week	NOUN	O	O
period	NOUN	O	O
starting	ADJ	O	O
with	ADP	O	O
a	DET	O	O
run-in	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
placebo	NOUN	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Daily	ADJ	O	B-PHYSICAL
pollen	ADJ	O	I-PHYSICAL
counts	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
'	PUNCT	O	O
diary	PUNCT	O	O
cards	VERB	O	O
revealed	VERB	O	O
that	PUNCT	O	O
both	PUNCT	O	O
drugs	NOUN	O	O
had	ADP	O	O
a	DET	O	O
beneficial	ADJ	O	O
therapeutic	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
budesonide	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
more	DET	O	O
active	ADJ	O	O
than	PUNCT	O	O
Becotide	NOUN	O	O
Nasal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
both	PUNCT	O	O
drugs	NOUN	O	O
were	VERB	O	O
few	ADJ	O	O
and	CCONJ	O	O
transient	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
immediate	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
of	ADP	O	O
adjunctive	ADJ	O	O
doxycycline	NOUN	O	O
in	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
localized	VERB	O	O
juvenile	ADJ	O	O
periodontitis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
immediate	ADJ	O	B-OTHER
clinical	ADJ	O	I-OTHER
and	CCONJ	O	I-OTHER
microbiological	ADJ	O	I-OTHER
efficacy	NOUN	O	I-OTHER
of	ADP	O	O
doxycycline	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg	NOUN	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
benefit	NOUN	O	O
of	ADP	O	O
adjunctive	ADJ	O	O
medication	NOUN	O	O
in	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
localized	VERB	O	O
juvenile	ADJ	O	O
periodontitis	NOUN	O	O
.	PUNCT	O	O

Measurements	NOUN	O	O
of	ADP	O	O
gingival	ADJ	O	B-PHYSICAL
fluid	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
probing	PROPN	O	B-PHYSICAL
depths	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
bleeding	VERB	O	B-PHYSICAL
on	ADP	O	I-PHYSICAL
probing	ADP	O	I-PHYSICAL
and	CCONJ	O	O
suppuration	NOUN	O	B-PHYSICAL
were	VERB	O	O
determined	VERB	O	O
at	ADP	O	O
2	NUM	O	O
periodontal	ADJ	O	O
sites	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
2	NUM	O	O
without	ADP	O	O
radiographic	ADJ	O	O
attachment	NOUN	O	O
loss	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
weeks	NOUN	O	O
0	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
.	PUNCT	O	O

Subgingival	PUNCT	O	B-PHYSICAL
bacterial	ADJ	O	I-PHYSICAL
samples	NOUN	O	I-PHYSICAL
were	VERB	O	O
taken	VERB	O	O
with	ADP	O	O
curettes	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
same	ADJ	O	O
sites	NOUN	O	O
.	PUNCT	O	O

Spirochaetes	PUNCT	O	O
were	VERB	O	O
searched	VERB	O	O
for	ADP	O	O
by	ADP	O	O
dark-field	NOUN	O	O
microscopy	NOUN	O	O
.	PUNCT	O	O

Actinobacillus	NOUN	O	O
actinomycetemcomitans	NOUN	O	O
,	PUNCT	O	O
pigmented	ADP	O	O
and	CCONJ	O	O
non-pigmented	VERB	O	O
Bacteroides	PUNCT	O	O
spp.	NOUN	O	O
,	PUNCT	O	O
Capnocytophaga	NOUN	O	O
,	PUNCT	O	O
Fusobacterium	NOUN	O	O
and	CCONJ	O	O
Actinomyces	NOUN	O	O
spp	NOUN	O	O
.	PUNCT	O	O

were	VERB	O	O
cultured	VERB	O	O
on	ADP	O	O
various	ADJ	O	O
selective	ADJ	O	O
and	CCONJ	O	O
non-selective	ADJ	O	O
media	NOUN	O	O
.	PUNCT	O	O

Bacterial	ADJ	O	O
species	NOUN	O	O
found	VERB	O	O
at	ADP	O	O
least	ADV	O	O
in	ADP	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
comprising	VERB	O	O
on	ADP	O	O
average	ADJ	O	O
5	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
more	DET	O	O
of	ADP	O	O
the	DET	O	O
cultivable	NOUN	O	O
flora	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
short-term	NOUN	O	B-OTHER
clinical	ADJ	O	I-OTHER
nor	CCONJ	O	I-OTHER
microbiological	ADJ	O	I-OTHER
efficacy	NOUN	O	I-OTHER
beyond	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
course	NOUN	O	O
of	ADP	O	O
mechanical	ADJ	O	O
debridement	NOUN	O	O
alone	ADJ	O	O
was	ADV	O	O
found	VERB	O	O
by	ADP	O	O
using	VERB	O	O
systemic	ADJ	O	O
medication	NOUN	O	O
with	ADP	O	O
doxycycline	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
localized	VERB	O	O
juvenile	ADJ	O	O
periodontitis	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
purification	NOUN	O	I-PHYSICAL
for	ADP	O	O
critical	ADJ	O	O
care	NOUN	O	O
medicine	NOUN	O	O
:	PUNCT	O	O
endotoxin	NOUN	O	O
adsorption	NOUN	O	O
.	PUNCT	O	O

Many	PUNCT	O	O
kinds	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
purifying	ADP	O	O
technologies	NOUN	O	O
have	CCONJ	O	O
been	PUNCT	O	O
applied	VERB	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
since	ADP	O	O
1979	NUM	O	O
when	ADP	O	O
plasma	NOUN	O	O
exchange	NOUN	O	O
with	ADP	O	O
hollow-fiber	ADJ	O	O
membranes	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
technologies	NOUN	O	O
have	CCONJ	O	O
been	PUNCT	O	O
applied	VERB	O	O
not	ADV	O	O
only	ADV	O	O
to	ADP	O	O
the	DET	O	O
removal	NOUN	O	O
of	ADP	O	O
toxic	ADJ	O	O
substances	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
also	ADV	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
objective	ADJ	O	O
diseases	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
removal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
factors	NOUN	O	O
relating	ADJ	O	O
to	ADP	O	O
the	DET	O	O
associated	VERB	O	O
inflammation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
summarizes	VERB	O	O
these	DET	O	O
methods	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
efficacies	NOUN	O	O
for	ADP	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
those	PUNCT	O	O
with	ADP	O	O
severe	ADJ	O	O
sepsis	NOUN	O	O
.	PUNCT	O	O

Attempts	PUNCT	O	O
have	PUNCT	O	O
been	PUNCT	O	O
made	VERB	O	O
to	PART	O	O
remove	NOUN	O	O
endotoxin	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
main	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
sepsis	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
circulation	NOUN	O	O
using	VERB	O	O
polymyxin	NOUN	O	O
B	NOUN	O	O
immobilized	VERB	O	O
fiber	NOUN	O	O
,	PUNCT	O	O
charcoal	ADJ	O	O
hemoperfusion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
or	CCONJ	O	O
whole	ADJ	O	O
blood	NOUN	O	O
exchange	NOUN	O	O
.	PUNCT	O	O

Attempts	PUNCT	O	O
have	PUNCT	O	O
also	ADV	O	O
been	PUNCT	O	O
made	VERB	O	O
to	PART	O	O
remove	ADJ	O	O
proinflammatory	ADJ	O	O
cytokines	NOUN	O	O
,	PUNCT	O	O
eicosanoides	CCONJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
coagulative	ADJ	O	O
factors	NOUN	O	O
from	ADP	O	O
the	DET	O	O
circulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
human	NOUN	O	O
body	NOUN	O	O
.	PUNCT	O	O

Continuous	ADJ	O	O
hemofiltration	NOUN	O	O
or	CCONJ	O	O
hemodiafiltration	NOUN	O	O
is	VERB	O	O
the	DET	O	O
representative	ADJ	O	O
technology	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
these	DET	O	O
methods	NOUN	O	O
has	VERB	O	O
been	PUNCT	O	O
established	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
several	ADJ	O	O
issues	NOUN	O	O
remain	VERB	O	O
unresolved	PROPN	O	O
.	PUNCT	O	O

All	DET	O	O
methods	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
sepsis	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
with	ADP	O	O
reference	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
indications	NOUN	O	B-OTHER
,	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
clinical	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
endotoxin	NOUN	O	O
removal	NOUN	O	O
with	ADP	O	O
polymyxin	NOUN	O	O
B	NOUN	O	O
immobilized	PUNCT	O	O
fiber	NOUN	O	O
are	VERB	O	O
summarized	VERB	O	O
in	ADP	O	O
this	DET	O	O
article	NOUN	O	O
.	PUNCT	O	O

In	ADJ	O	O
vitro	ADJ	O	O
biocompatibility	NOUN	O	O
tests	NOUN	O	O
of	ADP	O	O
glass	NOUN	O	O
ionomer	NOUN	O	O
cements	NOUN	O	O
impregnated	ADP	O	O
with	ADP	O	O
collagen	NOUN	O	O
or	CCONJ	O	O
bioactive	ADJ	O	O
glass	NOUN	O	O
to	ADP	O	O
fibroblasts	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
AND	CCONJ	O	O
DESIGN	NOUN	O	O
To	ADV	O	O
evaluate	NOUN	O	O
the	DET	O	O
biocompatibility	NOUN	O	O
of	ADP	O	O
glass	NOUN	O	O
ionomer	NOUN	O	O
cement	NOUN	O	O
(	PUNCT	O	O
GIC	NOUN	O	O
)	PUNCT	O	O
impregnated	VERB	O	O
with	ADP	O	O
collagen	NOUN	O	O
or	CCONJ	O	O
bioactive	ADJ	O	O
glass	NOUN	O	O
to	ADP	O	O
BHK-21	NOUN	O	O
fibroblasts	NOUN	O	O
in	ADP	O	O
vitro	ADV	O	O
.	PUNCT	O	O

Mineral	NOUN	O	O
Trioxide	NOUN	O	O
Aggregate	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
the	DET	O	O
standard	CCONJ	O	O
for	ADP	O	O
comparison	NOUN	O	O
.	PUNCT	O	O

Human	NOUN	O	O
maxillary	ADJ	O	O
central	ADJ	O	O
incisors	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
70	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
instrumented	VERB	O	O
with	ADP	O	O
a	DET	O	O
rotary	ADJ	O	O
NiTi	NOUN	O	O
system	NOUN	O	O
and	CCONJ	O	O
filled	VERB	O	O
.	PUNCT	O	O

Following	ADP	O	O
resection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
apical	ADJ	O	O
3mm	ADP	O	O
,	PUNCT	O	O
root	NOUN	O	O
end	NOUN	O	O
cavities	NOUN	O	O
were	VERB	O	O
prepared	VERB	O	O
and	CCONJ	O	O
restored	VERB	O	O
with	ADP	O	O
conventional	ADJ	O	O
GIC	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
GIC	NOUN	O	O
with	ADP	O	O
0.01	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
0.1	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
1	NUM	O	O
%	SYM	O	O
collagen	NOUN	O	O
(	PUNCT	O	O
groups	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
respectively	ADV	O	O
)	PUNCT	O	O
or	CCONJ	O	O
,	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
50	NUM	O	O
%	SYM	O	O
bioactive	ADJ	O	O
glass	NOUN	O	O
(	PUNCT	O	O
groups	NOUN	O	O
5	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
Mineral	NOUN	O	O
Trioxide	NOUN	O	O
Aggregate	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
8	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
root	NOUN	O	O
slices	NOUN	O	O
were	VERB	O	O
incubated	VERB	O	O
in	ADP	O	O
tissue	NOUN	O	O
culture	NOUN	O	O
plates	NOUN	O	O
with	ADP	O	O
BHK-21	NOUN	O	O
fibroblast	NOUN	O	O
cell	NOUN	O	O
line	NOUN	O	O
.	PUNCT	O	O

Phase	NOUN	O	O
contrast	NOUN	O	O
and	CCONJ	O	O
scanning	ADJ	O	O
electron	NOUN	O	O
microscopes	ADP	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
score	DET	O	O
cell	NOUN	O	B-OTHER
quantity	NOUN	O	I-OTHER
,	PUNCT	O	O
morphology	NOUN	O	B-OTHER
and	CCONJ	O	O
cell	NOUN	O	B-OTHER
attachment	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
were	VERB	O	O
statistically	ADV	O	O
analyzed	VERB	O	O
by	ADP	O	O
one	NUM	O	O
way	NOUN	O	O
ANOVA	NOUN	O	O
with	ADP	O	O
Post	PUNCT	O	B-OTHER
Hoc	NOUN	O	I-OTHER
Tukey	NOUN	O	I-OTHER
HSD	NOUN	O	I-OTHER
test	NOUN	O	I-OTHER
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
AND	CCONJ	O	O
CONCLUSIONS	NOUN	O	O
Group	NOUN	O	O
5	NUM	O	O
showed	VERB	O	O
the	DET	O	O
highest	PUNCT	O	O
scores	NOUN	O	O
which	ADP	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
all	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
except	PUNCT	O	O
group	NOUN	O	O
8	NUM	O	O
,	PUNCT	O	O
with	ADP	O	O
which	DET	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Glass	ADJ	O	O
ionomer	NOUN	O	O
cement	NOUN	O	O
with	ADP	O	O
10	NUM	O	O
%	SYM	O	O
bioactive	ADJ	O	O
glass	NOUN	O	O
showed	VERB	O	O
better	PUNCT	O	B-OTHER
adhesion	NOUN	O	I-OTHER
and	CCONJ	O	O
spreading	DET	O	B-OTHER
of	ADP	O	I-OTHER
cells	NOUN	O	I-OTHER
than	PUNCT	O	O
glass	NOUN	O	O
ionomer	NOUN	O	O
cement	NOUN	O	O
with	ADP	O	O
0.01	NUM	O	O
%	ADP	O	O
collagen	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
biocompatibility	NOUN	O	O
of	ADP	O	O
collagen	NOUN	O	B-OTHER
and	CCONJ	O	O
bioactive	ADJ	O	B-OTHER
glass	NOUN	O	I-OTHER
was	VERB	O	O
concentration	NOUN	O	O
dependent	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
bioactive	ADJ	O	O
glass	NOUN	O	O
improved	VERB	O	O
the	DET	O	O
biocompatibility	NOUN	O	O
of	ADP	O	O
glass	NOUN	O	O
ionomer	NOUN	O	O
cement	NOUN	O	O
to	ADP	O	O
fibroblasts	PUNCT	O	O
better	PUNCT	O	O
than	PUNCT	O	O
addition	NOUN	O	O
of	ADP	O	O
collagen	NOUN	O	O
.	PUNCT	O	O

Osteoporosis	NOUN	O	O
and	CCONJ	O	O
gait	NOUN	O	O
and	CCONJ	O	O
balance	NOUN	O	O
disturbances	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
sarcopenic	ADJ	O	O
obese	PUNCT	O	O
New	ADJ	O	O
Zealanders	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
Bone	NOUN	O	O
,	PUNCT	O	O
muscle	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fat	NOUN	O	O
may	PROPN	O	O
affect	VERB	O	O
gait	NOUN	O	O
and	CCONJ	O	O
balance	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Osteoporosis	NOUN	O	O
was	VERB	O	O
prevalent	ADJ	O	O
in	ADP	O	O
low	ADJ	O	O
muscle	NOUN	O	O
mass	NOUN	O	O
participants	NOUN	O	O
and	CCONJ	O	O
related	VERB	O	O
to	ADP	O	O
gait	NOUN	O	O
and	CCONJ	O	O
balance	NOUN	O	O
deficits	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
muscle	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
fat	NOUN	O	O
mass	NOUN	O	O
had	PUNCT	O	O
more	DET	O	O
functional	ADJ	O	O
deficits	NOUN	O	O
and	CCONJ	O	O
poorer	PUNCT	O	O
bone	NOUN	O	O
health	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
has	ADP	O	O
implications	NOUN	O	O
for	ADP	O	O
falls	CCONJ	O	O
risk	NOUN	O	O
and	CCONJ	O	O
fractures	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Decreasing	ADJ	O	O
bone	NOUN	O	O
density	NOUN	O	O
and	CCONJ	O	O
muscle	NOUN	O	O
mass	NOUN	O	O
and	CCONJ	O	O
increasing	ADJ	O	O
fat	NOUN	O	O
mass	NOUN	O	O
may	VERB	O	O
act	VERB	O	O
synergistically	ADV	O	O
to	PART	O	O
affect	ADJ	O	O
gait	NOUN	O	O
and	CCONJ	O	O
balance	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
eighty-three	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
72.7	NUM	O	O
+/-	SYM	O	O
6	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
range	NOUN	O	O
56-93	NUM	O	O
;	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
28.2	NUM	O	O
+/-	SYM	O	O
4.9	NUM	O	O
,	PUNCT	O	O
range	NOUN	O	O
16.6-46.0	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
recruited	VERB	O	O
from	ADP	O	O
a	DET	O	O
New	ADJ	O	O
Zealand	NOUN	O	O
falls	PUNCT	O	O
prevention	NOUN	O	O
intervention	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
and	CCONJ	O	O
appendicular	ADJ	O	B-PHYSICAL
skeletal	ADJ	O	I-PHYSICAL
muscle	NOUN	O	I-PHYSICAL
mass	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ASM	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
percent	NOUN	O	B-PHYSICAL
fat	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
bone	NOUN	O	B-PHYSICAL
mineralization	NOUN	O	I-PHYSICAL
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
dual	ADJ	O	O
energy	NOUN	O	O
X-ray	NOUN	O	O
absorptiometry	NOUN	O	O
and	CCONJ	O	O
used	VERB	O	O
to	PART	O	O
characterize	NOUN	O	O
normal	ADJ	O	O
lean	PUNCT	O	O
(	PUNCT	O	O
NL	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
51	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sarcopenic	ADJ	O	O
(	PUNCT	O	O
SS	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
18	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sarcopenic	ADJ	O	O
obese	ADJ	O	O
(	PUNCT	O	O
SO	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
29	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
obese	ADP	O	O
(	PUNCT	O	O
OO	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
85	NUM	O	O
)	PUNCT	O	O
phenotypes	NOUN	O	O
.	PUNCT	O	O

Functional	ADJ	O	O
performance	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
using	SYM	O	O
timed	PUNCT	O	O
up	PUNCT	O	O
and	CCONJ	O	O
go	NOUN	O	O
,	PUNCT	O	O
chair	PUNCT	O	O
stand	CCONJ	O	O
,	PUNCT	O	O
single	ADJ	O	O
leg	NOUN	O	O
stand	CCONJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
step	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Regression	NOUN	O	O
models	NOUN	O	O
were	VERB	O	O
adjusted	VERB	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
medications	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Femoral	ADJ	O	B-PHYSICAL
neck	ADJ	O	I-PHYSICAL
osteoporosis	NOUN	O	I-PHYSICAL
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
22	NUM	O	O
%	SYM	O	O
SS	NOUN	O	O
,	PUNCT	O	O
17	NUM	O	O
%	SYM	O	O
SO	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
%	SYM	O	O
NL	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
7	NUM	O	O
%	SYM	O	O
OO	NOUN	O	O
.	PUNCT	O	O

Femoral	ADJ	O	O
neck	NOUN	O	O
osteoporosis	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
ASM	NOUN	O	B-PHYSICAL
predicted	ADP	O	O
poor	ADJ	O	O
chair	PUNCT	O	B-PHYSICAL
stand	CCONJ	O	I-PHYSICAL
performance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
beta	NOUN	O	O
-3.3	NUM	O	O
,	PUNCT	O	O
standard	ADJ	O	O
error	NOUN	O	O
1.6	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

SO	NOUN	O	O
scored	PUNCT	O	O
lowest	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
chair	PUNCT	O	O
stand	CCONJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
step	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Higher	PUNCT	O	B-PHYSICAL
ASM	NOUN	O	I-PHYSICAL
predicted	VERB	O	O
faster	PUNCT	O	O
timed	ADP	O	O
up	PUNCT	O	O
and	CCONJ	O	O
go	ADP	O	O
performance	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Osteoporosis	NOUN	O	O
was	VERB	O	O
prevalent	ADJ	O	O
in	ADP	O	O
low	ADJ	O	O
ASM	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
SS	NOUN	O	O
and	CCONJ	O	O
SO	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
related	VERB	O	O
to	ADP	O	O
gait	NOUN	O	O
and	CCONJ	O	O
balance	NOUN	O	O
deficits	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
the	DET	O	O
SO	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
has	PUNCT	O	O
implications	NOUN	O	O
for	ADP	O	O
falls	CCONJ	O	O
risk	NOUN	O	O
,	PUNCT	O	O
fractures	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Efficacy	NOUN	O	O
of	ADP	O	O
paliperidone	NOUN	O	O
extended-release	NOUN	O	O
tablets	NOUN	O	O
in	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
social	ADJ	O	B-MENTAL
functions	CCONJ	O	I-MENTAL
in	ADP	O	O
schizophrenics	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
and	CCONJ	O	O
controlled	VERB	O	O
study	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	ADJ	O	O
explore	CCONJ	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
paliperidone	NOUN	O	O
extended-release	NOUN	O	O
tablets	NOUN	O	O
in	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
social	ADJ	O	B-MENTAL
functions	CCONJ	O	I-MENTAL
in	ADP	O	O
schizophrenics	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
81	NUM	O	O
schizophrenics	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
study	NOUN	O	O
group	NOUN	O	O
with	ADP	O	O
paliperidone	NOUN	O	O
extended-release	NOUN	O	O
tablets	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
with	ADP	O	O
risperidone	NUM	O	O
for	ADP	O	O
a	DET	O	O
12-week	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
assessed	VERB	O	O
and	CCONJ	O	O
analyzed	VERB	O	O
by	ADP	O	O
positive	ADJ	O	O
and	CCONJ	O	O
negative	ADJ	O	O
symptoms	NOUN	O	O
scales	NOUN	O	O
(	PUNCT	O	O
PANSS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
social	ADJ	O	O
disability	NOUN	O	O
screening	NUM	O	O
schedule	NOUN	O	O
(	PUNCT	O	O
SDSS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
emergent	ADJ	O	O
symptom	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
TESS	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	VERB	O	O
and	CCONJ	O	O
12	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
study	ADV	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
factors	NOUN	O	O
and	CCONJ	O	O
total	ADJ	O	O
scores	NOUN	O	O
of	ADP	O	O
PANSS	NOUN	O	O
in	ADP	O	O
the	DET	O	O
12	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
[	PUNCT	O	O
(	PUNCT	O	O
12.0	NUM	O	O
?	PUNCT	O	O

2.8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
12.1	NUM	O	O
?	PUNCT	O	O

3.6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
26.2	NUM	O	O
?	PUNCT	O	O

5.0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
50.2	NUM	O	O
?	PUNCT	O	O

8.7	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
were	VERB	O	O
all	PUNCT	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
at	ADP	O	O
baseline	NOUN	O	O
[	PUNCT	O	O
(	PUNCT	O	O
24.7	NUM	O	O
?	PUNCT	O	O

5.3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
23.8	NUM	O	O
?	PUNCT	O	O

3.6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
45.0	NUM	O	O
?	PUNCT	O	O

2.9	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
93.5	NUM	O	O
?	PUNCT	O	O

6.8	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
9.60-16.78	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
study	ADV	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
positive	ADJ	O	O
factor	NOUN	O	O
,	PUNCT	O	O
negative	ADJ	O	O
factor	NOUN	O	O
and	CCONJ	O	O
total	ADJ	O	O
scores	NOUN	O	O
of	ADP	O	O
PANSS	NOUN	O	O
in	ADP	O	O
the	DET	O	O
12	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
[	PUNCT	O	O
(	PUNCT	O	O
12.0	NUM	O	O
?	PUNCT	O	O

2.8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
12.1	NUM	O	O
?	PUNCT	O	O

3.6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
50.2	NUM	O	O
?	PUNCT	O	O

8.7	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
were	VERB	O	O
all	PUNCT	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
6	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
[	PUNCT	O	O
(	PUNCT	O	O
14.2	NUM	O	O
?	PUNCT	O	O

1.8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
14.6	NUM	O	O
?	PUNCT	O	O

2.4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
56.5	NUM	O	O
?	PUNCT	O	O

6.4	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
2.58-4.26	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
12	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
factors	NOUN	O	O
and	CCONJ	O	O
total	ADJ	O	O
scores	NOUN	O	O
of	ADP	O	O
PANSS	NOUN	O	O
in	ADP	O	O
study	ADV	O	O
group	NOUN	O	O
[	PUNCT	O	O
(	PUNCT	O	O
12.0	NUM	O	O
?	PUNCT	O	O

2.8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
12.1	NUM	O	O
?	PUNCT	O	O

3.6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
26.2	NUM	O	O
?	PUNCT	O	O

5.0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
50.2	NUM	O	O
?	PUNCT	O	O

8.7	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
were	VERB	O	O
all	PUNCT	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
control	NOUN	O	O
group	NOUN	O	O
[	PUNCT	O	O
(	PUNCT	O	O
16.9	NUM	O	O
?	PUNCT	O	O

4.9	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
18.7	NUM	O	O
?	PUNCT	O	O

5.3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
32.5	NUM	O	O
?	PUNCT	O	O

5.1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
68.1	NUM	O	O
?	PUNCT	O	O

13.0	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
-4.28	NUM	O	O
--	PUNCT	O	O
5.67	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
study	ADV	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
total	ADJ	O	O
scores	NOUN	O	O
of	ADP	O	O
SDSS	NOUN	O	O
in	ADP	O	O
the	DET	O	O
12	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
5.93	NUM	O	O
?	PUNCT	O	O

2.78	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
at	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
13.9	NUM	O	O
?	PUNCT	O	O

3.4	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
10.83	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
study	ADV	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
total	ADJ	O	O
scores	NOUN	O	O
of	ADP	O	O
SDSS	NOUN	O	O
in	ADP	O	O
the	DET	O	O
12	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
5.9	NUM	O	O
?	PUNCT	O	O

2.8	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
6	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
7.6	NUM	O	O
?	PUNCT	O	O

2.9	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
5.21	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

But	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
1.88	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
12	NUM	O	O
(	PUNCT	O	O
th	PUNCT	O	O
)	PUNCT	O	O
weekend	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
total	ADJ	O	O
scores	NOUN	O	O
of	ADP	O	O
SDSS	NOUN	O	O
in	ADP	O	O
study	ADV	O	O
group	NOUN	O	O
(	PUNCT	O	O
5.9	NUM	O	O
?	PUNCT	O	O

2.8	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
8.8	NUM	O	O
?	PUNCT	O	O

2.9	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
t	NOUN	O	O
=	SYM	O	O
-4.49	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
severe	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Paliperidone	NOUN	O	O
extended-release	NOUN	O	O
tablets	NOUN	O	O
are	VERB	O	O
effective	ADJ	O	O
to	PART	O	O
improve	VERB	O	O
social	ADJ	O	O
functions	NOUN	O	O
and	CCONJ	O	O
psychiatric	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
schizophrenics	NOUN	O	O
.	PUNCT	O	O

Ursodeoxycholic	ADJ	O	O
acid	NOUN	O	O
has	CCONJ	O	O
no	DET	O	O
influence	NOUN	O	O
on	ADP	O	O
function	NOUN	O	O
after	ADP	O	O
restorative	ADJ	O	O
proctocolectomy	NOUN	O	B-PHYSICAL
in	ADP	O	O
ulcerative	ADJ	O	O
colitis	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Poor	ADJ	O	O
pouch	DET	O	O
function	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
impaired	VERB	O	O
bile	NOUN	O	O
acid	NOUN	O	O
absorption	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
faecal	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
bile	NOUN	O	O
acids	NOUN	O	O
.	PUNCT	O	O

Bile	NOUN	O	O
acid	NOUN	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
might	PUNCT	O	O
therefore	ADV	O	O
be	DET	O	O
of	ADP	O	O
clinical	ADJ	O	O
benefit	NOUN	O	O
,	PUNCT	O	O
provided	CCONJ	O	O
that	PUNCT	O	O
diarrhoea	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
aggravated	VERB	O	O
by	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
investigate	NOUN	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
exogenous	ADJ	O	O
bile	NOUN	O	O
acid	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
poor	ADJ	O	O
pouch	DET	O	O
function	NOUN	O	O
after	ADP	O	O
restorative	ADJ	O	O
proctocolectomy	NOUN	O	O
for	ADP	O	O
ulcerative	ADJ	O	O
colitis	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Twenty	NUM	O	O
ulcerative	ADJ	O	O
colitis	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
poor	ADJ	O	O
pouch	DET	O	O
function	NOUN	O	O
(	PUNCT	O	O
score	NOUN	O	O
>	SYM	O	O
4	NUM	O	O
on	ADP	O	O
a	DET	O	O
12-point	NOUN	O	O
score	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
recruited	VERB	O	O
for	ADP	O	O
inclusion	NOUN	O	O
to	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
crossover	NOUN	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
ursodeoxycholic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg/kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
divided	VERB	O	O
doses	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
completed	NOUN	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
functional	ADJ	O	B-PHYSICAL
score	NOUN	O	O
or	CCONJ	O	B-PHYSICAL
bowel	NOUN	O	I-PHYSICAL
frequency	NOUN	O	B-PHYSICAL
following	VERB	O	O
treatment	NOUN	O	O
irrespective	ADJ	O	O
of	ADP	O	O
whether	ADP	O	O
the	DET	O	O
active	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
before	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
We	PRON	O	O
conclude	VERB	O	O
that	PUNCT	O	O
ursodeoxycholic	ADJ	O	O
acid	NOUN	O	O
given	VERB	O	O
over	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
influence	NOUN	O	O
on	ADP	O	O
functional	ADJ	O	B-PHYSICAL
score	PUNCT	O	O

Environmental	ADJ	O	O
enrichment	ADJ	O	O
as	ADP	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Enriched	VERB	O	O
sensorimotor	NOUN	O	O
environments	NOUN	O	O
enable	PUNCT	O	O
rodents	NOUN	O	O
to	PART	O	O
compensate	VERB	O	O
for	ADP	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
neurological	ADJ	O	O
challenges	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
those	PUNCT	O	O
induced	VERB	O	O
in	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
sensorimotor	NOUN	O	O
deficits	NOUN	O	O
in	ADP	O	O
most	DET	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
attempted	VERB	O	O
to	PART	O	O
translate	NOUN	O	O
that	ADP	O	O
approach	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
3-12	NUM	O	O
year-old	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
sensorimotor	NOUN	O	O
enrichment	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
received	VERB	O	O
daily	ADJ	O	O
olfactory/tactile	NOUN	O	O
stimulation	NOUN	O	O
along	PUNCT	O	O
with	ADP	O	O
exercises	NOUN	O	O
that	ADP	O	O
stimulated	VERB	O	O
other	ADJ	O	O
paired	ADP	O	O
sensory	ADJ	O	O
modalities	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
administered	VERB	O	O
tests	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	O
performance	NOUN	O	O
and	CCONJ	O	O
autism	NOUN	O	O
severity	NOUN	O	O
to	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
at	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Severity	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
autism	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
as	PUNCT	O	O
assessed	VERB	O	O
with	ADP	O	O
the	DET	O	O
Childhood	NOUN	O	B-OTHER
Autism	NOUN	O	I-OTHER
Rating	PUNCT	O	I-OTHER
Scale	NOUN	O	O
,	PUNCT	O	O
improved	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
enriched	VERB	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Indeed	ADV	O	O
,	PUNCT	O	O
42	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
enriched	VERB	O	O
group	NOUN	O	O
and	CCONJ	O	O
only	ADV	O	O
7	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
what	PUNCT	O	O
we	ADJ	O	O
considered	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
clinically	ADV	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
points	NOUN	O	O
on	ADP	O	O
that	PUNCT	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Sensorimotor	NOUN	O	O
enrichment	ADJ	O	O
also	ADV	O	O
produced	VERB	O	O
a	DET	O	O
clear	ADJ	O	B-OTHER
improvement	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
cognition	NOUN	O	I-OTHER
,	PUNCT	O	O
as	CCONJ	O	O
determined	VERB	O	O
by	ADP	O	O
their	ADP	O	O
Leiter-R	NOUN	O	O
Visualization	NOUN	O	O
and	CCONJ	O	O
Reasoning	PUNCT	O	O
scores	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
average	ADJ	O	O
scores	NOUN	O	O
for	ADP	O	O
the	DET	O	O
enriched	VERB	O	O
group	NOUN	O	O
was	VERB	O	O
11.3	NUM	O	O
points	ADP	O	O
higher	PUNCT	O	O
than	CCONJ	O	O
that	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
69	NUM	O	O
%	SYM	O	O
of	ADP	O	O
parents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
enriched	VERB	O	O
group	NOUN	O	O
and	CCONJ	O	O
31	NUM	O	O
%	SYM	O	O
of	ADP	O	O
parents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
reported	VERB	O	O
improvement	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
child	NOUN	O	O
over	ADP	O	O
the	DET	O	O
6-month	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Environmental	ADJ	O	O
enrichment	ADJ	O	O
therefore	ADV	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
effective	ADJ	O	O
in	ADP	O	O
ameliorating	PUNCT	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
dalcetrapib	ADP	O	O
on	ADP	O	O
atherosclerotic	ADJ	O	O
disease	NOUN	O	O
using	VERB	O	O
novel	ADJ	O	O
non-invasive	ADJ	O	O
multimodality	NOUN	O	O
imaging	VERB	O	O
(	PUNCT	O	O
dal-PLAQUE	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Dalcetrapib	NUM	O	O
modulates	NOUN	O	O
cholesteryl	NOUN	O	O
ester	NOUN	O	O
transfer	NOUN	O	O
protein	NOUN	O	O
(	PUNCT	O	O
CETP	NOUN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
to	PART	O	O
raise	ADJ	O	O
high-density	NOUN	O	O
lipoprotein	NOUN	O	O
cholesterol	NOUN	O	O
(	PUNCT	O	O
HDL-C	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
failure	NOUN	O	O
of	ADP	O	O
torcetrapib	ADJ	O	O
it	PUNCT	O	O
was	VERB	O	O
unknown	VERB	O	O
if	PUNCT	O	O
HDL	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
interaction	NOUN	O	O
with	ADP	O	O
CETP	NOUN	O	O
had	VERB	O	O
pro-atherogenic	ADJ	O	O
or	CCONJ	O	O
pro-inflammatory	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O

dal-PLAQUE	NOUN	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
multicentre	NOUN	O	O
study	NOUN	O	O
using	VERB	O	O
novel	ADJ	O	O
non-invasive	ADJ	O	O
multimodality	NOUN	O	O
imaging	VERB	O	O
to	ADJ	O	O
assess	NOUN	O	O
structural	ADJ	O	O
and	CCONJ	O	O
inflammatory	ADJ	O	O
indices	NOUN	O	O
of	ADP	O	O
atherosclerosis	NOUN	O	O
as	ADP	O	O
primary	ADJ	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
phase	NOUN	O	O
2b	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
multicentre	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
aged	PROPN	O	O
18-75	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
,	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
,	PUNCT	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
(	PUNCT	O	O
1:1	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
dalcetrapib	PUNCT	O	O
600	NUM	O	O
mg/day	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Randomisation	NOUN	O	O
was	VERB	O	O
done	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
computer-generated	VERB	O	O
randomisation	NOUN	O	O
code	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
stratified	VERB	O	O
by	ADP	O	O
centre	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
and	CCONJ	O	O
investigators	NOUN	O	O
were	VERB	O	O
masked	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Coprimary	NOUN	O	O
endpoints	NOUN	O	O
were	VERB	O	O
MRI-assessed	VERB	O	B-OTHER
indices	NOUN	O	I-OTHER
(	PUNCT	O	O
total	ADJ	O	O
vessel	NOUN	O	B-OTHER
area	NOUN	O	O
,	PUNCT	O	O
wall	NOUN	O	B-OTHER
area	NOUN	O	O
,	PUNCT	O	O
wall	NOUN	O	B-OTHER
thickness	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
normalised	PUNCT	O	B-OTHER
wall	NOUN	O	I-OTHER
index	NOUN	O	I-OTHER
[	PUNCT	O	O
average	PUNCT	O	O
carotid	ADJ	O	O
]	PUNCT	O	O
)	PUNCT	O	O
after	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
18	NUM	O	O
)	PUNCT	O	O
F-fluorodeoxyglucose	VERB	O	O
(	PUNCT	O	O
(	PUNCT	O	O
18	NUM	O	O
)	PUNCT	O	O
F-FDG	NOUN	O	O
)	PUNCT	O	O
PET/CT	NOUN	O	O
assessment	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	O
inflammation	NOUN	O	O
within	ADP	O	O
an	DET	O	O
index	NOUN	O	O
vessel	NOUN	O	O
(	PUNCT	O	O
right	PUNCT	O	O
carotid	ADJ	O	O
,	PUNCT	O	O
left	ADJ	O	O
carotid	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
ascending	ADV	O	O
thoracic	ADJ	O	O
aorta	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no-harm	NOUN	O	O
boundaries	NOUN	O	O
established	VERB	O	O
before	ADP	O	O
unblinding	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
was	VERB	O	O
by	ADP	O	O
intention	NOUN	O	O
to	PART	O	O
treat	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
registered	NOUN	O	O
at	ADP	O	O
ClinicalTrials.gov	PUNCT	O	O
,	PUNCT	O	O
NCT00655473	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
189	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
screened	NUM	O	O
and	CCONJ	O	O
130	NUM	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
66	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
dalcetrapib	ADP	O	O
(	PUNCT	O	O
64	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
coprimary	ADJ	O	O
MRI	NOUN	O	O
and	CCONJ	O	O
PET/CT	ADP	O	O
endpoints	NOUN	O	O
,	PUNCT	O	O
CIs	PUNCT	O	O
were	VERB	O	O
below	ADP	O	O
the	DET	O	O
no-harm	NOUN	O	O
boundary	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
adverse	ADJ	O	O
change	NOUN	O	O
was	VERB	O	O
numerically	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
dalcetrapib	PUNCT	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

MRI-derived	VERB	O	B-OTHER
change	NOUN	O	I-OTHER
in	PUNCT	O	I-OTHER
total	PUNCT	O	O

Atrial	ADJ	O	O
natriuretic	ADJ	O	O
factor	NOUN	O	O
inhibits	VERB	O	O
metoclopramide	CCONJ	O	O
stimulated	ADV	O	O
aldosterone	NOUN	O	B-PHYSICAL
release	NOUN	O	I-PHYSICAL
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
.	PUNCT	O	O

Atrial	ADJ	O	O
natriuretic	ADJ	O	O
factor	NOUN	O	O
(	PUNCT	O	O
ANF	NOUN	O	O
)	PUNCT	O	O
has	VERB	O	O
an	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
angiotensin	NOUN	O	B-PHYSICAL
II	NUM	O	I-PHYSICAL
and	CCONJ	O	O
ACTH	NOUN	O	B-PHYSICAL
stimulated	PUNCT	O	I-PHYSICAL
aldosterone	NOUN	O	I-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
selectivity	NOUN	O	O
of	ADP	O	O
this	DET	O	O
aldosterone	NOUN	O	O
suppressing	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
ANF	NOUN	O	O
is	VERB	O	O
unclear	ADJ	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
ANF	NOUN	O	O
on	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
aldosterone	NOUN	O	I-PHYSICAL
due	ADP	O	O
to	ADP	O	O
metoclopramide	CCONJ	O	B-OTHER
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
.	PUNCT	O	O

Eight	NUM	O	O
normal	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
on	ADP	O	O
three	NUM	O	O
occasions	NOUN	O	O
.	PUNCT	O	O

Metoclopramide	CCONJ	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
slow	ADJ	O	O
i.v	NUM	O	O
.	PUNCT	O	O
)	PUNCT	O	O

was	VERB	O	O
given	VERB	O	O
on	ADP	O	O
all	DET	O	O
study	ADJ	O	O
days	NOUN	O	O
and	CCONJ	O	O
each	DET	O	O
volunteer	ADV	O	O
was	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	ADV	O	O
45	NUM	O	O
min	NOUN	O	O
infusion	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
5	NUM	O	O
%	SYM	O	O
D-glucose	NOUN	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ANF	NOUN	O	O
(	PUNCT	O	O
99-126	NUM	O	O
)	PUNCT	O	O
3	NUM	O	O
or	CCONJ	O	O
15	NUM	O	O
pmol	NOUN	O	O
kg-1	NOUN	O	O
min-1	NOUN	O	O
.	PUNCT	O	O

3	NUM	O	O
.	PUNCT	O	O

Metoclopramide	CCONJ	O	O
increased	VERB	O	O
plasma	NOUN	O	B-PHYSICAL
aldosterone	NOUN	O	I-PHYSICAL
to	ADP	O	O
approximately	ADV	O	O
170	NUM	O	O
%	SYM	O	O
of	ADP	O	O
baseline	NOUN	O	O
levels	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Concomitant	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
ANF	NOUN	O	O
3	NUM	O	O
pmol	NOUN	O	O
kg-1	NOUN	O	O
min-1	NOUN	O	O
and	CCONJ	O	O
15	NUM	O	O
pmol	NOUN	O	O
kg-1	NOUN	O	O
min-1	NOUN	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
this	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
aldosterone	NOUN	O	O
to	ADP	O	O
approximately	ADV	O	O
130	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
110	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
baseline	NOUN	O	O
values	NOUN	O	O
respectively	ADV	O	O
.	PUNCT	O	O

4	NUM	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
light	NOUN	O	O
of	ADP	O	O
previous	ADJ	O	O
findings	NOUN	O	O
,	PUNCT	O	O
that	ADP	O	O
the	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ANF	NOUN	O	O
represents	NOUN	O	O
a	DET	O	O
non-selective	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
ANF	NOUN	O	O
on	ADP	O	O
aldosterone	NOUN	O	B-PHYSICAL
release	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Determination	NOUN	O	O
of	ADP	O	O
vital	ADJ	O	O
status	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DIG	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Digitalis	NOUN	O	O
Investigation	NOUN	O	O
Group	NOUN	O	O
(	PUNCT	O	O
DIG	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
was	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
whose	ADP	O	O
primary	ADJ	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	VERB	O	O
digoxin	NOUN	O	O
had	PUNCT	O	O
beneficial	ADJ	O	O
,	PUNCT	O	O
harmful	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
total	ADJ	O	O
mortality	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
in	ADP	O	O
sinus	NOUN	O	O
rhythm	NOUN	O	O
and	CCONJ	O	O
whose	ADP	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
was	VERB	O	O
<	SYM	O	O
/=0.45	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
as	ADP	O	O
a	DET	O	O
large	ADJ	O	O
simple	ADJ	O	O
trial	NOUN	O	O
with	ADP	O	O
a	DET	O	O
large	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
centers	NOUN	O	O
(	PUNCT	O	O
302	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
United	ADV	O	O
States	NOUN	O	O
and	CCONJ	O	O
Canada	PUNCT	O	O
,	PUNCT	O	O
many	DET	O	O
of	ADP	O	O
which	ADP	O	O
were	VERB	O	O
inexperienced	VERB	O	O
in	ADP	O	O
research	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
ensure	NOUN	O	O
that	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
reported	VERB	O	O
accurately	ADV	O	O
without	ADP	O	O
possible	ADJ	O	O
bias	NOUN	O	O
due	PUNCT	O	O
to	PUNCT	O	O
missing	PUNCT	O	O
data	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
study	PUNCT	O	O
leadership	PUNCT	O	O
decided	CCONJ	O	O
that	PUNCT	O	O
no	DET	O	O
outcome	NOUN	O	O
results	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
reported	VERB	O	O
until	ADP	O	O
the	DET	O	O
vital	ADJ	O	O
status	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
known	VERB	O	O
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
97	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
study	ADJ	O	O
participants	NOUN	O	O
.	PUNCT	O	O

Planning	VERB	O	O
for	ADP	O	O
closeout	ADP	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
began	VERB	O	O
a	DET	O	O
year	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
common	ADJ	O	O
end	NOUN	O	O
date	NOUN	O	O
of	ADP	O	O
December	NOUN	O	O
31	NUM	O	O
,	PUNCT	O	O
1995	NUM	O	O
and	CCONJ	O	O
included	ADJ	O	O
plans	NOUN	O	O
for	ADP	O	O
obtaining	DET	O	O
vital	ADJ	O	O
status	NOUN	O	O
on	ADP	O	O
December	NOUN	O	O
31	NUM	O	O
,	PUNCT	O	O
1995	NUM	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
postcards	NOUN	O	O
at	ADP	O	O
their	PUNCT	O	O
final	ADJ	O	O
study	NOUN	O	O
visit	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
completed	VERB	O	O
and	CCONJ	O	O
mailed	VERB	O	O
on	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
January	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
1996	NUM	O	O
.	PUNCT	O	O

Of	ADP	O	O
5602	NUM	O	O
postcards	NOUN	O	O
distributed	VERB	O	O
,	PUNCT	O	O
5070	NUM	O	O
(	PUNCT	O	O
90.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
completed	VERB	O	O
and	CCONJ	O	O
returned	PUNCT	O	O
.	PUNCT	O	O

A	PUNCT	O	O
contract	PUNCT	O	O
search	NOUN	O	O
agency	NOUN	O	O
was	VERB	O	O
hired	NUM	O	O
to	ADP	O	O
locate	PUNCT	O	O
the	DET	O	O
remaining	VERB	O	O
participants	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
7788	NUM	O	O
participants	NOUN	O	O
entered	VERB	O	O
into	ADP	O	O
the	DET	O	O
DIG	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
97	NUM	O	O
participants	NOUN	O	O
(	PUNCT	O	O
1.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
could	VERB	O	O
not	ADV	O	O
have	VERB	O	O
their	CCONJ	O	O
vital	ADJ	O	B-PHYSICAL
status	NOUN	O	I-PHYSICAL
as	PUNCT	O	O
of	ADP	O	O
December	NOUN	O	O
31	NUM	O	O
,	PUNCT	O	O
1995	NUM	O	O
determined	PROPN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
recommended	VERB	O	O
that	ADP	O	O
investigators	NOUN	O	O
having	VERB	O	O
an	DET	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
with	ADP	O	O
a	DET	O	O
common	ADJ	O	O
end	NOUN	O	O
date	NOUN	O	O
include	ADP	O	O
plans	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
protocols	NOUN	O	O
for	ADP	O	O
obtaining	DET	O	O
their	PUNCT	O	O
measures	NOUN	O	O
and	CCONJ	O	O
activate	VERB	O	O
those	PUNCT	O	O
plans	NOUN	O	O
as	PUNCT	O	O
early	ADJ	O	O
as	VERB	O	O
possible	ADJ	O	O
during	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
CX516	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
AMPA-modulating	VERB	O	O
compound	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
cognition	NOUN	O	B-MENTAL
and	CCONJ	O	O
behavior	NOUN	O	B-MENTAL
in	ADP	O	O
fragile	ADJ	O	O
X	NUM	O	O
syndrome	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
Phase	NOUN	O	O
II	NUM	O	O
,	PUNCT	O	O
4-week	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Ampakine	NOUN	O	O
compound	ADP	O	O
CX516	NOUN	O	O
as	ADP	O	O
a	DET	O	O
potential	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
underlying	ADP	O	O
disorder	NOUN	O	O
in	ADP	O	O
fragile	ADJ	O	O
X	NUM	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
FXS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
baseline	NOUN	O	O
screening	PUNCT	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
with	ADP	O	O
FXS	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
49	NUM	O	O
)	PUNCT	O	O
underwent	VERB	O	O
a	DET	O	O
1-week	NOUN	O	O
placebo	NOUN	O	O
lead-in	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADJ	O	O
study	NOUN	O	O
drug	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
a	DET	O	O
4-week	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Cognitive	ADJ	O	B-MENTAL
and	CCONJ	O	O
behavioral	ADJ	O	B-MENTAL
outcome	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
prior	PUNCT	O	O
to	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
weeks	NOUN	O	O
posttreatment	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
minimal	ADJ	O	B-ADVERSE-EFFECTS
side	NOUN	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	B-OTHER
changes	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
safety	NOUN	O	I-OTHER
parameters	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
12.5	NUM	O	O
%	SYM	O	O
frequency	NOUN	O	O
of	ADP	O	O
allergic	ADJ	O	B-PHYSICAL
rash	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
CX516	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
subject	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
substantial	ADJ	O	B-ADVERSE-EFFECTS
rash	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
no	DET	O	O
significant	ADJ	O	B-MENTAL
improvement	NOUN	O	I-MENTAL
in	ADP	O	O
memory	NOUN	O	B-MENTAL
,	PUNCT	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
in	ADP	O	O
secondary	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
language	NOUN	O	B-MENTAL
,	PUNCT	O	I-MENTAL
attention/executive	ADJ	O	I-MENTAL
function	NOUN	O	I-MENTAL
,	PUNCT	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
,	PUNCT	O	I-MENTAL
and	CCONJ	O	I-MENTAL
overall	ADJ	O	I-MENTAL
functioning	VERB	O	I-MENTAL
in	ADP	O	O
CX516-treated	VERB	O	O
subjects	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
did	PUNCT	O	O
demonstrate	VERB	O	O
that	ADP	O	O
many	DET	O	O
outcome	NOUN	O	O
measures	NOUN	O	B-OTHER
were	VERB	O	O
reproducible	ADJ	O	O
in	ADP	O	O
this	DET	O	O
test-retest	ADV	O	O
setting	VERB	O	O
for	ADP	O	O
the	DET	O	O
FXS	NOUN	O	O
population	NOUN	O	O
,	PUNCT	O	O
yet	ADV	O	O
some	PUNCT	O	O
were	VERB	O	O
too	ADV	O	O
difficult	ADJ	O	O
or	CCONJ	O	O
variable	ADJ	O	O
.	PUNCT	O	O

Adult	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
FXS	NOUN	O	O
were	VERB	O	O
able	ADJ	O	O
to	ADP	O	O
complete	ADJ	O	O
an	DET	O	O
intensive	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
some	DET	O	O
valid	ADP	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
for	ADP	O	O
future	ADJ	O	O
FXS	NOUN	O	O
trial	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

Problems	NOUN	O	O
with	ADP	O	O
potency	NOUN	O	O
of	ADP	O	O
CX516	NOUN	O	O
in	ADP	O	O
other	ADJ	O	O
studies	NOUN	O	O
have	CCONJ	O	O
suggested	VERB	O	O
dosing	VERB	O	O
may	ADJ	O	O
have	PUNCT	O	O
been	PUNCT	O	O
inadequate	PUNCT	O	O
for	ADP	O	O
therapeutic	ADJ	O	O
effect	NOUN	O	O
and	CCONJ	O	O
thus	ADV	O	O
it	PRON	O	O
remains	NOUN	O	O
unclear	ADJ	O	O
whether	ADP	O	O
modulation	NOUN	O	O
of	ADP	O	O
AMPA-mediated	VERB	O	O
neurotransmission	NOUN	O	O
is	VERB	O	O
a	DET	O	O
viable	ADJ	O	B-OTHER
therapeutic	ADJ	O	I-OTHER
strategy	NOUN	O	I-OTHER
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
FXS	NOUN	O	O
.	PUNCT	O	O

Topiramate	ADV	O	O
improves	NOUN	O	O
health-related	VERB	O	B-PHYSICAL
quality	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
life	NOUN	O	I-PHYSICAL
when	ADP	O	O
used	VERB	O	O
to	PART	O	O
prevent	NOUN	O	O
migraine	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
health-related	VERB	O	B-PHYSICAL
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
HRQoL	NOUN	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
measures	NOUN	O	I-PHYSICAL
among	ADP	O	O
patients	NOUN	O	O
receiving	CCONJ	O	O
topiramate	NOUN	O	O
(	PUNCT	O	O
TPM	NOUN	O	O
)	PUNCT	O	O
100	NUM	O	O
mg/d	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
divided	VERB	O	O
doses	NOUN	O	O
for	ADP	O	O
migraine	NOUN	O	O
prevention	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
26-week	NOUN	O	O
trials	NOUN	O	O
with	ADP	O	O
similar	ADJ	O	O
protocols	NOUN	O	O
and	CCONJ	O	O
study	ADV	O	O
populations	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Migraine	ADV	O	O
substantially	ADV	O	O
impairs	VERB	O	O
HRQoL	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
work	ADP	O	B-OTHER
productivity	NOUN	O	I-OTHER
before	ADP	O	O
,	PUNCT	O	O
during	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
attacks	NOUN	O	O
.	PUNCT	O	O

Approximately	ADV	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
migraine	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
recommended	VERB	O	O
for	ADP	O	O
preventive	ADJ	O	O
therapies	NOUN	O	O
,	PUNCT	O	O
yet	ADV	O	O
only	ADV	O	O
3	NUM	O	O
%	SYM	O	O
to	ADP	O	O
5	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
receive	VERB	O	O
them	PRON	O	O
.	PUNCT	O	O

TPM	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	B-OTHER
and	CCONJ	O	B-OTHER
generally	ADV	O	B-OTHER
well-tolerated	VERB	O	B-OTHER
migraine	NOUN	O	O
prophylactic	PUNCT	O	O
(	PUNCT	O	O
preventive	ADP	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
for	ADP	O	O
adults	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
demonstrated	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trials	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADP	O	O
common	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
studies	NOUN	O	O
of	ADP	O	O
TPM	NOUN	O	O
in	ADP	O	O
migraine	NOUN	O	O
prevention	NOUN	O	O
are	VERB	O	O
paresthesia	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
fatigue	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
anorexia	PUNCT	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
taste	NOUN	O	B-ADVERSE-EFFECTS
alteration	ADP	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
diarrhea	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
The	DET	O	O
Migraine-Specific	ADJ	O	B-PHYSICAL
Questionnaire	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
MSQ	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
version	ADJ	O	O
2.1	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
TPM	NOUN	O	O
100	NUM	O	O
mg/d	NOUN	O	O
on	ADP	O	O
the	DET	O	O
functionality	ADJ	O	O
and	CCONJ	O	O
HRQoL	NOUN	O	O
of	ADP	O	O
randomized	VERB	O	O
intent-to-treat	NOUN	O	O
(	PUNCT	O	O
ITT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
study-completer	NOUN	O	O
populations	NOUN	O	O
pooled	VERB	O	O
from	ADP	O	O
three	NUM	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trials	NOUN	O	O
.	PUNCT	O	O

MSQ	NOUN	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
0	NUM	O	O
to	ADP	O	O
100	NUM	O	O
,	PUNCT	O	O
higher	PUNCT	O	O
score	NOUN	O	O
indicates	PART	O	O
better	PUNCT	O	O
functioning	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
the	DET	O	O
following	ADP	O	O
three	NUM	O	O
domains	NOUN	O	O
:	PUNCT	O	O
role	NOUN	O	O
restriction	NOUN	O	O
(	PUNCT	O	O
examines	PROPN	O	O
the	DET	O	O
degree	NOUN	O	O
to	ADP	O	O
which	PUNCT	O	O
performance	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
activities	NOUN	O	O
is	VERB	O	O
limited	VERB	O	O
by	ADP	O	O
migraine	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
role	NOUN	O	O
prevention	NOUN	O	O
(	PUNCT	O	O
examines	PROPN	O	O
the	DET	O	O
degree	NOUN	O	O
to	ADP	O	O
which	PUNCT	O	O
performance	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
activities	NOUN	O	O
is	VERB	O	O
interrupted	VERB	O	O
by	ADP	O	O
migraine	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
emotional	ADJ	O	B-MENTAL
function	NOUN	O	I-MENTAL
(	PUNCT	O	O
examines	NUM	O	O
feelings	NOUN	O	O
of	ADP	O	O
frustration	NOUN	O	O
and	CCONJ	O	O
helplessness	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
migraine	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Between-group	ADP	O	O
differences	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
MSQ	PUNCT	O	B-PHYSICAL

Activator	NOUN	O	O
protein-1	NOUN	O	O
(	PUNCT	O	O
AP-1	NOUN	O	O
)	PUNCT	O	O
signalling	VERB	O	O
in	ADP	O	O
human	NOUN	O	O
atherosclerosis	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
systematic	ADJ	O	O
evaluation	NOUN	O	O
and	CCONJ	O	O
intervention	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Animal	NOUN	O	O
studies	NOUN	O	O
implicate	VERB	O	O
the	DET	O	O
AP-1	NOUN	O	O
(	PUNCT	O	O
activator	NOUN	O	O
protein-1	NOUN	O	O
)	PUNCT	O	O
pro-inflammatory	ADJ	O	O
pathway	NOUN	O	O
as	ADP	O	O
a	DET	O	O
promising	ADJ	O	O
target	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
atherosclerotic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
unclear	ADJ	O	O
whether	ADP	O	O
these	DET	O	O
observations	NOUN	O	O
apply	VERB	O	O
to	ADP	O	O
human	NOUN	O	O
atherosclerosis	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
we	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
profile	NOUN	O	O
of	ADP	O	O
AP-1	NOUN	O	O
activation	NOUN	O	O
through	ADP	O	O
histological	ADJ	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
tested	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
benefit	NOUN	O	O
of	ADP	O	O
AP-1	NOUN	O	O
inhibition	NOUN	O	O
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

AP-1	NOUN	O	O
activation	NOUN	O	O
was	VERB	O	O
quantified	VERB	O	O
by	ADP	O	O
phospho-c-Jun	NOUN	O	O
nuclear	ADJ	O	O
translocation	NOUN	O	O
(	PUNCT	O	O
immunohistochemistry	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
a	DET	O	O
biobank	CCONJ	O	O
of	ADP	O	O
aortic	ADJ	O	O
wall	NOUN	O	O
samples	NOUN	O	O
from	ADP	O	O
organ	NOUN	O	O
donors	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
AP-1	NOUN	O	B-PHYSICAL
inhibition	NOUN	O	I-PHYSICAL
on	ADP	O	O
vascular	ADJ	O	O
parameters	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
through	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADP	O	O
placebo-controlled	VERB	O	O
cross-over	NOUN	O	O
study	ADJ	O	O
of	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
doxycycline	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
symptomatic	ADJ	O	O
peripheral	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Vascular	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
brachial	ADJ	O	O
dilation	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
by	ADP	O	O
plasma	NOUN	O	O
samples	NOUN	O	O
analysed	VERB	O	O
for	ADP	O	O
hs-CRP	NOUN	O	O
(	PUNCT	O	O
high-sensitivity	NOUN	O	O
C-reactive	ADJ	O	O
protein	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
IL-6	NOUN	O	O
(	PUNCT	O	O
interleukin-6	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
IL-8	NOUN	O	O
,	PUNCT	O	O
ICAM-1	NOUN	O	O
(	PUNCT	O	O
intercellular	ADJ	O	O
adhesion	NOUN	O	O
molecule-1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
vWF	NOUN	O	O
(	PUNCT	O	O
von	PUNCT	O	O
Willebrand	NOUN	O	O
factor	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
MCP-1	NOUN	O	O
(	PUNCT	O	O
monocyte	NOUN	O	O
chemoattractant	NOUN	O	O
protein-1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
PAI-1	NOUN	O	O
(	PUNCT	O	O
plasminogen	NOUN	O	O
activator	NOUN	O	O
inhibitor-1	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fibrinogen	NOUN	O	O
.	PUNCT	O	O

Histological	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
atherosclerosis	NOUN	O	O
showed	VERB	O	O
minimal	ADJ	O	O
AP-1	NOUN	O	O
activation	NOUN	O	O
in	ADP	O	O
non-diseased	VERB	O	O
arterial	ADJ	O	O
wall	NOUN	O	O
(	PUNCT	O	O
i.e	ADV	O	O
.	PUNCT	O	O

vessel	NOUN	O	O
wall	NOUN	O	O
without	ADP	O	O
any	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
atherosclerotic	ADJ	O	O
disease	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
gradual	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
AP-1	NOUN	O	O
activation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
non-progressive	ADJ	O	O
and	CCONJ	O	O
progressive	ADJ	O	O
phases	NOUN	O	O
of	ADP	O	O
atherosclerosis	NOUN	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.044	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
progressive	ADJ	O	O
and	CCONJ	O	O
vulnerable	ADJ	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
phospho-c-Jun	NOUN	O	O
diminished	VERB	O	O
as	PUNCT	O	O
the	DET	O	O
lesion	NOUN	O	O
stabilized	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.016	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
significantly	ADV	O	O
differ	VERB	O	O
from	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
aortic	ADJ	O	O
wall	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.33	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
doxycycline	NOUN	O	O
intervention	NOUN	O	O
only	ADV	O	O
revealed	VERB	O	O
a	DET	O	O
borderline-significant	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
circulating	VERB	O	O
hs-CRP	NOUN	O	O
levels	NOUN	O	O
(	PUNCT	O	O
-0.51	ADP	O	O
?g/ml	PUNCT	O	O
,	PUNCT	O	O
P=0.05	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
did	DET	O	O
not	ADV	O	O
affect	VERB	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
inflammation	NOUN	O	O
and	CCONJ	O	O
vascular	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
studies	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
characterize	ADJ	O	O
AP-1	NOUN	O	O
as	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
target	NOUN	O	O
for	ADP	O	O
progressive	ADJ	O	O
human	NOUN	O	O
atherosclerotic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
of	ADP	O	O
chlorhexidine	NOUN	O	O
gluconate	VERB	O	O
use	NUM	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
perirectal	ADJ	O	O
infections	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
rectal	ADJ	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
is	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

Complications	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
rectal	ADJ	O	O
lesions	NOUN	O	O
may	VERB	O	O
be	ADJ	O	O
severe	ADJ	O	O
enough	DET	O	O
to	ADP	O	O
cause	NOUN	O	O
life-threatening	VERB	O	O
septicemia	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
research	NOUN	O	O
evaluating	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
preventive	ADJ	O	O
perirectal	ADJ	O	O
skin	NOUN	O	O
care	NOUN	O	O
is	ADP	O	O
scarce	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
's	PUNCT	O	O
purpose	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	VERB	O	O
using	PUNCT	O	O
chlorhexidine	NOUN	O	O
gluconate	ADJ	O	O
(	PUNCT	O	O
CHG	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
prophylactic	ADJ	O	O
perirectal	ADJ	O	O
skin-care	NOUN	O	O
regimen	NOUN	O	O
decreases	ADP	O	O
perirectal	ADJ	O	O
infections	NOUN	O	O
and	CCONJ	O	O
whether	ADP	O	O
it	PRON	O	O
produces	NOUN	O	O
more	PUNCT	O	O
skin	NOUN	O	O
irritation	NOUN	O	O
than	PUNCT	O	O
a	DET	O	O
nonmedicated	VERB	O	O
skin	NOUN	O	O
cleanser	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
sample	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
40	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
16	NUM	O	O
of	ADP	O	O
whom	ADP	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
use	PUNCT	O	O
chlorhexidine	PUNCT	O	O
and	CCONJ	O	O
24	NUM	O	O
of	ADP	O	O
whom	ADP	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
use	PUNCT	O	O
nonmedicated	PUNCT	O	O
skin	NOUN	O	O
cleanser	ADJ	O	O
.	PUNCT	O	O

Chi-square	PUNCT	O	O
and	CCONJ	O	O
t-tests	ADV	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
analyze	NOUN	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
skin	NOUN	O	B-PHYSICAL
breakdown	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
rectal	ADJ	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
the	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
factors	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
positive	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
rectal	ADJ	O	O
infections	NOUN	O	O
,	PUNCT	O	O
fissures	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
hemorrhoids	NOUN	O	O
;	PUNCT	O	O
presence	NOUN	O	O
of	ADP	O	O
hemorrhoids	NOUN	O	O
;	PUNCT	O	O
severity	NOUN	O	O
of	ADP	O	O
diarrhea	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
duration	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
granulocytopenia	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
positive	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
severity	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
granulocytopenia	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
rectal	ADJ	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
perirectal	ADJ	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.35	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
skin	NOUN	O	B-PHYSICAL
breakdown	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.18	NUM	O	O
)	PUNCT	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
CHG	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
offer	VERB	O	O
increased	VERB	O	O
protection	NOUN	O	O
against	ADP	O	O
perirectal	ADJ	O	O
infections	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	SYM	O	O
intensive	ADJ	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
nor	CCONJ	O	O
is	VERB	O	O
it	PRON	O	O
more	ADJ	O	O
irritating	PUNCT	O	O
than	PUNCT	O	O
a	DET	O	O
nonmedicated	VERB	O	O
skin	NOUN	O	O
cleanser	ADJ	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	ADV	O	O
needed	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
hygienic	ADJ	O	O
measures	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
using	PUNCT	O	O
skin	NOUN	O	O
disinfectants	NOUN	O	O
to	PART	O	O
prevent	ADJ	O	O
infections	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
are	VERB	O	O
immunocompromised	VERB	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Triple	ADJ	O	O
therapy	NOUN	O	O
regimens	NOUN	O	O
involving	PUNCT	O	O
H2	NOUN	O	O
blockaders	NOUN	O	O
for	ADP	O	O
therapy	NOUN	O	O
of	ADP	O	O
Helicobacter	NOUN	O	B-PHYSICAL
pylori	NOUN	O	I-PHYSICAL
infections	NOUN	O	I-PHYSICAL
]	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

Comparison	NOUN	O	B-OTHER
of	ADP	O	O
ranitidine	NOUN	O	O
and	CCONJ	O	O
lansoprazole	PUNCT	O	O
in	ADP	O	O
short-term	NOUN	O	O
low-dose	NOUN	O	O
triple	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
infection	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
1-week	NOUN	O	O
low-dose	NOUN	O	O
triple-therapy	NOUN	O	O
drug	NOUN	O	O
regimens	NOUN	O	O
involving	PUNCT	O	O
antisecretory	ADJ	O	O
drugs	NOUN	O	O
for	ADP	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
infection	NOUN	O	O
,	PUNCT	O	O
99	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
infection	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
lansoprazole	PUNCT	O	O
(	PUNCT	O	O
LPZ	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ranitidine	NOUN	O	O
(	PUNCT	O	O
RNT	NOUN	O	O
)	PUNCT	O	O
used	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
clarithromycin	NOUN	O	O
(	PUNCT	O	O
CAM	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
metrinidazole	PUNCT	O	O
(	PUNCT	O	O
MTZ	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
drug	NOUN	O	O
combination	NOUN	O	O
and	CCONJ	O	O
administration	NOUN	O	O
periods	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PPI	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
LPZ	NOUN	O	O
30	PUNCT	O	O
mg	NOUN	O	O
,	PUNCT	O	O
CAM	NOUN	O	O
400	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
MTZ	NOUN	O	O
500	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
LCM	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ranitidine	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
RNT	NOUN	O	O
300	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
CAM	NOUN	O	O
400	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
MTZ	NOUN	O	O
500	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
RCM	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
cure	ADV	O	B-OTHER
rate	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
H.	NOUN	O	O
pylori	NOUN	O	B-PHYSICAL
infection	NOUN	O	I-PHYSICAL
was	VERB	O	O
88	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
LCM	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
79-97	NUM	O	O
and	CCONJ	O	O
92	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
RCM	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
84-99	NUM	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Intravenous	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
postpartum	NOUN	O	O
anemia	NOUN	O	O
with	ADP	O	O
trivalent	ADJ	O	O
ferrum	NOUN	O	O
preparation	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
OF	ADP	O	O
THE	DET	O	O
STUDY	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
the	DET	O	O
effectivity	NOUN	O	O
and	CCONJ	O	O
safeness	ADP	O	B-OTHER
of	ADP	O	O
intravenous	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
pospartal	ADJ	O	O
anemia	NOUN	O	O
with	ADP	O	O
trivalent	ADJ	O	O
ferrum	NOUN	O	O
preparation	NOUN	O	O
.	PUNCT	O	O

TYPE	NOUN	O	O
OF	ADP	O	O
THE	DET	O	O
STUDY	NOUN	O	O
Prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
Department	NOUN	O	O
of	ADP	O	O
Obstetric	ADJ	O	O
and	CCONJ	O	O
Gynecology	NOUN	O	O
2nd	ADJ	O	O
Medical	ADJ	O	O
Faculty	NOUN	O	O
Charles	NUM	O	O
University	NOUN	O	O
and	CCONJ	O	O
Teaching	PUNCT	O	O
Hospital	NOUN	O	O
Motol	NOUN	O	O
,	PUNCT	O	O
Prague	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Department	NOUN	O	O
of	ADP	O	O
Obstetric	ADJ	O	O
and	CCONJ	O	O
Gynecology	NOUN	O	O
1st	ADJ	O	O
Medical	ADJ	O	O
Faculty	NOUN	O	O
and	CCONJ	O	O
Teaching	PUNCT	O	O
Hospital	NOUN	O	O
Bulovka	NOUN	O	O
,	PUNCT	O	O
Prague	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
500	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
sacharose	NOUN	O	O
ferric	ADJ	O	O
oxide	NOUN	O	O
(	PUNCT	O	O
Venofer	NOUN	O	O
)	PUNCT	O	O
was	ADV	O	O
intravenously	ADV	O	O
administered	VERB	O	O
in	ADP	O	O
two	NUM	O	O
days	NOUN	O	O
regimen	NOUN	O	O
to	ADP	O	O
50	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
lab	NOUN	O	O
signs	NOUN	O	O
of	ADP	O	O
postpartal	ADJ	O	O
anemia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
administered	VERB	O	O
drug	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
comparsion	NOUN	O	O
of	ADP	O	O
values	NOUN	O	O
of	ADP	O	O
red	ADJ	O	O
blood	NOUN	O	O
count	NOUN	O	O
recovered	VERB	O	O
before	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
2nd	ADJ	O	O
or	CCONJ	O	O
3rd	ADJ	O	O
day	NOUN	O	O
post	PUNCT	O	O
administration	NOUN	O	O
and	CCONJ	O	O
two	NUM	O	O
weeks	NOUN	O	O
later	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
values	NOUN	O	O
of	ADP	O	O
soluble	ADJ	O	O
transferrin	NOUN	O	O
receptors	NOUN	O	O
and	CCONJ	O	O
ferritin	NOUN	O	O
were	VERB	O	O
observed	NUM	O	O
as	ADP	O	O
markers	NOUN	O	O
of	ADP	O	O
iron	NOUN	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
saturation	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
body	NOUN	O	B-PHYSICAL
iron	NOUN	O	I-PHYSICAL
reserves	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
too	ADV	O	O
.	PUNCT	O	O

Integral	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
the	DET	O	O
monitoring	VERB	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
during	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Venofer	VERB	O	O
came	VERB	O	O
in	ADP	O	O
sight	PUNCT	O	O
as	CCONJ	O	O
effective	ADJ	O	O
drug	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
pospartal	ADJ	O	B-PHYSICAL
anemia	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
could	VERB	O	O
become	VERB	O	O
as	ADP	O	O
the	DET	O	O
alternative	ADJ	O	O
to	ADP	O	O
blood	NOUN	O	O
transfusion	NOUN	O	O
in	ADP	O	O
mid-severe	NOUN	O	O
cases	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
should	VERB	O	O
be	VERB	O	O
emphasized	PUNCT	O	O
that	PUNCT	O	O
we	PRON	O	O
have	PUNCT	O	O
not	ADV	O	O
encountered	PUNCT	O	O
any	DET	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
event	NOUN	O	I-ADVERSE-EFFECTS
with	ADP	O	O
intravenous	ADJ	O	O
trivalent	ADJ	O	O
saccharose	NOUN	O	O
ferric	ADJ	O	O
oxide	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
somatostatin	NOUN	O	O
(	PUNCT	O	O
octreotide	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
hypothyroidism	NOUN	O	O
.	PUNCT	O	O

Somatostatin	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
pineal	ADJ	O	O
gland	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
animal	NOUN	O	O
species	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
suggests	NOUN	O	O
that	ADP	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Whether	ADP	O	O
somatostatin	NOUN	O	O
has	PUNCT	O	O
regulatory	ADJ	O	O
influence	NOUN	O	O
on	ADP	O	O
melatonin	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
man	NOUN	O	O
has	PUNCT	O	O
never	ADV	O	O
been	PUNCT	O	O
unequivocally	ADV	O	O
shown	ADP	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
nocturnal	ADJ	O	B-PHYSICAL
melatonin	NOUN	O	I-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
8	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
untreated	VERB	O	O
primary	ADJ	O	O
hypothyroidism	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
disease	NOUN	O	O
state	NOUN	O	O
that	ADP	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	CCONJ	O	O
nocturnal	ADJ	O	O
secretion	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
participants	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
subcutaneous	ADJ	O	O
injections	NOUN	O	O
at	ADP	O	O
18:00	NOUN	O	O
h	NOUN	O	O
and	CCONJ	O	O
23:00	PUNCT	O	O
h	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
saline	ADJ	O	O
or	CCONJ	O	O
octreotide	ADJ	O	O
(	PUNCT	O	O
Sandostatin	NOUN	O	O
;	PUNCT	O	O
each	DET	O	O
injection	NOUN	O	O
50	NUM	O	O
microg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
nights	NOUN	O	O
when	ADP	O	O
the	DET	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
octreotide	NOUN	O	O
,	PUNCT	O	O
melatonin	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
recorded	VERB	O	O
during	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
.	PUNCT	O	O

Also	PUNCT	O	O
the	DET	O	O
urinary	ADJ	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
melatonin	NOUN	O	I-PHYSICAL
was	NUM	O	O
of	ADP	O	O
similar	ADJ	O	O
magnitude	NOUN	O	O
at	ADP	O	O
these	DET	O	O
two	NUM	O	O
occasions	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
GH	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
the	ADP	O	O
nights	ADP	O	O
the	DET	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
octreotide	NOUN	O	O
(	PUNCT	O	O
GH	NOUN	O	O
AUC	NOUN	O	O
22.6+/-5.4	NOUN	O	O
mU/l	PUNCT	O	O
x	SYM	O	O
h	NOUN	O	O
during	ADP	O	O
octreotide	ADJ	O	O
and	CCONJ	O	O
126.6+/-21.9	NUM	O	O
mU/l	PUNCT	O	O
x	SYM	O	O
h	NOUN	O	O
during	ADP	O	O
saline	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
hypothyroidism	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
similar	ADJ	O	O
nocturnal	ADJ	O	B-PHYSICAL
melatonin	NOUN	O	I-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
during	ADP	O	O
octreotide	ADJ	O	O
and	CCONJ	O	O
saline	NOUN	O	O
.	PUNCT	O	O

Urinary	ADJ	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
melatonin	NOUN	O	I-PHYSICAL
also	ADV	O	O
remained	VERB	O	O
unchanged	PROPN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
did	PUNCT	O	O
GH	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
nocturnal	ADJ	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
TSH	NOUN	O	I-PHYSICAL
was	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
significantly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
octreotide	NOUN	O	O
(	PUNCT	O	O
TSH	NOUN	O	O
AUC	NOUN	O	O
562+/-136	PUNCT	O	O
mU/l	PUNCT	O	O
x	SYM	O	O
h	NOUN	O	O
during	ADP	O	O
octreotide	ADJ	O	O
and	CCONJ	O	O
851+/-185	PUNCT	O	O
mU/l	PUNCT	O	O
x	SYM	O	O
h	NOUN	O	O
during	ADP	O	O
saline	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
thus	ADV	O	O
suggesting	VERB	O	O
that	ADP	O	O
100	NUM	O	O
microg	NOUN	O	O
of	ADP	O	O
octreotide	PUNCT	O	O
should	VERB	O	O
be	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
inhibit	NOUN	O	O
also	ADV	O	O
the	DET	O	O
pinealocytes	ADJ	O	O
if	PUNCT	O	O
their	VERB	O	O
function	NOUN	O	O
were	VERB	O	O
regulated	VERB	O	O
by	ADP	O	O
somatostatin	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
exogenous	ADJ	O	O
somatostatin	NOUN	O	O
--	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
octreotide	ADJ	O	O
--	PUNCT	O	O
fails	NOUN	O	O
to	PART	O	O
influence	ADJ	O	O
nocturnal	ADJ	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
urinary	ADJ	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
melatonin	NOUN	O	I-PHYSICAL
in	ADP	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
hypothyroidism	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
reasonable	ADJ	O	O
to	PART	O	O
assume	PUNCT	O	O
that	ADP	O	O
endogenous	ADJ	O	O
somatostatin	NOUN	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
regulator	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	O
secretion	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Is	PUNCT	O	O
anti-Pseudomonas	NOUN	O	O
therapy	NOUN	O	O
warranted	ADJ	O	O
in	ADP	O	O
acute	ADJ	O	O
respiratory	ADJ	O	B-PHYSICAL
exacerbations	NOUN	O	I-PHYSICAL
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
cystic	ADJ	O	O
fibrosis	NOUN	O	O
?	PUNCT	O	O

A	DET	O	O
controlled	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
clarify	NOUN	O	O
the	DET	O	O
indications	NOUN	O	O
for	ADP	O	O
antibiotic	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
cystic	ADJ	O	O
fibrosis	NOUN	O	O
hospitalized	VERB	O	O
with	ADP	O	O
respiratory	ADJ	O	O
exacerbations	NOUN	O	O
.	PUNCT	O	O

Twenty-two	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
CF	NOUN	O	O
and	CCONJ	O	O
signs	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
lower	PUNCT	O	O
respiratory	ADJ	O	O
infection	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
cloxacillin	NOUN	O	O
or	CCONJ	O	O
carbenicillin	NOUN	O	O
plus	CCONJ	O	O
gentamicin	NOUN	O	O
administered	ADP	O	O
intravenously	ADV	O	O
for	ADP	O	O
ten	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Other	ADJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
were	VERB	O	O
constant	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
groups	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
all	DET	O	O
respects	ADP	O	O
and	CCONJ	O	O
Pseudomonas	NOUN	O	O
aeruginosa	NOUN	O	O
was	VERB	O	O
the	DET	O	O
predominant	ADJ	O	O
sputum	NOUN	O	O
pathogen	NOUN	O	O
in	ADP	O	O
most	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
chest	NOUN	O	B-PHYSICAL
radiograph	NOUN	O	I-PHYSICAL
changes	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
evidence	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
airway	NOUN	O	I-PHYSICAL
obstruction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Placebo-controlled	DET	O	O
acute	ADJ	O	O
dosage	NOUN	O	O
naltrexone	NUM	O	O
study	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
autistic	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
23	NUM	O	O
autistic	ADJ	O	O
children	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
40-mg	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
opiate	ADJ	O	O
antagonist	NOUN	O	O
naltrexone	NUM	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
by	ADP	O	O
detailed	ADV	O	O
playroom	NOUN	O	O
observations	NOUN	O	O
,	PUNCT	O	O
actometers	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
parents	NOUN	O	O
'	PUNCT	O	O
checklist	NOUN	O	O
ratings	NOUN	O	O
(	PUNCT	O	O

Infliximab	NOUN	O	O
in	ADP	O	O
ankylosing	ADP	O	O
spondylitis	ADJ	O	O
:	PUNCT	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
methotrexate	NOUN	O	O
?	PUNCT	O	O

A	DET	O	O
pharmacokinetic	ADJ	O	O
comparative	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Methotrexate	NOUN	O	O
(	PUNCT	O	O
MTX	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
modify	PUNCT	O	O
infliximab	NOUN	O	O
pharmacokinetics	NOUN	O	O
in	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
its	PUNCT	O	O
combination	NOUN	O	O
with	ADP	O	O
infliximab	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
ankylosing	ADP	O	O
spondylitis	ADJ	O	O
(	PUNCT	O	O
AS	ADP	O	O
)	PUNCT	O	O
is	VERB	O	O
not	ADV	O	O
recommended	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
MTX	NOUN	O	O
on	ADP	O	O
infliximab	NOUN	O	O
exposure	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
AS	CCONJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
AS	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
predominantly	ADV	O	O
axial	ADJ	O	O
symptoms	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
infliximab	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
infusions	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg/kg	NOUN	O	O
at	ADP	O	O
weeks	NOUN	O	O
0	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
infliximab	NOUN	O	O
combined	PROPN	O	O
with	ADP	O	O
MTX	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg/week	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Infliximab	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
2	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
each	DET	O	O
infusion	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
14	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
estimated	PUNCT	O	O
individual	VERB	O	O
cumulative	ADJ	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
versus	CCONJ	O	O
time	NOUN	O	O
curves	NOUN	O	O
(	PUNCT	O	O
AUC	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
infliximab	NOUN	O	B-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
between	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
week	NOUN	O	O
18	NUM	O	O
(	PUNCT	O	O
AUC	NOUN	O	O
(	PUNCT	O	O
0-18	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
evaluations	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
each	DET	O	O
visit	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Bath	NOUN	O	B-OTHER
Ankylosing	VERB	O	I-OTHER
Spondylitis	ADP	O	I-OTHER
Disease	NOUN	O	I-OTHER
Activity	NOUN	O	I-OTHER
Index	NOUN	O	O
(	PUNCT	O	B-OTHER
BASDAI	NOUN	O	I-OTHER
)	PUNCT	O	B-OTHER
score	NOUN	O	O
was	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty-six	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
(	PUNCT	O	O
infliximab	NOUN	O	O
group	NOUN	O	O
:	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
,	PUNCT	O	O
infliximab	NOUN	O	O
+	DET	O	O
MTX	NOUN	O	O
group	NOUN	O	O
:	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
14	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
507	NUM	O	O
serum	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
measurement	NOUN	O	O
of	ADP	O	O
infliximab	NOUN	O	B-PHYSICAL
concentration	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
did	ADP	O	O
not	ADV	O	O
differ	VERB	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
AUC	NOUN	O	B-OTHER
(	PUNCT	O	B-PHYSICAL

Comparative	ADJ	O	B-PHYSICAL
bioavailability	NOUN	O	I-PHYSICAL
of	ADP	O	O
two	NUM	O	O
formulations	NOUN	O	O
of	ADP	O	O
terbinafine	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
from	ADP	O	O
a	DET	O	O
cross-over	NOUN	O	O
,	PUNCT	O	O
randomised	ADP	O	O
,	PUNCT	O	O
open-label	NOUN	O	O
bioequivalence	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
open-label	NOUN	O	O
,	PUNCT	O	O
randomised	VERB	O	O
,	PUNCT	O	O
cross-over	ADP	O	O
single	ADJ	O	O
dose	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
2	NUM	O	O
periods	NOUN	O	O
x	SYM	O	O
2	NUM	O	O
sequences	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
washout	PUNCT	O	O
period	NOUN	O	O
of	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
comparative	ADJ	O	B-PHYSICAL
bioavailability	NOUN	O	I-PHYSICAL
of	ADP	O	O
two	NUM	O	O
formulations	NOUN	O	O
of	ADP	O	O
terbinafine	NOUN	O	O
(	PUNCT	O	O
CAS	NOUN	O	O
78628-80-5	PUNCT	O	O
)	PUNCT	O	O
250	NUM	O	O
mg	NOUN	O	O
tablets	ADV	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
samples	NOUN	O	I-PHYSICAL
were	VERB	O	O
obtained	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
+0.333	ADJ	O	O
;	PUNCT	O	O
0.667	NUM	O	O
;	PUNCT	O	O
1.00	ADV	O	O
;	PUNCT	O	O
1.33	NUM	O	O
;	PUNCT	O	O
1.67	NUM	O	O
;	PUNCT	O	O
2.00	NUM	O	O
;	PUNCT	O	O
2.33	ADV	O	O
;	PUNCT	O	O
2.67	NUM	O	O
;	PUNCT	O	O
3.00	ADV	O	O
;	PUNCT	O	O
3.50	ADV	O	O
;	PUNCT	O	O
4.00	ADV	O	O
;	PUNCT	O	O
6.00	ADV	O	O
;	PUNCT	O	O
8.00	ADV	O	O
;	PUNCT	O	O
12.0	NUM	O	O
;	PUNCT	O	O
24.0	NUM	O	O
;	PUNCT	O	O
36.0	NUM	O	O
;	PUNCT	O	O
48.0	NUM	O	O
and	CCONJ	O	O
72.0	NUM	O	O
h	NOUN	O	O
post-administration	NOUN	O	O
.	PUNCT	O	O

Terbinafine	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
high	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
liquid	NOUN	O	I-PHYSICAL
chromatography	NOUN	O	I-PHYSICAL
with	ADP	O	O
tandem	NOUN	O	O
mass	NOUN	O	O
detection	NOUN	O	O
(	PUNCT	O	O
HPLC-MS/MS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
lower	PUNCT	O	O
limit	NOUN	O	O
of	ADP	O	O
quantification	NOUN	O	O
was	VERB	O	O
set	ADP	O	O
at	ADP	O	O
9.99	NUM	O	O
ng/mL	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pharmacokinetic	ADJ	O	B-OTHER
parameters	NOUN	O	I-OTHER
used	VERB	O	O
for	ADP	O	O
the	DET	O	O
bioequivalence	NOUN	O	B-MENTAL
assessment	NOUN	O	I-MENTAL
(	PUNCT	O	O
AUClast	NOUN	O	B-MENTAL
,	PUNCT	O	O
AUCinf	PUNCT	O	B-MENTAL
and	CCONJ	O	O
Cmax	NOUN	O	B-MENTAL
)	PUNCT	O	O
were	VERB	O	O
determined	VERB	O	O
from	ADP	O	O
the	DET	O	O
terbinafine	NOUN	O	O
concentration	NOUN	O	O
data	NOUN	O	O
using	PRON	O	O
non-compartmental	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Bilateral	ADJ	O	O
transversus	PUNCT	O	O
abdominis	NOUN	O	O
plane	NOUN	O	O
block	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
decrease	NUM	O	O
postoperative	ADJ	O	O
pain	NOUN	O	O
after	ADP	O	O
laparoscopic	ADJ	O	O
cholecystectomy	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
local	ADJ	O	O
anesthetic	ADJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
trocar	PUNCT	O	O
insertion	NOUN	O	O
sites	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVES	NOUN	O	O
Transversus	PUNCT	O	O
abdominis	NOUN	O	O
plane	NOUN	O	O
(	PUNCT	O	O
TAP	NOUN	O	O
)	PUNCT	O	O
block	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
pain	NOUN	O	O
and	CCONJ	O	O
analgesic	ADP	O	O
requirements	NOUN	O	O
after	ADP	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Our	VERB	O	O
hypothesis	NOUN	O	O
was	VERB	O	O
that	ADP	O	O
bilateral	PUNCT	O	O
TAP	NOUN	O	O
blocks	NOUN	O	O
decrease	NOUN	O	O
pain	NOUN	O	O
after	ADP	O	O
laparoscopic	ADJ	O	O
cholecystectomy	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
local	ADJ	O	O
anesthetic	ADJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
trocar	PUNCT	O	O
insertion	NOUN	O	O
sites	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Eighty	PUNCT	O	O
patients	NOUN	O	O
undergoing	SYM	O	O
laparoscopic	PUNCT	O	O
cholecystectomy	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	ADP	O	O
either	PUNCT	O	O
bilateral	PUNCT	O	O
TAP	NOUN	O	O
blocks	DET	O	O
or	CCONJ	O	O
local	ADJ	O	O
anesthetic	ADJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
trocar	PUNCT	O	O
insertion	NOUN	O	O
sites	NOUN	O	O
with	ADP	O	O
ropivacaine	NOUN	O	O
0.5	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
scores	NOUN	O	O
and	CCONJ	O	O
analgesic	PUNCT	O	O
use	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
hrs	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Eighty	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
exclusions	NOUN	O	O
,	PUNCT	O	O
data	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
on	ADP	O	O
39	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
T	NOUN	O	O
(	PUNCT	O	O
bilateral	ADJ	O	O
TAP	NOUN	O	O
block	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
35	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
infiltration	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	B-PHYSICAL
in	ADP	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
on	ADP	O	I-PAIN
the	DET	O	I-PAIN
numeric	ADJ	O	I-PAIN
analog	NOUN	O	I-PAIN
scale	NOUN	O	O
(	PUNCT	O	O
0-10	NUM	O	O
)	PUNCT	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
hrs	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.18	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
24	NUM	O	O
hrs	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.23	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	B-OTHER
interval	NOUN	O	I-OTHER
from	ADP	O	I-OTHER
anesthesia	NOUN	O	I-OTHER
start	ADJ	O	I-OTHER
to	ADP	O	I-OTHER
surgery	NOUN	O	I-OTHER
start	NOUN	O	I-OTHER
was	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
T	NOUN	O	O
than	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
48	NUM	O	O
vs	CCONJ	O	O
35	NUM	O	O
mins	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	B-PHYSICAL
difference	NOUN	O	I-PHYSICAL
found	VERB	O	O
in	ADP	O	O
analgesic	CCONJ	O	B-OTHER
use	NOUN	O	I-OTHER
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
hrs	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Bilateral	ADJ	O	O
ultrasound-guided	VERB	O	O
TAP	NOUN	O	O
block	NOUN	O	O
is	VERB	O	O
equivalent	ADJ	O	O
to	ADP	O	O
local	PUNCT	O	O
anesthetic	ADJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
trocar	PUNCT	O	O
insertion	NOUN	O	O
sites	NOUN	O	O
for	ADP	O	O
overall	PUNCT	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
in	ADP	O	O
a	DET	O	O
heterogeneous	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
undergoing	SYM	O	O
laparoscopic	PUNCT	O	O
cholecystectomy	NOUN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
ganciclovir	NOUN	O	O
dosing	NUM	O	O
in	ADP	O	O
transplant	ADJ	O	O
recipients	NOUN	O	O
and	CCONJ	O	O
dialysis	NOUN	O	O
patients	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
An	DET	O	O
oral	ADJ	O	O
formulation	NOUN	O	O
of	ADP	O	O
ganciclovir	NOUN	O	O
(	PUNCT	O	O
GCV	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
recently	ADV	O	O
approved	VERB	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
cytomegalovirus	NOUN	O	O
disease	NOUN	O	O
in	ADP	O	O
solid	ADJ	O	O
organ	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
bioavailability	NOUN	O	O
of	ADP	O	O
GCV	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
test	NOUN	O	O
a	DET	O	O
dosing	VERB	O	O
algorithm	NOUN	O	O
in	ADP	O	O
transplant	NOUN	O	O
and	CCONJ	O	O
dialysis	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Pharmacokinetic	ADJ	O	O
studies	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
in	ADP	O	O
23	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
either	PUNCT	O	O
a	DET	O	O
recipient	NOUN	O	O
of	ADP	O	O
an	DET	O	O
organ	NOUN	O	O
transplant	NOUN	O	O
or	CCONJ	O	O
on	ADP	O	O
hemodialysis	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
dosing	VERB	O	O
was	VERB	O	O
established	VERB	O	O
by	ADP	O	O
the	DET	O	O
following	VERB	O	O
algorithm	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
calculated	VERB	O	O
creatinine	NOUN	O	O
clearance	NOUN	O	O
(	PUNCT	O	O
CrCl	ADJ	O	O
)	PUNCT	O	O
:	PUNCT	O	O
CrCl	ADJ	O	O
=	ADJ	O	O
[	PUNCT	O	O
(	PUNCT	O	O
140-age	NOUN	O	O
)	PUNCT	O	O
x	SYM	O	O
body	NOUN	O	O
weight	NOUN	O	O
]	PUNCT	O	O
/	SYM	O	O
(	PUNCT	O	O
72	NUM	O	O
x	PUNCT	O	O
Cr	NOUN	O	O
)	PUNCT	O	O
x	SYM	O	O
0.85	NUM	O	O
for	ADP	O	O
women	NOUN	O	O
that	PUNCT	O	O
is	VERB	O	O
,	PUNCT	O	O
CrCl	ADJ	O	O
>	SYM	O	O
50	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
1000	NUM	O	O
mg	NOUN	O	O
every	DET	O	O
8	NUM	O	O
hr	NOUN	O	O
;	PUNCT	O	O
CrCl	NOUN	O	O
of	ADP	O	O
25-50	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
1000	NUM	O	O
mg	NOUN	O	O
every	DET	O	O
24	NUM	O	O
hr	NOUN	O	O
;	PUNCT	O	O
CrCl	NOUN	O	O
of	ADP	O	O
10-24	NUM	O	O
ml/	NOUN	O	O
min	NOUN	O	O
,	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
every	DET	O	O
day	NOUN	O	O
;	PUNCT	O	O
CrCl	ADJ	O	O
<	SYM	O	O
10	NUM	O	O
ml/min	NOUN	O	O
(	PUNCT	O	O
or	CCONJ	O	O
on	ADP	O	O
dialysis	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
after	ADP	O	O
dialysis	NOUN	O	O
.	PUNCT	O	O

GCV	NOUN	O	O
was	VERB	O	O
taken	VERB	O	O
within	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
a	DET	O	O
meal	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
received	ADP	O	O
oral	ADJ	O	O
GCV	NOUN	O	O
for	ADP	O	O
between	ADP	O	O
12	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
14	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	O
specimens	NOUN	O	O
(	PUNCT	O	O
or	CCONJ	O	O
plasma	NOUN	O	O
from	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
hemodialysis	NOUN	O	O
)	PUNCT	O	O
obtained	VERB	O	O
at	ADP	O	O
steady	ADJ	O	O
state	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
for	ADP	O	O
GCV	NOUN	O	O
concentrations	NOUN	O	O
by	ADP	O	O
high-performance	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
nine	NUM	O	O
of	ADP	O	O
the	DET	O	O
transplant	ADJ	O	O
recipients	NOUN	O	O
,	PUNCT	O	O
absolute	ADJ	O	B-PHYSICAL
bioavailability	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
comparing	PUNCT	O	O
GCV	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
after	ADP	O	O
single	ADJ	O	O
oral	ADJ	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
GCV	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
following	ADJ	O	O
GCV	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
mean	NOUN	O	O
+/-SD	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
determined	VERB	O	O
:	PUNCT	O	O
with	ADP	O	O
CrCl	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=70	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
minimum	NOUN	O	O
steady-state	NOUN	O	O
concentration	NOUN	O	O
(	PUNCT	O	O
Cmin	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
maximum	NOUN	O	O
concentration	NOUN	O	O
(	PUNCT	O	O
Cmax	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
0.78+/-0.46	PUNCT	O	O
microg/ml	NOUN	O	O
and	CCONJ	O	O
1.42+/-0.37	ADV	O	O
microg/ml	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
24-hr	NOUN	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
time	NOUN	O	O
curve	NOUN	O	O
(	PUNCT	O	O
AUC0-24	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
24.7+/-7.8	NUM	O	O
microg	NOUN	O	O
x	SYM	O	O
hr/ml	NOUN	O	O
;	PUNCT	O	O
with	ADP	O	O
CrCl	NOUN	O	O
of	ADP	O	O
50-69	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Cmin	NOUN	O	O
and	CCONJ	O	O
Cmax	NOUN	O	O
were	VERB	O	O
1.93+/-0.48	ADV	O	O
and	CCONJ	O	O
2.57+/-0.39	NOUN	O	O
microg/ml	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
AUC0-24	NOUN	O	O
of	ADP	O	O
52.1+/-10.1	NUM	O	O
microg	NOUN	O	O
x	SYM	O	O
hr/ml	NOUN	O	O
;	PUNCT	O	O
with	ADP	O	O
CrCl	NOUN	O	O
of	ADP	O	O
25-50	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Cmin	NOUN	O	O
and	CCONJ	O	O
Cmax	NOUN	O	O
were	VERB	O	O
0.41+/-0.27	ADV	O	O
and	CCONJ	O	O
1.17+/-0.32	NOUN	O	O
microg/ml	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
AUC0-24	NOUN	O	O
of	ADP	O	O
14.6+/-7.4	NOUN	O	O
microg	NOUN	O	O
x	SYM	O	O
hr/ml	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
CrCl	NOUN	O	O
of	ADP	O	O
23.8	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Cmin	NOUN	O	O
and	CCONJ	O	O
Cmax	NOUN	O	O
were	VERB	O	O
0.32	NUM	O	O
and	CCONJ	O	O
0.7	NUM	O	O
microg/ml	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
AUC0-24	NOUN	O	O
of	ADP	O	O
10.7	NUM	O	O
microg	NOUN	O	O
x	SYM	O	O
hr/ml	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
CrCl	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
10	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
Cmin	NOUN	O	O
and	CCONJ	O	O
Cmax	NOUN	O	O
were	VERB	O	O
0.75+/-0.42	PUNCT	O	O
and	CCONJ	O	O
1.59+/-0.55	ADV	O	O
microg/ml	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
AUC0-24	NOUN	O	O
of	ADP	O	O
64.6+/-18.8	PUNCT	O	O
microg	NOUN	O	O
x	SYM	O	O
hr/ml	NOUN	O	O
.	PUNCT	O	O

Absolute	ADJ	O	B-PHYSICAL
bioavailability	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
nine	NUM	O	O
patients	NOUN	O	O
so	ADP	O	O
analyzed	ADP	O	O
,	PUNCT	O	O
was	VERB	O	O
7.2+/-2.4	PUNCT	O	O
%	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
those	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
end-stage	NOUN	O	O
renal	ADJ	O	O
failure	NOUN	O	O
,	PUNCT	O	O
GCV	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
fell	VERB	O	O
during	ADP	O	O
dialysis	NOUN	O	O
from	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
1.47+/-0.48	PUNCT	O	O
microg/ml	NOUN	O	O
before	ADP	O	O
dialysis	NOUN	O	O
to	VERB	O	O
0.69+/-0.38	PUNCT	O	O
microg/ml	NOUN	O	O
after	ADP	O	O
dialysis	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
bioavailability	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
GCV	NOUN	O	O
in	ADP	O	O
transplant	ADJ	O	O
patients	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
observed	VERB	O	O
in	ADP	O	O
human	NOUN	O	O
immunodeficiency	NOUN	O	O
virus-infected	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
levels	NOUN	O	O
between	ADP	O	O
0.5	NUM	O	O
and	CCONJ	O	O
1	NUM	O	O
microg/ml	NOUN	O	O
(	PUNCT	O	O
within	ADP	O	O
the	DET	O	O
IC50	NOUN	O	O
of	ADP	O	O
most	CCONJ	O	O
cytomegalovirus	NOUN	O	O
isolates	NOUN	O	O
)	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
with	ADP	O	O
tolerable	ADJ	O	O
oral	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
proposed	VERB	O	O
dosing	VERB	O	O
algorithm	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
adequate	ADJ	O	O
levels	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
CrCl	ADJ	O	O
greater	PUNCT	O	O
than	VERB	O	O
50	NUM	O	O
ml/min	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
dialysis	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
CrCl	ADJ	O	O
between	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
ml/min	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
levels	NOUN	O	O
achieved	VERB	O	O
were	VERB	O	O
low	ADJ	O	O
and	CCONJ	O	O
these	DET	O	O
patients	NOUN	O	O
would	ADP	O	O
likely	PUNCT	O	O
benefit	NOUN	O	O
from	ADP	O	O
increased	VERB	O	O
doses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
aging	VERB	O	O
on	ADP	O	O
circulating	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
proinflammatory	ADJ	O	O
cytokines	NOUN	O	O
during	ADP	O	O
septic	ADJ	O	O
shock	NOUN	O	O
.	PUNCT	O	O

Norasept	PUNCT	O	O
II	NUM	O	O
Study	NOUN	O	O
Investigators	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
As	ADP	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
population	NOUN	O	O
that	ADP	O	O
is	VERB	O	O
older	PUNCT	O	O
continues	VERB	O	O
to	PUNCT	O	O
rise	NOUN	O	O
,	PUNCT	O	O
infection	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
people	NOUN	O	O
has	PUNCT	O	O
become	VERB	O	O
an	DET	O	O
important	ADJ	O	O
healthcare	NOUN	O	O
problem	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
aging	ADP	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
multiple	ADJ	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
immune	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
aging	VERB	O	O
on	ADP	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
proinflammatory	ADJ	O	B-PHYSICAL
cytokines	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	PUNCT	O	O
well	PUNCT	O	O
studied	CCONJ	O	O
under	ADP	O	O
conditions	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
aging	VERB	O	O
on	ADP	O	O
circulating	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
the	DET	O	O
proinflammatory	ADJ	O	O
cytokines	NOUN	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
cohort	NOUN	O	O
of	ADP	O	O
septic	ADJ	O	O
shock	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
aging	ADV	O	O
would	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
diminished	VERB	O	O
proinflammatory	ADJ	O	O
cytokine	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
sepsis	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
septic	ADJ	O	O
shock	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
limb	NOUN	O	O
of	ADP	O	O
the	DET	O	O
North	NOUN	O	O
American	ADJ	O	O
Sepsis	NOUN	O	O
Trial	NOUN	O	O
(	PUNCT	O	O
NORASEPT	NOUN	O	O
II	NUM	O	O
)	PUNCT	O	O
study	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
The	DET	O	O
intensive	ADJ	O	O
care	NOUN	O	O
units	NOUN	O	O
of	ADP	O	O
105	NUM	O	O
hospitals	PROPN	O	O
in	ADP	O	O
the	DET	O	O
United	ADV	O	O
States	NOUN	O	O
and	CCONJ	O	O
Canada	PUNCT	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
Nine	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
thirty	NUM	O	O
patients	NOUN	O	O
presenting	ADJ	O	O
to	ADP	O	O
hospital	NOUN	O	O
within	ADP	O	O
12	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
septic	ADJ	O	O
shock	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
Interleukin-6	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
IL-6	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
tumor	NOUN	O	B-PHYSICAL
necrosis	NOUN	O	I-PHYSICAL
factor-alpha	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
TNF-alpha	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
soluble	ADJ	O	B-PHYSICAL
tumor	NOUN	O	I-PHYSICAL
necrosis	NOUN	O	I-PHYSICAL
factor-receptor-55	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
sTNF-R55	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
soluble	ADJ	O	B-PHYSICAL
tumor	NOUN	O	I-PHYSICAL
necrosis	NOUN	O	I-PHYSICAL
factor-receptor-75	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
sTNF-R75	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
enrollment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	ADV	O	O
population	NOUN	O	O
was	ADP	O	O
broken	NUM	O	O
down	ADJ	O	O
into	ADP	O	O
five	NUM	O	O
age	NOUN	O	O
groups	NOUN	O	O
as	ADP	O	O
follows	VERB	O	O
:	PUNCT	O	O
less	ADV	O	O
than	ADP	O	O
50	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
one	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
50	NUM	O	O
to	ADP	O	O
64	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
two	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
65	NUM	O	O
to	ADP	O	O
74	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
three	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
75	NUM	O	O
to	ADP	O	O
84	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
four	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
85	NUM	O	O
or	CCONJ	O	O
older	PUNCT	O	O
(	PUNCT	O	O
group	NOUN	O	O
five	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-OTHER
,	PUNCT	O	O
demographic	ADJ	O	B-OTHER
,	PUNCT	O	O
and	PUNCT	O	O

Perceptual	ADJ	O	B-MENTAL
learning	PUNCT	O	I-MENTAL
of	ADP	O	I-MENTAL
speech	NOUN	O	I-MENTAL
under	ADP	O	O
optimal	ADJ	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Humans	NOUN	O	O
have	CCONJ	O	O
a	DET	O	O
remarkable	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
understand	CCONJ	O	O
spoken	PUNCT	O	O
language	NOUN	O	O
despite	ADP	O	O
the	DET	O	O
large	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
variability	NOUN	O	O
in	ADP	O	O
speech	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
research	NOUN	O	O
has	PUNCT	O	O
shown	VERB	O	O
that	ADP	O	O
listeners	NOUN	O	O
can	VERB	O	O
use	ADV	O	O
lexical	ADJ	O	O
information	NOUN	O	O
to	PART	O	O
guide	NOUN	O	O
their	ADP	O	O
interpretation	NOUN	O	O
of	ADP	O	O
atypical	ADJ	O	O
sounds	NOUN	O	O
in	ADP	O	O
speech	NOUN	O	O
(	PUNCT	O	O
Norris	NOUN	O	O
,	PUNCT	O	O
McQueen	PUNCT	O	O
,	PUNCT	O	O
&	CCONJ	O	O
Cutler	PUNCT	O	O
,	PUNCT	O	O
2003	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
kind	ADV	O	O
of	ADP	O	O
lexically	ADV	O	O
induced	ADJ	O	O
perceptual	ADJ	O	B-MENTAL
learning	ADV	O	I-MENTAL
enables	NUM	O	O
people	NOUN	O	O
to	PUNCT	O	O
adjust	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
variations	NOUN	O	O
in	ADP	O	O
utterances	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
talker-specific	ADJ	O	O
characteristics	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
individual	ADJ	O	O
identity	NOUN	O	O
and	CCONJ	O	O
dialect	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
investigated	ADP	O	O
perceptual	ADJ	O	B-MENTAL
learning	PROPN	O	I-MENTAL
in	ADP	O	O
two	NUM	O	O
optimal	ADJ	O	O
conditions	NOUN	O	O
:	PUNCT	O	O
conversational	ADJ	O	O
speech	NOUN	O	O
(	PUNCT	O	O
Experiment	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
clear	ADJ	O	O
speech	NOUN	O	O
(	PUNCT	O	O
Experiment	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
adverse	ADJ	O	O
conditions	NOUN	O	O
:	PUNCT	O	O
noise	NOUN	O	O
(	PUNCT	O	O
Experiment	NOUN	O	O
3a	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
two	NUM	O	O
cognitive	ADJ	O	O
loads	NOUN	O	O
(	PUNCT	O	O
Experiments	PROPN	O	O
4a	NOUN	O	O
and	CCONJ	O	O
4b	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Perceptual	ADJ	O	B-MENTAL
learning	PUNCT	O	I-MENTAL
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
optimal	ADJ	O	O
conditions	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
cognitive	ADJ	O	O
load	ADP	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
noise	ADJ	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
perceptual	ADJ	O	B-MENTAL
learning	PUNCT	O	I-MENTAL
occurred	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
of	ADP	O	O
two	NUM	O	O
sessions	NOUN	O	O
for	ADP	O	O
each	DET	O	O
participant	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
only	ADV	O	O
for	ADP	O	O
atypical	ADJ	O	O
/s/	PUNCT	O	O
sounds	NOUN	O	O
and	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
atypical	ADJ	O	O
/f/	PUNCT	O	O
sounds	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
learning	ADV	O	O
and	CCONJ	O	O
nonlearning	PUNCT	O	O
reflects	PUNCT	O	O
a	DET	O	O
balance	NOUN	O	O
between	ADP	O	O
flexibility	NOUN	O	O
and	CCONJ	O	O
stability	NOUN	O	O
that	ADP	O	O
the	DET	O	O
speech	NOUN	O	O
system	NOUN	O	O
must	VERB	O	O
have	PUNCT	O	O
to	PART	O	O
deal	ADV	O	O
with	ADP	O	O
speech	NOUN	O	O
variability	NOUN	O	O
in	ADP	O	O
the	DET	O	O
diverse	ADJ	O	O
conditions	NOUN	O	O
that	PUNCT	O	O
speech	NOUN	O	O
is	VERB	O	O
encountered	VERB	O	O
.	PUNCT	O	O

Oesophageal	ADJ	O	O
intubation	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
undetected	VERB	O	O
by	ADP	O	O
auscultation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
chest	NOUN	O	O
.	PUNCT	O	O

Prompt	NOUN	O	O
detection	NOUN	O	O
of	ADP	O	O
oesophageal	ADJ	O	O
intubation	NOUN	O	O
is	VERB	O	O
a	DET	O	O
primary	ADJ	O	O
concern	NOUN	O	O
in	ADP	O	O
anaesthetic	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
blind	NOUN	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
evaluates	VERB	O	O
three	NUM	O	O
widely	ADV	O	O
used	NUM	O	O
tests	NOUN	O	O
of	ADP	O	O
intubation	NOUN	O	O
.	PUNCT	O	O

Forty	CCONJ	O	O
patients	NOUN	O	O
had	ADP	O	O
both	CCONJ	O	O
their	PUNCT	O	O
trachea	NOUN	O	O
and	CCONJ	O	O
oesophagus	NOUN	O	O
intubated	PUNCT	O	O
,	PUNCT	O	O
each	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
twice	ADV	O	O
.	PUNCT	O	O

Auscultation	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
epigastrium	NOUN	O	I-OTHER
,	PUNCT	O	O
right	ADP	O	O
and	CCONJ	O	O
left	ADJ	O	O
axilla	NOUN	O	O
is	VERB	O	O
more	ADV	O	O
reliable	ADJ	O	O
than	PUNCT	O	O
auscultation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
chest	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
anaesthetist	NOUN	O	O
's	PUNCT	O	O
feeling	ADP	O	O
when	ADP	O	O
he	NOUN	O	O
squeezes	ADP	O	O
the	DET	O	O
bag	NOUN	O	O
.	PUNCT	O	O

P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O
=	SYM	O	O
0.048	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
tests	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
after	ADP	O	O
gastric	ADJ	O	O
distension	NOUN	O	O
with	ADP	O	O
gas	NOUN	O	O
had	PUNCT	O	O
occurred	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
auscultation	NOUN	O	O
of	ADP	O	O
epigastrium	NOUN	O	O
,	PUNCT	O	O
right	ADP	O	O
and	CCONJ	O	O
left	ADJ	O	O
axilla	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
adrenocorticotrophic	ADJ	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
4-9	PUNCT	O	O
)	PUNCT	O	O
analog	NOUN	O	O
ORG	NOUN	O	O
2766	NUM	O	O
in	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
:	PUNCT	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
organization	NOUN	O	O
of	ADP	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
14	NUM	O	O
autistic	ADJ	O	O
children	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
neuropeptide	NOUN	O	O
ORG	NOUN	O	O
2766	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
synthetic	ADJ	O	O
analog	NOUN	O	O
of	ADP	O	O
adrenocorticotrophic	ADJ	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
ACTH	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
4-9	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ORG	NOUN	O	O
2766	NUM	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
during	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
amount	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
improved	VERB	O	O
quality	NOUN	O	O
of	ADP	O	O
the	DET	O	O
social	ADJ	O	O
interaction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
autistic	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
a	DET	O	O
familiar	PUNCT	O	O
experimenter	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
interaction	NOUN	O	O
were	VERB	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
.	PUNCT	O	O

Following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
ORG	NOUN	O	O
2766	NUM	O	O
gaze	NOUN	O	O
and	PUNCT	O	O

Randomized	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
chlorambucil	NOUN	O	O
(	PUNCT	O	O
CB	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
interferon	NOUN	O	O
(	PUNCT	O	O
alfa-2b	NOUN	O	O
)	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
CB	NOUN	O	O
in	ADP	O	O
low-grade	NOUN	O	O
non-Hodgkin	NOUN	O	O
's	PUNCT	O	O
lymphoma	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
interim	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

Non-Hodgkin	NOUN	O	O
's	PUNCT	O	O
Lymphoma	NOUN	O	O
Cooperative	ADJ	O	O
Study	NOUN	O	O
Group	NOUN	O	O
.	PUNCT	O	O

Alpha	NOUN	O	O
interferon	NOUN	O	O
has	PUNCT	O	O
shown	VERB	O	O
initial	PUNCT	O	O
promise	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
low-grade	NOUN	O	O
non-Hodgkin	NOUN	O	O
's	PUNCT	O	O
lymphoma	NOUN	O	O
(	PUNCT	O	O
NHL	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
especially	ADV	O	O
with	ADP	O	O
the	DET	O	O
nodular	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
enrolled	ADP	O	O
70	NUM	O	O
NHL	NOUN	O	O
patients	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
either	PUNCT	O	O
chlorambucil	NOUN	O	O
(	PUNCT	O	O
CB	NOUN	O	O
;	PUNCT	O	O
10	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
CB	NOUN	O	O
plus	CCONJ	O	O
interferon	NOUN	O	O
alfa-2b	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
million	NUM	O	O
units	NOUN	O	O
(	PUNCT	O	O
MU	NOUN	O	O
)	PUNCT	O	O
/m2	ADV	O	O
subcutaneously	ADV	O	O
three	NUM	O	O
times	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
63	NUM	O	O
evaluable	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
similar	ADJ	O	O
response	NOUN	O	O
rates	NOUN	O	O
(	PUNCT	O	O
62.1	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
64.7	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
)	PUNCT	O	O
were	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
no	DET	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
those	ADP	O	O
who	ADP	O	O
received	VERB	O	O
interferon	NOUN	O	O
alfa-2b	NOUN	O	O
during	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
phase	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
favourable	ADJ	O	O
trend	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
incidence	NOUN	O	O
of	ADP	O	O
relapse	NOUN	O	B-PHYSICAL
compared	VERB	O	O
to	ADP	O	O
those	PUNCT	O	O
who	ADP	O	O
had	PUNCT	O	O
received	PUNCT	O	O
chlorambucil	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

During	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
interferon	NOUN	O	O
alfa-2b	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
relapse	NOUN	O	I-PHYSICAL
have	CCONJ	O	O
yet	ADV	O	O
been	PUNCT	O	O
seen	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
no	DET	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

A	PUNCT	O	O
longer	PUNCT	O	O
observation	NOUN	O	O
period	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PART	O	O
make	NOUN	O	O
a	DET	O	O
definitive	ADJ	O	O
conclusion	NOUN	O	O
about	ADP	O	O
the	DET	O	O
usefulness	NOUN	O	O
of	ADP	O	O
interferon	NOUN	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
to	PUNCT	O	O
evaluate	NOUN	O	O
further	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combined	VERB	O	O
schedule	NOUN	O	O
of	ADP	O	O
chlorambucil	NOUN	O	O
and	CCONJ	O	O
interferon	NOUN	O	O
induction	NOUN	O	O
on	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
remission	NOUN	O	O
.	PUNCT	O	O

Local	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	O
after	ADP	O	O
rubber	NOUN	O	O
band	NOUN	O	O
ligation	NOUN	O	O
of	ADP	O	O
hemorrhoids	NOUN	O	O
:	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	PUNCT	O	O
local	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	O
after	ADP	O	O
hemorrhoidal	ADP	O	O
banding	ADP	O	O
causes	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	B-PAIN
pain	NOUN	O	I-PAIN
and	CCONJ	O	I-PAIN
in	ADP	O	I-PAIN
the	DET	O	I-PAIN
incidence	NOUN	O	O
of	ADP	O	B-PAIN
associated	PUNCT	O	B-PAIN
symptoms	NOUN	O	B-PAIN
.	PUNCT	O	O

METHODS	NOUN	O	O
After	ADP	O	O
hemorrhoidal	ADP	O	O
banding	ADP	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
local	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	O
with	ADP	O	O
1:200,000	CCONJ	O	O
epinephrine	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
injection	NOUN	O	O
,	PUNCT	O	O
just	ADP	O	O
superior	ADJ	O	O
to	ADP	O	O
each	DET	O	O
band	NOUN	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
was	VERB	O	O
graded	VERB	O	O
by	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
the	DET	O	O
study	NOUN	O	O
nurse	ADJ	O	O
within	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
any	DET	O	O
associated	PUNCT	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

At	ADP	O	O
intervals	NOUN	O	O
6	NUM	O	O
,	PUNCT	O	O
24	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
48	NUM	O	O
hours	NOUN	O	O
postbanding	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
recorded	PUNCT	O	O

[	PUNCT	O	O
Rilmenidine	PUNCT	O	O
sympatholytic	ADJ	O	O
activity	NOUN	O	O
preserves	PUNCT	O	O
mental	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
orthostatic	ADJ	O	I-MENTAL
sympathetic	ADJ	O	I-MENTAL
response	NOUN	O	I-MENTAL
and	CCONJ	O	O
epinephrine	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
]	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Heightened	PROPN	O	O
central	ADJ	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
outflow	PUNCT	O	O
is	PUNCT	O	O
common	ADJ	O	O
in	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
,	PUNCT	O	O
contributing	VERB	O	O
to	ADV	O	O
hypertension	NOUN	O	O
development	NOUN	O	O
and	CCONJ	O	O
perhaps	ADV	O	O
also	ADV	O	O
to	PUNCT	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
activation	NOUN	O	O
is	VERB	O	O
a	DET	O	O
proven	VERB	O	O
trigger	ADP	O	O
for	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
cardiovascular	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
antihypertensive	ADJ	O	O
drugs	NOUN	O	O
inhibiting	ADV	O	O
sympathetic	ADJ	O	O
outflow	ADP	O	O
represent	ADP	O	O
a	DET	O	O
theoretically	ADV	O	O
attractive	ADJ	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
To	ADP	O	O
study	NOUN	O	O
the	DET	O	O
sympatholytic	ADJ	O	O
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
lowering	PUNCT	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
imidazoline	ADJ	O	O
binding	DET	O	O
agent	NOUN	O	O
rilmenidine	PUNCT	O	O
at	ADP	O	O
rest	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
reflex	NOUN	O	O
sympathetic	ADJ	O	O
activation	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
The	DET	O	O
HERA	NOUN	O	O
study	NOUN	O	O
(	PUNCT	O	O
Hyperium	NOUN	O	O
Effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
sympathetic	ADJ	O	O
Reflex	NOUN	O	O
activation	NOUN	O	O
and	CCONJ	O	O
Adrenaline	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
6-week	NOUN	O	O
cross-over	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
1-week	NOUN	O	O
placebo	NOUN	O	O
run-in	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
2-week	NOUN	O	O
active	ADJ	O	O
treatment	NOUN	O	O
intervals	NOUN	O	O
(	PUNCT	O	O
rilmenidine	PUNCT	O	O
1	NUM	O	O
mg	NOUN	O	O
bid	PUNCT	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
intervening	PUNCT	O	O
one	NUM	O	O
week	NOUN	O	O
placebo	NOUN	O	O
wash-out	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
15	NUM	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
noradrenaline	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
adrenaline	PUNCT	O	I-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
kinetics	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
intra-arterial	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
measurements	NOUN	O	I-PHYSICAL
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
rest	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
mental	ADJ	O	O
stress	NOUN	O	O
(	PUNCT	O	O
difficult	ADJ	O	O
mental	ADJ	O	O
arithmetic	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
during	ADP	O	O
head-up	ADJ	O	O
tilting	PUNCT	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
2-week	NOUN	O	O
dosing	PUNCT	O	O
periods	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
noradrenaline	NOUN	O	O
spillover	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
indicative	ADJ	O	O
of	ADP	O	O
whole	ADJ	O	O
body	NOUN	O	O
sympathetic	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
reduced	VERB	O	O
35	NUM	O	O
%	SYM	O	O
by	ADP	O	O
rilmenidine	PUNCT	O	O
at	ADP	O	O
rest	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
remained	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
during	ADP	O	O
mental	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
tilting	PUNCT	O	O
,	PUNCT	O	O
although	CCONJ	O	O
the	DET	O	O
increases	CCONJ	O	O
in	ADP	O	O
noradrenaline	NOUN	O	B-PHYSICAL
spillover	NOUN	O	I-PHYSICAL
with	ADP	O	O
both	PUNCT	O	O
stimuli	NOUN	O	O
were	VERB	O	O
preserved	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
intraarterial	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
ran	NOUN	O	O
in	ADP	O	O
parallel	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
supine	NOUN	O	O
resting	VERB	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
BP	NOUN	O	B-PHYSICAL
rise	NOUN	O	I-PHYSICAL
during	ADP	O	O
mental	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
fall	NOUN	O	O
in	ADP	O	O
BP	NOUN	O	B-PHYSICAL
with	ADP	O	O
tilting	ADP	O	O
.	PUNCT	O	O

On	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
adrenaline	PUNCT	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
was	VERB	O	O
162	NUM	O	O
+/-	SYM	O	O
27	NUM	O	O
ng/min	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
,	PUNCT	O	O
SE	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
rest	NOUN	O	O
,	PUNCT	O	O
increased	PUNCT	O	O
by	ADP	O	O
77	NUM	O	O
+/-	SYM	O	O
42	NUM	O	O
ng/min	PUNCT	O	O
with	ADP	O	O
mental	ADJ	O	O
stress	NOUN	O	O
(	PUNCT	O	O
p=0.019	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
unchanged	VERB	O	O
with	ADP	O	O
tilting	ADP	O	O
.	PUNCT	O	O

Rilmenidine	ADJ	O	O
left	ADJ	O	O
adrenaline	ADJ	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
untouched	VERB	O	O
under	ADP	O	O
all	DET	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
confirms	NOUN	O	O
a	DET	O	O
sympatholytic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
rilmenidine	PUNCT	O	O
during	ADP	O	O
supine	NOUN	O	O
rest	NOUN	O	O
but	CCONJ	O	O
demonstrates	NOUN	O	O
that	ADP	O	O
sympathetic	ADJ	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
during	ADP	O	O
mental	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
tilting	PUNCT	O	O
are	VERB	O	O
preserved	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
latter	ADJ	O	O
underlying	SYM	O	O
a	DET	O	O
perhaps	PUNCT	O	O
surprising	VERB	O	O
absence	NOUN	O	O
of	ADP	O	O
postural	ADJ	O	O
hypotension	NOUN	O	O
on	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
reflexive	ADJ	O	O
sympathetic	ADJ	O	O
responses	NOUN	O	O
contrasts	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
rilmenidine	PUNCT	O	O
in	ADP	O	O
experimental	ADJ	O	O
animals	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
emphasises	PUNCT	O	O
the	DET	O	O
previously	ADV	O	O
demonstrated	PUNCT	O	O
unique	ADJ	O	O
importance	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
of	ADP	O	O
suprabulbar	ADJ	O	O
noradrenergic	ADJ	O	O
neuronal	ADJ	O	O
projections	NOUN	O	O
from	ADP	O	O
the	DET	O	O
brainstem	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
are	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
imidazoline	ADJ	O	O
binding	VERB	O	O
agents	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
regulating	VERB	O	O
tonic	ADJ	O	B-PHYSICAL
sympathetic	ADJ	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
in	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Sympathetic	ADJ	O	O
nervous	ADJ	O	O
inhibition	NOUN	O	O
with	ADP	O	O
rilmenidine	PUNCT	O	O
contrasted	PROPN	O	O
with	ADP	O	O
an	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
secretion	NOUN	O	O
of	ADP	O	O
adrenaline	ADJ	O	O
affirming	PUNCT	O	O
that	PUNCT	O	O
here	ADV	O	O
,	PUNCT	O	O
as	VERB	O	O
elsewhere	VERB	O	O
,	PUNCT	O	O
sympathetic	ADJ	O	B-MENTAL
nervous	ADJ	O	I-MENTAL
and	CCONJ	O	O
adrenal	ADJ	O	B-PHYSICAL
medullary	ADJ	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
can	VERB	O	O
be	VERB	O	O
disconnected	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
effectiveness	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
panic	ADJ	O	O
disorder	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Effectiveness	NOUN	O	O
studies	NOUN	O	O
have	PUNCT	O	O
tested	VERB	O	O
interventions	NOUN	O	O
to	PROPN	O	O
improve	ADP	O	O
quality	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
care	NOUN	O	I-OTHER
for	ADP	O	O
depression	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
none	NUM	O	O
,	PUNCT	O	O
to	ADP	O	O
our	PUNCT	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
have	ADP	O	O
been	PUNCT	O	O
completed	VERB	O	O
for	ADP	O	O
panic	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
PD	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
this	PUNCT	O	O
setting	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
sought	ADP	O	O
to	ADJ	O	O
test	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	B-OTHER
effectiveness	NOUN	O	I-OTHER
of	ADP	O	O
PD	NOUN	O	O
pharmacotherapy	NOUN	O	O
embedded	ADP	O	O
in	ADP	O	O
a	DET	O	O
disease	NOUN	O	O
management	NOUN	O	O
framework	NOUN	O	O
of	ADP	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
(	PUNCT	O	O
CC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
fifteen	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
PD	NOUN	O	O
from	ADP	O	O
3	NUM	O	O
primary	ADJ	O	O
care	NOUN	O	O
clinics	ADV	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
CC	NOUN	O	O
or	CCONJ	O	O
usual	ADJ	O	O
care	NOUN	O	O
(	PUNCT	O	O
UC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
in	ADP	O	O
CC	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
57	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
educational	ADJ	O	O
videotapes	NOUN	O	O
and	CCONJ	O	O
pamphlets	ADJ	O	O
;	PUNCT	O	O
pharmacotherapy	NOUN	O	O
with	ADP	O	O
the	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	O
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
paroxetine	NOUN	O	O
;	PUNCT	O	O
2	NUM	O	O
psychiatrist	NOUN	O	O
visits	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
telephone	NOUN	O	O
calls	ADP	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
8	NUM	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
up	PUNCT	O	O
to	ADP	O	O
5	NUM	O	O
telephone	NOUN	O	O
calls	NOUN	O	O
between	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
'	PUNCT	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Usual	ADJ	O	O
care	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
58	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
their	PUNCT	O	O
primary	ADJ	O	O
care	NOUN	O	O
physician	NOUN	O	O
.	PUNCT	O	O

Telephone	NOUN	O	O
assessments	NOUN	O	O
of	ADP	O	O
panic	ADJ	O	B-MENTAL
,	PUNCT	O	O
anxiety	NOUN	O	B-MENTAL
sensitivity	NOUN	O	I-MENTAL
,	PUNCT	O	O
depression	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
disability	NOUN	O	B-MENTAL
variables	NOUN	O	I-MENTAL
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
'	PUNCT	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Adequacy	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
pharmacotherapy	NOUN	O	I-OTHER
was	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
an	DET	O	O
algorithm	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
studies	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Patients	NOUN	O	O
in	ADP	O	O
CC	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
receive	NOUN	O	O
adequate	ADJ	O	B-OTHER
(	PUNCT	O	O
type	NOUN	O	O
,	PUNCT	O	O

Safety	NOUN	O	O
of	ADP	O	O
injectable	ADJ	O	O
opioid	NOUN	O	O
maintenance	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
heroin	ADJ	O	O
dependence	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
There	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
growing	VERB	O	O
debate	NOUN	O	O
about	ADP	O	O
injectable	ADJ	O	O
opioid	NOUN	O	O
treatment	NOUN	O	O
programs	NOUN	O	O
in	ADP	O	O
many	DET	O	O
Western	NOUN	O	O
countries	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
injectable	ADJ	O	O
opioids	NOUN	O	O
in	ADP	O	O
a	DET	O	O
controlled	VERB	O	O
treatment	NOUN	O	O
setting	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Twenty-five	PUNCT	O	O
opioid-dependent	ADJ	O	O
patients	NOUN	O	O
on	ADP	O	O
intravenous	ADJ	O	O
(	PUNCT	O	O
IV	NUM	O	O
)	PUNCT	O	O
heroin	ADJ	O	O
or	CCONJ	O	O
IV	NUM	O	O
methadone	NOUN	O	O
maintenance	NOUN	O	O
treatment	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
their	ADP	O	O
individual	ADJ	O	O
prescribed	PUNCT	O	O
IV	NUM	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	B-OTHER
drug	NOUN	O	I-OTHER
effects	NOUN	O	I-OTHER
were	VERB	O	O
recorded	VERB	O	O
,	PUNCT	O	O
focusing	VERB	O	O
on	ADP	O	O
electrocardiography	NOUN	O	B-OTHER
,	PUNCT	O	O
respiratory	ADJ	O	B-PHYSICAL
movements	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
arterial	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
oxygen	NOUN	O	I-PHYSICAL
saturation	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
electroencephalography	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
EEG	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
heroin	ADJ	O	O
injection	NOUN	O	O
,	PUNCT	O	O
marked	VERB	O	O
respiratory	ADJ	O	B-PHYSICAL
depression	NOUN	O	I-PHYSICAL
progressing	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
Cheyne-Stokes	PUNCT	O	B-PHYSICAL
pattern	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
.	PUNCT	O	O

Peripheral	ADJ	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
oxygenation	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
to	ADP	O	O
78.9	NUM	O	O
+/-	SYM	O	O
8.7	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
)	PUNCT	O	O
ranging	CCONJ	O	O
from	ADP	O	O
52	NUM	O	O
%	SYM	O	O
-90	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

During	ADP	O	O
hypoxia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
7	NUM	O	O
of	ADP	O	O
the	DET	O	O
16	ADJ	O	O
subjects	NOUN	O	O
experienced	PUNCT	O	O
intermittent	ADJ	O	O
and	CCONJ	O	O
somewhat	ADV	O	O
severe	ADJ	O	O
bradycardia	NUM	O	B-PHYSICAL
.	PUNCT	O	O

Five	NUM	O	O
subjects	NOUN	O	O
exhibited	ADP	O	O
paroxysmal	ADJ	O	B-PHYSICAL
EEG	NOUN	O	I-PHYSICAL
patterns	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

After	ADP	O	O
methadone	NOUN	O	O
injection	NOUN	O	O
,	PUNCT	O	O
respiratory	ADJ	O	B-PHYSICAL
depression	NOUN	O	I-PHYSICAL
was	VERB	O	O
less	ADV	O	O
pronounced	ADP	O	O
than	PUNCT	O	O
after	PUNCT	O	O
heroin	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
relevant	ADJ	O	O
bradycardia	NOUN	O	B-PHYSICAL
was	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Opioid	NOUN	O	O
doses	NOUN	O	O
commonly	ADV	O	O
prescribed	VERB	O	O
in	ADP	O	O
IV	NUM	O	O
opioid	NOUN	O	O
treatment	NOUN	O	O
induce	VERB	O	O
marked	VERB	O	O
respiratory	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
circulatory	ADJ	O	I-PHYSICAL
depression	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
occasionally	VERB	O	O
irregular	ADJ	O	B-PHYSICAL
paroxysmal	ADJ	O	I-PHYSICAL
EEG	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	ADV	O	O
needed	VERB	O	O
to	PART	O	O
optimize	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
of	ADP	O	O
IV	NUM	O	O
opioid	NOUN	O	O
treatment	NOUN	O	O
to	PART	O	O
prevent	ADJ	O	O
serious	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
the	PUNCT	O	O
observed	VERB	O	O
effects	NOUN	O	O
raises	PUNCT	O	O
questions	NOUN	O	O
about	ADP	O	O
the	DET	O	O
appropriateness	NOUN	O	O
of	ADP	O	O
IV	NUM	O	O
opioid	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
form	NOUN	O	O
.	PUNCT	O	O

Phosphate	NOUN	O	O
binder	ADJ	O	O
impact	NOUN	O	O
on	ADP	O	O
bone	NOUN	O	B-PHYSICAL
remodeling	VERB	O	I-PHYSICAL
and	CCONJ	O	O
coronary	ADJ	O	B-PHYSICAL
calcification	NOUN	O	I-PHYSICAL
--	PUNCT	O	O
results	ADJ	O	O
from	ADP	O	O
the	DET	O	O
BRiC	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
AIMS	NOUN	O	O
Calcium-containing	PROPN	O	O
phosphate	NOUN	O	O
binders	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
increase	NOUN	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	B-PHYSICAL
calcification	NOUN	O	I-PHYSICAL
in	ADP	O	O
hemodialysis	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
that	PUNCT	O	O
compares	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	O
acetate	NOUN	O	O
and	CCONJ	O	O
sevelamer	NOUN	O	O
on	ADP	O	O
coronary	ADJ	O	B-PHYSICAL
calcification	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
CAC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
bone	NOUN	O	B-PHYSICAL
histology	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
101	NUM	O	O
hemodialysis	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
for	ADP	O	O
each	DET	O	O
phosphate	NOUN	O	O
binder	ADJ	O	O
and	CCONJ	O	O
submitted	VERB	O	O
to	PUNCT	O	O
multislice	PUNCT	O	O
coronary	ADJ	O	O
tomographies	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
biopsies	NOUN	O	O
at	ADP	O	O
entry	NOUN	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
71	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
concluded	VERB	O	O
the	DET	O	O
study	NOUN	O	O
had	PUNCT	O	O
similar	ADJ	O	O
baseline	NOUN	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
sevelamer	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
higher	CCONJ	O	O
levels	NOUN	O	O
of	ADP	O	O
intact	ADJ	O	B-PHYSICAL
parathyroid	NOUN	O	I-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
498	NUM	O	O
+/-	SYM	O	O
352	NUM	O	O
vs.	CCONJ	O	O
326	ADP	O	O
+/-	SYM	O	O
236	NUM	O	O
pg/ml	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.017	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bone	NOUN	O	B-PHYSICAL
alkaline	ADJ	O	I-PHYSICAL
phosphatase	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
38	NUM	O	O
+/-	SYM	O	O
24	NUM	O	O
vs.	CCONJ	O	O
28	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
U/l	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
deoxypyridinoline	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
135	NUM	O	O
+/-	SYM	O	O
107	NUM	O	O
vs.	CCONJ	O	O
89	NUM	O	O
+/-	SYM	O	O
71	NUM	O	O
nmol/l	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
lower	PUNCT	O	B-PHYSICAL
LDL	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
74	NUM	O	O
+/-	SYM	O	O
21	NUM	O	O
vs.	CCONJ	O	O
91	NUM	O	O
+/-	SYM	O	O
28	NUM	O	O
mg/dl	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.015	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Phosphorus	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
5.8	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
vs.	CCONJ	O	O
6	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
mg/dl	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.47	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
calcium	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
1.27	NUM	O	O
+/-	SYM	O	O
0.07	NUM	O	O
vs.	CCONJ	O	O
1.23	NUM	O	O
+/-	SYM	O	O
0.08	NUM	O	O
mmol/l	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.68	NUM	O	O
)	PUNCT	O	O
levels	NOUN	O	O
did	ADP	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CAC	NOUN	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
35	NUM	O	O
vs.	CCONJ	O	O
24	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.94	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
bone	NOUN	O	B-PHYSICAL
histological	ADJ	O	I-PHYSICAL
diagnosis	NOUN	O	I-PHYSICAL
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sevelamer	NOUN	O	O
group	NOUN	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
turnover	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
had	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
bone	NOUN	O	B-PHYSICAL
resorption	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
eroded	PUNCT	O	O
surface	NOUN	O	O
,	PUNCT	O	O
ES/BS	CCONJ	O	O
=	ADP	O	O
9.0	NUM	O	O
+/-	SYM	O	O
5.9	NUM	O	O
vs.	CCONJ	O	O
13.1	NUM	O	O
+/-	SYM	O	O
9.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
turnover	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
had	PUNCT	O	O
an	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
bone	NOUN	O	B-PHYSICAL
formation	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
BFR/BS	NOUN	O	O
=	SYM	O	O
0.015	NUM	O	O
+/-	SYM	O	O
0.016	NUM	O	O
vs.	CCONJ	O	O
0.062	NUM	O	O
+/-	SYM	O	O
0.078	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
for	ADP	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
0.017	NUM	O	O
+/-	SYM	O	O
0.016	NUM	O	O
vs.	CCONJ	O	O
0.071	ADP	O	O
+/-	SYM	O	O
0.084	NUM	O	O
microm	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
/microm	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
/day	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.010	NUM	O	O
for	ADP	O	O
sevelamer	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
CAC	NOUN	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
bone	NOUN	O	B-PHYSICAL
remodeling	VERB	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
sevelamer	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
radiation	NOUN	O	O
related	VERB	O	O
morbidity	NOUN	O	B-MENTAL
observed	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
neutron	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
is	VERB	O	O
an	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
morbidity	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
and	CCONJ	O	O
bowel	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
d	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
)	PUNCT	O	O
+Be	ADP	O	O
neutrons	NOUN	O	O
versus	CCONJ	O	O
megavoltage	NOUN	O	O
photons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	B-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
and	CCONJ	O	O
bowel	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
worse	ADJ	O	O
after	ADP	O	O
photon	PUNCT	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
photons	NOUN	O	O
45.7	NUM	O	O
%	SYM	O	O
had	PUNCT	O	O
severe	ADJ	O	O
reactions	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
bladder	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
10.6	NUM	O	O
%	SYM	O	O
after	ADP	O	O
neutron	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Severe	ADJ	O	B-PHYSICAL
acute	ADJ	O	I-PHYSICAL
bowel	NOUN	O	I-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
8.5	NUM	O	O
%	DET	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
after	ADP	O	O
photon	PUNCT	O	O
therapy	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
3.8	NUM	O	O
%	SYM	O	O
after	ADP	O	O
neutron	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Late	ADJ	O	B-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
worse	ADJ	O	O
after	ADP	O	O
neutrons	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	B-PHYSICAL
late	ADJ	O	I-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
bladder	NOUN	O	I-PHYSICAL
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
58.5	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
after	ADP	O	O
neutron	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
40.5	NUM	O	O
%	SYM	O	O
after	ADP	O	O
photon	CCONJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
bowel	NOUN	O	O
they	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
53.3	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
after	ADP	O	O
neutron	NOUN	O	O
therapy	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
8	NUM	O	O
%	SYM	O	O
after	ADP	O	O
photon	CCONJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
disparity	NOUN	O	O
in	ADP	O	O
the	DET	O	B-MENTAL
degree	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
early	PUNCT	O	I-MENTAL
and	CCONJ	O	I-MENTAL
late	ADJ	O	I-MENTAL
complications	NOUN	O	I-MENTAL
makes	NOUN	O	O
assessment	NOUN	O	O
of	ADP	O	O
RBE	NOUN	O	B-MORTALITY
values	NOUN	O	I-MORTALITY
difficult	ADJ	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
estimated	VERB	O	O
that	ADP	O	O
for	ADP	O	O
bladder	NOUN	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
the	DET	O	O
RBE	NOUN	O	B-PHYSICAL
value	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
for	ADP	O	O
photon	PUNCT	O	O
dose	NOUN	O	O
fractions	NOUN	O	O
of	ADP	O	O
2.75	NUM	O	O
Gy	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
less	ADV	O	O
than	ADP	O	O
3.3	NUM	O	O
for	ADP	O	O
early	ADJ	O	O
reactions	NOUN	O	O
and	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
3.4	NUM	O	O
for	ADP	O	O
late	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
respective	ADJ	O	O
RBE	NOUN	O	B-PHYSICAL
values	NOUN	O	I-PHYSICAL
for	ADP	O	O
early	PUNCT	O	O
and	CCONJ	O	O
late	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bowel	NOUN	O	O
are	VERB	O	O
less	ADV	O	O
than	PUNCT	O	O
3.4	NUM	O	O
and	CCONJ	O	O
3.8	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
of	ADP	O	O
neuropathic	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
and	CCONJ	O	O
pain	NOUN	O	B-PAIN
in	ADP	O	O
complex	PUNCT	O	B-PAIN
regional	ADJ	O	I-PAIN
pain	NOUN	O	B-PAIN
syndrome	NOUN	O	I-PAIN
I	NUM	O	O
to	ADP	O	O
carbamazepine	NOUN	O	O
and	CCONJ	O	O
sustained-release	NOUN	O	O
morphine	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
stimulation	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blinded	ADV	O	O
randomized	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Forty-three	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
peripheral	ADJ	O	O
neuropathic	ADJ	O	O
pain	NOUN	O	O
,	PUNCT	O	O
exclusively	ADV	O	O
pain	NOUN	O	O
reduced	VERB	O	O
by	ADP	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
SCS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
switched	VERB	O	O
into	ADP	O	O
a	DET	O	O
painful	ADJ	O	O
state	NOUN	O	O
after	ADP	O	O
SCS	NOUN	O	O
inactivation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
mode	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
pain-relieving	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	O
(	PUNCT	O	O
CMZ	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
opioids	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blinded	ADV	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Phase	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
CMZ	NOUN	O	O
(	PUNCT	O	O
600	ADP	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
during	ADP	O	O
an	DET	O	O
SCS-free	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Phase	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
after	ADP	O	O
a	DET	O	O
CMZ	NOUN	O	O
elimination	NOUN	O	O
interval	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
38	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
sustained-release	NOUN	O	O
morphine	NOUN	O	O
(	PUNCT	O	O
90	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
intolerable	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
authorized	VERB	O	O
to	PUNCT	O	O
reactivate	ADV	O	O
their	NOUN	O	O
SCS	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pain	NOUN	O	B-PAIN
intensity	NOUN	O	I-PAIN
was	VERB	O	O
rated	VERB	O	O
on	ADP	O	O
a	DET	O	O
numeric	ADJ	O	B-OTHER
analog	NOUN	O	I-OTHER
scale	NOUN	O	I-OTHER
.	PUNCT	O	O

In	ADP	O	O
38	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
completed	PUNCT	O	O
Phase	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
significant	ADJ	O	O
delay	NOUN	O	B-PAIN
in	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
increase	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
CMZ	NOUN	O	O
group	NOUN	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.038	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
Phase	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
trend	NOUN	O	O
observed	VERB	O	O
with	ADP	O	O
morphine	NOUN	O	O
was	VERB	O	O
insignificant	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.41	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
CMZ	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
morphine	NOUN	O	O
patient	NOUN	O	O
showed	VERB	O	O
complete	ADJ	O	B-PAIN
pain	PUNCT	O	I-PAIN

Fadrozole	PUNCT	O	O
HCL	NOUN	O	O
(	PUNCT	O	O
CGS-16949A	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
postmenopausal	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
carcinoma	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
randomized	VERB	O	O
double	VERB	O	O
blind	ADP	O	O
controlled	VERB	O	O
multiinstitutional	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Breast	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
prior	PUNCT	O	O
response	NOUN	O	O
to	ADP	O	O
endocrine	ADJ	O	O
therapy	NOUN	O	O
achieve	PUNCT	O	O
subsequent	ADJ	O	O
benefit	NOUN	O	O
from	ADP	O	O
additional	ADJ	O	O
endocrine	ADJ	O	O
therapies	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
an	DET	O	O
aromatase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
fadrozole	PUNCT	O	O
HCL	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
in	ADP	O	O
post	PUNCT	O	O
menopausal	ADJ	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
disease	NOUN	O	O
progression	NOUN	O	O
after	ADP	O	O
receiving	ADP	O	O
antiestrogen	NOUN	O	O
therapy	NOUN	O	O
either	CCONJ	O	O
for	ADP	O	O
metastatic	ADJ	O	O
disease	NOUN	O	O
or	CCONJ	O	O
as	PUNCT	O	O
adjuvant	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
2	NUM	O	O
multiinstitutional	ADJ	O	O
prospective	ADJ	O	O
trials	NOUN	O	O
,	PUNCT	O	O
683	NUM	O	O
postmenopausal	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	ADP	O	O
either	PUNCT	O	O
fadrozole	PUNCT	O	O
HCL	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
daily	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
mg	NOUN	O	O
4	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
fashion	NOUN	O	O
after	ADP	O	O
progression	NOUN	O	O
on	ADP	O	O
first-line	NOUN	O	O
hormonal	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Objective	ADJ	O	B-PHYSICAL
response	NOUN	O	O
rates	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	B-PHYSICAL
progression	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
survival	NOUN	O	B-MORTALITY
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
regimens	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Results	PUNCT	O	O
of	ADP	O	O
intent-to-treat	NOUN	O	O
analyses	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
in	ADP	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
progression	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
objective	ADJ	O	B-PHYSICAL
response	NOUN	O	O
rates	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
response	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
survival	NOUN	O	B-MORTALITY
in	ADP	O	O
either	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
clinically	ADV	O	O
meaningful	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
experiences	ADJ	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
except	PUNCT	O	O
that	PUNCT	O	O
weight	NOUN	O	O
gain	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
fluid	NOUN	O	B-ADVERSE-EFFECTS
retention	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
dyspnea	NOUN	O	B-ADVERSE-EFFECTS
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
more	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
those	PUNCT	O	O
receiving	PUNCT	O	O
fadrozole	PUNCT	O	O
HCL	NOUN	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
vomiting	VERB	O	B-ADVERSE-EFFECTS
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
more	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fadrozole	PUNCT	O	O
HCL	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
those	PUNCT	O	O
receiving	VERB	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Fadrozole	PUNCT	O	O
HCL	NOUN	O	O
was	VERB	O	O
as	PUNCT	O	O
efficacious	ADJ	O	B-PHYSICAL
as	VERB	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
carcinoma	NOUN	O	O
after	ADP	O	O
one	NUM	O	O
hormonal	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
experiences	NOUN	O	O
were	VERB	O	O
mild	ADJ	O	O
with	ADP	O	O
both	PUNCT	O	O
therapies	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
wiht	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
frequency	NOUN	O	O
of	ADP	O	O
weight	PUNCT	O	O

Microbial	ADJ	O	O
protein	NOUN	O	O
synthesis	NOUN	O	O
,	PUNCT	O	O
nitrogen	NOUN	O	O
capture	NOUN	O	O
efficiency	NOUN	O	O
and	CCONJ	O	O
nutrient	NOUN	O	O
utilisation	NOUN	O	O
in	ADP	O	O
sheep	NOUN	O	O
fed	VERB	O	O
on	ADP	O	O
finger	NOUN	O	O
millet	NOUN	O	O
straw	NOUN	O	O
(	PUNCT	O	O
Eleucine	NOUN	O	O
coracana	ADP	O	O
)	PUNCT	O	O
-based	ADP	O	O
diet	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
rumen-degradable	ADJ	O	O
nitrogen	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Microbial	ADJ	O	O
protein	NOUN	O	O
synthesised	VERB	O	O
in	ADP	O	O
the	DET	O	O
rumen	VERB	O	O
is	VERB	O	O
a	DET	O	O
very	ADJ	O	O
important	ADJ	O	O
protein	NOUN	O	O
source	NOUN	O	O
for	ADP	O	O
ruminants	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
essential	ADJ	O	O
to	PART	O	O
provide	NOUN	O	O
an	DET	O	O
adequate	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
rumen-degradable	ADJ	O	O
nitrogen	NOUN	O	O
(	PUNCT	O	O
RDN	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
optimum	NOUN	O	O
microbial	ADJ	O	O
protein	NOUN	O	O
synthesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rumen	CCONJ	O	O
on	ADP	O	O
straw-based	VERB	O	O
diets	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
RDN	NOUN	O	O
requirement	NOUN	O	O
for	ADP	O	O
optimum	NOUN	O	O
microbial	ADJ	O	O
protein	NOUN	O	O
synthesis	NOUN	O	O
(	PUNCT	O	O
MPS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nitrogen	NOUN	O	O
capture	NOUN	O	O
efficiency	NOUN	O	O
(	PUNCT	O	O
NCE	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nutrient	NOUN	O	O
utilisation	NOUN	O	O
in	ADP	O	O
Nellore	ADP	O	O
rams	CCONJ	O	O
fed	VERB	O	O
on	ADP	O	O
a	DET	O	O
finger	NOUN	O	O
millet	NOUN	O	O
straw	NOUN	O	O
(	PUNCT	O	O
FMS	NOUN	O	O
)	PUNCT	O	O
-based	ADP	O	O
diet	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-six	NUM	O	O
Nellore	PUNCT	O	O
sheep	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
nine	NUM	O	O
animals	NOUN	O	O
each	DET	O	O
using	ADJ	O	O
a	DET	O	O
balanced	VERB	O	O
,	PUNCT	O	O
completely	ADV	O	O
randomised	VERB	O	O
design	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
animals	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
RDN0	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
fed	VERB	O	O
with	ADP	O	O
ad	PUNCT	O	O
libitum	PUNCT	O	O
FMS	NOUN	O	O
.	PUNCT	O	O

Those	PUNCT	O	O
in	ADP	O	O
groups	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
(	PUNCT	O	O
RDN1	NOUN	O	O
,	PUNCT	O	O
RDN2	NOUN	O	O
and	CCONJ	O	O
RDN3	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
supplemented	VERB	O	O
with	ADP	O	O
groundnut	NOUN	O	O
cake	VERB	O	O
to	PART	O	O
provide	NOUN	O	O
RDN	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
of	ADP	O	O
14	NUM	O	O
,	PUNCT	O	O
18	NUM	O	O
and	CCONJ	O	O
23	NUM	O	O
g	ADP	O	O
RDN	NOUN	O	O
kg??	NOUN	O	O
digestible	ADJ	O	O
organic	ADJ	O	O
matter	NOUN	O	O
intake	NOUN	O	O
(	PUNCT	O	O
DOMI	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
21	NUM	O	O
,	PUNCT	O	O
27	NUM	O	O
and	CCONJ	O	O
35	NUM	O	O
g	ADP	O	O
RDN	NOUN	O	O
kg??	NOUN	O	O
digestible	ADJ	O	O
organic	ADJ	O	O
matter	NOUN	O	O
apparently	ADV	O	O
digested	VERB	O	O
in	ADP	O	O
the	DET	O	O
rumen	NOUN	O	O
(	PUNCT	O	O
DOMR	NOUN	O	O
)	PUNCT	O	O
respectively	ADV	O	O
along	PUNCT	O	O
with	ADP	O	O
FMS	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
digestibility	NOUN	O	O
coefficients	PUNCT	O	O
of	ADP	O	O
all	DET	O	O
nutrients	NOUN	O	O
and	CCONJ	O	O
MPS	NOUN	O	O
increased	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
quadratically	ADV	O	O
with	ADP	O	O
increasing	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
RDN	NOUN	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

NCE	NOUN	O	O
decreased	VERB	O	O
linearly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
as	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
RDN	NOUN	O	O
increased	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
12	NUM	O	O
g	ADP	O	O
RDN	NOUN	O	O
kg??	NOUN	O	O
DOMI	ADP	O	O
or	CCONJ	O	O
19	NUM	O	O
g	ADP	O	O
RDN	NOUN	O	O
kg??	NOUN	O	O
DOMR	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
adequate	ADJ	O	O
for	ADP	O	O
optimum	NOUN	O	O
MPS	NOUN	O	O
,	PUNCT	O	O
NCE	NOUN	O	O
and	CCONJ	O	O
digestibility	NOUN	O	O
of	ADP	O	O
nutrients	NOUN	O	O
in	ADP	O	O
sheep	NOUN	O	O
fed	VERB	O	O
on	ADP	O	O
an	DET	O	O
FMS-based	NOUN	O	O
diet	NOUN	O	O
.	PUNCT	O	O

Sustained	VERB	O	O
oral	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
toothbrushes	DET	O	O
and	CCONJ	O	O
dentifrice	NOUN	O	O
by	ADP	O	O
previous	ADJ	O	O
users	NOUN	O	O
of	ADP	O	O
traditional	ADJ	O	O
materials	NOUN	O	O
in	ADP	O	O
a	DET	O	O
rural	ADJ	O	O
population	NOUN	O	O
in	ADP	O	O
Andhra	NOUN	O	O
Pradesh	NOUN	O	O
,	PUNCT	O	O
India	PUNCT	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
year	NOUN	O	O
later	ADJ	O	O
,	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
regular	ADJ	O	O
brushing	PUNCT	O	O
with	ADP	O	O
dentifrices	NOUN	O	O
on	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
health	NOUN	O	O
of	ADP	O	O
an	DET	O	O
economically	ADV	O	O
disadvantaged	VERB	O	O
rural	ADJ	O	O
population	NOUN	O	O
in	ADP	O	O
Andhra	NOUN	O	O
Pradesh	NOUN	O	O
,	PUNCT	O	O
India	PUNCT	O	O
who	ADP	O	O
were	VERB	O	O
primarily	ADJ	O	O
users	NOUN	O	O
of	ADP	O	O
traditional	ADJ	O	O
materials	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
150	NUM	O	O
of	ADP	O	O
the	DET	O	O
original	ADJ	O	O
study	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Examination	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
improvements	NOUN	O	O
in	ADP	O	O
oral	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
oral	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
behaviour	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
toothbrush	NOUN	O	O
and	CCONJ	O	O
dentifrice	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
being	VERB	O	O
unsupported	PUNCT	O	O
,	PUNCT	O	O
had	PUNCT	O	O
been	ADP	O	O
sustained	VERB	O	O
since	ADP	O	O
completion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
original	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Data	ADP	O	O
analysis	NOUN	O	O
showed	VERB	O	O
sustained	DET	O	O
,	PUNCT	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
gingival	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
as	VERB	O	I-PHYSICAL
measured	VERB	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
gingival	ADJ	O	I-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
plaque	NOUN	O	I-PHYSICAL
indices	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
GBI	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
PI	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
comparing	ADP	O	O
users	NOUN	O	O
and	CCONJ	O	O
non-users	PROPN	O	O
of	ADP	O	O
toothbrushes	DET	O	O
and	CCONJ	O	O
dentifrice	NOUN	O	O
in	ADP	O	O
the	DET	O	O
original	ADJ	O	O
study	NOUN	O	O
(	PUNCT	O	O
PI	NOUN	O	O
:	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
;	PUNCT	O	O
GBI	NOUN	O	O
:	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
sustained	VERB	O	B-OTHER
use	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
toothbrushes	DET	O	I-OTHER
and	CCONJ	O	O
dentifrice	NOUN	O	B-OTHER
by	ADP	O	O
60	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
at	ADP	O	O
follow-up	NOUN	O	O
one	NUM	O	O
year	NOUN	O	O
later	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
shows	NOUN	O	O
a	DET	O	O
beneficial	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
on	ADP	O	B-PHYSICAL
oral	PUNCT	O	I-PHYSICAL

Investigation	NOUN	O	O
of	ADP	O	O
erosion	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
abrasion	NOUN	O	B-PHYSICAL
on	ADP	O	O
enamel	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
dentine	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
a	DET	O	O
model	NOUN	O	O
in	ADP	O	O
situ	ADJ	O	O
using	PUNCT	O	O
toothpastes	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
abrasivity	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Studies	NOUN	O	O
in	ADP	O	O
vitro	ADJ	O	O
suggest	VERB	O	O
that	ADP	O	O
abrasion	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
erosion	NOUN	O	B-PHYSICAL
may	VERB	O	O
act	VERB	O	O
synergistically	ADV	O	O
to	PART	O	O
produce	CCONJ	O	O
wear	PUNCT	O	O
of	ADP	O	O
enamel	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
dentine	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Methods	NOUN	O	O
in	ADP	O	O
situ	PUNCT	O	O
are	ADJ	O	O
recently	ADV	O	O
available	ADP	O	O
to	PART	O	O
study	ADP	O	O
separately	ADV	O	O
erosion	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
abrasion	NOUN	O	B-PHYSICAL
of	ADP	O	O
dental	ADJ	O	B-PHYSICAL
tissues	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PROPN	O	O
combine	NOUN	O	O
two	NUM	O	O
in	PUNCT	O	O
situ	ADJ	O	O
protocols	NOUN	O	O
to	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
interplay	NOUN	O	O
between	ADP	O	O
erosion	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
abrasion	NOUN	O	B-PHYSICAL
of	ADP	O	O
enamel	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
dentine	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

METHOD	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
a	DET	O	O
single-blind	NOUN	O	O
,	PUNCT	O	O
randomised	VERB	O	O
,	PUNCT	O	O
five-treatment	PUNCT	O	O
cross-over	NOUN	O	O
design	NOUN	O	O
involving	VERB	O	O
15	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
each	DET	O	O
10-day	NOUN	O	O
study	NUM	O	O
period	NOUN	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
wore	ADP	O	O
from	ADP	O	O
0900	NUM	O	O
to	ADP	O	O
1700	NUM	O	O
h	NOUN	O	O
an	DET	O	O
upper	ADJ	O	O
removable	ADJ	O	O
acrylic	ADJ	O	O
appliance	PUNCT	O	O
holding	ADJ	O	O
one	NUM	O	O
polished	ADP	O	O
enamel	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
polished	ADP	O	O
dentine	NOUN	O	O
specimen	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
specimen	NOUN	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
were	ADJ	O	O
:	PUNCT	O	O
1	NUM	O	O
.	PUNCT	O	O

Drinking	VERB	O	O
water	NOUN	O	O
and	CCONJ	O	O
brushing	PUNCT	O	O
with	ADP	O	O
toothpaste	NOUN	O	O
A	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
.	PUNCT	O	O

Drinking	VERB	O	O
water	NOUN	O	O
and	CCONJ	O	O
brushing	PUNCT	O	O
with	ADP	O	O
toothpaste	PUNCT	O	O
B	NOUN	O	O
.	PUNCT	O	O

3	NUM	O	O
.	PUNCT	O	O

Drinking	PROPN	O	O
orange	NOUN	O	O
juice	NOUN	O	O
.	PUNCT	O	O

4	NUM	O	O
.	PUNCT	O	O

Drinking	PROPN	O	O
orange	NOUN	O	O
juice	ADP	O	O
and	CCONJ	O	O
brushing	PUNCT	O	O
with	ADP	O	O
toothpaste	NOUN	O	O
A	NOUN	O	O
.	PUNCT	O	O

5	NUM	O	O
.	PUNCT	O	O

Drinking	PROPN	O	O
orange	NOUN	O	O
juice	ADP	O	O
and	CCONJ	O	O
brushing	PUNCT	O	O
with	ADP	O	O
toothpaste	PUNCT	O	O
B	NOUN	O	O
.	PUNCT	O	O

Drinking	PROPN	O	O
and	CCONJ	O	O
brushing	PUNCT	O	O
times	NOUN	O	O
were	VERB	O	O
around	ADP	O	O
0900	NUM	O	O
,	PUNCT	O	O
1100	NUM	O	O
,	PUNCT	O	O
1300	NUM	O	O
and	CCONJ	O	O
1500	NUM	O	O
h.	NOUN	O	O
Drinks	PUNCT	O	O
were	VERB	O	O
consumed	VERB	O	O
as	ADP	O	O
250	NUM	O	O
ml	NOUN	O	O
over	ADP	O	O
10	NUM	O	O
min	NOUN	O	O
and	CCONJ	O	O
brushing	PUNCT	O	O
ex	ADP	O	O
vivo	NUM	O	O
for	ADP	O	O
1	NUM	O	O
min	NOUN	O	O
to	ADP	O	O
each	CCONJ	O	O
specimen	NOUN	O	O
.	PUNCT	O	O

Measurement	NOUN	O	O
of	ADP	O	O
tissue	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
was	VERB	O	O
made	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
of	ADP	O	O
each	DET	O	O
period	NOUN	O	O
using	VERB	O	O
a	DET	O	O
profilometer	ADJ	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
All	PUNCT	O	O
treatments	NOUN	O	O
produced	VERB	O	O
increasing	ADP	O	O
tissue	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
over	ADP	O	I-PHYSICAL
time	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
considerably	ADV	O	O
greater	PUNCT	O	O
for	ADP	O	O
dentine	NOUN	O	O
than	PUNCT	O	O
enamel	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
enamel	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
data	NOUN	O	O
at	ADP	O	O
days	NOUN	O	O
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
for	ADP	O	O
erosion	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
i.e	ADV	O	O
.	PUNCT	O	O

orange	ADV	O	O
juice	ADV	O	O
was	VERB	O	O
significantly	ADV	O	O
more	DET	O	O
erosive	ADJ	O	O
than	PUNCT	O	O
water	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
for	ADP	O	O
abrasion	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
i.e	ADV	O	O
.	PUNCT	O	O

no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
toothpaste	NOUN	O	O
treatments	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
combined	VERB	O	O
orange	NOUN	O	O
juice	ADP	O	O
and	CCONJ	O	O
toothpaste	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
directional	ADJ	O	O
for	ADP	O	O
synergy	NOUN	O	O
but	CCONJ	O	O
did	PUNCT	O	O
not	ADV	O	O
reach	ADJ	O	O
significance	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
dentine	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
,	PUNCT	O	O
many	DET	O	O
specimens	NOUN	O	O
exceeded	ADP	O	O
the	DET	O	O
50	NUM	O	O
microm	NOUN	O	O
set	ADV	O	O
limit	VERB	O	O
of	ADP	O	O
the	DET	O	O
profilometer	ADP	O	O
and	CCONJ	O	O
only	ADJ	O	O
day	NOUN	O	O
5	NUM	O	O
data	NOUN	O	O
were	VERB	O	O
considered	VERB	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
effects	NOUN	O	O
for	ADP	O	O
erosion	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
orange	ADV	O	O
juice	NOUN	O	O
produced	ADV	O	O
significantly	ADV	O	O
more	DET	O	O
erosion	NOUN	O	O
than	PUNCT	O	O
water	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
abrasion	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
paste	NOUN	O	O
A	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
more	DET	O	O
abrasive	VERB	O	O
to	ADP	O	O
dentine	NOUN	O	O
than	PUNCT	O	O
paste	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
synergy	NOUN	O	O
effect	NOUN	O	O
could	SYM	O	O
not	ADV	O	O
be	VERB	O	O
examined	VERB	O	O
for	ADP	O	O
dentine	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
truncation	NOUN	O	O
effect	NOUN	O	O
as	ADP	O	O
the	DET	O	O
set	ADJ	O	O
limit	VERB	O	O
of	ADP	O	O
the	DET	O	O
profilometer	VERB	O	O
was	VERB	O	O
exceeded	ADP	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Erosion	NOUN	O	O
increases	NOUN	O	O
the	DET	O	O
susceptibility	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
enamel	NOUN	O	I-PHYSICAL
to	ADP	O	O
toothpaste	PUNCT	O	B-PHYSICAL
abrasion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Dentine	PUNCT	O	O
is	VERB	O	O
considerably	ADV	O	O
more	ADV	O	O
susceptible	ADJ	O	O
than	PUNCT	O	O
enamel	NOUN	O	O
to	VERB	O	O
erosion	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
abrasion	NOUN	O	B-PHYSICAL
alone	ADJ	O	O
or	CCONJ	O	O
combined	PUNCT	O	O
.	PUNCT	O	O

Dentine	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
appears	NOUN	O	O
to	PUNCT	O	O
correlate	NOUN	O	O
with	ADP	O	O
toothpaste	NOUN	O	O
abrasivity	NOUN	O	O
(	PUNCT	O	O
RDA	NOUN	O	O
value	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
prevention	NOUN	O	O
program	NOUN	O	O
effectiveness	NOUN	O	O
with	ADP	O	O
clustered	ADP	O	O
data	NOUN	O	O
using	VERB	O	O
generalized	VERB	O	O
estimating	ADV	O	O
equations	NOUN	O	O
.	PUNCT	O	O

Experimental	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
prevention	NOUN	O	O
programs	NOUN	O	O
often	ADV	O	O
randomize	ADJ	O	O
clusters	NOUN	O	O
of	ADP	O	O
individuals	NOUN	O	O
rather	PUNCT	O	O
than	ADP	O	O
individuals	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
the	DET	O	O
correlation	NOUN	O	O
among	ADP	O	O
individuals	NOUN	O	O
within	ADP	O	O
clusters	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
accounted	VERB	O	O
for	ADP	O	O
in	PUNCT	O	O
statistical	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
standard	ADJ	O	O
errors	NOUN	O	O
are	VERB	O	O
biased	PROPN	O	O
,	PUNCT	O	O
potentially	ADV	O	O
resulting	VERB	O	O
in	ADP	O	O
misleading	ADP	O	O
conclusions	NOUN	O	O
about	PUNCT	O	O
the	DET	O	O
significance	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrates	NOUN	O	O
the	DET	O	O
generalized	VERB	O	O
estimating	ADV	O	O
equations	NOUN	O	O
(	PUNCT	O	O
GEE	NOUN	O	O
)	PUNCT	O	O
method	NOUN	O	O
,	PUNCT	O	O
focusing	VERB	O	O
specifically	ADV	O	O
on	ADP	O	O
the	DET	O	O
GEE-independent	ADJ	O	O
method	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
control	NOUN	O	O
for	ADP	O	O
within-cluster	ADJ	O	O
correlation	NOUN	O	O
in	ADP	O	O
regression	NOUN	O	O
models	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
continuous	ADJ	O	B-OTHER
or	CCONJ	O	O
binary	ADJ	O	B-OTHER
outcomes	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
GEE-independent	ADJ	O	O
method	NOUN	O	O
yields	NOUN	O	O
consistent	ADJ	O	B-OTHER
and	CCONJ	O	O
robust	ADJ	O	B-OTHER
variance	PUNCT	O	O

Timing	DET	O	B-MORTALITY
of	ADP	O	I-MORTALITY
death	NOUN	O	I-MORTALITY
and	CCONJ	O	O
myocardial	ADJ	O	B-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
non-ST	NOUN	O	O
elevation	NOUN	O	O
acute	ADJ	O	O
coronary	ADJ	O	O
syndromes	NOUN	O	O
:	PUNCT	O	O
insights	NOUN	O	O
from	ADP	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Adverse	ADJ	O	O
events	NOUN	O	O
occur	VERB	O	O
following	ADJ	O	O
non-ST	NOUN	O	O
elevation	NOUN	O	O
acute	ADJ	O	O
coronary	ADJ	O	O
syndromes	NOUN	O	O
(	PUNCT	O	O
NSTE	NOUN	O	O
ACS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
timing	VERB	O	O
of	ADP	O	O
these	DET	O	O
events	NOUN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
index	NOUN	O	O
event	NOUN	O	O
is	VERB	O	O
less	DET	O	O
clear	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Accordingly	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
evaluated	VERB	O	O
26,466	NUM	O	O
NSTE	NOUN	O	O
ACS	NOUN	O	O
patients	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Global	ADJ	O	O
Use	NOUN	O	O
of	ADP	O	O
Strategies	NOUN	O	O
to	VERB	O	O
Open	ADJ	O	O
Occluded	ADJ	O	O
Arteries	NOUN	O	O
in	ADP	O	O
Acute	ADJ	O	O
Coronary	ADJ	O	O
Syndromes	NOUN	O	O
(	PUNCT	O	O
GUSTO-IIb	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Platelet	NOUN	O	O
Glycoprotein	NOUN	O	O
IIb/IIIa	NOUN	O	O
in	ADP	O	O
Unstable	ADJ	O	O
Angina	NOUN	O	O
:	PUNCT	O	O
Receptor	NOUN	O	O
Suppression	NOUN	O	O
Using	PROPN	O	O
Integrilin	NOUN	O	O
Therapy	NOUN	O	O
(	PUNCT	O	O
PURSUIT	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Platelet	NOUN	O	O
IIb/IIIa	NOUN	O	O
Antagonism	NOUN	O	O
for	ADP	O	O
the	DET	O	O
Reduction	NOUN	O	O
of	ADP	O	O
Acute	ADJ	O	O
Coronary	ADJ	O	O
Syndrome	NOUN	O	O
Events	NOUN	O	O
in	ADP	O	O
a	DET	O	O
Global	ADJ	O	O
Organization	NOUN	O	O
Network	NOUN	O	O
(	PUNCT	O	O
PARAGON	NOUN	O	O
)	PUNCT	O	O
A	DET	O	O
and	CCONJ	O	O
B	NOUN	O	O
trials	NOUN	O	O
to	PART	O	O
ascertain	NOUN	O	O
the	DET	O	O
timing	VERB	O	O
of	ADP	O	O
adverse	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

Outcomes	NOUN	O	O
of	ADP	O	O
interest	NOUN	O	O
were	VERB	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
myocardial	ADJ	O	B-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
MI	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
death	NOUN	O	B-MORTALITY
or	CCONJ	O	O
MI	NOUN	O	O
at	ADP	O	O
180	NUM	O	B-PHYSICAL
days	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Logistic	ADJ	O	O
regression	NOUN	O	O
modeling	ADJ	O	O
for	ADP	O	O
death	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
categorize	ADJ	O	O
patients	NOUN	O	O
into	ADP	O	O
low-	ADP	O	O
,	PUNCT	O	O
medium-	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
high-risk	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
6.2	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
died	VERB	O	B-MORTALITY
,	PUNCT	O	O
12.1	NUM	O	O
%	SYM	O	O
had	PUNCT	O	O
MI	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
15.7	NUM	O	O
%	SYM	O	O
suffered	VERB	O	O
death	NOUN	O	B-MORTALITY
or	PUNCT	O	O
MI	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

From	ADP	O	O
15	NUM	O	O
%	SYM	O	O
to	ADP	O	O
40	NUM	O	O
%	SYM	O	O
of	ADP	O	O
these	DET	O	O
events	NOUN	O	O
occurred	VERB	O	O
beyond	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
13	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
died	VERB	O	O
in	ADP	O	O
low-	ADJ	O	O
,	PUNCT	O	O
medium-	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
high-risk	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-MORTALITY
dying	CCONJ	O	I-MORTALITY
beyond	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
44	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
43	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
41	NUM	O	O
%	SYM	O	O
of	ADP	O	O
death	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
whereas	ADP	O	O
death	NOUN	O	B-MORTALITY
or	CCONJ	O	O
MI	NOUN	O	B-MORTALITY
increased	VERB	O	O
with	ADP	O	O
higher	PUNCT	O	O
risk	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
14	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
23	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
proportion	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
patients	NOUN	O	I-PHYSICAL
with	ADP	O	O
this	DET	O	O
event	NOUN	O	O
beyond	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
did	ADP	O	O
not	ADV	O	O
differ	VERB	O	O
in	ADP	O	O
the	DET	O	O
three	NUM	O	O
strata	NOUN	O	O
(	PUNCT	O	O
22	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
25	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	ADP	O	O
Our	PUNCT	O	O
study	NOUN	O	O
provides	NOUN	O	O
important	ADJ	O	O
insights	NOUN	O	O
into	ADP	O	O
the	DET	O	O
timing	VERB	O	O
of	ADP	O	O
adverse	ADJ	O	O
events	NOUN	O	O
and	CCONJ	O	O
suggests	NOUN	O	O
that	ADP	O	O
the	DET	O	O
substantial	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
suffer	ADP	O	O
subsequent	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
after	ADP	O	O
their	PUNCT	O	O
index	NOUN	O	O
NSTE	NOUN	O	O
ACS	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
data	NOUN	O	O
call	PUNCT	O	O
for	ADP	O	O
continuous	ADJ	O	O
surveillance	NOUN	O	O
for	ADP	O	O
these	DET	O	O
events	NOUN	O	O
and	CCONJ	O	O
efforts	NOUN	O	O
beyond	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
phase	NOUN	O	O
at	ADP	O	O
increasing	ADV	O	O
adherence	NOUN	O	O
to	ADP	O	O
evidence-based	ADJ	O	O
therapies	NOUN	O	O
to	PART	O	O
improve	ADJ	O	O
the	DET	O	O
outcomes	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomised	VERB	O	O
comparison	NOUN	O	O
of	ADP	O	O
UK	ADP	O	O
genetic	ADJ	O	O
risk	NOUN	O	O
counselling	ADJ	O	O
services	NOUN	O	O
for	ADP	O	O
familial	ADJ	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
psychosocial	ADJ	O	B-MENTAL
outcomes	NOUN	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
psychosocial	ADJ	O	B-MENTAL
outcomes	NOUN	O	I-MENTAL
for	ADP	O	O
50	NUM	O	O
new	ADJ	O	O
clinic	ADJ	O	O
attendees	NOUN	O	O
,	PUNCT	O	O
referred	VERB	O	O
for	ADP	O	O
cancer	NOUN	O	O
genetic	ADJ	O	O
counselling	VERB	O	O
to	ADP	O	O
five	ADV	O	O
UK	ADV	O	O
centres	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
centres	NOUN	O	O
represented	VERB	O	O
England	PUNCT	O	O
,	PUNCT	O	O
Scotland	PUNCT	O	O
and	CCONJ	O	O
Wales	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
randomly	ADV	O	O
selected	VERB	O	O
from	ADP	O	O
groups	NOUN	O	O
ranked	VERB	O	O
by	ADP	O	O
different	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	O
genetics	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

Questionnaires	NOUN	O	O
assessed	VERB	O	O
demographic	ADJ	O	B-OTHER
data	NOUN	O	I-OTHER
,	PUNCT	O	O
risk	NOUN	O	O
perception	NOUN	O	O
,	PUNCT	O	O
mental	ADJ	O	O
health	NOUN	O	O
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
health	NOUN	O	B-OTHER
services	NOUN	O	I-OTHER
pre-consultation	NOUN	O	I-OTHER
and	CCONJ	O	O
at	ADP	O	O
1	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Satisfaction	NOUN	O	B-OTHER
was	VERB	O	O
measured	VERB	O	O
for	ADP	O	O
attendees	NOUN	O	O
and	CCONJ	O	O
referring	PUNCT	O	O
doctors	NOUN	O	O
at	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
256	NUM	O	O
unaffected	VERB	O	O
adults	NOUN	O	O
fulfilled	PUNCT	O	O
the	DET	O	O
study	ADV	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
five	NUM	O	O
centres	NOUN	O	O
varied	VERB	O	O
widely	ADV	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
service	NOUN	O	O
organisation	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
all	DET	O	O
had	PUNCT	O	O
a	DET	O	O
greater	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	O
unaffected	VERB	O	O
attendees	NOUN	O	O
with	ADP	O	O
a	DET	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
risk	NOUN	O	O
(	PUNCT	O	O
61-91	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
than	ADP	O	O
either	PUNCT	O	O
a	DET	O	O
bowel	NOUN	O	O
cancer	NOUN	O	O
risk	NOUN	O	O
(	PUNCT	O	O
0-33	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
risk	NOUN	O	O
(	PUNCT	O	O
3-25	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
psychosocial	ADJ	O	B-MENTAL
data	NOUN	O	I-MENTAL
between	ADP	O	O
centres	NOUN	O	O
pre-counselling	CCONJ	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
over	PUNCT	O	O
time	NOUN	O	O
occurred	VERB	O	O
for	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
centres	NOUN	O	O
for	ADP	O	O
risk	NOUN	O	O
perception	NOUN	O	B-OTHER
or	CCONJ	O	O
general	ADJ	O	B-MENTAL
psychological	ADJ	O	I-MENTAL
distress	NOUN	O	I-MENTAL
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
centres	NOUN	O	O
in	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	B-PHYSICAL
worry	PUNCT	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
recommended	VERB	O	O
to	PUNCT	O	O
have	PUNCT	O	O
mammographic	ADJ	O	O
surveillance	NOUN	O	O
who	ADP	O	O
had	ADJ	O	O
not	ADV	O	O
received	PUNCT	O	O
this	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
one-third	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
for	ADP	O	O
whom	ADP	O	O
mammography	NOUN	O	O
had	PUNCT	O	O
been	PUNCT	O	O
recommended	VERB	O	O
had	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
screened	VERB	O	O
within	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Subsequent	ADJ	O	O
attendance	NOUN	O	O
at	ADP	O	O
the	DET	O	O
GP	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
at	ADP	O	O
a	DET	O	O
hospital	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
risk	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
differences	NOUN	O	O
between	ADP	O	O
centres	NOUN	O	O
could	VERB	O	O
not	ADV	O	O
be	ADP	O	O
analysed	VERB	O	O
.	PUNCT	O	O

Satisfaction	NOUN	O	B-OTHER
differed	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
centres	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
:	PUNCT	O	O
14	NUM	O	O
aspects	NOUN	O	O
of	ADP	O	O
service	NOUN	O	O
provision	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
3	NUM	O	O
:	PUNCT	O	O
17	NUM	O	O
items	ADJ	O	O
concerning	SYM	O	O
communication	NOUN	O	O
;	PUNCT	O	O
satisfaction	NOUN	O	O
was	VERB	O	O
high	ADJ	O	O
overall	ADV	O	O
.	PUNCT	O	O

Over	ADV	O	O
90	NUM	O	O
%	SYM	O	O
of	ADP	O	O
referring	VERB	O	O
doctors	NOUN	O	O
were	VERB	O	O
moderately/very	PUNCT	O	O
satisfied	VERB	O	O
with	ADP	O	O
the	DET	O	O
service	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
23	NUM	O	O
%	SYM	O	O
were	VERB	O	O
dissatisfied	VERB	O	O
with	ADP	O	O
waiting	PUNCT	O	O
times	NOUN	O	O
and	CCONJ	O	O
19	NUM	O	O
%	SYM	O	O
with	ADP	O	O
access	NOUN	O	O
to	ADP	O	O
preventive	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
differed	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
centres	NOUN	O	O
for	ADP	O	O
doctor	NOUN	O	O
's	PUNCT	O	O
satisfaction	NOUN	O	O
with	ADP	O	O
the	DET	O	O
provision	NOUN	O	O
of	ADP	O	O
referral	ADJ	O	O
criteria	NOUN	O	O
and	CCONJ	O	O
prescribing	VERB	O	O
information	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
relatively	ADV	O	O
few	ADJ	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
psychosocial	ADJ	O	B-MENTAL
outcomes	NOUN	O	I-MENTAL
between	ADP	O	O
centres	NOUN	O	O
,	PUNCT	O	O
considering	ADP	O	O
the	DET	O	O
wide	ADJ	O	O
variation	NOUN	O	O
in	ADP	O	O
service	NOUN	O	O
organisation	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
consistent	ADJ	O	O
across	ADP	O	O
the	DET	O	O
centres	NOUN	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
differences	NOUN	O	O
could	ADP	O	O
not	ADV	O	O
be	VERB	O	O
linked	VERB	O	O
to	ADP	O	O
specific	ADJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
service	NOUN	O	O
provision	NOUN	O	O
.	PUNCT	O	O

Dronabinol	NOUN	O	O
versus	CCONJ	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
versus	CCONJ	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
cancer-associated	VERB	O	O
anorexia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
North	NOUN	O	O
Central	ADJ	O	O
Cancer	NOUN	O	O
Treatment	NOUN	O	O
Group	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
determine	NOUN	O	O
whether	ADP	O	O
dronabinol	NOUN	O	O
administered	VERB	O	O
alone	ADJ	O	O
or	CCONJ	O	O
with	ADP	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
was	VERB	O	O
more	DET	O	O
,	PUNCT	O	O
less	DET	O	O
,	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
in	ADP	O	O
efficacy	NOUN	O	O
to	ADP	O	O
single-agent	PUNCT	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
for	ADP	O	O
palliating	VERB	O	O
cancer-associated	VERB	O	O
anorexia	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Four	NUM	O	O
hundred	NUM	O	O
sixty-nine	NOUN	O	O
assessable	ADJ	O	O
advanced	VERB	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
oral	ADJ	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
800	NUM	O	O
mg/d	NOUN	O	O
liquid	NOUN	O	O
suspension	NOUN	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
oral	ADJ	O	O
dronabinol	NOUN	O	O
2.5	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
both	PUNCT	O	O
agents	NOUN	O	O
.	PUNCT	O	O

Eligible	ADJ	O	O
patients	NOUN	O	O
acknowledged	VERB	O	O
that	ADP	O	O
loss	NOUN	O	O
of	ADP	O	O
appetite	NOUN	O	O
or	CCONJ	O	O
weight	NOUN	O	O
was	VERB	O	O
a	DET	O	O
problem	NOUN	O	O
and	CCONJ	O	O
reported	VERB	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
pounds	NOUN	O	O
or	CCONJ	O	O
more	DET	O	O
during	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
and/or	CCONJ	O	O
a	DET	O	O
daily	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
less	ADV	O	O
than	CCONJ	O	O
20	NUM	O	O
calories/kg	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Groups	PUNCT	O	O
were	VERB	O	O
comparable	ADJ	O	O
at	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
tumor	NOUN	O	O
type	NOUN	O	O
,	PUNCT	O	O
weight	NOUN	O	O
loss	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
performance	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
greater	PUNCT	O	O
percentage	NOUN	O	O
of	ADP	O	O
megestrol	NOUN	O	O
acetate-treated	VERB	O	O
patients	NOUN	O	O
reported	ADV	O	O
appetite	NOUN	O	B-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
weight	NOUN	O	O
gain	NOUN	O	B-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
dronabinol-treated	VERB	O	O
patients	NOUN	O	O
:	PUNCT	O	O
75	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
49	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=.0001	ADP	O	O
)	PUNCT	O	O
for	ADP	O	O
appetite	NOUN	O	O
and	CCONJ	O	O
11	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
3	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=.02	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
>	ADJ	O	O
or	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
%	SYM	O	O
baseline	NOUN	O	O
weight	NOUN	O	O
gain	NOUN	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
appetite	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
weight	NOUN	O	B-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
Functional	ADJ	O	O
Assessment	NOUN	O	O
of	ADP	O	O
Anorexia/Cachexia	NOUN	O	O
Therapy	NOUN	O	O
questionnaire	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
emphasizes	NOUN	O	O
anorexia-related	ADJ	O	O
questions	NOUN	O	O
,	PUNCT	O	O
demonstrated	VERB	O	O
an	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
(	PUNCT	O	B-OTHER
QOL	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
among	ADP	O	O
megestrol	NOUN	O	O
acetate-treated	VERB	O	O
and	CCONJ	O	O
combination-treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
single-item	NOUN	O	O
Uniscale	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
global	ADJ	O	O
QOL	NOUN	O	B-OTHER
instrument	NOUN	O	O
,	PUNCT	O	O
found	VERB	O	O
comparable	ADJ	O	O
scores	NOUN	O	O
.	PUNCT	O	O

Toxicity	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
also	ADV	O	O
comparable	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
impotence	NOUN	O	B-PHYSICAL
among	ADP	O	O
men	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
megestrol	NOUN	O	O
acetate	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
In	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
and	CCONJ	O	O
schedules	NOUN	O	O
we	ADJ	O	O
studied	VERB	O	O
,	PUNCT	O	O
megestrol	NUM	O	O
acetate	NOUN	O	O
provided	ADP	O	O
superior	ADJ	O	O
anorexia	NOUN	O	O
palliation	NOUN	O	O
among	ADP	O	O
advanced	VERB	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
dronabinol	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
therapy	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
confer	ADJ	O	O
additional	ADJ	O	O
benefit	NOUN	O	O
.	PUNCT	O	O

Bevacizumab	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
macular	ADJ	O	O
laser	NOUN	O	O
grid	NOUN	O	O
photocoagulation	NOUN	O	O
for	ADP	O	O
cystoid	NOUN	O	O
macular	ADJ	O	O
edema	NOUN	O	O
in	ADP	O	O
branch	NOUN	O	O
retinal	ADJ	O	O
vein	NOUN	O	O
occlusion	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
To	ADV	O	O
evaluate	NOUN	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
cystoid	NOUN	O	O
macular	ADJ	O	O
edema	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
intravitreal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
bevacizumab	PUNCT	O	O
and	CCONJ	O	O
macular	ADJ	O	O
grid	NOUN	O	O
laser	NOUN	O	O
photocoagulation	NOUN	O	O
(	PUNCT	O	O
GLP	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
perfused	VERB	O	O
branch	NOUN	O	O
retinal	ADJ	O	O
vein	NOUN	O	O
occlusion	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Thirty	NUM	O	O
eyes	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
cystoid	NOUN	O	O
macular	ADJ	O	O
edema	NOUN	O	O
secondary	ADJ	O	O
to	ADP	O	O
nonischemic	ADJ	O	O
branch	NOUN	O	O
retinal	ADJ	O	O
vein	NOUN	O	O
occlusion	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
GLP	NOUN	O	O
group	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
intravitreal	ADJ	O	O
bevacizumab	PUNCT	O	O
(	PUNCT	O	O
IB	NOUN	O	O
)	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

Complete	ADJ	O	B-PHYSICAL
ophthalmologic	ADJ	O	I-PHYSICAL
examinations	NOUN	O	I-PHYSICAL
were	VERB	O	O
performed	VERB	O	O
just	ADV	O	O
before	PUNCT	O	O
GLP	NOUN	O	O
and	CCONJ	O	O
IB	NOUN	O	O
injection	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
logarithm	NOUN	O	O
of	ADP	O	B-PHYSICAL
minimum	NOUN	O	I-PHYSICAL
angle	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
resolution	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
logMAR	NUM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
best-corrected	VERB	O	I-PHYSICAL
visual	ADJ	O	I-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BCVA	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
central	ADJ	O	B-PHYSICAL
macular	ADJ	O	I-PHYSICAL
thickness	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
CMT	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
shown	VERB	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
optical	ADJ	O	B-PHYSICAL
coherence	NOUN	O	O
tomography-3	NOUN	O	B-PHYSICAL
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Baseline	NOUN	O	O
BCVA	NOUN	O	O
(	PUNCT	O	O
logMAR	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
CMT	NOUN	O	O
were	VERB	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
0.89	NUM	O	O
+/-	SYM	O	O
0.13	NUM	O	O
and	CCONJ	O	O
650	NUM	O	O
+/-	SYM	O	O
140	NUM	O	O
microm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
GLP	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
0.87	NUM	O	O
+/-	SYM	O	O
0.16	NUM	O	O
and	CCONJ	O	O
690	NUM	O	O
+/-	SYM	O	O
120	NUM	O	O
microm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
IB	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
GLP	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
BCVA	NOUN	O	B-PHYSICAL
had	PUNCT	O	O
improved	VERB	O	O
by	ADP	O	O
0.19	NUM	O	O
,	PUNCT	O	O
0.22	NUM	O	O
,	PUNCT	O	O
0.21	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0.20	NUM	O	O
logMAR	NUM	O	O
,	PUNCT	O	O
CMT	NOUN	O	B-PHYSICAL
had	PUNCT	O	O
decreased	VERB	O	O
by	ADP	O	O
40	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
41.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
40.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
42	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
IB	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
BCVA	NOUN	O	B-PHYSICAL
had	PUNCT	O	O
improved	VERB	O	O
by	ADP	O	O
0.31	NUM	O	O
,	PUNCT	O	O
0.32	NUM	O	O
,	PUNCT	O	O
0.30	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0.31	NUM	O	O
logMAR	NUM	O	B-PHYSICAL
and	CCONJ	O	O
CMT	NOUN	O	B-PHYSICAL
had	PUNCT	O	O
decreased	VERB	O	O
by	ADP	O	O
59.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
59	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
60	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
60.3	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
group	NOUN	O	O
receiving	CCONJ	O	O
bevacizumab	ADJ	O	O
had	PUNCT	O	O
better	PUNCT	O	O
BCVA	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
lower	PUNCT	O	O
CMT	NOUN	O	B-PHYSICAL
values	NOUN	O	O
at	ADP	O	O
all	DET	O	O
time	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Intravitreal	PUNCT	O	O
bevacizumab	PUNCT	O	O
injection	NOUN	O	O
improves	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
caregiver	NOUN	O	O
intervention	NOUN	O	O
on	ADP	O	O
negative	ADJ	O	O
caregiver	NOUN	O	O
appraisals	NOUN	O	O
of	ADP	O	O
behavior	ADJ	O	O
problems	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Alzheimer	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Behavioral	ADJ	O	O
problems	NOUN	O	O
are	VERB	O	O
among	ADP	O	O
the	DET	O	O
most	VERB	O	O
challenging	VERB	O	O
aspects	NOUN	O	O
of	ADP	O	O
caring	ADJ	O	O
for	ADP	O	O
a	DET	O	O
person	NOUN	O	O
with	ADP	O	O
Alzheimer	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
406	NUM	O	O
spouses-caregivers	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Alzheimer	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
was	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
an	DET	O	O
active	ADJ	O	O
multicomponent	PUNCT	O	O
counseling	PUNCT	O	O
and	CCONJ	O	O
support	ADP	O	O
intervention	NOUN	O	O
condition	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
usual	ADJ	O	O
care	NOUN	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Caregivers	NOUN	O	O
reported	VERB	O	O
on	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
troublesome	PUNCT	O	B-MENTAL
patient	NOUN	O	I-MENTAL
behaviors	NOUN	O	I-MENTAL
and	CCONJ	O	I-MENTAL
their	ADJ	O	I-MENTAL
reactions	NOUN	O	I-MENTAL
to	ADP	O	I-MENTAL
them	PUNCT	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
regular	ADJ	O	O
follow-up	NOUN	O	O
interviews	NOUN	O	O
.	PUNCT	O	O

Random-effects	VERB	O	O
regression	NOUN	O	O
models	NOUN	O	O
over	ADP	O	O
the	DET	O	O
first	ADJ	O	O
4	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
randomization	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
did	DET	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
behavioral	ADJ	O	O
problems	NOUN	O	O
,	PUNCT	O	O
it	PROPN	O	O
did	PUNCT	O	O
significantly	ADV	O	O
reduce	VERB	O	O
caregivers	NOUN	O	B-MENTAL
'	PUNCT	O	O
reaction	PUNCT	O	B-MENTAL

Etanercept	PUNCT	O	O
treatment	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
established	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
:	PUNCT	O	O
7	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
experience	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
longterm	NOUN	O	O
etanercept	PUNCT	O	O
treatment	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
disease	NOUN	O	O
modifying	NUM	O	O
antirheumatic	ADJ	O	O
drug	NOUN	O	O
(	PUNCT	O	O
DMARD	NOUN	O	O
)	PUNCT	O	O
refractory	ADJ	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
(	PUNCT	O	O
RA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Safety	NOUN	O	O
results	NOUN	O	O
are	VERB	O	O
reported	VERB	O	O
for	ADP	O	O
714	NUM	O	O
patients	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
etanercept	PUNCT	O	O
in	ADP	O	O
one	NUM	O	O
of	ADP	O	O
7	NUM	O	O
initial	ADJ	O	O
trials	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
longterm	NOUN	O	O
extension	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
results	CCONJ	O	O
are	VERB	O	O
reported	VERB	O	O
for	ADP	O	O
581	NUM	O	O
patients	NOUN	O	O
who	PROPN	O	O
enrolled	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
extension	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
714	NUM	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
trials	NOUN	O	O
,	PUNCT	O	O
581	NUM	O	O
(	PUNCT	O	O
81	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
enrolled	ADV	O	O
in	ADP	O	O
the	DET	O	O
extension	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
388	NUM	O	O
(	PUNCT	O	O
54	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
are	VERB	O	O
continuing	PUNCT	O	O
to	DET	O	O
receive	ADP	O	O
etanercept	PUNCT	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
longest	PUNCT	O	O
individual	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
8.2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
3139	NUM	O	O
total	ADJ	O	O
patient-years	NOUN	O	O
of	ADP	O	O
etanercept	PUNCT	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

Rates	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
overall	PUNCT	O	O
rate=14.8	PUNCT	O	O
events/100	PUNCT	O	O
patient-yrs	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
infections	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
overall	ADJ	O	O
rate=4.2	NOUN	O	O
events/100	PUNCT	O	O
patient-yrs	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cancer	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
overall	PUNCT	O	O
rate=1.0	ADP	O	O
events/100	PUNCT	O	O
patient-yrs	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
deaths	NOUN	O	B-MORTALITY
(	PUNCT	O	O
overall	PUNCT	O	O
rate=0.7	PUNCT	O	O
events/100	PUNCT	O	O
patient-yrs	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
stable	ADJ	O	O
each	DET	O	O
year	NOUN	O	O
,	PUNCT	O	O
through	ADP	O	O
8	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
etanercept	PUNCT	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
356	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
completed	PROPN	O	O
6	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
etanercept	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
response	NOUN	O	O
rates	NOUN	O	B-OTHER
were	VERB	O	O
ACR20=73	ADP	O	O
%	SYM	O	O
,	PUNCT	O	O
ACR50=52	ADJ	O	O
%	SYM	O	O
,	PUNCT	O	O
ACR70=27	NOUN	O	O
%	SYM	O	O
,	PUNCT	O	O
DAS28	NOUN	O	O
CRP	NOUN	O	O
good	ADJ	O	O
response=52	NOUN	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
DAS28	NOUN	O	O
CRP	NOUN	O	O
remission=37	NOUN	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
responses	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
167	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
completed	CCONJ	O	O
Year	NOUN	O	O
7	NUM	O	O
.	PUNCT	O	O

Doses	NOUN	O	B-OTHER
of	ADP	O	O
concomitant	ADJ	O	O
methotrexate	NOUN	O	O
or	CCONJ	O	O
corticosteroids	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
many	DET	O	O
patients	NOUN	O	O
who	PROPN	O	O
maintained	VERB	O	O
clinical	ADJ	O	O
responses	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
safety	NOUN	O	B-OTHER
profile	NOUN	O	I-OTHER
of	ADP	O	O
etanercept	PUNCT	O	O
was	VERB	O	O
consistent	ADJ	O	O
over	PUNCT	O	O
time	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
rates	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
reported	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
RA	NOUN	O	O
in	ADP	O	O
general	NOUN	O	O
.	PUNCT	O	O

Durable	ADJ	O	O
clinical	ADJ	O	O
responses	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
years	NOUN	O	O
or	CCONJ	O	O
more	DET	O	O
.	PUNCT	O	O

The	DET	O	O
benefit-to-risk	NOUN	O	O
ratio	NOUN	O	O
for	ADP	O	O
longterm	NOUN	O	O
etanercept	PUNCT	O	O
treatment	NOUN	O	O
remains	NOUN	O	O
highly	ADV	O	O
favorable	ADJ	O	O
.	PUNCT	O	O

Hypoxic	ADJ	O	O
exercise	NOUN	O	O
training	ADV	O	O
reduces	SYM	O	O
senescent	ADJ	O	B-PHYSICAL
T-lymphocyte	NOUN	O	I-PHYSICAL
subsets	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
integration	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
immune	ADJ	O	O
responses	NOUN	O	O
depends	NOUN	O	O
on	ADP	O	O
the	DET	O	O
regulated	ADP	O	O
trafficking	ADJ	O	O
of	ADP	O	O
T-lymphocytes	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
elucidates	ADV	O	O
how	ADP	O	O
various	ADJ	O	O
exercises	DET	O	O
regimens	CCONJ	O	O
with/without	PUNCT	O	O
hypoxia	NOUN	O	O
affect	VERB	O	O
phenotypic	ADJ	O	B-PHYSICAL
characteristics	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
T-lymphocyte	NOUN	O	I-PHYSICAL
subsets	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Fifty	NUM	O	O
sedentary	ADJ	O	O
males	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
five	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=10	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
one	NUM	O	O
of	ADP	O	O
five	NUM	O	O
interventions	NOUN	O	O
:	PUNCT	O	O
normoxic	ADJ	O	O
(	PUNCT	O	O
21	NUM	O	O
%	SYM	O	O
O?	NOUN	O	O
)	PUNCT	O	O
resting	PUNCT	O	O
(	PUNCT	O	O
N-C	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hypoxic	ADJ	O	O
(	PUNCT	O	O
15	NUM	O	O
%	SYM	O	O
O?	NOUN	O	O
)	PUNCT	O	O
resting	PUNCT	O	O
(	PUNCT	O	O
H-C	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
normoxic	ADJ	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
W	NOUN	O	O
(	PUNCT	O	O
max	NOUN	O	O
)	PUNCT	O	O
under	ADP	O	O
21	NUM	O	O
%	SYM	O	O
O?	NOUN	O	O
,	PUNCT	O	O
N-T	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hypoxic-relative	ADJ	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
maximal	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
reserve	NOUN	O	O
under	ADP	O	O
15	NUM	O	O
%	SYM	O	O
O?	NOUN	O	O
,	PUNCT	O	O
H-RT	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
hypoxic-absolute	NOUN	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
W	NOUN	O	O
(	PUNCT	O	O
max	NOUN	O	O
)	PUNCT	O	O
under	ADP	O	O
15	NUM	O	O
%	SYM	O	O
O?	NOUN	O	O
,	PUNCT	O	O
H-AT	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
30	NUM	O	O
min/day	PUNCT	O	O
,	PUNCT	O	O
5	NUM	O	O
days/week	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
strenuous	ADJ	O	O
exercise	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
exhaustion	NOUN	O	O
increased	PUNCT	O	O
the	DET	O	O
mobilization	NOUN	O	O
of	ADP	O	O
CD3	NOUN	O	O
,	PUNCT	O	O
CD4	NOUN	O	O
,	PUNCT	O	O
CD8	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
CD8	NOUN	O	O
(	PUNCT	O	O
bright	ADJ	O	O
)	PUNCT	O	O
lymphocytes	NOUN	O	O
expressing	PROPN	O	O
activated	NOUN	O	O
(	PUNCT	O	O
CD11a	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
senescent	ADJ	O	O
(	PUNCT	O	O
KLRG1	NOUN	O	O
)	PUNCT	O	O
molecules	NOUN	O	O
into	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
compartment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
H-AT	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
up-regulated	ADP	O	O
co-stimulatory	PUNCT	O	O
molecule	NOUN	O	O
CD28	NOUN	O	O
expression	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
depressed	VERB	O	O
KLRG1	NOUN	O	O
level	NOUN	O	O
on	ADP	O	O
CD3	NOUN	O	O
,	PUNCT	O	O
CD4	NOUN	O	O
,	PUNCT	O	O
CD8	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
CD8	NOUN	O	O
(	PUNCT	O	O
bright	ADJ	O	O
)	PUNCT	O	O
lymphocytes	NOUN	O	O
at	ADP	O	O
rest	NOUN	O	O
or	CCONJ	O	O
following	PUNCT	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Simultaneously	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
intervention	NOUN	O	O
increased	VERB	O	O
interferon-?	PUNCT	O	O
(	PUNCT	O	O
IFN-?	NOUN	O	O
)	PUNCT	O	O
level	NOUN	O	O
and	CCONJ	O	O
unchanged	VERB	O	O
interleukin-4	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
,	PUNCT	O	O
decreased	VERB	O	O
myeloperoxidase	NOUN	O	O
(	PUNCT	O	O
MPO	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
interleukin-6	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
resting	VERB	O	O
and	CCONJ	O	O
exercise-induced	VERB	O	O
mobilizations	NOUN	O	O
of	ADP	O	O
various	ADJ	O	O
T-lymphocyte	NOUN	O	O
subsets	NOUN	O	O
and	CCONJ	O	O
productions	NOUN	O	O
of	ADP	O	O
cytokines	NOUN	O	O
and	CCONJ	O	O
MPO	NOUN	O	O
occurred	VERB	O	O
following	VERB	O	O
the	DET	O	O
N-C	NOUN	O	O
,	PUNCT	O	O
H-C	NOUN	O	O
,	PUNCT	O	O
N-T	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
H-RT	NOUN	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
4-week	NOUN	O	O
H-AT	NOUN	O	O
intervention	NOUN	O	O
reduced	CCONJ	O	O
senescent	ADJ	O	O
T-lymphocyte	NOUN	O	O
subsets	NOUN	O	O
with	ADP	O	O
increasing	ADJ	O	O
IFN-?	NOUN	O	O
level	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
,	PUNCT	O	O
which	DET	O	O
responses	NOUN	O	O
are	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
depressed	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
pro-inflammatory	ADJ	O	O
cytokine	NOUN	O	O
production	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
can	PROPN	O	O
help	VERB	O	O
to	ADJ	O	O
determine	ADV	O	O
an	DET	O	O
effective	ADJ	O	O
hypoxic	ADJ	O	O
exercise	NOUN	O	O
regimen	NOUN	O	O
to	PART	O	O
minimize	NOUN	O	O
immune	ADJ	O	O
dysfunction	NOUN	O	O
by	ADP	O	O
retarding	PUNCT	O	O
T-lymphocyte	NOUN	O	O
senescence	ADP	O	O
.	PUNCT	O	O

Should	CCONJ	O	O
insertion	NOUN	O	O
of	ADP	O	O
intramedullary	ADJ	O	O
nails	NOUN	O	O
for	ADP	O	O
tibial	ADJ	O	O
fractures	NOUN	O	O
be	CCONJ	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
reaming	ADP	O	O
?	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
with	ADP	O	O
3.8	NUM	O	O
years	NOUN	O	O
'	PUNCT	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
if	PUNCT	O	O
any	DET	O	O
differences	NOUN	O	O
exist	VERB	O	O
in	ADP	O	O
healing	VERB	O	B-PHYSICAL
and	CCONJ	O	O
complications	NOUN	O	O
between	ADP	O	O
reamed	VERB	O	O
and	CCONJ	O	O
unreamed	VERB	O	O
nailing	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
tibial	ADJ	O	O
shaft	ADJ	O	O
fractures	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Level	NOUN	O	O
1	NUM	O	O
trauma	NOUN	O	O
center	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
Forty-five	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
displaced	VERB	O	O
closed	VERB	O	O
and	CCONJ	O	O
open	ADJ	O	O
Gustilo	NOUN	O	O
type	NOUN	O	O
I-IIIA	ADJ	O	O
fractures	NOUN	O	O
of	ADP	O	O
the	DET	O	O
central	ADJ	O	O
two	NUM	O	O
thirds	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tibia	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
Stabilization	NOUN	O	O
of	ADP	O	O
tibial	ADJ	O	O
fractures	NOUN	O	O
either	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
slotted	VERB	O	O
,	PUNCT	O	O
stainless	NOUN	O	O
steel	NOUN	O	O
reamed	VERB	O	O
nail	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
solid	ADP	O	O
,	PUNCT	O	O
titanium	NOUN	O	O
unreamed	NOUN	O	O
nail	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASUREMENTS	NOUN	O	O
Nonunions	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
fracture	NOUN	O	I-OTHER
healing	VERB	O	I-OTHER
,	PUNCT	O	I-OTHER
and	CCONJ	O	I-OTHER
rate	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
malunions	NOUN	O	I-OTHER
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
average	ADJ	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
fracture	NOUN	O	I-OTHER
healing	VERB	O	I-OTHER
was	VERB	O	O
16.7	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
reamed	VERB	O	O
group	NOUN	O	O
and	CCONJ	O	O
25.7	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
unreamed	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
three	NUM	O	O
nonunions	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
all	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
unreamed	VERB	O	O
nail	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
of	ADP	O	O
these	DET	O	O
fractures	NOUN	O	O
healed	VERB	O	O
after	ADP	O	O
dynamization	NOUN	O	B-PHYSICAL
by	ADP	O	I-PHYSICAL
removing	VERB	O	I-PHYSICAL
static	ADJ	O	I-PHYSICAL
interlocking	ADP	O	I-PHYSICAL
screws	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
third	ADJ	O	O
nonunion	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
heal	PUNCT	O	B-PHYSICAL
despite	ADP	O	O
exchange	NOUN	O	O
reamed	DET	O	O
nailing	VERB	O	O
2	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
dynamization	NOUN	O	O
with	ADP	O	O
a	DET	O	O
fibular	ADJ	O	O
osteotomy	NOUN	O	O
after	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
two	NUM	O	O
malunions	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
reamed	VERB	O	O
group	NOUN	O	O
and	CCONJ	O	O
four	NUM	O	O
malunions	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
unreamed	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
for	ADP	O	O
all	DET	O	O
other	ADJ	O	O
outcome	NOUN	O	O
measurements	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Unreamed	PUNCT	O	O
nailing	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
tibial	ADJ	O	O
shaft	ADJ	O	O
fractures	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
higher	PUNCT	O	O
rates	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	B-OTHER
operations	NOUN	O	I-OTHER
and	CCONJ	O	O
malunions	NOUN	O	B-OTHER
compared	VERB	O	O
with	ADP	O	O
reamed	VERB	O	O
nailing	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
fracture	NOUN	O	I-OTHER
healing	VERB	O	I-OTHER
was	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
with	ADP	O	O
unreamed	NOUN	O	O
nails	VERB	O	O
.	PUNCT	O	O

Dofequidar	NOUN	O	O
fumarate	NOUN	O	O
(	PUNCT	O	O
MS-209	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fluorouracil	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
or	CCONJ	O	O
recurrent	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
dofequidar	NOUN	O	O
plus	CCONJ	O	O
cyclophosphamide	NOUN	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fluorouracil	NOUN	O	O
(	PUNCT	O	O
CAF	NOUN	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
CAF	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
or	CCONJ	O	O
recurrent	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Dofequidar	NOUN	O	O
is	VERB	O	O
a	DET	O	O
novel	ADJ	O	O
,	PUNCT	O	O
orally	ADV	O	O
active	ADJ	O	O
quinoline	NUM	O	O
derivative	NOUN	O	O
that	ADP	O	O
reverses	PUNCT	O	O
multidrug	NOUN	O	O
resistance	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
six	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
CAF	NOUN	O	O
therapy	NOUN	O	O
:	PUNCT	O	O
28	NUM	O	O
days/cycle	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
doxorubicin	NOUN	O	O
(	PUNCT	O	O
25	ADP	O	O
mg/m2	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fluorouracil	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg/m2	ADV	O	O
)	PUNCT	O	O
administered	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg	NOUN	O	O
orally	ADV	O	O
[	PUNCT	O	O
PO	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
administered	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
through	ADP	O	O
14	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
dofequidar	NOUN	O	O
(	PUNCT	O	O
900	NUM	O	O
mg	NOUN	O	O
PO	NOUN	O	O
)	PUNCT	O	O
30	NUM	O	O
minutes	NOUN	O	O
before	CCONJ	O	O
each	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
overall	ADJ	O	B-PHYSICAL
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ORR	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
partial	ADJ	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
complete	ADJ	O	B-PHYSICAL
response	NOUN	O	O
)	PUNCT	O	B-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
total	NOUN	O	O
,	PUNCT	O	O
221	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
assessable	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
ORR	NOUN	O	B-PHYSICAL
was	VERB	O	O
42.6	NUM	O	O
%	SYM	O	O
for	ADP	O	O
CAF	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
53.1	NUM	O	O
%	SYM	O	O
for	ADP	O	O
dofequidar	NOUN	O	O
+	SYM	O	O
CAF	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
24.6	NUM	O	O
%	ADJ	O	O
relative	ADJ	O	O
improvement	NOUN	O	O
and	CCONJ	O	O
10.5	NUM	O	O
%	SYM	O	O
absolute	ADJ	O	O
increase	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.077	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
for	ADP	O	O
prolonged	VERB	O	B-ADVERSE-EFFECTS
progression-free	NOUN	O	B-ADVERSE-EFFECTS
survival	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	I-ADVERSE-EFFECTS
PFS	NOUN	O	I-ADVERSE-EFFECTS
;	PUNCT	O	O
median	ADJ	O	O
241	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
CAF	NOUN	O	O
v	CCONJ	O	O
366	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
dofequidar	NOUN	O	O
+	SYM	O	O
CAF	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.145	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
retrospectively	ADV	O	O
defined	VERB	O	O
subgroups	NOUN	O	O
,	PUNCT	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	PUNCT	O	O

A	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
cisapride	NOUN	O	O
in	ADP	O	O
anorexia	PUNCT	O	O
nervosa	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
cisapride	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
three	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
improving	VERB	O	O
gastric	ADJ	O	B-PHYSICAL
emptying	ADJ	O	I-PHYSICAL
,	PUNCT	O	O
reducing	VERB	O	O
distress	NOUN	O	B-MENTAL
during	ADP	O	I-MENTAL
meals	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
facilitating	PUNCT	O	O
weight	NOUN	O	O
gain	NOUN	O	B-MENTAL
in	ADP	O	O
anorexia	PUNCT	O	O
nervosa	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
conducted	VERB	O	O
an	DET	O	O
8-week	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
on	ADP	O	O
29	NUM	O	O
inpatients	NOUN	O	O
.	PUNCT	O	O

Measures	NOUN	O	O
included	VERB	O	O
scintigraphic	ADJ	O	O
gastric	ADJ	O	O
emptying	PUNCT	O	O
studies	NOUN	O	O
at	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
8	NUM	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
subjective	ADJ	O	B-MENTAL
distress	NOUN	O	I-MENTAL
during	ADP	O	I-MENTAL
meals	NOUN	O	I-MENTAL
measured	VERB	O	O
by	ADP	O	O
visual	ADJ	O	B-OTHER
analogue	NOUN	O	I-OTHER
scales	NOUN	O	I-OTHER
;	PUNCT	O	O
self-rating	CCONJ	O	B-OTHER
of	ADP	O	I-OTHER
degree	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
global	ADJ	O	I-OTHER
improvement	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
symptoms	NOUN	O	I-OTHER
associated	VERB	O	O
with	ADP	O	B-OTHER
eating	ADP	O	B-OTHER
at	ADP	O	O
end	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
weight	NOUN	O	O
measured	ADP	O	O
weekly	ADV	O	O
.	PUNCT	O	O

Gastric	ADJ	O	B-PHYSICAL
emptying	ADJ	O	B-PHYSICAL
improved	VERB	O	O
significantly	ADV	O	O
but	CCONJ	O	O
equally	ADV	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
over	ADP	O	O
the	DET	O	O
study	ADV	O	O
period	NOUN	O	O
.	PUNCT	O	O

Yet	ADV	O	O
subjective	ADJ	O	O
measures	NOUN	O	O
were	VERB	O	O
better	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
cisapride	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
they	ADV	O	O
rated	PUNCT	O	O
themselves	PUNCT	O	O
as	PUNCT	O	O
more	CCONJ	O	O
hungry	NOUN	O	B-MENTAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
more	DET	O	O
improved	VERB	O	O
on	ADP	O	O
the	DET	O	O
global	ADJ	O	O
measure	NOUN	O	O
of	ADP	O	O
change	NOUN	O	B-OTHER
in	ADP	O	B-OTHER
symptoms	NOUN	O	I-OTHER
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Even	ADV	O	O
so	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
cisapride	NOUN	O	O
group	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
gain	VERB	O	O
more	DET	O	O
weight	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
correlation	NOUN	O	O
between	PUNCT	O	O

TEN	NUM	O	O
versus	CCONJ	O	O
TPN	NOUN	O	O
following	VERB	O	O
major	ADJ	O	O
abdominal	ADJ	O	O
trauma	NOUN	O	O
--	PUNCT	O	O
reduced	VERB	O	O
septic	ADJ	O	O
morbidity	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
animal	NOUN	O	O
models	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
enteral	ADJ	O	O
feeding	ADJ	O	O
(	PUNCT	O	O
TEN	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
parenteral	ADJ	O	O
nutrition	NOUN	O	O
(	PUNCT	O	O
TPN	NOUN	O	O
)	PUNCT	O	O
improves	NOUN	O	O
resistance	NOUN	O	O
to	ADP	O	O
infection	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
TEN	NUM	O	O
vs.	CCONJ	O	O
TPN	NOUN	O	O
in	ADP	O	O
the	DET	O	O
critically	ADV	O	O
injured	NUM	O	O
.	PUNCT	O	O

Seventy-five	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
an	DET	O	O
abdominal	ADJ	O	O
trauma	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
ATI	NOUN	O	O
)	PUNCT	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
less	ADV	O	O
than	ADP	O	O
40	NUM	O	O
were	VERB	O	O
randomized	VERB	O	O
at	ADP	O	O
initial	ADJ	O	O
laparotomy	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
TEN	NUM	O	O
(	PUNCT	O	O
Vivonex	PUNCT	O	O
TEN	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
TPN	NOUN	O	O
(	PUNCT	O	O
Freamine	NUM	O	O
HBC	NOUN	O	O
6.9	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
Trophamine	NUM	O	O
6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
both	CCONJ	O	O
regimens	NOUN	O	O
contained	VERB	O	O
2.5	NUM	O	O
%	SYM	O	O
fat	NOUN	O	O
,	PUNCT	O	O
33	NUM	O	O
%	SYM	O	O
branched	VERB	O	O
chain	NOUN	O	O
amino	ADJ	O	O
acids	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
had	PUNCT	O	O
a	DET	O	O
calorie	NOUN	O	O
to	ADP	O	O
nitrogen	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
150:1	NOUN	O	O
.	PUNCT	O	O

TEN	NUM	O	O
was	VERB	O	O
delivered	VERB	O	O
via	ADP	O	O
a	DET	O	O
needle	NOUN	O	O
catheter	NOUN	O	O
jejunostomy	NOUN	O	O
.	PUNCT	O	O

Nutritional	ADJ	O	O
support	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
within	ADP	O	O
12	NUM	O	O
hours	NOUN	O	O
postoperatively	NUM	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
infused	VERB	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
sufficient	ADJ	O	O
to	ADP	O	O
render	NOUN	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
positive	ADJ	O	O
nitrogen	NOUN	O	O
balance	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	ADV	O	O
groups	NOUN	O	O
(	PUNCT	O	O
TEN	NUM	O	O
=	SYM	O	O
29	NUM	O	O
vs	CCONJ	O	O
TPN	NOUN	O	O
=	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
injury	NOUN	O	O
severity	NOUN	O	O
and	CCONJ	O	O
initial	ADJ	O	O
metabolic	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Jejunal	PUNCT	O	O
feeding	ADP	O	O
was	VERB	O	O
tolerated	VERB	O	B-OTHER
unconditionally	NOUN	O	O
in	ADP	O	O
25	NUM	O	O
(	PUNCT	O	O
86	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
TEN	NUM	O	O
group	NOUN	O	O
.	PUNCT	O	O

Nitrogen	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
remained	VERB	O	O
equivalent	ADJ	O	O
throughout	ADP	O	O
the	DET	O	O
study	ADV	O	O
period	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
day	NOUN	O	O
5	NUM	O	O
TEN	NUM	O	O
=	SYM	O	O
-0.3	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
vs.	CCONJ	O	O
TPN	NOUN	O	O
0.1	NUM	O	O
+/-	SYM	O	O
0.8	NUM	O	O
gm/day	NOUN	O	O
.	PUNCT	O	O

Traditional	ADJ	O	O
nutritional	ADJ	O	B-PHYSICAL
protein	NOUN	O	I-PHYSICAL
markers	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
albumin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
transferrin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	O
E1	NOUN	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
failure	NOUN	O	O
in	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
trauma	NOUN	O	O
patients	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
and	CCONJ	O	O
correlation	NOUN	O	O
with	ADP	O	O
plasma	NOUN	O	O
suppressive	ADJ	O	O
factors	NOUN	O	O
for	ADP	O	O
neutrophil	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
group	NOUN	O	O
of	ADP	O	O
48	NUM	O	O
critically	ADV	O	O
injured	VERB	O	O
patients	NOUN	O	O
were	VERB	O	O
entered	VERB	O	O
into	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
PGE1	NOUN	O	O
for	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
respiratory	ADJ	O	I-PHYSICAL
failure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
.	PUNCT	O	O

Secondary	ADJ	O	O
assessments	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
PGE1	NOUN	O	O
infusion	NOUN	O	O
on	ADP	O	O
plasma	NOUN	O	O
mediated	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
PMN	NOUN	O	O
superoxide	NOUN	O	O
production	NOUN	O	O
and	CCONJ	O	O
loss	NOUN	O	O
of	ADP	O	O
PMN	NOUN	O	O
granule	NOUN	O	O
enzyme	NOUN	O	O
content	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
respiratory	ADJ	O	I-PHYSICAL
failure	NOUN	O	I-PHYSICAL
was	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
PGE1	NOUN	O	O
group	NOUN	O	O
--	PUNCT	O	O
13	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
32	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	PUNCT	O	O
did	PUNCT	O	O
not	ADV	O	O
reach	ADJ	O	O
significance	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	O
morality	NOUN	O	O
was	VERB	O	O
equivalent	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
--	PUNCT	O	O
26	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
PGE1	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
28	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
suppressive	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
plasma	NOUN	O	O
was	VERB	O	O
assayed	VERB	O	O
by	ADP	O	O
measurement	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
PMN	NOUN	O	O
superoxide	NOUN	O	O
production	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
normal	ADJ	O	O
control	NOUN	O	O
plasma	NOUN	O	O
(	PUNCT	O	O
ratio	NOUN	O	O
P	NOUN	O	O
:	PUNCT	O	O
C	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
baseline	NOUN	O	O
ratio	NOUN	O	O
P	NOUN	O	O
:	PUNCT	O	O
C	NOUN	O	O
was	VERB	O	O
62	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
PGE1	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
60	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
day	NOUN	O	O
1	NUM	O	O
plasma	NOUN	O	O
samples	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
reversal	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
suppressive	ADJ	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
PGE1	NOUN	O	O
group	NOUN	O	O
--	PUNCT	O	O
ratio	NOUN	O	O
P	NOUN	O	O
:	PUNCT	O	O
C	NOUN	O	O
88	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
67	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
the	DET	O	O
full	ADJ	O	O
7	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
infusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
plasma	NOUN	O	B-PHYSICAL
suppressive	ADJ	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
remained	VERB	O	O
significantly	ADV	O	O
diminished	ADP	O	O
in	ADP	O	O
the	DET	O	O
PGE1	NOUN	O	O
group	NOUN	O	O
--	PUNCT	O	O
ratio	NOUN	O	O
P	NOUN	O	O
:	PUNCT	O	O
C	NOUN	O	O
77	NUM	O	O
+/-	SYM	O	O
4	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
61	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
baseline	NOUN	O	O
lysozyme	NOUN	O	O
content	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
PMN	NOUN	O	O
's	PUNCT	O	O
relative	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
normal	ADJ	O	O
control	NOUN	O	O
PMNs	NOUN	O	O
(	PUNCT	O	O
ratio	NOUN	O	O
P	NOUN	O	O
:	PUNCT	O	O
C	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
119	NUM	O	O
+/-	SYM	O	O
14	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
PGE1	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
lysozyme	NOUN	O	O
content	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
PGE1	NOUN	O	O
group	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
1	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
--	PUNCT	O	O
ratio	NOUN	O	O
P	NOUN	O	O
:	PUNCT	O	O
C	NOUN	O	O
79	NUM	O	O
+/-	SYM	O	O
8	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
suppressive	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

Does	PUNCT	O	O
surface	NOUN	O	O
preparation	NOUN	O	O
alter	PART	O	O
ALA	NOUN	O	B-OTHER
uptake	NOUN	O	I-OTHER
in	ADP	O	O
superficial	ADJ	O	O
non-melanoma	NOUN	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
in	ADP	O	O
vivo	ADV	O	O
?	PUNCT	O	O

BACKGROUND/PURPOSE	PUNCT	O	O
Photodynamic	PUNCT	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
PDT	NOUN	O	O
)	PUNCT	O	O
using	SYM	O	O
aminolaevulinic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
ALA	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
non-melanoma	NOUN	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Surface	NOUN	O	O
preparation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lesion	NOUN	O	O
is	VERB	O	O
commonly	ADV	O	O
performed	VERB	O	O
before	ADP	O	O
application	NOUN	O	O
of	ADP	O	O
ALA	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
preparation	NOUN	O	O
varies	NOUN	O	O
from	ADP	O	O
centre	NOUN	O	O
to	PUNCT	O	O
centre	NOUN	O	O
and	CCONJ	O	O
there	PUNCT	O	O
has	DET	O	O
been	ADP	O	O
no	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
its	DET	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
surface	NOUN	O	O
preparation	NOUN	O	O
on	ADP	O	O
the	DET	O	O
local	ADJ	O	O
uptake	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
ALA	NOUN	O	I-OTHER
by	ADP	O	O
recording	PUNCT	O	O
fluorescence	NOUN	O	O
from	ADP	O	O
accumulated	VERB	O	O
protoporphyrin	NOUN	O	O
IX	NUM	O	O
(	PUNCT	O	O
PPIX	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
16	NUM	O	O
lesions	NOUN	O	O
,	PUNCT	O	O
either	PUNCT	O	O
superficial	ADJ	O	O
basal	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
(	PUNCT	O	O
BCC	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
Bowen	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
(	PUNCT	O	O
BD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Each	DET	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lesion	NOUN	O	O
was	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
no	DET	O	O
surface	NOUN	O	O
preparation	NOUN	O	O
or	CCONJ	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
surface	NOUN	O	O
preparation	NOUN	O	O
(	PUNCT	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PUNCT	O	O
gentle	PUNCT	O	O
curettage	NOUN	O	O
or	CCONJ	O	O
abrasion	NOUN	O	O
with	ADP	O	O
a	DET	O	O
spatula	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ALA	NOUN	O	O
was	VERB	O	O
left	VERB	O	O
for	ADP	O	O
4	NUM	O	O
h	NOUN	O	O
(	PUNCT	O	O
BCC	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
6	NUM	O	O
h	NOUN	O	O
(	PUNCT	O	O
BD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

PPIX	NOUN	O	B-OTHER
fluorescence	NOUN	O	I-OTHER
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
an	DET	O	O
excitation	NOUN	O	O
wavelength	NOUN	O	O
of	ADP	O	O
405+/-5	NOUN	O	O
nm	NOUN	O	O
and	CCONJ	O	O
emission	NOUN	O	O
spectrum	NOUN	O	O
recorded	PROPN	O	O
using	VERB	O	O
a	DET	O	O
photodiode	NOUN	O	O
array	NOUN	O	O
.	PUNCT	O	O

Spectra	PROPN	O	O
were	VERB	O	O
measured	VERB	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
surface	NOUN	O	O
preparation	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
immediately	ADV	O	O
before	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
d	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
laser	NOUN	O	O
irradiation	NOUN	O	O
at	ADP	O	O
630	NUM	O	O
nm	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
fluorescence	NOUN	O	B-OTHER
after	ADP	O	I-OTHER
incubation	NOUN	O	I-OTHER
to	VERB	O	O
that	PUNCT	O	O
before	ADP	O	O
incubation	NOUN	O	O
was	DET	O	O
6.1+/-1.2	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
non-prepared	DET	O	O
section	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
increased	VERB	O	O
slightly	ADV	O	O
but	CCONJ	O	O
not	ADV	O	O
significantly	ADV	O	O
to	ADP	O	O
6.8	NUM	O	O
+/-1.8	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
prepared	VERB	O	O
section	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
curettage	NOUN	O	B-OTHER
and	CCONJ	O	O
abrasion	NOUN	O	B-OTHER
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
outcome	NOUN	O	O
after	ADP	O	O
PDT	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
clinical	ADJ	O	O
assessment	NOUN	O	O
agrees	NOUN	O	O
with	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
data	NOUN	O	O
as	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
between	ADP	O	O
prepared	VERB	O	O
and	CCONJ	O	O
unprepared	PUNCT	O	O
halves	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lesion	NOUN	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
PDT	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
our	ADJ	O	O
data	NOUN	O	O
seem	VERB	O	O
to	ADP	O	O
suggest	NOUN	O	O
that	PUNCT	O	O
for	ADP	O	O
most	CCONJ	O	O
BCC	NOUN	O	O
and	CCONJ	O	O
BD	NOUN	O	O
lesions	NOUN	O	O
,	PUNCT	O	O
surface	NOUN	O	O
preparation	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
increase	VERB	O	O
ALA	NOUN	O	B-OTHER
uptake	NOUN	O	I-OTHER
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
live	ADJ	O	O
and	CCONJ	O	O
videotape	NOUN	O	O
ratings	NOUN	O	O
:	PUNCT	O	O
clomipramine	NOUN	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	O
in	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
compared	DET	O	O
live	ADJ	O	O
ratings	NOUN	O	O
with	ADP	O	O
ratings	NOUN	O	O
of	ADP	O	O
videotapes	PUNCT	O	O
and	CCONJ	O	O
compared	PUNCT	O	O
response	NOUN	O	O
to	ADP	O	O
clomipramine	NOUN	O	O
with	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
haloperidol	NOUN	O	O
in	ADP	O	O
8	NUM	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
5.62	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
met	VERB	O	O
criteria	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
consecutive	ADJ	O	O
admissions	NOUN	O	O
to	ADP	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
clomipramine	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Live	ADJ	O	O
ratings	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
by	ADP	O	O
two	NUM	O	O
raters	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pre-treatment	NOUN	O	O
placebo	NOUN	O	O
baseline	NOUN	O	O
period	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
period	NOUN	O	O
on	ADP	O	O
the	DET	O	O
CPRS	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
CGI	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
videotaped	NUM	O	O
.	PUNCT	O	O

Employing	ADP	O	O
the	DET	O	O
same	ADJ	O	O
instruments	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
videotapes	NOUN	O	O
were	VERB	O	O
rated	VERB	O	O
by	ADP	O	O
two	NUM	O	O
raters	NOUN	O	O
who	DET	O	O
did	CCONJ	O	O
not	ADV	O	O
know	VERB	O	O
the	DET	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
blind	VERB	O	O
to	ADP	O	O
study	PUNCT	O	O
design	NOUN	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
study	ADV	O	O
phase	NOUN	O	O
.	PUNCT	O	O

Ratings	PROPN	O	B-OTHER
of	ADP	O	I-OTHER
videotapes	PUNCT	O	I-OTHER
significantly	ADV	O	O
differed	CCONJ	O	O
from	ADP	O	O
live	ADJ	O	B-OTHER
ratings	NOUN	O	I-OTHER
.	PUNCT	O	O

A	DET	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
for	ADP	O	O
haloperidol	NOUN	O	O
was	VERB	O	O
detected	ADJ	O	O
only	ADV	O	O
on	ADP	O	O
live	ADJ	O	B-OTHER
ratings	NOUN	O	I-OTHER
and	CCONJ	O	O
not	ADV	O	O
on	ADP	O	O
ratings	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
videotapes	NOUN	O	I-OTHER
.	PUNCT	O	O

No	DET	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
for	ADP	O	O
clomipramine	NOUN	O	O
in	ADP	O	O
either	CCONJ	O	O
live	ADJ	O	B-OTHER
or	CCONJ	O	O
videotape	NOUN	O	B-OTHER
ratings	NOUN	O	I-OTHER
.	PUNCT	O	O

Rapid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	O
reduces	NOUN	O	O
vascular	ADJ	O	O
pain	NOUN	O	O
and	CCONJ	O	O
facilitates	SYM	O	O
Laryngeal	ADJ	O	O
Mask	NOUN	O	O
Airway	NOUN	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
rapid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	O
in	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
ability	NOUN	O	O
to	PART	O	O
facilitate	SYM	O	O
Laryngeal	ADJ	O	O
Mask	NOUN	O	O
Airway	NOUN	O	O
(	PUNCT	O	O
LMA	NOUN	O	O
)	PUNCT	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
single-blinded	SYM	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	ADJ	O	O
University	NOUN	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
120	NUM	O	O
ASA	NOUN	O	O
physical	ADJ	O	O
status	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
elective	ADJ	O	O
orthopedic	ADJ	O	O
surgeries	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
4	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
A	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	O
2.0	NUM	O	O
mg/kg	NOUN	O	O
at	ADP	O	O
3.3	NUM	O	O
mg/sec	ADJ	O	O
.	PUNCT	O	O

Group	NOUN	O	O
B	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
lidocaine	NOUN	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	O
2.0	NUM	O	O
mg/kg	NOUN	O	O
at	ADP	O	O
3.3	NUM	O	O
mg/sec	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
lidocaine	NOUN	O	O
1.0	NUM	O	O
mg/kg	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	O
2.0	NUM	O	O
mg/kg	NOUN	O	O
at	ADP	O	O
3.3	NUM	O	O
mg/sec	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
D	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	O
2.0	NUM	O	O
mg/kg	NOUN	O	O
at	ADP	O	O
50	NUM	O	O
mg/sec	ADJ	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
Pain	NOUN	O	O
on	ADP	O	O
injection	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
a	DET	O	O
4-point	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Scale	NOUN	O	O
and	CCONJ	O	O
success	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
smooth	ADJ	O	O
LMA	NOUN	O	O
insertion	NOUN	O	O
also	ADV	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
RESULTS	NOUN	O	O
Rapid	ADJ	O	O
injection	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
painful	ADJ	O	B-PAIN
than	PUNCT	O	O
after	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
lidocaine	NOUN	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
slow	ADJ	O	O
injection	NOUN	O	O
after	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
lidocaine	NOUN	O	O
1.0	NUM	O	O
mg/kg	NOUN	O	O
.	PUNCT	O	O

Rapid	ADJ	O	O
injection	NOUN	O	O
facilitated	PUNCT	O	O
LMA	NOUN	O	B-OTHER
insertion	NOUN	O	I-OTHER
,	PUNCT	O	O
unlike	ADP	O	O
slow	ADJ	O	O
injection	NOUN	O	O
with	ADP	O	O
lidocaine	NOUN	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
pretreatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
similarly	ADV	O	O
successful	ADJ	O	O
to	ADP	O	O
slow	ADJ	O	O
injection	NOUN	O	O
after	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
lidocaine	NOUN	O	O
1.0	NUM	O	O
mg/kg	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
rapid	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	O
reduces	NOUN	O	O
pain	NOUN	O	O
and	CCONJ	O	O
facilitates	NOUN	O	O
LMA	NOUN	O	O
insertion	NOUN	O	O
versus	CCONJ	O	O
slow	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	O
.	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
leukocyte	NOUN	O	O
IFN-alpha	NOUN	O	O
on	ADP	O	O
the	DET	O	O
immune	ADJ	O	B-PHYSICAL
response	NOUN	O	O
to	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
HBV	NOUN	O	I-PHYSICAL
vaccine	NOUN	O	B-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
unvaccinated	VERB	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

HBV	NOUN	O	O
vaccine	NOUN	O	O
needs	NOUN	O	O
3	NUM	O	O
injections	NOUN	O	O
over	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
to	PART	O	O
induce	ADJ	O	O
immunity	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
adjuvants	NOUN	O	O
capable	ADJ	O	O
of	ADP	O	O
inducing	VERB	O	O
earlier	PUNCT	O	O
immune	ADJ	O	O
protection	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
highly	ADV	O	O
desirable	ADJ	O	O
.	PUNCT	O	O

Most	DET	O	O
adjuvants	NOUN	O	O
may	VERB	O	O
act	NUM	O	O
by	ADP	O	O
inducing	PUNCT	O	O
cytokines	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
among	ADP	O	O
them	NUM	O	O
,	PUNCT	O	O
type	NOUN	O	O
I	NUM	O	O
interferons	NOUN	O	O
(	PUNCT	O	O
IFNs	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
deserve	ADP	O	O
a	DET	O	O
special	ADJ	O	O
attention	NOUN	O	O
in	ADP	O	O
view	NOUN	O	O
of	ADP	O	O
the	DET	O	O
potent	ADJ	O	O
immunomostimulatory	ADJ	O	O
activity	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
mouse	NOUN	O	O
models	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
dendritic	ADJ	O	O
cell	NOUN	O	O
functions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
IFN-alpha	NOUN	O	O
administered	DET	O	O
as	ADP	O	O
an	DET	O	O
adjuvant	ADJ	O	O
of	ADP	O	O
HBV	NOUN	O	O
vaccine	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
unvaccinated	VERB	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
enhancing	ADP	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
antibody	NOUN	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
an	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
transient	ADJ	O	O
upregulation	NOUN	O	O
of	ADP	O	O
costimulatory	ADJ	O	O
molecule	NOUN	O	O
expression	NOUN	O	O
on	PUNCT	O	O

Take	ADV	O	O
a	DET	O	O
walk	NOUN	O	O
in	ADP	O	O
the	DET	O	O
park	PUNCT	O	O
?	PUNCT	O	O

A	CCONJ	O	O
cross-over	NOUN	O	O
pilot	NOUN	O	O
trial	NOUN	O	O
comparing	ADJ	O	O
brisk	PUNCT	O	O
walking	NUM	O	O
in	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
environments	NOUN	O	O
:	PUNCT	O	O
park	VERB	O	O
and	CCONJ	O	O
urban	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
whether	ADP	O	O
differences	NOUN	O	O
exist	VERB	O	O
between	ADP	O	O
a	DET	O	O
30	NUM	O	O
minute	ADJ	O	O
brisk	PUNCT	O	O
walk	NOUN	O	O
taken	VERB	O	O
in	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
environments	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
which	PUNCT	O	O
environment	NOUN	O	O
best	ADV	O	O
facilitates	PUNCT	O	O
current	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
guidelines	NOUN	O	O
:	PUNCT	O	O
park	ADP	O	O
or	CCONJ	O	O
urban	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
randomised	VERB	O	O
cross-over	NOUN	O	O
pilot	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
participants	NOUN	O	O
performed	VERB	O	O
a	DET	O	O
self-timed	ADV	O	O
30	NUM	O	O
minute	ADJ	O	O
brisk	PUNCT	O	O
walk	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
environments	NOUN	O	O
,	PUNCT	O	O
park	PUNCT	O	O
and	CCONJ	O	O
urban	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
Glasgow	PUNCT	O	O
,	PUNCT	O	O
Scotland	PUNCT	O	O
(	PUNCT	O	O
October	NOUN	O	O
2009	NUM	O	O
to	ADP	O	O
January	NOUN	O	O
2010	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cadence	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
recorded	PROPN	O	O
using	VERB	O	O
the	DET	O	O
activPAL?	NOUN	O	O
activity	NOUN	O	O
monitor	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
measure	NOUN	O	O
intensity	NOUN	O	O
.	PUNCT	O	O

Outcome	NOUN	O	O
measures	NOUN	O	O
were	ADV	O	O
:	PUNCT	O	O
mean	NOUN	O	O
cadence	NOUN	O	O
;	PUNCT	O	O
moderate-to-vigorous	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
time	NOUN	O	O
accumulated	VERB	O	O
in	ADP	O	O
bouts	NOUN	O	O
lasting	PUNCT	O	O
?	PUNCT	O	O

10	NUM	O	O
min	NOUN	O	O
;	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
walking	VERB	O	O
breaks	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
duration	NOUN	O	O
.	PUNCT	O	O

RESULTS	VERB	O	O
A	PUNCT	O	O
convenience	NOUN	O	O
sample	NOUN	O	O
of	ADP	O	O
40	NUM	O	O
healthy	ADJ	O	O
adults	NOUN	O	O
was	VERB	O	O
recruited	VERB	O	O
:	PUNCT	O	O
16	NUM	O	O
males	PROPN	O	O
,	PUNCT	O	O
24	NUM	O	O
females	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
22.9	NUM	O	O
(	PUNCT	O	O
5.5	NUM	O	O
)	PUNCT	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
cadence	NOUN	O	O
for	ADP	O	O
the	DET	O	O
whole	ADJ	O	O
walk	NOUN	O	O
was	ADJ	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
park	CCONJ	O	O
:	PUNCT	O	O
119.3	NUM	O	O
(	PUNCT	O	O
8.3	NUM	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
110.9	NUM	O	O
(	PUNCT	O	O
8.9	NUM	O	O
)	PUNCT	O	O
steps/min	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
accumulated	VERB	O	O
more	DET	O	O
moderate-to-vigorous	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
?	PUNCT	O	O

10	NUM	O	O
minute	ADJ	O	O
bouts	PUNCT	O	O
during	ADP	O	O
park	CCONJ	O	O
walks	PUNCT	O	O
:	PUNCT	O	O
25.5	NUM	O	O
(	PUNCT	O	O
9.6	NUM	O	O
)	PUNCT	O	O
[	PUNCT	O	O
median	ADJ	O	O
(	PUNCT	O	O
interquartile	NOUN	O	O
range	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
vs.	CCONJ	O	O
14.0	NUM	O	O
(	PUNCT	O	O
20.3	NUM	O	O
)	PUNCT	O	O
min	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
self-timed	VERB	O	O
duration	NOUN	O	O
between	ADP	O	O
locations	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Participants	NOUN	O	O
accumulated	VERB	O	O
more	DET	O	O
moderate-to-vigorous	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
bouts	NOUN	O	O
?	PUNCT	O	O

10	NUM	O	O
min	NOUN	O	O
in	ADP	O	O
duration	NOUN	O	O
on	PUNCT	O	O
park	CCONJ	O	O
walks	PUNCT	O	O
due	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
interruptions	NOUN	O	O
in	ADP	O	O
walking	ADP	O	O
.	PUNCT	O	O

Hence	ADV	O	O
the	DET	O	O
park	ADJ	O	O
environment	NOUN	O	O
better	PUNCT	O	O
facilitated	ADP	O	O
the	DET	O	O
achievement	NOUN	O	O
of	ADP	O	O
current	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
guidelines	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
research	NOUN	O	O
involving	VERB	O	O
a	DET	O	O
larger	PUNCT	O	O
,	PUNCT	O	O
more	DET	O	O
heterogeneous	ADJ	O	O
sample	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O

Profound	ADJ	O	O
luteinizing	VERB	O	O
hormone	NOUN	O	O
suppression	NOUN	O	O
after	ADP	O	O
stopping	PUNCT	O	O
the	DET	O	O
gonadotropin-releasing	VERB	O	O
hormone-agonist	NOUN	O	O
leuprolide	NOUN	O	O
acetate	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
LH	NOUN	O	O
during	ADP	O	O
continued	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
leuprolide	NOUN	O	O
acetate	NOUN	O	O
(	PUNCT	O	O
LA	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
levels	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
week	NOUN	O	O
after	ADP	O	O
discontinuing	PUNCT	O	O
LA	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Clinical	ADJ	O	O
assisted	VERB	O	O
conception	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

PATIENTS	ADP	O	O
Women	NOUN	O	O
undergoing	VERB	O	O
controlled	VERB	O	O
ovarian	ADJ	O	O
stimulation	NOUN	O	O
for	ADP	O	O
assisted	VERB	O	O
conception	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
LA	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
short	ADJ	O	O
or	CCONJ	O	O
ultrashort	PUNCT	O	O
protocols	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
alternative	ADJ	O	O
protocol	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
then	ADV	O	O
in	ADP	O	O
a	DET	O	O
second	ADJ	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
thus	ADP	O	O
her	PUNCT	O	O
own	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Serum	NOUN	O	B-PHYSICAL
LH	NOUN	O	I-PHYSICAL
over	PUNCT	O	I-PHYSICAL
time	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
When	ADP	O	O
LA	NOUN	O	O
was	VERB	O	O
stopped	PUNCT	O	O
after	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
,	PUNCT	O	O
LH	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
fell	VERB	O	O
profoundly	ADV	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
levels	NOUN	O	O
when	ADP	O	O
LA	NOUN	O	O
was	VERB	O	O
continued	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Loss	NOUN	O	O
of	ADP	O	O
LH	NOUN	O	B-MENTAL
after	ADP	O	O
stopping	VERB	O	O
LA	NOUN	O	O
is	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
be	PUNCT	O	O
clinically	ADV	O	O
important	ADJ	O	O
in	ADP	O	O
ovarian	ADJ	O	O
stimulation	NOUN	O	O
regimens	CCONJ	O	O
that	ADP	O	O
use	PUNCT	O	O
pure	ADJ	O	O
FSH	NOUN	O	O
with	ADP	O	O
LA	NOUN	O	O
in	ADP	O	O
ultrashort	PUNCT	O	O
protocols	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
LH	NOUN	O	B-PHYSICAL
lasts	VERB	O	O
at	ADP	O	O
least	ADV	O	O
1	NUM	O	O
week	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
explainable	ADJ	O	O
by	ADP	O	O
persistent	ADJ	O	O
suppression	NOUN	O	O
of	ADP	O	O
endogenous	ADJ	O	O
GnRH	NOUN	O	O
by	ADP	O	O
LA	NOUN	O	O
during	ADP	O	O
this	DET	O	O
time	NOUN	O	O
.	PUNCT	O	O

Hitting	VERB	O	O
the	DET	O	O
target	NOUN	O	O
:	PUNCT	O	O
relatively	ADV	O	O
easy	PUNCT	O	O
,	PUNCT	O	O
yet	ADV	O	O
absolutely	ADV	O	O
difficult	ADJ	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
generally	ADP	O	O
agreed	PROPN	O	O
that	ADP	O	O
absolute-direction	NOUN	O	O
judgments	NOUN	O	O
require	VERB	O	O
information	NOUN	O	O
about	PUNCT	O	O
eye	NOUN	O	O
position	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
relative-direction	NOUN	O	O
judgments	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
source	NOUN	O	O
of	ADP	O	O
this	ADP	O	O
eye-position	NOUN	O	O
information	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
during	ADP	O	O
monocular	ADJ	O	O
viewing	VERB	O	O
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
matter	NOUN	O	O
of	ADP	O	O
debate	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
may	VERB	O	O
be	PUNCT	O	O
either	CCONJ	O	O
binocular	ADJ	O	O
eye	NOUN	O	O
position	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
position	NOUN	O	O
of	ADP	O	O
the	DET	O	O
viewing-eye	NOUN	O	O
only	ADV	O	O
,	PUNCT	O	O
that	ADP	O	O
is	VERB	O	O
crucial	ADJ	O	O
.	PUNCT	O	O

Using	PRON	O	O
more	ADV	O	O
ecologically	ADV	O	O
valid	PUNCT	O	O
stimulus	NOUN	O	O
situations	ADJ	O	O
than	PUNCT	O	O
the	DET	O	O
traditional	ADJ	O	O
LED	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dark	ADJ	O	O
,	PUNCT	O	O
we	PRON	O	O
performed	VERB	O	O
two	NUM	O	O
experiments	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
experiment	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
observers	PUNCT	O	O
threw	PUNCT	O	O
darts	NOUN	O	O
at	ADP	O	O
targets	NOUN	O	O
that	PUNCT	O	O
were	VERB	O	O
fixated	ADP	O	O
either	CCONJ	O	O
monocularly	ADV	O	O
or	CCONJ	O	O
binocularly	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
experiment	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
observers	PUNCT	O	O
aimed	VERB	O	O
a	DET	O	O
laser	NOUN	O	O
gun	NOUN	O	O
at	ADP	O	O
targets	NOUN	O	O
while	ADP	O	O
fixating	PUNCT	O	O
either	PUNCT	O	O
the	DET	O	O
rear	ADJ	O	O
or	CCONJ	O	O
the	DET	O	O
front	NOUN	O	O
gunsight	NOUN	O	O
monocularly	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
target	NOUN	O	O
either	PUNCT	O	O
monocularly	ADV	O	O
or	CCONJ	O	O
binocularly	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
measured	VERB	O	O
the	DET	O	O
accuracy	NOUN	O	O
and	CCONJ	O	O
precision	NOUN	O	O
of	ADP	O	O
the	DET	O	O
observers	ADJ	O	O
'	PUNCT	O	O
absolute-	NOUN	O	O
and	CCONJ	O	O
relative-direction	NOUN	O	O
judgments	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
relative-direction	NOUN	O	O
judgments	NOUN	O	O
were	VERB	O	O
precise	ADJ	O	O
and	CCONJ	O	O
independent	ADJ	O	O
of	ADP	O	O
phoria	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
monocular	ADJ	O	O
absolute-direction	NOUN	O	O
judgments	NOUN	O	O
were	VERB	O	O
inaccurate	VERB	O	B-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
inaccuracy	NOUN	O	B-MENTAL
was	VERB	O	O
predictable	ADJ	O	O
from	ADP	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
phoria	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
confirm	VERB	O	O
that	ADP	O	O
relative-direction	NOUN	O	O
judgments	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
require	VERB	O	O
information	NOUN	O	O
about	PUNCT	O	O
eye	NOUN	O	O
position	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
they	PRON	O	O
show	VERB	O	O
that	ADP	O	O
binocular	ADJ	O	O
eye-position	NOUN	O	O
information	NOUN	O	O
is	VERB	O	O
crucial	ADJ	O	O
when	ADP	O	O
judging	PUNCT	O	O
the	DET	O	O
absolute	ADJ	O	O
direction	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
monocular	ADJ	O	O
and	CCONJ	O	O
binocular	ADJ	O	O
targets	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
strength	NOUN	O	O
training	VERB	O	O
on	ADP	O	O
central	ADJ	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
in	ADP	O	O
middle-aged	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Contrary	PUNCT	O	O
to	ADP	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
strength	NOUN	O	O
training	VERB	O	O
(	PUNCT	O	O
ST	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
decreased	VERB	O	O
central	ADJ	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
in	ADP	O	O
young	ADJ	O	O
men	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
unknown	VERB	O	O
whether	ADP	O	O
ST	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
concurrent	ADJ	O	O
endurance	NOUN	O	O
training	VERB	O	O
,	PUNCT	O	O
would	PUNCT	O	O
have	CCONJ	O	O
a	DET	O	O
similar	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
with	ADP	O	O
reduced	VERB	O	O
baseline	NOUN	O	O
arterial	ADJ	O	B-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
primary	ADJ	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
ST	NOUN	O	O
program	NOUN	O	O
on	ADP	O	O
central	ADJ	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
in	ADP	O	O
middle-aged	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
controlled	VERB	O	O
intervention	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
which	DET	O	O
37	NUM	O	O
healthy	ADJ	O	O
,	PUNCT	O	O
sedentary	ADJ	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
(	PUNCT	O	O
52+/-2	NOUN	O	O
years	NOUN	O	O
)	PUNCT	O	O
performed	DET	O	O
13	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
ST	NOUN	O	O
(	PUNCT	O	O
n=13	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ST+aerobic	ADJ	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
n=12	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
stretching	VERB	O	O
exercises	NOUN	O	O
as	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=12	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Participants	PUNCT	O	O
were	VERB	O	O
rigorously	ADV	O	O
screened	VERB	O	O
for	ADP	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
and	CCONJ	O	O
underwent	VERB	O	O
pre-post	CCONJ	O	O
testing	VERB	O	O
for	ADP	O	O
carotid	ADJ	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
via	ADP	O	O
simultaneous	ADJ	O	O
ultrasound	NOUN	O	O
and	CCONJ	O	O
applanation	NOUN	O	O
tonometry	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
carotid-femoral	ADJ	O	O
pulse	NOUN	O	O
wave	NOUN	O	O
velocity	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
endothelin-1	NOUN	O	O
and	CCONJ	O	O
angiotensin	NOUN	O	B-PHYSICAL
II	NUM	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
carotid	ADJ	O	B-PHYSICAL
artery	NOUN	O	I-PHYSICAL
vasoreactivity	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
cold	NOUN	O	O
pressor	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
ST	NOUN	O	O
performed	VERB	O	O
alone	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
improved	DET	O	O
maximal	ADJ	O	B-PHYSICAL
muscle	NOUN	O	I-PHYSICAL
strength	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
increased	ADV	O	O
total	ADJ	O	O
lean	ADJ	O	B-PHYSICAL
body	NOUN	O	B-PHYSICAL
mass	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
both	CCONJ	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
carotid	ADJ	O	B-OTHER
artery	NOUN	O	I-OTHER
compliance	NOUN	O	I-OTHER
or	CCONJ	O	O
carotid-femoral	ADJ	O	B-PHYSICAL
pulse	NOUN	O	I-PHYSICAL
wave	NOUN	O	I-PHYSICAL
velocity	NOUN	O	I-PHYSICAL
following	ADJ	O	O
ST	NOUN	O	B-OTHER
or	CCONJ	O	I-OTHER
ST+aerobic	ADJ	O	I-OTHER
exercise	NOUN	O	B-OTHER
.	PUNCT	O	O

Carotid	ADJ	O	B-PHYSICAL
artery	NOUN	O	B-PHYSICAL
compliance	NOUN	O	I-PHYSICAL
increased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
23	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
following	VERB	O	O
stretching	VERB	O	O
which	ADP	O	O
may	VERB	O	O
be	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
carotid	ADJ	O	O
pulse	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
vasoconstrictor	NOUN	O	I-PHYSICAL
hormones	DET	O	I-PHYSICAL
or	PUNCT	O	O

[	PUNCT	O	O
Plasma	NOUN	O	O
separation	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
CVVHF	NOUN	O	O
in	ADP	O	O
septic	ADJ	O	O
and	CCONJ	O	O
SIRS	NOUN	O	O
patients	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
non-randomized	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
59	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
sepsis	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
43	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
SIRS	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
16	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
on	ADP	O	O
a	DET	O	O
surgical	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
22	NUM	O	O
patients	NOUN	O	O
plasmapheresis	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
continuous	ADJ	O	O
venovenous	ADJ	O	O
hemofiltration	NOUN	O	O
(	PUNCT	O	O
CVVHF	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Lethality	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
56	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
sepsis	NOUN	O	B-PHYSICAL
group	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
therapy	NOUN	O	B-MENTAL
group	NOUN	O	I-MENTAL
lethality	NOUN	O	B-MORTALITY
was	VERB	O	O
significantly	ADV	O	B-MENTAL
lower	PUNCT	O	O
in	ADP	O	B-MENTAL
patients	NOUN	O	I-MENTAL
with	ADP	O	I-MENTAL
plasmapheresis	NOUN	O	B-MENTAL
,	PUNCT	O	O
even	ADV	O	O
though	CCONJ	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
the	DET	O	O
organic	ADJ	O	O
failure	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
higher	PUNCT	O	O
.	PUNCT	O	O

Finally	ADV	O	O
the	DET	O	O
dependency	NOUN	O	O
of	ADP	O	O
lethality	NOUN	O	B-MENTAL
and	CCONJ	O	B-MENTAL
age	NOUN	O	O
was	VERB	O	B-MENTAL
similar	ADJ	O	I-MENTAL
in	ADP	O	I-MENTAL
both	CCONJ	O	I-MENTAL
groups	NOUN	O	I-MENTAL
.	PUNCT	O	O

Intranasal	ADJ	O	O
recombinant	ADJ	O	O
alfa-2b	NOUN	O	O
interferon	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
naturally	ADV	O	B-PHYSICAL
occurring	PUNCT	O	I-PHYSICAL
common	ADJ	O	I-PHYSICAL
colds	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
naturally	ADV	O	O
occurring	PUNCT	O	O
common	ADJ	O	O
colds	NOUN	O	O
of	ADP	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
duration	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
nasal	ADJ	O	O
sprays	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
alfa-2b	NOUN	O	O
interferon	NOUN	O	O
at	ADP	O	O
10	NUM	O	O
or	CCONJ	O	O
20	NUM	O	O
MU/day	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
four	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
10-MU	ADP	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
74	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
20-MU	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
74	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
72	NUM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
had	DET	O	O
comparable	ADJ	O	O
frequencies	NOUN	O	O
of	ADP	O	O
documented	VERB	O	O
rhinovirus	NOUN	O	O
colds	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
to	ADP	O	O
65	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
durations	NOUN	O	O
of	ADP	O	O
pretreatment	NOUN	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
26	NUM	O	O
to	ADP	O	O
27	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
colds	NOUN	O	I-PHYSICAL
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
longer	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
20-MU	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
10-MU	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.06	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
proven	VERB	O	O
rhinovirus	NOUN	O	O
colds	NOUN	O	O
treated	VERB	O	O
within	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
duration	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
20-MU	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
9	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
differences	NOUN	O	O
favoring	ADV	O	O
interferon	NOUN	O	O
treatment	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
respiratory	ADJ	O	O
symptom	NOUN	O	O
scores	NOUN	O	O
or	CCONJ	O	O
resolution	NOUN	O	O
of	ADP	O	O
specific	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
days	NOUN	O	O
5	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
,	PUNCT	O	O
nasal	ADJ	O	O
washings	DET	O	O
from	ADP	O	O
compliant	NOUN	O	O
subjects	NOUN	O	O
with	ADP	O	O
proven	VERB	O	O
rhinovirus	NOUN	O	O
colds	NOUN	O	O
yielded	VERB	O	O
rhinoviruses	NOUN	O	O
more	ADV	O	O
often	ADV	O	O
in	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
47	NUM	O	O
and	CCONJ	O	O
48	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
interferon	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
recipients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
0.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
new	ADJ	O	O
respiratory	ADJ	O	B-PHYSICAL
illness	NOUN	O	I-PHYSICAL
occurrence	NOUN	O	I-PHYSICAL
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
household	PUNCT	O	O
contacts	NOUN	O	O
.	PUNCT	O	O

Interferon	NOUN	O	O
recipients	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
frequencies	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
in	ADP	O	O
nasal	ADJ	O	B-ADVERSE-EFFECTS
mucus	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
16	NUM	O	O
to	ADP	O	O
18	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
did	PUNCT	O	O
placebo	NOUN	O	O
recipients	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
during	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Antibiotics	NOUN	O	B-PHYSICAL
for	ADP	O	O
presumed	ADP	O	O
secondary	ADJ	O	O
infections	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
more	ADV	O	O
often	ADV	O	O
in	ADP	O	O
the	DET	O	O
20-MU	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nasal	ADJ	O	O
sprays	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
alfa-2b	NOUN	O	O
interferon	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
an	DET	O	O
effective	ADJ	O	B-PHYSICAL
treatment	NOUN	O	O
for	ADP	O	B-PHYSICAL
natural	ADJ	O	I-PHYSICAL
colds	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
were	VERB	O	O
associated	VERB	O	O
with	PUNCT	O	O

Age	NOUN	O	O
and	CCONJ	O	O
autonomic	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
interrelationships	PUNCT	O	O
between	ADP	O	O
lung	NOUN	O	O
volume	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
aging	VERB	O	O
and	CCONJ	O	O
autonomic	ADJ	O	O
input	NOUN	O	O
on	ADP	O	O
interrelationships	PUNCT	O	O
between	ADP	O	O
respiratory	ADJ	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
variability	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
collected	PROPN	O	O
5	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
lung	NOUN	O	O
volume	NOUN	O	O
of	ADP	O	O
R-R	NOUN	O	O
interval	NOUN	O	O
data	NOUN	O	O
from	ADP	O	O
7	NUM	O	O
young	ADJ	O	O
[	PUNCT	O	O
27	NUM	O	O
+/-	SYM	O	O
3	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
)	PUNCT	O	O
yr	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
older	PUNCT	O	O
(	PUNCT	O	O
69	NUM	O	O
+/-	SYM	O	O
6	NUM	O	O
yr	NOUN	O	O
)	PUNCT	O	O
healthy	ADJ	O	O
supine	NOUN	O	O
humans	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
double	PUNCT	O	O
pharmacological	ADJ	O	O
autonomic	ADJ	O	O
blockade	NOUN	O	O
with	ADP	O	O
propranolol	NOUN	O	O
(	PUNCT	O	O
0.2	NUM	O	O
mg/kg	NOUN	O	O
iv	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
atropine	NOUN	O	O
(	PUNCT	O	O
0.04	NUM	O	O
mg/kg	NOUN	O	O
iv	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Estimates	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
power	NOUN	O	O
spectra	NOUN	O	O
and	CCONJ	O	O
linear	ADJ	O	O
transfer	NOUN	O	O
functions	DET	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
generated	VERB	O	O
by	ADP	O	O
Fourier	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Age	NOUN	O	O
,	PUNCT	O	O
double	PUNCT	O	O
blockade	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
age-drug	NOUN	O	O
interactions	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
for	ADP	O	O
repeated	VERB	O	O
measures	NOUN	O	O
.	PUNCT	O	O

Basal	ADJ	O	O
R-R	NOUN	O	O
intervals	NOUN	O	O
were	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

Double	DET	O	O
blockade	NOUN	O	O
decreased	ADV	O	O
R-R	NOUN	O	B-PHYSICAL
intervals	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
variability	NOUN	O	O
in	ADP	O	O
both	PUNCT	O	O
age	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
R-R	NOUN	O	O
intervals	NOUN	O	O
decreased	VERB	O	O
less	ADV	O	O
in	ADP	O	O
older	PUNCT	O	O
than	CCONJ	O	O
in	ADP	O	O
young	ADJ	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
basal	ADJ	O	B-PHYSICAL
respiratory	ADJ	O	I-PHYSICAL
intervals	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
standard	ADJ	O	O
deviation	NOUN	O	O
were	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
older	PUNCT	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
double	PUNCT	O	O
blockade	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
and	CCONJ	O	O
older	PUNCT	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Lung	NOUN	O	B-PHYSICAL
volume-to-heart	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
spectral	ADJ	O	I-PHYSICAL
coherence	NOUN	O	I-PHYSICAL
was	ADV	O	O
highest	PUNCT	O	O
at	ADP	O	O
frequencies	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
respiration	NOUN	O	O
and	CCONJ	O	O
greater	PUNCT	O	O
in	ADP	O	O
young	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
older	PUNCT	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.07	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Double	DET	O	O
blockade	NOUN	O	O
decreased	VERB	O	O
lung	NOUN	O	B-PHYSICAL
volume-to-heart	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
variability	NOUN	O	O
transfer	NOUN	O	O
function	NUM	O	O
magnitude	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.007	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
phase	NOUN	O	O
angle	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
without	ADP	O	O
age	NOUN	O	O
effects	NOUN	O	O
or	CCONJ	O	O
age-drug	NOUN	O	O
interactions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
respiration	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Prognosis	NOUN	O	O
of	ADP	O	O
advanced	VERB	O	O
hepatocellular	ADJ	O	O
carcinoma	NOUN	O	O
:	PUNCT	O	O
comparison	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
staging	VERB	O	O
systems	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
French	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
assess	NOUN	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
staging	VERB	O	O
systems	NOUN	O	O
[	PUNCT	O	O
Okuda	NOUN	O	O
,	PUNCT	O	O
Cancer	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Liver	NOUN	O	O
Italian	ADJ	O	O
Program	NOUN	O	O
(	PUNCT	O	O
CLIP	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Barcelona	NOUN	O	O
Clinic	PUNCT	O	O
Liver	NOUN	O	O
Cancer	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
BCLC	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
,	PUNCT	O	O
for	ADP	O	O
predicting	VERB	O	O
survival	NOUN	O	B-MORTALITY
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatocellular	ADJ	O	O
carcinoma	NOUN	O	O
(	PUNCT	O	O
HCC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
to	PUNCT	O	O
explore	NOUN	O	O
how	ADP	O	O
to	PUNCT	O	O
improve	ADJ	O	O
prognostic	ADJ	O	O
classification	NOUN	O	O
among	ADP	O	O
French	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
HCC	NOUN	O	O
whose	ADP	O	O
main	ADJ	O	O
etiology	NOUN	O	O
is	VERB	O	O
alcoholic	ADJ	O	O
cirrhosis	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
have	PUNCT	O	O
pooled	VERB	O	O
two	NUM	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
in	ADP	O	O
palliative	ADJ	O	O
condition	NOUN	O	O
from	ADP	O	O
the	DET	O	O
F?d?ration	NOUN	O	O
Francophone	NOUN	O	O
de	ADP	O	O
Cancerologie	ADJ	O	O
Digestive	ADJ	O	O
.	PUNCT	O	O

They	PRON	O	O
had	PUNCT	O	O
included	PUNCT	O	O
416	NUM	O	O
and	CCONJ	O	O
122	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Performances	NOUN	O	O
of	ADP	O	O
Okuda	NOUN	O	O
,	PUNCT	O	O
CLIP	NOUN	O	O
and	CCONJ	O	O
BCLC	NOUN	O	O
scores	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
compared	VERB	O	O
using	PROPN	O	O
Akaike	ADJ	O	O
information	NOUN	O	O
criterion	NOUN	O	O
,	PUNCT	O	O
discriminatory	ADJ	O	O
ability	NOUN	O	O
(	PUNCT	O	O
Harrell	NOUN	O	O
's	PUNCT	O	O
C	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
Royston	NOUN	O	O
's	PUNCT	O	O
D	NOUN	O	O
statistics	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
monotonicity	NOUN	O	O
of	ADP	O	O
gradients	NOUN	O	O
and	CCONJ	O	O
predictive	ADJ	O	O
accuracy	NOUN	O	O
(	PUNCT	O	O
Schemper	PUNCT	O	O
statistics	NOUN	O	O
Vs	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

To	PART	O	O
explore	VERB	O	O
how	ADP	O	O
to	PUNCT	O	O
improve	ADJ	O	O
classifications	NOUN	O	O
,	PUNCT	O	O
univariate	ADJ	O	O
and	CCONJ	O	O
multivariate	ADJ	O	O
Cox	NOUN	O	O
model	NOUN	O	O
analyses	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
pooled	VERB	O	O
database	NOUN	O	O
included	VERB	O	O
538	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
survival	NOUN	O	O
was	ADV	O	O
5.3	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
4.6-6.2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
all	DET	O	O
statistics	NOUN	O	O
CLIP	NOUN	O	O
staging	VERB	O	O
system	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
better	PUNCT	O	O
prognostic	ADJ	O	O
ability	NOUN	O	O
.	PUNCT	O	O

Performances	NOUN	O	O
of	ADP	O	O
all	DET	O	O
staging	VERB	O	O
systems	NOUN	O	O
were	NUM	O	O
rather	ADP	O	O
disappointing	PUNCT	O	O
.	PUNCT	O	O

World	NOUN	O	O
Health	NOUN	O	O
Organization	NOUN	O	O
performance	NOUN	O	O
status	NOUN	O	O
(	PUNCT	O	O
WHO	NOUN	O	O
PS	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
CLIP	NOUN	O	O
or	CCONJ	O	O
alpha-fetoprotein	NOUN	O	O
for	ADP	O	O
BCLC	NOUN	O	O
allowed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
prognostic	ADJ	O	O
information	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Our	PUNCT	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
CLIP	NOUN	O	O
staging	ADV	O	O
seems	SYM	O	O
to	DET	O	O
be	PUNCT	O	O
most	PUNCT	O	O
adapted	VERB	O	O
to	ADP	O	O
palliative	ADJ	O	O
setting	ADP	O	O
and	CCONJ	O	O
that	ADP	O	O
it	PRON	O	O
could	VERB	O	O
be	ADP	O	O
better	PUNCT	O	O
by	ADP	O	O
associating	PUNCT	O	O
WHO	NOUN	O	O
PS	NOUN	O	O
.	PUNCT	O	O

Parenteral	ADJ	O	O
nutrition	NOUN	O	O
and	CCONJ	O	O
protein	NOUN	O	O
sparing	PUNCT	O	O
after	ADP	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
do	PUNCT	O	O
we	PRON	O	O
need	VERB	O	O
glucose	NOUN	O	O
?	PUNCT	O	O

Although	ADP	O	O
capable	ADJ	O	O
of	ADP	O	O
inducing	VERB	O	O
an	DET	O	O
anabolic	ADJ	O	O
state	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
parenteral	ADJ	O	O
nutrition	NOUN	O	O
,	PUNCT	O	O
including	CCONJ	O	O
glucose	NOUN	O	O
,	PUNCT	O	O
leads	NOUN	O	O
to	ADP	O	O
hyperglycemia	NOUN	O	O
.	PUNCT	O	O

Even	ADV	O	O
moderate	ADJ	O	O
increases	CCONJ	O	O
in	ADP	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
poor	ADJ	O	O
surgical	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
amino	ADJ	O	O
acids	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	O
supply	NOUN	O	O
,	PUNCT	O	O
spare	NOUN	O	O
protein	NOUN	O	O
while	ADP	O	O
preventing	PUNCT	O	O
hyperglycemia	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
14	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
colonic	ADJ	O	O
cancer	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADJ	O	O
undergo	VERB	O	O
a	DET	O	O
6-hour	NOUN	O	O
stable	ADJ	O	O
isotope	NOUN	O	O
infusion	NOUN	O	O
study	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
fasting	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
3-hour	NOUN	O	O
infusions	NOUN	O	O
of	ADP	O	O
amino	ADJ	O	O
acids	NOUN	O	O
,	PUNCT	O	O
Travasol	NOUN	O	O
[	PUNCT	O	O
Baxter	NOUN	O	O
,	PUNCT	O	O
Montreal	PUNCT	O	O
,	PUNCT	O	O
Canada	PUNCT	O	O
]	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
at	ADP	O	O
0.02	NUM	O	O
mL.kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.min	PUNCT	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
glucose	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
mg.kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.min	PUNCT	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
second	ADJ	O	O
day	NOUN	O	O
after	PUNCT	O	O
colorectal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Protein	NOUN	O	B-PHYSICAL
breakdown	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
protein	NOUN	O	B-PHYSICAL
oxidation	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
protein	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
glucose	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
stable	ADJ	O	O
isotope	NOUN	O	O
tracer	NOUN	O	O
kinetics	NOUN	O	O
using	ADJ	O	O
l-	PUNCT	O	O
[	PUNCT	O	O
1-	NUM	O	O
(	PUNCT	O	O
13	NUM	O	O
)	PUNCT	O	O
C	NOUN	O	O
]	PUNCT	O	O
leucine	NOUN	O	O
and	CCONJ	O	O
[	PUNCT	O	O
6,6-	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
H2	NOUN	O	O
]	PUNCT	O	O
glucose	NOUN	O	O
.	PUNCT	O	O

Circulating	VERB	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
cortisol	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
insulin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
glucagon	NOUN	O	B-PHYSICAL
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
amino	ADJ	O	O
acids	NOUN	O	O
increased	ADV	O	O
protein	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
from	ADP	O	O
-16+/-4	NOUN	O	O
micromol.kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.h	PUNCT	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
fasted	VERB	O	O
state	NOUN	O	O
to	ADP	O	O
16+/-3	NOUN	O	O
micromol.kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.h	PUNCT	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Combined	VERB	O	O
infusion	NOUN	O	O
of	ADP	O	O
amino	ADJ	O	O
acids	NOUN	O	O
and	CCONJ	O	O
glucose	NOUN	O	O
increased	ADV	O	O
protein	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
from	ADP	O	O
-17+/-7	VERB	O	O
to	ADP	O	O
7+/-5	CCONJ	O	O
micromol.kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.h	PUNCT	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
protein	NOUN	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
during	ADP	O	O
nutrition	NOUN	O	O
was	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P=.07	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Combined	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
amino	ADJ	O	O
acids	NOUN	O	O
and	CCONJ	O	O
glucose	NOUN	O	O
decreased	VERB	O	O
endogenous	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
production	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P=.001	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
stimulated	VERB	O	O
insulin	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P=.001	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
extent	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
amino	ADJ	O	O
acids	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Hyperglycemia	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
,	PUNCT	O	O
10.1+/-1.9	NOUN	O	O
micromol/L	NOUN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
excluding	CCONJ	O	O
glucose	NOUN	O	O
from	ADP	O	O
a	DET	O	O
short-term	NOUN	O	O
feeding	ADP	O	O
protocol	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
diminish	VERB	O	O
the	DET	O	O
protein-sparing	ADV	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
amino	ADJ	O	O
acids	NOUN	O	O
and	CCONJ	O	O
avoids	NOUN	O	O
hyperglycemia	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Variations	NOUN	O	O
in	ADP	O	O
EEG	NOUN	O	B-PHYSICAL
discharges	ADJ	O	I-PHYSICAL
predict	ADJ	O	O
ADHD	NOUN	O	O
severity	NOUN	O	O
within	ADP	O	O
individual	ADJ	O	O
Smith-Lemli-Opitz	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
We	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
EEG	NOUN	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
Smith-Lemli-Opitz	PUNCT	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
SLOS	NOUN	O	O
)	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
interictal	ADJ	O	O
epileptiform	NUM	O	O
discharges	ADJ	O	O
(	PUNCT	O	O
IEDs	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
within-subject	ADP	O	O
variations	NOUN	O	O
in	ADP	O	O
attentional	ADJ	O	O
symptom	NOUN	O	O
severity	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
for	ADP	O	O
SLOS	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
performed	VERB	O	O
cross-sectional	ADJ	O	O
and	CCONJ	O	O
repeated-measure	NOUN	O	O
observational	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
EEG	NOUN	O	O
findings	NOUN	O	O
and	CCONJ	O	O
cognitive/behavioral	ADJ	O	O
factors	NOUN	O	O
on	ADP	O	O
23	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
aged	PROPN	O	O
4-17	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

EEGs	NOUN	O	O
were	VERB	O	O
reviewed	VERB	O	O
for	ADP	O	O
clinical	ADJ	O	O
abnormalities	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
IEDs	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
readers	NOUN	O	O
blinded	VERB	O	O
to	ADP	O	O
participants	NOUN	O	O
'	PUNCT	O	O
behavioral	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Between-group	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
baseline	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
IEDs	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

Within-subject	PUNCT	O	O
analyses	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
IEDs	NOUN	O	O
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
attention-deficit/hyperactivity	NOUN	O	B-PHYSICAL
disorder	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ADHD	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
85	NUM	O	O
EEGs	PUNCT	O	O
,	PUNCT	O	O
43	NUM	O	O
(	PUNCT	O	O
51	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
abnormal	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
predominantly	ADP	O	O
because	PUNCT	O	O
of	ADP	O	O
IEDs	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
one	NUM	O	O
subject	NOUN	O	O
had	PUNCT	O	O
documented	VERB	O	O
clinical	ADJ	O	B-ADVERSE-EFFECTS
seizures	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

IEDs	NOUN	O	O
clustered	VERB	O	O
in	ADP	O	O
13	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
57	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
9	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
39	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
EEGs	NOUN	O	O
consistently	ADV	O	O
free	ADJ	O	O
of	ADP	O	O
IEDs	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
group	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
sex	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
intellectual	ADJ	O	O
disability	NOUN	O	O
,	PUNCT	O	O
language	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
baseline	NOUN	O	O
ADHD	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
autistic	ADJ	O	O
symptoms	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
more	ADV	O	O
prevalent	ADJ	O	O
in	ADP	O	O
the	DET	O	O
IED	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
according	PUNCT	O	O
to	ADP	O	O
Autism	NOUN	O	B-MENTAL
Diagnostic	ADJ	O	I-MENTAL
Observation	NOUN	O	I-MENTAL
Schedule-2	NOUN	O	I-MENTAL
criteria	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
.	PUNCT	O	O

Within	ADP	O	O
individuals	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
IEDs	NOUN	O	O
on	ADP	O	O
a	DET	O	O
particular	ADJ	O	O
EEG	NOUN	O	O
predicted	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
average	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
27	NUM	O	O
%	SYM	O	O
increase	NOUN	O	O
in	ADP	O	O
ADHD	NOUN	O	B-MENTAL
symptom	NOUN	O	I-MENTAL
severity	NOUN	O	I-MENTAL
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Epileptiform	PUNCT	O	O
discharges	ADJ	O	O
are	CCONJ	O	O
common	ADJ	O	O
in	ADP	O	O
SLOS	NOUN	O	O
,	PUNCT	O	O
despite	ADP	O	O
a	DET	O	O
relatively	ADV	O	O
low	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	O
.	PUNCT	O	O

Fluctuations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
epileptiform	VERB	O	O
discharges	ADJ	O	O
within	ADP	O	O
individual	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
a	DET	O	O
developmental	ADJ	O	O
disability	NOUN	O	O
syndrome	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
fluctuations	NOUN	O	O
in	ADP	O	O
ADHD	NOUN	O	O
symptomatology	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
seizures	NOUN	O	O
.	PUNCT	O	O

Cyclosporin	NOUN	O	O
A	DET	O	O
increases	ADP	O	O
somatomedin	NOUN	O	B-ADVERSE-EFFECTS
C	NOUN	O	I-ADVERSE-EFFECTS
insulin-like	ADJ	O	I-ADVERSE-EFFECTS
growth	NOUN	O	I-ADVERSE-EFFECTS
factor	NOUN	O	O
I	NUM	O	B-ADVERSE-EFFECTS
levels	NOUN	O	B-ADVERSE-EFFECTS
in	ADP	O	O
chronic	ADJ	O	O
rheumatic	ADJ	O	O
diseases	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
whether	ADP	O	O
anabolic	ADJ	O	O
hormones	NOUN	O	O
that	ADP	O	O
affect	VERB	O	O
the	DET	O	O
musculoskeletal	ADJ	O	O
system	NOUN	O	O
and	CCONJ	O	O
active	ADJ	O	O
on	ADP	O	O
the	DET	O	O
immune	ADJ	O	O
cells	NOUN	O	O
changed	VERB	O	O
during	ADP	O	O
cyclosporin	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
CysA	NOUN	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	ADJ	O	O
carried	PUNCT	O	O
out	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatic	ADJ	O	O
disease	NOUN	O	O
attending	VERB	O	O
the	DET	O	O
outpatient	ADJ	O	O
clinic	NOUN	O	O
for	ADP	O	O
rheumatic	ADJ	O	O
diseases	NOUN	O	O
.	PUNCT	O	O

Twenty-four	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
arthritis	NOUN	O	O
[	PUNCT	O	O
20	NUM	O	O
with	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
(	PUNCT	O	O
RA	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
with	ADP	O	O
psoriatic	ADJ	O	O
arthritis	NOUN	O	O
(	PUNCT	O	O
PsA	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
2	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
RA	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
PsA	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
randomly	ADV	O	O
given	VERB	O	O
CysA	NOUN	O	O
5	NUM	O	O
mg/kg	NOUN	O	O
daily	ADP	O	O
or	CCONJ	O	O
hydroxychloroquine	NOUN	O	O
(	PUNCT	O	O
OH-Chlor	NOUN	O	O
)	PUNCT	O	O
6	NUM	O	O
mg/kg	NOUN	O	O
daily	ADP	O	O
in	ADP	O	O
divided	VERB	O	O
doses	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
significant	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
insulin-like	ADJ	O	B-PHYSICAL
growth	NOUN	O	I-PHYSICAL
factor	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
IGF-I	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
somatomedin	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
and	CCONJ	O	O
of	PUNCT	O	O

Effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
intervention	NOUN	O	O
in	ADP	O	O
improving	VERB	O	O
pain	NOUN	O	O
control	NOUN	O	O
in	ADP	O	O
outpatients	ADJ	O	O
with	ADP	O	O
cancer	NOUN	O	O
treated	VERB	O	O
by	ADP	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
multicomponent	ADJ	O	O
clinical	ADJ	O	O
intervention	NOUN	O	O
to	PART	O	O
reduce	NOUN	O	O
pain	NOUN	O	O
in	ADP	O	O
outpatients	ADJ	O	O
with	ADP	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
MATERIALS	CCONJ	O	O
Sixty-four	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
intervention	NOUN	O	O
including	ADJ	O	O
an	DET	O	O
information	NOUN	O	O
session	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pain	NOUN	O	O
diary	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
possibility	NOUN	O	O
to	ADV	O	O
contact	NOUN	O	O
a	DET	O	O
physician	NOUN	O	O
to	PUNCT	O	O
adjust	PUNCT	O	O
the	DET	O	O
pain	NOUN	O	O
medication	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
usual	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	O
by	ADP	O	O
the	DET	O	O
staff	NOUN	O	O
radiation	NOUN	O	O
oncologist	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
reported	VERB	O	O
their	PUNCT	O	O
average	ADJ	O	O
and	CCONJ	O	O
worst	PUNCT	O	O
pain	NOUN	O	B-PAIN
levels	NOUN	O	I-PAIN
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
study	ADV	O	O
groups	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
baseline	NOUN	O	O
characteristics	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	O
levels	NOUN	O	O
at	ADP	O	O
randomization	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
average	ADJ	O	O
and	CCONJ	O	O
worst	PUNCT	O	O
pain	NOUN	O	O
experienced	VERB	O	O
by	ADP	O	O
patients	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
intervention	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
inferior	ADJ	O	O
to	ADP	O	O
the	DET	O	O
average	ADJ	O	O
pain	NOUN	O	O
experienced	VERB	O	O
by	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
2.9/10	NUM	O	O
vs.	CCONJ	O	O
4.4/10	NOUN	O	O
and	CCONJ	O	O
4.2/10	NOUN	O	O
vs.	CCONJ	O	O
5.5/10	ADV	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
patients	NOUN	O	O
decreased	VERB	O	O
their	ADP	O	O
pain	NOUN	O	O
levels	NOUN	O	O
more	ADV	O	O
than	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
patients	NOUN	O	O
did	PUNCT	O	O
over	PUNCT	O	O
time	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
An	DET	O	O
intervention	NOUN	O	O
including	DET	O	O
patient	NOUN	O	O
education	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
pain	NOUN	O	B-PAIN
diary	PUNCT	O	I-PAIN
,	PUNCT	O	O
and	CCONJ	O	O
defining	VERB	O	O
a	DET	O	O
procedure	NOUN	O	O
for	ADP	O	O
therapeutic	ADJ	O	O
adjustments	NOUN	O	O
can	VERB	O	O
be	NOUN	O	O
effective	ADJ	O	O
to	PART	O	O
improve	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
relief	NOUN	O	I-PAIN
in	ADP	O	O
outpatients	ADJ	O	B-PHYSICAL
with	ADP	O	I-PHYSICAL
cancer	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
intervention	NOUN	O	O
in	ADP	O	O
autistic	ADJ	O	O
syndromes	NOUN	O	O
.	PUNCT	O	O

Impaired	VERB	O	O
social	ADJ	O	O
interaction	NOUN	O	O
,	PUNCT	O	O
communication	NOUN	O	O
and	CCONJ	O	O
imaginative	ADJ	O	O
skills	NOUN	O	O
characterize	VERB	O	O
autistic	ADJ	O	O
syndromes	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
syndromes	NOUN	O	O
urinary	ADJ	O	O
peptide	NOUN	O	O
abnormalities	NOUN	O	O
,	PUNCT	O	O
derived	VERB	O	O
from	ADP	O	O
gluten	PUNCT	O	O
,	PUNCT	O	O
gliadin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
casein	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

They	PRON	O	O
reflect	ADP	O	O
processes	NOUN	O	O
with	ADP	O	O
opioid	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
single	ADJ	O	O
blind	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
gluten	ADJ	O	O
and	CCONJ	O	O
casein-free	ADJ	O	O
diet	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
syndromes	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
peptide	NOUN	O	O
abnormalities	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomly	ADV	O	O
selected	VERB	O	O
diet	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
with	ADP	O	O
10	NUM	O	O
children	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
participated	ADJ	O	O
.	PUNCT	O	O

Observations	NOUN	O	B-OTHER
and	CCONJ	O	O
tests	NOUN	O	B-OTHER
were	VERB	O	O
done	PUNCT	O	O
before	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	B-OTHER
for	ADP	O	O
the	DET	O	O
group	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
on	ADP	O	O
diet	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
than	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
sexual	ADJ	O	I-PHYSICAL
outcomes	NOUN	O	I-PHYSICAL
in	ADP	O	O
women	NOUN	O	O
experiencing	ADJ	O	O
vaginal	ADJ	O	O
and	CCONJ	O	O
Caesarean	NOUN	O	O
births	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
urinary	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
sexual	ADJ	O	I-PHYSICAL
consequences	NOUN	O	I-PHYSICAL
of	ADP	O	O
vaginal	ADJ	O	O
delivery	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
Caesarean	NOUN	O	O
section	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
cohort	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
data	NOUN	O	O
from	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
episiotomy	NOUN	O	O
conducted	VERB	O	O
in	ADP	O	O
3	NUM	O	O
Montreal	ADJ	O	O
hospitals	PROPN	O	O
in	ADP	O	O
1990-1991	NUM	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
999	NUM	O	O
trial	NOUN	O	O
participants	NOUN	O	O
for	ADP	O	O
whom	ADP	O	O
follow-up	NOUN	O	O
data	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
,	PUNCT	O	O
135	NUM	O	O
delivered	VERB	O	O
by	ADP	O	O
Caesarean	NOUN	O	O
section	NOUN	O	O
(	PUNCT	O	O
CS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
864	NUM	O	O
had	PUNCT	O	O
a	DET	O	O
vaginal	ADJ	O	O
birth	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
stratifying	ADP	O	O
for	ADP	O	O
parity	NOUN	O	O
,	PUNCT	O	O
we	NOUN	O	O
compared	PUNCT	O	O
rates	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	B-PHYSICAL
incontinence	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
UI	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
sexual	ADJ	O	B-PHYSICAL
functioning	ADP	O	I-PHYSICAL
at	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
postpartum	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
a	DET	O	O
VB	NOUN	O	O
with	ADP	O	O
the	DET	O	O
rates	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
a	DET	O	O
CS	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Primiparous	ADJ	O	O
women	NOUN	O	O
reported	ADP	O	O
unspecified	VERB	O	O
UI	NOUN	O	B-PHYSICAL
at	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
postpartum	PUNCT	O	O
more	ADV	O	O
often	ADV	O	O
(	PUNCT	O	O
17.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
VB	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
CS	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
6.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
difference	NOUN	O	O
remained	VERB	O	O
significant	ADJ	O	O
whether	ADP	O	O
or	CCONJ	O	O
not	ADP	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
prior	ADP	O	O
history	NOUN	O	O
of	ADP	O	O
UI	NOUN	O	O
.	PUNCT	O	O

Multiparous	ADJ	O	O
women	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
rates	NOUN	O	B-PHYSICAL
of	ADP	O	O
UI	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
17.1	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
CS	NOUN	O	O
16.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whether	ADP	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
prior	ADP	O	O
history	NOUN	O	O
of	ADP	O	O
UI	NOUN	O	O
or	CCONJ	O	O
not	ADV	O	O
.	PUNCT	O	O

Stress	NOUN	O	O
incontinence	NOUN	O	B-PHYSICAL
was	VERB	O	O
greater	PUNCT	O	O
among	ADP	O	O
primiparous	ADJ	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
VB	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
34.5	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
CS	NOUN	O	O
12.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
regardless	PUNCT	O	O
of	PUNCT	O	O
prior	PUNCT	O	O
UI	NOUN	O	O
history	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
whose	ADJ	O	O
UI	NOUN	O	B-PHYSICAL
was	VERB	O	O
severe	ADJ	O	O
enough	NOUN	O	O
to	ADP	O	O
wear	CCONJ	O	O
a	DET	O	O
pad	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
primiparous	ADJ	O	O
women	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
16.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CS	NOUN	O	O
15.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
multiparous	ADJ	O	O
women	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
23.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CS	NOUN	O	O
25.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Women	NOUN	O	B-MENTAL
's	PUNCT	O	O
sexual	ADJ	O	B-MENTAL
dissatisfaction	NOUN	O	I-MENTAL
was	VERB	O	O
greater	PUNCT	O	O
among	ADP	O	O
primiparous	ADJ	O	O
women	NOUN	O	O
who	ADP	O	O
had	ADJ	O	O
a	DET	O	O
vaginal	ADJ	O	O
birth	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
70.1	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CS	NOUN	O	O
54.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
multiparous	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rates	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	B-PHYSICAL
dissatisfaction	NOUN	O	I-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
(	PUNCT	O	O
VB	NOUN	O	O
64.2	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CS	NOUN	O	O
71.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
dyspareunia	DET	O	B-PHYSICAL
for	ADP	O	O
each	DET	O	O
mode	NOUN	O	O
of	ADP	O	O
delivery	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
primiparous	ADJ	O	O
women	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
30.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CS	NOUN	O	O
31.6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
both	CCONJ	O	O
primiparous	ADJ	O	O
and	CCONJ	O	O
multiparous	ADJ	O	O
women	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
intact	ADJ	O	O
perineums	ADP	O	O
after	ADP	O	O
VB	NOUN	O	O
had	PUNCT	O	O
less	DET	O	O
dyspareunia	PUNCT	O	B-PHYSICAL
than	PUNCT	O	O
those	PUNCT	O	O
undergoing	VERB	O	O
CS	NOUN	O	O
(	PUNCT	O	O
VB	NOUN	O	O
26.2	NUM	O	O
,	PUNCT	O	O
CS	NOUN	O	O
40.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
experiencing	CCONJ	O	O
dyspareunia	ADV	O	B-PHYSICAL
was	ADV	O	O
greatest	PUNCT	O	O
among	ADP	O	O
those	ADP	O	O
who	ADP	O	O
had	ADP	O	O
an	DET	O	O
episiotomy	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
forceps	NOUN	O	O
.	PUNCT	O	O

Music	ADJ	O	O
or	CCONJ	O	O
guided	ADJ	O	O
imagery	NOUN	O	O
for	ADP	O	O
women	NOUN	O	O
undergoing	VERB	O	O
colposcopy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
of	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
anxiety	NOUN	O	B-PAIN
,	PUNCT	O	O
perceived	DET	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
and	CCONJ	O	O
patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
It	PRON	O	O
was	VERB	O	O
hypothesized	VERB	O	O
that	PUNCT	O	O
music	ADJ	O	O
or	CCONJ	O	O
guided	ADJ	O	O
imagery	NOUN	O	O
versus	CCONJ	O	O
usual	ADJ	O	O
care	NOUN	O	O
would	VERB	O	O
result	VERB	O	O
in	ADP	O	O
less	DET	O	O
anxiety	NOUN	O	B-MENTAL
and	CCONJ	O	O
perceived	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
for	ADP	O	O
colposcopy	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
music	ADP	O	O
,	PUNCT	O	O
guided	DET	O	O
imagery	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
usual	ADJ	O	O
care	NOUN	O	O
after	ADP	O	O
completing	ADJ	O	O
a	DET	O	O
baseline	NOUN	O	O
questionnaire	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
completed	VERB	O	O
a	DET	O	O
postprocedure	NOUN	O	O
questionnaire	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Study	ADP	O	O
participants	NOUN	O	O
(	PUNCT	O	O
N=170	NOUN	O	O
)	PUNCT	O	O
had	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
age	NOUN	O	O
of	ADP	O	O
28.4	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
SD=9.6	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
18-60	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
formed	VERB	O	O
a	DET	O	O
racially	PUNCT	O	O
diverse	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Education/income	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
low	ADJ	O	O
.	PUNCT	O	O

No	DET	O	O
between-group	ADP	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
postprocedure	NOUN	O	B-PAIN
anxiety	NOUN	O	I-PAIN
or	CCONJ	O	O
pain	NOUN	O	B-PAIN
rating	ADP	O	I-PAIN
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Mind-body	NOUN	O	O
interventions	NOUN	O	O
had	CCONJ	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
impact	NOUN	O	O
on	ADP	O	O
reported	PUNCT	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O
perceived	DET	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
or	CCONJ	O	O
satisfaction	NOUN	O	B-OTHER
with	ADP	O	I-OTHER
care	NOUN	O	I-OTHER
,	PUNCT	O	O
even	ADV	O	O
for	ADP	O	O
those	ADJ	O	O
who	ADP	O	O
anticipated	PUNCT	O	O
the	DET	O	O
most	PUNCT	O	O
pain	NOUN	O	O
or	CCONJ	O	O
started	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
anxiety	NOUN	O	O
.	PUNCT	O	O

Cone	NOUN	O	O
biopsy	NOUN	O	O
:	PUNCT	O	O
has	PUNCT	O	O
endocervical	ADJ	O	O
sampling	ADP	O	O
a	DET	O	O
role	NOUN	O	O
?	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	NOUN	O	O
the	DET	O	O
sensitivity	NOUN	O	O
,	PUNCT	O	O
specificity	NOUN	O	O
and	CCONJ	O	O
predictive	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
endocervical	ADJ	O	O
sampling	PART	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
abnormal	ADJ	O	O
cervical	ADJ	O	O
smears	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
methods	NOUN	O	O
of	ADP	O	O
endocervical	ADJ	O	O
sampling	VERB	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Colposcopy	NOUN	O	O
clinic	NOUN	O	O
at	ADP	O	O
Aberdeen	ADV	O	O
Royal	ADJ	O	O
Infirmary	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
100	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
abnormal	ADJ	O	O
cervical	ADJ	O	O
smears	NOUN	O	O
selected	VERB	O	O
for	ADP	O	O
cone	NOUN	O	O
biopsy	NOUN	O	O
according	PUNCT	O	O
to	ADP	O	O
current	ADJ	O	O
colposcopy	NOUN	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
53	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PUNCT	O	O
have	PUNCT	O	O
endocervical	ADJ	O	O
sampling	VERB	O	O
with	ADP	O	O
the	DET	O	O
Kevorkian	ADJ	O	O
curette	NOUN	O	O
and	CCONJ	O	O
47	NUM	O	O
to	ADP	O	O
have	PUNCT	O	O
sampling	VERB	O	O
with	ADP	O	O
the	DET	O	O
Medscand	PUNCT	O	O
endocervical	ADJ	O	O
brush	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Cytology	NOUN	O	B-OTHER
and	CCONJ	O	O
histology	NOUN	O	B-OTHER
results	NOUN	O	I-OTHER
from	ADP	O	I-OTHER
endocervical	ADJ	O	I-OTHER
sampling	PUNCT	O	I-OTHER
compared	VERB	O	O
with	ADP	O	O
cone	NOUN	O	B-OTHER
biopsy	NOUN	O	I-OTHER
histology	NOUN	O	I-OTHER
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
overall	ADJ	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
endocervical	ADJ	O	B-OTHER
sampling	VERB	O	I-OTHER
was	VERB	O	O
56	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
false	ADJ	O	O
negative	ADJ	O	O
rate	NOUN	O	B-OTHER
of	ADP	O	O
44	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
a	DET	O	O
negative	ADJ	O	O
predictive	ADJ	O	B-OTHER
value	NOUN	O	I-OTHER
of	ADP	O	O
26	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Endocervical	ADJ	O	O
sampling	ADV	O	O
should	SYM	O	O
not	ADV	O	O
influence	VERB	O	O
management	NOUN	O	O
when	ADP	O	O
colposcopy	NOUN	O	O
is	VERB	O	O
unsatisfactory	ADJ	O	O
.	PUNCT	O	O

Ciprofloxacin/dexamethasone	NOUN	O	O
drops	PUNCT	O	O
decrease	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
physician	NOUN	O	O
and	CCONJ	O	O
patient	NOUN	O	O
outcomes	NOUN	O	O
of	ADP	O	O
otorrhea	NOUN	O	B-PHYSICAL
after	ADP	O	O
tube	NOUN	O	O
placement	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
ciprofloxacin	NOUN	O	O
0.3	NUM	O	O
%	SYM	O	O
/dexamethasone	NOUN	O	O
0.1	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
CIPRODEX	NOUN	O	O
,	PUNCT	O	O
Alcon	NOUN	O	O
,	PUNCT	O	O
Ft.	NOUN	O	O
Worth	PUNCT	O	O
,	PUNCT	O	O
TX	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
post-operative	ADJ	O	O
otorrhea	NOUN	O	O
following	ADJ	O	O
TT	NOUN	O	O
placement	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
single-center	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
evaluator-blinded	PUNCT	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
children	NOUN	O	O
undergoing	SYM	O	O
bilateral	PUNCT	O	O
TT	NOUN	O	O
placement	NOUN	O	O
were	VERB	O	O
categorized	VERB	O	O
as	ADP	O	O
having	VERB	O	O
unilateral	ADJ	O	O
(	PUNCT	O	O
wet/dry	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bilateral	ADJ	O	O
(	PUNCT	O	O
wet/wet	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
(	PUNCT	O	O
dry/dry	PUNCT	O	O
)	PUNCT	O	O
effusion	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
Ciprodex	NOUN	O	O
or	CCONJ	O	O
no	DET	O	O
treatment	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
post-operatively	ADV	O	O
and	CCONJ	O	O
returned	VERB	O	O
at	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Physician-observed	PUNCT	O	B-PHYSICAL
otorrhea	NOUN	O	I-PHYSICAL
was	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
5	NUM	O	O
(	PUNCT	O	O
4.95	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
receiving	VERB	O	O
Ciprodex	NOUN	O	O
and	CCONJ	O	O
39	NUM	O	O
(	PUNCT	O	O
39.39	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
receiving	VERB	O	O
no	DET	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
decreased	VERB	O	O
otorrhea	NOUN	O	B-PHYSICAL
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
greatest	PUNCT	O	O
benefit	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bilateral	ADJ	O	O
effusion	NOUN	O	O
(	PUNCT	O	O
93	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ciprodex	ADJ	O	O
treatment	NOUN	O	O
also	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
clinically	ADV	O	B-PHYSICAL
diagnosed	ADJ	O	I-PHYSICAL
otitis	ADJ	O	I-PHYSICAL
media	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
OM	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
effusion	NOUN	O	B-PHYSICAL
following	VERB	O	O
TT	NOUN	O	O
placement	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=0.0006	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Ciprodex	NOUN	O	O
reduced	VERB	O	O
early	ADJ	O	B-PHYSICAL
post-operative	ADJ	O	I-PHYSICAL
otorrhea	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
clinically	ADV	O	B-PHYSICAL
diagnosed	VERB	O	I-PHYSICAL
OM	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
effusion	NOUN	O	B-PHYSICAL
following	VERB	O	O
TT	NOUN	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
greatest	ADP	O	O
reduction	NOUN	O	O
in	ADP	O	O
otorrhea	NOUN	O	B-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bilateral	ADJ	O	O
effusion	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Bronchial	ADJ	O	B-PHYSICAL
matrix	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
inflammation	NOUN	O	I-PHYSICAL
respond	VERB	O	O
to	ADP	O	O
inhaled	PUNCT	O	O
steroids	NOUN	O	O
despite	ADP	O	O
ongoing	ADP	O	O
allergen	NOUN	O	O
exposure	NOUN	O	O
in	ADP	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Inflammatory	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
structural	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
airway	NOUN	O	I-PHYSICAL
mucosa	NOUN	O	I-PHYSICAL
are	VERB	O	O
chronic	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanisms	NOUN	O	O
underlying	VERB	O	O
these	DET	O	O
changes	NOUN	O	O
and	CCONJ	O	O
their	ADP	O	O
modulation	NOUN	O	O
by	ADP	O	O
steroid	NOUN	O	O
prophylaxis	NOUN	O	O
have	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
clarified	VERB	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
We	PRON	O	O
postulated	VERB	O	O
that	ADP	O	O
asymptomatic	ADJ	O	O
ongoing	VERB	O	O
allergen	NOUN	O	O
exposure	NOUN	O	O
could	VERB	O	O
drive	VERB	O	O
airway	NOUN	O	O
inflammation	NOUN	O	O
as	VERB	O	O
well	PUNCT	O	O
as	CCONJ	O	O
changes	VERB	O	O
in	ADP	O	O
the	DET	O	O
extracellular	ADJ	O	O
matrix	NOUN	O	O
(	PUNCT	O	O
ECM	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
inhaled	PUNCT	O	O
steroids	NOUN	O	O
could	ADV	O	O
prevent	VERB	O	O
this	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
exposed	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
asthma	NOUN	O	O
to	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
repeated	VERB	O	O
low-dose	NOUN	O	O
allergen	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
concomitant	ADJ	O	O
inhaled	VERB	O	O
steroid	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Bronchial	ADJ	O	O
biopsies	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
taken	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
this	DET	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
stained	VERB	O	O
and	CCONJ	O	O
digitally	ADV	O	O
analysed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
ECM	NOUN	O	O
proteins	NOUN	O	O
in	ADP	O	O
asthmatics	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADJ	O	O
Low-dose	ADJ	O	O
allergen	NOUN	O	O
exposure	NOUN	O	O
alone	ADJ	O	O
resulted	ADP	O	O
in	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
bronchial	ADJ	O	B-PHYSICAL
epithelial	ADJ	O	I-PHYSICAL
macrophages	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Despite	ADP	O	O
ongoing	DET	O	O
allergen	NOUN	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
inhaled	VERB	O	O
steroids	NOUN	O	O
reduced	ADP	O	O
the	DET	O	O
numbers	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
mucosal	ADJ	O	I-PHYSICAL
eosinophils	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
neutrophils	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
T	NOUN	O	B-PHYSICAL
lymphocytes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

At	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
density	NOUN	O	O
of	ADP	O	O
the	DET	O	O
proteoglycans	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
PGS	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
biglycan	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
decorin	NOUN	O	B-PHYSICAL
were	VERB	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
higher	PUNCT	O	O
and	CCONJ	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
bronchial	ADJ	O	O
mucosa	NOUN	O	O
of	ADP	O	O
asthmatics	NOUN	O	O
as	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
normal	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Steroid	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
allergen	NOUN	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
the	DET	O	O
mean	NOUN	O	O
density	NOUN	O	O
of	ADP	O	O
the	DET	O	O
PGS	NOUN	O	B-PHYSICAL
biglycan	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
versican	ADP	O	B-PHYSICAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
chronic	ADJ	O	O
allergen	NOUN	O	O
exposure	NOUN	O	O
induces	NOUN	O	O
inflammatory	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bronchial	ADJ	O	O
mucosa	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
ongoing	DET	O	O
allergen	NOUN	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
steroid	NOUN	O	O
treatment	NOUN	O	O
decreases	VERB	O	O
mucosal	ADJ	O	B-PHYSICAL
inflammatory	ADJ	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
while	ADP	O	O
altering	VERB	O	O
PG	NOUN	O	O
density	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
latter	ADJ	O	O
observation	NOUN	O	O
highlights	PUNCT	O	O
the	DET	O	O
need	ADP	O	O
to	PART	O	O
examine	NOUN	O	O
steroid-induced	VERB	O	B-OTHER
changes	NOUN	O	I-OTHER
closely	ADV	O	O
in	ADP	O	O
the	DET	O	O
airway	NOUN	O	O
structure	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

Failure	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	O
to	PART	O	O
reduce	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
neutropenia	NOUN	O	O
during	ADP	O	O
induction	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

Fifty-four	PUNCT	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
daunorubicin	NOUN	O	O
,	PUNCT	O	O
cytosine	NOUN	O	O
arabinoside	NOUN	O	O
and	CCONJ	O	O
thioquanine	ADP	O	O
for	ADP	O	O
acute	ADJ	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
oral	ADJ	O	O
lithium	NOUN	O	O
carbonate	NOUN	O	O
1200	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
or	CCONJ	O	O
no	DET	O	O
lithium	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
neutropenia	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
less	ADV	O	O
than	ADP	O	O
0.5	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
/L	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
22.5	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
lithium	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
24	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
remissions	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
relapse-free	PUNCT	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
and	CCONJ	O	O
survival	NOUN	O	B-MORTALITY
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
the	DET	O	O
lithium	NOUN	O	O
treated	VERB	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
apparent	ADJ	O	O
clinical	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	O
to	PART	O	O
reduce	ADJ	O	O
the	DET	O	O
period	NOUN	O	O
of	ADP	O	O
neutropenia	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
remission	NOUN	O	O
induction	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

Low-dose	ADJ	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
and	CCONJ	O	O
angiotensin	NOUN	O	O
II-converting	PUNCT	O	O
enzyme	NOUN	O	O
inhibitors	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
glomerulonephritis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
renin-angiotensin	NOUN	O	O
system	NOUN	O	O
is	VERB	O	O
thought	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
renal	ADJ	O	O
diseases	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
diabetic	ADJ	O	O
and	CCONJ	O	O
non-diabetic	ADJ	O	O
origin	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	ADP	O	O
been	PUNCT	O	O
confirmed	VERB	O	O
that	ADP	O	O
angiotensin-converting	VERB	O	O
enzyme	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
ACEIs	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
receptor	NOUN	O	O
blockers	NOUN	O	O
(	PUNCT	O	O
ARBs	NOUN	O	O
)	PUNCT	O	O
reduce	VERB	O	O
urinary	ADJ	O	O
protein	NOUN	O	O
excretion	NOUN	O	O
and	CCONJ	O	O
attenuate	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
injury	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
data	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
renal	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
ACEIs	PUNCT	O	O
and	CCONJ	O	O
ARBs	NOUN	O	O
,	PUNCT	O	O
either	PUNCT	O	O
singly	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
scarce	NOUN	O	O
and	CCONJ	O	O
usually	ADV	O	O
concern	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
standard	ADJ	O	O
or	CCONJ	O	O
high	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O

MATERIAL	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
9-month	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
18	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
enalapril	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
18	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
enalapril	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
16	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
proteinuria	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
kidney	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
metabolic	ADJ	O	B-PHYSICAL
profile	NOUN	O	I-PHYSICAL
in	ADP	O	O
54	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
biopsy-proven	PUNCT	O	O
chronic	ADJ	O	O
glomerulonephritis	NOUN	O	O
,	PUNCT	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
normal	ADJ	O	O
or	CCONJ	O	O
slightly	ADV	O	O
impaired	VERB	O	O
kidney	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	B-PHYSICAL
evaluation	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
laboratory	NOUN	O	I-PHYSICAL
tests	NOUN	O	I-PHYSICAL
were	VERB	O	O
performed	VERB	O	O
before	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
baseline	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
significant	ADJ	O	O
decreases	DET	O	O
in	ADP	O	O
proteinuria	NOUN	O	B-PHYSICAL
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
:	PUNCT	O	O
losartan	NOUN	O	O
,	PUNCT	O	O
22.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
enalapril	NOUN	O	O
,	PUNCT	O	O
43	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.012	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
combined	VERB	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
anti-proteinuric	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
was	VERB	O	O
even	ADV	O	O
greater	PUNCT	O	O
after	ADP	O	O
9	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
:	PUNCT	O	O
losartan	NOUN	O	O
,	PUNCT	O	O
44.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
enalapril	NOUN	O	O
,	PUNCT	O	O
49.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
combined	VERB	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
51	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
losartan	NOUN	O	O
and	CCONJ	O	O
enalapril	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
impact	NOUN	O	O
on	ADP	O	O
proteinuria	NOUN	O	B-PHYSICAL
level	NOUN	O	O
.	PUNCT	O	O

Proteinuria	NOUN	O	B-PHYSICAL
reduction	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
combined	VERB	O	O
therapy	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
losartan	NOUN	O	O
treatment	NOUN	O	O
after	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Creatinine	NOUN	O	B-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
serum	NOUN	O	B-PHYSICAL
creatinine	NOUN	O	I-PHYSICAL
were	VERB	O	O
stable	ADJ	O	O
during	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
study	NOUN	O	O
period	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
lipids	NOUN	O	B-PHYSICAL
,	PUNCT	O	I-PHYSICAL
serum	NOUN	O	I-PHYSICAL
uric	ADJ	O	I-PHYSICAL
acid	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
protein	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
These	PUNCT	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
proteinuria	NOUN	O	O
is	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
or	CCONJ	O	O
enalapril	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
seems	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
beneficial	ADJ	O	O
and	CCONJ	O	O
may	VERB	O	O
offer	VERB	O	O
an	DET	O	O
additional	ADJ	O	O
renoprotective	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
needs	CCONJ	O	O
to	PART	O	O
be	PUNCT	O	O
confirmed	VERB	O	O
in	ADP	O	O
a	DET	O	O
study	NOUN	O	O
with	ADP	O	O
a	DET	O	O
larger	PUNCT	O	O
sample	NOUN	O	O
size	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
The	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
enalapril	NOUN	O	O
and	CCONJ	O	O
indapamide	NOUN	O	O
on	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
central	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
through	ADP	O	O
pulse	NOUN	O	O
wave	NOUN	O	O
analysis	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
angiotensin-converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	NOUN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
enalapril	NOUN	O	O
and	CCONJ	O	O
diuretic	NOUN	O	O
indapamide	NOUN	O	O
on	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	B-PHYSICAL
central	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
Chinese	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
study	NOUN	O	O
was	ADV	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADP	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

Informed	VERB	O	O
consent	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
by	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
placebo	NOUN	O	O
run-in	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
105	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
or	CCONJ	O	O
moderate	ADJ	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
enalapril	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
indapamide	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Radial	ADJ	O	O
pulse	NOUN	O	O
wave	NOUN	O	O
recordings	CCONJ	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
all	DET	O	O
the	DET	O	O
patients	NOUN	O	O
before	ADP	O	O
the	DET	O	O
active	ADJ	O	O
treatments	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
those	PUNCT	O	O
patients	NOUN	O	O
who	ADP	O	O
have	PUNCT	O	O
finished	VERB	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
active	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
into	ADP	O	O
the	DET	O	O
final	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
one	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
51	NUM	O	O
in	ADP	O	O
enalapril	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
50	NUM	O	O
in	ADP	O	O
indapamide	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
completed	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
values	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
baseline	NOUN	O	O
data	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
all	ADJ	O	O
the	DET	O	O
parameters	NOUN	O	O
of	ADP	O	O
pulse	NOUN	O	B-PHYSICAL
wave	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
except	VERB	O	O
heart	NOUN	O	O
rates	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
and	CCONJ	O	O
augmentation	NOUN	O	O
index	NOUN	O	O
in	ADP	O	O
indapamide	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
decreased	VERB	O	O
significantly	ADV	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
values	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
all	DET	O	O
the	DET	O	O
parameters	NOUN	O	O
of	ADP	O	O
pulse	NOUN	O	O
wave	NOUN	O	O
except	VERB	O	O
that	CCONJ	O	O
the	DET	O	O
central	ADJ	O	B-PHYSICAL
systolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
augmentation	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
augmentation	NOUN	O	B-PHYSICAL
index	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
enalapril	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
indapamide	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
enalapril	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
reduced	ADJ	O	O
values	NOUN	O	O
of	ADP	O	O
systolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
pulse	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
central	ADJ	O	I-PHYSICAL
aorta	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
larger	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
brachial	ADJ	O	O
artery	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
difference	NOUN	O	B-PHYSICAL
was	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
indapamide	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Enalapril	NOUN	O	O
and	CCONJ	O	O
indapamide	NOUN	O	O
are	ADP	O	O
both	CCONJ	O	O
similarly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
peripheral	ADJ	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
enalapril	NOUN	O	O
is	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
central	ADJ	O	B-PHYSICAL
systolic	ADJ	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
augmentation	NOUN	O	I-PHYSICAL
index	NOUN	O	I-PHYSICAL
than	ADP	O	O
indapamide	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
is	VERB	O	O
probably	ADV	O	O
due	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
wave	NOUN	O	B-PHYSICAL
reflection	NOUN	O	I-PHYSICAL
caused	VERB	O	O
by	ADP	O	O
enalapril	NOUN	O	O
.	PUNCT	O	O

Sustained	VERB	O	O
ventricular	ADJ	O	O
arrhythmias	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
:	PUNCT	O	O
results	ADJ	O	O
from	ADP	O	O
the	DET	O	O
GUSTO-III	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
In	ADP	O	O
many	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
ventricular	ADJ	O	O
arrhythmias	NOUN	O	O
will	VERB	O	O
develop	ADV	O	O
early	DET	O	O
after	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
timing	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
outcomes	NOUN	O	O
of	ADP	O	O
such	ADP	O	O
arrhythmias	NOUN	O	O
in	ADP	O	O
the	DET	O	O
international	ADJ	O	O
Global	ADJ	O	O
Utilization	NOUN	O	O
of	ADP	O	O
Streptokinase	NOUN	O	O
and	CCONJ	O	O
TPA	NOUN	O	O
(	PUNCT	O	O
alteplase	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
Occluded	PROPN	O	O
Coronary	ADJ	O	O
Arteries	NOUN	O	O
(	PUNCT	O	O
GUSTO	NOUN	O	O
)	PUNCT	O	O
-III	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
identified	VERB	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
inhospital	ADJ	O	O
ventricular	ADJ	O	O
fibrillation	NOUN	O	O
(	PUNCT	O	O
VF	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
ventricular	ADJ	O	O
tachycardia	NOUN	O	O
(	PUNCT	O	O
VT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
compared	PUNCT	O	O
30-day	NOUN	O	O
and	CCONJ	O	O
1-year	NOUN	O	O
mortality	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	PROPN	O	O
did	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1121	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
did	DET	O	O
not	ADV	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
13,921	NUM	O	O
)	PUNCT	O	O
have	PUNCT	O	O
these	DET	O	O
arrhythmias	NOUN	O	O
during	ADP	O	O
the	DET	O	O
index	NOUN	O	O
hospitalization	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Significant	ADJ	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
inhospital	ADJ	O	O
VF	NOUN	O	O
were	VERB	O	O
higher	PUNCT	O	O
Killip	NOUN	O	B-PHYSICAL
class	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
lower	PUNCT	O	B-PHYSICAL
baseline	NOUN	O	O
systolic	ADJ	O	B-PHYSICAL
pressure	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
intravenous	ADJ	O	B-OTHER
preenrollment	ADJ	O	I-OTHER
lidocaine	NOUN	O	B-OTHER
use	NOUN	O	B-OTHER
,	PUNCT	O	O
shorter	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
thrombolysis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
beta-blocker	NOUN	O	O
use	NOUN	O	O
<	SYM	O	O
2	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
enrollment	NOUN	O	O
;	PUNCT	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
inhospital	ADJ	O	O
VT	NOUN	O	O
were	VERB	O	O
lower	VERB	O	O
baseline	NOUN	O	O
systolic	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
intravenous	ADJ	O	B-PHYSICAL
lidocaine	NOUN	O	I-PHYSICAL
use	NOUN	O	O
before	ADP	O	O
enrollment	NOUN	O	O
,	PUNCT	O	O
higher	PUNCT	O	O
Killip	NOUN	O	O
class	NOUN	O	O
,	PUNCT	O	O
faster	PUNCT	O	O
baseline	NOUN	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
advanced	VERB	O	O
age	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
30-day	NOUN	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
rate	NOUN	O	I-MORTALITY
was	VERB	O	O
31	NUM	O	O
%	SYM	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
VF	NOUN	O	O
,	PUNCT	O	O
24	NUM	O	O
%	SYM	O	O
in	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
VT	NOUN	O	O
,	PUNCT	O	O
44	NUM	O	O
%	SYM	O	O
in	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
both	CCONJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6	NUM	O	O
%	SYM	O	O
in	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
neither	CCONJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
=.001	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
corresponding	VERB	O	O
1-year	NOUN	O	B-MORTALITY
mortality	PUNCT	O	I-MORTALITY

Clinical	ADJ	O	O
description	NOUN	O	O
of	ADP	O	O
encephalopathic	ADJ	O	O
syndromes	NOUN	O	O
and	CCONJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
their	PUNCT	O	O
occurrence	NOUN	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
during	ADP	O	O
melarsoprol	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
African	ADJ	O	O
trypanosomiasis	NOUN	O	O
.	PUNCT	O	O

Encephalopathies	NUM	O	O
are	VERB	O	O
the	DET	O	O
most	PUNCT	O	O
feared	VERB	O	O
complications	NOUN	O	O
of	ADP	O	O
sleeping	VERB	O	O
sickness	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
melarsoprol	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
existence	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
encephalopathic	ADJ	O	O
syndromes	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
encephalopathies	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
with	ADP	O	O
588	NUM	O	O
patients	NOUN	O	O
under	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
melarsoprol	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
38	NUM	O	O
encephalopathy	NOUN	O	O
cases	NOUN	O	O
were	VERB	O	O
classified	VERB	O	O
into	ADP	O	O
three	NUM	O	O
types	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
leading	ADJ	O	O
clinical	ADJ	O	O
picture	NOUN	O	O
:	PUNCT	O	O
coma	NOUN	O	O
type	NOUN	O	O
,	PUNCT	O	O
convulsion	NOUN	O	O
type	NOUN	O	O
and	CCONJ	O	O
psychotic	ADJ	O	O
reactions	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
convulsion	NOUN	O	O
type	NOUN	O	O
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
transient	ADJ	O	O
event	NOUN	O	O
of	ADP	O	O
short	ADJ	O	O
duration	NOUN	O	O
with	ADP	O	O
convulsions	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
post-ictal	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
signs	NOUN	O	O
of	ADP	O	O
a	DET	O	O
generalized	VERB	O	O
disease	NOUN	O	O
.	PUNCT	O	O

None	NUM	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
died	VERB	O	O
from	ADP	O	O
the	DET	O	O
reaction	NOUN	O	O
.	PUNCT	O	O

Febrile	ADJ	O	B-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
48	NUM	O	O
h	NOUN	O	O
preceding	VERB	O	O
the	DET	O	O
reaction	NOUN	O	O
were	VERB	O	O
generally	ADV	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

Twenty-five	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
coma	NOUN	O	O
type	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
a	DET	O	O
progredient	ADJ	O	O
coma	NOUN	O	O
lasting	PUNCT	O	O
several	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

Those	ADP	O	O
patients	NOUN	O	O
often	ADV	O	O
had	PUNCT	O	O
signs	NOUN	O	O
of	ADP	O	O
a	DET	O	O
generalized	VERB	O	O
disease	NOUN	O	O
such	PUNCT	O	O
as	ADP	O	O
fever	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
84	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
headache	ADJ	O	B-PHYSICAL
(	PUNCT	O	O
72	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
bullous	ADJ	O	O
skin	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
reactions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
mortality	NOUN	O	B-MORTALITY
was	VERB	O	O
high	ADJ	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
(	PUNCT	O	O
52	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

About	PUNCT	O	O
14/16	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
encephalopathic	ADJ	O	O
syndrome	NOUN	O	O
of	ADP	O	O
the	DET	O	O
coma	NOUN	O	O
type	NOUN	O	O
were	VERB	O	O
infected	VERB	O	O
with	ADP	O	O
malaria	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
psychotic	ADJ	O	O
reactions	NOUN	O	O
or	CCONJ	O	O
abnormal	ADJ	O	O
psychiatric	ADJ	O	O
behaviour	NOUN	O	O
(	PUNCT	O	O
3/38	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
patient	NOUN	O	O
who	ADP	O	O
died	VERB	O	B-MORTALITY
after	ADP	O	O
alcohol	NOUN	O	O
intake	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
from	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
encephalopathic	ADJ	O	I-PHYSICAL
syndromes	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
analysed	VERB	O	O
(	PUNCT	O	O
n=34	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
5.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
of	ADP	O	O
which	ADP	O	O
38.2	NUM	O	O
%	SYM	O	O
died	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
did	CCONJ	O	O
not	ADV	O	O
find	VERB	O	O
any	DET	O	O
parameters	NOUN	O	O
of	ADP	O	O
predictive	ADJ	O	O
value	NOUN	O	O
for	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	PUNCT	O	B-PHYSICAL
an	DET	O	I-PHYSICAL
encephalopathic	ADJ	O	I-PHYSICAL
syndrome	NOUN	O	I-PHYSICAL
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
signs	NOUN	O	O
before	ADP	O	O
treatment	NOUN	O	O
initiation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
appearance	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
febrile	ADJ	O	B-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
11.5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
headache	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
2.5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bullous	ADJ	O	B-PHYSICAL
eruptions	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
4.5	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
systolic	ADJ	O	B-PHYSICAL
hypotension	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
2.6	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
encephalopathic	ADJ	O	O
syndromes	NOUN	O	O
especially	DET	O	O
of	ADP	O	O
the	DET	O	O
coma	NOUN	O	O
type	NOUN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
6-mercaptopurine	NOUN	O	O
versus	CCONJ	O	O
oral	ADJ	O	O
6-thioguanine	NOUN	O	O
and	CCONJ	O	O
veno-occlusive	ADJ	O	O
disease	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
standard-risk	NOUN	O	O
acute	ADJ	O	O
lymphoblastic	ADJ	O	O
leukemia	NOUN	O	O
:	PUNCT	O	O
report	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Children	NOUN	O	O
's	PUNCT	O	O
Oncology	NOUN	O	O
Group	NOUN	O	O
CCG-1952	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Children	NOUN	O	O
's	PUNCT	O	O
Cancer	NOUN	O	O
Group	NOUN	O	O
1952	NUM	O	O
(	PUNCT	O	O
CCG-1952	NOUN	O	O
)	PUNCT	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
studied	VERB	O	O
the	DET	O	O
substitution	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
6-thioguanine	NOUN	O	O
(	PUNCT	O	O
TG	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
6-mercaptopurine	NOUN	O	O
(	PUNCT	O	O
MP	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
triple	ADJ	O	O
intrathecal	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ITT	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
intrathecal	ADJ	O	O
methotrexate	NOUN	O	O
(	PUNCT	O	O
IT-MTX	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
standard-risk	NOUN	O	O
acute	ADJ	O	O
lymphoblastic	ADJ	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
remission	NOUN	O	O
induction	NOUN	O	O
,	PUNCT	O	O
2027	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
MP	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1010	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
TG	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1017	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
IT-MTX	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1018	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ITT	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1009	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
thiopurine	NOUN	O	O
comparison	NOUN	O	O
are	ADP	O	O
as	PUNCT	O	O
follows	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
estimated	VERB	O	O
7-year	NOUN	O	O
event-free	CCONJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	I-MORTALITY
EFS	NOUN	O	I-MORTALITY
)	PUNCT	O	I-MORTALITY
for	ADP	O	O
subjects	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
TG	NOUN	O	O
was	VERB	O	O
84.1	NUM	O	O
%	ADJ	O	O
(	PUNCT	O	O
+/-	PROPN	O	O
1.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
to	ADP	O	O
MP	NOUN	O	O
was	VERB	O	O
79.0	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
+/-	PROPN	O	O
2.1	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.004	NUM	O	O
log	NOUN	O	O
rank	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
although	ADP	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
91.9	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
+/-	PROPN	O	O
1.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
91.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
+/-	PROPN	O	O
1.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.6	PUNCT	O	O
log	NOUN	O	O
rank	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
TG	NOUN	O	O
starting	PUNCT	O	O
dose	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
from	ADP	O	O
60	NUM	O	O
to	ADP	O	O
50	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
per	ADP	O	O
day	NOUN	O	O
after	PUNCT	O	O
recognition	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-PHYSICAL
veno-occlusive	ADJ	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
VOD	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
257	NUM	O	O
patients	NOUN	O	O
on	ADP	O	O
TG	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
developed	VERB	O	O
VOD	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
disproportionate	ADJ	O	B-PHYSICAL
thrombocytopenia	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
switched	VERB	O	O
to	ADP	O	O
MP	NOUN	O	O
.	PUNCT	O	O

Once	PUNCT	O	O
portal	NOUN	O	B-PHYSICAL
hypertension	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
,	PUNCT	O	O
all	DET	O	O
subjects	NOUN	O	O
on	ADP	O	O
TG	NOUN	O	O
were	VERB	O	O
changed	NUM	O	O
to	ADP	O	O
MP	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
benefit	NOUN	O	O
of	ADP	O	O
randomization	NOUN	O	O
to	ADP	O	O
TG	NOUN	O	O
over	ADP	O	O
MP	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
EFS	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
evident	ADJ	O	O
primarily	ADV	O	O
in	ADP	O	O
boys	NOUN	O	O
who	ADP	O	O
began	ADV	O	O
TG	NOUN	O	O
at	ADP	O	O
60	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
relative	ADJ	O	O
hazard	NOUN	O	O
rate	NOUN	O	O
[	PUNCT	O	O
RHR	NOUN	O	O
]	PUNCT	O	O
0.65	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
toxicities	NOUN	O	O
of	ADP	O	O
TG	NOUN	O	O
preclude	PUNCT	O	O
its	ADP	O	O
protracted	VERB	O	O
use	NOUN	O	O
as	PUNCT	O	O
given	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
registered	NOUN	O	O
at	ADP	O	O
http	PUNCT	O	O
:	PUNCT	O	O
//clinicaltrials.gov	PUNCT	O	O
as	PUNCT	O	O
NCT00002744	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
types	NOUN	O	O
of	ADP	O	O
social	ADJ	O	O
support	NOUN	O	O
and	CCONJ	O	O
education	NOUN	O	O
on	ADP	O	O
adaptation	NOUN	O	O
to	ADP	O	O
early-stage	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
Roy	NOUN	O	O
adaptation	NOUN	O	O
model-based	VERB	O	O
support	NOUN	O	O
and	CCONJ	O	O
education	NOUN	O	O
intervention	NOUN	O	O
for	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
early-stage	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
three-group	NOUN	O	O
,	PUNCT	O	O
three-phase	NOUN	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
125	NUM	O	O
women	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
13	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
individual	ADP	O	O
telephone	NOUN	O	O
and	CCONJ	O	O
in-person	NOUN	O	O
group	NOUN	O	O
support	NOUN	O	O
and	CCONJ	O	O
education	NOUN	O	O
,	PUNCT	O	O
Control	NOUN	O	O
Group	NOUN	O	O
1	NUM	O	O
received	PUNCT	O	O
13	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
telephone-only	PUNCT	O	O
individual	ADJ	O	O
support	NOUN	O	O
and	CCONJ	O	O
education	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Control	NOUN	O	O
Group	NOUN	O	O
2	NUM	O	O
received	VERB	O	O
one-time	ADJ	O	O
mailed	PUNCT	O	O
educational	ADJ	O	O
information	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
Control	NOUN	O	O
Group	NOUN	O	O
1	NUM	O	O
reported	PUNCT	O	O
less	ADV	O	O
mood	PUNCT	O	B-MENTAL
disturbance	NOUN	O	I-MENTAL
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
all	DET	O	O
three	NUM	O	O
phases	NOUN	O	O
,	PUNCT	O	O
less	DET	O	B-MENTAL
loneliness	NOUN	O	I-MENTAL
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
Phases	NOUN	O	O
II	NUM	O	O
and	CCONJ	O	O
III	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
higher-quality	NOUN	O	B-MENTAL
relationship	NOUN	O	I-MENTAL
with	ADP	O	I-MENTAL
a	DET	O	I-MENTAL
significant	ADJ	O	I-MENTAL
other	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
Phase	NOUN	O	O
II	NUM	O	O
than	PUNCT	O	O
did	PUNCT	O	O
Control	NOUN	O	O
Group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

No	DET	O	O
group	NOUN	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
cancer-related	VERB	O	B-PHYSICAL
worry	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
well-being	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
individual	ADJ	O	O
telephone	NOUN	O	O
support	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
alternative	ADJ	O	O
to	ADP	O	O
in-person	NOUN	O	O
support	ADV	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
telephone	NOUN	O	O
interventions	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
using	VERB	O	O
ethnically	NUM	O	O
and	CCONJ	O	O
economically	ADV	O	O
heterogeneous	ADJ	O	O
samples	NOUN	O	O
.	PUNCT	O	O

Efficiency	NOUN	O	O
of	ADP	O	O
slush	NOUN	O	O
nitrogen	NOUN	O	O
vitrification	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
oocytes	NOUN	O	O
vitrified	ADP	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
cumulus	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
survival	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
and	CCONJ	O	O
meiotic	ADJ	O	B-PHYSICAL
spindle	NOUN	O	I-PHYSICAL
competence	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficiency	NOUN	O	O
of	ADP	O	O
slush	NOUN	O	O
nitrogen	NOUN	O	O
vitrification	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
oocytes	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
cumulus	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
survival	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
and	CCONJ	O	O
maintenance	NOUN	O	O
of	ADP	O	O
meiotic	ADJ	O	B-PHYSICAL
spindle	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
comparative	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Medical	ADJ	O	O
center	NOUN	O	O
.	PUNCT	O	O

PATIENT	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
274	NUM	O	O
oocytes	NOUN	O	O
obtained	VERB	O	O
from	ADP	O	O
46	NUM	O	O
couples	ADJ	O	O
undergoing	CCONJ	O	O
infertility	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
Metaphase	NOUN	O	O
II	NUM	O	O
oocytes	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
groups	NOUN	O	O
A	DET	O	O
and	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
vitrified	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
cumulus	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOMES	NOUN	O	O
MEASURE	PUNCT	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
Survival	NOUN	O	B-MORTALITY
rates	NOUN	O	I-MORTALITY
and	CCONJ	O	O
maintenance	NOUN	O	O
of	ADP	O	O
meiotic	ADJ	O	B-OTHER
spindle	NOUN	O	I-OTHER
observed	DET	O	I-OTHER
immediately	ADV	O	I-OTHER
after	ADP	O	I-OTHER
warming	VERB	O	I-OTHER
and	CCONJ	O	I-OTHER
3	NUM	O	I-OTHER
hours	NOUN	O	I-OTHER
after	ADP	O	I-OTHER
incubation	NOUN	O	I-OTHER
.	PUNCT	O	O

RESULT	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
survival	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
,	PUNCT	O	O
but	CCONJ	O	O
a	DET	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
percentage	NOUN	O	O
of	ADP	O	O
detectable	ADJ	O	B-PHYSICAL
spindle	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
completely	ADV	O	O
denuded	VERB	O	O
oocytes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
either	PUNCT	O	O
immediately	ADV	O	O
after	ADP	O	O
warming	VERB	O	O
or	CCONJ	O	O
3	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
incubation	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
Complete	ADJ	O	O
denudation	NOUN	O	O
of	ADP	O	O
oocytes	NOUN	O	O
before	ADP	O	O
slush	NOUN	O	O
nitrogen	NOUN	O	O
vitrification	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
influence	ADV	O	O
survival	NOUN	O	B-MORTALITY
rates	NOUN	O	I-MORTALITY
but	CCONJ	O	O
positively	ADV	O	O
affects	NOUN	O	O
oocyte	NOUN	O	O
meiotic	ADJ	O	B-PHYSICAL
spindle	NOUN	O	I-PHYSICAL
competence	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
support	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
cumulus	NOUN	O	O
cells	NOUN	O	O
during	ADP	O	O
vitrification	NOUN	O	O
represent	VERB	O	O
an	DET	O	O
obstacle	ADJ	O	O
to	VERB	O	O
cryoprotectant	PUNCT	O	O
penetration	NOUN	O	O
more	ADV	O	O
than	PUNCT	O	O
having	DET	O	O
a	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
oocyte	NOUN	O	O
.	PUNCT	O	O

Beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
soy-based	ADV	O	O
dietary	ADJ	O	O
supplement	NOUN	O	O
on	ADP	O	O
lipid	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
cardiovascular	ADJ	O	B-PHYSICAL
risk	NOUN	O	O
markers	NOUN	O	B-PHYSICAL
in	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetic	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Consumption	NOUN	O	O
of	ADP	O	O
soy	NOUN	O	O
protein	NOUN	O	O
has	ADP	O	O
recently	ADV	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
improve	ADJ	O	O
the	DET	O	O
blood	NOUN	O	B-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
levels	NOUN	O	B-PHYSICAL
in	ADP	O	O
nondiabetic	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
if	PUNCT	O	O
a	DET	O	O
dietary	ADJ	O	O
supplement	NOUN	O	O
of	ADP	O	O
soy	NOUN	O	O
protein	NOUN	O	O
,	PUNCT	O	O
isoflavones	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cotyledon	NOUN	O	O
fiber	NOUN	O	O
(	PUNCT	O	O
Abalon	NOUN	O	O
)	PUNCT	O	O
affects	NOUN	O	O
cardiovascular	ADJ	O	B-PHYSICAL
risk	NOUN	O	O
markers	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
insulin	NOUN	O	B-PHYSICAL
levels	NOUN	O	B-PHYSICAL
in	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetic	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

RESEARCH	NOUN	O	O
DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Twenty	PUNCT	O	O
type	NOUN	O	O
2	NUM	O	O
diabetic	ADJ	O	O
subjects	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
a	DET	O	O
crossover	ADP	O	O
trial	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
double-blind	ADJ	O	O
supplementation	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
Abalon	NOUN	O	O
(	PUNCT	O	O
soy	NOUN	O	O
protein	NOUN	O	O
[	PUNCT	O	O
50	ADP	O	O
g/day	PUNCT	O	O
]	PUNCT	O	O
with	ADP	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
isoflavones	NOUN	O	O
[	PUNCT	O	O
minimum	NOUN	O	O
165	PUNCT	O	O
mg/day	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
cotyledon	NOUN	O	O
fiber	NOUN	O	O
[	PUNCT	O	O
20	ADP	O	O
g/day	PUNCT	O	O
]	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
casein	NOUN	O	O
[	PUNCT	O	O
50	ADP	O	O
g/day	PUNCT	O	O
]	PUNCT	O	O
and	CCONJ	O	O
cellulose	ADJ	O	O
[	PUNCT	O	O
20	ADP	O	O
g/day	PUNCT	O	O
]	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
separated	VERB	O	O
by	ADP	O	O
a	DET	O	O
3-week	NOUN	O	O
wash-out	PUNCT	O	O
period	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
results	NOUN	O	O
are	VERB	O	O
expressed	VERB	O	O
as	ADP	O	O
means	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
mean	NOUN	O	O
treatment	NOUN	O	O
difference	NOUN	O	O
between	ADP	O	O
Abalon	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
demonstrated	PUNCT	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
mean	NOUN	O	O
values	NOUN	O	O
after	ADP	O	O
Abalon	NOUN	O	O
for	ADP	O	O
LDL	NOUN	O	B-PHYSICAL
cholesterol	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
10	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
LDL/UHDL	PUNCT	O	B-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
12	NUM	O	O
+/-	SYM	O	O
18	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
apolipoprotein	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
apo	NOUN	O	O
)	PUNCT	O	O
B100	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
+/-	SYM	O	O
38	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
triglycerides	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
22	NUM	O	O
+/-	SYM	O	O
10	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
homocysteine	PUNCT	O	B-PHYSICAL
(	PUNCT	O	O
14	NUM	O	O
+/-	SYM	O	O
21	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
total	ADJ	O	O
cholesterol	NOUN	O	B-PHYSICAL
value	NOUN	O	I-PHYSICAL
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
less	ADV	O	O
significant	ADJ	O	O
but	CCONJ	O	O
still	PUNCT	O	O
lower	PUNCT	O	O
(	PUNCT	O	O
8	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.08	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
change	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
HDL	NOUN	O	B-PHYSICAL
cholesterol	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
apo	NOUN	O	B-PHYSICAL
B100/apo	VERB	O	B-PHYSICAL
A1	NOUN	O	B-PHYSICAL
ratio	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
plasminogen	NOUN	O	B-PHYSICAL
activator	NOUN	O	B-PHYSICAL
inhibitor	PUNCT	O	I-PHYSICAL

Theta	NOUN	O	O
burst	NOUN	O	O
stimulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rehabilitation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
limb	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
semirandomized	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
stroke	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Noninvasive	ADJ	O	O
cortical	ADJ	O	O
stimulation	NOUN	O	O
could	VERB	O	O
represent	VERB	O	O
an	DET	O	O
add-on	NOUN	O	O
treatment	NOUN	O	O
to	PART	O	O
enhance	ADJ	O	O
motor	NOUN	O	B-PHYSICAL
recovery	NOUN	O	I-PHYSICAL
after	ADP	O	O
stroke	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
its	VERB	O	O
clinical	ADJ	O	O
value	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
anticipated	VERB	O	O
size	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
remains	NOUN	O	O
largely	ADV	O	O
unknown	VERB	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
authors	NOUN	O	O
designed	VERB	O	O
a	DET	O	O
small	ADJ	O	O
semi-randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
explore	NOUN	O	O
whether	PUNCT	O	O
long-lasting	ADJ	O	O
clinically	ADV	O	O
important	ADJ	O	O
gains	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
by	ADP	O	O
adding	VERB	O	O
theta	NOUN	O	O
burst	NOUN	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
TBS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
form	NOUN	O	O
of	ADP	O	O
repetitive	ADJ	O	O
transcranial	ADJ	O	O
magnetic	ADJ	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
TMS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
rehabilitation	NOUN	O	O
program	NOUN	O	O
for	ADP	O	O
the	DET	O	O
hand	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
41	NUM	O	O
chronic	ADJ	O	O
stroke	NOUN	O	O
patients	NOUN	O	O
received	VERB	O	O
excitatory	ADJ	O	O
TBS	NOUN	O	O
to	ADP	O	O
the	DET	O	O
ipsilesional	ADJ	O	O
hemisphere	VERB	O	O
or	CCONJ	O	O
inhibitory	ADJ	O	O
TBS	NOUN	O	O
to	ADP	O	O
the	DET	O	O
contralesional	ADJ	O	O
hemisphere	VERB	O	O
in	ADP	O	O
2	NUM	O	O
centers	NOUN	O	O
;	PUNCT	O	O
each	DET	O	O
active	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
group	NOUN	O	O
receiving	SYM	O	O
sham	ADJ	O	O
TBS	NOUN	O	O
.	PUNCT	O	O

TBS	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
working	VERB	O	O
days	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
and	CCONJ	O	O
therapists	NOUN	O	O
were	VERB	O	O
blinded	ADP	O	O
to	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
TBS	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
(	PUNCT	O	O
9-hole	NOUN	O	O
Peg	NOUN	O	O
Test	NOUN	O	O
[	PUNCT	O	O
9HPT	NUM	O	O
]	PUNCT	O	O
,	PUNCT	O	O
Jebsen	PUNCT	O	O
Taylor	NOUN	O	O
Test	NOUN	O	O
[	PUNCT	O	O
JTT	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
grip	NOUN	O	O
and	CCONJ	O	O
pinch-grip	NOUN	O	O
dynamometry	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
assessed	VERB	O	O
4	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
90	NUM	O	O
days	NOUN	O	O
post	PUNCT	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinically	ADV	O	O
important	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
10	NUM	O	O
%	DET	O	O
of	ADP	O	O
the	DET	O	O
maximum	NOUN	O	O
score	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
active	ADJ	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
sham	ADJ	O	O
groups	NOUN	O	O
in	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
achieved	VERB	O	O
small	ADJ	O	O
sustainable	ADJ	O	O
improvements	NOUN	O	B-PHYSICAL
--	PUNCT	O	I-PHYSICAL
9HPT	NUM	O	I-PHYSICAL
,	PUNCT	O	O
5	NUM	O	B-PHYSICAL
%	SYM	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
maximum	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	NOUN	O	O
]	PUNCT	O	O
=	ADP	O	O
3	NUM	O	O
%	SYM	O	O
-7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
JTT	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
5.7	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
CI	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
%	SYM	O	O
-8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
grip	NOUN	O	B-PHYSICAL
strength	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
CI	NOUN	O	O
=	SYM	O	O
2	NUM	O	O
%	SYM	O	O
-10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
--	PUNCT	O	O
all	PUNCT	O	O
below	ADP	O	O
the	DET	O	O
defined	ADP	O	O
clinically	ADV	O	O
important	ADJ	O	O
level	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Cortical	ADJ	O	O
stimulation	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
augment	VERB	O	O
the	DET	O	O
gains	NOUN	O	O
from	ADP	O	O
a	DET	O	O
late	ADJ	O	O
rehabilitation	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
size	NOUN	O	O
anticipated	PROPN	O	O
by	ADP	O	O
the	DET	O	O
authors	NOUN	O	O
was	VERB	O	O
overestimated	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
can	VERB	O	O
improve	VERB	O	O
the	DET	O	O
design	NOUN	O	O
of	ADP	O	O
future	ADJ	O	O
work	NOUN	O	O
on	ADP	O	O
therapeutic	ADJ	O	O
uses	NOUN	O	O
of	ADP	O	O
TMS	NOUN	O	O
.	PUNCT	O	O

Promoting	VERB	O	O
social	ADJ	O	O
skill	ADJ	O	O
development	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorders	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
feasibility	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
design	NOUN	O	O
was	VERB	O	O
employed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
a	DET	O	O
social	ADJ	O	O
skills	NOUN	O	O
intervention	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Aims	NOUN	O	O
included	DET	O	O
evaluating	SYM	O	O
the	DET	O	O
acceptability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
program	NOUN	O	O
and	CCONJ	O	O
gathering	PUNCT	O	O
preliminary	ADJ	O	O
evidence	NOUN	O	O
on	ADP	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

Forty-four	ADP	O	O
children	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
8-11	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
or	CCONJ	O	O
wait	NOUN	O	O
list	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
a	DET	O	O
16-week	NOUN	O	O
group	NOUN	O	O
intervention	NOUN	O	O
designed	VERB	O	O
to	VERB	O	O
teach	PUNCT	O	O
appropriate	PUNCT	O	O
social	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
group	NOUN	O	O
comparisons	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
children	NOUN	O	O
in	ADP	O	O
treatment	NOUN	O	O
were	VERB	O	O
rated	VERB	O	O
as	PUNCT	O	O
improved	NOUN	O	O
on	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
unblinded	VERB	O	B-MENTAL
parent	NOUN	O	I-MENTAL
report	NOUN	O	I-MENTAL
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
on	ADP	O	O
the	DET	O	O
secondary	ADJ	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
parent	NOUN	O	B-MENTAL
questionnaire	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
reported	VERB	O	O
a	DET	O	O
high	ADJ	O	O
level	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
satisfaction	NOUN	O	I-OTHER
with	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
supports	NOUN	O	O
the	DET	O	O
feasibility	NOUN	O	O
of	ADP	O	O
this	DET	O	O
intervention	NOUN	O	O
to	ADP	O	O
families	NOUN	O	O
and	CCONJ	O	O
highlights	PUNCT	O	O
challenges	NOUN	O	O
for	ADP	O	O
future	ADJ	O	O
research	NOUN	O	O
in	ADP	O	O
social	ADJ	O	O
skills	NOUN	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Pilot	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
a	DET	O	O
moderate	ADJ	O	O
dose	NOUN	O	O
multivitamin/mineral	ADJ	O	O
supplement	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Determine	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
moderate	ADJ	O	O
dose	NOUN	O	O
multivitamin/mineral	ADJ	O	O
supplement	NOUN	O	O
on	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
3-month	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
Twenty	PUNCT	O	O
(	PUNCT	O	O
20	NUM	O	O
)	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
3-8	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
A	DET	O	O
Global	ADJ	O	O
Impressions	NOUN	O	O
parental	ADJ	O	O
questionnaire	NOUN	O	O
found	ADP	O	O
that	ADP	O	O
the	DET	O	O
supplement	ADJ	O	O
group	NOUN	O	O
reported	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvements	NOUN	O	B-OTHER
in	ADP	O	O
sleep	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
gastrointestinal	ADJ	O	I-PHYSICAL
problems	NOUN	O	I-PHYSICAL
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-PHYSICAL
B	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
6	NUM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
prior	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
study	NOUN	O	O
found	VERB	O	O
that	ADP	O	O
the	DET	O	O
autistic	ADJ	O	O
children	NOUN	O	O
had	PUNCT	O	O
substantially	ADV	O	O
elevated	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
B6	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
typical	ADJ	O	O
children	NOUN	O	O
(	PUNCT	O	O
75	NUM	O	O
%	SYM	O	O
higher	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0000001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Vitamin	NOUN	O	B-PHYSICAL
C	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
had	VERB	O	O
levels	NOUN	O	O
that	ADP	O	O
were	VERB	O	O
significantly	ADV	O	O
below	ADP	O	O
average	CCONJ	O	O
for	ADP	O	O
typical	ADJ	O	O
children	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
supplement	ADJ	O	O
group	NOUN	O	O
had	PUNCT	O	O
near-average	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
The	DET	O	O
finding	VERB	O	O
of	ADP	O	O
high	ADJ	O	B-PHYSICAL
vitamin	NOUN	O	I-PHYSICAL
B	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
6	NUM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
is	ADV	O	O
consistent	ADJ	O	O
with	ADP	O	O
recent	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
pyridoxal-5-phosphate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
low	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
pyridoxal	ADJ	O	B-PHYSICAL
kinase	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
pyridoxal	CCONJ	O	O
is	VERB	O	O
only	ADV	O	O
poorly	ADV	O	O
converted	VERB	O	O
to	ADP	O	O
pyridoxal-5-phosphate	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
enzymatically	ADJ	O	O
active	ADJ	O	O
form	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	PUNCT	O	O
may	VERB	O	O
explain	VERB	O	O
the	DET	O	O
functional	ADJ	O	O
need	NOUN	O	O
for	ADP	O	O
high-dose	NOUN	O	O
vitamin	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
supplementation	NOUN	O	O
in	ADP	O	O
many	DET	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Maternal	ADJ	O	B-PHYSICAL
erythropoietin	NOUN	O	I-PHYSICAL
in	ADP	O	O
singleton	NOUN	O	O
pregnancies	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
on	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
hematinic	ADJ	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Our	PUNCT	O	O
purpose	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
study	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
hematinic	ADJ	O	O
supplementation	NOUN	O	O
on	ADP	O	O
the	DET	O	O
maternal	ADJ	O	B-PHYSICAL
erythropoietin	NOUN	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
during	ADP	O	O
singleton	NOUN	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
97	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
first-trimester	NOUN	O	O
hemoglobin	NOUN	O	O
level	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
14.0	NUM	O	O
gm/dl	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
iron	NOUN	O	O
and	CCONJ	O	O
folic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
hematinic	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
53	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
44	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Serial	ADJ	O	B-PHYSICAL
hemoglobin	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
hematocrit	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
serum	NOUN	O	B-PHYSICAL
erythropoietin	NOUN	O	I-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
from	ADP	O	O
maternal	ADJ	O	O
blood	NOUN	O	O
and	CCONJ	O	O
from	ADP	O	O
cord	NOUN	O	O
blood	NOUN	O	O
on	ADP	O	O
delivery	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
ferritin	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
trimester	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
36	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
gestation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
cord	NOUN	O	O
blood	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
hemoglobin	NOUN	O	B-PHYSICAL
was	VERB	O	O
lower	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
40	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
gestation	NOUN	O	O
than	PUNCT	O	O
when	PUNCT	O	O
first	PUNCT	O	O
examined	ADP	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
serum	NOUN	O	O
erythropoietin	NOUN	O	O
was	VERB	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
serum	NOUN	O	B-PHYSICAL
ferritin	NOUN	O	I-PHYSICAL
was	VERB	O	O
lower	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
at	ADP	O	O
36	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
gestation	NOUN	O	O
than	PUNCT	O	O
at	ADP	O	O
presentation	NOUN	O	O
but	CCONJ	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hematinic	ADJ	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
hemoglobin	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
hematocrit	NOUN	O	B-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
until	ADP	O	O
the	DET	O	O
third	ADJ	O	O
trimester	NOUN	O	O
but	CCONJ	O	O
thereafter	ADV	O	O
were	VERB	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hematinic	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
maternal	ADJ	O	B-PHYSICAL
serum	NOUN	O	I-PHYSICAL
erythropoietin	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hematinic	ADJ	O	O
group	NOUN	O	O
after	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
cord	NOUN	O	B-PHYSICAL
blood	NOUN	O	O
hematologic	ADJ	O	O
values	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Maternal	ADJ	O	B-PHYSICAL
serum	NOUN	O	I-PHYSICAL
erythropoietin	NOUN	O	I-PHYSICAL
increased	VERB	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
response	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
the	DET	O	O
third	ADJ	O	O
trimester	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hematinic-supplemented	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

Activation	NOUN	O	O
and	CCONJ	O	O
intermuscular	ADJ	O	O
coherence	NOUN	O	O
of	ADP	O	O
distal	ADJ	O	O
arm	NOUN	O	O
muscles	NOUN	O	O
during	ADP	O	O
proximal	ADJ	O	O
muscle	NOUN	O	O
contraction	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
human	NOUN	O	O
upper	ADJ	O	O
extremity	NOUN	O	O
(	PUNCT	O	O
UE	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
unintended	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
proximal	ADJ	O	O
muscle	NOUN	O	O
activation	NOUN	O	O
on	ADP	O	O
muscles	NOUN	O	O
controlling	VERB	O	O
the	DET	O	O
hand	NOUN	O	O
could	VERB	O	O
be	ADJ	O	O
an	DET	O	O
important	ADJ	O	O
aspect	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
control	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
necessary	ADJ	O	O
coordination	NOUN	O	O
of	ADP	O	O
distal	ADJ	O	O
and	CCONJ	O	O
proximal	ADJ	O	O
segments	NOUN	O	O
during	ADP	O	O
functional	ADJ	O	O
activities	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
elucidate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
concurrent	ADJ	O	O
activation	NOUN	O	O
of	ADP	O	O
elbow	NOUN	O	O
muscles	NOUN	O	O
on	ADP	O	O
the	DET	O	O
coordination	NOUN	O	O
between	ADP	O	O
hand	NOUN	O	O
muscles	NOUN	O	O
performing	PUNCT	O	O
a	DET	O	O
grip	NOUN	O	O
task	NOUN	O	O
.	PUNCT	O	O

Eleven	ADJ	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
performed	PUNCT	O	O
precision	NOUN	O	O
grip	NOUN	O	O
tasks	NOUN	O	O
while	ADP	O	O
a	DET	O	O
constant	ADJ	O	O
extension	NOUN	O	O
or	CCONJ	O	O
flexion	NOUN	O	O
moment	ADJ	O	O
was	VERB	O	O
applied	VERB	O	O
to	ADP	O	O
their	PUNCT	O	O
elbow	NOUN	O	O
joints	NOUN	O	O
,	PUNCT	O	O
inducing	PUNCT	O	O
a	DET	O	O
sustained	VERB	O	O
submaximal	ADJ	O	O
contraction	NOUN	O	O
of	ADP	O	O
elbow	NOUN	O	O
muscles	NOUN	O	O
to	ADP	O	O
counter	ADJ	O	O
the	DET	O	O
applied	ADP	O	O
torque	NOUN	O	O
.	PUNCT	O	O

Activation	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
hand	NOUN	O	O
muscles	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
during	ADP	O	O
each	DET	O	O
task	NOUN	O	O
condition	NOUN	O	O
using	VERB	O	O
surface	NOUN	O	O
electromyography	NOUN	O	O
(	PUNCT	O	O
EMG	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

When	PUNCT	O	O
concurrent	ADJ	O	O
activation	NOUN	O	O
of	ADP	O	O
elbow	NOUN	O	O
muscles	NOUN	O	O
was	VERB	O	O
induced	VERB	O	O
,	PUNCT	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
activation	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hand	NOUN	O	O
muscles	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
greater	PUNCT	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
extrinsic	ADJ	O	O
finger	NOUN	O	O
extensor	NOUN	O	O
(	PUNCT	O	O
23.2	NUM	O	O
%	ADV	O	O
increase	NOUN	O	O
under	ADP	O	O
30	NUM	O	O
%	SYM	O	O
elbow	NOUN	O	O
extensor	NOUN	O	O
activation	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
extrinsic	ADJ	O	O
finger	NOUN	O	O
flexor	NOUN	O	O
(	PUNCT	O	O
14.2	NUM	O	O
%	ADV	O	O
increase	NOUN	O	O
under	ADP	O	O
30	NUM	O	O
%	SYM	O	O
elbow	NOUN	O	O
flexor	NOUN	O	O
activation	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.130	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Elbow	NOUN	O	B-PHYSICAL
muscle	NOUN	O	I-PHYSICAL
activation	NOUN	O	I-PHYSICAL
also	ADV	O	O
induced	ADJ	O	O
involuntary	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intrinsic	ADJ	O	B-PHYSICAL
thumb	NOUN	O	I-PHYSICAL
flexor	NOUN	O	I-PHYSICAL
activation	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
44.6	NUM	O	O
%	ADV	O	O
increase	NOUN	O	O
under	ADP	O	O
30	NUM	O	O
%	SYM	O	O
elbow	NOUN	O	O
extensor	NOUN	O	O
activation	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

EMG-EMG	PUNCT	O	O
coherence	NOUN	O	O
analyses	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
elbow	NOUN	O	B-PHYSICAL
muscle	NOUN	O	I-PHYSICAL
activation	NOUN	O	I-PHYSICAL
significantly	ADV	O	O
reduced	VERB	O	O
intermuscular	ADJ	O	B-PHYSICAL
coherence	NOUN	O	O
between	ADP	O	B-PHYSICAL
distal	ADJ	O	I-PHYSICAL
muscle	PUNCT	O	I-PHYSICAL

Stepping	VERB	O	O
Stones	VERB	O	O
Triple	ADJ	O	O
P	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
RCT	NOUN	O	O
of	ADP	O	O
a	DET	O	O
parenting	ADP	O	O
program	NOUN	O	O
with	ADP	O	O
parents	NOUN	O	O
of	ADP	O	O
a	DET	O	O
child	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
an	DET	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Whilst	PUNCT	O	O
the	DET	O	O
Triple	ADJ	O	O
P	NOUN	O	O
Positive	ADJ	O	O
Parenting	PUNCT	O	O
Program	NOUN	O	O
has	ADP	O	O
a	DET	O	O
large	ADJ	O	O
evidence	NOUN	O	O
base	NOUN	O	O
(	PUNCT	O	O
Sanders	PUNCT	O	O
,	PUNCT	O	O
Clinical	ADJ	O	O
Child	NOUN	O	O
and	CCONJ	O	O
Family	NOUN	O	O
Psychology	NOUN	O	O
Review	NOUN	O	O
2:71-90	NOUN	O	O
,	PUNCT	O	O
1999	NUM	O	O
;	PUNCT	O	O
Sanders	PROPN	O	O
,	PUNCT	O	O
Journal	CCONJ	O	O
of	ADP	O	O
Consulting	ADP	O	O
and	CCONJ	O	O
Clinical	ADJ	O	O
Psychology	NOUN	O	O
68:624-640	PUNCT	O	O
,	PUNCT	O	O
2000	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
preliminary	ADJ	O	O
evidence	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
Stepping	PUNCT	O	O
Stones	NOUN	O	O
Triple	ADJ	O	O
P	NOUN	O	O
is	VERB	O	O
also	ADV	O	O
efficacious	ADJ	O	O
(	PUNCT	O	O
Roberts	NOUN	O	O
,	PUNCT	O	O
Journal	CCONJ	O	O
of	ADP	O	O
Clinical	ADJ	O	O
Child	NOUN	O	O
and	CCONJ	O	O
Adolescent	NOUN	O	O
Psychology	NOUN	O	O
,	PUNCT	O	O
35	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
:180-193	NOUN	O	O
,	PUNCT	O	O
2006	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	ADP	O	O
date	NOUN	O	O
Stepping	PUNCT	O	O
Stones	NOUN	O	O
has	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
evaluated	VERB	O	O
with	ADP	O	O
the	DET	O	O
ASD	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

Fifty-nine	DET	O	O
families	NOUN	O	O
with	ADP	O	O
a	DET	O	O
child	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
aged	PUNCT	O	O
between	ADP	O	O
2	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
participated	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
demonstrate	VERB	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
parental	ADJ	O	B-MENTAL
reports	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
child	NOUN	O	I-MENTAL
behaviour	NOUN	O	I-MENTAL
and	CCONJ	O	O
parenting	PUNCT	O	B-MENTAL
styles	NOUN	O	I-MENTAL
with	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
treatment	NOUN	O	O
effects	NOUN	O	B-MENTAL
for	ADP	O	I-MENTAL
child	NOUN	O	I-MENTAL
behaviour	NOUN	O	B-MENTAL
,	PUNCT	O	O
parental	ADJ	O	B-MENTAL
over	ADP	O	B-MENTAL
reactivity	NOUN	O	I-MENTAL
and	CCONJ	O	O
parental	ADJ	O	B-MENTAL
verbosity	NOUN	O	I-MENTAL
being	VERB	O	O
maintained	VERB	O	O
at	ADP	O	O
follow-up	NOUN	O	O
6	NUM	O	O
months	NOUN	O	O
later	ADJ	O	O
.	PUNCT	O	O

Further	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
parental	ADJ	O	B-MENTAL
satisfaction	NOUN	O	I-MENTAL
and	CCONJ	O	O
conflict	PUNCT	O	B-MENTAL
about	PUNCT	O	I-MENTAL

Growth	NOUN	O	O
hormone	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
cortical	ADJ	O	B-PHYSICAL
bone	NOUN	O	I-PHYSICAL
dimensions	NOUN	O	I-PHYSICAL
in	ADP	O	O
young	ADJ	O	O
adults	NOUN	O	O
with	ADP	O	O
childhood-onset	NOUN	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
deficiency	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
Growth	NOUN	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
GH	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
adults	NOUN	O	O
with	ADP	O	O
childhood-onset	NOUN	O	O
GH	NOUN	O	O
deficiency	NOUN	O	O
has	ADP	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
bone	NOUN	O	B-PHYSICAL
mass	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
shows	NOUN	O	O
that	ADP	O	O
cortical	ADJ	O	O
bone	NOUN	O	O
dimensions	NOUN	O	O
also	ADV	O	O
benefit	PUNCT	O	O
from	ADP	O	O
GH	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
endosteal	ADJ	O	O
expansion	NOUN	O	O
and	CCONJ	O	O
increased	PART	O	O
cortical	ADJ	O	O
thickness	NOUN	O	O
leading	ADJ	O	O
to	ADP	O	O
improved	VERB	O	B-PHYSICAL
bone	NOUN	O	I-PHYSICAL
strength	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
In	ADP	O	O
young	ADJ	O	O
adults	NOUN	O	O
with	ADP	O	O
childhood-onset	NOUN	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
deficiency	NOUN	O	O
(	PUNCT	O	O
CO	NOUN	O	O
GHD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
GH	NOUN	O	O
treatment	NOUN	O	O
after	ADP	O	O
final	ADJ	O	O
height	NOUN	O	O
is	VERB	O	O
reached	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
spine	NOUN	O	O
and	CCONJ	O	O
hip	NOUN	O	O
bone	NOUN	O	O
mineral	NOUN	O	O
density	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
GH	NOUN	O	B-PHYSICAL
on	ADP	O	O
cortical	ADJ	O	B-PHYSICAL
bone	NOUN	O	I-PHYSICAL
dimensions	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
160	NUM	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
21.2	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
males	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
CO	NOUN	O	O
GHD	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
2:1	NOUN	O	O
to	ADP	O	O
GH	NOUN	O	O
or	CCONJ	O	O
no	DET	O	O
treatment	NOUN	O	O
for	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Cortical	ADJ	O	O
bone	NOUN	O	O
dimensions	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
digital	ADJ	O	O
x-ray	NOUN	O	O
radiogrammetry	NOUN	O	O
of	ADP	O	O
the	DET	O	O
metacarpal	ADJ	O	O
bones	PUNCT	O	O
every	DET	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
cortical	ADJ	O	O
thickness	NOUN	O	O
was	VERB	O	O
increased	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
(	PUNCT	O	O
6.43	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CI	NOUN	O	O
3.34	NUM	O	O
to	ADP	O	O
9.61	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
metacarpal	ADJ	O	O
index	NOUN	O	O
(	PUNCT	O	O
MCI	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
6.14	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CI	NOUN	O	O
3.95	NUM	O	O
to	ADP	O	O
8.38	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
endosteal	ADJ	O	O
diameter	NOUN	O	O
decreased	NOUN	O	O
(	PUNCT	O	O
-4.64	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CI	NOUN	O	O
-7.15	NUM	O	O
to	ADP	O	O
-2.05	PUNCT	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Total	ADJ	O	O
bone	NOUN	O	O
width	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
0.68	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CI	NOUN	O	O
-1.17	NUM	O	O
to	ADP	O	O
2.57	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
not	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
NS	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
gender	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
on	ADP	O	O
bone	NOUN	O	O
width	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
endosteal	ADJ	O	O
diameter	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
cortical	ADJ	O	O
thickness	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
MCI	NOUN	O	O
(	PUNCT	O	O
NS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Cortical	ADJ	O	O
bone	NOUN	O	O
reacts	NOUN	O	O
promptly	ADV	O	O
to	ADP	O	O
reinstitution	NOUN	O	O
of	ADP	O	O
GH	NOUN	O	O
beyond	ADP	O	O
the	DET	O	O
attainment	NOUN	O	O
of	ADP	O	O
final	ADJ	O	O
height	NOUN	O	O
by	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
cortical	ADJ	O	O
thickness	NOUN	O	O
through	ADP	O	O
endosteal	ADJ	O	O
bone	NOUN	O	O
growth	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
leads	NOUN	O	O
to	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
peak	ADJ	O	O
bone	NOUN	O	O
mass	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
cortical	ADJ	O	O
bone	NOUN	O	O
fragility	NOUN	O	O
later	ADJ	O	O
in	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
Lactobacillus	NOUN	O	O
GG	NOUN	O	O
on	ADP	O	O
enteric	ADJ	O	B-PHYSICAL
microflora	NOUN	O	I-PHYSICAL
in	ADP	O	O
low-birth-weight	ADJ	O	O
neonates	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Colonization	NOUN	O	O
patterns	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
by	ADP	O	O
anaerobic	ADJ	O	O
flora	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
neonatal	ADJ	O	O
gut	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Probiotics	NOUN	O	O
could	ADV	O	O
affect	VERB	O	O
disease	NOUN	O	B-PHYSICAL
risk	NOUN	O	I-PHYSICAL
either	CCONJ	O	O
directly	ADV	O	O
through	ADP	O	O
colonization	NOUN	O	O
or	CCONJ	O	O
indirectly	ADV	O	O
by	ADP	O	O
promoting	PROPN	O	O
changes	NOUN	O	O
in	ADP	O	O
gut	NOUN	O	O
microbial	ADJ	O	O
ecology	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
To	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
Lactobacillus	NOUN	O	O
GG	NOUN	O	O
(	PUNCT	O	O
LGG	NOUN	O	O
)	PUNCT	O	O
to	VERB	O	O
colonize	PUNCT	O	O
the	DET	O	O
neonatal	ADJ	O	B-PHYSICAL
gut	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
modify	VERB	O	I-PHYSICAL
its	VERB	O	I-PHYSICAL
microbial	ADJ	O	I-PHYSICAL
ecology	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
71	NUM	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
of	ADP	O	O
less	ADV	O	O
than	ADP	O	O
2000	NUM	O	O
g	NOUN	O	O
birth	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

Infants	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
1500	NUM	O	O
g	NOUN	O	O
(	PUNCT	O	O
24	NUM	O	O
treated	PUNCT	O	O
,	PUNCT	O	O
15	NUM	O	O
control	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
LGG	NOUN	O	O
orally	ADV	O	O
twice	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Those	PUNCT	O	O
infants	NOUN	O	O
weighing	CCONJ	O	O
1500	NUM	O	O
to	ADP	O	O
1999	NUM	O	O
g	NOUN	O	O
(	PUNCT	O	O
23	NUM	O	O
treated	PUNCT	O	O
,	PUNCT	O	O
9	NUM	O	O
control	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Stools	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
before	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
to	ADP	O	O
8	PUNCT	O	O
(	PUNCT	O	O
and	CCONJ	O	O
day	NOUN	O	O
14	NUM	O	O
and	CCONJ	O	O
21	NUM	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
infants	NOUN	O	O
weighing	CCONJ	O	O
less	NOUN	O	O
than	PUNCT	O	O
1500	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
quantitative	ADJ	O	B-PHYSICAL
aerobic	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
anaerobic	ADJ	O	I-PHYSICAL
cultures	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	ADJ	O	O
Colonization	NOUN	O	O
with	ADP	O	O
LGG	NOUN	O	B-PHYSICAL
occurred	VERB	O	I-PHYSICAL
in	ADP	O	O
5	NUM	O	O
of	ADP	O	O
24	NUM	O	O
(	PUNCT	O	O
21	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
infants	NOUN	O	O
who	PROPN	O	O
weighed	PROPN	O	O
less	ADV	O	O
than	ADP	O	O
1500	NUM	O	O
g	NOUN	O	O
versus	CCONJ	O	O
11	NUM	O	O
of	ADP	O	O
23	NUM	O	O
(	PUNCT	O	O
47	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
larger	PUNCT	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Colonization	NOUN	O	B-PHYSICAL
was	VERB	O	O
limited	VERB	O	O
to	ADP	O	O
infants	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
not	ADV	O	O
on	ADP	O	O
antibiotics	NOUN	O	O
within	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
LGG	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
paucity	NOUN	O	O
of	ADP	O	O
bacterial	ADJ	O	O
species	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
although	CCONJ	O	O
larger	PUNCT	O	O
infants	NOUN	O	O
had	PUNCT	O	O
more	DET	O	O
bacterial	ADJ	O	B-PHYSICAL
species	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
1.59	NUM	O	O
+/-	SYM	O	O
0.13	NUM	O	O
(	PUNCT	O	O
SEM	NOUN	O	O
)	PUNCT	O	O
vs	CCONJ	O	O
1.11	NUM	O	O
+/-	SYM	O	O
0.12	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
higher	PUNCT	O	O
mean	NOUN	O	O
log	NOUN	O	B-PHYSICAL
colony	NOUN	O	I-PHYSICAL
forming	VERB	O	I-PHYSICAL
units	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
CFU	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
(	PUNCT	O	O
8.79	NUM	O	O
+/-	SYM	O	O
0.43	NUM	O	O
vs	CCONJ	O	O
7.22	NUM	O	O
+/-	SYM	O	O
0.63	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
infants	NOUN	O	O
weighing	CCONJ	O	O
less	NOUN	O	O
than	PUNCT	O	O
1500	NUM	O	O
g	ADP	O	O
LGG	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
in	ADP	O	O
infants	NOUN	O	O
weighing	CCONJ	O	O
less	NOUN	O	O
than	PUNCT	O	O
1500	NUM	O	O
g	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
species	NOUN	O	B-PHYSICAL
number	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
day	NOUN	O	I-PHYSICAL
7	NUM	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
with	ADP	O	I-PHYSICAL
further	ADJ	O	I-PHYSICAL
increases	CCONJ	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
day	NOUN	O	I-PHYSICAL
21	NUM	O	I-PHYSICAL
.	PUNCT	O	O

This	DET	O	O
increase	NOUN	O	O
was	VERB	O	O
mainly	ADV	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
increased	CCONJ	O	O
Gram	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
anaerobic	ADJ	O	O
species	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
species	NOUN	O	B-PHYSICAL
number	NOUN	O	I-PHYSICAL
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
log	NOUN	O	B-PHYSICAL
CFU	ADJ	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
Gram	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
-	SYM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
bacteria	NOUN	O	I-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
change	NUM	O	O
in	ADP	O	O
treated	VERB	O	O
infants	NOUN	O	O
weighing	CCONJ	O	O
less	NOUN	O	O
than	PUNCT	O	O
1500	NUM	O	O
g.	PUNCT	O	O
However	PROPN	O	O
,	PUNCT	O	O
Gram	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
+	SYM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
mean	NOUN	O	O
log	NOUN	O	B-PHYSICAL
CFU	NOUN	O	B-PHYSICAL
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
21	NUM	O	O
(	PUNCT	O	O
6.1	NUM	O	O
+/-	SYM	O	O
0.9	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
day	NOUN	O	O
0	NUM	O	O
(	PUNCT	O	O
3.5	NUM	O	O
+/-	SYM	O	O
0.9	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
species	NOUN	O	B-PHYSICAL
number	ADJ	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
quantitative	ADJ	O	I-PHYSICAL
counts	NOUN	O	B-PHYSICAL
were	VERB	O	O
noted	NUM	O	O
after	ADP	O	O
LGG	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
infants	NOUN	O	O
weighing	CCONJ	O	O
1500	NUM	O	O
to	ADP	O	O
1999	NUM	O	O
g	ADP	O	O
LGG	NOUN	O	B-OTHER
was	VERB	O	I-OTHER
well	VERB	O	I-OTHER
tolerated	ADP	O	I-OTHER
in	ADP	O	O
all	DET	O	O
infants	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	PUNCT	O	O

Short-term	NOUN	O	O
metabolic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
prednisone	NOUN	O	O
administration	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

AIMS	NOUN	O	O
Supraphysiologic	ADJ	O	O
glucocorticoid	NOUN	O	O
activity	NOUN	O	O
is	VERB	O	O
well	ADV	O	O
established	ADP	O	O
to	ADP	O	O
cause	PUNCT	O	O
impaired	VERB	O	O
glucose	NOUN	O	B-PHYSICAL
tolerance	NOUN	O	O
and	CCONJ	O	O
insulin	NOUN	O	B-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
yet	ADV	O	O
no	DET	O	O
study	NOUN	O	O
has	PUNCT	O	O
evaluated	VERB	O	O
dose-dependent	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
low-dose	NOUN	O	O
prednisone	NOUN	O	O
during	ADP	O	O
short-term	NOUN	O	O
oral	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
quantify	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
daily	PUNCT	O	O
10	NUM	O	O
or	CCONJ	O	O
25	NUM	O	O
mg	NOUN	O	O
prednisone	NOUN	O	O
administration	NOUN	O	O
for	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
on	ADP	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
by	ADP	O	O
employing	VERB	O	O
a	DET	O	O
two-step	NOUN	O	O
hyperinsulinemic	ADJ	O	O
euglycemic	ADJ	O	O
glucose	NOUN	O	O
clamp	NOUN	O	O
(	PUNCT	O	O
Step	NOUN	O	O
1	NUM	O	O
:	PUNCT	O	O
insulin	NOUN	O	O
infusion	NOUN	O	O
=	SYM	O	O
20	NUM	O	O
mU/m?/min	NOUN	O	O
;	PUNCT	O	O
Step	NOUN	O	O
2	NUM	O	O
:	PUNCT	O	O
insulin	NOUN	O	O
infusion	NOUN	O	O
=	SYM	O	O
80	NUM	O	O
mU/m?/min	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
healthy	ADJ	O	O
,	PUNCT	O	O
lean	ADJ	O	O
males	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	O
infused	VERB	O	O
at	ADP	O	O
steady-state	NOUN	O	O
to	ADJ	O	O
maintain	ADV	O	O
stable	ADJ	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
[	PUNCT	O	O
90	NUM	O	O
mg/dl	NOUN	O	O
(	PUNCT	O	O
4.95	NUM	O	O
mmol/l	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
calculate	NOUN	O	O
several	ADJ	O	O
indices	NOUN	O	O
of	ADP	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
During	ADP	O	O
Step	NOUN	O	O
1	NUM	O	O
of	ADP	O	O
the	DET	O	O
clamp	NOUN	O	O
,	PUNCT	O	O
whole	ADJ	O	O
body	NOUN	O	O
glucose	NOUN	O	O
disposal	ADJ	O	O
(	PUNCT	O	O
M	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
35	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
M/I	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
29	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.025	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
25	NUM	O	O
mg	NOUN	O	O
prednisone	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
appreciable	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg	NOUN	O	O
prednisone	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

During	ADP	O	O
Step	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
M	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
33	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
25	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NOUN	O	O
prednisone	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
M/I	NOUN	O	O
ratio	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
31	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
13	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.026	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
Si	NOUN	O	O
,	PUNCT	O	O
calculated	VERB	O	O
as	ADP	O	O
the	DET	O	O
quotient	NOUN	O	O
of	ADP	O	O
augmentation	NOUN	O	O
of	ADP	O	O
M/I	NOUN	O	O
between	ADP	O	O
Step	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
,	PUNCT	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
35.3	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
23.5	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
25	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NOUN	O	O
prednisone	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Administration	NOUN	O	O
of	ADP	O	O
relatively	ADV	O	O
low	ADJ	O	O
pharmacological	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
prednisone	NOUN	O	O
for	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
impaired	VERB	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose-dependent	ADJ	O	O
manner	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
males	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
observed	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
are	VERB	O	O
likely	ADV	O	O
to	PART	O	O
be	PUNCT	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
individuals	NOUN	O	O
predisposed	VERB	O	O
to	ADJ	O	O
develop	NOUN	O	O
glucose	NOUN	O	O
intolerance	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
limit	NOUN	O	O
to	ADP	O	O
exercise	NOUN	O	O
tolerance	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
:	PUNCT	O	O
mind	NOUN	O	O
over	ADP	O	O
muscle	NOUN	O	O
?	PUNCT	O	O

In	ADP	O	O
exercise	NOUN	O	O
physiology	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
has	PUNCT	O	O
been	PUNCT	O	O
traditionally	ADV	O	O
assumed	VERB	O	O
that	ADP	O	O
high-intensity	NOUN	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
stops	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
point	NOUN	O	O
commonly	ADV	O	O
called	VERB	O	O
exhaustion	NOUN	O	O
because	PUNCT	O	O
fatigued	DET	O	O
subjects	NOUN	O	O
are	VERB	O	O
no	DET	O	O
longer	PUNCT	O	O
able	ADJ	O	O
to	PART	O	O
generate	NOUN	O	O
the	DET	O	O
power	NOUN	O	O
output	NOUN	O	O
required	VERB	O	O
by	ADP	O	O
the	DET	O	O
task	NOUN	O	O
despite	ADP	O	O
their	PUNCT	O	O
maximal	ADJ	O	O
voluntary	PUNCT	O	O
effort	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
the	DET	O	O
validity	NOUN	O	O
of	ADP	O	O
this	DET	O	O
assumption	NOUN	O	O
by	ADP	O	O
measuring	VERB	O	O
maximal	ADJ	O	B-PHYSICAL
voluntary	PUNCT	O	I-PHYSICAL
cycling	ADJ	O	I-PHYSICAL
power	NOUN	O	I-PHYSICAL
before	ADP	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
,	PUNCT	O	O
1,075	NUM	O	O
+/-	SYM	O	O
214	NUM	O	O
W	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
immediately	ADV	O	O
after	PUNCT	O	O
(	PUNCT	O	O
731	NUM	O	O
+/-	SYM	O	O
206	NUM	O	O
W	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
exhaustive	ADJ	O	O
cycling	ADJ	O	O
exercise	NOUN	O	O
at	ADP	O	O
242	NUM	O	O
+/-	SYM	O	O
24	NUM	O	O
W	NOUN	O	O
(	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
of	ADP	O	O
peak	ADJ	O	O
aerobic	ADJ	O	O
power	NOUN	O	O
measured	VERB	O	O
during	ADP	O	O
a	DET	O	O
preliminary	ADJ	O	O
incremental	ADJ	O	O
exercise	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
ten	NUM	O	O
fit	PUNCT	O	O
male	NOUN	O	O
human	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Perceived	VERB	O	B-PHYSICAL
exertion	NOUN	O	I-PHYSICAL
during	ADP	O	O
exhaustive	ADJ	O	O
cycling	ADJ	O	O
exercise	NOUN	O	O
was	ADJ	O	O
strongly	ADV	O	O
correlated	VERB	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
-0.82	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
exhaustion	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
10.5	NUM	O	O
+/-	SYM	O	O
2.1	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	DET	O	O
challenge	ADP	O	O
the	DET	O	O
long-standing	VERB	O	O
assumption	NOUN	O	O
that	ADP	O	O
muscle	NOUN	O	O
fatigue	NOUN	O	O
causes	NOUN	O	O
exhaustion	NOUN	O	O
during	ADP	O	O
high-intensity	NOUN	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
exercise	NOUN	O	O
tolerance	NOUN	O	O
in	ADP	O	O
highly	ADV	O	O
motivated	DET	O	O
subjects	NOUN	O	O
is	VERB	O	O
ultimately	ADV	O	O
limited	VERB	O	O
by	ADP	O	O
perception	NOUN	O	O
of	ADP	O	O
effort	NOUN	O	O
.	PUNCT	O	O

Ropivacaine-clonidine	ADJ	O	O
combination	NOUN	O	O
for	ADP	O	O
caudal	ADJ	O	O
blockade	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Adding	PUNCT	O	O
clonidine	NOUN	O	O
to	ADP	O	O
weak	ADJ	O	O
ropivacaine	NOUN	O	O
solutions	NOUN	O	O
(	PUNCT	O	O
<	PROPN	O	O
0.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
could	VERB	O	O
potentially	ADV	O	O
enhance	ADJ	O	B-OTHER
analgesia	NOUN	O	I-OTHER
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
further	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	B-PHYSICAL
unwanted	VERB	O	I-PHYSICAL
motor	NOUN	O	I-PHYSICAL
blockade	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
postoperative	ADJ	O	O
pain-relieving	PUNCT	O	B-PAIN
quality	NOUN	O	I-PAIN
of	ADP	O	O
a	DET	O	O
ropivacaine	NOUN	O	O
0.1	NUM	O	O
%	SYM	O	O
-clonidine	ADJ	O	O
mixture	NOUN	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
plain	ADJ	O	O
ropivacaine	NOUN	O	O
0.2	NUM	O	O
%	SYM	O	O
following	ADV	O	O
caudal	ADJ	O	O
administration	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
observer-blinded	VERB	O	O
fashion	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
ASA	NOUN	O	O
1	NUM	O	O
paediatric	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
subumbilical	ADJ	O	O
surgery	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
caudal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
plain	ADJ	O	O
ropivacaine	NOUN	O	O
0.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
1	NUM	O	O
ml/kg	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
R0.2	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
ropivacaine	NOUN	O	O
0.1	NUM	O	O
%	SYM	O	O
with	ADP	O	O
clonidine	NOUN	O	O
2	NUM	O	O
microg/kg	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
ml/kg	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
R0.1C	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Objective	ADJ	O	O
pain	NOUN	O	O
scale	NOUN	O	O
score	NOUN	O	O
and	CCONJ	O	O
need	ADP	O	O
for	ADP	O	O
supplemental	ADJ	O	O
analgesia	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
analgesia	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
h	NOUN	O	O
postoperatively	NOUN	O	O
.	PUNCT	O	O

Residual	ADJ	O	O
postoperative	ADJ	O	B-PHYSICAL
sedation	NOUN	O	I-PHYSICAL
was	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
R0.1C	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
18/20	PUNCT	O	O
)	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
managed	PROPN	O	O
without	ADP	O	O
supplemental	ADJ	O	B-PHYSICAL
analgesia	NOUN	O	I-PHYSICAL
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
h	NOUN	O	O
postoperatively	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
R0.2	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
11/20	PUNCT	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P=0.034	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
degree	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	B-PHYSICAL
duration	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
postoperative	ADJ	O	I-PHYSICAL
sedation	NOUN	O	I-PHYSICAL
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-PHYSICAL
motor	NOUN	O	I-PHYSICAL
blockade	NOUN	O	I-PHYSICAL
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
microg/kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
ropivacaine	NOUN	O	O
0.1	NUM	O	O
%	PUNCT	O	O
is	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
improved	VERB	O	O
quality	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
postoperative	ADJ	O	I-OTHER
analgesia	NOUN	O	I-OTHER
compared	VERB	O	O
to	ADP	O	O
plain	ADJ	O	O
0.2	NUM	O	O
%	SYM	O	O
ropivacaine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
improved	VERB	O	B-OTHER
analgesic	PUNCT	O	I-OTHER
quality	NOUN	O	I-OTHER
of	ADP	O	O
the	DET	O	O
clonidine-ropivacaine	NOUN	O	O
mixture	NOUN	O	O
is	VERB	O	O
achieved	VERB	O	O
without	ADP	O	O
causing	DET	O	O
any	DET	O	O
significant	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

Randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
entecavir	NOUN	O	O
prophylaxis	NOUN	O	O
for	ADP	O	O
rituximab-associated	VERB	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
virus	NOUN	O	O
reactivation	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
lymphoma	NOUN	O	O
and	CCONJ	O	O
resolved	PUNCT	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
antiviral	ADJ	O	O
prophylaxis	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
virus	NOUN	O	O
(	PUNCT	O	O
HBV	NOUN	O	O
)	PUNCT	O	O
reactivation	NOUN	O	O
before	PUNCT	O	O
rituximab-based	VERB	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
lymphoma	NOUN	O	O
and	CCONJ	O	O
resolved	PUNCT	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
is	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Eighty	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
CD20	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
lymphoma	NOUN	O	O
and	CCONJ	O	O
resolved	PUNCT	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
prophylactic	ADP	O	O
entecavir	NOUN	O	O
(	PUNCT	O	O
ETV	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
chemotherapy	NOUN	O	O
to	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
completing	ADJ	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
ETV	NOUN	O	O
prophylactic	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
41	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
to	PART	O	O
receive	NOUN	O	O
therapeutic	ADJ	O	O
ETV	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
HBV	NOUN	O	O
reactivation	NOUN	O	O
and	CCONJ	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
surface	NOUN	O	O
antigen	NOUN	O	O
(	PUNCT	O	O
HBsAg	NOUN	O	O
)	PUNCT	O	O
reverse	ADJ	O	O
seroconversion	NOUN	O	O
since	ADP	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
39	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Fifty-eight	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
72.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
positive	ADJ	O	O
for	ADP	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
surface	NOUN	O	O
antibody	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
HBV	NOUN	O	O
DNA	NOUN	O	O
was	VERB	O	O
undetectable	ADJ	O	O
in	ADP	O	O
50	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
62.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
18-month	NOUN	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
(	PUNCT	O	O
2.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ETV	NOUN	O	O
prophylactic	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
seven	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
17.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
developed	VERB	O	O
HBV	NOUN	O	O
reactivation	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.027	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	B-PHYSICAL
HBV	NOUN	O	I-PHYSICAL
reactivation	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
at	ADP	O	O
months	NOUN	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
18	NUM	O	O
after	ADP	O	O
chemotherapy	NOUN	O	O
were	VERB	O	O
8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
11.2	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
25.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4.3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
ETV	NOUN	O	O
prophylactic	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.019	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
HBsAg	NOUN	O	B-PHYSICAL
reverse	ADJ	O	I-PHYSICAL
seroconversion	NOUN	O	I-PHYSICAL
after	ADP	O	O
HBV	NOUN	O	O
reactivation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	B-PHYSICAL
HBsAg	NOUN	O	I-PHYSICAL
reverse	ADJ	O	I-PHYSICAL
seroconversion	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
at	ADP	O	O
months	NOUN	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
18	NUM	O	O
since	ADP	O	O
chemotherapy	NOUN	O	O
were	VERB	O	O
0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
6.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
16.3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	CCONJ	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ETV	NOUN	O	O
prophylactic	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.032	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
detectable	ADJ	O	O
or	CCONJ	O	O
undetectable	ADJ	O	O
viral	ADJ	O	O
load	NOUN	O	O
could	VERB	O	O
develop	VERB	O	O
HBV	NOUN	O	B-PHYSICAL
reactivation	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
HBsAg	NOUN	O	B-PHYSICAL
reverse	ADJ	O	I-PHYSICAL
seroconversion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Undetectable	ADJ	O	O
HBV	NOUN	O	O
viral	ADJ	O	O
load	NOUN	O	O
before	ADP	O	O
chemotherapy	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
confer	VERB	O	O
reactivation-free	ADJ	O	O
status	NOUN	O	O
.	PUNCT	O	O

Antiviral	ADJ	O	O
prophylaxis	NOUN	O	O
can	PRON	O	O
potentially	ADV	O	O
prevent	VERB	O	O
rituximab-associated	VERB	O	O
HBV	NOUN	O	O
reactivation	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
lymphoma	NOUN	O	O
and	CCONJ	O	O
resolved	PUNCT	O	O
hepatitis	NOUN	O	O
B	NOUN	O	O
.	PUNCT	O	O

Single	ADJ	O	O
nucleotide	NOUN	O	O
polymorphism	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hypoxia-inducible	ADJ	O	O
factor-1alpha	NOUN	O	O
gene	NOUN	O	O
in	ADP	O	O
colorectal	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

Colorectal	ADJ	O	O
carcinoma	NOUN	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	VERB	O	O
common	ADJ	O	O
malignancies	NOUN	O	O
in	ADP	O	O
the	DET	O	O
world	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
its	PUNCT	O	O
incidence	NOUN	O	O
has	PUNCT	O	O
increased	PUNCT	O	O
in	ADP	O	O
recent	ADJ	O	O
years	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	PUNCT	O	O
reported	VERB	O	O
that	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
hypoxia-inducible	ADJ	O	O
factor	NOUN	O	O
(	PUNCT	O	O
HIF	NOUN	O	O
)	PUNCT	O	O
-1alpha	NOUN	O	O
correlates	NOUN	O	O
with	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
VEGF	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
tumor	NOUN	O	O
stage	NOUN	O	O
,	PUNCT	O	O
lymphatic	ADJ	O	O
invasion	NOUN	O	O
,	PUNCT	O	O
venous	ADJ	O	O
invasion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
liver	NOUN	O	O
metastasis	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	ADV	O	O
also	ADV	O	O
been	PUNCT	O	O
reported	VERB	O	O
that	ADP	O	O
a	DET	O	O
single	ADJ	O	O
nucleotide	NOUN	O	O
polymorphism	NOUN	O	O
(	PUNCT	O	O
SNP	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
exon	NOUN	O	O
12	NUM	O	O
of	ADP	O	O
HIF-1alpha	NOUN	O	O
gene	NOUN	O	O
is	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
renal	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
and	CCONJ	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	ADJ	O	O
squamous	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
C1772T	NOUN	O	O
polymorphism	NOUN	O	O
in	ADP	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
healthy	ADJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
to	PART	O	O
clarify	NOUN	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
HIF-1alpha	NOUN	O	O
activation	NOUN	O	O
in	ADP	O	O
colorectal	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
exon	NOUN	O	O
12	NUM	O	O
genotype	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
sex	NOUN	O	O
or	CCONJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
distribution	NOUN	O	O
of	ADP	O	O
HIF-1alpha	NOUN	O	B-PHYSICAL
genotypes	VERB	O	I-PHYSICAL
in	ADP	O	O
controls	NOUN	O	O
was	VERB	O	O
89	NUM	O	O
C/C	NOUN	O	O
(	PUNCT	O	O
89	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
11	NUM	O	O
C/T	ADV	O	O
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0	NUM	O	O
T/T	PUNCT	O	O
(	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
distribution	NOUN	O	O
of	ADP	O	O
HIF-1alpha	NOUN	O	B-PHYSICAL
genotypes	VERB	O	I-PHYSICAL
in	ADP	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
was	VERB	O	O
100	NUM	O	O
C/C	ADJ	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
0	NUM	O	O
C/T	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0	NUM	O	O
T/T	PUNCT	O	O
(	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
genotype	NOUN	O	O
distribution	NOUN	O	O
between	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
C1772T	NOUN	O	B-PHYSICAL
polymorphism	NOUN	O	I-PHYSICAL
in	ADP	O	O
HIF-1alpha	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
involved	VERB	O	O
in	ADP	O	O
progression	NOUN	O	O
or	CCONJ	O	O
metastasis	NOUN	O	O
of	ADP	O	O
colorectal	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

Is	PUNCT	O	O
a	DET	O	O
2-week	NOUN	O	O
duration	NOUN	O	O
sufficient	ADJ	O	O
for	ADP	O	O
stenting	VERB	O	O
in	ADP	O	O
endopyelotomy	NOUN	O	O
?	PUNCT	O	O

PURPOSE	NOUN	O	O
Internal	ADJ	O	O
stenting	VERB	O	O
is	VERB	O	O
an	DET	O	O
integral	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
endopyelotomy	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
show	VERB	O	O
good	ADJ	O	O
healing	VERB	O	O
after	ADP	O	O
1	NUM	O	O
to	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
ureterotomy	NOUN	O	O
.	PUNCT	O	O

Inherent	ADJ	O	O
stent	NOUN	O	O
related	VERB	O	O
problems	NOUN	O	O
warrant	VERB	O	O
a	DET	O	O
minimum	NOUN	O	O
possible	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
stenting	VERB	O	O
without	ADP	O	O
compromising	PUNCT	O	O
the	DET	O	O
results	CCONJ	O	O
of	ADP	O	O
endopyelotomy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
optimum	NOUN	O	B-OTHER
duration	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
stenting	VERB	O	I-OTHER
after	ADP	O	O
endopyelotomy	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
57	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
ureteropelvic	ADJ	O	O
junction	NOUN	O	O
obstruction	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PUNCT	O	O
undergo	PUNCT	O	O
7/14Fr	PUNCT	O	O
internal	ADJ	O	O
endopyelotomy	NOUN	O	O
stent	NOUN	O	O
placement	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
symptom	NOUN	O	O
based	VERB	O	O
questionnaire	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
at	ADP	O	O
stent	NOUN	O	O
removal	NOUN	O	O
.	PUNCT	O	O

Followup	NOUN	O	O
was	VERB	O	O
done	PUNCT	O	O
with	ADP	O	O
diuretic	NOUN	O	O
scanning	VERB	O	O
at	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
yearly	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thereafter	ADV	O	O
with	ADP	O	O
diuretic	NOUN	O	O
renography	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
each	DET	O	O
group	NOUN	O	O
26	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
symptoms	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
ipsilateral	ADJ	O	B-PHYSICAL
glomerular	ADJ	O	I-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Mean	DET	O	O
followup	NOUN	O	O
was	VERB	O	O
22.3	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
12	NUM	O	O
to	ADP	O	O
36	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
21.3	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
12	NUM	O	O
to	ADP	O	O
35	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
24	NUM	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
92.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
23	NUM	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
90.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
had	VERB	O	O
an	DET	O	O
improved	VERB	O	O
drainage	NOUN	O	B-OTHER
pattern	NOUN	O	I-OTHER
.	PUNCT	O	O

This	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Stent	NOUN	O	B-PHYSICAL
related	VERB	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
a	DET	O	O
good	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	B-ADVERSE-EFFECTS
tract	NOUN	O	I-ADVERSE-EFFECTS
infections	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
11.5	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
38.1	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
group	NOUN	O	O
2	NUM	O	O
patients	NOUN	O	O
64	NUM	O	O
%	SYM	O	O
preferred	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
stenting	ADV	O	I-OTHER
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Two	NUM	O	O
weeks	NOUN	O	O
seems	NOUN	O	O
to	DET	O	O
be	PUNCT	O	O
a	DET	O	O
sufficient	ADJ	O	O
duration	NOUN	O	O
to	PART	O	O
allow	NOUN	O	O
functional	ADJ	O	O
restoration	NOUN	O	O
across	ADP	O	O
the	DET	O	O
ureteropelvic	ADJ	O	O
junction	NOUN	O	O
after	ADP	O	O
endopyelotomy	NOUN	O	O
and	CCONJ	O	O
decrease	ADP	O	O
stent	NOUN	O	B-ADVERSE-EFFECTS
related	VERB	O	I-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Short-term	NOUN	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
training	VERB	O	O
in	ADP	O	O
obese	DET	O	O
humans	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
improves	NOUN	O	O
whole-body	NOUN	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
through	ADP	O	O
gains	NOUN	O	O
in	ADP	O	O
peripheral	ADJ	O	O
,	PUNCT	O	O
not	ADV	O	O
hepatic	ADJ	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
.	PUNCT	O	O

CONTEXT	NOUN	O	O
Short-term	NOUN	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
training	VERB	O	O
can	VERB	O	O
improve	VERB	O	O
whole-body	NOUN	O	B-PHYSICAL
insulin	NOUN	O	I-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
in	ADP	O	O
humans	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
contributions	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	O
and	CCONJ	O	O
hepatic	ADJ	O	O
tissues	NOUN	O	O
to	ADP	O	O
these	DET	O	O
improvements	NOUN	O	O
are	PROPN	O	O
not	ADV	O	O
known	VERB	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Our	PUNCT	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
7-d	NOUN	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
training	VERB	O	O
on	ADP	O	O
peripheral	ADJ	O	O
and	CCONJ	O	O
hepatic	ADJ	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
during	ADP	O	O
isoglycemic/hyperinsulinemic	ADJ	O	O
clamp	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
energy	NOUN	O	O
balance	NOUN	O	O
group	NOUN	O	O
consumed	PUNCT	O	O
an	DET	O	O
isocaloric	ADJ	O	O
diet	NOUN	O	O
consisting	VERB	O	O
of	ADP	O	O
50	NUM	O	O
%	SYM	O	O
carbohydrate	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
fat	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
20	NUM	O	O
%	ADV	O	O
protein	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
d.	NOUN	O	O
The	DET	O	O
energy	NOUN	O	O
balance	NOUN	O	O
plus	CCONJ	O	O
exercise	NOUN	O	O
group	NOUN	O	O
consumed	PUNCT	O	O
a	DET	O	O
similar	ADJ	O	O
diet	NOUN	O	O
over	ADP	O	O
the	DET	O	O
15	NUM	O	O
d	NOUN	O	O
and	CCONJ	O	O
performed	PART	O	O
50-min	NOUN	O	O
of	ADP	O	O
treadmill	NOUN	O	O
walking	PUNCT	O	O
at	ADP	O	O
70	NUM	O	O
%	SYM	O	O
of	ADP	O	O
maximum	NOUN	O	O
oxygen	NOUN	O	O
consumption	NOUN	O	O
maximum	NOUN	O	O
during	ADP	O	O
the	DET	O	O
second	ADJ	O	O
7	NUM	O	O
d	NOUN	O	O
of	ADP	O	O
the	DET	O	O
15-d	NOUN	O	O
study	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
subject	NOUN	O	O
underwent	VERB	O	O
an	DET	O	O
initial	ADJ	O	O
isoglycemic/hyperinsulinemic	ADJ	O	O
clamp	NOUN	O	O
after	ADP	O	O
1-wk	PUNCT	O	O
dietary	ADJ	O	O
control	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
second	ADJ	O	O
clamp	NOUN	O	O
after	ADP	O	O
completing	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
Ohio	PUNCT	O	O
State	NOUN	O	O
University	NOUN	O	O
's	PUNCT	O	O
General	ADJ	O	O
Clinical	ADJ	O	O
Research	NOUN	O	O
Center	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
There	PUNCT	O	O
were	VERB	O	O
18	NUM	O	O
obese	PUNCT	O	O
,	PUNCT	O	O
mildly	ADV	O	O
diabetic	ADJ	O	O
humans	NOUN	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
Aerobic	ADJ	O	O
exercise	NOUN	O	O
training	VERB	O	O
was	VERB	O	O
performed	VERB	O	O
for	ADP	O	O
7	NUM	O	O
d.	NOUN	O	O
MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Whole-body	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
peripheral	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

In	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
hypertensive	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
incidental	DET	O	O
and	CCONJ	O	O
unilateral	ADJ	O	O
renal	ADJ	O	O
artery	NOUN	O	O
stenosis	NOUN	O	O
percutaneous	ADJ	O	O
revascularization	NOUN	O	O
with	ADP	O	O
stent	NOUN	O	O
improves	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
control	NOUN	O	I-PHYSICAL
but	CCONJ	O	O
not	ADV	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

AIM	NOUN	O	O
In	ADP	O	O
high-risk	NOUN	O	O
hypertensive	ADJ	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
HTs	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
incidental	DET	O	O
unilateral	ADJ	O	O
renal	ADJ	O	O
artery	NOUN	O	O
stenosis	NOUN	O	O
(	PUNCT	O	O
RAS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
percutaneous	ADJ	O	O
revascularization	NOUN	O	O
with	ADP	O	O
stent	NOUN	O	O
(	PUNCT	O	O
PR-STENT	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
BP	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
GFR	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
is	VERB	O	O
not	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Eighteen	PUNCT	O	O
HTs	ADP	O	O
aged	ADP	O	O
65.7	NUM	O	O
?	PUNCT	O	O

9.2	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
angiographically	ADJ	O	O
diagnosed	ADP	O	O
unilateral	ADJ	O	O
RAS	NOUN	O	O
(	PUNCT	O	O
?	PUNCT	O	O

60	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
PR-STENT	NOUN	O	O
(	PUNCT	O	O
N=9	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
to	ADP	O	O
NO-STENT	NOUN	O	O
(	PUNCT	O	O
N=9	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BP	NOUN	O	O
(	PUNCT	O	O
mercury	NOUN	O	O
sphygmomanometer	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
GFR	NOUN	O	O
(	PUNCT	O	O
99mTc-DTPA	PUNCT	O	O
clearances	CCONJ	O	O
during	ADP	O	O
renal	ADJ	O	O
scintigraphy	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
evaluated	ADP	O	O
yearly	PUNCT	O	O
for	ADP	O	O
three	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Echo-Doppler	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
arteries	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	ADP	O	O
verify	NOUN	O	O
the	DET	O	O
anatomic	ADJ	O	O
patency	NOUN	O	O
and	CCONJ	O	O
flow	NOUN	O	O
velocities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
reperfused	ADJ	O	O
artery	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
compared	VERB	O	O
BP	NOUN	O	O
and	CCONJ	O	O
GFR	NOUN	O	O
values	NOUN	O	O
changes	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
;	PUNCT	O	O
differences	NOUN	O	O
for	ADP	O	O
continuous	ADJ	O	O
variables	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
between	ADP	O	O
groups	NOUN	O	O
with	ADP	O	O
the	DET	O	O
Tukey	NOUN	O	O
's	PUNCT	O	O
post	PUNCT	O	O
hoc	CCONJ	O	O
test	NOUN	O	O
after	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
change	NOUN	O	O
of	ADP	O	O
BP	NOUN	O	O
between	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
GFR	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
BMI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Baseline	NOUN	O	O
systolic	ADJ	O	O
BP	NOUN	O	O
and	CCONJ	O	O
GFR	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
GFR	NOUN	O	O
increase	NOUN	O	O
observed	PRON	O	O
in	ADP	O	O
PR-STENT	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
NO-STENT	NOUN	O	O
at	ADP	O	O
univariate	ADJ	O	O
analysis	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
62.5	NUM	O	O
?	PUNCT	O	O

19.2	NUM	O	O
vs.	CCONJ	O	O
42.24	NUM	O	O
?	PUNCT	O	O

17.6	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
disappeared	ADP	O	O
after	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
confounding	VERB	O	O
factors	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
systolic	ADJ	O	O
BP	NOUN	O	O
remained	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
PR-STENT	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
NO-STENT	NOUN	O	O
(	PUNCT	O	O
140.1	NUM	O	O
?	PUNCT	O	O

4.6	NUM	O	O
vs.	CCONJ	O	O
170.0	NUM	O	O
?	PUNCT	O	O

8.3	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
also	ADV	O	O
after	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
GFR	NOUN	O	O
and	CCONJ	O	O
BMI	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
PR-STENT	NOUN	O	O
reduces	NOUN	O	O
systolic	ADJ	O	O
BP	NOUN	O	O
without	ADP	O	O
improving	VERB	O	O
GFR	NOUN	O	O
.	PUNCT	O	O

Due	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
strong	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
high	ADJ	O	O
BP	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	O
damage	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
raises	PUNCT	O	O
the	DET	O	O
question	NOUN	O	O
on	ADP	O	O
whether	PUNCT	O	O
PR-STENT	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
all	DET	O	O
HTs	NOUN	O	O
with	ADP	O	O
unilateral	ADJ	O	O
and	CCONJ	O	O
incidental	DET	O	O
RAS	NOUN	O	O
.	PUNCT	O	O

Perceptual	ADJ	O	B-OTHER
wind-up	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
human	NOUN	O	O
oesophagus	NOUN	O	O
is	VERB	O	O
enhanced	VERB	O	O
by	ADP	O	O
central	ADJ	O	O
sensitisation	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Oesophageal	PUNCT	O	O
acid	NOUN	O	O
infusion	NOUN	O	O
induces	NOUN	O	O
enhanced	VERB	O	O
pain	NOUN	O	O
hypersensitivity	NOUN	O	O
in	ADP	O	O
non-acid	NOUN	O	O
exposed	VERB	O	O
upper	ADJ	O	O
oesophagus	NOUN	O	O
(	PUNCT	O	O
secondary	ADJ	O	O
hyperalgesia	CCONJ	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
non-cardiac	PUNCT	O	O
chest	NOUN	O	O
pain	NOUN	O	O
,	PUNCT	O	O
thus	ADV	O	O
suggesting	VERB	O	O
central	ADJ	O	O
sensitisation	NOUN	O	O
contributes	NOUN	O	O
to	ADP	O	O
visceral	ADJ	O	O
pain	NOUN	O	O
hypersensitivity	NOUN	O	O
in	ADP	O	O
functional	ADJ	O	O
gut	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
FGD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Perceptual	ADJ	O	O
wind-up	PUNCT	O	O
(	PUNCT	O	O
increased	VERB	O	O
pain	NOUN	O	O
perception	NOUN	O	O
to	ADP	O	O
constant	ADJ	O	O
intensity	NOUN	O	O
sensory	ADJ	O	O
stimuli	NOUN	O	O
at	ADP	O	O
frequencies	NOUN	O	O
>	SYM	O	O
or=0.3	NOUN	O	O
Hz	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
proxy	NOUN	O	O
for	ADP	O	O
central	ADJ	O	O
sensitisation	NOUN	O	O
to	PART	O	O
investigate	ADJ	O	O
pain	NOUN	O	O
syndromes	NOUN	O	O
where	ADP	O	O
pain	NOUN	O	O
hypersensitivity	NOUN	O	O
is	VERB	O	O
important	ADJ	O	O
(	PUNCT	O	O
for	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
fibromyalgia	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

AIMS	ADP	O	O
Wind-up	PUNCT	O	O
in	ADP	O	O
central	ADJ	O	O
sensitisation	NOUN	O	O
induced	VERB	O	O
human	NOUN	O	O
visceral	ADJ	O	O
pain	NOUN	O	O
hypersensitivity	NOUN	O	O
has	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
explored	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesised	VERB	O	O
that	ADP	O	O
if	VERB	O	O
wind-up	PUNCT	O	O
is	ADP	O	O
a	DET	O	O
proxy	NOUN	O	O
for	ADP	O	O
central	ADJ	O	O
sensitisation	NOUN	O	O
induced	VERB	O	O
human	NOUN	O	O
visceral	ADJ	O	O
pain	NOUN	O	O
hypersensitivity	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
oesophageal	ADJ	O	O
wind-up	NOUN	O	O
should	ADP	O	O
be	VERB	O	O
enhanced	VERB	O	O
by	ADP	O	O
secondary	ADJ	O	O
hyperalgesia	CCONJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
eight	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
(	PUNCT	O	O
seven	NUM	O	O
males	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
32	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
perception	NOUN	O	O
at	ADP	O	O
pain	NOUN	O	O
threshold	NOUN	O	O
to	ADP	O	O
a	DET	O	O
train	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
electrical	ADJ	O	O
stimuli	NOUN	O	O
applied	VERB	O	O
to	ADP	O	O
the	DET	O	O
hand	NOUN	O	O
and	CCONJ	O	O
upper	ADJ	O	O
oesophagus	NOUN	O	O
(	PUNCT	O	O
UO	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
either	CCONJ	O	O
0.1	ADP	O	O
Hz	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
2	NUM	O	O
Hz	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
one	NUM	O	O
hour	NOUN	O	O
after	ADP	O	O
a	DET	O	O
30	NUM	O	O
minute	ADJ	O	O
lower	PUNCT	O	O
oesophageal	ADJ	O	O
acid	NOUN	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADP	O	O
Wind-up	PUNCT	O	B-OTHER
occurred	VERB	O	O
only	ADV	O	O
with	ADP	O	O
the	DET	O	O
2	NUM	O	O
Hz	NOUN	O	O
train	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
UO	NOUN	O	O
and	CCONJ	O	O
hand	NOUN	O	O
(	PUNCT	O	O
both	CCONJ	O	O
p=0.01	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Following	ADP	O	O
acid	NOUN	O	O
infusion	NOUN	O	O
,	PUNCT	O	O
pain	NOUN	O	B-PAIN
threshold	NOUN	O	I-PAIN
decreased	VERB	O	O
(	PUNCT	O	O
17	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
%	SYM	O	O
;	PUNCT	O	O
p=0.01	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
UO	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	O
hyperalgesia	ADV	O	O
.	PUNCT	O	O

Wind-up	PUNCT	O	B-OTHER
to	ADP	O	I-OTHER
the	DET	O	I-OTHER
2	NUM	O	I-OTHER
Hz	NOUN	O	I-OTHER
train	PUNCT	O	I-OTHER
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
UO	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
wind-up	PUNCT	O	O
ratio	NOUN	O	O
1.4	NUM	O	O
(	PUNCT	O	O
0.1	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
1.6	NUM	O	O
(	PUNCT	O	O
0.1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
p=0.03	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
hand	NOUN	O	O
(	PUNCT	O	O
wind-up	PUNCT	O	O
ratio	NOUN	O	O
1.3	NUM	O	O
(	PUNCT	O	O
0.1	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
1.3	NUM	O	O
(	PUNCT	O	O
0.1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
p=0.3	NOUN	O	O
)	PUNCT	O	O
CONCLUSION	NOUN	O	O
Enhanced	ADV	O	O
wind-up	PUNCT	O	O
after	ADP	O	O
secondary	ADJ	O	O
oesophageal	ADJ	O	O
hyperalgesia	NOUN	O	O
suggests	ADJ	O	O
that	ADP	O	O
visceral	ADJ	O	O
pain	NOUN	O	O
hypersensitivity	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
central	ADJ	O	O
sensitisation	NOUN	O	O
results	PROPN	O	O
from	ADP	O	O
increased	VERB	O	O
central	ADJ	O	O
neuronal	ADJ	O	O
excitability	NOUN	O	O
.	PUNCT	O	O

Wind-up	PUNCT	O	O
may	CCONJ	O	O
offer	VERB	O	O
new	ADJ	O	O
opportunities	NOUN	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
neuronal	ADJ	O	O
changes	NOUN	O	O
to	PUNCT	O	O
symptoms	PUNCT	O	O
in	ADP	O	O
FGD	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
outcome	NOUN	O	O
of	ADP	O	O
appliance	PUNCT	O	O
therapy	NOUN	O	O
in	ADP	O	O
temporomandibular	ADJ	O	O
disorder	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
myofascial	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
after	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
long-term	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
stabilization	NOUN	O	O
appliance	ADP	O	O
(	PUNCT	O	O
group	NOUN	O	O
T	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
control	NOUN	O	O
appliance	ADP	O	O
(	PUNCT	O	O
group	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
temporomandibular	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
TMD	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
myofascial	ADJ	O	O
pain	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
29	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
myofascial	ADJ	O	O
pain	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
after	ADP	O	O
10	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
stabilization	NOUN	O	O
appliance	ADP	O	O
or	CCONJ	O	O
a	DET	O	O
control	ADP	O	O
appliance	ADP	O	O
.	PUNCT	O	O

All	DET	O	O
60	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
1	PUNCT	O	O
of	ADP	O	O
3	NUM	O	O
groups	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
demand	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Seventeen	PUNCT	O	O
patients	NOUN	O	O
from	ADP	O	O
group	NOUN	O	O
C	NOUN	O	O
requested	VERB	O	O
another	PUNCT	O	O
appliance	ADP	O	O
and	CCONJ	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
stabilization	NOUN	O	O
appliance	ADP	O	O
,	PUNCT	O	O
thus	ADV	O	O
creating	PUNCT	O	O
a	DET	O	O
mixed	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
M	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
improvement	NOUN	O	O
of	ADP	O	O
overall	ADJ	O	B-PHYSICAL
subjective	ADJ	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
in	ADP	O	O
an	DET	O	O
intent-to-treat	NOUN	O	O
analysis	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
T	NOUN	O	O
and	CCONJ	O	O
C	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
at	ADP	O	O
the	DET	O	O
follow-ups	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
survival	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
compliance	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
groups	NOUN	O	O
T	NOUN	O	O
and	CCONJ	O	O
C.	NOUN	O	O
At	ADP	O	O
the	DET	O	O
6-	NUM	O	O
and	CCONJ	O	O
12-month	NOUN	O	O
follow-ups	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
myofascial	ADJ	O	B-PAIN
pain	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
measured	VERB	O	O
on	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
all	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
of	ADP	O	O
myofascial	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
T	NOUN	O	O
at	ADP	O	O
the	DET	O	O
follow-ups	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
number	NOUN	O	O
of	ADP	O	O
tender	NOUN	O	B-PHYSICAL
sites	NOUN	O	I-PHYSICAL
on	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
masticatory	ADJ	O	I-PHYSICAL
muscles	NOUN	O	I-PHYSICAL
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
T	NOUN	O	O
at	ADP	O	O
the	DET	O	O
follow-ups	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
support	VERB	O	O
the	DET	O	O
conclusion	NOUN	O	O
that	ADP	O	O
the	DET	O	O
positive	ADJ	O	O
treatment	NOUN	O	O
outcome	NOUN	O	O
obtained	VERB	O	O
by	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
stabilization	NOUN	O	O
appliance	CCONJ	O	O
to	ADP	O	O
alleviate	CCONJ	O	O
the	DET	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
myofascial	ADJ	O	O
pain	NOUN	O	O
persisted	VERB	O	O
after	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Most	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
groups	NOUN	O	O
T	NOUN	O	O
and	CCONJ	O	O
M	NOUN	O	O
reported	ADP	O	O
positive	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
overall	PUNCT	O	B-PHYSICAL
subjective	ADJ	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
in	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
recommend	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
stabilization	NOUN	O	O
appliance	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
TMD	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
myofascial	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
.	PUNCT	O	O

Local	ADJ	O	O
warming	PROPN	O	O
and	CCONJ	O	O
insertion	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	O
venous	ADJ	O	O
cannulas	ADJ	O	O
:	PUNCT	O	O
single	ADJ	O	O
blinded	VERB	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
and	CCONJ	O	O
single	ADJ	O	O
blinded	VERB	O	O
randomised	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
whether	VERB	O	O
local	ADJ	O	O
warming	DET	O	O
of	ADP	O	O
the	DET	O	O
lower	PUNCT	O	O
arm	NOUN	O	O
and	CCONJ	O	O
hand	NOUN	O	O
facilitates	PUNCT	O	O
peripheral	ADJ	O	B-PHYSICAL
venous	ADJ	O	I-PHYSICAL
cannulation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

DESIGN	NOUN	O	O
Single	PUNCT	O	O
blinded	VERB	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
and	CCONJ	O	O
single	ADJ	O	O
blinded	VERB	O	O
randomised	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Neurosurgical	ADJ	O	O
unit	NOUN	O	O
and	CCONJ	O	O
haematology	NOUN	O	O
ward	NOUN	O	O
of	ADP	O	O
university	NOUN	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
100	NUM	O	O
neurosurgical	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
40	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
leukaemia	NOUN	O	O
who	ADP	O	O
required	VERB	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Neurosurgical	ADJ	O	O
patients	NOUN	O	O
'	PUNCT	O	O
hands	NOUN	O	O
and	CCONJ	O	O
forearms	ADP	O	O
were	ADV	O	O
covered	VERB	O	O
for	ADP	O	O
15	NUM	O	O
minutes	NOUN	O	O
with	ADP	O	O
a	DET	O	O
carbon	NOUN	O	O
fibre	NOUN	O	O
heating	ADJ	O	O
mitt	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	PUNCT	O	O
active	ADJ	O	O
warming	PUNCT	O	O
at	ADP	O	O
52	NUM	O	O
degrees	NOUN	O	O
C	NUM	O	O
or	CCONJ	O	O
passive	ADJ	O	O
insulation	NOUN	O	O
(	PUNCT	O	O
heater	NOUN	O	O
not	ADV	O	O
activated	VERB	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
same	ADJ	O	O
warming	VERB	O	O
system	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
for	ADP	O	O
10	NUM	O	O
minutes	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
leukaemia	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	PUNCT	O	O
active	ADJ	O	O
warming	ADP	O	O
or	CCONJ	O	O
passive	ADJ	O	O
insulation	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
given	VERB	O	O
alternative	ADJ	O	O
treatment	NOUN	O	O
during	ADP	O	O
the	DET	O	O
subsequent	ADJ	O	O
visit	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
PRIMARY	ADP	O	O
:	PUNCT	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
for	ADP	O	I-OTHER
insertion	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
18	NUM	O	I-OTHER
gauge	ADJ	O	I-OTHER
cannula	NOUN	O	I-OTHER
into	ADP	O	I-OTHER
vein	NOUN	O	I-OTHER
on	ADP	O	I-OTHER
back	ADP	O	I-OTHER
of	ADP	O	I-OTHER
hand	NOUN	O	I-OTHER
.	PUNCT	O	O

SECONDARY	ADJ	O	O
:	PUNCT	O	O
time	NOUN	O	B-OTHER
required	ADJ	O	I-OTHER
for	ADP	O	I-OTHER
successful	ADJ	O	I-OTHER
cannulation	NOUN	O	I-OTHER
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
neurosurgical	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
it	ADP	O	O
took	PROPN	O	O
36	NUM	O	O
seconds	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
31	NUM	O	O
to	ADP	O	O
40	NUM	O	O
seconds	NOUN	O	O
)	PUNCT	O	O
to	VERB	O	O
insert	PUNCT	O	B-OTHER
a	DET	O	I-OTHER
cannula	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
active	ADJ	O	O
warming	DET	O	O
group	NOUN	O	O
and	CCONJ	O	O
62	NUM	O	O
(	PUNCT	O	O
50	NUM	O	O
to	ADP	O	O
74	PUNCT	O	O
)	PUNCT	O	O
seconds	NOUN	O	O
in	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
insulation	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P=0.002	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
first	VERB	O	O
attempts	PUNCT	O	O
failed	PUNCT	O	B-OTHER
in	ADP	O	O
the	DET	O	O
active	ADJ	O	O
warming	DET	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
14	NUM	O	O
(	PUNCT	O	O
28	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
insulation	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P=0.008	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
crossover	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
leukaemia	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
insertion	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
20	NUM	O	O
seconds	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
to	ADP	O	O
32	NUM	O	O
,	PUNCT	O	O
P=0.013	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
active	ADJ	O	O
warming	PROPN	O	O
and	CCONJ	O	O
that	ADP	O	O
failure	NOUN	O	B-OTHER
rates	NOUN	O	I-OTHER
at	ADP	O	I-OTHER
first	VERB	O	I-OTHER
attempt	NOUN	O	I-OTHER
were	VERB	O	O
6	NUM	O	O
%	SYM	O	O
with	ADP	O	O
warming	PROPN	O	O
and	CCONJ	O	O
30	NUM	O	O
%	SYM	O	O
with	ADP	O	O
passive	ADJ	O	O
insulation	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Local	ADJ	O	O
warming	ADP	O	O
facilitates	DET	O	O
the	DET	O	O
insertion	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	B-OTHER
venous	ADJ	O	I-OTHER
cannulas	ADP	O	I-OTHER
,	PUNCT	O	O
reducing	ADP	O	O
both	PUNCT	O	O
time	NOUN	O	B-OTHER
and	CCONJ	O	I-OTHER
number	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
attempts	CCONJ	O	I-OTHER
required	VERB	O	I-OTHER
.	PUNCT	O	O

This	PUNCT	O	O
may	CCONJ	O	O
decrease	VERB	O	O
the	DET	O	O
time	NOUN	O	O
staff	NOUN	O	O
spend	NOUN	O	O
inserting	PUNCT	O	B-OTHER
cannulas	ADP	O	I-OTHER
,	PUNCT	O	O
reduce	PART	O	O
supply	NOUN	O	B-OTHER
costs	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
improve	VERB	O	O
patient	NOUN	O	O
satisfaction	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Opiate	ADJ	O	O
hypothesis	NOUN	O	O
in	ADP	O	O
infantile	ADJ	O	O
autism	NOUN	O	O
?	PUNCT	O	O

Therapeutic	ADJ	O	O
trials	NOUN	O	O
with	ADP	O	O
naltrexone	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
opioid	NOUN	O	O
hypothesis	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
childhood	NOUN	O	O
autism	NOUN	O	O
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
excessive	ADJ	O	O
brain	NOUN	O	O
opioid	NOUN	O	O
activity	NOUN	O	O
during	ADP	O	O
neonatal	ADJ	O	O
period	NOUN	O	O
which	ADP	O	O
may	VERB	O	O
constitutionally	ADV	O	O
inhibit	VERB	O	O
social	ADJ	O	O
motivation	NOUN	O	O
,	PUNCT	O	O
yielding	PUNCT	O	O
autistic	ADJ	O	O
isolation	NOUN	O	O
and	CCONJ	O	O
aloofness	NOUN	O	O
(	PUNCT	O	O
Panksepp	PUNCT	O	O
,	PUNCT	O	O
1979	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
hypothesis	NOUN	O	O
has	PUNCT	O	O
now	ADV	O	O
received	VERB	O	O
strong	ADJ	O	O
support	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
currently	ADV	O	O
based	VERB	O	O
on	ADP	O	O
three	NUM	O	O
types	NOUN	O	O
of	ADP	O	O
arguments	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
similarity	NOUN	O	O
between	ADP	O	O
autistic	ADJ	O	O
symptomatology	NOUN	O	O
and	CCONJ	O	O
abnormal	ADJ	O	O
behaviors	NOUN	O	O
induced	VERB	O	O
in	ADP	O	O
young	ADJ	O	O
animals	NOUN	O	O
by	ADP	O	O
injections	NOUN	O	O
of	ADP	O	O
exogenous	ADJ	O	O
opioids	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
increasing	VERB	O	O
social	ADJ	O	O
aloofness	NOUN	O	O
and	CCONJ	O	O
decreasing	ADJ	O	O
social	ADJ	O	O
vocalization	ADJ	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
direct	ADJ	O	O
biochemical	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
abnormalities	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	O
endogenous	ADJ	O	O
opioids	NOUN	O	O
being	DET	O	O
reported	VERB	O	O
in	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
therapeutic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
long	ADJ	O	O
lasting	ADP	O	O
opioid	NOUN	O	O
receptor	NOUN	O	O
blocking	DET	O	O
agent	NOUN	O	O
naltrexone	NUM	O	O
in	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
article	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
give	VERB	O	O
description	NOUN	O	O
of	ADP	O	O
open	ADJ	O	O
and	CCONJ	O	O
double-blind	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
naltrexone	NUM	O	O
in	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Naltrexone	NUM	O	O
has	PUNCT	O	O
been	PUNCT	O	O
tested	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
open	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
an	DET	O	O
open	ADJ	O	O
trial	NOUN	O	O
with	ADP	O	O
naltrexone	NUM	O	O
in	ADP	O	O
2	NUM	O	O
autistic	ADJ	O	O
girls	NOUN	O	O
,	PUNCT	O	O
displaying	ADP	O	O
serious	ADJ	O	O
self-injurious	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
reduced	ADJ	O	O
crying	PROPN	O	O
and	CCONJ	O	O
a	DET	O	O
marked	VERB	O	O
preference	NOUN	O	O
for	ADP	O	O
salty	NOUN	O	O
and	CCONJ	O	O
spicy	NUM	O	O
foods	NOUN	O	O
,	PUNCT	O	O
symptoms	NOUN	O	O
that	ADP	O	O
could	ADJ	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
dysfunction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
opioid	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
dosages	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
mg/kg/day	PUNCT	O	O
,	PUNCT	O	O
we	NOUN	O	O
observed	VERB	O	O
an	DET	O	O
immediate	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
hyperactivity	NOUN	O	B-MENTAL
,	PUNCT	O	O
self-injurious	ADJ	O	B-MENTAL
behavior	NOUN	O	I-MENTAL
and	CCONJ	O	O
aggressiveness	ADP	O	B-MENTAL
,	PUNCT	O	O
while	ADP	O	B-MENTAL
attention	NOUN	O	I-MENTAL
improved	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
social	ADJ	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
,	PUNCT	O	O
smiling	PUNCT	O	B-MENTAL
,	PUNCT	O	O
social	ADJ	O	B-MENTAL
seeking	PUNCT	O	I-MENTAL
behaviors	NOUN	O	I-MENTAL
and	CCONJ	O	O
play	ADJ	O	B-MENTAL
interactions	NOUN	O	I-MENTAL
increased	VERB	O	O
(	PUNCT	O	O
Leboyer	NOUN	O	O
,	PUNCT	O	O
Bouvard	PUNCT	O	O
et	CCONJ	O	O
Dugas	NOUN	O	O
,	PUNCT	O	O
1988	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Campbell	PUNCT	O	O
et	CCONJ	O	O
al	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

1988	NUM	O	O
)	PUNCT	O	O
has	PUNCT	O	O
also	ADV	O	O
reported	VERB	O	O
a	DET	O	O
tranquilizing	VERB	O	B-MENTAL
and	CCONJ	O	I-MENTAL
a	DET	O	I-MENTAL
stimulating	ADJ	O	I-MENTAL
effect	NOUN	O	O
in	ADP	O	O
6	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
8	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
did	CCONJ	O	O
confirm	VERB	O	O
these	DET	O	O
preliminary	ADJ	O	O
results	DET	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
performed	VERB	O	O
on	ADP	O	O
4	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
cross-over	NOUN	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
dosages	NOUN	O	O
of	ADP	O	O
naltrexone	NUM	O	O
(	PUNCT	O	O
0.5	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
mg/kg/day	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
mecamylamine	PUNCT	O	O
on	ADP	O	O
human	NOUN	O	O
cigarette	NOUN	O	O
smoking	VERB	O	O
and	CCONJ	O	O
subjective	ADJ	O	O
ratings	NOUN	O	O
.	PUNCT	O	O

Multiple	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
cigarette	NOUN	O	O
smoking	VERB	O	O
,	PUNCT	O	O
subjective	ADJ	O	O
effect	NOUN	O	O
and	CCONJ	O	O
physiological	ADJ	O	O
effect	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
during	ADP	O	O
90-min	NOUN	O	O
test	NUM	O	O
sessions	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
sessions	PUNCT	O	O
subjects	NOUN	O	O
received	VERB	O	O
oral	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
mecamylamine	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
,	PUNCT	O	O
5.0	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
dose	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
three	NUM	O	O
times	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
block	NOUN	O	O
sequence	NOUN	O	O
.	PUNCT	O	O

Mecamylamine	NOUN	O	O
increased	CCONJ	O	O
several	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
cigarette	NOUN	O	O
smoking	VERB	O	O
,	PUNCT	O	O
including	CCONJ	O	O
number	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
cigarettes	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
puffs	PUNCT	O	B-PHYSICAL
per	ADP	O	I-PHYSICAL
cigarette	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
expired	ADP	O	B-PHYSICAL
air	NOUN	O	I-PHYSICAL
carbon	NOUN	O	I-PHYSICAL
monoxide	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Mecamylamine	ADV	O	O
also	ADV	O	O
produced	ADP	O	O
modest	ADJ	O	O
,	PUNCT	O	O
dose-related	VERB	O	O
decreases	CCONJ	O	O
in	ADP	O	O
standing	NUM	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
increases	NOUN	O	O
in	ADP	O	O
standing	NUM	O	B-PHYSICAL
heart	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
subjective	ADJ	O	O
effects	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
mecamylamine	PUNCT	O	O
were	VERB	O	O
not	ADV	O	O
characteristic	ADJ	O	O
of	ADP	O	O
those	PUNCT	O	O
of	ADP	O	O
psychoactive	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Mecamylamine	ADV	O	O
appears	PART	O	O
to	PUNCT	O	O
have	PUNCT	O	O
increased	DET	O	O
cigarette	NOUN	O	O
smoking	VERB	O	O
by	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
effective	ADJ	O	O
dose	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	O
available	ADJ	O	O
from	ADP	O	O
cigarette	NOUN	O	O
smoking	VERB	O	O
.	PUNCT	O	O

Monitoring	ADV	O	O
acute	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
athletic	ADJ	O	O
performance	NOUN	O	O
with	ADP	O	O
mixed	VERB	O	O
linear	ADJ	O	O
modeling	PUNCT	O	O
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
There	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
need	NOUN	O	O
for	ADP	O	O
a	DET	O	O
sophisticated	PUNCT	O	O
approach	NOUN	O	O
to	PART	O	O
track	CCONJ	O	O
athletic	ADJ	O	O
performance	NOUN	O	O
and	CCONJ	O	O
to	PUNCT	O	O
quantify	NOUN	O	O
factors	NOUN	O	O
affecting	VERB	O	O
it	NUM	O	O
in	ADP	O	O
practical	ADJ	O	O
settings	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
demonstrate	ADJ	O	O
the	DET	O	O
application	NOUN	O	O
of	ADP	O	O
mixed	VERB	O	O
linear	ADJ	O	O
modeling	PUNCT	O	O
for	ADP	O	O
monitoring	VERB	O	O
athletic	ADJ	O	O
performance	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Elite	ADJ	O	O
sprint	NOUN	O	O
and	CCONJ	O	O
middle-distance	ADP	O	O
swimmers	NOUN	O	O
(	PUNCT	O	O
three	NUM	O	O
females	NOUN	O	O
and	CCONJ	O	O
six	NUM	O	O
males	NOUN	O	O
;	PUNCT	O	O
aged	PUNCT	O	O
21-26	NUM	O	O
yr	NOUN	O	O
)	PUNCT	O	O
performed	DET	O	O
6-13	DET	O	O
time	NOUN	O	O
trials	NOUN	O	O
in	ADP	O	O
training	VERB	O	O
and	CCONJ	O	O
competition	NOUN	O	O
in	ADP	O	O
the	DET	O	O
9	NUM	O	O
wk	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
including	PUNCT	O	O
Olympic-qualifying	ADJ	O	O
trials	NOUN	O	O
,	PUNCT	O	O
all	CCONJ	O	O
in	ADP	O	O
their	PUNCT	O	O
specialty	NOUN	O	O
event	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
included	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
diet-controlled	PUNCT	O	O
crossover	NOUN	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADP	O	O
the	DET	O	O
swimmers	NOUN	O	O
consumed	PUNCT	O	O
caffeine	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	NOUN	O	O
x	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
swimmers	NOUN	O	O
also	ADV	O	O
knowingly	ADV	O	O
consumed	PUNCT	O	O
varying	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	O
in	ADP	O	O
some	DET	O	O
time	NOUN	O	O
trials	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	DET	O	O
mixed	NOUN	O	O
linear	ADJ	O	O
modeling	VERB	O	O
of	ADP	O	O
log-transformed	PUNCT	O	O
swim	PUNCT	O	O
time	NOUN	O	O
to	PART	O	O
quantify	NOUN	O	O
effects	NOUN	O	B-OTHER
on	ADP	O	I-OTHER
performance	NOUN	O	I-OTHER
in	ADP	O	O
training	VERB	O	O
versus	CCONJ	O	O
competition	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
morning	NOUN	O	O
versus	CCONJ	O	O
evening	NOUN	O	O
swims	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	O
.	PUNCT	O	O

Predictor	NOUN	O	O
variables	NOUN	O	O
were	VERB	O	O
coded	VERB	O	O
as	ADP	O	O
0	NUM	O	O
or	CCONJ	O	O
1	NUM	O	O
to	PUNCT	O	O
represent	ADJ	O	O
absence	NOUN	O	O
or	CCONJ	O	O
presence	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
of	ADP	O	O
each	DET	O	O
condition	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
included	VERB	O	O
as	PUNCT	O	O
fixed	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
date	NOUN	O	O
of	ADP	O	O
each	DET	O	O
performance	NOUN	O	O
test	NOUN	O	O
was	VERB	O	O
included	VERB	O	O
as	ADP	O	O
a	DET	O	O
continuous	ADJ	O	O
linear	ADJ	O	O
fixed	VERB	O	O
effect	NOUN	O	O
and	CCONJ	O	O
interacted	DET	O	O
with	ADP	O	O
the	DET	O	O
random	ADJ	O	O
effect	NOUN	O	O
for	ADP	O	O
the	DET	O	O
athlete	NOUN	O	O
to	ADP	O	O
represent	ADJ	O	O
individual	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
linear	ADJ	O	O
trends	NOUN	O	O
in	ADP	O	O
performance	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
Most	PUNCT	O	O
effects	NOUN	O	O
were	VERB	O	O
clear	ADJ	O	O
,	PUNCT	O	O
owing	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
high	ADJ	O	O
reliability	NOUN	O	O
of	ADP	O	O
performance	NOUN	O	O
times	NOUN	O	O
in	ADP	O	O
training	VERB	O	O
and	CCONJ	O	O
competition	NOUN	O	O
(	PUNCT	O	O
typical	ADJ	O	O
errors	NOUN	O	O
of	ADP	O	O
0.9	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
0.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Performance	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
improved	VERB	O	O
linearly	ADV	O	O
by	ADP	O	O
0.8	NUM	O	O
%	SYM	O	O
per	ADP	O	O
4	NUM	O	O
wk	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
swimmers	NOUN	O	O
performed	ADJ	O	B-OTHER
substantially	ADV	O	I-OTHER
better	PUNCT	O	I-OTHER
in	ADP	O	O
evenings	NOUN	O	O
versus	CCONJ	O	O
mornings	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
competition	NOUN	O	O
versus	CCONJ	O	O
training	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
100-mg	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	O
enhanced	ADJ	O	O
performance	NOUN	O	O
in	ADP	O	O
training	VERB	O	B-OTHER
and	CCONJ	O	O
competition	NOUN	O	B-OTHER
by	ADP	O	O
approximately	ADV	O	O
1.3	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
substantial	ADJ	O	O
but	CCONJ	O	O
unclear	ADJ	O	O
individual	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
training	ADV	O	O
and	CCONJ	O	O
caffeine	NOUN	O	O
(	PUNCT	O	O
SD	NOUN	O	O
of	ADP	O	O
0.3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
0.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Mixed	NOUN	O	O
linear	ADJ	O	O
modeling	VERB	O	O
can	VERB	O	O
be	VERB	O	O
applied	VERB	O	O
successfully	ADV	O	O
to	ADP	O	O
monitor	NOUN	O	O
factors	NOUN	O	O
affecting	VERB	O	O
performance	NOUN	O	O
in	ADP	O	O
a	DET	O	O
squad	NOUN	O	O
of	ADP	O	O
elite	ADJ	O	O
athletes	NOUN	O	O
.	PUNCT	O	O

Bradykinin-induced	VERB	O	O
cough	NOUN	O	O
reflex	NOUN	O	O
markedly	ADV	O	O
increases	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cough	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
captopril	NOUN	O	O
and	CCONJ	O	O
enalapril	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	NOUN	O	O
)	PUNCT	O	O
inhibitors	NOUN	O	O
on	ADP	O	O
cough	NOUN	O	B-ADVERSE-EFFECTS
responses	NOUN	O	I-ADVERSE-EFFECTS
to	ADP	O	O
bradykinin	NOUN	O	O
(	PUNCT	O	O
BK	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
substance	NOUN	O	O
P	NOUN	O	O
(	PUNCT	O	O
SP	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
citric	ADJ	O	O
acid	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	NOUN	O	O
,	PUNCT	O	O
random	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
10	NUM	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
receiving	DET	O	O
ACE	NOUN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
five	NUM	O	O
had	PUNCT	O	O
reported	PUNCT	O	O
cough	NOUN	O	O
with	ADP	O	O
ACE	NOUN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Cough	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
citric	ADJ	O	O
acid	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
cough	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
SP	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
-5	NUM	O	O
)	PUNCT	O	O
M	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
cause	ADP	O	O
cough	NOUN	O	O
in	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

BK	NOUN	O	O
caused	PUNCT	O	O
cough	NOUN	O	B-ADVERSE-EFFECTS
at	ADP	O	O
13.4	NUM	O	O
+/-	SYM	O	O
1.2	NUM	O	O
(	PUNCT	O	O
-log	NOUN	O	O
M	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cough	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
ACE	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
cause	ADP	O	O
cough	NOUN	O	B-ADVERSE-EFFECTS
at	ADP	O	O
concentrations	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
-5	NUM	O	O
)	PUNCT	O	O
M	NOUN	O	O
in	ADP	O	O
other	ADJ	O	O
5	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
ACE	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
free	ADJ	O	O
from	ADP	O	O
cough	NOUN	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
BK	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
cause	ADP	O	O
cough	NOUN	O	B-PHYSICAL
up	PUNCT	O	O
to	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
-5	NUM	O	O
)	PUNCT	O	O
M	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
one	NUM	O	O
who	ADP	O	O
coughed	CCONJ	O	O
at	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
-9	NUM	O	O
)	PUNCT	O	O
M	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
responses	NOUN	O	O
to	ADP	O	O
citric	ADJ	O	O
acid	NOUN	O	O
.	PUNCT	O	O

BK	NOUN	O	O
caused	PUNCT	O	O
cough	NOUN	O	B-PHYSICAL
at	ADP	O	O
14.3	NUM	O	O
+/-	SYM	O	O
0.7	NUM	O	O
(	PUNCT	O	O
-log	NOUN	O	O
M	NOUN	O	O
)	PUNCT	O	O
although	ADP	O	O
BK1-7	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
major	ADJ	O	O
metabolite	NOUN	O	O
of	ADP	O	O
BK	NOUN	O	O
by	ADP	O	O
ACE	NOUN	O	O
,	PUNCT	O	O
caused	VERB	O	O
cough	NOUN	O	B-PHYSICAL
at	ADP	O	O
5.7	NUM	O	O
+/-	SYM	O	O
0.7	NUM	O	O
(	PUNCT	O	O
-log	NOUN	O	O
M	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
another	DET	O	O
3	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cough	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
ACE	NOUN	O	O
inhibitor	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
impaired	VERB	O	O
metabolism	NOUN	O	O
of	ADP	O	O
BK	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
ACE	NOUN	O	O
inhibitors	NOUN	O	O
may	VERB	O	O
relate	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
cough	NOUN	O	O
in	ADP	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
receiving	DET	O	O
ACE	NOUN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Marimastat	NOUN	O	O
as	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
gastric	ADJ	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
orally	ADV	O	O
administered	VERB	O	O
matrix	NOUN	O	O
metalloproteinase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
marimastat	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
prolong	NOUN	O	O
survival	NOUN	O	B-MORTALITY
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
non-resectable	ADJ	O	O
gastric	ADJ	O	O
and	CCONJ	O	O
gastro-oesophageal	ADJ	O	O
adenocarcinoma	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
sixty-nine	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
histological	ADJ	O	O
proof	NOUN	O	O
of	ADP	O	O
adenocarcinoma	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
had	PUNCT	O	O
received	PUNCT	O	O
no	DET	O	O
more	ADV	O	O
than	PUNCT	O	O
a	DET	O	O
single	ADJ	O	O
regimen	NOUN	O	O
of	ADP	O	O
5-fluorouracil-based	VERB	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	ADP	O	O
either	PUNCT	O	O
marimastat	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
b.d	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
as	VERB	O	O
long	VERB	O	O
as	PUNCT	O	O
was	NOUN	O	O
tolerable	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
with	ADP	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
to	ADP	O	O
disease	NOUN	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
point	NOUN	O	O
of	ADP	O	O
protocol-defined	ADJ	O	O
study	NOUN	O	O
completion	NOUN	O	O
(	PUNCT	O	O
85	NUM	O	O
%	SYM	O	O
mortality	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
arm	NOUN	O	O
)	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
modest	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
survival	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intention-to-treat	NOUN	O	O
population	NOUN	O	O
in	ADP	O	O
favour	NOUN	O	O
of	ADP	O	O
marimastat	NOUN	O	O
(	PUNCT	O	O
P=0.07	NOUN	O	O
log-rank	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
hazard	NOUN	O	O
ratio=1.23	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
0.98-1.55	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
survival	NOUN	O	B-MORTALITY
benefit	NOUN	O	I-MORTALITY
was	VERB	O	O
maintained	VERB	O	O
over	ADP	O	O
a	DET	O	O
further	ADJ	O	O
2	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
P=0.024	NOUN	O	O
,	PUNCT	O	O
hazard	NOUN	O	O
ratio=1.27	NOUN	O	O
(	PUNCT	O	O
1.03-1.57	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
survival	NOUN	O	B-MORTALITY
was	ADV	O	O
138	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
160	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
marimastat	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
2-year	NOUN	O	O
survival	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
9	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
benefit	NOUN	O	I-MORTALITY
was	VERB	O	O
identified	VERB	O	O
at	ADP	O	O
study	NOUN	O	O
completion	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pre-defined	VERB	O	O
sub-group	NOUN	O	O
of	ADP	O	O
123	NUM	O	O
patients	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
received	VERB	O	O
prior	PUNCT	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
P=0.045	NOUN	O	O
,	PUNCT	O	O
hazard	NOUN	O	O
ratio=1.53	NOUN	O	O
(	PUNCT	O	O
1.00-2.34	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
benefit	NOUN	O	O
increased	PUNCT	O	O
with	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
additional	ADJ	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
P=0.006	NOUN	O	O
,	PUNCT	O	O
hazard	NOUN	O	O
ratio=1.68	NOUN	O	O
(	PUNCT	O	O
1.16-2.44	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
2-year	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
of	ADP	O	O
5	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
18	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Progression-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
also	ADV	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
for	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
marimastat	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P=0.009	NOUN	O	O
,	PUNCT	O	O
hazard	NOUN	O	O
ratio=1.32	NOUN	O	O
(	PUNCT	O	O
1.07-1.63	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Marimastat	NOUN	O	O
treatment	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
musculoskeletal	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
and	CCONJ	O	I-PAIN
inflammation	NOUN	O	I-PAIN
.	PUNCT	O	O

Events	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
anaemia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
abdominal	ADJ	O	B-PHYSICAL
pain	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
jaundice	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
weight	NOUN	O	O
loss	NOUN	O	B-PHYSICAL
were	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
arm	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
first	ADJ	O	O
demonstrations	NOUN	O	O
of	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
benefit	NOUN	O	O
for	ADP	O	O
a	DET	O	O
matrix	NOUN	O	O
metalloproteinase	NOUN	O	O
inhibitor	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
greatest	VERB	O	O
benefit	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
previously	ADV	O	O
received	PUNCT	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
further	ADJ	O	O
randomised	DET	O	O
study	NOUN	O	O
of	ADP	O	O
marimastat	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O

Aerobic	ADJ	O	O
and	CCONJ	O	O
strength	NOUN	O	O
training	ADV	O	O
reduces	NOUN	O	O
adiposity	NOUN	O	B-PHYSICAL
in	ADP	O	O
overweight	DET	O	O
Latina	PUNCT	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADP	O	O
date	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
study	NOUN	O	O
has	PUNCT	O	O
examined	VERB	O	O
the	DET	O	O
synergistic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
nutrition	NOUN	O	O
and	CCONJ	O	O
combination	NOUN	O	O
of	ADP	O	O
aerobic	ADJ	O	O
and	CCONJ	O	O
strength	NOUN	O	O
training	VERB	O	O
(	PUNCT	O	O
CAST	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
both	PUNCT	O	O
adiposity	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
metabolic	ADJ	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
in	ADP	O	O
overweight	DET	O	O
Latina	PUNCT	O	O
adolescent	NOUN	O	O
females	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
if	PUNCT	O	O
a	DET	O	O
16-wk	NOUN	O	O
nutrition	NOUN	O	O
plus	CCONJ	O	O
CAST	NOUN	O	O
pilot	NOUN	O	O
study	NOUN	O	O
had	CCONJ	O	O
stronger	PUNCT	O	O
effects	NOUN	O	O
on	ADP	O	O
reducing	NUM	O	O
adiposity	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
on	ADP	O	O
improving	VERB	O	O
glucose/insulin	NOUN	O	B-PHYSICAL
indices	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
(	PUNCT	O	O
C	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nutrition	NOUN	O	O
only	ADV	O	O
(	PUNCT	O	O
N	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
nutrition	NOUN	O	O
plus	CCONJ	O	O
strength	NOUN	O	O
training	VERB	O	O
(	PUNCT	O	O
N	NOUN	O	O
+	SYM	O	O
ST	NOUN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
16-wk	NOUN	O	O
randomized	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
41	NUM	O	O
overweight	VERB	O	O
Latina	PUNCT	O	O
girls	NOUN	O	O
(	PUNCT	O	O
15.2	NUM	O	O
+/-	SYM	O	O
1.1	NUM	O	O
yr	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
C	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
N	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
N	NOUN	O	O
+	SYM	O	O
ST	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
N	NOUN	O	O
+	SYM	O	O
CAST	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
intervention	NOUN	O	O
groups	NOUN	O	O
received	DET	O	O
modified	VERB	O	O
carbohydrate	NOUN	O	O
nutrition	NOUN	O	O
classes	NOUN	O	O
(	PUNCT	O	O
once	PUNCT	O	O
a	DET	O	O
week	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
N	NOUN	O	O
+	SYM	O	O
ST	NOUN	O	O
also	ADV	O	O
received	CCONJ	O	O
strength	NOUN	O	O
training	VERB	O	O
(	PUNCT	O	O
twice	CCONJ	O	O
a	DET	O	O
week	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
N	NOUN	O	O
+	SYM	O	O
CAST	NOUN	O	O
received	VERB	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
strength	NOUN	O	O
and	CCONJ	O	O
aerobic	ADJ	O	O
training	SYM	O	O
(	PUNCT	O	O
twice	CCONJ	O	O
a	DET	O	O
week	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
following	ADP	O	O
were	VERB	O	O
measured	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
intervention	NOUN	O	O
:	PUNCT	O	O
strength	NOUN	O	B-PHYSICAL
by	ADP	O	O
one	NUM	O	O
repetition	NOUN	O	O
maximum	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	B-MENTAL
activity	NOUN	O	I-MENTAL
by	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
7-d	NOUN	O	I-MENTAL
accelerometry	NOUN	O	I-MENTAL
and	CCONJ	O	O
the	DET	O	O
3-d	NOUN	O	B-MENTAL
physical	ADJ	O	I-MENTAL
activity	NOUN	O	I-MENTAL
recall	VERB	O	I-MENTAL
,	PUNCT	O	O
dietary	ADJ	O	B-MENTAL
intake	NOUN	O	I-MENTAL
by	ADP	O	O
3-d	NOUN	O	O
records	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	B-PHYSICAL
composition	NOUN	O	I-PHYSICAL
by	ADP	O	O
dual-energy	NOUN	O	O
x-ray	NOUN	O	O
absorptiometry	NOUN	O	O
(	PUNCT	O	O
DEXA	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
glucose/insulin	NOUN	O	B-PHYSICAL
indices	NOUN	O	I-PHYSICAL
by	ADP	O	O
oral	ADJ	O	O
glucose	NOUN	O	O
tolerance	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
glucose	NOUN	O	O
tolerance	NOUN	O	O
test	NOUN	O	O
with	ADP	O	O
minimal	ADJ	O	O
modeling	VERB	O	O
.	PUNCT	O	O

Across	ADP	O	O
intervention	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
effects	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
using	VERB	O	O
ANCOVA	NOUN	O	O
with	ADP	O	O
post	PUNCT	O	O
hoc	PUNCT	O	O
pairwise	PUNCT	O	O
comparisons	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
significant	ADJ	O	O
overall	ADJ	O	O
intervention	NOUN	O	O
effects	NOUN	O	O
for	ADP	O	O
all	DET	O	O
adiposity	NOUN	O	B-PHYSICAL
measures	NOUN	O	O
(	PUNCT	O	O
weight	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
[	PUNCT	O	O
BMI	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
BMI	NOUN	O	O
z-scores	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
DEXA	NOUN	O	B-PHYSICAL
total	ADJ	O	O
body	NOUN	O	B-PHYSICAL
fat	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
N	NOUN	O	O
+	DET	O	O
CAST	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
3	NUM	O	O
%	SYM	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
N	NOUN	O	O
+	SYM	O	O
ST	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
an	DET	O	O
intervention	NOUN	O	O
effect	NOUN	O	O
for	ADP	O	O
fasting	ADV	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
with	ADP	O	O
the	DET	O	O
N	NOUN	O	O
group	NOUN	O	O
increasing	VERB	O	O
by	ADP	O	O
3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
the	DET	O	O
N	NOUN	O	O
+	DET	O	O
CAST	NOUN	O	O
group	NOUN	O	O
decreasing	NUM	O	O
by	ADP	O	O
4	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
CAST	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
nutrition	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
nutrition	NOUN	O	O
plus	CCONJ	O	O
strength	NOUN	O	O
training	VERB	O	O
for	ADP	O	O
reducing	VERB	O	O
multiple	ADJ	O	B-PHYSICAL
adiposity	NOUN	O	I-PHYSICAL
outcomes	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
fasting	VERB	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
in	ADP	O	O
overweight	ADP	O	O
Latina	PUNCT	O	O
girls	ADP	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
further	ADJ	O	O
research	NOUN	O	O
investigating	VERB	O	O
and	CCONJ	O	O
identifying	PUNCT	O	O
intervention	NOUN	O	O
approaches	NOUN	O	O
that	ADP	O	O
improve	VERB	O	O
both	PUNCT	O	O

Lack	NOUN	O	O
of	ADP	O	O
effect	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	O
on	ADP	O	O
the	DET	O	O
restenosis	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
on	ADP	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
after	ADP	O	O
balloon	NOUN	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
September	NOUN	O	O
1985	NUM	O	O
and	CCONJ	O	O
April	NOUN	O	O
1987	NUM	O	O
,	PUNCT	O	O
110	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
who	ADP	O	O
had	CCONJ	O	O
successful	ADJ	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
prospective	ADJ	O	O
controlled	VERB	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	O
on	ADP	O	O
restenosis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
warfarin	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
56	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
54	NUM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
previous	ADJ	O	O
coronary	ADJ	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
or	CCONJ	O	O
coronary	ADJ	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
,	PUNCT	O	O
severity	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
multivessel	NOUN	O	O
disease	NOUN	O	O
or	CCONJ	O	O
of	ADP	O	O
total	ADJ	O	O
coronary	ADJ	O	O
occlusions	NOUN	O	O
.	PUNCT	O	O

Warfarin	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
on	ADP	O	O
the	DET	O	O
day	NOUN	O	O
of	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
dosage	NOUN	O	O
was	VERB	O	O
adjusted	VERB	O	O
to	ADJ	O	O
maintain	ADV	O	O
the	DET	O	O
thromboplastin	NOUN	O	O
international	ADJ	O	O
normalised	VERB	O	O
ratio	NOUN	O	O
greater	PUNCT	O	O
than	VERB	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
2.5	NUM	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
five	NUM	O	O
(	PUNCT	O	O
96	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
verapamil	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
antianginal	ADJ	O	O
drugs	NOUN	O	O
were	VERB	O	O
prescribed	PROPN	O	O
as	PUNCT	O	O
needed	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
dextran	NOUN	O	O
and	CCONJ	O	O
heparin	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
during	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
and	CCONJ	O	O
heparin	NOUN	O	O
was	VERB	O	O
continued	VERB	O	O
for	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
eight	NUM	O	O
(	PUNCT	O	O
98	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
up	PUNCT	O	O
clinically	ADV	O	O
after	ADP	O	O
a	DET	O	O
median	ADJ	O	O
of	ADP	O	O
five	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
1-20	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eighty	PUNCT	O	O
five	NUM	O	O
(	PUNCT	O	O
77	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
follow	CCONJ	O	O
up	PUNCT	O	O
angiography	NOUN	O	O
at	ADP	O	O
five	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
warfarin	NOUN	O	O
group	NOUN	O	O
symptoms	NOUN	O	B-PHYSICAL
improved	VERB	O	B-OTHER
in	ADP	O	O
46	NUM	O	O
(	PUNCT	O	O
85	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
by	ADP	O	O
at	ADP	O	O
least	ADV	O	O
1	NUM	O	O
angina	NOUN	O	O
class	NOUN	O	O
and	CCONJ	O	O
31	NUM	O	O
(	PUNCT	O	O
57	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
symptom	NOUN	O	B-OTHER
free	ADJ	O	I-OTHER
;	PUNCT	O	O
the	DET	O	O
exercise	NOUN	O	O
test	NOUN	O	O
remained	ADP	O	O
positive	ADJ	O	O
in	ADP	O	O
20	NUM	O	O
(	PUNCT	O	O
36	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
angiographic	ADJ	O	B-PHYSICAL
restenosis	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
25	NUM	O	O
%	SYM	O	O
per	ADP	O	O
lesion	NOUN	O	O
and	CCONJ	O	O
29	NUM	O	O
%	SYM	O	O
per	ADP	O	O
patient	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
major	ADJ	O	B-ADVERSE-EFFECTS
bleeding	VERB	O	I-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
46	NUM	O	O
(	PUNCT	O	O
85	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
improved	VERB	O	O
by	ADP	O	O
at	ADP	O	O
least	ADV	O	O
1	NUM	O	O
angina	NOUN	O	O
class	NOUN	O	O
and	CCONJ	O	O
31	NUM	O	O
(	PUNCT	O	O
57	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
symptom	NOUN	O	O
free	ADJ	O	O
;	PUNCT	O	O
the	DET	O	O
exercise	NOUN	O	B-OTHER
test	NOUN	O	I-OTHER
was	VERB	O	O
positive	ADJ	O	O
in	ADP	O	O
11	NUM	O	O
(	PUNCT	O	O
21	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
angiographic	ADJ	O	B-PHYSICAL
restenosis	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
33	NUM	O	O
%	SYM	O	O
per	ADP	O	O
lesion	NOUN	O	O
and	CCONJ	O	O
37	NUM	O	O
%	SYM	O	O
per	ADP	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
angiographic	ADJ	O	O
restenosis	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
lower	PUNCT	O	O
with	ADP	O	O
warfarin	NOUN	O	O
,	PUNCT	O	O
none	NUM	O	O
of	ADP	O	O
these	DET	O	O
differences	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	O
and	CCONJ	O	O
warfarin	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
better	PUNCT	O	O
than	VERB	O	O
verapamil	NOUN	O	O
alone	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
symptom	NOUN	O	O
recurrence	NOUN	O	O
or	CCONJ	O	O
angiographic	ADJ	O	B-PHYSICAL
restenosis	NOUN	O	I-PHYSICAL
after	ADP	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
.	PUNCT	O	O

Rational-emotive	ADJ	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
interpersonal	PUNCT	O	B-MENTAL
anxiety	NOUN	O	I-MENTAL
in	ADP	O	O
junior	PUNCT	O	O
high	ADJ	O	O
school	NOUN	O	O
students	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
rational-emotive	ADJ	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
rational-emotive	ADJ	O	O
imagery	NOUN	O	O
.	PUNCT	O	O

Fifty-nine	DET	O	O
junior	PUNCT	O	O
high	ADJ	O	O
school	NOUN	O	O
students	NOUN	O	O
who	PROPN	O	O
volunteered	PUNCT	O	O
to	ADJ	O	O
participate	ADP	O	O
in	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
interpersonal	PUNCT	O	B-MENTAL
anxiety	NOUN	O	I-MENTAL
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
rational-emotive	ADJ	O	O
therapy	NOUN	O	O
without	ADP	O	O
imagery	ADJ	O	O
(	PUNCT	O	O
RET	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rational-emotive	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
imagery	NOUN	O	O
(	PUNCT	O	O
REI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
relationship-oriented	VERB	O	O
counseling	VERB	O	O
(	PUNCT	O	O
ROC	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
waiting-list	NOUN	O	O
control	NOUN	O	O
(	PUNCT	O	O
WLC	NOUN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Groups	NOUN	O	O
met	ADJ	O	O
for	ADP	O	O
seven	NUM	O	O
50-minute	NOUN	O	O
treatment	NOUN	O	O
sessions	NOUN	O	O
during	ADP	O	O
a	DET	O	O
three-week	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Assessments	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
at	ADP	O	O
pretreatment	NOUN	O	O
,	PUNCT	O	O
posttreatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
three-week	ADJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
self-report	ADJ	O	B-OTHER
and	CCONJ	O	I-OTHER
sociometric	ADJ	O	I-OTHER
measures	NOUN	O	I-OTHER
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
treatment	NOUN	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
postassessment	NOUN	O	O
,	PUNCT	O	O
both	PUNCT	O	O
the	DET	O	O
RET	NOUN	O	O
and	CCONJ	O	O
REI	ADJ	O	O
groups	NOUN	O	O
were	VERB	O	O
rated	VERB	O	O
on	ADP	O	O
sociometric	ADJ	O	B-MENTAL
measures	NOUN	O	I-MENTAL
as	ADP	O	O
significantly	VERB	O	O
less	ADV	O	O
interpersonally	NOUN	O	O
anxious	ADJ	O	B-OTHER
than	PUNCT	O	O
the	DET	O	O
WLC	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
scores	NOUN	O	O
favored	VERB	O	O
the	DET	O	O
RET	NOUN	O	O
and	CCONJ	O	O
REI	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
these	DET	O	O
groups	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
ROC	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
self-report	ADJ	O	B-OTHER
measure	ADV	O	I-OTHER
did	CCONJ	O	O
not	ADV	O	O
significantly	ADV	O	O
differentiate	PUNCT	O	O
between	ADP	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
REI	ADJ	O	O
group	NOUN	O	O
demonstrated	VERB	O	O
significant	ADJ	O	O
pre-	ADJ	O	O
to	ADP	O	O
follow-up	NOUN	O	O
changes	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
RET	NOUN	O	O
and	CCONJ	O	O
REI	ADJ	O	O
groups	NOUN	O	O
yielded	VERB	O	O
greater	PUNCT	O	O
reductions	NOUN	O	O
in	ADP	O	O
irrational	ADJ	O	B-MENTAL
thinking	PUNCT	O	I-MENTAL
than	PUNCT	O	O
did	PUNCT	O	O
the	DET	O	O
ROC	NOUN	O	O
and	CCONJ	O	O
WLC	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
the	DET	O	O
results	NOUN	O	O
supported	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
rational-emotive	ADJ	O	O
imagery	VERB	O	O
as	PUNCT	O	O
a	DET	O	O
component	NOUN	O	O
of	ADP	O	O
rational-emotive	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
practical	ADJ	O	O
implications	NOUN	O	O
of	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
clomiphene	NOUN	O	O
citrate-resistant	PUNCT	O	O
anovulation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
contraceptive	ADJ	O	O
pill	ADJ	O	O
suppression	NOUN	O	O
and	CCONJ	O	O
repeat	NOUN	O	O
clomiphene	NOUN	O	O
citrate	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
and	CCONJ	O	O
endocrine	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
of	ADP	O	O
oral	ADJ	O	O
contraceptive	ADJ	O	O
ovarian	ADJ	O	O
suppression	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
clomiphene	NOUN	O	O
citrate	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	PROPN	O	O
previously	ADP	O	O
were	VERB	O	O
clomiphene	NOUN	O	O
citrate	NOUN	O	O
resistant	ADJ	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Forty-eight	PUNCT	O	O
patients	NOUN	O	O
from	ADP	O	O
a	DET	O	O
private	ADJ	O	O
tertiary	ADJ	O	O
infertility	ADJ	O	O
clinic	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
prospectively	ADV	O	O
to	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
oral	ADJ	O	O
contraceptive/clomiphene	NOUN	O	O
citrate	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
received	VERB	O	O
continuous	ADJ	O	O
oral	ADJ	O	O
contraceptives	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
clomiphene	NOUN	O	O
citrate	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
to	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
no	DET	O	O
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cycle	NOUN	O	O
before	ADP	O	O
clomiphene	NOUN	O	O
citrate	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
17	NUM	O	O
beta-estradiol	NOUN	O	B-OTHER
,	PUNCT	O	O
follicle-stimulating	VERB	O	B-OTHER
hormone	NOUN	O	I-OTHER
,	PUNCT	O	O
luteinizing	ADP	O	B-OTHER
hormone	NOUN	O	I-OTHER
,	PUNCT	O	O
and	PUNCT	O	O

[	PUNCT	O	O
The	DET	O	O
application	NOUN	O	O
of	ADP	O	O
naphcon	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
during	ADP	O	O
Lasik	PUNCT	O	O
surgery	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
Naphcon	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
for	ADP	O	O
preventing	VERB	O	O
conjunctival	ADJ	O	O
bleeding	VERB	O	O
during	ADP	O	O
Lasik	PUNCT	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
cases	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
treating	VERB	O	O
group	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
randomly	ADV	O	O
according	PUNCT	O	O
to	PUNCT	O	O
using	ADP	O	O
and	CCONJ	O	O
not	ADV	O	O
using	PUNCT	O	O
Naphcon	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
before	ADP	O	O
Lasik	PUNCT	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Treating	ADJ	O	O
group	NOUN	O	O
patients	NOUN	O	O
received	VERB	O	O
three	NUM	O	O
times	NOUN	O	O
Naphcon	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
during	ADP	O	O
15	NUM	O	O
minutes	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
conjunctival	ADJ	O	B-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
from	ADP	O	O
treating	VERB	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
8	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
15	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
significant	ADJ	O	O
statistical	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
them	PRON	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Naphcon	NOUN	O	O
eye	NOUN	O	O
drop	VERB	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
agent	NOUN	O	O
to	PART	O	O
prevent	ADJ	O	O
conjunctival	ADJ	O	O
bleeding	VERB	O	O
.	PUNCT	O	O

Enhanced	VERB	O	O
inotropic	ADJ	O	O
state	NOUN	O	O
of	ADP	O	O
the	DET	O	O
failing	VERB	O	O
left	ADJ	O	O
ventricle	NOUN	O	O
by	ADP	O	O
cardiac	ADJ	O	O
contractility	NOUN	O	O
modulation	NOUN	O	O
electrical	ADJ	O	O
signals	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
myocardial	ADJ	O	B-PHYSICAL
oxygen	NOUN	O	I-PHYSICAL
consumption	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Previous	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
experimentally	ADV	O	O
induced	PUNCT	O	O
heart	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
HF	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
that	ADP	O	O
electrical	ADJ	O	O
signals	NOUN	O	O
applied	VERB	O	O
to	ADP	O	O
the	DET	O	O
failing	VERB	O	O
myocardium	NOUN	O	O
during	ADP	O	O
the	DET	O	O
absolute	ADJ	O	O
refractory	ADJ	O	O
period	NOUN	O	O
improved	VERB	O	O
left	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
LV	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
these	DET	O	O
same	ADJ	O	O
cardiac	ADJ	O	O
contractility	NOUN	O	O
modulating	SYM	O	O
(	PUNCT	O	O
CCM	NOUN	O	O
)	PUNCT	O	O
electrical	ADJ	O	O
signals	NOUN	O	O
on	ADP	O	O
myocardial	ADJ	O	B-PHYSICAL
oxygen	NOUN	O	I-PHYSICAL
consumption	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
MVO	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
2	NUM	O	B-PHYSICAL
)	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
dogs	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
HF	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
Six	NUM	O	O
dogs	NOUN	O	O
with	ADP	O	O
microembolizations-induced	VERB	O	O
HF	NOUN	O	O
and	CCONJ	O	O
9	NUM	O	O
HF	NOUN	O	O
patients	NOUN	O	O
underwent	VERB	O	O
CCM	NOUN	O	O
leads	NOUN	O	O
and	CCONJ	O	O
generator	NOUN	O	O
(	PUNCT	O	O
OPTIMIZER	NOUN	O	O
II	NUM	O	O
)	PUNCT	O	O
implantation	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
baseline	NOUN	O	O
measurements	NOUN	O	O
,	PUNCT	O	O
CCM	NOUN	O	O
signals	NOUN	O	O
were	VERB	O	O
delivered	VERB	O	O
continuously	ADV	O	O
for	ADP	O	O
2	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

MVO	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
2	NUM	O	B-PHYSICAL
)	PUNCT	O	O
was	VERB	O	O
measured	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
CCM	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
CCM	NOUN	O	O
therapy	NOUN	O	O
increased	VERB	O	O
LV	NOUN	O	B-PHYSICAL
ejection	NOUN	O	I-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
at	ADP	O	O
2	NUM	O	O
hours	NOUN	O	O
(	PUNCT	O	O
26	NUM	O	O
+/-	SYM	O	O
1	NUM	O	O
versus	CCONJ	O	O
31	NUM	O	O
+/-	SYM	O	O
2	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
without	ADP	O	O
increasing	VERB	O	O
MVO	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
2	NUM	O	B-PHYSICAL
)	PUNCT	O	O
(	PUNCT	O	O
257	NUM	O	O
+/-	SYM	O	O
41	NUM	O	O
versus	CCONJ	O	O
180	NUM	O	O
+/-	SYM	O	O
34	NUM	O	O
micromol/min	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
CCM	NOUN	O	O
therapy	NOUN	O	O
increased	VERB	O	O
LV	NOUN	O	B-PHYSICAL
peak	NOUN	O	O
+dP/dt	ADV	O	B-PHYSICAL
by	ADP	O	O
10.1	NUM	O	O
+/-	SYM	O	O
1.5	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

As	PUNCT	O	O
with	ADP	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
LV	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
after	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
of	ADP	O	O
CCM	NOUN	O	O
therapy	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
increased	NOUN	O	O
MVO	NOUN	O	B-PHYSICAL
(	PUNCT	O	O

Randomised	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
ganciclovir	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
cytomegalovirus	NOUN	O	O
disease	NOUN	O	O
in	ADP	O	O
liver-transplant	ADJ	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Oral	ADJ	O	O
Ganciclovir	NOUN	O	O
International	ADJ	O	O
Transplantation	NOUN	O	O
Study	NOUN	O	O
Group	NOUN	O	O
[	PUNCT	O	O
corrected	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Cytomegalovirus	NOUN	O	O
(	PUNCT	O	O
CMV	NOUN	O	O
)	PUNCT	O	O
disease	NOUN	O	O
is	VERB	O	O
a	DET	O	O
frequent	ADJ	O	O
cause	ADJ	O	O
of	ADP	O	O
serious	ADJ	O	O
morbidity	NOUN	O	O
after	ADP	O	O
solid-organ	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prophylactic	ADP	O	O
regimens	NOUN	O	O
used	VERB	O	O
to	PART	O	O
prevent	ADJ	O	O
CMV	NOUN	O	O
infection	NOUN	O	O
and	CCONJ	O	O
disease	NOUN	O	O
have	PUNCT	O	O
shown	VERB	O	O
limited	VERB	O	O
benefit	NOUN	O	O
in	ADP	O	O
seronegative	ADJ	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
ganciclovir	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
CMV	NOUN	O	O
disease	NOUN	O	O
following	VERB	O	O
orthotopic	ADJ	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Between	ADP	O	O
December	NOUN	O	O
,	PUNCT	O	O
1993	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
April	NOUN	O	O
,	PUNCT	O	O
1995	NUM	O	O
,	PUNCT	O	O
304	NUM	O	O
liver-transplant	ADJ	O	O
recipients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
oral	ADJ	O	O
ganciclovir	NOUN	O	O
1000	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
matching	VERB	O	O
placebo	NOUN	O	O
three	NUM	O	O
times	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
.	PUNCT	O	O

Seronegative	ADJ	O	O
recipients	NOUN	O	O
of	ADP	O	O
seronegative	ADJ	O	O
livers	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

Study	ADJ	O	O
drug	NOUN	O	O
was	VERB	O	O
administered	NUM	O	O
as	PUNCT	O	O
soon	VERB	O	O
as	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
able	ADJ	O	O
to	PART	O	O
take	ADJ	O	O
medication	NOUN	O	O
by	ADP	O	O
mouth	NOUN	O	O
(	PUNCT	O	O
no	ADP	O	O
later	PUNCT	O	O
than	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
)	PUNCT	O	O
until	ADP	O	O
the	DET	O	O
98th	ADJ	O	O
day	NOUN	O	O
after	ADP	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
specified	VERB	O	O
times	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
first	ADJ	O	O
6	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
for	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
CMV	NOUN	O	B-OTHER
infection	NOUN	O	I-OTHER
,	PUNCT	O	O
CMV	NOUN	O	B-OTHER
disease	NOUN	O	I-OTHER
,	PUNCT	O	O
rejection	NOUN	O	B-OTHER
,	PUNCT	O	O
opportunistic	ADJ	O	B-OTHER
infections	NOUN	O	I-OTHER
,	PUNCT	O	O
and	PUNCT	O	O

Alternative	ADJ	O	O
voice	NOUN	O	O
after	ADP	O	O
laryngectomy	NOUN	O	O
using	VERB	O	O
a	DET	O	O
sound-producing	PUNCT	O	O
voice	NOUN	O	O
prosthesis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
improve	ADJ	O	O
the	DET	O	O
voice	NOUN	O	O
quality	NOUN	O	O
of	ADP	O	O
female	NOUN	O	O
laryngectomees	NOUN	O	O
and/or	CCONJ	O	O
laryngectomees	NOUN	O	O
with	ADP	O	O
a	DET	O	O
hypotonic	ADJ	O	O
pharyngoesophageal	ADJ	O	O
(	PUNCT	O	O
PE	NOUN	O	O
)	PUNCT	O	O
segment	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pneumatic	ADJ	O	B-PHYSICAL
artificial	ADJ	O	I-PHYSICAL
source	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
voice	NOUN	O	I-PHYSICAL
incorporated	ADP	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
regular	ADJ	O	I-PHYSICAL
tracheoesophageal	DET	O	I-PHYSICAL
(	PUNCT	O	O
TE	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
shunt	NOUN	O	B-PHYSICAL
valve	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Experimental	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
new	ADJ	O	O
sound	ADJ	O	O
source	NOUN	O	O
consists	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
silicone	NUM	O	O
lip	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
performs	NOUN	O	O
an	DET	O	O
oscillatory	ADJ	O	O
movement	NOUN	O	O
driven	VERB	O	O
by	ADP	O	O
expired	PUNCT	O	O
pulmonary	ADJ	O	O
air	NOUN	O	O
flowing	NUM	O	O
along	ADP	O	O
the	DET	O	O
outward-striking	VERB	O	O
lip	NOUN	O	O
through	ADP	O	O
the	DET	O	O
TE	NOUN	O	O
shunt	NOUN	O	O
valve	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prototype	NOUN	O	O
of	ADP	O	O
this	DET	O	O
pneumatic	ADJ	O	O
sound	ADJ	O	O
source	NOUN	O	O
is	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
vitro	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
six	NUM	O	O
laryngectomees	NOUN	O	O
.	PUNCT	O	O

In	ADJ	O	O
vivo	ADJ	O	O
evaluation	NOUN	O	O
includes	ADP	O	O
speech	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
maximal	ADJ	O	O
phonation	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
perceptual	ADJ	O	O
voice	NOUN	O	O
evaluation	NOUN	O	O
of	ADP	O	O
read-aloud	NOUN	O	O
prose	ADP	O	O
by	ADP	O	O
an	DET	O	O
expert	NOUN	O	O
listener	PUNCT	O	O
,	PUNCT	O	O
speech	NOUN	O	O
intelligibility	NOUN	O	O
measurements	NOUN	O	O
with	ADP	O	O
12	NUM	O	O
listeners	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
self-assessment	VERB	O	O
by	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
extensive	ADJ	O	B-OTHER
acoustical	ADJ	O	I-OTHER
and	CCONJ	O	O
aerodynamic	ADJ	O	B-PHYSICAL
in	ADJ	O	B-PHYSICAL
vivo	ADJ	O	I-PHYSICAL
registrations	ADJ	O	I-PHYSICAL
are	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
a	DET	O	O
newly	ADV	O	B-OTHER
developed	VERB	O	I-OTHER
data	NOUN	O	O
acquisition	NOUN	O	B-OTHER
system	NOUN	O	I-OTHER
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
current	ADJ	O	O
prototype	NOUN	O	O
seems	NOUN	O	O
beneficial	ADJ	O	O
in	ADP	O	O
female	NOUN	O	O
laryngectomees	NOUN	O	O
with	ADP	O	O
a	DET	O	O
hypotonic	ADJ	O	O
PE	NOUN	O	O
segment	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

For	ADP	O	O
them	PUNCT	O	O
the	DET	O	O
sound-producing	PUNCT	O	O
voice	NOUN	O	O
prosthesis	NOUN	O	O
improves	NOUN	O	B-PHYSICAL
voice	NOUN	O	I-PHYSICAL
quality	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
increases	PUNCT	O	O
the	DET	O	B-PHYSICAL
average	ADJ	O	O
pitch	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
voice	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
without	ADP	O	B-PHYSICAL
decreasing	ADP	O	I-PHYSICAL
intelligibility	NOUN	O	O
or	CCONJ	O	B-PHYSICAL
necessitating	PUNCT	O	I-PHYSICAL
other	PUNCT	O	B-PHYSICAL

[	PUNCT	O	O
Supplementary	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
Esberitox	PUNCT	O	O
of	ADP	O	O
female	NOUN	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
curative	ADJ	O	O
adjuvant	NOUN	O	O
irradiation	NOUN	O	O
following	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

1	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
supposed	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
a	DET	O	O
possible	ADJ	O	O
prevention	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
reduction	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
toxicity	NOUN	O	I-PHYSICAL
of	ADP	O	O
radiotherapy	NOUN	O	O
by	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
Esberitox	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
question	NOUN	O	O
arose	VERB	O	O
when	ADP	O	O
performing	PUNCT	O	O
an	DET	O	O
investigation	NOUN	O	O
about	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
Esberitox	DET	O	O
in	ADP	O	O
a	DET	O	O
combined	VERB	O	O
chemo-radiotherapy	NOUN	O	O
.	PUNCT	O	O

Whereas	ADP	O	O
the	DET	O	O
latter	ADJ	O	O
induces	NOUN	O	O
above	ADP	O	O
all	PUNCT	O	O
a	DET	O	O
systemic	ADJ	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hemopoietic	ADJ	O	O
system	NOUN	O	O
,	PUNCT	O	O
radiotherapy	NOUN	O	O
is	VERB	O	O
a	DET	O	O
regional	ADJ	O	O
noxa	PUNCT	O	O
.	PUNCT	O	O

2	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
with	ADP	O	O
50	NUM	O	O
patients	NOUN	O	O
submitted	VERB	O	O
to	ADP	O	O
curative	ADJ	O	O
adjuvant	NOUN	O	O
irradiation	NOUN	O	O
following	VERB	O	O
surgery	NOUN	O	O
for	ADP	O	O
mammary	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
radiotherapy	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
way	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
irradiations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
thoracic	ADJ	O	O
wall	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
regional	ADJ	O	O
lymph	NOUN	O	O
nodes	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
built	PUNCT	O	O
by	ADP	O	O
randomization	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
an	DET	O	O
additional	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
Esberitox	DET	O	O
,	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
receive	VERB	O	O
an	DET	O	O
additional	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

3	NUM	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
protective	ADJ	O	O
influence	NOUN	O	O
of	ADP	O	O
Esberitox	ADV	O	O
could	VERB	O	O
be	VERB	O	O
demonstrated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
parameters	NOUN	O	O
investigated	VERB	O	O
were	VERB	O	O
the	DET	O	O
peripheral	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
leucocytes	PROPN	O	B-PHYSICAL
,	PUNCT	O	O
granulocytes	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
lymphocytes	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
monocytes	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
thrombocytes	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
hemoglobin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
hematocrit	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
incidence	PUNCT	O	O

[	PUNCT	O	O
Dexmedetomidine	NOUN	O	O
use	NOUN	O	O
for	ADP	O	O
postoperative	ADJ	O	B-PHYSICAL
adrenergic	ADJ	O	I-PHYSICAL
analgesia	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
sedation	NOUN	O	I-PHYSICAL
in	ADP	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Comparative	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
analgesia	NOUN	O	O
and	CCONJ	O	O
sedation	NOUN	O	O
with	ADP	O	O
trimeperidine	ADJ	O	O
and	CCONJ	O	O
dexmedetomidine	PUNCT	O	O
and	CCONJ	O	O
their	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
haemodynamics	NOUN	O	O
and	CCONJ	O	O
vegetative	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

Assessment	NOUN	O	O
of	ADP	O	O
analgesia	NOUN	O	O
and	CCONJ	O	O
sedation	NOUN	O	O
during	ADP	O	O
vagotonia	NOUN	O	O
(	PUNCT	O	O
first	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
hypokinetic	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
haemodynamics	NOUN	O	O
(	PUNCT	O	O
second	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
with	ADP	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
VAS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Richmond	NOUN	O	B-PHYSICAL
scale	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
dexmedetomidine	PUNCT	O	O
is	VERB	O	O
more	ADV	O	O
effective	ADJ	O	B-OTHER
and	CCONJ	O	O
safer	PUNCT	O	B-OTHER
than	PUNCT	O	O
trimeperidine	ADP	O	O
for	ADP	O	O
analgesia	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
sedation	NOUN	O	B-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
spontaneous	ADJ	O	O
breathing	VERB	O	O
after	ADP	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Dexmedetomidine	PUNCT	O	O
use	NOUN	O	O
allows	NOUN	O	O
keeping	VERB	O	O
optimal	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
haemodynamics	NOUN	O	O
and	CCONJ	O	O
vegetative	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
parameters	NOUN	O	O
on	ADP	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Daclizumab	NOUN	O	O
high-yield	NOUN	O	O
process	NOUN	O	O
in	ADP	O	O
relapsing-remitting	PUNCT	O	B-PHYSICAL
multiple	ADJ	O	I-PHYSICAL
sclerosis	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
SELECT	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Daclizumab	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
humanised	VERB	O	O
monoclonal	ADJ	O	O
antibody	NOUN	O	O
,	PUNCT	O	O
modulates	NOUN	O	O
interleukin-2	NOUN	O	O
signalling	VERB	O	O
by	ADP	O	O
blocking	VERB	O	O
the	DET	O	O
?	PUNCT	O	O

subunit	NOUN	O	O
(	PUNCT	O	O
CD25	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
interleukin-2	NOUN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
assessed	VERB	O	O
whether	ADP	O	O
daclizumab	NOUN	O	O
high-yield	NOUN	O	O
process	NOUN	O	O
(	PUNCT	O	O
HYP	NOUN	O	O
)	PUNCT	O	O
would	VERB	O	O
be	NOUN	O	O
effective	ADJ	O	O
when	ADP	O	O
given	VERB	O	O
as	ADP	O	O
monotherapy	NOUN	O	O
for	ADP	O	O
a	DET	O	O
1	NUM	O	O
year	NOUN	O	O
treatment	NOUN	O	O
period	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
relapsing-remitting	PUNCT	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	ADJ	O	O
did	CCONJ	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
at	ADP	O	O
76	NUM	O	O
centres	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Czech	NOUN	O	O
Republic	ADJ	O	O
,	PUNCT	O	O
Germany	PUNCT	O	O
,	PUNCT	O	O
Hungary	PUNCT	O	O
,	PUNCT	O	O
India	PUNCT	O	O
,	PUNCT	O	O
Poland	PUNCT	O	O
,	PUNCT	O	O
Russia	NOUN	O	O
,	PUNCT	O	O
Ukraine	NOUN	O	O
,	PUNCT	O	O
Turkey	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
UK	NOUN	O	O
between	ADP	O	O
Feb	NOUN	O	O
15	NUM	O	O
,	PUNCT	O	O
2008	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
May	NOUN	O	O
14	NUM	O	O
,	PUNCT	O	O
2010	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
aged	DET	O	O
18-55	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
relapsing-remitting	PUNCT	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
(	PUNCT	O	O
1:1:1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
via	ADP	O	O
a	DET	O	O
central	ADJ	O	O
interactive	ADJ	O	O
voice	NOUN	O	O
response	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
subcutaneous	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
150	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
300	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
every	DET	O	O
4	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
52	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
and	CCONJ	O	O
study	ADV	O	O
personnel	NOUN	O	O
were	VERB	O	O
masked	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
assignment	NOUN	O	O
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
site	NOUN	O	O
pharmacist	NOUN	O	O
who	ADP	O	O
prepared	VERB	O	O
the	DET	O	O
study	ADP	O	O
drug	NOUN	O	O
for	ADP	O	O
injection	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
interaction	NOUN	O	O
with	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
annualised	VERB	O	O
relapse	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
was	VERB	O	O
by	ADP	O	O
intention	NOUN	O	O
to	PART	O	O
treat	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
registered	PUNCT	O	O
with	ADP	O	O
ClinicalTrials.gov	PUNCT	O	O
,	PUNCT	O	O
number	NOUN	O	O
NCT00390221	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
204	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
208	NUM	O	O
to	ADP	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
150	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
209	NUM	O	O
to	ADP	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
300	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
whom	ADP	O	O
188	NUM	O	O
(	PUNCT	O	O
92	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
192	NUM	O	O
(	PUNCT	O	O
92	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
197	NUM	O	O
(	PUNCT	O	O
94	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
completed	VERB	O	O
follow-up	NOUN	O	O
to	ADP	O	O
week	NOUN	O	O
52	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
annualised	VERB	O	O
relapse	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
lower	PUNCT	O	O
for	ADP	O	O
patients	NOUN	O	O
given	VERB	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
150	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
0?21	ADJ	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0?16-0?29	ADV	O	O
;	PUNCT	O	O
54	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
33-68	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0?0001	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
300	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
0?23	ADP	O	O
,	PUNCT	O	O
0?17-0?31	ADV	O	O
,	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
28-65	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p=0?00015	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
for	ADP	O	O
those	ADJ	O	O
given	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
0?46	NUM	O	O
,	PUNCT	O	O
0?37-0?57	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

More	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
relapse	NOUN	O	O
free	ADJ	O	O
in	ADP	O	O
the	DET	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
150	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
81	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
300	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
than	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
64	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0?0001	DET	O	O
in	ADP	O	O
the	DET	O	O
150	NUM	O	O
mg	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
p=0?0003	NUM	O	O
in	ADP	O	O
the	DET	O	O
300	NUM	O	O
mg	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

12	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
15	NUM	O	O
(	PUNCT	O	O
7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
daclizumab	NOUN	O	O
150	NUM	O	O
mg	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
19	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
300	NUM	O	O
mg	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
excluding	ADJ	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
relapse	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
given	VERB	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
150	NUM	O	O
mg	NOUN	O	O
who	ADP	O	O
was	VERB	O	O
recovering	ADV	O	O
from	ADP	O	O
a	DET	O	O
serious	ADJ	O	O
rash	NOUN	O	O
died	VERB	O	O
because	PUNCT	O	O
of	ADP	O	O
local	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
a	DET	O	O
psoas	NOUN	O	O
abscess	NOUN	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
Subcutaneous	ADJ	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
administered	VERB	O	O
every	DET	O	O
4	NUM	O	O
weeks	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
clinically	ADV	O	O
important	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
disease	NOUN	O	O
activity	NOUN	O	O
during	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Our	DET	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
for	ADP	O	O
daclizumab	NOUN	O	O
HYP	NOUN	O	O
to	PROPN	O	O
offer	ADJ	O	O
an	DET	O	O
additional	ADJ	O	O
treatment	NOUN	O	O
option	NOUN	O	O
for	ADP	O	O
relapsing-remitting	ADV	O	O
disease	NOUN	O	O
.	PUNCT	O	O

FUNDING	PUNCT	O	O
Biogen	NOUN	O	O
Idec	ADJ	O	O
and	CCONJ	O	O
AbbVie	PUNCT	O	O
Biotherapeutics	PROPN	O	O
Inc	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
mizolastine	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
in	ADP	O	O
a	DET	O	O
placebo-controlled	ADV	O	O
comparison	NOUN	O	O
with	ADP	O	O
loratadine	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
idiopathic	ADJ	O	O
urticaria	NOUN	O	O
:	PUNCT	O	O
results	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
MILOR	NOUN	O	O
Study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Mizolastine	ADV	O	O
is	VERB	O	O
a	DET	O	O
novel	ADJ	O	O
histamine	NOUN	O	O
H1-antagonist	NOUN	O	O
registered	NOUN	O	O
in	ADP	O	O
Europe	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
allergic	ADJ	O	O
rhinitis	NOUN	O	O
and	CCONJ	O	O
urticaria	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
mizolastine	ADV	O	O
with	ADP	O	O
loratadine	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
idiopathic	ADJ	O	O
urticaria	NOUN	O	O
(	PUNCT	O	O
CIU	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
multicentre	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
group	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
in	ADP	O	O
which	ADP	O	O
247	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
CIU	NOUN	O	O
were	VERB	O	O
randomised	NUM	O	O
after	ADP	O	O
a	DET	O	O
1-week	NOUN	O	O
placebo	NOUN	O	O
run-in	NOUN	O	O
period	NOUN	O	O
to	ADP	O	O
10	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
mizolastine	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
88	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
daily	PUNCT	O	O
loratadine	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
79	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
80	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
4-week	NOUN	O	O
treatment	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Mizolastine	PUNCT	O	O
and	CCONJ	O	O
loratadine	NOUN	O	O
both	CCONJ	O	O
relieved	PUNCT	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
CIU	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

After	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
pruritus	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
visual	ADJ	O	I-PHYSICAL
analogue	NOUN	O	I-PHYSICAL
score	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
VAS	NOUN	O	O
)	PUNCT	O	B-PHYSICAL
assessed	VERB	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
patients	NOUN	O	B-PHYSICAL
)	PUNCT	O	I-PHYSICAL
decreased	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
mizolastine	ADP	O	O
and	CCONJ	O	O
loratadine	NOUN	O	O
groups	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
mizolastine	ADV	O	O
:	PUNCT	O	O
-36.7	PUNCT	O	O
mm	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
;	PUNCT	O	O
loratadine	NOUN	O	O
:	PUNCT	O	O
-29.8	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0071	ADV	O	O
;	PUNCT	O	O
placebo	NOUN	O	O
:	PUNCT	O	O
-16.3	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
this	DET	O	O
improvement	NOUN	O	O
with	ADP	O	O
both	CCONJ	O	O
active	ADJ	O	O
treatments	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
difference	NOUN	O	O
being	VERB	O	O
significant	ADJ	O	O
only	ADV	O	O
for	ADP	O	O
the	DET	O	O
mizolastine	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0090	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
active	ADJ	O	O
treatments	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
reduced	ADP	O	O
weekly	ADV	O	O
episodes	PUNCT	O	B-PHYSICAL
of	ADP	O	B-PHYSICAL
urticaria	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
significant	ADJ	O	O
after	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
mizolastine	ADV	O	O
:	PUNCT	O	O
7.9	NUM	O	O
episodes	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0061	NUM	O	O
;	PUNCT	O	O
loratadine	NOUN	O	O
:	PUNCT	O	O
8.3	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0221	NUM	O	O
;	PUNCT	O	O
placebo	NOUN	O	O
:	PUNCT	O	O
13.3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Angioedema	NOUN	O	B-PHYSICAL
was	VERB	O	O
improved	VERB	O	O
to	ADP	O	O
a	DET	O	O
clinically	ADV	O	O
significant	ADJ	O	O
extent	NOUN	O	O
with	ADP	O	O
mizolastine	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
loratadine	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
those	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
this	DET	O	O
symptom	NOUN	O	O
before	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	B-OTHER
tolerability	NOUN	O	I-OTHER
of	ADP	O	O
both	PUNCT	O	O
treatments	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
repolarisation	NOUN	O	I-PHYSICAL
with	ADP	O	O
either	PUNCT	O	O
mizolastine	ADP	O	O
or	CCONJ	O	O
loratadine	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Mizolastine	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
)	PUNCT	O	O
is	VERB	O	O
confirmed	VERB	O	O
as	PUNCT	O	O
an	PUNCT	O	O

An	DET	O	O
assessment	NOUN	O	O
of	ADP	O	O
beta-adrenoceptor	NOUN	O	O
blockade	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
by	ADP	O	O
prizidilol	NOUN	O	O
hydrochloride	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
Prizidilol	NOUN	O	O
hydrochloride	NOUN	O	O
(	PUNCT	O	O
SK	NOUN	O	O
&	CCONJ	O	O
F	NOUN	O	O
92657	NUM	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
new	ADJ	O	O
compound	NOUN	O	O
which	ADP	O	O
causes	ADP	O	O
both	PUNCT	O	O
arteriolar	ADJ	O	O
dilatation	NOUN	O	O
and	CCONJ	O	O
beta-adrenoceptor	NOUN	O	B-PHYSICAL
blockade	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
on	ADP	O	O
the	DET	O	O
responses	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
to	ADP	O	O
isoprenaline	PUNCT	O	O
infusion	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
studied	VERB	O	O
in	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
Isoprenaline	ADP	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
dose-response	NOUN	O	I-PHYSICAL
curves	NOUN	O	I-PHYSICAL
showed	VERB	O	O
parallel	ADJ	O	O
shifts	DET	O	O
to	ADP	O	O
the	DET	O	O
right	ADJ	O	O
after	ADP	O	O
oral	ADJ	O	O
prizidilol	NOUN	O	O
,	PUNCT	O	O
indicating	ADP	O	O
antagonism	NOUN	O	O
by	ADP	O	O
this	DET	O	O
compound	CCONJ	O	O
at	ADP	O	O
beta-adrenoceptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O

3	NUM	O	O
Isoprenaline	PUNCT	O	O
dose-response	NOUN	O	O
curves	NOUN	O	O
for	ADP	O	O
decreases	CCONJ	O	O
in	ADP	O	O
diastolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
also	ADV	O	O
showed	VERB	O	O
shifts	NOUN	O	O
to	ADP	O	O
the	DET	O	O
right	ADJ	O	O
after	ADP	O	O
oral	ADJ	O	O
prizidilol	NOUN	O	O
,	PUNCT	O	O
providing	CCONJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
beta-adrenoceptor	NOUN	O	O
antagonism	NOUN	O	O
by	ADP	O	O
this	PUNCT	O	O
drug	NOUN	O	O
in	ADP	O	O
peripheral	ADJ	O	O
resistance	NOUN	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

4	NUM	O	O
The	DET	O	O
peak	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
40	NUM	O	O
mg	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	O
was	VERB	O	O
greater	PUNCT	O	O
than	CCONJ	O	O
that	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
200	NUM	O	O
mg	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
prizidilol	NOUN	O	O
but	CCONJ	O	O
both	PUNCT	O	O
drugs	NOUN	O	O
caused	VERB	O	O
persistent	ADJ	O	O
beta-adrenoceptor	NOUN	O	B-PHYSICAL
blockade	NOUN	O	I-PHYSICAL
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
7	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
ingestion	NOUN	O	O
.	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
postural	ADJ	O	B-OTHER
stability	NOUN	O	I-OTHER
by	ADP	O	O
computerised	VERB	O	O
posturography	NOUN	O	O
following	VERB	O	O
outpatient	ADJ	O	O
paediatric	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
propofol/alfentanil/N2O	NOUN	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
thiopentone/halothane/N2O	PUNCT	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Simple	ADJ	O	O
clinical	ADJ	O	O
tests	NOUN	O	O
,	PUNCT	O	O
like	ADP	O	O
Romberg	NOUN	O	O
's	PUNCT	O	O
test	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
walking	VERB	O	O
test	ADP	O	O
,	PUNCT	O	O
have	CCONJ	O	O
proved	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
inadequate	ADJ	O	O
guidelines	NOUN	O	O
for	ADP	O	O
safe	ADJ	O	B-OTHER
discharge	NOUN	O	I-OTHER
after	ADP	O	O
outpatient	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomised	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
therefore	ADV	O	O
planned	ADP	O	O
to	PART	O	O
compare	NOUN	O	O
postural	ADJ	O	O
stability	NOUN	O	O
measured	VERB	O	O
by	ADP	O	O
computerised	VERB	O	O
posturography	NOUN	O	O
in	ADP	O	O
31	NUM	O	O
oral	ADJ	O	O
midazolam-atropine	ADJ	O	O
premedicated	PRON	O	O
children	NOUN	O	O
aged	PROPN	O	O
6.9	NUM	O	O
(	PUNCT	O	O
s.e	PUNCT	O	O
.	PUNCT	O	O

0.4	NUM	O	O
)	PUNCT	O	O
years	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
been	ADP	O	O
anaesthetised	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
propofol/alfentanil/N2O	NOUN	O	O
or	CCONJ	O	O
thiopentone/halothane/N2O	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
sway	NOUN	O	B-MENTAL
velocity	NOUN	O	I-MENTAL
of	ADP	O	O
the	DET	O	O
children	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
before	ADP	O	O
premedication	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
sway	NOUN	O	B-MENTAL
velocity	NOUN	O	I-MENTAL
had	PUNCT	O	O
returned	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
values	NOUN	O	O
3	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
in	ADP	O	O
all	DET	O	O
children	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
received	CCONJ	O	O
propofol/alfentanil/N2O	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
12	NUM	O	O
of	ADP	O	O
the	DET	O	O
15	NUM	O	O
children	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
received	PUNCT	O	O
thiopentone/halothane/N2O	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
quantified	VERB	O	O
version	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Romberg	ADV	O	B-OTHER
test	NOUN	O	I-OTHER
performed	VERB	O	O
with	ADP	O	O
eyes	NOUN	O	O
open	PUNCT	O	O
or	CCONJ	O	O
closed	PUNCT	O	O
was	PROPN	O	O
not	ADV	O	O
impaired	VERB	O	O
after	ADP	O	O
anaesthesia	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
in	ADP	O	O
children	ADJ	O	O
poor	ADJ	O	O
equilibrium	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
compensated	ADV	O	O
by	ADP	O	O
vision	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
recovery	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
times	NOUN	O	O
to	ADP	O	O
eye	NOUN	O	B-PHYSICAL
opening	ADJ	O	I-PHYSICAL
,	PUNCT	O	O
to	PUNCT	O	O
responding	PUNCT	O	O
to	ADP	O	O
command	NOUN	O	O
or	CCONJ	O	O
to	PUNCT	O	O
being	ADV	O	O
fully	ADV	O	O
awake	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
anaesthesia	NOUN	O	O
methods	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
recovery	NOUN	O	O
assessed	VERB	O	O
by	ADP	O	O
postural	ADJ	O	O
stability	NOUN	O	O
,	PUNCT	O	O
propofol/alfentanil/N2O	NOUN	O	O
anaesthesia	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
preferable	ADJ	O	O
to	ADP	O	O
thiopentone/halothane/N2O	PUNCT	O	O
anaesthesia	NOUN	O	O
after	ADP	O	O
minor	ADJ	O	O
paediatric	ADJ	O	O
otolaryngological	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Insular	ADJ	O	O
and	CCONJ	O	O
anterior	ADJ	O	O
cingulate	ADJ	O	O
circuits	PUNCT	O	O
in	ADP	O	O
smokers	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
.	PUNCT	O	O

Schizophrenia	NOUN	O	O
(	PUNCT	O	O
SZ	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
rates	NOUN	O	O
of	ADP	O	O
smoking	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
previously	ADV	O	O
found	PUNCT	O	O
that	ADP	O	O
resting	ADJ	O	O
state	NOUN	O	O
functional	ADJ	O	O
connectivity	NOUN	O	O
(	PUNCT	O	O
rsFC	NOUN	O	O
)	PUNCT	O	O
between	ADP	O	O
the	DET	O	O
dorsal	ADJ	O	O
anterior	ADJ	O	O
cingulate	NOUN	O	O
(	PUNCT	O	O
dACC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
striatum	NOUN	O	O
is	VERB	O	O
independently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
nicotine	NOUN	O	O
addiction	NOUN	O	O
and	CCONJ	O	O
psychiatric	ADJ	O	O
illness	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
the	DET	O	O
insula	NOUN	O	O
is	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
nicotine	NOUN	O	O
dependence	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
SZ	NOUN	O	O
smokers	NOUN	O	O
will	VERB	O	O
have	CCONJ	O	O
greater	PUNCT	O	O
dysfunction	NOUN	O	O
in	ADP	O	O
smoking-related	VERB	O	O
insular	ADJ	O	O
and	CCONJ	O	O
dACC	NOUN	O	O
circuits	PUNCT	O	O
than	PUNCT	O	O
normal	ADJ	O	O
control	NOUN	O	O
smokers	NOUN	O	O
(	PUNCT	O	O
NC	NOUN	O	O
)	PUNCT	O	O
independent	ADJ	O	O
of	ADP	O	O
smoking	NUM	O	O
severity	NOUN	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
an	DET	O	O
inherent	ADJ	O	O
disease-related	VERB	O	O
weakening	ADJ	O	O
of	ADP	O	O
smoking-related	ADJ	O	O
circuits	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	O
challenge	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
demonstrate	NOUN	O	O
that	ADP	O	O
decreased	VERB	O	O
rsFC	NOUN	O	O
in	ADP	O	O
identified	ADV	O	O
circuits	PUNCT	O	O
reflects	ADP	O	O
addiction	NOUN	O	O
trait	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
pharmacological	ADJ	O	O
state	NOUN	O	O
.	PUNCT	O	O

Twenty-four	PUNCT	O	O
NC	NOUN	O	O
smokers	NOUN	O	O
and	CCONJ	O	O
20	NUM	O	O
smokers	ADJ	O	O
with	ADP	O	O
SZ	NOUN	O	O
matched	PROPN	O	O
on	ADP	O	O
nicotine	NOUN	O	O
addiction	NOUN	O	O
severity	NOUN	O	O
participated	DET	O	O
in	ADP	O	O
a	DET	O	O
resting	VERB	O	O
state	NOUN	O	O
fMRI	NOUN	O	O
study	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
scanned	VERB	O	O
during	ADP	O	O
two	NUM	O	O
separate	ADJ	O	O
sessions	NOUN	O	O
while	ADP	O	O
receiving	VERB	O	O
a	DET	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
nicotine	NOUN	O	O
patch	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

Using	PROPN	O	O
individualized	PRON	O	O
,	PUNCT	O	O
anatomically	ADV	O	O
defined	ADP	O	O
anterior	ADJ	O	O
and	CCONJ	O	O
posterior	ADJ	O	O
insula	NOUN	O	O
and	CCONJ	O	O
dACC	NOUN	O	O
as	ADP	O	O
regions	VERB	O	O
of	ADP	O	O
interest	NOUN	O	O
(	PUNCT	O	O
ROI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whole	ADJ	O	O
brain	NOUN	O	O
rsFC	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
using	SYM	O	O
each	DET	O	O
ROI	NOUN	O	O
as	ADP	O	O
a	DET	O	O
seed	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
negative	ADJ	O	O
correlations	NOUN	O	O
between	ADP	O	O
smoking	ADJ	O	B-MENTAL
severity	NOUN	O	I-MENTAL
and	CCONJ	O	O
rsFC	NOUN	O	B-PHYSICAL
between	ADP	O	I-PHYSICAL
insula	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
dACC	NOUN	O	O
and	CCONJ	O	O
striatum	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
smokers	ADJ	O	O
with	ADP	O	O
SZ	NOUN	O	O
demonstrated	VERB	O	O
additive	ADJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
circuit	NOUN	O	O
strength	NOUN	O	O
between	ADP	O	O
the	DET	O	O
dACC	NOUN	O	O
and	CCONJ	O	O
insula	ADJ	O	O
compared	VERB	O	O
to	ADP	O	O
NC	NOUN	O	O
smokers	ADJ	O	O
independent	ADJ	O	O
of	ADP	O	O
smoking	VERB	O	O
severity	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	B-OTHER
challenge	NOUN	O	I-OTHER
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
alter	VERB	O	B-PHYSICAL
rsFC	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
insula-dACC-striatal	ADJ	O	I-PHYSICAL
circuits	ADV	O	I-PHYSICAL
.	PUNCT	O	O

Reduced	VERB	O	O
rsFC	NOUN	O	B-PHYSICAL
strength	NOUN	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
insula	NOUN	O	O
,	PUNCT	O	O
dACC	NOUN	O	O
and	CCONJ	O	O
striatum	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
nicotine	NOUN	O	O
addiction	NOUN	O	O
severity	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
non-psychiatrically	NOUN	O	O
ill	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
SZ	NOUN	O	O
smokers	NOUN	O	O
.	PUNCT	O	O

Decreased	VERB	O	O
insula-dACC	NOUN	O	O
rsFC	NOUN	O	O
may	PUNCT	O	O
index	NOUN	O	O
overlapping	VERB	O	O
circuitry	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
smoking	PUNCT	O	O
and	CCONJ	O	O
SZ	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetics	NOUN	O	O
and	CCONJ	O	O
pharmacodynamics	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
epoetin	NOUN	O	O
alfa	NOUN	O	O
dosing	ADP	O	O
regimens	NOUN	O	O
in	ADP	O	O
anemic	PUNCT	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
without	ADP	O	O
acute	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	ADJ	O	O
describe	PROPN	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	O
profiles	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
different	ADJ	O	O
dosing	ADP	O	O
regimens	NOUN	O	O
for	ADP	O	O
epoetin	NOUN	O	O
alfa	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
whether	ADP	O	O
more	DET	O	O
rapid	ADJ	O	O
and	CCONJ	O	O
robust	ADJ	O	O
reticulocytosis	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
elicited	VERB	O	O
with	ADP	O	O
more	ADV	O	O
frequent	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
epoetin	NOUN	O	O
alfa	NOUN	O	O
in	ADP	O	O
anemic	PUNCT	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
open-label	NOUN	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
28-day	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
Ten	NUM	O	O
centers	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	ADV	O	O
States	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
Adult	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
>	SYM	O	O
or=18	NOUN	O	O
years	NOUN	O	O
)	PUNCT	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
hemoglobin	NOUN	O	O
<	SYM	O	O
or=12	NOUN	O	O
g/dL	ADV	O	O
,	PUNCT	O	O
expected	PUNCT	O	O
hospitalization	NOUN	O	O
of	ADP	O	O
>	SYM	O	O
or=7	CCONJ	O	O
days	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
ongoing	VERB	O	O
acute	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
One	PUNCT	O	O
of	ADP	O	O
six	NUM	O	O
dosing	VERB	O	O
epoetin	NOUN	O	O
alfa	NOUN	O	O
regimens	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
follows	VERB	O	O
:	PUNCT	O	O
40,000	NUM	O	O
IU	NOUN	O	O
once	PUNCT	O	O
weekly	ADV	O	O
,	PUNCT	O	O
subcutaneously	ADV	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
intravenously	DET	O	O
(	PUNCT	O	O
IV	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
15,000	NUM	O	O
IU	NOUN	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
,	PUNCT	O	O
subcutaneously	ADV	O	O
(	PUNCT	O	O
group	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
IV	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
D	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
or	CCONJ	O	O
40,000	NUM	O	O
IU	NOUN	O	O
day	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
,	PUNCT	O	O
subcutaneously	ADV	O	O
(	PUNCT	O	O
group	NOUN	O	O
E	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
IV	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
F	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
15,000	NUM	O	O
IU	NOUN	O	O
once	PUNCT	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
on	ADP	O	O
[	PUNCT	O	O
corrected	PUNCT	O	O
]	PUNCT	O	O
days	NOUN	O	O
5-15	NUM	O	O
[	PUNCT	O	O
corrected	NOUN	O	O
]	PUNCT	O	O
MEASUREMENTS	NOUN	O	O
Serum	NOUN	O	B-PHYSICAL
erythropoietin	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
absolute	ADJ	O	B-PHYSICAL
reticulocyte	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

MAIN	ADJ	O	O
RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
60	ADV	O	O
patients	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
enrolled	VERB	O	O
(	PUNCT	O	O
60	NUM	O	O
%	ADV	O	O
men	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
53	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
Acute	ADJ	O	O
Physiology	NOUN	O	O
and	CCONJ	O	O
Chronic	ADJ	O	O
Health	NOUN	O	O
Evaluation	NOUN	O	O
II	NUM	O	O
score	NOUN	O	O
,	PUNCT	O	O
19.5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
30	NUM	O	O
were	VERB	O	O
evaluable	ADJ	O	O
for	ADP	O	O
both	CCONJ	O	O
pharmacokinetics	NOUN	O	O
and	CCONJ	O	O
pharmacodynamics	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Erythropoietin	NOUN	O	B-PHYSICAL
exposure	NOUN	O	I-PHYSICAL
was	ADP	O	O
approximately	ADV	O	O
ten	NUM	O	O
times	NOUN	O	O
greater	PUNCT	O	O
for	ADP	O	O
IV	NUM	O	O
dosing	VERB	O	O
than	PUNCT	O	O
for	ADP	O	O
subcutaneous	ADJ	O	O
dosing	VERB	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
absolute	ADJ	O	B-PHYSICAL
reticulocyte	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
peaked	VERB	O	O
at	ADP	O	O
day	NOUN	O	O
11	NUM	O	O
or	CCONJ	O	O
15	NUM	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
and	CCONJ	O	O
appeared	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
greater	PUNCT	O	O
for	ADP	O	O
subcutaneous	ADJ	O	O
dosing	VERB	O	O
(	PUNCT	O	O
mean	NOUN	O	O
peak	ADJ	O	O
response	NOUN	O	O
149-169	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
/L	PUNCT	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
IV	NUM	O	O
dosing	VERB	O	O
(	PUNCT	O	O
mean	NOUN	O	O
peak	ADJ	O	O
response	NOUN	O	O
138-147	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
/L	PUNCT	O	O
)	PUNCT	O	O
at	ADP	O	O
most	DET	O	O
visits	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
frequently	ADV	O	O
reported	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
pyrexia	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
18	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hypokalemia	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
15	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hypophosphatemia	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
15	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
of	ADP	O	O
anemic	PUNCT	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
epoetin	NOUN	O	O
alfa	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
dosing	ADP	O	O
regimens	ADV	O	O
were	VERB	O	O
well	VERB	O	O
tolerated	PUNCT	O	B-OTHER
and	CCONJ	O	O
appeared	VERB	O	O
to	ADV	O	O
effect	ADP	O	O
reticulocytosis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
peak	ADJ	O	O
at	ADP	O	O
day	NOUN	O	O
11	NUM	O	O
or	CCONJ	O	O
15	NUM	O	O
in	ADP	O	O
most	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pharmacokinetics	NOUN	O	O
of	ADP	O	O
epoetin	NOUN	O	O
alfa	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
predict	VERB	O	O
pharmacodynamic	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
in	ADP	O	O
anemic	PUNCT	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
methotrexate	ADJ	O	O
and	CCONJ	O	O
hydroxychloroquine	NOUN	O	O
for	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
increases	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
methotrexate	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
examine	NOUN	O	O
the	DET	O	O
bioavailability	NOUN	O	O
of	ADP	O	O
methotrexate	NOUN	O	O
(	PUNCT	O	O
MTX	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
hydroxychloroquine	NOUN	O	O
(	PUNCT	O	O
HCQ	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
vice	PUNCT	O	O
versa	ADV	O	O
,	PUNCT	O	O
to	PART	O	O
determine	NOUN	O	O
a	DET	O	O
possible	ADJ	O	O
pharmacokinetic	ADJ	O	O
explanation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
that	VERB	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
with	ADP	O	O
MTX	NOUN	O	O
and	CCONJ	O	O
HCQ	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
,	PUNCT	O	O
clinically	ADV	O	O
,	PUNCT	O	O
to	PART	O	O
be	PUNCT	O	O
more	ADV	O	O
potent	ADJ	O	O
than	PUNCT	O	O
MTX	NOUN	O	O
used	VERB	O	O
alone	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
crossover	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
received	VERB	O	O
,	PUNCT	O	O
on	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
5	NUM	O	O
dosing	PUNCT	O	O
occasions	NOUN	O	O
,	PUNCT	O	O
MTX	NOUN	O	O
alone	ADJ	O	O
as	ADP	O	O
tablets	VERB	O	O
or	CCONJ	O	O
intravenous	ADJ	O	O
solution	NOUN	O	O
,	PUNCT	O	O
HCQ	NOUN	O	O
alone	ADJ	O	O
as	ADP	O	O
a	DET	O	O
tablet	NOUN	O	O
or	CCONJ	O	O
oral	ADJ	O	O
solution	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
coadministered	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
MTX	NOUN	O	O
tablets	NOUN	O	O
with	ADP	O	O
an	DET	O	O
HCQ	NOUN	O	O
tablet	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
concentration-time	NOUN	O	B-OTHER
curve	NOUN	O	O
(	PUNCT	O	B-OTHER
AUC	NOUN	O	I-OTHER
)	PUNCT	O	B-OTHER
was	VERB	O	O
determined	VERB	O	O
for	ADP	O	O
each	DET	O	O
subject	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
each	DET	O	O
dosing	ADJ	O	O
occasion	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
each	DET	O	O
compound	CCONJ	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
mean	NOUN	O	O
AUC	NOUN	O	B-OTHER
for	ADP	O	I-OTHER
MTX	NOUN	O	I-OTHER
was	VERB	O	O
increased	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
maximum	NOUN	O	B-OTHER
MTX	NOUN	O	I-OTHER
concentration	NOUN	O	O
(	PUNCT	O	B-OTHER
Cmax	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
decreased	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.025	NUM	O	O
)	PUNCT	O	O
when	ADP	O	O
MTX	NOUN	O	O
was	VERB	O	O
coadministered	VERB	O	O
with	ADP	O	O
HCQ	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
MTX	NOUN	O	O
administered	VERB	O	O
alone	ADJ	O	O
.	PUNCT	O	O

The	PUNCT	O	O

Comparing	VERB	O	O
microvascular	ADJ	O	B-PHYSICAL
alterations	NOUN	O	I-PHYSICAL
during	ADP	O	O
minimal	ADJ	O	O
extracorporeal	ADJ	O	O
circulation	NOUN	O	O
and	CCONJ	O	O
conventional	ADJ	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
in	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
graft	NOUN	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Minimal	ADJ	O	O
extracorporeal	ADJ	O	O
circulation	NOUN	O	O
(	PUNCT	O	O
MECC	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
introduced	VERB	O	O
in	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
graft	NOUN	O	O
(	PUNCT	O	O
CABG	NOUN	O	O
)	PUNCT	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
offering	PUNCT	O	O
clinical	ADJ	O	O
benefits	NOUN	O	O
owing	PUNCT	O	O
to	ADP	O	O
reduced	PUNCT	O	O
hemodilution	NOUN	O	O
and	CCONJ	O	O
no	DET	O	O
blood-air	ADJ	O	O
interface	NOUN	O	O
.	PUNCT	O	O

Yet	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
MECC	NOUN	O	O
on	ADP	O	O
the	DET	O	O
intraoperative	ADJ	O	O
microvascular	ADJ	O	O
perfusion	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
conventional	ADJ	O	O
extracorporeal	ADJ	O	O
circulation	NOUN	O	O
(	PUNCT	O	O
CECC	NOUN	O	O
)	PUNCT	O	O
have	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
studied	VERB	O	O
so	PUNCT	O	O
far	ADP	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
analyze	NOUN	O	O
alterations	NOUN	O	O
in	ADP	O	O
microvascular	ADJ	O	B-PHYSICAL
perfusion	NOUN	O	I-PHYSICAL
at	ADP	O	O
4	NUM	O	O
predefined	DET	O	O
time	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
T1-T4	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
on-pump	NOUN	O	O
CABG	NOUN	O	O
using	SYM	O	O
orthogonal	ADJ	O	O
polarization	NOUN	O	O
spectral	ADJ	O	O
imaging	PROPN	O	O
.	PUNCT	O	O

Forty	CCONJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
for	ADP	O	O
being	VERB	O	O
operated	VERB	O	O
on	ADP	O	O
with	ADP	O	O
either	CCONJ	O	O
MECC	NOUN	O	O
or	CCONJ	O	O
CECC	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
functional	ADJ	O	B-PHYSICAL
capillary	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
FCD	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
flow	NOUN	O	I-PHYSICAL
velocity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
vessel	NOUN	O	B-PHYSICAL
diameter	NOUN	O	I-PHYSICAL
were	VERB	O	O
analyzed	VERB	O	O
by	ADP	O	O
a	DET	O	O
blinded	VERB	O	O
investigator	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	PUNCT	O	O
start	NOUN	O	O
of	ADP	O	O
extracorporeal	ADJ	O	O
circulation	NOUN	O	O
(	PUNCT	O	O
ECC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
aortic	ADJ	O	O
crossclamping	PUNCT	O	O
(	PUNCT	O	O
T2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
both	CCONJ	O	O
groups	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
drop	NOUN	O	O
of	ADP	O	O
FCD	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
FCD	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
MECC	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
206.8	ADP	O	O
?	PUNCT	O	O

33.6	NUM	O	O
cm/cm?	NOUN	O	O
in	ADP	O	O
CECC	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
217.8	NUM	O	O
?	PUNCT	O	O

35.3	NUM	O	O
cm/cm?	NOUN	O	O
in	ADP	O	O
MECC	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.034	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
late	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ECC	NOUN	O	O
(	PUNCT	O	O
T3	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
FCD	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MECC	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
already	ADV	O	O
recovered	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
FCD	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CECC	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
still	ADV	O	O
significantly	ADV	O	O
depressed	VERB	O	O
(	PUNCT	O	O
223.1	ADP	O	O
?	PUNCT	O	O

35.6	NUM	O	O
cm/cm?	NOUN	O	O
in	ADP	O	O
MECC	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.100	NUM	O	O
vs	CCONJ	O	O
T1	NOUN	O	O
;	PUNCT	O	O
211.1	NUM	O	O
?	PUNCT	O	O

36.9	NUM	O	O
cm/cm?	NOUN	O	O
in	ADP	O	O
CECC	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.017	NUM	O	O
vs	CCONJ	O	O
T1	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
termination	NOUN	O	O
of	ADP	O	O
ECC	NOUN	O	O
(	PUNCT	O	O
T4	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
FCD	NOUN	O	O
recovered	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
to	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
flow	NOUN	O	O
velocity	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
MECC	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
intergroup	NOUN	O	O
difference	NOUN	O	O
after	ADP	O	O
aortic	ADJ	O	O
crossclamping	PUNCT	O	O
(	PUNCT	O	O
T2	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Orthogonal	ADJ	O	O
polarization	NOUN	O	O
spectral	ADJ	O	O
imaging	DET	O	O
data	NOUN	O	O
reveal	VERB	O	O
an	DET	O	O
impairment	NOUN	O	O
of	ADP	O	O
microvascular	ADJ	O	O
perfusion	NOUN	O	O
during	ADP	O	O
on-pump	NOUN	O	O
CABG	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
FCD	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
faster	PUNCT	O	O
recovery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
microvascular	ADJ	O	O
perfusion	NOUN	O	O
in	ADP	O	O
MECC	NOUN	O	O
during	ADP	O	O
the	DET	O	O
reperfusion	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Beneficial	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
microvascular	ADJ	O	O
organ	NOUN	O	O
perfusion	NOUN	O	O
could	PUNCT	O	O
partly	ADV	O	O
explain	VERB	O	O
the	DET	O	O
perioperative	ADJ	O	O
advantages	NOUN	O	O
reported	VERB	O	O
for	ADP	O	O
MECC	NOUN	O	O
.	PUNCT	O	O

Chlorthalidone	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
increase	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
nifedipine	NOUN	O	O
in	ADP	O	O
essential	ADJ	O	O
hypertensives	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
crossover	NOUN	O	O
multicentre	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
nifedipine	NOUN	O	O
+	DET	O	O
chlorthalidone	NOUN	O	O
exerts	NOUN	O	O
an	DET	O	O
additive	ADJ	O	B-PHYSICAL
antihypertensive	ADJ	O	I-PHYSICAL
effect	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
single-drug	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
66	NUM	O	O
uncomplicated	VERB	O	O
essential	ADJ	O	O
hypertensives	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
of	ADP	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
100	NUM	O	O
and	CCONJ	O	O
less	ADV	O	O
than	CCONJ	O	O
115	NUM	O	O
mmHg	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
a	DET	O	O
1-month	NOUN	O	O
washout	PUNCT	O	O
placebo	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
crossover	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
nifedipine	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
chlorthalidone	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
a	DET	O	O
day	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
combined	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
doses	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
corresponding	VERB	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
randomly	ADV	O	O
allocated	VERB	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
three	NUM	O	O
active	ADJ	O	O
treatments	NOUN	O	O
significantly	ADV	O	O
reduced	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
without	ADP	O	O
changing	VERB	O	O
the	DET	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
body	NOUN	O	B-PHYSICAL
weight	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
absolute	ADJ	O	O
and	CCONJ	O	O
percentage	NOUN	O	O
decreases	VERB	O	O
in	ADP	O	O
mean	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
induced	VERB	O	O
by	ADP	O	O
nifedipine	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
and	CCONJ	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
those	ADP	O	O
induced	VERB	O	O
by	ADP	O	O
chlorthalidone	NOUN	O	O
.	PUNCT	O	O

Taken	VERB	O	O
together	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
nifedipine	NOUN	O	O
+	SYM	O	O
chlorthalidone	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
exert	VERB	O	O
any	DET	O	O
additive	ADJ	O	B-PHYSICAL
antihypertensive	ADJ	O	I-PHYSICAL
effect	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
nifedipine	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

This	PUNCT	O	O
finding	VERB	O	O
indicates	NOUN	O	O
that	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
a	DET	O	O
dihydropyridine	NOUN	O	O
calcium	NOUN	O	O
antagonist	NOUN	O	O
+	DET	O	O
a	DET	O	O
thiazide	NOUN	O	O
diuretic	NOUN	O	O
is	VERB	O	O
probably	ADV	O	O
devoid	PUNCT	O	O
of	ADP	O	O
any	DET	O	O
particular	ADJ	O	O
clinical	ADJ	O	B-PHYSICAL
significance	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
uncomplicated	VERB	O	O
essential	ADJ	O	O
hypertensives	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
study	NOUN	O	O
between	ADP	O	O
ticlopidine	NOUN	O	O
and	CCONJ	O	O
cyclosporin	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Previous	ADJ	O	O
uncontrolled	VERB	O	O
studies	NOUN	O	O
have	ADP	O	O
suggested	VERB	O	O
an	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
ticlopidine	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
major	ADJ	O	O
antiplatelet	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cyclosporin	NOUN	O	O
in	ADP	O	O
heart-	NOUN	O	O
and	CCONJ	O	O
kidney-transplant	ADJ	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aims	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
fashion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
possible	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
cyclosporin	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
ticlopidine	NOUN	O	O
(	PUNCT	O	O
250	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
tolerability	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
combination	NOUN	O	O
in	ADP	O	O
heart-transplant	ADJ	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Twenty	NUM	O	O
heart-transplant	ADJ	O	O
recipients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
into	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
treated	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
drawn	VERB	O	O
for	ADP	O	O
time-course	PUNCT	O	O
evaluation	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	O
blood	NOUN	O	O
levels	NOUN	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
following	VERB	O	O
the	DET	O	O
morning	NOUN	O	O
intake	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
for	ADP	O	O
platelet	NOUN	O	O
aggregation	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Twenty	VERB	O	O
four-hour	NOUN	O	O
urine	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
6-beta-hydroxycortisol	NOUN	O	O
measurements	NOUN	O	O
,	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Although	ADP	O	O
given	VERB	O	O
at	ADP	O	O
half	ADP	O	O
the	DET	O	O
recommended	VERB	O	O
daily	ADJ	O	O
dosage	NOUN	O	O
,	PUNCT	O	O
ticlopidine	NOUN	O	O
significantly	ADV	O	O
reduced	CCONJ	O	O
platelet	NOUN	O	B-PHYSICAL
aggregation	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	O
parameters	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
bioavailability	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
cyclosporin	NOUN	O	I-OTHER
A	NOUN	O	O
was	NUM	O	O
not	ADV	O	O
significantly	ADV	O	O
modified	VERB	O	O
by	ADP	O	O
ticlopidine	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ticlopidine	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
withdrawn	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
major	ADJ	O	O
fall	NOUN	O	B-OTHER
in	ADP	O	I-OTHER
cyclosporin	NOUN	O	I-OTHER
blood	NOUN	O	I-OTHER
level	NOUN	O	I-OTHER
within	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Urinary	ADJ	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
6-beta-hydroxycortisol	NOUN	O	I-PHYSICAL
was	VERB	O	O
augmented	VERB	O	O
after	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ticlopidine	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
metabolism	NOUN	O	O
might	VERB	O	O
have	PUNCT	O	O
occurred	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
also	ADV	O	O
show	VERB	O	O
quite	ADP	O	O
a	DET	O	O
large	ADJ	O	O
intra-individual	ADJ	O	O
variability	NOUN	O	O
in	ADP	O	O
cyclosporin	NOUN	O	B-PHYSICAL
bioavailability	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
poor	ADJ	O	O
absorption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
formulation	NOUN	O	O
and/or	CCONJ	O	O
poor	ADJ	O	O
compliance	NOUN	O	O
might	PUNCT	O	O
have	PUNCT	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
decreased	VERB	O	O
cyclosporin	NOUN	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
withdrawn	PUNCT	O	O
from	ADP	O	O
this	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
previous	ADJ	O	O
uncontrolled	VERB	O	O
studies	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Cyclosporin	NOUN	O	O
bioavailability	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
clearly	ADV	O	O
modified	PUNCT	O	O
by	ADP	O	O
a	DET	O	O
half	PUNCT	O	O
dosage	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
recommend	VERB	O	O
closely	ADV	O	O
monitoring	VERB	O	O
cyclosporin	NOUN	O	O
blood	NOUN	O	O
levels	NOUN	O	O
when	ADP	O	O
prescribing	ADP	O	O
ticlopidine	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
needed	VERB	O	O
with	ADP	O	O
new	ADJ	O	O
formulations	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	O
or	CCONJ	O	O
when	ADP	O	O
using	VERB	O	O
the	DET	O	O
full	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	O
.	PUNCT	O	O

Improving	VERB	O	O
the	DET	O	O
immunogenicity	NOUN	O	B-PHYSICAL
of	ADP	O	O
pneumococcal	ADJ	O	O
conjugate	PUNCT	O	O
vaccine	NOUN	O	O
in	ADP	O	O
HIV-infected	VERB	O	O
adults	NOUN	O	O
with	ADP	O	O
a	DET	O	O
toll-like	ADJ	O	O
receptor	NOUN	O	O
9	NUM	O	O
agonist	NOUN	O	O
adjuvant	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Persons	NOUN	O	O
infected	VERB	O	O
with	ADP	O	O
human	NOUN	O	O
immunodeficiency	NOUN	O	O
virus	NOUN	O	O
(	PUNCT	O	O
HIV	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
often	ADV	O	O
hyporesponsive	ADJ	O	O
to	ADP	O	O
immunization	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
pneumococcal	ADJ	O	O
vaccines	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
adding	VERB	O	O
CPG	NOUN	O	O
7909	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
toll-like	ADJ	O	O
receptor	NOUN	O	O
9	NUM	O	O
(	PUNCT	O	O
TLR9	NOUN	O	O
)	PUNCT	O	O
agonist	NOUN	O	O
and	CCONJ	O	O
vaccine	NOUN	O	O
adjuvant	ADJ	O	O
,	PUNCT	O	O
to	PUNCT	O	O
7-valent	ADJ	O	O
pneumococcal	ADJ	O	O
conjugate	PUNCT	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
7vPnC	NOUN	O	O
)	PUNCT	O	O
would	ADJ	O	O
increase	VERB	O	O
its	ADP	O	O
immunogenicity	NOUN	O	O
in	ADP	O	O
HIV-infected	VERB	O	O
adults	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
phase	NOUN	O	O
1b/2a	NOUN	O	O
trial	NOUN	O	O
randomizing	PUNCT	O	O
HIV-positive	ADJ	O	O
patients	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
double	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
7vPnC	ADJ	O	O
(	PUNCT	O	O
Prevnar	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
0	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
dose	NOUN	O	O
of	ADP	O	O
23-valent	ADJ	O	O
pneumococcal	ADJ	O	O
polysaccharide	ADP	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
PPV-23	NOUN	O	O
;	PUNCT	O	O
Pneumo	NOUN	O	O
Novum	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
9	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
experimental	ADJ	O	O
patients	NOUN	O	O
receiving	VERB	O	O
1	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
CPG	NOUN	O	O
7909	NUM	O	O
added	VERB	O	O
to	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
their	ADP	O	O
3	NUM	O	O
vaccine	NOUN	O	O
doses	NOUN	O	O
;	PUNCT	O	O
control	NOUN	O	O
patients	NOUN	O	O
had	PUNCT	O	O
phosphate-buffered	ADP	O	O
saline	NOUN	O	O
added	VERB	O	O
instead	PUNCT	O	O
.	PUNCT	O	O

Immunogenicity	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
safety	NOUN	O	B-PHYSICAL
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
up	PUNCT	O	O
to	ADP	O	O
10	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
vaccine	NOUN	O	B-PHYSICAL
high	ADJ	O	I-PHYSICAL
responders	NOUN	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
9	NUM	O	I-PHYSICAL
months	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
2-fold	ADP	O	O
increase	NOUN	O	O
in	ADP	O	O
IgG	NOUN	O	O
levels	NOUN	O	O
to	ADP	O	O
>	ADP	O	O
or	CCONJ	O	O
=	SYM	O	O
1	NUM	O	O
microg/mL	NOUN	O	O
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
5	NUM	O	O
of	ADP	O	O
7	NUM	O	O
of	ADP	O	O
the	DET	O	O
7vPnC	ADJ	O	O
serotypes	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Ninety-seven	PUNCT	O	O
participants	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
vaccine	NOUN	O	B-PHYSICAL
high	ADJ	O	I-PHYSICAL
responders	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
48	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
among	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
49	NUM	O	O
;	PUNCT	O	O
48.8	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
25.0	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
9	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Greater	PUNCT	O	O
proportions	NOUN	O	O
of	ADP	O	O
high	ADJ	O	B-PHYSICAL
responders	NOUN	O	I-PHYSICAL
were	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
at	ADP	O	O
3	NUM	O	O
(	PUNCT	O	O
51.1	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
39.6	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.26	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
4	NUM	O	O
(	PUNCT	O	O
77.3	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
56.3	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
87.8	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
51.1	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mild	ADJ	O	B-PHYSICAL
systemic	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
injection	NOUN	O	I-PHYSICAL
site	NOUN	O	I-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
to	ADP	O	O
7vPnC	ADJ	O	O
were	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
81.3	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CPG	NOUN	O	O
7909	NUM	O	O
did	PUNCT	O	O
not	ADV	O	O
increase	NOUN	O	O
non-7vPnC	NOUN	O	B-PHYSICAL
IgG	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
after	ADP	O	O
PPV-23	NOUN	O	O
immunization	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
CD4	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
+	SYM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
cell	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
organ	NOUN	O	B-PHYSICAL
functions	ADJ	O	I-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
TLR9	NOUN	O	O
agonist	NOUN	O	O
to	ADP	O	O
7vPnC	ADJ	O	O
significantly	PRON	O	O
enhanced	PROPN	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
vaccine	NOUN	O	B-PHYSICAL
high	ADJ	O	I-PHYSICAL
responders	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
ClinicalTrials.gov	PUNCT	O	O
identifier	NOUN	O	O
:	PUNCT	O	O
NCT00562939	PUNCT	O	O
.	PUNCT	O	O

Intravenous	ADP	O	O
aflibercept	PUNCT	O	O
administered	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
irinotecan	PUNCT	O	O
,	PUNCT	O	O
5-fluorouracil	NOUN	O	O
and	CCONJ	O	O
leucovorin	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADP	O	O
solid	ADJ	O	O
tumours	NOUN	O	O
:	PUNCT	O	O
results	DET	O	O
from	ADP	O	O
the	DET	O	O
expansion	NOUN	O	O
cohort	NOUN	O	O
of	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
I	NUM	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Following	VERB	O	O
the	DET	O	O
dose-escalation	ADJ	O	O
stage	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
double-blind	ADJ	O	O
expansion	NOUN	O	O
stage	NOUN	O	O
of	ADP	O	O
the	DET	O	O
phase	NOUN	O	O
I	NUM	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
,	PUNCT	O	O
pharmacodynamics	NOUN	O	O
,	PUNCT	O	O
pharmacokinetics	NOUN	O	O
,	PUNCT	O	O
anti-vascular	ADJ	O	O
effects	NOUN	O	O
and	CCONJ	O	O
antitumour	ADP	O	O
activity	NOUN	O	O
of	ADP	O	O
aflibercept	CCONJ	O	O
4	NUM	O	O
mg/kg	NOUN	O	O
with	ADP	O	O
irinotecan	PUNCT	O	O
,	PUNCT	O	O
5-fluorouracil	NOUN	O	O
and	CCONJ	O	O
leucovorin	NOUN	O	O
(	PUNCT	O	O
LV5FU2	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
advanced	ADP	O	O
solid	ADJ	O	O
tumours	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
at	ADP	O	O
cycle-1	NOUN	O	O
to	ADP	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
aflibercept	ADP	O	O
(	PUNCT	O	O
4	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
then	ADV	O	O
irinotecan-LV5FU2	PUNCT	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
.	PUNCT	O	O

Subsequently	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
patients	NOUN	O	O
received	DET	O	O
aflibercept	PUNCT	O	O
with	ADP	O	O
irinotecan-LV5FU2	ADP	O	O
every	DET	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Anti-vascular	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
using	SYM	O	O
dynamic	ADJ	O	O
contrast-enhanced	VERB	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	VERB	O	O
(	PUNCT	O	O
DCE-MRI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty-seven	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
;	PUNCT	O	O
14	NUM	O	O
received	DET	O	O
placebo	NOUN	O	O
in	ADP	O	O
cycle-1	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
aflibercept	CCONJ	O	O
in	ADP	O	O
later	PUNCT	O	O
cycles	NOUN	O	O
and	CCONJ	O	O
13	NUM	O	O
received	PUNCT	O	O
aflibercept	PUNCT	O	O
4	NUM	O	O
mg/kg	ADP	O	O
upfront	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
aflibercept	VERB	O	B-PHYSICAL
cycles	NOUN	O	I-PHYSICAL
was	VERB	O	O
16	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
1-44	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
12	NUM	O	O
patients	NOUN	O	O
received	PUNCT	O	O
?20	PUNCT	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

Most	PUNCT	O	O
frequent	ADJ	O	O
grade	NOUN	O	O
3/4	NUM	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	ADP	O	O
neutropenia	NOUN	O	O
(	PUNCT	O	O
37	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fatigue	NOUN	O	O
(	PUNCT	O	O
33	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
hypertension	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
anti-aflibercept	NOUN	O	O
antibodies	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
achieved	VERB	O	O
partial	ADJ	O	O
responses	NOUN	O	O
and	CCONJ	O	O
17	NUM	O	O
had	PUNCT	O	O
stable	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
lasting	PUNCT	O	O
>	SYM	O	O
3	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
free	ADJ	O	O
over	ADP	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor-bound	ADP	O	O
aflibercept	PUNCT	O	O
were	ADP	O	O
adequate	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
steady-state	NOUN	O	O
achieved	VERB	O	O
from	ADP	O	O
cycle-3	NOUN	O	O
.	PUNCT	O	O

Exploratory	ADJ	O	O
DCE-MRI	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
perfusion	NOUN	O	O
changes	NOUN	O	O
with	ADP	O	O
aflibercept	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Aflibercept	PUNCT	O	O
4	NUM	O	O
mg/kg	NOUN	O	O
plus	CCONJ	O	O
irinotecan-LV5FU2	PUNCT	O	O
every	DET	O	O
2	NUM	O	O
weeks	NOUN	O	O
had	PUNCT	O	O
acceptable	ADJ	O	O
toxicity	NOUN	O	O
and	CCONJ	O	O
pharmacokinetics	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
showed	VERB	O	O
promising	PUNCT	O	O
antitumour	ADP	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
glucose	NOUN	O	O
infusion	NOUN	O	O
on	ADP	O	O
fetal	ADJ	O	O
acid-base	NOUN	O	O
status	NOUN	O	O
in	ADP	O	O
human	NOUN	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
maternal	ADJ	O	O
and	CCONJ	O	O
fetal	ADJ	O	O
metabolic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
commonly	ADV	O	O
used	VERB	O	O
intravenous	ADJ	O	O
fluids	NOUN	O	O
administered	VERB	O	O
before	ADP	O	O
regional	ADJ	O	O
anesthesia	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
32	NUM	O	O
gravid	NOUN	O	O
women	NOUN	O	O
undergoing	VERB	O	O
elective	ADJ	O	O
cesarean	NOUN	O	O
section	NOUN	O	O
at	ADP	O	O
term	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
one	NUM	O	O
of	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
1	NUM	O	O
L	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
5	NUM	O	O
%	SYM	O	O
dextrose	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
gm	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
Ringer	ADV	O	O
's	PUNCT	O	O
lactate	NOUN	O	O
or	CCONJ	O	O
isotonic	ADJ	O	O
saline	ADJ	O	O
solution	NOUN	O	O
before	ADP	O	O
epidural	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
infusion	NOUN	O	I-PHYSICAL
resulted	VERB	O	O
in	ADP	O	O
maternal	ADJ	O	B-ADVERSE-EFFECTS
hyperglycemia	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
hyperinsulinemia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
lactate	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Cord	NOUN	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
,	PUNCT	O	O
insulin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lactate	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
key	ADJ	O	O
finding	DET	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
the	DET	O	O
significant	ADJ	O	B-PHYSICAL
lowering	DET	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
pH	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
umbilical	ADJ	O	I-PHYSICAL
cord	NOUN	O	I-PHYSICAL
vein	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
7.31	NUM	O	O
+/-	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
artery	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
7.21	NUM	O	O
+/-	SYM	O	O
0.06	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
glucose-infused	VERB	O	O
group	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
non-glucose	ADJ	O	B-PHYSICAL
infusion	NOUN	O	I-PHYSICAL
groups	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Confounding	ADJ	O	O
perinatal	ADJ	O	O
factors	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
maternal	ADJ	O	B-PHYSICAL
position	NOUN	O	O
,	PUNCT	O	O
maternal	ADJ	O	B-PHYSICAL
hypotension	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
prolonged	DET	O	O
time	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
influence	VERB	O	O
the	DET	O	O
fetal	ADJ	O	O
acid-base	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
acute	ADJ	O	O
maternal	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
infusion	NOUN	O	I-PHYSICAL
in	ADP	O	O
normal	ADJ	O	O
patients	NOUN	O	O
can	ADJ	O	O
cause	ADP	O	O
fetal	ADJ	O	B-PHYSICAL
hyperglycemia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
metabolic	ADJ	O	B-PHYSICAL
acidosis	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
neonatal	ADJ	O	B-PHYSICAL
hypoglycemia	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
may	VERB	O	O
be	PUNCT	O	O
of	ADP	O	O
particular	ADJ	O	O
clinical	ADJ	O	O
importance	NOUN	O	O
when	ADP	O	O
fetal	ADJ	O	B-PHYSICAL
distress	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
fetal	ADJ	O	B-PHYSICAL
hypoxemia	NOUN	O	I-PHYSICAL
is	VERB	O	O
due	CCONJ	O	O
to	ADP	O	O
other	CCONJ	O	O
perinatal	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

Under	ADP	O	O
these	DET	O	O
circumstances	NOUN	O	O
,	PUNCT	O	O
acute	ADJ	O	B-PHYSICAL
maternal	ADJ	O	I-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
infusion	NOUN	O	I-PHYSICAL
may	SYM	O	O
further	ADV	O	O
contribute	VERB	O	O
to	ADP	O	O
fetal	ADJ	O	B-PHYSICAL
metabolic	ADJ	O	I-PHYSICAL
acidosis	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Rosiglitazone	NOUN	O	O
and	CCONJ	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
clozapine-treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
have	ADP	O	O
shown	VERB	O	O
that	VERB	O	O
insulin	NOUN	O	O
resistance	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
cognitive	ADJ	O	O
impairment	NOUN	O	O
.	PUNCT	O	O

Peroxisome	NOUN	O	O
proliferator-activated	VERB	O	O
receptor-?	NOUN	O	O
(	PUNCT	O	O
PPAR-?	NUM	O	O
)	PUNCT	O	O
agonists	NOUN	O	O
improve	VERB	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
rosiglitazone	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
PPAR-?	ADJ	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
cognition	NOUN	O	O
in	ADP	O	O
clozapine-treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
an	DET	O	O
eight-week	NOUN	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	PUNCT	O	O
pilot	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
clozapine-treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	ADJ	O	O
rosiglitazone	NOUN	O	O
(	PUNCT	O	O
4mg/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
neuropsychological	ADJ	O	O
battery	NOUN	O	O
including	VERB	O	O
the	DET	O	O
Digit	NOUN	O	O
Span	NOUN	O	O
subtest	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Wechsler	PUNCT	O	O
Adult	NOUN	O	O
Intelligence	NOUN	O	O
Scale-III	ADV	O	O
(	PUNCT	O	O
WAIS-III	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
verbal	ADJ	O	O
fluency	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Hopkins	ADV	O	O
Verbal	ADJ	O	O
Learning	PUNCT	O	O
Test	NOUN	O	O
(	PUNCT	O	O
HVLT	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
Trail-Making	PUNCT	O	O
Test	NOUN	O	O
(	PUNCT	O	O
TMT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Wisconsin	NOUN	O	O
Card	NOUN	O	O
Sorting	PUNCT	O	O
Test	NOUN	O	O
(	PUNCT	O	O
WCST	ADV	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
week	NOUN	O	O
eight	NUM	O	O
.	PUNCT	O	O

Nineteen	NUM	O	O
patients	NOUN	O	O
completed	NOUN	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
on	ADP	O	O
any	DET	O	O
demographic	ADJ	O	O
or	CCONJ	O	O
general	ADJ	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
between	ADP	O	O
the	DET	O	O
rosiglitazone	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=9	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=10	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

When	ADP	O	O
baseline	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
controlled	VERB	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
change	ADV	O	O
scores	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-MENTAL
performance	NOUN	O	I-MENTAL
over	ADP	O	O
eight	NUM	O	O
weeks	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	PUNCT	O	O
pilot	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
rosiglitazone	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
cognitive	ADJ	O	B-MENTAL
benefit	NOUN	O	I-MENTAL
in	ADP	O	O
clozapine-treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
.	PUNCT	O	O

Future	ADJ	O	O
studies	NOUN	O	O
with	ADP	O	O
longer	PUNCT	O	O
treatment	NOUN	O	O
duration	NOUN	O	O
and	CCONJ	O	O
larger	PUNCT	O	O
sample	NOUN	O	O
size	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	ADP	O	O
further	ADJ	O	O
explore	PUNCT	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
rosiglitazone	NOUN	O	O
in	ADP	O	O
improving	VERB	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
.	PUNCT	O	O

Mecamylamine	ADV	O	O
reduces	NOUN	O	O
some	DET	O	O
EEG	NOUN	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
of	ADP	O	O
nicotine	NOUN	O	O
chewing	VERB	O	O
gum	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

Spontaneous	ADJ	O	B-PHYSICAL
EEG	NOUN	O	I-PHYSICAL
was	VERB	O	O
recorded	VERB	O	O
in	ADP	O	O
nine	DET	O	O
cigarette	NOUN	O	O
smokers	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
been	PUNCT	O	O
abstinent	ADP	O	O
from	ADP	O	O
tobacco	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
hr	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
capsule	NOUN	O	O
containing	VERB	O	O
either	PUNCT	O	O
centrally	ADV	O	O
acting	PUNCT	O	O
nicotine	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
mecamylamine	PUNCT	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
60-min	NOUN	O	O
intervals	NOUN	O	O
after	ADP	O	O
the	DET	O	O
capsule	NOUN	O	O
was	VERB	O	O
ingested	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
subjects	NOUN	O	O
chewed	ADV	O	O
two	NUM	O	O
pieces	NOUN	O	O
of	ADP	O	O
gum	NOUN	O	O
containing	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
or	CCONJ	O	O
8	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	O
and	CCONJ	O	O
mecamylamine	PUNCT	O	O
dose	NOUN	O	O
combinations	NOUN	O	O
were	VERB	O	O
randomized	PUNCT	O	O
across	ADP	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
three-minute	ADJ	O	O
periods	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	B-PHYSICAL
EEG	NOUN	O	I-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
before	ADP	O	O
the	DET	O	O
capsule	NOUN	O	O
and	CCONJ	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
gum	NOUN	O	O
chewing	VERB	O	O
from	ADP	O	O
bipolar	ADJ	O	O
electrode	NOUN	O	O
montages	NOUN	O	O
at	ADP	O	O
the	DET	O	O
following	PUNCT	O	O
positions	NOUN	O	O
:	PUNCT	O	O
Cz-T5	NOUN	O	O
,	PUNCT	O	O
Cz-T6	NOUN	O	O
,	PUNCT	O	O
Cz-F7	NOUN	O	O
and	CCONJ	O	O
Cz-F8	NUM	O	O
.	PUNCT	O	O

During	ADP	O	O
one	NUM	O	O
period	NOUN	O	O
the	DET	O	O
subjects	NOUN	O	O
relaxed	NUM	O	O
with	ADP	O	O
eyes	NOUN	O	O
closed	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
period	NOUN	O	O
they	PRON	O	O
performed	VERB	O	O
a	DET	O	O
math	ADP	O	O
task	NOUN	O	O
with	ADP	O	O
eyes	NOUN	O	O
open	PUNCT	O	O
.	PUNCT	O	O

When	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
individually	ADV	O	O
,	PUNCT	O	O
mecamylamine	PUNCT	O	O
decreased	VERB	O	O
beta	NOUN	O	B-PHYSICAL
power	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
nicotine	NOUN	O	O
gum	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
alpha	NOUN	O	B-PHYSICAL
frequency	NOUN	O	O
.	PUNCT	O	O

Mecamylamine	ADJ	O	O
pretreatment	NOUN	O	O
prevented	VERB	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
alpha	NOUN	O	B-PHYSICAL
frequency	NOUN	O	I-PHYSICAL
caused	VERB	O	O
by	ADP	O	O
the	DET	O	O
4	NUM	O	O
mg	NOUN	O	O
gum	NOUN	O	O
dose	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
8	NUM	O	O
mg	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Alpha	NOUN	O	B-OTHER
power	NOUN	O	I-OTHER
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
the	DET	O	O
8	NUM	O	O
mg	NOUN	O	O
gum	NOUN	O	O
dose	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
increase	VERB	O	O
was	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
mecamylamine	PUNCT	O	O
.	PUNCT	O	O

Self-reported	PUNCT	O	O
ratings	NOUN	O	O
of	ADP	O	O
the	DET	O	O
strength	NOUN	O	B-PHYSICAL
of	ADP	O	O
the	DET	O	O
gum	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
diminished	VERB	O	O
by	ADP	O	O
mecamylamine	PUNCT	O	O
pretreatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
earlier	PUNCT	O	O
studies	NOUN	O	O
which	ADP	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
tobacco	NOUN	O	O
administration	NOUN	O	O
and	CCONJ	O	O
withdrawal	NOUN	O	O
are	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
central	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	O
.	PUNCT	O	O

Racial	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
and	CCONJ	O	O
repeat	NOUN	O	O
lower	PUNCT	O	O
extremity	NOUN	O	O
amputation	NOUN	O	O
:	PUNCT	O	O
results	ADJ	O	O
from	ADP	O	O
a	DET	O	O
multihospital	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	ADP	O	O
African	ADJ	O	O
Americans	PUNCT	O	O
have	PUNCT	O	O
a	DET	O	O
much	ADJ	O	O
higher	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
major	ADJ	O	B-PHYSICAL
(	PUNCT	O	O
above-	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
below-knee	NOUN	O	O
)	PUNCT	O	O
lower	CCONJ	O	O
extremity	NOUN	O	O
amputation	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
lower	PUNCT	O	O
rate	NOUN	O	O
of	ADP	O	O
limb-preserving	PROPN	O	B-PHYSICAL
vascular	ADJ	O	I-PHYSICAL
surgery	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
angioplasty	NOUN	O	O
than	VERB	O	O
white	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
analyzes	PUNCT	O	O
two	NUM	O	O
potential	ADJ	O	O
pathways	NOUN	O	O
for	ADP	O	O
racial	ADJ	O	O
disparities	NOUN	O	O
:	PUNCT	O	O
primary	ADJ	O	O
amputation	NOUN	O	O
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
major	ADJ	O	O
amputation	NOUN	O	O
performed	VERB	O	O
without	ADP	O	O
any	DET	O	O
prior	PUNCT	O	O
attempt	ADJ	O	O
at	ADP	O	O
revascularization	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
repeat	NOUN	O	O
amputation	NOUN	O	O
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
major	ADJ	O	O
amputation	NOUN	O	O
subsequent	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
previous	ADJ	O	O
through-foot	NOUN	O	O
or	CCONJ	O	O
major	ADJ	O	O
amputation	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Randomly	ADV	O	O
selected	VERB	O	O
medical	ADJ	O	O
records	NOUN	O	O
were	VERB	O	O
reviewed	VERB	O	O
for	ADP	O	O
248	ADJ	O	O
African	ADJ	O	O
American	ADJ	O	O
,	PUNCT	O	O
30	NUM	O	O
Hispanic	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
235	NUM	O	O
white	ADJ	O	O
or	CCONJ	O	O
other-race	ADJ	O	O
patients	NOUN	O	O
undergoing	PRON	O	O
above-	NOUN	O	O
or	CCONJ	O	O
below-knee	NOUN	O	O
amputation	NOUN	O	O
between	ADP	O	O
1995	NUM	O	O
and	CCONJ	O	O
2003	NUM	O	O
at	ADP	O	O
three	NUM	O	O
Chicago	PUNCT	O	O
teaching	VERB	O	O
hospitals	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
disease	NOUN	O	O
prevalence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
,	PUNCT	O	O
preadmission	NOUN	O	O
functional	ADJ	O	O
status	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
vascular	ADJ	O	O
history	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
test	NOUN	O	O
the	DET	O	O
risk-adjusted	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
race	NOUN	O	O
and	CCONJ	O	O
ethnicity	NOUN	O	O
on	ADP	O	O
rates	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
repeat	NOUN	O	B-PHYSICAL
amputation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Controlling	ADJ	O	O
for	ADP	O	O
demographic	ADJ	O	O
,	PUNCT	O	O
functional	ADJ	O	O
,	PUNCT	O	O
chronic	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
characteristics	NOUN	O	O
,	PUNCT	O	O
African	ADJ	O	O
American	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
1.7	PUNCT	O	O
times	ADP	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
undergone	ADP	O	O
both	PUNCT	O	O
primary	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
repeat	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
amputation	NOUN	O	O
than	PUNCT	O	O
white	PUNCT	O	O
or	CCONJ	O	O
other-race	ADJ	O	O
amputees	ADV	O	O
.	PUNCT	O	O

Race	NOUN	O	O
remained	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
independent	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
even	ADV	O	O
after	PUNCT	O	O
controlling	ADJ	O	O
for	ADP	O	O
the	DET	O	O
higher	PUNCT	O	O
severity	NOUN	O	O
of	ADP	O	O
illness	NOUN	O	O
,	PUNCT	O	O
greater	PUNCT	O	O
disability	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
more	DET	O	O
complex	ADJ	O	O
presentation	NOUN	O	O
of	ADP	O	O
African	ADJ	O	O
American	ADJ	O	O
amputees	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Higher	PUNCT	O	O
rates	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
repeat	NOUN	O	I-PHYSICAL
amputation	NOUN	O	I-PHYSICAL
for	ADP	O	O
African	ADJ	O	O
American	ADJ	O	O
patients	NOUN	O	O
at	ADP	O	O
study	PUNCT	O	O
hospitals	PROPN	O	O
,	PUNCT	O	O
which	ADP	O	O
all	DET	O	O
have	CCONJ	O	O
significant	ADJ	O	O
vascular	ADJ	O	O
surgery	NOUN	O	O
capacity	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
aggressive	ADJ	O	O
policy	NOUN	O	O
of	ADP	O	O
limb	NOUN	O	O
salvage	NOUN	O	O
,	PUNCT	O	O
suggest	VERB	O	O
that	ADP	O	O
these	DET	O	O
rates	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
even	ADV	O	O
higher	PUNCT	O	O
at	ADP	O	O
less	VERB	O	O
well	VERB	O	O
equipped	DET	O	O
institutions	NOUN	O	O
.	PUNCT	O	O

Improving	ADV	O	O
access	NOUN	O	O
to	ADP	O	O
primary	ADJ	O	O
and	CCONJ	O	O
preventive	ADJ	O	O
care	NOUN	O	O
for	ADP	O	O
lower-income	NOUN	O	O
patients	NOUN	O	O
could	VERB	O	O
reduce	VERB	O	O
amputation	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
among	ADP	O	O
African	ADJ	O	O
Americans	PUNCT	O	O
.	PUNCT	O	O

Tegaserod	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
5-hydroxytryptamine	NOUN	O	O
type	NOUN	O	O
4	NUM	O	O
receptor	NOUN	O	O
partial	ADJ	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
devoid	CCONJ	O	O
of	ADP	O	O
electrocardiographic	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Certain	ADJ	O	O
GI	NOUN	O	O
prokinetic	ADJ	O	O
agents	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
affect	ADJ	O	O
cardiac	ADJ	O	O
repolarization	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
life-threatening	VERB	O	O
arrhythmias	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
selective	ADJ	O	O
5-hydroxytryptamine	NOUN	O	O
type	NOUN	O	O
4	NUM	O	O
receptor	NOUN	O	O
partial	ADJ	O	O
agonist	NOUN	O	O
tegaserod	NOUN	O	O
is	VERB	O	O
a	DET	O	O
novel	ADJ	O	O
promotile	ADP	O	O
agent	NOUN	O	O
developed	VERB	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
functional	ADJ	O	O
motility	NOUN	O	O
disorders	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
irritable	ADJ	O	O
bowel	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
IBS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
cardiac	ADJ	O	B-OTHER
safety	NOUN	O	I-OTHER
profile	NOUN	O	I-OTHER
of	ADP	O	O
tegaserod	NOUN	O	O
through	ADP	O	O
analysis	NOUN	O	O
of	ADP	O	O
electrocardiographic	ADJ	O	O
data	NOUN	O	O
from	ADP	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
conducted	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
IBS	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
study	NOUN	O	O
conducted	VERB	O	O
in	ADP	O	O
healthy	ADJ	O	O
male	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
three	NUM	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
group	NOUN	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
2516	NUM	O	O
IBS	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
abdominal	ADJ	O	O
pain	NOUN	O	O
and	CCONJ	O	O
constipation	NOUN	O	O
received	ADP	O	O
tegaserod	NOUN	O	O
2	NUM	O	O
or	CCONJ	O	O
6	NUM	O	O
mg	NOUN	O	O
b.i.d	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

n	NOUN	O	O
=	SYM	O	O
1679	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
837	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
12	NUM	O	O
wk	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
36	NUM	O	O
healthy	ADJ	O	O
male	NOUN	O	O
subjects	NOUN	O	O
received	VERB	O	O
iv	PUNCT	O	O
.	PUNCT	O	O

single	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
tegaserod	NOUN	O	O
(	PUNCT	O	O
0.8	NUM	O	O
mg	NOUN	O	O
to	ADP	O	O
20	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Standard	ADJ	O	O
12-lead	NOUN	O	O
electrocardiograms	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
data	NOUN	O	O
collected	VERB	O	O
during	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prolongation	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
QTc	PUNCT	O	I-PHYSICAL
interval	NOUN	O	I-PHYSICAL
was	VERB	O	O
the	DET	O	O
same	ADP	O	O
for	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
tegaserod	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
was	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
overall	ADJ	O	B-PHYSICAL
electrocardiographic	ADJ	O	I-PHYSICAL
abnormalities	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

No	DET	O	O
ventricular	ADJ	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
supraventricular	ADJ	O	I-PHYSICAL
tachycardia	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Comparable	ADJ	O	O
electrocardiographic	ADJ	O	B-PHYSICAL
results	NOUN	O	I-PHYSICAL
were	VERB	O	O
obtained	VERB	O	O
during	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
tegaserod	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
tegaserod	NOUN	O	O
at	ADP	O	O
i.v	NUM	O	O
.	PUNCT	O	O

doses	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
up	PUNCT	O	O
to	ADP	O	O
100	NUM	O	O
times	NOUN	O	O
those	VERB	O	O
measured	VERB	O	O
after	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
mg	NOUN	O	O
b.i.d	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O

did	PUNCT	O	O
not	ADV	O	O
influence	NUM	O	O
electrocardiographic	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Tegaserod	NOUN	O	O
is	VERB	O	O
devoid	CCONJ	O	O
of	ADP	O	O
electrocardiographic	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
is	VERB	O	O
not	ADV	O	O
expected	VERB	O	O
to	ADP	O	O
adversely	PUNCT	O	O
influence	VERB	O	O
cardiac	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
confirm	DET	O	O
preclinical	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
magnesium	NOUN	O	O
supplementation	NOUN	O	O
improves	NOUN	O	O
the	DET	O	O
metabolic	ADJ	O	B-PHYSICAL
profile	NOUN	O	I-PHYSICAL
of	ADP	O	O
metabolically	ADV	O	O
obese	ADP	O	O
,	PUNCT	O	O
normal-weight	ADJ	O	O
individuals	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
AIMS	ADP	O	O
We	ADJ	O	O
undertook	ADJ	O	O
this	DET	O	O
study	NOUN	O	O
to	DET	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
magnesium	NOUN	O	O
supplementation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
metabolic	ADJ	O	B-OTHER
profile	ADJ	O	I-OTHER
and	CCONJ	O	O
blood	NOUN	O	B-OTHER
pressure	NOUN	O	I-OTHER
in	ADP	O	O
metabolically	ADV	O	O
obese	ADP	O	O
,	PUNCT	O	O
normal-weight	NOUN	O	O
(	PUNCT	O	O
MONW	NOUN	O	O
)	PUNCT	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
47	NUM	O	O
MONW	NOUN	O	O
individuals	NOUN	O	O
with	ADP	O	O
hypomagnesemia	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
clinical	CCONJ	O	O
a	DET	O	O
randomized	VERB	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Individuals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
30	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
MgCl2	NOUN	O	O
5	NUM	O	O
%	SYM	O	O
solution	NOUN	O	O
(	PUNCT	O	O
equivalent	PUNCT	O	O
to	ADP	O	O
382	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
magnesium	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
individuals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
30	PUNCT	O	O
mL	NOUN	O	O
of	ADP	O	O
placebo	NOUN	O	O
solution	NOUN	O	O
,	PUNCT	O	O
once	PUNCT	O	O
daily	ADJ	O	O
during	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
obesity	NOUN	O	O
or	CCONJ	O	O
overweight	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
fasting	VERB	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
?100	PUNCT	O	O
mg/dL	NOUN	O	O
,	PUNCT	O	O
HOMA-IR	NOUN	O	O
index	NOUN	O	O
?3	PUNCT	O	O
,	PUNCT	O	O
triglyceride	NOUN	O	O
levels	NOUN	O	O
?150	PUNCT	O	O
mg/dL	NOUN	O	O
and/or	CCONJ	O	O
systolic	ADJ	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
?140	PUNCT	O	O
and	CCONJ	O	O
90	NUM	O	O
mmHg	NOUN	O	O
defined	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
MONW	NOUN	O	O
phenotype	NOUN	O	O
.	PUNCT	O	O

Hypomagnesemia	NOUN	O	O
was	VERB	O	O
defined	VERB	O	O
by	ADP	O	O
serum	NOUN	O	O
magnesium	NOUN	O	O
concentration	NOUN	O	O
?1.8	PUNCT	O	O
mg/dL	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
basal	ADJ	O	O
conditions	NOUN	O	O
there	VERB	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
systolic	ADJ	O	O
(	PUNCT	O	O
-2.1	NUM	O	O
vs.	CCONJ	O	O
3.9	NUM	O	O
%	SYM	O	O
mmHg	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
(	PUNCT	O	O
-3.8	ADP	O	O
vs.	CCONJ	O	O
7.5	NUM	O	O
%	SYM	O	O
mmHg	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
,	PUNCT	O	O
HOMA-IR	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
-46.5	NUM	O	O
vs.	CCONJ	O	O
-5.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fasting	ADP	O	O
glucose	NOUN	O	O
(	PUNCT	O	O
-12.3	PUNCT	O	O
vs.	CCONJ	O	O
-1.8	ADP	O	O
%	ADV	O	O
mg/dL	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
triglyceride	NOUN	O	O
levels	NOUN	O	O
(	PUNCT	O	O
-47.4	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
10.1	NUM	O	O
%	SYM	O	O
mg/dL	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
MgCl2	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
individuals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Oral	ADJ	O	O
magnesium	NOUN	O	O
supplementation	NOUN	O	O
improves	NOUN	O	O
the	DET	O	O
metabolic	ADJ	O	O
profile	ADJ	O	O
and	CCONJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
of	ADP	O	O
MONW	NOUN	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
of	ADP	O	O
nebulized	VERB	O	O
flunisolide	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
salbutamol	NOUN	O	O
and	CCONJ	O	O
ipratropium	NOUN	O	O
bromide	NOUN	O	O
in	ADP	O	O
stable	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
moderate-to-severe	NOUN	O	O
chronic	ADJ	O	O
obstructive	ADJ	O	O
pulmonary	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
nebulized	ADJ	O	O
corticosteroids	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
exacerbation	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
obstructive	ADJ	O	O
pulmonary	ADJ	O	O
disease	NOUN	O	O
(	PUNCT	O	O
COPD	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
poorly	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
nebulized	VERB	O	O
flunisolide	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
+	SYM	O	O
salbutamol/ipratropium	NOUN	O	O
bromide	NOUN	O	O
(	PUNCT	O	O
1,875/375	NOUN	O	O
microg	NOUN	O	O
)	PUNCT	O	O
b.i.d	ADP	O	O
.	PUNCT	O	O

in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
+	SYM	O	O
salbutamol/ipratropium	NOUN	O	O
bromide	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
114	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
COPD	NOUN	O	O
of	ADP	O	O
moderate-to-severe	NOUN	O	O
degree	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
exacerbations	NOUN	O	I-PHYSICAL
over	ADP	O	O
a	DET	O	O
6-month	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
respiratory	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
forced	VERB	O	I-PHYSICAL
expiratory	ADJ	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
s	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
FEV	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
shuttle	PART	O	I-PHYSICAL
walking	PUNCT	O	I-PHYSICAL
test	NOUN	O	I-PHYSICAL
distance	NOUN	O	O
and	CCONJ	O	B-PHYSICAL
St.	NOUN	O	O
George	NOUN	O	B-PHYSICAL
's	PUNCT	O	O
Respiratory	ADJ	O	B-PHYSICAL
Questionnaire	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
total	ADJ	O	O
number	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
exacerbations	NOUN	O	I-PHYSICAL
was	ADJ	O	O
slightly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
flunisolide	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
19	NUM	O	O
vs.	CCONJ	O	O
34	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.054	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-PHYSICAL
experiencing	PRON	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
least	ADV	O	B-PHYSICAL
one	NUM	O	B-PHYSICAL
exacerbation	NOUN	O	B-PHYSICAL
during	ADP	O	I-PHYSICAL
the	DET	O	B-PHYSICAL
study	NOUN	O	B-PHYSICAL
was	VERB	O	O
also	ADV	O	O
decreased	VERB	O	O
(	PUNCT	O	O
16	NUM	O	O
vs.	CCONJ	O	O
26	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.059	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O
type	NOUN	O	O
3	NUM	O	O
Anthonisens	NOUN	O	B-PHYSICAL
's	PUNCT	O	O
exacerbations	NOUN	O	B-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
flunisolide	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.044	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
scores	NOUN	O	O
were	VERB	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
flunisolide	NOUN	O	O
group	NOUN	O	O
but	CCONJ	O	O
nonsignificant	ADJ	O	O
for	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
and	CCONJ	O	O
intra-arterial	ADJ	O	O
urokinase	NOUN	O	O
thrombolysis	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
ischaemic	ADJ	O	O
stroke	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
fibrinolysis	NOUN	O	O
(	PUNCT	O	O
IVF	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
rt-PA	NOUN	O	O
(	PUNCT	O	O
alteplase	NOUN	O	O
)	PUNCT	O	O
provides	NOUN	O	O
significant	ADJ	O	O
benefits	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	O
ischaemic	ADJ	O	O
stroke	NOUN	O	O
when	ADP	O	O
it	PRON	O	O
is	VERB	O	O
given	VERB	O	O
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
three	NUM	O	O
hours	NOUN	O	O
following	VERB	O	O
stroke	NOUN	O	O
onset	NOUN	O	O
.	PUNCT	O	O

Intra-arterial	ADJ	O	O
fibrinolysis	NOUN	O	O
(	PUNCT	O	O
IAF	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
pro-urokinase	NOUN	O	O
in	ADP	O	O
PROACT	NOUN	O	O
II	NUM	O	O
study	NOUN	O	O
provides	NOUN	O	O
quite	ADV	O	O
the	DET	O	O
same	ADJ	O	O
benefit	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
6	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

IVF	NOUN	O	O
and	CCONJ	O	O
IAF	NOUN	O	O
have	PUNCT	O	O
never	ADV	O	O
been	PUNCT	O	O
compared	VERB	O	O
.	PUNCT	O	O

To	PART	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
IVF	NOUN	O	O
and	CCONJ	O	O
IAF	NOUN	O	O
with	ADP	O	O
urokinase	NOUN	O	O
given	VERB	O	O
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
6	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
ischaemic	ADJ	O	O
stroke	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
fulfilling	VERB	O	O
the	DET	O	O
selection	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
urokinase	NOUN	O	O
900,000	NUM	O	O
units	NOUN	O	O
via	ADP	O	O
intravenous	ADJ	O	O
or	CCONJ	O	O
intra-arterial	ADJ	O	O
routes	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
randomised	VERB	O	O
monocentre	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
done	PUNCT	O	O
between	ADP	O	O
December	NOUN	O	O
1995	NUM	O	O
and	CCONJ	O	O
August	NOUN	O	O
1997	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	B-OTHER
patients	NOUN	O	I-OTHER
with	ADP	O	I-OTHER
a	DET	O	I-OTHER
modified	VERB	O	O
Rankin	PUNCT	O	B-OTHER
score	PUNCT	O	O

Evidence	NOUN	O	O
for	ADP	O	O
poorer	PUNCT	O	O
outcome	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
negative	ADJ	O	O
trauma-related	VERB	O	O
cognitions	NOUN	O	O
receiving	VERB	O	O
prolonged	VERB	O	O
exposure	NOUN	O	O
plus	CCONJ	O	O
cognitive	ADJ	O	O
restructuring	ADP	O	O
:	PUNCT	O	O
implications	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
matching	PUNCT	O	O
in	ADP	O	O
posttraumatic	ADJ	O	O
stress	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
current	ADJ	O	O
article	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
address	VERB	O	O
the	DET	O	O
existing	VERB	O	O
assumption	NOUN	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
on	ADP	O	O
cognitive	ADJ	O	O
behavioral	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
PTSD	NOUN	O	O
that	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
negative	ADJ	O	O
trauma-related	VERB	O	O
cognitions	NOUN	O	O
would	VERB	O	O
benefit	VERB	O	O
more	ADV	O	O
from	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
package	NOUN	O	O
that	DET	O	O
includes	ADP	O	O
exposure	NOUN	O	O
and	CCONJ	O	O
cognitive	ADJ	O	O
techniques	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
that	ADP	O	O
includes	ADP	O	O
exposure	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

To	PART	O	O
test	ADP	O	O
this	DET	O	O
assumption	NOUN	O	O
,	PUNCT	O	O
54	NUM	O	O
PTSD	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
prolonged	ADJ	O	O
exposure	NOUN	O	O
therapy	NOUN	O	O
or	CCONJ	O	O
prolonged	VERB	O	O
exposure	NOUN	O	O
therapy	NOUN	O	O
plus	CCONJ	O	O
cognitive	ADJ	O	O
restructuring	ADP	O	O
.	PUNCT	O	O

Contrary	PUNCT	O	O
to	ADP	O	O
expectations	PROPN	O	O
,	PUNCT	O	O
findings	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
characterized	VERB	O	O
by	ADP	O	O
more	ADV	O	O
severe	ADJ	O	O
pretreatment	NOUN	O	O
trauma-related	DET	O	O
cognitions	NOUN	O	O
(	PUNCT	O	O
and	CCONJ	O	O
more	ADV	O	O
severe	ADJ	O	O
pretreatment	NOUN	O	O
PTSD	NOUN	O	O
symptoms	NOUN	O	O
)	PUNCT	O	O
fared	VERB	O	O
slightly	ADV	O	O
worse	ADJ	O	O
in	ADP	O	O
treatment	NOUN	O	O
combining	PUNCT	O	O
exposure	NOUN	O	O
and	CCONJ	O	O
cognitive	ADJ	O	O
restructuring	ADP	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
pre-	ADJ	O	O
and	CCONJ	O	O
post-treatment	NOUN	O	B-MENTAL
measures	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
negative	ADJ	O	O
cognitions	NOUN	O	B-MENTAL
and	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
androgen	NOUN	O	O
ablation	NOUN	O	O
on	ADP	O	O
pathologic	ADJ	O	B-PHYSICAL
stage	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
resection	NOUN	O	B-PHYSICAL
limit	ADV	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
prostate	NOUN	O	I-PHYSICAL
cancer	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Initial	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Italian	ADJ	O	O
PROSIT	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
likelihood	NOUN	O	O
of	ADP	O	O
finding	VERB	O	O
organ-confined	VERB	O	O
untreated	VERB	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
PCa	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
pathological	ADJ	O	O
examination	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
radical	ADJ	O	O
prostatectomy	NOUN	O	O
(	PUNCT	O	O
RP	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
only	ADV	O	O
50	NUM	O	O
%	SYM	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
clinically	ADV	O	O
organ-confined	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
tumour	NOUN	O	O
is	VERB	O	O
present	ADJ	O	O
at	ADP	O	O
the	DET	O	O
resection	NOUN	O	O
margin	NOUN	O	O
in	ADP	O	O
approximately	ADV	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
clinical	ADJ	O	O
T2	NOUN	O	O
(	PUNCT	O	O
clinical	ADJ	O	O
stage	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
cases	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
issue	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
understaging	PUNCT	O	O
and	CCONJ	O	O
of	DET	O	O
resection	NOUN	O	O
limit	ADV	O	O
positivity	NOUN	O	O
have	CCONJ	O	O
led	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
novel	ADJ	O	O
management	NOUN	O	O
practices	PROPN	O	O
,	PUNCT	O	O
including	CCONJ	O	O
neoadjuvant	PUNCT	O	O
hormonal	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
NHT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
optimal	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
NHT	NOUN	O	O
is	VERB	O	O
unknown	VERB	O	O
.	PUNCT	O	O

We	ADP	O	O
undertook	ADJ	O	O
the	DET	O	O
present	ADJ	O	O
analysis	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	B-PHYSICAL
NHT	NOUN	O	O
on	ADP	O	O
pathologic	ADJ	O	B-PHYSICAL
stage	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
PCa	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
resection	NOUN	O	B-PHYSICAL
limit	ADV	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
and	CCONJ	O	O
treated	VERB	O	O
with	ADP	O	O
total	ADJ	O	O
androgen	NOUN	O	O
ablation	NOUN	O	O
either	CCONJ	O	O
for	ADP	O	O
three	NUM	O	O
or	CCONJ	O	O
six	NUM	O	O
months	NOUN	O	O
before	ADP	O	O
RP	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
January	NOUN	O	O
1996	NUM	O	O
and	CCONJ	O	O
February	PUNCT	O	O
1998	NUM	O	O
,	PUNCT	O	O
259	DET	O	O
men	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
underwent	VERB	O	O
radical	ADJ	O	O
retropubic	ADJ	O	O
prostatectomy	NOUN	O	O
and	CCONJ	O	O
bilateral	ADJ	O	O
pelvic	ADJ	O	O
node	NOUN	O	O
dissection	NOUN	O	O
in	ADP	O	O
the	DET	O	O
26	NUM	O	O
centres	NOUN	O	O
participating	VERB	O	O
in	ADP	O	O
the	DET	O	O
Italian	ADJ	O	O
randomised	VERB	O	O
prospective	ADJ	O	O
PROSIT	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Whole	ADJ	O	O
mount	NOUN	O	O
sectioning	ADJ	O	O
of	ADP	O	O
the	DET	O	O
complete	ADJ	O	O
RP	NOUN	O	O
specimens	NOUN	O	O
was	VERB	O	O
adopted	VERB	O	O
in	ADP	O	O
each	DET	O	O
centre	NOUN	O	O
for	ADP	O	O
accurately	ADV	O	O
evaluating	ADP	O	O
the	DET	O	O
pathologic	ADJ	O	B-PHYSICAL
stage	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
resection	NOUN	O	B-PHYSICAL
limit	ADV	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

By	ADP	O	O
February	PUNCT	O	O
1998	NUM	O	O
,	PUNCT	O	O
haematoxylin	NOUN	O	O
and	CCONJ	O	O
eosin	NOUN	O	O
stained	VERB	O	O
sections	NOUN	O	O
from	ADP	O	O
155	NUM	O	O
RP	NOUN	O	O
specimens	NOUN	O	O
had	VERB	O	O
been	PUNCT	O	O
received	VERB	O	O
and	CCONJ	O	O
evaluated	VERB	O	O
by	ADP	O	O
the	DET	O	O
reviewing	ADJ	O	O
pathologist	NOUN	O	O
(	PUNCT	O	O
RM	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

64	NUM	O	O
cases	NOUN	O	O
had	ADP	O	O
not	ADV	O	O
been	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
total	ADJ	O	O
androgen	NOUN	O	O
ablation	NOUN	O	O
(	PUNCT	O	O
e.g	NUM	O	O
.	PUNCT	O	O

NHT	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
RP	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
,	PUNCT	O	O
whereas	ADP	O	O
58	ADP	O	O
and	CCONJ	O	O
33	NUM	O	O
had	PUNCT	O	O
been	ADV	O	O
treated	VERB	O	O
for	ADP	O	O
three	NUM	O	O
and	CCONJ	O	O
six	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

114	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
clinical	ADJ	O	O
stage	NOUN	O	O
B	NOUN	O	O
whereas	ADP	O	O
41	NUM	O	O
were	PUNCT	O	O
clinical	ADJ	O	O
stage	NOUN	O	O
C.	NOUN	O	O
After	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
androgen	NOUN	O	O
ablation	NOUN	O	O
,	PUNCT	O	O
pathological	ADJ	O	B-PHYSICAL
stage	NOUN	O	I-PHYSICAL
B	NOUN	O	I-PHYSICAL
was	VERB	O	O
more	ADV	O	O
prevalent	ADJ	O	O
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
B	NOUN	O	O
tumours	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
untreated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
57	NUM	O	O
%	SYM	O	O
in	ADP	O	O
treated	VERB	O	O
patients	NOUN	O	O
vs.	CCONJ	O	O
36	NUM	O	O
%	SYM	O	O
in	ADP	O	O
untreated	VERB	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
cancers	NOUN	O	B-PHYSICAL
with	ADP	O	B-PHYSICAL
negative	ADJ	O	O
margins	NOUN	O	B-PHYSICAL
was	VERB	O	O
statistically	ADV	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
neoadjuvant	PUNCT	O	O
therapy	NOUN	O	O
than	CCONJ	O	O
those	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
immediate	ADJ	O	O
surgery	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
69	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
42	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
NHT	NOUN	O	O
therapy	NOUN	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-PHYSICAL
with	ADP	O	I-PHYSICAL
pathological	ADJ	O	B-PHYSICAL
stage	NOUN	O	I-PHYSICAL
B	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
67	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
36	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
negative	ADJ	O	O
margins	NOUN	O	B-PHYSICAL
was	VERB	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
after	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
92	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
42	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
clinical	ADJ	O	O
C	NOUN	O	O
tumours	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	PUNCT	O	O

Bupropion	NOUN	O	O
SR	NOUN	O	O
and	CCONJ	O	O
counseling	VERB	O	O
for	ADP	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
in	ADP	O	O
actual	ADJ	O	O
practice	NOUN	O	O
:	PUNCT	O	O
predictors	NOUN	O	O
of	ADP	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
date	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
one	ADP	O	O
study	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
published	VERB	O	O
on	ADP	O	O
individual	ADJ	O	O
characteristics	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
outcome	NOUN	O	O
following	VERB	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
bupropion	NOUN	O	O
SR	NOUN	O	O
for	ADP	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	NOUN	O	O
treatment	NOUN	O	O
outcome	NOUN	O	O
beyond	ADP	O	O
the	DET	O	O
6-week	NOUN	O	O
end-of-treatment	PUNCT	O	O
point	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
characteristics	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
more	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
smoking	VERB	O	O
endpoints	NOUN	O	O
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
bupropion	NOUN	O	O
SR	NOUN	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
1,524	NUM	O	O
smokers	NOUN	O	O
(	PUNCT	O	O
649	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
875	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
average	ADJ	O	O
age	NOUN	O	O
45.1	NUM	O	O
years	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
one	NUM	O	O
of	ADP	O	O
four	NUM	O	O
combinations	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	O
SR	NOUN	O	O
(	PUNCT	O	O
150	ADP	O	O
or	CCONJ	O	O
300	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
counseling	SYM	O	O
(	PUNCT	O	O
tailored	PUNCT	O	O
mailings	PUNCT	O	O
or	CCONJ	O	O
proactive	ADJ	O	O
telephone	NOUN	O	O
counseling	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
assessed	VERB	O	O
for	ADP	O	O
point-prevalent	ADJ	O	O
smoking	DET	O	O
status	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Multiple	ADJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
of	ADP	O	O
potential	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
12-month	NOUN	O	O
point-prevalent	ADJ	O	O
smoking	PROPN	O	O
and	CCONJ	O	O
for	ADP	O	O
persistent	ADJ	O	O
smoking	ADP	O	O
(	PUNCT	O	O
point-prevalent	ADJ	O	O
smoking	VERB	O	O
at	ADP	O	O
both	PUNCT	O	O
follow-ups	PUNCT	O	O
)	PUNCT	O	O
following	VERB	O	O
treatment	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
for	ADP	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
combined	ADP	O	O
and	CCONJ	O	O
separately	ADV	O	O
.	PUNCT	O	O

Risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
smoking	VERB	O	O
at	ADP	O	O
both	CCONJ	O	O
endpoints	NOUN	O	O
in	ADP	O	O
the	DET	O	O
combined	VERB	O	O
sample	NOUN	O	O
included	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
tailored	VERB	O	O
mailings	DET	O	O
,	PUNCT	O	O
female	NOUN	O	O
gender	NOUN	O	O
,	PUNCT	O	O
younger	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
higher	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
tobacco	NOUN	O	O
dependence	NOUN	O	O
,	PUNCT	O	O
shorter	PUNCT	O	O
previous	ADJ	O	O
quit	NOUN	O	O
attempts	PUNCT	O	O
,	PUNCT	O	O
previous	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
report	NOUN	O	O
of	ADP	O	O
current	ADJ	O	O
depressive	ADJ	O	O
symptoms	NOUN	O	O
or	CCONJ	O	O
lifetime	NOUN	O	O
depression	NOUN	O	O
.	PUNCT	O	O

Risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
smoking	VERB	O	O
following	ADP	O	O
treatment	NOUN	O	O
identified	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
only	ADV	O	O
included	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
lower	PUNCT	O	O
dose	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	O
SR	NOUN	O	O
,	PUNCT	O	O
younger	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
higher	PUNCT	O	O
perceived	DET	O	O
stress	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
those	ADP	O	O
that	ADV	O	O
were	VERB	O	O
unique	ADJ	O	O
to	ADP	O	O
men	NOUN	O	O
included	VERB	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
lifetime	NOUN	O	O
depression	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
implications	NOUN	O	O
for	ADP	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
more	ADV	O	B-OTHER
effective	ADJ	O	I-OTHER
treatments	NOUN	O	I-OTHER
in	ADP	O	O
general	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
individual	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
likelihood	NOUN	O	O
of	ADP	O	O
returning	ADJ	O	B-MENTAL
to	ADP	O	I-MENTAL
smoking	ADP	O	I-MENTAL
following	PUNCT	O	I-MENTAL
treatment	NOUN	O	I-MENTAL
for	ADP	O	O
quitting	PROPN	O	O
.	PUNCT	O	O

Social	ADJ	O	O
stories	NOUN	O	O
:	PUNCT	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
effectiveness	NOUN	O	O
in	ADP	O	O
increasing	ADP	O	O
game	NOUN	O	O
play	NOUN	O	O
skills	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
using	VERB	O	O
a	DET	O	O
pretest	ADV	O	O
posttest	ADV	O	O
repeated	VERB	O	O
measures	NOUN	O	O
randomized	VERB	O	O
control	NOUN	O	O
group	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
increasing	ADJ	O	O
body	NOUN	O	O
of	ADP	O	O
literature	NOUN	O	O
has	PUNCT	O	O
indicated	VERB	O	O
that	ADP	O	O
social	ADJ	O	O
stories	NOUN	O	O
are	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
way	NOUN	O	O
to	VERB	O	O
teach	PUNCT	O	O
individuals	PUNCT	O	O
diagnosed	VERB	O	O
with	ADP	O	O
autism	NOUN	O	O
appropriate	ADJ	O	O
social	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
compared	VERB	O	O
two	NUM	O	O
formats	NOUN	O	O
of	ADP	O	O
a	DET	O	O
social	ADJ	O	O
story	ADJ	O	O
targeting	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
social	ADJ	O	B-MENTAL
skills	NOUN	O	I-MENTAL
during	ADP	O	O
game	NOUN	O	O
play	NUM	O	O
using	SYM	O	O
a	DET	O	O
pretest	ADV	O	O
posttest	ADV	O	O
repeated	VERB	O	O
measures	NOUN	O	O
randomized	VERB	O	O
control	NOUN	O	O
group	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
45	NUM	O	O
children	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
Autism	NOUN	O	O
Spectrum	NOUN	O	O
Disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
ages	NOUN	O	O
7-14	PUNCT	O	O
were	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
standard	PUNCT	O	O
,	PUNCT	O	O
directive	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
story	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
and	CCONJ	O	O
directive	ADJ	O	O
story	ADJ	O	O
formats	NOUN	O	O
were	VERB	O	O
equally	ADV	O	O
as	PUNCT	O	O
effective	ADJ	O	O
in	ADP	O	O
eliciting	VERB	O	B-OTHER
,	PUNCT	O	O
generalizing	PUNCT	O	B-OTHER
and	CCONJ	O	O
maintaining	ADP	O	B-MENTAL
the	DET	O	I-MENTAL
targeted	VERB	O	I-MENTAL
social	ADJ	O	I-MENTAL
skills	NOUN	O	I-MENTAL
in	ADP	O	O
participants	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
prior	VERB	O	O
game	NOUN	O	O
play	PUNCT	O	O
experience	ADJ	O	O
and	CCONJ	O	O
Verbal	ADJ	O	B-MENTAL
Comprehension	NOUN	O	I-MENTAL
Index	NOUN	O	O
(	PUNCT	O	B-MENTAL
VCI	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
scores	NOUN	O	I-MENTAL
from	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
WISC-IV	NOUN	O	I-MENTAL
intelligence	PUNCT	O	I-MENTAL

A	DET	O	O
randomized	VERB	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
prelinguistic	ADJ	O	O
communication	NOUN	O	O
interventions	NOUN	O	O
on	ADP	O	O
the	DET	O	O
acquisition	NOUN	O	O
of	ADP	O	O
spoken	PUNCT	O	O
communication	NOUN	O	O
in	ADP	O	O
preschoolers	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
This	PUNCT	O	O
randomized	VERB	O	O
group	NOUN	O	O
experiment	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
communication	NOUN	O	O
interventions	NOUN	O	O
(	PUNCT	O	O
Responsive	ADJ	O	O
Education	NOUN	O	O
and	CCONJ	O	O
Prelinguistic	PUNCT	O	O
Milieu	NOUN	O	O
Teaching	PUNCT	O	O
[	PUNCT	O	O
RPMT	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Picture	NOUN	O	O
Exchange	NOUN	O	O
Communication	NOUN	O	O
System	NOUN	O	O
[	PUNCT	O	O
PECS	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
spoken	PUNCT	O	O
communication	NOUN	O	O
in	ADP	O	O
36	NUM	O	O
preschoolers	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Each	PUNCT	O	O
treatment	NOUN	O	O
was	VERB	O	O
delivered	VERB	O	O
to	ADP	O	O
children	NOUN	O	O
for	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
total	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
hr	NOUN	O	O
over	ADP	O	O
a	DET	O	O
6-month	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Spoken	PUNCT	O	O
communication	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
a	DET	O	O
rigorous	ADJ	O	O
test	NOUN	O	O
of	ADP	O	O
generalization	NOUN	O	O
at	ADP	O	O
pretreatment	NOUN	O	O
,	PUNCT	O	O
posttreatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6-month	NOUN	O	O
follow-up	NOUN	O	O
periods	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
PECS	NOUN	O	B-PHYSICAL
was	VERB	O	I-PHYSICAL
more	ADV	O	I-PHYSICAL
successful	ADJ	O	I-PHYSICAL
than	PUNCT	O	I-PHYSICAL
RPMT	ADJ	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
increasing	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
nonimitative	ADJ	O	B-MENTAL
spoken	PUNCT	O	I-MENTAL
communication	NOUN	O	I-MENTAL
acts	VERB	O	I-MENTAL
and	CCONJ	O	O
the	DET	O	B-PHYSICAL
number	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
different	ADJ	O	I-PHYSICAL
nonimitative	ADJ	O	I-PHYSICAL
words	NOUN	O	I-PHYSICAL
used	VERB	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
posttreatment	ADJ	O	I-PHYSICAL
period	NOUN	O	O
.	PUNCT	O	O

Considering	PUNCT	O	O
growth	NOUN	O	O
over	ADP	O	O
all	DET	O	O
3	NUM	O	O
measurement	NOUN	O	O
periods	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
exploratory	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
growth	NOUN	O	B-MENTAL
rate	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
number	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
different	ADJ	O	I-MENTAL
nonimitative	ADJ	O	I-MENTAL
words	NOUN	O	I-MENTAL
was	ADV	O	O
faster	PUNCT	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
PECS	NOUN	O	I-PHYSICAL
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
RPMT	ADJ	O	O
group	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
who	ADP	O	O
began	ADV	O	O
treatment	NOUN	O	O
with	ADP	O	O
relatively	ADV	O	O
high	ADJ	O	O
object	NOUN	O	O
exploration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
analogous	ADJ	O	B-MENTAL
slopes	ADP	O	I-MENTAL
were	VERB	O	O
steeper	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
RPMT	ADJ	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
PECS	NOUN	O	O
group	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
who	ADP	O	O
began	ADV	O	O
treatment	NOUN	O	O
with	ADP	O	O
relatively	ADV	O	O
low	ADJ	O	O
object	NOUN	O	O
exploration	NOUN	O	O
.	PUNCT	O	O

Rationale	NOUN	O	O
and	CCONJ	O	O
design	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
an	DET	O	O
evidence-based	VERB	O	O
prescription	NOUN	O	O
drug	NOUN	O	O
label	NOUN	O	O
on	ADP	O	O
actual	ADJ	O	O
medication	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Medication	NOUN	O	O
errors	NOUN	O	O
are	NOUN	O	O
an	DET	O	O
important	ADJ	O	O
public	ADJ	O	O
health	NOUN	O	O
concern	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
poor	ADJ	O	O
understanding	VERB	O	O
of	ADP	O	O
medication	NOUN	O	O
labels	ADP	O	O
are	VERB	O	O
a	DET	O	O
root	NOUN	O	O
cause	NUM	O	O
.	PUNCT	O	O

Research	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
labels	ADJ	O	O
are	VERB	O	O
variable	ADJ	O	O
,	PUNCT	O	O
of	ADP	O	O
poor	ADJ	O	O
quality	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
not	ADV	O	O
patient-centered	NUM	O	O
.	PUNCT	O	O

No	DET	O	O
real-world	NOUN	O	O
trials	NOUN	O	O
have	ADJ	O	O
evaluated	VERB	O	O
whether	ADP	O	O
improved	VERB	O	O
medication	NOUN	O	O
labels	NOUN	O	O
can	VERB	O	O
affect	VERB	O	O
appropriate	ADJ	O	O
medication	NOUN	O	O
use	NOUN	O	O
,	PUNCT	O	O
adherence	NOUN	O	O
or	CCONJ	O	O
health	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

TRIAL	NOUN	O	O
DESIGN	NOUN	O	O
We	PRON	O	O
developed	VERB	O	O
an	DET	O	O
evidence-based	VERB	O	O
prescription	NOUN	O	O
label	NOUN	O	O
that	ADP	O	O
addresses	PART	O	O
both	PUNCT	O	O
content	NOUN	O	O
and	CCONJ	O	O
format	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
enhanced	VERB	O	O
label	NOUN	O	O
includes	NOUN	O	O
a	DET	O	O
universal	ADJ	O	O
medication	NOUN	O	O
schedule	NOUN	O	O
(	PUNCT	O	O
UMS	NOUN	O	O
)	PUNCT	O	O
that	PUNCT	O	O
standardizes	ADP	O	O
the	DET	O	O
directions	NOUN	O	O
for	ADP	O	O
use	NOUN	O	O
incorporating	PROPN	O	O
1	NUM	O	O
)	PUNCT	O	O
standard	DET	O	O
time	NOUN	O	O
periods	NOUN	O	O
for	ADP	O	O
administration	NOUN	O	O
(	PUNCT	O	O
morning	NOUN	O	O
,	PUNCT	O	O
noon	NOUN	O	O
,	PUNCT	O	O
evening	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bedtime	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
numeric	ADJ	O	O
vs.	CCONJ	O	O
alpha	NOUN	O	O
characters	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
'carriage	PUNCT	O	O
returns	ADP	O	O
'	PUNCT	O	O
to	PUNCT	O	O
separate	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
graphic	ADJ	O	O
aid	ADP	O	O
to	ADP	O	O
visually	CCONJ	O	O
depict	PUNCT	O	O
dose	NOUN	O	O
and	CCONJ	O	O
frequency	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
will	VERB	O	O
evaluate	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
providing	PUNCT	O	O
this	DET	O	O
label	NOUN	O	O
to	ADP	O	O
randomly	ADV	O	O
sampled	DET	O	O
patients	NOUN	O	O
who	NUM	O	O
receive	PUNCT	O	O
their	ADP	O	O
care	NOUN	O	O
from	ADP	O	O
free	ADJ	O	O
clinics	ADP	O	O
,	PUNCT	O	O
mobile	ADJ	O	O
vans	ADP	O	O
and	CCONJ	O	O
federally	ADV	O	O
qualified	VERB	O	O
health	NOUN	O	O
centers	NOUN	O	O
(	PUNCT	O	O
FQHCs	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
Northern	NOUN	O	O
Virginia	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
will	ADV	O	O
recruit	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
or	CCONJ	O	O
hypertension	NOUN	O	O
;	PUNCT	O	O
these	DET	O	O
patients	NOUN	O	O
will	ADP	O	O
be	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
all	PUNCT	O	O
of	ADP	O	O
their	ADP	O	O
medications	NOUN	O	O
with	ADP	O	O
improved	NOUN	O	O
labels	NOUN	O	O
or	CCONJ	O	O
to	PART	O	O
receive	PART	O	O
prescriptions	ADJ	O	O
with	ADP	O	O
standard	ADJ	O	O
labels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
will	PUNCT	O	O
be	VERB	O	O
the	DET	O	O
patient	NOUN	O	B-MENTAL
's	PUNCT	O	O
ability	NOUN	O	B-MENTAL
to	PUNCT	O	I-MENTAL
correctly	DET	O	I-MENTAL
demonstrate	VERB	O	I-MENTAL
dosing	ADJ	O	I-MENTAL
instructions	NOUN	O	I-MENTAL
.	PUNCT	O	O

Other	ADJ	O	O
outcomes	NOUN	O	O
include	VERB	O	O
adherence	NOUN	O	B-MENTAL
,	PUNCT	O	O
error	ADJ	O	O
rates	NOUN	O	B-OTHER
and	CCONJ	O	O
health	NOUN	O	B-PHYSICAL
outcomes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
To	ADP	O	O
our	PUNCT	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
prescription	NOUN	O	O
label	NOUN	O	O
improvement	NOUN	O	O
on	ADP	O	O
understanding	VERB	O	B-MENTAL
,	PUNCT	O	O
medication	NOUN	O	B-MENTAL
use	NOUN	O	I-MENTAL
and	CCONJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
setting	VERB	O	O
.	PUNCT	O	O

If	ADP	O	O
successful	ADJ	O	O
,	PUNCT	O	O
these	DET	O	O
findings	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
implemented	PROPN	O	O
broadly	ADP	O	O
to	PART	O	O
promote	PUNCT	O	O
safe	ADJ	O	O
and	CCONJ	O	O
appropriate	ADJ	O	O
medication	NOUN	O	O
use	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
support	NOUN	O	O
evidence-based	VERB	O	O
standards	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
labels	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
Chinese	NOUN	O	O
medical	ADJ	O	O
herbs	NOUN	O	O
complex	NOUN	O	O
on	ADP	O	O
cellular	ADJ	O	O
immunity	NOUN	O	O
and	CCONJ	O	O
toxicity-related	VERB	O	O
conditions	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Rose	NOUN	O	O
geranium	NOUN	O	O
(	PUNCT	O	O
Pelargonium	NOUN	O	O
graveolens	NOUN	O	O
,	PUNCT	O	O
Geraniaceae	NOUN	O	O
)	PUNCT	O	O
has	ADP	O	O
anti-cancer	NOUN	O	O
and	CCONJ	O	O
anti-inflammatory	ADJ	O	O
properties	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
promotes	VERB	O	O
wound	NOUN	O	O
healing	VERB	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
Ganoderma	NOUN	O	O
tsugae	NOUN	O	O
(	PUNCT	O	O
Ganodermataceae	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Codonopsis	NOUN	O	O
pilosula	NOUN	O	O
(	PUNCT	O	O
Campanulaceae	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Angelica	NOUN	O	O
sinensis	NOUN	O	O
(	PUNCT	O	O
Apiaceae	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
traditional	ADJ	O	O
Chinese	NOUN	O	O
herbs	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
immunomodulatory	ADJ	O	O
functions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
Chinese	NOUN	O	O
medicinal	ADJ	O	O
herb	ADJ	O	O
complex	NOUN	O	O
,	PUNCT	O	O
RG-CMH	NOUN	O	O
,	PUNCT	O	O
which	DET	O	O
represents	NOUN	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
rose	ADP	O	O
geranium	NOUN	O	O
and	CCONJ	O	O
extracts	NOUN	O	O
of	ADP	O	O
G.	PUNCT	O	O
tsugae	ADP	O	O
,	PUNCT	O	O
C.	NOUN	O	O
pilosula	NOUN	O	O
and	CCONJ	O	O
A.	NOUN	O	O
sinensis	NOUN	O	O
,	PUNCT	O	O
can	VERB	O	O
improve	VERB	O	O
the	DET	O	O
immune	ADJ	O	O
cell	NOUN	O	O
count	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
receiving	VERB	O	O
chemotherapy	NOUN	O	O
and/or	CCONJ	O	O
radiotherapy	NOUN	O	O
to	PROPN	O	O
prevent	ADJ	O	O
leucopenia	NOUN	O	O
and	CCONJ	O	O
immune	ADJ	O	O
impairment	NOUN	O	O
that	ADP	O	O
usually	ADV	O	O
occurs	NOUN	O	O
during	ADP	O	O
cancer	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
fifty-eight	PUNCT	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
chemotherapy	NOUN	O	O
or	CCONJ	O	O
radiotherapy	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

Immune	ADJ	O	O
cell	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
patient	NOUN	O	O
serum	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
before	CCONJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
following	DET	O	O
,	PUNCT	O	O
6	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
either	PUNCT	O	O
an	DET	O	O
RG-CMH	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
RG-CMH	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
leucocytes	NOUN	O	I-PHYSICAL
from	ADP	O	O
31?5	NOUN	O	O
%	SYM	O	O
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
to	ADP	O	O
13?4	ADP	O	O
%	SYM	O	O
for	ADP	O	O
the	DET	O	O
RG-CMH	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
neutrophils	NOUN	O	O
significantly	ADV	O	O
decreased	VERB	O	O
from	ADP	O	O
35?6	NOUN	O	O
%	SYM	O	O
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
to	VERB	O	O
11?0	NOUN	O	O
%	SYM	O	O
for	ADP	O	O
the	DET	O	O
RG-CMH	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

RG-CMH	NOUN	O	O
intervention	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
levels	NOUN	O	O
of	ADP	O	O
T	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
helper	NOUN	O	O
T	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
cytotoxic	ADJ	O	O
T	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
natural	ADJ	O	O
killer	NOUN	O	O
cells	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
RG-CMH	NOUN	O	O
to	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
chemotherapy/radiotherapy	NOUN	O	O
may	PUNCT	O	O
have	PUNCT	O	O
the	DET	O	O
capacity	NOUN	O	O
to	ADP	O	O
delay	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
ease	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
levels	NOUN	O	O
of	ADP	O	O
leucocytes	NOUN	O	O
and	CCONJ	O	O
neutrophils	NOUN	O	O
that	ADP	O	O
are	VERB	O	O
experienced	VERB	O	O
by	ADP	O	O
patients	NOUN	O	O
during	ADP	O	O
cancer	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Immunoenhanced	DET	O	O
enteral	ADJ	O	O
nutrition	NOUN	O	O
formulas	PUNCT	O	O
in	ADP	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	ADJ	O	O
cancer	NOUN	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Significant	ADJ	O	O
malnutrition	NOUN	O	O
exists	NOUN	O	O
in	ADP	O	O
a	DET	O	O
high	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Malnutrition	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
defects	NOUN	O	O
in	ADP	O	O
immune	ADJ	O	O
function	NOUN	O	O
that	ADP	O	O
may	VERB	O	O
impair	VERB	O	O
the	DET	O	O
host	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
malignancy	NOUN	O	O
.	PUNCT	O	O

Malnutrition	NOUN	O	O
and	CCONJ	O	O
immunosupression	NOUN	O	O
make	VERB	O	O
patients	NOUN	O	O
highly	ADV	O	O
susceptible	ADJ	O	O
to	ADP	O	O
postoperative	ADJ	O	O
infections	NOUN	O	O
and	CCONJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Compare	ADV	O	O
two	NUM	O	O
immunoenhanced	VERB	O	O
enteral	ADJ	O	O
nutritions	NOUN	O	O
with	ADP	O	O
a	DET	O	O
control	NOUN	O	O
diet	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
evaluate	ADJ	O	O
the	DET	O	O
effect	NOUN	O	O
in	ADP	O	O
postoperative	ADJ	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
length	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
stay	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
inflammatory	ADJ	O	B-PHYSICAL
markers	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

PATIENTS	NOUN	O	O
A	PUNCT	O	O
population	NOUN	O	O
of	ADP	O	O
44	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
oral	ADJ	O	O
and	CCONJ	O	O
laryngeal	ADJ	O	O
cancer	NOUN	O	O
was	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
three	DET	O	O
groups	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
group	NOUN	O	O
I	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
patients	NOUN	O	O
receiving	VERB	O	O
an	DET	O	O
arginine-enhanced	VERB	O	O
formula	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
II	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
patients	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
standard	ADJ	O	O
polymeric	ADJ	O	O
formula	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
group	NOUN	O	O
III	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
receiving	VERB	O	O
an	DET	O	O
arginine	NOUN	O	O
,	PUNCT	O	O
RNA	NOUN	O	O
and	CCONJ	O	O
omega-3	NOUN	O	O
fatty	ADJ	O	O
acids	NOUN	O	O
enhanced	PUNCT	O	O
formula	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
an	DET	O	O
isonitrogenous	ADJ	O	O
way	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
enteral	ADJ	O	B-PHYSICAL
nutrition	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
an	DET	O	O
average	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
14,5	NOUN	O	O
+/-	SYM	O	O
8	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
length	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-PHYSICAL
stay	NOUN	O	I-PHYSICAL
was	VERB	O	O
similar	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
19,8	NOUN	O	O
+/-	SYM	O	O
8,5	NOUN	O	O
days	NOUN	O	O
.	PUNCT	O	O

Wound	NOUN	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
general	ADJ	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
were	VERB	O	O
more	ADV	O	O
frequent	ADP	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Fistula	NOUN	O	O
rates	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
improved	VERB	O	O
in	ADP	O	O
the	DET	O	O
enhanced	VERB	O	O
diet	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
intergroup	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
trend	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
plasma	NOUN	O	O
proteins	NOUN	O	O
(	PUNCT	O	O
albumin	NOUN	O	O
,	PUNCT	O	O
transferrin	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
lymphocytes	NOUN	O	O
,	PUNCT	O	O
weight	NOUN	O	O
,	PUNCT	O	O
IL-6	NOUN	O	O
,	PUNCT	O	O
CPR	NOUN	O	O
and	CCONJ	O	O
TNFalpha	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
highest	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
TNFalpha	NOUN	O	B-OTHER
at	ADP	O	O
the	DET	O	O
fourteenth	NOUN	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
.	PUNCT	O	O

Gastrointestinal	ADJ	O	O
tolerance	NOUN	O	O
and	CCONJ	O	O
diarrhoea	NOUN	O	O
rate	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
all	DET	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Immunoenhanced	PROPN	O	O
enteral	ADJ	O	O
nutrition	NOUN	O	O
formulas	PUNCT	O	O
improved	VERB	O	O
the	DET	O	O
infection	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
the	DET	O	O
postoperative	ADJ	O	O
of	ADP	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
fistula	NOUN	O	O
rates	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
observed	VERB	O	O
that	ADP	O	O
technical	ADJ	O	O
problems	NOUN	O	O
and	CCONJ	O	O
nutritional	ADJ	O	O
status	NOUN	O	O
might	VERB	O	O
have	PUNCT	O	O
played	VERB	O	O
an	DET	O	O
equally	ADV	O	O
important	ADJ	O	O
role	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
therefore	ADV	O	O
the	DET	O	O
positive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
immunonutrition	NOUN	O	O
in	ADP	O	O
this	DET	O	O
parameter	NOUN	O	O
might	PUNCT	O	O
have	PUNCT	O	O
been	PUNCT	O	O
overestimated	VERB	O	O
.	PUNCT	O	O

Randomized	VERB	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
human	NOUN	O	O
volunteer	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
live	ADJ	O	O
oral	ADJ	O	O
cholera	NOUN	O	O
vaccine	NOUN	O	O
VA1.3	NUM	O	O
for	ADP	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
immune	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
live	ADJ	O	O
oral	ADJ	O	O
cholera	NOUN	O	O
vaccine	NOUN	O	O
developed	VERB	O	O
from	ADP	O	O
a	DET	O	O
non-toxigenic	ADJ	O	O
Vibrio	NOUN	O	O
cholerae	NOUN	O	O
O1	NOUN	O	O
El	NOUN	O	O
Tor	PUNCT	O	O
strain	NOUN	O	O
VA1.3	NUM	O	O
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
randomized	VERB	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
study	NOUN	O	O
for	ADP	O	O
safety	NOUN	O	O
and	CCONJ	O	O
immunogenicity	NOUN	O	O
in	ADP	O	O
304	NUM	O	O
men	NOUN	O	O
aged	VERB	O	O
between	ADP	O	O
16	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
years	NOUN	O	O
from	ADP	O	O
Kolkata	NOUN	O	O
,	PUNCT	O	O
India	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
CFU	NOUN	O	O
(	PUNCT	O	O
n=186	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n=116	NOUN	O	O
)	PUNCT	O	O
containing	VERB	O	O
the	DET	O	O
diluent	ADJ	O	O
buffer	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
vaccine	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
elicit	VERB	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
except	PUNCT	O	O
in	ADP	O	O
two	NUM	O	O
vaccine	NOUN	O	O
recipients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	B-ADVERSE-EFFECTS
diarrhoea	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
vomiting	PUNCT	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

None	NUM	O	O
excreted	PUNCT	O	O
the	DET	O	O
vaccine	NOUN	O	O
strain	NOUN	O	O
.	PUNCT	O	O

Vibriocidal	ADJ	O	B-PHYSICAL
antibody	NOUN	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
developed	PUNCT	O	O
in	ADP	O	O
105/186	ADV	O	O
(	PUNCT	O	O
57	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
5/116	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
vaccine	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
recipients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
,	PUNCT	O	O
anti-CT	NOUN	O	B-PHYSICAL
antibody	NOUN	O	I-PHYSICAL
rose	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
>	PROPN	O	O
or	CCONJ	O	O
=2-folds	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
23/30	PUNCT	O	O
(	PUNCT	O	O
77	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
6/19	NOUN	O	O
(	PUNCT	O	O
32	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
vaccine	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
recipients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
studies	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
VA1.3	NUM	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
is	VERB	O	O
safe	ADJ	O	B-OTHER
and	CCONJ	O	O
immunogenic	ADJ	O	B-OTHER
in	ADP	O	O
adults	NOUN	O	O
from	ADP	O	O
a	DET	O	O
cholera	NOUN	O	O
endemic	ADJ	O	O
region	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
stable	ADJ	O	O
prostacyclin	NOUN	O	O
analogue	NOUN	O	O
(	PUNCT	O	O
iloprost	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
ischaemic	ADJ	O	O
ulcers	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lower	PUNCT	O	O
limb	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
Scandinavian-Polish	NOUN	O	O
placebo	NOUN	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
randomised	VERB	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
of	ADP	O	O
the	DET	O	O
prostacyclin	NOUN	O	O
analogue	NOUN	O	O
iloprost	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
during	ADP	O	O
a	DET	O	O
2	NUM	O	O
week	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
month	NOUN	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
in	ADP	O	O
103	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
ischaemic	ADJ	O	O
ulcers	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
active	ADJ	O	O
treatment	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Responders	NOUN	O	O
were	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
those	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
achieved	PUNCT	O	O
healing	VERB	O	O
of	ADP	O	O
at	ADJ	O	O
least	ADV	O	O
one	NUM	O	O
third	ADJ	O	O
of	ADP	O	O
the	DET	O	O
ulcer	NOUN	O	O
area	NOUN	O	O
during	ADP	O	O
the	DET	O	O
study	ADV	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	O
responder	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
41.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
25	NUM	O	O
%	SYM	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.086	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Side	NOUN	O	O
effects	NOUN	O	O
including	VERB	O	O
flushing	VERB	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
headache	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
were	VERB	O	O
common	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
study	ADV	O	O
population	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
mortality	NOUN	O	B-MORTALITY
of	ADP	O	O
23	NUM	O	O
%	SYM	O	O
during	ADP	O	O
the	DET	O	O
6	NUM	O	O
month	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
amputation	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
43.5	NUM	O	O
%	SYM	O	O
for	ADP	O	O
iloprost	PUNCT	O	O
and	CCONJ	O	O
50	NUM	O	O
%	SYM	O	O
for	ADP	O	O
placebo	NOUN	O	O
treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	PUNCT	O	O
severely	PRON	O	O
diseased	VERB	O	O
population	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
a	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
limited	VERB	O	O
to	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
sufficiently	ADV	O	O
improve	VERB	O	O
ulcer	NOUN	O	B-PHYSICAL
healing	VERB	O	I-PHYSICAL
.	PUNCT	O	O

Cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
non-depolarizing	VERB	O	O
neuromuscular	ADJ	O	O
blockers	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
aortic	ADJ	O	O
valve	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
compare	NOUN	O	O
haemodynamic	ADJ	O	O
responses	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
equipotent	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
neuromuscular	ADJ	O	O
blockers	NOUN	O	O
and	CCONJ	O	O
high-dose	NOUN	O	O
fentanyl	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
micrograms.kg-1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
40	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
aortic	ADJ	O	O
valve	NOUN	O	O
stenosis	NOUN	O	O
(	PUNCT	O	O
AS	ADP	O	O
)	PUNCT	O	O
and	CCONJ	O	O
20	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
aortic	ADJ	O	O
insufficiency	NOUN	O	O
(	PUNCT	O	O
AI	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
four	NUM	O	O
study	ADV	O	O
groups	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
the	DET	O	O
following	PUNCT	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
pancuronium	NOUN	O	O
0.12	NUM	O	O
mg.kg-1	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
vecuronium	NOUN	O	O
0.12	NUM	O	O
mg.kg-1	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
atracurium	NOUN	O	O
0.4	NUM	O	O
mg.kg-1	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
pancuronium-metocurine	NOUN	O	O
mixture	NOUN	O	O
(	PUNCT	O	O
0.4	NUM	O	O
mg	NOUN	O	O
+	SYM	O	O
1.6	NUM	O	O
mg/ml	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
1	NUM	O	O
ml/10	NOUN	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Neuromuscular	ADJ	O	O
blockers	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
with	ADP	O	O
the	DET	O	O
fentanyl	NOUN	O	O
;	PUNCT	O	O
haemodynamics	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
with	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
awake	ADJ	O	O
(	PUNCT	O	O
baseline	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
at	ADP	O	O
two	NUM	O	O
minutes	NOUN	O	O
post-induction	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
two	NUM	O	O
and	CCONJ	O	O
five	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
intubation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
AS	ADP	O	O
,	PUNCT	O	O
pancuronium	NOUN	O	O
increased	VERB	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
more	ADV	O	O
than	PUNCT	O	O
vecuronium	NOUN	O	O
or	CCONJ	O	O
atracurium	NOUN	O	O
;	PUNCT	O	O
heart	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
were	VERB	O	O
also	ADV	O	O
higher	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
pancuronium-metocurine	NOUN	O	O
mixture	NOUN	O	O
than	PUNCT	O	O
with	ADP	O	O
vecuronium	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
ECG	NOUN	O	B-PHYSICAL
signs	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
ischaemia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
given	ADJ	O	O
pancuronium	NOUN	O	O
developed	VERB	O	O
severe	ADJ	O	B-PHYSICAL
hypotension	NOUN	O	I-PHYSICAL
associated	VERB	O	O
with	ADP	O	B-PHYSICAL
tachycardia	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Reductions	NOUN	O	O
in	ADP	O	O
SVR	NOUN	O	B-PHYSICAL
after	ADP	O	O
atracurium	NOUN	O	O
allowed	VERB	O	O
small	ADJ	O	O
but	CCONJ	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
decreases	PROPN	O	O
in	ADP	O	O
MAP	NOUN	O	B-PHYSICAL
which	ADP	O	O
were	VERB	O	O
well	VERB	O	B-OTHER
tolerated	ADP	O	I-OTHER
;	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
did	PUNCT	O	O
develop	VERB	O	O
severe	ADJ	O	B-PHYSICAL
hypotension	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Intubation	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
increases	NOUN	O	O
in	ADP	O	O
MAP	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
pancuronium-metocurine	NOUN	O	O
mixture	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Vecuronium	NOUN	O	O
permitted	VERB	O	O
the	DET	O	O
most	ADP	O	O
stable	ADJ	O	O
overall	ADJ	O	B-PHYSICAL
haemodynamic	ADJ	O	B-PHYSICAL
course	NOUN	O	B-PHYSICAL
at	ADP	O	O
all	DET	O	O
measurement	NOUN	O	O
times	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
AI	NOUN	O	O
showed	VERB	O	O
stable	ADJ	O	B-PHYSICAL
haemodynamics	NOUN	O	B-PHYSICAL
after	ADP	O	O
vecuronium	NOUN	O	O
,	PUNCT	O	O
pancuronium	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
pancuronium-metocurine	NOUN	O	O
mixture	NOUN	O	O
;	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
became	ADP	O	O
tachycardic	NOUN	O	B-PHYSICAL
following	PUNCT	O	O
vecuronium	NOUN	O	O
.	PUNCT	O	O

Atracurium	NOUN	O	O
caused	VERB	O	O
unexplained	VERB	O	O
elevations	NOUN	O	O
in	PUNCT	O	O

[	PUNCT	O	O
Clinical	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
retarding	VERB	O	B-PHYSICAL
aging	ADJ	O	I-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
tongbu	NOUN	O	O
recipe	NOUN	O	O
to	ADP	O	O
traditional	ADJ	O	O
Chinese	NOUN	O	O
medicine	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PART	O	O
study	NOUN	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
Tongbu	NOUN	O	O
No	ADP	O	O
.	PUNCT	O	O

1	NUM	O	O
(	PUNCT	O	O
TB1	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
prescription	NOUN	O	O
for	ADP	O	O
reinforcing	ADJ	O	O
Kidney	NOUN	O	O
and	CCONJ	O	O
Spleen	NOUN	O	O
,	PUNCT	O	O
clearing	PUNCT	O	O
up	PUNCT	O	O
the	DET	O	O
bowel	NOUN	O	O
viscera	PUNCT	O	O
to	PUNCT	O	O
send	CCONJ	O	O
Turbid	NOUN	O	O
downward	ADJ	O	O
and	CCONJ	O	O
regulating	ADP	O	O
Qi	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
retarding	VERB	O	B-PHYSICAL
aging	VERB	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
indexes	PUNCT	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
56	NUM	O	O
old	ADJ	O	O
subjects	NOUN	O	O
randomized	PUNCT	O	O
into	ADP	O	O
3	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
TB1	NOUN	O	O
(	PUNCT	O	O
containing	ADP	O	O
ginseng	PUNCT	O	O
leaf	PUNCT	O	O
,	PUNCT	O	O
cistanche	NOUN	O	O
,	PUNCT	O	O
fleeceflower	PUNCT	O	O
root	NOUN	O	O
,	PUNCT	O	O
immature	ADJ	O	O
bitter	ADJ	O	O
orange	NOUN	O	O
,	PUNCT	O	O
rhubarb	NOUN	O	O
,	PUNCT	O	O
etc	NOUN	O	O
)	PUNCT	O	O
could	VERB	O	O
improve	VERB	O	O
various	ADJ	O	O
symptoms	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
aging	VERB	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
had	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
in	ADP	O	O
regulating	VERB	O	B-PHYSICAL
immune	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
endocrinal	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
scavenging	ADP	O	B-PHYSICAL
free	ADJ	O	I-PHYSICAL
radicals	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
adjusting	SYM	O	B-PHYSICAL
coli	NOUN	O	I-PHYSICAL
flora	ADJ	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
TB1	NOUN	O	O
and	CCONJ	O	O
TB2	NOUN	O	O
(	PUNCT	O	O
containing	ADP	O	O
ginseng	PUNCT	O	O
leaf	PUNCT	O	O
,	PUNCT	O	O
cistanche	NOUN	O	O
and	CCONJ	O	O
fleeceflower	PUNCT	O	O
root	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
different	ADJ	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
TB1	NOUN	O	O
has	ADP	O	O
a	DET	O	O
good	ADJ	O	O
comprehensive	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
retarding	VERB	O	B-PHYSICAL
aging	VERB	O	I-PHYSICAL
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
radiation	NOUN	O	O
dose	NOUN	O	O
on	ADP	O	O
local	ADJ	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
after	ADP	O	O
breast	NOUN	O	O
conserving	PROPN	O	O
treatment	NOUN	O	O
:	PUNCT	O	O
EORTC	NOUN	O	O
trial	NOUN	O	O
22881-10882	NUM	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
determine	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
boost	CCONJ	O	O
radiation	NOUN	O	O
after	ADP	O	O
breast	NOUN	O	O
conservative	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
BCT	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
local	ADJ	O	O
control	NOUN	O	O
depends	NOUN	O	O
on	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
evaluate	ADJ	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
policy	NOUN	O	O
with	ADP	O	O
a	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
We	ADJ	O	O
used	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
EORTC	NOUN	O	O
22881-10882	NUM	O	O
trial	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
of	ADP	O	O
77.4	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
receiving	VERB	O	O
BCT	NOUN	O	O
and	CCONJ	O	O
50Gy	PUNCT	O	O
whole	ADJ	O	O
breast	NOUN	O	O
irradiation	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
no	CCONJ	O	O
boost	ADV	O	O
and	CCONJ	O	O
16Gy	PUNCT	O	O
boost	PUNCT	O	O
(	PUNCT	O	O
N=5318	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
univariate	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
boost	ADP	O	O
reduced	DET	O	O
local	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
by	ADP	O	O
a	DET	O	O
factor	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Multivariate	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
local	ADJ	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
increased	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
(	PUNCT	O	O
P=0.0003	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
relative	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
boost	ADV	O	O
on	ADP	O	O
local	ADJ	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
depends	NOUN	O	O
on	ADP	O	O
age	NOUN	O	O
(	PUNCT	O	O
P=0.97	NOUN	O	O
)	PUNCT	O	O
However	ADV	O	O
in	ADP	O	O
younger	PUNCT	O	O
patients	NOUN	O	O
the	DET	O	O
5-year	ADJ	O	O
local	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
,	PUNCT	O	O
therefore	ADV	O	O
the	DET	O	O
absolute	ADJ	O	O
reduction	NOUN	O	O
was	VERB	O	O
greater	PUNCT	O	O
.	PUNCT	O	O

If	PUNCT	O	O
the	DET	O	O
threshold-age	NOUN	O	O
for	ADP	O	O
boost	PUNCT	O	O
treatment	NOUN	O	O
were	VERB	O	O
set	ADP	O	O
at	ADP	O	O
40	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
8.4	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
study	ADV	O	O
population	NOUN	O	O
would	VERB	O	O
receive	VERB	O	O
a	DET	O	O
boost	ADV	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
a	DET	O	O
5-year	ADJ	O	O
local	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
of	ADP	O	O
6.1	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
study	ADV	O	O
population	NOUN	O	O
.	PUNCT	O	O

Changing	PROPN	O	O
the	DET	O	O
threshold-age	NOUN	O	O
to	ADP	O	O
60	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
67	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
study	ADV	O	O
population	NOUN	O	O
would	VERB	O	O
receive	VERB	O	O
a	DET	O	O
boost	ADV	O	O
and	CCONJ	O	O
the	DET	O	O
5-year	ADJ	O	O
local	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
would	VERB	O	O
be	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
4.4	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
younger	PUNCT	O	O
patients	NOUN	O	O
a	DET	O	O
boost	PUNCT	O	O
dose	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
absolute	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
local	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
reduction	NOUN	O	B-OTHER
was	ADJ	O	O
however	ADV	O	O
similar	ADJ	O	O
for	ADP	O	O
all	DET	O	O
ages	NOUN	O	O
.	PUNCT	O	O

Applying	VERB	O	O
a	DET	O	O
treatment	NOUN	O	O
policy	NOUN	O	O
with	ADP	O	O
a	DET	O	O
threshold-age	NOUN	O	O
of	ADP	O	O
60	PUNCT	O	O
would	ADJ	O	O
result	PRON	O	O
in	ADP	O	O
0.6	NUM	O	O
%	ADV	O	O
increase	NOUN	O	O
in	ADP	O	O
local	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
study	NOUN	O	O
population	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
sparing	PUNCT	O	O
the	PUNCT	O	O
boost	CCONJ	O	O
to	ADP	O	O
1/3	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Two-year	ADJ	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
immediate	ADJ	O	O
replacement	NOUN	O	O
vs.	CCONJ	O	O
immediate	ADJ	O	O
restoration	NOUN	O	O
of	ADP	O	O
single	ADJ	O	O
tooth	NOUN	O	O
in	ADP	O	O
the	DET	O	O
esthetic	ADJ	O	O
zone	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
immediate	ADJ	O	O
restoration	NOUN	O	O
of	ADP	O	O
single	ADJ	O	O
implants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
esthetic	ADJ	O	O
zones	NOUN	O	O
performed	VERB	O	O
on	ADP	O	O
implants	NOUN	O	O
placed	PUNCT	O	O
immediately	ADV	O	O
after	ADP	O	O
tooth	NOUN	O	O
extraction	NOUN	O	O
or	CCONJ	O	O
8	NUM	O	O
weeks	NOUN	O	O
later	ADJ	O	O
(	PUNCT	O	O
immediate	ADJ	O	O
replacement	NOUN	O	O
vs.	CCONJ	O	O
immediate	ADJ	O	O
restoration	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixteen	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
women	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
men	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
age	NOUN	O	O
of	ADP	O	O
35	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
ranging	PUNCT	O	O
from	ADP	O	O
21	NUM	O	O
to	ADP	O	O
49	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
from	ADP	O	O
2004	NUM	O	O
to	ADP	O	O
2005	NUM	O	O
for	ADP	O	O
single-tooth	PUNCT	O	O
replacement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
arch	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
test	ADV	O	O
group	NOUN	O	O
patients	NOUN	O	O
received	DET	O	O
implants	NOUN	O	O
placed	ADP	O	O
and	CCONJ	O	O
restored	ADJ	O	O
(	PUNCT	O	O
non-occlusal	ADJ	O	O
loading	VERB	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
tooth	NOUN	O	O
extraction	NOUN	O	O
;	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
implants	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
8	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
tooth	NOUN	O	O
extraction	NOUN	O	O
and	CCONJ	O	O
immediately	ADV	O	O
restored	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
the	DET	O	O
patients	NOUN	O	O
received	DET	O	O
tapered	PUNCT	O	O
effect	NOUN	O	O
(	PUNCT	O	O
TE	NOUN	O	O
)	PUNCT	O	O
implants	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Straumann	NOUN	O	O
Dental	ADJ	O	O
Implant	NOUN	O	O
System	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
following	ADJ	O	O
parameters	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
the	DET	O	O
moment	ADJ	O	O
of	ADP	O	O
provisional	ADJ	O	O
restoration	NOUN	O	O
(	PUNCT	O	O
within	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
implant	NOUN	O	O
placement	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
2	NUM	O	O
years	NOUN	O	O
follow-up	NOUN	O	O
visit	NOUN	O	O
:	PUNCT	O	O
marginal	ADJ	O	B-PHYSICAL
bone	NOUN	O	I-PHYSICAL
resorption	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
papilla	NOUN	O	B-PHYSICAL
index	NOUN	O	O
,	PUNCT	O	O
position	NOUN	O	O
of	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
mucosal	ADJ	O	I-PHYSICAL
margin	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
implant	NOUN	O	B-PHYSICAL
stability	NOUN	O	I-PHYSICAL
quotient	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
moment	ADJ	O	O
of	ADP	O	O
implant	NOUN	O	O
placement	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
moment	ADJ	O	O
of	ADP	O	O
the	DET	O	O
delivery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
definitive	ADJ	O	O
restoration	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
studied	DET	O	O
parameters	NOUN	O	O
between	ADP	O	O
the	DET	O	O
test	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
implant	NOUN	O	B-PHYSICAL
stability	NOUN	O	O
quotient	NOUN	O	O
values	NOUN	O	O
between	ADP	O	O
the	DET	O	O
test	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
moment	ADJ	O	O
of	ADP	O	O
implant	NOUN	O	O
placement	NOUN	O	O
but	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
more	DET	O	O
significant	ADJ	O	O
at	ADP	O	O
the	DET	O	O
loading	VERB	O	O
of	ADP	O	O
the	DET	O	O
definitive	ADJ	O	O
restoration	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
immediate	ADJ	O	O
replacement	NOUN	O	O
without	ADP	O	O
functional	ADJ	O	O
loading	VERB	O	O
may	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
a	DET	O	O
valuable	ADJ	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
for	ADP	O	O
selected	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
single-tooth	PUNCT	O	O
replacement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
esthetic	ADJ	O	O
area	NOUN	O	O
when	ADP	O	O
TE	NOUN	O	O
implants	NOUN	O	O
are	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

Implant	NOUN	O	B-PHYSICAL
stability	NOUN	O	I-PHYSICAL
at	ADP	O	O
the	DET	O	O
moment	ADJ	O	O
of	ADP	O	O
implant	NOUN	O	O
placement	NOUN	O	O
is	VERB	O	O
slightly	ADV	O	O
inferior	ADJ	O	O
in	ADP	O	O
the	DET	O	O
immediate	ADJ	O	O
replacement	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
does	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
result	NOUN	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
control	NOUN	O	I-PAIN
for	ADP	O	O
outpatient	ADJ	O	O
oral	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

16	NUM	O	O
healthy	ADJ	O	O
patients	NOUN	O	O
requiring	DET	O	O
removal	NOUN	O	O
of	ADP	O	O
bilateral	ADJ	O	O
symmetrically-impacted	ADJ	O	O
mandibular	ADJ	O	O
third	ADJ	O	O
molars	NOUN	O	O
participated	DET	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
randomised	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
to	ADP	O	O
test	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
control	NOUN	O	I-PAIN
using	VERB	O	O
a	DET	O	O
long-acting	VERB	O	O
anti-inflammatory	ADJ	O	O
agent	NOUN	O	O
(	PUNCT	O	O
diflunisal	ADP	O	O
)	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
a	DET	O	O
long-acting	VERB	O	O
local	ADJ	O	O
anaesthetic	ADJ	O	O
agent	NOUN	O	O
(	PUNCT	O	O
bupivacaine	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
more	DET	O	O
traditional	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
using	PUNCT	O	O
an	DET	O	O
oral	ADJ	O	O
analgesic	CCONJ	O	O
with	ADP	O	O
shorter	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
(	PUNCT	O	O
paracetamol	NOUN	O	O
with	ADP	O	O
codeine	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
lignocaine	ADP	O	O
as	ADP	O	O
the	DET	O	O
local	ADJ	O	O
anaesthetic	ADJ	O	O
.	PUNCT	O	O

Using	ADJ	O	O
a	DET	O	O
visual	ADJ	O	B-PAIN
analogue	NOUN	O	I-PAIN
pain	NOUN	O	I-PAIN
scale	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
reported	VERB	O	O
that	ADP	O	O
significantly	ADV	O	O
reduced	ADV	O	O
pain	NOUN	O	B-PAIN
was	VERB	O	O
experienced	VERB	O	O
over	ADP	O	O
the	DET	O	O
first	ADJ	O	O
4	NUM	O	O
days	NOUN	O	O
postoperatively	ADV	O	O
with	ADP	O	O
the	DET	O	O
diflunisal/bupivacaine	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
patient	NOUN	O	B-PAIN
preference	NOUN	O	I-PAIN
for	ADP	O	O
this	DET	O	O
treatment	NOUN	O	O
was	VERB	O	O
highly	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
represents	NOUN	O	O
the	DET	O	O
first	CCONJ	O	O
such	DET	O	O
study	NOUN	O	O
of	ADP	O	O
diflunisal	ADJ	O	O
used	PUNCT	O	O
for	ADP	O	O
an	DET	O	O
extended	VERB	O	O
course	NOUN	O	O
in	ADP	O	O
oral	ADJ	O	O
surgery	NOUN	O	O
with	ADP	O	O
pain	NOUN	O	B-PAIN
assessment	NOUN	O	O
over	ADP	O	O
the	DET	O	O
same	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
side-effects	NOUN	O	B-ADVERSE-EFFECTS
or	CCONJ	O	I-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
reactions	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
encountered	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
immunogenicity	NOUN	O	B-PHYSICAL
of	ADP	O	O
three	NUM	O	O
Haemophilus	NOUN	O	O
influenzae	PUNCT	O	O
type	NOUN	O	O
B	NOUN	O	O
conjugate	PUNCT	O	O
vaccines	NOUN	O	O
after	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
vaccination	NOUN	O	O
series	NOUN	O	O
in	ADP	O	O
Philippine	PUNCT	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
antibody	NOUN	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	O
three	NUM	O	O
Haemophilus	NOUN	O	O
influenzae	PUNCT	O	O
type	NOUN	O	O
b	NOUN	O	O
(	PUNCT	O	O
Hib	NOUN	O	O
)	PUNCT	O	O
capsular	ADJ	O	O
polysaccharide-protein	NOUN	O	O
conjugate	ADJ	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
PRP-OMP	NOUN	O	O
,	PUNCT	O	O
PRP-T	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
HbOC	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
174	NUM	O	O
Philippine	PUNCT	O	O
infants	NOUN	O	O
after	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
vaccination	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
Hib	NOUN	O	O
vaccines	NOUN	O	O
(	PUNCT	O	O
Hib	NOUN	O	O
groups	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
into	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Vaccination	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
at	ADP	O	O
six	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
14	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
local	ADJ	O	O
Expanded	ADP	O	O
Program	NOUN	O	O
of	ADP	O	O
Immunization	NOUN	O	O
schedule	NOUN	O	O
.	PUNCT	O	O

Sera	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
at	ADP	O	O
six	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
for	ADP	O	O
the	DET	O	O
Hib	NOUN	O	O
groups	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
the	DET	O	O
third	ADJ	O	O
dose	NOUN	O	O
for	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Anti-Hib	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
the	DET	O	O
Farr-type	NOUN	O	O
radioimmunoassay	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.3626	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
prevaccination	NOUN	O	B-PHYSICAL
anti-Hib	NOUN	O	I-PHYSICAL
geometric	ADJ	O	O
mean	NOUN	O	O
concentration	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
GMC	NOUN	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
among	ADP	O	O
the	DET	O	O
three	NUM	O	O
Hib	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Differences	NOUN	O	O
in	ADP	O	O
the	PUNCT	O	O

Virtual	ADJ	O	O
reality	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
pain	NOUN	O	O
reduction	NOUN	O	O
in	ADP	O	O
adolescents	NOUN	O	O
undergoing	VERB	O	O
burn	NOUN	O	O
wound	NOUN	O	O
care	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Effective	ADJ	O	O
pain	NOUN	O	O
management	NOUN	O	O
remains	NOUN	O	O
a	DET	O	O
challenge	NOUN	O	O
for	ADP	O	O
adolescents	NOUN	O	O
during	ADP	O	O
conscious	ADJ	O	O
burn	NOUN	O	O
wound	NOUN	O	O
care	NOUN	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Virtual	ADJ	O	O
reality	NOUN	O	O
(	PUNCT	O	O
VR	NOUN	O	O
)	PUNCT	O	O
shows	VERB	O	O
promise	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
non-pharmacological	ADJ	O	O
adjunct	NOUN	O	O
in	ADP	O	O
reducing	PROPN	O	O
pain	NOUN	O	O
.	PUNCT	O	O

AIMS	PUNCT	O	O
This	DET	O	O
study	NOUN	O	O
assessed	VERB	O	O
off-the-shelf	PUNCT	O	O
VR	NOUN	O	O
for	ADP	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
its	PUNCT	O	O
effect	NOUN	O	O
on	ADP	O	O
reducing	SYM	O	O
acute	ADJ	O	O
pain	NOUN	O	O
intensity	NOUN	O	O
during	ADP	O	O
adolescent	NOUN	O	O
burn	ADJ	O	O
wound	NOUN	O	O
care	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
its	ADP	O	O
clinical	ADJ	O	O
utility	NOUN	O	O
in	ADP	O	O
a	DET	O	O
busy	NOUN	O	O
hospital	NOUN	O	O
setting	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty-one	NUM	O	O
adolescents	NOUN	O	O
(	PUNCT	O	O
11-17	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
participated	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
pain	NOUN	O	O
outcomes	NOUN	O	O
including	VERB	O	O
adolescent	NOUN	O	O
self-report	ADJ	O	O
,	PUNCT	O	O
nursing	ADP	O	O
staff	NOUN	O	O
behavioral	ADJ	O	O
observation	NOUN	O	O
,	PUNCT	O	O
caregiver	NOUN	O	O
observation	NOUN	O	O
and	CCONJ	O	O
physiological	ADJ	O	O
measures	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
.	PUNCT	O	O

Length	NOUN	O	O
of	ADP	O	O
procedure	NOUN	O	O
times	NOUN	O	O
and	CCONJ	O	O
adolescent	NOUN	O	O
reactions	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
recorded	VERB	O	O
to	PART	O	O
inform	VERB	O	O
clinical	ADJ	O	O
utility	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADJ	O	O
Nursing	PUNCT	O	O
staff	NOUN	O	O
reported	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
during	ADP	O	O
dressing	PUNCT	O	O
removal	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
less	DET	O	O
rescue	PUNCT	O	B-PHYSICAL
doses	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
Entonox	NOUN	O	I-PHYSICAL
given	ADJ	O	O
to	ADP	O	O
those	PUNCT	O	O
receiving	VERB	O	O
VR	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
those	PUNCT	O	O
receiving	VERB	O	O
standard	ADJ	O	O
distraction	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
all	DET	O	O
other	ADJ	O	O
pain	NOUN	O	O
outcomes	NOUN	O	O
and	CCONJ	O	O
length	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
for	ADP	O	O
lower	PUNCT	O	O
pain	NOUN	O	B-OTHER
scores	NOUN	O	I-OTHER
and	PUNCT	O	I-OTHER
treatment	PUNCT	O	O

Levobunolol	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
timolol	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
four-year	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Fifty-one	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
raised	VERB	O	O
intraocular	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
IOP	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
up	PUNCT	O	O
to	ADV	O	O
four	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
one	NUM	O	O
of	ADP	O	O
three	NUM	O	O
ophthalmic	ADJ	O	O
solutions	NOUN	O	O
:	PUNCT	O	O
0.5	NUM	O	O
%	SYM	O	O
levobunolol	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
%	SYM	O	O
levobunolol	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
0.5	NUM	O	O
%	SYM	O	O
timolol	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
as	ADP	O	O
a	DET	O	O
double-masked	NOUN	O	O
,	PUNCT	O	O
randomised	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
which	DET	O	O
medications	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
twice	ADV	O	O
daily	ADJ	O	O
to	ADP	O	O
both	PUNCT	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

Levobunolol	NOUN	O	O
and	CCONJ	O	O
timolol	NOUN	O	O
were	VERB	O	O
equally	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
overall	ADJ	O	B-PHYSICAL
mean	NOUN	O	O
IOP	NOUN	O	B-PHYSICAL
;	PUNCT	O	O
reductions	NOUN	O	O
were	VERB	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
8.8	NUM	O	O
mmHg	NOUN	O	O
in	ADP	O	O
all	DET	O	O
three	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
showed	VERB	O	O
levobunolol	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
as	PUNCT	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
as	PUNCT	O	O
timolol	ADJ	O	O
in	ADP	O	O
the	DET	O	O
long-term	NOUN	O	O
control	NOUN	O	O
of	PUNCT	O	O
raised	PUNCT	O	O

Behavioral	ADJ	O	B-MENTAL
changes	NOUN	O	I-MENTAL
in	ADP	O	O
autistic	ADJ	O	O
individuals	NOUN	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
wearing	PUNCT	O	O
ambient	ADJ	O	O
transitional	ADJ	O	O
prism	NOUN	O	O
lenses	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
crossover	NOUN	O	O
design	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
wearing	DET	O	O
ambient	ADJ	O	O
lenses	ADP	O	O
to	PUNCT	O	O
reduce	NOUN	O	O
the	DET	O	O
behavioral	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Eighteen	PUNCT	O	O
autistic	ADJ	O	O
individuals	NOUN	O	O
,	PUNCT	O	O
ranging	VERB	O	O
in	ADP	O	O
age	NOUN	O	O
from	ADP	O	O
7	NUM	O	O
to	ADP	O	O
18	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
participated	DET	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Behavior	NOUN	O	B-MENTAL
,	PUNCT	O	O
attention	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
orientation	NOUN	O	B-MENTAL
were	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
1	NUM	O	O
1/2	NOUN	O	O
months	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
condition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
behavior	NOUN	O	B-MENTAL
problems	NOUN	O	I-MENTAL
at	ADP	O	O
the	DET	O	O
1	NUM	O	O
1/2	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
month	NOUN	O	O
assessment	NOUN	O	O
periods	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
slight	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
these	DET	O	O
benefits	NOUN	O	O
at	ADP	O	O
the	DET	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
month	NOUN	O	O
assessment	NOUN	O	O
periods	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
prediction	NOUN	O	O
that	ADP	O	O
ambient	ADJ	O	O
lenses	NOUN	O	O
,	PUNCT	O	O
worn	PUNCT	O	O
without	ADP	O	O
engaging	PUNCT	O	O
in	ADP	O	O
visual-motor	NOUN	O	O
exercises	NOUN	O	O
,	PUNCT	O	O
have	CCONJ	O	O
positive	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
autistic	ADJ	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

Low-dose	NOUN	O	O
mifepristone	NOUN	O	O
for	ADP	O	O
uterine	ADJ	O	O
leiomyomata	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
mifepristone	NOUN	O	O
on	ADP	O	O
uterine	ADJ	O	B-PHYSICAL
leiomyoma	NOUN	O	I-PHYSICAL
size	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
measure	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty	CCONJ	O	O
premenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
large	ADJ	O	O
,	PUNCT	O	O
symptomatic	ADJ	O	O
leiomyomata	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
5	NUM	O	O
or	CCONJ	O	O
10	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
mifepristone	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
an	DET	O	O
open-label	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Uterine	ADJ	O	O
volume	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
bimonthly	PUNCT	O	O
intervals	NOUN	O	O
by	ADP	O	O
sonography	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
hemoglobin	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
follicle-stimulating	VERB	O	O
hormone	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
liver	NOUN	O	O
enzymes	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
endometrial	ADJ	O	O
samples	NOUN	O	O
,	PUNCT	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
menstrual	ADJ	O	O
bleeding	VERB	O	O
were	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Nineteen	PUNCT	O	O
of	ADP	O	O
20	NUM	O	O
subjects	NOUN	O	O
taking	ADP	O	O
5	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
20	NUM	O	O
subjects	NOUN	O	O
taking	ADP	O	O
10	NUM	O	O
mg	NOUN	O	O
completed	ADV	O	O
all	PUNCT	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
uterine	ADJ	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
shrank	NOUN	O	I-PHYSICAL
by	ADP	O	O
48	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
5-mg	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
49	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
10-mg	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
nonsignificant	ADJ	O	O
difference	NOUN	O	O
.	PUNCT	O	O

Leiomyoma-related	VERB	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
were	VERB	O	O
comparably	ADV	O	O
reduced	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Amenorrhea	NOUN	O	B-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
60-65	NUM	O	O
%	SYM	O	O
of	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Hemoglobin	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
increased	PRON	O	O
by	ADP	O	O
2.5	NUM	O	O
g/dL	ADV	O	O
in	ADP	O	O
anemic	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
hot	ADJ	O	B-PHYSICAL
flashes	NOUN	O	I-PHYSICAL
increased	VERB	O	O
significantly	ADV	O	O
over	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
10-mg	PUNCT	O	O
group	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
5-mg	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

Simple	ADJ	O	B-PHYSICAL
endometrial	ADJ	O	I-PHYSICAL
hyperplasia	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
28	NUM	O	O
%	SYM	O	O
of	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
atypical	ADJ	O	B-PHYSICAL
hyperplasia	NOUN	O	I-PHYSICAL
was	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Mifepristone	NOUN	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
10	NUM	O	O
mg	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
comparable	ADJ	O	O
leiomyoma	NOUN	O	B-PHYSICAL
regression	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
improvement	NOUN	O	B-OTHER
in	ADP	O	I-OTHER
symptoms	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
few	ADJ	O	O
side	NOUN	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Further	DET	O	O
study	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
long-term	NOUN	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
low-dose	NOUN	O	O
mifepristone	NOUN	O	O
.	PUNCT	O	O

Prevalence	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
outcome	NOUN	O	O
of	ADP	O	O
cervicitis	NOUN	O	B-PHYSICAL
of	ADP	O	O
unknown	VERB	O	O
etiology	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Mucopurulent	ADJ	O	O
cervicitis	NOUN	O	O
(	PUNCT	O	O
MPC	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
clinical	ADJ	O	O
syndrome	NOUN	O	O
characterized	VERB	O	O
by	ADP	O	O
mucopurulent	ADJ	O	O
discharge	NOUN	O	O
from	ADP	O	O
the	DET	O	O
cervix	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
inflammation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
a	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
placebo	NOUN	O	O
versus	CCONJ	O	O
empiric	ADJ	O	O
antibiotic	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
cure	NOUN	O	O
of	ADP	O	O
MPC	NOUN	O	B-PHYSICAL
of	ADP	O	O
unknown	VERB	O	O
etiology	NOUN	O	O
at	ADP	O	O
2-month	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Unfortunately	ADV	O	O
,	PUNCT	O	O
enrollment	NOUN	O	O
was	VERB	O	O
terminated	VERB	O	O
because	PUNCT	O	O
of	ADP	O	O
low	ADJ	O	O
accrual	ADJ	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
cervicitis	NOUN	O	O
of	ADP	O	O
unknown	VERB	O	O
etiology	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
important	ADJ	O	O
prevalence	NOUN	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
data	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Five	NUM	O	O
hundred	NUM	O	O
seventy-seven	PUNCT	O	O
women	NOUN	O	O
were	VERB	O	O
screened	VERB	O	O
for	ADP	O	O
MPC	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
with	ADP	O	O
MPC	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
arm	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
2	NUM	O	O
arms	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
etiology	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
rates	NOUN	O	I-OTHER
,	PUNCT	O	O
adverse	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
AEs	ADP	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
rates	NOUN	O	O
of	ADP	O	O
pelvic	ADJ	O	B-PHYSICAL
inflammatory	ADJ	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
thirty-one	NOUN	O	O
(	PUNCT	O	O
23	NUM	O	O
%	SYM	O	O
[	PUNCT	O	O
131/577	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
screened	VERB	O	O
women	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
MPC	NOUN	O	O
.	PUNCT	O	O

Eighty-seven	PUNCT	O	O
were	VERB	O	O
enrolled	VERB	O	O
and	CCONJ	O	O
randomized	NUM	O	O
.	PUNCT	O	O

After	ADP	O	O
excluding	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
sexually	ADV	O	O
transmitted	VERB	O	O
infections	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
exclusions	NOUN	O	O
,	PUNCT	O	O
61	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
53/87	PUNCT	O	O
)	PUNCT	O	O
had	PUNCT	O	O
cervicitis	NOUN	O	B-PHYSICAL
of	ADP	O	O
unknown	VERB	O	O
etiology	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	B-OTHER
clinical	ADJ	O	I-OTHER
failure	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
30	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
10/33	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
clinical	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
only	ADV	O	O
24	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
8/33	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Rates	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
arms	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
24	NUM	O	O
gastrointestinal	ADJ	O	B-PHYSICAL
AEs	ADP	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
arm	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
1	NUM	O	O
AE	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
arm	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
More	PUNCT	O	O
than	ADP	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
MPC	NOUN	O	O
were	ADV	O	O
of	ADP	O	O
unknown	VERB	O	O
etiology	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
rates	NOUN	O	I-OTHER
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
were	VERB	O	O
extremely	ADV	O	O
low	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
most	DET	O	O
women	NOUN	O	O
concluding	PUNCT	O	O
the	DET	O	O
study	NOUN	O	O
with	ADP	O	O
a	DET	O	O
partial	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

Gastrointestinal	ADJ	O	B-PHYSICAL
AEs	ADP	O	I-PHYSICAL
were	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
arm	ADP	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
combined	VERB	O	O
oral	ADJ	O	O
contraceptives	NOUN	O	O
containing	VERB	O	O
ethinyl	NOUN	O	O
estradiol	NOUN	O	O
20	NUM	O	O
microg	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
drospirenone	NOUN	O	O
or	CCONJ	O	O
desogestrel	NOUN	O	O
on	ADP	O	O
lipids	NOUN	O	O
,	PUNCT	O	O
hemostatic	ADJ	O	O
parameters	NOUN	O	O
and	CCONJ	O	O
carbohydrate	NOUN	O	O
metabolism	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
ethinyl	NOUN	O	O
estradiol	NOUN	O	O
20	NUM	O	O
microg/drospirenone	NOUN	O	O
3	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
EE	NOUN	O	O
20	NUM	O	O
microg/DRSP	NOUN	O	O
3	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
administered	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
24/4	NOUN	O	O
regimen	NOUN	O	O
with	ADP	O	O
ethinyl	NOUN	O	O
estradiol	NOUN	O	O
20	NUM	O	O
microg/desogestrel	NOUN	O	O
150	NUM	O	O
microg	NOUN	O	O
(	PUNCT	O	O
EE	NOUN	O	O
20	NUM	O	O
microg/DSG	NUM	O	O
150	NUM	O	O
microg	NOUN	O	O
)	PUNCT	O	O
administered	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
21/7	PUNCT	O	O
regimen	NOUN	O	O
on	ADP	O	O
lipid	NOUN	O	O
,	PUNCT	O	O
carbohydrate	NOUN	O	O
and	CCONJ	O	O
hemostatic	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
In	ADP	O	O
this	DET	O	O
open-label	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
healthy	ADJ	O	O
women	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
EE	NOUN	O	O
20	NUM	O	O
microg/DRSP	NOUN	O	O
3	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
EE	NOUN	O	O
20	NUM	O	O
microg/DSG	NUM	O	O
150	NUM	O	O
microg	NOUN	O	O
for	ADP	O	O
seven	NUM	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
differences	NOUN	O	O
in	ADP	O	O
high-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
HDL	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
-	PUNCT	O	O
and	CCONJ	O	O
low-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
LDL	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
-cholesterol	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
at	ADP	O	O
cycle	NOUN	O	O
7	NUM	O	O
compared	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
variables	NOUN	O	O
included	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
other	ADJ	O	O
lipid	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
hemostatic	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
carbohydrate	NOUN	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Both	PUNCT	O	O
treatments	ADJ	O	O
increased	VERB	O	O
HDL-cholesterol	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
decreased	VERB	O	O
LDL-cholesterol	NOUN	O	B-PHYSICAL
by	ADP	O	O
a	DET	O	O
comparable	ADJ	O	O
extent	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
slightly	ADV	O	O
elevated	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
C-peptide	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
measured	VERB	O	O
during	ADP	O	O
oral	ADJ	O	O
glucose	NOUN	O	O
tolerance	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
within	ADP	O	O
normal	ADJ	O	O
reference	NOUN	O	O
ranges	ADJ	O	O
at	ADP	O	O
cycle	NOUN	O	O
7	NUM	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
lipid	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
hemostatic	ADJ	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
carbohydrate	NOUN	O	I-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
were	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
EE	NOUN	O	O
20	NUM	O	O
microg/DRSP	NOUN	O	O
3	NUM	O	O
mg	NOUN	O	O
has	CCONJ	O	O
a	DET	O	O
good	ADJ	O	O
safety	NOUN	O	O
profile	ADJ	O	O
comparable	ADJ	O	O
with	ADP	O	O
EE	NOUN	O	O
20	NUM	O	O
microg/DSG	NUM	O	O
150	NUM	O	O
microg	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
ozone	NOUN	O	O
application	NOUN	O	O
on	ADP	O	O
the	DET	O	O
resin-dentin	NOUN	O	B-OTHER
microtensile	ADJ	O	I-OTHER
bond	NOUN	O	I-OTHER
strength	NOUN	O	I-OTHER
.	PUNCT	O	O

When	ADP	O	O
ozone	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
during	ADP	O	O
caries	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
bond	NOUN	O	O
strength	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
compromised	VERB	O	O
by	ADP	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
oxygen	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
antioxidant	NOUN	O	O
agents	NOUN	O	O
neutralizes	NOUN	O	O
the	DET	O	O
free	ADJ	O	O
oxygen	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
ozone	NOUN	O	O
and	CCONJ	O	O
sodium	NOUN	O	O
ascorbate	NOUN	O	O
on	ADP	O	O
resin-dentin	NOUN	O	O
microtensile	ADJ	O	O
bond	NOUN	O	O
strength	NOUN	O	O
(	PUNCT	O	O
?TBS	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Forty	CCONJ	O	O
human	NOUN	O	O
third	ADJ	O	O
molars	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
Group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
not	ADV	O	O
treated	PUNCT	O	O
with	ADP	O	O
ozone	NOUN	O	O
;	PUNCT	O	O
Group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
ozone	NOUN	O	O
application	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
acid	NOUN	O	O
etching	VERB	O	O
;	PUNCT	O	O
Group	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
acid	NOUN	O	O
etching	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
ozone	NOUN	O	O
application	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
Group	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
ozone	NOUN	O	O
and	CCONJ	O	O
application	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	O
ascorbate	NOUN	O	O
.	PUNCT	O	O

Bonded	PUNCT	O	O
beams	NOUN	O	O
(	PUNCT	O	O
1.0	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
tested	VERB	O	O
under	ADP	O	O
tension	NOUN	O	O
(	PUNCT	O	O
0.5	NUM	O	O
mm	NOUN	O	O
min	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
?TBS	PUNCT	O	O
values	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
using	VERB	O	O
one-way	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
(	PUNCT	O	O
ANOVA	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Tukey	ADJ	O	O
test	NOUN	O	O
(	PUNCT	O	O
p=0.05	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
beams	NOUN	O	O
that	PUNCT	O	O
fractured	ADP	O	O
were	VERB	O	O
analyzed	VERB	O	O
under	ADP	O	O
stereomicroscopy	NOUN	O	O
(	PUNCT	O	O
40?	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Group	NOUN	O	O
1	NUM	O	O
had	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
?TBS	PUNCT	O	O
values	NOUN	O	O
than	PUNCT	O	O
Group	NOUN	O	O
2	NUM	O	O
or	CCONJ	O	O
3	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
?TBS	PUNCT	O	O
values	NOUN	O	O
of	ADP	O	O
Groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
were	VERB	O	O
similar	ADJ	O	O
and	CCONJ	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
those	ADP	O	O
of	ADP	O	O
Group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
ozone	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
2	NUM	O	O
resulted	VERB	O	O
in	ADP	O	O
lower	PUNCT	O	O
values	NOUN	O	O
of	ADP	O	O
?TBS	PUNCT	O	O
in	ADP	O	O
all	DET	O	O
conditions	NOUN	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
predominant	ADJ	O	O
failure	NOUN	O	O
mode	NOUN	O	O
was	VERB	O	O
adhesive	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
application	NOUN	O	O
of	ADP	O	O
ozone	NOUN	O	O
decreased	VERB	O	O
the	DET	O	O
?TBS	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
dentin-composite	NOUN	O	O
resin	NOUN	O	O
interface	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
values	NOUN	O	O
were	VERB	O	O
reversed	VERB	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
Groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
when	ADP	O	O
sodium	NOUN	O	O
ascorbate	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

Differences	NOUN	O	O
in	ADP	O	O
reach	NOUN	O	B-OTHER
and	CCONJ	O	O
attrition	NOUN	O	O
between	ADP	O	B-OTHER
Web-based	PUNCT	O	I-OTHER
and	CCONJ	O	O
print-delivered	VERB	O	B-OTHER
tailored	VERB	O	I-OTHER
interventions	NOUN	O	I-OTHER
among	ADP	O	O
adults	NOUN	O	O
over	ADP	O	O
50	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
:	PUNCT	O	O
clustered	VERB	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
Internet	NOUN	O	O
has	PUNCT	O	O
the	DET	O	O
potential	ADJ	O	O
to	PART	O	O
provide	NOUN	O	O
large	ADJ	O	O
populations	NOUN	O	O
with	ADP	O	O
individual	ADJ	O	O
health	NOUN	O	O
promotion	NOUN	O	O
advice	NOUN	O	O
at	ADP	O	O
a	DET	O	O
relatively	ADV	O	O
low	ADJ	O	O
cost	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
high	ADJ	O	O
rates	NOUN	O	O
of	ADP	O	O
Internet	NOUN	O	O
access	NOUN	O	O
,	PUNCT	O	O
actual	ADJ	O	O
reach	NOUN	O	O
by	ADP	O	O
Web-based	VERB	O	O
interventions	NOUN	O	O
is	VERB	O	O
often	ADV	O	O
disappointingly	PRON	O	O
low	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
differences	NOUN	O	O
in	ADP	O	O
use	NOUN	O	O
between	ADP	O	O
demographic	ADJ	O	O
subgroups	NOUN	O	O
are	PROPN	O	O
present	ADJ	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
Web-based	VERB	O	O
interventions	NOUN	O	O
often	ADV	O	O
have	PUNCT	O	O
to	PART	O	O
deal	ADV	O	O
with	ADP	O	O
high	ADJ	O	O
rates	NOUN	O	O
of	ADP	O	O
attrition	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
aims	ADP	O	O
to	PART	O	O
assess	CCONJ	O	O
user	VERB	O	B-OTHER
characteristics	NOUN	O	I-OTHER
related	VERB	O	I-OTHER
to	ADP	O	I-OTHER
participation	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
attrition	NOUN	O	I-OTHER
when	ADP	O	O
comparing	PUNCT	O	O
Web-based	VERB	O	O
and	CCONJ	O	O
print-delivered	VERB	O	O
tailored	VERB	O	O
interventions	NOUN	O	O
containing	VERB	O	O
similar	ADJ	O	O
content	NOUN	O	O
and	CCONJ	O	O
thereby	ADV	O	O
to	PART	O	O
provide	NOUN	O	O
recommendations	NOUN	O	O
in	ADP	O	O
choosing	VERB	O	O
the	DET	O	O
appropriate	ADJ	O	O
delivery	NOUN	O	O
mode	NOUN	O	O
for	ADP	O	O
a	DET	O	O
particular	ADJ	O	O
target	NOUN	O	O
audience	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
distribution	NOUN	O	O
of	ADP	O	O
a	DET	O	O
Web-based	VERB	O	O
and	CCONJ	O	O
a	DET	O	O
print-delivered	VERB	O	O
version	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Active	ADJ	O	O
Plus	CCONJ	O	O
intervention	NOUN	O	O
in	ADP	O	O
a	DET	O	O
clustered	ADJ	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
(	PUNCT	O	O
RCT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
via	ADP	O	O
direct	ADJ	O	O
mailing	PUNCT	O	O
within	ADP	O	O
the	DET	O	O
participating	PUNCT	O	O
Municipal	ADJ	O	O
Health	NOUN	O	O
Council	NOUN	O	O
regions	NOUN	O	O
and	CCONJ	O	O
randomized	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
printed	VERB	O	O
or	CCONJ	O	O
Web-based	VERB	O	O
intervention	NOUN	O	O
by	ADP	O	O
their	PUNCT	O	O
region	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
the	DET	O	O
answers	NOUN	O	O
given	VERB	O	O
in	ADP	O	O
a	DET	O	O
prior	ADJ	O	O
assessment	NOUN	O	O
,	PUNCT	O	O
participants	NOUN	O	O
received	PUNCT	O	O
tailored	VERB	O	O
advice	NOUN	O	O
on	ADP	O	O
3	NUM	O	O
occasions	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
within	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
2	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
within	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
based	ADP	O	O
on	ADP	O	O
a	DET	O	O
second	ADJ	O	O
assessment	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
printed	DET	O	O
or	CCONJ	O	O
Web-based	VERB	O	O
)	PUNCT	O	O
results	PUNCT	O	O
were	VERB	O	O
analyzed	VERB	O	O
using	VERB	O	O
ANOVA	NOUN	O	O
and	CCONJ	O	O
chi-square	NOUN	O	O
tests	NOUN	O	O
to	PUNCT	O	O
establish	ADJ	O	O
the	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
user	VERB	O	O
characteristics	NOUN	O	O
between	ADP	O	O
both	PUNCT	O	O
intervention	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
to	PUNCT	O	O
study	VERB	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
the	DET	O	O
user	VERB	O	B-MENTAL
characteristics	NOUN	O	I-MENTAL
and	CCONJ	O	O
the	DET	O	O
delivery	NOUN	O	O
mode	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prediction	NOUN	O	O
of	ADP	O	O
dropout	NOUN	O	O
rate	NOUN	O	B-OTHER
within	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
printed	VERB	O	O
intervention	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
higher	PUNCT	O	B-MENTAL
participation	NOUN	O	I-MENTAL
rate	NOUN	O	I-MENTAL
(	PUNCT	O	O
19	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
Web-based	VERB	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Web-based	VERB	O	O
intervention	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
younger	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
more	ADV	O	O
often	ADP	O	O
men	NOUN	O	O
(	PUNCT	O	O
P=.01	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
higher	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
BMI	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P=.001	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
lower	PUNCT	O	O
intention	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
physically	ADV	O	O
active	ADJ	O	O
(	PUNCT	O	O
P=.03	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
participants	NOUN	O	O
of	ADP	O	O
the	DET	O	O
printed	VERB	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dropout	ADP	O	O
rate	NOUN	O	B-OTHER
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
Web-based	ADJ	O	O
intervention	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
53	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
print-delivered	VERB	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
39	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
low	ADJ	O	O
intention	NOUN	O	B-MENTAL
to	PART	O	I-MENTAL
be	PUNCT	O	I-MENTAL
physically	ADV	O	I-MENTAL
active	ADJ	O	I-MENTAL
was	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
predictor	NOUN	O	O
for	ADP	O	O
dropout	NOUN	O	O
within	ADP	O	O
both	CCONJ	O	O
delivery	NOUN	O	O
modes	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
dropout	NOUN	O	O
rate	NOUN	O	O
between	ADP	O	O
the	DET	O	O
Web-based	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
printed	VERB	O	O
intervention	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
explained	VERB	O	O
by	ADP	O	O
user	PUNCT	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
reach	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
tailored	DET	O	B-MENTAL
physical	ADJ	O	I-MENTAL
activity	NOUN	O	I-MENTAL
(	PUNCT	O	O
PA	NOUN	O	B-MENTAL
)	PUNCT	O	O
intervention	NOUN	O	O
in	ADP	O	O
a	DET	O	O
printed	VERB	O	O
or	CCONJ	O	O
Web-based	VERB	O	O
delivery	NOUN	O	O
mode	NOUN	O	O
differed	VERB	O	O
between	ADP	O	O
sociodemographic	ADJ	O	O
subgroups	NOUN	O	O
of	ADP	O	O
participants	NOUN	O	O
over	ADP	O	O
50	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
reach	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Web-based	ADJ	O	O
intervention	NOUN	O	O
is	VERB	O	O
lower	PUNCT	O	O
,	PUNCT	O	O
Web-based	VERB	O	O
interventions	NOUN	O	O
can	ADP	O	O
be	ADJ	O	O
a	DET	O	O
good	ADJ	O	O
channel	NOUN	O	O
to	ADP	O	O
reach	NOUN	O	O
high-risk	NOUN	O	O
populations	NOUN	O	O
(	PUNCT	O	O
lower	CCONJ	O	O
PA	NOUN	O	O
intention	NOUN	O	O
and	CCONJ	O	O
higher	PUNCT	O	O
BMI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
dropout	ADP	O	O
rate	NOUN	O	B-OTHER
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
Web-based	ADJ	O	O
intervention	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
specific	ADJ	O	O
user	VERB	O	O
characteristics	NOUN	O	O
explained	VERB	O	O
the	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
dropout	ADP	O	O
rates	NOUN	O	B-OTHER
between	ADP	O	O
the	DET	O	O
delivery	NOUN	O	O
modes	NOUN	O	O
.	PUNCT	O	O

More	DET	O	O
research	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
what	PUNCT	O	O
caused	VERB	O	O
the	DET	O	O
high	ADJ	O	O
rate	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
dropout	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
Web-based	ADJ	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
Dutch	NOUN	O	O
Trial	NOUN	O	O
Register	NOUN	O	O
(	PUNCT	O	O
NTR	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
2297	NUM	O	O
:	PUNCT	O	O
http	PUNCT	O	O
:	PUNCT	O	O
//www.trialregister.nl/trialreg/admin/rctview.asp	ADV	O	O
?	PUNCT	O	O

TC=2297	PUNCT	O	O
(	PUNCT	O	O
Archived	PUNCT	O	O
by	ADP	O	O
WebCite	NOUN	O	O
at	ADP	O	O
http	PUNCT	O	O
:	PUNCT	O	O
//www.webcitation.org/65TkwoESp	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Human	NOUN	O	O
motor	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
simultaneous	ADJ	O	O
aversive	ADJ	O	O
stimulation	NOUN	O	O
and	CCONJ	O	O
failure	NOUN	O	O
on	ADP	O	O
a	DET	O	O
valued	PUNCT	O	O
task	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
presentation	NOUN	O	O
of	ADP	O	O
an	DET	O	O
aversive	ADJ	O	O
stimulus	NOUN	O	O
and	CCONJ	O	O
simultaneous	ADJ	O	O
failure	NOUN	O	O
on	ADP	O	O
a	DET	O	O
bogus	NOUN	O	O
intelligence	NOUN	O	O
test	NOUN	O	O
upon	ADP	O	O
a	DET	O	O
subject	NOUN	O	O
's	PUNCT	O	O
aggressive	ADJ	O	B-MENTAL
reactions	NOUN	O	I-MENTAL
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
subject	NOUN	O	O
's	PUNCT	O	O
fist	NOUN	O	B-MENTAL
clenching	PUNCT	O	I-MENTAL
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
indicator	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
aggression	NOUN	O	I-MENTAL
.	PUNCT	O	O

Four	NUM	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
generated	VERB	O	O
by	ADP	O	O
the	DET	O	O
combinations	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
kinds	NOUN	O	O
of	ADP	O	O
stimulus	NOUN	O	O
delivered	VERB	O	O
to	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
aversive	ADJ	O	O
or	CCONJ	O	O
nonaversive	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
outcomes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
task	NOUN	O	O
(	PUNCT	O	O
failure	NOUN	O	O
or	CCONJ	O	O
success	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

20	NUM	O	O
female	NOUN	O	O
and	CCONJ	O	O
20	NUM	O	O
male	NOUN	O	O
students	NOUN	O	O
(	PUNCT	O	O
ages	NOUN	O	O
:	PUNCT	O	O
17-34	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
instructed	VERB	O	O
,	PUNCT	O	O
upon	ADP	O	O
the	DET	O	O
reception	NOUN	O	O
of	ADP	O	O
an	DET	O	O
aversive	ADJ	O	O
or	CCONJ	O	O
nonaversive	ADJ	O	O
acoustic	ADJ	O	O
signal	NOUN	O	O
,	PUNCT	O	O
to	PUNCT	O	O
press	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
right	ADJ	O	O
hand	NOUN	O	O
a	DET	O	O
device	NOUN	O	O
that	PUNCT	O	O
displayed	VERB	O	O
a	DET	O	O
slide	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
slide	NOUN	O	O
presented	ADP	O	O
an	DET	O	O
item	NOUN	O	O
from	ADP	O	O
an	DET	O	O
intelligence	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
to	CCONJ	O	O
which	PUNCT	O	O
the	DET	O	O
subjects	NOUN	O	O
were	PUNCT	O	O
either	PUNCT	O	O
allowed	NUM	O	O
to	ADJ	O	O
answer	ADP	O	O
successfully	ADP	O	O
(	PUNCT	O	O
success	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
not	ADV	O	O
(	PUNCT	O	O
failure	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Failure	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
subject	NOUN	O	O
's	PUNCT	O	O
autonomic	ADJ	O	B-MENTAL
arousal	ADJ	O	I-MENTAL
,	PUNCT	O	O
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
photoplethysmographic	ADJ	O	O
sensors	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
all	DET	O	O
stimulation	NOUN	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
the	DET	O	O
condition	NOUN	O	O
with	ADP	O	O
aversive	ADJ	O	O
stimulation	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
speed	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
clenching	PROPN	O	I-MENTAL
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
interpreted	VERB	O	O
as	PUNCT	O	O
indicating	PUNCT	O	O
subject	NOUN	O	O
's	PUNCT	O	O
tendencies	DET	O	B-MENTAL
to	ADP	O	I-MENTAL
aggression	NOUN	O	I-MENTAL
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
frustration	NOUN	O	O
.	PUNCT	O	O

Pre-bent	ADJ	O	O
instruments	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
single-port	NOUN	O	O
laparoscopic	ADJ	O	O
surgery	NOUN	O	O
versus	CCONJ	O	O
conventional	ADJ	O	O
laparoscopic	ADJ	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
comparative	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
performance	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dry	ADJ	O	O
lab	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Different	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
single-incision	NOUN	O	O
laparoscopic	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
SILS	NOUN	O	O
)	PUNCT	O	O
have	CCONJ	O	O
become	VERB	O	O
increasingly	ADV	O	O
popular	ADJ	O	O
.	PUNCT	O	O

Although	ADP	O	O
SILS	NOUN	O	O
is	VERB	O	O
technically	ADV	O	O
even	ADV	O	O
more	DET	O	O
challenging	PUNCT	O	O
than	PUNCT	O	O
conventional	ADJ	O	O
laparoscopy	NOUN	O	O
,	PUNCT	O	O
published	DET	O	O
data	NOUN	O	O
of	ADP	O	O
first	ADJ	O	O
clinical	ADJ	O	O
series	NOUN	O	O
seem	VERB	O	O
to	PART	O	O
demonstrate	NOUN	O	O
the	DET	O	O
feasibility	NOUN	O	O
of	ADP	O	O
these	DET	O	O
approaches	NOUN	O	O
.	PUNCT	O	O

Various	ADJ	O	O
attempts	PUNCT	O	O
have	PUNCT	O	O
been	PUNCT	O	O
made	VERB	O	O
to	PART	O	O
overcome	NOUN	O	O
restrictions	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
loss	NOUN	O	O
of	ADP	O	O
triangulation	NOUN	O	O
in	ADP	O	O
SILS	NOUN	O	O
by	ADP	O	O
specially	ADJ	O	O
designed	DET	O	O
SILS-specific	ADJ	O	O
instruments	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
involving	PUNCT	O	O
novices	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dry	ADJ	O	O
lab	NOUN	O	O
compared	ADP	O	O
task	NOUN	O	B-MENTAL
performances	NOUN	O	I-MENTAL
between	ADP	O	O
conventional	ADJ	O	O
laparoscopic	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
CLS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
single-port	NOUN	O	O
laparoscopic	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
SPLS	NOUN	O	O
)	PUNCT	O	O
using	VERB	O	O
newly	ADV	O	O
designed	PUNCT	O	O
pre-bent	ADJ	O	O
instruments	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
medical	ADJ	O	O
students	NOUN	O	O
without	ADP	O	O
previous	ADJ	O	O
experience	NOUN	O	O
in	ADP	O	O
laparoscopic	ADJ	O	O
techniques	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADJ	O	O
undergo	VERB	O	O
one	NUM	O	O
of	ADP	O	O
three	NUM	O	O
procedures	NOUN	O	O
:	PUNCT	O	O
CLS	NOUN	O	O
,	PUNCT	O	O
SPLS	NOUN	O	O
using	VERB	O	O
two	NUM	O	O
pre-bent	ADJ	O	O
instruments	NOUN	O	O
(	PUNCT	O	O
SPLS-pp	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
SPLS	NOUN	O	O
using	VERB	O	O
one	NUM	O	O
pre-bent	ADJ	O	O
and	CCONJ	O	O
one	NUM	O	O
straight	NOUN	O	O
laparoscopic	ADJ	O	O
instrument	NOUN	O	O
(	PUNCT	O	O
SPLS-ps	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
dry	ADJ	O	O
lab	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
participants	NOUN	O	O
performed	DET	O	O
four	NUM	O	O
typical	ADJ	O	O
laparoscopic	ADJ	O	O
tasks	NOUN	O	O
of	ADP	O	O
increasing	VERB	O	O
difficulty	NOUN	O	O
.	PUNCT	O	O

Evaluation	NOUN	O	O
included	VERB	O	O
performance	NOUN	O	B-MENTAL
times	NOUN	O	I-MENTAL
or	CCONJ	O	O
number	NOUN	O	O
of	ADP	O	O
completed	VERB	O	O
tasks	NOUN	O	O
within	ADP	O	O
a	DET	O	O
given	PUNCT	O	O
time	NOUN	O	O
frame	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
performances	NOUN	O	B-MENTAL
were	VERB	O	O
videotaped	ADJ	O	O
and	CCONJ	O	O
evaluated	VERB	O	O
for	ADP	O	O
unsuccessful	ADJ	O	B-MENTAL
attempts	PUNCT	O	I-MENTAL
and	CCONJ	O	O
unwanted	VERB	O	B-MENTAL
interactions	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
instruments	NOUN	O	I-MENTAL
.	PUNCT	O	O

Using	PRON	O	O
subjective	ADJ	O	B-OTHER
questionnaires	NOUN	O	I-OTHER
,	PUNCT	O	O
the	DET	O	O
participants	NOUN	O	O
rated	ADP	O	B-MENTAL
difficulties	NOUN	O	I-MENTAL
with	ADP	O	I-MENTAL
two-dimensional	ADJ	O	I-MENTAL
vision	NOUN	O	I-MENTAL
and	CCONJ	O	O
coordination	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
instruments	NOUN	O	I-MENTAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Task	NOUN	O	B-MENTAL
performances	NOUN	O	I-MENTAL
were	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
CLS	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
either	CCONJ	O	O
SPLS	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
SPLS-ps	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
tendency	NOUN	O	O
toward	ADP	O	O
better	PUNCT	O	O
performances	NOUN	O	B-OTHER
than	PUNCT	O	O
the	DET	O	O
SPLS-pp	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Video	PUNCT	O	O
sequences	NOUN	O	O
and	CCONJ	O	O
participants`	PUNCT	O	O
questionnaires	NOUN	O	O
showed	VERB	O	O
instrument	ADJ	O	B-MENTAL
interaction	NOUN	O	I-MENTAL
as	VERB	O	O
the	DET	O	O
major	ADJ	O	B-ADVERSE-EFFECTS
problem	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
the	DET	O	O
single-incision	NOUN	O	O
surgery	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Although	ADP	O	O
SILS	NOUN	O	O
is	VERB	O	O
feasible	ADJ	O	O
,	PUNCT	O	O
as	CCONJ	O	O
shown	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
series	NOUN	O	O
published	VERB	O	O
by	ADP	O	O
laparoscopically	ADV	O	O
experienced	VERB	O	O
experts	NOUN	O	O
,	PUNCT	O	O
SILS	ADJ	O	O
techniques	NOUN	O	O
are	PROPN	O	O
demanding	ADP	O	O
due	PUNCT	O	O
to	ADP	O	O
restrictions	NOUN	O	O
that	ADP	O	O
come	VERB	O	O
with	ADP	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
triangulation	NOUN	O	O
.	PUNCT	O	O

These	PUNCT	O	O
can	VERB	O	O
be	PART	O	O
compensated	PUNCT	O	O
only	ADV	O	O
partially	ADV	O	O
by	ADP	O	O
currently	ADV	O	O
available	ADJ	O	O
SILS-designed	VERB	O	O
instruments	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
future	NOUN	O	O
of	ADP	O	O
SILS	ADJ	O	O
depends	NOUN	O	O
on	ADP	O	O
further	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
the	DET	O	O
available	ADJ	O	O
equipment	ADJ	O	O
or	CCONJ	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
approaches	NOUN	O	O
such	CCONJ	O	O
as	PUNCT	O	O
needlescopically	VERB	O	O
assisted	ADJ	O	O
or	CCONJ	O	O
robotically	ADV	O	O
assisted	VERB	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Markers	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	B-PHYSICAL
inflammation	NOUN	O	I-PHYSICAL
predict	ADJ	O	O
survival	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
renal	ADJ	O	O
cell	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
host	NOUN	O	O
inflammatory	ADJ	O	O
response	NOUN	O	O
has	VERB	O	O
a	DET	O	O
vital	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
carcinogenesis	NOUN	O	O
and	CCONJ	O	O
tumour	NOUN	O	O
progression	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
prognostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
markers	NOUN	O	O
(	PUNCT	O	O
albumin	NOUN	O	O
,	PUNCT	O	O
white-cell	VERB	O	O
count	NOUN	O	O
and	CCONJ	O	O
its	DET	O	O
components	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
platelets	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
pre-treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
renal	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
(	PUNCT	O	O
RCC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Using	ADJ	O	O
data	NOUN	O	O
from	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
multivariable	ADJ	O	O
proportional	ADJ	O	O
hazards	NOUN	O	O
models	NOUN	O	O
were	VERB	O	O
generated	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	B-PHYSICAL
markers	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
established	ADP	O	O
prognostic	ADJ	O	B-PHYSICAL
factors	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
performance	NOUN	O	O
status	NOUN	O	O
,	PUNCT	O	O
calcium	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
haemoglobin	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
OS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
a	DET	O	O
new	ADJ	O	O
prognostic	ADJ	O	O
classification	NOUN	O	O
incorporating	SYM	O	O
additional	ADJ	O	O
information	NOUN	O	O
from	ADP	O	O
inflammatory	ADJ	O	O
markers	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
416	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
362	NUM	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Elevated	VERB	O	B-PHYSICAL
neutrophil	NOUN	O	I-PHYSICAL
counts	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
elevated	ADP	O	B-PHYSICAL
platelet	NOUN	O	I-PHYSICAL
counts	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	B-PHYSICAL
high	ADJ	O	I-PHYSICAL
neutrophil-lymphocyte	NOUN	O	I-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
were	VERB	O	O
significant	ADJ	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
for	ADP	O	O
shorter	PUNCT	O	O
OS	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
with	ADP	O	O
established	ADP	O	O
prognostic	ADJ	O	O
factors	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
markers	NOUN	O	O
improves	NOUN	O	O
the	DET	O	O
discriminatory	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prognostic	ADJ	O	O
classification	NOUN	O	O
as	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
established	VERB	O	O
factors	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
C-statistic	ADJ	O	O
0.673	NUM	O	O
vs	CCONJ	O	O
0.654	PUNCT	O	O
,	PUNCT	O	O
P=0.002	NOUN	O	O
for	ADP	O	O
the	DET	O	O
difference	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
25.8	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P=0.004	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
more	ADV	O	O
appropriately	ADV	O	O
classified	VERB	O	O
using	VERB	O	O
the	DET	O	O
new	ADJ	O	O
classification	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Markers	PROPN	O	O
of	ADP	O	O
systemic	ADJ	O	O
inflammation	NOUN	O	O
contribute	VERB	O	O
significantly	ADV	O	O
to	ADP	O	O
prognostic	ADJ	O	O
classification	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
established	VERB	O	O
factors	NOUN	O	O
for	ADP	O	O
pre-treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
RCC	NOUN	O	O
.	PUNCT	O	O

Upon	ADP	O	O
validation	NOUN	O	O
of	ADP	O	O
these	DET	O	O
data	NOUN	O	O
in	ADP	O	O
independent	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
stratification	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
using	VERB	O	O
these	DET	O	O
markers	NOUN	O	O
in	ADP	O	O
future	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O

Evaluating	ADP	O	O
online	ADV	O	O
continuing	VERB	O	O
medical	ADJ	O	O
education	NOUN	O	O
seminars	NOUN	O	O
:	PUNCT	O	O
evidence	NOUN	O	O
for	ADP	O	O
improving	VERB	O	O
clinical	ADJ	O	O
practices	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
potential	ADJ	O	O
for	ADP	O	O
online	ADV	O	O
continuing	VERB	O	O
medical	ADJ	O	O
education	NOUN	O	O
(	PUNCT	O	O
CME	NOUN	O	O
)	PUNCT	O	O
seminars	PROPN	O	O
to	PROPN	O	O
improve	ADP	O	B-OTHER
quality	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
care	NOUN	O	I-OTHER
.	PUNCT	O	O

Primary	ADJ	O	O
care	NOUN	O	O
physicians	NOUN	O	O
(	PUNCT	O	O
113	NUM	O	O
)	PUNCT	O	O
participated	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
an	DET	O	O
online	ADV	O	O
CME	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

Physicians	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
view	ADJ	O	O
either	CCONJ	O	O
a	DET	O	O
seminar	CCONJ	O	O
about	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
seminar	ADJ	O	O
about	ADP	O	O
systolic	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
the	DET	O	O
seminar	ADJ	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
were	VERB	O	O
presented	VERB	O	O
with	ADP	O	O
4	NUM	O	O
clinical	ADJ	O	O
vignettes	NOUN	O	O
and	CCONJ	O	O
asked	PROPN	O	O
to	PART	O	O
describe	ADP	O	O
what	DET	O	O
tests	NOUN	O	O
,	PUNCT	O	O
treatments	ADJ	O	O
,	PUNCT	O	O
counseling	DET	O	O
,	PUNCT	O	O
or	CCONJ	O	O
referrals	PUNCT	O	O
they	PRON	O	O
would	ADJ	O	O
recommend	VERB	O	O
.	PUNCT	O	O

Physicians	NOUN	O	O
who	PROPN	O	O
viewed	VERB	O	O
the	DET	O	O
seminars	ADV	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
recommend	VERB	O	B-MENTAL
guideline-consistent	ADJ	O	I-MENTAL
care	NOUN	O	I-MENTAL
to	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vignettes	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
who	PROPN	O	O
viewed	VERB	O	O
the	DET	O	O
diabetes	NOUN	O	O
seminar	ADJ	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PUNCT	O	O
order	ADP	O	B-MENTAL
an	DET	O	I-MENTAL
eye	NOUN	O	I-MENTAL
exam	NOUN	O	I-MENTAL
for	ADP	O	I-MENTAL
diabetes	NOUN	O	I-MENTAL
patients	NOUN	O	I-MENTAL
(	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
physicians	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
27	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
some	DET	O	O
guidelines	NOUN	O	O
there	VERB	O	O
were	VERB	O	O
no	DET	O	O
group	NOUN	O	O
differences	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
early	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
online	ADV	O	O
CME	NOUN	O	O
programs	NOUN	O	O
to	PROPN	O	O
improve	ADP	O	O
physician	NOUN	O	B-OTHER
clinical	ADJ	O	I-OTHER
practice	NOUN	O	I-OTHER
.	PUNCT	O	O

Randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
of	ADP	O	O
customized	VERB	O	O
preventive	ADJ	O	O
medicine	NOUN	O	O
reminder	ADP	O	O
letters	CCONJ	O	O
in	ADP	O	O
a	DET	O	O
community	NOUN	O	O
practice	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
test	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
customized	DET	O	O
,	PUNCT	O	O
family-oriented	ADP	O	O
reminder	ADP	O	O
letters	CCONJ	O	O
in	ADP	O	O
activating	ADJ	O	O
patients	NOUN	O	O
to	ADP	O	O
seek	PROPN	O	O
appropriate	ADJ	O	O
preventive	ADJ	O	O
services	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
group	NOUN	O	O
received	VERB	O	O
computer-generated	VERB	O	O
,	PUNCT	O	O
customized	PUNCT	O	O
letters	NOUN	O	O
explaining	PUNCT	O	O
recommended	PUNCT	O	O
preventive	ADJ	O	O
procedures	NOUN	O	O
for	ADP	O	O
each	DET	O	O
family	NOUN	O	O
member	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
a	DET	O	O
form	ADV	O	O
letter	NOUN	O	O
listing	SYM	O	O
recommendations	NOUN	O	O
for	ADP	O	O
all	DET	O	O
preventive	ADJ	O	O
procedures	NOUN	O	O
for	ADP	O	O
all	DET	O	O
age	NOUN	O	O
and	CCONJ	O	O
sex	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
third	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
no	DET	O	O
letters	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
A	PUNCT	O	O
private	ADJ	O	O
medical	ADJ	O	O
centre	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
university	NOUN	O	O
affiliation	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
rural	ADJ	O	O
Quebec	ADP	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
From	ADP	O	O
8770	NUM	O	O
patients	NOUN	O	O
who	PROPN	O	O
met	VERB	O	O
study	ADV	O	O
criteria	NOUN	O	O
,	PUNCT	O	O
719	NUM	O	O
families	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
selected	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
1971	NUM	O	O
of	ADP	O	O
1998	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
these	DET	O	O
families	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
The	DET	O	O
Family	NOUN	O	B-PHYSICAL
Received	PUNCT	O	I-PHYSICAL
Index	NOUN	O	I-PHYSICAL
is	VERB	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
all	DET	O	O
procedures	NOUN	O	O
for	ADP	O	O
which	ADP	O	O
a	DET	O	O
family	NOUN	O	O
was	VERB	O	O
overdue	PUNCT	O	O
that	PUNCT	O	O
they	PRON	O	O
received	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
Family	NOUN	O	B-PHYSICAL
End-of-study	NOUN	O	I-PHYSICAL
Up-to-date	PUNCT	O	I-PHYSICAL
Index	NOUN	O	I-PHYSICAL
is	VERB	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
procedures	NOUN	O	O
for	ADP	O	O
which	ADP	O	O
the	DET	O	O
family	NOUN	O	O
was	VERB	O	O
eligible	ADJ	O	O
and	CCONJ	O	O
for	ADP	O	O
which	ADP	O	O
they	PUNCT	O	O
were	VERB	O	O
up-to-date	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
Family	NOUN	O	B-PHYSICAL
Received	PUNCT	O	I-PHYSICAL
Index	NOUN	O	I-PHYSICAL
for	ADP	O	O
families	NOUN	O	O
mailed	PUNCT	O	O
customized	PUNCT	O	O
letters	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
than	PUNCT	O	O
double	PUNCT	O	O
the	DET	O	O
index	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
not	ADV	O	O
mailed	PUNCT	O	O
letters	PROPN	O	O
(	PUNCT	O	O
Kruskal-Wallis	NOUN	O	O
P	NOUN	O	O
=	SYM	O	O
.0139	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Family	NOUN	O	B-PHYSICAL
End-of-study	NOUN	O	I-PHYSICAL
Up-to-date	PUNCT	O	I-PHYSICAL
indices	ADJ	O	I-PHYSICAL
also	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
families	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
sent	NOUN	O	O
customized	VERB	O	O
letters	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
be	PUNCT	O	O
up-to-date	PUNCT	O	O
than	ADP	O	O
families	NOUN	O	O
not	ADV	O	O
sent	PUNCT	O	O
letters	ADJ	O	O
(	PUNCT	O	O
Kruskal-Wallis	NOUN	O	O
P	NOUN	O	O
=	SYM	O	O
.0054	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
appeared	VERB	O	O
between	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
preventive	ADJ	O	O
measures	NOUN	O	O
received	VERB	O	O
by	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
form-letter	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
a	DET	O	O
clinically	ADV	O	O
small	ADJ	O	O
but	CCONJ	O	O
statistically	ADV	O	O
significant	ADJ	O	O
value	NOUN	O	O
to	ADP	O	O
customizing	CCONJ	O	O
reminder	ADP	O	O
letters	NOUN	O	O
.	PUNCT	O	O

Incidence	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
false-negative	ADJ	O	O
sextant	ADJ	O	O
prostate	NOUN	O	O
biopsies	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Since	ADP	O	O
most	DET	O	O
patients	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
undergo	ADV	O	O
repeat	NOUN	O	O
sextant	ADJ	O	O
prostate	NOUN	O	O
biopsies	NOUN	O	O
after	ADP	O	O
a	DET	O	O
biopsy	NOUN	O	O
is	VERB	O	O
positive	ADJ	O	O
for	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
true	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
false-negative	ADJ	O	O
biopsies	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
well	VERB	O	O
defined	CCONJ	O	O
.	PUNCT	O	O

We	PRON	O	O
assess	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
false-negative	ADJ	O	O
sextant	ADJ	O	O
prostate	NOUN	O	O
biopsies	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
radical	ADJ	O	O
prostatectomy	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
118	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
biopsy	NOUN	O	O
proved	CCONJ	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
underwent	VERB	O	O
repeat	NOUN	O	O
sextant	ADJ	O	O
prostate	NOUN	O	O
biopsy	NOUN	O	O
before	ADP	O	O
enrollment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
radical	ADJ	O	O
prostatectomy	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
neoadjuvant	PUNCT	O	O
hormonal	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
parameters	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
to	PART	O	O
determine	ADJ	O	O
potential	ADJ	O	O
sources	NOUN	O	O
of	ADP	O	O
bias	NOUN	O	O
.	PUNCT	O	O

Pathological	ADJ	O	O
parameters	NOUN	O	O
and	CCONJ	O	O
prostate	NOUN	O	B-ADVERSE-EFFECTS
specific	ADJ	O	I-ADVERSE-EFFECTS
antigen	NOUN	O	I-ADVERSE-EFFECTS
relapse-free	PUNCT	O	I-ADVERSE-EFFECTS
survival	NOUN	O	I-ADVERSE-EFFECTS
rates	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
compared	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
false-negative	ADJ	O	O
biopsies	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
118	ADJ	O	O
patients	NOUN	O	O
27	NUM	O	O
(	PUNCT	O	O
23	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
a	DET	O	O
negative	ADJ	O	O
repeat	NOUN	O	O
sextant	ADJ	O	O
biopsy	NOUN	O	O
.	PUNCT	O	O

Except	PUNCT	O	O
for	ADP	O	O
initial	ADJ	O	O
clinical	ADJ	O	O
stage	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
clinical	ADJ	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
pathological	ADJ	O	I-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	CCONJ	O	O
prostate	NOUN	O	B-PHYSICAL
specific	ADJ	O	I-PHYSICAL
antigen	NOUN	O	I-PHYSICAL
relapse	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
negative	ADJ	O	O
versus	CCONJ	O	O
positive	ADJ	O	O
repeat	NOUN	O	O
biopsies	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	ADP	O	O
Our	PUNCT	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
this	DET	O	O
23	NUM	O	O
%	SYM	O	O
incidence	NOUN	O	O
of	ADP	O	O
false-negative	ADJ	O	O
biopsies	NOUN	O	O
represents	NOUN	O	O
significant	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

This	PUNCT	O	O
relatively	ADV	O	O
high	ADJ	O	O
incidence	NOUN	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
consider	NOUN	O	O
in	ADP	O	O
treatment	NOUN	O	O
modalities	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
prostate	NOUN	O	O
biopsy	NOUN	O	O
may	VERB	O	O
be	NOUN	O	O
performed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
split-course	PUNCT	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
continuous	ADJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
unresectable	ADJ	O	O
bronchogenic	ADJ	O	O
carcinoma	NOUN	O	O
:	PUNCT	O	O
5	NUM	O	O
year	NOUN	O	O
results	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
eighty-eight	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
inoperable	ADJ	O	O
or	CCONJ	O	O
unresectable	ADJ	O	O
bronchogenic	ADJ	O	O
carcinoma	NOUN	O	O
were	VERB	O	O
stratified	VERB	O	O
by	ADP	O	O
cell	NOUN	O	O
type	NOUN	O	O
,	PUNCT	O	O
TNM	NOUN	O	O
staging	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prior	VERB	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
randomized	PUNCT	O	O
into	ADP	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
continuous	ADJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
split-course	PUNCT	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
or	CCONJ	O	O
objective	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Survival	NOUN	O	B-MORTALITY
rates	NOUN	O	I-MORTALITY
for	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
squamous	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
,	PUNCT	O	O
small	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
adrenocarcinoma	NOUN	O	O
were	VERB	O	O
the	DET	O	O
same	ADP	O	O
after	ADP	O	O
both	CCONJ	O	O
regimens	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Split-course	ADJ	O	B-OTHER
therapy	NOUN	O	I-OTHER
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
better	PUNCT	O	O
survival	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
large	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
was	VERB	O	O
small	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
doubt	ADP	O	O
that	CCONJ	O	O
the	DET	O	O
difference	NOUN	O	O
is	VERB	O	O
clinically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Objective	ADJ	O	B-PHYSICAL
roentgenographic	ADJ	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
was	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
improved	VERB	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
in	ADP	O	O
squamous	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
three	NUM	O	O
cell	NOUN	O	O
types	NOUN	O	O
.	PUNCT	O	O

Split-course	ADJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
is	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
continuous	ADJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
because	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
better	PUNCT	O	B-OTHER
tolerated	ADP	O	I-OTHER
by	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
and	CCONJ	O	O
because	PUNCT	O	O
re-examination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
second	ADJ	O	O
half	NOUN	O	O
of	ADP	O	O
split-course	PUNCT	O	O
therapy	NOUN	O	O
permits	NOUN	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
metastatic	ADJ	O	O
disease	NOUN	O	O
that	ADP	O	O
has	PUNCT	O	O
become	NUM	O	O
manifest	ADV	O	O
during	ADP	O	O
the	DET	O	O
rest	NOUN	O	O
period	NOUN	O	O
and	CCONJ	O	O
spares	NOUN	O	O
the	DET	O	O
patient	NOUN	O	O
the	DET	O	O
futile	ADJ	O	O
second	ADJ	O	O
half	NOUN	O	O
of	ADP	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Sustained	VERB	O	O
benefit	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
glucose	NOUN	O	O
monitoring	VERB	O	O
on	ADP	O	O
A1C	NOUN	O	O
,	PUNCT	O	O
glucose	NOUN	O	O
profiles	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hypoglycemia	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
long-term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
glucose	NOUN	O	O
monitoring	VERB	O	O
(	PUNCT	O	O
CGM	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
intensively	ADV	O	O
treated	VERB	O	O
adults	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

RESEARCH	NOUN	O	O
DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
We	PRON	O	O
studied	VERB	O	O
83	NUM	O	O
of	ADP	O	O
86	NUM	O	O
individuals	NOUN	O	O
>	SYM	O	O
or=25	ADJ	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
who	ADP	O	O
used	VERB	O	O
CGM	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
6-month	NOUN	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
in	ADP	O	O
a	DET	O	O
subsequent	ADJ	O	O
6-month	NOUN	O	O
extension	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
median	ADJ	O	O
CGM	NOUN	O	O
use	NOUN	O	O
was	VERB	O	O
6.8	NUM	O	O
days	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
change	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
A1C	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
was	VERB	O	O
-0.4	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
baseline	NOUN	O	O
A1C	NOUN	O	O
>	SYM	O	O
or=7.0	NOUN	O	O
%	SYM	O	O
.	PUNCT	O	O

A1C	NOUN	O	B-PHYSICAL
remained	VERB	O	O
stable	ADJ	O	O
at	ADP	O	O
6.4	NUM	O	O
%	SYM	O	O
in	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
baseline	NOUN	O	O
A1C	NOUN	O	O
<	SYM	O	O
7.0	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
hypoglycemia	NOUN	O	I-PHYSICAL
was	VERB	O	O
21.8	NUM	O	O
and	CCONJ	O	O
7.1	NUM	O	O
events	NOUN	O	O
per	ADP	O	O
100	NUM	O	O
person-years	PROPN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
and	CCONJ	O	O
last	PUNCT	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Time	NOUN	O	B-PHYSICAL
per	ADP	O	I-PHYSICAL
day	NOUN	O	I-PHYSICAL
with	ADP	O	I-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
range	NOUN	O	O
of	ADP	O	O
71-180	NUM	O	O
mg/dl	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
intensively	ADV	O	O
treated	VERB	O	O
adults	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
,	PUNCT	O	O
CGM	CCONJ	O	O
use	NOUN	O	O
and	CCONJ	O	O
benefit	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
sustained	VERB	O	O
for	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Growth	NOUN	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
GH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	O
GH-releasing	VERB	O	O
hormone	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
combined	VERB	O	O
with	ADP	O	O
arginine	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
adrenal	ADJ	O	O
incidentaloma	NOUN	O	O
:	PUNCT	O	O
evidence	NOUN	O	O
for	ADP	O	O
enhanced	NOUN	O	O
somatostatinergic	ADJ	O	O
tone	NOUN	O	O
.	PUNCT	O	O

Spontaneous	ADJ	O	O
and	CCONJ	O	O
stimulated	PUNCT	O	O
GH	NOUN	O	O
secretion	NOUN	O	O
is	VERB	O	O
blunted	VERB	O	O
in	ADP	O	O
hypercortisolemic	ADJ	O	O
states	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
increased	PUNCT	O	O
hypothalamic	ADJ	O	O
somatostatinergic	ADJ	O	O
tone	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
data	NOUN	O	O
are	VERB	O	O
available	ADJ	O	O
on	ADP	O	O
the	DET	O	O
characteristics	NOUN	O	O
of	ADP	O	O
GH	NOUN	O	O
secretion	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
incidentally	ADV	O	O
discovered	PUNCT	O	O
adrenal	ADJ	O	O
adenomas	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
represent	VERB	O	O
an	DET	O	O
interesting	VERB	O	O
model	NOUN	O	O
for	ADP	O	O
studying	VERB	O	O
GH	NOUN	O	O
secretion	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
slight	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
cortisol	NOUN	O	O
excess	ADJ	O	O
may	ADP	O	O
frequently	ADV	O	O
be	PUNCT	O	O
observed	VERB	O	O
in	ADP	O	O
such	DET	O	O
patients	NOUN	O	O
who	ADP	O	O
do	PUNCT	O	O
not	ADV	O	O
present	PUNCT	O	O
with	ADP	O	O
any	DET	O	O
clear	ADJ	O	O
Cushingoid	NOUN	O	O
sign	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
7	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
48-63	NUM	O	O
yr	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
adrenal	ADJ	O	O
mass	NOUN	O	O
discovered	ADP	O	O
serendipitously	ADV	O	O
underwent	ADP	O	O
,	PUNCT	O	O
on	ADP	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
GHRH	NOUN	O	O
injection	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
combined	VERB	O	O
with	ADP	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
functional	ADJ	O	O
somatostatin	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
arginine	NOUN	O	O
.	PUNCT	O	O

Thirteen	ADP	O	O
age-matched	DET	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
served	VERB	O	O
as	ADP	O	O
controls	VERB	O	O
.	PUNCT	O	O

Briefly	ADP	O	O
,	PUNCT	O	O
arginine	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
infused	VERB	O	O
from	ADP	O	O
-30	PUNCT	O	O
to	ADP	O	O
0	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
GHRH	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
microg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
as	ADP	O	O
a	DET	O	O
bolus	NOUN	O	O
at	ADP	O	O
0	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
measurement	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
GH	NOUN	O	O
[	PUNCT	O	O
immunoradiometric	ADJ	O	O
assay	NOUN	O	O
(	PUNCT	O	O
IRMA	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
every	DET	O	O
15	NUM	O	O
min	NOUN	O	O
for	ADP	O	O
150	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	O
IGF-I	NOUN	O	O
(	PUNCT	O	O
RIA	NOUN	O	O
after	ADP	O	O
acid-ethanol	NOUN	O	O
extraction	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
a	DET	O	O
morning	NOUN	O	O
sample	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
cortical	ADJ	O	O
adenoma	NOUN	O	O
was	VERB	O	O
based	VERB	O	O
on	ADP	O	O
computed	PUNCT	O	O
tomography	NOUN	O	O
features	NOUN	O	O
and	CCONJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
uptake	NOUN	O	O
on	ADP	O	O
adrenal	ADJ	O	O
scintigraphy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
obesity	NOUN	O	O
and/or	CCONJ	O	O
diabetes	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
design	NOUN	O	O
included	VERB	O	O
also	ADV	O	O
an	DET	O	O
endocrine	ADJ	O	O
work-up	ADJ	O	O
aimed	ADJ	O	O
to	ADV	O	O
study	NOUN	O	O
the	DET	O	O
hypothalamic-pituitary-adrenal	ADJ	O	B-PHYSICAL
axis	NOUN	O	I-PHYSICAL
[	PUNCT	O	I-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
free	ADJ	O	I-PHYSICAL
cortisol	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
UFC	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
cortisol	NOUN	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
0800	NUM	O	I-PHYSICAL
h	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
plasma	NOUN	O	B-PHYSICAL
ACTH	NOUN	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
0800	NUM	O	I-PHYSICAL
h	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
morning	NOUN	O	B-PHYSICAL
cortisol	NOUN	O	I-PHYSICAL
after	ADP	O	I-PHYSICAL
overnight	CCONJ	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
mg	NOUN	O	I-PHYSICAL
dexamethasone	NOUN	O	I-PHYSICAL
]	PUNCT	O	O
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
showed	VERB	O	O
abnormalities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypothalamic-pituitary-adrenal	ADJ	O	B-PHYSICAL
axis	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
including	CCONJ	O	O
borderline	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
increased	VERB	O	O
UFC	NOUN	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
4	NUM	O	O
of	ADP	O	O
them	PRON	O	O
accompanied	VERB	O	O
by	ADP	O	O
blunted	VERB	O	O
ACTH	NOUN	O	O
in	ADP	O	O
2	NUM	O	O
cases	NOUN	O	O
and	CCONJ	O	O
failure	NOUN	O	O
of	ADP	O	O
cortisol	NOUN	O	O
to	ADP	O	O
suppress	ADP	O	O
after	ADP	O	O
dexamethasone	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
;	PUNCT	O	O
the	DET	O	O
fifth	ADJ	O	O
patient	NOUN	O	O
displayed	VERB	O	O
low	ADJ	O	O
ACTH	NOUN	O	O
and	CCONJ	O	O
resistance	NOUN	O	O
to	ADP	O	O
dexamethasone	NOUN	O	O
suppression	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
patients	NOUN	O	O
had	ADP	O	O
a	DET	O	O
unilateral	ADJ	O	O
uptake	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tracer	NOUN	O	O
on	ADP	O	O
the	DET	O	O
side	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mass	NOUN	O	O
with	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
contralateral	ADJ	O	O
normal	ADJ	O	O
adrenal	ADJ	O	O
gland	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
displayed	VERB	O	O
greater	PUNCT	O	O
UFC	NOUN	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
lower	PUNCT	O	B-PHYSICAL
ACTH	NOUN	O	I-PHYSICAL
concentrations	ADJ	O	I-PHYSICAL
than	PUNCT	O	O
the	DET	O	O
controls	NOUN	O	O
.	PUNCT	O	O

GH	NOUN	O	B-PHYSICAL
release	NOUN	O	I-PHYSICAL
after	ADP	O	I-PHYSICAL
GHRH	NOUN	O	I-PHYSICAL
treatment	NOUN	O	I-PHYSICAL
was	VERB	O	O
blunted	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
bearing	SYM	O	O
adrenal	ADJ	O	O
incidentaloma	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
GH	NOUN	O	O
peak	NOUN	O	O
,	PUNCT	O	O
5.7	NUM	O	O
+/-	SYM	O	O
5.2	NUM	O	O
vs.	CCONJ	O	O
18.0	NUM	O	O
+/-	SYM	O	O
7.0	NUM	O	O
microg/L	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
GHRH	ADP	O	O
plus	CCONJ	O	O
arginine	NOUN	O	O
was	VERB	O	O
able	ADJ	O	O
to	PART	O	O
elicit	NOUN	O	O
a	DET	O	O
comparable	ADJ	O	O
response	NOUN	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
GH	NOUN	O	O
peak	NOUN	O	O
,	PUNCT	O	O
33.5	NUM	O	O
+/-	SYM	O	O
20.3	NUM	O	O
vs.	CCONJ	O	O
33.7	NUM	O	O
+/-	SYM	O	O
17.5	NUM	O	O
microg/L	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
NS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ratio	NOUN	O	O
between	ADP	O	O
GH	NOUN	O	B-PHYSICAL
peaks	CCONJ	O	I-PHYSICAL
after	ADP	O	I-PHYSICAL
GHRH	ADP	O	I-PHYSICAL
plus	CCONJ	O	I-PHYSICAL
arginine	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
after	ADP	O	O
GHRH	ADP	O	B-PHYSICAL
plus	CCONJ	O	O
saline	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
751	NUM	O	O
+/-	SYM	O	O
531	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
81	NUM	O	O
+/-	SYM	O	O
45	NUM	O	O
%	ADJ	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
data	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
when	ADP	O	O
comparing	VERB	O	O
GH	NOUN	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
after	ADP	O	O
GHRH	ADP	O	O
plus	CCONJ	O	O
saline	ADJ	O	O
or	CCONJ	O	O
GHRH	ADP	O	O
plus	CCONJ	O	O
arginine	NOUN	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
incidental	DET	O	O
adrenal	ADJ	O	O
adenomas	NOUN	O	O
the	DET	O	O
GH	NOUN	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	ADP	O	O
GHRH	NOUN	O	O
is	VERB	O	O
blunted	VERB	O	O
due	CCONJ	O	O
to	ADP	O	O
increased	VERB	O	O
somatostatinergic	ADJ	O	B-PHYSICAL
tone	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
as	PUNCT	O	O
it	DET	O	O
can	VERB	O	O
be	VERB	O	O
restored	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
functional	ADJ	O	O
somatostatin	NOUN	O	O
antagonist	NOUN	O	O
arginine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
blunted	VERB	O	O
GH	NOUN	O	O
release	NOUN	O	O
to	ADP	O	O
GHRH	NOUN	O	O
may	VERB	O	O
be	ADJ	O	O
an	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
long	VERB	O	O
lasting	NOUN	O	O
sign	NOUN	O	O
of	ADP	O	O
autonomous	ADJ	O	O
cortisol	NOUN	O	O
secretion	NOUN	O	O
by	ADP	O	O
the	DET	O	O
adrenal	ADJ	O	O
adenoma	NOUN	O	O
.	PUNCT	O	O

Impact	NOUN	O	B-OTHER
of	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
combination	NOUN	O	O
of	ADP	O	O
clindamycin	NOUN	O	O
phosphate	NOUN	O	O
1.2	NUM	O	O
%	ADP	O	O
-benzoyl	DET	O	O
peroxide	NOUN	O	O
2.5	NUM	O	O
%	SYM	O	O
aqueous	ADJ	O	O
gel	NOUN	O	O
on	ADP	O	O
health-related	VERB	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
in	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
acne	NOUN	O	O
vulgaris	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
acne-specific	ADJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
(	PUNCT	O	O
Acne-QoL	NOUN	O	O
)	PUNCT	O	O
questionnaire	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
to	PART	O	O
measure	VERB	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
impact	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
facial	ADJ	O	I-PHYSICAL
acne	NOUN	O	I-PHYSICAL
across	ADP	O	O
4	NUM	O	O
domains	NOUN	O	O
(	PUNCT	O	O
acne	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
role-emotional	ADJ	O	O
,	PUNCT	O	O
self-perception	NOUN	O	O
,	PUNCT	O	O
role-social	ADJ	O	O
)	PUNCT	O	O
of	ADP	O	O
health-related	VERB	O	B-PHYSICAL
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
HRQL	NOUN	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
.	PUNCT	O	O

This	DET	O	O
analysis	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
clindamycin	NOUN	O	O
phosphate	NOUN	O	O
1.2	NUM	O	O
%	ADP	O	O
-benzoyl	DET	O	O
peroxide	NOUN	O	O
2.5	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
clindamycin-BPO	NOUN	O	O
2.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
gel	NOUN	O	O
on	ADP	O	O
HRQL	NOUN	O	O
in	ADP	O	O
a	DET	O	O
combined	ADP	O	O
study	NOUN	O	O
population	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
2813	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
acne	NOUN	O	O
vulgaris	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
results	NOUN	O	O
presented	VERB	O	O
within	ADP	O	O
do	PUNCT	O	O
not	ADV	O	O
include	VERB	O	O
factors	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
and	CCONJ	O	O
study-by-treatment	PUNCT	O	O
interaction	NOUN	O	O
,	PUNCT	O	O
analyses	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
to	ADP	O	O
confirm	ADJ	O	O
that	ADP	O	O
the	DET	O	O
results	NOUN	O	O
were	VERB	O	O
consistent	ADJ	O	O
across	ADP	O	O
the	DET	O	O
2	NUM	O	O
identical	ADJ	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
studies	NOUN	O	O
and	CCONJ	O	O
within	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
across	ADP	O	O
studies	NOUN	O	O
to	ADP	O	O
justify	VERB	O	O
pooling	PUNCT	O	O
the	DET	O	O
data	NOUN	O	O
from	ADP	O	O
both	CCONJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Acne-QoL	NOUN	O	B-PHYSICAL
questionnaire	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
week	NOUN	O	O
12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
clindamycin-BPO	NOUN	O	O
2.5	NUM	O	O
%	SYM	O	O
gel	NOUN	O	O
significantly	ADV	O	O
improved	VERB	O	O
participant-reported	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
and	CCONJ	O	O
physician	NOUN	O	O
computer	NOUN	O	O
mediated	ADP	O	O
communication	NOUN	O	O
skill	ADP	O	O
training	SYM	O	O
on	ADP	O	O
reported	VERB	O	O
communication	NOUN	O	O
and	CCONJ	O	O
patient	NOUN	O	O
satisfaction	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
parallel	DET	O	B-MENTAL
patient	NOUN	O	I-MENTAL
and	CCONJ	O	I-MENTAL
physician	NOUN	O	I-MENTAL
computer-mediated	VERB	O	I-MENTAL
communication	NOUN	O	I-MENTAL
skill	PUNCT	O	I-MENTAL
training	SYM	O	I-MENTAL
on	ADP	O	O
participants	NOUN	O	O
'	PUNCT	O	O
report	NOUN	O	O
of	ADP	O	O
skill	DET	O	O
use	ADP	O	O
and	CCONJ	O	O
patient	NOUN	O	O
satisfaction	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Separate	ADJ	O	O
patient	NOUN	O	O
and	CCONJ	O	O
clinician	NOUN	O	O
web-tools	PROPN	O	O
comprised	ADP	O	O
of	ADP	O	O
over	PUNCT	O	O
500	NUM	O	O
,	PUNCT	O	O
10-s	ADP	O	O
video	ADJ	O	O
clips	NOUN	O	O
demonstrating	VERB	O	O
patient-centered	VERB	O	B-MENTAL
skills	NOUN	O	I-MENTAL
in	ADP	O	O
various	ADJ	O	O
ways	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
clinician	NOUN	O	O
members	NOUN	O	O
of	ADP	O	O
the	DET	O	O
American	ADJ	O	O
Academy	PUNCT	O	O
of	ADP	O	O
Family	NOUN	O	O
Physicians	PROPN	O	O
National	ADJ	O	O
Research	NOUN	O	O
Network	NOUN	O	O
participated	VERB	O	O
by	ADP	O	O
enrolling	ADP	O	O
194	NUM	O	O
patients	NOUN	O	O
into	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
patient	NOUN	O	O
trial	NOUN	O	O
and	CCONJ	O	O
29	NUM	O	O
physicians	NOUN	O	O
into	ADP	O	O
a	DET	O	O
non-randomized	ADJ	O	O
clinician	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
respective	ADJ	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
participants	NOUN	O	O
completed	ADV	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
self-report	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
visit	NOUN	O	O
communication	NOUN	O	B-OTHER
and	CCONJ	O	O
satisfaction	NOUN	O	B-OTHER
.	PUNCT	O	O

RESULTS	CCONJ	O	O
Intervention	NOUN	O	O
patients	NOUN	O	O
reported	VERB	O	O
using	SYM	O	O
more	ADP	O	O
skills	NOUN	O	B-MENTAL
than	CCONJ	O	O
controls	CCONJ	O	O
in	ADP	O	O
five	NUM	O	O
of	ADP	O	O
six	NUM	O	O
skill	PUNCT	O	O
areas	NOUN	O	O
,	PUNCT	O	O
including	CCONJ	O	O
identification	NOUN	O	O
of	ADP	O	O
problems/concerns	PUNCT	O	B-MENTAL
,	PUNCT	O	O
information	NOUN	O	O
exchange	NOUN	O	B-MENTAL
,	PUNCT	O	O
treatment	NOUN	O	O
adherence	NOUN	O	B-MENTAL
,	PUNCT	O	O
shared	VERB	O	O
decision-making	PROPN	O	B-MENTAL
and	CCONJ	O	O
interpersonal	PUNCT	O	B-MENTAL
rapport	NOUN	O	I-MENTAL
(	PUNCT	O	O
all	DET	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
post	PUNCT	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
reported	VERB	O	O
using	SYM	O	O
more	ADP	O	O
skills	NOUN	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
5	NUM	O	O
areas	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
p	NOUN	O	O
<	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intervention	NOUN	O	O
group	NOUN	O	O
patients	NOUN	O	O
reported	VERB	O	O
higher	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
satisfaction	NOUN	O	O
than	PUNCT	O	O
controls	CCONJ	O	O
in	ADP	O	O
five	NUM	O	O
of	ADP	O	O
six	NUM	O	O
domains	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Communication	NOUN	O	O
skill	ADJ	O	O
training	SYM	O	O
delivered	VERB	O	O
in	ADP	O	O
a	DET	O	O
computer	NOUN	O	O
mediated	PUNCT	O	O
format	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
positive	ADJ	O	O
and	CCONJ	O	O
parallel	ADP	O	B-OTHER
impact	NOUN	O	I-OTHER
on	ADP	O	O
both	PUNCT	O	O
patient	NOUN	O	O
and	CCONJ	O	O
clinician	NOUN	O	O
reported	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
patient-centered	VERB	O	B-MENTAL
communication	NOUN	O	I-MENTAL
and	CCONJ	O	O
in	ADP	O	O
patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
.	PUNCT	O	O

PRACTICE	NOUN	O	O
IMPLICATIONS	NOUN	O	O
Computer-mediated	VERB	O	O
interventions	NOUN	O	O
are	VERB	O	O
cost	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
effective	ADJ	O	O
thereby	PUNCT	O	O
increasing	ADP	O	O
patient	NOUN	O	O
and	CCONJ	O	O
clinician	NOUN	O	O
willingness	ADP	O	O
to	ADP	O	O
undertake	NOUN	O	O
training	ADV	O	O
.	PUNCT	O	O

Left	ADJ	O	O
thoracoabdominal	ADJ	O	O
approach	NOUN	O	O
versus	CCONJ	O	O
abdominal-transhiatal	ADJ	O	O
approach	NOUN	O	O
for	ADP	O	O
gastric	ADJ	O	O
cancer	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardia	NOUN	O	O
or	CCONJ	O	O
subcardia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Because	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
inaccessibility	ADJ	O	O
of	ADP	O	O
mediastinal	ADJ	O	O
nodal	ADJ	O	O
metastases	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
left	ADJ	O	O
thoracoabdominal	ADJ	O	O
approach	NOUN	O	O
(	PUNCT	O	O
LTA	PUNCT	O	O
)	PUNCT	O	O
has	PUNCT	O	O
often	ADV	O	O
been	PUNCT	O	O
used	VERB	O	O
to	PART	O	O
treat	NOUN	O	O
gastric	DET	O	O
cancer	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardia	NOUN	O	O
or	CCONJ	O	O
subcardia	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
phase	NOUN	O	O
III	NUM	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PROPN	O	O
aimed	VERB	O	O
to	PART	O	O
compare	ADP	O	B-OTHER
LTA	NOUN	O	O
with	ADP	O	O
the	DET	O	O
abdominal-transhiatal	ADJ	O	O
approach	NOUN	O	O
(	PUNCT	O	O
TH	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
these	DET	O	O
tumours	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Between	ADP	O	O
July	NOUN	O	O
,	PUNCT	O	O
1995	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
December	NOUN	O	O
,	PUNCT	O	O
2003	NUM	O	O
,	PUNCT	O	O
167	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
from	ADP	O	O
27	NUM	O	O
Japanese	ADJ	O	O
hospitals	NOUN	O	O
and	CCONJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
TH	NOUN	O	O
(	PUNCT	O	O
n=82	NOUN	O	O
)	PUNCT	O	O
or	PUNCT	O	O
LTA	NOUN	O	O
(	PUNCT	O	O
n=85	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
,	PUNCT	O	O
and	CCONJ	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
were	VERB	O	O
disease-free	ADJ	O	B-PHYSICAL
survival	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
postoperative	ADJ	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
hospital	NOUN	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
,	PUNCT	O	O
and	CCONJ	O	O
postoperative	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
change	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
projected	VERB	O	O
sample	NOUN	O	O
size	NOUN	O	O
was	VERB	O	O
302	NUM	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
first	ADJ	O	O
interim	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
predicted	VERB	O	O
probability	NOUN	O	O
of	ADP	O	O
LTA	NOUN	O	O
having	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
better	PUNCT	O	O
overall	ADP	O	O
survival	NOUN	O	O
than	PUNCT	O	O
TH	NOUN	O	O
at	ADP	O	O
the	DET	O	O
final	ADJ	O	O
analysis	NOUN	O	O
was	VERB	O	O
only	ADV	O	O
3.65	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
closed	VERB	O	O
immediately	ADV	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
was	VERB	O	O
by	ADP	O	O
intention	NOUN	O	O
to	PART	O	O
treat	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
registered	PUNCT	O	O
with	ADP	O	O
,	PUNCT	O	O
number	NOUN	O	O
NCT00149266	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
5-year	NOUN	O	B-MORTALITY
overall	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
52.3	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
40.4-64.1	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
TH	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
37.9	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
26.1-49.6	ADP	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
LTA	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
death	NOUN	O	B-MORTALITY
for	ADP	O	O
LTA	NOUN	O	B-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
TH	NOUN	O	O
was	VERB	O	O
1.36	NUM	O	O
(	PUNCT	O	O
0.89-2.08	NUM	O	O
,	PUNCT	O	O
p=0.92	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
died	VERB	O	B-MORTALITY
in	ADP	O	O
hospital	NOUN	O	O
after	PUNCT	O	O
LTA	NOUN	O	O
but	CCONJ	O	O
none	NUM	O	O
after	ADP	O	O
TH	NOUN	O	O
.	PUNCT	O	O

Morbidity	NOUN	O	B-PHYSICAL
was	VERB	O	O
worse	ADJ	O	O
after	PUNCT	O	O
LTA	CCONJ	O	O
than	PUNCT	O	O
after	ADP	O	O
TH	NOUN	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
Because	PUNCT	O	O
LTA	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
improve	PUNCT	O	O
survival	NOUN	O	O
after	ADP	O	O
TH	NOUN	O	O
and	CCONJ	O	O
leads	NOUN	O	O
to	ADP	O	O
increased	VERB	O	O
morbidity	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardia	NOUN	O	O
or	CCONJ	O	O
subcardia	NOUN	O	O
,	PUNCT	O	O
LTA	NOUN	O	O
can	ADP	O	O
not	ADV	O	O
be	VERB	O	O
justified	VERB	O	O
to	PART	O	O
treat	NOUN	O	O
these	DET	O	O
tumours	NOUN	O	O
.	PUNCT	O	O

Prevention	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
loss	NOUN	O	O
in	ADP	O	O
survivors	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
A	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Few	ADJ	O	O
data	NOUN	O	O
are	VERB	O	O
available	ADJ	O	O
on	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
once-weekly	PUNCT	O	O
oral	ADJ	O	O
bisphosphonate	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
survivors	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Our	PUNCT	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
risedronate	NOUN	O	O
,	PUNCT	O	O
35	NUM	O	O
mg	NOUN	O	O
weekly	ADV	O	O
,	PUNCT	O	O
is	VERB	O	O
efficacious	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
bone	NOUN	O	O
loss	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
chemotherapy-induced	VERB	O	O
menopause	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
over	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
AND	CCONJ	O	O
PARTICIPANTS	ADP	O	O
Participants	NOUN	O	O
included	VERB	O	O
87	NUM	O	O
newly	ADV	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
status	NOUN	O	O
post	PUNCT	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
recruited	VERB	O	O
from	ADP	O	O
a	DET	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
clinic	NOUN	O	O
in	ADP	O	O
an	DET	O	O
academic	ADJ	O	O
medical	ADJ	O	O
center	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
Participants	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
risedronate	NOUN	O	O
35	NUM	O	O
mg/wk	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
The	DET	O	O
primary	ADJ	O	O
outcomes	NOUN	O	O
were	VERB	O	O
the	DET	O	O
12-month	NOUN	O	B-PHYSICAL
changes	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
spine	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
hip	NOUN	O	B-PHYSICAL
bone	NOUN	O	I-PHYSICAL
mineral	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Secondary	ADJ	O	O
outcomes	NOUN	O	O
included	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
markers	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
bone	NOUN	O	I-PHYSICAL
resorption	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
urine	NOUN	O	I-PHYSICAL
N-telopeptide	NOUN	O	I-PHYSICAL
cross-linked	VERB	O	I-PHYSICAL
collagen	NOUN	O	I-PHYSICAL
type	NOUN	O	O
I	NUM	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
formation	NOUN	O	B-PHYSICAL
(	PUNCT	O	B-PHYSICAL
osteocalcin	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
N-terminal	ADJ	O	B-PHYSICAL
propeptide	PUNCT	O	I-PHYSICAL

Photodynamic	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
5-aminolaevulinic	ADJ	O	O
acid	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
recalcitrant	VERB	O	O
foot	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
hand	NOUN	O	B-PHYSICAL
warts	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
randomised	DET	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Photodynamic	PUNCT	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
PDT	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
topical	ADJ	O	O
5-aminolaevulinic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
ALA	NOUN	O	O
)	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
irradiation	NOUN	O	O
with	ADP	O	O
incoherent	ADJ	O	O
light	ADJ	O	O
(	PUNCT	O	O
ALA-PDT	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
recalcitrant	VERB	O	O
warts	NOUN	O	O
have	PUNCT	O	O
had	PUNCT	O	O
beneficial	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	ADP	O	O
undertook	ADJ	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
parallel	PUNCT	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
ALA-PDT	NOUN	O	O
versus	CCONJ	O	O
placeboPDT	NOUN	O	O
for	ADP	O	O
recalcitrant	VERB	O	O
foot	NOUN	O	O
and	CCONJ	O	O
hand	NOUN	O	O
warts	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Recalcitrant	PUNCT	O	O
foot	NOUN	O	O
and	CCONJ	O	O
hand	NOUN	O	O
warts	ADV	O	O
were	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
six	PUNCT	O	O
repetitive	ADJ	O	O
ALA-PDT	NOUN	O	O
or	CCONJ	O	O
placebo-PDT	NOUN	O	O
interventions	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
encompassing	PUNCT	O	O
paring	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
keratolytic	ADJ	O	O
(	PUNCT	O	O
Verucid	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Standardised	ADP	O	O
photographs	PUNCT	O	O
of	ADP	O	O
each	DET	O	O
wart	ADJ	O	O
were	VERB	O	O
taken	VERB	O	O
before	ADP	O	O
,	PUNCT	O	O
during	ADP	O	O
(	PUNCT	O	O
week	NOUN	O	O
7	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
weeks	NOUN	O	O
14	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
area	NOUN	O	O
of	ADP	O	O
each	DET	O	O
wart	ADJ	O	O
compared	VERB	O	O
with	ADP	O	O
entry	NOUN	O	O
area	NOUN	O	O
was	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
variable	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
from	ADP	O	O
photographs	PUNCT	O	O
by	ADP	O	O
an	DET	O	O
evaluator	NOUN	O	O
unaware	PUNCT	O	O
of	ADP	O	O
treatment	NOUN	O	O
allocation	NOUN	O	O
for	ADP	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
intensity	NOUN	O	I-PAIN
immediately	ADV	O	O
and	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
each	DET	O	O
intervention	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
a	DET	O	O
five-point	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
232	NUM	O	O
foot	NOUN	O	O
and	CCONJ	O	O
hand	NOUN	O	O
warts	NOUN	O	O
in	ADP	O	O
45	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
entered	VERB	O	O
into	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
:	PUNCT	O	O
117	NUM	O	O
warts	NOUN	O	O
were	VERB	O	O
allocated	NUM	O	O
to	ADP	O	O
ALA-PDT	NOUN	O	O
and	CCONJ	O	O
115	NUM	O	O
warts	NOUN	O	O
to	ADP	O	O
placebo-PDT	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
week	NOUN	O	O
14	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
relative	ADJ	O	B-PHYSICAL
reduction	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
wart	NOUN	O	I-PHYSICAL
area	NOUN	O	O
was	VERB	O	O
98	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
ALA-PDT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
interquartile	NOUN	O	O
range	NOUN	O	O
100	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
55	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
52	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
0	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p=0.0006	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
week	NOUN	O	O
18	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
relative	ADJ	O	B-PHYSICAL
reduction	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
wart	NOUN	O	I-PHYSICAL
area	NOUN	O	O
was	VERB	O	O
100	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
ALA-PDT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
57	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
71	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
0	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo-PDT	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
p=0.008	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
vanishing	NUM	O	B-OTHER
warts	NOUN	O	I-OTHER
and	CCONJ	O	O
the	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
relative	ADJ	O	B-OTHER
wart	NOUN	O	I-OTHER
area	NOUN	O	O
of	ADP	O	B-OTHER
persisting	ADV	O	I-OTHER
warts	NOUN	O	B-OTHER
at	ADP	O	O
week	NOUN	O	O
14	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
were	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
favour	NOUN	O	O
of	ADP	O	O
ALA-PDT	NOUN	O	O
.	PUNCT	O	O

Significantly	ADV	O	O
more	DET	O	O
ALA-PDT	NOUN	O	O
warts	NOUN	O	O
were	VERB	O	O
graded	VERB	O	O
at	ADP	O	O
a	DET	O	O
higher	PUNCT	O	B-PAIN
pain	PUNCT	O	I-PAIN

Can	PUNCT	O	O
patient	NOUN	O	O
coaching	VERB	O	O
reduce	VERB	O	O
racial/ethnic	ADJ	O	O
disparities	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	O
pain	NOUN	O	O
control	NOUN	O	O
?	PUNCT	O	O

Secondary	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Minority	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	O
experience	NOUN	O	O
worse	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
their	PUNCT	O	O
pain	NOUN	O	O
than	PUNCT	O	O
do	PUNCT	O	O
their	PUNCT	O	O
white	ADJ	O	O
counterparts	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
disparity	NOUN	O	O
may	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
reflect	VERB	O	O
more	DET	O	O
miscommunication	NOUN	O	O
between	ADP	O	O
minority	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
physicians	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
examined	VERB	O	O
whether	ADP	O	O
patient	NOUN	O	O
coaching	CCONJ	O	O
could	PUNCT	O	O
reduce	VERB	O	O
disparities	DET	O	O
in	ADP	O	O
pain	NOUN	O	B-PAIN
control	NOUN	O	I-PAIN
in	ADP	O	O
a	DET	O	O
secondary	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty-seven	PUNCT	O	O
English-speaking	ADJ	O	O
adult	NOUN	O	O
cancer	NOUN	O	O
outpatients	ADJ	O	O
,	PUNCT	O	O
including	VERB	O	O
15	NUM	O	O
minorities	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
moderate	ADJ	O	O
pain	NOUN	O	O
over	ADP	O	O
the	DET	O	O
prior	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
34	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
33	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Experimental	ADJ	O	O
patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
20-minute	NOUN	O	O
individualized	VERB	O	O
education	NOUN	O	O
and	CCONJ	O	O
coaching	NUM	O	O
session	NOUN	O	O
to	PART	O	O
increase	NOUN	O	O
knowledge	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	O
self-management	ADJ	O	O
,	PUNCT	O	O
to	PART	O	O
redress	ADP	O	O
personal	ADJ	O	O
misconceptions	NOUN	O	O
about	PUNCT	O	O
pain	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PUNCT	O	O
rehearse	PUNCT	O	O
an	DET	O	O
individually	ADV	O	O
scripted	VERB	O	O
patient-physician	ADJ	O	O
dialog	NOUN	O	O
about	ADP	O	O
pain	NOUN	O	B-PAIN
control	NOUN	O	I-PAIN
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
standardized	VERB	O	O
information	NOUN	O	O
on	ADP	O	O
controlling	PUNCT	O	O
pain	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
average	ADJ	O	O
pain	NOUN	O	B-PAIN
(	PUNCT	O	O
0-10	NUM	O	O
scale	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
collected	VERB	O	O
at	ADP	O	O
enrollment	NOUN	O	O
and	CCONJ	O	O
2-week	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
enrollment	NOUN	O	O
,	PUNCT	O	O
minority	NOUN	O	O
patients	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
more	DET	O	O
pain	NOUN	O	B-PAIN
than	ADP	O	O
their	PUNCT	O	O
white	ADJ	O	O
counterparts	NOUN	O	O
(	PUNCT	O	O
6.0	NUM	O	O
vs	CCONJ	O	O
5.0	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
minorities	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
continued	VERB	O	O
to	ADP	O	O
have	PUNCT	O	O
more	DET	O	O
pain	NOUN	O	B-PAIN
(	PUNCT	O	O
6.4	NUM	O	O
vs	CCONJ	O	O
4.7	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
disparities	NOUN	O	O
were	VERB	O	O
eliminated	NOUN	O	O
(	PUNCT	O	O
4.0	NUM	O	O
vs	CCONJ	O	O
4.3	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.71	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
on	ADP	O	O
reducing	PROPN	O	O
disparities	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	DET	O	O
Patient	NOUN	O	O
coaching	VERB	O	O
offers	PUNCT	O	O
promise	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
means	NOUN	O	O
of	ADP	O	O
reducing	VERB	O	O
racial/ethnic	ADJ	O	B-PAIN
disparities	NOUN	O	I-PAIN
in	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
control	NOUN	O	I-PAIN
.	PUNCT	O	O

Larger	PUNCT	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	ADP	O	O
validate	VERB	O	O
these	DET	O	O
findings	NOUN	O	O
and	CCONJ	O	O
to	PUNCT	O	O
explore	NOUN	O	O
possible	ADJ	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

Methodological	ADJ	O	O
issues	NOUN	O	O
in	ADP	O	O
designing	ADP	O	O
a	DET	O	O
multisite	PUNCT	O	O
trial	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	ADJ	O	O
describe	PROPN	O	O
the	DET	O	O
methodological	ADJ	O	O
challenges	NOUN	O	O
and	CCONJ	O	O
decisions	NOUN	O	O
made	VERB	O	O
in	ADP	O	O
developing	VERB	O	O
a	DET	O	O
multisite	NOUN	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Review	PUNCT	O	O
the	DET	O	O
design	NOUN	O	O
considerations	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
accompanied	VERB	O	O
by	ADP	O	O
severe	ADJ	O	O
tantrums	ADP	O	O
,	PUNCT	O	O
aggressive	ADJ	O	O
and/or	CCONJ	O	O
self-injurious	ADJ	O	O
behaviors	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
design	NOUN	O	O
considerations	NOUN	O	O
include	VERB	O	O
the	DET	O	O
definition	NOUN	O	O
of	ADP	O	O
inclusion	NOUN	O	O
criteria	NOUN	O	O
that	DET	O	O
are	VERB	O	O
relevant	ADJ	O	O
to	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
and	CCONJ	O	O
matching	ADV	O	O
study	NOUN	O	O
design	NOUN	O	O
to	ADP	O	O
the	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
evaluating	ADJ	O	O
short-	ADJ	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
ethical	ADJ	O	O
and	CCONJ	O	O
scientific	ADJ	O	O
issues	NOUN	O	O
concern	ADJ	O	O
the	DET	O	O
length	NOUN	O	O
of	ADP	O	O
trial	NOUN	O	O
and	CCONJ	O	O
sample	NOUN	O	O
size	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
We	ADP	O	O
undertook	ADJ	O	O
a	DET	O	O
short-term	NOUN	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
trial	NOUN	O	O
design	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
extended	VERB	O	O
open-label	NOUN	O	O
maintenance	NOUN	O	O
on	ADP	O	O
risperidone	NUM	O	O
to	ADP	O	O
confirm	ADP	O	O
durability	NOUN	O	B-OTHER
of	ADP	O	O
treatment	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
monitor	NOUN	O	O
safety	NOUN	O	B-OTHER
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
placebo-controlled	ADV	O	O
discontinuation	NOUN	O	O
study	NOUN	O	O
tested	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
continuous	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
standard	ADJ	O	O
pharmacological	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
remains	NOUN	O	O
the	DET	O	O
most	PUNCT	O	O
appropriate	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
testing	NUM	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
relevance	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
enhanced	VERB	O	O
by	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
an	DET	O	O
extended	VERB	O	O
maintenance	NOUN	O	O
phase	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
discontinuation	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
study	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Ligaclip	ADV	O	O
with	ADP	O	O
bipolar	ADJ	O	O
energy	NOUN	O	O
to	PART	O	O
prevent	NOUN	O	O
lymphocele	NOUN	O	O
during	ADP	O	O
laparoscopic	ADJ	O	O
pelvic	ADJ	O	O
lymphadenectomy	NOUN	O	O
for	ADP	O	O
gynecologic	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	PUNCT	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
pilot	NOUN	O	O
study	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Ligaclip	ADV	O	O
(	PUNCT	O	O
Ethicon	NOUN	O	O
Endo-Surgery	NOUN	O	O
,	PUNCT	O	O
Cincinnati	NOUN	O	O
,	PUNCT	O	O
OH	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
bipolar	ADJ	O	O
coagulation	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
lymphoceles	PUNCT	O	O
after	ADP	O	O
laparoscopic	ADJ	O	O
pelvic	ADJ	O	O
lymphadenectomy	NOUN	O	O
for	ADP	O	O
gynecologic	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Thirty	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
gynecologic	ADJ	O	O
malignancy	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
had	CCONJ	O	O
laparoscopic	ADJ	O	O
pelvic	ADJ	O	O
lymphadenectomy	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
for	ADP	O	O
lymphadenectomy	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
side	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pelvis	NOUN	O	O
using	VERB	O	O
the	DET	O	O
Ligaclip	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
side	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
bipolar	ADJ	O	O
coagulation	NOUN	O	O
to	ADP	O	O
seal	ADJ	O	O
lymphatic	ADJ	O	O
vessels	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
ultrasound	NOUN	O	O
examination	NOUN	O	O
,	PUNCT	O	O
we	NOUN	O	O
detected	VERB	O	O
lymphocele	NOUN	O	B-PHYSICAL
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
33	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Lymphocele	NOUN	O	B-PHYSICAL
developed	PUNCT	O	O
in	ADP	O	O
9	NUM	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
on	ADP	O	O
the	DET	O	O
side	NOUN	O	O
where	ADP	O	O
laparoscopic	ADJ	O	O
pelvic	ADJ	O	O
lymphadenectomy	NOUN	O	O
was	VERB	O	O
perfomed	NOUN	O	O
using	VERB	O	O
bipolar	PUNCT	O	O
coagulation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
1	NUM	O	O
(	PUNCT	O	O
3.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patient	NOUN	O	O
on	ADP	O	O
the	DET	O	O
side	NOUN	O	O
where	ADP	O	O
laparoscopic	ADJ	O	O
pelvic	ADJ	O	O
lymphadenectomy	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
the	DET	O	O
Ligaclip	NOUN	O	O
.	PUNCT	O	O

Univariate	ADJ	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
Ligaclip	NOUN	O	O
's	PUNCT	O	O
use	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
electrocoagulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
laparoscopic	ADJ	O	O
pelvic	ADJ	O	O
lymphadenectomy	NOUN	O	O
is	VERB	O	O
an	DET	O	O
independent	ADJ	O	O
predictive	ADJ	O	O
factor	NOUN	O	O
for	ADP	O	O
development	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
lymphocele	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.006	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
demonstrates	NOUN	O	O
that	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
the	PUNCT	O	O
Ligaclip	ADV	O	O
to	ADP	O	O
close	ADJ	O	O
lymphatic	ADJ	O	O
vessels	NOUN	O	O
may	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
lymphoceles	PUNCT	O	B-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
undergoing	SYM	O	O
laparoscopic	PUNCT	O	O
pelvic	ADJ	O	O
lymphadenectomy	NOUN	O	O
.	PUNCT	O	O

Role	NOUN	O	O
of	ADP	O	O
oxidized	VERB	O	O
regenerated	CCONJ	O	O
cellulose	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
infections	NOUN	O	O
at	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
site	NOUN	O	O
:	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
in	ADP	O	O
98	NUM	O	O
patients	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
a	DET	O	O
dirty	CCONJ	O	O
wound	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
whether	ADP	O	O
oxidized	VERB	O	B-PHYSICAL
regenerated	CCONJ	O	I-PHYSICAL
cellulose	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
ORC	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
applied	VERB	O	O
to	PUNCT	O	O
dirty	PUNCT	O	O
surgical	ADJ	O	O
wounds	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
able	ADJ	O	O
to	PART	O	O
reduce	NOUN	O	O
the	DET	O	O
microbial	ADJ	O	O
load	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
consequently	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
infection	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
as	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
conventional	ADJ	O	O
local	ADJ	O	O
wound	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
included	VERB	O	O
98	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
underwent	VERB	O	O
intestinal	ADJ	O	O
recanalization	NOUN	O	O
procedures	NOUN	O	O
between	ADP	O	O
December	NOUN	O	O
2003	NUM	O	O
and	CCONJ	O	O
December	NOUN	O	O
2008	NUM	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
stoma	NOUN	O	O
as	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
site	NOUN	O	O
.	PUNCT	O	O

Authors	NOUN	O	O
considered	VERB	O	O
several	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
SSI	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
surgical	ADJ	O	B-PHYSICAL
wound	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
previous	ADJ	O	O
site	NOUN	O	O
of	ADP	O	O
the	DET	O	O
stoma	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
packed	VERB	O	O
with	ADP	O	O
ORC	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
48	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
gauze	PUNCT	O	O
soaked	VERB	O	O
in	ADP	O	O
iodine	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

Microbial	ADJ	O	B-PHYSICAL
contamination	NOUN	O	I-PHYSICAL
was	VERB	O	O
evaluated	VERB	O	O
with	ADP	O	O
three	NUM	O	O
swabs	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
subcutaneous	ADJ	O	O
tissue	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
dermis	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
operating	VERB	O	O
room	NOUN	O	O
before	PUNCT	O	O
wound	NOUN	O	O
packing	VERB	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
2nd	ADJ	O	O
and	CCONJ	O	O
3rd	ADJ	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
(	PUNCT	O	O
before	ADP	O	O
suturing	PUNCT	O	O
the	DET	O	O
skin	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
wound	NOUN	O	B-PHYSICAL
dehiscence	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
no	DET	O	O
clinically	ADV	O	B-PHYSICAL
evident	ADJ	O	I-PHYSICAL
superficial	ADJ	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
deep	ADJ	O	I-PHYSICAL
surgical	ADJ	O	I-PHYSICAL
site	NOUN	O	I-PHYSICAL
infections	NOUN	O	I-PHYSICAL
in	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
all	DET	O	O
data	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
or	CCONJ	O	O
reduced	VERB	O	B-PHYSICAL
bacterial	ADJ	O	I-PHYSICAL
contamination	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
and	CCONJ	O	O
third	ADJ	O	O
swab	NOUN	O	O
in	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
66	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
Group	NOUN	O	O
A	NOUN	O	O
versus	CCONJ	O	O
12	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
Group	NOUN	O	O
B	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Although	ADP	O	O
it	PRON	O	O
is	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
consider	NOUN	O	O
all	DET	O	O
factors	NOUN	O	O
which	ADP	O	O
can	VERB	O	O
have	PUNCT	O	O
an	DET	O	O
influence	NOUN	O	O
on	ADP	O	O
SSI	NOUN	O	O
and	CCONJ	O	O
use	ADP	O	O
all	DET	O	O
the	DET	O	O
means	NOUN	O	O
shown	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
effective	ADJ	O	O
to	PART	O	O
reduce	NOUN	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
SSI	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
rationale	NOUN	O	O
for	ADP	O	O
using	NOUN	O	O
ORC	NOUN	O	O
to	ADJ	O	O
prevent	NOUN	O	O
this	DET	O	O
kind	ADV	O	O
of	ADP	O	O
infection	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
undergo	VERB	O	O
dirty	CCONJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
highly	ADV	O	O
active	ADJ	O	O
antiretroviral	ADP	O	O
treatment	NOUN	O	O
strategies	NOUN	O	O
consisting	DET	O	O
of	ADP	O	O
non-nucleoside	NOUN	O	O
reverse	ADJ	O	O
transcriptase	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
protease	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
nucleoside	NOUN	O	O
reverse	ADJ	O	O
transcriptase	NOUN	O	O
inhibitors	NOUN	O	O
as	ADP	O	O
initial	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
CPCRA	NOUN	O	O
058	NUM	O	O
FIRST	PUNCT	O	O
Study	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
long-term	NOUN	O	O
randomised	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Long-term	NOUN	O	O
data	NOUN	O	O
from	ADP	O	O
randomised	VERB	O	O
trials	NOUN	O	O
on	ADP	O	O
the	DET	O	O
consequences	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
protease	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
PI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
non-nucleoside	NOUN	O	O
reverse	ADJ	O	O
transcriptase	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
NNRTI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	PUNCT	O	O
are	VERB	O	O
lacking	ADJ	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PUNCT	O	O
report	VERB	O	O
results	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
FIRST	PUNCT	O	O
trial	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
compared	VERB	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
strategies	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
immunological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
virological	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Between	ADP	O	O
1999	NUM	O	O
and	CCONJ	O	O
2002	NUM	O	O
,	PUNCT	O	O
1397	NUM	O	O
antiretroviral-treatment-naive	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
presenting	PUNCT	O	O
at	ADP	O	O
18	NUM	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
units	NOUN	O	O
with	ADP	O	O
80	NUM	O	O
research	NOUN	O	O
sites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
USA	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
in	ADP	O	O
a	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
1:1:1	NOUN	O	O
to	ADP	O	O
a	DET	O	O
protease	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
PI	NOUN	O	O
)	PUNCT	O	O
strategy	NOUN	O	O
(	PUNCT	O	O
PI	NOUN	O	O
plus	CCONJ	O	O
nucleoside	NOUN	O	O
reverse	ADJ	O	O
transcriptase	NOUN	O	O
inhibitor	NOUN	O	O
[	PUNCT	O	O
NRTI	NOUN	O	O
]	PUNCT	O	O
;	PUNCT	O	O
n=470	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
non-nucleoside	NOUN	O	O
reverse	ADJ	O	O
transcriptase	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
NNRTI	NOUN	O	O
)	PUNCT	O	O
strategy	NOUN	O	O
(	PUNCT	O	O
NNRTI	NOUN	O	O
plus	CCONJ	O	O
NRTI	NOUN	O	O
;	PUNCT	O	O
n=463	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
three-class	NOUN	O	O
strategy	NOUN	O	O
(	PUNCT	O	O
PI	NOUN	O	O
plus	CCONJ	O	O
NNRTI	NOUN	O	O
plus	CCONJ	O	O
NRTI	NOUN	O	O
;	PUNCT	O	O
n=464	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
endpoints	NOUN	O	O
were	VERB	O	O
a	DET	O	O
composite	NOUN	O	O
of	ADP	O	O
an	DET	O	O
AIDS-defining	ADP	O	B-PHYSICAL
event	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
or	CCONJ	O	O
CD4	NOUN	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
decline	DET	O	I-PHYSICAL
to	ADP	O	O
less	DET	O	O
than	PUNCT	O	O
200	NUM	O	O
cells	NOUN	O	O
per	ADP	O	O
mm3	NOUN	O	O
for	ADP	O	O
the	DET	O	O
PI	NOUN	O	O
versus	CCONJ	O	O
NNRTI	NOUN	O	O
comparison	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
average	PUNCT	O	O
change	NOUN	O	O
in	ADP	O	O
CD4	NOUN	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
at	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
32	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
the	DET	O	O
three-class	NOUN	O	O
versus	CCONJ	O	O
combined	VERB	O	O
two-class	NOUN	O	O
comparison	NOUN	O	O
.	PUNCT	O	O

Analyses	NOUN	O	O
were	VERB	O	O
by	ADP	O	O
intention-to-treat	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
registered	PUNCT	O	O
ClinicalTrials.gov	PUNCT	O	O
,	PUNCT	O	O
number	NOUN	O	O
NCT00000922	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
1397	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
the	DET	O	O
composite	PUNCT	O	O
endpoint	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
388	NUM	O	O
participants	NOUN	O	O
developed	VERB	O	O
the	DET	O	O
composite	PUNCT	O	B-OTHER
endpoint	NOUN	O	I-OTHER
,	PUNCT	O	O
302	NUM	O	O
developed	VERB	O	O
AIDS	NOUN	O	O
or	CCONJ	O	O
died	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
188	NUM	O	O
died	PROPN	O	O
.	PUNCT	O	O

NNRTI	NOUN	O	O
versus	CCONJ	O	O
PI	NOUN	O	O
hazard	NOUN	O	O
ratios	NOUN	O	B-OTHER
(	PUNCT	O	O
HRs	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
composite	PUNCT	O	O
endpoint	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
AIDS	NOUN	O	B-MORTALITY
or	CCONJ	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
for	ADP	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
virological	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
were	VERB	O	O
1.02	PUNCT	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.79-1.31	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
1.07	NUM	O	O
(	PUNCT	O	O
0.80-1.41	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
0.95	NUM	O	O
(	PUNCT	O	O
0.66-1.37	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0.66	NUM	O	O
(	PUNCT	O	O
0.56-0.78	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

1196	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
the	DET	O	O
three-class	NOUN	O	O
versus	CCONJ	O	O
combined	VERB	O	O
two-class	NOUN	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
change	NOUN	O	O
in	ADP	O	O
CD4	NOUN	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
at	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
32	NUM	O	O
months	NOUN	O	O
was	VERB	O	O
+234	PUNCT	O	O
cells	NOUN	O	O
per	ADP	O	O
mm3	NOUN	O	O
and	CCONJ	O	O
+227	ADV	O	O
cells	NOUN	O	O
per	ADP	O	O
mm3	NOUN	O	O
for	ADP	O	O
the	DET	O	O
three-class	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
combined	VERB	O	O
two-class	NOUN	O	O
strategies	NOUN	O	O
(	PUNCT	O	O
p=0.62	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

HRs	ADV	O	B-OTHER
(	PUNCT	O	O
three-class	NOUN	O	O
vs	CCONJ	O	O
combined	VERB	O	O
two-class	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
AIDS	NOUN	O	B-MORTALITY
or	CCONJ	O	O
death	NOUN	O	B-MORTALITY
and	CCONJ	O	O
virological	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
were	VERB	O	O
1.15	NUM	O	O
(	PUNCT	O	O
0.91-1.45	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
0.87	NUM	O	O
(	PUNCT	O	O
0.75-1.00	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

HRs	ADV	O	B-OTHER
(	PUNCT	O	O
three-class	NOUN	O	O
vs	CCONJ	O	O
combined	VERB	O	O
two-class	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
AIDS	NOUN	O	B-MORTALITY
or	CCONJ	O	O
death	NOUN	O	B-MORTALITY
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
baseline	NOUN	O	O
CD4	NOUN	O	O
cell	NOUN	O	O
counts	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
cells	NOUN	O	O
per	ADP	O	O
mm3	NOUN	O	O
or	CCONJ	O	O
less	DET	O	O
and	CCONJ	O	O
of	ADP	O	O
more	ADV	O	O
than	PUNCT	O	O
200	NUM	O	O
cells	NOUN	O	O
per	ADP	O	O
mm3	NOUN	O	O
(	PUNCT	O	O
p=0.38	NOUN	O	O
for	ADP	O	O
interaction	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
baseline	NOUN	O	O
HIV	NOUN	O	O
RNA	NOUN	O	O
concentrations	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
100	NUM	O	O
000	NUM	O	O
copies	NOUN	O	O
per	ADP	O	O
mL	NOUN	O	O
and	CCONJ	O	O
100,000	NUM	O	O
copies	NOUN	O	O
per	ADP	O	O
mL	NOUN	O	O
or	CCONJ	O	O
more	DET	O	O
(	PUNCT	O	O
p=0.26	NOUN	O	O
for	ADP	O	O
interaction	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
assigned	VERB	O	O
the	DET	O	O
three-class	NOUN	O	O
strategy	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	ADP	O	O
discontinue	ADP	O	B-OTHER
treatment	NOUN	O	I-OTHER
because	PUNCT	O	O
of	ADP	O	O
toxic	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
than	PUNCT	O	O
were	VERB	O	O
those	PUNCT	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
two-class	NOUN	O	O
strategies	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
1.58	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
Initial	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
an	DET	O	O
NNRTI-based	VERB	O	O
regimen	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
PI-based	VERB	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
both	CCONJ	O	O
together	ADV	O	O
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
good	ADJ	O	O
strategy	NOUN	O	O
for	ADP	O	O
long-term	NOUN	O	O
antiretroviral	ADJ	O	O
management	NOUN	O	O
in	ADP	O	O
treatment-naive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
HIV	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overt	ADJ	O	O
aggression	NOUN	O	O
scale	NOUN	O	O
for	ADP	O	O
rating	VERB	O	O
aggression	NOUN	O	O
in	ADP	O	O
outpatient	ADJ	O	O
youth	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
:	PUNCT	O	O
preliminary	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Aggression	NOUN	O	O
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
and	CCONJ	O	O
costly	PUNCT	O	O
problem	NOUN	O	O
in	ADP	O	O
youth	NOUN	O	O
with	ADP	O	O
developmental	ADJ	O	O
disabilities	NOUN	O	O
.	PUNCT	O	O

Rating	ADJ	O	O
scales	NOUN	O	O
that	PUNCT	O	O
accurately	PUNCT	O	O
capture	NOUN	O	O
and	CCONJ	O	O
measure	PUNCT	O	O
subtypes	NOUN	O	O
of	ADP	O	O
aggression	NOUN	O	O
phenomenology	NOUN	O	O
,	PUNCT	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
are	VERB	O	O
urgently	ADV	O	O
needed	PROPN	O	O
,	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
and	CCONJ	O	O
research	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
studied	VERB	O	O
the	DET	O	O
Overt	ADJ	O	O
Aggression	NOUN	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
OAS	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
preliminary	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
eight	NUM	O	O
outpatients	NOUN	O	O
who	PROPN	O	O
participated	VERB	O	O
in	ADP	O	O
an	DET	O	O
ongoing	ADJ	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	O
for	ADP	O	O
aggression	NOUN	O	O
in	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
'	PUNCT	O	O
OAS	NOUN	O	B-MENTAL
aggression	NOUN	O	I-MENTAL
scores	NOUN	O	I-MENTAL
showed	VERB	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
already	ADV	O	O
validated	ADP	O	O
retrospectively	ADV	O	O
rated	VERB	O	O
Aberrant	ADJ	O	O
Behavior	NOUN	O	O
Checklist	NOUN	O	O
Community	NOUN	O	O
Scale	NOUN	O	O
irritability	NOUN	O	O
subscale	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
OAS	NOUN	O	B-MENTAL
in	ADP	O	O
outpatients	ADJ	O	O
with	ADP	O	O
aggression	NOUN	O	O
and	CCONJ	O	O
developmental	ADJ	O	O
disabilities	PUNCT	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O

MRI	NOUN	O	B-PHYSICAL
signal	NOUN	O	I-PHYSICAL
hyperintensities	DET	O	I-PHYSICAL
and	CCONJ	O	O
failure	NOUN	O	B-PHYSICAL
to	ADJ	O	I-PHYSICAL
remit	PUNCT	O	I-PHYSICAL
following	ADP	O	O
antidepressant	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
MRI	NOUN	O	O
signal	NOUN	O	O
hyperintensities	CCONJ	O	O
predict	VERB	O	O
poor	ADJ	O	O
remission	NOUN	O	B-PHYSICAL
to	ADP	O	O
antidepressant	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
using	VERB	O	O
volumetrics	NOUN	O	O
in	ADP	O	O
outpatient	ADJ	O	O
samples	NOUN	O	O
have	ADP	O	O
relied	VERB	O	O
on	ADP	O	O
total	ADJ	O	O
lesion	NOUN	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
test	VERB	O	O
whether	PUNCT	O	O
remission	NOUN	O	O
from	ADP	O	O
geriatric	ADJ	O	O
depression	NOUN	O	O
depends	NOUN	O	O
on	ADP	O	O
lesion	NOUN	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
region	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
interest	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ROI	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

METHOD	NOUN	O	O
Thirty-eight	PUNCT	O	O
patients	NOUN	O	O
received	VERB	O	O
baseline	NOUN	O	O
MRIs	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
larger	PUNCT	O	O
12-week	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
comparing	VERB	O	O
sertraline	NOUN	O	O
and	CCONJ	O	O
nortriptyline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
late-life	NOUN	O	O
depression	NOUN	O	O
.	PUNCT	O	O

MRIcro	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
quantify	NOUN	O	O
MRI-hyperintensity	NOUN	O	O
volume	NOUN	O	O
into	ADP	O	O
total	ADJ	O	O
hyperintensity	NOUN	O	O
,	PUNCT	O	O
deep	ADJ	O	O
white	ADJ	O	O
matter	NOUN	O	O
hyperintensity	NOUN	O	O
(	PUNCT	O	O
DWMH	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
periventricular	ADJ	O	O
hyperintensity	NOUN	O	O
(	PUNCT	O	O
PVH	NOUN	O	O
)	PUNCT	O	O
volumes	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
versus	CCONJ	O	O
low	ADJ	O	O
total	NOUN	O	O
,	PUNCT	O	O
DWMH	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
PVH	NOUN	O	B-PHYSICAL
volumes	NOUN	O	I-PHYSICAL
were	VERB	O	O
defined	VERB	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
highest	PUNCT	O	O
quartile	NOUN	O	O
of	ADP	O	O
their	PUNCT	O	O
respective	ADJ	O	O
distributions	NOUN	O	O
.	PUNCT	O	O

Remission	NOUN	O	B-MENTAL
from	ADP	O	I-MENTAL
depression	NOUN	O	I-MENTAL
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
24-item	NOUN	O	O
Hamilton	PUNCT	O	B-MENTAL
Rating	PUNCT	O	I-MENTAL
Scale	NOUN	O	I-MENTAL
for	ADP	O	I-MENTAL
Depression	NOUN	O	I-MENTAL
score	NOUN	O	O
?	PUNCT	O	O

7	NUM	O	O
for	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Patients	NOUN	O	O
classified	PUNCT	O	O
as	ADP	O	O
having	VERB	O	O
high	ADJ	O	O
DWMH	NOUN	O	O
were	VERB	O	O
7.14	NUM	O	O
times	NOUN	O	O
more	ADV	O	O
likely	ADJ	O	O
not	ADV	O	O
to	ADP	O	O
remit	PUNCT	O	O
following	ADP	O	O
antidepressant	NOUN	O	O
treatment	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
classified	PUNCT	O	O
as	ADP	O	O
having	VERB	O	O
low	ADJ	O	O
DWMH	NOUN	O	O
(	PUNCT	O	O
p=0.02	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
for	ADP	O	O
PVH	NOUN	O	O
(	PUNCT	O	O
OR=4.17	NOUN	O	O
,	PUNCT	O	O
p=0.16	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
total	ADJ	O	O
volumes	NOUN	O	O
(	PUNCT	O	O
OR=5.00	PUNCT	O	O
,	PUNCT	O	O
p=0.05	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Importantly	ADV	O	O
,	PUNCT	O	O
adjusting	ADJ	O	O
for	ADP	O	O
age	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
change	VERB	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
these	DET	O	O
effects	NOUN	O	O
.	PUNCT	O	O

LIMITATIONS	NOUN	O	O
A	DET	O	O
small	ADJ	O	O
and	CCONJ	O	O
predominantly	ADV	O	O
White	PUNCT	O	O
sample	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
to	ADP	O	O
test	VERB	O	O
whether	PUNCT	O	O
remission	NOUN	O	O
from	ADP	O	O
geriatric	ADJ	O	O
depression	NOUN	O	O
depends	NOUN	O	O
on	ADP	O	O
lesion	NOUN	O	O
volume	NOUN	O	O
by	ADP	O	O
ROI	NOUN	O	O
in	ADP	O	O
an	DET	O	O
outpatient	ADJ	O	O
sample	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
remission	NOUN	O	O
rates	NOUN	O	O
and	CCONJ	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
when	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
having	VERB	O	O
high	ADJ	O	O
DWMH	NOUN	O	O
,	PUNCT	O	O
PVH	NOUN	O	O
or	CCONJ	O	O
total	ADJ	O	O
volume	NOUN	O	O
suggesting	VERB	O	O
that	ADP	O	O
lesion	NOUN	O	O
location	NOUN	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
critical	ADJ	O	O
.	PUNCT	O	O

Using	PROPN	O	O
personalized	VERB	O	O
feedback	NOUN	O	O
to	PART	O	O
reduce	NOUN	O	O
alcohol	NOUN	O	O
use	NOUN	O	O
among	ADP	O	O
hazardous	ADJ	O	O
drinking	VERB	O	O
college	NOUN	O	O
students	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
moderating	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
alcohol-related	VERB	O	O
negative	ADJ	O	O
consequences	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
Web-based	ADP	O	O
screening	VERB	O	O
and	CCONJ	O	O
brief	ADJ	O	O
interventions	NOUN	O	O
that	CCONJ	O	O
include	DET	O	O
personalized	PUNCT	O	O
feedback	NOUN	O	O
about	ADP	O	O
their	PUNCT	O	O
alcohol	NOUN	O	O
use	NOUN	O	O
have	ADP	O	O
proven	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
particularly	ADV	O	O
promising	PUNCT	O	O
for	ADP	O	O
reducing	SYM	O	O
hazardous	ADJ	O	O
drinking	PROPN	O	O
among	ADP	O	O
university	NOUN	O	O
students	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
increasing	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
these	DET	O	O
approaches	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
is	ADV	O	O
still	ADV	O	O
relatively	ADV	O	O
little	DET	O	O
known	VERB	O	O
about	PUNCT	O	O
how	PUNCT	O	O
the	DET	O	O
content	NOUN	O	O
of	ADP	O	O
these	DET	O	O
interventions	NOUN	O	O
may	VERB	O	O
influence	VERB	O	O
outcomes	NOUN	O	O
and	CCONJ	O	O
who	ADP	O	O
may	VERB	O	O
benefit	VERB	O	O
most	PUNCT	O	O
from	ADP	O	O
these	DET	O	O
approaches	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
sought	ADP	O	O
to	PART	O	O
address	NOUN	O	O
these	DET	O	O
issues	NOUN	O	O
by	ADP	O	O
examining	ADV	O	O
how	ADP	O	O
individual	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
alcohol	NOUN	O	O
consequences	NOUN	O	O
influence	PUNCT	O	O
outcomes	NOUN	O	O
of	ADP	O	O
a	DET	O	O
laboratory-based	VERB	O	O
computerized	VERB	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One-hundred	ADP	O	O
and	CCONJ	O	O
nineteen	NUM	O	O
introductory	ADJ	O	O
psychology	NOUN	O	O
students	NOUN	O	O
who	DET	O	O
either	PUNCT	O	O
had	PUNCT	O	O
two	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
heavy	ADJ	O	O
episodic	ADJ	O	O
drinking	ADV	O	O
in	ADP	O	O
the	DET	O	O
past	ADJ	O	O
month	NOUN	O	O
or	CCONJ	O	O
scored	VERB	O	O
?8	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
AUDIT	NOUN	O	O
participated	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
for	ADP	O	O
course	NOUN	O	O
credit	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
1	PUNCT	O	O
of	ADP	O	O
4	NUM	O	O
conditions	NOUN	O	O
in	ADP	O	O
this	DET	O	O
2	NUM	O	O
Intervention	NOUN	O	O
(	PUNCT	O	O
Alcohol	NOUN	O	O
Feedback	NOUN	O	O
vs.	CCONJ	O	O
Control	NOUN	O	O
)	PUNCT	O	O
?2	PUNCT	O	O
Assessment	NOUN	O	O
(	PUNCT	O	O
Motivational	ADJ	O	O
Assessment	NOUN	O	O
vs.	CCONJ	O	O
No	DET	O	O
Motivational	ADJ	O	O
Assessment	NOUN	O	O
)	PUNCT	O	O
between-subjects	PUNCT	O	O
design	NOUN	O	O
.	PUNCT	O	O

Quantity	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	O
consumed	PUNCT	O	O
per	CCONJ	O	O
week	NOUN	O	O
and	CCONJ	O	O
heavy	ADJ	O	B-MENTAL
episodic	ADJ	O	I-MENTAL
drinking	ADV	O	I-MENTAL
one	NUM	O	I-MENTAL
month	NOUN	O	I-MENTAL
later	PUNCT	O	I-MENTAL
were	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
dependent	ADJ	O	O
variables	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Controlling	ADJ	O	O
for	ADP	O	O
corresponding	PUNCT	O	O
baseline	NOUN	O	O
alcohol	NOUN	O	O
measures	NOUN	O	O
,	PUNCT	O	O
hierarchical	ADJ	O	O
linear	ADJ	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
intervention	NOUN	O	O
condition	NOUN	O	O
and	CCONJ	O	O
baseline	NOUN	O	O
alcohol-related	VERB	O	O
consequences	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
those	ADJ	O	O
who	ADP	O	O
reported	VERB	O	O
more	ADP	O	O
alcohol	NOUN	O	O
consequences	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
alcohol	NOUN	O	O
intervention	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
significantly	ADV	O	O
less	DET	O	O
alcohol	NOUN	O	O
use	NOUN	O	O
and	CCONJ	O	O
fewer	PUNCT	O	O
heavy	ADJ	O	B-MENTAL
drinking	VERB	O	I-MENTAL
episodes	NOUN	O	I-MENTAL
at	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
no	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
intervention	NOUN	O	O
conditions	NOUN	O	O
for	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
few	ADJ	O	O
baseline	NOUN	O	O
consequences	NOUN	O	O
.	PUNCT	O	O

Assessment	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
moderate	ADJ	O	O
intervention	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
feedback-based	VERB	O	O
computerized	VERB	O	O
intervention	NOUN	O	O
that	ADP	O	O
includes	VERB	O	O
normative	ADJ	O	O
information	NOUN	O	O
about	PUNCT	O	O
alcohol	NOUN	O	O
use	NOUN	O	O
and	CCONJ	O	O
consequences	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
for	ADP	O	O
hazardous	ADJ	O	O
drinking	VERB	O	O
students	NOUN	O	O
who	DET	O	O
are	VERB	O	O
experiencing	ADV	O	O
higher	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
alcohol-related	VERB	O	O
consequences	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Comparison	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
analgesic	ADJ	O	O
methods	NOUN	O	O
for	ADP	O	O
postoperative	ADJ	O	O
pain	NOUN	O	O
relief	NOUN	O	O
and	CCONJ	O	O
their	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
interleukin-6	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
following	VERB	O	O
radical	ADJ	O	O
surgery	NOUN	O	O
for	ADP	O	O
gastric	ADJ	O	O
carcinoma	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
preemptive	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
postoperative	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
,	PUNCT	O	O
postoperative	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
alone	ADJ	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
analgesia	NOUN	O	O
for	ADP	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
relief	NOUN	O	I-PAIN
and	CCONJ	O	O
their	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
interleukin-6	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
IL-6	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
following	VERB	O	O
radical	ADJ	O	O
surgery	NOUN	O	O
for	ADP	O	O
gastric	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty-six	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
gastric	ADJ	O	O
carcinoma	NOUN	O	O
scheduled	VERB	O	O
for	ADP	O	O
gastrectomy	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
3	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
namely	DET	O	O
group	NOUN	O	O
P	NOUN	O	O
(	PUNCT	O	O
n=22	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
group	NOUN	O	O
E	NOUN	O	O
(	PUNCT	O	O
n=22	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
V	NUM	O	O
(	PUNCT	O	O
n=22	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	PUNCT	O	O
receive	NOUN	O	O
preemptive	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
postoperative	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
,	PUNCT	O	O
exclusive	ADJ	O	O
postoperative	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
exclusive	ADJ	O	O
postoperative	ADJ	O	O
intravenous	ADJ	O	O
analgesia	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Hemodynamic	ADJ	O	B-PHYSICAL
data	NOUN	O	I-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
all	CCONJ	O	O
the	DET	O	O
patients	NOUN	O	O
during	ADP	O	O
the	DET	O	O
operation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
VAS	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
pain	NOUN	O	B-PAIN
intensity	NOUN	O	I-PAIN
at	ADP	O	O
4	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
16	NUM	O	O
,	PUNCT	O	O
24	NUM	O	O
,	PUNCT	O	O
48	NUM	O	O
and	CCONJ	O	O
72	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
IL-6	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
24	NUM	O	O
,	PUNCT	O	O
48	NUM	O	O
,	PUNCT	O	O
72	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
No	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
hemodynamics	NOUN	O	O
during	ADP	O	O
the	DET	O	O
preoperative	ADJ	O	O
periods	NOUN	O	O
.	PUNCT	O	O

VAS	NOUN	O	O
and	CCONJ	O	O
IL-6	NOUN	O	B-PHYSICAL
were	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
P	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
E	NOUN	O	O
and	CCONJ	O	O
V	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
E	NOUN	O	O
had	PUNCT	O	O
lower	PUNCT	O	O
measurement	NOUN	O	O
than	PUNCT	O	O
group	NOUN	O	O
V	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Preemptive	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
postoperative	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
provides	NOUN	O	O
more	DET	O	O
satisfactory	ADJ	O	O
pain	NOUN	O	B-PAIN
relief	NOUN	O	I-PAIN
and	CCONJ	O	O
more	DET	O	O
effectively	ADV	O	O
prevents	NOUN	O	O
IL-6	NOUN	O	B-PHYSICAL
increment	NOUN	O	I-PHYSICAL
than	PUNCT	O	O
exclusive	ADJ	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
or	CCONJ	O	O
intravenous	ADJ	O	O
analgesia	NOUN	O	O
after	ADP	O	O
gastrectomy	NOUN	O	O
for	ADP	O	O
gastric	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

Nephrotoxicity	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	O
A	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
newly	ADJ	O	O
diagnosed	VERB	O	O
type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
18	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
.	PUNCT	O	O

All	PUNCT	O	O
were	ADJ	O	O
participating	VERB	O	O
in	ADP	O	O
the	DET	O	O
Canadian-European	ADV	O	O
randomized	VERB	O	O
placebo-controlled	VERB	O	O
cyclosporin	NOUN	O	O
trial	NOUN	O	O
in	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
Type	NOUN	O	O
1	NUM	O	O
diabetic	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
nine	NUM	O	O
being	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
nine	NUM	O	O
to	ADP	O	O
cyclosporin	NOUN	O	O
A	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
to	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
cyclosporin	NOUN	O	O
A	NOUN	O	O
caused	ADP	O	O
significant	ADJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	B-ADVERSE-EFFECTS
filtration	NOUN	O	I-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
before	ADP	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
,	PUNCT	O	O
cyclosporin	NOUN	O	O
97	NUM	O	O
+/-	SYM	O	O
18	NUM	O	O
vs	CCONJ	O	O
placebo	NOUN	O	O
125	NUM	O	O
+/-	SYM	O	O
16	NUM	O	O
ml	NOUN	O	O
min-1	NOUN	O	O
1.73-m-2	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
renal	ADJ	O	B-ADVERSE-EFFECTS
plasma	NOUN	O	I-ADVERSE-EFFECTS
flow	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
454	NUM	O	O
+/-	SYM	O	O
83	NUM	O	O
vs	CCONJ	O	O
536	NUM	O	O
+/-	SYM	O	O
70	NUM	O	O
ml	NOUN	O	O
min-1	NOUN	O	O
1.73-m-2	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lithium	NOUN	O	B-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
17	NUM	O	O
+/-	SYM	O	O
3	NUM	O	O
vs	CCONJ	O	O
28	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
ml	NOUN	O	O
min-1	NOUN	O	O
1.73-m-2	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
fractional	ADJ	O	B-PHYSICAL
proximal	ADJ	O	I-PHYSICAL
reabsorption	NOUN	O	I-PHYSICAL
was	VERB	O	O
increased	VERB	O	O
(	PUNCT	O	O
0.82	NUM	O	O
+/-	SYM	O	O
0.03	NUM	O	O
vs	CCONJ	O	O
0.78	NUM	O	O
+/-	SYM	O	O
0.03	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
fractional	ADJ	O	B-PHYSICAL
distal	ADJ	O	I-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
reabsorption	NOUN	O	I-PHYSICAL
reduced	NOUN	O	O
(	PUNCT	O	O
0.88	NUM	O	O
+/-	SYM	O	O
0.03	NUM	O	O
vs	CCONJ	O	O
0.94	NUM	O	O
+/-	SYM	O	O
0.02	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
are	VERB	O	O
in	ADP	O	O
accordance	NOUN	O	O
with	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
nephrotoxic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	O
A	DET	O	O
results	ADV	O	O
from	ADP	O	O
a	DET	O	O
preferential	ADJ	O	O
constriction	NOUN	O	O
of	ADP	O	O
afferent	NOUN	O	O
glomerular	ADJ	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
year	NOUN	O	O
after	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
variables	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
blood	NOUN	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
control	NOUN	O	I-PHYSICAL
which	ADP	O	O
was	VERB	O	O
worse	ADJ	O	O
in	ADP	O	O
the	DET	O	O
cyclosporin	NOUN	O	O
A	DET	O	O
treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
corrected	VERB	O	O
for	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
control	NOUN	O	O
it	PROPN	O	O
appeared	VERB	O	O
that	ADP	O	O
in	ADP	O	O
three	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
nine	NUM	O	O
patients	NOUN	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
had	PUNCT	O	O
not	ADV	O	O
completely	ADV	O	O
returned	VERB	O	O
to	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
range	NOUN	O	O
of	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
nephrotoxic	ADJ	O	O
side-effects	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	O
A	PUNCT	O	O
treatment	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
are	VERB	O	O
reversible	ADJ	O	O
.	PUNCT	O	O

There	PUNCT	O	O
are	PROPN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
signs	NOUN	O	O
of	ADP	O	O
minor	ADJ	O	O
and	CCONJ	O	O
perhaps	ADV	O	O
chronic	ADJ	O	O
renal	ADJ	O	O
injury	NOUN	O	O
.	PUNCT	O	O

Sivelestat	NOUN	O	O
sodium	NOUN	O	O
hydrate	NOUN	O	O
improves	VERB	O	O
septic	ADJ	O	O
acute	ADJ	O	O
lung	NOUN	O	O
injury	NOUN	O	O
by	ADP	O	O
reducing	VERB	O	O
alveolar	ADJ	O	O
dysfunction	NOUN	O	O
.	PUNCT	O	O

Sivelestat	NOUN	O	O
sodium	NOUN	O	O
hydrate	NOUN	O	O
(	PUNCT	O	O
sivelestat	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
polymorphonuclear	ADJ	O	O
leukocyte	NOUN	O	O
elastase	NOUN	O	O
(	PUNCT	O	O
PMN-E	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
administered	VERB	O	O
sivelestat	NOUN	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
septic	ADJ	O	O
acute	ADJ	O	O
lung	NOUN	O	O
injury	NOUN	O	O
(	PUNCT	O	O
ALI	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
examine	NOUN	O	O
its	PUNCT	O	O
usefulness	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoints	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
were	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
artificial	ADJ	O	B-OTHER
ventilation	NOUN	O	I-OTHER
and	CCONJ	O	O
pulmonary	ADJ	O	B-PHYSICAL
oxygenation	NOUN	O	I-PHYSICAL
ability	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
were	VERB	O	O
mortality	NOUN	O	B-MORTALITY
and	CCONJ	O	O
the	DET	O	O
concentrations	NOUN	O	O
of	ADP	O	O
PMN-E	NOUN	O	O
,	PUNCT	O	B-MORTALITY
SP-D	NOUN	O	O
,	PUNCT	O	B-MORTALITY
TNF-alpha	NOUN	O	I-MORTALITY
and	CCONJ	O	I-MORTALITY
IL-8	NOUN	O	I-MORTALITY
in	ADP	O	B-MORTALITY
blood	NOUN	O	I-MORTALITY
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
sivelestat	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
artificial	ADJ	O	B-OTHER
ventilation	NOUN	O	I-OTHER
,	PUNCT	O	O
pulmonary	ADJ	O	O
oxygenation	NOUN	O	O
ability	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
blood	NOUN	O	B-PHYSICAL
PMN-E	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
SP-D	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
TNF-alpha	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
IL-8	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
significantly	ADV	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
sivelestat	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PUNCT	O	O
reduce	PUNCT	O	O

Preservative-free	ADJ	O	O
ocular	ADJ	O	O
hydrating	PUNCT	O	O
agents	NOUN	O	O
in	ADP	O	O
symptomatic	ADJ	O	O
contact	NOUN	O	O
lens	NOUN	O	O
wearers	NOUN	O	O
:	PUNCT	O	O
saline	ADP	O	O
versus	CCONJ	O	O
PVP	NOUN	O	O
solution	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
compare	ADV	O	O
two	NUM	O	O
preservative-free	ADJ	O	O
hydrating	ADP	O	O
agents	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
multidose	NOUN	O	O
(	PUNCT	O	O
ABAK	NOUN	O	O
)	PUNCT	O	O
bottles	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
contact	NOUN	O	O
lens	NOUN	O	O
wearers	NOUN	O	O
experiencing	PUNCT	O	O
symptoms	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	B-PHYSICAL
dryness	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
endpoint	NOUN	O	O
of	ADP	O	O
this	DET	O	O
4-week	NOUN	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
study	NOUN	O	O
comparing	VERB	O	O
a	DET	O	O
2	NUM	O	O
%	SYM	O	O
polyvinylpyrrolidone	NOUN	O	O
(	PUNCT	O	O
PVP	NOUN	O	O
)	PUNCT	O	O
solution	NOUN	O	O
with	ADP	O	O
a	DET	O	O
0.9	NUM	O	O
%	ADP	O	O
NaCl	NOUN	O	O
solution	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
ocular	ADJ	O	O
discomfort	NOUN	O	O
using	VERB	O	O
a	DET	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
biomicroscopic	ADJ	O	O
examination	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
test	NOUN	O	O
of	ADP	O	O
tolerability	NOUN	O	O
on	ADP	O	O
instillation	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
performed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-nine	NUM	O	O
subjects	NOUN	O	O
were	VERB	O	O
enrolled	NOUN	O	O
(	PUNCT	O	O
23	NUM	O	O
PVP	NOUN	O	O
;	PUNCT	O	O
16	NUM	O	O
NaCl	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
age	NOUN	O	O
was	VERB	O	O
30	NUM	O	O
;	PUNCT	O	O
subjects	NOUN	O	O
were	VERB	O	O
predominantly	ADV	O	O
female	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mostly	ADV	O	O
wore	PUNCT	O	O
frequent-replacement	ADP	O	O
contact	NOUN	O	O
lenses	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
all	CCONJ	O	O
exposed	ADV	O	O
to	ADP	O	O
environmental	ADJ	O	O
factors	NOUN	O	O
such	ADP	O	O
as	ADP	O	O
routine	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
video	ADJ	O	O
monitors	NOUN	O	O
or	CCONJ	O	O
air	NOUN	O	O
conditioning	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
at	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
D0	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
PVP	NOUN	O	O
and	CCONJ	O	O
NaCl	NOUN	O	O
improved	VERB	O	O
the	DET	O	O
comfort	NOUN	O	O
of	ADP	O	O
contact	NOUN	O	B-OTHER
lens	NOUN	O	I-OTHER
wear	VERB	O	I-OTHER
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0003	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
them	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.25	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
daily	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
lens	NOUN	O	O
wear	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
daily	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
instillations	NOUN	O	O
to	PUNCT	O	O
relieve	PUNCT	O	O
discomfort	NOUN	O	O
(	PUNCT	O	O
4.2	NUM	O	O
+/-	SYM	O	O
2.0	NUM	O	O
for	ADP	O	O
PVP	NOUN	O	O
ABAK	NOUN	O	O
;	PUNCT	O	O
4.6	NUM	O	O
+/-	SYM	O	O
1.9	NUM	O	O
for	ADP	O	O
NaCl	NOUN	O	O
ABAK	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
comparable	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
PVP	NOUN	O	O
use	NUM	O	O
led	VERB	O	O
to	ADP	O	O
more	CCONJ	O	O
favorable	ADJ	O	O
evolution	NOUN	O	O
of	ADP	O	O
fluorescein-staining	VERB	O	B-OTHER
corneal	ADJ	O	I-OTHER
punctuations	NOUN	O	I-OTHER
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.028	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Safety	NOUN	O	B-OTHER
was	VERB	O	O
good	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
minimal	ADJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
considered	DET	O	O
unrelated	VERB	O	O
to	ADP	O	O
the	DET	O	O
products	NOUN	O	O
.	PUNCT	O	O

Lens	NOUN	O	B-OTHER
wettability	NOUN	O	I-OTHER
was	ADP	O	O
excellent	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
deposits	NOUN	O	O
.	PUNCT	O	O

Most	DET	O	O
subjects	NOUN	O	O
also	ADV	O	O
found	PROPN	O	O
the	DET	O	O
ABAK	NOUN	O	O
bottles	NOUN	O	O
convenient	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Ocular	PUNCT	O	O
hydration	NOUN	O	O
improves	VERB	O	O
comfort	ADP	O	B-OTHER
in	ADP	O	O
contact	NOUN	O	O
lens	NOUN	O	O
wearers	NOUN	O	O
.	PUNCT	O	O

NaCl	NOUN	O	O
is	VERB	O	O
an	DET	O	O
appropriate	ADJ	O	O
first-line	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
for	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
fluorescein-staining	VERB	O	O
punctuations	NOUN	O	O
,	PUNCT	O	O
lubrication	NOUN	O	O
with	ADP	O	O
PVP	NOUN	O	O
is	VERB	O	O
preferable	ADJ	O	O
.	PUNCT	O	O

Predictors	NOUN	O	O
of	ADP	O	O
recruited	VERB	O	O
melanoma	NOUN	O	O
families	NOUN	O	O
into	ADP	O	O
a	DET	O	O
behavioral	ADJ	O	O
intervention	NOUN	O	O
project	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Examination	NOUN	O	O
of	ADP	O	O
families	NOUN	O	O
represents	NOUN	O	O
an	DET	O	O
important	ADJ	O	O
priority	NOUN	O	O
in	ADP	O	O
health	NOUN	O	O
research	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
paper	NOUN	O	O
we	PRON	O	O
report	NOUN	O	B-OTHER
on	ADP	O	O
individual	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
family-level	VERB	O	I-MENTAL
factors	NOUN	O	I-MENTAL
associated	VERB	O	O
with	ADP	O	O
enrollment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
cancer	NOUN	O	O
prevention	NOUN	O	O
research	NOUN	O	O
project	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
approached	VERB	O	O
families	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
melanoma	NOUN	O	O
for	ADP	O	O
possible	ADJ	O	O
participation	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
web-based	VERB	O	O
communication	NOUN	O	O
and	CCONJ	O	O
support	VERB	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
recruited	VERB	O	O
three	NUM	O	O
family	NOUN	O	O
members	NOUN	O	O
per	ADP	O	O
family	NOUN	O	O
for	ADP	O	O
assessment	NOUN	O	O
-	PUNCT	O	O
the	DET	O	O
melanoma	NOUN	O	O
case	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
first-degree	ADJ	O	O
relative	ADJ	O	O
(	PUNCT	O	O
FDR	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
relative	ADJ	O	O
who	CCONJ	O	O
is	VERB	O	O
a	DET	O	O
parent	NOUN	O	O
of	ADP	O	O
a	DET	O	O
child	NOUN	O	O
age	NOUN	O	O
18	NUM	O	O
or	CCONJ	O	O
younger	PUNCT	O	O
.	PUNCT	O	O

Recruitment	NOUN	O	O
involved	ADP	O	O
three	NUM	O	O
steps	NOUN	O	O
:	PUNCT	O	O
requesting	PUNCT	O	O
the	DET	O	O
physician	NOUN	O	O
's	PUNCT	O	O
consent	NOUN	O	O
to	ADP	O	O
approach	NOUN	O	O
the	DET	O	O
melanoma	NOUN	O	O
case	NOUN	O	O
,	PUNCT	O	O
approaching	PUNCT	O	O
the	DET	O	O
case	NOUN	O	O
to	ADP	O	O
request	PUNCT	O	O
their	ADP	O	O
participation	NOUN	O	O
and	CCONJ	O	O
family	NOUN	O	O
contact	NOUN	O	O
information	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
they	PUNCT	O	O
approaching	CCONJ	O	O
the	DET	O	O
FDRs	NOUN	O	O
and	CCONJ	O	O
parents	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
1380	NUM	O	O
families	NOUN	O	O
approached	DET	O	O
,	PUNCT	O	O
313	NUM	O	O
were	VERB	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
263	PUNCT	O	O
were	VERB	O	O
excluded	VERB	O	O
because	ADP	O	O
we	PRON	O	O
could	ADP	O	O
not	ADV	O	O
find	VERB	O	O
or	PUNCT	O	O
contact	NOUN	O	O
a	DET	O	O
family	NOUN	O	O
member	NOUN	O	O
(	PUNCT	O	O
FDR	NOUN	O	O
or	CCONJ	O	O
parent	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
331	NUM	O	O
did	PUNCT	O	O
not	ADV	O	O
have	PUNCT	O	O
eligible	ADJ	O	O
family	NOUN	O	O
members	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
473	NUM	O	O
refused	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
frequently	ADV	O	O
noted	PUNCT	O	O
reason	NOUN	O	O
for	ADP	O	O
refusal	ADJ	O	B-OTHER
was	PUNCT	O	O
being	SYM	O	O
too	ADV	O	O
busy	NOUN	O	O
or	CCONJ	O	O
having	VERB	O	O
no	DET	O	O
time	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
participation	NOUN	O	O
for	ADP	O	O
cases	NOUN	O	O
(	PUNCT	O	O
OR=1.6	NOUN	O	O
;	PUNCT	O	O
CI=1.01-2.51	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
FDRs	PUNCT	O	O
(	PUNCT	O	O
OR=2.15	NOUN	O	O
;	PUNCT	O	O
CI=1.11-4.13	NOUN	O	O
)	PUNCT	O	O
included	VERB	O	O
higher	PUNCT	O	B-MENTAL
educational	ADJ	O	I-MENTAL
attainment	NOUN	O	I-MENTAL
.	PUNCT	O	O

FDRs	PUNCT	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	ADP	O	O
enroll	PUNCT	O	O
if	PUNCT	O	O
they	ADV	O	O
were	PUNCT	O	O
female	NOUN	O	O
(	PUNCT	O	O
OR=1.77	PUNCT	O	O
;	PUNCT	O	O
CI=1.1-.85	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
parents	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	ADP	O	O
enroll	PUNCT	O	O
if	PUNCT	O	O
the	DET	O	O
case	NOUN	O	O
had	PUNCT	O	O
been	PUNCT	O	O
diagnosed	VERB	O	B-PHYSICAL
more	ADV	O	I-PHYSICAL
recently	ADV	O	I-PHYSICAL
(	PUNCT	O	O
OR=3.3	ADP	O	O
;	PUNCT	O	O
CI=1.9-5.93	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
if	PUNCT	O	O
the	DET	O	O
parent	NOUN	O	B-OTHER
was	VERB	O	I-OTHER
partnered	VERB	O	I-OTHER
(	PUNCT	O	O
OR=4.37	NOUN	O	O
;	PUNCT	O	O
CI=1.86-10.26	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
if	PUNCT	O	O
the	DET	O	O
parent	NOUN	O	B-MENTAL
lived	VERB	O	I-MENTAL
in	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
same	ADJ	O	I-MENTAL
city	NOUN	O	I-MENTAL
as	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
case	NOUN	O	I-MENTAL
(	PUNCT	O	O
OR=2.88	PUNCT	O	O
;	PUNCT	O	O
CI=1.08-7.68	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
can	VERB	O	O
provide	VERB	O	O
information	NOUN	O	O
on	ADP	O	O
potential	ADJ	O	O
directions	NOUN	O	O
for	ADP	O	O
future	PUNCT	O	O
family	NOUN	O	O
recruitment	NOUN	O	O
.	PUNCT	O	O

Olanzapine	NOUN	O	O
versus	CCONJ	O	O
haloperidol	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	B-PHYSICAL
disorder	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
an	DET	O	O
open	ADJ	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Conventional	ADJ	O	O
neuroleptics	NOUN	O	O
ameliorate	NOUN	O	O
symptoms	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
they	PUNCT	O	O
are	VERB	O	O
known	VERB	O	O
to	ADP	O	O
cause	PROPN	O	O
dyskinesias	NOUN	O	O
.	PUNCT	O	O

Atypical	ADJ	O	O
neuroleptics	NOUN	O	O
,	PUNCT	O	O
including	SYM	O	O
olanzapine	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
have	PUNCT	O	O
less	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
dyskinesia	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
their	VERB	O	O
efficacy	NOUN	O	O
in	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
open-label	NOUN	O	O
olanzapine	NOUN	O	O
as	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
by	ADP	O	O
using	PART	O	O
haloperidol	NOUN	O	O
as	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
comparator	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
In	ADP	O	O
a	DET	O	O
parallel	ADJ	O	O
groups	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
DSM-IV	NOUN	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
7.8+/-2.1	NOUN	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
open	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
olanzapine	NOUN	O	O
or	CCONJ	O	O
haloperidol	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
final	ADJ	O	O
dosages	NOUN	O	O
were	VERB	O	O
7.9+/-2.5	CCONJ	O	O
mg/day	NOUN	O	O
for	ADP	O	O
olanzapine	NOUN	O	O
and	CCONJ	O	O
1.4+/-0.7	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
haloperidol	NOUN	O	O
.	PUNCT	O	O

Outcome	NOUN	O	O
measures	NOUN	O	O
included	VERB	O	O
the	DET	O	O
Clinical	ADJ	O	B-MENTAL
Global	PUNCT	O	I-MENTAL
Impressions	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
CGI	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
and	CCONJ	O	O
the	DET	O	O
Children	NOUN	O	O
's	PUNCT	O	O
Psychiatric	ADJ	O	O
Rating	PUNCT	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
CPRS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Both	PUNCT	O	O
groups	NOUN	O	O
had	PUNCT	O	O
symptom	NOUN	O	B-MENTAL
reduction	NOUN	O	I-MENTAL
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
six	NUM	O	O
in	ADP	O	O
the	DET	O	O
olanzapine	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
three	NUM	O	O
of	ADP	O	O
six	NUM	O	O
in	ADP	O	O
the	DET	O	O
haloperidol	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
rated	VERB	O	O
as	ADP	O	O
responders	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
CGI	NOUN	O	B-MENTAL
Improvement	NOUN	O	O
item	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
showed	VERB	O	O
improvement	NOUN	O	O
on	ADP	O	O
the	DET	O	O
CPRS	NOUN	O	B-MENTAL
Autism	NOUN	O	I-MENTAL
Factor	NOUN	O	I-MENTAL
(	PUNCT	O	O
F1,9	NOUN	O	O
=	SYM	O	O
24.4	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.0008	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Side	NOUN	O	O
effects	NOUN	O	O
included	ADP	O	O
drowsiness	PUNCT	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
weight	NOUN	O	O
gain	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
olanzapine	NOUN	O	O
is	VERB	O	O
a	DET	O	O
promising	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Further	PUNCT	O	O
placebo-controlled	VERB	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
studies	NOUN	O	O
of	ADP	O	O
olanzapine	NOUN	O	O
in	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
are	VERB	O	O
required	VERB	O	O
.	PUNCT	O	O

Long-term	NOUN	O	O
follow-up	NOUN	O	O
of	ADP	O	O
cytostatic	ADJ	O	O
intravesical	ADJ	O	O
instillation	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

Is	PUNCT	O	O
short-term	NOUN	O	O
,	PUNCT	O	O
intensive	ADJ	O	O
instillation	NOUN	O	O
better	PUNCT	O	O
than	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
?	PUNCT	O	O

OBJECTIVES	ADP	O	O
Comparisons	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
3-year	NOUN	O	O
protocols	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
20-week	NOUN	O	O
protocol	NOUN	O	O
of	ADP	O	O
mitomycin	NUM	O	O
C	NOUN	O	O
instillation	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
3-year	NOUN	O	O
protocol	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	O
instillation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	B-PHYSICAL
tumors	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
progression	NOUN	O	B-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
whose	ADP	O	O
superficial	VERB	O	O
bladder	NOUN	O	O
tumors	NOUN	O	O
had	VERB	O	O
been	ADP	O	O
removed	VERB	O	O
by	ADP	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
parallel	ADJ	O	O
group	NOUN	O	O
multicenter	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
.	PUNCT	O	O

419	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
after	ADP	O	O
a	DET	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
of	ADP	O	O
57	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Cox	NOUN	O	O
proportional	ADJ	O	O
hazards	NOUN	O	O
analysis	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
An	DET	O	O
overall	ADJ	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
22.7	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
an	DET	O	O
overall	ADJ	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
9.8	NUM	O	O
%	SYM	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

For	ADP	O	O
time	NOUN	O	O
to	ADP	O	O
progression	NOUN	O	O
a	DET	O	O
significant	ADJ	O	O
overall	ADJ	O	B-OTHER
treatment	NOUN	O	I-OTHER
effect	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	O
status	NOUN	O	O
before	ADP	O	O
entry	NOUN	O	O
into	ADP	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0059	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pairwise	PUNCT	O	O
comparisons	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
mitomycin	NOUN	O	O
protocol	NOUN	O	O
with	ADP	O	O
short-term	NOUN	O	O
intensive	ADJ	O	O
(	PUNCT	O	O
weekly	ADV	O	O
)	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
long-term	NOUN	O	O
maintenance	NOUN	O	O
instillation	NOUN	O	O
to	ADP	O	O
have	PUNCT	O	O
a	DET	O	O
highly	ADV	O	O
beneficial	ADJ	O	B-OTHER
effect	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
long-term	NOUN	O	O
maintenance	NOUN	O	O
instillation	NOUN	O	O
only	ADV	O	O
especially	ADV	O	O
for	ADP	O	O
patients	NOUN	O	O
entering	CCONJ	O	O
the	DET	O	O
study	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
tumors	NOUN	O	O
(	PUNCT	O	O
RR	NOUN	O	O
=	SYM	O	O
0.06	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
[	PUNCT	O	O
0.008	NUM	O	O
,	PUNCT	O	O
0.506	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
intensive	ADJ	O	B-PHYSICAL
therapeutic	ADJ	O	I-PHYSICAL
instillation	NOUN	O	I-PHYSICAL
may	VERB	O	O
have	CCONJ	O	O
an	DET	O	O
advantage	NOUN	O	O
over	ADP	O	O
less	DET	O	O
intensive	ADJ	O	O
,	PUNCT	O	O
prophylactic	ADP	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
crossover	NOUN	O	O
comparison	NOUN	O	O
of	ADP	O	O
pindolol	NOUN	O	O
,	PUNCT	O	O
metoprolol	NOUN	O	O
,	PUNCT	O	O
atenolol	NOUN	O	O
and	CCONJ	O	O
labetalol	NOUN	O	O
in	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
randomized	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
atenolol	NOUN	O	O
,	PUNCT	O	O
labetalol	NOUN	O	O
,	PUNCT	O	O
metoprolol	NOUN	O	O
and	CCONJ	O	O
pindolol	NOUN	O	O
.	PUNCT	O	O

Considerable	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
dose	NOUN	O	B-OTHER
(	PUNCT	O	O
atenolol	NOUN	O	O
138	NUM	O	O
+/-	SYM	O	O
13	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
;	PUNCT	O	O
labetalol	NOUN	O	O
308	NUM	O	O
+/-	SYM	O	O
34	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
;	PUNCT	O	O
metoprolol	NOUN	O	O
234	NUM	O	O
+/-	SYM	O	O
22	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
;	PUNCT	O	O
and	CCONJ	O	O
pindolol	NOUN	O	O
24	NUM	O	O
+/-2	ADJ	O	O
mg	NOUN	O	O
daily	ADJ	O	O
were	VERB	O	O
required	VERB	O	O
to	PART	O	O
produce	ADV	O	O
similar	ADJ	O	O
antihypertensive	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

3	NUM	O	O
The	DET	O	O
overall	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
side-effects	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
atenolol	NOUN	O	O
,	PUNCT	O	O
metoprolol	NOUN	O	O
and	CCONJ	O	O
pindolol	NOUN	O	O
but	CCONJ	O	O
was	VERB	O	O
slightly	ADV	O	O
less	DET	O	O
with	ADP	O	O
labetalol	NOUN	O	O
.	PUNCT	O	O

Sleep	NOUN	O	B-MENTAL
disturbances	NOUN	O	I-MENTAL
and	CCONJ	O	O
abnormal	ADJ	O	B-MENTAL
dreaming	ADJ	O	I-MENTAL
patterns	NOUN	O	I-MENTAL
were	VERB	O	O
most	PUNCT	O	O
frequent	CCONJ	O	O
with	ADP	O	O
pindolol	NOUN	O	O
.	PUNCT	O	O

4	NUM	O	O
There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significantly	ADV	O	B-PHYSICAL
greater	PUNCT	O	O
fall	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
pulse	PUNCT	O	I-PHYSICAL

Effects	NOUN	O	O
of	ADP	O	O
cuff	ADJ	O	O
inflation	NOUN	O	O
on	ADP	O	O
self-recorded	VERB	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
continuously	ADV	O	O
recorded	PUNCT	O	O
'Finapres	PUNCT	O	O
'	PUNCT	O	O
finger	NOUN	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
ten	NUM	O	O
normotensive	ADJ	O	O
and	CCONJ	O	O
seven	NUM	O	O
hypertensive	ADJ	O	O
subjects	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
self-inflation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cuff	ADJ	O	O
or	CCONJ	O	O
just	ADV	O	O
wearing	CCONJ	O	O
the	DET	O	O
inflated	PUNCT	O	O
cuff	ADJ	O	O
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Inflating	PUNCT	O	O
the	DET	O	O
cuff	ADJ	O	O
caused	VERB	O	O
an	DET	O	O
instantaneous	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
systolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
of	ADP	O	O
13	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
(	PUNCT	O	O
hypertensive	ADJ	O	O
and	CCONJ	O	O
normotensive	ADJ	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Wearing	PUNCT	O	O
the	DET	O	O
inflated	PUNCT	O	O
cuff	ADJ	O	O
did	PUNCT	O	O
not	ADV	O	O
change	NUM	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Thus	PUNCT	O	O
the	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
pressure	NOUN	O	B-PHYSICAL
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
muscular	ADJ	O	O
activity	NOUN	O	O
required	VERB	O	O
for	ADP	O	O
cuff	ADJ	O	O
inflation	NOUN	O	O
.	PUNCT	O	O

Systolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
took	PRON	O	O
on	ADP	O	O
average	ADJ	O	O
7	NUM	O	O
s	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
most	CCONJ	O	O
21	NUM	O	O
s	ADP	O	O
to	PUNCT	O	O
return	CCONJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
level	NOUN	O	O
after	ADP	O	O
stopping	ADP	O	O
cuff	ADJ	O	O
inflation	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
first	ADJ	O	O
Korotkoff	NOUN	O	O
sounds	NOUN	O	O
may	VERB	O	O
already	ADV	O	O
be	PUNCT	O	O
heard	NOUN	O	O
after	ADP	O	O
10-15	NUM	O	O
s	NOUN	O	O
when	ADP	O	O
following	PUNCT	O	O
recommended	VERB	O	O
procedures	NOUN	O	O
,	PUNCT	O	O
self-recorded	VERB	O	B-PHYSICAL
systolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
may	VERB	O	O
be	VERB	O	O
recorded	VERB	O	O
as	PUNCT	O	O
too	ADV	O	O
high	ADJ	O	O
when	PUNCT	O	O
subjects	NOUN	O	O
inflate	ADP	O	O
their	PUNCT	O	O
cuff	ADJ	O	O
at	ADP	O	O
too	ADV	O	O
low	PUNCT	O	O
a	DET	O	O
pressure	NOUN	O	O
or	CCONJ	O	O
deflate	PUNCT	O	O
it	ADP	O	O
too	ADV	O	O
fast	ADJ	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
trial	NOUN	O	O
:	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
ribavirin	NOUN	O	O
predicts	PROPN	O	O
EVR	NOUN	O	O
and	CCONJ	O	O
SVR	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
HCV	NOUN	O	O
genotype	NOUN	O	O
1	NUM	O	O
infection	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
peginterferon	ADJ	O	O
alpha-2a	NOUN	O	O
plus	CCONJ	O	O
ribavirin	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
reduced	VERB	O	O
drug	NOUN	O	O
exposure	NOUN	O	O
on	ADP	O	O
outcomes	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
C	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	PUNCT	O	O
determined	VERB	O	O
in	ADP	O	O
routine	ADJ	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
peginterferon	PUNCT	O	O
alpha-2a	NOUN	O	O
and	CCONJ	O	O
ribavirin	NOUN	O	O
on	ADP	O	O
early	ADJ	O	O
virological	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
EVR	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
sustained	VERB	O	O
virological	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
SVR	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
treatment-naive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
HCV	NOUN	O	O
genotype	NOUN	O	O
1	NUM	O	O
infection	NOUN	O	O
enrolled	ADJ	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
expanded	PUNCT	O	O
access	NOUN	O	O
programme	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Eight	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
ninety-one	PUNCT	O	O
patients	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
48	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
an	DET	O	O
initial	ADJ	O	O
ribavirin	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
800	NUM	O	O
or	CCONJ	O	O
1000/1200	NOUN	O	O
mg/day	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Ribavirin	NOUN	O	O
1000	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
<	SYM	O	O
75	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
1200	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
>	PROPN	O	O
or=75	PUNCT	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
peginterferon	ADP	O	O
alpha-2a	NOUN	O	O
180	NUM	O	O
microg/week	NOUN	O	O
were	VERB	O	O
considered	VERB	O	O
optimal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
reduced	VERB	O	B-PHYSICAL
drug	NOUN	O	I-PHYSICAL
exposure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
expressed	VERB	O	O
as	ADP	O	O
a	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
optimal	ADJ	O	O
)	PUNCT	O	O
on	ADP	O	O
EVR	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
SVR	NOUN	O	B-PHYSICAL
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Mean	VERB	O	O
ribavirin	NOUN	O	B-OTHER
exposure	NOUN	O	I-OTHER
in	ADP	O	O
week	NOUN	O	O
0-12	NUM	O	O
was	VERB	O	O
70	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
96	NUM	O	O
%	SYM	O	O
in	ADP	O	O
patients	NOUN	O	O
assigned	VERB	O	O
to	ADP	O	O
ribavirin	NOUN	O	O
800	NUM	O	O
and	CCONJ	O	O
1000/1200	NOUN	O	O
mg/day	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

EVR	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
SVR	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
were	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
assigned	VERB	O	O
to	ADP	O	O
ribavirin	NOUN	O	O
800	ADJ	O	O
than	PUNCT	O	O
1000/1200	NOUN	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
EVR	NOUN	O	O
,	PUNCT	O	O
75	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
84	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
;	PUNCT	O	O
SVR	NOUN	O	O
,	PUNCT	O	O
45	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
54	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.011	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
achievement	NOUN	O	O
of	ADP	O	O
EVR	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
SVR	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
ribavirin	NOUN	O	O
dose	NOUN	O	O
over	ADP	O	O
the	DET	O	O
first	ADJ	O	O
12	NUM	O	O
weeks	NOUN	O	O
expressed	VERB	O	O
either	PUNCT	O	O
as	PUNCT	O	O
absolute	ADJ	O	O
dose	NOUN	O	O
or	CCONJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
optimal	ADJ	O	O
dose	NOUN	O	O
received	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
for	ADP	O	O
both	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Ribavirin	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
week	ADJ	O	O
12	NUM	O	O
is	VERB	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
EVR	NOUN	O	O
and	CCONJ	O	O
SVR	NOUN	O	O
in	ADP	O	O
genotype	NOUN	O	O
1	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Maintenance	NOUN	O	O
of	ADP	O	O
an	DET	O	O
optimal	ADJ	O	O
ribavirin	NOUN	O	O
dose	NOUN	O	O
is	VERB	O	O
the	DET	O	O
most	VERB	O	O
important	ADJ	O	O
modifiable	ADJ	O	O
factor	NOUN	O	O
during	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
C	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
phase	NOUN	O	O
II	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
dose	NOUN	O	O
schedules	NOUN	O	O
of	ADP	O	O
carboplatin/paclitaxel/cetuximab	NOUN	O	O
in	ADP	O	O
stage	NOUN	O	O
IIIB/IV	NOUN	O	O
non-small-cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
NSCLC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
This	DET	O	O
trial	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
weekly	ADV	O	O
cetuximab	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
schedules	NOUN	O	O
of	ADP	O	O
paclitaxel/carboplatin	NOUN	O	O
for	ADP	O	O
stage	NOUN	O	O
IIIB/IV	NOUN	O	O
non-small-cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
NSCLC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
168	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
previously	ADV	O	O
untreated	VERB	O	O
stage	NOUN	O	O
IIIB/IV	NOUN	O	O
NSCLC	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
arm	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
cetuximab	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
followed	VERB	O	O
by	ADP	O	O
weekly	ADV	O	O
250	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
+	SYM	O	O
paclitaxel	NOUN	O	O
(	PUNCT	O	O
Taxol	ADV	O	O
)	PUNCT	O	O
(	PUNCT	O	O
225	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
/carboplatin	NOUN	O	O
(	PUNCT	O	O
AUC6	NOUN	O	O
)	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
arm	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
same	ADJ	O	O
cetuximab	NOUN	O	O
regimen	NOUN	O	O
plus	CCONJ	O	O
paclitaxel	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
carboplatin	NOUN	O	O
(	PUNCT	O	O
AUC6	NOUN	O	O
)	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
every	DET	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
continued	VERB	O	O
for	ADP	O	O
a	DET	O	O
four-cycle	NOUN	O	O
maximum	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
complete	ADJ	O	O
response	NOUN	O	O
,	PUNCT	O	O
partial	ADJ	O	O
response	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
stable	ADJ	O	O
disease	NOUN	O	O
after	ADP	O	O
four	NUM	O	O
cycles	NOUN	O	O
could	VERB	O	O
receive	VERB	O	O
cetuximab	NOUN	O	O
250	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
/week	NOUN	O	O
until	ADP	O	O
disease	NOUN	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
unacceptable	ADJ	O	I-PHYSICAL
toxicity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	PUNCT	O	O
progression-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	I-MORTALITY
PFS	NOUN	O	I-MORTALITY
)	PUNCT	O	I-MORTALITY
.	PUNCT	O	O

RESULTS	ADJ	O	O
Median	ADJ	O	O
PFS	NOUN	O	B-PHYSICAL
was	VERB	O	O
4.7	NUM	O	O
and	CCONJ	O	O
4.3	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
arms	NOUN	O	O
A	DET	O	O
and	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
6-month	NOUN	O	O
PFS	NOUN	O	O
,	PUNCT	O	O
27.3	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
30.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Median	ADJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
11.4	NUM	O	O
versus	CCONJ	O	O
9.8	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
arms	NOUN	O	O
A	DET	O	O
and	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
estimated	DET	O	O
1-year	ADJ	O	O
survival	NOUN	O	O
,	PUNCT	O	O
47.7	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
39.3	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
objective	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
29.6	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
25	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
regimen	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	VERB	O	B-OTHER
with	ADP	O	O
rash	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
hematologic	ADJ	O	I-PHYSICAL
toxicity	NOUN	O	I-PHYSICAL
being	VERB	O	O
most	CCONJ	O	O
common	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
meet	VERB	O	O
the	DET	O	O
prespecified	ADJ	O	O
benchmark	ADJ	O	O
of	ADP	O	O
35	NUM	O	O
%	SYM	O	O
6-month	NOUN	O	O
PFS	NOUN	O	O
rate	NOUN	O	O
;	PUNCT	O	O
both	PUNCT	O	O
combination	NOUN	O	O
schedules	NOUN	O	O
of	ADP	O	O
cetuximab	NOUN	O	O
plus	CCONJ	O	O
paclitaxel/carboplatin	NOUN	O	O
were	VERB	O	O
feasible	ADJ	O	O
and	CCONJ	O	O
equivalent	ADJ	O	O
for	ADP	O	O
treating	VERB	O	O
advanced	NOUN	O	O
NSCLC	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
external	ADJ	O	O
beam	VERB	O	O
radiotherapy	NOUN	O	O
versus	CCONJ	O	O
cryoablation	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
localized	VERB	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
A	PUNCT	O	O
recent	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
external	ADJ	O	O
beam	PUNCT	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
EBRT	PUNCT	O	O
)	PUNCT	O	O
to	ADP	O	O
cryoablation	NOUN	O	O
for	ADP	O	O
localized	VERB	O	O
disease	NOUN	O	O
showed	VERB	O	O
cryoablation	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
noninferior	ADJ	O	O
to	PUNCT	O	O
external	ADJ	O	O
beam	PUNCT	O	O
EBRT	NOUN	O	O
in	ADP	O	O
disease	NOUN	O	O
progression	NOUN	O	O
and	CCONJ	O	O
overall	ADJ	O	O
and	CCONJ	O	O
disease-specific	ADJ	O	O
survival	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
(	PUNCT	O	B-OTHER
QOL	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
outcomes	NOUN	O	O
for	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
From	ADP	O	O
December	NOUN	O	O
1997	NUM	O	O
through	ADP	O	O
February	PUNCT	O	O
2003	NUM	O	O
,	PUNCT	O	O
244	NUM	O	O
men	NOUN	O	O
with	ADP	O	O
newly	ADJ	O	O
diagnosed	DET	O	O
localized	PUNCT	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
cryoablation	NOUN	O	O
or	CCONJ	O	O
EBRT	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
dose	NOUN	O	O
68	NUM	O	O
Gy	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	CCONJ	O	O
neoadjuvant	PUNCT	O	O
antiandrogen	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
completed	VERB	O	O
the	DET	O	O
EORTC	NOUN	O	O
QLQ	NOUN	O	O
C30	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
Prostate	NOUN	O	O
Cancer	NOUN	O	O
Index	NOUN	O	O
(	PUNCT	O	O
PCI	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
1.5	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
,	PUNCT	O	O
18	NUM	O	O
,	PUNCT	O	O
24	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
36	NUM	O	O
months	NOUN	O	O
post-treatment	PUNCT	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Regardless	PUNCT	O	O
of	ADP	O	O
treatment	NOUN	O	O
arm	ADP	O	O
,	PUNCT	O	O
participants	NOUN	O	O
reported	ADP	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
QOL	NOUN	O	B-OTHER
with	ADP	O	O
few	ADJ	O	O
exceptions	NOUN	O	O
.	PUNCT	O	O

cryoablation	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
more	DET	O	O
acute	ADJ	O	B-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
dysfunction	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
mean	NOUN	O	O
PCI	NOUN	O	O
urinary	ADJ	O	O
function	NOUN	O	O
cryoablation=69.4	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
EBRT=90.7	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
resolved	VERB	O	O
over	PUNCT	O	O
time	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
late	ADJ	O	B-OTHER
arising	ADJ	O	I-OTHER
QOL	NOUN	O	I-OTHER
issues	NOUN	O	I-OTHER
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
EBRT	ADP	O	O
and	CCONJ	O	O
cryoablation	NOUN	O	O
participants	NOUN	O	O
reported	ADV	O	O
decreases	DET	O	O
in	ADP	O	O
sexual	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
at	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
with	ADP	O	O
the	DET	O	O
cryoablation	NOUN	O	O
patients	NOUN	O	O
reporting	PUNCT	O	O
poorer	PUNCT	O	O
functioning	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
cryoablation=7.2	NOUN	O	O
:	PUNCT	O	O
mean	NOUN	O	O
EBRT=32.9	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
sexual	ADJ	O	B-PHYSICAL
function	ADV	O	I-PHYSICAL
score	NOUN	O	I-PHYSICAL
was	VERB	O	O
15	NUM	O	O
points	ADP	O	O
lower	PUNCT	O	O
at	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
for	ADP	O	O
the	DET	O	O
cryoablation	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
13	NUM	O	O
%	ADP	O	O
more	DET	O	O
of	ADP	O	O
the	DET	O	O
cryoablation	NOUN	O	O
men	NOUN	O	O
said	PUNCT	O	O
that	ADP	O	O
sexuality	NOUN	O	O
was	VERB	O	O
a	DET	O	O
moderate	ADJ	O	O
or	CCONJ	O	O
big	NOUN	O	O
problem	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
long-term	NOUN	O	O
QOL	NOUN	O	B-OTHER
advantage	PUNCT	O	O
for	ADP	O	O
either	CCONJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
apparent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
poorer	PUNCT	O	O
sexual	ADJ	O	B-MENTAL
function	NOUN	O	I-MENTAL
reported	VERB	O	O
by	ADP	O	O
those	ADP	O	O
treated	VERB	O	O
with	ADP	O	O
cryoablation	NOUN	O	O
.	PUNCT	O	O

Men	NOUN	O	O
who	ADP	O	O
wish	NOUN	O	O
to	PART	O	O
increase	NOUN	O	O
their	ADP	O	O
odds	NOUN	O	O
of	ADP	O	O
retaining	NUM	O	O
sexual	ADJ	O	B-MENTAL
function	NOUN	O	I-MENTAL
might	VERB	O	O
be	VERB	O	O
counseled	VERB	O	O
to	ADP	O	O
choose	NOUN	O	O
EBRT	NOUN	O	O
over	ADP	O	O
cryoablation	NOUN	O	O
.	PUNCT	O	O

In-season	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
short-term	NOUN	O	O
sprint	NOUN	O	O
and	CCONJ	O	O
power	NOUN	O	O
training	VERB	O	O
programs	NOUN	O	O
on	ADP	O	O
elite	ADJ	O	O
junior	PUNCT	O	O
soccer	NOUN	O	O
players	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
in-season	NOUN	O	O
short-term	NOUN	O	O
sprint	NOUN	O	O
and	CCONJ	O	O
power	NOUN	O	O
training	NUM	O	O
protocols	NOUN	O	O
on	ADP	O	O
vertical	ADJ	O	O
countermovement	ADJ	O	O
jump	NOUN	O	O
height	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
arms	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sprint	NOUN	O	O
(	PUNCT	O	O
Sprint-15m	NOUN	O	O
)	PUNCT	O	O
speed	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
agility	NOUN	O	O
(	PUNCT	O	O
Agility-15m	NOUN	O	O
)	PUNCT	O	O
speed	DET	O	O
in	ADP	O	O
male	NOUN	O	O
elite	ADJ	O	O
junior	PUNCT	O	O
soccer	NOUN	O	O
players	ADJ	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
highly	ADV	O	O
trained	VERB	O	O
soccer	NOUN	O	O
players	ADJ	O	O
(	PUNCT	O	O
age	NOUN	O	O
18.3	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
height	PUNCT	O	O
177	NUM	O	O
+/-	SYM	O	O
4	NUM	O	O
cm	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
71.4	NUM	O	O
+/-	SYM	O	O
6.9	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
sum	NOUN	O	O
skinfolds	CCONJ	O	O
48.1	NUM	O	O
+/-	SYM	O	O
11.4	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
members	NOUN	O	O
of	ADP	O	O
a	DET	O	O
professional	ADJ	O	O
soccer	NOUN	O	O
academy	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
CONTRAST	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
SPRINT	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
training	VERB	O	O
intervention	NOUN	O	O
consisted	ADJ	O	O
of	ADP	O	O
6	NUM	O	O
supervised	PUNCT	O	O
training	ADJ	O	O
sessions	NOUN	O	O
over	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
targeting	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
players	ADJ	O	O
'	PUNCT	O	O
speed	NOUN	O	B-MENTAL
and	CCONJ	O	O
power	NOUN	O	B-MENTAL
.	PUNCT	O	O

CONTRAST	NOUN	O	O
protocol	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
alternating	PUNCT	O	O
heavy-light	ADJ	O	O
resistance	NOUN	O	O
(	PUNCT	O	O
15-50	NUM	O	O
%	SYM	O	O
body	NOUN	O	O
mass	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
soccer-specific	ADJ	O	O
drills	NOUN	O	O
(	PUNCT	O	O
small-sided	PROPN	O	O
games	NOUN	O	O
or	CCONJ	O	O
technical	ADJ	O	O
skills	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

SPRINT	NOUN	O	O
training	ADJ	O	O
protocol	NOUN	O	O
used	PUNCT	O	O
line	NOUN	O	O
30-m	NOUN	O	O
sprints	NOUN	O	O
(	PUNCT	O	O
2-4	NUM	O	O
sets	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
x	SYM	O	O
30	NUM	O	O
m	NOUN	O	O
with	ADP	O	O
180	NUM	O	O
and	CCONJ	O	O
90	NUM	O	O
seconds	NOUN	O	O
of	ADP	O	O
recovery	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
baseline	NOUN	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
physical	ADJ	O	B-PHYSICAL
test	ADV	O	I-PHYSICAL
performance	NOUN	O	I-PHYSICAL
was	VERB	O	O
evident	ADJ	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
time	NOUN	O	O
x	SYM	O	O
training	ADV	O	O
group	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
for	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
vertical	ADJ	O	B-OTHER
jump	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
Agility-15m	NOUN	O	I-OTHER
variables	NOUN	O	I-OTHER
(	PUNCT	O	O
p	NOUN	O	B-PHYSICAL
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
time	NOUN	O	O
x	SYM	O	O
training	ADV	O	O
group	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
for	ADP	O	O
Sprint-15m	NOUN	O	O
performance	NOUN	O	O
with	ADP	O	O
the	DET	O	O
CONTRAST	NOUN	O	O
group	NOUN	O	O
showing	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
scores	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
SPRINT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
7.23	NUM	O	O
+/-	SYM	O	O
0.18	NUM	O	O
vs.	CCONJ	O	O
7.09	NUM	O	O
+/-	SYM	O	O
0.20	DET	O	O
m.s	ADV	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
light	NOUN	O	O
of	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
CONTRAST	NOUN	O	O
training	VERB	O	O
should	VERB	O	O
be	VERB	O	O
preferred	VERB	O	O
to	ADP	O	O
line	NOUN	O	O
sprint	NOUN	O	O
training	VERB	O	O
in	ADP	O	O
the	DET	O	O
short	ADJ	O	O
term	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
elite	ADJ	O	O
soccer	NOUN	O	O
players	ADJ	O	O
when	ADP	O	O
the	DET	O	O
aim	NOUN	O	O
is	VERB	O	O
to	PART	O	O
improve	PUNCT	O	O
soccer-specific	ADJ	O	B-MENTAL
sprint	NOUN	O	I-MENTAL
performance	NOUN	O	I-MENTAL
(	PUNCT	O	O
15	NUM	O	B-PHYSICAL
m	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
competitive	ADJ	O	O
season	ADJ	O	O
.	PUNCT	O	O

Long-term	NOUN	O	O
decrease	NOUN	O	O
in	ADP	O	O
bladder	NOUN	O	B-PHYSICAL
cancer	NOUN	O	I-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
with	ADP	O	O
hexaminolevulinate	PUNCT	O	O
enabled	VERB	O	O
fluorescence	NOUN	O	O
cystoscopy	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
We	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
hexaminolevulinate	PUNCT	O	O
fluorescence	NOUN	O	O
cystoscopic	ADJ	O	O
detection	NOUN	O	O
of	ADP	O	O
papillary	ADJ	O	O
,	PUNCT	O	O
nonmuscle	NOUN	O	O
invasive	ADJ	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
on	ADP	O	O
the	DET	O	O
long-term	NOUN	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Long-term	NOUN	O	O
followup	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
551	NUM	O	O
participants	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
fluorescence	NOUN	O	O
cystoscopy	NOUN	O	O
for	ADP	O	O
Ta	NOUN	O	O
or	CCONJ	O	O
T1	NOUN	O	O
urothelial	ADJ	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
original	ADJ	O	O
study	NOUN	O	O
280	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADJ	O	O
cystoscopy	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
271	NUM	O	O
in	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
cystoscopy	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
with	ADP	O	O
cystoscopy	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
initial	ADJ	O	O
resection	NOUN	O	O
or	CCONJ	O	O
until	ADP	O	O
recurrence	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
study	NOUN	O	O
extension	NOUN	O	O
protocol	NOUN	O	O
was	ADJ	O	O
done	PUNCT	O	O
for	ADP	O	O
long-term	NOUN	O	O
followup	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Followup	NOUN	O	O
information	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
for	ADP	O	O
261	ADJ	O	O
of	ADP	O	O
the	DET	O	O
280	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
93	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
255	NUM	O	O
of	ADP	O	O
the	DET	O	O
271	NUM	O	O
(	PUNCT	O	O
94	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
followup	NOUN	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADJ	O	O
and	CCONJ	O	O
fluorescence	NOUN	O	O
groups	NOUN	O	O
was	VERB	O	O
53.0	NUM	O	O
and	CCONJ	O	O
55.1	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
83	NUM	O	O
(	PUNCT	O	O
31.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
97	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
38	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
remained	VERB	O	O
tumor	NOUN	O	O
free	ADJ	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Median	ADJ	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
was	VERB	O	O
9.4	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
16.4	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
intravesical	ADJ	O	B-OTHER
therapy	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
46	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
45	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cystectomy	NOUN	O	O
was	VERB	O	O
done	PUNCT	O	O
in	ADP	O	O
22	NUM	O	O
of	ADP	O	O
280	NUM	O	O
cases	NOUN	O	O
(	PUNCT	O	O
7.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
13	NUM	O	O
of	ADP	O	O
the	DET	O	O
271	NUM	O	O
(	PUNCT	O	O
4.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.16	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Hexaminolevulinate	ADV	O	O
fluorescence	NOUN	O	O
cystoscopy	NOUN	O	O
significantly	ADV	O	O
improves	NOUN	O	O
long-term	NOUN	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
time	NOUN	O	O
to	ADP	O	O
recurrence	NOUN	O	O
with	ADP	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
improved	VERB	O	O
bladder	NOUN	O	O
preservation	NOUN	O	O
.	PUNCT	O	O

Cognitive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	O
carbonate	NOUN	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	O
in	ADP	O	O
treatment-resistant	ADJ	O	O
aggressive	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	O
carbonate	NOUN	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	O
on	ADP	O	O
cognition	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
a	DET	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
61	NUM	O	O
treatment-resistant	ADJ	O	O
,	PUNCT	O	O
hospitalized	DET	O	O
school-aged	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

They	ADP	O	O
all	ADV	O	O
had	PUNCT	O	O
a	DET	O	O
DSM-III	NUM	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
conduct	NOUN	O	O
disorder	NOUN	O	O
--	PUNCT	O	O
undersocialized	ADP	O	O
,	PUNCT	O	O
aggressive	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
profile	NOUN	O	O
of	ADP	O	O
highly	ADV	O	O
explosive	ADJ	O	O
and	CCONJ	O	O
aggressive	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
a	DET	O	O
two-week	NOUN	O	O
placebo-baseline	NOUN	O	O
period	NOUN	O	O
and	CCONJ	O	O
again	ADV	O	O
after	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
cognition	NOUN	O	O
were	VERB	O	O
mild	ADJ	O	O
.	PUNCT	O	O

Haloperidol	NOUN	O	O
(	PUNCT	O	O
mean	ADP	O	O
dose	NOUN	O	O
,	PUNCT	O	O
2.95	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
caused	VERB	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
Porteus	NOUN	O	B-MENTAL
Maze	NOUN	O	I-MENTAL
test	NOUN	O	I-MENTAL
quotient	NOUN	O	I-MENTAL
scores	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
slowing	VERB	O	O
of	DET	O	O
reaction	NOUN	O	O
time	NOUN	O	O
(	PUNCT	O	O
RT	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
a	DET	O	O
simple	ADJ	O	O
RT	NOUN	O	O
task	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	O
carbonate	NOUN	O	O
(	PUNCT	O	O
mean	ADP	O	O
dose	NOUN	O	O
,	PUNCT	O	O
1,166	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
adversely	ADV	O	O
affected	VERB	O	O
qualitative	ADJ	O	B-MENTAL
scores	NOUN	O	I-MENTAL
on	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
Porteus	ADJ	O	I-MENTAL
Maze	NOUN	O	I-MENTAL
test	NOUN	O	I-MENTAL
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
treatment	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
the	DET	O	O
Matching	PUNCT	O	O
Familiar	NOUN	O	O
Figures	NOUN	O	O
Test	NOUN	O	O
,	PUNCT	O	O
short-term	NOUN	O	O
recognition	NOUN	O	O
memory	NOUN	O	O
and	CCONJ	O	O
concept	NOUN	O	B-MENTAL
attainment	NOUN	O	I-MENTAL
tasks	NOUN	O	I-MENTAL
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
Stroop	NOUN	O	O
Test	NOUN	O	O
.	PUNCT	O	O

Just-in-time	NOUN	O	O
evidence-based	VERB	O	O
e-mail	NOUN	O	O
reminders	NOUN	O	O
in	ADP	O	O
home	NOUN	O	O
health	NOUN	O	O
care	NOUN	O	O
:	PUNCT	O	O
impact	NOUN	O	O
on	ADP	O	O
nurse	ADJ	O	O
practices	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
test	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
interventions	NOUN	O	O
designed	VERB	O	O
to	PART	O	O
improve	ADJ	O	O
the	DET	O	O
adoption	NOUN	O	O
of	ADP	O	O
evidence-based	VERB	O	O
practices	NOUN	O	O
by	ADP	O	O
home	NOUN	O	O
health	NOUN	O	O
nurses	NOUN	O	O
caring	ADJ	O	O
for	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
HF	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

DATA	NOUN	O	O
SOURCES/STUDY	CCONJ	O	O
SETTING	DET	O	O
Information	NOUN	O	O
on	ADP	O	O
nurse	ADJ	O	O
practices	NOUN	O	O
was	VERB	O	O
abstracted	VERB	O	O
from	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
records	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
admitted	VERB	O	O
between	ADP	O	O
June	NOUN	O	O
2000	NUM	O	O
and	CCONJ	O	O
November	NOUN	O	O
2001	NUM	O	O
to	ADP	O	O
the	DET	O	O
care	NOUN	O	O
of	ADP	O	O
354	NUM	O	O
study	ADV	O	O
nurses	NOUN	O	O
at	ADP	O	O
a	DET	O	O
large	ADJ	O	O
,	PUNCT	O	O
urban	ADJ	O	O
,	PUNCT	O	O
nonprofit	PUNCT	O	O
home	NOUN	O	O
care	NOUN	O	O
agency	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
employed	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
design	NOUN	O	O
with	ADP	O	O
nurses	NOUN	O	O
assigned	NUM	O	O
to	ADP	O	O
usual	ADJ	O	O
care	NOUN	O	O
or	CCONJ	O	O
one	NUM	O	O
of	ADP	O	O
two	NUM	O	O
intervention	NOUN	O	O
groups	NOUN	O	O
upon	ADP	O	O
identification	NOUN	O	O
of	ADP	O	O
an	DET	O	O
eligible	ADJ	O	O
patient	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
basic	ADJ	O	O
intervention	NOUN	O	O
was	VERB	O	O
a	DET	O	O
one-time	ADJ	O	O
e-mail	NOUN	O	O
reminder	ADP	O	O
highlighting	SYM	O	O
six	NUM	O	O
HF-specific	ADJ	O	O
clinical	ADJ	O	O
recommendations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
augmented	VERB	O	O
intervention	NOUN	O	O
consisted	ADJ	O	O
of	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
e-mail	NOUN	O	O
reminder	ADJ	O	O
supplemented	VERB	O	O
by	ADP	O	O
provider	NOUN	O	O
prompts	NOUN	O	O
,	PUNCT	O	O
patient	NOUN	O	O
education	NOUN	O	O
material	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
nurse	ADJ	O	O
specialist	NOUN	O	O
outreach	ADJ	O	O
.	PUNCT	O	O

DATA	NOUN	O	O
COLLECTION	NOUN	O	O
At	ADP	O	O
each	DET	O	O
home	NOUN	O	O
health	NOUN	O	O
visit	NOUN	O	O
provided	VERB	O	O
by	ADP	O	O
a	DET	O	O
study	NOUN	O	O
nurse	PUNCT	O	O
to	ADP	O	O
an	DET	O	O
eligible	ADJ	O	O
HF	NOUN	O	O
patient	NOUN	O	O
during	ADP	O	O
the	DET	O	O
45-day	NOUN	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
structured	VERB	O	O
chart	NOUN	O	O
abstraction	NOUN	O	O
tool	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
collect	PUNCT	O	O
information	NOUN	O	O
on	ADP	O	O
whether	ADP	O	O
the	DET	O	O
nurse	ADJ	O	O
provided	VERB	O	O
the	DET	O	O
care	NOUN	O	O
practices	PROPN	O	O
highlighted	VERB	O	O
in	ADP	O	O
the	DET	O	O
e-mail	NOUN	O	O
reminder	ADP	O	O
.	PUNCT	O	O

PRINCIPAL	NOUN	O	O
FINDINGS	NOUN	O	O
Both	CCONJ	O	O
the	DET	O	O
basic	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
augmented	DET	O	O
interventions	NOUN	O	O
greatly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
practice	NOUN	O	O
of	ADP	O	O
evidence-based	VERB	O	B-OTHER
care	NOUN	O	I-OTHER
,	PUNCT	O	O
according	CCONJ	O	O
to	ADP	O	O
patient	NOUN	O	O
records	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
areas	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
assessment	NOUN	O	O
and	CCONJ	O	O
instructions	NOUN	O	O
about	PUNCT	O	O
HF	NOUN	O	O
disease	NOUN	O	O
management	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
not	ADP	O	O
all	DET	O	O
results	ADP	O	O
were	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
at	ADP	O	O
conventional	ADJ	O	O
levels	NOUN	O	O
,	PUNCT	O	O
intervention	NOUN	O	B-OTHER
effects	NOUN	O	I-OTHER
were	VERB	O	O
positive	ADJ	O	O
in	ADP	O	O
virtually	ADV	O	O
all	DET	O	O
cases	NOUN	O	O
and	CCONJ	O	O
effect	NOUN	O	O
magnitudes	NOUN	O	B-OTHER
frequently	ADV	O	I-OTHER
were	VERB	O	O
large	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
strongly	ADV	O	O
support	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
just-in-time	NOUN	O	B-OTHER
evidence-based	VERB	O	I-OTHER
reminders	NOUN	O	I-OTHER
as	ADP	O	O
a	DET	O	O
means	NOUN	O	O
of	ADP	O	O
changing	PROPN	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
among	ADP	O	O
home	NOUN	O	O
health	NOUN	O	O
nurses	NOUN	O	O
who	ADP	O	O
are	VERB	O	O
geographically	ADV	O	O
dispersed	PROPN	O	O
and	CCONJ	O	O
spend	PUNCT	O	O
much	ADV	O	O
of	ADP	O	O
their	PUNCT	O	O
time	NOUN	O	O
in	ADP	O	O
the	DET	O	O
field	NOUN	O	O
.	PUNCT	O	O

Physical	ADJ	O	O
activity	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
an	DET	O	O
allogeneic	ADJ	O	O
hematopoietic	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
:	PUNCT	O	O
benefits	NOUN	O	O
of	ADP	O	O
a	DET	O	O
moderate	ADJ	O	O
exercise	NOUN	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	PUNCT	O	O
An	DET	O	O
allogeneic	ADJ	O	O
hematopoietic	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
HSCT	NOUN	O	O
)	PUNCT	O	O
can	VERB	O	O
have	PUNCT	O	O
profound	ADJ	O	O
and	CCONJ	O	O
lasting	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
's	PUNCT	O	O
physical	ADJ	O	O
and	CCONJ	O	O
psychological	ADJ	O	O
well-being	PUNCT	O	O
.	PUNCT	O	O

So	ADP	O	O
far	ADV	O	O
,	PUNCT	O	O
only	ADV	O	O
few	ADJ	O	O
studies	NOUN	O	O
have	ADP	O	O
investigated	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
activity	NOUN	O	O
over	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
inpatient	NOUN	O	O
phase	NOUN	O	O
of	ADP	O	O
an	DET	O	O
allogeneic	ADJ	O	O
HSCT	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
controlled	VERB	O	O
moderate	ADJ	O	O
exercise	NOUN	O	O
program	NOUN	O	O
starting	ADJ	O	O
parallel	ADJ	O	O
to	ADP	O	O
chemotherapeutic	ADJ	O	O
conditioning	VERB	O	O
and	CCONJ	O	O
total	ADJ	O	O
body	NOUN	O	O
irradiation	NOUN	O	O
on	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PUNCT	O	O
physical	ADJ	O	O
and	CCONJ	O	O
psychological	ADJ	O	O
constitution	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Forty-seven	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
an	DET	O	O
allogeneic	ADJ	O	O
HSCT	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
an	DET	O	O
exercise	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
EG	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
CG	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
EG	NOUN	O	O
took	PROPN	O	O
part	NOUN	O	O
in	ADP	O	O
an	DET	O	O
endurance	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
daily	PUNCT	O	O
living-training	PUNCT	O	O
twice	CCONJ	O	O
a	DET	O	O
day	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
CG	NOUN	O	O
received	VERB	O	O
the	DET	O	O
clinic	NOUN	O	O
's	PUNCT	O	O
standard	ADJ	O	O
physiotherapy	NOUN	O	O
program	NOUN	O	O
once	PUNCT	O	O
a	DET	O	O
day	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Significant	ADJ	O	O
differences	NOUN	O	O
and/or	CCONJ	O	O
trends	NOUN	O	O
in	ADP	O	O
favor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
EG	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
regarding	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
endurance	NOUN	O	B-PHYSICAL
performance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P=0.002	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
muscular	ADJ	O	B-PHYSICAL
strength	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P=0.022	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fatigue	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P=0.046	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
emotional	ADJ	O	B-PHYSICAL
state	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P=0.028	NOUN	O	O
)	PUNCT	O	O
without	ADP	O	O
posing	SYM	O	O
an	DET	O	O
additional	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
the	DET	O	O
individual	ADJ	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	ADV	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
training	DET	O	O
program	NOUN	O	O
is	VERB	O	O
feasible	ADJ	O	O
and	CCONJ	O	O
seems	NOUN	O	O
to	PART	O	O
have	PUNCT	O	O
positive	ADJ	O	O
influences	NOUN	O	O
on	ADP	O	O
physical	ADJ	O	B-PHYSICAL
performance	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
quality	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
life	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
an	DET	O	O
allogeneic	ADJ	O	O
HSCT	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
confirm	NOUN	O	O
these	DET	O	O
results	NOUN	O	O
.	PUNCT	O	O

Tomato	NOUN	O	O
paste	NOUN	O	O
rich	ADJ	O	O
in	ADP	O	O
lycopene	NOUN	O	O
protects	PUNCT	O	O
against	ADP	O	O
cutaneous	ADJ	O	B-PHYSICAL
photodamage	NOUN	O	I-PHYSICAL
in	ADP	O	O
humans	NOUN	O	O
in	DET	O	O
vivo	ADJ	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Previous	ADJ	O	O
epidemiological	ADJ	O	O
,	PUNCT	O	O
animal	NOUN	O	O
and	CCONJ	O	O
human	NOUN	O	O
data	NOUN	O	O
report	NOUN	O	O
that	ADP	O	O
lycopene	NOUN	O	O
has	PUNCT	O	O
a	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
against	ADP	O	O
ultraviolet	ADJ	O	B-PHYSICAL
radiation	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
UVR	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
-induced	VERB	O	B-PHYSICAL
erythema	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
We	PRON	O	O
examined	VERB	O	O
whether	ADP	O	O
tomato	NOUN	O	O
paste	NOUN	O	O
--	PUNCT	O	O
rich	ADJ	O	O
in	ADP	O	O
lycopene	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
powerful	ADJ	O	O
antioxidant	NOUN	O	O
--	PUNCT	O	O
can	VERB	O	O
protect	VERB	O	O
human	NOUN	O	O
skin	NOUN	O	O
against	ADP	O	O
UVR-induced	VERB	O	O
effects	NOUN	O	O
partially	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
i.e	PUNCT	O	O
.	PUNCT	O	O

erythema	NOUN	O	O
,	PUNCT	O	O
matrix	NOUN	O	O
changes	NOUN	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	O
DNA	NOUN	O	O
(	PUNCT	O	O
mtDNA	NOUN	O	O
)	PUNCT	O	O
damage	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
healthy	ADJ	O	O
women	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
33	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
range	NOUN	O	O
21-47	NUM	O	O
;	PUNCT	O	O
phototype	NOUN	O	O
I/II	NOUN	O	O
)	PUNCT	O	O
ingested	ADP	O	O
55	NUM	O	O
g	ADP	O	O
tomato	NOUN	O	O
paste	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
mg	NOUN	O	O
lycopene	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
olive	NOUN	O	O
oil	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
olive	VERB	O	O
oil	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Pre-	PUNCT	O	O
and	CCONJ	O	O
postsupplementation	NOUN	O	O
,	PUNCT	O	O
UVR	PUNCT	O	O

Double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
on	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
a	DET	O	I-OTHER
physostigmine	ADJ	O	I-OTHER
patch	NOUN	O	I-OTHER
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
senile	ADJ	O	O
dementia	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Alzheimer	PUNCT	O	O
type	NOUN	O	O
.	PUNCT	O	O

Owing	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
physostigmine	ADJ	O	O
when	PUNCT	O	O
administered	VERB	O	O
by	ADP	O	O
conventional	ADJ	O	O
routes	NOUN	O	O
,	PUNCT	O	O
long-term	NOUN	O	O
cholinergic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
Alzheimer	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
is	VERB	O	O
difficult	ADJ	O	O
to	ADJ	O	O
manage	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
overcome	NOUN	O	O
the	DET	O	O
problems	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
physostigmine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
improve	ADJ	O	O
patients	NOUN	O	B-MENTAL
'	PUNCT	O	O
compliance	NOUN	O	B-MENTAL
,	PUNCT	O	O
a	DET	O	O
transdermal	ADJ	O	O
therapeutic	ADJ	O	O
system	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
this	DET	O	O
system	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
comparing	PUNCT	O	O
patches	NOUN	O	O
containing	VERB	O	O
30	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
60	NUM	O	O
mg	NOUN	O	O
physostigmine	NOUN	O	O
with	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
patch	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
followed	VERB	O	O
the	DET	O	O
basic	ADJ	O	O
principles	NOUN	O	O
of	ADP	O	O
the	DET	O	O
various	ADJ	O	O
guidelines	NOUN	O	O
on	ADP	O	O
the	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
anti-dementia	NOUN	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
included	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
probable	ADJ	O	O
Alzheimer	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
204	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
probable	ADJ	O	O
Alzheimer	PUNCT	O	O
's	PUNCT	O	O
disease	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	PUNCT	O	O
,	PUNCT	O	O
136	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
eligible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
according-to-protocol	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
167	NUM	O	O
subjects	NOUN	O	O
for	ADP	O	O
the	DET	O	O
intention-to-treat	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
181	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
tested	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
physostigmine	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
placebo	NOUN	O	O
after	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
contrary	PUNCT	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
even	ADV	O	O
a	DET	O	O
slight	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
,	PUNCT	O	O
trend	NOUN	O	O
toward	ADP	O	O
a	DET	O	O
better	PUNCT	O	O
outcome	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
physostigmine	ADJ	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	O
approximately	ADV	O	O
100	NUM	O	O
pg/ml	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
,	PUNCT	O	O
showing	VERB	O	O
a	DET	O	O
high	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
interindividual	ADJ	O	O
variability	NOUN	O	O
and	CCONJ	O	O
no	DET	O	O
linear	ADJ	O	O
dose	NOUN	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
30	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
60	NUM	O	O
mg	NOUN	O	O
dosages	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
cholinesterase	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
physostigmine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
physostigmine	ADJ	O	O
patch	NOUN	O	O
application	NOUN	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
60	NUM	O	O
mg	NOUN	O	O
apparently	ADV	O	O
did	PUNCT	O	O
not	ADV	O	O
lead	VERB	O	O
to	ADP	O	O
physostigmine	PUNCT	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	B-PHYSICAL
that	DET	O	O
were	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
compensate	VERB	O	O
for	ADP	O	O
cholinergic	ADJ	O	O
deficiencies	NOUN	O	O
in	ADP	O	O
affected	VERB	O	O
brain	NOUN	O	O
areas	NOUN	O	O
and	CCONJ	O	O
produce	NOUN	O	O
clinical	ADJ	O	O
benefits	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
transdermal	ADJ	O	O
system	NOUN	O	O
were	VERB	O	O
generally	VERB	O	O
well	VERB	O	B-OTHER
tolerated	ADP	O	I-OTHER
under	ADP	O	O
the	DET	O	O
study	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Modifications	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patch	NOUN	O	O
system	NOUN	O	O
may	ADP	O	O
perhaps	NOUN	O	O
make	VERB	O	O
it	ADV	O	O
possible	ADJ	O	O
to	PART	O	O
achieve	VERB	O	O
higher	PUNCT	O	O

[	PUNCT	O	O
4	NUM	O	O
years	NOUN	O	O
'	PUNCT	O	O
experience	NOUN	O	O
with	ADP	O	O
a	DET	O	O
balloon-expandable	ADJ	O	O
endoprosthesis	NOUN	O	O
.	PUNCT	O	O

Experimental	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
application	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
4-year	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
the	DET	O	O
balloon-expandable	ADJ	O	O
Palmaz	NOUN	O	O
stent	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
comparing	VERB	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
and	CCONJ	O	O
traditional	ADJ	O	O
balloon	NOUN	O	O
angioplasty	NOUN	O	O
of	ADP	O	O
iliac	PUNCT	O	O
arteries	NOUN	O	O
in	ADP	O	O
arterial	ADJ	O	O
occlusive	ADJ	O	O
disease	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
long-term	NOUN	O	O
results	NOUN	O	O
,	PUNCT	O	O
recorded	PROPN	O	O
after	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
indicate	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
complication	NOUN	O	B-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
after	ADP	O	O
stenting	NUM	O	O
2/62	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
angioplasty	NOUN	O	O
5/69	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
patency	NOUN	O	B-OTHER
(	PUNCT	O	O
greater	PUNCT	O	O
than	VERB	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
70	NUM	O	O
%	SYM	O	O
of	ADP	O	O
original	ADJ	O	O
lumen	NOUN	O	O
size	NOUN	O	O
upon	ADP	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
or	CCONJ	O	O
balloon	NOUN	O	O
inflation	NOUN	O	O
:	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
after	ADP	O	O
stenting	NUM	O	O
and	CCONJ	O	O
72	NUM	O	O
%	SYM	O	O
after	ADP	O	O
angioplasty	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-OTHER
improvement	NOUN	O	I-OTHER
after	ADP	O	O
2	NUM	O	O
years	NOUN	O	B-PHYSICAL
was	VERB	O	O
89	NUM	O	O
%	SYM	O	O
after	ADP	O	O
stenting	NUM	O	O
and	CCONJ	O	O
70	NUM	O	O
%	SYM	O	O
after	ADP	O	O
angioplasty	NOUN	O	O
.	PUNCT	O	O

Parallel	ADJ	O	O
to	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
,	PUNCT	O	O
experimental	ADJ	O	O
canine	ADJ	O	O
artery	NOUN	O	O
stenting	PUNCT	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
long-term	NOUN	O	O
patency	NOUN	O	O
of	ADP	O	O
stents	ADJ	O	O
exposed	VERB	O	O
to	ADP	O	O
restricted	PUNCT	O	O
flow	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
neointimal	ADJ	O	B-PHYSICAL
healing	VERB	O	I-PHYSICAL
were	VERB	O	O
found	VERB	O	O
between	ADP	O	O
normally	ADV	O	O
perfused	PUNCT	O	O
stents	NOUN	O	O
and	CCONJ	O	O
stents	ADJ	O	O
with	ADP	O	O
artificially	ADJ	O	O
reduced	VERB	O	O
flow	NOUN	O	O
:	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
total	ADJ	O	O
observation	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
the	DET	O	O
neointimal	ADJ	O	B-PHYSICAL
height	NOUN	O	I-PHYSICAL
was	VERB	O	O
up	PUNCT	O	O
to	PUNCT	O	O
200	NUM	O	O
%	SYM	O	O
higher	PUNCT	O	O
in	ADP	O	O
flow-restricted	VERB	O	O
stents	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
histological	ADJ	O	B-PHYSICAL
composition	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
neointima	NOUN	O	I-PHYSICAL
was	VERB	O	O
the	DET	O	O
same	ADJ	O	O
as	PUNCT	O	O
with	ADP	O	O
normally	ADV	O	O
perfused	PUNCT	O	O
stents	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Comparative	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
nebivolol	NOUN	O	O
and	CCONJ	O	O
valsartan	NOUN	O	O
on	ADP	O	O
atrial	ADJ	O	O
electromechanical	ADJ	O	B-PHYSICAL
coupling	VERB	O	I-PHYSICAL
in	ADP	O	O
newly	ADV	O	O
diagnosed	ADJ	O	O
stage	NOUN	O	O
1	NUM	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVES	ADJ	O	O
Hypertension	NOUN	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
AF	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

Increased	ADP	O	O
atrial	ADJ	O	O
electromechanical	ADJ	O	O
coupling	VERB	O	O
time	NOUN	O	O
interval	NOUN	O	O
measured	VERB	O	O
by	ADP	O	O
tissue	NOUN	O	O
Doppler	NOUN	O	O
is	VERB	O	O
accepted	VERB	O	O
as	ADP	O	O
an	DET	O	O
important	ADJ	O	O
factor	NOUN	O	O
for	ADP	O	O
prediction	NOUN	O	O
of	ADP	O	O
AF	NOUN	O	B-PHYSICAL
development	NOUN	O	I-PHYSICAL
in	ADP	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
valsartan	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
angiotensin	NOUN	O	O
receptor	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
nebivolol	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
beta-blocker	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
atrial	ADJ	O	O
electromechanical	ADJ	O	O
coupling	VERB	O	O
in	ADP	O	O
newly	ADV	O	O
diagnosed	ADJ	O	O
stage	NOUN	O	O
1	NUM	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
included	VERB	O	O
60	NUM	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
stage	NOUN	O	O
1	NUM	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
other	ADJ	O	O
systemic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
nebivolol	NOUN	O	O
5	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
patients	NOUN	O	O
;	PUNCT	O	O
21	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
9	NUM	O	O
men	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
48.4	NUM	O	O
?	PUNCT	O	O

11.4	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
valsartan	NOUN	O	O
160	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
patients	NOUN	O	O
;	PUNCT	O	O
21	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
9	NUM	O	O
men	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
49.8	NUM	O	O
?	PUNCT	O	O

11.3	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
the	DET	O	O
patients	NOUN	O	O
underwent	VERB	O	O
tissue	NOUN	O	O
Doppler	NOUN	O	O
echocardiographic	ADJ	O	O
examination	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
three	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
on	ADP	O	O
atrial	ADJ	O	O
electromechanical	ADJ	O	O
coupling	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Baseline	NOUN	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
,	PUNCT	O	O
electrocardiographic	ADJ	O	O
and	CCONJ	O	O
echocardiographic	ADJ	O	O
findings	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
atrial	ADJ	O	O
electromechanical	ADJ	O	O
coupling	VERB	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
drugs	NOUN	O	O
significantly	ADV	O	O
reduced	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
similar	ADJ	O	O
efficacy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Atrial	ADJ	O	O
electromechanical	ADJ	O	O
coupling	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Prolonged	PROPN	O	O
interatrial	ADJ	O	O
electromechanical	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
in	ADP	O	O
hypertensives	NOUN	O	O
are	VERB	O	O
improved	VERB	O	O
with	ADP	O	O
antihypertensive	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Amphotericin	NOUN	O	O
versus	CCONJ	O	O
pentamidine	NOUN	O	O
in	ADP	O	O
antimony-unresponsive	ADJ	O	O
kala-azar	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	O
B	NOUN	O	O
and	CCONJ	O	O
pentamidine	NOUN	O	O
isethionate	VERB	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
120	NUM	O	O
uncomplicated	VERB	O	O
and	CCONJ	O	O
parasitologically	ADV	O	O
confirmed	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
antimony-unresponsive	ADJ	O	O
kala-azar	NOUN	O	O
.	PUNCT	O	O

Doses	NOUN	O	O
were	VERB	O	O
twenty	NUM	O	O
intramuscular	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
pentamidine	NOUN	O	O
4	NUM	O	O
mg/kg	NOUN	O	O
on	ADP	O	O
alternate	NOUN	O	O
days	NOUN	O	O
or	CCONJ	O	O
fourteen	NUM	O	O
definitive	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
infused	VERB	O	O
in	ADP	O	O
5	NUM	O	O
%	SYM	O	O
dextrose	NOUN	O	O
on	ADP	O	O
alternate	NOUN	O	O
days	NOUN	O	O
.	PUNCT	O	O

48	NUM	O	O
(	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
given	PUNCT	O	O
pentamidine	ADP	O	O
showed	VERB	O	O
initial	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
and	CCONJ	O	O
46	NUM	O	O
(	PUNCT	O	O
77	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
showed	VERB	O	O
definitive	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
compared	VERB	O	O
with	ADP	O	O
60	NUM	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
59	NUM	O	O
(	PUNCT	O	O
98	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
cases	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
amphotericin	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Amphotericin	NOUN	O	O
also	ADV	O	O
brought	PUNCT	O	O
about	ADP	O	O
quicker	PUNCT	O	O
abatement	ADJ	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
fever	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
more	DET	O	O
complete	ADJ	O	B-ADVERSE-EFFECTS
spleen	NOUN	O	I-ADVERSE-EFFECTS
regression	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
intranasal	ADJ	O	O
oxytocin	NOUN	O	O
on	ADP	O	O
the	DET	O	O
neural	ADJ	O	O
basis	NOUN	O	O
of	ADP	O	O
face	PUNCT	O	O
processing	VERB	O	O
in	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
altered	CCONJ	O	O
face	ADP	O	O
processing	ADP	O	O
and	CCONJ	O	O
decreased	VERB	O	O
activity	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
regions	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
face	PUNCT	O	O
processing	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
neuropeptide	NOUN	O	O
oxytocin	NOUN	O	O
has	VERB	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
promote	CCONJ	O	O
face	PUNCT	O	O
processing	PUNCT	O	O
and	CCONJ	O	O
modulate	NOUN	O	O
brain	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
oxytocin	NOUN	O	O
on	ADP	O	O
the	DET	O	O
neural	ADJ	O	O
basis	NOUN	O	O
of	ADP	O	O
face	PUNCT	O	O
processing	VERB	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
Asperger	ADJ	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
AS	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
group	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
individuals	NOUN	O	O
with	ADP	O	O
AS	ADP	O	O
and	CCONJ	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
neurotypical	ADJ	O	O
control	NOUN	O	O
participants	NOUN	O	O
performed	VERB	O	O
a	DET	O	O
face-matching	PROPN	O	O
and	CCONJ	O	O
a	DET	O	O
house-matching	ADV	O	O
task	NOUN	O	O
during	ADP	O	O
functional	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
IU	NOUN	O	O
intranasally	ADV	O	O
administered	ADP	O	O
oxytocin	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
within-subject	PUNCT	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Under	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
AS	PUNCT	O	O
group	NOUN	O	O
showed	VERB	O	O
decreased	ADV	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	B-PHYSICAL
right	ADJ	O	I-PHYSICAL
amygdala	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
fusiform	NOUN	O	I-PHYSICAL
gyrus	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
inferior	ADJ	O	I-PHYSICAL
occipital	ADJ	O	I-PHYSICAL
gyrus	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
during	ADP	O	O
face	PUNCT	O	O
processing	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
oxytocin	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
right	VERB	O	B-PHYSICAL
amygdala	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
facial	ADJ	O	I-PHYSICAL
stimuli	NOUN	O	I-PHYSICAL
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
AS	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
oxytocin	NOUN	O	O
increases	NOUN	O	O
the	DET	O	O
saliency	NOUN	O	O
of	ADP	O	O
social	ADJ	O	O
stimuli	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
ASD	NOUN	O	O
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
oxytocin	NOUN	O	O
might	PART	O	O
promote	ADJ	O	O
face	PUNCT	O	O
processing	PUNCT	O	O
and	CCONJ	O	O
eye	NOUN	O	O
contact	NOUN	O	O
in	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
as	VERB	O	O
prerequisites	VERB	O	O
for	ADP	O	O
neurotypical	ADJ	O	O
social	ADJ	O	O
interaction	NOUN	O	O
.	PUNCT	O	O

TENS	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
writer	ADJ	O	O
's	PUNCT	O	O
cramp	NOUN	O	O
dystonia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

Manipulation	NOUN	O	O
of	ADP	O	O
afferent	NOUN	O	O
inputs	ADP	O	O
may	ADP	O	O
temporarily	PUNCT	O	O
modulate	ADV	O	O
dystonic	ADJ	O	O
spasms	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
writer	ADJ	O	O
's	PUNCT	O	O
cramp	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
study	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
transcutaneous	ADJ	O	O
electrical	ADJ	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
TENS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
treatment	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
four	NUM	O	O
measures	NOUN	O	O
of	ADP	O	O
dystonic	ADJ	O	B-PHYSICAL
impairment	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
TENS	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	B-OTHER
improvement	NOUN	O	I-OTHER
that	ADP	O	O
persisted	VERB	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
of	ADP	O	O
the	DET	O	O
four	NUM	O	O
measures	NOUN	O	O
.	PUNCT	O	O

Predictive	ADJ	O	O
validity	NOUN	O	O
of	ADP	O	O
a	DET	O	O
medication	NOUN	O	O
adherence	NOUN	O	O
measure	NOUN	O	O
in	ADP	O	O
an	DET	O	O
outpatient	ADJ	O	O
setting	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examines	NOUN	O	O
the	DET	O	O
psychometric	ADJ	O	O
properties	NOUN	O	O
and	CCONJ	O	O
tests	ADJ	O	O
the	DET	O	O
concurrent	ADJ	O	O
and	CCONJ	O	O
predictive	ADJ	O	O
validity	NOUN	O	O
of	ADP	O	O
a	DET	O	O
structured	VERB	O	O
,	PUNCT	O	O
self-reported	VERB	O	O
medication	NOUN	O	O
adherence	NOUN	O	O
measure	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
also	ADV	O	O
assessed	ADP	O	O
various	ADJ	O	O
psychosocial	ADJ	O	B-MENTAL
determinants	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
adherence	NOUN	O	I-MENTAL
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
knowledge	NOUN	O	B-MENTAL
,	PUNCT	O	O
social	ADJ	O	B-MENTAL
support	NOUN	O	I-MENTAL
,	PUNCT	O	O
satisfaction	NOUN	O	B-OTHER
with	ADP	O	I-OTHER
care	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
complexity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medical	ADJ	O	B-OTHER
regimen	NOUN	O	I-OTHER
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
1367	NUM	O	O
patients	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
was	VERB	O	O
52.5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
40.8	NUM	O	O
%	SYM	O	O
were	ADP	O	O
male	NOUN	O	O
,	PUNCT	O	O
76.5	NUM	O	O
%	SYM	O	O
were	VERB	O	O
black	NOUN	O	O
,	PUNCT	O	O
50.8	NUM	O	O
%	SYM	O	O
graduated	PUNCT	O	O
from	ADP	O	O
high	ADJ	O	O
school	NOUN	O	O
,	PUNCT	O	O
26	NUM	O	O
%	SYM	O	O
were	VERB	O	O
married	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
54.1	NUM	O	O
%	SYM	O	O
had	PUNCT	O	O
income	NOUN	O	O
<	SYM	O	O
$	SYM	O	O
5,000	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
8-item	NOUN	O	O
medication	NOUN	O	O
adherence	NOUN	O	O
scale	NOUN	O	O
was	VERB	O	O
reliable	ADJ	O	O
(	PUNCT	O	O
alpha=.83	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
control	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Using	ADJ	O	O
a	DET	O	O
cutpoint	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
6	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
measure	ADP	O	O
to	PART	O	O
identify	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
poor	ADJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
control	NOUN	O	I-PHYSICAL
was	VERB	O	O
estimated	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
93	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
specificity	NOUN	O	O
was	VERB	O	O
53	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
medication	NOUN	O	O
adherence	NOUN	O	O
measure	NOUN	O	O
proved	ADV	O	O
to	PART	O	O
be	PUNCT	O	O
reliable	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
good	ADJ	O	O
concurrent	ADJ	O	O
and	CCONJ	O	O
predictive	ADJ	O	O
validity	NOUN	O	O
in	ADP	O	O
primarily	ADV	O	O
low-income	NOUN	O	O
,	PUNCT	O	O
minority	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
might	CCONJ	O	O
function	VERB	O	O
as	ADP	O	O
a	DET	O	O
screening	VERB	O	O
tool	NOUN	O	O
in	ADP	O	O
outpatient	ADJ	O	O
settings	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
patient	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Histopathologic	ADJ	O	B-PHYSICAL
changes	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
eyelid	ADJ	O	I-PHYSICAL
skin	NOUN	O	I-PHYSICAL
following	PUNCT	O	O
trichloroacetic	ADJ	O	O
acid	NOUN	O	O
chemical	ADJ	O	O
peel	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
trichloroacetic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
TCA	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
periorbital	ADJ	O	O
and	CCONJ	O	O
eyelid	PUNCT	O	O
peel	PUNCT	O	O
for	ADP	O	O
skin	NOUN	O	O
rejuvenation	NOUN	O	O
is	VERB	O	O
gaining	PUNCT	O	O
significant	ADJ	O	O
acceptance	NOUN	O	O
among	ADP	O	O
oculoplastic	ADJ	O	O
surgeons	NOUN	O	O
,	PUNCT	O	O
dermatologists	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
surgery	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
the	DET	O	O
current	ADJ	O	O
enthusiasm	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
remain	VERB	O	O
potentially	ADV	O	O
serious	ADJ	O	O
complications	NOUN	O	O
resulting	VERB	O	O
from	ADP	O	O
any	DET	O	O
periorbital	ADJ	O	O
peel	NOUN	O	O
.	PUNCT	O	O

Cases	NOUN	O	O
of	ADP	O	O
cicatricial	ADJ	O	O
ectropion	NUM	O	O
have	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
in	ADP	O	O
phenol-peeled	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lower	ADP	O	O
eyelid	ADJ	O	O
ectropion	NUM	O	O
has	PUNCT	O	O
reportedly	ADV	O	O
occurred	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
deep	ADJ	O	O
eyelid	ADJ	O	O
peel	PUNCT	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
a	DET	O	O
blepharoplasty	NOUN	O	O
(	PUNCT	O	O
1,2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

To	DET	O	O
avoid	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
necessary	ADJ	O	O
to	ADJ	O	O
better	PUNCT	O	O
understand	PUNCT	O	O
the	DET	O	O
depth	NOUN	O	O
of	ADP	O	O
the	DET	O	O
wound	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
different	ADJ	O	O
strengths	PUNCT	O	O
and	CCONJ	O	O
combinations	NOUN	O	O
of	ADP	O	O
peeling	PROPN	O	O
agents	NOUN	O	O
applied	VERB	O	O
to	ADP	O	O
living	PUNCT	O	O
eyelid	PUNCT	O	O
tissue	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
more	DET	O	O
important	ADJ	O	O
,	PUNCT	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
concentrations	NOUN	O	O
of	ADP	O	O
TCA	NOUN	O	O
that	ADP	O	O
are	VERB	O	O
likely	ADV	O	O
to	PART	O	O
lead	PUNCT	O	O
to	ADP	O	O
cicatricial	ADJ	O	O
ectropion	NUM	O	O
when	ADP	O	O
applied	VERB	O	O
in	ADP	O	O
a	DET	O	O
consistent	ADJ	O	O
fashion	NOUN	O	O
.	PUNCT	O	O

We	ADJ	O	O
chose	PUNCT	O	O
upper-eyelid	ADP	O	O
skin	NOUN	O	O
because	ADP	O	O
it	PRON	O	O
is	VERB	O	O
easier	ADJ	O	O
to	PUNCT	O	O
obtain	ADV	O	O
for	ADP	O	O
histopathologic	ADJ	O	O
study	NOUN	O	O
than	PUNCT	O	O
lower-eyelid	PUNCT	O	O
skin	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
our	PUNCT	O	O
experience	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
more	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
hypertrophic	ADJ	O	O
changes	NOUN	O	O
after	ADP	O	O
chemical	ADJ	O	O
peeling	ADP	O	O
or	CCONJ	O	O
carbon	NOUN	O	O
dioxide	PUNCT	O	O
laser	NOUN	O	O
resurfacing	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
applied	VERB	O	O
TCA	NOUN	O	O
to	ADP	O	O
the	DET	O	O
preseptal	ADJ	O	O
skin	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
48	NUM	O	O
h	NOUN	O	O
before	ADP	O	O
standard	ADJ	O	O
upper-eyelid	ADJ	O	O
blepharoplasty	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
acid	NOUN	O	O
was	VERB	O	O
applied	VERB	O	O
to	ADJ	O	O
produce	NOUN	O	O
a	DET	O	O
frost	ADV	O	O
,	PUNCT	O	O
using	VERB	O	O
varying	VERB	O	O
concentrations	NOUN	O	O
of	ADP	O	O
acid	NOUN	O	O
,	PUNCT	O	O
ranging	CCONJ	O	O
from	ADP	O	O
20	NUM	O	O
to	ADP	O	O
50	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
treated	VERB	O	O
skin	NOUN	O	O
removed	VERB	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
blepharoplasty	NOUN	O	O
was	VERB	O	O
reviewed	VERB	O	O
in	ADP	O	O
a	DET	O	O
masked	ADJ	O	O
fashion	NOUN	O	O
by	ADP	O	O
a	DET	O	O
dermatopathologist	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
depth	NOUN	O	O
of	ADP	O	O
necrosis	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
superficial	ADJ	O	B-PHYSICAL
peels	NOUN	O	I-PHYSICAL
with	ADP	O	I-PHYSICAL
necrosis	NOUN	O	I-PHYSICAL
involving	VERB	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
epidermis	NOUN	O	O
were	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
the	DET	O	O
lowest-concentration	NOUN	O	O
combination	NOUN	O	O
of	ADP	O	O
TCA	NOUN	O	O
applied	VERB	O	B-OTHER
(	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
followed	VERB	O	O
by	ADP	O	O
0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

As	ADP	O	O
the	DET	O	O
strength	NOUN	O	B-OTHER
increased	ADP	O	O
,	PUNCT	O	O
so	PUNCT	O	O
did	PUNCT	O	O
the	DET	O	O
depth	NOUN	O	O
of	ADP	O	O
peel	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
%	SYM	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
second	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
%	SYM	O	O
produced	VERB	O	O
the	DET	O	O
deepest	ADV	O	B-PHYSICAL
peel	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
with	ADP	O	O
necrosis	NOUN	O	O
into	ADP	O	O
the	DET	O	O
papillary	ADJ	O	O
dermis	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
finding	VERB	O	O
would	ADJ	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
chance	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
cicatricial	ADJ	O	O
ectropion	NUM	O	O
with	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
tested	VERB	O	O
combinations	NOUN	O	O
of	ADP	O	O
TCA	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
very	PUNCT	O	O
remote	NOUN	O	O
.	PUNCT	O	O

Custom	ADJ	O	O
tray	NOUN	O	O
application	NOUN	O	O
of	ADP	O	O
peroxide	NOUN	O	O
gel	NOUN	O	O
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
scaling	ADP	O	O
and	CCONJ	O	O
root	NOUN	O	O
planing	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
periodontitis	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
after	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Scaling	PUNCT	O	O
and	CCONJ	O	O
root	NOUN	O	O
planing	PUNCT	O	O
(	PUNCT	O	O
SRP	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
non-surgical	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
periodontitis	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
its	PUNCT	O	O
effectiveness	NOUN	O	O
is	VERB	O	O
limited	VERB	O	O
.	PUNCT	O	O

Consequently	ADV	O	O
,	PUNCT	O	O
various	ADJ	O	O
adjunctive	ADJ	O	O
therapies	NOUN	O	O
have	NOUN	O	O
been	PUNCT	O	O
investigated	VERB	O	O
to	PART	O	O
improve	ADJ	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
SRP	NOUN	O	O
procedure	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
combined	PUNCT	O	O
with	ADP	O	O
local	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
hydrogen	NOUN	O	O
peroxide	NOUN	O	O
gel	NOUN	O	O
using	VERB	O	O
customized	VERB	O	O
trays	ADP	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
periodontitis	NOUN	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
An	DET	O	O
examiner-blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
among	ADP	O	O
30	NUM	O	O
subjects	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
advanced	VERB	O	O
periodontitis	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
SRP	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
SRP	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
prescription	NOUN	O	O
custom-tray	NOUN	O	O
application	NOUN	O	O
(	PUNCT	O	O
Perio	NOUN	O	O
Tray	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
1.7	NUM	O	O
%	SYM	O	O
hydrogen	NOUN	O	O
peroxide	NOUN	O	O
gel	NOUN	O	O
(	PUNCT	O	O
Perio	NOUN	O	O
Gel	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
extended	VERB	O	O
to	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Following	PUNCT	O	O
impressions	NOUN	O	O
for	ADP	O	O
the	DET	O	O
test	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
subjects	NOUN	O	O
brushed	PUNCT	O	O
twice	ADV	O	O
daily	ADJ	O	O
with	ADP	O	O
a	DET	O	O
regular	ADJ	O	O
dentifrice	NOUN	O	O
and	CCONJ	O	O
toothbrush	NOUN	O	O
for	ADP	O	O
a	DET	O	O
four-week	NOUN	O	O
acclimation	NOUN	O	O
phase	NOUN	O	O
to	PART	O	O
standardize	DET	O	O
oral	ADJ	O	O
conditions	NOUN	O	O
(	PUNCT	O	O
while	PUNCT	O	O
trays	NOUN	O	O
were	VERB	O	O
fabricated	ADJ	O	O
)	PUNCT	O	O
prior	PUNCT	O	O
to	ADP	O	O
initiating	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
phase	NOUN	O	O
.	PUNCT	O	O

SRP	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
three	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
assessments	NOUN	O	O
,	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
pocket	NOUN	O	B-PHYSICAL
probing	VERB	O	I-PHYSICAL
depth	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
PPD	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	B-PHYSICAL
bleeding	ADJ	O	I-PHYSICAL
index	NOUN	O	O
(	PUNCT	O	O
BI	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
conducted	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
two	NUM	O	O
,	PUNCT	O	O
five	NUM	O	O
,	PUNCT	O	O
13	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
26	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
peroxide	NOUN	O	O
gel	NOUN	O	O
applications	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
variables	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
by	ADP	O	O
ANCOVA	NOUN	O	O
and	CCONJ	O	O
paired	VERB	O	O
t-tests	NOUN	O	O
after	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
interval	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
test	NOUN	O	O
and	CCONJ	O	O
15	NUM	O	O
control	NOUN	O	O
subjects	NOUN	O	O
completed	DET	O	O
the	DET	O	O
original	ADJ	O	O
three-month	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
whom	ADP	O	O
10	NUM	O	O
test	NOUN	O	O
and	CCONJ	O	O
13	NUM	O	O
control	NOUN	O	O
subjects	NOUN	O	O
finished	ADV	O	O
the	DET	O	O
three-month	NOUN	O	O
extension	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
two	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
peroxide	NOUN	O	O
gel	NOUN	O	O
use	ADP	O	O
prior	PUNCT	O	O
to	ADP	O	O
SRP	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
PPD	NOUN	O	B-PHYSICAL
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
significantly	ADV	O	O
decreased	VERB	O	O
from	ADP	O	O
baseline	NOUN	O	O
by	ADP	O	O
0.21	NUM	O	O
mm	NOUN	O	O
and	CCONJ	O	O
mean	NOUN	O	O
BI	NOUN	O	B-PHYSICAL
significantly	ADV	O	O
dropped	VERB	O	O
by	ADP	O	O
0.14	NUM	O	O
;	PUNCT	O	O
clinical	ADJ	O	O
parameters	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
unchanged	VERB	O	O
.	PUNCT	O	O

Two	NUM	O	O
weeks	NOUN	O	O
following	VERB	O	O
SRP	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
PPD	NOUN	O	B-PHYSICAL
significantly	ADV	O	O
decreased	VERB	O	O
from	ADP	O	O
baseline	NOUN	O	O
by	ADP	O	O
0.65	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.17	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
BI	NOUN	O	O
significantly	ADV	O	O
dropped	VERB	O	O
by	ADP	O	O
0.17	NUM	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.05	NUM	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
weeks	NOUN	O	O
following	VERB	O	O
SRP	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
PPD	NOUN	O	B-PHYSICAL
decreases	CCONJ	O	O
were	VERB	O	O
0.77	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.13	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
BI	NOUN	O	B-PHYSICAL
reductions	NOUN	O	O
were	VERB	O	O
0.14	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.00	NUM	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
subjects	NOUN	O	O
who	ADP	O	O
completed	PROPN	O	O
the	DET	O	O
three-month	NOUN	O	O
extension	NOUN	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
23	NUM	O	O
weeks	NOUN	O	O
post-SRP	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mean	NOUN	O	O
PPD	NOUN	O	B-PHYSICAL
decreases	CCONJ	O	O
were	VERB	O	O
0.72	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.13	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
BI	NOUN	O	B-PHYSICAL
reductions	NOUN	O	O
were	VERB	O	O
0.05	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.01	NUM	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
deeper	PUNCT	O	O
pockets	NOUN	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
>	SYM	O	O
5	NUM	O	O
mm	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
the	DET	O	O
same	ADJ	O	O
relationship	NOUN	O	O
for	ADP	O	O
PPD	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
larger	PUNCT	O	O
differences	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
two	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
peroxide	NOUN	O	O
gel	NOUN	O	O
use	ADP	O	O
prior	PUNCT	O	O
to	ADP	O	O
SRP	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
PPD	NOUN	O	B-PHYSICAL
decreased	VERB	O	O
by	ADP	O	O
0.48	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
0.04	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
SRP	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
PPD	NOUN	O	B-PHYSICAL
decreased	ADP	O	O
from	ADP	O	O
baseline	NOUN	O	O
by	ADP	O	O
1.40	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.60	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
SRP	NOUN	O	O
by	ADP	O	O
1.57	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
test	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
0.58	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
extension	NOUN	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
23	NUM	O	O
weeks	NOUN	O	O
post-SRP	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mean	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
sclerotherapy	NOUN	O	O
with	ADP	O	O
staple	PUNCT	O	O
transection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
esophagus	NOUN	O	O
for	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
control	NOUN	O	O
of	ADP	O	O
bleeding	VERB	O	B-PHYSICAL
from	ADP	O	O
esophageal	ADJ	O	O
varices	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
two	ADP	O	O
procedures	NOUN	O	O
for	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
bleeding	PUNCT	O	B-PHYSICAL
esophageal	ADJ	O	O
varices	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	DET	O	O
did	ADP	O	O
not	ADV	O	O
respond	VERB	O	O
to	ADP	O	O
blood	NOUN	O	O
transfusion	NOUN	O	O
and	CCONJ	O	O
vasoactive	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
randomly	PUNCT	O	O
assigned	PUNCT	O	O
101	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cirrhosis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
and	CCONJ	O	O
bleeding	PART	O	O
esophageal	ADJ	O	O
varices	NOUN	O	O
to	ADP	O	O
undergo	VERB	O	O
either	PUNCT	O	O
emergency	NOUN	O	O
sclerotherapy	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
50	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
staple	PUNCT	O	O
transection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
esophagus	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
51	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
assigned	VERB	O	O
to	PUNCT	O	O
sclerotherapy	NOUN	O	O
and	CCONJ	O	O
12	NUM	O	O
assigned	VERB	O	O
to	ADP	O	O
staple	PUNCT	O	O
transection	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
actually	ADV	O	O
undergo	VERB	O	O
those	ADP	O	O
procedures	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
all	DET	O	O
analyses	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
on	ADP	O	O
an	DET	O	O
intention-to-treat	NOUN	O	O
basis	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
mortality	NOUN	O	B-MORTALITY
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
death	NOUN	O	B-MORTALITY
for	ADP	O	O
staple	PUNCT	O	O
transection	NOUN	O	O
as	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
sclerotherapy	NOUN	O	O
was	VERB	O	O
0.88	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.51	NUM	O	O
to	ADP	O	O
1.54	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mortality	NOUN	O	B-MORTALITY
at	ADP	O	O
six	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
44	NUM	O	O
percent	NOUN	O	O
among	ADP	O	O
those	DET	O	O
assigned	VERB	O	O
to	PUNCT	O	O
sclerotherapy	NOUN	O	O
and	CCONJ	O	O
35	NUM	O	O
percent	NOUN	O	O
among	ADP	O	O
those	DET	O	O
assigned	VERB	O	O
to	ADP	O	O
staple	PUNCT	O	O
transection	NOUN	O	O
.	PUNCT	O	O

Complication	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
interval	NOUN	O	O
of	ADP	O	O
five	NUM	O	B-PHYSICAL
days	NOUN	O	I-PHYSICAL
without	ADP	O	I-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
was	VERB	O	O
achieved	VERB	O	O
in	ADP	O	O
88	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
those	ADJ	O	O
assigned	VERB	O	O
to	ADP	O	O
staple	PUNCT	O	O
transection	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
62	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
those	ADJ	O	O
assigned	VERB	O	O
to	PUNCT	O	O
sclerotherapy	NOUN	O	O
after	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
82	NUM	O	O
percent	NOUN	O	O
after	ADP	O	O
three	NUM	O	O
injections	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
only	ADV	O	O
2	NUM	O	O
of	ADP	O	O
the	DET	O	O
11	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
a	DET	O	O
third	ADJ	O	O
sclerotherapy	NOUN	O	O
injection	NOUN	O	O
was	PUNCT	O	O
bleeding	PUNCT	O	B-PHYSICAL
controlled	VERB	O	I-PHYSICAL
for	ADP	O	O
more	ADV	O	O
than	ADP	O	O
five	DET	O	O
days	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
9	NUM	O	O
died	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
staple	PUNCT	O	O
transection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
esophagus	NOUN	O	O
is	PUNCT	O	O
as	PUNCT	O	O
safe	ADJ	O	B-OTHER
as	VERB	O	I-OTHER
sclerotherapy	NOUN	O	I-OTHER
for	ADP	O	O
the	DET	O	O
emergency	NOUN	O	B-PHYSICAL
treatment	NOUN	O	O
of	PUNCT	O	B-PHYSICAL

Serotonergic	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
TSH	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
PRL	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
obese	PUNCT	O	O
men	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
evaluate	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
inhibitory	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
TSH	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
stimulatory	ADJ	O	B-PHYSICAL
control	NOUN	O	O
of	ADP	O	B-PHYSICAL
prolactin	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
PRL	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
secretion	NOUN	O	B-PHYSICAL
exerted	VERB	O	O
by	ADP	O	O
endogenous	ADJ	O	O
serotonin	NOUN	O	O
was	VERB	O	O
altered	VERB	O	O
in	ADP	O	O
obesity	NOUN	O	O
,	PUNCT	O	O
22	NUM	O	O
obese	PUNCT	O	O
men	NOUN	O	O
and	CCONJ	O	O
10	NUM	O	O
normal	ADJ	O	O
controls	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
with	ADP	O	O
TRH	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
micrograms	NOUN	O	O
IV	NUM	O	O
bolus	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
(	PUNCT	O	O
experimental	ADJ	O	O
test	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
absence	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
serotonergic	ADJ	O	O
agonist	NOUN	O	O
fenfluramine	NOUN	O	O
(	PUNCT	O	O
60	NUM	O	O
mg	NOUN	O	O
PO	NOUN	O	O
90	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
TRH	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Control	NOUN	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
tests	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
performed	VERB	O	O
in	ADP	O	O
seven	NUM	O	O
male	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
subclinical	ADJ	O	O
hypothyroidism	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
repeated	VERB	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
obese	ADP	O	O
subjects	NOUN	O	O
after	ADP	O	O
substantial	ADJ	O	O
weight	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O

Basal	ADJ	O	B-PHYSICAL
TSH	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
obese	PUNCT	O	O
men	NOUN	O	O
.	PUNCT	O	O

Normal	ADJ	O	B-PHYSICAL
TSH	NOUN	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	B-PHYSICAL
TRH	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
peak	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
14	NUM	O	O
mU/L	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
all	DET	O	O
normal	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
peak	ADJ	O	O
+/-	SYM	O	O
SE	PUNCT	O	O
9.8	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
mU/L	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
obese	PUNCT	O	O
men	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
nine	NUM	O	O
in	ADP	O	O
whom	ADP	O	O
the	DET	O	O
TRH-induced	VERB	O	B-PHYSICAL
TSH	NOUN	O	I-PHYSICAL
rise	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
than	CCONJ	O	O
normal	ADJ	O	O
(	PUNCT	O	O
group	NOUN	O	O
I	NUM	O	O
:	PUNCT	O	O
mean	NOUN	O	O
peak	ADJ	O	O
=	SYM	O	O
16.5	NUM	O	O
+/-	SYM	O	O
0.5	NUM	O	O
mU/L	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
13	NUM	O	O
in	ADP	O	O
whom	ADP	O	O
it	PRON	O	O
was	VERB	O	O
normal	ADJ	O	O
(	PUNCT	O	O
group	NOUN	O	O
II	NUM	O	O
:	PUNCT	O	O
mean	NOUN	O	O
peak	ADJ	O	O
=	SYM	O	O
10.6	NUM	O	O
+/-	SYM	O	O
0.7	NUM	O	O
mU/L	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
hypothyroid	PUNCT	O	O
men	ADP	O	O
all	DET	O	O
had	PUNCT	O	O
elevated	PUNCT	O	O

Low	ADJ	O	O
protein	NOUN	O	O
provision	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
year	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
during	ADP	O	O
foetal	ADJ	O	O
life	NOUN	O	O
,	PUNCT	O	O
affects	NOUN	O	O
metabolic	ADJ	O	B-PHYSICAL
traits	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
organ	NOUN	O	B-PHYSICAL
mass	NOUN	O	I-PHYSICAL
development	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
growth	NOUN	O	B-PHYSICAL
in	ADP	O	O
male	NOUN	O	O
mink	PUNCT	O	O
(	PUNCT	O	O
Neovison	NOUN	O	O
vison	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Low	ADJ	O	O
protein	NOUN	O	O
provision	NOUN	O	O
in	ADP	O	O
utero	NOUN	O	O
and	CCONJ	O	O
post-partum	NOUN	O	O
may	VERB	O	O
induce	VERB	O	O
metabolic	ADJ	O	B-PHYSICAL
disorders	NOUN	O	I-PHYSICAL
in	ADP	O	O
adulthood	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
in	ADP	O	O
mink	PUNCT	O	O
have	PUNCT	O	O
mainly	ADV	O	O
focused	VERB	O	O
on	ADP	O	O
short-term	NOUN	O	O
consequences	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
protein	NOUN	O	O
provision	NOUN	O	O
in	ADP	O	O
utero	NOUN	O	O
whereas	ADP	O	O
the	DET	O	O
long-term	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
low	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
LP	NOUN	O	O
)	PUNCT	O	O
provision	NOUN	O	O
in	ADP	O	O
metabolically	ADV	O	O
programmed	ADJ	O	O
mink	ADV	O	O
are	VERB	O	O
unknown	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
low	ADJ	O	O
protein	NOUN	O	O
provision	NOUN	O	O
in	ADP	O	O
utero	NOUN	O	O
affects	NOUN	O	O
the	DET	O	O
long-term	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
adequate	ADJ	O	O
(	PUNCT	O	O
AP	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
LP	NOUN	O	O
provision	NOUN	O	O
after	ADP	O	O
weaning	NUM	O	O
in	ADP	O	O
male	NOUN	O	O
mink	PUNCT	O	O
.	PUNCT	O	O

Eighty-six	NUM	O	O
male	NOUN	O	O
mink	PUNCT	O	O
were	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
low	ADJ	O	O
(	PUNCT	O	O
19	NUM	O	O
%	SYM	O	O
of	ADP	O	O
ME	NOUN	O	O
from	ADP	O	O
CP	NOUN	O	O
;	PUNCT	O	O
crude	ADJ	O	O
protein	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
adequate	ADJ	O	O
(	PUNCT	O	O
31	NUM	O	O
%	SYM	O	O
of	ADP	O	O
ME	NOUN	O	O
from	ADP	O	O
CP	NOUN	O	O
)	PUNCT	O	O
protein	NOUN	O	O
provision	NOUN	O	O
in	ADP	O	O
utero	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	ADP	O	O
LP	NOUN	O	O
(	PUNCT	O	O
~20	NOUN	O	O
%	NOUN	O	O
of	ADP	O	O
ME	NOUN	O	O
from	ADP	O	O
CP	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
AP	NOUN	O	O
(	PUNCT	O	O
30-42	NUM	O	O
%	SYM	O	O
of	ADP	O	O
ME	NOUN	O	O
from	ADP	O	O
CP	NOUN	O	O
)	PUNCT	O	O
provision	NOUN	O	O
post-weaning	VERB	O	O
.	PUNCT	O	O

Being	ADV	O	O
metabolically	ADV	O	O
programmed	PUNCT	O	O
by	ADP	O	O
low	ADJ	O	O
protein	NOUN	O	O
provision	NOUN	O	O
in	ADP	O	O
utero	NOUN	O	O
did	DET	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
post-weaning	DET	O	B-PHYSICAL
diets	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Dietary	ADJ	O	B-PHYSICAL
protein	NOUN	O	I-PHYSICAL
content	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
LP	NOUN	O	O
feed	NUM	O	O
after	ADP	O	O
weaning	VERB	O	O
was	VERB	O	O
below	ADP	O	O
requirements	NOUN	O	O
;	PUNCT	O	O
evidenced	VERB	O	O
by	ADP	O	O
lower	PUNCT	O	O
nitrogen	NOUN	O	O
retention	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
preventing	VERB	O	O
LP	NOUN	O	O
mink	PUNCT	O	O
from	ADP	O	O
attaining	VERB	O	O
their	ADJ	O	O
growth	NOUN	O	O
potential	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

LP	NOUN	O	O
mink	VERB	O	O
had	PUNCT	O	O
a	DET	O	O
lower	PUNCT	O	O
liver	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
pancreas	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
kidney	NOUN	O	B-PHYSICAL
weight	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
lower	PUNCT	O	O
plasma	NOUN	O	B-PHYSICAL
IGF-1	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
at	ADP	O	O
8	NUM	O	O
and	CCONJ	O	O
25	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
higher	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-PHYSICAL
lipidosis	NOUN	O	I-PHYSICAL
at	ADP	O	O
25	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
LP	NOUN	O	O
mink	VERB	O	O
had	PUNCT	O	O
a	DET	O	O
higher	PUNCT	O	B-PHYSICAL
body	NOUN	O	I-PHYSICAL
fat	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
lower	PUNCT	O	O
body	NOUN	O	B-PHYSICAL
CP	NOUN	O	I-PHYSICAL
content	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
50	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
some	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
low	ADJ	O	B-PHYSICAL
protein	NOUN	O	I-PHYSICAL
provision	NOUN	O	I-PHYSICAL
in	ADP	O	O
utero	NOUN	O	O
can	ADV	O	O
be	VERB	O	O
alleviated	VERB	O	O
by	ADP	O	O
an	DET	O	O
adequate	ADJ	O	O
nutrient	NOUN	O	B-PHYSICAL
supply	NOUN	O	I-PHYSICAL
post-partum	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
long-term	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
low	ADJ	O	O
protein	NOUN	O	O
provision	NOUN	O	O
in	ADP	O	O
mink	PUNCT	O	O
reduces	NOUN	O	O
their	ADP	O	O
growth	NOUN	O	B-PHYSICAL
potential	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
induces	NOUN	O	B-PHYSICAL
transient	ADJ	O	I-PHYSICAL
hepatic	ADJ	O	I-PHYSICAL
lipidosis	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
modified	VERB	O	B-PHYSICAL
body	NOUN	O	I-PHYSICAL
composition	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Pulse	ADJ	O	O
oximeter	NOUN	O	O
perfusion	NOUN	O	O
index	NOUN	O	O
as	ADP	O	O
an	DET	O	O
early	ADJ	O	O
indicator	NOUN	O	O
of	ADP	O	O
sympathectomy	NOUN	O	O
after	ADP	O	O
epidural	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
pulse	NOUN	O	O
oximeter	NOUN	O	O
perfusion	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
PI	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
used	VERB	O	O
to	PART	O	O
indicate	NOUN	O	O
sympathectomy-induced	VERB	O	O
vasodilatation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
pulse	NOUN	O	O
oximeter	NOUN	O	O
PI	NOUN	O	O
provides	NOUN	O	O
an	DET	O	O
earlier	PUNCT	O	O
and	CCONJ	O	O
clearer	NOUN	O	O
indication	NOUN	O	O
of	ADP	O	O
sympathectomy	NOUN	O	O
following	VERB	O	O
epidural	ADJ	O	O
anesthesia	NOUN	O	O
than	ADP	O	O
skin	NOUN	O	O
temperature	NOUN	O	O
and	CCONJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty	PUNCT	O	O
patients	NOUN	O	O
received	ADP	O	O
lumbar	ADJ	O	O
epidural	ADJ	O	O
catheters	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
10	NUM	O	O
ml	NOUN	O	O
0.5	NUM	O	O
%	SYM	O	O
bupivacaine	NOUN	O	O
or	CCONJ	O	O
10	NUM	O	O
ml	NOUN	O	O
0.25	NUM	O	O
%	SYM	O	O
bupivacaine	NOUN	O	O
.	PUNCT	O	O

PI	NOUN	O	O
in	ADP	O	O
the	DET	O	O
toe	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
mean	NOUN	O	O
arterial	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
MAP	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	O
toe	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
were	VERB	O	O
all	PUNCT	O	O
assessed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
min	NOUN	O	O
following	VERB	O	O
epidural	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
epidural	ADJ	O	O
anesthesia	NOUN	O	O
over	PUNCT	O	O
time	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
repeated	VERB	O	O
measures	NOUN	O	B-OTHER
analysis	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
variance	NOUN	O	I-OTHER
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
we	NOUN	O	O
defined	VERB	O	O
clinically	ADV	O	B-PHYSICAL
evident	ADJ	O	I-PHYSICAL
sympathectomy	NOUN	O	I-PHYSICAL
criteria	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
100	NUM	O	I-PHYSICAL
%	SYM	O	I-PHYSICAL
increase	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
PI	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
15	NUM	O	I-PHYSICAL
%	SYM	O	I-PHYSICAL
decrease	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
MAP	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
degrees	NOUN	O	I-PHYSICAL
C	NUM	O	I-PHYSICAL
increase	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
toe	NOUN	O	I-PHYSICAL
temperature	NOUN	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
numbers	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
demonstrating	VERB	O	O
these	DET	O	O
changes	NOUN	O	B-PHYSICAL
for	ADP	O	O
each	DET	O	O
test	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
using	VERB	O	O
the	DET	O	O
McNemar	NOUN	O	B-OTHER
test	NOUN	O	B-OTHER
for	ADP	O	O
each	DET	O	O
time	NOUN	O	O
point	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty-nine	NUM	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
photoplethysmography	NOUN	O	B-PHYSICAL
signals	NOUN	O	I-PHYSICAL
that	PUNCT	O	O
met	VERB	O	O
a	DET	O	O
priori	ADJ	O	O
signal	NOUN	O	O
quality	NOUN	O	O
criteria	NOUN	O	O
for	ADP	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
20	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
PI	NOUN	O	B-PHYSICAL
increased	VERB	O	O
by	ADP	O	O
326	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
10	NUM	O	O
%	SYM	O	O
decrease	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
3	NUM	O	O
%	SYM	O	O
increase	NOUN	O	O
in	ADP	O	O
MAP	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
toe	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

For	ADP	O	O
PI	NOUN	O	O
15/29	PUNCT	O	O
,	PUNCT	O	O
26/29	PUNCT	O	O
and	CCONJ	O	O
29/29	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
met	VERB	O	O
the	DET	O	O
sympathectomy	NOUN	O	B-PHYSICAL
criteria	NOUN	O	I-PHYSICAL
at	ADP	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
4/29	NOUN	O	O
,	PUNCT	O	O
6/29	CCONJ	O	O
and	CCONJ	O	O
18/29	PUNCT	O	O
for	ADP	O	O
MAP	NOUN	O	B-PHYSICAL
changes	NOUN	O	O
and	CCONJ	O	O
3/29	PUNCT	O	O
,	PUNCT	O	O
8/29	NUM	O	O
and	CCONJ	O	O
14/29	PUNCT	O	O
for	ADP	O	O
toe	PUNCT	O	O

Ascorbic	ADJ	O	O
acid	NOUN	O	O
and	CCONJ	O	O
performance	NOUN	O	B-PHYSICAL
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
on	ADP	O	O
performance	NOUN	O	B-PHYSICAL
of	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
g	NOUN	O	O
ascorbic	ADJ	O	O
acid	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
from	ADP	O	O
0.5-5.5	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
ingestion	NOUN	O	O
in	ADP	O	O
six	NUM	O	O
healthy	ADJ	O	O
females	NOUN	O	O
.	PUNCT	O	O

Diazepam	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
included	VERB	O	O
as	ADP	O	O
an	DET	O	O
active	ADJ	O	O
control	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	NOUN	O	O
impaired	ADV	O	O
digit	NOUN	O	B-PHYSICAL
symbol	NOUN	O	I-PHYSICAL
substitution	NOUN	O	O
,	PUNCT	O	B-PHYSICAL
visuomotor	NOUN	O	I-PHYSICAL
coordination	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
complex	PUNCT	O	I-PHYSICAL
reaction	NOUN	O	I-PHYSICAL
time	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
any	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
ascorbic	ADJ	O	O
acid	NOUN	O	O
on	PUNCT	O	O

Neurophysiological	ADJ	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
botulinum	NOUN	O	O
neurotoxin	NOUN	O	O
type	NOUN	O	O
a	DET	O	O
free	ADJ	O	O
of	ADP	O	O
complexing	PUNCT	O	O
proteins	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Safety	NOUN	O	B-OTHER
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
botulinum	NOUN	O	O
neurotoxin	NOUN	O	O
type	NOUN	O	O
A	PUNCT	O	O
preparation	NOUN	O	O
NT	NOUN	O	O
201	NUM	O	O
(	PUNCT	O	O
Xeomin	NOUN	O	O
,	PUNCT	O	O
Merz	NOUN	O	O
Pharmaceuticals	NOUN	O	O
GmbH	NOUN	O	O
,	PUNCT	O	O
Frankfurt	PUNCT	O	O
am	PUNCT	O	O
Main	PUNCT	O	O
,	PUNCT	O	O
Germany	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
over	ADP	O	O
52	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
32	NUM	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Electroneurographic	ADJ	O	B-OTHER
assessments	NOUN	O	B-PHYSICAL
with	ADP	O	O
surface	NOUN	O	O
electrodes	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
after	ADP	O	O
single	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
NT	NOUN	O	O
201	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
16	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
32	NUM	O	O
units	NOUN	O	O
)	PUNCT	O	O
into	ADP	O	O
the	DET	O	O
extensor	NOUN	O	O
digitorum	NOUN	O	O
brevis	ADP	O	O
(	PUNCT	O	O
EDB	NOUN	O	O
)	PUNCT	O	O
muscle	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
same	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
Botox	NOUN	O	O
;	PUNCT	O	O
Allergan	PUNCT	O	O
Pharmaceuticals	NOUN	O	O
(	PUNCT	O	O
Ireland	PUNCT	O	O
)	PUNCT	O	O
Ltd.	NOUN	O	O
Westport	NOUN	O	O
,	PUNCT	O	O
Ireland	PUNCT	O	O
)	PUNCT	O	O
into	ADP	O	O
the	DET	O	O
contralateral	ADJ	O	O
EDB	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
All	PUNCT	O	O
NT	NOUN	O	O
201	NUM	O	O
and	CCONJ	O	O
BTXCo	PUNCT	O	O
doses	NOUN	O	O
achieved	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
reduction	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
compound	ADJ	O	I-PHYSICAL
muscle	NOUN	O	I-PHYSICAL
action	NOUN	O	I-PHYSICAL
potential	ADJ	O	I-PHYSICAL
M-wave	NOUN	O	I-PHYSICAL
amplitude	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
EDB	NOUN	O	O
muscle	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
week	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
highest	PUNCT	O	O
dose	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
significantly	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
than	CCONJ	O	O
the	DET	O	O
lowest	PUNCT	O	O
dose	NOUN	O	O
(	PUNCT	O	O
NT	NOUN	O	O
201	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.019	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.195-1.370	ADV	O	O
;	PUNCT	O	O
and	CCONJ	O	O
BTXCo	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.309-1.167	CCONJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Duration	NOUN	O	B-OTHER
of	ADP	O	O
effect	NOUN	O	O
was	DET	O	O
dose	NOUN	O	O
dependent	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
values	NOUN	O	O
of	ADP	O	O
compound	ADJ	O	B-PHYSICAL
muscle	NOUN	O	I-PHYSICAL
action	NOUN	O	I-PHYSICAL
potential	ADJ	O	I-PHYSICAL
M-wave	NOUN	O	I-PHYSICAL
amplitudes	VERB	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
adjacent	ADJ	O	I-PHYSICAL
muscles	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
abductor	NOUN	O	O
digiti	PUNCT	O	O
quinti	PUNCT	O	O
and	CCONJ	O	O
abductor	NOUN	O	O
hallucis	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
above	ADP	O	O
the	DET	O	O
predefined	VERB	O	O
threshold	NOUN	O	O
of	ADP	O	O
effect	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
relevant	ADJ	O	O
diffusion-induced	VERB	O	O
reduction	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

NT	NOUN	O	O
201	NUM	O	O
and	CCONJ	O	O
BTXCo	NOUN	O	O
were	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	B-OTHER
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
NT	NOUN	O	O
201	NUM	O	O
is	VERB	O	O
effective	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
in	ADP	O	O
inducing	VERB	O	O
the	DET	O	O
desired	VERB	O	O
paretic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Residual	ADJ	O	O
platelet	NOUN	O	O
reactivity	NOUN	O	O
,	PUNCT	O	O
bleedings	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
adherence	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
having	ADJ	O	O
coronary	ADJ	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
prasugrel	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
guidelines	NOUN	O	O
have	PUNCT	O	O
recommended	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	O
and	CCONJ	O	O
prasugrel	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
coronary	ADJ	O	O
syndromes	NOUN	O	O
undergoing	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
prasugrel	NOUN	O	O
use	NOUN	O	O
has	VERB	O	O
been	PUNCT	O	O
evaluated	VERB	O	O
only	ADV	O	O
in	ADP	O	O
randomized	VERB	O	O
trials	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
sought	ADP	O	O
to	PART	O	O
evaluate	NOUN	O	O
bleeding	DET	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
adherence	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
real-world	NOUN	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
prasugrel	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
total	ADJ	O	O
298	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
68	NUM	O	O
?	PUNCT	O	O

10	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
(	PUNCT	O	O
31	NUM	O	O
%	SYM	O	O
>	SYM	O	O
75	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
)	PUNCT	O	O
underwent	VERB	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
and	CCONJ	O	O
received	ADJ	O	O
prasugrel	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Indications	ADJ	O	O
to	ADP	O	O
prasugrel	NOUN	O	O
therapy	NOUN	O	O
were	VERB	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
ST-elevation	NOUN	O	O
acute	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
(	PUNCT	O	O
41	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
drug-eluting	ADJ	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
in	ADP	O	O
diabetics	NOUN	O	O
(	PUNCT	O	O
24	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
stent	NOUN	O	O
thrombosis	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
left	ADJ	O	O
main	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
drug-eluting	ADP	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
residual	ADJ	O	O
platelet	NOUN	O	O
reactivity	NOUN	O	O
on	ADP	O	O
clopidogrel	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
26	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
loading	VERB	O	O
of	ADP	O	O
prasugrel	NOUN	O	O
60	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Patients	ADP	O	O
?75	PUNCT	O	O
years	NOUN	O	O
old	ADJ	O	O
and	CCONJ	O	O
with	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
?60	NOUN	O	O
kg	NOUN	O	O
received	VERB	O	O
a	DET	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
all	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Follow-up	NOUN	O	O
data	NOUN	O	O
including	VERB	O	O
adherence	NOUN	O	O
to	ADP	O	O
prasugrel	NOUN	O	O
therapy	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
by	ADP	O	O
telephone	NOUN	O	O
interviews	NOUN	O	O
or	CCONJ	O	O
outpatient	ADJ	O	O
visits	NOUN	O	O
.	PUNCT	O	O

Minimal	ADJ	O	O
follow-up	NOUN	O	O
length	NOUN	O	O
was	VERB	O	O
6	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
9	NUM	O	O
?	PUNCT	O	O

3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Major	ADJ	O	O
,	PUNCT	O	O
minor	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
minimal	ADJ	O	O
bleedings	NOUN	O	O
(	PUNCT	O	O
Thrombolysis	NOUN	O	O
In	ADP	O	O
Myocardial	ADJ	O	O
Infarction	NOUN	O	O
criteria	NOUN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
2.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
4.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15.1	NUM	O	O
%	DET	O	O
of	ADP	O	O
enrolled	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
residual	ADJ	O	O
platelet	NOUN	O	O
reactivity	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
female	NOUN	O	O
gender	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.29	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
bleeding	VERB	O	O
events	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
frequent	ADJ	O	O
minimal	ADJ	O	O
bleeding	VERB	O	O
event	NOUN	O	O
was	VERB	O	O
epistaxis	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
8	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
2.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
permanently	ADV	O	O
discontinued	PUNCT	O	O
prasugrel	NOUN	O	O
therapy	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
bleeding	VERB	O	O
events	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
possible	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
medical	ADJ	O	O
decisions	NOUN	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
bleeding	PUNCT	O	O
or	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
4.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
temporarily	PUNCT	O	O
discontinued	ADP	O	O
prasugrel	NOUN	O	O
(	PUNCT	O	O
average	NOUN	O	O
6.5	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
mainly	ADV	O	O
because	PUNCT	O	O
of	ADP	O	O
surgical	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
definite	ADJ	O	O
or	CCONJ	O	O
probable	PUNCT	O	O
stent	NOUN	O	O
thrombosis	NOUN	O	O
occurred	VERB	O	O
,	PUNCT	O	O
although	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
develop	VERB	O	O
de	PUNCT	O	O
novo	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
an	DET	O	O
ischemic	ADJ	O	O
stroke	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
11	PUNCT	O	O
deaths	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
or	CCONJ	O	O
refractory	ADJ	O	O
cardiogenic	ADJ	O	O
shock	NOUN	O	O
in	ADP	O	O
9	NUM	O	O
,	PUNCT	O	O
pulmonary	ADJ	O	O
embolism	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cancer	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
,	PUNCT	O	O
major	ADJ	O	O
and	CCONJ	O	O
minor	ADJ	O	O
bleeding	VERB	O	O
event	NOUN	O	O
rates	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
prasugrel	NOUN	O	O
therapy	NOUN	O	O
are	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
those	DET	O	O
reported	VERB	O	O
in	ADP	O	O
controlled	VERB	O	O
randomized	VERB	O	O
trials	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
minimal	ADJ	O	O
bleeding	VERB	O	O
event	NOUN	O	O
rate	NOUN	O	O
is	VERB	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
reported	DET	O	O
but	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
seem	VERB	O	O
to	PART	O	O
affect	NOUN	O	O
adherence	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
mood	PUNCT	O	O
profiles	NOUN	O	O
during	ADP	O	O
malaria	NOUN	O	O
chemoprophylaxis	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
four-arm	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
To	ADP	O	O
objectively	DET	O	O
compare	ADP	O	O
the	DET	O	O
mood	PUNCT	O	O
profiles	NOUN	O	O
of	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
malaria	NOUN	O	O
chemoprophylaxis	NOUN	O	O
regimens	NOUN	O	O
(	PUNCT	O	O
atovaquone-proguanil	PUNCT	O	O
,	PUNCT	O	O
chloroquine-proguanil	VERB	O	O
,	PUNCT	O	O
doxycycline	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
mefloquine	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
nonimmune	ADP	O	O
tourists	DET	O	O
to	ADP	O	O
sub-Saharan	NOUN	O	O
Africa	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
four-arm	NOUN	O	O
study	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
run-in	NOUN	O	O
phase	NOUN	O	O
conducted	VERB	O	O
at	ADP	O	O
travel	NOUN	O	O
clinics	ADP	O	O
in	ADP	O	O
Switzerland	ADV	O	O
,	PUNCT	O	O
Germany	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Israel	PUNCT	O	O
,	PUNCT	O	O
we	NOUN	O	O
compared	PUNCT	O	O
moods	NOUN	O	O
and	CCONJ	O	O
feelings	NOUN	O	O
in	ADP	O	O
chemoprophylaxis	NOUN	O	O
users	NOUN	O	O
(	PUNCT	O	O
n=	NUM	O	O
547	NUM	O	O
)	PUNCT	O	O
by	ADP	O	O
administering	NOUN	O	O
the	DET	O	O
standardized	VERB	O	O
Profile	NOUN	O	O
of	ADP	O	O
Mood	PUNCT	O	O
States	NOUN	O	O
(	PUNCT	O	O
POMS	NOUN	O	O
)	PUNCT	O	O
questionnaire	NOUN	O	O
.	PUNCT	O	O

This	PUNCT	O	O
is	VERB	O	O
designed	VERB	O	O
to	PART	O	O
provide	NOUN	O	O
data	NOUN	O	O
on	ADP	O	O
six	NUM	O	O
categories	NOUN	O	O
of	ADP	O	O
feelings	NOUN	O	O
:	PUNCT	O	O
tension	NOUN	O	O
,	PUNCT	O	O
depression	NOUN	O	O
,	PUNCT	O	O
anger	NOUN	O	O
,	PUNCT	O	O
vigor	NOUN	O	O
,	PUNCT	O	O
fatigue	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
confusion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
questionnaire	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
four	NUM	O	O
time	NOUN	O	O
points	NOUN	O	O
:	PUNCT	O	O
recruitment	NOUN	O	O
(	PUNCT	O	O
T1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
13	NUM	O	O
to	ADP	O	O
11	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
departure	NOUN	O	O
(	PUNCT	O	O
T2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
6	NUM	O	O
to	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
departure	NOUN	O	O
(	PUNCT	O	O
T3	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
7	NUM	O	O
to	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
return	NOUN	O	O
from	ADP	O	O
Africa	ADV	O	O
(	PUNCT	O	O
T4	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
overall	PUNCT	O	O
mood	PUNCT	O	B-MENTAL
impact	NOUN	O	O
between	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
arms	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
scores	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
range	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
means	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
than	PUNCT	O	O
1	NUM	O	O
SD	NOUN	O	O
from	ADP	O	O
the	DET	O	O
norm	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
POMS	NOUN	O	O
data	NOUN	O	O
were	VERB	O	O
reanalyzed	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
sex	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
medication	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
control	NUM	O	O
time	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
T1-T4	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
interaction	NOUN	O	O
effects	NOUN	O	O
between	ADP	O	O
sex	NOUN	O	O
and	CCONJ	O	O
medication	NOUN	O	O
group	NOUN	O	O
--	PUNCT	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mefloquine	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
more	DET	O	O
fatigue	NOUN	O	B-MENTAL
(	PUNCT	O	O
p=	NOUN	O	O
.011	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
confusion	NOUN	O	B-MENTAL
(	PUNCT	O	O
p=	NOUN	O	O
.011	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
men	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
below	ADP	O	O
median	ADJ	O	O
age	NOUN	O	O
34	NUM	O	O
y	NOUN	O	O
vs	CCONJ	O	O
median	ADJ	O	O
age	NOUN	O	O
and	CCONJ	O	O
above	ADP	O	O
)	PUNCT	O	O
were	VERB	O	O
noted	VERB	O	O
on	ADP	O	O
the	DET	O	O
tension	NOUN	O	B-MENTAL
and	CCONJ	O	O
fatigue	NOUN	O	B-MENTAL
scales	NOUN	O	O
in	ADP	O	O
that	CCONJ	O	O
less	DET	O	O
tension	NOUN	O	B-MENTAL
(	PUNCT	O	O
p=	NOUN	O	O
.045	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
less	DET	O	O
fatigue	NOUN	O	B-MENTAL
(	PUNCT	O	O
p=	NOUN	O	O
.000	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
those	PUNCT	O	O
aged	PUNCT	O	O
34	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
.	PUNCT	O	O

Younger	PUNCT	O	O
participants	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
<	ADP	O	O
34	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
reported	VERB	O	O
more	DET	O	O
confusion	NOUN	O	B-MENTAL
(	PUNCT	O	O
p=	NOUN	O	O
.013	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
T2	NOUN	O	O
than	PUNCT	O	O
at	ADP	O	O
T1	NOUN	O	O
and	CCONJ	O	O
T4	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Although	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
mood	PUNCT	O	O
profiles	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
the	DET	O	O
users	NOUN	O	O
of	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
malaria	NOUN	O	O
chemoprophylaxis	NOUN	O	O
regimens	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
that	ADP	O	O
women	NOUN	O	O
using	VERB	O	O
mefloquine	NOUN	O	O
showed	VERB	O	O
more	DET	O	O
fatigue	NOUN	O	O
and	CCONJ	O	O
confusion	NOUN	O	O
than	ADP	O	O
men	NOUN	O	O
and	CCONJ	O	O
that	PUNCT	O	O
younger	PUNCT	O	O
persons	NOUN	O	O
aged	ADV	O	O
less	ADV	O	O
than	ADP	O	O
34	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
regardless	CCONJ	O	O
of	ADP	O	O
chemoprophylaxis	NOUN	O	O
used	VERB	O	O
,	PUNCT	O	O
reported	VERB	O	O
more	DET	O	O
tension	NOUN	O	O
and	CCONJ	O	O
fatigue	NOUN	O	O
than	ADP	O	O
their	PUNCT	O	O
older	PUNCT	O	O
counterparts	NOUN	O	O
.	PUNCT	O	O

Gabapentin	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
after	ADP	O	O
vaginal	ADJ	O	O
hysterectomy	NOUN	O	O
.	PUNCT	O	O

Gabapentin	NOUN	O	O
alleviates	NOUN	O	O
and/or	CCONJ	O	O
prevents	NOUN	O	O
acute	ADJ	O	B-PAIN
nociceptive	ADJ	O	I-PAIN
and	CCONJ	O	I-PAIN
inflammatory	ADJ	O	I-PAIN
pain	NOUN	O	I-PAIN
both	PUNCT	O	O
in	ADP	O	O
animals	NOUN	O	O
and	CCONJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
when	ADP	O	O
given	VERB	O	O
before	ADP	O	O
trauma	NOUN	O	O
.	PUNCT	O	O

Gabapentin	NOUN	O	O
might	VERB	O	O
also	ADV	O	O
reduce	VERB	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
.	PUNCT	O	O

To	PART	O	O
test	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
gabapentin	NOUN	O	O
reduces	NOUN	O	O
the	DET	O	O
postoperative	ADJ	O	B-PHYSICAL
need	NOUN	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
additional	ADJ	O	I-PHYSICAL
pain	NOUN	O	I-PHYSICAL
treatment	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
postoperative	ADJ	O	O
opioid	NOUN	O	O
sparing	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
gabapentin	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
gave	PROPN	O	O
1200	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
gabapentin	NOUN	O	O
or	CCONJ	O	O
15	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
oxazepam	NOUN	O	O
(	PUNCT	O	O
active	ADJ	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
2.5	NUM	O	O
h	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
to	ADP	O	O
patients	NOUN	O	O
undergoing	SYM	O	O
elective	ADJ	O	O
vaginal	ADJ	O	O
hysterectomy	NOUN	O	O
in	ADP	O	O
an	DET	O	O
active	ADJ	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
blind	ADJ	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

Gabapentin	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
additional	ADJ	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
treatment	NOUN	O	I-PAIN
(	PUNCT	O	O
PCA	NOUN	O	O
boluses	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
microg	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
40	NUM	O	O
%	SYM	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
20	NUM	O	O
postoperative	ADJ	O	O
hours	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2	NUM	O	O
postoperative	ADJ	O	O
hours	NOUN	O	O
pain	NOUN	O	O
scores	NOUN	O	O
at	ADP	O	O
rest	NOUN	O	O
and	CCONJ	O	O
worst	PUNCT	O	B-PAIN
pain	NOUN	O	I-PAIN
score	NOUN	O	I-PAIN
(	PUNCT	O	O
VAS	NOUN	O	O
0-100	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
active	ADJ	O	O
placebo	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
gabapentin-treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
gabapentin	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
degree	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
postoperative	ADJ	O	I-PHYSICAL
nausea	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	B-ADVERSE-EFFECTS
vomiting/retching	PUNCT	O	I-ADVERSE-EFFECTS
possibly	ADV	O	O
either	PUNCT	O	O
due	ADP	O	O
to	ADP	O	O
the	DET	O	O
diminished	VERB	O	O
need	NOUN	O	O
for	ADP	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
treatment	NOUN	O	O
with	ADP	O	O
opioids	NOUN	O	O
or	CCONJ	O	O
because	PUNCT	O	O
of	ADP	O	O
an	DET	O	O
anti-emetic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
gabapentin	NOUN	O	O
itself	ADV	O	O
.	PUNCT	O	O

No	DET	O	O
preoperative	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
encountered	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
premedication	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
15	NUM	O	O
mg	NOUN	O	O
oxazepam	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
effective	ADP	O	O
in	ADP	O	O
relieving	NUM	O	O
preoperative	ADJ	O	B-PHYSICAL
anxiety	NOUN	O	I-PHYSICAL
than	PUNCT	O	O
1200	NUM	O	O
mg	NOUN	O	O
gabapentin	NOUN	O	O
.	PUNCT	O	O

Influenza	NOUN	O	O
and	CCONJ	O	O
pneumococcal	ADJ	O	O
vaccination	NOUN	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
C-reactive	ADJ	O	O
protein	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
mild	ADJ	O	O
inflammation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	ADP	O	O
set	ADP	O	O
up	ADJ	O	O
to	ADP	O	O
examine	NOUN	O	O
whether	ADP	O	O
an	DET	O	O
influenza	NOUN	O	O
vaccine	NOUN	O	O
or	CCONJ	O	O
an	DET	O	O
influenza	NOUN	O	O
vaccine	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
pneumococcal	ADJ	O	O
vaccine	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
to	ADJ	O	O
study	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
mild	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
inflammatory	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
19	NUM	O	O
subjects	NOUN	O	O
received	VERB	O	O
the	DET	O	O
influenza	NOUN	O	O
vaccine	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
subjects	NOUN	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
influenza	NOUN	O	O
and	CCONJ	O	O
pneumococcal	ADJ	O	O
vaccine	NOUN	O	O
.	PUNCT	O	O

CRP	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
prothrombin	NOUN	O	B-PHYSICAL
fragment	NOUN	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
2	NUM	O	I-PHYSICAL
(	PUNCT	O	O
F1+2	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
times	NOUN	O	O
after	ADP	O	O
vaccination	NOUN	O	O
.	PUNCT	O	O

Influenza	NOUN	O	O
vaccination	NOUN	O	O
increased	VERB	O	O
CRP	NOUN	O	B-PHYSICAL
by	ADP	O	O
0.20	NUM	O	O
mg/L	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
influenza	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
pneumococcal	ADJ	O	O
vaccine	NOUN	O	O
increased	PUNCT	O	O
CRP	NOUN	O	B-PHYSICAL
by	ADP	O	O
0.60	NUM	O	O
mg/L	NOUN	O	O
.	PUNCT	O	O

F1+2	NOUN	O	B-PHYSICAL
increased	VERB	O	O
0.15	NUM	O	O
nmol/L	ADP	O	O
after	ADP	O	O
the	DET	O	O
combined	VERB	O	O
vaccination	NOUN	O	O
;	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
influenza	NOUN	O	B-PHYSICAL
vaccination	NOUN	O	I-PHYSICAL
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Our	DET	O	O
findings	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
influenza	NOUN	O	O
vaccine	NOUN	O	O
alone	ADJ	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
influenza	NOUN	O	O
and	CCONJ	O	O
pneumococcal	ADJ	O	O
vaccine	NOUN	O	O
increases	PUNCT	O	O
CRP-levels	CCONJ	O	B-PHYSICAL
with	ADP	O	O
a	DET	O	O
peak	ADJ	O	O
2	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
vaccination	NOUN	O	O
.	PUNCT	O	O

Superior	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
extended-release	NOUN	O	O
dipyridamole	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
arterial	ADJ	O	O
thrombogenesis	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Recent	ADJ	O	O
ex	ADP	O	O
vivo	ADP	O	O
platelet	NOUN	O	O
aggregometry	NOUN	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
clopidogrel	NOUN	O	O
75	NUM	O	O
mg/day	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
ASA	NOUN	O	O
)	PUNCT	O	O
75	NUM	O	O
mg/day	NOUN	O	O
is	VERB	O	O
a	DET	O	O
more	ADV	O	O
potent	ADJ	O	O
antiplatelet	NOUN	O	O
regimen	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
marketed	VERB	O	O
combination	NOUN	O	O
of	ADP	O	O
dipyridamole+ASA	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
antithrombotic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
dual	ADJ	O	O
antiplatelet	NOUN	O	O
regimens	NOUN	O	O
using	VERB	O	O
a	DET	O	O
human	NOUN	O	O
ex	ADP	O	O
vivo	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	O
thrombosis	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
two	NUM	O	O
10-day	NOUN	O	O
treatment	NOUN	O	O
periods	NOUN	O	O
separated	VERB	O	O
by	ADP	O	O
a	DET	O	O
14-day	NOUN	O	O
washout	PUNCT	O	O
period	NOUN	O	O
,	PUNCT	O	O
23	NUM	O	O
healthy	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
received	VERB	O	O
once-daily	NOUN	O	O
clopidogrel	NOUN	O	O
75	NUM	O	O
mg	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
75	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
twice-daily	PUNCT	O	O
extended-release	NOUN	O	O
dipyridamole	NOUN	O	O
200	PUNCT	O	O
mg	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
25	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Assessments	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
Day	NOUN	O	O
10	NUM	O	O
of	ADP	O	O
each	DET	O	O
period	NOUN	O	O
.	PUNCT	O	O

Arterial	ADJ	O	O
thrombus	NOUN	O	O
formation	NOUN	O	O
was	VERB	O	O
induced	PUNCT	O	O
ex	CCONJ	O	O
vivo	ADJ	O	O
by	ADP	O	O
exposing	VERB	O	O
a	DET	O	O
collagen-coated	VERB	O	O
surface	NOUN	O	O
in	ADP	O	O
a	DET	O	O
parallel-plate	CCONJ	O	O
perfusion	NOUN	O	O
chamber	NOUN	O	O
to	ADP	O	O
native	ADJ	O	O
blood	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
arterial	ADJ	O	O
wall	NOUN	O	O
shear	NOUN	O	O
rate	NOUN	O	O
2600	NUM	O	O
s	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Total	ADJ	O	O
platelet	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
fibrin	NOUN	O	B-PHYSICAL
deposition	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
immunoenzymatic	ADJ	O	O
methods	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Compared	VERB	O	O
with	ADP	O	O
baseline	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
platelet	NOUN	O	B-PHYSICAL
deposition	NOUN	O	I-PHYSICAL
was	VERB	O	O
63.9+/-5.9	NOUN	O	O
%	ADP	O	O
with	ADP	O	O
clopidogrel	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
18.4+/-5.6	NOUN	O	O
%	SYM	O	O
for	ADP	O	O
extended-release	NOUN	O	O
dipyridamole	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
67	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
49-79	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Corresponding	VERB	O	O
figures	NOUN	O	O
for	ADP	O	O
fibrin	NOUN	O	B-PHYSICAL
deposition	NOUN	O	I-PHYSICAL
were	VERB	O	O
64.9+/-4.8	NOUN	O	O
%	SYM	O	O
and	CCONJ	O	O
18.3+/-9.7	NOUN	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
58	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
45-67	NUM	O	O
%	ADV	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
treatments	NOUN	O	O
were	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	B-OTHER
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Clopidogrel	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
showed	VERB	O	O
significantly	ADV	O	O
superior	ADJ	O	O
antithrombotic	ADJ	O	O
efficacy	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
extended-release	NOUN	O	O
dipyridamole	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
arterial	ADJ	O	O
thrombogenesis	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

West	ADV	O	O
Midlands	PROPN	O	O
Oncology	NOUN	O	O
Association	NOUN	O	O
trials	NOUN	O	O
of	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
operable	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
results	DET	O	O
after	ADP	O	O
a	DET	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

I	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
involved	PUNCT	O	O
axillary	ADJ	O	O
lymph	NOUN	O	O
nodes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
test	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
regimen	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
chemotherapy	NOUN	O	O
known	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
active	ADJ	O	O
in	ADP	O	O
advanced	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
when	ADP	O	O
given	VERB	O	O
as	ADP	O	O
an	DET	O	O
adjuvant	NOUN	O	O
treatment	NOUN	O	O
after	ADP	O	O
mastectomy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
569	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	O
of	ADP	O	O
the	DET	O	O
breast	NOUN	O	O
and	CCONJ	O	O
involvement	NOUN	O	O
of	ADP	O	O
axillary	ADJ	O	O
lymph	NOUN	O	O
nodes	NOUN	O	O
were	VERB	O	O
randomised	NUM	O	O
,	PUNCT	O	O
after	ADP	O	O
simple	ADJ	O	O
mastectomy	NOUN	O	O
with	ADP	O	O
axillary	ADJ	O	O
sampling	VERB	O	O
,	PUNCT	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
no	DET	O	O
adjuvant	NOUN	O	O
treatment	NOUN	O	O
or	CCONJ	O	O
intravenous	ADJ	O	O
adriamycin	NOUN	O	O
50	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
vincristine	NOUN	O	O
1	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
cyclophosphamide	NOUN	O	O
250	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
methotrexate	PUNCT	O	O
150	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
fluorouracil	NOUN	O	O
250	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
AVCMF	NOUN	O	O
)	PUNCT	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
eight	NUM	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

Randomisation	NOUN	O	O
was	VERB	O	O
stratified	VERB	O	O
according	ADP	O	O
to	ADP	O	O
menopausal	ADJ	O	O
status	NOUN	O	O
and	CCONJ	O	O
tumour	NOUN	O	O
size	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
within	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
in	ADP	O	O
94	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Eighty-eight	PUNCT	O	O
per	ADP	O	O
cent	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
received	VERB	O	O
at	ADP	O	O
least	ADV	O	O
seven	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
no	DET	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
relapse-free	PUNCT	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
prolonged	VERB	O	O
by	ADP	O	O
14	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
AVCMF	NOUN	O	O
(	PUNCT	O	O
chi2	NOUN	O	O
1	NUM	O	O
=	SYM	O	O
11.7	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0006	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
premenopausal	ADJ	O	O
group	NOUN	O	O
this	PUNCT	O	O
period	NOUN	O	O
was	VERB	O	O
17	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
chi2	NOUN	O	O
1	NUM	O	O
=	SYM	O	O
8.8	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
8	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
post-menopausal	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
chi2	NOUN	O	O
1	NUM	O	O
=	SYM	O	O
3.3	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.07	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
nor	CCONJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
in	ADP	O	O
these	DET	O	O
subgroups	NOUN	O	O
was	NUM	O	O
significantly	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Study	NOUN	O	O
on	ADP	O	O
classification	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
vulvovaginal	ADJ	O	O
candidiasis	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
vulvovaginal	ADJ	O	O
candidiasis	NOUN	O	O
(	PUNCT	O	O
VVC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
study	NOUN	O	O
the	DET	O	O
mycologic	ADJ	O	B-PHYSICAL
eradication	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
different	ADJ	O	O
miconazole	NOUN	O	O
treatment	NOUN	O	O
courses	ADP	O	O
for	ADP	O	O
VVC	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Three	NUM	O	O
hundred	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
VVC	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
Candidas	NOUN	O	O
were	VERB	O	O
cultured	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
and	CCONJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
6	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
7	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
uncomplicated	VERB	O	O
and	CCONJ	O	O
complicated	PUNCT	O	O
VVC	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Among	ADP	O	O
300	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
VVC	NOUN	O	O
,	PUNCT	O	O
uncomplicated	VERB	O	O
,	PUNCT	O	O
complicated	ADP	O	O
and	CCONJ	O	O
recurrent	ADJ	O	O
VVC	NOUN	O	O
were	VERB	O	O
56.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
44.0	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
9.7	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
29/300	NOUN	O	O
)	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

C.	NOUN	O	O
albicans	NOUN	O	O
was	VERB	O	O
isolated	VERB	O	O
most	PUNCT	O	O
frequently	ADV	O	O
90.3	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
271/300	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
C.	NOUN	O	O
glabrata	ADJ	O	O
(	PUNCT	O	O
7.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
C.	NOUN	O	O
tropicalis	NOUN	O	O
(	PUNCT	O	O
1.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
C.	NOUN	O	O
krusei	NOUN	O	O
(	PUNCT	O	O
0.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
C.	NOUN	O	O
parapsilosis	NOUN	O	O
(	PUNCT	O	O
0.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mycologic	ADJ	O	B-PHYSICAL
eradication	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
3	NUM	O	O
day	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
day	NOUN	O	O
and	CCONJ	O	O
7	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
courses	DET	O	O
for	ADP	O	O
uncomplicated	VERB	O	O
VVC	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
14	NUM	O	O
was	VERB	O	O
96.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
93.5	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
98.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eradication	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
3	NUM	O	O
day	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
day	NOUN	O	O
and	CCONJ	O	O
7	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
courses	DET	O	O
for	ADP	O	O
complicated	PUNCT	O	O
VVC	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
14	NUM	O	O
was	VERB	O	O
86.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
92.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
86.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eradication	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
3	NUM	O	O
day	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
day	NOUN	O	O
and	CCONJ	O	O
7	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
courses	DET	O	O
for	ADP	O	O
uncomplicated	VERB	O	O
VVC	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
35	NUM	O	O
was	VERB	O	O
93.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
95.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
89.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eradication	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
3	NUM	O	O
day	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
day	NOUN	O	O
and	CCONJ	O	O
7	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
courses	DET	O	O
for	ADP	O	O
complicated	PUNCT	O	O
VVC	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
35	NUM	O	O
was	VERB	O	O
89.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
97.3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
86.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Treatment	NOUN	O	O
of	ADP	O	O
VVC	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
individualized	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
women	NOUN	O	O
with	ADP	O	O
complicated	VERB	O	O
VVC	NOUN	O	O
achieve	PUNCT	O	O
superior	ADJ	O	O
mycologic	ADJ	O	B-PHYSICAL
eradication	NOUN	O	I-PHYSICAL
by	ADP	O	O
a	DET	O	O
6	NUM	O	O
day	NOUN	O	O
miconazole	NOUN	O	O
course	NOUN	O	O
.	PUNCT	O	O

Visual	ADJ	O	O
and	CCONJ	O	O
kinesthetic	ADJ	O	O
locomotor	NOUN	O	O
imagery	NOUN	O	O
training	SYM	O	O
integrated	VERB	O	O
with	ADP	O	O
auditory	ADJ	O	O
step	NOUN	O	O
rhythm	NOUN	O	O
for	ADP	O	O
walking	VERB	O	O
performance	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
stroke	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
and	CCONJ	O	O
kinesthetic	ADJ	O	O
locomotor	NOUN	O	O
imagery	NOUN	O	O
training	SYM	O	O
on	ADP	O	O
walking	VERB	O	B-MENTAL
performance	NOUN	O	I-MENTAL
and	CCONJ	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	B-OTHER
feasibility	NOUN	O	I-OTHER
of	ADP	O	O
incorporating	VERB	O	O
auditory	ADJ	O	O
step	NOUN	O	O
rhythm	NOUN	O	O
into	ADP	O	O
the	DET	O	O
training	VERB	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Laboratory	NOUN	O	O
of	ADP	O	O
a	DET	O	O
Department	NOUN	O	O
of	ADP	O	O
Physical	PUNCT	O	O
Therapy	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
Fifteen	PUNCT	O	O
subjects	NOUN	O	O
with	ADP	O	O
post-stroke	NOUN	O	O
hemiparesis	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
Four	CCONJ	O	O
locomotor	NOUN	O	O
imagery	PUNCT	O	O
trainings	NOUN	O	O
on	ADP	O	O
walking	VERB	O	O
performance	NOUN	O	O
:	PUNCT	O	O
visual	ADJ	O	O
locomotor	NOUN	O	O
imagery	NOUN	O	O
training	VERB	O	O
,	PUNCT	O	O
kinesthetic	ADJ	O	O
locomotor	NOUN	O	O
imagery	NOUN	O	O
training	VERB	O	O
,	PUNCT	O	O
visual	ADJ	O	O
locomotor	NOUN	O	O
imagery	NOUN	O	O
training	SYM	O	O
with	ADP	O	O
auditory	ADJ	O	O
step	NOUN	O	O
rhythm	NOUN	O	O
and	CCONJ	O	O
kinesthetic	ADJ	O	O
locomotor	NOUN	O	O
imagery	NOUN	O	O
training	SYM	O	O
with	ADP	O	O
auditory	ADJ	O	O
step	NOUN	O	O
rhythm	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
The	DET	O	O
timed	PUNCT	O	B-OTHER
up-and-go	NOUN	O	I-OTHER
test	NOUN	O	I-OTHER
and	CCONJ	O	O
electromyographic	ADJ	O	B-OTHER
and	CCONJ	O	O
kinematic	ADJ	O	B-OTHER
analyses	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
affected	ADP	O	O
lower	PUNCT	O	O
limb	NOUN	O	B-OTHER
during	ADP	O	O
one	NUM	O	O
gait	NOUN	O	B-PHYSICAL
cycle	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
the	DET	O	O
interventions	NOUN	O	O
,	PUNCT	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	PUNCT	O	O

Predicting	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
anthelmintic	ADJ	O	O
treatment	NOUN	O	O
on	ADP	O	O
milk	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
dairy	NOUN	O	I-PHYSICAL
cattle	NOUN	O	I-PHYSICAL
in	ADP	O	O
Canada	PUNCT	O	O
using	VERB	O	O
an	DET	O	O
Ostertagia	ADJ	O	O
ostertagi	NOUN	O	O
ELISA	NOUN	O	O
from	ADP	O	O
individual	ADJ	O	O
milk	NOUN	O	O
samples	NOUN	O	O
.	PUNCT	O	O

Gastrointestinal	ADJ	O	O
nematodes	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
Ostertagia	VERB	O	O
ostertagi	NOUN	O	O
and	CCONJ	O	O
several	ADJ	O	O
species	PUNCT	O	O
of	ADP	O	O
Cooperia	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
ubiquitous	ADJ	O	O
in	ADP	O	O
temperate	NOUN	O	O
climates	PUNCT	O	O
and	CCONJ	O	O
have	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
detrimental	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
production	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
dairy	NOUN	O	O
cattle	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
published	VERB	O	O
meta-analysis	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
overall	ADJ	O	O
,	PUNCT	O	O
producers	ADJ	O	O
lose	VERB	O	O
approximately	ADV	O	O
0.35	NUM	O	O
kg	NOUN	O	O
of	ADP	O	O
milk	NOUN	O	O
per	ADP	O	O
parasitized	PUNCT	O	O
cow	ADV	O	O
per	CCONJ	O	O
day	NOUN	O	O
.	PUNCT	O	O

Enzyme-linked	VERB	O	O
immunosorbent	ADJ	O	O
assays	NOUN	O	O
(	PUNCT	O	O
ELISAs	PUNCT	O	O
)	PUNCT	O	O
have	CCONJ	O	O
the	DET	O	O
ability	NOUN	O	O
to	PART	O	O
quantify	NOUN	O	O
nematode	NOUN	O	O
infections	NOUN	O	O
in	ADP	O	O
cattle	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thus	ADV	O	O
,	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
estimate	NOUN	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
milk	NOUN	O	O
production	NOUN	O	O
loss	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
differing	PROPN	O	O
levels	NOUN	O	O
of	ADP	O	O
parasitism	NOUN	O	O
at	ADP	O	O
the	DET	O	O
individual	ADJ	O	O
cow	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

ELISA	NOUN	O	O
results	ADJ	O	O
from	ADP	O	O
individual	ADJ	O	O
cow	NOUN	O	O
milk	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
predict	NOUN	O	O
milk	NOUN	O	O
production	NOUN	O	O
response	NOUN	O	O
following	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
anthelmintic	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
field	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
increase	NOUN	O	O
statistical	ADJ	O	O
power	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
data	NOUN	O	O
collected	VERB	O	O
from	ADP	O	O
this	DET	O	O
field	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
pooled	VERB	O	O
with	ADP	O	O
data	NOUN	O	O
from	ADP	O	O
two	NUM	O	O
other	ADJ	O	O
published	ADP	O	O
field	NOUN	O	O
trials	NOUN	O	O
to	PUNCT	O	O
form	NOUN	O	O
an	DET	O	O
individual	ADJ	O	O
patient	NOUN	O	O
data	NOUN	O	O
meta-analysis	NOUN	O	O
(	PUNCT	O	O
IPDMA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
ability	NOUN	O	O
to	PART	O	O
predict	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
anthelmintic	ADJ	O	O
treatment	NOUN	O	O
on	ADP	O	O
milk	NOUN	O	O
production	NOUN	O	O
depends	NOUN	O	O
on	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
parasitism	NOUN	O	O
quantified	VERB	O	O
by	ADP	O	O
an	DET	O	O
ELISA	NOUN	O	O
measuring	VERB	O	O
milk	NOUN	O	B-PHYSICAL
antibodies	NOUN	O	I-PHYSICAL
against	ADP	O	O
O.	NOUN	O	O
ostertagi	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
reported	PUNCT	O	O
as	ADP	O	O
optical	ADJ	O	B-OTHER
density	NOUN	O	I-OTHER
ratios	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
ODRs	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
estimates	NOUN	O	O
from	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
ODR	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
on	ADP	O	O
milk	NOUN	O	O
production	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
how	PUNCT	O	O
well	PUNCT	O	O
the	PUNCT	O	O
ODR	NOUN	O	O
predicted	VERB	O	O
the	DET	O	O
response	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
anticipated	NUM	O	O
that	PUNCT	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
milk	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
ODR	NOUN	O	B-OTHER
was	VERB	O	O
unlikely	ADV	O	O
to	PART	O	O
be	PUNCT	O	O
linear	ADJ	O	O
,	PUNCT	O	O
so	PUNCT	O	O
fractional	ADP	O	O
polynomials	VERB	O	O
were	VERB	O	O
applied	VERB	O	O
to	ADP	O	O
the	DET	O	O
continuous	ADJ	O	O
ODR	NOUN	O	B-PHYSICAL
values	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
interaction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
field	NOUN	O	O
trial	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
(	PUNCT	O	O
p=0.138	NOUN	O	O
)	PUNCT	O	O
toward	ADP	O	O
a	DET	O	O
beneficial	ADJ	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
when	ADP	O	O
the	DET	O	O
individual	ADJ	O	O
ODR	NOUN	O	B-OTHER
values	NOUN	O	I-OTHER
,	PUNCT	O	O
measured	VERB	O	O
in	ADP	O	O
late	ADJ	O	O
lactation	NOUN	O	O
and	CCONJ	O	O
using	VERB	O	O
Svanovir	NOUN	O	O
(	PUNCT	O	O
?	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O

were	VERB	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
0.12	NUM	O	O
.	PUNCT	O	O

When	ADP	O	O
individual	ADJ	O	O
data	NOUN	O	O
from	ADP	O	O
two	NUM	O	O
other	ADJ	O	O
similar	ADJ	O	O
studies	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
an	DET	O	O
IPDMA	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
interaction	NOUN	O	O
terms	NOUN	O	O
became	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p=0.009	NOUN	O	O
)	PUNCT	O	O
indicating	ADP	O	O
that	ADP	O	O
there	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
beneficial	ADJ	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
when	ADP	O	O
ODR	NOUN	O	O
values	NOUN	O	O
are	VERB	O	O
slightly	ADV	O	O
elevated	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
graph	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
demonstrate	ADJ	O	O
the	DET	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
estimated	VERB	O	O
difference	NOUN	O	O
of	ADP	O	O
kg/cow/day	NUM	O	O
of	ADP	O	O
milk	NOUN	O	O
yield	NOUN	O	O
between	ADP	O	O
the	DET	O	O
treated	VERB	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
cows	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
intervals	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
the	DET	O	O
ODR	NOUN	O	O
values	NOUN	O	O
increase	ADP	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PUNCT	O	O
note	PUNCT	O	O
that	PUNCT	O	O
the	DET	O	O
methods	NOUN	O	O
of	ADP	O	O
quantifying	VERB	O	O
the	DET	O	O
ODR	NOUN	O	O
values	NOUN	O	O
differed	VERB	O	O
between	ADP	O	O
the	DET	O	O
three	NUM	O	O
studies	NOUN	O	O
in	ADP	O	O
the	DET	O	O
IPDMA	NOUN	O	O
,	PUNCT	O	O
therefore	ADV	O	O
some	DET	O	O
caution	NOUN	O	O
should	ADP	O	O
be	VERB	O	O
used	VERB	O	O
when	ADP	O	O
using	VERB	O	O
these	DET	O	O
final	ADJ	O	O
estimated	VERB	O	O
values	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
shape	NOUN	O	O
and	CCONJ	O	O
magnitude	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
fixed	VERB	O	O
model	NOUN	O	O
estimates	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
very	ADV	O	O
similar	ADJ	O	O
between	ADP	O	O
the	DET	O	O
field	NOUN	O	O
trial	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
IPDMA	NOUN	O	O
suggesting	PROPN	O	O
that	ADP	O	O
any	DET	O	O
bias	NOUN	O	O
would	PUNCT	O	O
likely	ADJ	O	O
be	ADP	O	O
minimal	ADJ	O	O
.	PUNCT	O	O

Thromboprophylaxis	NOUN	O	O
by	ADP	O	O
low-molecular-weight	NOUN	O	O
heparin	NOUN	O	O
in	ADP	O	O
elective	ADJ	O	O
hip	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
thromboprophylaxis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
total	ADJ	O	O
hip	NOUN	O	O
replacement	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
compared	VERB	O	O
a	DET	O	O
low-molecular-weight	NOUN	O	O
heparin	NOUN	O	O
with	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
120	NUM	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
112	NUM	O	O
completed	PUNCT	O	O
the	DET	O	O
trial	NOUN	O	O
;	PUNCT	O	O
58	NUM	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
54	NUM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
(	PUNCT	O	O
16	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
19	NUM	O	O
(	PUNCT	O	O
35	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
developed	VERB	O	O
deep	ADJ	O	B-PHYSICAL
venous	ADJ	O	I-PHYSICAL
thrombosis	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
diagnosed	VERB	O	O
by	ADP	O	O
the	DET	O	O
125I-fibrinogen	NOUN	O	O
uptake	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Verification	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
by	ADP	O	O
phlebography	NOUN	O	O
in	ADP	O	O
86	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Prolonged	VERB	O	O
surgery	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
thrombosis	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
more	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
deep	ADJ	O	B-PHYSICAL
venous	ADJ	O	I-PHYSICAL
thrombosis	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
four	NUM	O	O
postoperative	ADJ	O	O
days	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
groups	NOUN	O	O
did	ADP	O	O
not	ADV	O	O
differ	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
peroperative	ADJ	O	O
and	CCONJ	O	O
postoperative	ADJ	O	B-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
.	PUNCT	O	O

Low-molecular-weight	ADJ	O	O
heparin	NOUN	O	O
offers	NOUN	O	O
safe	ADJ	O	O
and	CCONJ	O	O
easily	ADV	O	O
administered	PUNCT	O	O
thromboprophylaxis	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
hip	NOUN	O	O
replacement	NOUN	O	O
.	PUNCT	O	O

Predictors	NOUN	O	O
of	ADP	O	O
stable	ADJ	O	O
return-to-work	NOUN	O	O
in	ADP	O	O
non-acute	NOUN	O	O
,	PUNCT	O	O
non-specific	ADJ	O	O
spinal	ADJ	O	O
pain	NOUN	O	O
:	PUNCT	O	O
low	ADJ	O	O
total	ADJ	O	O
prior	PUNCT	O	O
sick-listing	PUNCT	O	O
,	PUNCT	O	O
high	ADJ	O	O
self	PUNCT	O	O
prediction	NOUN	O	O
and	CCONJ	O	O
young	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
two-year	ADJ	O	O
prospective	ADJ	O	O
cohort	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Non-specific	ADJ	O	O
spinal	ADJ	O	O
pain	NOUN	O	O
(	PUNCT	O	O
NSP	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
comprising	CCONJ	O	O
back	ADP	O	O
and/or	CCONJ	O	O
neck	ADJ	O	O
pain	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
leading	ADJ	O	O
disorders	NOUN	O	O
in	ADP	O	O
long-term	NOUN	O	O
sick-listing	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
2000-2004	NUM	O	O
,	PUNCT	O	O
125	PUNCT	O	O
Swedish	VERB	O	O
primary-care	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
non-acute	NOUN	O	O
NSP	NOUN	O	O
,	PUNCT	O	O
full-time	NOUN	O	O
sick-listed	VERB	O	O
6	NUM	O	O
weeks-2	NOUN	O	O
years	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
a	DET	O	O
cognitive-behavioural	ADJ	O	O
programme	NOUN	O	O
with	ADP	O	O
traditional	ADJ	O	O
primary	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
cohort	NOUN	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
re-assessment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
data	NOUN	O	O
from	ADP	O	O
the	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
the	DET	O	O
2	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
single	ADJ	O	O
cohort	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	DET	O	O
which	ADP	O	O
baseline	NOUN	O	O
variables	NOUN	O	O
predict	VERB	O	O
a	DET	O	O
stable	ADJ	O	O
return-to-work	NOUN	O	O
during	ADP	O	O
a	DET	O	O
2-year	NOUN	O	O
period	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
:	PUNCT	O	O
objective	ADJ	O	O
variables	NOUN	O	O
from	ADP	O	O
function	PUNCT	O	O
tests	NOUN	O	O
,	PUNCT	O	O
socioeconomic	ADJ	O	O
,	PUNCT	O	O
subjective	ADJ	O	O
and/or	CCONJ	O	O
treatment	NOUN	O	O
variables	NOUN	O	O
.	PUNCT	O	O

Stable	ADJ	O	O
return-to-work	NOUN	O	O
was	VERB	O	O
a	DET	O	O
return-to-work	NOUN	O	O
lasting	ADJ	O	O
for	ADP	O	O
at	VERB	O	O
least	ADV	O	O
1	NUM	O	O
month	NOUN	O	O
from	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Stable	ADJ	O	O
return-to-work	NOUN	O	O
was	VERB	O	O
the	DET	O	O
outcome	NOUN	O	O
variable	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
above-mentioned	VERB	O	O
factors	NOUN	O	O
were	VERB	O	O
the	DET	O	O
predictive	ADJ	O	O
variables	NOUN	O	O
in	ADP	O	O
multiple-logistic	ADJ	O	O
regression	NOUN	O	O
models	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
per	ADP	O	O
follow-up	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
,	PUNCT	O	O
18	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
factors	NOUN	O	O
from	ADP	O	O
univariate	ADJ	O	O
analyzes	DET	O	O
with	ADP	O	O
a	DET	O	O
p-value	NOUN	O	O
of	ADP	O	O
at	ADP	O	O
most	CCONJ	O	O
.10	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
non-significant	ADJ	O	O
variables	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
stepwise	ADJ	O	O
to	PART	O	O
yield	VERB	O	O
models	NOUN	O	O
comprising	CCONJ	O	O
only	ADJ	O	O
significant	ADJ	O	O
factors	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

As	ADP	O	O
the	DET	O	O
comparatively	NOUN	O	O
few	ADJ	O	O
cases	NOUN	O	O
made	PUNCT	O	O
it	PUNCT	O	O
risky	PUNCT	O	O
to	PART	O	O
associate	NOUN	O	O
certain	ADJ	O	O
predictors	NOUN	O	O
with	ADP	O	O
certain	ADJ	O	O
time-points	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
finally	ADV	O	O
considered	PUNCT	O	O
the	DET	O	O
predictors	NOUN	O	O
which	ADP	O	O
were	VERB	O	O
represented	VERB	O	O
in	ADP	O	O
at	DET	O	O
least	ADV	O	O
3	NUM	O	O
follow-ups	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
are	VERB	O	O
presented	VERB	O	O
with	ADP	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
(	PUNCT	O	O
OR	CCONJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Three	NUM	O	O
variables	NOUN	O	O
qualified	VERB	O	O
,	PUNCT	O	O
all	DET	O	O
of	ADP	O	O
them	PRON	O	O
represented	VERB	O	O
in	ADP	O	O
3	NUM	O	O
follow-ups	ADP	O	O
:	PUNCT	O	O
Low	ADJ	O	B-OTHER
total	ADJ	O	O
prior	PUNCT	O	B-OTHER
sick-listing	PUNCT	O	I-OTHER
(	PUNCT	O	I-OTHER
including	PROPN	O	I-OTHER
all	DET	O	I-OTHER
diagnoses	NOUN	O	I-OTHER
)	PUNCT	O	B-OTHER
was	VERB	O	O
the	DET	O	O
strongest	PUNCT	O	B-OTHER
predictor	NOUN	O	I-OTHER
in	ADP	O	O
2	NUM	O	O
follow-ups	PROPN	O	O
,	PUNCT	O	O
18	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
OR	ADV	O	O
4.8	NUM	O	O
[	PUNCT	O	O
1.9-12.3	PUNCT	O	O
]	PUNCT	O	O
and	CCONJ	O	O
3.8	NUM	O	O
[	PUNCT	O	O
1.6-8.7	ADP	O	O
]	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
High	PUNCT	O	B-OTHER

Secondary	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
macrovascular	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
PROactive	ADJ	O	O
Study	NOUN	O	O
(	PUNCT	O	O
PROspective	ADJ	O	O
pioglitAzone	NOUN	O	O
Clinical	ADJ	O	O
Trial	NOUN	O	O
In	ADP	O	O
macroVascular	ADJ	O	O
Events	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
and	CCONJ	O	O
non-fatal	ADJ	O	O
myocardial	ADJ	O	B-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
stroke	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
is	VERB	O	O
indirect	ADJ	O	O
evidence	NOUN	O	O
that	ADP	O	O
agonists	NOUN	O	O
of	ADP	O	O
peroxisome	NOUN	O	O
proliferator-activated	VERB	O	O
receptor	NOUN	O	O
gamma	NOUN	O	O
(	PUNCT	O	O
PPAR	NOUN	O	O
gamma	NOUN	O	O
)	PUNCT	O	O
could	VERB	O	O
reduce	VERB	O	O
macrovascular	ADJ	O	B-PHYSICAL
complications	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Our	PUNCT	O	O
aim	NOUN	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
was	VERB	O	O
to	ADV	O	O
ascertain	NOUN	O	O
whether	PUNCT	O	O
pioglitazone	ADJ	O	O
reduces	NOUN	O	O
macrovascular	ADJ	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
in	ADP	O	O
high-risk	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	ADJ	O	O
did	CCONJ	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
5238	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
evidence	NOUN	O	O
of	ADP	O	O
macrovascular	ADJ	O	B-PHYSICAL
disease	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
recruited	VERB	O	O
patients	NOUN	O	O
from	ADP	O	O
primary-care	ADJ	O	O
practices	NOUN	O	O
and	CCONJ	O	O
hospitals	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
assigned	VERB	O	O
patients	NOUN	O	O
to	ADP	O	O
oral	ADJ	O	O
pioglitazone	NOUN	O	O
titrated	PUNCT	O	O
from	ADP	O	O
15	NUM	O	O
mg	NOUN	O	O
to	ADP	O	O
45	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
n=2605	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
matching	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n=2633	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	PART	O	O
be	PUNCT	O	O
taken	VERB	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
glucose-lowering	VERB	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
medications	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
the	DET	O	O
composite	NOUN	O	B-MORTALITY
of	ADP	O	I-MORTALITY
all-cause	NOUN	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
,	PUNCT	O	O
non	ADJ	O	B-PHYSICAL
fatal	ADJ	O	I-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
including	PROPN	O	O
silent	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
stroke	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
acute	ADJ	O	B-PHYSICAL
coronary	ADJ	O	I-PHYSICAL
syndrome	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
endovascular	ADJ	O	B-PHYSICAL
or	CCONJ	O	O
surgical	ADJ	O	B-PHYSICAL
intervention	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
coronary	ADJ	O	I-PHYSICAL
or	CCONJ	O	O
leg	NOUN	O	B-PHYSICAL
arteries	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
amputation	NOUN	O	B-PHYSICAL
above	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
ankle	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Analysis	NOUN	O	O
was	VERB	O	O
by	ADP	O	O
intention	NOUN	O	O
to	PART	O	O
treat	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
registered	VERB	O	O
as	PUNCT	O	O
an	DET	O	O
International	ADJ	O	O
Standard	NOUN	O	O
Randomised	PROPN	O	O
Controlled	VERB	O	O
Trial	NOUN	O	O
,	PUNCT	O	O
number	NOUN	O	O
ISRCTN	NOUN	O	O
NCT00174993	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
Two	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
lost	VERB	O	O
to	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
time	NOUN	O	O
of	ADP	O	O
observation	NOUN	O	O
was	ADV	O	O
34.5	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

514	NUM	O	O
of	ADP	O	O
2605	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pioglitazone	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
572	NUM	O	O
of	ADP	O	O
2633	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
one	NUM	O	O
event	NOUN	O	O
in	ADP	O	O
the	DET	O	O
primary	ADJ	O	B-PHYSICAL
composite	ADJ	O	I-PHYSICAL
endpoint	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
HR	NOUN	O	O
0.90	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.80-1.02	NUM	O	O
,	PUNCT	O	O
p=0.095	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
secondary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
the	DET	O	O
composite	NOUN	O	B-MORTALITY
of	ADP	O	I-MORTALITY
all-cause	NOUN	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
,	PUNCT	O	O
non-fatal	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Learning	VERB	O	O
curve	NOUN	O	O
in	ADP	O	O
multidetector	NOUN	O	O
CT	NOUN	O	O
coronary	ADJ	O	O
angiography	NOUN	O	O
(	PUNCT	O	O
MDCT-CA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Coronary	ADJ	O	O
angiography	NOUN	O	O
using	VERB	O	O
multidetector	NOUN	O	O
computed	VERB	O	O
tomography	NOUN	O	O
(	PUNCT	O	O
MDCT-CA	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
recent	ADJ	O	O
technique	NOUN	O	O
for	ADP	O	O
the	DET	O	O
nonivasive	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
diagnostic	ADJ	O	B-OTHER
accuracy	NOUN	O	O
of	ADP	O	B-OTHER
coronary	ADJ	O	I-OTHER
artery	NOUN	O	I-OTHER
stenosis	NOUN	O	I-OTHER
evaluation	NOUN	O	B-OTHER
obtained	VERB	O	O
by	ADP	O	O
three	NUM	O	O
readers	NOUN	O	O
at	ADP	O	O
different	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
training	VERB	O	O
or	CCONJ	O	O
at	ADP	O	O
different	ADJ	O	O
points	NOUN	O	O
of	ADP	O	O
the	DET	O	O
learning	VERB	O	O
curve	NOUN	O	O
proposed	VERB	O	O
by	ADP	O	O
the	DET	O	O
international	ADJ	O	O
guidelines	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Three	NUM	O	O
radiologists	NOUN	O	O
in	ADP	O	O
training	VERB	O	O
with	ADP	O	O
different	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
experience	NOUN	O	O
in	ADP	O	O
MDCT-CA	NOUN	O	O
scored	PUNCT	O	O
50	NUM	O	O
cases	NOUN	O	O
at	ADP	O	O
various	ADJ	O	O
time	NOUN	O	O
points	NOUN	O	O
of	ADP	O	O
the	DET	O	O
learning	VERB	O	O
curve	NOUN	O	O
:	PUNCT	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trainee	NOUN	O	O
radiologists	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
stenosis	NOUN	O	B-OTHER
on	ADP	O	I-OTHER
each	ADP	O	B-OTHER
coronary	ADJ	O	I-OTHER
segment	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
overall	ADJ	O	B-OTHER
accuracy	NOUN	O	B-OTHER
was	VERB	O	O
calculated	VERB	O	O
on	ADP	O	O
a	DET	O	O
per-segment	NOUN	O	O
,	PUNCT	O	O
pervessel	NOUN	O	O
and	CCONJ	O	O
per-patient	PUNCT	O	O
basis	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
All	PUNCT	O	O
readers	NOUN	O	O
improved	ADJ	O	B-OTHER
analysis	NOUN	O	I-OTHER
accuracy	PUNCT	O	O

Comparative	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
carbenicillin	NOUN	O	O
and	CCONJ	O	O
ampicillin	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
purulent	VERB	O	O
meningitis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
therapeutic	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
carbenicillin	NOUN	O	O
(	PUNCT	O	O
CB	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ampicillin	NOUN	O	O
(	PUNCT	O	O
AMP	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
purulent	VERB	O	O
meningitis	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
86	NUM	O	O
pediatric	ADJ	O	O
and	CCONJ	O	O
adult	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
41	NUM	O	O
Haemophilus	NOUN	O	O
influenzae	ADV	O	O
,	PUNCT	O	O
22	NUM	O	O
Streptococcus	NOUN	O	O
pneumoniae	NOUN	O	O
,	PUNCT	O	O
13	NUM	O	O
Neisseria	NOUN	O	O
meningitidis	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
of	ADP	O	O
unknown	VERB	O	O
etiology	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
isolates	NOUN	O	O
,	PUNCT	O	O
incuding	PUNCT	O	O
H.	NOUN	O	O
influenzae	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
susceptible	ADJ	O	O
to	ADP	O	O
CB	NOUN	O	O
and	CCONJ	O	O
AMP	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
cerebrospinal	ADJ	O	B-PHYSICAL
fluid	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
CSF	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
antibiotic	ADJ	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
0.85	NUM	O	O
and	CCONJ	O	O
1.60	NUM	O	O
mug/ml	NOUN	O	O
for	ADP	O	O
CB	NOUN	O	O
and	CCONJ	O	O
AMP	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
during	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
daily	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
400	NUM	O	O
mg/kg	NOUN	O	O
and	CCONJ	O	O
0.65	NUM	O	O
and	CCONJ	O	O
0.45	NUM	O	O
mug/ml	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
daily	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg/kg	NOUN	O	O
.	PUNCT	O	O

Higher	PUNCT	O	B-PHYSICAL
CSF	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
up	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
median	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
4.5	NUM	O	O
mug/ml	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
CSF	NOUN	O	O
protein	NOUN	O	O
concentrations	NOUN	O	O
>	SYM	O	O
/=75	PUNCT	O	O
mg/100	PUNCT	O	O
ml	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
were	VERB	O	O
equivalent	ADJ	O	O
on	ADP	O	O
either	CCONJ	O	O
antibiotic	ADJ	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
AMP	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
45	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
8	NUM	O	O
had	PUNCT	O	O
significant	ADJ	O	B-ADVERSE-EFFECTS
residua	PUNCT	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
3	NUM	O	O
died	ADV	O	B-MORTALITY
;	PUNCT	O	O
among	ADP	O	O
CB	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
41	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
5	NUM	O	O
had	PUNCT	O	O
residua	PUNCT	O	O
and	CCONJ	O	O
none	NUM	O	O
died	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
38	NUM	O	O
%	SYM	O	O
of	ADP	O	O
H.	NOUN	O	O
influenzae	PUNCT	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
CB	NOUN	O	O
had	VERB	O	O
positive	ADJ	O	O
CSF	NOUN	O	B-PHYSICAL
cultures	NOUN	O	I-PHYSICAL
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
follow-up	NOUN	O	O
lumbar	ADJ	O	O
punctures	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
only	ADV	O	O
5.8	NUM	O	O
%	SYM	O	O
of	ADP	O	O
AMP	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
H.	NOUN	O	O
influenzae	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
significance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
delay	NOUN	O	O
of	ADP	O	O
CSF	NOUN	O	B-PHYSICAL
sterilization	NOUN	O	I-PHYSICAL
among	ADP	O	O
CB-treated	VERB	O	O
patients	NOUN	O	O
is	VERB	O	O
unknown	VERB	O	O
,	PUNCT	O	O
since	ADP	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
persistence	NOUN	O	O
of	ADP	O	O
hemophilus	NOUN	O	O
organisms	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

AMP	NOUN	O	O
and	CCONJ	O	O
CB	NOUN	O	O
are	VERB	O	O
equivalent	ADJ	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
bacterial	ADJ	O	O
meningitis	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
susceptible	ADJ	O	O
organisms	NOUN	O	O
.	PUNCT	O	O

Pentoxifylline	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
HIV	NOUN	O	O
seropositive	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
elevated	VERB	O	O
TNF	NOUN	O	O
.	PUNCT	O	O

Tumor	NOUN	O	O
necrosis	NOUN	O	O
factor-alpha	NOUN	O	O
(	PUNCT	O	O
TNF-alpha	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
thought	VERB	O	O
to	PART	O	O
induce	NOUN	O	O
cachexia	NOUN	O	O
in	ADP	O	O
subjects	NOUN	O	O
infected	VERB	O	O
with	ADP	O	O
human	NOUN	O	O
immunodeficiency	NOUN	O	O
virus	NOUN	O	O
(	PUNCT	O	O
HIV	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
suggested	VERB	O	O
that	ADP	O	O
HIV-seropositive	ADJ	O	O
patients	NOUN	O	O
would	VERB	O	O
benefit	VERB	O	O
from	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
pentoxifylline	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
known	VERB	O	O
suppressor	NOUN	O	O
of	ADP	O	O
TNF-alpha	NOUN	O	O
production	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
how	ADP	O	O
pentoxifylline	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
800	NUM	O	O
mg	NOUN	O	O
thrice	ADP	O	O
daily	ADJ	O	O
would	ADP	O	O
influence	VERB	O	O
the	DET	O	O
cellular	ADJ	O	B-PHYSICAL
immune	ADJ	O	I-PHYSICAL
system	NOUN	O	I-PHYSICAL
in	ADP	O	O
HIV-seropositive	ADJ	O	O
persons	NOUN	O	O
with	ADP	O	O
elevated	VERB	O	O
TNF-alpha	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
HIV-seropositive	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
elevated	VERB	O	O
amounts	NOUN	O	O
of	ADP	O	O
TNF-alpha	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
at	VERB	O	O
least	ADV	O	O
at	ADP	O	O
two	NUM	O	O
occasions	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
an	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
controlled	DET	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
cross-over	ADP	O	O
study	NOUN	O	O
consisting	DET	O	O
of	ADP	O	O
a	DET	O	O
6	NUM	O	O
week	NOUN	O	O
treatment	NOUN	O	O
period	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
6	NUM	O	O
week	NOUN	O	O
control	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
each	DET	O	O
period	NOUN	O	O
.	PUNCT	O	O

Pentoxifylline	NOUN	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	B-PHYSICAL
plasma-TNF-alpha	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
subpopulations	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
mononuclear	ADJ	O	B-PHYSICAL
cells	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
the	DET	O	B-PHYSICAL
proliferative	ADJ	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
nor	CCONJ	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
natural	ADJ	O	I-PHYSICAL
killer	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
NK	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lymphokine	PUNCT	O	B-PHYSICAL
activated	VERB	O	B-PHYSICAL
killer	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
LAK	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
cell	NOUN	O	B-PHYSICAL
activities	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
pentoxifylline	NOUN	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
the	DET	O	O
weight	NOUN	O	O
,	PUNCT	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
well	VERB	O	B-PHYSICAL
being	PUNCT	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
tiredness	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
subjects	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
frequently	ADV	O	O
reported	ADP	O	O
gastrointestinal	ADJ	O	B-ADVERSE-EFFECTS
side	NOUN	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

In	PUNCT	O	O
vitro	ADJ	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
pentoxifylline	NOUN	O	O
at	ADP	O	O
suprapharmacological	ADJ	O	O
concentrations	NOUN	O	O
inhibited	VERB	O	O
the	PUNCT	O	O

[	PUNCT	O	O
Clinical	ADJ	O	O
observation	NOUN	O	O
on	ADP	O	O
effect	NOUN	O	O
of	ADP	O	O
fuzheng	VERB	O	O
yiliu	PUNCT	O	O
granule	NOUN	O	O
on	ADP	O	O
cell	NOUN	O	O
cycle	NOUN	O	O
and	CCONJ	O	O
nuclear	ADJ	O	O
transcription	NOUN	O	O
factor-kappa	NOUN	O	O
B	NOUN	O	O
in	ADP	O	O
tissue	NOUN	O	O
of	ADP	O	O
esophageal-gastric	ADJ	O	O
carcinoma	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
observe	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
Fuzheng	NOUN	O	O
Yiliu	PUNCT	O	O
Granule	NOUN	O	O
(	PUNCT	O	O
FZYLG	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
cell	NOUN	O	O
cycle	NOUN	O	O
and	CCONJ	O	O
nuclear	ADJ	O	O
transcription	NOUN	O	O
factor-kappa	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
NF-kappa	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
tissue	NOUN	O	O
of	ADP	O	O
esophageal-gastric	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Seventy-six	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
esophageal	ADJ	O	O
gastric	ADJ	O	O
carcinoma	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
FZYLG	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

FZYLG	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
the	DET	O	O
former	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
tumor	NOUN	O	O
tissue	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
was	VERB	O	O
resected	VERB	O	O
and	CCONJ	O	O
cell	NOUN	O	B-PHYSICAL
cycle	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
apoptosis	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
NF-kappa	NOUN	O	O
B	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
flowcytometry	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Level	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
NF-kappa	NOUN	O	I-PHYSICAL
B	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
treated	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	VERB	O	O
that	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
treated	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
G0/G1	NOUN	O	B-PHYSICAL
stage	NOUN	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
increased	ADP	O	O
and	CCONJ	O	O
that	PUNCT	O	O
of	ADP	O	O
S	NOUN	O	O
stage	ADP	O	B-PHYSICAL
significantly	ADV	O	O
decreased	VERB	O	O
(	PUNCT	O	O
both	CCONJ	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
obvious	ADJ	O	O
cell	NOUN	O	B-PHYSICAL
apoptosis	NOUN	O	I-PHYSICAL
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
treated	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
apoptosis	NOUN	O	B-PHYSICAL
rate	NOUN	O	O
of	ADP	O	O
which	ADP	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	VERB	O	O
that	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
FZYLG	NOUN	O	O
can	ADJ	O	O
increase	VERB	O	O
the	DET	O	O
NF-kappa	NOUN	O	O
B	NOUN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
block	ADP	O	O
the	DET	O	O
proliferation	NOUN	O	O
to	PART	O	O
promote	NOUN	O	O
the	DET	O	O
apoptosis	NOUN	O	B-PHYSICAL
of	ADP	O	O
tumor	NOUN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Does	PUNCT	O	O
waiting	ADP	O	O
matter	NOUN	O	O
?	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
non-urgent	ADJ	O	O
rheumatology	NOUN	O	O
out-patient	ADP	O	O
referrals	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
examine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
waiting	PROPN	O	O
times	NOUN	O	O
on	ADP	O	O
the	DET	O	O
health	NOUN	O	O
status	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
referred	VERB	O	O
for	ADP	O	O
a	DET	O	O
non-urgent	ADJ	O	O
rheumatology	NOUN	O	O
opinion	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
study	NOUN	O	O
evaluating	PUNCT	O	O
a	DET	O	O
'fast	PUNCT	O	O
track	NOUN	O	O
'	PUNCT	O	O
appointment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
6-week	NOUN	O	O
target	NOUN	O	O
waiting	SYM	O	O
time	NOUN	O	O
against	ADP	O	O
an	DET	O	O
'ordinary	PUNCT	O	O
'	PUNCT	O	O
appointment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
main	ADJ	O	O
city	NOUN	O	O
out-patient	ADP	O	O
clinic	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rheumatology	NOUN	O	O
service	NOUN	O	O
for	ADP	O	O
the	DET	O	O
Lothian	PUNCT	O	O
and	CCONJ	O	O
Borders	PUNCT	O	O
region	NOUN	O	O
(	PUNCT	O	O
population	NOUN	O	O
approximately	ADV	O	O
1	NUM	O	O
million	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Health	NOUN	O	B-PHYSICAL
status	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
using	SYM	O	O
the	DET	O	O
SF12	NOUN	O	B-PHYSICAL
physical	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
mental	ADJ	O	I-PHYSICAL
summary	NOUN	O	I-PHYSICAL
component	NOUN	O	I-PHYSICAL
T-scores	VERB	O	I-PHYSICAL
and	CCONJ	O	O
pain	NOUN	O	B-PAIN
was	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
a	DET	O	O
100	NUM	O	O
mm	NOUN	O	O
visual	ADJ	O	B-OTHER
analogue	NOUN	O	I-OTHER
pain	NOUN	O	I-OTHER
scale	NOUN	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
outcomes	NOUN	O	O
were	VERB	O	O
health	NOUN	O	B-PHYSICAL
utility	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
perceived	DET	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
both	PUNCT	O	O
measured	VERB	O	O
with	ADP	O	O
the	DET	O	O
EuroQol	PUNCT	O	O
instrument	NOUN	O	O
,	PUNCT	O	O
mental	ADJ	O	O
health	NOUN	O	O
measured	VERB	O	O
with	ADP	O	O
the	DET	O	O
Hospital	NOUN	O	O
Anxiety	NOUN	O	B-MENTAL
and	CCONJ	O	I-MENTAL
Depression	NOUN	O	I-MENTAL
scale	NOUN	O	O
,	PUNCT	O	O
disability	NOUN	O	B-PHYSICAL
with	ADP	O	O
the	DET	O	O
modified	VERB	O	O
Health	NOUN	O	O
Assessment	NOUN	O	O
Questionnaire	NOUN	O	O
and	CCONJ	O	O
economic	ADJ	O	O
costs	NOUN	O	O
measured	VERB	O	O
from	ADP	O	O
a	DET	O	O
societal	ADJ	O	O
perspective	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Mean	NOUN	O	O
waiting	ADP	O	B-OTHER
times	NOUN	O	I-OTHER
were	VERB	O	O
43	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
sigma	NOUN	O	O
=	SYM	O	O
+/-16	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
105	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
sigma	NOUN	O	O
=	SYM	O	O
+/-51	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
'fast	PUNCT	O	O
track	NOUN	O	O
'	PUNCT	O	O
and	CCONJ	O	O
'ordinary	PUNCT	O	O
'	PUNCT	O	O
appointments	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
[	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
scores	NOUN	O	O
for	ADP	O	O
pain	NOUN	O	B-PAIN
:	PUNCT	O	O
11	NUM	O	O
(	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
16	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
physical	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
4	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
mental	ADJ	O	B-MENTAL
health	NOUN	O	I-MENTAL
status	NOUN	O	I-MENTAL
:	PUNCT	O	O
2	NUM	O	O
(	PUNCT	O	O
0.1	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
health	NOUN	O	B-PHYSICAL
utility	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
0.11	NUM	O	O
(	PUNCT	O	O
0.07	NUM	O	O
,	PUNCT	O	O
0.16	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
by	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
15-month	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
either	CCONJ	O	O
arm	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Rationing	PUNCT	O	O
by	ADP	O	O
delay	PUNCT	O	O
was	ADV	O	O
not	ADV	O	O
detrimental	ADJ	O	O
to	ADP	O	O
either	CCONJ	O	O
mental	ADJ	O	O
or	CCONJ	O	O
physical	ADJ	O	O
health	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
in	ADP	O	O
both	PUNCT	O	O
arms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
and	CCONJ	O	O
similar	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
health	NOUN	O	O
by	ADP	O	O
15	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Expenditure	NOUN	O	O
of	ADP	O	O
resources	NOUN	O	O
on	ADP	O	O
waiting	PROPN	O	O
times	NOUN	O	O
without	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
is	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
be	PUNCT	O	O
wasteful	ADJ	O	O
and	CCONJ	O	O
additional	ADJ	O	O
resources	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
directed	VERB	O	O
at	ADP	O	O
achieving	VERB	O	O
the	DET	O	O
greatest	PUNCT	O	O
clinical	ADJ	O	O
benefit	NOUN	O	O
.	PUNCT	O	O

More	DET	O	O
research	NOUN	O	O
into	ADP	O	O
effective	ADJ	O	O
methods	NOUN	O	O
of	ADP	O	O
controlling	VERB	O	O
demand	NOUN	O	O
and	CCONJ	O	O
better	PUNCT	O	O
identification	NOUN	O	O
of	ADP	O	O
those	ADP	O	O
who	ADP	O	O
would	VERB	O	O
benefit	VERB	O	O
from	ADP	O	O
access	NOUN	O	O
to	ADP	O	O
specialist	NOUN	O	O
care	NOUN	O	O
is	PUNCT	O	O
needed	VERB	O	O
.	PUNCT	O	O

Heart	NOUN	O	O
rate	NOUN	O	O
variability	NOUN	O	O
characteristics	NOUN	O	O
in	ADP	O	O
sedentary	ADJ	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
following	VERB	O	O
six	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
training	VERB	O	O
:	PUNCT	O	O
the	DET	O	O
DREW	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Decreased	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
variability	NOUN	O	O
(	PUNCT	O	O
HRV	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
have	CCONJ	O	O
lower	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
HRV	NOUN	O	O
than	PUNCT	O	O
premenopausal	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
may	VERB	O	O
be	VERB	O	O
additionally	ADV	O	O
complicated	VERB	O	O
by	ADP	O	O
lifestyle	NOUN	O	O
related	VERB	O	O
behaviors	NOUN	O	O
such	ADP	O	O
as	ADP	O	O
physical	ADJ	O	O
inactivity	NOUN	O	O
and	CCONJ	O	O
obesity	NOUN	O	O
.	PUNCT	O	O

Though	ADP	O	O
cardiorespiratory	ADJ	O	O
exercise	NOUN	O	O
training	PUNCT	O	O
increases	CCONJ	O	O
HRV	NOUN	O	O
,	PUNCT	O	O
little	PUNCT	O	O
is	VERB	O	O
known	VERB	O	O
regarding	VERB	O	O
the	DET	O	O
exercise	NOUN	O	O
dose	NOUN	O	O
necessary	ADJ	O	O
to	PART	O	O
promote	NOUN	O	O
this	DET	O	O
improvement	NOUN	O	O
.	PUNCT	O	O

METHODOLOGY/PRINCIPAL	ADV	O	O
FINDINGS	NOUN	O	O
Our	ADJ	O	O
primary	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
measure	VERB	O	O
HRV	NOUN	O	O
in	ADP	O	O
post-menopausal	ADJ	O	O
women	NOUN	O	O
following	VERB	O	O
6-months	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
training	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
supine	NOUN	O	O
resting	VERB	O	O
HRV	NOUN	O	O
in	ADP	O	O
373	NUM	O	O
post-menopausal	ADJ	O	O
women	NOUN	O	O
(	PUNCT	O	O
45-75	PUNCT	O	O
y	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
6-months	NOUN	O	O
of	ADP	O	O
randomly	ADV	O	O
assigned	VERB	O	O
and	CCONJ	O	O
double-blinded	PUNCT	O	O
administered	DET	O	O
exercise	NOUN	O	O
training	VERB	O	O
exercise	NOUN	O	O
training	VERB	O	O
at	ADP	O	O
50	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
150	NUM	O	O
%	DET	O	O
of	ADP	O	O
the	DET	O	O
NIH	NOUN	O	O
Consensus	NOUN	O	O
Development	NOUN	O	O
Panel	NOUN	O	O
's	PUNCT	O	O
recommended	DET	O	O
minimal	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

This	PUNCT	O	O
corresponded	CCONJ	O	O
to	ADP	O	O
4	PUNCT	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
12	NUM	O	O
kcal/kg	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
(	PUNCT	O	O
KKW	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
energy	NOUN	O	O
expenditure	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
we	PUNCT	O	O
observed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
HRV	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
hormone	NOUN	O	B-PHYSICAL
replacement	NOUN	O	O
use	PUNCT	O	O
between	ADP	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
we	PROPN	O	O
did	CCONJ	O	O
observe	PUNCT	O	O
that	ADP	O	O
Caucasian	ADJ	O	O
women	NOUN	O	O
and	CCONJ	O	O
those	PUNCT	O	O
taking	PUNCT	O	O
antidepressant	NOUN	O	O
medications	NOUN	O	O
had	ADP	O	O
lower	ADP	O	O
levels	NOUN	O	O
of	ADP	O	O
baseline	NOUN	O	O
HRV	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

After	ADP	O	O
6-months	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
observed	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
dependent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
all	PUNCT	O	O
parasympathetically	ADJ	O	O
derived	VERB	O	O
time	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
frequency	NOUN	O	O
domain	NOUN	O	B-PHYSICAL
measurements	NOUN	O	B-PHYSICAL
across	ADP	O	O
exercise	NOUN	O	O
groups	NOUN	O	O
after	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
ethnicity	NOUN	O	O
,	PUNCT	O	O
antidepressants	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
baseline	NOUN	O	O
rMSSD	NOUN	O	O
(	PUNCT	O	O
all	ADP	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
the	PUNCT	O	O

Milk	NOUN	O	O
protein	NOUN	O	O
quantity	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
in	ADP	O	O
low-birth-weight	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

IV	NUM	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
on	ADP	O	O
tyrosine	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
phenylalanine	NOUN	O	B-PHYSICAL
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
.	PUNCT	O	O

Well	VERB	O	O
,	PUNCT	O	O
appropriate-for-gestational	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
low-birth-weight	ADJ	O	O
infants	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
three	NUM	O	O
gestational	ADJ	O	O
age	NOUN	O	O
groups	NOUN	O	O
and	CCONJ	O	O
assigned	PUNCT	O	O
randomly	ADV	O	O
within	ADP	O	O
each	DET	O	O
age	NOUN	O	O
group	NOUN	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
five	NUM	O	O
feeding	ADP	O	O
regimens	NOUN	O	O
:	PUNCT	O	O
pooled	DET	O	O
human	NOUN	O	O
milk	NOUN	O	O
(	PUNCT	O	O
BM	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
formula	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
F1	NOUN	O	O
)	PUNCT	O	O
=	ADP	O	O
1.5	NUM	O	O
gm/dl	NOUN	O	O
protein	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
parts	NOUN	O	O
bovine	ADJ	O	O
whey	PUNCT	O	O
proteins	NOUN	O	O
:	PUNCT	O	O
40	NUM	O	O
parts	NOUN	O	O
bovine	ADJ	O	O
caseins	NOUN	O	O
;	PUNCT	O	O
F2	NOUN	O	O
=	SYM	O	O
3.0	NUM	O	O
gm/dl	NOUN	O	O
,	PUNCT	O	O
60:40	NOUN	O	O
;	PUNCT	O	O
F3	NOUN	O	O
=	DET	O	O
1.5	NUM	O	O
gm/dl	NOUN	O	O
,	PUNCT	O	O
18:82	NOUN	O	O
;	PUNCT	O	O
F4	NOUN	O	O
=	SYM	O	O
3.0	NUM	O	O
gm/dl	NOUN	O	O
,	PUNCT	O	O
18:82	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
tyrosine	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
phenylalanine	NOUN	O	B-PHYSICAL
were	VERB	O	O
far	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
infants	NOUN	O	O
fed	VERB	O	O
F1	NOUN	O	O
to	ADP	O	O
F4	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
F2	NOUN	O	O
and	CCONJ	O	O
F4	NOUN	O	O
,	PUNCT	O	O
than	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
infants	NOUN	O	O
fed	VERB	O	O
BM	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
offer	VERB	O	O
further	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
the	DET	O	O
limited	VERB	O	O
capacity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
low-birth-weight	ADJ	O	O
infant	NOUN	O	O
to	ADP	O	O
catabolize	PROPN	O	B-PHYSICAL
tyrosine	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Infants	NOUN	O	O
fed	VERB	O	O
F3	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
plasma	NOUN	O	B-PHYSICAL
tyrosine	NOUN	O	I-PHYSICAL
concentrations	ADJ	O	I-PHYSICAL
than	ADP	O	O
infants	NOUN	O	O
fed	VERB	O	O
F1	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
those	PUNCT	O	O
fed	VERB	O	O
F4	NOUN	O	O
had	PUNCT	O	O
higher	PUNCT	O	O
concentrations	NOUN	O	O
than	PUNCT	O	O
those	PUNCT	O	O
fed	VERB	O	O
F2	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
increased	VERB	O	O
plasma	NOUN	O	B-PHYSICAL
tyrosine	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
in	ADP	O	O
low-birth-weight	ADJ	O	O
infants	NOUN	O	O
are	VERB	O	O
related	VERB	O	O
directly	ADP	O	O
both	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
quantity	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
the	DET	O	O
protein	NOUN	O	O
in	ADP	O	O
their	DET	O	O
diets	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
acebutolol	NOUN	O	O
on	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
performance	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
acebutolol	NOUN	O	O
on	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
performance	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
by	ADP	O	O
various	ADJ	O	O
noninvasive	ADJ	O	O
means	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
studies	NOUN	O	O
.	PUNCT	O	O

M-mode	ADJ	O	O
echocardiographic	ADJ	O	O
measurements	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
in	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
receiving	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
acebutolol	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
propranolol	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
or	CCONJ	O	O
near-normal	ADJ	O	O
resting	PUNCT	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
neither	CCONJ	O	O
drug	NOUN	O	O
induced	VERB	O	O
depression	NOUN	O	O
of	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
26	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
angina	NOUN	O	O
pectoris	NOUN	O	O
receiving	VERB	O	O
acebutolol	NOUN	O	O
under	ADP	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
gated	VERB	O	O
(	PUNCT	O	O
equilibrium	NOUN	O	O
)	PUNCT	O	O
myocardial	ADJ	O	O
blood	NOUN	O	O
pool	NOUN	O	O
imaging	ADJ	O	O
using	ADV	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
labeled	VERB	O	O
with	ADP	O	O
technetium	NOUN	O	O
99m	NOUN	O	O
showed	CCONJ	O	O
acebutolol	NOUN	O	O
to	ADP	O	O
have	PUNCT	O	O
no	DET	O	O
clinically	ADV	O	O
significant	ADJ	O	O
negative	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
performance	NOUN	O	O
at	ADP	O	O
rest	NOUN	O	O
or	CCONJ	O	O
during	ADP	O	O
supine	NOUN	O	O
bicycle	NOUN	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Acebutolol	NOUN	O	O
at	ADP	O	O
effective	ADJ	O	O
antianginal	ADJ	O	O
doses	NOUN	O	O
modestly	ADV	O	O
improved	VERB	O	O
resting	VERB	O	B-PHYSICAL
global	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
regional	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
angina	NOUN	O	O
pectoris	NOUN	O	O
,	PUNCT	O	O
single-pass	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
with	ADP	O	O
indium	NOUN	O	O
113	NUM	O	O
under	ADP	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
conditions	NOUN	O	O
similarly	ADV	O	O
showed	ADV	O	O
acebutolol	NOUN	O	O
to	ADP	O	O
have	PUNCT	O	O
no	DET	O	O
clinically	ADV	O	O
significant	ADJ	O	O
negative	ADJ	O	O
inotropic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
acebutolol	NOUN	O	O
is	VERB	O	O
safe	ADJ	O	O
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	O
disease	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
ejection	NOUN	O	O
fractions	NOUN	O	O
but	CCONJ	O	O
,	PUNCT	O	O
as	CCONJ	O	O
with	ADP	O	O
all	DET	O	O
beta	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
should	ADP	O	O
be	VERB	O	O
used	VERB	O	O
cautiously	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
markedly	ADV	O	O
reduced	PUNCT	O	O
resting	VERB	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Risperidone	NUM	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
serious	ADJ	O	O
behavioral	ADJ	O	O
problems	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Atypical	ADJ	O	O
antipsychotic	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
which	PUNCT	O	O
block	VERB	O	O
postsynaptic	ADJ	O	O
dopamine	NOUN	O	O
and	CCONJ	O	O
serotonin	NOUN	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
have	VERB	O	O
advantages	NOUN	O	O
over	ADP	O	O
traditional	ADJ	O	O
antipsychotic	ADJ	O	O
medications	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
beneficial	ADJ	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
who	CCONJ	O	O
have	PUNCT	O	O
serious	ADJ	O	O
behavioral	ADJ	O	O
disturbances	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
data	NOUN	O	O
on	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
are	VERB	O	O
limited	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
multisite	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
accompanied	VERB	O	O
by	ADP	O	O
severe	ADJ	O	O
tantrums	ADP	O	O
,	PUNCT	O	O
aggression	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
self-injurious	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
5	NUM	O	O
to	ADP	O	O
17	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
the	DET	O	O
score	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Irritability	NOUN	O	O
subscale	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Aberrant	ADJ	O	O
Behavior	NOUN	O	O
Checklist	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
rating	VERB	O	O
on	ADP	O	O
the	DET	O	O
Clinical	ADJ	O	O
Global	PUNCT	O	O
Impressions	NOUN	O	O
-	PUNCT	O	O
Improvement	NOUN	O	O
(	PUNCT	O	O
CGI-I	NOUN	O	O
)	PUNCT	O	O
scale	NOUN	O	O
at	ADP	O	O
eight	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
101	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
82	NUM	O	O
boys	NOUN	O	O
and	CCONJ	O	O
19	NUM	O	O
girls	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
[	PUNCT	O	O
+/-SD	PUNCT	O	O
]	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
8.8+/-2.7	NOUN	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
risperidone	NUM	O	O
(	PUNCT	O	O
49	NUM	O	O
children	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
52	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
risperidone	NUM	O	O
for	ADP	O	O
eight	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
dose	NOUN	O	O
range	NOUN	O	O
,	PUNCT	O	O
0.5	NUM	O	O
to	ADP	O	O
3.5	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
56.9	NUM	O	O
percent	NOUN	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Irritability	NOUN	O	B-MENTAL
score	NOUN	O	I-MENTAL
,	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
14.1	NUM	O	O
percent	NOUN	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
response	NOUN	O	O
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
at	VERB	O	O
least	DET	O	O
a	DET	O	O
25	NUM	O	O
percent	NOUN	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Irritability	NOUN	O	B-MENTAL
score	NOUN	O	I-MENTAL
and	CCONJ	O	O
a	DET	O	O
rating	PUNCT	O	O
of	ADP	O	O
much	DET	O	O
improved	ADP	O	O
or	CCONJ	O	O
very	ADV	O	O
much	DET	O	O
improved	VERB	O	O
on	ADP	O	O
the	DET	O	O
CGI-I	NOUN	O	B-MENTAL
scale	NOUN	O	I-MENTAL
,	PUNCT	O	O
was	VERB	O	O
69	NUM	O	O
percent	NOUN	O	O
in	ADP	O	O
the	DET	O	O
risperidone	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
34	NUM	O	O
of	ADP	O	O
49	NUM	O	O
children	NOUN	O	O
had	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
response	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
percent	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
of	ADP	O	O
52	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Risperidone	NUM	O	O
therapy	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
average	ADJ	O	O
weight	NOUN	O	O
gain	NOUN	O	B-PHYSICAL
of	ADP	O	O
2.7+/-2.9	NOUN	O	O
kg	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
0.8+/-2.2	PUNCT	O	O
kg	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Increased	VERB	O	O
appetite	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
fatigue	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
drowsiness	PUNCT	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
dizziness	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
drooling	PUNCT	O	B-ADVERSE-EFFECTS
were	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
the	DET	O	O
risperidone	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
for	ADP	O	O
each	DET	O	O
comparison	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
thirds	NOUN	O	O
of	ADP	O	O
the	DET	O	O
children	NOUN	O	O
with	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
risperidone	NUM	O	O
at	ADP	O	O
eight	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
23	NUM	O	O
of	ADP	O	O
34	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
benefit	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
at	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Risperidone	NUM	O	O
was	VERB	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	VERB	O	O
tolerated	ADP	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
tantrums	ADV	O	O
,	PUNCT	O	O
aggression	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
self-injurious	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
short	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
limits	NOUN	O	O
inferences	PUNCT	O	O
about	PUNCT	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
tardive	ADJ	O	O
dyskinesia	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
of	ADP	O	O
outpatient	ADJ	O	O
induction	NOUN	O	O
with	ADP	O	O
low-dose	NOUN	O	O
intravaginal	ADJ	O	O
prostaglandin	NOUN	O	O
E2	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Our	PUNCT	O	O
purpose	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
a	DET	O	O
protocol	NOUN	O	O
for	ADP	O	O
outpatient	ADJ	O	O
induction	NOUN	O	O
is	VERB	O	O
safe	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
effective	ADJ	O	O
for	ADP	O	O
initiating	VERB	O	O
labor	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
100	NUM	O	O
low-risk	NOUN	O	O
patients	NOUN	O	O
having	ADJ	O	O
well-dated	VERB	O	O
pregnancies	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
with	ADP	O	O
a	DET	O	O
Bishop	ADJ	O	O
score	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
6	NUM	O	O
at	ADP	O	O
38	NUM	O	O
to	ADP	O	O
40	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
gestation	NOUN	O	O
were	VERB	O	O
administered	ADP	O	O
either	CCONJ	O	O
2	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
intravaginal	ADJ	O	O
prostaglandin	NOUN	O	O
E2	NOUN	O	O
gel	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
as	ADP	O	O
outpatients	VERB	O	O
while	ADP	O	O
undergoing	ADP	O	O
fetal	ADJ	O	O
monitoring	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
median	ADJ	O	O
interval	NOUN	O	O
from	ADP	O	O
randomization	NOUN	O	O
to	ADP	O	B-PHYSICAL
delivery	NOUN	O	I-PHYSICAL
was	VERB	O	O
4	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prostaglandin	NOUN	O	O
E2	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
0	NUM	O	O
to	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
10	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
0	NUM	O	O
to	ADP	O	O
26	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Twenty-seven	PUNCT	O	O
of	ADP	O	O
50	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
54	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
prostaglandin	NOUN	O	O
E2	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
admitted	VERB	O	O
for	ADP	O	O
labor	NOUN	O	O
during	ADP	O	O
the	DET	O	O
dosing	ADJ	O	O
interval	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
10	NUM	O	O
placebo-treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
gestational	ADJ	O	B-PHYSICAL
age	NOUN	O	O
at	ADP	O	B-PHYSICAL
delivery	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
39.9	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
weeks	NOUN	O	O
vs	CCONJ	O	O
40.5	NUM	O	O
+/-	SYM	O	O
0.99	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
as	CCONJ	O	O
was	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
postdates	PUNCT	O	B-MENTAL

Walking	VERB	O	O
trials	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
:	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
vs	CCONJ	O	O
two	NUM	O	O
daily	ADJ	O	O
bouts	NOUN	O	O
on	ADP	O	O
aerobic	ADJ	O	B-PHYSICAL
fitness	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
vs	CCONJ	O	O
two	NUM	O	O
daily	ADJ	O	O
bouts	NOUN	O	O
of	ADP	O	O
walking	NUM	O	O
on	ADP	O	O
aerobic	ADJ	O	B-PHYSICAL
fitness	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
body	NOUN	O	B-PHYSICAL
composition	NOUN	O	I-PHYSICAL
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
thirty-four	NOUN	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
exercise	NOUN	O	O
groups	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
130	NUM	O	O
completed	PUNCT	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subjects	NOUN	O	O
walked	PUNCT	O	O
5	NUM	O	O
d/week	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
weeks	NOUN	O	O
at	ADP	O	O
65	NUM	O	O
%	SYM	O	O
of	ADP	O	O
their	PUNCT	O	O
maximal	ADJ	O	O
aerobic	ADJ	O	O
power	NOUN	O	O
expending	CCONJ	O	O
300	NUM	O	O
kcal	NOUN	O	O
(	PUNCT	O	O
1255	ADP	O	O
kJ	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
exercise	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
(	PUNCT	O	O
Group	NOUN	O	O
S1	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
two	NUM	O	O
daily	ADJ	O	O
sessions	NOUN	O	O
(	PUNCT	O	O
Group	NOUN	O	O
S2	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

VO	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
2max	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
a	DET	O	O
direct	ADJ	O	O
maximal	ADJ	O	O
treadmill	ADP	O	O
test	NOUN	O	O
.	PUNCT	O	O

Body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
BMI	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
calculated	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
fat	NOUN	O	O
(	PUNCT	O	O
fat	NOUN	O	O
%	ADV	O	O
)	PUNCT	O	O
estimated	VERB	O	O
using	CCONJ	O	O
skinfold	PUNCT	O	O
measurements	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
net	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
VO	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
2max	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
was	VERB	O	O
2.5	NUM	O	O
mL	NOUN	O	O
min/kg	PUNCT	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.5	NUM	O	O
,	PUNCT	O	O
3.5	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
8.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
Group	NOUN	O	O
S1	NOUN	O	O
and	CCONJ	O	O
2.5	NUM	O	O
mL	NOUN	O	O
min/kg	PUNCT	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.5	NUM	O	O
,	PUNCT	O	O
3.5	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
8.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
Group	NOUN	O	O
S2	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
net	ADJ	O	B-PHYSICAL
change	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
body	NOUN	O	I-PHYSICAL
mass	NOUN	O	I-PHYSICAL
was	VERB	O	O
-1.2	NUM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI-1.9	NOUN	O	O
,	PUNCT	O	O
-0.5	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
Group	NOUN	O	O
S1	NOUN	O	O
and	CCONJ	O	O
-1.1	NUM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
-1.8	NUM	O	O
,	PUNCT	O	O
-0.4	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
Group	NOUN	O	O
S2	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
net	ADJ	O	B-PHYSICAL
fat	NOUN	O	I-PHYSICAL
%	DET	O	I-PHYSICAL
change	NOUN	O	I-PHYSICAL
was	VERB	O	O
-2.1	ADV	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI-2.7	NOUN	O	O
,	PUNCT	O	O
-1.4	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
Group	NOUN	O	O
S1	NOUN	O	O
and	CCONJ	O	O
-1.7	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI-2.3	NOUN	O	O
,	PUNCT	O	O
-1.0	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
Group	NOUN	O	O
S2	NOUN	O	O
.	PUNCT	O	O

Exercise	NOUN	O	O
improved	VERB	O	O
the	DET	O	O
maximal	ADJ	O	O
aerobic	ADJ	O	O
power	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	O
composition	NOUN	O	O
equally	ADV	O	O
when	ADP	O	O
walking	ADP	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
two	NUM	O	O
daily	ADJ	O	O
bouts	NOUN	O	O
.	PUNCT	O	O

Epileptogenic	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
folic	ADJ	O	O
acid	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
induces	NOUN	O	O
SLE	NOUN	O	O
(	PUNCT	O	O
folic	ADJ	O	O
acid	NOUN	O	O
and	CCONJ	O	O
epilepsy	NOUN	O	O
)	PUNCT	O	O
OBJECTIVE	NOUN	O	O
To	PART	O	O
study	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
folic	ADJ	O	O
acid-containing	PROPN	O	O
multivitamin	NOUN	O	O
supplementation	NOUN	O	O
in	ADP	O	O
epileptic	ADJ	O	O
women	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
structural	ADJ	O	O
birth	NOUN	O	O
defects	NOUN	O	O
and	CCONJ	O	O
epilepsy-related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
First	ADJ	O	O
a	DET	O	O
randomised	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
later	PUNCT	O	O
periconception	NOUN	O	O
care	NOUN	O	O
including	ADJ	O	O
in	ADP	O	O
total	ADJ	O	O
12225	NUM	O	O
females	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
60	NUM	O	O
epileptic	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
periconceptional	ADJ	O	O
folic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
0.8	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
-containing	ADP	O	O
multivitamin	NOUN	O	O
supplementation	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
one	NUM	O	O
developed	VERB	O	O
epilepsy-related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
during	ADP	O	O
the	DET	O	O
periconception	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
epileptic	ADJ	O	O
woman	NOUN	O	O
delivered	ADV	O	O
a	DET	O	O
newborn	NOUN	O	O
with	ADP	O	O
cleft	NOUN	O	O
lip	NOUN	O	O
and	CCONJ	O	O
palate	NOUN	O	O
.	PUNCT	O	O

Another	DET	O	O
patient	NOUN	O	O
exhibited	VERB	O	O
with	ADP	O	O
a	DET	O	O
cluster	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	B-ADVERSE-EFFECTS
after	ADP	O	O
the	DET	O	O
periconception	NOUN	O	O
period	NOUN	O	O
using	VERB	O	O
another	DET	O	O
multivitamin	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
22-year-old	PUNCT	O	O
epileptic	ADJ	O	O
woman	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
continuously	ADV	O	O
by	ADP	O	O
carbamazepine	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
folic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
-containing	ADP	O	O
multivitamin	NOUN	O	O
from	ADP	O	O
the	DET	O	O
20th	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

She	NOUN	O	O
developed	VERB	O	O
status	NOUN	O	B-ADVERSE-EFFECTS
epilepticus	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
later	PUNCT	O	O
symptoms	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	B-ADVERSE-EFFECTS
lupus	NOUN	O	I-ADVERSE-EFFECTS
erythematodes	VERB	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Her	PUNCT	O	O
pregnancy	NOUN	O	O
ended	PUNCT	O	O
with	ADP	O	O
stillbirth	PUNCT	O	B-MORTALITY
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
epileptic	ADJ	O	O
pregnant	ADJ	O	O
patient	NOUN	O	O
's	PUNCT	O	O
autoimmune	ADJ	O	O
disease	NOUN	O	O
(	PUNCT	O	O
probably	ADV	O	O
drug-induced	VERB	O	O
lupus	NOUN	O	O
)	PUNCT	O	O
could	VERB	O	O
damage	VERB	O	O
the	DET	O	O
blood-brain	ADJ	O	O
barrier	NOUN	O	O
,	PUNCT	O	O
therefore	ADV	O	O
the	DET	O	O
therapeutic	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
>	ADJ	O	O
or	CCONJ	O	O
=1	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
folic	ADJ	O	O
acid	NOUN	O	O
triggered	VERB	O	O
a	DET	O	O
cluster	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

Physiological	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
<	PROPN	O	O
1	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
folic	ADJ	O	O
acid	NOUN	O	O
both	PUNCT	O	O
in	ADP	O	O
healthy	ADJ	O	O
and	CCONJ	O	O
60	NUM	O	O
epileptic	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
all	CCONJ	O	O
without	ADP	O	O
any	DET	O	O
autoimmune	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
did	CCONJ	O	O
not	ADV	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
epileptic	ADJ	O	B-PHYSICAL
seizures	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Impact	NOUN	O	O
of	ADP	O	O
an	DET	O	O
Asha	ADJ	O	O
intervention	NOUN	O	O
on	ADP	O	O
depressive	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
among	ADP	O	O
rural	ADJ	O	O
women	NOUN	O	O
living	CCONJ	O	O
with	ADP	O	O
AIDS	NOUN	O	O
in	ADP	O	O
India	PUNCT	O	O
:	PUNCT	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Asha-Life	NOUN	O	O
and	CCONJ	O	O
Usual	ADJ	O	O
Care	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
pilot	NOUN	O	O
study	NOUN	O	O
is	VERB	O	O
to	PUNCT	O	O
conduct	ADP	O	O
an	DET	O	O
intervention	NOUN	O	O
with	ADP	O	O
68	NUM	O	O
rural	ADJ	O	O
women	NOUN	O	O
living	CCONJ	O	O
with	ADP	O	O
AIDS	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
programs	NOUN	O	O
on	ADP	O	O
depressive	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Asha-Life	PUNCT	O	O
intervention	NOUN	O	O
engaging	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
HIV-trained	ADJ	O	O
village	PUNCT	O	O
woman	NOUN	O	O
,	PUNCT	O	O
Asha	NOUN	O	O
(	PUNCT	O	O
Accredited	NOUN	O	O
Social	ADJ	O	O
Health	NOUN	O	O
Activist	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
to	PART	O	O
participate	NOUN	O	O
in	ADP	O	O
the	DET	O	O
care	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
living	CCONJ	O	O
with	ADP	O	O
AIDS	NOUN	O	O
(	PUNCT	O	O
WLA	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
along	PUNCT	O	O
with	ADP	O	O
other	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
providers	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
a	DET	O	O
Usual	ADJ	O	O
Care	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
high	ADJ	O	O
prevalence	NOUN	O	O
HIV/AIDS	NOUN	O	O
villages	ADJ	O	O
in	ADP	O	O
rural	ADJ	O	O
Andhra	NOUN	O	O
Pradesh	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
demographically	ADV	O	O
alike	PUNCT	O	O
and	CCONJ	O	O
served	ADP	O	O
by	ADP	O	O
distinct	ADJ	O	O
Public	ADJ	O	O
Health	NOUN	O	O
Centers	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
selected	VERB	O	O
randomly	ADV	O	O
from	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
16	NUM	O	O
villages	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
Asha-Life	NOUN	O	O
participants	NOUN	O	O
significantly	ADV	O	B-PHYSICAL
reduced	VERB	O	I-PHYSICAL
their	ADJ	O	O
depressive	ADJ	O	B-PHYSICAL
symptom	NOUN	O	I-PHYSICAL
scores	NOUN	O	I-PHYSICAL
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
Usual	ADJ	O	O
Care	NOUN	O	O
participants	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
women	NOUN	O	O
living	CCONJ	O	O
with	ADP	O	O
AIDS	NOUN	O	O
who	ADP	O	O
demonstrated	VERB	O	O
higher	PUNCT	O	O
depressive	ADJ	O	B-PHYSICAL
symptom	NOUN	O	I-PHYSICAL
scores	NOUN	O	I-PHYSICAL
at	ADP	O	O
baseline	NOUN	O	O
had	PUNCT	O	O
greater	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
depressive	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
than	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
lower	PUNCT	O	O
scores	NOUN	O	O
.	PUNCT	O	O

Prophylactic	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	O
in	ADP	O	O
bipolar	ADJ	O	O
disorder	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	ADJ	O	O
Phenytoin	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
anticonvulsant	ADJ	O	O
that	PUNCT	O	O
has	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
been	PUNCT	O	O
studied	VERB	O	O
prophylactically	ADV	O	O
in	ADP	O	O
bipolar	ADJ	O	O
(	PUNCT	O	O
BP	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
a	DET	O	O
study	NOUN	O	O
of	ADP	O	O
phenytoin	PUNCT	O	O
prophylaxis	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
and	CCONJ	O	O
is	VERB	O	O
herein	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Bipolar	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
who	ADP	O	O
had	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
one	NUM	O	O
episode	NOUN	O	O
per	ADP	O	O
year	NOUN	O	O
in	ADP	O	O
the	DET	O	O
previous	ADJ	O	O
2	NUM	O	O
years	NOUN	O	O
despite	ADP	O	O
ongoing	ADP	O	O
prophylaxis	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
stable	ADJ	O	O
for	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
1-13	NUM	O	O
)	PUNCT	O	O
before	ADP	O	O
entering	CCONJ	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Phenytoin	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
was	VERB	O	O
added	VERB	O	O
to	ADP	O	O
their	PUNCT	O	O
current	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
cross-over	NOUN	O	O
design	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
each	DET	O	O
phase	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
observation	NOUN	O	O
periods	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
each	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
23	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Three	NUM	O	O
patients	NOUN	O	O
had	PUNCT	O	O
relapse	NOUN	O	B-PHYSICAL
on	ADP	O	O
phenytoin	NOUN	O	O
and	CCONJ	O	O
nine	NUM	O	O
had	PUNCT	O	O
relapse	NOUN	O	O
on	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
prophylactic	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	O
in	ADP	O	O
BP	NOUN	O	O
disorder	NOUN	O	O
[	PUNCT	O	O
Cox	NOUN	O	B-PHYSICAL
's	PUNCT	O	O
F-test	ADP	O	B-PHYSICAL
for	ADP	O	O
comparing	PUNCT	O	O
survival	NOUN	O	B-MORTALITY
in	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
F	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
18	NUM	O	O
)	PUNCT	O	O
=	SYM	O	O
3.44	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
suggests	NOUN	O	O
prophylactic	ADP	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
of	ADP	O	O
add-on	NOUN	O	O
phenytoin	NOUN	O	O
in	ADP	O	O
BP	NOUN	O	O
illness	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
was	VERB	O	O
small	ADJ	O	O
and	CCONJ	O	O
confirmation	NOUN	O	O
is	VERB	O	O
necessary	ADJ	O	O
.	PUNCT	O	O

Laparoscopic	ADJ	O	O
vs	CCONJ	O	O
open	ADJ	O	O
appendectomy	NOUN	O	O
in	ADP	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Laparoscopic	ADJ	O	O
appendectomy	NOUN	O	O
(	PUNCT	O	O
LA	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
faster	PUNCT	O	O
recovery	NOUN	O	O
and	CCONJ	O	O
less	ADV	O	O
postoperative	ADJ	O	O
pain	NOUN	O	O
than	VERB	O	O
the	DET	O	O
open	ADJ	O	O
technique	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
few	ADJ	O	O
data	NOUN	O	O
are	VERB	O	O
available	ADJ	O	O
on	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
LA	NOUN	O	O
in	ADP	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
group	NOUN	O	O
of	ADP	O	O
106	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
BMI	NOUN	O	O
)	PUNCT	O	O
>	SYM	O	O
26.4	NUM	O	O
,	PUNCT	O	O
representing	VERB	O	O
the	DET	O	O
upper	ADJ	O	O
quintile	ADJ	O	O
of	ADP	O	O
500	NUM	O	O
prospectively	ADV	O	O
randomized	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PUNCT	O	O
undergo	ADP	O	O
either	PUNCT	O	O
laparoscopic	ADJ	O	O
or	CCONJ	O	O
open	ADJ	O	O
appendectomy	NOUN	O	O
(	PUNCT	O	O
OA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Operating	ADP	O	B-OTHER
and	CCONJ	O	I-OTHER
anesthesia	NOUN	O	I-OTHER
times	NOUN	O	I-OTHER
,	PUNCT	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
complications	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
hospital	NOUN	O	B-OTHER
stay	NOUN	O	I-OTHER
,	PUNCT	O	O
functional	ADJ	O	B-PHYSICAL
index	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
1	NUM	O	O
week	NOUN	O	O
postoperatively	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sick	NOUN	O	B-OTHER
leave	PUNCT	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
full	ADJ	O	I-OTHER
recovery	NOUN	O	I-OTHER
were	VERB	O	O
documented	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
OA	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
operating	VERB	O	B-OTHER
time	NOUN	O	I-OTHER
for	ADP	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
than	PUNCT	O	O
that	ADP	O	O
for	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
weight	NOUN	O	O
range	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
vs	CCONJ	O	O
35	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
LA	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
operating	DET	O	B-OTHER
time	NOUN	O	I-OTHER
between	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
and	CCONJ	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Overweight	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
underwent	VERB	O	O
LA	NOUN	O	O
had	PUNCT	O	O
longer	PUNCT	O	O
operating	PUNCT	O	B-OTHER
and	CCONJ	O	I-OTHER
anesthesia	NOUN	O	I-OTHER
times	NOUN	O	I-OTHER
than	CCONJ	O	O
their	CCONJ	O	O
OA	NOUN	O	O
counterparts	NOUN	O	O
(	PUNCT	O	O
55	NUM	O	O
vs	CCONJ	O	O
40	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
125	NUM	O	O
vs	CCONJ	O	O
100	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
underwent	VERB	O	O
OA	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
those	ADP	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
laparoscopic	ADJ	O	O
technique	NOUN	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
was	VERB	O	O
also	ADV	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
OA	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
weight	NOUN	O	O
after	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
may	PUNCT	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
be	PUNCT	O	O
of	ADP	O	O
less	PUNCT	O	O
importance	NOUN	O	O
since	ADP	O	O
the	DET	O	O
values	NOUN	O	O
are	VERB	O	O
low	ADJ	O	O
(	PUNCT	O	O
0.26	NUM	O	O
vs	CCONJ	O	O
0.09	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	ADV	O	O
operating	ADJ	O	O
techniques	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Hospital	NOUN	O	B-OTHER
stay	NOUN	O	I-OTHER
was	VERB	O	O
longer	PUNCT	O	O
for	ADP	O	O
overweight	PUNCT	O	O
patients	ADJ	O	O
than	PUNCT	O	O
for	ADP	O	O
normal-weight	NOUN	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
OA	NOUN	O	O
(	PUNCT	O	O
3.0	NUM	O	O
vs	CCONJ	O	O
2.0	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
functional	ADJ	O	O
index	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
any	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Sick	NOUN	O	B-OTHER
leave	PUNCT	O	I-OTHER
was	ADP	O	O
longer	PUNCT	O	O
for	ADP	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
underwent	VERB	O	O
OA	NOUN	O	O
than	PUNCT	O	O
for	ADP	O	O
normal-weight	NOUN	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
same	ADJ	O	O
technique	NOUN	O	O
(	PUNCT	O	O
17	NUM	O	O
vs	CCONJ	O	O
13	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
laparoscopic	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
overweight	ADJ	O	O
and	CCONJ	O	O
normal-weight	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
full	ADJ	O	I-OTHER
recovery	NOUN	O	I-OTHER
was	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
OA	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
LA	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
22	NUM	O	O
vs	CCONJ	O	O
15	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
submitted	VERB	O	O
to	ADP	O	O
LA	NOUN	O	O
had	PUNCT	O	O
less	ADV	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
and	CCONJ	O	O
a	DET	O	O
faster	PUNCT	O	O
postoperative	ADJ	O	B-OTHER
recovery	NOUN	O	I-OTHER
than	PUNCT	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
OA	NOUN	O	O
.	PUNCT	O	O

LA	NOUN	O	O
also	ADV	O	O
abolished	ADJ	O	O
some	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
negative	ADJ	O	O
effects	NOUN	O	O
that	PUNCT	O	O
overweight	ADV	O	O
had	PUNCT	O	O
on	ADP	O	O
operating	PUNCT	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
hospital	NOUN	O	B-OTHER
stay	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
sick	NOUN	O	B-OTHER
leave	PUNCT	O	I-OTHER
with	ADP	O	O
the	DET	O	O
open	ADJ	O	O
technique	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
anesthesia	NOUN	O	O
and	CCONJ	O	O
operating	PUNCT	O	O
times	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
in	ADP	O	O
LA	NOUN	O	O
for	ADP	O	O
both	CCONJ	O	O
overweight	PUNCT	O	O
patients	NOUN	O	O
and	CCONJ	O	O
those	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
BMI	NOUN	O	O
.	PUNCT	O	O

Do	PUNCT	O	O
colonic	ADJ	O	O
short-chain	NOUN	O	O
fatty	ADJ	O	O
acids	NOUN	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
long-term	NOUN	O	B-PHYSICAL
adaptation	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	PUNCT	O	O
consuming	PUNCT	O	O
a	DET	O	O
high-fiber	NOUN	O	O
diet	NOUN	O	O
?	PUNCT	O	O

BACKGROUND	NOUN	O	O
We	ADP	O	O
recently	ADV	O	O
obtained	PUNCT	O	O
evidence	NOUN	O	O
of	ADP	O	O
long-term	NOUN	O	B-PHYSICAL
adaptation	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
intakes	NOUN	O	O
of	ADP	O	O
carbohydrate	NOUN	O	O
and	CCONJ	O	O
fiber	NOUN	O	O
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
We	PRON	O	O
determined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
carbohydrate	NOUN	O	O
and	CCONJ	O	O
fiber	NOUN	O	O
intakes	CCONJ	O	O
on	ADP	O	O
serum	NOUN	O	B-PHYSICAL
short-chain	NOUN	O	I-PHYSICAL
fatty	ADJ	O	I-PHYSICAL
acids	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
SCFAs	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
changes	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
serum	NOUN	O	I-PHYSICAL
acetate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
changes	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

DESIGN	NOUN	O	O
Subjects	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
62	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	ADP	O	O
approximately	ADV	O	O
10	NUM	O	O
%	SYM	O	O
of	ADP	O	O
energy	NOUN	O	O
from	ADP	O	O
low-fiber	NOUN	O	O
breakfast	NOUN	O	O
cereal	ADJ	O	O
(	PUNCT	O	O
LF	NOUN	O	O
diet	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
high-fiber	NOUN	O	O
breakfast	NOUN	O	O
cereal	ADJ	O	O
(	PUNCT	O	O
HF	NOUN	O	O
diet	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
monounsaturated	VERB	O	O
fatty	ADJ	O	O
acids	NOUN	O	O
(	PUNCT	O	O
MUFA	NOUN	O	O
diet	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
6	NUM	O	O
mo	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Carbohydrate	NOUN	O	B-PHYSICAL
intakes	NOUN	O	I-PHYSICAL
were	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
LF	NOUN	O	O
and	CCONJ	O	O
HF	NOUN	O	O
groups	NOUN	O	O
than	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
MUFA	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
54	NUM	O	O
%	SYM	O	O
compared	VERB	O	O
with	ADP	O	O
43	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
more	DET	O	O
fiber	NOUN	O	O
was	VERB	O	O
consumed	VERB	O	O
by	ADP	O	O
the	DET	O	O
HF	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
approximately	ADV	O	O
50	NUM	O	O
g/d	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
by	ADP	O	O
the	DET	O	O
LF	NOUN	O	O
or	CCONJ	O	O
MUFA	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
approximately	ADV	O	O
23	NUM	O	O
g/d	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Fasting	PUNCT	O	B-PHYSICAL
serum	NOUN	O	I-PHYSICAL
SCFAs	NOUN	O	I-PHYSICAL
did	ADP	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
over	ADP	O	O
the	DET	O	O
first	ADJ	O	O
3	NUM	O	O
mo	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
mo	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
acetate	NOUN	O	I-PHYSICAL
tended	VERB	O	O
(	PUNCT	O	O
NS	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
LF	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
from	ADP	O	O
69	NUM	O	O
+/-	SYM	O	O
4	NUM	O	O
to	ADP	O	O
59	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
micromol/L	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increase	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
HF	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
from	ADP	O	O
100	NUM	O	O
+/-	SYM	O	O
18	NUM	O	O
to	ADP	O	O
107	NUM	O	O
+/-	SYM	O	O
17	NUM	O	O
micromol/L	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MUFA	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
butyrate	NOUN	O	I-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
LF	NOUN	O	O
or	CCONJ	O	O
MUFA	NOUN	O	O
group	NOUN	O	O
but	CCONJ	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
HF	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
from	ADP	O	O
2.5	NUM	O	O
+/-	SYM	O	O
0.5	NUM	O	O
to	ADP	O	O
3.1	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
micromol/L	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	B-PHYSICAL
acetate	NOUN	O	I-PHYSICAL
from	ADP	O	O
0	NUM	O	O
to	ADP	O	O
3	NUM	O	O
mo	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
related	PUNCT	O	O
to	ADP	O	O
changes	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	B-PHYSICAL
acetate	NOUN	O	I-PHYSICAL
from	ADP	O	O
3	NUM	O	O
to	ADP	O	O
6	NUM	O	O
mo	NOUN	O	O
were	VERB	O	O
positively	ADV	O	O
related	ADP	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ratio	NOUN	O	O
of	ADP	O	B-PHYSICAL
total	CCONJ	O	O
to	ADP	O	B-PHYSICAL
HDL	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.041	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
fasting	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.013	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
postprandial	ADJ	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	B-PHYSICAL
=	SYM	O	B-PHYSICAL
0.016	NUM	O	O
)	PUNCT	O	O
triacylglycerols	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	PUNCT	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	B-PHYSICAL
SCFAs	NOUN	O	I-PHYSICAL
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
changes	NOUN	O	O
in	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	B-PHYSICAL
on	ADP	O	O
human	NOUN	O	O
circulation	NOUN	O	O
.	PUNCT	O	O

Prostaglandins	NOUN	O	O
(	PUNCT	O	O
PGs	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
E-type	NOUN	O	O
are	VERB	O	O
potent	ADJ	O	O
vasodilators	NOUN	O	O
in	ADP	O	O
most	DET	O	O
species	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
most	DET	O	O
vascular	ADJ	O	O
beds	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
vasoconstrictor	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
PGEs	NOUN	O	O
have	PUNCT	O	O
also	ADV	O	O
been	PUNCT	O	O
noted	VERB	O	O
at	ADP	O	O
selected	VERB	O	O
sites	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
PGE1	NOUN	O	O
analog	NOUN	O	O
with	ADP	O	O
antiulcer	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
human	NOUN	O	O
cardiovascular	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
this	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
group	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
a	DET	O	O
12	NUM	O	O
hour	NOUN	O	O
fast	ADJ	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
light	PUNCT	O	O
reflex	NOUN	O	O
plethysmography	NOUN	O	O
of	ADP	O	O
the	DET	O	O
finger	NOUN	O	O
,	PUNCT	O	O
resting	ADP	O	O
blood	NOUN	O	O
flow	NOUN	O	O
volume	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lower	PUNCT	O	O
arm	ADP	O	O
and	CCONJ	O	O
leg	NOUN	O	O
and	CCONJ	O	O
peripheral	ADJ	O	B-PHYSICAL
vascular	ADJ	O	I-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
10	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

intervals	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
permit	PUNCT	O	O
calculating	PUNCT	O	O
baseline	NOUN	O	O
values	NOUN	O	O
.	PUNCT	O	O

Misoprostol	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
mcg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
its	PUNCT	O	O
matching	VERB	O	O
placebo	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
orally	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
measurements	NOUN	O	O
were	VERB	O	O
repeated	VERB	O	O
at	ADP	O	O
10	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

intervals	NOUN	O	O
over	ADP	O	O
the	DET	O	O
next	ADJ	O	O
2	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
leg	NOUN	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
a	DET	O	O
corresponding	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
leg	NOUN	O	B-PHYSICAL
peripheral	ADJ	O	I-PHYSICAL
vascular	ADJ	O	I-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
misoprostol	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
noted	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
small	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
considered	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
of	ADP	O	O
clinical	ADJ	O	O
importance	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
adverse	ADJ	O	B-PHYSICAL
experiences	NOUN	O	I-PHYSICAL
were	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
mcg	NOUN	O	O
)	PUNCT	O	O
has	CCONJ	O	O
no	DET	O	O
clinically	ADV	O	O
significant	ADJ	O	O
vasoconstrictive	ADJ	O	B-PHYSICAL
or	CCONJ	O	O
vasodilative	ADJ	O	B-PHYSICAL
properties	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
caries	NOUN	O	O
formation	NOUN	O	O
in	VERB	O	O
vitro	ADJ	O	O
around	ADP	O	O
glass	NOUN	O	O
ionomer-lined	VERB	O	O
amalgam	NOUN	O	O
and	CCONJ	O	O
composite	ADJ	O	O
restorations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
in	DET	O	O
vitro	ADJ	O	O
secondary	ADJ	O	O
caries	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
glass-ionomer	NOUN	O	O
liner	PUNCT	O	O
's	PUNCT	O	O
effect	NOUN	O	O
on	ADP	O	O
wall-lesion	NOUN	O	O
inhibition	NOUN	O	O
when	ADP	O	O
a	DET	O	O
conventional	ADJ	O	O
and	CCONJ	O	O
a	DET	O	O
light-cured	PUNCT	O	O
glass	NOUN	O	O
ionomer	NOUN	O	O
liner	PUNCT	O	O
was	VERB	O	O
placed	VERB	O	O
under	ADP	O	O
amalgam	NOUN	O	O
and	CCONJ	O	O
composite	PUNCT	O	O
resin	NOUN	O	O
restorations	NOUN	O	O
.	PUNCT	O	O

Class	NOUN	O	O
V	NUM	O	O
preparations	NOUN	O	O
in	ADP	O	O
extracted	ADP	O	O
upper	ADJ	O	O
premolars	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
and	CCONJ	O	O
ten	NUM	O	O
restorations	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
for	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
following	DET	O	O
groups	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
i	NUM	O	O
)	PUNCT	O	O
two	NUM	O	O
layers	NOUN	O	O
of	ADP	O	O
copal	ADJ	O	O
varnish	ADJ	O	O
and	CCONJ	O	O
amalgam	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
ii	NUM	O	O
)	PUNCT	O	O
conventional	ADJ	O	O
glass-ionomer	NOUN	O	O
and	CCONJ	O	O
amalgam	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
iii	ADP	O	O
)	PUNCT	O	O
light-cured	NOUN	O	O
glass-ionomer	NOUN	O	O
and	CCONJ	O	O
amalgam	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
iv	PUNCT	O	O
)	PUNCT	O	O
bonding	DET	O	O
agent	NOUN	O	O
and	CCONJ	O	O
light-cured	PUNCT	O	O
composite	ADJ	O	O
resin	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
v	NUM	O	O
)	PUNCT	O	O
conventional	ADJ	O	O
glass-ionomer	NOUN	O	O
,	PUNCT	O	O
bonding	ADP	O	O
agent	NOUN	O	O
and	CCONJ	O	O
light-cured	PUNCT	O	O
composite	ADJ	O	O
resin	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
vi	CCONJ	O	O
)	PUNCT	O	O
light-cured	NOUN	O	O
glass-ionomer	NOUN	O	O
,	PUNCT	O	O
extended	PUNCT	O	O
0.3	NUM	O	O
mm	NOUN	O	O
short	ADJ	O	O
of	ADP	O	O
the	DET	O	O
enamel	NOUN	O	O
margin	NOUN	O	O
bonding	VERB	O	O
agent	NOUN	O	O
and	CCONJ	O	O
light-cured	PUNCT	O	O
composite	ADJ	O	O
resin	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
vii	ADP	O	O
)	PUNCT	O	O
light-cured	NOUN	O	O
glass-ionomer	NOUN	O	O
,	PUNCT	O	O
extended	PUNCT	O	O
1	NUM	O	O
mm	NOUN	O	O
short	ADJ	O	O
of	ADP	O	O
the	DET	O	O
enamel	NOUN	O	O
margin	NOUN	O	O
,	PUNCT	O	O
bonding	ADP	O	O
agent	NOUN	O	O
and	CCONJ	O	O
light-cured	PUNCT	O	O
composite	ADJ	O	O
resin	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
teeth	NOUN	O	O
were	VERB	O	O
thermocycled	NUM	O	O
and	CCONJ	O	O
artificial	ADJ	O	O
caries	NOUN	O	O
were	VERB	O	O
created	VERB	O	O
using	VERB	O	O
an	DET	O	O
acid-gel	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
artificial	ADJ	O	B-PHYSICAL
recurrent	ADJ	O	I-PHYSICAL
caries	NOUN	O	I-PHYSICAL
can	VERB	O	O
be	VERB	O	O
reduced	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
glass-ionomer	NOUN	O	O
liner	PUNCT	O	O
under	ADP	O	O
amalgam	NOUN	O	O
restorations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
that	ADP	O	O
when	ADP	O	O
the	DET	O	O
light-cured	PUNCT	O	O
glass-ionomer	NOUN	O	O
liner	PUNCT	O	O
was	VERB	O	O
placed	VERB	O	O
0.3	NUM	O	O
mm	NOUN	O	O
from	ADP	O	O
the	DET	O	O
cavosurface	ADJ	O	O
margin	NOUN	O	O
under	ADP	O	O
composite	ADJ	O	O
resin	NOUN	O	O
restoration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
artificial	ADJ	O	B-PHYSICAL
recurrent	ADJ	O	I-PHYSICAL
caries	NOUN	O	I-PHYSICAL
reduced	ADP	O	I-PHYSICAL
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	PUNCT	O	O
workplace	CCONJ	O	O
intervention	NOUN	O	O
for	ADP	O	O
increasing	VERB	O	O
outdoor	PUNCT	O	O
workers	NOUN	O	O
'	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
solar	ADJ	O	O
protection	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Outdoor	ADP	O	O
workers	NOUN	O	O
are	ADP	O	O
at	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	PUNCT	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
prevention	NOUN	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
can	PRON	O	O
potentially	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
potentiates	ADJ	O	O
the	DET	O	O
spontaneous	ADJ	O	O
remission	NOUN	O	O
of	ADP	O	O
existing	VERB	O	O
solar	ADJ	O	O
keratoses	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
a	DET	O	O
solar	PUNCT	O	O
protection	NOUN	O	O
intervention	NOUN	O	O
targeting	PUNCT	O	O
outdoor	PUNCT	O	O
workers	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Outdoor	NUM	O	O
workers	NOUN	O	O
were	ADJ	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
an	DET	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
65	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
77	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
individual	ADJ	O	O
skin	NOUN	O	O
screening	ADP	O	O
by	ADP	O	O
a	DET	O	O
dermatologist	NOUN	O	O
and	CCONJ	O	O
participated	PUNCT	O	O
in	ADP	O	O
an	DET	O	O
education	NOUN	O	O
session	NOUN	O	O
.	PUNCT	O	O

Pre-	PUNCT	O	O
and	CCONJ	O	O
posttest	ADV	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
included	VERB	O	O
solar	PUNCT	O	B-MENTAL
protection	NOUN	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
(	PUNCT	O	O
assessed	PROPN	O	O
using	VERB	O	O
a	DET	O	O
validated	VERB	O	O
diary	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
knowledge	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
attitudes	NOUN	O	B-MENTAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	B-OTHER
increase	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
outdoor	PUNCT	O	O
workers	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
using	SYM	O	O
a	DET	O	O
high	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
solar	ADJ	O	O
protection	NOUN	O	O
at	ADP	O	O
posttest	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
pretest	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
change	NOUN	O	B-OTHER
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
improved	VERB	O	B-OTHER
in	ADP	O	O
their	PUNCT	O	O
knowledge	NOUN	O	B-MENTAL
score	NOUN	O	I-MENTAL
,	PUNCT	O	O
the	DET	O	O
intervention	NOUN	O	B-OTHER
group	NOUN	O	O
showed	VERB	O	B-OTHER
a	DET	O	I-OTHER
significantly	ADV	O	I-OTHER
greater	PUNCT	O	O
improvement	NOUN	O	B-OTHER
at	ADP	O	O
posttest	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
changes	NOUN	O	B-OTHER
in	PUNCT	O	I-OTHER

Anatomical	ADJ	O	O
benefit	NOUN	O	O
from	ADP	O	O
ranibizumab	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
predominantly	ADV	O	O
classic	ADJ	O	O
neovascular	ADJ	O	O
age-related	VERB	O	O
macular	ADJ	O	O
degeneration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
2-year	NOUN	O	O
anchor	ADV	O	O
study	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
compare	NOUN	O	O
lesion	NOUN	O	O
anatomical	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
ranibizumab	ADJ	O	O
versus	PUNCT	O	O
verteporfin	NOUN	O	O
photodynamic	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
PDT	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ANCHOR	NOUN	O	O
(	PUNCT	O	O
Anti-VEGF	NOUN	O	O
Antibody	NOUN	O	O
for	ADP	O	O
the	DET	O	O
Treatment	NOUN	O	O
of	ADP	O	O
Predominantly	ADV	O	O
Classic	ADJ	O	O
Choroidal	ADJ	O	O
Neovascularization	NOUN	O	O
[	PUNCT	O	O
CNV	NOUN	O	O
]	PUNCT	O	O
in	ADP	O	O
Age-Related	VERB	O	O
Macular	ADJ	O	O
Degeneration	NOUN	O	O
)	PUNCT	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
2-year	NOUN	O	O
,	PUNCT	O	O
Phase	NOUN	O	O
III	NUM	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double-masked	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
423	NUM	O	O
patients	NOUN	O	O
received	ADJ	O	O
ranibizumab	ADP	O	O
(	PUNCT	O	O
0.3	ADP	O	O
or	CCONJ	O	O
0.5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
monthly	ADV	O	O
+	VERB	O	O
sham	ADJ	O	O
PDT	NOUN	O	O
or	CCONJ	O	O
PDT	NOUN	O	O
+	SYM	O	O
monthly	ADV	O	O
sham	ADJ	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Photodynamic	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
or	CCONJ	O	O
sham	ADJ	O	O
PDT	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
Day	NOUN	O	O
0	NUM	O	O
and	CCONJ	O	O
then	ADV	O	O
quarterly	ADJ	O	O
as	VERB	O	O
needed	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
central	ADJ	O	O
reading	VERB	O	O
center	NOUN	O	O
assessed	ADJ	O	O
fundus	ADV	O	O
photography	NOUN	O	O
and	CCONJ	O	O
fluorescein	NOUN	O	O
angiography	NOUN	O	O
images	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
subset	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
61	NUM	O	O
)	PUNCT	O	O
had	ADP	O	O
optical	ADJ	O	O
coherence	NOUN	O	O
tomography	NOUN	O	O
assessments	NOUN	O	O
.	PUNCT	O	O

Main	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
included	VERB	O	O
mean	NOUN	O	O
change	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
at	ADP	O	O
Months	NOUN	O	O
12	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
for	ADP	O	O
area	NOUN	O	O
of	ADP	O	O
classic	ADJ	O	O
CNV	NOUN	O	O
and	CCONJ	O	O
total	ADJ	O	O
area	NOUN	O	O
of	ADP	O	O
leakage	NOUN	O	O
from	ADP	O	O
CNV	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
Months	NOUN	O	O
12	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
,	PUNCT	O	O
ranibizumab	VERB	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
PDT	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
mean	NOUN	O	O
changes	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
total	ADJ	O	B-PHYSICAL
area	NOUN	O	O
of	ADP	O	O
lesion	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
CNV	NOUN	O	B-PHYSICAL
area	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
total	ADJ	O	B-PHYSICAL
area	NOUN	O	O
CNV	PUNCT	O	B-PHYSICAL

Effect	NOUN	O	O
of	ADP	O	O
mild	ADJ	O	O
endurance	NOUN	O	O
exercise	NOUN	O	O
training	VERB	O	O
and	CCONJ	O	O
pravastatin	NOUN	O	O
on	ADP	O	O
peripheral	ADJ	O	O
vasodilatation	NOUN	O	O
of	ADP	O	O
forearm	NOUN	O	O
resistance	NOUN	O	O
vessels	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Improved	NOUN	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
may	PART	O	O
contribute	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cholesterol	NOUN	O	O
lowering	ADP	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
(	PUNCT	O	O
CAD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
statin	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
are	VERB	O	O
disparate	ADJ	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Exercise	NOUN	O	O
training	VERB	O	O
has	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
to	PART	O	O
improve	ADP	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
of	ADP	O	O
or	CCONJ	O	O
with	ADP	O	O
established	CCONJ	O	O
CAD	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
mild	ADJ	O	O
exercise	NOUN	O	O
training	VERB	O	O
or	CCONJ	O	O
statin	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
forearm	NOUN	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
CAD	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
average	ADJ	O	O
cholesterol	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Twenty-eight	PUNCT	O	O
sedentary	ADJ	O	O
male	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
angiographically	ADV	O	O
documented	VERB	O	O
CAD	NOUN	O	O
and	CCONJ	O	O
average	ADJ	O	O
pretreatment	NOUN	O	O
total	ADJ	O	O
plasma	NOUN	O	O
cholesterol	NOUN	O	O
levels	NOUN	O	O
(	PUNCT	O	O
5.1+/-0.9	DET	O	O
mmol/l	NOUN	O	O
)	PUNCT	O	O
aged	PUNCT	O	O
42-75	NUM	O	O
years	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
in	ADP	O	O
a	DET	O	O
2	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
order	NOUN	O	O
to	ADP	O	O
either	CCONJ	O	O
statin	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
pravastatin	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
)	PUNCT	O	O
or	CCONJ	O	O
exercise	NOUN	O	O
training	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
mild	ADJ	O	O
endurance	NOUN	O	O
exercise	NOUN	O	O
three	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
times	CCONJ	O	O
a	DET	O	O
week	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
treatment	NOUN	O	O
on	ADP	O	O
endothelium-dependent	ADJ	O	O
and	CCONJ	O	O
independent	ADJ	O	O
vasodilation	NOUN	O	O
of	ADP	O	O
forearm	NOUN	O	O
resistance	NOUN	O	O
vessels	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
plethysmography	NOUN	O	O
.	PUNCT	O	O

Cardiopulmonary	ADJ	O	O
exercise	NOUN	O	O
testing	VERB	O	O
was	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
10	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Ten	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	O
therapy	NOUN	O	O
significantly	ADV	O	O
reduced	PUNCT	O	O
low-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
from	ADP	O	O
3.8+/-0.6	PUNCT	O	O
to	PUNCT	O	O
3.1+/-0.6	PUNCT	O	O
mmol/l	NOUN	O	O
at	ADP	O	O
study	NOUN	O	O
end	NOUN	O	O
,	PUNCT	O	O
P=0.04	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
to	PUNCT	O	O
high-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
from	ADP	O	O
4.9+/-0.8	ADJ	O	O
to	ADP	O	O
3.7+/-0.7	NOUN	O	O
mmol/l	NOUN	O	O
,	PUNCT	O	O
P=0.002	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Exercise	NOUN	O	O
training	VERB	O	O
did	PUNCT	O	O
not	ADV	O	O
significantly	ADV	O	O
modify	VERB	O	O
the	DET	O	O
lipid	NOUN	O	B-PHYSICAL
profile	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Peak	ADJ	O	O
oxygen	NOUN	O	B-PHYSICAL
consumption	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
maximal	ADJ	O	B-PHYSICAL
achieved	CCONJ	O	O
workload	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
exercise	NOUN	O	B-MENTAL
duration	NOUN	O	B-MENTAL
tended	VERB	O	O
to	PART	O	O
improve	VERB	O	O
in	ADP	O	O
the	DET	O	O
exercise	NOUN	O	O
training	DET	O	O
group	NOUN	O	O
but	CCONJ	O	O
remained	VERB	O	O
unchanged	VERB	O	O
in	ADP	O	O
the	DET	O	O
pravastatin-treated	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
10	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	O
nor	CCONJ	O	O
mild	ADJ	O	O
endurance	NOUN	O	O
exercise	NOUN	O	O
training	PUNCT	O	O
improved	PUNCT	O	O

Are	VERB	O	O
back	ADP	O	O
supports	PUNCT	O	O
plus	CCONJ	O	O
education	NOUN	O	O
more	ADV	O	O
effective	ADJ	O	O
than	ADP	O	O
education	NOUN	O	O
alone	ADJ	O	O
in	ADP	O	O
promoting	VERB	O	O
recovery	NOUN	O	O
from	ADP	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
?	PUNCT	O	O
:	PUNCT	O	O

Results	DET	O	O
from	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Randomized	PROPN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
back	ADP	O	O
support	NOUN	O	O
plus	CCONJ	O	O
education	NOUN	O	O
versus	CCONJ	O	O
education	NOUN	O	O
alone	ADJ	O	O
in	ADP	O	O
promoting	VERB	O	O
recovery	NOUN	O	O
from	ADP	O	O
a	DET	O	O
work-related	VERB	O	O
low	ADJ	O	O
back	ADP	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
WR-LBD	NOUN	O	O
)	PUNCT	O	O
while	ADP	O	O
simultaneously	ADV	O	O
considering	PUNCT	O	O
personal	ADJ	O	O
,	PUNCT	O	O
health	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
occupational	ADJ	O	O
factors	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
occupational	ADJ	O	O
factors	NOUN	O	O
on	ADP	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

SUMMARY	NOUN	O	O
OF	ADP	O	O
BACKGROUND	NOUN	O	O
DATA	NOUN	O	O
No	DET	O	O
randomized	ADV	O	O
studies	NOUN	O	O
of	ADP	O	O
active	ADJ	O	O
industrial	ADJ	O	O
workers	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
back	ADP	O	O
disorders	NOUN	O	O
exist	VERB	O	O
regarding	SYM	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
back	ADP	O	O
supports	NOUN	O	O
plus	CCONJ	O	O
education	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
433	NUM	O	O
actively	ADV	O	O
employed	VERB	O	O
hourly	PUNCT	O	O
union	NOUN	O	O
workers	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
a	DET	O	O
recent	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
WR-LBD	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
those	PUNCT	O	O
who	PROPN	O	O
wore	PUNCT	O	O
a	PUNCT	O	O
specially	ADJ	O	O
designed	VERB	O	O
back	NOUN	O	O
support	NOUN	O	O
plus	CCONJ	O	O
received	PUNCT	O	O
education	NOUN	O	O
on	ADP	O	O
back	ADP	O	O
health	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
those	PUNCT	O	O
who	ADP	O	O
received	VERB	O	O
education	NOUN	O	O
on	ADP	O	O
back	ADP	O	O
health	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Demographic	ADJ	O	O
,	PUNCT	O	O
health	NOUN	O	O
,	PUNCT	O	O
medical	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
occupational	ADJ	O	O
factors	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
through	ADP	O	O
interview	NOUN	O	O
or	CCONJ	O	O
abstraction	NOUN	O	O
of	ADP	O	O
computer	NOUN	O	O
files	NOUN	O	O
;	PUNCT	O	O
individual	ADJ	O	O
ergonomic	ADJ	O	O
exposures	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
a	DET	O	O
lumbar	ADJ	O	O
motion	NOUN	O	O
monitor	NOUN	O	O
.	PUNCT	O	O

Outcomes	NOUN	O	O
evaluated	VERB	O	O
over	ADP	O	O
a	DET	O	O
12-month	NOUN	O	O
period	NOUN	O	O
included	ADJ	O	O
:	PUNCT	O	O
self-reported	VERB	O	B-PAIN
measures	NOUN	O	I-PAIN
of	ADP	O	I-PAIN
back	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
back	ADP	O	O
pain	NOUN	O	O
disability	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
health	NOUN	O	O
,	PUNCT	O	O
mental	ADJ	O	B-MENTAL
health	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
administrative	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
recurrence	NOUN	O	O
,	PUNCT	O	O
lost	CCONJ	O	O
work	NUM	O	O
time	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
medical	ADJ	O	O
care	NOUN	O	O
utilization	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
study	ADJ	O	O
groups	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
mental	ADJ	O	O
or	CCONJ	O	O
physical	ADJ	O	O
health	NOUN	O	O
,	PUNCT	O	O
low	ADJ	O	B-PAIN
back	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
back	ADP	O	O
pain	NOUN	O	O
disability	NOUN	O	O
,	PUNCT	O	O
neurogenic	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
,	PUNCT	O	O
lost	PUNCT	O	O
work	NUM	O	O
time	NOUN	O	O
,	PUNCT	O	O
likelihood	NOUN	O	O
of	ADP	O	B-PHYSICAL
recurrence	NOUN	O	O
of	ADP	O	B-PHYSICAL
an	DET	O	I-PHYSICAL
episode	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
a	DET	O	B-PHYSICAL
back	PUNCT	O	I-PHYSICAL

Double	ADP	O	O
hearing	DET	O	O
protection	NOUN	O	O
and	CCONJ	O	O
speech	NOUN	O	O
intelligibility-room	PUNCT	O	O
for	ADP	O	O
improvement	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Double	VERB	O	O
hearing	DET	O	O
protection	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
many	DET	O	O
air	NOUN	O	O
forces	NOUN	O	O
around	ADP	O	O
the	DET	O	O
world	NOUN	O	O
for	ADP	O	O
protection	NOUN	O	O
in	ADP	O	O
noisy	ADJ	O	O
aircraft	NOUN	O	O
environments	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
helicopters	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
usual	ADJ	O	O
combination	NOUN	O	O
is	VERB	O	O
foam	ADP	O	O
ear	NOUN	O	O
plugs	NOUN	O	O
under	ADP	O	O
headset	NOUN	O	O
or	CCONJ	O	O
helmet	NOUN	O	O
muffs	NOUN	O	O
.	PUNCT	O	O

Much	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
research	NOUN	O	O
that	ADP	O	O
spurred	ADJ	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
foam	NOUN	O	O
earplugs	CCONJ	O	O
indicated	DET	O	O
little	DET	O	O
change	NOUN	O	O
in	ADP	O	O
speech	NOUN	O	O
intelligibility	NOUN	O	O
in	ADP	O	O
persons	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
hearing	ADP	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
aircrew	ADJ	O	O
often	ADP	O	O
complain	PUNCT	O	O
about	PUNCT	O	O
having	SYM	O	O
to	PART	O	O
maximize	NOUN	O	O
intercom	NOUN	O	O
volume	NOUN	O	O
for	ADP	O	O
speech	NOUN	O	O
understanding	VERB	O	O
,	PUNCT	O	O
causing	SYM	O	O
a	DET	O	O
situation	NOUN	O	O
with	ADP	O	O
no	DET	O	O
reserve	PUNCT	O	O
volume	NOUN	O	O
and	CCONJ	O	O
bad	ADJ	O	O
sound	ADJ	O	O
quality	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
recent	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
further	ADJ	O	O
developments	NOUN	O	O
have	PUNCT	O	O
included	VERB	O	O
so-called	PUNCT	O	O
hi-fi	ADP	O	O
plugs	NOUN	O	O
and	CCONJ	O	O
custom	NOUN	O	O
made	VERB	O	O
ear	NOUN	O	O
plugs	NOUN	O	O
which	ADP	O	O
are	VERB	O	O
claimed	VERB	O	O
to	PART	O	O
improve	PUNCT	O	O
speech	NOUN	O	O
communication	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
project	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
different	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
ear	NOUN	O	O
plugs	NOUN	O	O
and	CCONJ	O	O
their	ADP	O	O
effect	NOUN	O	O
on	ADP	O	O
speech	NOUN	O	O
intelligibility	NOUN	O	O
in	ADP	O	O
helicopter	ADJ	O	O
noise	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Each	ADP	O	O
of	ADP	O	O
nine	NUM	O	O
normal-hearing	VERB	O	O
pilot	ADP	O	O
subjects	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
in	ADP	O	O
an	DET	O	O
environment	NOUN	O	O
of	ADP	O	O
recorded	VERB	O	O
helicopter	ADJ	O	O
noise	NOUN	O	O
from	ADP	O	O
a	DET	O	O
BO-105	NOUN	O	O
helicopter	NOUN	O	O
.	PUNCT	O	O

Speech	NOUN	O	O
audiometry	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
under	ADP	O	O
four	NUM	O	O
different	ADJ	O	O
conditions	NOUN	O	O
:	PUNCT	O	O
headset	NOUN	O	O
only	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
different	ADJ	O	O
ear	NOUN	O	O
plugs	NOUN	O	O
worn	PUNCT	O	O
under	ADP	O	O
the	DET	O	O
headset	NOUN	O	O
.	PUNCT	O	O

Fitting	ADJ	O	O
of	ADP	O	O
the	DET	O	O
ear	NOUN	O	O
plugs	ADV	O	O
was	VERB	O	O
performed	VERB	O	O
by	ADP	O	O
an	DET	O	O
ear	NOUN	O	O
,	PUNCT	O	O
nose	NOUN	O	O
and	CCONJ	O	O
throat	NOUN	O	O
specialist	NOUN	O	O
to	PART	O	O
ensure	NOUN	O	O
similar	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sequence	NOUN	O	O
of	ADP	O	O
test	ADV	O	O
conditions	NOUN	O	O
was	VERB	O	O
randomized	DET	O	O
and	CCONJ	O	O
double-blind	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
subjective	ADJ	O	B-OTHER
rating	ADP	O	I-OTHER
scale	NOUN	O	I-OTHER
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Wearing	PUNCT	O	O
foam	ADV	O	O
ear	NOUN	O	O
plugs	NOUN	O	O
under	ADP	O	O
the	DET	O	O
headset	NOUN	O	O
decreased	ADP	O	O
speech	NOUN	O	B-MENTAL
intelligibility	NOUN	O	I-MENTAL
dramatically	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
hi-fi	ADP	O	O
plug	NOUN	O	O
was	VERB	O	O
somewhat	ADV	O	O
better	PUNCT	O	O
than	CCONJ	O	O
foam	NOUN	O	O
plugs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
custom	ADJ	O	O
made	PRON	O	O
ear	NOUN	O	O
plug	NOUN	O	O
provided	PROPN	O	O
a	DET	O	O
speech	NOUN	O	B-MENTAL
intelligibility	NOUN	O	I-MENTAL
close	ADJ	O	O
to	ADP	O	O
the	DET	O	O
headset-only	ADP	O	O
situation	NOUN	O	O
.	PUNCT	O	O

Subjective	ADJ	O	B-OTHER
rating	ADJ	O	I-OTHER
scores	NOUN	O	I-OTHER
coincided	VERB	O	O
with	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
In	ADP	O	O
helicopter	ADJ	O	O
noise	NOUN	O	O
,	PUNCT	O	O
custom	PUNCT	O	O
made	ADP	O	O
ear	NOUN	O	O
plugs	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
a	DET	O	O
much	ADP	O	O
improved	ADP	O	O
speech	NOUN	O	B-MENTAL
intelligibility	NOUN	O	I-MENTAL
over	PUNCT	O	O
conventional	ADJ	O	O
plugs	NOUN	O	O
when	ADP	O	O
worn	PUNCT	O	O
under	ADP	O	O
a	DET	O	O
headset	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
maintaining	PUNCT	O	O
improved	ADJ	O	O
noise	ADJ	O	O
protection	NOUN	O	B-MENTAL
over	ADP	O	O
the	DET	O	O
headset-alone	NOUN	O	O
situation	NOUN	O	O
.	PUNCT	O	O

Custom	NOUN	O	O
made	VERB	O	O
ear	NOUN	O	O
plugs	NOUN	O	O
might	PRON	O	O
therefore	ADV	O	O
be	VERB	O	O
a	DET	O	O
good	ADJ	O	O
alternative	ADJ	O	O
to	ADP	O	O
other	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
enhanced	VERB	O	B-OTHER
noise	PUNCT	O	O

Does	PUNCT	O	O
tetanus	NOUN	O	O
immune	ADJ	O	O
globulin	NOUN	O	O
interfere	NOUN	O	O
with	ADP	O	O
the	DET	O	O
immune	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	ADP	O	O
simultaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
tetanus-diphtheria	NOUN	O	O
vaccine	NOUN	O	O
?	PUNCT	O	O

A	DET	O	O
comparative	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
wounds	NOUN	O	O
,	PUNCT	O	O
sometimes	NOUN	O	O
it	PROPN	O	O
is	VERB	O	O
recommended	VERB	O	O
to	PART	O	O
give	PUNCT	O	O
an	DET	O	O
adult-type	NOUN	O	O
tetanus-diphtheria	NOUN	O	O
(	PUNCT	O	O
Td	NOUN	O	O
)	PUNCT	O	O
vaccine	NOUN	O	O
dose	NOUN	O	O
plus	CCONJ	O	O
tetanus	NOUN	O	O
immune	ADJ	O	O
globulin	NOUN	O	O
(	PUNCT	O	O
TIG	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
and	CCONJ	O	O
59	NUM	O	O
healthy	ADJ	O	O
young	ADJ	O	O
adults	NOUN	O	O
previously	ADV	O	O
immunized	ADP	O	O
against	ADP	O	O
tetanus	NOUN	O	O
(	PUNCT	O	O
T	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diphtheria	NOUN	O	O
(	PUNCT	O	O
D	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
intramuscularly	ADV	O	O
either	PUNCT	O	O
Td	NOUN	O	O
vaccine	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
Td	NOUN	O	O
vaccine	NOUN	O	O
plus	CCONJ	O	O
500	NUM	O	O
IU	NOUN	O	O
of	ADP	O	O
TIG	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
simultaneously	ADV	O	O
.	PUNCT	O	O

Antitoxin	NOUN	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
after	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Circulating	VERB	O	B-PHYSICAL
antibodies	NOUN	O	I-PHYSICAL
were	VERB	O	I-PHYSICAL
measured	VERB	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
enzyme-linked	VERB	O	I-PHYSICAL
immunosorbent	ADJ	O	I-PHYSICAL
assay	NOUN	O	O
(	PUNCT	O	O
ELISA	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
cutoff	NOUN	O	O
of	ADP	O	O
these	DET	O	O
tests	NOUN	O	O
was	VERB	O	O
0.1	NUM	O	O
IU/mL	NOUN	O	O
.	PUNCT	O	O

Titers	NOUN	O	O
of	ADP	O	O
0.1	NUM	O	O
IU/mL	NOUN	O	O
or	CCONJ	O	O
greater	PUNCT	O	O
were	NUM	O	O
considered	VERB	O	O
protective	ADJ	O	O
.	PUNCT	O	O

For	ADP	O	O
geometric	ADJ	O	O
mean	NOUN	O	O
titers	NOUN	O	O
(	PUNCT	O	O
GMT	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
antibody	NOUN	O	B-PHYSICAL
titers	NOUN	O	I-PHYSICAL
below	ADP	O	O
the	DET	O	O
cutoff	NOUN	O	O
of	ADP	O	O
the	DET	O	O
assay	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
,	PUNCT	O	O
arbitrarily	ADV	O	O
,	PUNCT	O	O
0.05	NUM	O	O
IU/mL	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
98	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
more	DET	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
had	PUNCT	O	O
circulating	NUM	O	B-PHYSICAL
T	NOUN	O	I-PHYSICAL
and	CCONJ	O	B-PHYSICAL
D	PUNCT	O	I-PHYSICAL

Pre-treatment	ADJ	O	O
proliferation	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	O
and	CCONJ	O	O
accelerated	VERB	O	O
radiotherapy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
pre-treatment	NOUN	O	O
proliferation	NOUN	O	O
characteristics	NOUN	O	O
,	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
Ki-67	NOUN	O	O
staining	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
in	ADP	O	O
the	DET	O	O
CHART	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
accelerated	VERB	O	O
radiotherapy	NOUN	O	O
in	ADP	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Histological	ADJ	O	O
material	NOUN	O	O
from	ADP	O	O
402	NUM	O	O
patients	NOUN	O	O
was	VERB	O	O
collected	ADV	O	O
and	CCONJ	O	O
stained	VERB	O	O
for	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
and	CCONJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
Ki-67	NOUN	O	O
staining	VERB	O	O
.	PUNCT	O	O

Locoregional	ADJ	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
overall	ADJ	O	O
survival	NOUN	O	O
were	VERB	O	O
the	DET	O	O
main	ADJ	O	O
clinical	ADJ	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

Increasing	ADP	O	O
Ki-67	NOUN	O	O
positivity	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
decreasing	PUNCT	O	O
differentiation	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increasing	PUNCT	O	O
N-stage	ADP	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Increasing	ADP	O	O
N-stage	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
proliferation	NOUN	O	O
pattern	NOUN	O	O
from	ADP	O	O
marginal	ADJ	O	O
to	ADP	O	O
random	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Using	ADJ	O	O
a	DET	O	O
multivariate	ADJ	O	O
model	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
trend	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
towards	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
benefit	NOUN	O	O
from	ADP	O	O
CHART	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lower	PUNCT	O	O
Ki-67	NOUN	O	O
tumours	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.08	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
this	PUNCT	O	O
became	CCONJ	O	O
significant	CCONJ	O	O
by	ADP	O	O
pooling	ADJ	O	O
the	DET	O	O
low	ADJ	O	O
and	CCONJ	O	O
intermediate	ADJ	O	O
Ki-67	NOUN	O	O
groups	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
high	ADJ	O	O
Ki-67	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.032	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tumours	NOUN	O	O
with	ADP	O	O
marginal	ADJ	O	O
proliferation	NOUN	O	O
pattern	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
lower	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
with	ADP	O	O
CHART	NOUN	O	O
versus	CCONJ	O	O
conventional	ADJ	O	O
for	ADP	O	O
locoregional	ADJ	O	O
control	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
presented	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
support	VERB	O	O
that	ADP	O	O
a	DET	O	O
high	ADJ	O	O
pre-treatment	NOUN	O	O
Ki-67	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	B-OTHER
benefit	NOUN	O	I-OTHER
from	ADP	O	O
accelerated	VERB	O	O
radiotherapy	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
sedative	ADJ	O	O
drugs	NOUN	O	O
under	ADP	O	O
peribulbar	ADJ	O	O
or	CCONJ	O	O
topical	ADJ	O	O
anesthesia	NOUN	O	O
during	ADP	O	O
phacoemulsification	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
dexmedetomidine	PUNCT	O	O
and	CCONJ	O	O
midazolam+fentanyl	NOUN	O	O
sedation	NOUN	O	O
primarily	ADV	O	O
based	VERB	O	O
on	ADP	O	O
patient	NOUN	O	O
satisfaction	NOUN	O	O
during	ADP	O	O
phacoemulsification	NOUN	O	O
under	ADP	O	O
topical	ADJ	O	O
and	CCONJ	O	O
peribulbar	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
80	NUM	O	O
American	ADJ	O	O
Society	NOUN	O	O
of	ADP	O	O
Anesthesiology	NOUN	O	O
grade	NOUN	O	O
I-II	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
underwent	VERB	O	O
phacoemulsification	NOUN	O	O
with	ADP	O	O
local	ADJ	O	O
anesthesia	NOUN	O	O
under	ADP	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
patients	NOUN	O	O
for	ADP	O	O
each	PUNCT	O	O
)	PUNCT	O	O
:	PUNCT	O	O
dexmedetomidine	PUNCT	O	O
and	CCONJ	O	O
topical	ADJ	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
dexmedetomidine	PUNCT	O	O
and	CCONJ	O	O
peribulbar	ADJ	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
midazolam+fentanyl	NOUN	O	O
and	CCONJ	O	O
topical	ADJ	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
midazolam+fentanyl	NOUN	O	O
and	CCONJ	O	O
peribulbar	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

Patient	NOUN	O	O
and	CCONJ	O	O
surgeon	NOUN	O	O
satisfaction	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
on	ADP	O	O
a	DET	O	O
5-point	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pain	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
verbal	ADJ	O	O
pain	NOUN	O	O
scale	NOUN	O	O
intraoperatively	ADV	O	O
and	CCONJ	O	O
postoperatively	NUM	O	O
.	PUNCT	O	O

Drugs	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
to	ADP	O	O
a	DET	O	O
Ramsay	NOUN	O	O
sedation	NOUN	O	O
scale	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
.	PUNCT	O	O

Topical	ADJ	O	O
and	CCONJ	O	O
peribulbar	ADJ	O	O
anesthesia	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
by	ADP	O	O
an	DET	O	O
ophthalmologist	NOUN	O	O
.	PUNCT	O	O

Hemodynamic	ADJ	O	O
,	PUNCT	O	O
respiratory	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intraocular	ADJ	O	O
pressure	NOUN	O	O
monitoring	VERB	O	O
was	VERB	O	O
done	PUNCT	O	O
.	PUNCT	O	O

Operative	ADJ	O	O
and	CCONJ	O	O
recovery	NOUN	O	O
times	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
the	DET	O	O
midazolam+fentanyl	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
better	PUNCT	O	O
patient	NOUN	O	B-OTHER
and	CCONJ	O	I-OTHER
surgeon	NOUN	O	I-OTHER
satisfaction	NOUN	O	I-OTHER
scores	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.005	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
verbal	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
scale	NOUN	O	I-PAIN
scores	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
needed	PUNCT	O	O
less	ADV	O	O
postoperative	ADJ	O	B-OTHER
analgesia	NOUN	O	I-OTHER
.	PUNCT	O	O

Ramsay	NOUN	O	B-OTHER
sedation	NOUN	O	I-OTHER
scale	NOUN	O	I-OTHER
scores	NOUN	O	O
were	VERB	O	O
between	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
.	PUNCT	O	O

Intraocular	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
alterations	NOUN	O	I-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Recovery	DET	O	B-OTHER
time	NOUN	O	I-OTHER
was	VERB	O	O
longer	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
dexmedetomidine	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
midazolam+fentanyl	NOUN	O	O
combination	NOUN	O	O
provided	VERB	O	O
high-level	NOUN	O	O
patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
scores	NOUN	O	I-OTHER
,	PUNCT	O	O
low-level	NOUN	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
,	PUNCT	O	O
and	CCONJ	O	O
shorter	PUNCT	O	O
recovery	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
both	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
peribulbar	ADJ	O	O
and	CCONJ	O	O
topical	ADJ	O	O
anesthesia	NOUN	O	O
procedures	NOUN	O	O
showed	VERB	O	O
similar	ADJ	O	O
efficiency	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Administration	NOUN	O	O
of	ADP	O	O
tobramycin	NOUN	O	O
aerosols	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
nosocomial	ADJ	O	O
pneumonia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
preliminary	ADJ	O	O
study	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
assess	NOUN	O	O
renal	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
respiratory	ADJ	O	I-PHYSICAL
tolerance	NOUN	O	I-PHYSICAL
of	ADP	O	O
aerosolized	PUNCT	O	O
tobramycin	NOUN	O	O
in	ADP	O	O
intubated	VERB	O	O
and	CCONJ	O	O
mechanically	ADV	O	O
ventilated	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
nosocomial	ADJ	O	O
pneumonia	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

Thirty-eight	PUNCT	O	O
mechanically	ADV	O	O
ventilated	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
documented	VERB	O	O
nosocomial	ADJ	O	O
pneumonia	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
betalactam	NOUN	O	O
and	CCONJ	O	O
tobramycin	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
aerosolized	PUNCT	O	O
tobramycin	NOUN	O	O
(	PUNCT	O	O
6	ADP	O	O
mg/kg/day	PUNCT	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
21	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
aerosol	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
via	ADP	O	O
a	DET	O	O
pneumatic	ADJ	O	O
nebulizer	NOUN	O	O
once	PUNCT	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Respiratory	ADJ	O	B-PHYSICAL
tolerance	NOUN	O	I-PHYSICAL
was	VERB	O	O
good	ADJ	O	O
in	ADP	O	O
all	ADP	O	O
but	CCONJ	O	O
two	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
acute	ADJ	O	B-PHYSICAL
renal	ADJ	O	I-PHYSICAL
failure	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
.	PUNCT	O	O

By	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
tobramycin	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
35	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
been	PUNCT	O	O
extubated	VERB	O	B-PHYSICAL
versus	CCONJ	O	O
3	NUM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
18.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.18	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

By	ADP	O	O
day	NOUN	O	O
28	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
patients	NOUN	O	O
had	PUNCT	O	O
died	ADP	O	B-MORTALITY
(	PUNCT	O	O
2	NUM	O	O
in	ADP	O	O
the	DET	O	O
tobramycin	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.23	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Aerosolized	PUNCT	O	O
tobramycin	NOUN	O	O
was	PUNCT	O	O
well	VERB	O	O
tolerated	ADP	O	O
in	ADP	O	O
ventilated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
documented	VERB	O	O
nosocomial	ADJ	O	O
pneumonia	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Cardiac	ADJ	O	O
protection	NOUN	O	O
is	VERB	O	O
a	DET	O	O
clinical	ADJ	O	O
evidence	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
Anaesthetics	PROPN	O	O
may	VERB	O	O
have	CCONJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
against	ADP	O	O
myocardial	ADJ	O	O
ischemia	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	ADP	O	O
if	PUNCT	O	O
sevoflurane	VERB	O	O
administration	NOUN	O	O
could	PUNCT	O	O
exert	VERB	O	O
myocardial	ADJ	O	B-PHYSICAL
protection	NOUN	O	I-PHYSICAL
during	ADP	O	O
following	ADP	O	O
coronary	ADJ	O	O
occlusion	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
a	CCONJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

EXPERIMENTAL	ADJ	O	O
DESIGN	NOUN	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

b	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

SETTING	ADJ	O	O
University	NOUN	O	O
Hospital	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
surgical	ADJ	O	O
operative	ADJ	O	O
theatre	NOUN	O	O
.	PUNCT	O	O

c	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
42	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
,	PUNCT	O	O
scheduled	VERB	O	O
to	PART	O	O
undergo	PUNCT	O	O
coronary	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

INCLUSION	NOUN	O	O
CRITERIA	NOUN	O	O
severe	ADJ	O	O
coronary	ADJ	O	O
stenosis	NOUN	O	O
of	ADP	O	O
anterior	ADJ	O	O
descending	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
;	PUNCT	O	O
no	DET	O	O
collateral	ADJ	O	O
flow	NOUN	O	O
on	ADP	O	O
angiography	NOUN	O	O
;	PUNCT	O	O
at	ADP	O	O
least	ADV	O	O
two	NUM	O	O
normokinetic	ADJ	O	O
segments	NOUN	O	O
in	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
region	NOUN	O	O
supplied	VERB	O	O
by	ADP	O	O
the	DET	O	O
vessel	NOUN	O	O
being	VERB	O	O
bypassed	VERB	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
S	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
not	ADV	O	O
(	PUNCT	O	O
group	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
sevoflurane	NOUN	O	O
administration	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
min	NOUN	O	O
just	ADV	O	O
before	PUNCT	O	O
coronary	ADJ	O	O
occlusion	NOUN	O	O
.	PUNCT	O	O

d	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Transoesophageal	PUNCT	O	O
Tissue	NOUN	O	O
Doppler	NOUN	O	O
echocardiographic	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
systolic	ADJ	O	O
and	CCONJ	O	O
early	ADJ	O	O
diastolic	ADJ	O	O
velocities	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
basally	ADV	O	O
and	CCONJ	O	O
60	NUM	O	O
s	NOUN	O	O
after	ADP	O	O
coronary	ADJ	O	O
occlusion	NOUN	O	O
by	ADP	O	O
the	DET	O	O
surgeon	NOUN	O	O
.	PUNCT	O	O

e	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MEASURES	NOUN	O	O
systolic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
early	ADJ	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
velocities	NOUN	O	I-PHYSICAL
were	VERB	O	O
registered	PUNCT	O	O
by	ADP	O	O
Tissue	NOUN	O	O
Doppler	NOUN	O	O
from	ADP	O	O
a	DET	O	O
long-axis	NOUN	O	O
view	NOUN	O	O
of	ADP	O	O
the	DET	O	O
interventricular	ADJ	O	O
septum	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
anterior	ADJ	O	O
wall	NOUN	O	O
of	ADP	O	O
the	DET	O	O
left	ADJ	O	O
ventricle	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
group	NOUN	O	O
C	NOUN	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
systolic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
intramyocardial	ADJ	O	I-PHYSICAL
velocities	NOUN	O	I-PHYSICAL
was	VERB	O	O
found	VERB	O	O
during	ADP	O	O
myocardial	ADJ	O	O
ischemia	NOUN	O	O
due	VERB	O	O
to	ADP	O	O
coronary	ADJ	O	O
occlusion	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Treatment	NOUN	O	O
with	ADP	O	O
sevoflurane	NOUN	O	O
before	ADP	O	O
coronary	ADJ	O	O
occlusion	NOUN	O	O
seem	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
functional	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
impairment	NOUN	O	I-PHYSICAL
due	CCONJ	O	O
to	ADP	O	O
ischemia	NOUN	O	O
.	PUNCT	O	O

Modified	VERB	O	O
constraint-induced	VERB	O	O
movement	NOUN	O	O
therapy	NOUN	O	O
improved	ADP	O	O
upper	ADJ	O	O
limb	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
subacute	ADJ	O	O
poststroke	NOUN	O	O
patients	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
small-scale	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Constraint-induced	VERB	O	O
movement	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
CIMT	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
advocated	VERB	O	O
as	ADP	O	O
a	DET	O	O
means	NOUN	O	O
of	ADP	O	O
facilitating	PUNCT	O	O
motor	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
poststroke	NOUN	O	O
patients	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
evidence	NOUN	O	O
for	ADP	O	O
its	PUNCT	O	O
efficacy	NOUN	O	O
is	VERB	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
modified	VERB	O	O
CIMT	NOUN	O	O
on	ADP	O	O
improving	VERB	O	O
paretic	ADJ	O	O
arm	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
poststroke	NOUN	O	O
patients	NOUN	O	O
during	ADP	O	O
a	DET	O	O
subacute	ADJ	O	O
rehabilitation	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	NOUN	O	O
single-blinded	VERB	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
at	ADP	O	O
the	DET	O	O
Loewenstein	NOUN	O	O
Rehabilitation	NOUN	O	O
Hospital	NOUN	O	O
,	PUNCT	O	O
Israel	PUNCT	O	O
.	PUNCT	O	O

Twenty-eight	PUNCT	O	O
subacute	ADJ	O	O
stroke	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
arm	NOUN	O	O
paresis	NOUN	O	O
after	ADP	O	O
a	DET	O	O
first	ADJ	O	O
ischemic	ADJ	O	O
stroke	NOUN	O	O
in	ADP	O	O
the	DET	O	O
middle	ADJ	O	O
cerebral	ADJ	O	O
artery	NOUN	O	O
area	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
a	DET	O	O
modified	VERB	O	O
CIMT	NOUN	O	O
or	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
by	ADP	O	O
a	DET	O	O
1:2	NUM	O	O
ratio	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
modified	VERB	O	O
CIMT	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
1-hour	NOUN	O	O
daily	ADJ	O	O
physical	ADJ	O	O
rehabilitation	NOUN	O	O
sessions	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
unaffected	VERB	O	O
arm	NOUN	O	O
was	VERB	O	O
restrained	VERB	O	O
during	ADP	O	O
the	DET	O	O
sessions	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
encouraged	VERB	O	O
to	ADP	O	O
wear	CCONJ	O	O
a	DET	O	O
restrictive	ADJ	O	O
mitten	ADP	O	O
up	PUNCT	O	O
to	ADP	O	O
4	NUM	O	O
hours	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
received	ADP	O	O
similar	ADJ	O	O
intensive	ADJ	O	O
regular	ADJ	O	O
rehabilitation	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
upper	ADJ	O	O
limb	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
developed	VERB	O	O
for	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
as	DET	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subjects	NOUN	O	O
were	VERB	O	O
asked	VERB	O	O
to	PART	O	O
perform	NOUN	O	O
the	DET	O	O
following	PUNCT	O	O
tasks	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
affected	ADP	O	O
hand	NOUN	O	O
for	ADP	O	O
30	NUM	O	O
seconds	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
transfer	NOUN	O	O
pegs	PUNCT	O	O
from	ADP	O	O
a	DET	O	O
saucer	NOUN	O	O
to	ADP	O	O
a	DET	O	O
pegboard	ADJ	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
grasp	ADP	O	O
,	PUNCT	O	O
carry	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
release	NOUN	O	O
a	DET	O	O
hard	PUNCT	O	O
rubber	NOUN	O	O
ball	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
eating	ADP	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
spoon	ADV	O	O
to	PART	O	O
remove	NOUN	O	O
the	DET	O	O
jelly	ADV	O	O
from	ADP	O	O
the	DET	O	O
plate	NOUN	O	O
,	PUNCT	O	O
bring	PUNCT	O	O
it	PUNCT	O	O
towards	ADP	O	O
the	DET	O	O
mouth	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
place	ADJ	O	O
it	NUM	O	O
on	ADP	O	O
another	DET	O	O
plate	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
repetitions	CCONJ	O	I-OTHER
in	ADP	O	I-OTHER
each	DET	O	I-OTHER
test	NOUN	O	I-OTHER
was	VERB	O	O
recorded	VERB	O	O
as	ADP	O	O
an	DET	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
modified	VERB	O	O
CIMT	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
significantly	ADP	O	O
higher	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
all	DET	O	O
3	NUM	O	O
tests	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
rehabilitation	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Our	PUNCT	O	O
study	NOUN	O	O
provides	NOUN	O	O
additional	ADJ	O	O
support	NOUN	O	O
for	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
modified	VERB	O	O
CIMT	NOUN	O	O
during	ADP	O	O
a	DET	O	O
subacute	ADJ	O	O
rehabilitation	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
poststroke	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

CIMT	NOUN	O	O
may	VERB	O	O
facilitate	VERB	O	O
functional	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
a	DET	O	O
plegic	ADJ	O	O
hand	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
A	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
diltiazem	NOUN	O	O
in	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
unstable	ADJ	O	O
angina	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
diltiazem	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
nitroglycerin	NOUN	O	O
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
unstable	ADJ	O	O
angina	NOUN	O	O
pectoris	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
open-label	NOUN	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
group	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
213	NUM	O	O
eligible	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
randomized	NUM	O	O
either	PUNCT	O	O
to	ADP	O	O
diltiazem	NOUN	O	O
or	CCONJ	O	O
nitroglycerin	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
diltiazem	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
from	ADP	O	O
100	NUM	O	O
microg/min	NOUN	O	O
at	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
largest	PUNCT	O	O
dosage	NOUN	O	O
was	VERB	O	O
200	PUNCT	O	O
-	PUNCT	O	O
300	NUM	O	O
microg/min	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
nitroglycerin	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
from	ADP	O	O
20	NUM	O	O
microg/min	NOUN	O	O
at	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
largest	PUNCT	O	O
dosage	NOUN	O	O
was	VERB	O	O
80	PUNCT	O	O
-	PUNCT	O	O
100	NUM	O	O
microg/min	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
infusion	NOUN	O	O
was	VERB	O	O
kept	PUNCT	O	O
over	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
endpoints	NOUN	O	O
included	ADJ	O	O
refractory	ADJ	O	B-PHYSICAL
angina	NOUN	O	I-PHYSICAL
pectoris	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
acute	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
emergency	NOUN	O	B-PHYSICAL
PTCA	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
CABG	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
Intravenous	ADJ	O	O
diltiazem	NOUN	O	O
was	VERB	O	O
effective	ADJ	O	O
on	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
electrocardiogram	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
its	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
intravenous	ADJ	O	O
nitroglycerin	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

2	NUM	O	O
)	PUNCT	O	O
Compared	VERB	O	O
with	ADP	O	O
nitroglycerin	NOUN	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
diltiazem	NOUN	O	O
lowered	VERB	O	B-PHYSICAL
heart	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
myocardial	ADJ	O	B-OTHER
oxygen	NOUN	O	I-OTHER
consumption	NOUN	O	I-OTHER
index	NOUN	O	I-OTHER
(	PUNCT	O	O
systolic	ADJ	O	O
pressure	NOUN	O	O
x	SYM	O	O
heart	NOUN	O	O
rate	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
more	DET	O	O
extent	NOUN	O	O
significantly	ADV	O	O
.	PUNCT	O	O
(	PUNCT	O	O

3	NUM	O	O
)	PUNCT	O	O
After	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
onsets	NOUN	O	O
of	ADP	O	O
refractory	ADJ	O	B-PHYSICAL
angina	NOUN	O	I-PHYSICAL
pectoris	NOUN	O	I-PHYSICAL
were	VERB	O	O
reduced	VERB	O	B-OTHER
more	ADV	O	I-OTHER
significantly	ADV	O	I-OTHER
in	ADP	O	O
the	DET	O	O
diltiazem	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
nitroglycerin	NOUN	O	O
group	NOUN	O	O
[	PUNCT	O	O
4	NUM	O	O
(	PUNCT	O	O
3.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
vs	CCONJ	O	O
13	NUM	O	O
(	PUNCT	O	O
11.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
RR	NOUN	O	O
0.32	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.11	NUM	O	O
-	PUNCT	O	O
0.96	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

4	NUM	O	O
)	PUNCT	O	O
The	DET	O	O
patients	NOUN	O	O
whose	ADJ	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
were	VERB	O	O
reduced	VERB	O	B-OTHER
significantly	ADV	O	I-OTHER
(	PUNCT	O	O
<	ADP	O	O
or=	NOUN	O	O
50	NUM	O	O
beats	NOUN	O	O
per	ADP	O	O
minute	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
diltiazem	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
nitroglycerin	NOUN	O	O
group	NOUN	O	O
[	PUNCT	O	O
8	NUM	O	O
(	PUNCT	O	O
7.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
vs	CCONJ	O	O
0	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

But	CCONJ	O	O
these	DET	O	O
patients	NOUN	O	O
could	PUNCT	O	O
tolerate	NOUN	O	O
the	DET	O	O
lower	PUNCT	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
very	VERB	O	O
well	VERB	O	O
in	PUNCT	O	O
the	DET	O	O
diltiazem	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

5	NUM	O	O
)	PUNCT	O	O
The	DET	O	O
needs	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	O
receptor	NOUN	O	O
blocker	NOUN	O	O
or	CCONJ	O	O
calcium	NOUN	O	O
antagonists	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
more	ADV	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
diltiazem	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
nitroglycerin	NOUN	O	O
group	NOUN	O	O
[	PUNCT	O	O
2	NUM	O	O
(	PUNCT	O	O
1.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
vs	CCONJ	O	O
13	NUM	O	O
(	PUNCT	O	O
11.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Intravenous	ADJ	O	O
diltiazem	NOUN	O	O
therapy	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
unstable	ADJ	O	O
angina	NOUN	O	O
pectoris	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
may	ADP	O	O
significantly	ADV	O	O
lower	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
refractory	ADJ	O	O
angina	NOUN	O	O
pectoris	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
nitroglycerin	NOUN	O	O
.	PUNCT	O	O

Is	PUNCT	O	O
psychotherapy	NOUN	O	O
more	ADV	O	O
effective	ADJ	O	O
when	ADP	O	O
therapists	DET	O	O
disclose	ADJ	O	O
information	NOUN	O	O
about	PUNCT	O	O
themselves	PUNCT	O	O
?	PUNCT	O	O

Theorists	NOUN	O	O
have	PUNCT	O	O
long	PUNCT	O	O
debated	PUNCT	O	O
the	DET	O	O
wisdom	PUNCT	O	O
of	ADP	O	O
therapists	ADJ	O	O
disclosing	PUNCT	O	B-OTHER
personal	ADJ	O	I-OTHER
information	NOUN	O	I-OTHER
during	ADP	O	O
psychotherapy	NOUN	O	O
.	PUNCT	O	O

Some	DET	O	O
observers	ADP	O	O
have	PUNCT	O	O
argued	PUNCT	O	O
that	PUNCT	O	O
such	DET	O	O
therapist	NOUN	O	O
self-disclosure	ADJ	O	O
impedes	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
others	NOUN	O	O
have	CCONJ	O	O
suggested	VERB	O	O
that	ADP	O	O
it	PRON	O	O
enhances	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	B-OTHER
.	PUNCT	O	O

To	PART	O	O
test	NOUN	O	O
these	DET	O	O
competing	ADJ	O	O
positions	NOUN	O	O
,	PUNCT	O	O
therapists	ADJ	O	O
at	ADP	O	O
a	DET	O	O
university	NOUN	O	O
counseling	DET	O	O
center	NOUN	O	O
were	VERB	O	O
instructed	VERB	O	O
to	PART	O	O
increase	NOUN	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
self-disclosures	NOUN	O	O
they	ADV	O	O
made	SYM	O	O
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
client	ADP	O	O
and	CCONJ	O	O
refrain	NOUN	O	O
from	ADP	O	O
making	VERB	O	O
self-disclosures	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
another	ADP	O	O
client	ADP	O	O
.	PUNCT	O	O

Analyses	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
clients	NOUN	O	O
receiving	DET	O	O
psychotherapy	NOUN	O	O
under	ADP	O	O
conditions	NOUN	O	O
of	ADP	O	O
heightened	ADJ	O	O
therapist	NOUN	O	O
disclosure	NOUN	O	O
not	ADV	O	O
only	ADJ	O	O
reported	PUNCT	O	O
lower	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	O
distress	NOUN	O	O
but	CCONJ	O	O
also	ADV	O	O
liked	PUNCT	O	B-OTHER
their	ADJ	O	I-OTHER
therapist	NOUN	O	I-OTHER
more	DET	O	O
.	PUNCT	O	O

Such	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
self-disclosure	NOUN	O	O
by	ADP	O	O
the	DET	O	O
therapist	NOUN	O	O
may	NOUN	O	O
improve	VERB	O	O
both	PUNCT	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	B-OTHER
relationship	NOUN	O	I-OTHER
and	CCONJ	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	B-MENTAL
.	PUNCT	O	O

Treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

Lack	NOUN	O	O
of	ADP	O	O
therapeutic	ADJ	O	B-PHYSICAL
benefit	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
increase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
toxicity	NOUN	O	B-ADVERSE-EFFECTS
from	ADP	O	O
aminophylline	NOUN	O	O
given	VERB	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
salbutamol	NOUN	O	O
delivered	VERB	O	O
by	ADP	O	O
metered-dose	NOUN	O	O
inhaler	ADJ	O	O
with	ADP	O	O
a	DET	O	O
spacer	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
if	PUNCT	O	O
intravenous	ADJ	O	O
aminophylline	ADJ	O	O
adds	VERB	O	O
any	PUNCT	O	O
benefit	NOUN	O	O
to	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
salbutamol	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	PROPN	O	O
presented	VERB	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
94	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
35.6	NUM	O	O
+/-	SYM	O	O
11.2	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
acute	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
salbutamol	NOUN	O	O
delivered	VERB	O	O
with	ADP	O	O
metered-dose	NOUN	O	O
inhaler	ADJ	O	O
(	PUNCT	O	O
MDI	NOUN	O	O
)	PUNCT	O	O
into	ADP	O	O
a	DET	O	O
spacer	NOUN	O	O
device	NOUN	O	O
(	PUNCT	O	O
Volumatic	ADJ	O	O
)	PUNCT	O	O
in	ADP	O	O
four	NUM	O	O
puffs	VERB	O	O
(	PUNCT	O	O
400	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
10-min	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
hydrocortisone	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
a	DET	O	O
loading	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
aminophylline	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
routine	ADJ	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
45	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
an	DET	O	O
equal	ADJ	O	O
volume	NOUN	O	O
of	ADP	O	O
placebo	NOUN	O	O
as	ADP	O	O
a	DET	O	O
loading	VERB	O	O
dose	NOUN	O	O
and	CCONJ	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
49	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
measurements	NOUN	O	O
of	ADP	O	O
peak	ADJ	O	O
expiratory	ADJ	O	B-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
FEV1	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
FVC	NOUN	O	B-PHYSICAL
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
aminophylline	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
more	DET	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
final	ADJ	O	O
mean	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
salbutamol	NOUN	O	O
(	PUNCT	O	O
6.3	NUM	O	O
+/-	SYM	O	O
44.5	NUM	O	O
mg	NOUN	O	O
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
5.8	NUM	O	O
+/-	SYM	O	O
4.2	NUM	O	O
mg	NOUN	O	O
for	ADP	O	O
the	DET	O	O
aminophylline	ADJ	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hospital	NOUN	O	O
admission	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
10.2	NUM	O	O
percent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
9.0	NUM	O	O
percent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
aminophylline	ADJ	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
duration	NOUN	O	O
of	ADP	O	O
Emergency	NOUN	O	O
Department	NOUN	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
+/-	SYM	O	O
1.83	NUM	O	O
h	NOUN	O	O
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
2.37	NUM	O	O
+/-	SYM	O	O
1.75	NUM	O	O
h	NOUN	O	O
for	ADP	O	O
the	DET	O	O
aminophylline	ADJ	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
were	VERB	O	O
similar	ADJ	O	O
when	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
in	ADP	O	O
accord	NOUN	O	O
with	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	B-PHYSICAL
obstruction	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
baseline	NOUN	O	O
FEV1	NOUN	O	O
<	SYM	O	O
30	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
predicted	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
theophylline	NOUN	O	B-PHYSICAL
level	NOUN	O	I-PHYSICAL
at	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
group	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
theophylline	NOUN	O	O
level	NOUN	O	O
<	SYM	O	O
10	NUM	O	O
mg/L	NOUN	O	O
vs	CCONJ	O	O
aminophylline	ADJ	O	O
group	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
theophylline	NOUN	O	O
level	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
mg/L	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
intravenous	ADJ	O	O
aminophylline	ADJ	O	O
adds	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
toxicity	NOUN	O	B-ADVERSE-EFFECTS
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
salbutamol	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
exacerbations	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
are	VERB	O	O
some	DET	O	O
benefits	NOUN	O	O
for	ADP	O	O
eradicating	NUM	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
non-ulcer	NOUN	O	O
dyspepsia	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
infection	NOUN	O	O
and	CCONJ	O	O
non-ulcer	NOUN	O	O
dyspepsia	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
whether	ADP	O	O
eradication	NOUN	O	O
of	ADP	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
might	ADP	O	O
be	PUNCT	O	O
of	ADP	O	O
benefit	NOUN	O	O
in	ADP	O	O
non-ulcer	NOUN	O	O
dyspepsia	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
randomly	PUNCT	O	O
assigned	PUNCT	O	O
129	NUM	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
infected	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
epigastric	ADJ	O	O
pain	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
gastro-oesophageal	ADJ	O	O
reflux	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
receive	NOUN	O	O
twice	PUNCT	O	O
daily	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
300	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
ranitidine	NOUN	O	O
,	PUNCT	O	O
1000	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
amoxicillin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
500	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
124	NUM	O	O
such	DET	O	O
patients	NOUN	O	O
to	PART	O	O
receive	PART	O	O
identical-appearing	ADJ	O	O
placebos	PUNCT	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Treatment	NOUN	O	O
was	VERB	O	O
successful	ADJ	O	O
(	PUNCT	O	O
decrease	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
62	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
active-treatment	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
60	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
N.S.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	B-PHYSICAL
eradication	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
H.	NOUN	O	O
pylori	NOUN	O	B-PHYSICAL
was	VERB	O	O
69	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
active-treatment	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
18	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Complete	ADJ	O	B-OTHER
relief	PUNCT	O	I-OTHER

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
a	DET	O	O
short	ADJ	O	O
nurse-based	VERB	O	O
and	CCONJ	O	O
a	DET	O	O
long	ADJ	O	O
multidisciplinary	ADJ	O	O
version	NOUN	O	O
of	ADP	O	O
structured	VERB	O	O
patient	NOUN	O	O
education	NOUN	O	O
in	ADP	O	O
irritable	ADJ	O	O
bowel	NOUN	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Structured	PUNCT	O	O
multidisciplinary	ADJ	O	O
patient	NOUN	O	O
group	NOUN	O	O
education	NOUN	O	O
has	VERB	O	O
positive	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
health-related	VERB	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
disease-related	VERB	O	O
knowledge	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
irritable	ADJ	O	O
bowel	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
IBS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
few	ADJ	O	O
studies	NOUN	O	O
comparing	DET	O	O
different	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
educational	ADJ	O	O
interventions	NOUN	O	O
are	PROPN	O	O
available	ADJ	O	O
.	PUNCT	O	O

Our	PUNCT	O	O
aim	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
multidisciplinary	ADJ	O	O
group	NOUN	O	O
education	NOUN	O	O
with	ADP	O	O
a	DET	O	O
short	ADJ	O	O
nurse-based	VERB	O	O
group	NOUN	O	O
education	NOUN	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
satisfaction	NOUN	O	O
with	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
in	ADP	O	O
IBS	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
IBS	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
Rome	NOUN	O	O
II	NUM	O	O
criteria	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
short	ADJ	O	O
nurse-based	VERB	O	O
or	CCONJ	O	O
a	DET	O	O
long	ADJ	O	O
multidisciplinary-based	ADJ	O	O
education	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
self-administered	ADJ	O	O
questionnaires	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
compared	VERB	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
No	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
effects	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
between-group	NOUN	O	O
comparisons	NOUN	O	O
at	ADP	O	O
any	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
assessments	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
positive	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
symptoms	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
knowledge	NOUN	O	B-MENTAL
,	PUNCT	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
satisfaction	NOUN	O	B-OTHER
with	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
short	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
long	ADJ	O	O
version	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
A	CCONJ	O	O
short	ADJ	O	O
,	PUNCT	O	O
nurse-based	PUNCT	O	O
educational	ADJ	O	O
intervention	NOUN	O	O
seems	NOUN	O	O
to	DET	O	O
be	PUNCT	O	O
as	CCONJ	O	O
efficacious	ADJ	O	O
as	ADP	O	O
a	DET	O	O
longer	PUNCT	O	O
multidisciplinary	ADJ	O	O
version	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
positive	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
patients	NOUN	O	O
'	PUNCT	O	O
well-being	PUNCT	O	O
were	ADP	O	O
found	VERB	O	O
to	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
extent	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
finding	PART	O	O
that	ADP	O	O
,	PUNCT	O	O
from	ADP	O	O
a	DET	O	O
cost-effective	ADJ	O	O
perspective	ADJ	O	O
,	PUNCT	O	O
could	VERB	O	O
contribute	VERB	O	O
toward	ADP	O	O
an	DET	O	O
optimized	VERB	O	O
management	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
IBS	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
motivational	ADJ	O	O
music	ADJ	O	O
on	ADP	O	O
lactate	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
during	ADP	O	O
recovery	NOUN	O	O
from	ADP	O	O
intense	ADJ	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
music	ADJ	O	O
played	VERB	O	O
during	ADP	O	O
an	DET	O	O
exercise	NOUN	O	O
task	NOUN	O	O
on	ADP	O	O
athletic	ADJ	O	O
performance	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
previously	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

Yet	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
results	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
applicable	ADJ	O	O
for	ADP	O	O
competitive	ADJ	O	O
athletes	NOUN	O	O
,	PUNCT	O	O
who	DET	O	O
can	CCONJ	O	O
use	VERB	O	O
music	ADJ	O	O
only	ADV	O	O
during	ADP	O	O
warm-up	NOUN	O	O
or	CCONJ	O	O
recovery	NOUN	O	O
from	ADP	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
motivational	ADJ	O	O
music	ADJ	O	O
(	PUNCT	O	O
music	ADJ	O	O
that	ADP	O	O
stimulates	NOUN	O	O
or	CCONJ	O	O
inspires	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
recovery	NOUN	O	O
from	ADP	O	O
intense	ADJ	O	B-PHYSICAL
exercise	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
on	ADP	O	O
activity	NOUN	O	B-PHYSICAL
pattern	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
rate	NOUN	O	O
of	ADP	O	O
perceived	DET	O	B-PHYSICAL
exertion	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RPE	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
lactate	NOUN	O	I-PHYSICAL
concentration	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
young	ADJ	O	O
,	PUNCT	O	O
active	ADJ	O	O
men	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
26.2	NUM	O	O
?	PUNCT	O	O

2.1	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
performed	VERB	O	O
a	DET	O	O
6-minute	PUNCT	O	O
run	PUNCT	O	O
at	ADP	O	O
peak	ADJ	O	O
oxygen	NOUN	O	O
consumption	NOUN	O	O
speed	NOUN	O	O
(	PUNCT	O	O
predetermined	NOUN	O	O
from	ADP	O	O
the	DET	O	O
VO	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
max	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
heart	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
RPE	NOUN	O	O
,	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
steps	NOUN	O	O
(	PUNCT	O	O
determined	PROPN	O	O
by	ADP	O	O
step	NOUN	O	O
counter	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
blood	NOUN	O	O
lactate	NOUN	O	O
concentrations	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
at	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
minutes	NOUN	O	O
during	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
from	ADP	O	O
the	DET	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
motivational	ADJ	O	O
music	ADJ	O	O
(	PUNCT	O	O
2	NUM	O	O
separate	ADJ	O	O
sessions	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mean	NOUN	O	O
HR	NOUN	O	O
during	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
music	ADP	O	O
.	PUNCT	O	O

Listening	ADJ	O	O
to	ADP	O	O
motivational	ADJ	O	O
music	ADJ	O	O
during	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	PUNCT	O	O
voluntary	PUNCT	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
participants	NOUN	O	O
,	PUNCT	O	O
determined	VERB	O	O
by	ADP	O	O
increased	DET	O	O
number	NOUN	O	O
of	ADP	O	O
steps	NOUN	O	O
(	PUNCT	O	O
499.4	ADP	O	O
?	PUNCT	O	O

220.1	ADJ	O	O
vs.	CCONJ	O	O
413.2	NUM	O	O
?	PUNCT	O	O

150.6	NUM	O	O
steps	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
music	ADP	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
p	NOUN	O	O
?	PUNCT	O	O

0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
increased	VERB	O	O
number	NOUN	O	O
of	ADP	O	O
steps	NOUN	O	O
during	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
was	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
lactate	NOUN	O	O
concentration	NOUN	O	O
percentage	NOUN	O	O
(	PUNCT	O	O
28.1	NUM	O	O
?	PUNCT	O	O

12.2	NUM	O	O
vs.	CCONJ	O	O
22.8	NUM	O	O
?	PUNCT	O	O

10.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
music	ADP	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
p	NOUN	O	O
?	PUNCT	O	O

0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
RPE	NOUN	O	O
(	PUNCT	O	O
77.7	NUM	O	O
?	PUNCT	O	O

14.4	NUM	O	O
vs.	CCONJ	O	O
73.1	NUM	O	O
?	PUNCT	O	O

14.7	NUM	O	O
%	SYM	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
music	ADP	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
p	NOUN	O	O
?	PUNCT	O	O

0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
listening	ADJ	O	O
to	ADP	O	O
motivational	ADJ	O	O
music	ADJ	O	O
during	ADP	O	O
nonstructured	ADV	O	O
recovery	NOUN	O	O
from	ADP	O	O
intense	ADJ	O	O
exercise	NOUN	O	O
leads	NOUN	O	O
to	ADP	O	O
increased	VERB	O	O
activity	NOUN	O	O
,	PUNCT	O	O
faster	PUNCT	O	O
lactate	NOUN	O	O
clearance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
reduced	VERB	O	O
RPE	NOUN	O	O
and	CCONJ	O	O
therefore	ADV	O	O
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
by	ADP	O	O
athletes	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
effort	NOUN	O	O
to	PART	O	O
enhance	NOUN	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
open-label	NOUN	O	O
extension	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
long-term	NOUN	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
treating	PUNCT	O	O
irritability	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
related	VERB	O	O
behaviors	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
6	NUM	O	O
month	NOUN	O	O
(	PUNCT	O	O
26	NUM	O	O
week	NOUN	O	O
)	PUNCT	O	O
open-label	NOUN	O	O
extension	NOUN	O	O
(	PUNCT	O	O
OLE	NOUN	O	O
)	PUNCT	O	O
study	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
5-17	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
who	PROPN	O	O
completed	PROPN	O	O
the	DET	O	O
previous	ADJ	O	O
fixed-dose	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
week	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
[	PUNCT	O	O
DB	NOUN	O	O
]	PUNCT	O	O
phase	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
flexibly	ADV	O	O
dosed	VERB	O	O
with	ADP	O	O
risperidone	NUM	O	O
based	VERB	O	O
on	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	NOUN	O	O
allowed	ADV	O	O
dose	NOUN	O	O
was	VERB	O	O
1.25	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
those	PUNCT	O	O
weighing	CCONJ	O	O
20	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
45	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.75	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
those	PUNCT	O	O
weighing	CCONJ	O	O
?	PUNCT	O	O

45	NUM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
primarily	ADV	O	O
assessed	ADP	O	O
risperidone	ADP	O	O
's	PUNCT	O	O
safety	NOUN	O	O
;	PUNCT	O	O
efficacy	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
as	ADP	O	O
a	DET	O	O
secondary	ADJ	O	O
end-point	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Fifty-six	ADJ	O	O
(	PUNCT	O	O
71	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
out	PUNCT	O	O
of	ADP	O	O
79	NUM	O	O
enrolled	VERB	O	O
patients	NOUN	O	O
completed	NOUN	O	O
the	DET	O	O
OLE	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
most	VERB	O	O
common	ADJ	O	O
discontinuations	NOUN	O	O
were	VERB	O	O
for	ADP	O	O
insufficient	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
7	NUM	O	O
[	PUNCT	O	O
9	NUM	O	O
%	SYM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
(	PUNCT	O	O
AE	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
5	NUM	O	O
[	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
common	ADJ	O	O
(	PUNCT	O	O
?	PUNCT	O	O

5	NUM	O	O
%	SYM	O	O
frequency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
group	NOUN	O	O
)	PUNCT	O	O
AEs	ADP	O	O
were	VERB	O	O
increased	PUNCT	O	O
appetite	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
%	ADJ	O	O
[	PUNCT	O	O
n=9	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
increased	DET	O	O
weight	NOUN	O	O
and	CCONJ	O	O
vomiting	PROPN	O	O
(	PUNCT	O	O
9	NUM	O	O
%	SYM	O	O
[	PUNCT	O	O
n=7	NOUN	O	O
]	PUNCT	O	O
each	ADP	O	O
)	PUNCT	O	O
;	PUNCT	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
pyrexia	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
upper	ADJ	O	O
respiratory	ADJ	O	O
tract	NOUN	O	O
infection	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
[	PUNCT	O	O
n=6	NOUN	O	O
]	PUNCT	O	O
each	ADP	O	O
)	PUNCT	O	O
;	PUNCT	O	O
nasopharyngitis	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
%	ADJ	O	O
[	PUNCT	O	O
n=5	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
somnolence	NOUN	O	O
and	CCONJ	O	O
fatigue	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
%	SYM	O	O
[	PUNCT	O	O
n=4	NOUN	O	O
]	PUNCT	O	O
each	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Extrapyramidal	ADJ	O	O
AEs	ADP	O	O
were	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
6	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Increase	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
weight	NOUN	O	O
(	PUNCT	O	O
11-15	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
5-10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
occurred	VERB	O	O
;	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
discontinued	PROPN	O	O
because	PUNCT	O	O
of	ADP	O	O
weight	NOUN	O	O
increase	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
potentially	ADV	O	O
prolactin-related	VERB	O	O
AE	NOUN	O	O
(	PUNCT	O	O
irregular	ADJ	O	O
menstruation	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
risperidone	NUM	O	O
high-dose	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
the	DET	O	O
greatest	PUNCT	O	O
mean	NOUN	O	O
improvement	NOUN	O	O
in	ADP	O	O
sleep	NOUN	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
24.6	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
groups	NOUN	O	O
showed	VERB	O	O
additional	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
efficacy	NOUN	O	O
scale	NOUN	O	O
scores	NOUN	O	O
during	ADP	O	O
the	DET	O	O
OLE	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
During	ADP	O	O
this	DET	O	O
OLE	NOUN	O	O
,	PUNCT	O	O
safety	NOUN	O	O
findings	NOUN	O	O
with	ADP	O	O
risperidone	NUM	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
maximum	NOUN	O	O
weight-based	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
1.25	NUM	O	O
mg/day	NOUN	O	O
or	CCONJ	O	O
1.75	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
those	ADJ	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
DB	NOUN	O	O
phase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
current	ADJ	O	O
safety	NOUN	O	O
information	NOUN	O	O
for	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
autistic	ADJ	O	O
,	PUNCT	O	O
psychiatric	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
experienced	VERB	O	O
some	DET	O	O
additional	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
irritability	NOUN	O	O
and	CCONJ	O	O
related	VERB	O	O
behaviors	NOUN	O	O
.	PUNCT	O	O

CLINICAL	ADJ	O	O
TRIALS	NOUN	O	O
REGISTRY	NOUN	O	O
This	DET	O	O
phase-4	NOUN	O	O
study	NOUN	O	O
is	VERB	O	O
registered	NOUN	O	O
at	ADP	O	O
ClinicalTrials.gov	PUNCT	O	O
(	PUNCT	O	O
NCT00576732	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
encoding	ADP	O	O
in	ADP	O	O
hypnosis	NOUN	O	O
and	CCONJ	O	O
post-hypnotic	ADJ	O	O
suggestion	NOUN	O	O
on	ADP	O	O
academic	ADJ	O	O
performance	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
proactive	CCONJ	O	O
learning	ADJ	O	O
in	ADP	O	O
hypnosis	NOUN	O	O
,	PUNCT	O	O
post-hypnotic	ADJ	O	O
suggestion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
academic	ADJ	O	O
performance	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
56	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
hypnotized	VERB	O	O
and	CCONJ	O	O
read	ADP	O	O
a	DET	O	O
passage	NOUN	O	O
while	ADP	O	O
in	ADP	O	O
hypnosis	NOUN	O	O
.	PUNCT	O	O

Concurrently	ADV	O	O
,	PUNCT	O	O
they	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
post-hypnotic	ADJ	O	O
suggestion	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
attempted	VERB	O	O
to	ADP	O	O
aid	PUNCT	O	O
recognition	NOUN	O	O
and	CCONJ	O	O
performance	NOUN	O	O
on	ADP	O	O
a	DET	O	O
test	NOUN	O	O
immediately	ADV	O	O
following	VERB	O	O
the	DET	O	O
hypnosis	NOUN	O	O
session	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
completed	ADV	O	O
a	DET	O	O
multiple-choice	NOUN	O	O
test	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
aforementioned	PUNCT	O	O
passage	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
covariance	NOUN	O	O
discerned	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
proactive	CCONJ	O	B-MENTAL
learning	PROPN	O	I-MENTAL
and	CCONJ	O	O
post-hypnotic	ADJ	O	B-MENTAL
suggestion	NOUN	O	I-MENTAL
on	ADP	O	O
test	PUNCT	O	B-MENTAL
performance	NOUN	O	I-MENTAL
,	PUNCT	O	O
while	ADP	O	O
controlling	ADJ	O	O
for	ADP	O	O
the	DET	O	O
variance	NOUN	O	O
introduced	PUNCT	O	O
by	ADP	O	O
scholastic	ADJ	O	B-OTHER
aptitude	ADJ	O	I-OTHER
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
ACT	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
the	DET	O	O
hypnosis	NOUN	O	O
sessions	NOUN	O	O
predicted	VERB	O	O
significantly	ADV	O	O
impaired	ADP	O	B-MENTAL
test	ADV	O	I-MENTAL
performance	NOUN	O	I-MENTAL
.	PUNCT	O	O

Albumin-glutaraldehyde	NOUN	O	O
bioadhesive	ADJ	O	O
(	PUNCT	O	O
Bioglue	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
after	ADP	O	O
stapled	VERB	O	O
hemorrhoidopexy	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Hemorrhoidopexy	NOUN	O	O
using	VERB	O	O
the	DET	O	O
circumferential	ADJ	O	O
stapler	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
established	VERB	O	O
method	NOUN	O	O
for	ADP	O	O
surgical	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prolapsing	ADJ	O	O
hemorrhoids	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
its	PUNCT	O	O
advantages	NOUN	O	O
,	PUNCT	O	O
complications	ADJ	O	O
such	CCONJ	O	O
as	ADP	O	O
anal	ADJ	O	O
canal	NOUN	O	O
stenosis	NOUN	O	O
,	PUNCT	O	O
hemorrhage	NOUN	O	O
and	CCONJ	O	O
anastomosis	NOUN	O	O
leak	ADJ	O	O
with	ADP	O	O
eventual	ADJ	O	O
intrapelvic	NOUN	O	O
sepsis	NOUN	O	O
can	PART	O	O
cause	ADP	O	O
serious	ADJ	O	O
postoperative	ADJ	O	O
problems	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
utility	NOUN	O	O
of	ADP	O	O
a	DET	O	O
surgical	ADJ	O	O
adhesive	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
biological	ADJ	O	O
albumin-glutaraldehyde	NOUN	O	O
glue	NOUN	O	O
Bioglue	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
these	DET	O	O
postoperative	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Between	ADP	O	O
January	NOUN	O	O
2002	NUM	O	O
and	CCONJ	O	O
November	NOUN	O	O
2004	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
stapled	ADP	O	O
hemorrhoidopexy	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
100	NUM	O	O
patients	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
Bioglue	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mucosa	NOUN	O	O
anastomosis	NOUN	O	O
area	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
standardized	VERB	O	O
postoperative	ADJ	O	O
analgesic	ADJ	O	O
,	PUNCT	O	O
laxative	ADJ	O	O
and	CCONJ	O	O
antibiotic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
evaluated	PUNCT	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
for	ADP	O	O
postoperative	ADJ	O	B-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
after	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
postoperatively	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
From	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
no	ADP	O	O
Bioglue	NOUN	O	O
application	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
anal	ADJ	O	B-ADVERSE-EFFECTS
stenosis	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
two	NUM	O	O
with	ADP	O	O
hemorrhage	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
three	NUM	O	O
had	PUNCT	O	O
anastomosis	NOUN	O	B-ADVERSE-EFFECTS
leak	ADP	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
one	NUM	O	O
had	PUNCT	O	O
thrombosis	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
whereas	ADP	O	O
none	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Bioglue	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
any	PUNCT	O	O
of	ADP	O	O
these	DET	O	O
complications	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
had	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	B-ADVERSE-EFFECTS
postoperative	ADJ	O	I-ADVERSE-EFFECTS
pain	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
3	NUM	O	O
each	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fecal	ADJ	O	B-ADVERSE-EFFECTS
incontinence	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
1	NUM	O	O
patient	NOUN	O	O
each	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	B-OTHER
difference	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
number	NOUN	O	B-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
In	ADP	O	O
this	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
using	VERB	O	O
Bioglue	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
circumferential	ADJ	O	O
stapled	ADP	O	O
hemorrhoidopexy	NOUN	O	O
we	PRON	O	O
have	PUNCT	O	O
shown	VERB	O	O
that	ADP	O	O
application	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glue	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	B-ADVERSE-EFFECTS
postoperative	ADJ	O	I-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Hemostasis	NOUN	O	O
by	ADP	O	O
bipolar	ADJ	O	O
coagulation	NOUN	O	O
versus	CCONJ	O	O
suture	NOUN	O	O
after	ADP	O	O
surgical	ADJ	O	O
stripping	ADJ	O	O
of	ADP	O	O
bilateral	ADJ	O	O
ovarian	ADJ	O	O
endometriomas	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
To	PROPN	O	O
estimate	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
suture	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ovary	NOUN	O	O
is	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
bipolar	ADJ	O	O
coagulation	NOUN	O	O
in	ADP	O	O
preserving	VERB	O	O
ovarian	ADJ	O	O
reserve	NOUN	O	O
in	ADP	O	O
infertile	ADJ	O	O
women	NOUN	O	O
undergoing	VERB	O	O
laparoscopic	ADJ	O	O
stripping	ADJ	O	O
of	ADP	O	O
bilateral	ADJ	O	O
endometriomas	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
(	PUNCT	O	O
Canadian	ADJ	O	O
Task	NOUN	O	O
Force	NOUN	O	O
classification	NOUN	O	O
I	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

SETTING	ADJ	O	O
University	NOUN	O	O
teaching	VERB	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
100	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
bilateral	ADJ	O	O
endometriomas	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Patients	NOUN	O	O
underwent	VERB	O	O
stripping	ADJ	O	O
of	ADP	O	O
bilateral	ADJ	O	O
endometriomas	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PUNCT	O	O
undergo	VERB	O	O
hemostasis	NOUN	O	O
by	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
laparoscopic	ADJ	O	O
suturing	PUNCT	O	O
(	PUNCT	O	O
LS	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
bipolar	ADJ	O	O
coagulation	NOUN	O	O
(	PUNCT	O	O
BC	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
ovarian	ADJ	O	B-PHYSICAL
reserve	NOUN	O	I-PHYSICAL
were	VERB	O	O
investigated	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
anti-Mullerian	ADJ	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
AMH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
basal	ADJ	O	B-PHYSICAL
follicle-stimulating	VERB	O	I-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
FSH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
from	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
MAIN	ADJ	O	O
RESULTS	NOUN	O	O
At	ADP	O	O
3-month	NOUN	O	O
,	PUNCT	O	O
6-month	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12-month	NOUN	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
study	ADP	O	O
groups	NOUN	O	O
,	PUNCT	O	O
postsurgical	ADJ	O	B-PHYSICAL
AMH	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
and	CCONJ	O	O
basal	ADJ	O	B-PHYSICAL
FSH	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
before	CCONJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mean	NOUN	O	O
percentage	NOUN	O	O
decrease	NOUN	O	O
of	ADP	O	O
AMH	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
BC	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
LS	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
3-	NUM	O	O
,	PUNCT	O	O
6-	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12-month	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
percentage	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
basal	ADJ	O	B-PHYSICAL
FSH	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
BC	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
LS	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
both	CCONJ	O	O
3-month	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.023	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
6-month	NOUN	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.029	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
at	ADP	O	O
12-month	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Pregnancy	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
conception	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
rate	NOUN	O	O
of	ADP	O	O
endometrioma	NOUN	O	O
recurrence	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
study	ADV	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Laparoscopic	ADJ	O	O
stripping	ADJ	O	O
of	ADP	O	O
ovarian	ADJ	O	O
endometriotic	ADJ	O	O
cyst	NOUN	O	O
significantly	ADV	O	O
decreases	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
AMH	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
increases	ADV	O	O
basal	ADJ	O	B-PHYSICAL
FSH	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
independent	ADJ	O	O
from	ADP	O	O
the	DET	O	O
method	NOUN	O	O
used	VERB	O	O
to	PART	O	O
obtain	NOUN	O	O
hemostasis	NOUN	O	O
on	ADP	O	O
the	DET	O	O
ovarian	ADJ	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
nutritional	ADJ	O	O
supplementation	NOUN	O	O
on	ADP	O	O
IQ	NOUN	O	B-MENTAL
and	CCONJ	O	O
certain	ADJ	O	O
other	ADJ	O	O
variables	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
Down	ADJ	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
24	NUM	O	O
Down	ADJ	O	O
syndrome	NOUN	O	O
children	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
6	NUM	O	O
to	ADP	O	O
17	NUM	O	O
years	NOUN	O	O
living	VERB	O	O
at	ADP	O	O
home	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
megadose	NOUN	O	O
multi-vitamin/mineral	ADJ	O	O
supplement	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
matched	VERB	O	O
group	NOUN	O	O
of	ADP	O	O
23	NUM	O	O
children	NOUN	O	O
received	VERB	O	O
a	DET	O	O
placebo	NOUN	O	O
in	ADP	O	O
identical	ADJ	O	O
form	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
children	NOUN	O	B-MENTAL
's	PUNCT	O	O
IQ	NOUN	O	B-MENTAL
,	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
levetiracetam	NOUN	O	O
on	ADP	O	O
essential	ADJ	O	B-PHYSICAL
tremor	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
1,000	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
levetiracetam	NOUN	O	O
on	ADP	O	O
essential	ADJ	O	O
tremor	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
hand	NOUN	O	B-PHYSICAL
tremor	NOUN	O	I-PHYSICAL
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
2	NUM	O	O
hours	NOUN	O	O
as	CCONJ	O	O
measured	VERB	O	O
by	ADP	O	O
accelerometry	NOUN	O	O
and	CCONJ	O	O
functional	ADJ	O	O
tests	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
's	PUNCT	O	O
response	NOUN	O	O
to	ADP	O	O
novel	ADJ	O	B-PHYSICAL
stimuli	NOUN	O	I-PHYSICAL
while	ADP	O	O
participating	ADP	O	O
in	ADP	O	O
interventions	NOUN	O	O
targeting	VERB	O	O
joint	NOUN	O	O
attention	NOUN	O	O
or	CCONJ	O	O
symbolic	ADJ	O	O
play	PUNCT	O	O
skills	NOUN	O	O
.	PUNCT	O	O

Thirty-five	PUNCT	O	O
children	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
autism	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
joint	NOUN	O	O
attention	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
symbolic	ADJ	O	O
play	VERB	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
5-8	NUM	O	O
week	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
novel	ADJ	O	O
probes	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
mastery	NOUN	O	O
of	ADP	O	O
joint	NOUN	O	B-MENTAL
attention	NOUN	O	I-MENTAL
skills	NOUN	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
probes	NOUN	O	O
consisted	DET	O	O
of	ADP	O	O
auditory	ADJ	O	O
and	CCONJ	O	O
visual	ADJ	O	O
stimuli	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
loud	ADJ	O	O
spider	NOUN	O	O
crawling	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
musical	ADP	O	O
ball	NOUN	O	O
bouncing	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
examined	CCONJ	O	O
affect	NOUN	O	O
,	PUNCT	O	O
gaze	NOUN	O	O
,	PUNCT	O	O
joint	NOUN	O	O
attention	NOUN	O	O
behaviors	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
verbalizations	NOUN	O	B-MENTAL
at	ADP	O	O
three	NUM	O	O
different	ADJ	O	O
time	NOUN	O	O
points	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
children	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
the	DET	O	O
joint	NOUN	O	O
attention	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	ADP	O	O
acknowledge	ADP	O	O
the	DET	O	O
probe	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
engage	NUM	O	I-MENTAL
in	ADP	O	I-MENTAL
shared	VERB	O	I-MENTAL
interactions	NOUN	O	I-MENTAL
between	ADP	O	O
intervener	NOUN	O	O
and	CCONJ	O	O
probe	PUNCT	O	O
upon	ADP	O	O
termination	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
joint	NOUN	O	O
attention	NOUN	O	O
group	NOUN	O	O
improved	VERB	O	O
in	ADP	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
spent	ADP	O	O
sharing	PUNCT	O	O
coordinated	VERB	O	O
joint	NOUN	O	O
looks	PUNCT	O	O
between	ADP	O	O
intervener	NOUN	O	O
and	CCONJ	O	O
probe	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
generalization	NOUN	O	O
of	ADP	O	O
joint	NOUN	O	O
attention	NOUN	O	O
skills	NOUN	O	O
to	ADP	O	O
a	DET	O	O
novel	ADJ	O	O
probe	NOUN	O	O
did	PUNCT	O	O
occur	ADP	O	O
for	ADP	O	O
the	DET	O	O
group	NOUN	O	O
targeting	VERB	O	O
joint	NOUN	O	O
attention	NOUN	O	O
and	CCONJ	O	O
provides	NOUN	O	O
further	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
joint	NOUN	O	O
attention	NOUN	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Interactions	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	O
and	CCONJ	O	O
methotrimeprazine	NOUN	O	O
in	ADP	O	O
mouse	NOUN	O	O
and	CCONJ	O	O
man	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
analgesia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
respiration	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
sedation	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Interactions	NOUN	O	O
between	ADP	O	O
morphine	NOUN	O	O
and	CCONJ	O	O
methotrimeprazine	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
studied	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
and	CCONJ	O	O
man	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
analgesia	NOUN	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
antinociceptive	ADJ	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
respiratory	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
sedation	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
volunteer	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
cross-over	NOUN	O	O
trial	NOUN	O	O
with	ADP	O	O
10	NUM	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
methotrimeprazine	NOUN	O	O
only	ADV	O	O
possessed	VERB	O	O
antinociceptive	ADJ	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
in	ADP	O	O
doses	NOUN	O	O
which	ADP	O	O
caused	VERB	O	O
marked	VERB	O	B-PHYSICAL
sedation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
small	ADJ	O	O
non-sedative	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
methotrimeprazine	NOUN	O	O
potentiated	VERB	O	O
the	DET	O	O
analgesic	ADP	O	B-PAIN
action	NOUN	O	I-PAIN
of	ADP	O	I-PAIN
morphine	NOUN	O	I-PAIN
.	PUNCT	O	O

The	DET	O	O
volunteer	NOUN	O	O
study	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
confirm	VERB	O	O
this	DET	O	O
finding	VERB	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Methotrimeprazine	NOUN	O	O
7.5	NUM	O	O
mg	NOUN	O	O
i.m	NUM	O	O
.	PUNCT	O	O

caused	ADP	O	O
significant	ADJ	O	B-PHYSICAL
sedation	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
did	PUNCT	O	O
not	ADV	O	O
alter	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	O
5	NUM	O	O
mg	NOUN	O	O
on	ADP	O	O
pain	NOUN	O	B-PAIN
threshold	NOUN	O	I-PAIN
or	CCONJ	O	O
ventilatory	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	ADP	O	O
carbon	NOUN	O	O
dioxide	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
postural	PUNCT	O	O
supports	VERB	O	O
on	ADP	O	O
neuromotor	NOUN	O	B-PHYSICAL
function	CCONJ	O	I-PHYSICAL
in	ADP	O	O
very	PUNCT	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
to	ADP	O	O
term	NOUN	O	O
equivalent	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
nappy	PUNCT	O	O
and/or	CCONJ	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	ADP	O	O
on	ADP	O	O
neuromotor	NOUN	O	B-PHYSICAL
function	CCONJ	O	I-PHYSICAL
in	ADP	O	O
very	PUNCT	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
when	ADP	O	O
nursed	VERB	O	O
prone	ADJ	O	O
to	ADP	O	O
term	NOUN	O	O
equivalent	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	CCONJ	O	O
randomized	VERB	O	O
observer	ADP	O	O
blind	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
123	NUM	O	O
very	ADJ	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
the	DET	O	O
neonatal	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sole	ADJ	O	O
tertiary	ADJ	O	O
referral	ADJ	O	O
centre	NOUN	O	O
in	ADP	O	O
Western	NOUN	O	O
Australia	PUNCT	O	O
.	PUNCT	O	O

Infants	NOUN	O	O
were	VERB	O	O
stratified	VERB	O	O
by	ADP	O	O
gestational	ADJ	O	O
age	NOUN	O	O
(	PUNCT	O	O
<	PROPN	O	O
29	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
29-30	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
then	ADV	O	O
randomized	PUNCT	O	O
into	ADP	O	O
one	NUM	O	O
of	ADP	O	O
three	NUM	O	O
intervention	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
postural	ADJ	O	O
support	NOUN	O	O
nappy	PUNCT	O	O
,	PUNCT	O	O
postural	ADJ	O	O
support	NOUN	O	O
nappy	PUNCT	O	O
and	CCONJ	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
disposable	ADJ	O	O
nappy	ADJ	O	O
and	CCONJ	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	NOUN	O	O
.	PUNCT	O	O

Interventions	NOUN	O	O
started	VERB	O	O
when	ADP	O	O
infants	NOUN	O	O
were	VERB	O	O
stable	ADJ	O	O
and	CCONJ	O	O
ceased	VERB	O	O
when	PUNCT	O	O
routine	ADJ	O	O
side-lying	PUNCT	O	O
commenced	PROPN	O	O
.	PUNCT	O	O

Measurements	NOUN	O	O
of	ADP	O	O
shoulder	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
hip	NOUN	O	B-PHYSICAL
posture	NOUN	O	I-PHYSICAL
were	VERB	O	O
performed	VERB	O	O
pre-intervention	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
weeks	NOUN	O	O
post-intervention	NOUN	O	O
and	CCONJ	O	O
term	NOUN	O	O
postmenstrual	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Infants	NOUN	O	O
nursed	VERB	O	O
with	ADP	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	ADP	O	O
and	CCONJ	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
nappy	PUNCT	O	O
demonstrated	VERB	O	O
improved	ADP	O	O
hip	NOUN	O	B-PHYSICAL
posture	NOUN	O	I-PHYSICAL
to	ADP	O	O
term	NOUN	O	O
equivalent	ADJ	O	O
age	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
infants	NOUN	O	O
nursed	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	VERB	O	O
only	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
nappy	PUNCT	O	O
only	ADV	O	O
.	PUNCT	O	O

Infants	NOUN	O	O
nursed	VERB	O	O
with	ADP	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	VERB	O	O
either	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
nappy	PUNCT	O	O
demonstrated	VERB	O	O
improved	VERB	O	O
shoulder	NOUN	O	B-PHYSICAL
posture	NOUN	O	I-PHYSICAL
to	ADP	O	O
term	NOUN	O	O
equivalent	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Combined	PROPN	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	ADP	O	O
and	CCONJ	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
nappy	PUNCT	O	O
while	PUNCT	O	O
very	DET	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
are	VERB	O	O
nursed	PUNCT	O	O
prone	ADP	O	O
improves	NOUN	O	O
hip	NOUN	O	B-PHYSICAL
posture	NUM	O	I-PHYSICAL
up	CCONJ	O	O
to	ADP	O	O
term	NOUN	O	O
postmenstrual	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
postural	ADJ	O	O
support	NOUN	O	O
roll	VERB	O	O
improves	ADV	O	O
shoulder	NOUN	O	B-PHYSICAL
posture	NUM	O	I-PHYSICAL
up	PUNCT	O	O
to	ADP	O	O
term	NOUN	O	O
equivalent	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

Sialyl	NOUN	O	O
Lewisa	VERB	O	O
expression	NOUN	O	O
as	ADP	O	O
a	DET	O	O
predictor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prognosis	NOUN	O	O
of	ADP	O	O
colon	NOUN	O	O
carcinoma	NOUN	O	O
patients	NOUN	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
metastatic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
tumors	NOUN	O	O
is	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
the	DET	O	O
cell	NOUN	O	O
to	ADP	O	O
cell	NOUN	O	O
adhesion	NOUN	O	O
by	ADP	O	O
cell	NOUN	O	O
surface	NOUN	O	O
carbohydrate	NOUN	O	O
antigens	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
expression	NOUN	O	O
of	ADP	O	O
sialyl	NOUN	O	O
Lewis	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
important	ADJ	O	O
molecules	NOUN	O	O
of	ADP	O	O
cell	NOUN	O	O
surface	NOUN	O	O
carbohydrates	CCONJ	O	O
,	PUNCT	O	O
may	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
a	DET	O	O
prognostic	ADJ	O	O
marker	NOUN	O	O
of	ADP	O	O
aggressive	ADJ	O	O
and	CCONJ	O	O
metastasizing	VERB	O	O
tumor	NOUN	O	O
growth	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
prognostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
sialyl	NOUN	O	O
Lewis	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
in	ADP	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
sialyl	NOUN	O	O
Lewis	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
antigen	NOUN	O	O
in	ADP	O	O
233	NUM	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
specimens	NOUN	O	O
from	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
were	ADV	O	O
registered	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
adjuvant	NOUN	O	O
immunochemotherapy	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
course	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
prognosis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
after	ADP	O	O
all	PUNCT	O	O
the	DET	O	O
immunohistochemical	ADJ	O	O
analyses	NOUN	O	O
had	VERB	O	O
been	PUNCT	O	O
performed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Sialyl	NOUN	O	O
Lewis	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
both	CCONJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0006	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
disease-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
log-rank	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
result	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
assumed	VERB	O	O
to	PART	O	O
have	PUNCT	O	O
been	PUNCT	O	O
influenced	VERB	O	O
by	ADP	O	O
the	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
metastatic	ADJ	O	O
preponderance	NOUN	O	O
in	ADP	O	O
a	DET	O	O
high	ADJ	O	O
versus	CCONJ	O	O
low	ADJ	O	O
sialyl	NOUN	O	O
Lewis	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
tumor	NOUN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
This	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
sialyl	NOUN	O	O
Lewis	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
levels	NOUN	O	O
may	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
an	DET	O	O
indicator	NOUN	O	O
of	ADP	O	O
the	DET	O	O
metastatic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
would	VERB	O	O
strongly	ADV	O	O
predict	VERB	O	O
the	DET	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

Diet	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
status	NOUN	O	O
among	ADP	O	O
pregnant	ADJ	O	O
Pakistani	NOUN	O	O
women	NOUN	O	O
in	ADP	O	O
Oslo	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
diet	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
nutritional	ADJ	O	O
status	NOUN	O	O
of	ADP	O	O
pregnant	ADJ	O	O
Pakistani	NOUN	O	O
immigrant	NOUN	O	O
women	NOUN	O	O
have	CCONJ	O	O
been	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
Norwegian	PUNCT	O	O
women	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	PUNCT	O	O
cross-sectional	ADJ	O	O
survey	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
18th	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Women	NOUN	O	O
referred	VERB	O	O
to	ADP	O	O
routine	PUNCT	O	O
ultrasound	NOUN	O	O
examination	NOUN	O	O
at	ADP	O	O
Aker	NOUN	O	O
and	CCONJ	O	O
Ullev?l	PUNCT	O	O
Hospitals	PROPN	O	O
in	ADP	O	O
Norway	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
All	PUNCT	O	O
(	PUNCT	O	O
58	NUM	O	O
)	PUNCT	O	O
healthy	ADJ	O	O
women	NOUN	O	O
of	ADP	O	O
Pakistani	NOUN	O	O
origin	NOUN	O	O
referred	VERB	O	O
from	ADP	O	O
October	NOUN	O	O
of	ADP	O	O
1991	NUM	O	O
to	ADP	O	O
January	NOUN	O	O
of	ADP	O	O
1992	NUM	O	O
were	VERB	O	O
included	VERB	O	O
,	PUNCT	O	O
of	ADP	O	O
whom	ADP	O	O
38	NUM	O	O
(	PUNCT	O	O
66	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
participated	VERB	O	O
.	PUNCT	O	O

Forty-five	ADJ	O	O
Norwegian	NOUN	O	O
women	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
period	NOUN	O	O
and	CCONJ	O	O
38	NUM	O	O
(	PUNCT	O	O
84	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
these	DET	O	O
women	NOUN	O	O
participated	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
25-hydroxyvitamin	NOUN	O	O
D3	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
Pakistanis	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
Norwegians	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
19	NUM	O	O
nmol/l	NOUN	O	O
vs	CCONJ	O	O
55	NUM	O	O
nmol/l	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
83	NUM	O	O
%	ADJ	O	O
of	ADP	O	O
the	DET	O	O
Pakistani	PUNCT	O	O
women	NOUN	O	O
had	PUNCT	O	O
25-hydroxyvitamin	NOUN	O	B-PHYSICAL
D3	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
below	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
value	NOUN	O	O
(	PUNCT	O	O
<	PROPN	O	O
30	NUM	O	O
nmol/l	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
Pakistanis	NOUN	O	O
had	PUNCT	O	O
higher	CCONJ	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	B-PHYSICAL
parathyroid	PUNCT	O	I-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
median	ADJ	O	O
2.6	NUM	O	O
vs	CCONJ	O	O
1.6	NUM	O	O
pmol/l	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
Pakistanis	NOUN	O	O
also	ADV	O	O
had	PUNCT	O	O
a	DET	O	O
lower	PUNCT	O	O
dietary	ADJ	O	B-PHYSICAL
intake	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
vitamin	NOUN	O	I-PHYSICAL
D	NOUN	O	O
than	PUNCT	O	O
that	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
Norwegians	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
2.2	NUM	O	O
vs	CCONJ	O	O
3.3	NUM	O	O
micrograms/day	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
lower	PUNCT	O	O
total	ADJ	O	O
intake	NOUN	O	O
,	PUNCT	O	O
including	PUNCT	O	O
supplements	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
2.9	NUM	O	O
vs	CCONJ	O	O
7.0	NUM	O	O
micrograms/day	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
Pakistanis	NOUN	O	O
a	DET	O	O
correlation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
dietary	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
margarine	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
main	ADJ	O	O
source	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
in	ADP	O	O
the	DET	O	O
diet	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
25-hydroxyvitamin	NOUN	O	O
D3	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
,	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.48	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
general	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Pakistanis	NOUN	O	O
avoided	PUNCT	O	O
any	DET	O	O
direct	ADJ	O	O
sunshine	NOUN	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
outdoor	PUNCT	O	O
activity	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
25-hydroxyvitamin	NOUN	O	O
D3	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
Pakistani	PUNCT	O	O
women	NOUN	O	O
had	DET	O	O
a	DET	O	O
lower	PUNCT	O	O
intake	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
Norwegians	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
793	NUM	O	O
vs	CCONJ	O	O
1134	NUM	O	O
mg/day	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
has	PUNCT	O	O
shown	VERB	O	O
that	ADP	O	O
Pakistani	PUNCT	O	O
women	NOUN	O	O
living	VERB	O	O
in	ADP	O	O
Oslo	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
great	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	PUNCT	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
deficiency	NOUN	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
reasons	NOUN	O	O
for	ADP	O	O
this	PUNCT	O	O
are	PUNCT	O	O
avoidance	NOUN	O	O
of	ADP	O	O
sun	DET	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
low	ADJ	O	O
dietary	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
or	CCONJ	O	O
little	DET	O	O
use	NOUN	O	O
of	ADP	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomised	VERB	O	O
trial	NOUN	O	O
comparing	VERB	O	O
holmium	NOUN	O	O
laser	NOUN	O	O
enucleation	NOUN	O	O
versus	CCONJ	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
prostates	NOUN	O	O
larger	PUNCT	O	O
than	PUNCT	O	O
40	NUM	O	O
grams	NOUN	O	O
:	PUNCT	O	O
results	CCONJ	O	O
at	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
holmium	NOUN	O	O
laser	NOUN	O	O
enucleation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prostate	NOUN	O	O
(	PUNCT	O	O
HoLEP	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prostate	NOUN	O	O
(	PUNCT	O	O
TURP	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
men	NOUN	O	O
with	ADP	O	O
bladder	NOUN	O	O
outflow	PUNCT	O	O
obstruction	NOUN	O	O
(	PUNCT	O	O
BOO	NOUN	O	O
)	PUNCT	O	O
secondary	ADJ	O	O
to	ADP	O	O
benign	ADJ	O	O
prostatic	ADJ	O	O
hyperplasia	NOUN	O	O
with	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
24-month	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Sixty-one	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
HoLEP	NOUN	O	O
or	CCONJ	O	O
TURP	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	PUNCT	O	O
BOO	NOUN	O	O
proven	VERB	O	O
on	ADP	O	O
urodynamic	VERB	O	O
studies	NOUN	O	O
pre-operatively	ADJ	O	O
(	PUNCT	O	O
prostate	NOUN	O	O
size	NOUN	O	O
40-200	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
died	VERB	O	O
before	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
left	PUNCT	O	O
30	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

Perioperative	ADJ	O	O
data	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
symptom	NOUN	O	O
scores	NOUN	O	O
,	PUNCT	O	O
Quality	NOUN	O	O
of	ADP	O	O
Life	NOUN	O	O
(	PUNCT	O	O
QoL	NOUN	O	O
)	PUNCT	O	O
scores	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
maximum	NOUN	O	O
urinary	ADJ	O	O
flow	NOUN	O	O
rates	NOUN	O	O
(	PUNCT	O	O
Qmax	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
obtained	VERB	O	O
at	ADP	O	O
one	NUM	O	O
,	PUNCT	O	O
three	NUM	O	O
,	PUNCT	O	O
six,12	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
24	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Post-void	NOUN	O	B-PHYSICAL
residual	ADJ	O	O
volumes	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
transrectal	ADJ	O	B-PHYSICAL
ultrasound	NOUN	O	B-PHYSICAL
(	PUNCT	O	O

Outpatient	ADP	O	O
management	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	O
with	ADP	O	O
regular	ADJ	O	O
nebulized	ADJ	O	O
beta	NOUN	O	O
agonists	NOUN	O	O
:	PUNCT	O	O
comparison	NOUN	O	O
of	ADP	O	O
bitolterol	NOUN	O	O
mesylate	NOUN	O	O
and	CCONJ	O	O
isoproterenol	NOUN	O	O
.	PUNCT	O	O

Nebulized	VERB	O	O
bitolterol	NOUN	O	O
solution	NOUN	O	O
and	CCONJ	O	O
isoproterenol	NOUN	O	O
solution	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
when	ADP	O	O
used	VERB	O	O
on	ADP	O	O
a	DET	O	O
regular	ADJ	O	O
basis	NOUN	O	O
,	PUNCT	O	O
2.5	NUM	O	O
mg	NOUN	O	O
three	NUM	O	O
times	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
by	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
;	PUNCT	O	O
130	NUM	O	O
nonsteroid-dependent	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
two	ADJ	O	O
treatments	NOUN	O	O
concomitantly	ADV	O	O
with	ADP	O	O
their	PUNCT	O	O
regular	ADJ	O	O
asthma	NOUN	O	O
medications	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
study	ADJ	O	O
days	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
2	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
treatments	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
in	ADP	O	O
the	DET	O	O
office	NOUN	O	O
or	CCONJ	O	O
laboratory	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
with	ADP	O	O
pulmonary	ADJ	O	B-OTHER
function	NOUN	O	I-OTHER
tests	NOUN	O	I-OTHER
for	ADP	O	O
eight	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
medications	NOUN	O	O
induced	VERB	O	O
rapid	ADJ	O	B-PHYSICAL
bronchodilation	NOUN	O	I-PHYSICAL
that	ADP	O	O
had	ADP	O	O
a	DET	O	O
longer	PUNCT	O	O
duration	NOUN	O	B-OTHER
after	ADP	O	O
bitolterol	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
tremor	NOUN	O	B-PHYSICAL
was	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
the	DET	O	O
two	NUM	O	O
medications	NOUN	O	O
.	PUNCT	O	O

Tachycardia	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
palpitations	NOUN	O	B-PHYSICAL
were	VERB	O	O
more	ADV	O	O
frequent	ADP	O	O
following	ADJ	O	O
isoproterenol	NOUN	O	O
.	PUNCT	O	O

Bitolterol	NOUN	O	O
has	CCONJ	O	O
a	DET	O	O
much	ADJ	O	O
longer	PUNCT	O	O
duration	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
action	NOUN	O	I-OTHER
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
suitable	ADJ	O	O
bronchodilator	NOUN	O	O
for	ADP	O	O
regular	ADJ	O	O
nebulizer	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

Randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
education	NOUN	O	O
and	CCONJ	O	O
feedback	NOUN	O	O
for	ADP	O	O
implementation	NOUN	O	O
of	ADP	O	O
guidelines	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
guidelines	NOUN	O	O
on	ADP	O	O
resource	NOUN	O	O
utilization	NOUN	O	O
for	ADP	O	O
complex	ADJ	O	O
conditions	NOUN	O	O
with	ADP	O	O
substantial	ADJ	O	O
barriers	NOUN	O	O
to	ADP	O	O
clinician	PUNCT	O	O
behavior	NOUN	O	O
change	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	PUNCT	O	O
well	PUNCT	O	O
studied	CCONJ	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
a	DET	O	O
multifaceted	VERB	O	O
guideline	NOUN	O	O
implementation	NOUN	O	O
intervention	NOUN	O	O
on	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
clinician	NOUN	O	O
utilization	NOUN	O	O
of	ADP	O	O
radiologic	ADJ	O	O
and	CCONJ	O	O
specialty	NOUN	O	O
services	NOUN	O	O
for	ADP	O	O
the	DET	O	O
care	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Physician	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
guideline	NOUN	O	O
education	NOUN	O	O
and	CCONJ	O	O
individual	ADJ	O	O
feedback	NOUN	O	O
,	PUNCT	O	O
supporting	ADP	O	O
patient	NOUN	O	O
education	NOUN	O	O
materials	ADP	O	O
,	PUNCT	O	O
both	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
neither	CCONJ	O	O
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
on	ADP	O	O
guideline	NOUN	O	O
adherence	NOUN	O	O
and	CCONJ	O	O
resource	NOUN	O	O
utilization	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
during	ADP	O	O
the	DET	O	O
12-month	NOUN	O	O
period	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
implementation	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
Fourteen	PUNCT	O	O
physician	NOUN	O	O
groups	NOUN	O	O
with	ADP	O	O
120	NUM	O	O
primary	ADJ	O	O
care	NOUN	O	O
physician	NOUN	O	O
and	CCONJ	O	O
associate	ADV	O	O
practitioners	NOUN	O	O
from	ADP	O	O
2	NUM	O	O
group	NOUN	O	O
model	NOUN	O	O
HMO	NOUN	O	O
practices	PROPN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Guideline	NOUN	O	O
implementation	NOUN	O	O
utilized	VERB	O	O
an	DET	O	O
education/audit/feedback	NOUN	O	O
model	NOUN	O	O
with	ADP	O	O
local	ADJ	O	O
peer	NOUN	O	O
opinion	NOUN	O	O
leaders	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
education	NOUN	O	O
component	NOUN	O	O
included	ADP	O	O
written	PUNCT	O	O
and	CCONJ	O	O
videotaped	ADJ	O	O
materials	NOUN	O	O
on	ADP	O	O
the	DET	O	O
care	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
RESULTS	NOUN	O	O
The	DET	O	O
clinician	NOUN	O	O
intervention	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
absolute	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
guideline-consistent	ADJ	O	B-MENTAL
behavior	NOUN	O	I-MENTAL
of	ADP	O	O
5.4	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
a	DET	O	O
decline	NOUN	O	O
of	ADP	O	O
2.7	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=.04	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
education	NOUN	O	O
intervention	NOUN	O	O
produced	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
guideline-consistent	ADJ	O	B-PHYSICAL
behavior	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
poorly	ADV	O	O
adopted	VERB	O	O
.	PUNCT	O	O

Patient	ADJ	O	O
characteristics	NOUN	O	O
including	VERB	O	O
duration	NOUN	O	B-PAIN
of	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
prior	ADP	O	B-PAIN
history	NOUN	O	I-PAIN
of	ADP	O	I-PAIN
low	ADJ	O	I-PAIN
back	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
and	CCONJ	O	O
number	NOUN	O	B-PAIN
of	ADP	O	I-PAIN
visits	NOUN	O	I-PAIN
during	ADP	O	O
the	DET	O	O
illness	NOUN	O	O
episode	NOUN	O	O
were	VERB	O	O
strong	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
service	NOUN	O	O
utilization	NOUN	O	O
and	CCONJ	O	O
guideline-consistent	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Implementation	NOUN	O	O
of	ADP	O	O
an	DET	O	O
education	NOUN	O	O
and	CCONJ	O	O
feedback-supported	VERB	O	O
acute	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
care	NOUN	O	O
guideline	NOUN	O	O
for	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
clinicians	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
guideline-consistent	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

Patient	NOUN	O	O
education	NOUN	O	O
materials	NOUN	O	O
did	CCONJ	O	O
not	ADV	O	O
enhance	ADJ	O	O
guideline	NOUN	O	O
effectiveness	NOUN	O	O
.	PUNCT	O	O

Implementation	NOUN	O	O
barriers	NOUN	O	O
could	ADJ	O	O
limit	VERB	O	O
the	DET	O	O
utility	NOUN	O	O
of	ADP	O	O
this	DET	O	O
approach	NOUN	O	O
in	ADP	O	O
usual	ADJ	O	O
care	NOUN	O	O
settings	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	O
on	ADP	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	B-OTHER
of	ADP	O	O
morphine	NOUN	O	O
sulfate	NOUN	O	O
and	CCONJ	O	O
naltrexone	NUM	O	O
hydrochloride	NOUN	O	O
extended	VERB	O	O
release	NOUN	O	O
capsules	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
contraindicated	VERB	O	O
,	PUNCT	O	O
coingestion	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	O
and	CCONJ	O	O
opioids	NOUN	O	O
by	ADP	O	O
patients	NOUN	O	O
or	CCONJ	O	O
drug	NOUN	O	O
abusers	NOUN	O	O
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
health	NOUN	O	O
concern	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
dangerous	ADJ	O	O
additive	ADJ	O	O
and	CCONJ	O	O
potentially	ADV	O	O
life-threatening	VERB	O	O
sedative	NOUN	O	O
and	CCONJ	O	O
respiratory	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
alcohol	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
disrupt	NOUN	O	O
the	DET	O	O
extended-release	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
certain	ADJ	O	O
extended-release	NOUN	O	O
opioid	NOUN	O	O
formulations	NOUN	O	O
,	PUNCT	O	O
releasing	VERB	O	O
a	DET	O	O
hazardous	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
opioid	NOUN	O	O
over	ADP	O	O
a	DET	O	O
short	ADJ	O	O
time	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Morphine	NOUN	O	O
sulfate	NOUN	O	O
and	CCONJ	O	O
naltrexone	NUM	O	O
hydrochloride	NOUN	O	O
extended	VERB	O	O
release	NOUN	O	O
capsules	NOUN	O	O
(	PUNCT	O	O
MS-sNT	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
contain	PART	O	O
naltrexone	NUM	O	O
sequestered	NOUN	O	O
in	ADP	O	O
each	DET	O	O
pellet	NOUN	O	O
core	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
indicated	VERB	O	O
for	ADP	O	O
management	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
,	PUNCT	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
pain	NOUN	O	O
.	PUNCT	O	O

Sequestered	VERB	O	O
naltrexone	NUM	O	O
is	VERB	O	O
designed	VERB	O	O
for	ADP	O	O
release	NOUN	O	O
upon	ADP	O	O
product	NOUN	O	O
tampering	PUNCT	O	O
(	PUNCT	O	O
crushing	PUNCT	O	O
)	PUNCT	O	O
to	ADP	O	O
potentially	ADV	O	O
mitigate	ADJ	O	O
morphine-induced	DET	O	O
subjective	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
open-label	NOUN	O	O
,	PUNCT	O	O
single-dose	NOUN	O	O
,	PUNCT	O	O
4-way	DET	O	O
crossover	NOUN	O	O
,	PUNCT	O	O
pharmacokinetic	ADJ	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
study	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
relative	ADJ	O	B-OTHER
bioavailability	NOUN	O	I-OTHER
of	ADP	O	O
morphine	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
naltrexone	NUM	O	B-PHYSICAL
when	ADP	O	O
MS-sNT	ADJ	O	O
is	NOUN	O	O
administered	VERB	O	O
(	PUNCT	O	O
under	ADP	O	O
fasting	VERB	O	O
conditions	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
increasing	ADJ	O	O
doses	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
alcohol	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Thirty-two	NUM	O	O
healthy	ADJ	O	O
,	PUNCT	O	O
opioid-naive	ADJ	O	O
adults	NOUN	O	O
were	VERB	O	O
randomized	ADP	O	O
to	PUNCT	O	O
MS-sNT	ADJ	O	O
administered	ADP	O	O
with	ADP	O	O
240	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
40	NUM	O	O
%	SYM	O	O
alcohol	NOUN	O	O
or	CCONJ	O	O
water	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
drug	NOUN	O	B-PHYSICAL
interaction	NOUN	O	I-PHYSICAL
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
morphine	NOUN	O	O
in	ADP	O	O
MS-sNT	ADJ	O	O
and	CCONJ	O	O
4	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
20	NUM	O	O
%	SYM	O	O
alcohol	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
with	ADP	O	O
40	NUM	O	O
%	SYM	O	O
alcohol	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
overall	ADJ	O	B-OTHER
morphine	NOUN	O	I-OTHER
exposure	NOUN	O	I-OTHER
but	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
2-fold	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
C	NOUN	O	B-OTHER
(	PUNCT	O	I-OTHER
max	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
and	CCONJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
t	NOUN	O	O
(	PUNCT	O	B-OTHER
max	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
from	ADP	O	O
9	NUM	O	O
to	ADP	O	O
4	NUM	O	O
hours	NOUN	O	O
versus	CCONJ	O	O
MS-sNT	ADJ	O	O
taken	ADJ	O	O
with	ADP	O	O
water	NOUN	O	O
.	PUNCT	O	O

Naltrexone	NUM	O	B-OTHER
sequestering	VERB	O	I-OTHER
was	VERB	O	I-OTHER
successful	ADJ	O	I-OTHER
in	ADP	O	O
all	DET	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
and	CCONJ	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
coadministration	NOUN	O	O
with	ADP	O	O
alcohol	NOUN	O	O
over	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
range	NOUN	O	O
tested	VERB	O	O
.	PUNCT	O	O

RCT	NOUN	O	O
of	ADP	O	O
a	DET	O	O
manualized	VERB	O	O
social	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
high-functioning	PUNCT	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
RCT	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
manualized	VERB	O	O
social	ADJ	O	O
intervention	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
HFASDs	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
or	CCONJ	O	O
wait-list	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
included	VERB	O	O
instruction	NOUN	O	O
and	CCONJ	O	O
therapeutic	ADJ	O	O
activities	NOUN	O	O
targeting	VERB	O	O
social	ADJ	O	O
skills	NOUN	O	O
,	PUNCT	O	O
face-emotion	NOUN	O	O
recognition	NOUN	O	O
,	PUNCT	O	O
interest	NOUN	O	O
expansion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
interpretation	NOUN	O	O
of	ADP	O	O
non-literal	ADJ	O	O
language	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
response-cost	NOUN	O	O
program	NOUN	O	O
was	VERB	O	O
applied	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
problem	NOUN	O	O
behaviors	NOUN	O	O
and	CCONJ	O	O
foster	NOUN	O	O
skills	NOUN	O	O
acquisition	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
treatment	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
five	NUM	O	O
of	ADP	O	O
seven	NUM	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
(	PUNCT	O	O
parent	NOUN	O	B-MENTAL
ratings	NOUN	O	I-MENTAL
and	CCONJ	O	O
direct	ADJ	O	O
child	NOUN	O	O
measures	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
measures	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
staff	NOUN	O	B-OTHER
ratings	NOUN	O	I-OTHER
(	PUNCT	O	O
treatment	NOUN	O	O
group	NOUN	O	O
only	ADV	O	O
)	PUNCT	O	O
corroborated	VERB	O	O
gains	NOUN	O	O
reported	VERB	O	O
by	ADP	O	O
parents	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
parent	NOUN	O	B-OTHER
,	PUNCT	O	O
child	NOUN	O	B-OTHER
and	CCONJ	O	O
staff	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
were	VERB	O	O
reported	VERB	O	O
,	PUNCT	O	O
along	PUNCT	O	O
with	ADP	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
fidelity	NOUN	O	B-MENTAL
.	PUNCT	O	O

Standardized	VERB	O	O
effect	NOUN	O	O
size	NOUN	O	O
estimates	NOUN	O	O
were	VERB	O	O
primarily	ADV	O	O
in	ADP	O	O
the	DET	O	O
medium	ADJ	O	O
and	CCONJ	O	O
large	ADJ	O	O
ranges	PUNCT	O	O
and	CCONJ	O	O
favored	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
capsulectomy	NOUN	O	O
,	PUNCT	O	O
anterior	ADJ	O	O
vitrectomy	NOUN	O	O
,	PUNCT	O	O
lensectomy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
posterior	ADJ	O	O
chamber	NOUN	O	O
lens	NOUN	O	O
implantation	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
:	PUNCT	O	O
limbal	ADJ	O	O
versus	CCONJ	O	O
pars	NOUN	O	O
plana	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
compare	NOUN	O	O
the	DET	O	O
results	CCONJ	O	O
of	ADP	O	O
a	DET	O	O
limbal	ADJ	O	O
versus	CCONJ	O	O
a	DET	O	O
pars	NOUN	O	O
plana	NOUN	O	O
approach	NOUN	O	O
for	ADP	O	O
primary	ADJ	O	O
posterior	ADJ	O	O
capsulectomy	NOUN	O	O
and	CCONJ	O	O
anterior	ADJ	O	O
vitrectomy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
childhood	NOUN	O	B-PHYSICAL
cataract	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

SETTING	VERB	O	O
Department	NOUN	O	O
of	ADP	O	O
Ophthalmology	NOUN	O	O
,	PUNCT	O	O
Labbafinejad	NOUN	O	O
Medical	ADJ	O	O
Center	NOUN	O	O
,	PUNCT	O	O
Tehran	NOUN	O	O
,	PUNCT	O	O
Iran	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	CCONJ	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
double-masked	PROPN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
45	NUM	O	O
eyes	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
being	VERB	O	O
matched	PROPN	O	O
,	PUNCT	O	O
38	NUM	O	O
eyes	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
2	NUM	O	O
equal	ADJ	O	O
groups	NOUN	O	O
for	ADP	O	O
data	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
eyes	NOUN	O	O
had	PUNCT	O	O
lensectomy	NOUN	O	O
and	CCONJ	O	O
posterior	ADJ	O	O
chamber	NOUN	O	O
intraocular	ADJ	O	O
lens	NOUN	O	O
(	PUNCT	O	O
PC	NOUN	O	O
IOL	NUM	O	O
)	PUNCT	O	O
implantation	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
posterior	ADJ	O	O
capsulectomy	NOUN	O	O
and	CCONJ	O	O
anterior	ADJ	O	O
vitrectomy	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
through	ADP	O	O
the	DET	O	O
limbus	NOUN	O	O
in	ADP	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
eyes	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
pars	NOUN	O	O
plana	NOUN	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
half	NOUN	O	O
.	PUNCT	O	O

Main	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
included	VERB	O	O
visual	ADJ	O	B-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
estimated	ADP	O	O
red	ADJ	O	B-PHYSICAL
reflex	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
postsurgical	ADJ	O	B-PHYSICAL
inflammatory	ADJ	O	I-PHYSICAL
reaction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
corneal	ADJ	O	B-PHYSICAL
clarity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
posterior	ADJ	O	B-PHYSICAL
synechias	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
iris	NOUN	O	B-PHYSICAL
capture	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
IOL	NUM	O	B-PHYSICAL
position	NOUN	O	O
,	PUNCT	O	O
capsulectomy	NOUN	O	B-PHYSICAL
size	NOUN	O	O
,	PUNCT	O	O
glaucoma	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
cystoid	NOUN	O	B-PHYSICAL
macular	ADJ	O	I-PHYSICAL
edema	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
retinal	ADJ	O	B-PHYSICAL
tear	NOUN	O	O
,	PUNCT	O	O
and	PUNCT	O	O

Training	PUNCT	O	O
referential	ADP	O	O
communicative	ADJ	O	O
skills	NOUN	O	O
to	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
reports	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
referential	ADJ	O	O
communication	NOUN	O	O
training	VERB	O	O
in	ADP	O	O
individuals	NOUN	O	O
formally	ADV	O	O
diagnosed	VERB	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
20	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
(	PUNCT	O	O
M	NOUN	O	O
age	NOUN	O	O
=	SYM	O	O
14.3	NUM	O	O
yr.	NOUN	O	O
,	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
4.2	NUM	O	O
;	PUNCT	O	O
6	NUM	O	O
girls	NOUN	O	O
,	PUNCT	O	O
14	NUM	O	O
boys	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
speakers	NOUN	O	O
and	CCONJ	O	O
20	NUM	O	O
control	NOUN	O	O
children	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
acted	VERB	O	O
as	PUNCT	O	O
listeners	VERB	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
all	PUNCT	O	O
enrolled	ADV	O	O
in	ADP	O	O
mainstream	NOUN	O	O
compulsory	ADJ	O	O
education	NOUN	O	O
.	PUNCT	O	O

Inclusion/exclusion	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
defined	VERB	O	O
according	ADP	O	O
to	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
ASD	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
additional	ADJ	O	O
or	CCONJ	O	O
associated	VERB	O	O
disability	NOUN	O	O
,	PUNCT	O	O
previous	ADJ	O	O
training	VERB	O	O
in	ADP	O	O
referential	ADJ	O	O
communication	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
any	DET	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Speakers	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
trained	PROPN	O	O
vs	CCONJ	O	O
untrained	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Linguistic	ADJ	O	B-PHYSICAL
age	NOUN	O	O
,	PUNCT	O	O
cognitive	ADJ	O	O
level	NOUN	O	O
and	CCONJ	O	O
autistic	ADJ	O	O
symptoms	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
Peabody	NOUN	O	O
Picture	NOUN	O	O
Vocabulary	PUNCT	O	O
Test	NOUN	O	O
(	PUNCT	O	O
PPVT	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
Wechsler	ADP	O	O
Intelligence	ADP	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
WISC-R	NOUN	O	O
or	CCONJ	O	O
WAIS-III	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Autistic	ADJ	O	O
Behavior	NOUN	O	O
Checklist	NOUN	O	O
(	PUNCT	O	O
ABC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Communicative	ADJ	O	O
abilities	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
through	ADP	O	O
two	NUM	O	O
indexes	PUNCT	O	O
related	VERB	O	O
to	ADP	O	O
message	NOUN	O	O
complexity	NOUN	O	O
and	CCONJ	O	O
self-regulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trained	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
trained	VERB	O	O
in	ADP	O	O
referential	ADJ	O	O
communication	NOUN	O	O
tasks	NOUN	O	O
(	PUNCT	O	O
task	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
role	NOUN	O	O
taking	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
task	NOUN	O	O
evaluation	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
untrained	ADJ	O	O
group	NOUN	O	O
took	PROPN	O	O
part	NOUN	O	O
in	ADP	O	O
a	DET	O	O
communicative	ADJ	O	O
game	NOUN	O	O
but	CCONJ	O	O
without	ADP	O	O
any	DET	O	O
specific	ADJ	O	O
communicative	ADJ	O	O
training	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
complexity	NOUN	O	O
of	ADP	O	O
emitted	PUNCT	O	B-PHYSICAL
messages	NOUN	O	I-PHYSICAL
had	ADP	O	O
improved	PUNCT	O	O
statistically	ADJ	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
trained	ADJ	O	O
group	NOUN	O	O
as	ADP	O	O
an	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
training	VERB	O	O
.	PUNCT	O	O

Ecological	ADJ	O	O
referential	ADJ	O	O
communication	NOUN	O	O
is	VERB	O	O
shown	VERB	O	O
to	DET	O	O
be	PUNCT	O	O
an	DET	O	O
appropriate	ADJ	O	O
paradigm	NOUN	O	O
for	ADP	O	O
studying	VERB	O	O
the	DET	O	O
communicative	ADJ	O	O
process	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
products	NOUN	O	O
and	CCONJ	O	O
could	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
develop	NOUN	O	O
and	CCONJ	O	O
implement	PUNCT	O	O
a	DET	O	O
training	DET	O	O
program	NOUN	O	O
focused	VERB	O	O
on	ADP	O	O
those	PUNCT	O	O
skills	NOUN	O	O
in	ADP	O	O
which	DET	O	O
individuals	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
are	VERB	O	O
most	DET	O	O
deficient	ADJ	O	O
.	PUNCT	O	O

Antioxidant	NOUN	O	O
supplementation	NOUN	O	O
and	CCONJ	O	O
exercise-induced	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
the	DET	O	O
60-year-old	PUNCT	O	O
as	VERB	O	O
measured	PUNCT	O	O
by	ADP	O	O
antipyrine	ADP	O	O
hydroxylates	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
antioxidant	NOUN	O	O
supplementation	NOUN	O	O
on	ADP	O	O
exercise-induced	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
(	PUNCT	O	O
60	NUM	O	O
(	PUNCT	O	O
SE	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
years	NOUN	O	O
;	PUNCT	O	O
BMI	NOUN	O	O
26	NUM	O	O
(	PUNCT	O	O
SE	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
kg/m	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
in	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
supplementation	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
11	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
100	NUM	O	O
mg	NOUN	O	O
dl-alpha-tocopheryl	NOUN	O	O
acetate	NOUN	O	O
,	PUNCT	O	O
200	NUM	O	O
mg	NOUN	O	O
ascorbic	ADJ	O	O
acid	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
mg	NOUN	O	O
beta-carotene	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
9	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
12	NUM	O	O
week	NOUN	O	O
supplementation	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
cycled	VERB	O	O
for	ADP	O	O
45	NUM	O	O
min	NOUN	O	O
at	ADP	O	O
submaximal	ADJ	O	O
intensity	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
maximal	ADJ	O	O
workload	ADJ	O	O
capacity	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Antipyrine	ADJ	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
marker	NOUN	O	O
for	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Antipyrine	ADJ	O	O
reacts	PUNCT	O	O
quickly	ADJ	O	O
with	ADP	O	O
hydroxyl	NOUN	O	O
radicals	NOUN	O	O
to	PUNCT	O	O
form	ADP	O	O
para-	PUNCT	O	O
and	CCONJ	O	O
ortho-hydroxyantipyrine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
latter	ADJ	O	O
metabolite	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
formed	VERB	O	O
in	ADP	O	O
man	NOUN	O	O
through	ADP	O	O
the	DET	O	O
mono-oxygenase	NOUN	O	O
pathway	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
P450	NOUN	O	O
.	PUNCT	O	O

Daily	VERB	O	O
supplementation	NOUN	O	O
significantly	ADV	O	O
increased	ADV	O	O
plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
alpha-tocopherol	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
beta-carotene	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
supplemented	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
Delta	NOUN	O	O
14.4	NUM	O	O
(	PUNCT	O	O
SE	NOUN	O	O
3.2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
0.4	NUM	O	O
(	PUNCT	O	O
se	PUNCT	O	O
0.1	NUM	O	O
)	PUNCT	O	O
micromol/l	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
,	PUNCT	O	O
within	ADP	O	O
and	CCONJ	O	O
between	DET	O	O
groups	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
exercise-induced	PUNCT	O	B-PHYSICAL
increase	NOUN	O	O
in	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
ratios	NOUN	O	I-PHYSICAL
para-	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
ortho-hydroxyantipyrine	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
antipyrine	ADJ	O	B-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
supplementation	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
exercise-induced	VERB	O	B-PHYSICAL
increase	NOUN	O	O
in	ADP	O	B-PHYSICAL
thiobarbituric	ADJ	O	I-PHYSICAL
acid	NOUN	O	I-PHYSICAL
reactive	ADJ	O	I-PHYSICAL
substances	NOUN	O	I-PHYSICAL
in	ADP	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
60-year-old	PUNCT	O	O
subjects	NOUN	O	O
antioxidant	NOUN	O	O
supplementation	NOUN	O	O
had	PUNCT	O	O

A	DET	O	O
controlled	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
indomethacin	NOUN	O	O
in	ADP	O	O
uremic	ADJ	O	B-PHYSICAL
pericarditis	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

To	PART	O	O
determine	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
indomethacin	NOUN	O	O
on	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
uremic	ADJ	O	O
pericarditis	NOUN	O	O
we	PRON	O	O
performed	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
blind	ADP	O	O
study	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
endstage	NOUN	O	O
chronic	ADJ	O	O
renal	ADJ	O	O
failure	NOUN	O	O
and	CCONJ	O	O
pericarditis	NOUN	O	O
randomly	ADV	O	O
received	PUNCT	O	O
indomethacin	NOUN	O	O
,	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
four	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
,	PUNCT	O	O
(	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
13	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
3-week	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
peritoneal	ADJ	O	O
or	CCONJ	O	O
hemodialysis	NOUN	O	O
treatment	NOUN	O	O
concurrently	ADV	O	O
with	ADP	O	O
the	DET	O	O
study	ADP	O	O
drug	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
indomethacin	NOUN	O	O
produced	VERB	O	O
an	DET	O	O
immediate	ADJ	O	O
and	CCONJ	O	O
sustained	VERB	O	O
reduction	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
fever	NOUN	O	I-PHYSICAL
in	ADP	O	O
all	ADP	O	O
but	CCONJ	O	O
one	NUM	O	O
patient	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
indomethacin	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
chest	NOUN	O	B-PAIN
pain	NOUN	O	I-PAIN
(	PUNCT	O	O
mean	NOUN	O	O
days	NOUN	O	O
+/-	SYM	O	O
SE	NOUN	O	O
:	PUNCT	O	O
placebo	NOUN	O	O
1.4	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
,	PUNCT	O	O
indomethacin	NOUN	O	O
5.5	NUM	O	O
+/-	SYM	O	O
3.3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
pericardial	ADJ	O	B-PHYSICAL
friction	NOUN	O	I-PHYSICAL
rub	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
placebo	NOUN	O	O
10.3	NUM	O	O
+/-	SYM	O	O
1.7	NUM	O	O
,	PUNCT	O	O
indomethacin	NOUN	O	O
16.0	NUM	O	O
+/-	SYM	O	O
3.8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
pericardial	ADJ	O	B-PHYSICAL
effusion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Further	ADV	O	O
,	PUNCT	O	O
indomethacin	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
diminish	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
invasive	ADJ	O	B-PHYSICAL
surgical	ADJ	O	I-PHYSICAL
procedures	NOUN	O	I-PHYSICAL
for	ADP	O	O
relief	NOUN	O	O
of	ADP	O	O
tamponade	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
three	NUM	O	O
of	ADP	O	O
13	NUM	O	O
placebo	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
of	ADP	O	O
11	NUM	O	O
indomethacin	NOUN	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
result	NOUN	O	O
in	ADP	O	O
decreased	VERB	O	O
mortality	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
.	PUNCT	O	O

Death	NOUN	O	B-MORTALITY
(	PUNCT	O	O
not	ADV	O	O
due	PUNCT	O	O
to	ADP	O	O
pericarditis	NOUN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
indomethacin	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
patient	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
the	DET	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
our	PUNCT	O	O
patients	ADJ	O	O
pericarditis	NOUN	O	O
encompassed	VERB	O	O
a	DET	O	O
wide	ADJ	O	O
spectrum	NOUN	O	O
ranging	ADJ	O	O
from	ADP	O	O
a	DET	O	O
mild	ADJ	O	B-PHYSICAL
illness	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
several	ADJ	O	I-PHYSICAL
days	ADJ	O	B-PHYSICAL
duration	NOUN	O	I-PHYSICAL
to	ADP	O	O
a	DET	O	O
painful	ADP	O	O
and	PUNCT	O	O
debilitating	PUNCT	O	B-PHYSICAL

Clinic	PUNCT	O	O
visit	NOUN	O	O
and	CCONJ	O	O
waiting	PUNCT	O	O
:	PUNCT	O	O
patient	NOUN	O	B-MENTAL
education	NOUN	O	I-MENTAL
and	CCONJ	O	O
satisfaction	NOUN	O	B-OTHER
.	PUNCT	O	O

Patients	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
taught	ADV	O	O
about	ADP	O	O
their	PUNCT	O	O
health	NOUN	O	O
problems	NOUN	O	O
while	ADP	O	O
waiting	VERB	O	O
in	ADP	O	O
the	DET	O	O
clinic	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
104	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
satisfied	VERB	O	B-OTHER
with	ADP	O	I-OTHER
the	DET	O	I-OTHER
education	NOUN	O	I-OTHER
received	PRON	O	O
during	ADP	O	O
that	CCONJ	O	O
visit	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
101	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
longer	PUNCT	O	O
patients	NOUN	O	O
waited	VERB	O	O
in	ADP	O	O
the	DET	O	O
clinic	NOUN	O	O
to	PART	O	O
see	NOUN	O	O
their	ADP	O	O
providers	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
less	DET	O	O
satisfied	ADP	O	B-OTHER
they	PUNCT	O	O
were	SYM	O	O
with	ADP	O	O
the	DET	O	O
clinic	PUNCT	O	O
visit	NOUN	O	O
.	PUNCT	O	O

Longterm	NOUN	O	B-OTHER
safety	NOUN	O	I-OTHER
,	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
and	PUNCT	O	O

The	DET	O	O
dud	PUNCT	O	O
effect	NOUN	O	O
:	PUNCT	O	O
adding	VERB	O	O
highly	NUM	O	O
dissimilar	ADJ	O	O
fillers	PUNCT	O	O
increases	PUNCT	O	O
confidence	NOUN	O	O
in	ADP	O	O
lineup	NOUN	O	O
identifications	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
research	NOUN	O	O
in	ADP	O	O
decision-making	VERB	O	O
has	PUNCT	O	O
demonstrated	VERB	O	O
the	DET	O	O
dud-alternative	PUNCT	O	O
effect	NOUN	O	O
--	PUNCT	O	O
the	DET	O	O
tendency	NOUN	O	O
to	ADP	O	O
become	ADJ	O	O
more	DET	O	O
confident	VERB	O	O
that	PUNCT	O	O
a	DET	O	O
chosen	ADP	O	O
response	NOUN	O	O
option	NOUN	O	O
is	VERB	O	O
correct	ADJ	O	O
if	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
surrounded	VERB	O	O
by	ADP	O	O
implausible	ADJ	O	O
response	NOUN	O	O
options	NOUN	O	O
(	PUNCT	O	O
Windschitl	PUNCT	O	O
&	CCONJ	O	O
Chambers	PROPN	O	O
,	PUNCT	O	O
J	NOUN	O	O
Exp	NOUN	O	O
Psychol	NOUN	O	O
30:198-215	NOUN	O	O
,	PUNCT	O	O
2004	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
finding	VERB	O	O
may	VERB	O	O
be	NOUN	O	O
applicable	ADJ	O	O
to	ADP	O	O
a	DET	O	O
lineup	NOUN	O	O
task	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
duds	NOUN	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
highly	ADV	O	O
dissimilar	ADJ	O	O
fillers	ADP	O	O
)	PUNCT	O	O
may	ADJ	O	O
increase	VERB	O	O
a	DET	O	O
witness	PUNCT	O	B-MENTAL
's	PUNCT	O	O
confidence	NOUN	O	B-MENTAL
that	CCONJ	O	O
an	DET	O	O
identified	PUNCT	O	O
(	PUNCT	O	O
non-dud	PUNCT	O	O
)	PUNCT	O	O
lineup	NOUN	O	O
member	NOUN	O	O
is	VERB	O	O
the	DET	O	O
criminal	ADJ	O	O
.	PUNCT	O	O

Four	NUM	O	O
studies	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
665	NUM	O	O
)	PUNCT	O	O
demonstrate	VERB	O	O
that	ADP	O	O
the	DET	O	O
mere	ADJ	O	O
presence	NOUN	O	O
of	ADP	O	O
highly	ADV	O	O
dissimilar	ADJ	O	O
fillers	PUNCT	O	O
inflates	DET	O	O
witnesses	NOUN	O	B-OTHER
'	PUNCT	O	O
confidence	NOUN	O	B-OTHER
in	ADP	O	O
a	DET	O	O
mistaken	PUNCT	O	O
identification	NOUN	O	O
(	PUNCT	O	O
Studies	NOUN	O	O
1-4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
provides	NOUN	O	O
evidence	NOUN	O	O
that	ADP	O	O
this	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
food	NOUN	O	O
on	ADP	O	O
the	DET	O	O
antiviral	ADJ	O	B-OTHER
activity	NOUN	O	I-OTHER
of	ADP	O	O
didanosine	NOUN	O	O
enteric-coated	VERB	O	O
capsules	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
comparative	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
food	NOUN	O	O
on	ADP	O	O
the	DET	O	O
antiviral	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
enteric-coated	VERB	O	O
(	PUNCT	O	O
EC	NOUN	O	O
)	PUNCT	O	O
capsules	NOUN	O	O
of	ADP	O	O
didanosine	NOUN	O	O
(	PUNCT	O	O
ddI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
pilot	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
open-label	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
28-day	NOUN	O	O
ddI-EC	NOUN	O	O
capsules	NOUN	O	O
monotherapy-administered	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
fasted	VERB	O	O
state	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
n=11	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
food	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
n=10	ADV	O	O
)	PUNCT	O	O
to	ADP	O	O
treatment-na?ve	NOUN	O	O
chronically	ADV	O	O
HIV-1-infected	VERB	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	NOUN	O	O
the	DET	O	O
antiviral	ADJ	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
HIV-1	NOUN	O	O
RNA	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
day	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
day	NOUN	O	O
7	NUM	O	O
and	CCONJ	O	O
weekly	ADV	O	O
thereafter	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
HIV-1	NOUN	O	O
RNA	NOUN	O	O
curve	NOUN	O	O
minus	NOUN	O	O
baseline	NOUN	O	O
weighted	VERB	O	O
by	ADP	O	O
time	NOUN	O	O
(	PUNCT	O	O
AUCMB/day	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
calculated	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Mean	VERB	O	O
baseline	NOUN	O	O
HIV-1	NOUN	O	O
RNA	NOUN	O	O
was	VERB	O	O
4.2	NUM	O	O
log	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
)	PUNCT	O	O
copies/mL	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
3.8	NUM	O	O
log	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
)	PUNCT	O	O
copies/mL	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

After	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
HIV-1	NOUN	O	O
RNA	NOUN	O	O
reduction	NOUN	O	O
was	VERB	O	O
0.99	NUM	O	O
log	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
)	PUNCT	O	O
copies/mL	NOUN	O	O
[	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	NOUN	O	O
)	PUNCT	O	O
0.45-1.53	NUM	O	O
]	PUNCT	O	O
for	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
0.89	NUM	O	O
log	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
)	PUNCT	O	O
copies/mL	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.38-1.40	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

AUCMB/day	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
0.775	NUM	O	O
log	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
)	PUNCT	O	O
copies/mL	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.33-1.22	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
0.774	ADP	O	O
log	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
)	PUNCT	O	O
copies/mL	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.48-1.07	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
showing	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
decrease	NOUN	O	O
of	ADP	O	O
HIV-1	NOUN	O	O
RNA	NOUN	O	O
(	PUNCT	O	O
P=0.995	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
ddI	NOUN	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
28	NUM	O	O
were	VERB	O	O
0.0234	NUM	O	O
mg/L	NOUN	O	O
for	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
0.0227	NUM	O	O
mg/L	NOUN	O	O
for	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
P=0.96	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
this	PUNCT	O	O
pilot	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
food	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
have	PUNCT	O	O
any	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
antiviral	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
ddI-EC	NOUN	O	O
capsules	NOUN	O	O
.	PUNCT	O	O

Overexpression	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
VEGF	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
its	ADP	O	O
cellular	ADJ	O	O
receptor	NOUN	O	O
KDR	NOUN	O	O
(	PUNCT	O	O
VEGFR-2	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

Vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
VEGF	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
its	ADP	O	O
cellular	ADJ	O	O
receptor	NOUN	O	O
VEGFR-2	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
implicated	VERB	O	O
as	ADP	O	O
the	DET	O	O
main	ADJ	O	O
endothelial	ADJ	O	O
pathway	NOUN	O	O
required	VERB	O	O
for	ADP	O	O
tumor	NOUN	O	O
neovascularization	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
VEGF/VEGFR-2	NOUN	O	O
system	NOUN	O	O
for	ADP	O	O
angiogenesis	NOUN	O	O
in	ADP	O	O
hematologic	ADJ	O	O
malignancies	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
AML	NOUN	O	O
remains	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
elucidated	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
32	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
newly	ADJ	O	O
diagnosed	ADV	O	O
untreated	VERB	O	O
AML	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
observed	VERB	O	O
by	ADP	O	O
immunohistochemical	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
biopsies	NOUN	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
VEGF	NOUN	O	O
and	CCONJ	O	O
VEGFR-2	NOUN	O	O
expression	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
10	NUM	O	O
control	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
VEGFR-1	NOUN	O	O
staining	VERB	O	O
levels	NOUN	O	O
in	ADP	O	O
AML	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
range	NOUN	O	O
as	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Expression	NOUN	O	O
of	ADP	O	O
VEGF	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
VEGFR-2	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
microvessel	NOUN	O	O
density	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
low	ADJ	O	O
degree	NOUN	O	O
(	PUNCT	O	O
VEGF	NOUN	O	O
:	PUNCT	O	O
P	NOUN	O	O
=0.024	PUNCT	O	O
;	PUNCT	O	O
VEGFR-2	NOUN	O	O
:	PUNCT	O	O
P	NOUN	O	O
=0.040	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
correlated	VERB	O	O
well	VERB	O	O
with	CCONJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
microvessel	NOUN	O	O
density	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
(	PUNCT	O	O
s	NOUN	O	O
)	PUNCT	O	O
=0.566	PUNCT	O	O
and	CCONJ	O	O
0.609	ADP	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
achieved	ADJ	O	O
a	DET	O	O
complete	ADJ	O	O
remission	NOUN	O	B-PHYSICAL
following	VERB	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
VEGFR-2	NOUN	O	B-PHYSICAL
staining	PUNCT	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
into	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
range	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
our	PUNCT	O	O
results	NOUN	O	O
provide	VERB	O	O
evidence	NOUN	O	O
for	ADP	O	O
increased	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
VEGF/VEGFR-2	PUNCT	O	O
of	ADP	O	O
leukemic	ADP	O	B-PHYSICAL
blasts	ADP	O	I-PHYSICAL
and	CCONJ	O	O
correlation	NOUN	O	O
with	ADP	O	O
angiogenesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
of	ADP	O	O
AML	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
VEGF/VEGFR-2	NOUN	O	O
might	PUNCT	O	O
constitute	VERB	O	O
promising	VERB	O	O
targets	NOUN	O	O
for	ADP	O	O
antiangiogenic	ADJ	O	O
and	CCONJ	O	O
antileukemic	ADJ	O	O
treatment	NOUN	O	O
strategies	NOUN	O	O
in	ADP	O	O
AML	NOUN	O	O
.	PUNCT	O	O

Gene	NOUN	O	O
expression	NOUN	O	O
of	ADP	O	O
endothelin-1	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
of	ADP	O	O
broiler	NOUN	O	O
chickens	NOUN	O	O
with	ADP	O	O
T	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
-induced	VERB	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
T	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
-induced	VERB	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
on	ADP	O	O
endothelin	NOUN	O	O
(	PUNCT	O	O
ET	NOUN	O	O
)	PUNCT	O	O
production	NOUN	O	O
and	CCONJ	O	O
genes	NOUN	O	B-PHYSICAL
expression	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
ET-1	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
ET	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
A	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	B-PHYSICAL
ET	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
B	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
receptors	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
ET	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
A	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
R	NOUN	O	O
and	CCONJ	O	B-PHYSICAL
ET	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
B	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
R	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
rearing	DET	O	O
,	PUNCT	O	O
semiquantitative	ADJ	O	O
RT-PCR	NOUN	O	O
and	CCONJ	O	O
enzyme	NOUN	O	O
immunometric	ADJ	O	O
assay	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
ventricles	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
ET-1	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
its	ADJ	O	I-PHYSICAL
receptor	NOUN	O	I-PHYSICAL
genes	NOUN	O	I-PHYSICAL
were	VERB	O	O
expressed	VERB	O	O
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
and	CCONJ	O	O
left	ADJ	O	O
ventricles	NOUN	O	O
of	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
T	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
-treated	DET	O	O
broilers	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
,	PUNCT	O	O
28	NUM	O	O
and	CCONJ	O	O
49	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
reductions	NOUN	O	O
of	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
relative	ADJ	O	I-PHYSICAL
amounts	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
ET-1	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
both	PUNCT	O	B-PHYSICAL
ventricles	NOUN	O	B-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
ET	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
A	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
R	PUNCT	O	O

[	PUNCT	O	O
Postoperative	PUNCT	O	O
analgesia	NOUN	O	O
:	PUNCT	O	O
peridural	ADJ	O	O
morphine	NOUN	O	O
versus	CCONJ	O	O
sublingual	ADJ	O	O
buprenorphine	ADJ	O	O
.	PUNCT	O	O

Comparative	ADJ	O	O
clinical	ADJ	O	O
study	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
herein	ADV	O	O
present	ADJ	O	O
their	PUNCT	O	O
personal	ADJ	O	O
series	NOUN	O	O
on	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
analgesic	ADP	O	O
efficacy	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
opiodes	PUNCT	O	O
,	PUNCT	O	O
peridural	ADJ	O	O
morphine	NOUN	O	O
hydrochloride	NOUN	O	O
(	PUNCT	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
administered	VERB	O	O
to	ADV	O	O
group	NOUN	O	O
A	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sublingual	ADJ	O	O
buprenorphine	ADJ	O	O
(	PUNCT	O	O
0.4	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
administered	VERB	O	O
to	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
post-operative	ADJ	O	O
pain	NOUN	O	O
in	ADP	O	O
major	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
on	ADP	O	O
44	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
male	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
,	PUNCT	O	O
classified	PUNCT	O	O
as	ADP	O	O
ASA	NOUN	O	O
II	NUM	O	O
and	CCONJ	O	O
III	NUM	O	O
.	PUNCT	O	O

Statistical	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BP	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
cardiac	ADJ	O	B-PHYSICAL
frequency	NOUN	O	O
)	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
respiratory	ADJ	O	B-PHYSICAL
frequency	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
pain	NOUN	O	B-PAIN
score	NOUN	O	I-PAIN
showed	VERB	O	O
an	DET	O	O
overlapping	VERB	O	O
progression	NOUN	O	O
among	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Triple	ADJ	O	O
antiretroviral	ADP	O	O
compared	PUNCT	O	O
with	DET	O	O
zidovudine	NOUN	O	O
and	CCONJ	O	O
single-dose	NOUN	O	O
nevirapine	NOUN	O	O
prophylaxis	NOUN	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
and	CCONJ	O	O
breastfeeding	DET	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
mother-to-child	PUNCT	O	O
transmission	NOUN	O	O
of	ADP	O	O
HIV-1	NOUN	O	O
(	PUNCT	O	O
Kesho	NOUN	O	O
Bora	NOUN	O	O
study	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Breastfeeding	PUNCT	O	O
is	VERB	O	O
essential	ADJ	O	O
for	ADP	O	O
child	NOUN	O	O
health	NOUN	O	O
and	CCONJ	O	O
development	NOUN	O	O
in	ADP	O	O
low-resource	NOUN	O	O
settings	NOUN	O	O
but	CCONJ	O	O
carries	DET	O	O
a	DET	O	O
significant	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
transmission	NOUN	O	O
of	ADP	O	O
HIV-1	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
late	ADJ	O	O
stages	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
triple	ADJ	O	O
antiretroviral	ADP	O	O
compared	PUNCT	O	O
with	DET	O	O
zidovudine	NOUN	O	O
and	CCONJ	O	O
single-dose	NOUN	O	O
nevirapine	NOUN	O	O
prophylaxis	NOUN	O	O
in	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
infected	VERB	O	O
with	ADP	O	O
HIV	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Pregnant	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
WHO	NOUN	O	O
stage	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
3	NUM	O	O
HIV-1	NOUN	O	O
infection	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
CD4	NOUN	O	O
cell	NOUN	O	O
counts	NOUN	O	O
of	ADP	O	O
200-500	NUM	O	O
cells	NOUN	O	O
per	PUNCT	O	O
?L	PUNCT	O	O
were	PUNCT	O	O
enrolled	VERB	O	O
at	ADP	O	O
five	NUM	O	O
study	ADV	O	O
sites	NOUN	O	O
in	ADP	O	O
Burkina	NOUN	O	O
Faso	NOUN	O	O
,	PUNCT	O	O
Kenya	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
South	NOUN	O	O
Africa	PUNCT	O	O
to	ADJ	O	O
start	PUNCT	O	O
study	NOUN	O	O
treatment	NOUN	O	O
at	ADP	O	O
28-36	NUM	O	O
weeks	NOUN	O	O
'	PUNCT	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
(	PUNCT	O	O
1:1	NUM	O	O
)	PUNCT	O	O
by	ADP	O	O
a	DET	O	O
computer	NOUN	O	O
generated	VERB	O	O
random	ADJ	O	O
sequence	NOUN	O	O
to	ADP	O	O
either	CCONJ	O	O
triple	ADJ	O	O
antiretroviral	ADJ	O	O
prophylaxis	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
300	NUM	O	O
mg	NOUN	O	O
zidovudine	NOUN	O	O
,	PUNCT	O	O
150	NUM	O	O
mg	NOUN	O	O
lamivudine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NOUN	O	O
lopinavir	NOUN	O	O
plus	CCONJ	O	O
100	NUM	O	O
mg	NOUN	O	O
ritonavir	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
until	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
breastfeeding	ADJ	O	O
to	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
6?5	ADJ	O	O
months	NOUN	O	O
post	PUNCT	O	O
partum	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
zidovudine	NOUN	O	O
and	CCONJ	O	O
single-dose	NOUN	O	O
nevirapine	NOUN	O	O
(	PUNCT	O	O
300	NUM	O	O
mg	NOUN	O	O
zidovudine	NOUN	O	O
twice	PUNCT	O	O
daily	ADJ	O	O
until	ADP	O	O
delivery	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
600	NUM	O	O
mg	NOUN	O	O
zidovudine	NOUN	O	O
plus	CCONJ	O	O
200	NUM	O	O
mg	NOUN	O	O
nevirapine	NOUN	O	O
at	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
labour	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
after	ADP	O	O
a	DET	O	O
protocol	NOUN	O	O
amendment	ADJ	O	O
in	ADP	O	O
December	NOUN	O	O
,	PUNCT	O	O
2006	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
week	NOUN	O	O
post-partum	NOUN	O	O
zidovudine	NOUN	O	O
300	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
daily	VERB	O	O
and	CCONJ	O	O
lamivudine	NOUN	O	O
150	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
daily	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
infants	NOUN	O	O
received	VERB	O	O
a	DET	O	O
0?6	PUNCT	O	O
mL	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
nevirapine	NOUN	O	O
at	ADP	O	O
birth	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
from	ADP	O	O
December	NOUN	O	O
,	PUNCT	O	O
2006	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
mg/kg	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
of	DET	O	O
zidovudine	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
after	ADP	O	O
birth	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
and	CCONJ	O	O
investigators	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
masked	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoints	NOUN	O	O
were	VERB	O	O
HIV-free	ADJ	O	O
infant	NOUN	O	O
survival	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
HIV-free	ADJ	O	O
survival	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
infants	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
ever	ADV	O	O
breastfed	ADV	O	O
;	PUNCT	O	O
AIDS-free	PUNCT	O	O
survival	NOUN	O	O
in	ADP	O	O
mothers	NOUN	O	O
at	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
mothers	NOUN	O	O
and	CCONJ	O	O
babies	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
was	VERB	O	O
by	ADP	O	O
intention	NOUN	O	O
to	PART	O	O
treat	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
registered	PUNCT	O	O
with	ADP	O	O
Current	ADJ	O	O
Controlled	VERB	O	O
Trials	NOUN	O	O
,	PUNCT	O	O
ISRCTN71468401	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
From	ADP	O	O
June	NOUN	O	O
,	PUNCT	O	O
2005	NUM	O	O
,	PUNCT	O	O
to	ADP	O	O
August	NOUN	O	O
,	PUNCT	O	O
2008	NUM	O	O
,	PUNCT	O	O
882	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
824	NUM	O	O
of	ADP	O	O
whom	ADP	O	O
were	VERB	O	O
randomised	NUM	O	O
and	CCONJ	O	O
gave	PROPN	O	O
birth	NOUN	O	O
to	ADP	O	O
805	NUM	O	O
singleton	NOUN	O	O
or	CCONJ	O	O
first	ADP	O	O
,	PUNCT	O	O
liveborn	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
HIV	NOUN	O	O
transmission	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
was	PUNCT	O	O
3?3	PUNCT	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1?9-5?6	NOUN	O	O
%	ADV	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
triple	ADJ	O	O
antiretroviral	ADJ	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
5?0	NOUN	O	O
%	SYM	O	O
(	PUNCT	O	O
3?3-7?7	NOUN	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
zidovudine	NOUN	O	O
and	CCONJ	O	O
single-dose	NOUN	O	O
nevirapine	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
was	VERB	O	O
5?4	PUNCT	O	O
%	SYM	O	O
(	PUNCT	O	O
3?6-8?1	NOUN	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
triple	ADJ	O	O
antiretroviral	ADJ	O	O
group	NOUN	O	O
compared	VERB	O	O
with	PUNCT	O	O
9?5	PUNCT	O	O
%	SYM	O	O
(	PUNCT	O	O
7?0-12?9	NOUN	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
zidovudine	NOUN	O	O
and	CCONJ	O	O
single-dose	NOUN	O	O
nevirapine	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p=0?029	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
HIV	NOUN	O	O
transmission	NOUN	O	O
or	CCONJ	O	O
death	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
was	VERB	O	O
10?2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
7?6-13?6	NOUN	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
triple	ADJ	O	O
antiretroviral	ADJ	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
16?0	NOUN	O	O
%	VERB	O	O
(	PUNCT	O	O
12?7-20?0	PUNCT	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
zidovudine	NOUN	O	O
and	CCONJ	O	O
single-dose	NOUN	O	O
nevirapine	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p=0?017	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
infants	NOUN	O	O
whose	DET	O	O
mothers	NOUN	O	O
declared	ADP	O	O
they	PUNCT	O	O
intended	PUNCT	O	O
to	ADP	O	O
breastfeed	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
cumulative	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
HIV	NOUN	O	O
transmission	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
was	VERB	O	O
5?6	PUNCT	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
3?4-8?9	NOUN	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
triple	ADJ	O	O
antiretroviral	ADJ	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
10?7	PUNCT	O	O
%	SYM	O	O
(	PUNCT	O	O
7?6-14?8	ADV	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
zidovudine	NOUN	O	O
and	CCONJ	O	O
single-dose	NOUN	O	O
nevirapine	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p=0?02	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

AIDS-free	ADJ	O	O
survival	NOUN	O	O
in	ADP	O	O
mothers	NOUN	O	O
at	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
a	DET	O	O
different	ADJ	O	O
publication	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
laboratory	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
mothers	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
babies	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
Triple	ADJ	O	O
antiretroviral	ADP	O	O
prophylaxis	NOUN	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
and	CCONJ	O	O
breastfeeding	PUNCT	O	O
is	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
reduces	NOUN	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
HIV	NOUN	O	O
transmission	NOUN	O	O
to	ADP	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Revised	VERB	O	O
WHO	NOUN	O	O
guidelines	NOUN	O	O
now	ADV	O	O
recommend	VERB	O	O
antiretroviral	ADP	O	O
prophylaxis	NOUN	O	O
(	PUNCT	O	O
either	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
mother	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
baby	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
breastfeeding	PUNCT	O	O
if	PUNCT	O	O
the	DET	O	O
mother	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
already	ADV	O	O
receiving	SYM	O	O
antiretroviral	PUNCT	O	O
treatment	NOUN	O	O
for	ADP	O	O
her	PUNCT	O	O
own	ADJ	O	O
health	NOUN	O	O
.	PUNCT	O	O

FUNDING	PUNCT	O	O
Agence	ADP	O	O
nationale	NOUN	O	O
de	ADP	O	O
recherches	NOUN	O	O
sur	NOUN	O	O
le	ADP	O	O
sida	PUNCT	O	O
et	CCONJ	O	O
les	DET	O	O
h?patites	PUNCT	O	O
virales	ADP	O	O
,	PUNCT	O	O
Department	NOUN	O	O
for	ADP	O	O
International	ADJ	O	O
Development	NOUN	O	O
,	PUNCT	O	O
European	ADJ	O	O
and	CCONJ	O	O
Developing	PROPN	O	O
Countries	NOUN	O	O
Clinical	ADJ	O	O
Trials	NOUN	O	O
Partnership	NOUN	O	O
,	PUNCT	O	O
Thrasher	NOUN	O	O
Research	NOUN	O	O
Fund	NOUN	O	O
,	PUNCT	O	O
Belgian	PUNCT	O	O
Directorate	NOUN	O	O
General	NOUN	O	O
for	ADP	O	O
International	ADJ	O	O
Cooperation	NOUN	O	O
,	PUNCT	O	O
Centers	NOUN	O	O
for	ADP	O	O
Disease	NOUN	O	O
Control	NOUN	O	O
and	CCONJ	O	O
Prevention	NOUN	O	O
,	PUNCT	O	O
Eunice	NOUN	O	O
Kennedy	NOUN	O	O
Shriver	NOUN	O	O
National	ADJ	O	O
Institute	NOUN	O	O
of	ADP	O	O
Child	NOUN	O	O
Health	NOUN	O	O
and	CCONJ	O	O
Human	NOUN	O	O
Development	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
UNDP/UNFPA/World	NOUN	O	O
Bank/WHO	NOUN	O	O
Special	ADJ	O	O
Programme	NOUN	O	O
of	ADP	O	O
Research	NOUN	O	O
,	PUNCT	O	O
Development	NOUN	O	O
and	CCONJ	O	O
Research	NOUN	O	O
Training	PROPN	O	O
in	ADP	O	O
Human	NOUN	O	O
Reproduction	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
common	ADJ	O	O
variant	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CD38	NOUN	O	O
gene	NOUN	O	O
on	ADP	O	O
social	ADJ	O	B-MENTAL
processing	VERB	O	I-MENTAL
in	ADP	O	O
an	DET	O	O
oxytocin	NOUN	O	O
challenge	NOUN	O	O
study	NOUN	O	O
:	PUNCT	O	O
possible	ADJ	O	O
links	ADJ	O	O
to	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intranasal	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
oxytocin	NOUN	O	O
(	PUNCT	O	O
OT	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	ADJ	O	O
influence	ADJ	O	O
behavioral	ADJ	O	B-MENTAL
and	CCONJ	O	O
neural	ADJ	O	B-MENTAL
correlates	PUNCT	O	I-MENTAL
of	ADP	O	I-MENTAL
social	ADJ	O	I-MENTAL
processing	VERB	O	I-MENTAL
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
are	VERB	O	O
probably	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
genetic	ADJ	O	O
variations	NOUN	O	O
within	ADP	O	O
the	DET	O	O
OT	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
potential	ADJ	O	O
candidate	NOUN	O	O
could	VERB	O	O
be	ADJ	O	O
the	DET	O	O
CD38	NOUN	O	O
gene	NOUN	O	O
,	PUNCT	O	O
which	DET	O	O
codes	DET	O	O
for	ADP	O	O
a	DET	O	O
transmembrane	ADJ	O	O
protein	NOUN	O	O
engaged	VERB	O	O
in	ADP	O	O
OT	NOUN	O	O
secretion	NOUN	O	O
processes	NOUN	O	O
.	PUNCT	O	O

A	CCONJ	O	O
common	ADJ	O	O
variation	NOUN	O	O
in	ADP	O	O
this	DET	O	O
gene	NOUN	O	O
(	PUNCT	O	O
rs3796863	PUNCT	O	O
)	PUNCT	O	O
was	ADJ	O	O
recently	ADV	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Using	VERB	O	O
an	DET	O	O
imaging	VERB	O	O
genetics	NOUN	O	O
approach	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
an	DET	O	O
intranasal	ADJ	O	O
OT	NOUN	O	O
application	NOUN	O	O
on	ADP	O	O
neural	ADJ	O	B-MENTAL
processing	VERB	O	I-MENTAL
of	ADP	O	I-MENTAL
social	ADJ	O	I-MENTAL
stimuli	NOUN	O	I-MENTAL
in	ADP	O	O
55	NUM	O	O
healthy	ADJ	O	O
young	ADJ	O	O
men	NOUN	O	O
depending	VERB	O	O
on	ADP	O	O
their	PUNCT	O	O
CD38	NOUN	O	O
gene	NOUN	O	O
variant	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
crossover	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

Genotype	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
influence	NOUN	O	O
on	ADP	O	O
both	CCONJ	O	O
behavioral	ADJ	O	B-MENTAL
and	CCONJ	O	O
neuronal	ADJ	O	B-MENTAL
measures	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
social	ADJ	O	I-MENTAL
processing	VERB	O	I-MENTAL
.	PUNCT	O	O

Homozygotic	ADJ	O	O
risk	NOUN	O	O
allele	NOUN	O	O
carriers	NOUN	O	O
showed	VERB	O	O
slower	PUNCT	O	O
reaction	NOUN	O	O
times	NOUN	O	O
(	PUNCT	O	O
RT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
higher	PUNCT	O	O
activation	NOUN	O	O
of	ADP	O	O
left	ADJ	O	B-MENTAL
fusiform	NOUN	O	I-MENTAL
gyrus	NOUN	O	I-MENTAL
during	ADP	O	O
visual	ADJ	O	O
processing	VERB	O	O
of	ADP	O	O
social	ADJ	O	B-MENTAL
stimuli	NOUN	O	I-MENTAL
.	PUNCT	O	O

Under	ADP	O	O
OT	NOUN	O	O
activation	NOUN	O	B-MENTAL
differences	NOUN	O	I-MENTAL
between	ADP	O	O
genotypes	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
evident	ADJ	O	O
(	PUNCT	O	O
though	CCONJ	O	O
not	ADV	O	O
statistically	ADJ	O	O
significantly	ADV	O	O
increased	ADP	O	O
)	PUNCT	O	O
and	CCONJ	O	O
RT	NOUN	O	O
were	VERB	O	O
accelerated	VERB	O	O
in	ADP	O	O
homozygotic	ADJ	O	O
risk	NOUN	O	O
allele	NOUN	O	O
carriers	NOUN	O	O
.	PUNCT	O	O

According	PUNCT	O	O
to	ADP	O	O
our	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
rs3796863	PUNCT	O	B-MENTAL
mainly	PUNCT	O	I-MENTAL
influences	PUNCT	O	I-MENTAL
fusiform	NOUN	O	I-MENTAL
gyrus	NOUN	O	I-MENTAL
activation	NOUN	O	I-MENTAL
,	PUNCT	O	O
an	DET	O	O
area	NOUN	O	O
which	ADP	O	O
has	PUNCT	O	O
been	PUNCT	O	O
widely	ADV	O	O
discussed	VERB	O	O
in	ADP	O	O
ASD	NOUN	O	O
research	NOUN	O	O
.	PUNCT	O	O

OT	NOUN	O	O
seems	NOUN	O	O
to	PART	O	O
modulate	NOUN	O	O
this	DET	O	O
effect	NOUN	O	O
by	ADP	O	O
enhancing	ADP	O	O
activation	NOUN	O	B-MENTAL
differences	NOUN	O	I-MENTAL
between	ADP	O	O
allele	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
suggests	VERB	O	O
an	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
genetic	ADJ	O	B-PHYSICAL
makeup	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
OT	NOUN	O	B-PHYSICAL
availability	NOUN	O	I-PHYSICAL
on	ADP	O	O
fusiform	NOUN	O	B-MENTAL
gyrus	NOUN	O	I-MENTAL
activation	NOUN	O	I-MENTAL
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
support	VERB	O	O
recent	ADJ	O	O
approaches	NOUN	O	O
to	PART	O	O
apply	CCONJ	O	O
OT	NOUN	O	O
as	ADP	O	O
a	DET	O	O
pharmacological	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
ASD	NOUN	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetic-pharmacodynamic	ADJ	O	B-OTHER
modelling	ADJ	O	I-OTHER
of	ADP	O	O
the	DET	O	O
antihistaminic	ADJ	O	O
(	PUNCT	O	O
H1	NOUN	O	O
)	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
bilastine	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PUNCT	O	O
model	NOUN	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
pharmacodynamic	ADJ	O	B-PHYSICAL
relationship	NOUN	O	O
of	ADP	O	O
bilastine	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
histamine	NOUN	O	O
H	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
single-	CCONJ	O	O
and	CCONJ	O	O
multiple-dose	PUNCT	O	O
studies	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
adult	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
pharmacokinetic	ADJ	O	O
model	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
from	ADP	O	O
different	ADJ	O	O
single-dose	NOUN	O	O
and	CCONJ	O	O
multiple-dose	PUNCT	O	O
studies	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
single-dose	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
183	NUM	O	O
subjects	NOUN	O	O
received	VERB	O	O
oral	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
bilastine	ADJ	O	O
2.5	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
120	NUM	O	O
,	PUNCT	O	O
160	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
and	CCONJ	O	O
220	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
multiple-dose	PUNCT	O	O
studies	NOUN	O	O
,	PUNCT	O	O
127	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
received	ADV	O	O
bilastine	NOUN	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
40	NUM	O	O
,	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
140	NUM	O	O
or	CCONJ	O	O
200	NUM	O	O
mg/day	PUNCT	O	O
as	ADP	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
during	ADP	O	O
a	DET	O	O
4-	PUNCT	O	O
,	PUNCT	O	O
7-	NUM	O	O
or	CCONJ	O	O
14-day	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pharmacokinetic	ADJ	O	B-OTHER
profile	NOUN	O	I-OTHER
of	ADP	O	O
bilastine	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
using	SYM	O	O
a	DET	O	O
simultaneous	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
all	DET	O	O
concentration-time	NOUN	O	B-OTHER
data	NOUN	O	I-OTHER
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
nonlinear	ADJ	O	O
mixed-effects	VERB	O	O
modelling	PUNCT	O	O
population	NOUN	O	O
pharmacokinetic	ADJ	O	O
software	NOUN	O	O
NONMEM	NOUN	O	O
version	NOUN	O	O
6.1	NUM	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
modelled	VERB	O	O
according	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
two-compartment	NOUN	O	O
open	VERB	O	O
model	NOUN	O	O
with	ADP	O	O
first-order	ADJ	O	O
absorption	NOUN	O	O
and	CCONJ	O	O
elimination	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
pharmacodynamic	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
bilastine	ADJ	O	O
(	PUNCT	O	O
inhibition	NOUN	O	O
of	ADP	O	O
histamine-induced	ADP	O	O
wheal	ADJ	O	O
and	CCONJ	O	O
flare	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
assessed	VERB	O	O
on	ADP	O	O
a	DET	O	O
preselected	VERB	O	O
time	NOUN	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
predicted	VERB	O	O
typical	ADJ	O	B-OTHER
pharmacokinetic	ADJ	O	I-OTHER
profile	NOUN	O	I-OTHER
(	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	O
model	NOUN	O	O
previously	ADV	O	O
developed	VERB	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
indirect	ADJ	O	O
response	NOUN	O	O
model	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
to	PART	O	O
describe	VERB	O	O
the	DET	O	O
pharmacodynamic	ADJ	O	B-OTHER
relationships	NOUN	O	I-OTHER
between	ADP	O	O
flare	NOUN	O	O
or	CCONJ	O	O
wheal	ADP	O	O
areas	NOUN	O	O
and	CCONJ	O	O
bilastine	ADP	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
once	PUNCT	O	O
values	NOUN	O	O
of	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
that	ADP	O	O
produced	VERB	O	B-OTHER
50	NUM	O	I-OTHER
%	SYM	O	I-OTHER
inhibition	NOUN	O	I-OTHER
(	PUNCT	O	O
IC	NOUN	O	B-OTHER
(	PUNCT	O	O
50	NUM	O	B-OTHER
)	PUNCT	O	O
)	PUNCT	O	O
had	PUNCT	O	O
been	PUNCT	O	O
estimated	VERB	O	O
for	ADP	O	O
wheal	ADP	O	O
and	CCONJ	O	O
flare	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
simulations	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
to	ADP	O	O
predict	NOUN	O	O
plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
for	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
of	ADP	O	O
bilastine	ADJ	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
mg	NOUN	O	O
at	ADP	O	O
steady	ADJ	O	O
state	NOUN	O	O
(	PUNCT	O	O
72-96	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
non-compartmental	ADJ	O	O
analysis	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
linear	ADJ	O	O
kinetics	NOUN	O	O
of	ADP	O	O
bilastine	ADJ	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
range	NOUN	O	O
studied	VERB	O	O
.	PUNCT	O	O

Bilastine	NOUN	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
two-compartmental	ADP	O	O
kinetics	NOUN	O	O
with	ADP	O	O
a	DET	O	O
rapid-absorption	NOUN	O	O
phase	NOUN	O	O
(	PUNCT	O	O
first-order	NOUN	O	O
absorption	NOUN	O	O
rate	NOUN	O	O
constant	ADJ	O	O
=	SYM	O	O
1.50	NUM	O	O
h	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
plasma	NOUN	O	B-PHYSICAL
peak	ADJ	O	O
concentrations	NOUN	O	B-PHYSICAL
were	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
following	VERB	O	O
administration	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
maximal	ADJ	O	B-OTHER
response	NOUN	O	I-OTHER
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
approximately	ADV	O	O
4	NUM	O	O
hours	NOUN	O	O
or	CCONJ	O	O
later	PUNCT	O	O
.	PUNCT	O	O

Concerning	PROPN	O	O
the	DET	O	O
selected	VERB	O	O
pharmacodynamic	ADJ	O	O
model	NOUN	O	O
to	ADP	O	O
fit	PROPN	O	O
the	DET	O	O
data	NOUN	O	O
(	PUNCT	O	O
type	NOUN	O	O
I	NUM	O	O
indirect	ADJ	O	O
response	NOUN	O	O
model	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
this	DET	O	O
selection	NOUN	O	O
is	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
inhibitory	ADJ	O	O
bilastine	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
that	ADP	O	O
decrease	VERB	O	O
the	DET	O	O
input	NOUN	O	B-OTHER
response	NOUN	O	O
function	NOUN	O	B-OTHER
,	PUNCT	O	O
i.e	PUNCT	O	O
.	PUNCT	O	O

the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
the	DET	O	O
skin	NOUN	O	O
reaction	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
model	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
best	DET	O	O
fit	NOUN	O	O
of	ADP	O	O
wheal	ADP	O	O
and	CCONJ	O	O
flare	NOUN	O	O
data	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
estimates	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
relative	ADJ	O	O
standard	ADJ	O	O
errors	NOUN	O	O
expressed	VERB	O	O
in	ADP	O	O
percentages	NOUN	O	O
in	ADP	O	O
parentheses	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
apparent	ADJ	O	B-PHYSICAL
zero-order	ADJ	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
constant	NOUN	O	B-PHYSICAL
for	ADP	O	I-PHYSICAL
flare	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
wheal	ADP	O	B-PHYSICAL
spontaneous	ADJ	O	B-PHYSICAL
appearance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
k	NOUN	O	O
(	PUNCT	O	O
in	PUNCT	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
first-order	ADJ	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
constant	ADJ	O	B-PHYSICAL
for	ADP	O	I-PHYSICAL
flare	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
wheal	ADP	O	B-PHYSICAL
disappearance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
k	NOUN	O	O
(	PUNCT	O	O
out	PUNCT	O	O
)	PUNCT	O	O
)	PUNCT	O	O
and	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
prophylactic	ADJ	O	O
calcium	NOUN	O	O
and	CCONJ	O	O
magnesium	NOUN	O	O
infusions	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
oxaliplatin-based	VERB	O	O
systemic	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
advanced	VERB	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Peripheral	ADJ	O	O
sensory	ADJ	O	O
neurotoxicity	NOUN	O	O
is	VERB	O	O
a	DET	O	O
frequent	ADJ	O	O
and	CCONJ	O	O
potentially	ADV	O	O
debilitating	NUM	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
oxaliplatin	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Calcium	NOUN	O	O
and	CCONJ	O	O
magnesium	NOUN	O	O
(	PUNCT	O	O
Ca/Mg	ADP	O	O
)	PUNCT	O	O
infusions	NOUN	O	O
are	PROPN	O	O
frequently	ADV	O	O
used	VERB	O	O
to	PART	O	O
prevent	ADJ	O	O
this	DET	O	O
toxicity	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
concerns	PUNCT	O	O
about	CCONJ	O	O
a	DET	O	O
negative	ADJ	O	O
impact	NOUN	O	O
of	ADP	O	O
Ca/Mg	ADP	O	O
infusions	NOUN	O	O
on	ADP	O	O
outcome	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
raised	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
retrospectively	ADV	O	O
assessed	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
Ca/Mg	ADP	O	O
infusions	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
on	ADP	O	O
clinical	ADJ	O	B-PHYSICAL
outcome	NOUN	O	I-PHYSICAL
in	ADP	O	O
advanced	VERB	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
ACC	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
treated	VERB	O	O
in	ADP	O	O
the	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
CAIRO2	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Seven	ADJ	O	O
hundred	NUM	O	O
and	CCONJ	O	O
fifty	NUM	O	O
five	NUM	O	O
previously	ADV	O	O
untreated	VERB	O	O
ACC	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	PUNCT	O	O
between	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
capecitabine	NOUN	O	O
,	PUNCT	O	O
oxaliplatin	NOUN	O	O
and	CCONJ	O	O
bevacizumab	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
same	ADJ	O	O
combination	NOUN	O	O
with	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
cetuximab	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
retrospectively	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Ca/Mg	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
received	VERB	O	O
Ca/Mg	ADP	O	O
at	VERB	O	O
least	DET	O	O
during	ADP	O	O
their	PROPN	O	O
first	ADJ	O	O
treatment	NOUN	O	O
cycle	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Ca/Mg	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Seven	PUNCT	O	O
hundred	NUM	O	O
and	CCONJ	O	O
thirty	NUM	O	O
two	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluable	ADJ	O	O
for	ADP	O	O
this	DET	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Ca/Mg	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
551	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Ca/Mg	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
181	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
all	DET	O	O
grade	NOUN	O	O
neurotoxicity	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
Ca/Mg	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
Ca/Mg	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
was	VERB	O	O
85	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
92	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
grade	NOUN	O	O
?	PUNCT	O	O

2	NUM	O	O
neurotoxicity	NOUN	O	O
was	VERB	O	O
40	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
45	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.22	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
PFS	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Ca/Mg	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
Ca/Mg	ADP	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
was	VERB	O	O
10.1	NUM	O	O
versus	CCONJ	O	O
10.7	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.92	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
OS	NOUN	O	O
was	VERB	O	O
19.8	NUM	O	O
versus	CCONJ	O	O
20.7	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
response	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
43.1	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
50	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.11	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
largest	PUNCT	O	O
retrospective	ADJ	O	O
analysis	NOUN	O	O
to	ADP	O	O
date	NOUN	O	O
we	PRON	O	O
observed	VERB	O	O
that	ADP	O	O
Ca/Mg	ADP	O	O
infusions	NOUN	O	O
significantly	ADV	O	O
reduced	VERB	O	O
all	DET	O	O
grade	NOUN	O	O
oxaliplatin-related	VERB	O	O
neurotoxicity	NOUN	O	O
.	PUNCT	O	O

Ca/Mg	ADP	O	O
infusions	NOUN	O	O
did	DET	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
splinting	NOUN	O	O
of	ADP	O	O
teeth	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
reconstructive	ADJ	O	O
periodontal	ADJ	O	O
surgery	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
splinting	NOUN	O	O
teeth	NOUN	O	O
on	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
periodontal	ADJ	O	O
reconstructive	ADJ	O	O
surgery	NOUN	O	O
using	ADJ	O	O
a	DET	O	O
specific	ADJ	O	O
carbonate	NOUN	O	O
bone	NOUN	O	O
replacement	NOUN	O	O
graft	NOUN	O	O
(	PUNCT	O	O
BRG	NOUN	O	O
)	PUNCT	O	O
material	NOUN	O	O
.	PUNCT	O	O

Forty-five	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
periodontal	ADJ	O	O
surgery	NOUN	O	O
approach	NOUN	O	O
.	PUNCT	O	O

Natural	ADJ	O	O
coral	PUNCT	O	O
calcium	NOUN	O	O
BRG	NOUN	O	O
was	VERB	O	O
utilised	VERB	O	O
in	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
33-patient	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
three	NUM	O	O
equal	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
presplint	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
teeth	NOUN	O	O
were	VERB	O	O
splinted	VERB	O	O
to	ADP	O	O
at	PUNCT	O	O
least	ADV	O	O
two	NUM	O	O
rigid	ADJ	O	O
teeth	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
postsplint	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
teeth	NOUN	O	O
were	VERB	O	O
splinted	VERB	O	O
at	ADP	O	O
suture	NOUN	O	O
removal	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
nonsplint	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
treated	VERB	O	O
teeth	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
splinted	VERB	O	O
at	ADP	O	O
all	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
12	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
teeth	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
surgical	ADJ	O	O
debridement	NOUN	O	O
(	PUNCT	O	O
DEBR	NOUN	O	O
)	PUNCT	O	O
alone	ADJ	O	O
and	CCONJ	O	O
not	ADV	O	O
splinted	VERB	O	O
.	PUNCT	O	O

Periodontal	ADJ	O	O
probing	VERB	O	O
depth	NOUN	O	O
(	PUNCT	O	O
PPD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
probing	PUNCT	O	O
attachment	NOUN	O	O
level	NOUN	O	O
(	PUNCT	O	O
CPAL	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tooth	NOUN	O	O
mobility	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
using	SYM	O	O
desmodontometry	NOUN	O	O
(	PUNCT	O	O
DDM	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
periotest	ADV	O	O
(	PUNCT	O	O
PTV	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
reproducible	ADJ	O	O
methods	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
various	ADJ	O	O
periods	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
afterwards	ADP	O	O
.	PUNCT	O	O

A	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
PPD	NOUN	O	B-OTHER
(	PUNCT	O	O
5.4	ADP	O	O
mm	NOUN	O	O
,	PUNCT	O	O
SD	NOUN	O	O
1.4	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tooth	NOUN	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
DDM-horizontal	ADJ	O	O
257	NUM	O	O
microns	NOUN	O	O
,	PUNCT	O	O
SD	NOUN	O	O
60	NUM	O	O
microns	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
gain	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
CPAL	NOUN	O	I-OTHER
(	PUNCT	O	O
5.1	NUM	O	O
mm	NOUN	O	O
,	PUNCT	O	O
SD	NOUN	O	O
1.4	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
seen	VERB	O	O
following	SYM	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
BRG	NOUN	O	O
in	ADP	O	O
presplint	NOUN	O	O
teeth	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
same	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
PPD	NOUN	O	B-OTHER
and	CCONJ	O	O
tooth	NOUN	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
reduced	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
nonsplint	PUNCT	O	O
teeth	NOUN	O	O
.	PUNCT	O	O

DEBR	NOUN	O	O
alone	ADJ	O	O
showed	VERB	O	O
reductions	NOUN	O	O
in	ADP	O	O
tooth	NOUN	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
PPD	NOUN	O	B-OTHER
and	CCONJ	O	O
a	DET	O	O
significantly	ADV	O	O
smaller	PUNCT	O	O
gain	CCONJ	O	O
in	ADP	O	O
CPAL	NOUN	O	B-OTHER
than	PUNCT	O	O
in	ADP	O	O
presplint	NOUN	O	O
teeth	NOUN	O	O
treated	PUNCT	O	O
with	ADP	O	O
BRG	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
less	ADV	O	O
favourable	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
periodontal	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
postsplint	NOUN	O	O
or	CCONJ	O	O
nonsplint	NOUN	O	O
teeth	NOUN	O	O
seemed	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
due	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
BRG	NOUN	O	B-PHYSICAL
material	NOUN	O	I-PHYSICAL
caused	VERB	O	O
by	ADP	O	O
tooth	NOUN	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
an	DET	O	O
undisturbed	PUNCT	O	O
wound	NOUN	O	O
healing	ADJ	O	O
process	NOUN	O	O
using	VERB	O	O
BRG	NOUN	O	O
together	ADV	O	O
with	ADP	O	O
tooth	NOUN	O	O
stability	NOUN	O	O
is	VERB	O	O
beneficial	ADJ	O	O
to	ADP	O	O
overall	ADJ	O	B-PHYSICAL
clinical	ADJ	O	I-PHYSICAL
success	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Stability	NOUN	O	O
,	PUNCT	O	O
tipping	ADP	O	O
and	CCONJ	O	O
relapse	NOUN	O	O
of	ADP	O	O
bone-borne	VERB	O	O
versus	CCONJ	O	O
tooth-borne	NOUN	O	O
surgically	ADV	O	O
assisted	VERB	O	O
rapid	ADJ	O	O
maxillary	ADJ	O	O
expansion	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
patient	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
stability	NOUN	O	O
,	PUNCT	O	O
tipping	ADP	O	O
and	CCONJ	O	O
relapse	NOUN	O	O
after	PUNCT	O	O
surgically	ADV	O	O
assisted	VERB	O	O
rapid	ADJ	O	O
maxillary	ADJ	O	O
expansion	NOUN	O	O
(	PUNCT	O	O
SARME	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
comparing	ADP	O	O
bone-borne	VERB	O	O
and	CCONJ	O	O
tooth-borne	NOUN	O	O
devices	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
skeletally	ADV	O	O
matured	PUNCT	O	O
non-syndromal	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
transverse	ADJ	O	O
maxillary	ADJ	O	O
hypoplasia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
open-label	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
bone-borne	VERB	O	O
(	PUNCT	O	O
n=25	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tooth-borne	NOUN	O	O
(	PUNCT	O	O
n=21	NOUN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
surgical	ADJ	O	O
technique	NOUN	O	O
for	ADP	O	O
corticotomy	NOUN	O	O
was	VERB	O	O
the	DET	O	O
same	ADP	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Expansion	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
a	DET	O	O
bone-borne	VERB	O	O
or	CCONJ	O	O
tooth-borne	NOUN	O	O
device	NOUN	O	O
.	PUNCT	O	O

Dental	ADJ	O	O
study	NOUN	O	O
casts	CCONJ	O	O
,	PUNCT	O	O
lateral	ADJ	O	O
and	CCONJ	O	O
postero-anterior	ADJ	O	O
cephalograms	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
before	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
distraction	NOUN	O	O
phase	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
12-month	NOUN	O	O
follow	VERB	O	O
up	ADJ	O	O
.	PUNCT	O	O

Stability	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
segmental	ADJ	O	B-PHYSICAL
maxillary	ADJ	O	I-PHYSICAL
tipping	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
relapse	NOUN	O	B-PHYSICAL
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

23	NUM	O	O
bone-borne	VERB	O	O
and	CCONJ	O	O
19	NUM	O	O
tooth-borne	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Widening	VERB	O	B-PHYSICAL
was	VERB	O	O
comparable	ADJ	O	O
at	ADP	O	O
canine	ADJ	O	O
,	PUNCT	O	O
premolar	ADJ	O	O
and	CCONJ	O	O
molar	PUNCT	O	O
level	NOUN	O	O
.	PUNCT	O	O

Relapse	NOUN	O	B-PHYSICAL
was	ADJ	O	O
not	ADV	O	O
significant	ADJ	O	O
and	CCONJ	O	O
at	ADP	O	O
follow	PUNCT	O	O
up	PUNCT	O	O
the	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
distance	NOUN	O	O
was	VERB	O	O
sustained	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
palatal	ADJ	O	B-PHYSICAL
width	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
premolar	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
molar	PUNCT	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
maxilla	NOUN	O	O
moves	ADP	O	O
slightly	ADV	O	O
downward	PUNCT	O	O
in	ADP	O	O
SARME	NOUN	O	O
.	PUNCT	O	O

Segmental	ADJ	O	B-PHYSICAL
maxillary	ADJ	O	I-PHYSICAL
tipping	PUNCT	O	I-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
and	CCONJ	O	O
did	DET	O	O
not	ADV	O	O
affect	VERB	O	O
relapse	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
is	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
SARME	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
widening	PUNCT	O	O
achieved	VERB	O	O
at	ADP	O	O
dental	ADJ	O	O
level	NOUN	O	O
is	VERB	O	O
stable	ADJ	O	O
after	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Over-correction	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
necessary	ADJ	O	O
.	PUNCT	O	O

Tipping	DET	O	O
of	ADP	O	O
the	DET	O	O
maxillary	ADJ	O	O
segments	NOUN	O	O
and	CCONJ	O	O
increases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
retention	NOUN	O	B-PHYSICAL
period	NOUN	O	I-PHYSICAL
are	VERB	O	O
equal	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Divalproex	PUNCT	O	O
sodium	NOUN	O	O
vs	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
irritability	NOUN	O	B-MENTAL
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
ASDs	ADJ	O	O
)	PUNCT	O	O
are	VERB	O	O
neurodevelopmental	ADJ	O	O
disorders	NOUN	O	O
characterized	VERB	O	O
by	ADP	O	O
social	ADJ	O	O
and	CCONJ	O	O
language	NOUN	O	O
deficits	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
repetitive	ADJ	O	O
behaviors	NOUN	O	O
and	CCONJ	O	O
interests	NOUN	O	O
.	PUNCT	O	O

Irritability/aggression	NOUN	O	O
is	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
comorbid	ADJ	O	O
symptom	NOUN	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
greatly	ADV	O	O
impacts	PUNCT	O	O
burden	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
divalproex	PUNCT	O	O
sodium	NOUN	O	O
for	ADP	O	O
irritability/aggression	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
a	DET	O	O
12-week	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
efficacy	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
by	ADP	O	O
an	DET	O	O
independent	ADJ	O	O
evaluator	NOUN	O	O
blinded	PUNCT	O	O
to	ADP	O	O
randomization	NOUN	O	O
condition	NOUN	O	O
and	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
55	NUM	O	O
subjects	NOUN	O	O
gavetheir	PUNCT	O	O
consent	NOUN	O	O
and	CCONJ	O	O
27	NUM	O	O
were	VERB	O	O
randomized	VERB	O	O
in	ADP	O	O
a	DET	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
manner	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
9.46+/-2.46	PUNCT	O	O
,	PUNCT	O	O
mean	VERB	O	O
nonverbal	ADJ	O	O
IQ	NOUN	O	O
63.3+/-23.9	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
subjects	NOUN	O	O
from	ADP	O	O
the	DET	O	O
active	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
subject	NOUN	O	O
from	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
discontinued	VERB	O	O
the	DET	O	O
study	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
or	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
(	PUNCT	O	O
increased	VERB	O	O
irritability	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
Aberrant	ADJ	O	B-MENTAL
Behavior	NOUN	O	I-MENTAL
Checklist-Irritability	NOUN	O	I-MENTAL
subscale	NOUN	O	I-MENTAL
and	CCONJ	O	I-MENTAL
Clinical	ADJ	O	I-MENTAL
Global	ADJ	O	I-MENTAL
Impression-Improvement	NOUN	O	I-MENTAL
,	PUNCT	O	O
which	ADP	O	O
focused	VERB	O	O
on	ADP	O	O
irritability	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
62.5	NUM	O	O
%	SYM	O	O
of	ADP	O	O
divalproex	PUNCT	O	O
subjects	NOUN	O	O
vs	CCONJ	O	O
9	NUM	O	O
%	SYM	O	O
of	ADP	O	O
placebo	NOUN	O	O
subjects	NOUN	O	O
were	VERB	O	O
responders	NOUN	O	B-MENTAL
(	PUNCT	O	O
CGI-irritability	NOUN	O	O
OR	CCONJ	O	O
:	PUNCT	O	O
16.7	NUM	O	O
,	PUNCT	O	O
Fisher	NOUN	O	O
's	PUNCT	O	O
exact	PUNCT	O	O
p=0.008	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
noted	VERB	O	O
on	ADP	O	O
the	DET	O	O
ABC-Irritability	NOUN	O	B-MENTAL
subscale	NOUN	O	I-MENTAL
(	PUNCT	O	O
p=0.048	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
for	ADP	O	O
responders	NOUN	O	O
to	PUNCT	O	O
have	PUNCT	O	O
higher	PUNCT	O	O
valproate	NOUN	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
nonresponders	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
suggests	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
divalproex	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
irritability	NOUN	O	B-MENTAL
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
.	PUNCT	O	O

Larger	PUNCT	O	O
sample	NOUN	O	O
follow-up	NOUN	O	O
studies	NOUN	O	O
are	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
MA-sensitive	ADJ	O	O
leukocyte	NOUN	O	O
chemotaxis	NOUN	O	O
in	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
double-blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
griseofulvin	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Polymorphonuclear	ADJ	O	O
leukocyte	NOUN	O	O
(	PUNCT	O	O
PMN	NOUN	O	O
)	PUNCT	O	O
chemotaxis	NOUN	O	O
is	VERB	O	O
thought	VERB	O	O
to	PART	O	O
play	NOUN	O	O
an	DET	O	O
essential	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

PMN	NOUN	O	O
chemotaxis	NOUN	O	O
is	VERB	O	O
in	ADP	O	O
part	NOUN	O	O
sensitive	ADJ	O	O
to	ADP	O	O
microtubule	NOUN	O	O
antagonists	NOUN	O	O
(	PUNCT	O	O
MAs	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
e.g	NUM	O	O
.	PUNCT	O	O

colchicine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
antimycotic	ADJ	O	O
antibiotic	ADJ	O	O
griseofulvin	NOUN	O	O
inhibits	NOUN	O	O
the	DET	O	O
MA-sensitive	ADJ	O	O
PMN	NOUN	O	O
chemotaxis	NOUN	O	O
in	VERB	O	O
vitro	ADJ	O	O
in	ADP	O	O
concentrations	NOUN	O	O
far	ADV	O	O
below	ADP	O	O
those	ADJ	O	O
obtained	VERB	O	O
in	ADP	O	O
serum	NOUN	O	O
during	ADP	O	O
antimycotic	VERB	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
MA-sensitive	ADJ	O	O
chemotaxis	NOUN	O	O
in	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
could	VERB	O	O
thus	ADV	O	O
be	PUNCT	O	O
elucidated	VERB	O	O
by	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
griseofulvin	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Griseofulvin	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
m	NOUN	O	O
=	SYM	O	O
19	NUM	O	O
)	PUNCT	O	O
during	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
of	ADP	O	O
mild-moderate	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
beneficial	ADJ	O	B-OTHER
effect	NOUN	O	O
of	ADP	O	O
griseofulvin	NOUN	O	O
treatment	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
on	ADP	O	O
clinical	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
laboratory	NOUN	O	I-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
of	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
placebo-treated	ADV	O	O
patients	NOUN	O	O
showed	VERB	O	O
more	DET	O	O
improvement	NOUN	O	B-OTHER
than	ADP	O	O
the	DET	O	O
griseofulvin-treated	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
therefore	ADV	O	O
suggested	ADP	O	O
that	ADP	O	O
the	DET	O	O
MA-sensitive	ADJ	O	O
chemotaxis	NOUN	O	O
plays	NOUN	O	O
a	DET	O	O
reparative	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
inflammatory	ADJ	O	O
lesions	NOUN	O	O
of	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

What	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
optimum	NOUN	O	O
maximal	ADJ	O	O
gonadotropin	NOUN	O	O
dosage	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
microdose	NOUN	O	O
flare-up	PUNCT	O	O
cycles	NOUN	O	O
in	ADP	O	O
poor	ADJ	O	O
responders	NOUN	O	O
?	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
find	SYM	O	O
out	DET	O	O
the	DET	O	O
optimum	NOUN	O	O
maximal	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
follicle	NOUN	O	O
stimulating	ADJ	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
rFSH	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
microdose	NOUN	O	O
gonadotropin-releasing	PUNCT	O	O
hormone	NOUN	O	O
analog	NOUN	O	O
(	PUNCT	O	O
GnRH-a	NOUN	O	O
)	PUNCT	O	O
flare	NOUN	O	O
cycles	NOUN	O	O
in	ADP	O	O
poor	ADJ	O	O
responders	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Private	ADJ	O	O
infertility	ADJ	O	O
clinic	NOUN	O	O
.	PUNCT	O	O

PATIENT	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
119	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
into	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
The	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
underwent	VERB	O	O
a	DET	O	O
microdose	NOUN	O	O
protocol	NOUN	O	O
with	ADP	O	O
a	DET	O	O
GnRH-agonist	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
rFSH	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
third	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
GnRH-a	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
119	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
in	ADP	O	O
three	DET	O	O
groups	NOUN	O	O
to	PART	O	O
receive	ADJ	O	O
daily	PUNCT	O	O
fixed	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
300	NUM	O	O
IU	NOUN	O	O
of	ADP	O	O
rFSH	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
38	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
450	NUM	O	O
IU	NOUN	O	O
of	ADP	O	O
rFSH	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
39	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
600	NUM	O	O
IU	NOUN	O	O
of	ADP	O	O
rFSH	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
42	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURE	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
Peak	NOUN	O	O
E	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
levels	NOUN	O	O
,	PUNCT	O	O
days	NOUN	O	O
of	ADP	O	B-ADVERSE-EFFECTS
stimulation	NOUN	O	O
with	ADP	O	O
rFSH	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
rFSH	NOUN	O	O
dosage	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
number	NOUN	O	B-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
oocytes	NOUN	O	I-ADVERSE-EFFECTS
retrieved	VERB	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
M2	NOUN	O	O
oocytes	NOUN	O	B-ADVERSE-EFFECTS
retrieved	VERB	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
total	ADJ	O	O
number	NOUN	O	B-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
embryos	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
number	NOUN	O	B-ADVERSE-EFFECTS
of	ADP	O	B-ADVERSE-EFFECTS
embryos	NOUN	O	I-ADVERSE-EFFECTS
transferred	VERB	O	O
,	PUNCT	O	O
number	NOUN	O	B-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
Grade-1	NOUN	O	O
embryos	NOUN	O	B-ADVERSE-EFFECTS
transferred	ADP	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
pregnancy	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
positive	ADJ	O	O
fetal	ADJ	O	O
cardiac	ADJ	O	O
activity	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cancellation	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	B-ADVERSE-EFFECTS
stimulation	NOUN	O	O
and	CCONJ	O	O
embryo	NOUN	O	O
transfer	NOUN	O	O
.	PUNCT	O	O

RESULT	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O

Parietal	ADJ	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
in	ADP	O	O
duodenal	ADJ	O	O
ulcer	NOUN	O	O
patients	NOUN	O	O
after	ADP	O	O
short-term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
cimetidine	NOUN	O	O
and	CCONJ	O	O
antacids	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
endoscopically	ADV	O	O
proven	VERB	O	O
duodenal	ADJ	O	O
ulcers	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
cimetidine	NOUN	O	O
1	NUM	O	O
g	ADP	O	O
daily	ADP	O	O
or	CCONJ	O	O
with	ADP	O	O
antacids	NOUN	O	O
350	NUM	O	O
mmol	NOUN	O	O
daily	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
30	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	ADP	O	O
was	NUM	O	O
extended	VERB	O	O
to	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cimetidine	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
antacid	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
morphological	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
biopsies	NOUN	O	O
taken	VERB	O	O
via	ADP	O	O
a	DET	O	O
gastroscope	NOUN	O	O
from	ADP	O	O
the	DET	O	O
corpus	ADJ	O	O
mucosa	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
mucosal	ADJ	O	B-PHYSICAL
height	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
parietal	ADJ	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
per	ADP	O	I-PHYSICAL
unit	NOUN	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
cellular	ADJ	O	B-PHYSICAL
infiltration	NOUN	O	I-PHYSICAL
after	ADP	O	O
30	NUM	O	O
and	CCONJ	O	O
90	NUM	O	O
days	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
H-2	NOUN	O	O
receptor	NOUN	O	O
blockers	NOUN	O	O
nor	CCONJ	O	O
antacids	NOUN	O	O
alter	VERB	O	O
mucosal	ADJ	O	B-PHYSICAL
height	ADJ	O	I-PHYSICAL
or	CCONJ	O	O
parietal	ADJ	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Treatment	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
found	VERB	O	O
to	PART	O	O
induce	NOUN	O	O
gastritic	ADJ	O	B-PHYSICAL
changes	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
mucosa	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
granulocyte/colony-stimulating	PUNCT	O	O
factor	NOUN	O	O
on	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
respiratory	ADJ	O	O
distress	NOUN	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
granulocyte/colony-stimulating	PUNCT	O	O
factor	NOUN	O	O
(	PUNCT	O	O
G-CSF	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
respiratory	ADJ	O	O
distress	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
ARDS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ARDS	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
pulmonary	CCONJ	O	O
infection	NOUN	O	O
differed	VERB	O	O
between	ADP	O	O
the	DET	O	O
G-CSF	NOUN	O	O
group	NOUN	O	O
which	ADP	O	O
received	VERB	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
G-CSF	NOUN	O	O
and	CCONJ	O	O
historical	ADJ	O	O
controls	NOUN	O	O
without	ADP	O	O
G-CSF	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
132	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
hematological	ADJ	O	O
malignancy	NOUN	O	O
in	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
without	ADP	O	O
any	DET	O	O
main	ADJ	O	O
organ	NOUN	O	O
dysfunction	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
been	PUNCT	O	O
treated	VERB	O	O
between	ADP	O	O
April	NOUN	O	O
1983	NUM	O	O
and	CCONJ	O	O
December	NOUN	O	O
1997	NUM	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ARDS	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
pulmonary	CCONJ	O	O
infection	NOUN	O	O
between	ADP	O	O
those	PUNCT	O	O
who	ADP	O	O
received	VERB	O	O
G-CSF	NOUN	O	O
and	CCONJ	O	O
those	ADP	O	O
who	PROPN	O	O
did	CCONJ	O	O
not	ADV	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
remarkable	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
gender	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
distribution	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
diseases	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	B-OTHER
was	VERB	O	O
not	ADV	O	O
considered	VERB	O	O
to	PUNCT	O	O
significantly	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
though	CCONJ	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
regimens	NOUN	O	O
administered	VERB	O	O
differed	VERB	O	O
slightly	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
G-CSF	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
neutropenia	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
shorter	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
documented	VERB	O	O
infection	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
decreased	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
could	ADP	O	O
not	ADV	O	O
find	VERB	O	O
any	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
ARDS	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
pulmonary	CCONJ	O	B-PHYSICAL
infection	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
any	DET	O	O
anticancer	NOUN	O	O
agent	NOUN	O	O
or	CCONJ	O	O
antibiotics	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
kind	ADV	O	O
of	ADP	O	O
G-CSF	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ARDS	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
pulmonary	CCONJ	O	B-PHYSICAL
infection	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
per	ADP	O	O
chemotherapy	NOUN	O	O
session	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.10	NUM	O	O
,	PUNCT	O	O
per	ADP	O	O
case	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.30	NUM	O	O
,	PUNCT	O	O
chi2	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ARDS	NOUN	O	B-PHYSICAL
due	PUNCT	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
pulmonary	CCONJ	O	I-PHYSICAL
infection	NOUN	O	I-PHYSICAL
per	ADP	O	I-PHYSICAL
chemotherapy	NOUN	O	I-PHYSICAL
session	NOUN	O	I-PHYSICAL
was	VERB	O	O
4.21	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
showed	VERB	O	O
a	DET	O	O
higher	PUNCT	O	O
tendency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
G-CSF	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.100	DET	O	O
,	PUNCT	O	O
chi2	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ARDS	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
pulmonary	CCONJ	O	O
infection	NOUN	O	O
per	ADP	O	O
case	NOUN	O	O
was	VERB	O	O
25.4	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
G-CSF	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.025	NUM	O	O
,	PUNCT	O	O
chi2	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ARDS	NOUN	O	B-PHYSICAL
due	PUNCT	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
pulmonary	CCONJ	O	I-PHYSICAL
infection	NOUN	O	I-PHYSICAL
was	VERB	O	I-PHYSICAL
higher	PUNCT	O	O
in	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
G-CSF	PUNCT	O	I-PHYSICAL

Twenty-four	PUNCT	O	O
vs.	CCONJ	O	O
forty-eight	PUNCT	O	O
weeks	NOUN	O	O
of	ADP	O	O
re-therapy	NOUN	O	O
with	ADP	O	O
interferon	NOUN	O	O
alpha	NOUN	O	O
2b	NOUN	O	O
and	CCONJ	O	O
ribavirin	NOUN	O	O
in	ADP	O	O
interferon	NOUN	O	O
alpha	NOUN	O	O
monotherapy	NOUN	O	O
relapsers	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
C.	NOUN	O	O
BACKGROUND/AIM	NUM	O	O
Roughly	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
relapsed	VERB	O	O
after	ADP	O	O
a	DET	O	O
previous	ADJ	O	O
monotherapy	NOUN	O	O
with	ADP	O	O
interferon	NOUN	O	O
alpha	NOUN	O	O
,	PUNCT	O	O
will	VERB	O	O
respond	VERB	O	O
in	ADP	O	O
a	DET	O	O
sustained	VERB	O	O
fashion	NOUN	O	O
to	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
re-therapy	NOUN	O	O
with	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
interferon	NOUN	O	O
alpha	NOUN	O	O
plus	CCONJ	O	O
ribavirin	NOUN	O	O
.	PUNCT	O	O

Whether	VERB	O	O
prolonging	ADV	O	O
treatment	NOUN	O	O
duration	NOUN	O	O
to	ADP	O	O
48	NUM	O	O
weeks	NOUN	O	O
will	ADP	O	O
further	PUNCT	O	O
increase	NUM	O	O
sustained	PUNCT	O	O
response	NOUN	O	O
rates	NOUN	O	O
remains	NOUN	O	O
ill	ADJ	O	O
defined	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
randomised	VERB	O	O
controlled	DET	O	O
pilot	NOUN	O	O
trial	NOUN	O	O
we	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
a	DET	O	O
24	NUM	O	O
week	NOUN	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
48	NUM	O	O
week	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
interferon	NOUN	O	O
alpha	NOUN	O	O
and	CCONJ	O	O
ribavirin	NOUN	O	O
in	ADP	O	O
interferon	NOUN	O	O
monotherapy	NOUN	O	O
relapsers	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
C.	NOUN	O	O
METHODS	NOUN	O	O
Interferon	NOUN	O	O
alpha	NOUN	O	O
monotherapy	NOUN	O	O
relapsers	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	O
C	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	PART	O	O
interferon	NOUN	O	O
alpha	NOUN	O	O
2b	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
x	SYM	O	O
3	NUM	O	O
MIU	NOUN	O	O
sc	PUNCT	O	O
weekly	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
oral	ADJ	O	O
ribavirin	NOUN	O	O
(	PUNCT	O	O
1000/1200	NOUN	O	O
mg	NOUN	O	O
po	ADP	O	O
daily	ADP	O	O
)	PUNCT	O	O
for	ADP	O	O
either	CCONJ	O	O
24	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
48	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Virological	ADJ	O	O
response	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
HCV	NOUN	O	O
RNA	NOUN	O	O
PCR	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
10	NUM	O	O
(	PUNCT	O	O
initial	ADJ	O	O
response	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
end	NOUN	O	O
of-	NOUN	O	O
treatment	NOUN	O	O
response	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
sustained	PUNCT	O	O
response	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Only	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
negative	ADJ	O	O
HCV	NOUN	O	O
RNA	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
10	NUM	O	O
continued	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
recorded	VERB	O	O
at	ADP	O	O
regular	ADJ	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-seven	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
19	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
females	NOUN	O	O
,	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
43	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
24	NUM	O	O
week	NOUN	O	O
and	CCONJ	O	O
18	NUM	O	O
(	PUNCT	O	O
5	NUM	O	O
females	NOUN	O	O
,	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
40	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
48	NUM	O	O
week	NOUN	O	O
treatment	NOUN	O	O
arm	ADP	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
characteristics	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
treatment	NOUN	O	O
week	NOUN	O	O
10	NUM	O	O
,	PUNCT	O	O
12/19	PUNCT	O	O
(	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
24	NUM	O	O
week	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
14/18	PUNCT	O	O
(	PUNCT	O	O
78	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
48	NUM	O	O
week	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
lost	ADJ	O	B-PHYSICAL
HCV	NOUN	O	I-PHYSICAL
RNA	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
serum	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.33	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
initial	ADJ	O	O
responders	NOUN	O	O
remained	VERB	O	O
HCV	NOUN	O	B-PHYSICAL
RNA	NOUN	O	I-PHYSICAL
negative	ADJ	O	O
throughout	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Sustained	VERB	O	B-OTHER
response	NOUN	O	O
rates	NOUN	O	B-OTHER
were	ADP	O	O
10/19	PUNCT	O	O
(	PUNCT	O	O
53	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
24	NUM	O	O
week	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
13/18	PUNCT	O	O
(	PUNCT	O	O
72	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
48	NUM	O	O
week	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.31	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
discontinued	CCONJ	O	O
treatment	NOUN	O	O
early	ADJ	O	O
(	PUNCT	O	O
two	NUM	O	O
due	PUNCT	O	O
to	ADP	O	O
moderate	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
one	NUM	O	O
due	PUNCT	O	O
to	ADP	O	O
non-compliance	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Dose	NOUN	O	O
modifications	NOUN	O	O
were	ADP	O	O
necessary	ADJ	O	O
in	ADP	O	O
9	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
in	ADP	O	O
the	DET	O	O
24	NUM	O	O
week	NOUN	O	O
and	CCONJ	O	O
5	NUM	O	O
in	ADP	O	O
the	DET	O	O
48	NUM	O	O
week	NOUN	O	O
group	NOUN	O	O
for	ADP	O	O
anaemia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
neutropenia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
Ginkgo	NOUN	O	O
biloba	NOUN	O	O
added	VERB	O	O
to	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Ginkgo	NOUN	O	O
biloba	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
to	PART	O	O
affect	VERB	O	O
the	DET	O	O
neurotransmitter	NOUN	O	O
system	NOUN	O	O
and	CCONJ	O	O
to	PRON	O	O
have	PUNCT	O	O
antioxidant	NOUN	O	O
properties	NOUN	O	O
that	NUM	O	O
could	ADJ	O	O
impact	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
Autism	NOUN	O	O
Spectrum	NOUN	O	O
Disorder	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
decided	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
Ginkgo	NOUN	O	O
biloba	NOUN	O	O
extract	NOUN	O	O
(	PUNCT	O	O
Ginko	NOUN	O	O
T.D.	NOUN	O	O
,	PUNCT	O	O
Tolidaru	NOUN	O	O
,	PUNCT	O	O
Iran	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
adjunctive	ADJ	O	O
agent	NOUN	O	O
to	ADP	O	O
risperidone	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Forty-seven	NUM	O	O
outpatients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
DSM-IV-TR	NOUN	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
ages	NOUN	O	O
between	ADP	O	O
4	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
years	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
this	CCONJ	O	O
double	ADJ	O	O
blinded	ADP	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
group	NOUN	O	O
received	VERB	O	O
risperidone	NUM	O	O
plus	CCONJ	O	O
Ginko	NOUN	O	O
T.D	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
received	ADP	O	O
risperidone	ADP	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
was	VERB	O	O
1-3	NUM	O	O
mg/day	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
Ginko	NOUN	O	O
T.D	NOUN	O	O
.	PUNCT	O	O

was	VERB	O	O
80	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
under	ADP	O	O
30	NUM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
120	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
above	ADP	O	O
30	NUM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
using	SYM	O	O
Aberrant	ADJ	O	B-MENTAL
Behavior	NOUN	O	I-MENTAL
Checklist-Community	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
ABC-C	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
rating	ADP	O	I-MENTAL
scale	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
side	NOUN	O	B-MENTAL
effect	NOUN	O	O
check	ADV	O	B-MENTAL
list	NOUN	O	B-MENTAL
every	DET	O	O
2	NUM	O	O
weeks	NOUN	O	O
until	ADP	O	O
the	DET	O	O
endpoint	NOUN	O	O
.	PUNCT	O	O

None	NUM	O	O
of	ADP	O	O
the	DET	O	O
5	NUM	O	O
subscales	NOUN	O	O
of	ADP	O	O
ABC-C	NOUN	O	B-MENTAL
rating	PUNCT	O	I-MENTAL

Symptomatic	ADJ	O	O
and	CCONJ	O	O
functional	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
employed	PUNCT	O	O
depressed	VERB	O	O
patients	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
desvenlafaxine	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
desvenlafaxine	NOUN	O	O
(	PUNCT	O	O
administered	ADP	O	O
as	ADP	O	O
desvenlafaxine	NOUN	O	O
succinate	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
improving	VERB	O	O
depressive	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
and	CCONJ	O	O
functioning	SYM	O	B-MENTAL
exclusively	ADV	O	O
in	ADP	O	O
employed	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
major	ADJ	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
MDD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Gainfully	ADP	O	O
employed	VERB	O	O
(	PUNCT	O	O
?20	PUNCT	O	O
h/wk	NOUN	O	O
)	PUNCT	O	O
male	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
outpatients	ADJ	O	O
with	ADP	O	O
MDD	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
(	PUNCT	O	O
2:1	NUM	O	O
ratio	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
double-blind	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
desvenlafaxine	NOUN	O	O
50	NUM	O	O
mg/d	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
covariance	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
week	NOUN	O	O
12	NUM	O	O
adjusted	VERB	O	O
mean	NOUN	O	O
changes	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
on	ADP	O	O
the	DET	O	O
17-item	NOUN	O	O
Hamilton	PUNCT	O	O
Depression	NOUN	O	O
Rating	PUNCT	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
HAM-D??	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Sheehan	PUNCT	O	O
Disability	NOUN	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
SDS	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
key	ADJ	O	O
secondary	ADJ	O	O
outcome	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
intent-to-treat	NOUN	O	O
(	PUNCT	O	O
ITT	NOUN	O	O
)	PUNCT	O	O
population	NOUN	O	O
.	PUNCT	O	O

A	PUNCT	O	O
predefined	VERB	O	O
,	PUNCT	O	O
modified	VERB	O	O
ITT	NOUN	O	O
population	NOUN	O	O
(	PUNCT	O	O
ie	ADP	O	O
,	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ITT	NOUN	O	O
population	NOUN	O	O
with	ADP	O	O
baseline	NOUN	O	O
HAM-D??	ADV	O	O
?20	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

Tolerability	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
recording	ADV	O	O
adverse	ADJ	O	O
events	NOUN	O	O
and	CCONJ	O	O
change	ADP	O	O
on	ADP	O	O
the	DET	O	O
Arizona	NOUN	O	O
Sexual	ADJ	O	O
Experience	NOUN	O	O
Scale	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Baseline	NOUN	O	O
HAM-D??	ADP	O	O
scores	NOUN	O	O
for	ADP	O	O
desvenlafaxine	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
285	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
142	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
22.0	NUM	O	O
and	CCONJ	O	O
21.8	NUM	O	O
,	PUNCT	O	O
whereas	ADP	O	O
baseline	NOUN	O	O
SDS	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
19.8	NUM	O	O
and	CCONJ	O	O
20.4	NUM	O	O
.	PUNCT	O	O

Adjusted	VERB	O	O
mean	NOUN	O	O
differences	NOUN	O	O
between	ADP	O	O
desvenlafaxine	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
were	VERB	O	O
2.1	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
0.78-3.46	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
HAM-D??	NOUN	O	O
and	CCONJ	O	O
1.3	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
-0.09	ADJ	O	O
to	ADP	O	O
2.76	ADJ	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.067	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
SDS	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
modified	VERB	O	O
ITT	NOUN	O	O
sample	NOUN	O	O
,	PUNCT	O	O
desvenlafaxine	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
208	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
102	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
baseline	NOUN	O	O
HAM-D??	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
23.8	NUM	O	O
and	CCONJ	O	O
23.9	NUM	O	O
;	PUNCT	O	O
the	DET	O	O
SDS	NOUN	O	O
baseline	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
20.1	NUM	O	O
and	CCONJ	O	O
20.8	NUM	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
differences	NOUN	O	O
were	VERB	O	O
2.6	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
0.93-4.22	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
HAM-D??	NOUN	O	O
and	CCONJ	O	O
2.1	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
0.36-3.76	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.017	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
SDS	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
events	NOUN	O	O
and	CCONJ	O	O
Arizona	NOUN	O	O
Sexual	ADJ	O	O
Experience	NOUN	O	O
Scale	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Desvenlafaxine	NOUN	O	O
50	NUM	O	O
mg/d	ADV	O	O
was	VERB	O	O
efficacious	ADJ	O	O
for	ADP	O	O
treating	VERB	O	O
MDD	NOUN	O	O
in	ADP	O	O
gainfully	ADV	O	O
employed	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Between-group	ADP	O	O
differences	NOUN	O	O
on	ADP	O	O
the	DET	O	O
SDS	NOUN	O	O
narrowly	ADV	O	O
missed	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ITT	NOUN	O	O
population	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
totality	NOUN	O	O
of	ADP	O	O
data	NOUN	O	O
suggests	NOUN	O	O
functional	ADJ	O	O
improvements	NOUN	O	O
with	ADP	O	O
active	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Clonidine	NOUN	O	O
premedication	NOUN	O	O
improves	NOUN	O	O
metabolic	ADJ	O	B-PHYSICAL
control	NOUN	O	O
in	ADP	O	B-PHYSICAL
type	NOUN	O	O
2	NUM	O	B-PHYSICAL
diabetic	ADJ	O	B-PHYSICAL
patients	NOUN	O	I-PHYSICAL
during	ADP	O	O
ophthalmic	VERB	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
In	ADP	O	O
stressful	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
increasing	ADP	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
concentrations	NOUN	O	O
are	VERB	O	O
closely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
catecholamines	NOUN	O	O
and	CCONJ	O	O
cortisol	NOUN	O	O
release	NOUN	O	O
.	PUNCT	O	O

Clonidine	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
centrally	ADV	O	O
acting	VERB	O	O
alpha	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
-adrenoceptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
has	PUNCT	O	O
neuroendocrine	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
inhibition	NOUN	O	O
of	ADP	O	O
sympathoadrenal	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	O
on	ADP	O	O
blood	NOUN	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
control	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
insulin	NOUN	O	B-PHYSICAL
requirements	NOUN	O	B-PHYSICAL
during	ADP	O	O
ophthalmic	VERB	O	O
surgery	NOUN	O	O
when	ADP	O	O
given	VERB	O	O
as	ADP	O	O
premedication	NOUN	O	O
in	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetic	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
After	ADP	O	O
randomization	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
premedicated	VERB	O	O
with	ADP	O	O
clonidine	NOUN	O	O
or	CCONJ	O	O
flunitrazepam	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
insulin	NOUN	O	O
by	ADP	O	O
continuous	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

infusion	NOUN	O	O
to	PART	O	O
maintain	NOUN	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
in	ADP	O	O
the	DET	O	O
range	NOUN	O	O
5.5-11.1	PUNCT	O	O
mmol	NOUN	O	O
litre	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
glucose	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	ADP	O	O
every	DET	O	O
15	NUM	O	O
min	NOUN	O	O
during	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hourly	PROPN	O	O
for	ADP	O	O
6	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
C-peptide	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
counter-regulatory	ADJ	O	B-PHYSICAL
hormones	NOUN	O	I-PHYSICAL
were	VERB	O	O
also	ADV	O	O
measured	VERB	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Glycaemia	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
clonidine	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
median	ADJ	O	O
amount	NOUN	O	O
of	PUNCT	O	O

Levamisole	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
primary	ADJ	O	O
therapy	NOUN	O	O
of	ADP	O	O
laryngopharyngeal	PUNCT	O	O
epidermoid	NOUN	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
immune	ADJ	O	O
status	NOUN	O	O
.	PUNCT	O	O

Twenty-four	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
biopsy-proven	PUNCT	O	O
laryngeal	ADJ	O	O
or	CCONJ	O	O
hypopharyngeal	ADJ	O	O
carcinoma	NOUN	O	O
,	PUNCT	O	O
received	ADV	O	O
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
primary	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
surgery	NOUN	O	O
and/or	CCONJ	O	O
radiotherapy	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
levamisole	NOUN	O	O
(	PUNCT	O	O
150	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
during	ADP	O	O
three	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
,	PUNCT	O	O
every	DET	O	O
fortnight	ADV	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
following	CCONJ	O	O
a	DET	O	O
single-blind	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
randomized	VERB	O	O
method	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
investigation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
immune	ADJ	O	B-PHYSICAL
status	NOUN	O	O
was	VERB	O	O
done	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
healthy	ADJ	O	O
control-group	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
the	DET	O	O
immunity	NOUN	O	B-PHYSICAL
is	VERB	O	O
disturbed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
laryngo-pharyngeal	PUNCT	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
that	ADP	O	O
this	DET	O	O
disturbance	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
clearly	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
state	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
immunological	ADJ	O	O
measures	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
appear	VERB	O	O
relevant	ADJ	O	O
to	ADP	O	O
the	DET	O	O
significantly	ADV	O	O
favourable	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
levamisole	NOUN	O	O
on	ADP	O	O
the	DET	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

Ganitumab	PUNCT	O	O
with	ADP	O	O
either	CCONJ	O	O
exemestane	NOUN	O	O
or	CCONJ	O	O
fulvestrant	PUNCT	O	O
for	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
,	PUNCT	O	O
hormone-receptor-positive	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
phase	NOUN	O	O
2	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Insulin-like	ADJ	O	O
growth	NOUN	O	O
factors	NOUN	O	O
(	PUNCT	O	O
IGF-1	NOUN	O	O
and	CCONJ	O	O
IGF-2	NOUN	O	O
)	PUNCT	O	O
bind	VERB	O	O
to	ADP	O	O
the	DET	O	O
IGF-1	NOUN	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
IGF-1R	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
increasing	PUNCT	O	O
cell	NOUN	O	B-PHYSICAL
proliferation	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
survival	NOUN	O	B-MORTALITY
.	PUNCT	O	O

Ganitumab	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
monoclonal	ADJ	O	O
IgG1	NOUN	O	O
antibody	NOUN	O	O
that	ADP	O	O
blocks	PUNCT	O	O
IGF-1R	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
adding	VERB	O	O
ganitumab	PUNCT	O	O
to	ADP	O	O
endocrine	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hormone-receptor-positive	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	ADJ	O	O
did	VERB	O	O
this	DET	O	O
phase	NOUN	O	O
2	NUM	O	O
trial	NOUN	O	O
in	ADP	O	O
outpatient	ADJ	O	O
clinics	ADP	O	O
and	CCONJ	O	O
hospitals	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
enrolled	VERB	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
hormone-receptor-positive	ADJ	O	O
,	PUNCT	O	O
locally	ADV	O	O
advanced	VERB	O	O
or	CCONJ	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
endocrine	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
(	PUNCT	O	O
2:1	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
central	ADJ	O	O
randomisation	NOUN	O	O
schedule	NOUN	O	O
to	PUNCT	O	O
receive	NOUN	O	O
intravenous	ADJ	O	O
ganitumab	PUNCT	O	O
12	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
kg	NOUN	O	O
bodyweight	ADJ	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
open-label	NOUN	O	O
intramuscular	ADJ	O	O
fulvestrant	PUNCT	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
then	ADV	O	O
250	NUM	O	O
mg	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
15	NUM	O	O
,	PUNCT	O	O
29	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
oral	ADJ	O	O
exemestane	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
a	DET	O	O
28-day	NOUN	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
,	PUNCT	O	O
investigators	NOUN	O	O
,	PUNCT	O	O
study	VERB	O	O
monitors	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
sponsor	NOUN	O	O
staff	NOUN	O	O
were	VERB	O	O
masked	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
allocation	NOUN	O	O
.	PUNCT	O	O

Response	NOUN	O	O
was	VERB	O	O
assessed	ADJ	O	O
every	DET	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
median	ADJ	O	O
progression-free	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
intention-to-treat	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
analysed	VERB	O	O
overall	ADP	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
as	ADP	O	O
one	NUM	O	O
of	ADP	O	O
our	CCONJ	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
is	VERB	O	O
registered	NOUN	O	O
at	ADP	O	O
ClinicalTrials.gov	PUNCT	O	O
,	PUNCT	O	O
number	NOUN	O	O
NCT00626106	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
We	NOUN	O	O
screened	VERB	O	O
189	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
enrolled	VERB	O	O
156	NUM	O	O
(	PUNCT	O	O
106	NUM	O	O
in	ADP	O	O
the	DET	O	O
ganitumab	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
50	NUM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Median	ADJ	O	O
progression-free	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
the	DET	O	O
ganitumab	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
3?9	PUNCT	O	O
months	NOUN	O	O
,	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
3?6-5?3	ADJ	O	O
vs	CCONJ	O	O
5?7	NOUN	O	O
months	NOUN	O	O
,	PUNCT	O	O
4?4-7?4	NOUN	O	O
;	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
[	PUNCT	O	O
HR	NOUN	O	O
]	PUNCT	O	O
1?17	PUNCT	O	O
,	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0?91-1?50	PUNCT	O	O
;	PUNCT	O	O
p=0?44	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
overall	ADJ	O	O
survival	NOUN	O	O
was	VERB	O	O
worse	ADJ	O	O
in	ADP	O	O
the	DET	O	O
the	DET	O	O
ganitumab	PUNCT	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
1?78	PUNCT	O	O
,	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1?27-2?50	NOUN	O	O
;	PUNCT	O	O
p=0?025	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

With	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
hyperglycaemia	NOUN	O	O
,	PUNCT	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
generally	ADV	O	O
similar	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	PUNCT	O	O
common	ADJ	O	O
grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
higher	PUNCT	O	O
adverse	ADJ	O	O
event	NOUN	O	O
was	VERB	O	O
neutropenia-reported	VERB	O	O
by	ADP	O	O
six	NUM	O	O
of	ADP	O	O
106	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ganitumab	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
of	ADP	O	O
49	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Hyperglycaemia	NOUN	O	O
was	VERB	O	O
reported	VERB	O	O
by	ADP	O	O
12	NUM	O	O
of	ADP	O	O
106	NUM	O	O
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ganitumab	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
six	NUM	O	O
patients	NOUN	O	O
having	VERB	O	O
grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
4	NUM	O	O
hyperglycaemia	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
none	NUM	O	O
of	ADP	O	O
49	NUM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
by	ADP	O	O
27	NUM	O	O
of	ADP	O	O
106	NUM	O	O
(	PUNCT	O	O
25	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ganitumab	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
nine	NUM	O	O
of	ADP	O	O
49	NUM	O	O
(	PUNCT	O	O
18	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
Addition	NOUN	O	O
of	ADP	O	O
ganitumab	PUNCT	O	O
to	ADP	O	O
endocrine	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
previously	ADV	O	O
treated	PUNCT	O	O
hormone-receptor-positive	PUNCT	O	O
locally	ADV	O	O
advanced	VERB	O	O
or	CCONJ	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
improve	VERB	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
support	VERB	O	O
further	DET	O	O
study	NOUN	O	O
of	ADP	O	O
ganitumab	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

FUNDING	PUNCT	O	O
Amgen	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
routine	ADJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
lowering	ADJ	O	I-PHYSICAL
in	ADP	O	O
older	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
:	PUNCT	O	O
results	DET	O	O
from	ADP	O	O
the	DET	O	O
ADVANCE	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
lowering	ADJ	O	I-PHYSICAL
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
have	CCONJ	O	O
not	ADV	O	O
been	PUNCT	O	O
sufficiently	ADV	O	O
investigated	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Action	NOUN	O	O
in	ADP	O	O
Diabetes	NOUN	O	O
and	CCONJ	O	O
Vascular	ADJ	O	O
disease	NOUN	O	O
:	PUNCT	O	O
preterAx	NOUN	O	O
and	CCONJ	O	O
diamicroN-MR	ADJ	O	O
Controlled	VERB	O	O
Evaluation	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
routine	ADJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
lowering	ADJ	O	I-PHYSICAL
to	PART	O	O
prevent	NOUN	O	O
major	ADJ	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Eleven	ADP	O	O
thousand	CCONJ	O	O
one	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
forty	NUM	O	O
patients	NOUN	O	O
aged	VERB	O	O
at	DET	O	O
least	ADV	O	O
55	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
66+/-6	NOUN	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
perindopril-indapamide	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
a	DET	O	O
composite	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
major	ADJ	O	I-PHYSICAL
macrovascular	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
microvascular	ADJ	O	B-PHYSICAL
disease	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
active	ADJ	O	O
treatment	NOUN	O	O
on	ADP	O	O
outcomes	NOUN	O	O
were	VERB	O	O
estimated	VERB	O	O
in	ADP	O	O
subgroups	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
age	NOUN	O	O
:	PUNCT	O	O
below	ADP	O	O
65	NUM	O	O
,	PUNCT	O	O
65-74	NUM	O	O
and	CCONJ	O	O
at	ADP	O	O
least	ADV	O	O
75	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
During	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
4.3-year	NOUN	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
1799	NUM	O	O
(	PUNCT	O	O
16.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
major	ADJ	O	O
event	NOUN	O	O
.	PUNCT	O	O

Active	ADJ	O	O
treatment	NOUN	O	O
produced	ADP	O	O
similar	ADJ	O	O
relative	ADJ	O	O
risk	NOUN	O	O
reductions	NOUN	O	B-PHYSICAL
for	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
,	PUNCT	O	O
major	ADJ	O	B-PHYSICAL
macrovascular	ADJ	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
death	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
renal	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
across	ADP	O	O
age	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
heterogeneity	NOUN	O	O
>	SYM	O	O
0.3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Over	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
active	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
estimated	VERB	O	O
to	ADJ	O	O
prevent	ADJ	O	O
one	NUM	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
every	DET	O	O
21	NUM	O	O
,	PUNCT	O	O
71	NUM	O	O
and	CCONJ	O	O
118	NUM	O	O
patients	NOUN	O	O
of	ADP	O	O
at	ADP	O	O
least	ADV	O	O
75	NUM	O	O
,	PUNCT	O	O
65-74	NUM	O	O
and	CCONJ	O	O
below	ADP	O	O
65	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
patterns	NOUN	O	O
of	ADP	O	O
benefits	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
secondary	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
tolerability	NOUN	O	B-OTHER
between	ADP	O	O
randomized	VERB	O	O
allocations	NOUN	O	O
across	ADP	O	O
age	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
heterogeneity	NOUN	O	O
>	SYM	O	O
0.6	NUM	O	O
)	PUNCT	O	O
CONCLUSION	NOUN	O	O
Routine	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
perindopril-indapamide	NOUN	O	O
lowers	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
safely	ADV	O	O
and	CCONJ	O	O
reduces	NOUN	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
at	ADP	O	O
least	ADV	O	O
75	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
greater	PUNCT	O	O
absolute	ADJ	O	O
benefits	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
this	DET	O	O
age	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
offset	PUNCT	O	O
by	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Benzodiazepine	ADV	O	O
and	CCONJ	O	O
opioid	NOUN	O	O
sedation	NOUN	O	O
attenuate	VERB	O	O
the	DET	O	O
sympathetic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
fiberoptic	ADJ	O	B-OTHER
bronchoscopy	NOUN	O	I-OTHER
.	PUNCT	O	O

Prophylactic	ADJ	O	O
labetalol	NOUN	O	O
gave	VERB	O	O
no	DET	O	O
additional	ADJ	O	O
benefit	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Hypertension	NOUN	O	O
and	CCONJ	O	O
tachycardia	NOUN	O	O
are	VERB	O	O
common	ADJ	O	O
during	ADP	O	O
fiber-optic	ADJ	O	O
bronchoscopy	NOUN	O	O
(	PUNCT	O	O
FOB	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
this	PUNCT	O	O
may	VERB	O	O
lead	PUNCT	O	O
to	ADP	O	O
cardiac	ADJ	O	O
ischemia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prophylactic	ADJ	O	O
addition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
beta-adrenergic	ADJ	O	O
anatagonist	ADJ	O	O
might	PUNCT	O	O
mask	PUNCT	O	O
this	DET	O	O
response	NOUN	O	O
and	CCONJ	O	O
prevent	VERB	O	O
the	DET	O	O
deleterious	ADJ	O	O
cardiovascular	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
FOB	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
labetalol	NOUN	O	O
10mg	NOUN	O	O
iv	PUNCT	O	O
given	VERB	O	O
with	ADP	O	O
midazolam-alfentanil	PUNCT	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
monitored	VERB	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
HR	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
systolic/diastolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
SBP/DBP	ADP	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
throughout	ADP	O	O
the	DET	O	O
bronchoscopy	NOUN	O	O
and	CCONJ	O	O
calculated	PUNCT	O	O
the	DET	O	O
rate-pressure	NOUN	O	O
product	NOUN	O	O
(	PUNCT	O	O
RPP=	NOUN	O	O
(	PUNCT	O	O
HRxSBP	NOUN	O	O
)	PUNCT	O	O
/100	VERB	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One-hundred	PUNCT	O	O
twenty	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
HR	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
SBP	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
DBP	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
RPP	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
labetalol	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
during	ADP	O	I-ADVERSE-EFFECTS
bronchoscopy	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
undergoing	ADP	O	O
interventional	ADJ	O	O
bronchoscopy	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
towards	ADP	O	O
lower	PUNCT	O	O
SBP	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
p=0.06	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	DET	O	O
Patients	NOUN	O	O
undergoing	VERB	O	O
FOB	NOUN	O	O
under	ADP	O	O
adequate	ADJ	O	O
midazolam-alfentanil	ADJ	O	O
sedation	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
develop	VERB	O	O
excessive	ADJ	O	O
sympathetic	ADJ	O	O
drive	ADJ	O	O
that	ADP	O	O
may	VERB	O	O
lead	PUNCT	O	O
to	ADP	O	O
cardiac	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
labetalol	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
confer	VERB	O	O
additional	ADJ	O	O
benefit	NOUN	O	O
or	CCONJ	O	O
risk	NOUN	O	O
to	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ClinicalTrials.gov	PUNCT	O	O
number	NOUN	O	O
,	PUNCT	O	O
NCT00394537	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Sodium-potassium	NOUN	O	O
pump	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
white	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
from	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
hypertension	NOUN	O	O
--	PUNCT	O	O
The	DET	O	O
Odense	NOUN	O	O
Schoolchild	NOUN	O	O
Study	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
measured	VERB	O	O
the	DET	O	O
capacity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sodium-potassium	NOUN	O	O
pump	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
86rubidium	ADV	O	O
uptake	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	O
3H	NOUN	O	O
]	PUNCT	O	O
-ouabain	ADJ	O	O
binding	VERB	O	O
sites	NOUN	O	O
on	ADP	O	O
white	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
children	ADJ	O	O
aged	PROPN	O	O
9-11	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
partly	ADV	O	O
cross-sectionally	ADV	O	O
and	CCONJ	O	O
partly	ADV	O	O
longitudinally	ADV	O	O
after	ADP	O	O
a	DET	O	O
physical	ADJ	O	O
training	DET	O	O
programme	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
from	ADP	O	O
a	DET	O	O
hypertensive	ADJ	O	O
subgroup	NOUN	O	O
comprising	SYM	O	O
the	DET	O	O
upper	ADJ	O	O
5	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
distribution	NOUN	O	O
and	CCONJ	O	O
children	NOUN	O	O
from	ADP	O	O
a	DET	O	O
randomly	ADV	O	O
selected	ADP	O	O
normotensive	ADJ	O	O
subgroup	NOUN	O	O
were	VERB	O	O
eligible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
cross-sectional	ADJ	O	O
study	NOUN	O	O
40	NUM	O	O
children	NOUN	O	O
from	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	O
subgroup	NOUN	O	O
and	CCONJ	O	O
40	NUM	O	O
children	NOUN	O	O
from	ADP	O	O
the	DET	O	O
normotensive	ADJ	O	O
subgroup	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
86rubidium	ADP	O	B-PHYSICAL
uptake	NOUN	O	I-PHYSICAL
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
boys	NOUN	O	O
as	CCONJ	O	O
compared	VERB	O	O
to	ADP	O	O
girls	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
sexual	ADJ	O	O
maturation	NOUN	O	O
the	DET	O	O
observed	VERB	O	O
significant	ADJ	O	O
difference	NOUN	O	O
disappeared	NOUN	O	O
.	PUNCT	O	O

Important	ADJ	O	O
correlates	PUNCT	O	O
of	ADP	O	O
pump	NOUN	O	O
activity	NOUN	O	O
were	VERB	O	O
height	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
glucose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	O
fitness	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
training	PUNCT	O	O
study	NOUN	O	O
10	NUM	O	O
boys	NOUN	O	O
from	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	O
subgroup	NOUN	O	O
and	CCONJ	O	O
10	NUM	O	O
boys	NOUN	O	O
from	ADP	O	O
the	DET	O	O
normotensive	ADJ	O	O
subgroup	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
evaluated	VERB	O	O
after	ADP	O	O
eight	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
training	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
86rubidium	ADP	O	B-PHYSICAL
uptake	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
and	CCONJ	O	O
probably	ADV	O	O
the	DET	O	O
changes	NOUN	O	O
reflect	VERB	O	O
some	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	B-PHYSICAL
maturation	NOUN	O	I-PHYSICAL
on	ADP	O	I-PHYSICAL
cation	NOUN	O	I-PHYSICAL
handling	ADJ	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	B-PHYSICAL
maturation	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
capacity	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
sodium-potassium	NOUN	O	I-PHYSICAL
pump	NOUN	O	I-PHYSICAL
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Perioperative	PUNCT	O	O
immunotherapy	NOUN	O	O
with	ADP	O	O
recombinant	ADJ	O	O
interleukin	NOUN	O	O
2	NUM	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
surgery	NOUN	O	O
for	ADP	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Major	ADJ	O	O
surgery	NOUN	O	O
impairs	VERB	O	O
the	DET	O	O
cellular	ADJ	O	O
immune	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	PUNCT	O	O
therefore	ADV	O	O
studied	ADP	O	O
the	DET	O	O
immunological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
low-dose	NOUN	O	O
recombinant	ADJ	O	O
interleukin	NOUN	O	O
2	NUM	O	O
given	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
surgery	NOUN	O	O
for	ADP	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
has	PUNCT	O	O
potential	ADP	O	O
in	ADP	O	O
perioperative	ADJ	O	O
adjuvant	NOUN	O	O
immunotherapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PUNCT	O	O
control	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
13	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Immunological	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
both	PUNCT	O	O
lymphocyte	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
subset	NOUN	O	O
number	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
preoperatively	ADV	O	O
and	CCONJ	O	O
on	ADP	O	O
Days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
recombinant	ADJ	O	O
interleukin	NOUN	O	O
2	NUM	O	O
prevented	VERB	O	O
the	DET	O	O
postoperative	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
natural	ADJ	O	B-PHYSICAL
killer	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
lymphokine-activated	VERB	O	B-PHYSICAL
killer	NOUN	O	I-PHYSICAL
cell	NOUN	O	I-PHYSICAL
cytotoxicity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
clearly	ADV	O	O
demonstrated	VERB	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
in	ADP	O	O
vivo	ADP	O	B-PHYSICAL
T-cell	NOUN	O	I-PHYSICAL
activation	NOUN	O	I-PHYSICAL
with	ADP	O	O
an	DET	O	O
initial	ADJ	O	O
lymphopenia	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
rebound	NOUN	O	B-PHYSICAL
lymphocytosis	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
upregulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
subset	NOUN	O	B-PHYSICAL
markers	NOUN	O	I-PHYSICAL
CD25	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
interleukin	NOUN	O	B-PHYSICAL
2	NUM	O	I-PHYSICAL
receptor	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	O
CD45RO	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
T-memory	PUNCT	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
combined	VERB	O	O
effects	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
important	ADJ	O	O
consequences	NOUN	O	O
in	ADP	O	O
controlling	DET	O	O
metastatic	ADJ	O	O
dissemination	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	O
during	ADP	O	O
the	DET	O	O
vulnerable	ADJ	O	O
perioperative	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Atypical	ADJ	O	O
recruitment	NOUN	O	O
of	ADP	O	O
medial	ADJ	O	O
prefrontal	ADJ	O	O
cortex	NOUN	O	O
in	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
fMRI	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
executive	ADJ	O	O
function	NOUN	O	O
tasks	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
studies	NOUN	O	O
have	CCONJ	O	O
suggested	VERB	O	O
an	DET	O	O
uneven	NUM	O	O
profile	NOUN	O	O
of	ADP	O	O
executive	ADJ	O	O
dysfunction	NOUN	O	O
in	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
some	DET	O	O
authors	NOUN	O	O
have	ADP	O	O
reported	PUNCT	O	O
deficits	NOUN	O	O
on	ADP	O	O
newly	ADV	O	O
developed	VERB	O	O
tests	NOUN	O	O
of	ADP	O	O
executive	ADJ	O	O
function	NOUN	O	O
sensitive	ADJ	O	O
to	ADP	O	O
rostral	ADJ	O	O
prefrontal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
despite	ADP	O	O
spared	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
even	ADV	O	O
superior	ADJ	O	O
,	PUNCT	O	O
performance	NOUN	O	O
on	ADP	O	O
other	ADJ	O	O
tests	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
high-functioning	PUNCT	O	O
participants	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
(	PUNCT	O	O
N=15	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
age-	NOUN	O	O
and	CCONJ	O	O
IQ-matched	VERB	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
N=18	ADJ	O	O
)	PUNCT	O	O
on	ADP	O	O
two	NUM	O	O
executive	ADJ	O	O
function	ADV	O	O
tests	NOUN	O	O
,	PUNCT	O	O
whilst	ADP	O	O
undergoing	VERB	O	O
functional	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	VERB	O	O
(	PUNCT	O	O
fMRI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Behaviourally	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
classical	ADJ	O	O
test	NOUN	O	O
of	ADP	O	O
executive	PUNCT	O	O
function	NOUN	O	O
(	PUNCT	O	O
random	ADJ	O	O
response	NOUN	O	O
generation	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
BOLD	CCONJ	O	B-PHYSICAL
signal	PUNCT	O	I-PHYSICAL
differed	VERB	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cerebellum	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
frontal	ADJ	O	O
lobes	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
a	DET	O	O
new	ADJ	O	O
test	NOUN	O	O
of	ADP	O	O
executive	PUNCT	O	O
function	NOUN	O	O
(	PUNCT	O	O
selection	NOUN	O	O
between	ADP	O	O
stimulus-oriented	VERB	O	O
and	CCONJ	O	O
stimulus-independent	ADJ	O	O
thought	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
ASD	NOUN	O	O
group	NOUN	O	O
exhibited	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
signal-change	NOUN	O	O
in	ADP	O	O
medial	ADJ	O	B-PHYSICAL
rostral	ADJ	O	I-PHYSICAL
prefrontal	ADJ	O	I-PHYSICAL
cortex	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
especially	ADV	O	I-PHYSICAL
Brodmann	NOUN	O	I-PHYSICAL
Area	NOUN	O	O
10	NUM	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
stimulus-oriented	VERB	O	O
versus	CCONJ	O	O
stimulus-independent	ADJ	O	O
attention	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
new	ADJ	O	O
test	NOUN	O	O
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
classical	ADJ	O	O
test	NOUN	O	O
)	PUNCT	O	O
provided	VERB	O	O
evidence	NOUN	O	O
for	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
and	CCONJ	O	O
enalapril	NOUN	O	O
on	ADP	O	O
high-sensitivity	NOUN	O	O
C-reactive	ADJ	O	O
protein	NOUN	O	O
and	CCONJ	O	O
total	ADJ	O	O
antioxidant	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
with	ADP	O	O
Renin-Angiotensin	NOUN	O	O
system	NOUN	O	O
polymorphisms	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
As	ADP	O	O
renin-angiotensin	NOUN	O	O
system	NOUN	O	O
(	PUNCT	O	O
RAS	NOUN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
may	VERB	O	O
affect	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
inflammatory	ADJ	O	O
markers	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
enalapril	NOUN	O	O
(	PUNCT	O	O
E	NOUN	O	O
)	PUNCT	O	O
and/or	CCONJ	O	O
losartan	NOUN	O	O
(	PUNCT	O	O
L	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
these	DET	O	O
markers	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
with	ADP	O	O
RAS	NOUN	O	O
polymorphisms	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
After	ADP	O	O
determination	NOUN	O	O
by	ADP	O	O
PCR	NOUN	O	O
of	ADP	O	O
RAS	NOUN	O	O
genotypes	NOUN	O	O
,	PUNCT	O	O
consisting	SYM	O	O
of	ADP	O	O
the	DET	O	O
angiotensin-converting	ADJ	O	O
enzymes	NOUN	O	O
(	PUNCT	O	O
ACE	NOUN	O	O
I/D	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
angiotensinogens	ADP	O	O
(	PUNCT	O	O
AGT	NOUN	O	O
M235T	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
type	NOUN	O	O
1	NUM	O	O
receptors	NOUN	O	O
(	PUNCT	O	O
ATR1	NOUN	O	O
A1166C	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
76	NUM	O	O
recipients	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
randomly	ADV	O	O
and	CCONJ	O	O
assigned	PUNCT	O	O
4	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
second	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
E	NOUN	O	O
(	PUNCT	O	O
E	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
10	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
L	NOUN	O	O
(	PUNCT	O	O
L	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
50	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
alone	ADJ	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
third	ADJ	O	O
positive	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
E	NOUN	O	O
+	SYM	O	O
L	NOUN	O	O
(	PUNCT	O	O
E	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
L	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
10	NUM	O	O
mg/d	NOUN	O	O
+	SYM	O	O
50	NUM	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
fourth	ADJ	O	O
negative	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
18	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
no	DET	O	O
medication	NOUN	O	O
(	PUNCT	O	O
E	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
L	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

High-sensitivity	NOUN	O	O
C-reactive	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
hs-CRP	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
total	ADJ	O	O
antioxidant	NOUN	O	O
(	PUNCT	O	O
TA	NOUN	O	O
)	PUNCT	O	O
inflammatory	ADJ	O	O
and	CCONJ	O	O
antioxidative	ADJ	O	O
markers	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
after	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
2-week	NOUN	O	O
washout	PUNCT	O	O
period	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
E	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
group	NOUN	O	O
was	VERB	O	O
changed	NUM	O	O
to	ADP	O	O
L	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
vice	PUNCT	O	O
versa	ADV	O	O
in	ADP	O	O
a	DET	O	O
crossover	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
another	CCONJ	O	O
8	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
retesting	ADJ	O	O
hs-CRP	NOUN	O	O
and	CCONJ	O	O
TA	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
value	NOUN	O	O
of	ADP	O	O
P	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
.05	NUM	O	O
was	VERB	O	O
considered	VERB	O	O
significant	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
2	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
hs-CRP	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
TA	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
and	CCONJ	O	O
consequently	ADV	O	O
increased	VERB	O	O
among	ADP	O	O
the	DET	O	O
E	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
L	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
L	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
E	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
analyzing	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
RAS	NOUN	O	O
polymorphisms	NOUN	O	O
and	CCONJ	O	O
baseline	NOUN	O	O
hs-CRP	NOUN	O	O
or	CCONJ	O	O
TA	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
CC	NOUN	O	O
genotype	NOUN	O	O
of	ADP	O	O
ATR1	NOUN	O	O
showed	VERB	O	O
lower	PUNCT	O	O
hs-CRP	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
none	NUM	O	O
of	ADP	O	O
the	DET	O	O
RAS	NOUN	O	O
polymorphisms	NOUN	O	O
predicted	VERB	O	O
the	DET	O	O
antioxidant	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
anti-inflammatory	ADJ	O	B-PHYSICAL
response	NOUN	O	O
rates	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Although	ADP	O	O
hs-CRP	NOUN	O	B-PHYSICAL
was	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
CC	NOUN	O	O
genotype	NOUN	O	O
patients	NOUN	O	O
of	ADP	O	O
ATR1	NOUN	O	O
polymorphisms	NOUN	O	O
E	NOUN	O	O
and/or	CCONJ	O	O
L	NOUN	O	O
reduced	ADV	O	O
hs-CRP	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
TA	NOUN	O	O
regardless	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
RAS	NOUN	O	O
genotype	NOUN	O	O
.	PUNCT	O	O

Prazosin	NOUN	O	O
versus	CCONJ	O	O
captopril	NOUN	O	O
as	PUNCT	O	O
initial	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
on	ADP	O	O
hypertension	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
group	NOUN	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
,	PUNCT	O	I-OTHER
efficacy	NOUN	O	O
,	PUNCT	O	B-OTHER
and	CCONJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
alpha	NOUN	O	O
blocking	DET	O	O
agent	NOUN	O	O
prazosin	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
angiotensin	NOUN	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
captopril	NOUN	O	O
on	ADP	O	O
serum	NOUN	O	O
lipid	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
evaluations	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
31	NUM	O	O
patients	NOUN	O	O
after	ADP	O	O
a	DET	O	O
four-week	NOUN	O	O
placebo	NOUN	O	O
washout	PUNCT	O	O
period	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
prazosin	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
captopril	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
16	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Daily	DET	O	O
doses	NOUN	O	O
were	VERB	O	O
titrated	VERB	O	O
as	PUNCT	O	O
follows	VERB	O	O
:	PUNCT	O	O
for	ADP	O	O
prazosin	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
mg	NOUN	O	O
two	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
to	ADP	O	O
maximum	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
;	PUNCT	O	O
for	ADP	O	O
captopril	NOUN	O	O
,	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
three	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
to	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
450	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
diastolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
was	VERB	O	O
not	ADV	O	O
adequately	ADV	O	O
controlled	PROPN	O	O
(	PUNCT	O	O
less	ADV	O	O
than	PUNCT	O	O
85	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
monotherapy	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
polythiazide	NOUN	O	O
was	VERB	O	O
added	VERB	O	O
to	ADP	O	O
the	DET	O	O
daily	ADJ	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
groups	NOUN	O	O
for	ADP	O	O
the	DET	O	O
measured	VERB	O	O
variables	NOUN	O	O
in	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
parallel	ADJ	O	O
or	CCONJ	O	O
crossover	NOUN	O	O
phase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
15	NUM	O	O
prazosin-treated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
six	NUM	O	O
of	ADP	O	O
16	NUM	O	O
captopril-treated	VERB	O	O
patients	NOUN	O	O
required	VERB	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
thiazide	NOUN	O	O
to	PUNCT	O	O
achieve	PUNCT	O	O

The	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
including	PUNCT	O	O
clinical	ADJ	O	O
factors	NOUN	O	O
in	ADP	O	O
rectal	ADJ	O	O
normal	ADJ	O	O
tissue	NOUN	O	O
complication	NOUN	O	O
probability	NOUN	O	O
modeling	PUNCT	O	O
after	ADP	O	O
radiotherapy	NOUN	O	O
for	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADP	O	O
study	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
predisposing	ADJ	O	O
factors	NOUN	O	O
on	ADP	O	O
rectal	ADJ	O	O
normal	ADJ	O	O
tissue	NOUN	O	O
complication	NOUN	O	O
probability	NOUN	O	O
modeling	PROPN	O	O
using	ADP	O	O
the	DET	O	O
updated	VERB	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Dutch	NOUN	O	O
prostate	NOUN	O	O
dose-escalation	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
MATERIALS	NOUN	O	O
Toxicity	NOUN	O	O
data	NOUN	O	O
of	ADP	O	O
512	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
conformally	ADV	O	O
treated	ADP	O	O
to	ADP	O	O
68	NUM	O	O
Gy	NOUN	O	O
[	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
284	NUM	O	O
]	PUNCT	O	O
and	CCONJ	O	O
78	NUM	O	O
Gy	NOUN	O	O
[	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
228	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
complete	ADJ	O	O
follow-up	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
radiotherapy	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Scored	VERB	O	O
end	NOUN	O	O
points	NOUN	O	O
were	VERB	O	O
rectal	ADJ	O	O
bleeding	VERB	O	O
,	PUNCT	O	O
high	ADJ	O	O
stool	NOUN	O	O
frequency	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fecal	ADJ	O	O
incontinence	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
traditional	ADJ	O	O
dose-based	VERB	O	O
models	NOUN	O	O
(	PUNCT	O	O
Lyman-Kutcher-Burman	NOUN	O	O
(	PUNCT	O	O
LKB	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Relative	ADJ	O	O
Seriality	NOUN	O	O
(	PUNCT	O	O
RS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
logistic	ADJ	O	O
model	NOUN	O	O
were	VERB	O	O
fitted	VERB	O	O
using	VERB	O	O
a	DET	O	O
maximum	NOUN	O	O
likelihood	NOUN	O	O
approach	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
model	NOUN	O	O
fits	PUNCT	O	O
were	VERB	O	O
improved	VERB	O	O
by	ADP	O	O
including	PUNCT	O	O
the	DET	O	O
most	VERB	O	O
significant	ADJ	O	O
clinical	ADJ	O	O
factors	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
receiver	NOUN	O	O
operating	VERB	O	O
characteristic	ADJ	O	O
curve	NOUN	O	O
(	PUNCT	O	O
AUC	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
discriminating	VERB	O	O
ability	NOUN	O	O
of	ADP	O	O
all	DET	O	O
fits	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Including	PUNCT	O	O
clinical	ADJ	O	O
factors	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
predictive	ADJ	O	O
power	NOUN	O	O
of	ADP	O	O
the	DET	O	O
models	NOUN	O	O
for	ADP	O	O
all	DET	O	O
end	NOUN	O	O
points	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
optimal	ADJ	O	O
LKB	NOUN	O	O
,	PUNCT	O	O
RS	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
logistic	ADJ	O	O
models	NOUN	O	O
for	ADP	O	O
rectal	ADJ	O	O
bleeding	VERB	O	O
and	CCONJ	O	O
fecal	ADJ	O	O
incontinence	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.011-0.013	NUM	O	O
)	PUNCT	O	O
clinical	ADJ	O	O
factor	NOUN	O	O
was	VERB	O	O
previous	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

As	PUNCT	O	O
second	ADJ	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.012-0.016	NUM	O	O
)	PUNCT	O	O
factor	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
history	NOUN	O	O
was	VERB	O	O
included	VERB	O	O
in	ADP	O	O
all	DET	O	O
three	NUM	O	O
rectal	ADJ	O	O
bleeding	VERB	O	O
fits	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
including	PUNCT	O	O
diabetes	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.039-0.048	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
fecal	ADJ	O	O
incontinence	NOUN	O	O
modeling	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
LKB	NOUN	O	O
and	CCONJ	O	O
logistic	ADJ	O	O
models	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	B-PHYSICAL
stool	NOUN	O	I-PHYSICAL
frequency	NOUN	O	I-PHYSICAL
fits	PUNCT	O	O
only	ADV	O	O
benefitted	ADP	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003-0.006	PUNCT	O	O
)	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
inclusion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
toxicity	NOUN	O	O
score	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
all	DET	O	O
models	NOUN	O	O
rectal	ADJ	O	O
bleeding	VERB	O	O
fits	PUNCT	O	O
had	PUNCT	O	O
the	DET	O	O
highest	PUNCT	O	O
AUC	NOUN	O	O
(	PUNCT	O	O
0.77	NUM	O	O
)	PUNCT	O	O
where	ADP	O	O
it	PRON	O	O
was	VERB	O	O
0.63	NUM	O	O
and	CCONJ	O	O
0.68	NUM	O	O
for	ADP	O	O
high	ADJ	O	O
stool	NOUN	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
fecal	ADJ	O	O
incontinence	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

LKB	NOUN	O	O
and	CCONJ	O	O
logistic	ADJ	O	O
model	NOUN	O	O
fits	PUNCT	O	O
resulted	PUNCT	O	O
in	ADP	O	O
similar	ADJ	O	O
values	NOUN	O	O
for	ADP	O	O
the	DET	O	O
volume	NOUN	O	O
parameter	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
steepness	NOUN	O	O
parameter	NOUN	O	O
was	VERB	O	O
somewhat	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
logistic	ADJ	O	O
model	NOUN	O	O
,	PUNCT	O	O
also	ADV	O	O
resulting	VERB	O	O
in	ADP	O	O
a	DET	O	O
slightly	ADV	O	O
lower	PUNCT	O	O
D	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Anal	ADJ	O	O
wall	NOUN	O	O
DVHs	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
for	ADP	O	O
fecal	ADJ	O	O
incontinence	NOUN	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
anorectal	ADJ	O	O
wall	NOUN	O	O
dose	NOUN	O	O
best	ADV	O	O
described	DET	O	O
the	DET	O	O
other	ADJ	O	O
two	NUM	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Comparable	ADJ	O	O
prediction	NOUN	O	O
models	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
with	ADP	O	O
LKB	NOUN	O	O
,	PUNCT	O	O
RS	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
logistic	ADJ	O	O
NTCP	ADJ	O	O
models	NOUN	O	O
.	PUNCT	O	O

Including	PUNCT	O	O
clinical	ADJ	O	O
factors	NOUN	O	O
improved	VERB	O	O
the	DET	O	O
predictive	ADJ	O	O
power	NOUN	O	O
of	ADP	O	O
all	DET	O	O
models	NOUN	O	O
significantly	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
multicenter	NOUN	O	O
trial	NOUN	O	O
comparing	PUNCT	O	O
resection	NOUN	O	O
and	CCONJ	O	O
radiochemotherapy	NOUN	O	O
for	ADP	O	O
resectable	ADJ	O	O
locally	ADV	O	O
invasive	ADJ	O	O
pancreatic	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Though	ADP	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
resection	NOUN	O	O
for	ADP	O	O
locally	ADV	O	O
invasive	ADJ	O	O
pancreatic	ADJ	O	O
cancer	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
poor	ADJ	O	O
,	PUNCT	O	O
it	PUNCT	O	O
has	PUNCT	O	O
gradually	ADV	O	O
improved	ADP	O	O
in	ADP	O	O
Japan	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
5-year	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
is	VERB	O	O
now	ADV	O	O
about	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
advantage	NOUN	O	O
of	ADP	O	O
resection	NOUN	O	O
over	ADP	O	O
radiochemotherapy	NOUN	O	O
has	VERB	O	O
not	ADP	O	O
yet	ADV	O	O
been	PUNCT	O	O
confirmed	VERB	O	O
by	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
this	DET	O	O
study	NOUN	O	O
to	DET	O	O
compare	NOUN	O	O
surgical	ADJ	O	O
resection	NOUN	O	O
alone	ADJ	O	O
versus	CCONJ	O	O
radiochemotherapy	NOUN	O	O
without	ADP	O	O
resection	NOUN	O	O
for	ADP	O	O
locally	ADV	O	O
invasive	ADJ	O	O
pancreatic	ADJ	O	O
cancer	NOUN	O	O
using	VERB	O	O
a	DET	O	O
multicenter	NOUN	O	O
randomized	VERB	O	O
design	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
pancreatic	ADJ	O	O
cancer	NOUN	O	O
who	ADP	O	O
met	VERB	O	O
our	PUNCT	O	O
preoperative	ADJ	O	O
criteria	NOUN	O	O
for	ADP	O	O
inclusion	NOUN	O	O
(	PUNCT	O	O
pancreatic	ADJ	O	O
cancer	NOUN	O	O
invading	PUNCT	O	O
the	DET	O	O
pancreatic	ADJ	O	O
capsule	NOUN	O	O
without	ADP	O	O
involvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
superior	ADJ	O	O
mesenteric	ADJ	O	O
artery	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
common	ADJ	O	O
hepatic	ADJ	O	O
artery	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
without	ADP	O	O
distant	ADJ	O	O
metastasis	NOUN	O	O
)	PUNCT	O	O
underwent	VERB	O	O
laparotomy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
operative	ADJ	O	O
findings	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
our	PUNCT	O	O
criteria	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
a	DET	O	O
radical	PUNCT	O	O
resection	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
radiochemotherapy	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
/day	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
5-fluorouracil	NOUN	O	O
and	CCONJ	O	O
5040	NUM	O	O
cGy	NOUN	O	O
of	ADP	O	O
radiotherapy	NOUN	O	O
)	PUNCT	O	O
without	ADP	O	O
resection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
for	ADP	O	O
mean	NOUN	O	O
survival	NOUN	O	B-MORTALITY
,	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
1-year	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
,	PUNCT	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
scores	NOUN	O	B-MORTALITY
,	PUNCT	O	O
and	CCONJ	O	O
hematologic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
chemical	ADJ	O	I-PHYSICAL
data	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
resection	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
22	NUM	O	O
to	ADP	O	O
the	DET	O	O
radiochemotherapy	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
1	NUM	O	O
operative	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
.	PUNCT	O	O

The	DET	O	O
surgical	ADJ	O	O
resection	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
better	PUNCT	O	O
results	PUNCT	O	O
than	VERB	O	O
the	DET	O	O
radiochemotherapy	NOUN	O	O
group	NOUN	O	O
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
1-year	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
62	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
32	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P=.05	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mean	ADP	O	O
survival	NOUN	O	B-MORTALITY
time	NOUN	O	I-MORTALITY
(	PUNCT	O	O
>	PROPN	O	O
17	NUM	O	O
vs	CCONJ	O	O
11	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
0.46	NUM	O	O
,	PUNCT	O	O
P=.04	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
score	NOUN	O	O
or	CCONJ	O	O
laboratory	NOUN	O	B-PHYSICAL
data	NOUN	O	I-PHYSICAL
apart	PUNCT	O	O
from	ADP	O	O
increased	NOUN	O	O
diarrhea	NOUN	O	B-PHYSICAL
after	ADP	O	O
surgical	ADJ	O	O
resection	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Locally	ADJ	O	O
invasive	ADJ	O	O
pancreatic	ADJ	O	O
cancer	NOUN	O	O
without	ADP	O	O
distant	ADJ	O	O
metastases	NOUN	O	O
and	CCONJ	O	O
major	ADJ	O	O
arterial	ADJ	O	O
invasion	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
best	PUNCT	O	O
treated	PRON	O	O
by	ADP	O	O
surgical	ADJ	O	O
resection	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
immunoglobulin	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
fatigue	NOUN	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
chronic	ADJ	O	O
fatigue	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
CFS	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
profound	ADJ	O	O
fatigue	NOUN	O	O
,	PUNCT	O	O
neuropsychiatric	ADJ	O	O
dysfunction	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
frequent	ADJ	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
cell-mediated	VERB	O	O
immunity	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
effective	ADJ	O	O
therapy	NOUN	O	O
is	VERB	O	O
known	VERB	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Forty-nine	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
with	ADP	O	O
abnormal	ADJ	O	O
cell-mediated	VERB	O	O
immunity	NOUN	O	O
)	PUNCT	O	O
participated	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
high-dose	NOUN	O	O
intravenously	ADV	O	O
administered	ADP	O	O
immunoglobulin	NOUN	O	O
G.	PUNCT	O	O
The	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
three	NUM	O	O
intravenous	ADJ	O	O
infusions	NOUN	O	O
of	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
solution	NOUN	O	O
or	CCONJ	O	O
immunoglobulin	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
g/kg/month	NUM	O	O
.	PUNCT	O	O

Assessment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
associated	VERB	O	O
disability	NOUN	O	O
,	PUNCT	O	O
both	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
completed	VERB	O	O
at	ADP	O	O
detailed	VERB	O	O
interviews	NOUN	O	O
by	ADP	O	O
a	DET	O	O
physician	NOUN	O	O
and	CCONJ	O	O
psychiatrist	NOUN	O	O
,	PUNCT	O	O
who	PROPN	O	O
were	VERB	O	O
unaware	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
any	DET	O	O
change	NOUN	O	O
in	ADP	O	O
physical	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
functional	ADJ	O	O
capacity	NOUN	O	O
was	VERB	O	O
recorded	VERB	O	O
using	VERB	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scales	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
psychologic	ADJ	O	O
morbidity	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
using	SYM	O	O
patient-rated	VERB	O	O
indices	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	O
.	PUNCT	O	O

Cell-mediated	VERB	O	O
immunity	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
T-cell	NOUN	O	O
subset	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
delayed-type	NOUN	O	O
hypersensitivity	NOUN	O	O
skin	NOUN	O	O
testing	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lymphocyte	NOUN	O	O
transformation	NOUN	O	O
with	ADP	O	O
phytohemagglutinin	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
the	DET	O	O
interview	NOUN	O	O
conducted	VERB	O	O
by	ADP	O	O
the	DET	O	O
physician	NOUN	O	O
3	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
final	ADJ	O	O
infusion	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
of	ADP	O	O
23	NUM	O	O
(	PUNCT	O	O
43	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
immunoglobulin	NOUN	O	O
recipients	NOUN	O	O
and	CCONJ	O	O
three	NUM	O	O
of	ADP	O	O
the	DET	O	O
26	NUM	O	O
(	PUNCT	O	O
12	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
placebo	NOUN	O	O
recipients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
as	ADP	O	O
having	DET	O	O
responded	VERB	O	O
with	ADP	O	O
a	DET	O	O
substantial	ADJ	O	B-OTHER
reduction	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
their	PUNCT	O	I-OTHER
symptoms	NOUN	O	I-OTHER
and	CCONJ	O	O
recommencement	ADJ	O	B-OTHER
of	ADP	O	I-OTHER
work	NOUN	O	I-OTHER
,	PUNCT	O	O
leisure	NOUN	O	B-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
social	ADJ	O	B-MENTAL
activities	NOUN	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
designated	VERB	O	O
as	ADP	O	O
having	DET	O	O
responded	VERB	O	O
had	PUNCT	O	O
improvement	NOUN	O	O
in	ADP	O	O
physical	ADJ	O	O
,	PUNCT	O	O
psychologic	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
immunologic	ADJ	O	O
measures	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.01	NUM	O	O
for	ADP	O	O
each	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Immunomodulatory	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
immunoglobulin	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
CFS	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
finding	VERB	O	O
that	DET	O	O
supports	NOUN	O	O
the	DET	O	O
concept	NOUN	O	O
that	ADP	O	O
an	DET	O	O
immunologic	ADJ	O	O
disturbance	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Mitomycin	NOUN	O	O
C	NOUN	O	O
plus	CCONJ	O	O
HCFU	NOUN	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
noncuratively	PUNCT	O	O
resected	PUNCT	O	O
cases	NOUN	O	O
of	ADP	O	O
colorectal	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

Second	ADJ	O	O
report	NOUN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
5-year	PUNCT	O	O
survival	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Cooperative	ADJ	O	O
Study	NOUN	O	O
Group	NOUN	O	O
of	ADP	O	O
Kyushu	NOUN	O	O
and	CCONJ	O	O
Chugoku	NOUN	O	O
for	ADP	O	O
HCFU	NOUN	O	O
Adjuvant	NOUN	O	O
Chemotherapy	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
employing	SYM	O	O
mitomycin	NUM	O	O
C	NOUN	O	O
(	PUNCT	O	O
MMC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
carmofur	NOUN	O	O
(	PUNCT	O	O
HCFU	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
noncuratively	PUNCT	O	O
resected	PUNCT	O	O
colorectal	ADJ	O	O
carcinoma	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
cooperative	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
by	ADP	O	O
54	NUM	O	O
institutions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Kyushu	NOUN	O	O
and	CCONJ	O	O
Chugoku	NOUN	O	O
areas	NOUN	O	O
of	ADP	O	O
Japan	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
criteria	NOUN	O	O
for	ADP	O	O
patient	NOUN	O	O
selection	NOUN	O	O
were	VERB	O	O
as	ADP	O	O
follows	PUNCT	O	O
:	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
Age	NOUN	O	O
of	ADP	O	O
75	NUM	O	O
years	NOUN	O	O
or	CCONJ	O	O
less	DET	O	O
and	CCONJ	O	O
not	ADV	O	O
accompanied	VERB	O	O
by	ADP	O	O
any	DET	O	O
serious	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
)	PUNCT	O	O
Macroscopic	ADJ	O	O
diagnosis	NOUN	O	O
as	VERB	O	O
being	VERB	O	O
noncuratively	ADP	O	O
resected	VERB	O	O
on	ADP	O	O
completion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

3	NUM	O	O
)	PUNCT	O	O
Definitive	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
colorectal	ADJ	O	O
carcinomas	NOUN	O	O
,	PUNCT	O	O
histologically	ADV	O	O
.	PUNCT	O	O

4	NUM	O	O
)	PUNCT	O	O
No	DET	O	O
synchronous	ADJ	O	O
or	CCONJ	O	O
metachronous	ADJ	O	O
double	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
MMC	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
bolus	NOUN	O	O
intravenous	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mg	NOUN	O	O
MMC	NOUN	O	O
on	ADP	O	O
the	DET	O	O
day	NOUN	O	O
of	ADP	O	O
operation	NOUN	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NOUN	O	O
the	DET	O	O
next	ADJ	O	O
day	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
10	NUM	O	O
mg	NOUN	O	O
every	DET	O	O
4	NUM	O	O
weeks	NOUN	O	O
until	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	NOUN	O	O
had	PUNCT	O	O
been	PUNCT	O	O
administered	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
MMC	NOUN	O	O
+	SYM	O	O
HCFU	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
the	DET	O	O
same	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
Group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
600	NUM	O	O
mg/day	NOUN	O	O
of	ADP	O	O
HCFU	NOUN	O	O
from	ADP	O	O
the	DET	O	O
second	ADJ	O	O
week	NOUN	O	O
,	PUNCT	O	O
orally	ADV	O	O
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
one	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

Concerning	PROPN	O	O
the	DET	O	O
69-month	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
rate	NOUN	O	I-MORTALITY
,	PUNCT	O	O
a	DET	O	O
better	PUNCT	O	O
result	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
MMC	NOUN	O	O
+	SYM	O	O
HCFU	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
MMC	NOUN	O	O
only	DET	O	O
group	NOUN	O	O
(	PUNCT	O	O
generalized	VERB	O	O
Wilcoxon	NOUN	O	O
test	NOUN	O	O
:	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Significantly	ADV	O	O
better	PUNCT	O	O
survival	NOUN	O	B-MORTALITY
rates	NOUN	O	I-MORTALITY
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
those	PUNCT	O	O
cases	NOUN	O	O
with	ADP	O	O
disseminating	PUNCT	O	O
peritoneal	ADJ	O	O
metastasis	NOUN	O	O
,	PUNCT	O	O
hepatic	ADJ	O	O
metastasis	NOUN	O	O
and	CCONJ	O	O
stage	NOUN	O	O
V	NUM	O	O
cancer	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MMC	NOUN	O	O
+	SYM	O	O
HCFU	NOUN	O	O
group	NOUN	O	O
as	PUNCT	O	O
when	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
MMC	NOUN	O	O
only	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	B-ADVERSE-EFFECTS
side	NOUN	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
due	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
combined	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
HCFU	NOUN	O	O
were	VERB	O	O
recognized	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
combined	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
MMC	NOUN	O	O
and	CCONJ	O	O
HCFU	NOUN	O	O
was	VERB	O	O
suggested	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
noncuratively	PUNCT	O	O
resected	PUNCT	O	O
cases	NOUN	O	O
of	ADP	O	O
colorectal	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
biological	ADJ	O	O
factors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
etiopathogenesis	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
cervical	ADJ	O	O
spondylosis	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
cervical	ADJ	O	O
spondylosis	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
1	NUM	O	O
to	ADP	O	O
4	NUM	O	O
average	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
1/2	NOUN	O	O
)	PUNCT	O	O
years	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
co-relation	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
established	VERB	O	O
between	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
features	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
radiological	ADJ	O	O
findings	NOUN	O	O
in	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
found	VERB	O	O
that	ADP	O	O
parasites	ADV	O	B-OTHER
play	VERB	O	I-OTHER
an	DET	O	I-OTHER
important	ADJ	O	I-OTHER
role	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
the	DET	O	I-OTHER
multifactorial	ADJ	O	I-OTHER
etiology	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
this	PUNCT	O	I-OTHER
condition	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
their	ADJ	O	I-OTHER
eradication	NOUN	O	I-OTHER
by	ADP	O	I-OTHER
deworming	PUNCT	O	I-OTHER
drugs	NOUN	O	I-OTHER
gives	PART	O	I-OTHER
better	VERB	O	I-OTHER
results	PUNCT	O	I-OTHER
than	VERB	O	I-OTHER
the	DET	O	I-OTHER
traditional	ADJ	O	I-OTHER
therapies	NOUN	O	I-OTHER
.	PUNCT	O	O

Many	DET	O	O
new	ADJ	O	O
hypotheses	NOUN	O	O
are	VERB	O	O
proposed	VERB	O	O
to	PART	O	O
explain	NOUN	O	O
the	DET	O	O
same	PUNCT	O	O
.	PUNCT	O	O

Safety	NOUN	O	B-OTHER
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
low	ADJ	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
heparin	NOUN	O	O
(	PUNCT	O	O
Logiparin	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
dextran	NOUN	O	O
as	PUNCT	O	O
prophylaxis	NOUN	O	O
against	ADP	O	O
thrombosis	NOUN	O	O
after	ADP	O	O
total	ADJ	O	O
hip	NOUN	O	O
replacement	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	ADP	O	O
study	NOUN	O	O
the	DET	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
factor	NOUN	O	O
XaI	ADJ	O	O
and	CCONJ	O	O
IIaI	NOUN	O	O
activity	NOUN	O	O
an	DET	O	O
enzymatically	ADV	O	O
depolymerized	PART	O	O
low	ADJ	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
heparin	NOUN	O	O
(	PUNCT	O	O
LMW-heparin	NOUN	O	O
;	PUNCT	O	O
Logiparin	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
s.c.	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
35	NUM	O	O
XaI	ADJ	O	O
mu/kg	NOUN	O	O
b.w	NUM	O	O
.	PUNCT	O	O

once	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
to	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
total	ADJ	O	O
hip	NOUN	O	O
replacement	NOUN	O	O
(	PUNCT	O	O
THR	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
XaI	ADJ	O	O
activity	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
0.24	NUM	O	O
XaI	NOUN	O	O
units/ml	ADV	O	O
and	CCONJ	O	O
the	DET	O	O
IIaI	NOUN	O	O
activity	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
0.043	ADJ	O	O
IIaI	NOUN	O	O
mu/ml	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
accumulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
activities	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
phlebographically	ADV	O	B-PHYSICAL
verified	PUNCT	O	I-PHYSICAL
thrombi	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
any	DET	O	O
bleeding	VERB	O	B-PHYSICAL
complications	NOUN	O	I-PHYSICAL
were	VERB	O	O
registered	PUNCT	O	O
.	PUNCT	O	O

From	ADP	O	O
this	DET	O	O
study	NOUN	O	O
it	PUNCT	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
the	DET	O	O
given	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
Logiparin	NOUN	O	O
was	VERB	O	O
safe	ADJ	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
bleeding	VERB	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
main	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
thromboprophylactic	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
LMW-heparin	NOUN	O	O
(	PUNCT	O	O
Logiparin	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
35	NUM	O	O
XaI	ADJ	O	O
mu/kg	NOUN	O	O
b.w	NUM	O	O
.	PUNCT	O	O

once	PUNCT	O	O
daily	ADJ	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
dextran	NOUN	O	O
70	NUM	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
THR	NOUN	O	O
.	PUNCT	O	O

100	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
over-all	PUNCT	O	B-OTHER
thrombosis	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
28	NUM	O	O
%	SYM	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
LMW-heparin	NOUN	O	O
and	CCONJ	O	O
39	NUM	O	O
%	SYM	O	O
in	ADP	O	O
those	DET	O	O
given	VERB	O	O
dextran	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
non-significant	ADJ	O	O
difference	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
bleeding	VERB	O	B-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
deaths	NOUN	O	B-MORTALITY
or	CCONJ	O	O
pulmonary	ADJ	O	B-PHYSICAL
embolism	NOUN	O	I-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
in	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

Peroperative	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
transfusion	NOUN	O	I-PHYSICAL
requirements	NOUN	O	I-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
investigated	ADJ	O	O
LMW-heparin	NOUN	O	O
(	PUNCT	O	O
Logiparin	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
postoperative	ADJ	O	O
thromboembolism	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
total	ADJ	O	O
hip	NOUN	O	O
replacement	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
dosage	NOUN	O	O
can	PRON	O	O
probably	ADV	O	O
be	DET	O	O
optimized	VERB	O	O
.	PUNCT	O	O

Losartan	NOUN	O	O
vs.	CCONJ	O	O
amlodipine	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
elderly	PUNCT	O	O
oncologic	ADJ	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Elderly	ADJ	O	O
neoplastic	ADJ	O	O
patients	NOUN	O	O
frequently	ADV	O	O
may	VERB	O	O
show	VERB	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
hyperuricemia	ADJ	O	O
,	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
chemotherapeutic	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
which	ADP	O	O
is	VERB	O	O
an	DET	O	O
antihypertensive	ADJ	O	O
drug	NOUN	O	O
with	ADP	O	O
uricosuric	ADJ	O	O
properties	NOUN	O	O
vs.	CCONJ	O	O
amlodipine	NOUN	O	O
in	ADP	O	O
hypertensive	ADJ	O	O
neoplastic	ADJ	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
an	DET	O	O
open-labeled	ADP	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
comparative	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
as	ADP	O	O
a	DET	O	O
30-day	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Seventy	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
losartan	NOUN	O	O
or	CCONJ	O	O
amlodipine	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
blood	NOUN	O	O
urea	NOUN	O	O
nitrogen	NOUN	O	O
(	PUNCT	O	O
BUN	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
uric	ADJ	O	O
acid	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	O
and	CCONJ	O	O
uric	ADJ	O	O
acid	NOUN	O	O
clearance	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
day	NOUN	O	O
after	PUNCT	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
losartan	NOUN	O	O
group	NOUN	O	O
vs.	CCONJ	O	O
amlodipine	NOUN	O	O
group	NOUN	O	O
we	PRON	O	O
observed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	B-PHYSICAL
uric	ADJ	O	I-PHYSICAL
acid	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
18	NUM	O	O
mg/24	NOUN	O	O
h	NOUN	O	O
vs.	CCONJ	O	O
40	NUM	O	O
mg/24	NOUN	O	O
h.	NOUN	O	O
Thirty	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
chemotherapy	NOUN	O	O
we	PUNCT	O	O
observed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
azotemia	NOUN	O	B-PHYSICAL
of	ADP	O	O
0.0	NUM	O	O
mg/dl	NOUN	O	O
vs.	CCONJ	O	O
3.8	NUM	O	O
mg/dl	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
uric	ADJ	O	I-PHYSICAL
acid	NOUN	O	I-PHYSICAL
of	ADP	O	O
0.05	NUM	O	O
mg/dl	NOUN	O	O
vs.	CCONJ	O	O
0.49	NUM	O	O
mg/dl	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
urinary	ADJ	O	B-PHYSICAL
uric	ADJ	O	I-PHYSICAL
acid	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
23	NUM	O	O
mg/24	NOUN	O	O
h	NOUN	O	O
vs.	CCONJ	O	O
0.0	NUM	O	O
mg/24	NOUN	O	O
h	NOUN	O	O
,	PUNCT	O	O
GFR	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
ml/min/1.73	NOUN	O	O
m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
-8	NUM	O	O
ml/min/1.73	NOUN	O	O
m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
systolic	ADJ	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
SBP	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
3.6	NUM	O	O
mmHg	NOUN	O	O
vs.	CCONJ	O	O
0.8	NUM	O	O
mmHg	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
support	NOUN	O	O
the	DET	O	O
effective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
amlodipine	NOUN	O	O
in	ADP	O	O
treating	VERB	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
hyperuricemia	ADV	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
under	ADP	O	O
chemotherapeutic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Biochemical	ADJ	O	O
and	CCONJ	O	O
functional	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	O
phosphate	NOUN	O	O
in	ADP	O	O
cardioplegic	ADJ	O	O
solution	NOUN	O	O
during	ADP	O	O
aortic	ADJ	O	O
valve	NOUN	O	O
surgery	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
myocardial	ADJ	O	O
ischemia	NOUN	O	O
there	PUNCT	O	O
is	VERB	O	O
a	PUNCT	O	O
drop	PUNCT	O	O
in	ADP	O	O
high-energy	NOUN	O	B-PHYSICAL
phosphates	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
myocardium	NOUN	O	O
.	PUNCT	O	O

Cold	ADJ	O	O
potassium	NOUN	O	O
cardioplegia	NOUN	O	O
decreases	PROPN	O	O
but	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
altogether	CCONJ	O	O
prevent	VERB	O	O
this	DET	O	O
reduction	NOUN	O	O
.	PUNCT	O	O

Supplementation	NOUN	O	O
of	ADP	O	O
cardioplegic	ADJ	O	O
solutions	NOUN	O	O
with	ADP	O	O
the	DET	O	O
high-energy	NOUN	O	O
compound	ADP	O	O
creatine	NOUN	O	O
phosphate	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mmol/L	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
plain	ADJ	O	O
cardioplegic	ADJ	O	O
solutions	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
patients	NOUN	O	O
scheduled	VERB	O	O
for	ADP	O	O
aortic	ADJ	O	O
valve	NOUN	O	O
replacement	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
creatine	NOUN	O	O
phosphate	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
group	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	O
hemodynamic	ADJ	O	B-PHYSICAL
evaluation	NOUN	O	I-PHYSICAL
revealed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
group	NOUN	O	O
I	NUM	O	O
exhibited	VERB	O	O
a	DET	O	O
tendency	NOUN	O	O
toward	ADP	O	O
a	DET	O	O
better	PUNCT	O	O
stroke-work	NUM	O	B-PHYSICAL
index	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
135	NUM	O	O
+/-	SYM	O	O
18	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
102	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
%	SYM	O	O
recovery	NOUN	O	O
15	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
bypass	NOUN	O	O
and	CCONJ	O	O
145	NUM	O	O
+/-	SYM	O	O
16	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
119	NUM	O	O
+/-	SYM	O	O
11	NUM	O	O
%	SYM	O	O
recovery	NOUN	O	O
105	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
bypass	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
fewer	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
5/15	NOUN	O	O
)	PUNCT	O	O
needing	VERB	O	B-PHYSICAL
inotropic	ADJ	O	I-PHYSICAL
support	NOUN	O	I-PHYSICAL
compared	VERB	O	O
to	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
9/14	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
myocardial	ADJ	O	B-PHYSICAL
content	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
ATP	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
creatine	NOUN	O	B-PHYSICAL
phosphate	NOUN	O	I-PHYSICAL
showed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
during	ADP	O	O
ischemia	NOUN	O	O
and	CCONJ	O	O
reperfusion	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
protection	NOUN	O	O
during	ADP	O	O
ischemia	NOUN	O	O
was	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
prevent	ADJ	O	O
significant	ADJ	O	O
reductions	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-PHYSICAL
ATP	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
creatine	NOUN	O	I-PHYSICAL
phosphate	NOUN	O	I-PHYSICAL
irrespective	ADJ	O	O
of	ADP	O	O
supplementation	NOUN	O	O
with	ADP	O	O
CP	NOUN	O	O
.	PUNCT	O	O

Controlled	DET	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
partial	ADJ	O	O
ceramic	ADJ	O	O
crowns	NOUN	O	O
inserted	VERB	O	O
with	ADP	O	O
RelyX	NOUN	O	O
Unicem	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
selective	ADJ	O	O
enamel	NOUN	O	O
etching	CCONJ	O	O
.	PUNCT	O	O

1-year	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
compare	NOUN	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
partial	ADJ	O	B-OTHER
ceramic	ADJ	O	I-OTHER
crowns	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
PCCs	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
inserted	VERB	O	O
with	ADP	O	O
RelyX	NOUN	O	O
Unicem	NOUN	O	O
(	PUNCT	O	O
RXU	NOUN	O	O
)	PUNCT	O	O
either	CCONJ	O	O
with	ADP	O	O
(	PUNCT	O	O
RXU+E	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
without	ADP	O	O
(	PUNCT	O	O
RXU	NOUN	O	O
)	PUNCT	O	O
selective	ADJ	O	O
enamel	NOUN	O	O
etching	CCONJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
34	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
male	NOUN	O	O
,	PUNCT	O	O
19	NUM	O	O
female	NOUN	O	O
)	PUNCT	O	O
participated	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
investigation	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
68	NUM	O	O
PCC	NOUN	O	O
restorations	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
PCC	NOUN	O	O
was	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
insertion	NOUN	O	O
with	ADP	O	O
RXU	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
second	ADJ	O	O
PCC	NOUN	O	O
was	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
insertion	NOUN	O	O
with	ADP	O	O
RXU+E	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
PCCs	NOUN	O	O
were	ADP	O	O
CAD/CAM	ADP	O	O
fabricated	PUNCT	O	O
using	VERB	O	O
the	DET	O	O
Cerec	NOUN	O	O
3	NUM	O	O
system	NOUN	O	O
.	PUNCT	O	O

RXU	NOUN	O	O
:	PUNCT	O	O
25	NUM	O	O
PCCs	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
in	ADP	O	O
molars	NOUN	O	O
,	PUNCT	O	O
nine	NUM	O	O
in	ADP	O	O
premolars	PUNCT	O	O
.	PUNCT	O	O

RXU+E	NOUN	O	O
:	PUNCT	O	O
26	DET	O	O
PCCs	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
in	ADP	O	O
molars	NOUN	O	O
,	PUNCT	O	O
eight	NUM	O	O
in	ADP	O	O
premolars	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
restorations	NOUN	O	O
were	VERB	O	O
clinically	ADV	O	O
rated	VERB	O	O
using	VERB	O	O
modified	VERB	O	O
United	VERB	O	O
States	NOUN	O	O
Public	ADJ	O	O
Health	NOUN	O	O
Service	NOUN	O	O
(	PUNCT	O	O
USPHS	NOUN	O	O
)	PUNCT	O	O
criteria	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
placement	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
patient	NOUN	O	O
age	NOUN	O	O
was	VERB	O	O
41	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
24-59	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
(	PUNCT	O	O
25-75	ADP	O	O
%	SYM	O	O
)	PUNCT	O	O
PBI	NOUN	O	O
was	VERB	O	O
6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
3-9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
All	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
the	DET	O	O
three	NUM	O	O
recall	NOUN	O	O
appointments	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
PCC	NOUN	O	O
(	PUNCT	O	O
RXU	NOUN	O	O
)	PUNCT	O	O
debonded	VERB	O	B-PHYSICAL
after	PUNCT	O	O
11	NUM	O	O
months	NOUN	O	O
in	DET	O	O
situ	ADJ	O	O
,	PUNCT	O	O
one	NUM	O	O
PCC	NOUN	O	O
(	PUNCT	O	O
RXU+E	NOUN	O	O
)	PUNCT	O	O
fractured	PUNCT	O	B-PHYSICAL
after	PUNCT	O	O
12	NUM	O	O
months	NOUN	O	O
in	DET	O	O
situ	ADJ	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
restorations	NOUN	O	B-OTHER
had	PUNCT	O	O
to	PART	O	O
be	PUNCT	O	O
replaced	VERB	O	B-OTHER
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
12	NUM	O	O
months	NOUN	O	O
recall	PUNCT	O	O
,	PUNCT	O	O
66	NUM	O	O
of	ADP	O	O
68	NUM	O	O
controlled	VERB	O	O
restorations	NOUN	O	O
were	VERB	O	O
functional	ADJ	O	B-OTHER
without	PUNCT	O	O
need	NOUN	O	O
of	ADP	O	O
replacement	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
evaluation	NOUN	O	O
using	SYM	O	O
USHPS	NOUN	O	O
criteria	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
of	ADP	O	O
alfa	NOUN	O	O
ratings	NOUN	O	B-PHYSICAL
over	ADP	O	I-PHYSICAL
time	NOUN	O	I-PHYSICAL
with	ADP	O	O
respect	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
criteria	NOUN	O	I-OTHER
marginal	ADJ	O	I-OTHER
adaptation	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
marginal	ADJ	O	I-OTHER
discoloration	NOUN	O	I-OTHER
.	PUNCT	O	O

No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
luting	ADJ	O	O
techniques	NOUN	O	O
,	PUNCT	O	O
RXU	NOUN	O	O
and	CCONJ	O	O
RXU+E	NOUN	O	O
,	PUNCT	O	O
we	ADP	O	O
reobserved	ADV	O	O
during	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

Within	ADP	O	O
the	DET	O	O
limitations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
adhesive	ADP	O	O
luting	PUNCT	O	O
with	ADP	O	O
RXU	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
selective	ADJ	O	O
enamel	NOUN	O	O
etching	PUNCT	O	O
can	CCONJ	O	O
be	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
,	PUNCT	O	O
tolerability	NOUN	O	B-OTHER
and	CCONJ	O	O
pharmacokinetics	NOUN	O	B-OTHER
of	ADP	O	O
two	NUM	O	O
nelfinavir-based	VERB	O	O
regimens	NOUN	O	O
in	ADP	O	O
human	NOUN	O	O
immunodeficiency	NOUN	O	O
virus-infected	DET	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
:	PUNCT	O	O
pediatric	ADJ	O	O
AIDS	NOUN	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
group	NOUN	O	O
protocol	NOUN	O	O
403	ADJ	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Few	ADJ	O	O
combinations	NOUN	O	O
of	ADP	O	O
highly	ADV	O	O
active	ADJ	O	O
antiretrovirals	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
studied	VERB	O	O
in	ADP	O	O
nucleoside	NOUN	O	O
reverse	ADJ	O	O
transcription	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
NRTI	NOUN	O	O
)	PUNCT	O	O
-experienced	VERB	O	O
,	PUNCT	O	O
human	NOUN	O	O
immunodeficiency	NOUN	O	O
virus	NOUN	O	O
(	PUNCT	O	O
HIV	NOUN	O	O
)	PUNCT	O	O
-infected	DET	O	O
children	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
tolerability	NOUN	O	O
and	CCONJ	O	O
pharmacokinetics	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
combination	NOUN	O	O
therapies	NOUN	O	O
containing	VERB	O	O
an	DET	O	O
NRTI	NOUN	O	O
,	PUNCT	O	O
protease	NOUN	O	O
inhibitors	NOUN	O	O
+/-	VERB	O	O
a	DET	O	O
nonnucleoside	NOUN	O	O
reverse	ADJ	O	O
transcription	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
NNRTI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
phase	NOUN	O	O
II	NUM	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Forty-one	NUM	O	O
children	NOUN	O	O
and	CCONJ	O	O
youths	NOUN	O	O
between	ADP	O	O
5	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
21	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
prior	VERB	O	O
NRTI	NOUN	O	O
and	CCONJ	O	O
no	DET	O	O
prior	ADP	O	O
NNRTI	NOUN	O	O
or	CCONJ	O	O
protease	NOUN	O	O
inhibitor	NOUN	O	O
experience	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
nelfinavir	NOUN	O	O
(	PUNCT	O	O
NFV	NOUN	O	O
)	PUNCT	O	O
30	NUM	O	O
mg/kg	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
(	PUNCT	O	O
bid	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ritonavir	NOUN	O	O
(	PUNCT	O	O
RTV	NOUN	O	O
)	PUNCT	O	O
400	NUM	O	O
mg/m	ADJ	O	O
bid	ADJ	O	O
and	CCONJ	O	O
buffered	VERB	O	O
didanosine	NOUN	O	O
(	PUNCT	O	O
ddI	NOUN	O	O
)	PUNCT	O	O
240	NUM	O	O
mg/m	ADP	O	O
daily	ADV	O	O
(	PUNCT	O	O
arm	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
NFV	NOUN	O	O
50-55	DET	O	O
mg/kg	NOUN	O	O
bid	ADJ	O	O
,	PUNCT	O	O
nevirapine	NOUN	O	O
(	PUNCT	O	O
NVP	NOUN	O	O
)	PUNCT	O	O
120	NUM	O	O
mg/m	NOUN	O	O
bid	ADJ	O	O
and	CCONJ	O	O
stavudine	PUNCT	O	O
(	PUNCT	O	O
d4T	NOUN	O	O
)	PUNCT	O	O
1	NUM	O	O
mg/kg	NOUN	O	O
bid	ADP	O	O
(	PUNCT	O	O
arm	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
clinically	ADV	O	O
for	ADP	O	O
48	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Intensive	ADJ	O	O
pharmacokinetic	ADJ	O	O
sampling	VERB	O	O
occurred	VERB	O	O
after	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
HIV-1	NOUN	O	O
RNA	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=400	PUNCT	O	O
copies/mL	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
randomized	VERB	O	O
treatment	NOUN	O	O
at	ADP	O	O
48	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
65	NUM	O	O
%	SYM	O	O
among	ADP	O	O
children	NOUN	O	O
assigned	PUNCT	O	O
NFV	NOUN	O	O
+	SYM	O	O
RTV	NOUN	O	O
+	SYM	O	O
ddI	NOUN	O	O
versus	CCONJ	O	O
28	NUM	O	O
%	SYM	O	O
among	ADP	O	O
those	DET	O	O
assigned	PUNCT	O	O
NFV	NOUN	O	O
+	SYM	O	O
NVP	NOUN	O	O
+	SYM	O	O
d4T	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.039	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
median	ADJ	O	O
CD4	NOUN	O	B-PHYSICAL
%	ADV	O	I-PHYSICAL
change	NOUN	O	I-PHYSICAL
from	ADP	O	O
baseline	NOUN	O	O
to	PUNCT	O	O
week	ADJ	O	O
48	NUM	O	O
was	VERB	O	O
found	VERB	O	O
(	PUNCT	O	O
3	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
safety	NOUN	O	B-OTHER
or	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
between	ADP	O	O
children	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
NFV	NOUN	O	O
+	SYM	O	O
RTV	NOUN	O	O
+	SYM	O	O
ddI	NOUN	O	O
versus	CCONJ	O	O
NFV	NOUN	O	O
+	SYM	O	O
NVP	NOUN	O	O
+	SYM	O	O
d4T	ADV	O	O
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
rate	NOUN	O	O
of	ADP	O	O
permanent	ADJ	O	B-OTHER
discontinuation	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
study	VERB	O	I-OTHER
treatment	NOUN	O	I-OTHER
was	VERB	O	O
noted	VERB	O	O
among	ADP	O	O
children	NOUN	O	O
assigned	NUM	O	O
to	ADP	O	O
NFV	NOUN	O	O
+	SYM	O	O
NVP	NOUN	O	O
+	SYM	O	O
d4T	ADV	O	O
compared	NOUN	O	O
with	ADP	O	O
NFV	NOUN	O	O
+	SYM	O	O
RTV	NOUN	O	O
+	SYM	O	O
ddI	NOUN	O	O
[	PUNCT	O	O
7	NUM	O	O
of	ADP	O	O
20	NUM	O	O
(	PUNCT	O	O
35	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
2	NUM	O	O
of	ADP	O	O
21	NUM	O	O
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.12	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

NFV	NOUN	O	O
pharmacokinetic	ADJ	O	O
measurements	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
yet	ADV	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
NFV	NOUN	O	O
metabolite	NOUN	O	O
,	PUNCT	O	O
M8	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
subjects	NOUN	O	O
receiving	DET	O	O
RTV	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pharmacokinetics	NOUN	O	O
for	ADP	O	O
NVP	NOUN	O	O
,	PUNCT	O	O
RTV	NOUN	O	O
and	CCONJ	O	O
d4T	ADV	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	PUNCT	O	O
of	ADP	O	O
previously	ADV	O	O
reported	VERB	O	O
data	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Combination	NOUN	O	O
therapy	NOUN	O	O
containing	VERB	O	O
NFV	NOUN	O	O
+	SYM	O	O
RTV	NOUN	O	O
+	SYM	O	O
ddI	NOUN	O	O
appears	NOUN	O	O
more	ADV	O	O
efficacious	ADJ	O	O
in	ADP	O	O
NRTI-experienced	VERB	O	O
children	ADJ	O	O
than	PUNCT	O	O
a	DET	O	O
regimen	NOUN	O	O
containing	ADP	O	O
NFV	NOUN	O	O
+	SYM	O	O
NVP	NOUN	O	O
+	SYM	O	O
d4T	NOUN	O	O
.	PUNCT	O	O

Differences	NOUN	O	O
in	ADP	O	O
tolerability	NOUN	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
identified	VERB	O	O
.	PUNCT	O	O

Systemic	ADJ	O	O
exposure	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	ADV	O	O
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
reported	VERB	O	O
in	ADP	O	O
other	ADJ	O	O
HIV-infected	VERB	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
ALVAC-CEA/B7.1	ADJ	O	O
vaccine	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
vaccines	NOUN	O	O
and	CCONJ	O	O
chemotherapy	NOUN	O	O
holds	ADP	O	O
promise	PUNCT	O	O
for	ADP	O	O
cancer	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
cytotoxic	ADJ	O	O
chemotherapy	NOUN	O	O
on	ADP	O	O
vaccine-induced	VERB	O	O
antitumor	NOUN	O	O
immunity	NOUN	O	O
is	VERB	O	O
unknown	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
chemotherapy	NOUN	O	O
on	ADP	O	O
ALVAC-CEA/B7.1-induced	NOUN	O	O
T-cell	NOUN	O	O
immunity	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

EXPERIMENTAL	ADJ	O	O
DESIGN	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
fluorouracil	NOUN	O	O
,	PUNCT	O	O
leucovorin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
irinotecan	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
also	ADV	O	O
given	PUNCT	O	O
ALVAC-CEA/B7.1	ADJ	O	O
vaccine	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
tetanus	NOUN	O	O
toxoid	NOUN	O	O
adjuvant	NOUN	O	O
.	PUNCT	O	O

Eligible	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
ALVAC	ADJ	O	O
followed	VERB	O	O
by	ADP	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
booster	NOUN	O	O
vaccination	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ALVAC	ADJ	O	O
and	CCONJ	O	O
tetanus	NOUN	O	O
toxoid	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
chemotherapy	NOUN	O	O
alone	ADJ	O	O
followed	VERB	O	O
by	ADP	O	O
ALVAC	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
disease	NOUN	O	O
progression	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Humoral	ADJ	O	O
immune	ADJ	O	O
responses	ADV	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
standard	ADJ	O	O
ELISA	NOUN	O	O
assay	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
carcinoembryonic	ADJ	O	O
antigen	NOUN	O	O
(	PUNCT	O	O
CEA	NOUN	O	O
)	PUNCT	O	O
-specific	ADJ	O	O
T-cell	NOUN	O	O
responses	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
IFN-gamma	NOUN	O	O
enzyme-linked	DET	O	O
immunospot	ADJ	O	O
assay	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
One	NUM	O	O
hundred	PUNCT	O	O
eighteen	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	ADP	O	O
either	PUNCT	O	O
ALVAC	ADJ	O	O
before	ADP	O	O
and	CCONJ	O	O
concomitantly	ADV	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
39	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ALVAC	ADJ	O	O
with	ADP	O	O
tetanus	NOUN	O	O
adjuvant	ADJ	O	O
before	ADP	O	O
and	CCONJ	O	O
concomitantly	ADV	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
40	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
chemotherapy	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
ALVAC	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
39	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
largely	ADV	O	O
gastrointestinal	ADJ	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
hematologic	ADJ	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
42	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
40.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
showed	VERB	O	O
objective	ADJ	O	O
clinical	ADJ	O	O
responses	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
developed	VERB	O	O
antibody	NOUN	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
against	ADP	O	I-PHYSICAL
ALVAC	ADJ	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
increased	VERB	O	O
anti-CEA	NOUN	O	B-PHYSICAL
antibody	NOUN	O	I-PHYSICAL
titers	NOUN	O	I-PHYSICAL
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
only	ADV	O	O
three	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Increases	CCONJ	O	O
in	ADP	O	O
CEA-specific	ADJ	O	B-PHYSICAL
T	NOUN	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
50	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
37	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
groups	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
or	CCONJ	O	O
immune	ADJ	O	O
responses	NOUN	O	O
between	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
ALVAC-CEA/B7.1	ADJ	O	O
vaccine	NOUN	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
chemotherapy	NOUN	O	O
has	PUNCT	O	O
an	DET	O	O
acceptable	ADJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Systemic	ADJ	O	O
chemotherapy	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
generation	NOUN	O	O
of	ADP	O	O
CEA-specific	ADJ	O	B-PHYSICAL
T-cell	NOUN	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
following	ADP	O	O
vaccination	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
fluid	NOUN	O	O
types	NOUN	O	O
for	ADP	O	O
resuscitation	NOUN	O	O
after	ADP	O	O
acute	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
in	ADP	O	O
mallard	NOUN	O	O
ducks	VERB	O	O
(	PUNCT	O	O
Anas	NOUN	O	O
platyrhynchos	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
LD	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
acute	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
in	ADP	O	O
mallard	NOUN	O	O
ducks	VERB	O	O
(	PUNCT	O	O
Anas	NOUN	O	O
platyrhynchos	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
compare	VERB	O	O
the	DET	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
among	ADP	O	O
3	NUM	O	O
fluid	NOUN	O	O
resuscitation	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
determine	ADJ	O	O
the	DET	O	O
time	NOUN	O	O
required	ADJ	O	O
for	ADP	O	O
a	DET	O	O
regenerative	ADJ	O	O
RBC	NOUN	O	O
response	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Medical	ADJ	O	O
College	NOUN	O	O
of	ADP	O	O
Wisconsin	NOUN	O	O
Research	NOUN	O	O
facility	NOUN	O	O
.	PUNCT	O	O

ANIMALS	NOUN	O	O
Eighteen	NUM	O	O
mallard	NOUN	O	O
ducks	VERB	O	O
were	VERB	O	O
included	VERB	O	O
for	ADP	O	O
the	DET	O	O
LD	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
)	PUNCT	O	O
study	NOUN	O	O
and	CCONJ	O	O
28	NUM	O	O
for	ADP	O	O
the	DET	O	O
fluid	NOUN	O	O
resuscitation	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Phlebotomy	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
during	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
LD	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fluid	NOUN	O	O
resuscitation	NOUN	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Ducks	DET	O	O
in	ADP	O	O
the	DET	O	O
fluid	NOUN	O	O
resuscitation	NOUN	O	O
study	NOUN	O	O
received	VERB	O	O
a	DET	O	O
5	NUM	O	O
mL/kg	ADJ	O	O
intravenous	ADJ	O	O
bolus	NOUN	O	O
of	ADP	O	O
crystalloids	NOUN	O	O
,	PUNCT	O	O
hetastarch	NOUN	O	O
(	PUNCT	O	O
HES	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
hemoglobin-based	VERB	O	O
oxygen-carrying	ADJ	O	O
solution	NOUN	O	O
(	PUNCT	O	O
HBOCS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
MAIN	ADJ	O	O
RESULTS	NOUN	O	O
The	DET	O	O
LD	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
acute	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
was	VERB	O	O
60	NUM	O	O
%	SYM	O	O
of	ADP	O	O
total	ADJ	O	O
blood	NOUN	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

This	DET	O	O
blood	NOUN	O	O
volume	NOUN	O	O
was	VERB	O	O
removed	VERB	O	O
in	ADP	O	O
the	DET	O	O
fluid	NOUN	O	O
resuscitation	NOUN	O	O
study	PUNCT	O	O
to	PRON	O	O
create	ADJ	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
fluid	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
birds	ADP	O	O
in	ADP	O	O
the	DET	O	O
crystalloid	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
66	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
4	NUM	O	O
birds	ADP	O	O
in	ADP	O	O
the	DET	O	O
HES	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
birds	ADP	O	O
in	ADP	O	O
the	DET	O	O
HBOCS	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
died	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
statistical	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
mortality	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
was	VERB	O	O
seen	VERB	O	O
among	ADP	O	O
the	DET	O	O
3	NUM	O	O
fluid	NOUN	O	O
resuscitation	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Relative	ADJ	O	O
polychromasia	NOUN	O	O
evaluated	VERB	O	O
post-phlebotomy	NOUN	O	O
demonstrated	DET	O	O
regeneration	NOUN	O	O
starting	ADJ	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
continuing	PUNCT	O	O
through	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
LD	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
acute	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
in	ADP	O	O
mallard	NOUN	O	O
ducks	VERB	O	O
was	VERB	O	O
60	NUM	O	O
%	SYM	O	O
of	ADP	O	O
their	ADP	O	O
total	ADJ	O	O
blood	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
no	DET	O	O
statistical	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
mortality	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
was	VERB	O	O
appreciated	VERB	O	O
among	ADP	O	O
the	DET	O	O
3	NUM	O	O
fluid	NOUN	O	O
resuscitation	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
trend	NOUN	O	O
of	ADP	O	O
decreased	VERB	O	O
mortality	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
HBOCS	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
early	ADJ	O	O
regenerative	ADJ	O	O
response	NOUN	O	O
was	VERB	O	O
apparent	ADJ	O	O
following	ADJ	O	O
acute	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
experience	NOUN	O	O
of	ADP	O	O
pleasure	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
hearing	VERB	O	O
rehabilitation	NOUN	O	O
.	PUNCT	O	O

Hearing	VERB	O	O
loss	NOUN	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
major	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
social	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
daily	PUNCT	O	O
life	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
follow-up	NOUN	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
hearing-aid	PUNCT	O	O
use	NOUN	O	O
on	ADP	O	O
emotional	ADJ	O	O
experience	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
hearing	VERB	O	O
impairment	NOUN	O	O
.	PUNCT	O	O

Thirteen	PUNCT	O	O
individuals	NOUN	O	O
with	ADP	O	O
impaired	VERB	O	O
hearing	PUNCT	O	O
were	VERB	O	O
tested	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
hearing-aid	PUNCT	O	O
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
19	NUM	O	O
individuals	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
worn	PUNCT	O	O
hearing	PUNCT	O	O
aids	NOUN	O	O
for	ADP	O	O
many	DET	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
participants	NOUN	O	O
reported	VERB	O	O
their	ADP	O	O
daily	ADJ	O	B-MENTAL
emotional	ADJ	O	I-MENTAL
experiences	PROPN	O	I-MENTAL
,	PUNCT	O	O
by	ADP	O	O
completing	PUNCT	O	O
questionnaires	NOUN	O	B-MENTAL
relating	ADJ	O	I-MENTAL
to	ADP	O	I-MENTAL
sensory	ADJ	O	I-MENTAL
and	CCONJ	O	I-MENTAL
social	ADJ	O	I-MENTAL
pleasure	NOUN	O	I-MENTAL
.	PUNCT	O	O

After	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
hearing-aid	PUNCT	O	O
use	NOUN	O	O
,	PUNCT	O	O
individuals	NOUN	O	O
experienced	PUNCT	O	O
more	PUNCT	O	O
physical	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
social	ADJ	O	I-MENTAL
pleasure	NOUN	O	I-MENTAL
,	PUNCT	O	O
whereas	ADP	O	O
individuals	NOUN	O	O
using	VERB	O	O
hearing	VERB	O	O
aids	NOUN	O	O
for	ADP	O	O
long	ADJ	O	O
periods	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
reported	ADP	O	O
similar	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
pleasure	NOUN	O	O
at	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
a	DET	O	O
6-month	NOUN	O	O
interval	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
participants	NOUN	O	O
also	ADV	O	O
performed	VERB	O	O
a	DET	O	O
visual	ADJ	O	O
task	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADP	O	O
they	ADV	O	O
rated	PROPN	O	O
the	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
pleasure	ADJ	O	B-MENTAL
they	PUNCT	O	I-MENTAL
experienced	ADP	O	I-MENTAL
in	ADP	O	I-MENTAL
response	NOUN	O	O
to	ADP	O	B-MENTAL
emotionally	DET	O	I-MENTAL
positive	ADJ	O	O
and	CCONJ	O	B-MENTAL
neutral	ADJ	O	I-MENTAL
pictures	NOUN	O	I-MENTAL
differing	PUNCT	O	I-MENTAL
in	ADP	O	I-MENTAL
luminance	ADJ	O	B-MENTAL
contrast	NOUN	O	I-MENTAL
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
task	NOUN	O	O
,	PUNCT	O	O
pleasure	NOUN	O	O
typically	ADV	O	O
decreases	PUNCT	O	O
with	ADP	O	O
decreasing	DET	O	O
contrast	NOUN	O	O
of	ADP	O	O
the	DET	O	O
positive	ADJ	O	O
images	NOUN	O	O
displayed	VERB	O	O
.	PUNCT	O	O

Once	ADP	O	O
they	NOUN	O	O
had	PUNCT	O	O
been	PUNCT	O	O
fitted	VERB	O	O
with	ADP	O	O
hearing	VERB	O	O
aids	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
participants	NOUN	O	O
reported	ADP	O	O
lower	VERB	O	O
levels	NOUN	O	B-MENTAL
of	PUNCT	O	I-MENTAL

Utilization	NOUN	O	O
patterns	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	O
and	CCONJ	O	O
complementary/alternative	ADJ	O	O
treatments	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
and	CCONJ	O	O
developmental	ADJ	O	O
disabilities	NOUN	O	O
in	ADP	O	O
a	DET	O	O
population-based	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
utilization	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	O
treatments	NOUN	O	O
and	CCONJ	O	O
utilization	NOUN	O	O
of	ADP	O	O
complementary	ADJ	O	O
and	CCONJ	O	O
alternative	ADJ	O	O
medicine	NOUN	O	O
in	ADP	O	O
preschoolers	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
developmental	ADP	O	O
disabilities	NOUN	O	O
(	PUNCT	O	O
DD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Participants	PUNCT	O	O
were	VERB	O	O
578	NUM	O	O
children	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
part	NOUN	O	O
of	ADP	O	O
an	DET	O	O
ongoing	ADJ	O	O
population-based	VERB	O	O
,	PUNCT	O	O
case-control	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
2-	NUM	O	O
to	ADP	O	O
5-year	ADJ	O	O
olds	CCONJ	O	O
with	ADP	O	O
ASD	NOUN	O	O
,	PUNCT	O	O
DD	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
general	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
completed	ADV	O	O
an	DET	O	O
interview	NOUN	O	O
on	ADP	O	O
past	PUNCT	O	O
and	CCONJ	O	O
current	ADJ	O	O
services	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Four	NUM	O	O
hundred	NUM	O	O
fifty-three	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
and	CCONJ	O	O
125	NUM	O	O
DD	NOUN	O	O
children	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

ASD	NOUN	O	O
families	NOUN	O	O
received	VERB	O	O
more	PUNCT	O	O
hours	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	B-OTHER
services	NOUN	O	I-OTHER
compared	VERB	O	O
with	ADP	O	O
DD	NOUN	O	O
families	NOUN	O	O
(	PUNCT	O	O
17.8	ADP	O	O
vs	CCONJ	O	O
11	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
psychotropic	ADJ	O	O
medications	NOUN	O	O
was	VERB	O	O
low	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
approximately	ADJ	O	O
3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
complementary	ADJ	O	B-OTHER
and	CCONJ	O	O
alternative	ADJ	O	B-OTHER
medicine	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
CAM	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
use	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
in	ADP	O	O
ASD	NOUN	O	O
(	PUNCT	O	O
39	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
DD	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Hispanic	ADJ	O	O
families	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
used	ADV	O	O
CAM	NOUN	O	B-OTHER
less	ADV	O	O
often	ADV	O	O
than	PUNCT	O	O
non-Hispanic	ADP	O	O
families	NOUN	O	O
.	PUNCT	O	O

Variables	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
level	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
immunization	NOUN	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
presence	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
an	DET	O	I-PHYSICAL
identified	VERB	O	I-PHYSICAL
neurogenetic	ADJ	O	I-PHYSICAL
disorder	NOUN	O	I-PHYSICAL
were	VERB	O	O
not	ADV	O	O
predictive	ADJ	O	O
of	ADP	O	O
CAM	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
higher	PUNCT	O	O
level	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
parental	ADJ	O	I-OTHER
education	NOUN	O	I-OTHER
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
CAM	NOUN	O	B-OTHER
use	NOUN	O	O
in	ADP	O	O
ASD	NOUN	O	O
and	CCONJ	O	O
DD	NOUN	O	O
.	PUNCT	O	O

Families	NOUN	O	O
who	PROPN	O	O
used	VERB	O	O
>	PROPN	O	O
20	NUM	O	O
hours	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	O
services	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	ADP	O	O
use	VERB	O	O
CAM	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
potentially	ADV	O	O
unsafe	ADJ	O	O
or	CCONJ	O	O
disproven	PUNCT	O	O
CAM	NOUN	O	O
.	PUNCT	O	O

Underimmunized	ADV	O	O
children	NOUN	O	O
were	VERB	O	O
marginally	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	ADP	O	O
use	NOUN	O	O
CAM	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
more	ADJ	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
received	VERB	O	O
potentially	ADV	O	O
unsafe	ADJ	O	O
or	CCONJ	O	O
disproven	PUNCT	O	O
CAM	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Use	NOUN	O	O
of	ADP	O	O
CAM	NOUN	O	O
is	VERB	O	O
common	ADJ	O	O
in	ADP	O	O
families	NOUN	O	O
of	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
neurodevelopmental	ADJ	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
predicted	VERB	O	O
by	ADP	O	O
higher	PUNCT	O	O
parental	ADJ	O	O
education	NOUN	O	O
and	CCONJ	O	O
non-Hispanic	ADP	O	O
ethnicity	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
developmental	ADJ	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
research	NOUN	O	O
should	VERB	O	O
address	VERB	O	O
how	ADP	O	O
health	NOUN	O	O
care	NOUN	O	O
providers	ADV	O	O
can	VERB	O	O
support	VERB	O	O
families	NOUN	O	O
in	ADP	O	O
making	PUNCT	O	O
decisions	NOUN	O	O
about	PUNCT	O	O
CAM	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

Development	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
disease	NOUN	O	O
in	ADP	O	O
people	NOUN	O	O
at	ADP	O	O
high	ADJ	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
HOPE	NOUN	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
people	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
,	PUNCT	O	O
renal	ADJ	O	O
disease	NOUN	O	O
tends	NOUN	O	O
to	ADP	O	O
progress	PUNCT	O	O
from	ADP	O	O
microalbuminuria	NOUN	O	O
to	ADP	O	O
clinical	ADJ	O	O
proteinuria	NOUN	O	O
to	ADP	O	O
renal	ADJ	O	O
insufficiency	NOUN	O	O
.	PUNCT	O	O

Little	DET	O	O
evidence	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
published	VERB	O	O
for	ADP	O	O
the	DET	O	O
nondiabetic	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
retrospectively	ADP	O	O
analyzed	VERB	O	O
changes	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	O
over	ADP	O	O
4.5	NUM	O	O
yr	NOUN	O	O
in	ADP	O	O
the	DET	O	O
HOPE	NOUN	O	O
(	PUNCT	O	O
Heart	NOUN	O	O
Outcomes	NOUN	O	O
and	CCONJ	O	O
Prevention	NOUN	O	O
Evaluation	NOUN	O	O
)	PUNCT	O	O
study	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
compared	VERB	O	O
ramipril	NOUN	O	O
's	PUNCT	O	O
effects	NOUN	O	O
to	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
9297	NUM	O	O
participants	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
3577	NUM	O	O
with	ADP	O	O
diabetes	NOUN	O	O
and	CCONJ	O	O
1956	NUM	O	O
with	ADP	O	O
microalbuminuria	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
is	VERB	O	O
restricted	VERB	O	O
to	ADP	O	O
7674	NUM	O	O
participants	NOUN	O	O
with	ADP	O	O
albuminuria	NOUN	O	O
data	ADP	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Inclusion	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
known	VERB	O	O
vascular	ADJ	O	O
disease	NOUN	O	O
or	CCONJ	O	O
diabetes	NOUN	O	O
plus	CCONJ	O	O
one	NUM	O	O
other	ADJ	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
,	PUNCT	O	O
exclusion	NOUN	O	O
criteria	NOUN	O	O
included	VERB	O	O
heart	NOUN	O	O
failure	NOUN	O	O
or	CCONJ	O	O
known	ADJ	O	O
impaired	VERB	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
dipstick-positive	PUNCT	O	O
proteinuria	NOUN	O	O
(	PUNCT	O	O
>	PROPN	O	O
1+	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	O
>	SYM	O	O
2.3	NUM	O	O
mg/dl	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
microM	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
microalbuminuria	NOUN	O	O
predicted	VERB	O	O
subsequent	ADJ	O	O
clinical	ADJ	O	B-PHYSICAL
proteinuria	NOUN	O	I-PHYSICAL
for	ADP	O	O
the	DET	O	O
study	ADP	O	O
participants	NOUN	O	O
overall	ADJ	O	O
(	PUNCT	O	O
adjusted	VERB	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
[	PUNCT	O	O
OR	CCONJ	O	O
]	PUNCT	O	O
,	PUNCT	O	O
17.5	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
12.6	NUM	O	O
to	ADP	O	O
24.4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
participants	NOUN	O	O
without	ADP	O	O
diabetes	NOUN	O	O
(	PUNCT	O	O
OR	NOUN	O	O
,	PUNCT	O	O
16.7	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
8.6	NUM	O	O
to	ADP	O	O
32.4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
(	PUNCT	O	O
OR	NOUN	O	O
,	PUNCT	O	O
18.2	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
12.4	NUM	O	O
to	ADP	O	O
26.7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Any	DET	O	O
progression	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
albuminuria	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
defined	PROPN	O	O
as	PUNCT	O	O
new	ADJ	O	O
microalbuminuria	NOUN	O	O
or	CCONJ	O	O
new	ADJ	O	O
clinical	ADJ	O	O
proteinuria	NOUN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
1859	NUM	O	O
participants	NOUN	O	O
;	PUNCT	O	O
1542	NUM	O	O
developed	PUNCT	O	O
new	ADJ	O	O
microalbuminuria	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
317	NUM	O	O
participants	NOUN	O	O
developed	VERB	O	O
clinical	ADJ	O	B-PHYSICAL
proteinuria	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Ramipril	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
any	DET	O	O
progression	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
OR	NOUN	O	O
,	PUNCT	O	O
0.87	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
0.78	NUM	O	O
to	ADP	O	O
0.97	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0146	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

People	NOUN	O	O
without	ADP	O	O
and	CCONJ	O	O
with	ADP	O	O
diabetes	NOUN	O	O
who	DET	O	O
are	VERB	O	O
at	ADP	O	O
high	ADJ	O	B-PHYSICAL
risk	NOUN	O	O
for	ADP	O	B-PHYSICAL
cardiovascular	ADJ	O	I-PHYSICAL
disease	NOUN	O	B-PHYSICAL
are	VERB	O	O
also	ADV	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
a	DET	O	O
progressive	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
albuminuria	ADV	O	B-PHYSICAL
.	PUNCT	O	O

Microalbuminuria	NOUN	O	B-PHYSICAL
itself	ADV	O	O
predicts	VERB	O	O
clinical	ADJ	O	O
proteinuria	NOUN	O	O
in	ADP	O	O
nondiabetic	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
diabetic	ADJ	O	O
people	NOUN	O	O
.	PUNCT	O	O

Ramipril	NOUN	O	O
prevents	VERB	O	O
or	CCONJ	O	O
delays	PUNCT	O	O
the	PUNCT	O	O

Pars	NOUN	O	O
plana	NOUN	O	O
vitrectomy	NOUN	O	O
for	ADP	O	O
diabetic	ADJ	O	O
macular	ADJ	O	O
edema	NOUN	O	O
.	PUNCT	O	O

Internal	ADJ	O	O
limiting	ADP	O	O
membrane	NOUN	O	O
delamination	NOUN	O	O
vs	CCONJ	O	O
posterior	ADJ	O	O
hyaloid	ADJ	O	O
removal	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Diabetes	NOUN	O	O
mellitus	NOUN	O	O
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
subsequent	ADJ	O	O
ocular	ADJ	O	O
complications	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
cystoid	NOUN	O	O
macular	ADJ	O	O
edema	NOUN	O	O
(	PUNCT	O	O
CME	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
are	VERB	O	O
of	ADP	O	O
fundametal	ADJ	O	O
socio-economic	ADJ	O	O
relevance	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
internal	ADJ	O	O
limiting	ADP	O	O
membrane	NOUN	O	O
(	PUNCT	O	O
ILM	NOUN	O	O
)	PUNCT	O	O
removal	NOUN	O	O
on	ADP	O	O
longterm	NOUN	O	O
morphological	ADJ	O	O
and	CCONJ	O	O
functional	ADJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
(	PUNCT	O	O
DM	NOUN	O	O
)	PUNCT	O	O
type	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
CME	NOUN	O	O
without	ADP	O	O
evident	ADJ	O	O
vitreomacular	ADJ	O	O
traction	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Forty	CCONJ	O	O
eyes	NOUN	O	O
with	ADP	O	O
attached	VERB	O	O
posterior	ADJ	O	O
hyaloid	ADJ	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
trial	NOUN	O	O
and	CCONJ	O	O
randomized	VERB	O	O
intraoperatively	ADV	O	O
.	PUNCT	O	O

Prior	ADJ	O	O
focal	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
31	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
panretinal	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
25	NUM	O	O
)	PUNCT	O	O
laser	NOUN	O	O
coagulation	NOUN	O	O
was	VERB	O	O
permitted	VERB	O	O
.	PUNCT	O	O

Group	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
19	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
underwent	VERB	O	O
surgical	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
posterior	ADJ	O	O
vitreous	ADJ	O	O
detachment	NOUN	O	O
(	PUNCT	O	O
PVD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
group	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
20	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
PVD	NOUN	O	O
and	CCONJ	O	O
removal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ILM	NOUN	O	O
.	PUNCT	O	O

Eleven	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
detached	PROPN	O	O
posterior	ADJ	O	O
hyaloid	PUNCT	O	O
(	PUNCT	O	O
group	NOUN	O	O
III	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
not	ADV	O	O
randomized	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
ILM	NOUN	O	O
removal	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
eye	NOUN	O	O
had	PUNCT	O	O
to	PART	O	O
be	PUNCT	O	O
excluded	VERB	O	O
from	ADP	O	O
further	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Examinations	NOUN	O	O
included	VERB	O	O
ETDRS	NOUN	O	B-PHYSICAL
best-corrected	ADP	O	I-PHYSICAL
visual	ADJ	O	I-PHYSICAL
acuity	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BCVA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
fluorescein	NOUN	O	O
angiography	NOUN	O	O
(	PUNCT	O	O
FLA	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
OCT	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
postoperatively	ADV	O	O
.	PUNCT	O	O

Main	ADJ	O	O
outcome	NOUN	O	O
measure	ADV	O	O
was	VERB	O	O
BCVA	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
secondary	ADJ	O	O
was	VERB	O	O
foveal	ADJ	O	B-PHYSICAL
thickness	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Mean	ADP	O	O
BCVA	NOUN	O	B-PHYSICAL
over	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
remained	DET	O	O
unchanged	VERB	O	O
in	ADP	O	O
85	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
decreased	PUNCT	O	O
in	ADP	O	O
53	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
different	ADJ	O	O
[	PUNCT	O	O
group	NOUN	O	O
I	NUM	O	O
:	PUNCT	O	O
mean	NOUN	O	O
decrease	NOUN	O	O
log	NOUN	O	O
MAR	NOUN	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
(	PUNCT	O	O
0.06	NUM	O	O
;	PUNCT	O	O
0.32	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
group	NOUN	O	O
II	NUM	O	O
:	PUNCT	O	O
(	PUNCT	O	O
-0.02	NUM	O	O
;	PUNCT	O	O
0.11	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OCT	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
reduction	NOUN	O	O
of	ADP	O	O
foveal	ADJ	O	B-PHYSICAL
thickness	NOUN	O	I-PHYSICAL
following	DET	O	O
PVD	NOUN	O	O
with	ADP	O	O
ILM	NOUN	O	O
removal	NOUN	O	O
[	PUNCT	O	O
group	NOUN	O	O
I	NUM	O	O
:	PUNCT	O	O
mean	NOUN	O	O
change	NOUN	O	O
:	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
(	PUNCT	O	O
-208.95	NOUN	O	O
?m	PUNCT	O	O
;	PUNCT	O	O
-78.05	PUNCT	O	O
?m	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
group	NOUN	O	O
II	NUM	O	O
:	PUNCT	O	O
(	PUNCT	O	O
-80.90	PUNCT	O	O
?m	PUNCT	O	O
:	PUNCT	O	O
+59.17	CCONJ	O	O
?m	PUNCT	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Vitrectomy	NOUN	O	O
,	PUNCT	O	O
PVD	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
ILM	NOUN	O	O
removal	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
improve	VERB	O	O
vision	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
DM	NOUN	O	O
type	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
cystoid	NOUN	O	O
diabetic	ADJ	O	O
macular	ADJ	O	O
edema	NOUN	O	O
without	ADP	O	O
evident	ADJ	O	O
vitreoretinal	ADJ	O	O
traction	NOUN	O	O
.	PUNCT	O	O

ILM	NOUN	O	O
delamination	NOUN	O	O
shows	NOUN	O	O
improved	ADP	O	O
morphological	ADJ	O	O
results	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
beneficial	ADJ	O	O
in	ADP	O	O
eyes	NOUN	O	O
with	ADP	O	O
preexisting	PUNCT	O	O
PVD	NOUN	O	O
.	PUNCT	O	O

Predictive	ADJ	O	O
and	CCONJ	O	O
prognostic	ADJ	O	O
roles	NOUN	O	O
of	ADP	O	O
BRAF	NOUN	O	O
mutation	NOUN	O	O
in	ADP	O	O
stage	NOUN	O	O
III	NUM	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
results	CCONJ	O	O
from	ADP	O	O
intergroup	NOUN	O	O
trial	NOUN	O	O
CALGB	NOUN	O	O
89803	NUM	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Alterations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
RAS-RAF-MAP2K	NOUN	O	O
(	PUNCT	O	O
MEK	NOUN	O	O
)	PUNCT	O	O
-MAPK	NOUN	O	O
signaling	VERB	O	O
pathway	NOUN	O	O
are	VERB	O	O
major	ADJ	O	O
drivers	DET	O	O
in	ADP	O	O
colorectal	ADJ	O	O
carcinogenesis	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
BRAF	NOUN	O	O
mutation	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
microsatellite	NOUN	O	O
instability	NOUN	O	O
(	PUNCT	O	O
MSI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
typically	ADV	O	O
predicts	NOUN	O	O
inferior	ADJ	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
BRAF	NOUN	O	O
mutation	NOUN	O	O
on	ADP	O	O
survival	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
efficacy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
III	NUM	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
assessed	VERB	O	O
status	NOUN	O	O
of	ADP	O	O
BRAF	NOUN	O	O
c.1799T	NOUN	O	O
>	SYM	O	O
A	DET	O	O
(	PUNCT	O	O
p.V600E	NOUN	O	O
)	PUNCT	O	O
mutation	NOUN	O	O
and	CCONJ	O	O
MSI	NOUN	O	O
in	ADP	O	O
506	NUM	O	O
stage	NOUN	O	O
III	NUM	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
trial	NOUN	O	O
[	PUNCT	O	O
5-fluorouracil	NOUN	O	O
and	CCONJ	O	O
leucovorin	NOUN	O	O
(	PUNCT	O	O
FU/LV	NOUN	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
irinotecan	PUNCT	O	O
(	PUNCT	O	O
CPT11	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
FU	NOUN	O	O
and	CCONJ	O	O
LV	NOUN	O	O
(	PUNCT	O	O
IFL	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
CALGB	NOUN	O	O
89803	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Cox	NOUN	O	O
proportional	ADJ	O	O
hazards	NOUN	O	O
model	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
prognostic	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
BRAF	NOUN	O	O
mutation	NOUN	O	O
,	PUNCT	O	O
adjusting	ADJ	O	O
for	ADP	O	O
clinical	ADJ	O	O
features	NOUN	O	O
,	PUNCT	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
arm	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
MSI	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Compared	VERB	O	O
with	ADP	O	O
431	NUM	O	O
BRAF	NOUN	O	O
wild-type	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
75	NUM	O	O
BRAF-mutated	VERB	O	O
patients	NOUN	O	O
experienced	PUNCT	O	O
significantly	ADV	O	O
worse	ADJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
[	PUNCT	O	I-MORTALITY
OS	NOUN	O	I-MORTALITY
;	PUNCT	O	O
log-rank	NOUN	O	O
P	NOUN	O	O
=	SYM	O	O
0.015	NUM	O	O
;	PUNCT	O	O
multivariate	ADJ	O	O
HR	NOUN	O	O
=	SYM	O	O
1.66	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.05-2.63	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

By	ADP	O	O
assessing	VERB	O	O
combined	VERB	O	O
status	NOUN	O	O
of	ADP	O	O
BRAF	NOUN	O	O
and	CCONJ	O	O
MSI	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
seemed	ADP	O	O
that	ADP	O	O
BRAF-mutated	VERB	O	O
MSS	NOUN	O	O
(	PUNCT	O	O
microsatellite	NOUN	O	O
stable	ADJ	O	O
)	PUNCT	O	O
tumor	NOUN	O	O
was	VERB	O	O
an	DET	O	O
unfavorable	ADJ	O	O
subtype	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
BRAF	NOUN	O	O
wild-type	NOUN	O	O
MSI-high	ADJ	O	O
tumor	NOUN	O	O
was	VERB	O	O
a	DET	O	O
favorable	ADJ	O	O
subtype	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
BRAF-mutated	VERB	O	O
MSI-high	ADJ	O	O
tumor	NOUN	O	O
and	CCONJ	O	O
BRAF	NOUN	O	O
wild-type	NOUN	O	O
MSS	NOUN	O	O
tumor	NOUN	O	O
were	VERB	O	O
intermediate	ADJ	O	O
subtypes	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
BRAF-mutated	VERB	O	O
tumors	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
nonsignificant	ADJ	O	O
trend	NOUN	O	O
toward	ADP	O	O
improved	VERB	O	O
OS	ADV	O	B-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
IFL	ADJ	O	O
versus	CCONJ	O	O
FU/LV	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
multivariate	ADJ	O	O
HR	NOUN	O	O
=	SYM	O	O
0.52	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.25-1.10	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
BRAF	NOUN	O	O
wild-type	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
IFL	NOUN	O	O
conferred	VERB	O	O
no	DET	O	O
suggestion	NOUN	O	O
of	ADP	O	O
benefit	NOUN	O	O
beyond	ADP	O	O
FU/LV	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
multivariate	ADJ	O	O
HR	NOUN	O	O
=	SYM	O	O
1.02	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.72-1.46	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
BRAF	NOUN	O	O
mutation	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
inferior	ADJ	O	O
survival	NOUN	O	B-MORTALITY
in	ADP	O	O
stage	NOUN	O	O
III	NUM	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
assess	NOUN	O	O
whether	ADP	O	O
there	PUNCT	O	O
is	VERB	O	O
any	DET	O	O
predictive	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
BRAF	NOUN	O	O
mutation	NOUN	O	O
for	ADP	O	O
irinotecan-based	VERB	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
sildenafil	NOUN	O	O
to	PUNCT	O	O
control	NOUN	O	O
pulmonary	ADJ	O	B-PHYSICAL
hypertension	NOUN	O	I-PHYSICAL
after	ADP	O	O
congenital	ADJ	O	O
heart	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigates	NOUN	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
sildenafil	NOUN	O	O
in	ADP	O	O
decreasing	PUNCT	O	O
pulmonary	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
after	ADP	O	O
congenital	ADJ	O	O
heart	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
September	NOUN	O	O
2002	NUM	O	O
and	CCONJ	O	O
September	NOUN	O	O
2004	NUM	O	O
,	PUNCT	O	O
among	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
large	ADJ	O	O
septal	ADJ	O	O
defects	NOUN	O	O
,	PUNCT	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
[	PUNCT	O	O
pulmonary	ADJ	O	O
artery	NOUN	O	O
(	PUNCT	O	O
PA	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
aortic	ADJ	O	O
(	PUNCT	O	O
Ao	NOUN	O	O
)	PUNCT	O	O
pressure	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
0.76	NUM	O	O
+/-	SYM	O	O
0.17	NUM	O	O
]	PUNCT	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
desaturation	NOUN	O	O
(	PUNCT	O	O
Ao	NOUN	O	O
Sat	NOUN	O	O
=	SYM	O	O
0.89	NUM	O	O
+/-	SYM	O	O
0.11	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
oral	ADJ	O	O
sildenafil	NOUN	O	O
(	PUNCT	O	O
0.3	NUM	O	O
mg	NOUN	O	O
x	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
every	DET	O	O
3	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
24-48	NUM	O	O
hours	NOUN	O	O
(	PUNCT	O	O
sildenafil	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
22	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
similar	ADJ	O	O
pathologies	NOUN	O	O
who	DET	O	O
did	CCONJ	O	O
not	ADV	O	O
receive	VERB	O	O
sildenafil	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-PHYSICAL
PA	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
28.61	NUM	O	O
+/-	SYM	O	O
7.80	NUM	O	O
vs	CCONJ	O	O
39.40	NUM	O	O
+/-	SYM	O	O
10.80	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
PA/Ao	PUNCT	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
0.28	NUM	O	O
+/-	SYM	O	O
0.08	NUM	O	O
vs	CCONJ	O	O
0.41	NUM	O	O
+/-	SYM	O	O
0.11	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
sildenafil	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
and	CCONJ	O	O
0.001	ADP	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pulmonary	ADJ	O	B-PHYSICAL
hypertensive	ADJ	O	I-PHYSICAL
crisis	NOUN	O	I-PHYSICAL
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
4	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
none	NUM	O	O
in	ADP	O	O
the	DET	O	O
sildenafil	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
PA	NOUN	O	O
pressure	NOUN	O	O
following	PUNCT	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
(	PUNCT	O	O
26.30	NUM	O	O
+/-	SYM	O	O
6.66	NUM	O	O
vs	CCONJ	O	O
28.49	NUM	O	O
+/-	SYM	O	O
10.93	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.366	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
complications	NOUN	O	B-PHYSICAL
were	VERB	O	O
noticed	VERB	O	O
regarding	VERB	O	O
sildenafil	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
sildenafil	NOUN	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
to	PUNCT	O	O
control	NOUN	O	O
postoperative	ADJ	O	O
PA	NOUN	O	O
pressure	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Absence	NOUN	O	O
of	ADP	O	O
rebound	NOUN	O	O
pulmonary	ADJ	O	B-PHYSICAL
hypertension	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
availability	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
cost	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
are	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
its	PUNCT	O	O
major	ADJ	O	O
advantages	NOUN	O	O
.	PUNCT	O	O

Botulinum	NOUN	O	O
toxin	NOUN	O	O
a	PUNCT	O	O
has	PUNCT	O	O
antinociceptive	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
in	ADP	O	O
treating	VERB	O	O
interstitial	ADJ	O	O
cystitis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
To	PUNCT	O	O
present	ADJ	O	O
clinical	ADJ	O	O
evidence	NOUN	O	O
with	ADP	O	O
botulinum	NOUN	O	O
toxin	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
BTX-A	NOUN	O	O
)	PUNCT	O	O
suggesting	VERB	O	O
an	DET	O	O
antinociceptive	ADJ	O	B-PAIN
role	NOUN	O	I-PAIN
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
interstitial	ADJ	O	O
cystitis	NOUN	O	O
(	PUNCT	O	O
IC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intriguing	PUNCT	O	O
evidence	NOUN	O	O
in	ADP	O	O
a	DET	O	O
somatic	ADJ	O	O
pain	NOUN	O	O
model	NOUN	O	O
has	PUNCT	O	O
suggested	VERB	O	O
that	ADP	O	O
BTX-A	NOUN	O	O
injection	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
an	DET	O	O
antinociceptive	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
both	CCONJ	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
(	PUNCT	O	O
inflammatory	ADJ	O	O
)	PUNCT	O	O
pain	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Thirteen	PUNCT	O	O
female	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
in	ADP	O	O
the	DET	O	O
United	ADV	O	O
States	NOUN	O	O
and	CCONJ	O	O
7	NUM	O	O
in	ADP	O	O
Poland	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
IC	NOUN	O	O
according	ADV	O	O
to	ADP	O	O
the	DET	O	O
criteria	NOUN	O	O
of	ADP	O	O
the	DET	O	O
National	ADJ	O	O
Institute	NOUN	O	O
of	ADP	O	O
Diabetes	NOUN	O	O
,	PUNCT	O	O
Digestive	ADJ	O	O
and	CCONJ	O	O
Kidney	NOUN	O	O
Disease	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

Under	ADP	O	O
short	ADJ	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
or	CCONJ	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
100	NUM	O	O
to	ADP	O	O
200	ADV	O	O
U	NOUN	O	O
of	ADP	O	O
Dysport	NOUN	O	O
(	PUNCT	O	O
Polish	PUNCT	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
Botox	NOUN	O	O
(	PUNCT	O	O
U.S.	PUNCT	O	O
patients	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
through	ADP	O	O
a	DET	O	O
cystoscope	NOUN	O	O
into	ADP	O	O
20	NUM	O	O
to	ADP	O	O
30	NUM	O	O
sites	NOUN	O	O
submucosally	ADV	O	O
in	ADP	O	O
the	DET	O	O
trigone	ADV	O	O
and	CCONJ	O	O
floor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
with	ADP	O	O
the	DET	O	O
O'Leary-Sant	ADP	O	O
validated	VERB	O	B-PHYSICAL
IC	NOUN	O	I-PHYSICAL
questionnaire	NOUN	O	O
or	CCONJ	O	O
with	ADP	O	B-PHYSICAL
voiding	DET	O	I-PHYSICAL
charts	VERB	O	I-PHYSICAL
and	CCONJ	O	O
a	DET	O	O
visual	ADJ	O	O
analog	NOUN	O	O
pain	NOUN	O	O
scale	NOUN	O	O
1	NUM	O	O
month	NOUN	O	O
postoperatively	ADV	O	O
and	CCONJ	O	O
at	ADP	O	O
subsequent	ADJ	O	O
3-month	NOUN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Polish	PUNCT	O	O
patients	NOUN	O	O
also	ADV	O	O
underwent	ADV	O	O
pretreatment	NOUN	O	O
and	CCONJ	O	O
post-treatment	NOUN	O	O
urodynamic	VERB	O	B-PHYSICAL
evaluations	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Overall	ADJ	O	O
,	PUNCT	O	O
9	NUM	O	O
(	PUNCT	O	O
69	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
noted	VERB	O	O
subjective	ADP	O	B-OTHER
improvement	NOUN	O	I-OTHER
after	ADP	O	O
BTX-A	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Interstitial	ADJ	O	B-PHYSICAL
Cystitis	NOUN	O	I-PHYSICAL
Symptom	NOUN	O	I-PHYSICAL
Index	NOUN	O	O
and	CCONJ	O	B-PHYSICAL
Interstitial	ADJ	O	I-PHYSICAL
Cystitis	NOUN	O	I-PHYSICAL
Problem	NOUN	O	B-PHYSICAL
Index	NOUN	O	O
mean	NOUN	O	O
scores	NOUN	O	O
improved	PRON	O	O
by	ADP	O	O
71	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
69	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Daytime	NOUN	O	B-PAIN
frequency	NOUN	O	O
,	PUNCT	O	O

An	DET	O	O
exploratory	ADJ	O	O
,	PUNCT	O	O
pragmatic	ADJ	O	O
,	PUNCT	O	O
cluster	NOUN	O	O
randomised	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
practice	NOUN	O	O
nurse	ADJ	O	O
training	VERB	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	O
action	NOUN	O	O
plans	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
To	PROPN	O	O
investigate	NOUN	O	O
the	DET	O	O
feasibility	NOUN	O	B-OTHER
of	ADP	O	O
improving	VERB	O	O
asthma	NOUN	O	O
management	NOUN	O	O
-	PUNCT	O	O
in	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
implementation	NOUN	O	O
of	ADP	O	O
individualised	VERB	O	O
asthma	NOUN	O	O
action	NOUN	O	O
plans	NOUN	O	O
(	PUNCT	O	O
AAPs	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
poorly-controlled	VERB	O	O
adult	NOUN	O	O
asthma	NOUN	O	O
patients	NOUN	O	O
-	PUNCT	O	O
by	ADP	O	O
providing	NOUN	O	O
training	VERB	O	O
in	ADP	O	O
asthma-focused	VERB	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
communication	NOUN	O	O
skills	NOUN	O	O
for	ADP	O	O
practice	NOUN	O	O
nurses	NOUN	O	O
who	NUM	O	O
deliver	PUNCT	O	O
asthma	NOUN	O	O
clinics	PROPN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
pragmatic	ADJ	O	O
,	PUNCT	O	O
cluster	NOUN	O	O
randomised	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
an	DET	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
an	DET	O	O
interactive	ADJ	O	O
seminar	ADJ	O	O
)	PUNCT	O	O
delivered	VERB	O	O
at	ADP	O	O
practice	NOUN	O	O
level	NOUN	O	O
(	PUNCT	O	O
n=13	NOUN	O	O
practices	PROPN	O	O
;	PUNCT	O	O
6=intervention	NOUN	O	O
,	PUNCT	O	O
7=control	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
against	ADP	O	O
patient	NOUN	O	B-PHYSICAL
outcomes	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
routinely	ADV	O	B-PHYSICAL
available	ADJ	O	I-PHYSICAL
asthma	NOUN	O	I-PHYSICAL
outcome	NOUN	O	O
measures	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
beta2-agonist	NOUN	O	B-OTHER
prescription	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
and	CCONJ	O	O
number	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	B-OTHER
steroid	NOUN	O	I-OTHER
courses	DET	O	I-OTHER
)	PUNCT	O	O
for	ADP	O	O
asthma	NOUN	O	O
patients	NOUN	O	O
identified	ADJ	O	O
as	PUNCT	O	O
being	DET	O	O
poorly-controlled	PUNCT	O	O
from	ADP	O	O
practice	NOUN	O	O
records	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
questionnaire	NOUN	O	O
data	NOUN	O	O
-	PUNCT	O	B-PHYSICAL
Mini	PUNCT	O	I-PHYSICAL

Analgesic	PUNCT	O	O
efficacy	NOUN	O	O
of	ADP	O	O
low-dose	NOUN	O	O
diclofenac	NOUN	O	O
versus	CCONJ	O	O
paracetamol	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
postoperative	ADJ	O	O
dental	ADJ	O	O
pain	NOUN	O	O
.	PUNCT	O	O

AIMS	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
diclofenac-K	NOUN	O	O
(	PUNCT	O	O
12.5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
vs	CCONJ	O	O
paracetamol	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
given	VERB	O	O
in	ADP	O	O
a	DET	O	O
flexible	ADJ	O	O
dosage	NOUN	O	O
regimen	NOUN	O	O
to	PART	O	O
treat	NOUN	O	O
pain	NOUN	O	O
resulting	ADJ	O	O
from	ADP	O	O
extraction	NOUN	O	O
of	ADP	O	O
impacted	VERB	O	O
third	ADJ	O	O
molar	ADJ	O	O
teeth	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
2-day	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
double-dummy	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
diclofenac-K	NOUN	O	O
(	PUNCT	O	O
12.5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
tablets	NOUN	O	O
vs	CCONJ	O	O
paracetamol	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
tablets	ADV	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
or	CCONJ	O	O
severe	ADJ	O	O
pain	NOUN	O	O
within	ADP	O	O
8	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
extraction	NOUN	O	O
of	ADP	O	O
impacted	VERB	O	O
third	ADJ	O	O
molars	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2-tablet	NOUN	O	O
dose	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
took	ADJ	O	O
on	ADP	O	O
average	ADJ	O	O
2.5	NUM	O	O
additional	ADJ	O	O
tablets	ADV	O	O
of	ADP	O	O
diclofenac-K	NOUN	O	O
or	CCONJ	O	O
2.4	NUM	O	O
tablets	ADV	O	O
of	ADP	O	O
paracetamol	NOUN	O	O
,	PUNCT	O	O
almost	ADV	O	O
all	PUNCT	O	O
as	ADP	O	O
1-tablet	NOUN	O	O
doses	NOUN	O	O
.	PUNCT	O	O

Most	DET	O	O
placebo	NOUN	O	O
patients	NOUN	O	O
discontinued	VERB	O	O
by	ADP	O	O
taking	VERB	O	O
rescue	ADV	O	B-PHYSICAL
medication	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
ibuprofen	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
relief	NOUN	O	I-PAIN
after	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
diclofenac-K	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
x	SYM	O	O
12.5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.01	PUNCT	O	O
for	ADP	O	O
all	DET	O	O
efficacy	NOUN	O	O
outcomes	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
comparable	ADJ	O	O
to	ADP	O	O
paracetamol	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
x	SYM	O	O
500	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

About	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
each	DET	O	O
active	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
took	PROPN	O	O
rescue	NOUN	O	B-PHYSICAL
medication	NOUN	O	I-PHYSICAL
during	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
78	NUM	O	O
%	SYM	O	O
on	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

About	PUNCT	O	O
70	NUM	O	O
%	SYM	O	O
in	ADP	O	O
each	DET	O	O
active	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
considered	VERB	O	O
the	DET	O	O
overall	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
relief	NOUN	O	I-PAIN
to	PART	O	O
be	PUNCT	O	O
some	DET	O	O
,	PUNCT	O	O
a	DET	O	O
lot	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
complete	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
only	ADV	O	O
15	NUM	O	O
%	SYM	O	O
on	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
each	DET	O	O
active	ADJ	O	O
treatment	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
low	ADJ	O	O
and	CCONJ	O	O
comparable	ADJ	O	O
between	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
An	DET	O	O
initial	ADJ	O	O
double-dose	VERB	O	O
of	ADP	O	O
diclofenac-K	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
x	SYM	O	O
12.5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
paracetamol	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
x	SYM	O	O
500	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
adequately	ADV	O	O
relieved	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
intense	ADJ	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
flexible	ADJ	O	O
multiple	ADJ	O	O
dose	NOUN	O	O
regimen	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
tablets	ADV	O	O
)	PUNCT	O	O
maintained	VERB	O	O
adequate	PUNCT	O	O
pain	NOUN	O	B-PAIN
relief	NOUN	O	I-PAIN
thereafter	ADV	O	O
.	PUNCT	O	O

Most	DET	O	O
patients	NOUN	O	O
needed	ADJ	O	O
only	ADV	O	O
1-tablet	NOUN	O	O
doses	NOUN	O	O
following	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
2-tablet	NOUN	O	O
dose	ADJ	O	O
.	PUNCT	O	O

Which	ADP	O	O
socio-demographic	ADJ	O	O
factors	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
participation	NOUN	O	O
in	ADP	O	O
oral	ADJ	O	O
cancer	NOUN	O	O
screening	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
developing	VERB	O	O
world	NOUN	O	O
?	PUNCT	O	O

Results	DET	O	O
from	ADP	O	O
a	DET	O	O
population-based	VERB	O	O
screening	PUNCT	O	O
project	NOUN	O	O
in	ADP	O	O
India	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
examines	NOUN	O	O
socio-demographic	ADJ	O	O
determinants	NOUN	O	O
of	ADP	O	O
participation	NOUN	O	O
in	ADP	O	O
a	DET	O	O
population-based	VERB	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
that	PUNCT	O	O
proved	CCONJ	O	O
that	ADP	O	O
oral	ADJ	O	O
visual	ADJ	O	O
inspection	NOUN	O	O
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
oral	ADJ	O	B-MORTALITY
cancer	NOUN	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
in	ADP	O	O
high-risk	NOUN	O	O
individuals	NOUN	O	O
in	ADP	O	O
India	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Multivariate	PUNCT	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
establish	ADJ	O	O
socio-demographic	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
participants	NOUN	O	O
versus	CCONJ	O	O
non-participants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
arm	NOUN	O	O
.	PUNCT	O	O

Compliance	NOUN	O	B-MENTAL
with	ADP	O	I-MENTAL
referral	NOUN	O	I-MENTAL
was	VERB	O	O
analysed	VERB	O	O
according	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
socio-demographic	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
screen-positives	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
96,517	NUM	O	O
eligible	ADJ	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
87,655	NUM	O	O
were	VERB	O	O
screened	VERB	O	O
,	PUNCT	O	O
8688	NUM	O	O
individuals	NOUN	O	O
never	ADV	O	O
received	VERB	O	O
the	DET	O	O
invitation	NOUN	O	O
and	CCONJ	O	O
174	NUM	O	O
refused	VERB	O	O
screening	ADP	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
non-screened	VERB	O	O
,	PUNCT	O	O
a	DET	O	O
higher	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	O
screened	VERB	O	B-OTHER
individuals	NOUN	O	O
were	DET	O	O
women	NOUN	O	O
(	PUNCT	O	O
OR=4.51	NOUN	O	O
;	PUNCT	O	O
CI	NOUN	O	O
:	PUNCT	O	O
4.28-4.75	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
lived	VERB	O	O
in	ADP	O	O
better	PUNCT	O	O
housing	PUNCT	O	O
(	PUNCT	O	O
OR=1.35	NOUN	O	O
;	PUNCT	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.25-1.41	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
had	PUNCT	O	O
television/radio	NOUN	O	O
(	PUNCT	O	O
OR=1.50	NOUN	O	O
;	PUNCT	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.43-1.58	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
tobacco	NOUN	O	O
and	CCONJ	O	O
alcohol	NOUN	O	O
users	NOUN	O	O
(	PUNCT	O	O
OR=2.75	NOUN	O	O
;	PUNCT	O	O
CI	NOUN	O	O
:	PUNCT	O	O
2.57-2.95	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Being	ADV	O	O
65	NUM	O	O
and	CCONJ	O	O
older	PUNCT	O	O
decreased	ADP	O	O
the	DET	O	O
chances	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
screening	PUNCT	O	I-OTHER
(	PUNCT	O	O
OR=0.39	NOUN	O	O
;	PUNCT	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.37-0.42	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
living	PUNCT	O	O
in	ADP	O	O
high-size	NOUN	O	B-OTHER
households	NOUN	O	I-OTHER
(	PUNCT	O	O
OR=0.73	NOUN	O	O
;	PUNCT	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.68-0.78	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Sixty-three	PUNCT	O	O
percent	NOUN	O	O
of	ADP	O	O
5143	ADJ	O	O
screen-positives	PUNCT	O	O
complied	VERB	O	O
with	ADP	O	O
referral	NOUN	O	B-OTHER
.	PUNCT	O	O

Controlling	ADJ	O	O
for	ADP	O	O
all	DET	O	O
other	ADJ	O	O
factors	NOUN	O	O
,	PUNCT	O	O
individuals	NOUN	O	O
older	PUNCT	O	O
than	ADP	O	O
44	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
those	PUNCT	O	O
with	ADP	O	O
more	DET	O	O
advanced	VERB	O	O
lesions	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	ADJ	O	O
comply	PUNCT	O	O
with	ADP	O	O
referral	NOUN	O	B-OTHER
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Individuals	NOUN	O	O
living	ADP	O	O
in	ADP	O	O
better	PUNCT	O	O
housing	PUNCT	O	O
were	ADP	O	O
less	ADV	O	O
likely	ADJ	O	O
to	ADJ	O	O
comply	PUNCT	O	B-OTHER
with	ADP	O	I-OTHER
referral	NOUN	O	I-OTHER
(	PUNCT	O	O
OR=0.79	NOUN	O	O
;	PUNCT	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.65-0.95	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
adequate	PUNCT	O	O
coverage	NOUN	O	O
can	VERB	O	O
be	DET	O	O
obtained	VERB	O	O
in	ADP	O	O
population-based	VERB	O	O
oral	ADJ	O	O
screening	NUM	O	O
in	ADP	O	O
developing	VERB	O	O
countries	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
underscores	NOUN	O	O
the	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
patient-provider	NOUN	O	O
communication	NOUN	O	O
in	ADP	O	O
assuring	VERB	O	O
high	ADJ	O	O
compliance	NOUN	O	O
with	ADP	O	O
referral	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
home-based	VERB	O	O
intervention	NOUN	O	O
program	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
developmental	ADJ	O	O
delay	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
investigate	PUNCT	O	O
whether	ADP	O	O
provision	NOUN	O	O
of	ADP	O	O
a	DET	O	O
home-based	VERB	O	O
program	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
a	DET	O	O
center-based	VERB	O	O
program	NOUN	O	O
improves	NOUN	O	O
development	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
disabilities	NOUN	O	O
and	CCONJ	O	O
coping	PUNCT	O	O
abilities	NOUN	O	O
of	ADP	O	O
their	PUNCT	O	O
families	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
describe	VERB	O	O
the	DET	O	O
characteristics	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
families	NOUN	O	O
who	ADP	O	O
benefit	VERB	O	O
most	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Fifty-nine	PUNCT	O	O
children	NOUN	O	O
,	PUNCT	O	O
aged	PROPN	O	O
3-5	PUNCT	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
cerebral	ADJ	O	O
palsy	NOUN	O	O
,	PUNCT	O	O
participated	DET	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
group	NOUN	O	O
was	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
an	DET	O	O
additional	ADJ	O	O
program	NOUN	O	O
in	ADP	O	O
their	DET	O	O
homes	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
special	ADJ	O	O
education	NOUN	O	O
teacher	NOUN	O	O
provided	VERB	O	O
40	NUM	O	O
visits	NOUN	O	O
over	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
working	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
families	NOUN	O	O
to	ADP	O	O
help	PART	O	O
generalize	ADP	O	O
skills	NOUN	O	O
to	ADP	O	O
the	DET	O	O
home	NOUN	O	O
environment	NOUN	O	O
and	CCONJ	O	O
assist	PUNCT	O	O
with	ADP	O	O
their	PUNCT	O	O
concerns	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
children	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
families	NOUN	O	O
completed	VERB	O	O
questionnaires	NOUN	O	O
assessing	PUNCT	O	O
family	NOUN	O	B-MENTAL
stress	NOUN	O	O
,	PUNCT	O	O
support	ADP	O	O
,	PUNCT	O	O
and	PUNCT	O	O

Risperidone	NUM	O	O
dosing	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
2	NUM	O	O
risperidone	NUM	O	O
doses	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
96	NUM	O	O
;	PUNCT	O	O
5-17	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
received	CCONJ	O	O
risperidone	NUM	O	O
(	PUNCT	O	O
low-dose	NOUN	O	O
:	PUNCT	O	O
0.125	NUM	O	O
mg/day	NOUN	O	O
[	PUNCT	O	O
20	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
45	NUM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
0.175	NUM	O	O
mg/day	NOUN	O	O
[	PUNCT	O	O
>	PROPN	O	O
45	NUM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
or	CCONJ	O	O
high-dose	NOUN	O	O
:	PUNCT	O	O
1.25	NUM	O	O
mg/day	NOUN	O	O
[	PUNCT	O	O
20	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
45	NUM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
1.75	NUM	O	O
mg/day	NOUN	O	O
[	PUNCT	O	O
>	PROPN	O	O
45	NUM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
27-29	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
endpoint	PUNCT	O	O
change	PUNCT	O	O
in	ADP	O	O
Aberrant	ADJ	O	O
Behavior	NOUN	O	O
Checklist-Irritability	NOUN	O	O
(	PUNCT	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
high-dose-	NOUN	O	O
(	PUNCT	O	O
-12.4	NUM	O	O
[	PUNCT	O	O
6.5	NUM	O	O
]	PUNCT	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
low-dose	NOUN	O	O
(	PUNCT	O	O
-7.4	ADV	O	O
[	PUNCT	O	O
8.1	NUM	O	O
]	PUNCT	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.164	PUNCT	O	O
)	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
-3.5	NUM	O	O
[	PUNCT	O	O
10.7	ADP	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
Global	PUNCT	O	O
Impressions-Severity	NOUN	O	O
and	CCONJ	O	O
Children	ADP	O	O
's	PUNCT	O	O
Yale-Brown	NOUN	O	O
Obsessive	ADJ	O	O
Compulsive	ADJ	O	O
Scale	NOUN	O	O
scores	NOUN	O	O
improved	VERB	O	O
significantly	ADV	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
high-dose	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
ABC-I	NOUN	O	O
results	NOUN	O	O
.	PUNCT	O	O

Somnolence	NOUN	O	O
,	PUNCT	O	O
sedation	NOUN	O	O
and	CCONJ	O	O
increased	ADV	O	O
appetite	NOUN	O	O
occurred	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
high-versus	PUNCT	O	O
low-dose	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
increased	ADV	O	O
appetite	NOUN	O	O
occurred	VERB	O	O
most	PUNCT	O	O
frequently	ADV	O	O
.	PUNCT	O	O

Preoperative	ADJ	O	O
small-dose	NOUN	O	O
ketamine	NOUN	O	O
has	PUNCT	O	O
no	DET	O	O
preemptive	ADJ	O	O
analgesic	ADP	O	O
effect	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
total	ADJ	O	O
mastectomy	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
We	PUNCT	O	O
evaluated	VERB	O	O
the	DET	O	O
preemptive	ADJ	O	O
analgesic	ADP	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
small	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	O
given	VERB	O	O
before	ADP	O	O
or	CCONJ	O	O
immediately	ADV	O	O
after	ADP	O	O
surgery	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blinded	VERB	O	O
study	NOUN	O	O
performed	VERB	O	O
in	ADP	O	O
128	NUM	O	O
women	NOUN	O	O
undergoing	VERB	O	O
total	ADJ	O	O
mastectomy	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
1	NUM	O	O
patients	NOUN	O	O
received	ADP	O	O
ketamine	ADV	O	O
0.15	NUM	O	O
mg/kg	NOUN	O	O
as	ADP	O	O
a	DET	O	O
5-mL	NOUN	O	O
i.v	NUM	O	O
.	PUNCT	O	O

injection	NOUN	O	O
5	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
isotonic	VERB	O	O
saline	NOUN	O	O
5	NUM	O	O
mL	NOUN	O	O
i.v	NUM	O	O
.	PUNCT	O	O

at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
skin	NOUN	O	O
closure	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
2	NUM	O	O
received	VERB	O	O
5	NUM	O	O
mL	NOUN	O	O
i.v	NUM	O	O
.	PUNCT	O	O

of	ADP	O	O
isotonic	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
0.15	NUM	O	O
mg/kg	NOUN	O	O
i.v	NUM	O	O
.	PUNCT	O	O

ketamine	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
standard	ADJ	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
procedure	NOUN	O	O
including	DET	O	O
sufentanil	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
room	NOUN	O	O
,	PUNCT	O	O
patient-controlled	SYM	O	O
analgesia	NOUN	O	O
i.v	NUM	O	O
.	PUNCT	O	O

morphine	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
for	ADP	O	O
postoperative	ADJ	O	O
analgesia	NOUN	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	O
pain	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
morphine	NOUN	O	B-PAIN
consumption	NOUN	O	I-PAIN
and	CCONJ	O	I-PAIN
visual	ADJ	O	O
analog	NOUN	O	O
scale	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
resistance	NOUN	O	O
versus	CCONJ	O	O
endurance	NOUN	O	O
training	VERB	O	O
on	ADP	O	O
serum	NOUN	O	B-PHYSICAL
adiponectin	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
insulin	NOUN	O	B-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
index	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
endurance	NOUN	O	O
training	VERB	O	O
on	ADP	O	O
serum	NOUN	O	O
adiponectin	NOUN	O	O
and	CCONJ	O	O
insulin	NOUN	O	O
resistance	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
SI	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
healthy	ADJ	O	O
men	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Twenty-four	PUNCT	O	O
healthy	ADJ	O	O
males	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
35-48	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
participated	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
endurance	NOUN	O	O
training	ADV	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=8	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
resistance	NOUN	O	O
training	DET	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=8	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=8	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
samples	NOUN	O	I-PHYSICAL
were	VERB	O	O
taken	VERB	O	O
in	ADP	O	O
fasting	VERB	O	O
state	NOUN	O	O
from	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
groups	NOUN	O	O
performed	ADP	O	O
either	PUNCT	O	O
endurance	NOUN	O	O
or	CCONJ	O	O
resistance	NOUN	O	O
training	VERB	O	O
3	NUM	O	O
days	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
endurance	NOUN	O	O
training	ADV	O	O
programme	NOUN	O	O
included	VERB	O	O
continuous	ADJ	O	O
running	VERB	O	O
at	ADP	O	O
an	DET	O	O
intensity	NOUN	O	O
corresponding	CCONJ	O	O
to	ADP	O	O
75-85	NUM	O	O
%	SYM	O	O
of	ADP	O	O
maximal	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
resistance	NOUN	O	O
training	PUNCT	O	O
consisted	ADJ	O	O
of	ADP	O	O
four	NUM	O	O
sets	NOUN	O	O
of	ADP	O	O
circuit	NOUN	O	O
weight	NOUN	O	O
training	VERB	O	O
for	ADP	O	O
11	NUM	O	O
stations	ADJ	O	O
and	CCONJ	O	O
at	ADP	O	O
an	DET	O	O
intensity	NOUN	O	O
corresponding	CCONJ	O	O
to	ADP	O	O
50-60	NUM	O	O
%	SYM	O	O
of	ADP	O	O
one-repetition	NOUN	O	O
maximum	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	NOUN	O	O
numbers	NOUN	O	O
of	ADP	O	O
repetitions	CCONJ	O	O
in	ADP	O	O
each	DET	O	O
station	ADP	O	O
was	VERB	O	O
12	NUM	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
significant	ADJ	O	O
negative	ADJ	O	O
correlations	NOUN	O	O
between	ADP	O	O
serum	NOUN	O	B-PHYSICAL
adiponectin	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
body	NOUN	O	B-PHYSICAL
fat	NOUN	O	I-PHYSICAL
percentage	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
waist-to-hip	PUNCT	O	B-PHYSICAL
ratio	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	B-PHYSICAL
mass	NOUN	O	O
index	NOUN	O	O
and	CCONJ	O	O
the	DET	O	B-PHYSICAL
insulin	NOUN	O	B-PHYSICAL
resistance	NOUN	O	B-PHYSICAL
index	PUNCT	O	O

Complementary	ADJ	O	O
feeding	VERB	O	O
with	ADP	O	O
fortified	VERB	O	O
spread	PUNCT	O	O
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
stunting	NUM	O	I-PHYSICAL
in	ADP	O	O
6-	NUM	O	O
to	ADP	O	O
18-month-old	ADJ	O	O
rural	ADJ	O	O
Malawians	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
growth	NOUN	O	B-OTHER
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
malnutrition	NOUN	O	B-PHYSICAL
in	ADP	O	O
infants	NOUN	O	O
receiving	VERB	O	O
long-term	NOUN	O	O
dietary	ADJ	O	O
supplementation	NOUN	O	O
with	ADP	O	O
ready-to-use	NOUN	O	O
fortified	ADJ	O	O
spread	NOUN	O	O
(	PUNCT	O	O
FS	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
micronutrient-fortified	VERB	O	O
maize-soy	NOUN	O	O
flour	NOUN	O	O
(	PUNCT	O	O
likuni	NOUN	O	O
phala	NOUN	O	O
[	PUNCT	O	O
LP	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
single-blind	ADP	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Rural	ADJ	O	O
Malawi	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
182	NUM	O	O
six-month-old	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
Participants	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
1	NUM	O	O
year	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
supplementation	NOUN	O	O
with	ADP	O	O
71	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
LP	NOUN	O	O
(	PUNCT	O	O
282	NUM	O	O
kcal	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
50	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
FS	NOUN	O	O
(	PUNCT	O	O
FS50	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
256	NUM	O	O
kcal	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
25	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
FS	NOUN	O	O
(	PUNCT	O	O
FS25	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
130	NUM	O	O
[	PUNCT	O	O
corrected	PUNCT	O	O
]	PUNCT	O	O
kcal	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Weight	NOUN	O	O
and	CCONJ	O	O
length	NOUN	O	B-PHYSICAL
gains	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
incidences	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
stunting	DET	O	I-PHYSICAL
,	PUNCT	O	O
underweight	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
wasting	ADP	O	B-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Mean	ADP	O	O
weight	NOUN	O	O
and	CCONJ	O	O
length	NOUN	O	B-PHYSICAL
gains	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
LP	NOUN	O	O
,	PUNCT	O	O
FS50	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
FS25	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
2.37	NUM	O	O
,	PUNCT	O	O
2.47	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2.37	NUM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.66	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12.7	NUM	O	O
,	PUNCT	O	O
13.5	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
13.2	NUM	O	O
cm	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.23	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
same	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cumulative	ADJ	O	O
12-month	NOUN	O	O
incidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
stunting	DET	O	I-PHYSICAL
was	ADV	O	O
13.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
0.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3.5	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
of	ADP	O	O
severe	ADJ	O	O
underweight	NOUN	O	B-PHYSICAL
was	VERB	O	O
15.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
22.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
16.9	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.71	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
wasting	ADP	O	I-PHYSICAL
was	VERB	O	O
1.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
1.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.8	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
.99	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
LP-supplemented	ADJ	O	O
infants	NOUN	O	O
,	PUNCT	O	O
those	PUNCT	O	O
given	VERB	O	O
FS50	NOUN	O	O
gained	VERB	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
g	NOUN	O	O
more	DET	O	O
weight	NOUN	O	O
and	CCONJ	O	O
0.8	NUM	O	O
cm	NOUN	O	O
more	DET	O	O
length	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
baseline	NOUN	O	O
length	NOUN	O	O
and	CCONJ	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.04	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
below-median	ADJ	O	O
length	NOUN	O	O
at	ADP	O	O
enrollment	NOUN	O	O
,	PUNCT	O	O
those	PUNCT	O	O
given	VERB	O	O
FS50	NOUN	O	O
gained	VERB	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
1.9	NUM	O	O
cm	NOUN	O	O
more	ADV	O	O
than	ADP	O	O
individuals	NOUN	O	O
receiving	VERB	O	O
LP	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
One-year-long	ADP	O	O
complementary	ADJ	O	O
feeding	ADJ	O	O
with	DET	O	O
FS	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
have	PUNCT	O	O
a	DET	O	O
significantly	ADV	O	O
larger	PUNCT	O	O
effect	NOUN	O	O
than	PUNCT	O	O
LP	NOUN	O	O
on	ADP	O	O
mean	NOUN	O	O
weight	NOUN	O	O
gain	NOUN	O	B-PHYSICAL
in	ADP	O	O
all	DET	O	O
infants	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
likely	PUNCT	O	O
to	ADP	O	O
boost	PUNCT	O	O
linear	ADJ	O	B-PHYSICAL
growth	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
disadvantaged	VERB	O	O
individuals	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
hence	ADV	O	O
,	PUNCT	O	O
decrease	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
stunting	DET	O	I-PHYSICAL
.	PUNCT	O	O

Double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
plus	CCONJ	O	O
topiramate	PUNCT	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Autism	NOUN	O	O
is	VERB	O	O
a	DET	O	O
complex	ADJ	O	O
neurodevelopmental	ADJ	O	O
disorder	NOUN	O	O
that	PUNCT	O	O
forms	DET	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
spectrum	NOUN	O	O
of	ADP	O	O
related	VERB	O	O
disorders	NOUN	O	O
referred	VERB	O	O
to	ADP	O	O
as	PUNCT	O	O
Autism	NOUN	O	O
Spectrum	NOUN	O	O
Disorders	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
topiramate	NOUN	O	O
plus	CCONJ	O	O
risperidone	NUM	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Forty	PUNCT	O	O
children	NOUN	O	O
between	ADP	O	O
the	DET	O	O
ages	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
a	DET	O	O
DSM	NOUN	O	O
IV	NUM	O	O
clinical	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
who	ADP	O	O
were	ADP	O	O
outpatients	ADJ	O	O
from	ADP	O	O
a	DET	O	O
specialty	NOUN	O	O
clinic	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
children	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
a	DET	O	O
chief	ADJ	O	O
complaint	NOUN	O	O
of	ADP	O	O
severely	ADV	O	O
disruptive	ADJ	O	O
symptoms	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
topiramate+risperidone	ADP	O	O
(	PUNCT	O	O
Group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo+risperidone	NOUN	O	O
(	PUNCT	O	O
Group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
an	DET	O	O
8-week	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
was	VERB	O	O
titrated	VERB	O	O
up	CCONJ	O	O
to	ADP	O	O
2	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
between	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
40	NUM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
weighting	CCONJ	O	O
above	ADP	O	O
40	NUM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
topiramate	NOUN	O	O
was	VERB	O	O
titrated	VERB	O	O
up	CCONJ	O	O
to	PUNCT	O	O
200	NUM	O	O
mg/day	NOUN	O	O
depending	VERB	O	O
on	ADP	O	O
weight	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
<	SYM	O	O
30	NUM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
200	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
>	SYM	O	O
30	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
starting	ADJ	O	O
medication	NOUN	O	O
.	PUNCT	O	O

Measure	NOUN	O	O
of	ADP	O	O
outcome	NOUN	O	O
was	VERB	O	O
the	DET	O	O
Aberrant	ADJ	O	B-OTHER
Behavior	NOUN	O	I-OTHER
Checklist-Community	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
ABC-C	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
Rating	PUNCT	O	I-OTHER
Scale	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
protocols	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
as	ADP	O	O
the	DET	O	O
group	NOUN	O	O
that	PUNCT	O	O
received	CCONJ	O	O
topiramate	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
greater	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
ABC-C	NOUN	O	O
subscale	NOUN	O	O
scores	NOUN	O	O
for	ADP	O	O
irritability	NOUN	O	O
,	PUNCT	O	O
stereotypic	ADJ	O	B-PHYSICAL
behavior	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
hyperactivity/noncompliance	NOUN	O	B-MENTAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
topiramate	NOUN	O	O
with	ADP	O	O
risperidone	NUM	O	O
may	VERB	O	O
be	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
risperidone	NUM	O	O
monotherapy	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
the	DET	O	O
results	ADJ	O	O
need	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
further	ADV	O	O
confirmed	VERB	O	O
by	ADP	O	O
a	DET	O	O
larger	PUNCT	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Pimecrolimus	NOUN	O	O
cream	NUM	O	O
and	CCONJ	O	O
Tacrolimus	NOUN	O	O
ointment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
atopic	ADJ	O	B-PHYSICAL
dermatitis	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	VERB	O	O
on	ADP	O	O
patient	NOUN	O	O
preference	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Pimecrolimus	NOUN	O	O
cream	VERB	O	O
1	NUM	O	O
%	SYM	O	O
is	VERB	O	O
approved	VERB	O	O
for	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
atopic	ADJ	O	O
dermatitis	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
older	PUNCT	O	O
than	VERB	O	O
two	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Tacrolimus	NOUN	O	O
ointment	NOUN	O	O
0.03	PUNCT	O	O
%	SYM	O	O
is	VERB	O	O
approved	VERB	O	O
for	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
atopic	ADJ	O	O
dermatitis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
population	NOUN	O	O
between	ADP	O	O
two	NUM	O	O
to	PUNCT	O	O
seventeen	PUNCT	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
Tacrolimus	NOUN	O	O
0.1	NUM	O	O
%	SYM	O	O
ointment	NOUN	O	O
for	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
atopic	ADJ	O	O
dermatitis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
18	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
beyond	ADP	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
delivery	NOUN	O	O
system	NOUN	O	O
or	CCONJ	O	O
vehicle	NOUN	O	O
used	PRON	O	O
in	ADP	O	O
topical	ADJ	O	O
treatment	NOUN	O	O
formulations	NOUN	O	O
is	VERB	O	O
equally	ADV	O	O
important	ADJ	O	O
in	ADP	O	O
affecting	PUNCT	O	O
patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
,	PUNCT	O	O
tolerability	NOUN	O	B-OTHER
,	PUNCT	O	O
and	PUNCT	O	O

[	PUNCT	O	O
Evaluating	VERB	O	O
an	DET	O	O
interactive	ADJ	O	O
,	PUNCT	O	O
multi-media	PUNCT	O	O
learning	VERB	O	O
system	NOUN	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
open	ADJ	O	O
angle	NOUN	O	O
glaucoma	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Using	VERB	O	O
the	DET	O	O
interactive	ADJ	O	O
multimedia	NOUN	O	O
learning	ADP	O	O
system	NOUN	O	O
for	ADP	O	O
studying	VERB	O	O
open-angle	PUNCT	O	O
glaucoma	NOUN	O	O
[	PUNCT	O	O
3	NUM	O	O
]	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
case-controlled	ADV	O	O
study	NOUN	O	O
was	ADV	O	O
carried	VERB	O	O
out	ADP	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
value	NOUN	O	O
of	ADP	O	O
this	DET	O	O
new	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
learning	PUNCT	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
acceptance	NOUN	O	B-MENTAL
and	CCONJ	O	I-MENTAL
the	DET	O	I-MENTAL
imparting	PUNCT	O	I-MENTAL
of	ADP	O	I-MENTAL
knowledge	NOUN	O	I-MENTAL
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
describes	NOUN	O	O
details	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
presents	NOUN	O	O
their	DET	O	O
results	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
established	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
targeted	ADJ	O	O
questions	NOUN	O	O
asked	ADP	O	O
prior	PUNCT	O	O
to	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
learning	VERB	O	O
phase	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
frequencies	NOUN	O	O
and	CCONJ	O	O
significance	NOUN	O	O
testing	VERB	O	O
by	ADP	O	O
the	DET	O	O
Chi	NOUN	O	O
squared	ADP	O	O
method	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
the	DET	O	O
imparting	PUNCT	O	B-MENTAL
of	ADP	O	I-MENTAL
knowledge	NOUN	O	I-MENTAL
is	VERB	O	O
significantly	ADV	O	O
improved	VERB	O	O
when	ADP	O	O
this	DET	O	O
learning	NOUN	O	O
system	NOUN	O	O
is	VERB	O	O
employed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
its	ADP	O	O
first	ADJ	O	O
use	NOUN	O	O
,	PUNCT	O	O
acceptance	NOUN	O	O
of	ADP	O	O
this	DET	O	O
new	ADJ	O	B-MENTAL
medium	NOUN	O	I-MENTAL
rose	VERB	O	O
dramatically	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
COMPASS	NOUN	O	O
web-based	VERB	O	O
and	CCONJ	O	O
face-to-face	PUNCT	O	O
teacher	NOUN	O	O
coaching	PUNCT	O	O
in	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Most	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
rely	ADV	O	O
on	ADP	O	O
schools	NOUN	O	O
as	ADP	O	O
their	PUNCT	O	O
primary	ADJ	O	O
source	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
yet	PUNCT	O	O
research	NOUN	O	O
has	PUNCT	O	O
suggested	VERB	O	O
that	ADP	O	O
teachers	NOUN	O	O
rarely	ADV	O	O
use	PUNCT	O	O
evidence-based	ADJ	O	O
practices	PROPN	O	O
.	PUNCT	O	O

To	PART	O	O
address	NOUN	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
improved	CCONJ	O	O
educational	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
previously	ADV	O	O
tested	PUNCT	O	O
consultation	NOUN	O	O
intervention	NOUN	O	O
called	VERB	O	O
the	DET	O	O
Collaborative	ADJ	O	O
Model	NOUN	O	O
for	ADP	O	O
Promoting	PUNCT	O	O
Competence	NOUN	O	O
and	CCONJ	O	O
Success	NOUN	O	O
(	PUNCT	O	O
COMPASS	NOUN	O	O
;	PUNCT	O	O
Ruble	ADJ	O	O
,	PUNCT	O	O
Dalrymple	NOUN	O	O
,	PUNCT	O	O
&	CCONJ	O	O
McGrew	NOUN	O	O
,	PUNCT	O	O
2010	NUM	O	O
;	PUNCT	O	O
Ruble	ADJ	O	O
,	PUNCT	O	O
Dalrymple	NOUN	O	O
,	PUNCT	O	O
&	CCONJ	O	O
McGrew	NOUN	O	O
,	PUNCT	O	O
2012	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
a	DET	O	O
2nd	ADJ	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
web-based	ADV	O	O
group	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Forty-nine	NUM	O	O
teacher-child	ADJ	O	O
dyads	VERB	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
1	NUM	O	O
of	ADP	O	O
3	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
placebo	NOUN	O	O
control	NOUN	O	O
(	PUNCT	O	O
PBO	NOUN	O	O
)	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
COMPASS	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
face-to-face	NOUN	O	O
(	PUNCT	O	O
FF	NOUN	O	O
)	PUNCT	O	O
coaching	NUM	O	O
sessions	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
COMPASS	NOUN	O	O
followed	NOUN	O	O
by	ADP	O	O
web-based	PUNCT	O	O
(	PUNCT	O	O
WEB	NOUN	O	O
)	PUNCT	O	O
coaching	NUM	O	O
sessions	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
individualized	VERB	O	O
goals	NOUN	O	O
(	PUNCT	O	O
social	ADJ	O	O
,	PUNCT	O	O
communication	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
independence	NOUN	O	O
skills	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
selected	VERB	O	O
for	ADP	O	O
intervention	NOUN	O	O
for	ADP	O	O
each	DET	O	O
child	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
independent	ADJ	O	B-PHYSICAL
ratings	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
child	NOUN	O	I-PHYSICAL
goal	NOUN	O	I-PHYSICAL
attainment	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
several	ADJ	O	I-PHYSICAL
process	NOUN	O	I-PHYSICAL
measures	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
e.g.	ADP	O	O
,	PUNCT	O	O
consultant	NOUN	O	O
and	CCONJ	O	O
teacher	NOUN	O	O
fidelity	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Using	ADJ	O	O
an	DET	O	O
intent-to-treat	NOUN	O	O
approach	NOUN	O	O
,	PUNCT	O	O
findings	NOUN	O	O
replicated	VERB	O	O
earlier	PUNCT	O	O
results	ADP	O	O
with	ADP	O	O
a	DET	O	O
very	ADJ	O	O
large	ADJ	O	O
effect	NOUN	O	O
size	NOUN	O	O
(	PUNCT	O	O
d	NOUN	O	O
=	SYM	O	O
1.41	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
FF	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
large	ADJ	O	O
effect	NOUN	O	O
size	NOUN	O	O
(	PUNCT	O	O
d	NOUN	O	O
=	SYM	O	O
1.12	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
WEB	NOUN	O	O
group	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
the	DET	O	O
PBO	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
overall	ADJ	O	O
change	NOUN	O	O
across	ADP	O	O
goal	NOUN	O	O
domains	NOUN	O	O
between	ADP	O	O
the	DET	O	O
FF	NOUN	O	O
and	CCONJ	O	O
WEB	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
videoconferencing	VERB	O	O
technology	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
COMPASS	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
and	CCONJ	O	O
results	NOUN	O	O
in	ADP	O	O
improved	VERB	O	O
educational	ADJ	O	O
outcomes	NOUN	O	O
for	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Videoconferencing	VERB	O	O
technology	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
scalable	ADJ	O	O
tool	NOUN	O	O
,	PUNCT	O	O
has	PUNCT	O	O
promise	PUNCT	O	O
for	ADP	O	O
facilitating	NOUN	O	O
access	NOUN	O	O
to	ADP	O	O
autism	NOUN	O	O
specialists	NOUN	O	O
and	CCONJ	O	O
bridging	PUNCT	O	O
the	DET	O	O
research-to-practice	NOUN	O	O
gap	NOUN	O	O
.	PUNCT	O	O

Marginal	ADJ	O	O
benefit/disadvantage	NOUN	O	B-OTHER
of	ADP	O	O
granulocyte	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
therapy	NOUN	O	O
after	ADP	O	O
autologous	ADJ	O	O
blood	NOUN	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Japanese	ADJ	O	O
Cooperative	ADJ	O	O
Study	NOUN	O	O
Group	NOUN	O	O
of	ADP	O	O
PBSCT	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
74	NUM	O	O
children	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
scheduled	VERB	O	O
to	ADJ	O	O
undergo	PUNCT	O	O
high-dose	NOUN	O	O
chemotherapy	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
autologous	ADJ	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
PBSCT	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
prospectively	ADV	O	O
randomized	ADP	O	O
at	ADP	O	O
diagnosis	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
exogenous	ADJ	O	O
granulocyte	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
(	PUNCT	O	O
G-CSF	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
in	ADP	O	O
accelerating	PUNCT	O	O
hematopoietic	ADJ	O	B-PHYSICAL
recovery	NOUN	O	I-PHYSICAL
after	ADP	O	O
PBSCT	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
included	VERB	O	O
acute	ADJ	O	O
lymphoblastic	ADJ	O	O
leukemia	NOUN	O	O
(	PUNCT	O	O
ALL	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
27	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
neuroblastoma	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
29	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
miscellaneous	ADP	O	O
solid	ADP	O	O
tumors	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
18	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eligibility	NOUN	O	O
criteria	NOUN	O	O
included	ADP	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
primary	ADJ	O	O
PBSCT	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
chemotherapy-responsive	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
collected	VERB	O	O
cell	NOUN	O	O
number	NOUN	O	O
>	SYM	O	O
1	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
colony-forming	ADP	O	O
unit-granulocyte-macrophage	NOUN	O	O
(	PUNCT	O	O
CFU-GM	NOUN	O	O
)	PUNCT	O	O
/kg	ADV	O	O
and	CCONJ	O	O
>	SYM	O	O
1	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
CD34	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
cells/kg	NOUN	O	O
patient	NOUN	O	O
's	PUNCT	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
applying	VERB	O	O
the	DET	O	O
above	ADP	O	O
criteria	NOUN	O	O
,	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
due	PUNCT	O	O
to	ADP	O	O
disease	NOUN	O	O
progression	NOUN	O	O
before	ADP	O	O
PBSCT	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
low	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
harvested	VERB	O	O
cells	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
leaving	ADP	O	O
63	NUM	O	O
patients	NOUN	O	O
for	ADP	O	O
analysis	NOUN	O	O
;	PUNCT	O	O
32	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
300	NUM	O	O
microg/m2	PUNCT	O	O
of	ADP	O	O
G-CSF	NOUN	O	O
intravenously	ADV	O	O
over	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
from	ADP	O	O
day	NOUN	O	O
1	PUNCT	O	O
of	ADP	O	O
PBSCT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
31	NUM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
without	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
distinct	ADJ	O	O
disease-oriented	VERB	O	O
high-dose	NOUN	O	O
regimens	NOUN	O	O
without	ADP	O	O
total	ADJ	O	O
body	NOUN	O	O
irradiation	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
the	DET	O	O
MCVAC	NOUN	O	O
regimen	NOUN	O	O
using	PROPN	O	O
ranimustine	ADJ	O	O
(	PUNCT	O	O
MCNU	NOUN	O	O
,	PUNCT	O	O
450	PUNCT	O	O
mg/m2	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cytosine	NOUN	O	O
arabinoside	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
g/m2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
etoposide	NOUN	O	O
(	PUNCT	O	O
1.6	NUM	O	O
g/m2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ALL	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Hi-MEC	NOUN	O	O
regimen	NOUN	O	O
using	PUNCT	O	O
melphalan	NOUN	O	O
(	PUNCT	O	O
180	NUM	O	O
mg/m2	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
etoposide	NOUN	O	O
(	PUNCT	O	O
1.6	NUM	O	O
g/m2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
carboplatinum	NOUN	O	O
(	PUNCT	O	O
1.6	NUM	O	O
g/m2	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
solid	ADJ	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
two	NUM	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
three	NUM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
subsequently	ADV	O	O
removed	VERB	O	O
due	ADP	O	O
to	ADP	O	O
protocol	NOUN	O	O
violations	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
survived	PUNCT	O	B-MORTALITY
PBSCT	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
numbers	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
transfused	PUNCT	O	I-PHYSICAL
mononuclear	ADJ	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
MNC	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
CD34	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
+	SYM	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
CFU-GM	NOUN	O	I-PHYSICAL
were	VERB	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
4.5	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
to	ADP	O	O
19	NUM	O	O
)	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
)	PUNCT	O	O
/kg	ADV	O	O
,	PUNCT	O	O
8.0	NUM	O	O
(	PUNCT	O	O
1.1	NUM	O	O
to	ADP	O	O
25	NUM	O	O
)	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
/kg	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3.7	NUM	O	O
(	PUNCT	O	O
1.2	NUM	O	O
to	ADP	O	O
23	NUM	O	O
)	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
/kg	ADV	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
2.9	NUM	O	O
(	PUNCT	O	O
0.8	NUM	O	O
to	ADP	O	O
21	NUM	O	O
)	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
)	PUNCT	O	O
/kg	ADV	O	O
,	PUNCT	O	O
6.3	NUM	O	O
(	PUNCT	O	O
1.1	NUM	O	O
to	ADP	O	O
34	NUM	O	O
)	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
/kg	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5.5	NUM	O	O
(	PUNCT	O	O
1.3	NUM	O	O
to	ADP	O	O
37	NUM	O	O
)	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
/kg	ADV	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
28	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
PBSCT	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
time	NOUN	O	B-OTHER
to	PART	O	I-OTHER
achieve	NOUN	O	I-OTHER
an	DET	O	I-OTHER
absolute	ADJ	O	I-OTHER
neutrophil	NOUN	O	I-OTHER
count	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
ANC	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
of	ADP	O	I-OTHER
>	SYM	O	I-OTHER
0.5	NUM	O	O
x	SYM	O	B-OTHER
10	NUM	O	I-OTHER
(	PUNCT	O	I-OTHER
9	NUM	O	I-OTHER
)	PUNCT	O	I-OTHER
/L	PUNCT	O	I-OTHER
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
than	PUNCT	O	O
that	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
11	NUM	O	O
v	NUM	O	O
12	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
log-rank	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=.046	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
last	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
red	ADJ	O	O
blood	NOUN	O	O
cell	NOUN	O	O
(	PUNCT	O	O
RBC	NOUN	O	O
)	PUNCT	O	O
transfusion	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
11	NUM	O	O
v	NUM	O	O
day	NOUN	O	O
10	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
febrile	ADJ	O	B-OTHER
days	NOUN	O	I-OTHER
(	PUNCT	O	O
>	PROPN	O	O
38	NUM	O	O
degrees	NOUN	O	O
C	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
PBSCT	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
v	NUM	O	O
4	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
identical	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
platelet	NOUN	O	B-OTHER
recovery	NOUN	O	I-OTHER
to	ADP	O	I-OTHER
>	ADP	O	O
20	NUM	O	B-OTHER
x	SYM	O	I-OTHER
10	NUM	O	B-OTHER
(	PUNCT	O	O
9	NUM	O	B-OTHER
)	PUNCT	O	O
/L	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
in	ADP	O	O
treatment	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
26	NUM	O	O
v	NUM	O	O
16	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.009	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
>	SYM	O	O
50	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
/L	PUNCT	O	O
tended	VERB	O	O
to	PART	O	O
take	ADJ	O	O
longer	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
29	NUM	O	O
v	NUM	O	O
26	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.126	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
significantly	ADV	O	O
more	DET	O	O
platelet	NOUN	O	B-OTHER
transfusion-dependent	ADJ	O	I-OTHER
days	NOUN	O	B-OTHER
(	PUNCT	O	O
27	NUM	O	O
v	NUM	O	O
13	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
t-test	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=.037	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

When	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
disease	NOUN	O	O
cohorts	NOUN	O	O
,	PUNCT	O	O
ALL	PUNCT	O	O
patients	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
engraftment	ADJ	O	B-PHYSICAL
kinetics	NOUN	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
G-CSF	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
differences	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
solid	ADJ	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
concluded	VERB	O	O
that	ADP	O	O
the	DET	O	O
marginal	ADJ	O	O
clinical	ADJ	O	O
benefit	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
day	NOUN	O	O
earlier	PUNCT	O	O

Comparative	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	O
carbasalate	VERB	O	O
plus	CCONJ	O	O
metoclopramide	CCONJ	O	O
versus	CCONJ	O	O
ergotamine	NOUN	O	O
tartrate	NOUN	O	O
plus	CCONJ	O	O
caffeine	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
migraine	NOUN	O	O
attacks	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
double-dummy	NOUN	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
study	NOUN	O	O
aimed	PUNCT	O	O
at	ADP	O	O
comparing	PUNCT	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	O
carbasalate	NOUN	O	O
(	PUNCT	O	O
equivalent	ADJ	O	O
to	ADP	O	O
900	NUM	O	O
mg	NOUN	O	O
aspirin	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
metoclopramide	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
CM	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
ergotamine	NOUN	O	O
tartrate	NOUN	O	O
1	NUM	O	O
mg	NOUN	O	O
plus	CCONJ	O	O
caffeine	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
EC	NOUN	O	O
)	PUNCT	O	O
administered	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
acute	ADJ	O	O
migraine	NOUN	O	O
attacks	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
296	NUM	O	O
patients	NOUN	O	O
fulfilling	VERB	O	O
the	DET	O	O
International	ADJ	O	O
Headache	NOUN	O	O
Society	NOUN	O	O
diagnostic	ADJ	O	O
criteria	NOUN	O	O
for	ADP	O	O
migraine	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
total	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
or	CCONJ	O	O
two	NUM	O	O
migraine	NOUN	O	O
attacks	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
in	ADP	O	O
268	NUM	O	O
and	CCONJ	O	O
235	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
treated	VERB	O	O
attack	NOUN	O	O
was	VERB	O	O
headache	ADJ	O	O
relief	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
intensity	NOUN	O	O
decreasing	CCONJ	O	O
from	ADP	O	O
moderate	ADJ	O	O
or	CCONJ	O	O
severe	ADJ	O	O
to	ADP	O	O
mild	ADJ	O	O
or	CCONJ	O	O
absent	ADJ	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

Usual	ADJ	O	O
secondary	ADJ	O	O
efficacy	NOUN	O	O
endpoints	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
superiority	NOUN	O	O
of	ADP	O	O
CM	NOUN	O	O
over	ADP	O	O
EC	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
both	CCONJ	O	O
treated	VERB	O	O
attacks	NOUN	O	O
for	ADP	O	O
the	DET	O	O
main	ADJ	O	O
endpoint	NOUN	O	O
:	PUNCT	O	O
success	NOUN	O	O
in	ADP	O	O
54	NUM	O	O
versus	CCONJ	O	O
36	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
attack	NOUN	O	O
and	CCONJ	O	O
60	NUM	O	O
versus	CCONJ	O	O
44	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
for	ADP	O	O
the	DET	O	O
second	ADJ	O	O
attack	NOUN	O	O
.	PUNCT	O	O

CM	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
significantly	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
EC	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
attack	NOUN	O	O
for	ADP	O	O
complete	ADJ	O	B-PHYSICAL
headache	NOUN	O	I-PHYSICAL
relief	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
20	ADP	O	O
vs.	CCONJ	O	O
8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
42	NUM	O	O
vs.	CCONJ	O	O
63	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0	NUM	O	O
.	PUNCT	O	O

007	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
willingness	ADP	O	B-MENTAL
to	ADP	O	I-MENTAL
take	NOUN	O	I-MENTAL
the	DET	O	I-MENTAL
drug	NOUN	O	I-MENTAL
again	ADV	O	O
(	PUNCT	O	O
90	NUM	O	O
vs.	CCONJ	O	O
80	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.043	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
global	ADJ	O	B-OTHER
efficacy	NOUN	O	O
evaluation	NOUN	O	B-OTHER
,	PUNCT	O	O
rated	VERB	O	B-OTHER
by	ADP	O	I-OTHER
the	DET	O	B-OTHER
investigators	NOUN	O	I-OTHER
,	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
favorable	ADJ	O	O
to	ADP	O	O
CM	NOUN	O	O
for	ADP	O	O
both	PUNCT	O	O
attacks	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
attack	NOUN	O	O
and	CCONJ	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
for	ADP	O	O
the	DET	O	O
second	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	B-OTHER
'	PUNCT	O	O
evaluation	NOUN	O	B-OTHER
was	VERB	O	I-OTHER
significant	ADJ	O	B-OTHER
for	ADP	O	I-OTHER
the	DET	O	I-OTHER
first	ADJ	O	B-OTHER
attack	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
p	NOUN	O	I-OTHER
=	SYM	O	I-OTHER
0.002	NUM	O	O
)	PUNCT	O	B-OTHER
.	PUNCT	O	O

The	DET	O	O
global	ADJ	O	B-ADVERSE-EFFECTS
incidence	NOUN	O	O
of	ADP	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
45	NUM	O	O
%	SYM	O	O
higher	PUNCT	O	O
with	ADP	O	O
EC	NOUN	O	O
,	PUNCT	O	O
though	CCONJ	O	O
not	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
32	ADP	O	O
vs.	CCONJ	O	O
22	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.075	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

They	PUNCT	O	O
were	VERB	O	O
most	PUNCT	O	O
often	ADV	O	O
unspecific	ADJ	O	O
and	CCONJ	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	CCONJ	O	O
in	ADP	O	O
intensity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Tiotropium	ADV	O	O
Safety	NOUN	O	B-OTHER
and	CCONJ	O	O
Performance	NOUN	O	B-OTHER
in	ADP	O	O
Respimat	NOUN	O	O
Trial	NOUN	O	O
(	PUNCT	O	O
TIOSPIR	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
large	ADJ	O	O
scale	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
trial-design	PUNCT	O	O
and	CCONJ	O	O
rationale	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Tiotropium	ADV	O	O
bromide	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
COPD	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Comparing	ADJ	O	O
across	ADP	O	O
programs	NOUN	O	O
tiotropium	PUNCT	O	O
Respimat	NOUN	O	O
Soft	NOUN	O	O
Mist	NOUN	O	O
inhaler	ADJ	O	O
was	VERB	O	O
at	VERB	O	O
least	ADV	O	O
as	PUNCT	O	O
efficacious	ADJ	O	O
as	PUNCT	O	O
tiotropium	PUNCT	O	O
HandiHaler	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
concerns	CCONJ	O	O
have	PUNCT	O	O
been	PUNCT	O	O
raised	VERB	O	O
about	PUNCT	O	O
tiotropium	NOUN	O	O
's	PUNCT	O	O
safety	NOUN	O	O
when	ADP	O	O
given	VERB	O	O
via	ADP	O	O
Respimat	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
TIOSPIR	NOUN	O	O
trial	NOUN	O	O
(	PUNCT	O	O
NCT01126437	NOUN	O	O
)	PUNCT	O	O
compares	ADP	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
tiotropium	ADV	O	O
Respimat	NOUN	O	O
5	ADP	O	O
?g	PUNCT	O	O
once	PUNCT	O	O
daily	DET	O	O
(	PUNCT	O	O
marketed	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
2.5	ADP	O	O
?g	PUNCT	O	O
once	PUNCT	O	O
daily	DET	O	O
(	PUNCT	O	O
investigational	ADP	O	O
)	PUNCT	O	O
with	ADP	O	O
tiotropium	PUNCT	O	O
HandiHaler	CCONJ	O	O
18	NUM	O	O
?	PUNCT	O	O

once	PUNCT	O	O
daily	DET	O	O
(	PUNCT	O	O
marketed	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
hypotheses	ADP	O	O
to	PART	O	O
be	PUNCT	O	O
tested	VERB	O	O
are	VERB	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

that	ADP	O	O
tiotropium	PUNCT	O	O
Respimat	NOUN	O	O
5	ADP	O	O
?g	PUNCT	O	O
once	PUNCT	O	O
daily	ADJ	O	O
and	CCONJ	O	O
Respimat	NOUN	O	O
2.5	NUM	O	O
?g	PUNCT	O	O
once	PUNCT	O	O
daily	ADJ	O	O
are	CCONJ	O	O
non-inferior	ADJ	O	O
to	ADP	O	O
HandiHaler	PUNCT	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
all-cause	NOUN	O	O
mortality	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

that	ADP	O	O
tiotropium	PUNCT	O	O
Respimat	NOUN	O	O
5	ADP	O	O
?g	PUNCT	O	O
once	PUNCT	O	O
daily	ADJ	O	O
is	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
HandiHaler	PUNCT	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
to	PUNCT	O	O
first	ADJ	O	O
exacerbation	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
spirometry	NOUN	O	O
substudy	NOUN	O	O
evaluates	VERB	O	O
the	DET	O	O
bronchodilator	NOUN	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
dummy	NOUN	O	O
,	PUNCT	O	O
event-driven	PUNCT	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
group	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
can	PART	O	O
use	NOUN	O	O
any	DET	O	O
background	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
COPD	NOUN	O	O
except	VERB	O	O
inhaled	VERB	O	O
anticholinergic	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
encompasses	PUNCT	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
COPD	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
e.g	NUM	O	O
.	PUNCT	O	O

patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
cardiac	ADJ	O	O
diseases	NOUN	O	O
including	DET	O	O
arrhythmia	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
sites	NOUN	O	O
are	VERB	O	O
international	ADJ	O	O
and	CCONJ	O	O
include	VERB	O	O
both	PUNCT	O	O
primary	ADJ	O	O
care	NOUN	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
specialists	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
To	ADP	O	O
date	NOUN	O	O
,	PUNCT	O	O
over	ADP	O	O
17,000	NUM	O	O
participants	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
randomized	VERB	O	O
from	ADP	O	O
over	CCONJ	O	O
1200	NUM	O	O
sites	NOUN	O	O
in	ADP	O	O
50	NUM	O	O
countries	NOUN	O	O
with	ADP	O	O
an	DET	O	O
anticipated	VERB	O	O
treatment	NOUN	O	O
duration	NOUN	O	O
of	ADP	O	O
2-3	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
TIOSPIR	NOUN	O	O
will	VERB	O	O
provide	VERB	O	O
precise	ADJ	O	O
estimates	NOUN	O	O
of	ADP	O	O
the	DET	O	O
relative	ADJ	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Respimat	NOUN	O	O
and	CCONJ	O	O
HandiHaler	ADJ	O	O
formulations	NOUN	O	O
of	ADP	O	O
tiotropium	NOUN	O	O
,	PUNCT	O	O
assess	NOUN	O	O
potential	ADJ	O	O
dose-dependence	NOUN	O	O
of	ADP	O	O
important	ADJ	O	O
outcomes	NOUN	O	O
and	CCONJ	O	O
provide	VERB	O	O
information	NOUN	O	O
on	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
epidemiology	NOUN	O	O
of	ADP	O	O
COPD	NOUN	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
international	ADJ	O	O
patient	NOUN	O	O
cohort	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
dual-axis	NOUN	O	O
rotational	ADJ	O	O
coronary	ADJ	O	O
angiography	NOUN	O	O
(	PUNCT	O	O
XPERSWING	PUNCT	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
conventional	ADJ	O	O
technique	NOUN	O	O
in	ADP	O	O
routine	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVES	NOUN	O	O
Coronary	ADJ	O	O
angiography	NOUN	O	O
is	VERB	O	O
the	DET	O	O
gold	PUNCT	O	O
standard	NOUN	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
technique	NOUN	O	O
requires	NOUN	O	O
several	ADJ	O	O
orthogonal	ADJ	O	O
projections	NOUN	O	O
.	PUNCT	O	O

Rotational	ADJ	O	O
angiography	NOUN	O	O
is	VERB	O	O
a	DET	O	O
new	ADJ	O	O
technique	NOUN	O	O
which	ADP	O	O
involves	NOUN	O	O
pre-set	NOUN	O	O
rotation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
X-ray	NOUN	O	O
tube	NOUN	O	O
around	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
and	CCONJ	O	O
allows	NOUN	O	O
visualization	NOUN	O	O
of	ADP	O	O
each	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
in	ADP	O	O
different	ADJ	O	O
views	CCONJ	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
single	ADJ	O	O
contrast	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
conventional	ADJ	O	O
coronary	ADJ	O	O
angiography	NOUN	O	O
(	PUNCT	O	O
A	NOUN	O	O
)	PUNCT	O	O
vs	CCONJ	O	O
rotational	ADJ	O	O
angiography	NOUN	O	O
(	PUNCT	O	O
B	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
focusing	VERB	O	O
on	ADP	O	O
radiation	NOUN	O	O
dose	NOUN	O	O
,	PUNCT	O	O
amount	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	O
administered	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
total	ADJ	O	O
procedure	NOUN	O	O
time	NOUN	O	O
for	ADP	O	O
both	CCONJ	O	O
diagnostic	ADJ	O	O
and	CCONJ	O	O
therapeutic	ADJ	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Prospective	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
104	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
coronary	ADJ	O	O
angiography	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
these	DET	O	O
techniques	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
We	PRON	O	O
found	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
amount	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
contrast	NOUN	O	O
administered	PUNCT	O	B-OTHER
(	PUNCT	O	O
A	NOUN	O	O
vs	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
93.1	NUM	O	O
[	PUNCT	O	O
41.7	PUNCT	O	O
]	PUNCT	O	O
vs	CCONJ	O	O
50.9	ADP	O	O
[	PUNCT	O	O
14.7	NUM	O	O
]	PUNCT	O	O
mL	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
radiation	NOUN	O	B-OTHER
exposure	NOUN	O	I-OTHER
(	PUNCT	O	O
27.6	NUM	O	O
[	PUNCT	O	O
11.5	PUNCT	O	O
]	PUNCT	O	O
vs	CCONJ	O	O
18	NUM	O	O
[	PUNCT	O	O
6.4	NUM	O	O
]	PUNCT	O	O
mGycm	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
procedure	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
rotational	ADJ	O	O
angiography	NOUN	O	O
arm	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
when	ADP	O	O
only	ADV	O	O
the	DET	O	O
last	ADJ	O	O
50	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
procedure	NOUN	O	B-OTHER
time	NOUN	O	B-OTHER
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
,	PUNCT	O	O
probably	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
learning	VERB	O	O
curve	NOUN	O	O
of	ADP	O	O
the	DET	O	O
operators	NOUN	O	O
.	PUNCT	O	O

Angioplasty	NOUN	O	B-PHYSICAL
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
29	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
28	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
.	PUNCT	O	O

Contrast	NOUN	O	O
reduction	NOUN	O	B-OTHER
was	VERB	O	O
maintained	VERB	O	O
in	ADP	O	O
the	DET	O	O
rotational	ADJ	O	O
angiography	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
technique	NOUN	O	O
(	PUNCT	O	O
A	NOUN	O	O
vs	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
335.1	NUM	O	O
[	PUNCT	O	O
192.1	ADP	O	O
]	PUNCT	O	O
vs	CCONJ	O	O
238.5	ADP	O	O
[	PUNCT	O	O
114.4	ADP	O	O
]	PUNCT	O	O
mL	NOUN	O	O
;	PUNCT	O	O
P=.02	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
rotational	ADJ	O	O
angiography	NOUN	O	O
technique	NOUN	O	O
leads	NOUN	O	O
to	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	PUNCT	O	O

Depressive	ADJ	O	O
mood	PUNCT	O	O
symptoms	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
ovarian	ADJ	O	O
suppression	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
if	PUNCT	O	O
sertraline	NOUN	O	O
is	VERB	O	O
helpful	ADJ	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
depressive	ADJ	O	O
symptoms	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
ovarian	ADJ	O	O
suppression	NOUN	O	O
during	ADP	O	O
GnRH	NOUN	O	O
agonist	NOUN	O	O
therapy	NOUN	O	O
as	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
placebo-controlled	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Double-blind	ADJ	O	O
placebo-controlled	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
An	DET	O	O
obstetrics/gynecological	ADJ	O	O
office	NOUN	O	O
specializing	NUM	O	O
in	ADP	O	O
infertility	NOUN	O	O
in	ADP	O	O
an	DET	O	O
academic	ADJ	O	O
environment	NOUN	O	O
.	PUNCT	O	O

PATIENT	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
Premenstrual	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
laparoscopically	ADV	O	O
diagnosed	VERB	O	O
endometriosis	NOUN	O	O
who	ADP	O	O
required	VERB	O	O
GnRH	NOUN	O	O
agonist	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
did	DET	O	O
not	ADV	O	O
have	PUNCT	O	O
significant	ADJ	O	O
depressive	ADJ	O	O
or	CCONJ	O	O
premenstrual	ADJ	O	O
mood	ADJ	O	O
symptoms	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
Participants	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
sertraline	NOUN	O	O
treatment	NOUN	O	O
group	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
for	ADP	O	O
the	DET	O	O
3-month	NOUN	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GnRH	NOUN	O	O
agonist	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURE	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
The	DET	O	O
21-item	NOUN	O	O
Hamilton	PUNCT	O	O
Rating	PUNCT	O	O
Scale	NOUN	O	O
for	ADP	O	O
Depression	NOUN	O	O
(	PUNCT	O	O
HRSD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
an	DET	O	O
instrument	ADJ	O	O
designed	PRON	O	O
to	PART	O	O
assess	ADJ	O	O
depressive	ADJ	O	O
symptomatology	NOUN	O	O
.	PUNCT	O	O

RESULT	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
A	DET	O	O
Hotellings	NOUN	O	O
T	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
test	NOUN	O	O
for	ADP	O	O
repeated	VERB	O	O
measure	ADV	O	O
analysis	NOUN	O	O
indicated	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
between-group	ADP	O	O
difference	NOUN	O	O
across	ADP	O	O
time	NOUN	O	O
for	ADP	O	O
the	DET	O	O
HRSD	NOUN	O	O
(	PUNCT	O	O
T	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
=	ADP	O	O
13.3	NUM	O	O
;	PUNCT	O	O
F	NOUN	O	O
[	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
28	NUM	O	O
]	PUNCT	O	O
=	ADP	O	O
4.1	NUM	O	O
;	PUNCT	O	O
P=.02	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
sertraline	NOUN	O	O
treatment	NOUN	O	O
group	NOUN	O	O
manifesting	VERB	O	O
significantly	ADV	O	O
fewer	PUNCT	O	O
depressive	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
than	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
(	PUNCT	O	O
S	NOUN	O	O
)	PUNCT	O	O
The	DET	O	O
results	ADV	O	O
indicate	VERB	O	O
that	ADP	O	O
sertraline	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
option	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
depressive	ADJ	O	O
mood	PUNCT	O	O
symptoms	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
ovarian	ADJ	O	O
suppression	NOUN	O	O
during	ADP	O	O
GnRH	NOUN	O	O
agonist	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Predictors	NOUN	O	O
of	ADP	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
among	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	PUNCT	O	O
Many	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
continue	VERB	O	O
to	ADP	O	O
smoke	ADP	O	O
postdiagnosis	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
poorer	PUNCT	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Identifying	PUNCT	O	O
prospective	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
among	ADP	O	O
patients	NOUN	O	O
currently	ADV	O	O
receiving	CCONJ	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
treatment	NOUN	O	O
can	VERB	O	O
help	ADP	O	O
guide	PUNCT	O	O
the	DET	O	O
development	NOUN	O	O
and	CCONJ	O	O
implementation	NOUN	O	O
of	ADP	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
programs	NOUN	O	O
with	ADP	O	O
this	DET	O	O
population	NOUN	O	O
.	PUNCT	O	O

MATERIAL	NOUN	O	O
AND	CCONJ	O	O
METHODS	PUNCT	O	O
Data	NOUN	O	O
from	ADP	O	O
246	NUM	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
participating	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
placebo-controlled	VERB	O	O
smoking	ADJ	O	O
cessation	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
baseline	NOUN	O	O
predictors	NOUN	O	O
of	ADP	O	O
end-of-treatment	PUNCT	O	O
and	CCONJ	O	O
six-month	NOUN	O	O
postbaseline	NOUN	O	O
smoking	ADP	O	O
cessation	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
demographic	ADJ	O	O
,	PUNCT	O	O
smoking-related	ADJ	O	O
,	PUNCT	O	O
disease-related	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
psychological	ADJ	O	O
variables	NOUN	O	O
were	PROPN	O	O
examined	VERB	O	O
as	ADP	O	O
predictors	NOUN	O	O
of	ADP	O	O
biochemically-confirmed	ADJ	O	O
point-prevalence	NOUN	O	O
abstinence	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Multivariate	ADJ	O	B-OTHER
analysis	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
for	ADP	O	O
end-of-treatment	PUNCT	O	B-MENTAL
abstinence	NOUN	O	I-MENTAL
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
quit	NOUN	O	B-MENTAL
smoking	NUM	O	I-MENTAL
if	PUNCT	O	O
they	PRON	O	O
were	PRON	O	O
older	PUNCT	O	O
(	PUNCT	O	O
OR	NOUN	O	O
=	SYM	O	O
1.06	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.03-1.10	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
a	DET	O	O
non-tobacco	NOUN	O	O
related	VERB	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
OR	NOUN	O	O
=	ADP	O	O
2.54	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.24-5.20	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Likewise	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
six-month	NOUN	O	B-MENTAL
abstinence	NOUN	O	I-MENTAL
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
quit	NOUN	O	B-MENTAL
smoking	NUM	O	I-MENTAL
if	PUNCT	O	O
they	PRON	O	O
were	PRON	O	O
older	PUNCT	O	O
(	PUNCT	O	O
OR	NOUN	O	O
=	SYM	O	O
1.04	PUNCT	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
1.01-1.08	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
quit	NOUN	O	O
smoking	NUM	O	O
if	PUNCT	O	O
they	PRON	O	O
were	PUNCT	O	O
female	NOUN	O	O
(	PUNCT	O	O
OR	NOUN	O	O
=	SYM	O	O
0.47	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.22-0.97	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
tobacco-related	VERB	O	O
cancers	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
patients	NOUN	O	O
reported	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
levels	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
depression	NOUN	O	I-MENTAL
symptoms	NOUN	O	I-MENTAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
proved	CCONJ	O	O
predictive	ADJ	O	B-MENTAL
of	ADP	O	I-MENTAL
smoking	ADJ	O	I-MENTAL
relapse	NOUN	O	I-MENTAL
.	PUNCT	O	O

CONCLUSIONS	DET	O	O
Patient	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
gender	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cancer-type	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
important	ADJ	O	O
factors	NOUN	O	O
to	PART	O	O
consider	NOUN	O	O
when	CCONJ	O	O
developing	ADP	O	O
and	CCONJ	O	O
implementing	PUNCT	O	O
smoking	ADP	O	O
cessation	NOUN	O	O
interventions	NOUN	O	O
for	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
using	VERB	O	O
testosterone	NOUN	O	O
undecanoate	ADP	O	O
with	ADP	O	O
injectable	ADJ	O	O
norethisterone	NOUN	O	O
enanthate	PUNCT	O	O
:	PUNCT	O	O
effect	NOUN	O	O
on	ADP	O	O
anthropometric	ADJ	O	O
,	PUNCT	O	O
metabolic	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

Testosterone	NOUN	O	O
administered	ADP	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
progestogens	NOUN	O	O
in	ADP	O	O
male	NOUN	O	O
contraception	NOUN	O	O
induces	NOUN	O	O
reversible	ADJ	O	O
oligo-azoospermia	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
its	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
body	NOUN	O	O
composition	NOUN	O	O
and	CCONJ	O	O
metabolism	NOUN	O	O
are	VERB	O	O
less	ADV	O	O
known	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
analysed	VERB	O	O
anthropometric	ADJ	O	O
and	CCONJ	O	O
metabolic	ADJ	O	O
parameters	NOUN	O	O
in	ADP	O	O
five	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
males	NOUN	O	O
:	PUNCT	O	O
four	NUM	O	O
receiving	SYM	O	O
testosterone	NOUN	O	O
undecanoate	NOUN	O	O
(	PUNCT	O	O
TU	ADV	O	O
:	PUNCT	O	O
1000	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
norethisterone	NOUN	O	O
enanthate	PUNCT	O	O
(	PUNCT	O	O
NETE	NOUN	O	O
:	PUNCT	O	O
200	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
different	ADJ	O	O
intervals	NOUN	O	O
(	PUNCT	O	O
every	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
:	PUNCT	O	O
NETE-8	NOUN	O	O
;	PUNCT	O	O
every	DET	O	O
12	NUM	O	O
weeks	NOUN	O	O
:	PUNCT	O	O
NETE-12	NOUN	O	O
;	PUNCT	O	O
every	DET	O	O
6	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADP	O	O
every	DET	O	O
12	NUM	O	O
weeks	NOUN	O	O
:	PUNCT	O	O
NETE-6/12	NOUN	O	O
;	PUNCT	O	O
every	DET	O	O
6	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
TU	ADV	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
every	DET	O	O
12	NUM	O	O
weeks	NOUN	O	O
:	PUNCT	O	O
NETE-6/12/0	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
NETE-0/0	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
48	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
BMI	NOUN	O	O
)	PUNCT	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
waist	NOUN	O	I-PHYSICAL
circumference	NOUN	O	I-PHYSICAL
did	PUNCT	O	I-PHYSICAL
not	ADV	O	I-PHYSICAL
change	NUM	O	B-PHYSICAL
in	ADP	O	O
any	DET	O	O
groups	NOUN	O	O
except	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
NETE-8	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
BMI	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	B-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Lean	ADJ	O	B-PHYSICAL
body	NOUN	O	I-PHYSICAL
mass	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
MAMC	NOUN	O	I-PHYSICAL
or	CCONJ	O	B-PHYSICAL
AMA	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
increased	VERB	O	O
significantly	ADV	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
highest	PUNCT	O	O
hormonal	ADJ	O	O
dose	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
,	PUNCT	O	O
NETE-6/12	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
,	PUNCT	O	O
NETE-8	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
glucose	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
index	NOUN	O	O
and	CCONJ	O	O
lipid	NOUN	O	O
profile	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
in	PUNCT	O	O

Scent	ADJ	O	O
and	CCONJ	O	O
mood	PUNCT	O	O
state	NOUN	O	O
following	VERB	O	O
an	DET	O	O
anxiety-provoking	DET	O	O
task	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
assess	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
water	NOUN	O	O
,	PUNCT	O	O
lavender	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
rosemary	ADJ	O	O
scent	ADJ	O	O
on	ADP	O	O
physiology	NOUN	O	B-MENTAL
and	CCONJ	O	O
mood	PUNCT	O	B-MENTAL
state	NOUN	O	I-MENTAL
following	VERB	O	O
an	DET	O	O
anxiety-provoking	DET	O	O
task	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
nonsmoking	ADJ	O	O
participants	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
18-30	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
included	VERB	O	O
42	NUM	O	O
women	NOUN	O	O
and	CCONJ	O	O
31	NUM	O	O
men	NOUN	O	O
who	ADP	O	O
reported	VERB	O	O
demographic	ADJ	O	O
information	NOUN	O	O
and	CCONJ	O	O
measures	NOUN	O	O
of	ADP	O	O
external	ADJ	O	O
temperature	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
prior	PUNCT	O	O
to	ADP	O	O
introduction	NOUN	O	O
of	ADP	O	O
an	DET	O	O
anxiety-eliciting	VERB	O	O
task	NOUN	O	O
and	CCONJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
lavender	PUNCT	O	O
,	PUNCT	O	O
rosemary	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
water	NOUN	O	O
scents	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
the	DET	O	O
task	NOUN	O	O
,	PUNCT	O	O
participants	NOUN	O	O
completed	ADV	O	O
the	DET	O	O
Profile	NOUN	O	O
of	ADP	O	O
Mood	PUNCT	O	O
States	NOUN	O	O
to	PART	O	O
assess	PUNCT	O	O
mood	ADP	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
temperature	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
were	VERB	O	O
reassessed	PROPN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
rated	VERB	O	O
the	DET	O	O
pleasantness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
scent	ADJ	O	O
received	PUNCT	O	O
.	PUNCT	O	O

When	ADP	O	O
pleasantness	ADJ	O	O
ratings	NOUN	O	O
of	ADP	O	O
scent	ADJ	O	O
were	VERB	O	O
covaried	VERB	O	O
,	PUNCT	O	O
physiological	ADJ	O	B-PHYSICAL
changes	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
based	VERB	O	O
on	ADP	O	O
scent	ADJ	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
mood	PUNCT	O	B-MENTAL
ratings	NOUN	O	I-MENTAL
differed	VERB	O	O
by	ADP	O	O
scent	ADJ	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rosemary	NOUN	O	O
condition	NOUN	O	O
scored	PUNCT	O	O
higher	PUNCT	O	O
on	ADP	O	O
measures	NOUN	O	O
of	ADP	O	O
tension-anxiety	NOUN	O	B-MENTAL
and	CCONJ	O	O
confusion-bewilderment	PUNCT	O	B-MENTAL
relative	ADJ	O	O
to	ADP	O	O
the	PUNCT	O	O
lavender	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
lavender	ADJ	O	O
and	CCONJ	O	O
control	NOUN	O	O
conditions	NOUN	O	O
showed	VERB	O	O
higher	PUNCT	O	O
mean	NOUN	O	O
vigor-activity	NOUN	O	B-MENTAL
ratings	NOUN	O	I-MENTAL
relative	ADJ	O	O
to	ADP	O	O
the	DET	O	O
rosemary	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
both	CCONJ	O	O
rosemary	ADJ	O	O
and	CCONJ	O	O
lavender	PUNCT	O	O
scents	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
lower	PUNCT	O	O
mean	NOUN	O	O
ratings	NOUN	O	B-MENTAL
on	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
fatigue-inertia	NOUN	O	I-MENTAL
subscale	NOUN	O	I-MENTAL
,	PUNCT	O	O
relative	ADJ	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
when	ADP	O	O
individual	ADJ	O	O
perception	NOUN	O	O
of	ADP	O	O
scent	ADJ	O	O
pleasantness	NOUN	O	O
is	VERB	O	O
controlled	NOUN	O	O
,	PUNCT	O	O
scent	ADJ	O	O
has	PUNCT	O	O
the	DET	O	O
potential	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
different	ADJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
mood	PUNCT	O	O
following	ADP	O	O
an	DET	O	O
anxiety-provoking	DET	O	O
task	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
prophylactic	ADP	O	O
amiodarone	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatic	ADJ	O	O
valve	NOUN	O	O
disease	NOUN	O	O
undergoing	VERB	O	O
valve	NOUN	O	O
replacement	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
carried	VERB	O	O
out	ADP	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
prophylactic	ADP	O	O
single-dose	NOUN	O	O
intravenous	ADJ	O	O
amiodarone	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
valve	NOUN	O	O
replacement	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Maintenance	NOUN	O	O
of	ADP	O	O
sinus	NOUN	O	O
rhythm	NOUN	O	O
is	VERB	O	O
better	PUNCT	O	O
than	ADP	O	O
maintenance	NOUN	O	O
of	ADP	O	O
fixed	VERB	O	O
ventricular	ADJ	O	O
rate	NOUN	O	O
in	ADP	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
(	PUNCT	O	O
AF	NOUN	O	O
)	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
irritable	ADJ	O	O
left	ADJ	O	O
or	CCONJ	O	O
right	ADJ	O	O
atrium	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
enlargement	NOUN	O	O
.	PUNCT	O	O

Fifty-six	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
valvular	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
AF	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
I	NUM	O	O
or	CCONJ	O	O
the	DET	O	O
amiodarone	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=28	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
amiodarone	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
mg/kg	NOUN	O	O
in	ADP	O	O
100	NUM	O	O
ml	NOUN	O	O
normal	ADJ	O	O
saline	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
II	NUM	O	O
or	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
same	ADJ	O	O
volume	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
standardized	VERB	O	O
protocol	NOUN	O	O
for	ADP	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
for	ADP	O	O
all	CCONJ	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

AF	NOUN	O	B-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
7.14	NUM	O	O
%	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
,	PUNCT	O	O
28.57	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P=0.035	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
ventricular	ADJ	O	B-PHYSICAL
tachycardia/fibrillation	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
21.43	NUM	O	O
%	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
and	CCONJ	O	O
46.43	NUM	O	O
%	ADV	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
P=0.089	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
aortic	ADJ	O	O
clamp	NOUN	O	O
.	PUNCT	O	O

Most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
92.86	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
maintained	VERB	O	O
sinus	NOUN	O	B-PHYSICAL
rhythm	NOUN	O	I-PHYSICAL
without	ADP	O	I-PHYSICAL
cardioversion	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
defibrillation	NOUN	O	I-PHYSICAL
after	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
aortic	ADJ	O	O
cross	NOUN	O	O
clamp	NOUN	O	O
(	PUNCT	O	O
P=0.002	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Defibrillation	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
cardio	PUNCT	O	B-PHYSICAL
version	NOUN	O	I-PHYSICAL
was	VERB	O	O
needed	VERB	O	O
in	ADP	O	O
7.14	NUM	O	O
%	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
and	CCONJ	O	O
28.57	NUM	O	O
%	SYM	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
P=0.078	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
prophylactic	ADJ	O	O
intraoperative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
amiodarone	NOUN	O	O
decreased	PUNCT	O	O
post	PUNCT	O	B-PHYSICAL
bypass	PUNCT	O	I-PHYSICAL
arrhythmia	NOUN	O	I-PHYSICAL
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
intraoperative	ADJ	O	O
amiodarone	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
decrease	PROPN	O	O
postoperative	ADJ	O	O
arrhythmia	NOUN	O	O
in	ADP	O	O
open	ADJ	O	O
heart	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Evaluation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
wound	NOUN	O	O
closure	NOUN	O	O
device	NOUN	O	O
for	ADP	O	O
linear	ADJ	O	O
surgical	ADJ	O	O
incisions	NOUN	O	O
:	PUNCT	O	O
3M	NOUN	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
Surgical	ADJ	O	O
Skin	NOUN	O	O
Closure	NOUN	O	O
versus	CCONJ	O	O
subcuticular	ADJ	O	O
closure	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Technological	ADJ	O	O
innovations	NOUN	O	O
are	VERB	O	O
often	ADV	O	O
adopted	VERB	O	O
before	ADP	O	O
scientific	ADJ	O	O
comparison	NOUN	O	O
to	ADP	O	O
an	DET	O	O
accepted	VERB	O	O
standard	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
'	PUNCT	O	O
study	NOUN	O	O
compared	PUNCT	O	O
suture	NOUN	O	O
with	ADP	O	O
a	DET	O	O
new	ADJ	O	O
coaptive	ADJ	O	O
film	NOUN	O	O
device	NOUN	O	O
,	PUNCT	O	O
3M	NOUN	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
Surgical	ADJ	O	O
Skin	NOUN	O	O
Closure	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
linear	ADJ	O	O
incisions	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
undergoing	VERB	O	O
Wise-pattern	NOUN	O	O
breast	NOUN	O	O
reduction	NOUN	O	O
or	CCONJ	O	O
abdominal	ADJ	O	O
procedures	NOUN	O	O
had	PUNCT	O	O
paired	PUNCT	O	O
incisions	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
or	CCONJ	O	O
suture	NOUN	O	O
closure	NOUN	O	O
.	PUNCT	O	O

Key	NOUN	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
closure	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
patient	NOUN	O	B-OTHER
comfort	PUNCT	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
scar	NOUN	O	B-OTHER
quality	NOUN	O	I-OTHER
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
by	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
surgeons	NOUN	O	O
using	VERB	O	O
a	DET	O	O
new	ADJ	O	O
scar	NOUN	O	O
evaluation	NOUN	O	O
tool	NOUN	O	O
,	PUNCT	O	O
visual	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
linear	ADJ	O	O
scars	NOUN	O	O
.	PUNCT	O	O

Statistical	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
closure	NOUN	O	O
techniques	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
Wilcoxon	NOUN	O	O
signed	NOUN	O	O
rank	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
59	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
eight	NUM	O	O
were	VERB	O	O
excluded	VERB	O	O
from	ADP	O	O
randomization	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
surgeon	NOUN	O	O
judged	DET	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
to	PART	O	O
be	CCONJ	O	O
a	DET	O	O
nonviable	ADJ	O	O
closure	NOUN	O	O
technique	NOUN	O	O
for	ADP	O	O
mismatched	PUNCT	O	O
wound	NOUN	O	O
edges	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Fifty-one	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
breast	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
;	PUNCT	O	O
abdomen	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
27	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
.	PUNCT	O	O

Operative	ADJ	O	B-OTHER
time	NOUN	O	I-OTHER
with	ADP	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
for	ADP	O	O
breast	NOUN	O	O
was	VERB	O	O
2.0	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
1.1	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
suture	NOUN	O	O
closure	NOUN	O	O
at	ADP	O	O
4.6	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
1.5	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
versus	CCONJ	O	O
suture	NOUN	O	O
for	ADP	O	O
the	DET	O	O
abdomen	NOUN	O	O
was	VERB	O	O
faster	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
;	PUNCT	O	O
4.9	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
2.3	NUM	O	O
versus	CCONJ	O	O
10.1	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
3.4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Comfort	ADJ	O	O
scores	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
closures	ADP	O	O
[	PUNCT	O	O
5.8	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
2.7	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
6.9	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
2.0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
breast	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.142	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
7.7	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
1.8	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
7.7	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
2.3	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
abdomen	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.903	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Complication	NOUN	O	B-ADVERSE-EFFECTS
rates	NOUN	O	I-ADVERSE-EFFECTS
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
closure	NOUN	O	O
types	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	B-OTHER
'	PUNCT	O	O
visual	ADJ	O	B-OTHER
assessment	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
linear	ADJ	O	I-OTHER
scars	NOUN	O	I-OTHER
rating	PUNCT	O	I-OTHER
of	ADP	O	I-OTHER
breasts	NOUN	O	B-OTHER
was	VERB	O	O
3.8	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
2.9	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
and	CCONJ	O	O
better	PUNCT	O	O
at	ADP	O	O
2.6	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
=	SYM	O	O
2.9	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
suture	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.008	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One	NUM	O	O
surgeon	NOUN	O	O
rated	DET	O	O
breast	NOUN	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
scars	NOUN	O	O
worse	ADJ	O	O
than	VERB	O	O
suture	NOUN	O	O
scars	NOUN	O	O
(	PUNCT	O	O
4.3	NUM	O	O
versus	CCONJ	O	O
3.7	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.014	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
abdominal	ADJ	O	O
scars	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
or	CCONJ	O	O
surgeon	NOUN	O	O
ratings	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Steri-Strip	NOUN	O	O
S	NOUN	O	O
permits	VERB	O	O
faster	PUNCT	O	O
wound	NOUN	O	B-PHYSICAL
closure	NOUN	O	B-PHYSICAL
than	PUNCT	O	O
suture	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
reports	NOUN	O	O
of	ADP	O	O
comfort	NOUN	O	B-OTHER
and	PUNCT	O	O

Erythema	NOUN	O	O
migrans	ADJ	O	O
:	PUNCT	O	O
comparison	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
azithromycin	NOUN	O	O
,	PUNCT	O	O
doxycycline	NOUN	O	O
and	CCONJ	O	O
phenoxymethylpenicillin	NOUN	O	O
.	PUNCT	O	O

Azithromycin	NOUN	O	O
,	PUNCT	O	O
doxycycline	NOUN	O	O
and	CCONJ	O	O
phenoxymethylpenicillin	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
64	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
typical	ADJ	O	O
erythema	NOUN	O	O
migrans	ADJ	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
azithromycin	NOUN	O	O
,	PUNCT	O	O
250	NUM	O	O
mg	NOUN	O	O
bd	ADP	O	O
for	ADP	O	O
two	NUM	O	O
days	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
250	NUM	O	O
mg	NOUN	O	O
od	NOUN	O	O
for	ADP	O	O
eight	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
21	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
phenoxymethylpenicillin	NOUN	O	O
1	NUM	O	O
million	NUM	O	O
IU	NOUN	O	O
tds	NOUN	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
23	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
doxycycline	NOUN	O	O
,	PUNCT	O	O
100	NUM	O	O
mg	NOUN	O	O
bd	ADP	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
up	ADJ	O	O
for	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
persistence	NOUN	O	O
of	ADP	O	O
cutaneous	ADJ	O	B-PHYSICAL
lesions	NOUN	O	I-PHYSICAL
after	ADP	O	O
starting	ADJ	O	O
treatment	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
durations	NOUN	O	B-OTHER
were	VERB	O	O
10.5	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
the	DET	O	O
penicillin	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
8.8	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
the	DET	O	O
doxycycline	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
8.6	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
the	DET	O	O
azithromycin	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
resolution	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
associated	VERB	O	I-PHYSICAL
local	ADJ	O	I-PHYSICAL
and/or	CCONJ	O	I-PHYSICAL
systemic	ADJ	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
time	NOUN	O	O
was	VERB	O	O
shortest	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
azithromycin	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
phenoxymethylpenicillin	NOUN	O	O
and	CCONJ	O	O
two	NUM	O	O
given	VERB	O	O
doxycycline	NOUN	O	O
subsequently	ADV	O	O
developed	ADV	O	O
major	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
Lyme	NOUN	O	B-PHYSICAL
borreliosis	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
these	PUNCT	O	O
did	PUNCT	O	O
not	ADV	O	O
occur	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	SYM	O	O
azithromycin	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
azithromycin	NOUN	O	O
has	VERB	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
erythema	NOUN	O	O
migrans	ADJ	O	O
,	PUNCT	O	O
further	ADJ	O	O
studies	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
needed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
optimal	ADJ	O	O
dosage	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Naltrexone	NUM	O	O
in	ADP	O	O
young	ADJ	O	O
autistic	ADJ	O	O
children	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
crossover	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
naltrexone	NUM	O	O
,	PUNCT	O	O
an	DET	O	O
opiate	ADJ	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Thirteen	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
aged	ADP	O	O
3.4	NUM	O	O
to	ADP	O	O
8.3	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
5.4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
home	NOUN	O	O
,	PUNCT	O	O
school	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
outpatient	ADJ	O	O
laboratory	NOUN	O	O
.	PUNCT	O	O

Naltrexone	NUM	O	O
,	PUNCT	O	O
1.0	NUM	O	O
mg/kg	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
daily	ADP	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
crossover	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

Dependent	ADJ	O	O
measures	NOUN	O	O
included	DET	O	O
parent	NOUN	O	O
and	CCONJ	O	O
teacher	NOUN	O	O
Clinical	ADJ	O	B-MENTAL
Global	PUNCT	O	I-MENTAL
Impressions	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
CGI	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
,	PUNCT	O	O
Conners	PUNCT	O	B-MENTAL
Rating	PUNCT	O	I-MENTAL
Scales	PUNCT	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
Naltrexone	NUM	O	B-OTHER
Side-Effects	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
SE	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
Rating	PUNCT	O	I-OTHER
Scale	NOUN	O	O
;	PUNCT	O	O
laboratory	NOUN	O	B-MENTAL
CGI	NOUN	O	I-MENTAL
,	PUNCT	O	O
movement	NOUN	O	B-MENTAL
actometer	NOUN	O	I-MENTAL
readings	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
10-second	NOUN	O	B-MENTAL
interval	NOUN	O	I-MENTAL
recording	ADJ	O	I-MENTAL
system	NOUN	O	I-MENTAL
analysis	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
on-task	PUNCT	O	I-MENTAL
,	PUNCT	O	O
communication	NOUN	O	B-MENTAL
initiations	NOUN	O	I-MENTAL
,	PUNCT	O	O
disruptive	ADJ	O	B-MENTAL
behavior	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
self-stimulation	NOUN	O	B-MENTAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Eight	PUNCT	O	O
of	ADP	O	O
13	NUM	O	O
subjects	NOUN	O	O
improved	VERB	O	O
in	ADP	O	O
two	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
settings	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
parent	NOUN	O	B-MENTAL
measures	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
CGI	NOUN	O	I-MENTAL
,	PUNCT	O	O
Conners	PROPN	O	B-MENTAL
Impulsivity-Hyperactivity	NOUN	O	I-MENTAL
Factor	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
SE-Restlessness	NOUN	O	B-MENTAL
)	PUNCT	O	O
and	CCONJ	O	O
Teacher	NOUN	O	B-MENTAL
CGI	NOUN	O	I-MENTAL
achieved	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
.	PUNCT	O	O

Teacher	NOUN	O	B-MENTAL
SE-Restlessness	NOUN	O	I-MENTAL
and	CCONJ	O	O
initiation	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
communication	NOUN	O	I-MENTAL
in	ADP	O	O
the	DET	O	O
clinic	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
improvement	NOUN	O	O
.	PUNCT	O	O

Actometer	ADJ	O	B-PHYSICAL
readings	NOUN	O	I-PHYSICAL
improved	VERB	O	O
in	ADP	O	O
two	NUM	O	O
children	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
very	ADV	O	O
active	ADJ	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
side	NOUN	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
behavioral	ADJ	O	O
,	PUNCT	O	O
mild	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
transient	ADJ	O	O
.	PUNCT	O	O

Administering	ADP	O	O
the	DET	O	O
bitter	ADJ	O	O
tablet	NOUN	O	O
was	VERB	O	O
a	DET	O	O
challenge	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Naltrexone	NUM	O	O
offers	VERB	O	O
promise	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
agent	NOUN	O	O
for	ADP	O	O
modest	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
behavior	NOUN	O	O
and	CCONJ	O	O
social	ADJ	O	B-MENTAL
communication	NOUN	O	I-MENTAL
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Parent	NOUN	O	O
and	CCONJ	O	O
teacher	NOUN	O	O
measures	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
outpatient	ADJ	O	O
trials	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
change	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
of	ADP	O	O
activated	VERB	O	O
circulating	VERB	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
survivin	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
non-small	ADP	O	O
cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
after	ADP	O	O
antiangiogenesis	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Although	ADP	O	O
antiangiogenesis	NOUN	O	O
therapy	NOUN	O	O
plays	NOUN	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
anti-neoplastic	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
its	ADP	O	O
recognized	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
slight	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
is	VERB	O	O
no	DET	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
define	NOUN	O	O
ideal	ADJ	O	O
markers	NOUN	O	O
for	ADP	O	O
predicting	VERB	O	O
efficacy	NOUN	O	O
of	ADP	O	O
antiangiogenic	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
changes	NOUN	O	O
of	ADP	O	O
activated	VERB	O	O
circulating	VERB	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
(	PUNCT	O	O
aCECs	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
survivin	NOUN	O	O
after	ADP	O	O
anti-angiogenesis	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
their	NOUN	O	O
significance	NOUN	O	O
in	ADP	O	O
predicting	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
of	ADP	O	O
non-small	ADP	O	O
cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
NSCLC	NOUN	O	O
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
Endostar	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
activated	VERB	O	O
CECs	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
by	ADP	O	O
flow	NOUN	O	O
cytometry	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
survivin	NOUN	O	O
mRNA	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
real-time	NOUN	O	O
polymerase	NOUN	O	O
chain	NOUN	O	O
reaction	NOUN	O	O
(	PUNCT	O	O
PCR	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
activated	VERB	O	B-PHYSICAL
CECs	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
clinical	ADJ	O	O
benefit	ADP	O	O
cases	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.021	NUM	O	O
in	ADP	O	O
chemotherapy	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
in	ADP	O	O
chemotherapy	NOUN	O	O
plus	CCONJ	O	O
Endostar	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
increased	VERB	O	O
in	ADP	O	O
disease	NOUN	O	B-PHYSICAL
progressive	ADJ	O	I-PHYSICAL
cases	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.015	NUM	O	O
in	ADP	O	O
chemotherapy	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
P	NOUN	O	O
=	SYM	O	O
0.293	NUM	O	O
in	ADP	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
Endotatar	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
survivin	NOUN	O	B-PHYSICAL
mRNA	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
benefit	ADP	O	O
cases	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increased	PUNCT	O	O
in	ADP	O	O
disease	NOUN	O	B-PHYSICAL
progressive	ADJ	O	I-PHYSICAL
cases	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.018	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
positive	ADJ	O	O
correlation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
activated	VERB	O	B-PHYSICAL
CECs	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
survivin	NOUN	O	O
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
group	NOUN	O	O
pre-	ADJ	O	O
and	CCONJ	O	O
post-therapy	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
and	CCONJ	O	O
0.021	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
Endostar	NOUN	O	O
group	NOUN	O	O
pre-therapy	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.030	PUNCT	O	O
)	PUNCT	O	O
rather	PUNCT	O	O
than	ADP	O	O
post-therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
positive	ADJ	O	O
correlation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
decreased	VERB	O	O
activated	VERB	O	B-PHYSICAL
CECs	NOUN	O	I-PHYSICAL
after	ADP	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
progression	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
TTP	VERB	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.322	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.012	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
a	DET	O	O
negative	ADJ	O	O
correlation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
survivin	NOUN	O	B-PHYSICAL
mRNA	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
serum	NOUN	O	I-PHYSICAL
post-therapy	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
TTP	VERB	O	B-PHYSICAL
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
-0.291	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.048	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Activated	VERB	O	O
CECs	NOUN	O	O
and	CCONJ	O	O
survivin	NOUN	O	O
may	VERB	O	O
be	ADJ	O	O
ideal	ADJ	O	O
markers	NOUN	O	O
forecasting	PUNCT	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
prognosis	NOUN	O	O
of	ADP	O	O
NSCLC	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
former	ADJ	O	O
can	NOUN	O	O
reflect	VERB	O	O
more	DET	O	O
sensitively	ADV	O	O
antiangiogenic	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
latter	NOUN	O	O
is	PUNCT	O	O
more	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
shrinkage	NOUN	O	O
or	CCONJ	O	O
swelling	DET	O	O
of	ADP	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

Their	VERB	O	O
combination	NOUN	O	O
can	NOUN	O	O
evaluate	VERB	O	O
more	ADP	O	O
accurately	PUNCT	O	O
the	ADP	O	O
efficacy	NOUN	O	O
of	ADP	O	O
antiangiogenic	ADJ	O	O
therapy	NOUN	O	O
of	ADP	O	O
NSCLC	NOUN	O	O
.	PUNCT	O	O

Allopurinol	NOUN	O	O
improves	ADV	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
reduces	NOUN	O	O
oxidant-inflammatory	ADJ	O	O
enzyme	NOUN	O	O
of	ADP	O	O
myeloperoxidase	NOUN	O	O
in	ADP	O	O
metabolic	ADJ	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
tested	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metabolic	ADJ	O	O
syndrome	NOUN	O	O
whether	PUNCT	O	O
allopurinol	NOUN	O	O
through	ADP	O	O
decreasing	PUNCT	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
improves	ADV	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
ameliorates	NOUN	O	O
inflammatory	ADJ	O	O
state	NOUN	O	O
represented	ADJ	O	O
by	ADP	O	O
markers	NOUN	O	O
of	ADP	O	O
myeloperoxidase	NOUN	O	O
,	PUNCT	O	O
C-reactive	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
CRP	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fibrinogen	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
fashion	NOUN	O	O
;	PUNCT	O	O
subjects	NOUN	O	O
with	ADP	O	O
metabolic	ADJ	O	O
syndrome	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
allopurinol	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
28	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
22	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
one	NUM	O	O
month	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	ADV	O	O
and	CCONJ	O	O
the	DET	O	O
flow-mediated	ADV	O	B-PHYSICAL
dilation	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
FMD	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
isosorbide	PUNCT	O	B-PHYSICAL
dinitrate	PUNCT	O	I-PHYSICAL
(	PUNCT	O	O
ISDN	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
-mediated	VERB	O	B-PHYSICAL
dilation	NOUN	O	B-PHYSICAL
of	ADP	O	O
the	DET	O	O
brachial	ADJ	O	O
artery	NOUN	O	O
were	ADP	O	O
performed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Baseline	NOUN	O	O
clinical	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
allopurinol	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
demonstrated	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	B-OTHER
characteristics	NOUN	O	I-OTHER
,	PUNCT	O	O
endothelial	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
inflammatory	ADJ	O	B-PHYSICAL
markers	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
with	ADP	O	O
allopurinol	NOUN	O	O
,	PUNCT	O	O
FMD	NOUN	O	B-PHYSICAL
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
8.0	NUM	O	O
+/-	SYM	O	O
0.5	NUM	O	O
%	SYM	O	O
to	ADP	O	O
11.8	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
ISDN-mediated	VERB	O	B-PHYSICAL
dilation	NOUN	O	I-PHYSICAL
is	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
marker	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
allopurinol	NOUN	O	O
significantly	ADV	O	O
reduced	ADV	O	B-PHYSICAL
malondialdehyde	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
myeloperoxidase	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
with	ADP	O	O
allopurinol	NOUN	O	O
(	PUNCT	O	O
56.1	NUM	O	O
+/-	SYM	O	O
3.4	NUM	O	O
ng/ml	NOUN	O	O
vs.	CCONJ	O	O
44.4	NUM	O	O
+/-	SYM	O	O
2.4	NUM	O	O
ng/ml	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Surprisingly	ADV	O	O
,	PUNCT	O	O
neither	PUNCT	O	O

Topical	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
diclofenac	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
miosis	NOUN	O	B-PHYSICAL
during	ADP	O	O
vitrectomy	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
A	CCONJ	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
usefulness	NOUN	O	O
of	ADP	O	O
preoperative	ADJ	O	O
diclofenac	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
in	ADP	O	O
maintaining	VERB	O	O
mydriasis	NOUN	O	B-PHYSICAL
during	ADP	O	O
vitrectomy	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
reducing	VERB	O	O
postoperative	ADJ	O	B-PHYSICAL
inflammation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
Fifty	ADJ	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
vitrectomy	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
diclofenac	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
26	NUM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
standard	ADJ	O	O
preoperative	ADJ	O	O
regimen	NOUN	O	O
of	ADP	O	O
cyclopentolate	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
phenylephrine	NOUN	O	O
hydrochloride	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
diclofenac	NOUN	O	O
group	NOUN	O	O
also	ADV	O	O
received	PUNCT	O	O
diclofenac	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
preoperatively	ADV	O	O
.	PUNCT	O	O

Pupillary	ADJ	O	B-PHYSICAL
diameter	NOUN	O	I-PHYSICAL
was	VERB	O	O
recorded	VERB	O	O
at	ADP	O	O
four	NUM	O	O
time	NOUN	O	O
points	NOUN	O	O
during	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Inflammatory	ADJ	O	B-PHYSICAL
indices	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	PUNCT	O	O
postoperatively	ADV	O	O
using	PUNCT	O	O
slit-lamp	NOUN	O	O
examination	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
pupil	NOUN	O	B-PHYSICAL
size	NOUN	O	I-PHYSICAL
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.112	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
for	ADP	O	O
the	DET	O	O
next	ADJ	O	O
two	NUM	O	O
stages	NOUN	O	O
,	PUNCT	O	O
it	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
in	ADP	O	O
the	DET	O	O
diclofenac	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.012	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
for	ADP	O	O
anterior	ADJ	O	B-PHYSICAL
chamber	NOUN	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
and	PUNCT	O	O
redness	PUNCT	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
eye	NOUN	O	I-PHYSICAL
postoperatively	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.609	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O
=	SYM	O	O
0.123	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
anterior	ADJ	O	B-PHYSICAL
chamber	NOUN	O	I-PHYSICAL
flare	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.035	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
patients	ADP	O	O
felt	PUNCT	O	O
significantly	ADV	O	O
more	DET	O	O
pain	NOUN	O	B-PAIN
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Topical	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
diclofenac	NOUN	O	O
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
maintaining	VERB	O	B-PHYSICAL
mydriasis	NOUN	O	I-PHYSICAL
during	ADP	O	O
vitrectomy	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
reducing	VERB	O	O
postoperative	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
and	CCONJ	O	O
anterior	ADJ	O	B-PHYSICAL
chamber	NOUN	O	I-PHYSICAL
flare	NOUN	O	I-PHYSICAL
as	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
slit-lamp	NOUN	O	O
evaluations	NOUN	O	O
.	PUNCT	O	O

Promoting	ADV	O	O
health	NOUN	O	O
in	ADP	O	O
schools	NOUN	O	O
through	ADP	O	O
a	DET	O	O
board	ADP	O	O
game	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
prevention	NOUN	O	O
and	CCONJ	O	O
health	NOUN	O	O
promotion	NOUN	O	O
have	PUNCT	O	O
become	ADP	O	O
salient	ADJ	O	O
topics	NOUN	O	O
in	ADP	O	O
Canadian	ADJ	O	O
society	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
nursing	VERB	O	O
during	ADP	O	O
the	DET	O	O
past	ADJ	O	O
two	NUM	O	O
decades	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
noncommunicable	ADJ	O	O
chronic	ADJ	O	O
diseases	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
heart	NOUN	O	O
disease	NOUN	O	O
and	CCONJ	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
have	PROPN	O	O
been	PUNCT	O	O
linked	VERB	O	O
to	ADP	O	O
specific	ADJ	O	O
lifestyle	NOUN	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
or	CCONJ	O	O
habits	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
often	ADV	O	O
develop	ADV	O	O
early	ADJ	O	O
in	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
success	NOUN	O	O
of	ADP	O	O
public	ADJ	O	O
health	NOUN	O	O
efforts	NOUN	O	O
to	PART	O	O
improve	ADJ	O	O
the	DET	O	O
health	NOUN	O	O
status	NOUN	O	O
of	ADP	O	O
all	DET	O	O
Canadians	PUNCT	O	O
depends	NOUN	O	O
substantially	ADV	O	O
on	ADP	O	O
the	DET	O	O
success	NOUN	O	O
of	ADP	O	O
educational	ADJ	O	O
programs	NOUN	O	O
directed	VERB	O	O
toward	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Effective	ADJ	O	O
teaching	VERB	O	O
strategies	NOUN	O	O
that	ADP	O	O
seek	ADP	O	O
to	PART	O	O
promote	NOUN	O	O
health	NOUN	O	O
and	CCONJ	O	O
wellness	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
need	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
developed	VERB	O	O
and	CCONJ	O	O
empirically	ADJ	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Educational	ADJ	O	O
games	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
an	DET	O	O
efficient	ADJ	O	O
vehicle	NOUN	O	O
for	ADP	O	O
carrying	ADJ	O	O
out	PUNCT	O	O
developmentally	ADV	O	O
specific	ADJ	O	O
nursing	VERB	O	O
interventions	NOUN	O	O
in	ADP	O	O
school	NOUN	O	O
settings	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
begins	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
brief	ADJ	O	O
overview	NOUN	O	O
of	ADP	O	O
the	DET	O	O
historical	ADJ	O	O
origins	NOUN	O	O
of	ADP	O	O
games	NOUN	O	O
,	PUNCT	O	O
along	PUNCT	O	O
with	ADP	O	O
their	PUNCT	O	O
advantages	NOUN	O	O
and	CCONJ	O	O
disadvantages	ADJ	O	O
as	ADP	O	O
educational	ADJ	O	O
strategies	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pretest-posttest	ADV	O	O
control	NOUN	O	O
group	NOUN	O	O
design	NOUN	O	O
study	PUNCT	O	O
that	PUNCT	O	O
evaluated	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
board	ADP	O	O
game	NOUN	O	O
as	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
prevention	NOUN	O	O
teaching	VERB	O	O
strategy	NOUN	O	O
with	ADP	O	O
23	NUM	O	O
sixth	ADJ	O	O
grade	NOUN	O	O
children	NOUN	O	O
in	ADP	O	O
Winnipeg	PUNCT	O	O
,	PUNCT	O	O
Manitoba	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
had	PUNCT	O	O
significant	ADJ	O	O
gains	NOUN	O	O
in	ADP	O	O
knowledge	NOUN	O	B-MENTAL
related	VERB	O	I-MENTAL
to	ADP	O	I-MENTAL
anatomy	NOUN	O	I-MENTAL
and	CCONJ	O	I-MENTAL
physiology	NOUN	O	I-MENTAL
,	PUNCT	O	O
diet	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	B-MENTAL
lifestyle	NOUN	O	I-MENTAL
risk	NOUN	O	O
factors	NOUN	O	B-MENTAL
associated	VERB	O	I-MENTAL
with	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
development	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
heart	NOUN	O	I-MENTAL
disease	PUNCT	O	I-MENTAL

Comparative	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
microbiological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
subgingival	PUNCT	O	O
metronidazole	NOUN	O	O
application	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
periodontitis	NOUN	O	O
;	PUNCT	O	O
12-months	NOUN	O	O
results	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
microbiological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
subgingival	PUNCT	O	O
application	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
%	SYM	O	O
metronidazole	NOUN	O	O
dental	ADJ	O	O
gel	NOUN	O	O
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
scaling	ADP	O	O
and	CCONJ	O	O
root	NOUN	O	O
planing	PUNCT	O	O
(	PUNCT	O	O
SRP	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
adult	NOUN	O	O
periodontitis	NOUN	O	O
.	PUNCT	O	O

Eighty	PUNCT	O	O
teeth	NOUN	O	O
in	ADP	O	O
18	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
a	DET	O	O
split	ADJ	O	O
mouth	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
test	CCONJ	O	O
teeth	NOUN	O	O
received	VERB	O	O
SRP	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
25	NUM	O	O
%	SYM	O	O
metronidazole	NOUN	O	O
gel	NOUN	O	O
applied	PUNCT	O	O
subgingivally	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
0	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
teeth	NOUN	O	O
received	VERB	O	O
SRP	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
and	CCONJ	O	O
microbiological	ADJ	O	O
examinations	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
before	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
weeks	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
13	NUM	O	O
,	PUNCT	O	O
26	NUM	O	O
,	PUNCT	O	O
38	NUM	O	O
and	CCONJ	O	O
52	NUM	O	O
of	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Colony	NOUN	O	O
forming	VERB	O	O
units	NOUN	O	O
of	ADP	O	O
Porphyromonas	NOUN	O	O
gingivalis	NOUN	O	O
and	CCONJ	O	O
Prevotella	NOUN	O	O
intermedia	NOUN	O	O
/	SYM	O	O
Prevotella	ADP	O	O
nigrescens	NUM	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
treatments	NOUN	O	O
provided	VERB	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
all	DET	O	O
the	DET	O	O
clinical	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
microbiological	ADJ	O	I-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
none	NUM	O	O
of	ADP	O	O
the	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
study	ADV	O	O
groups	NOUN	O	O
were	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
provide	VERB	O	O
evidence	NOUN	O	O
in	ADP	O	O
favour	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
routine	ADJ	O	I-OTHER
use	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
adjunctive	ADJ	O	I-OTHER
metronidazole	NOUN	O	I-OTHER
dental	ADJ	O	I-OTHER
gel	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
adult	NOUN	O	B-PHYSICAL
periodontitis	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
prophylactic	ADJ	O	O
management	NOUN	O	O
and	CCONJ	O	O
therapeutics	ADJ	O	O
on	ADP	O	O
hypertensive	ADJ	O	B-PHYSICAL
disease	NOUN	O	I-PHYSICAL
in	ADP	O	O
pregnancy	NOUN	O	O
:	PUNCT	O	O
preliminary	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
controlled	VERB	O	O
prospective	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
pregnancy	NOUN	O	O
complicated	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
hypertension	NOUN	O	O
is	VERB	O	O
proposed	VERB	O	O
and	CCONJ	O	O
preliminary	ADJ	O	O
data	NOUN	O	O
on	ADP	O	O
population	NOUN	O	O
selection	NOUN	O	B-OTHER
and	CCONJ	O	O
pregnancy	NOUN	O	B-PHYSICAL
outcome	NOUN	O	I-PHYSICAL
are	ADP	O	O
presented	VERB	O	O
.	PUNCT	O	O

Sixty-three	PUNCT	O	O
women	NOUN	O	O
with	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
underlying	ADP	O	O
hypertensive	ADJ	O	O
disease	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
prospectively	ADV	O	O
throughout	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Twenty-three	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
in	ADP	O	O
a	DET	O	O
protocol	NOUN	O	O
of	ADP	O	O
intensified	PUNCT	O	O
prenatal	ADJ	O	O
care	NOUN	O	O
and	CCONJ	O	O
randomized	VERB	O	O
assignment	NOUN	O	O
of	ADP	O	O
antihypertensive	ADJ	O	O
agents	NOUN	O	O
:	PUNCT	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
hydralazine	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
methyldopa	NOUN	O	O
.	PUNCT	O	O

Forty	CCONJ	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
in	ADP	O	O
the	DET	O	O
high-risk	NOUN	O	O
pregnancy	NOUN	O	O
clinics	ADJ	O	O
at	ADP	O	O
Duke	NOUN	O	O
University	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
preeclampsia	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
randomized	VERB	O	O
prophylactic	ADP	O	O
antihypertensive	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
lower	PUNCT	O	O
than	ADP	O	O
that	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
nonrandomized	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
8.7	NUM	O	O
versus	CCONJ	O	O
32.5	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
other	ADJ	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	B-OTHER
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
63	NUM	O	O
hypertensive	ADJ	O	O
women	NOUN	O	O
had	DET	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	B-PHYSICAL
mellitus	NOUN	O	I-PHYSICAL
diagnosed	VERB	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
(	PUNCT	O	O
49.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
authors	NOUN	O	O
'	PUNCT	O	O
general	VERB	O	O
obstetric	ADJ	O	O
population	NOUN	O	O
(	PUNCT	O	O
8.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
audiotapes	NOUN	O	O
in	ADP	O	O
promoting	VERB	O	B-MENTAL
psychological	ADJ	O	I-MENTAL
well-being	PUNCT	O	I-MENTAL
in	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Open	ADJ	O	O
or	CCONJ	O	O
uncontrolled	VERB	O	O
studies	NOUN	O	O
have	ADP	O	O
suggested	VERB	O	O
that	ADP	O	O
providing	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
audiotapes	NOUN	O	O
of	ADP	O	O
their	ADP	O	O
clinical	ADJ	O	O
interviews	NOUN	O	O
can	PROPN	O	O
improve	VERB	O	O
information	NOUN	O	O
recall	NOUN	O	B-MENTAL
and	CCONJ	O	O
reduce	ADJ	O	O
psychological	ADJ	O	B-MENTAL
distress	NOUN	O	I-MENTAL
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
these	DET	O	O
hypotheses	NOUN	O	O
in	ADP	O	O
a	DET	O	O
'clinician-blind	PUNCT	O	O
'	PUNCT	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
117	NUM	O	O
patients	NOUN	O	O
newly	ADV	O	O
referred	ADP	O	O
to	ADP	O	O
a	DET	O	O
medical	ADJ	O	O
oncology	NOUN	O	O
clinic	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
given	VERB	O	O
'bad	PUNCT	O	O
news	NOUN	O	O
'	PUNCT	O	O
had	PUNCT	O	O
their	DET	O	O
consultations	NOUN	O	O
audiotaped	PUNCT	O	O
.	PUNCT	O	O

Blind	NOUN	O	O
to	ADP	O	O
the	DET	O	O
clinician	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
copy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tape	NOUN	O	O
to	PART	O	O
play	NOUN	O	O
at	ADP	O	O
home	NOUN	O	O
or	CCONJ	O	O
not	ADV	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
tape	NOUN	O	O
group	NOUN	O	O
patients	NOUN	O	O
reported	ADP	O	O
positive	ADJ	O	O
attitudes	NOUN	O	B-MENTAL
to	ADP	O	O
the	DET	O	O
audiotape	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
shown	VERB	O	O
to	PART	O	O
recall	ADV	O	B-MENTAL
significantly	ADV	O	I-MENTAL
more	DET	O	I-MENTAL
information	NOUN	O	O
about	ADP	O	B-MENTAL
their	PUNCT	O	I-MENTAL
illness	NOUN	O	B-MENTAL
than	PUNCT	O	O
did	PUNCT	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Overall	PUNCT	O	O
improvement	NOUN	O	O
in	ADP	O	O
psychological	ADJ	O	B-MENTAL
distress	NOUN	O	I-MENTAL
at	ADP	O	O
1	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
measured	VERB	O	O
with	ADP	O	O
the	DET	O	O
30-item	NOUN	O	B-MENTAL
General	VERB	O	I-MENTAL
Health	NOUN	O	B-MENTAL
Questionnaire	NOUN	O	O
and	CCONJ	O	B-MENTAL
the	PUNCT	O	I-MENTAL

Efficacy	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
azithromycin	NOUN	O	O
ophthalmic	VERB	O	O
solution	NOUN	O	O
1	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
posterior	ADJ	O	O
blepharitis	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Azithromycin	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
broad-spectrum	NOUN	O	O
antibiotic	CCONJ	O	O
with	ADP	O	O
potent	ADJ	O	O
anti-inflammatory	ADJ	O	O
activities	NOUN	O	O
,	PUNCT	O	O
has	PUNCT	O	O
the	DET	O	O
potential	ADJ	O	O
to	PUNCT	O	O
effectively	ADV	O	O
treat	PUNCT	O	O
blepharitis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
an	DET	O	O
inflammatory	ADJ	O	O
disease	NOUN	O	O
of	ADP	O	O
the	DET	O	O
eyelid	ADJ	O	O
with	ADP	O	O
abnormal	ADJ	O	O
eyelid	ADJ	O	O
flora	PUNCT	O	O
as	PUNCT	O	O
an	DET	O	O
etiologic	ADJ	O	O
determinant	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
azithromycin	NOUN	O	O
ophthalmic	VERB	O	O
solution	NOUN	O	O
1	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
AzaSite	NOUN	O	O
;	PUNCT	O	O
Inspire	ADP	O	O
Pharmaceuticals	PROPN	O	O
,	PUNCT	O	O
Inc	NOUN	O	O
,	PUNCT	O	O
NC	NOUN	O	O
,	PUNCT	O	O
USA	PUNCT	O	O
)	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
warm	NUM	O	O
compresses	PUNCT	O	O
(	PUNCT	O	O
azithromycin	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
warm	NUM	O	O
compresses	PUNCT	O	O
alone	ADJ	O	O
(	PUNCT	O	O
compress	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
posterior	ADJ	O	O
blepharitis	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Twenty-one	VERB	O	O
patients	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
posterior	ADJ	O	O
blepharitis	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
in	ADP	O	O
an	DET	O	O
open-label	NOUN	O	O
study	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
azithromycin	NOUN	O	O
plus	CCONJ	O	O
warm	NUM	O	O
compresses	PUNCT	O	O
(	PUNCT	O	O
10	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
compresses	PUNCT	O	O
alone	ADJ	O	O
(	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
instructed	VERB	O	O
to	PART	O	O
apply	NOUN	O	O
compresses	CCONJ	O	O
to	ADP	O	O
each	DET	O	O
eye	NOUN	O	O
for	ADP	O	O
5-10	NUM	O	O
minutes	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
eye	NOUN	O	O
in	ADP	O	O
the	DET	O	O
azithromycin	NOUN	O	O
group	NOUN	O	O
also	ADV	O	O
received	CCONJ	O	O
azithromycin	NOUN	O	O
solution	NOUN	O	O
(	PUNCT	O	O
1	ADP	O	O
drop	VERB	O	O
)	PUNCT	O	O
twice	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2	NUM	O	O
days	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
once	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
the	DET	O	O
next	ADJ	O	O
12	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
study	NOUN	O	O
initiation	NOUN	O	O
(	PUNCT	O	O
visit	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
end	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
visit	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
:	PUNCT	O	O
eyelid	ADJ	O	B-PHYSICAL
debris	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
eyelid	PUNCT	O	B-PHYSICAL
redness	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
eyelid	PUNCT	O	B-PHYSICAL
swelling	SYM	O	I-PHYSICAL
,	PUNCT	O	O
meibomian	ADJ	O	B-PHYSICAL
gland	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
MG	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
plugging	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
MG	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

At	ADP	O	O
visit	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
patients	NOUN	O	O
also	ADV	O	O
rated	VERB	O	O
their	ADP	O	O
degree	NOUN	O	O
of	ADP	O	O
overall	ADJ	O	B-OTHER
symptomatic	ADJ	O	I-OTHER
relief	NOUN	O	B-OTHER
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty	PUNCT	O	O
patients	NOUN	O	O
completed	NOUN	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
visit	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
azithromycin	NOUN	O	O
group	NOUN	O	O
demonstrated	VERB	O	O
significant	ADJ	O	B-MENTAL
improvements	NOUN	O	I-MENTAL
in	ADP	O	O
MG	NOUN	O	B-PHYSICAL
plugging	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
MG	NOUN	O	B-PHYSICAL
secretions	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
eyelid	PUNCT	O	B-PHYSICAL
redness	PUNCT	O	I-PHYSICAL
as	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
compress	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
azithromycin	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
MG	NOUN	O	B-PHYSICAL
plugging	PUNCT	O	I-PHYSICAL
resolved	PUNCT	O	O
completely	ADV	O	O
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
and	CCONJ	O	O
MG	NOUN	O	B-PHYSICAL
secretion	NOUN	O	I-PHYSICAL
returned	VERB	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
normal	ADJ	O	I-PHYSICAL
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
;	PUNCT	O	O
no	DET	O	O
such	DET	O	O
results	NOUN	O	O
were	ADV	O	O
seen	VERB	O	O
in	ADP	O	O
the	DET	O	O
compress	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
higher	PUNCT	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
azithromycin	NOUN	O	O
group	NOUN	O	O
rated	VERB	O	O
overall	ADJ	O	B-PHYSICAL
symptomatic	ADJ	O	I-PHYSICAL
relief	NOUN	O	I-PHYSICAL
as	ADP	O	O
excellent	ADJ	O	O
or	CCONJ	O	O
good	ADJ	O	O
.	PUNCT	O	O

Visual	ADJ	O	B-OTHER
acuity	NOUN	O	I-OTHER
measurements	PUNCT	O	I-OTHER

Naltrexone	NUM	O	O
in	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
and	CCONJ	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
critically	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
naltrexone	NUM	O	O
on	ADP	O	O
behavioral	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
and	CCONJ	O	O
learning	ADP	O	B-MENTAL
in	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
its	PUNCT	O	O
safety	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
a	DET	O	O
preliminary	ADJ	O	O
report	NOUN	O	O
on	ADP	O	O
18	NUM	O	O
children	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
3.08	NUM	O	O
to	ADP	O	O
7.99	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
who	PROPN	O	O
completed	PUNCT	O	O
this	DET	O	O
ongoing	ADV	O	O
study	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
naltrexone	NUM	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
received	ADJ	O	O
daily	ADJ	O	O
doses	NOUN	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Naltrexone	NUM	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
blind	PUNCT	O	O
Clinical	ADJ	O	B-MENTAL
Global	ADJ	O	I-MENTAL
Consensus	NOUN	O	I-MENTAL
Ratings	NOUN	O	I-MENTAL
(	PUNCT	O	O
unpublished	VERB	O	O
scale	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
other	ADJ	O	O
behavioral	ADJ	O	O
rating	PUNCT	O	O
measures	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
confirm	VERB	O	O
this	DET	O	O
result	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
only	ADV	O	O
a	DET	O	O
suggestion	NOUN	O	O
that	PUNCT	O	O
naltrexone	NUM	O	O
reduced	VERB	O	O
fidgety	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
hyperactive	ADJ	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
and	CCONJ	O	O
tended	VERB	O	O
to	ADP	O	O
alleviate	ADP	O	O
overall	VERB	O	B-MENTAL
symptomatology	NOUN	O	I-MENTAL
in	ADP	O	O
older	PUNCT	O	O
children	NOUN	O	O
.	PUNCT	O	O

Naltrexone	NUM	O	O
did	PUNCT	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
affect	NOUN	O	O
discrimination	NOUN	O	B-MENTAL
learning	PUNCT	O	I-MENTAL
.	PUNCT	O	O

Results	VERB	O	O
are	VERB	O	O
preliminary	ADJ	O	O
and	CCONJ	O	O
,	PUNCT	O	O
owing	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
small	ADJ	O	O
sample	NOUN	O	O
size	NOUN	O	O
,	PUNCT	O	O
can	PRON	O	O
be	VERB	O	O
considered	VERB	O	O
only	ADV	O	O
suggestive	ADJ	O	O
until	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
completed	NOUN	O	O
or	CCONJ	O	O
replication	NOUN	O	O
is	VERB	O	O
obtained	VERB	O	O
from	ADP	O	O
independent	ADJ	O	O
research	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
How	ADP	O	O
to	DET	O	O
treat	CCONJ	O	O
the	DET	O	O
relapse	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
NSCLC	NOUN	O	I-PHYSICAL
after	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
chemotherapy	NOUN	O	O
?	PUNCT	O	O

IFTC	NOUN	O	O
0702	NUM	O	O
randomized	VERB	O	O
phase	NOUN	O	O
III	NUM	O	O
study	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
As	ADP	O	O
chemotherapy	NOUN	O	O
gains	NOUN	O	O
wider	PUNCT	O	O
acceptance	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
earlier	PUNCT	O	O
stages	NOUN	O	O
of	ADP	O	O
NSCLC	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
the	DET	O	O
adjuvant	NOUN	O	O
and	CCONJ	O	O
neoadjuvant	PUNCT	O	O
setting	VERB	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
face	NUM	O	O
a	DET	O	O
growing	VERB	O	O
population	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
performance	NOUN	O	O
status	NOUN	O	O
patients	NOUN	O	O
who	ADP	O	O
have	PUNCT	O	O
relapsed	VERB	O	O
after	ADP	O	O
their	PUNCT	O	O
first-line	NOUN	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
type	NOUN	O	O
of	ADP	O	O
second-line	NOUN	O	O
chemotherapy	NOUN	O	O
after	ADP	O	O
initial	ADJ	O	O
adjuvant	NOUN	O	O
or	CCONJ	O	O
neoadjuvant	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
platinum-based	VERB	O	O
regimen	NOUN	O	O
remains	NOUN	O	O
largely	ADV	O	O
undefined	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
designed	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
classical	ADJ	O	O
mono	NOUN	O	O
chemotherapy	NOUN	O	O
docetaxel	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
docetaxel	VERB	O	O
cisplatin	NOUN	O	O
doublet	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
will	ADP	O	O
be	VERB	O	O
randomized	VERB	O	O
in	ADP	O	O
2	NUM	O	O
arms	NOUN	O	O
.	PUNCT	O	O

Arm	NOUN	O	O
:	PUNCT	O	O
docetaxel	ADJ	O	O
cisplatin	NOUN	O	O
(	PUNCT	O	O
cycles	NOUN	O	O
repeated	VERB	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
4	NUM	O	O
cycles	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
2	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
docetaxel	PUNCT	O	O
alone	ADJ	O	O
in	ADP	O	O
case	NOUN	O	O
of	ADP	O	O
objective	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
stabilisation	NOUN	O	O
.	PUNCT	O	O

Arm	NOUN	O	O
B	NOUN	O	O
:	PUNCT	O	O
docetaxel	PUNCT	O	O
alone	ADJ	O	O
(	PUNCT	O	O
cycles	NOUN	O	O
repeated	VERB	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
4	NUM	O	O
cycles	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
2	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
docetaxel	PUNCT	O	O
alone	ADJ	O	O
in	ADP	O	O
case	NOUN	O	O
of	ADP	O	O
objective	ADJ	O	O
response	NOUN	O	O
or	CCONJ	O	O
stabilisation	NOUN	O	O
.	PUNCT	O	O

EXPECTED	CCONJ	O	O
RESULTS	DET	O	O
300	NUM	O	O
patients	NOUN	O	O
will	ADP	O	O
be	VERB	O	O
randomized	VERB	O	O
with	ADP	O	O
a	DET	O	O
statistical	ADJ	O	O
hypothesis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
progression	NOUN	O	B-MORTALITY
free	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
of	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
4.5	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
arm	NOUN	O	O
.	PUNCT	O	O

National	ADJ	O	O
Surgical	ADJ	O	O
Adjuvant	NOUN	O	O
Breast	NOUN	O	O
and	CCONJ	O	O
Bowel	NOUN	O	O
Project	NOUN	O	O
's	PUNCT	O	O
Breast	NOUN	O	O
Cancer	NOUN	O	O
Prevention	NOUN	O	O
Trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Breast	NOUN	O	O
Cancer	NOUN	O	O
Prevention	NOUN	O	O
Trial	NOUN	O	O
is	VERB	O	O
the	DET	O	O
largest	PUNCT	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
prevention	NOUN	O	O
study	NOUN	O	O
ever	ADV	O	O
undertaken	VERB	O	O
.	PUNCT	O	O

Administered	VERB	O	O
by	ADP	O	O
the	DET	O	O
National	ADJ	O	O
Surgical	ADJ	O	O
Adjuvant	NOUN	O	O
Breast	NOUN	O	O
and	CCONJ	O	O
Bowel	NOUN	O	O
Project	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
trial	NOUN	O	O
seeking	ADJ	O	O
to	PART	O	O
demonstrate	NOUN	O	O
whether	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
,	PUNCT	O	O
tamoxifen	NOUN	O	O
,	PUNCT	O	O
can	VERB	O	O
prevent	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
in	ADP	O	O
high-risk	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objectives	NOUN	O	O
of	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
are	ADP	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
tamoxifen	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
1	NUM	O	O
)	PUNCT	O	O
reducing	SYM	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
incidence	NOUN	O	O
of	ADP	O	B-PHYSICAL
invasive	ADJ	O	I-PHYSICAL
breast	NOUN	O	I-PHYSICAL
cancer	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
reducing	NUM	O	O
breast	NOUN	O	B-MORTALITY
cancer	NOUN	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
,	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
reducing	PUNCT	O	B-MORTALITY
deaths	NOUN	O	I-MORTALITY
from	ADP	O	I-MORTALITY
cardiovascular	PUNCT	O	B-MORTALITY

Tinidazole	NOUN	O	O
and	CCONJ	O	O
metronidazole	NOUN	O	O
in	ADP	O	O
hepatic	ADJ	O	O
amoebiasis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	O
and	CCONJ	O	O
tinidazole	VERB	O	O
has	PUNCT	O	O
been	PUNCT	O	O
compared	VERB	O	O
in	ADP	O	O
31	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatic	ADJ	O	O
amoebiasis	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
those	PUNCT	O	O
with	ADP	O	O
unequivocal	ADJ	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
radiological	ADJ	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
evidence	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
amoebiasis	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
;	PUNCT	O	O
diagnostic	ADJ	O	O
and	CCONJ	O	O
therapeutic	ADJ	O	O
aspiration	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
where	ADP	O	O
necessary	ADJ	O	O
.	PUNCT	O	O

15	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
metronidazole	NOUN	O	O
and	CCONJ	O	O
16	NUM	O	O
tinidazole	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
drugs	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
orally	ADV	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
2g	NOUN	O	O
for	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
treatment	NOUN	O	O
extended	CCONJ	O	O
if	PUNCT	O	O
considered	PUNCT	O	O
clinically	ADV	O	O
advisable	ADJ	O	O
.	PUNCT	O	O

12	NUM	O	O
of	ADP	O	O
15	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
cured	VERB	O	B-PHYSICAL
with	ADP	O	O
metronidazole	NOUN	O	O
given	VERB	O	O
for	ADP	O	O
an	DET	O	O
average	PUNCT	O	O
period	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
4	NUM	O	O
to	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

15	NUM	O	O
of	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
93.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
given	PUNCT	O	O
tinidazole	VERB	O	O
were	VERB	O	O
cured	VERB	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
mean	NOUN	O	O
duration	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
treatment	NOUN	O	I-OTHER
was	VERB	O	O
4	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
3	NUM	O	O
to	ADP	O	O
6	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
fewer	PUNCT	O	B-ADVERSE-EFFECTS
side-effects	NOUN	O	I-ADVERSE-EFFECTS
with	ADP	O	O
tinidazole	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
amoebiasis	NOUN	O	O
in	ADP	O	O
Bangladesh	NOUN	O	O
,	PUNCT	O	O
tinidazole	VERB	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
superior	ADJ	O	O
to	ADP	O	O
metronidazole	NOUN	O	O
in	ADP	O	O
overall	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
because	PUNCT	O	O
a	DET	O	O
shorter	PUNCT	O	O
course	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
necessary	ADJ	O	O
and	CCONJ	O	O
it	NOUN	O	O
caused	PROPN	O	O
fewer	PUNCT	O	O
side-effects	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

Lung	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
respiratory	ADJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
a	DET	O	O
1-year	NOUN	O	O
randomized	VERB	O	O
smoking	ADJ	O	O
cessation	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
varenicline	NOUN	O	O
in	ADP	O	O
COPD	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	PUNCT	O	O
There	PUNCT	O	O
are	VERB	O	O
few	ADJ	O	O
data	NOUN	O	O
concerning	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
lung	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
respiratory	ADJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
smokers	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
obstructive	ADJ	O	O
pulmonary	ADJ	O	O
disease	NOUN	O	O
(	PUNCT	O	O
COPD	NOUN	O	O
)	PUNCT	O	O
weeks	NOUN	O	O
to	ADP	O	O
months	PUNCT	O	O
after	ADP	O	O
quitting	PUNCT	O	O
smoking	ADP	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
serial	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
spirometry	NOUN	O	O
and	CCONJ	O	O
Clinical	ADJ	O	O
COPD	NOUN	O	O
Questionnaire	NOUN	O	O
(	PUNCT	O	O
CCQ	NOUN	O	O
)	PUNCT	O	O
scores	NOUN	O	O
(	PUNCT	O	O
measuring	VERB	O	O
respiratory	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
health-related	VERB	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
COPD	NOUN	O	O
participants	NOUN	O	O
by	ADP	O	O
smoking	ADJ	O	O
status	NOUN	O	O
during	ADP	O	O
a	DET	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
smokers	ADJ	O	O
with	ADP	O	O
mild-to-moderate	ADJ	O	O
COPD	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
varenicline	NOUN	O	O
1	NUM	O	O
mg	NOUN	O	O
b.i.d	ADV	O	O
.	PUNCT	O	O

or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
followed	VERB	O	O
to	ADP	O	O
Week	NOUN	O	O
52	NUM	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
endpoints	NOUN	O	O
of	ADP	O	O
abstinence	NOUN	O	B-MENTAL
were	VERB	O	O
previously	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
endpoints	NOUN	O	O
were	VERB	O	O
mean	ADJ	O	O
changes	NOUN	O	B-OTHER
from	ADP	O	I-OTHER
baseline	NOUN	O	I-OTHER
in	ADP	O	O
post-bronchodilator	NOUN	O	B-PHYSICAL
forced	DET	O	I-PHYSICAL
expired	CCONJ	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
s	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
FEV	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
1	NUM	O	B-PHYSICAL
)	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
CCQ	NOUN	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Change	NOUN	O	B-OTHER
from	ADP	O	I-OTHER
baseline	NOUN	O	I-OTHER
in	ADP	O	O
post-bronchodilator	NOUN	O	O
FEV	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
improved	VERB	O	O
in	ADP	O	O
continuous	ADJ	O	O
abstainers	NOUN	O	O
(	PUNCT	O	O
121.8	NUM	O	O
mL	NOUN	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
continuous	ADJ	O	O
smokers	NOUN	O	O
(	PUNCT	O	O
37.9	NUM	O	O
mL	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
Week	NOUN	O	O
12	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0069	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
at	ADP	O	O
Weeks	NOUN	O	O
24	NUM	O	O
or	CCONJ	O	O
52	NUM	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
change	ADV	O	O
from	ADP	O	O
baseline	NOUN	O	O
at	ADP	O	B-OTHER
Week	NOUN	O	I-OTHER
12	NUM	O	I-OTHER
in	ADP	O	O
CCQ	NOUN	O	B-PHYSICAL
Total	VERB	O	O
Score	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
in	ADP	O	O
continuous	ADJ	O	O
abstainers	NOUN	O	O
(	PUNCT	O	O
-1.04	NUM	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
continuous	ADJ	O	O
smokers	NOUN	O	O
(	PUNCT	O	O
-0.53	ADP	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
this	DET	O	O
improvement	NOUN	O	O
was	VERB	O	O
sustained	VERB	O	O
at	ADP	O	O
Weeks	NOUN	O	O
24	NUM	O	O
and	CCONJ	O	O
52	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
1-year	ADJ	O	O
cessation	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
smokers	NOUN	O	O
with	ADP	O	O
COPD	NOUN	O	O
,	PUNCT	O	O
continuous	ADJ	O	B-MENTAL
abstinence	ADJ	O	B-MENTAL
compared	VERB	O	O
with	ADP	O	O
continuous	ADJ	O	O
smoking	PART	O	O
significantly	ADV	O	O
improved	PUNCT	O	O

[	PUNCT	O	O
Prevention	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-MENTAL
with	ADP	O	O
flunarizine	NOUN	O	O
and	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

UNLABELLED	PUNCT	O	O
30	PUNCT	O	O
children	NOUN	O	O
between	ADP	O	O
7	NUM	O	O
and	CCONJ	O	O
17	NUM	O	O
years	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
at	ADP	O	O
least	ADV	O	O
2	NUM	O	O
attacks/month	NOUN	O	O
of	ADP	O	O
common	ADJ	O	O
or	CCONJ	O	O
classical	ADJ	O	O
migraine	NOUN	O	O
since	ADP	O	O
more	ADV	O	O
than	PUNCT	O	O
1	NUM	O	O
year	NOUN	O	O
were	NOUN	O	O
studied	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
clinical	ADJ	O	O
exclusion	NOUN	O	O
of	ADP	O	O
symptomatic	ADJ	O	O
headache	NOUN	O	O
4	NUM	O	O
weeks	NOUN	O	O
were	VERB	O	O
documented	VERB	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
a	DET	O	O
migraine	NOUN	O	O
diary	PUNCT	O	O
.	PUNCT	O	O

Prophylaxis	NOUN	O	O
with	ADP	O	O
Calcium	NOUN	O	O
entry	NOUN	O	O
blocker	NOUN	O	O
Flunarizine	NOUN	O	O
(	PUNCT	O	O
Sibelium	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
Thromboxane	NOUN	O	O
A	DET	O	O
inhibitor	NOUN	O	O
Acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
ASS	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
design	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Medication	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
as	ADP	O	O
one	NUM	O	O
dosage	NOUN	O	O
in	ADP	O	O
the	DET	O	O
evening	NOUN	O	O
:	PUNCT	O	O
2-5	NUM	O	O
mg/kg	NOUN	O	O
KG	NOUN	O	O
ASS	NOUN	O	O
or	CCONJ	O	O
5-10	NUM	O	O
mg	NOUN	O	O
Flunarizine	NOUN	O	O
.	PUNCT	O	O

Documented	VERB	O	O
attack	NOUN	O	B-PHYSICAL
frequency	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	B-PHYSICAL
were	VERB	O	O
controlled	VERB	O	O
at	ADP	O	O
monthly	ADV	O	O
physical	ADJ	O	O
examinations	NOUN	O	O
.	PUNCT	O	O

Final	ADJ	O	O
results	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
attack	NOUN	O	B-PHYSICAL
frequency	NOUN	O	O
or	CCONJ	O	O
symptoms	NOUN	O	B-PHYSICAL
between	ADP	O	O
both	CCONJ	O	O
different	ADJ	O	O
therapeutic	ADJ	O	O
principals	NOUN	O	O
.	PUNCT	O	O

72.4	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
ASS	NOUN	O	O
73.3	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
Flunarizine	NOUN	O	O
71.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
attack-free	ADP	O	O
or	CCONJ	O	O
had	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
a	DET	O	O
50	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
.	PUNCT	O	O

Migraine	NOUN	O	B-PHYSICAL
frequency	NOUN	O	I-PHYSICAL
of	ADP	O	O
initially	ADV	O	O
7-8	PUNCT	O	O
was	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
1-2	NUM	O	O
attacks/month	NOUN	O	O
.	PUNCT	O	O

Duration	NOUN	O	B-PHYSICAL
remained	VERB	O	O
constant	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
1-3	PUNCT	O	O
h	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Side	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
slight	ADJ	O	B-ADVERSE-EFFECTS
body	NOUN	O	I-ADVERSE-EFFECTS
weight	NOUN	O	O
gain	NOUN	O	B-ADVERSE-EFFECTS
or	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
first-dose	NOUN	O	O
hypotension	NOUN	O	O
with	ADP	O	O
quinapril	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
2242	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
(	PUNCT	O	O
diastolic	ADJ	O	O
pressure	NOUN	O	O
95-120	NUM	O	O
mmHg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomised	PUNCT	O	O
on	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
basis	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
mg	NOUN	O	O
quinapril	NOUN	O	O
or	CCONJ	O	O
10	NUM	O	O
mg	NOUN	O	O
quinapril	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
who	ADP	O	O
:	PUNCT	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
met	VERB	O	O
the	DET	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
BP	NOUN	O	O
)	PUNCT	O	O
criteria	NOUN	O	O
for	ADP	O	O
first-dose	ADJ	O	O
hypotension	NOUN	O	O
(	PUNCT	O	O
sitting	PUNCT	O	O
or	CCONJ	O	O
standing	ADV	O	O
systolic	ADJ	O	O
BP	NOUN	O	O
<	SYM	O	O
100	NUM	O	O
mmHg	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
systolic	ADJ	O	O
BP	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
20	NUM	O	O
mmHg	NOUN	O	O
on	ADP	O	O
standing	VERB	O	O
)	PUNCT	O	O
;	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
had	PUNCT	O	O
symptoms	NOUN	O	O
suggestive	ADJ	O	O
of	ADP	O	O
hypotension	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
met	VERB	O	O
the	DET	O	O
BP	NOUN	O	O
criteria	NOUN	O	O
and	CCONJ	O	O
had	PUNCT	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
three	NUM	O	O
classifications	NOUN	O	O
there	VERB	O	O
were	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
incidences	DET	O	O
in	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
combined	VERB	O	O
active	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
between	ADP	O	O
those	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
quinapril	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
associated	VERB	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
low-risk	NOUN	O	O
population	NOUN	O	O
studied	VERB	O	O
,	PUNCT	O	O
it	PRON	O	O
would	PART	O	O
appear	VERB	O	O
that	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
first-dose	NOUN	O	O
hypotension	NOUN	O	O
with	ADP	O	O
quinapril	NOUN	O	O
is	ADJ	O	O
similar	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
not	ADV	O	O
dose-related	PUNCT	O	O
.	PUNCT	O	O

Rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
of	ADP	O	O
head	NOUN	O	O
trauma	NOUN	O	O
patients	NOUN	O	O
:	PUNCT	O	O
prevention	NOUN	O	O
of	ADP	O	O
fasciculations	NOUN	O	B-PHYSICAL
with	ADP	O	O
pancuronium	NOUN	O	O
versus	CCONJ	O	O
minidose	NOUN	O	O
succinylcholine	ADJ	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Fasciculations	PROPN	O	B-PHYSICAL
during	ADP	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
increased	VERB	O	O
intracranial	ADJ	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
emesis	NOUN	O	B-PHYSICAL
with	ADP	O	O
aspiration	NOUN	O	O
.	PUNCT	O	O

Standard	ADJ	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
requires	NOUN	O	O
a	DET	O	O
nondepolarizing	SYM	O	O
blocking	DET	O	O
agent	NOUN	O	O
before	ADP	O	O
succinylcholine	PUNCT	O	O
administration	NOUN	O	O
.	PUNCT	O	O

HYPOTHESIS	NOUN	O	O
Prevention	NOUN	O	O
of	ADP	O	O
fasciculations	NOUN	O	B-PHYSICAL
during	ADP	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
of	ADP	O	O
head	NOUN	O	O
trauma	NOUN	O	O
patients	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
accomplished	VERB	O	O
as	PUNCT	O	O
safely	PUNCT	O	O
and	CCONJ	O	O
effectively	ADV	O	O
with	ADP	O	O
minidose	NOUN	O	O
succinylcholine	ADJ	O	O
as	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
defasciculating	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
pancuronium	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	CCONJ	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
An	DET	O	O
inner-city	NOUN	O	O
county	NOUN	O	O
trauma	NOUN	O	O
center	NOUN	O	O
with	ADP	O	O
70,000	NUM	O	O
patient	NOUN	O	O
visits	NOUN	O	O
per	ADP	O	O
year	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
Sequential	PUNCT	O	O
adult	NOUN	O	O
head	NOUN	O	O
trauma	NOUN	O	O
patients	NOUN	O	O
requiring	VERB	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
who	ADP	O	O
had	ADJ	O	O
no	DET	O	O
contraindications	NOUN	O	O
to	ADP	O	O
succinylcholine	PUNCT	O	O
or	CCONJ	O	O
pancuronium	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Each	PUNCT	O	O
head	NOUN	O	O
trauma	NOUN	O	O
patient	NOUN	O	O
requiring	VERB	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
who	ADP	O	O
met	VERB	O	O
the	DET	O	O
inclusion	NOUN	O	O
criteria	NOUN	O	O
received	VERB	O	O
standard	ADJ	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
maneuvers	NOUN	O	O
and	CCONJ	O	O
lidocaine	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
IV	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
minidose	NOUN	O	O
succinylcholine	ADJ	O	O
(	PUNCT	O	O
0.1	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
pancuronium	NOUN	O	O
(	PUNCT	O	O
0.03	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
IV	NUM	O	O
one	NUM	O	O
minute	ADJ	O	O
prior	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
full	ADJ	O	O
paralytic	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
succinylcholine	ADJ	O	O
(	PUNCT	O	O
1.5	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
IV	NUM	O	O
.	PUNCT	O	O

Fasciculations	NOUN	O	B-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
using	VERB	O	O
a	DET	O	O
graded	VERB	O	B-OTHER
visual	ADJ	O	I-OTHER
scale	NOUN	O	I-OTHER
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
46	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
eight	NUM	O	O
of	ADP	O	O
19	NUM	O	O
(	PUNCT	O	O
42	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
pancuronium	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
six	NUM	O	O
of	ADP	O	O
27	NUM	O	O
(	PUNCT	O	O
22	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
succinylcholine	PUNCT	O	O
group	NOUN	O	O
experienced	VERB	O	O
fasciculations	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
fasciculations	NOUN	O	B-PHYSICAL
was	ADV	O	O
detected	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
using	PROPN	O	O
chi	NOUN	O	O
2	NUM	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Complete	ADJ	O	B-PHYSICAL
relaxation	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
cords	NOUN	O	I-PHYSICAL
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
all	ADP	O	O
but	CCONJ	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
patient	NOUN	O	O
in	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
experienced	ADP	O	O
emesis	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
significant	ADJ	O	B-PHYSICAL
dysrhythmias	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Pretreatment	NOUN	O	O
with	ADP	O	O
minidose	NOUN	O	O
succinylcholine	ADJ	O	O
causes	ADP	O	O
no	DET	O	O
greater	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
fasciculations	NOUN	O	B-PHYSICAL
than	CCONJ	O	O
pancuronium	NOUN	O	O
in	ADP	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
of	ADP	O	O
head	NOUN	O	O
trauma	NOUN	O	O
patients	NOUN	O	O
in	ADP	O	O
an	DET	O	O
ED	NOUN	O	O
setting	VERB	O	O
.	PUNCT	O	O

Thus	ADV	O	O
succinylcholine	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
the	DET	O	O
sole	ADJ	O	O
paralytic	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
rapid-sequence	NOUN	O	O
intubation	NOUN	O	O
of	ADP	O	O
head	NOUN	O	O
trauma	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

In	ADJ	O	O
vitro	ADJ	O	O
determination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
chromatic	ADJ	O	B-OTHER
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
silver	NOUN	O	O
nanoparticles	PUNCT	O	O
solution	NOUN	O	O
linked	VERB	O	O
to	ADP	O	O
the	DET	O	O
gantrez	ADJ	O	O
S-97	PUNCT	O	O
copolymer	NOUN	O	O
on	ADP	O	O
tooth	NOUN	O	O
enamel	NOUN	O	O
.	PUNCT	O	O

Silver	NOUN	O	O
nanoparticles	NOUN	O	O
(	PUNCT	O	O
NNPs	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
the	DET	O	O
bioadhesive	ADJ	O	O
Gantrez	NOUN	O	O
S-97	NUM	O	O
,	PUNCT	O	O
have	CCONJ	O	O
demonstrated	VERB	O	O
their	PUNCT	O	O
efficacy	NOUN	O	O
against	ADP	O	O
Streptococcus	NOUN	O	O
mutans	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
if	PUNCT	O	O
this	DET	O	O
combination	NOUN	O	O
changes	ADP	O	O
the	DET	O	O
color	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
teeth	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
work	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
measure	VERB	O	O
the	DET	O	O
color	ADJ	O	B-OTHER
changes	NOUN	O	I-OTHER
occurring	VERB	O	O
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
Gantrez-NNP	NOUN	O	O
combination	NOUN	O	O
on	ADP	O	O
enamel	NOUN	O	O
tooth	NOUN	O	O
blocks	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
study	ADV	O	O
groups	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
formed	VERB	O	O
:	PUNCT	O	O
enamel	NOUN	O	O
blocks	PUNCT	O	O
brushed	PUNCT	O	O
with	ADP	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
Gantrez-NNP	NOUN	O	O
combination	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
conventional	ADJ	O	O
toothpaste	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
1	NUM	O	O
minute	VERB	O	O
once	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
rinsed	NOUN	O	O
with	ADP	O	O
distilled	VERB	O	O
water	NOUN	O	O
and	CCONJ	O	O
placed	VERB	O	O
in	ADP	O	O
thymol	NOUN	O	O
solution	NOUN	O	O
.	PUNCT	O	O

Color	NOUN	O	B-OTHER
changes	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
the	DET	O	I-OTHER
enamel	NOUN	O	I-OTHER
blocks	CCONJ	O	I-OTHER
were	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
a	DET	O	O
Minolta	NOUN	O	B-OTHER
colorimeter	NOUN	O	I-OTHER
CR300	NOUN	O	I-OTHER
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
mixed	VERB	O	O
models	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
R	NOUN	O	O
2.10.1	NOUN	O	O
at	ADP	O	O
a	DET	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
the	DET	O	O
nonlinear	ADJ	O	O
mixed	VERB	O	O
effects	NOUN	O	O
(	PUNCT	O	O
NLME	NOUN	O	O
)	PUNCT	O	O
package	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
color	ADJ	O	B-OTHER
changes	NOUN	O	I-OTHER
over	PUNCT	O	I-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
only	ADV	O	O
a	DET	O	O
high	ADJ	O	B-PHYSICAL
luminosity	NOUN	O	I-PHYSICAL
equal	ADJ	O	I-PHYSICAL
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Our	PUNCT	O	O
study	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Gantrez-NNP	NOUN	O	O
combination	NOUN	O	O
is	VERB	O	O
safe	ADJ	O	B-OTHER
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
dental	ADJ	O	B-OTHER
esthetics	ADJ	O	I-OTHER
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
of	ADP	O	O
S.	NOUN	O	O
mutans	ADV	O	B-OTHER
.	PUNCT	O	O

Central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
serotonin	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	O
stress	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
indices	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	NOUN	O	O
)	PUNCT	O	O
serotonin	NOUN	O	O
function	NOUN	O	O
on	ADP	O	O
cardiovascular	ADJ	O	B-PHYSICAL
reactivity	NOUN	O	I-PHYSICAL
to	ADP	O	O
mental	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Lumbar	ADJ	O	O
puncture	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
54	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
to	PART	O	O
obtain	NOUN	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
(	PUNCT	O	O
CSF	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
determination	NOUN	O	O
of	ADP	O	O
5-hydroxyindoleacetic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
5HIAA	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Genotypes	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
a	DET	O	O
functional	ADJ	O	O
polymorphism	NOUN	O	O
of	ADP	O	O
the	DET	O	O
serotonin	NOUN	O	O
transporter	NOUN	O	O
gene	NOUN	O	O
promoter	NOUN	O	O
region	NOUN	O	O
(	PUNCT	O	O
5HTTLPR	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
then	ADV	O	O
underwent	PUNCT	O	O
mental	ADJ	O	O
stress	NOUN	O	O
testing	VERB	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Persons	NOUN	O	O
with	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
two	NUM	O	O
long	ADJ	O	O
(	PUNCT	O	O
l	NOUN	O	O
)	PUNCT	O	O
5HTTLPR	NOUN	O	O
alleles	NOUN	O	O
had	PUNCT	O	O
CSF	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
serotonin	NOUN	O	O
metabolite	NOUN	O	O
,	PUNCT	O	O
5HIAA	NOUN	O	O
,	PUNCT	O	O
that	ADP	O	O
were	VERB	O	O
50	NUM	O	O
%	SYM	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
those	ADP	O	O
of	ADP	O	O
persons	NOUN	O	O
with	ADP	O	O
the	DET	O	O
s/s	NOUN	O	O
5HTTLPR	NOUN	O	O
genotype	NOUN	O	O
.	PUNCT	O	O

Persons	NOUN	O	O
with	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
two	NUM	O	O
l	NOUN	O	O
alleles	NOUN	O	O
or	CCONJ	O	O
higher	PUNCT	O	O
CSF	NOUN	O	B-PHYSICAL
5HIAA	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
also	ADV	O	O
exhibited	VERB	O	O
greater	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	O
a	DET	O	O
mental	ADJ	O	O
stress	NOUN	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
the	DET	O	O
5HTTLPR	NOUN	O	O
polymorphism	NOUN	O	O
affects	NOUN	O	O
CNS	NOUN	O	O
serotonin	NOUN	O	O
function	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
they	PRON	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
general	ADJ	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
CNS	NOUN	O	O
serotonin	NOUN	O	O
function	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
potentially	ADV	O	O
health-damaging	PUNCT	O	O
biobehavioral	ADJ	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
l	NOUN	O	O
allele	NOUN	O	O
could	VERB	O	O
contribute	VERB	O	O
,	PUNCT	O	O
through	ADP	O	O
its	PUNCT	O	O
association	NOUN	O	O
with	ADP	O	O
increased	VERB	O	O
cardiovascular	ADJ	O	B-PHYSICAL
reactivity	NOUN	O	I-PHYSICAL
to	ADP	O	O
stress	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
increased	NOUN	O	O
risk	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Mitoxantrone	ADP	O	O
(	PUNCT	O	O
MTX	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
mitomycin	NUM	O	O
C	NOUN	O	O
(	PUNCT	O	O
MMC	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ablative	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
Ta	NOUN	O	O
,	PUNCT	O	O
T1	NOUN	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

Phase	NOUN	O	O
III	NUM	O	O
,	PUNCT	O	O
randomized	VERB	O	O
prospective	ADJ	O	O
study	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
ablation	NOUN	O	B-PHYSICAL
capacity	NOUN	O	I-PHYSICAL
of	ADP	O	O
mitoxantrone	PUNCT	O	O
in	ADP	O	O
Ta-T1	PUNCT	O	O
superficial	VERB	O	O
bladder	NOUN	O	O
tumors	NOUN	O	O
versus	CCONJ	O	O
mitomycin	NUM	O	O
C	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
drug	NOUN	O	O
whose	ADP	O	O
intravesical	ADJ	O	O
ablation	NOUN	O	O
properties	NOUN	O	O
are	VERB	O	O
well-known	VERB	O	O
.	PUNCT	O	O

Fifty-seven	ADJ	O	O
patients	NOUN	O	O
comprised	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
tumor	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
completely	ADV	O	O
resected	PUNCT	O	O
when	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
underwent	VERB	O	O
TUR	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
residual	ADJ	O	O
tumor	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
20	NUM	O	O
mg	NOUN	O	O
Mitoxantrone	ADV	O	O
or	CCONJ	O	O
40	NUM	O	O
mg	NOUN	O	O
mitomycin	NUM	O	O
C	NOUN	O	O
weekly	ADV	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
two	NUM	O	O
other	ADJ	O	O
instillations	CCONJ	O	O
every	DET	O	O
15	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
50	NUM	O	O
ml	NOUN	O	O
saline	ADJ	O	O
solution	NOUN	O	O
.	PUNCT	O	O

Response	NOUN	O	O
to	ADP	O	O
therapy	NOUN	O	B-OTHER
was	VERB	O	O
evaluated	VERB	O	O
between	ADP	O	O
the	DET	O	O
4th	NOUN	O	O
and	CCONJ	O	O
8th	ADJ	O	O
week	NOUN	O	O
and	CCONJ	O	O
classified	VERB	O	O
as	PUNCT	O	O
complete	ADJ	O	B-OTHER
response	NOUN	O	O
(	PUNCT	O	B-OTHER
CR	NOUN	O	I-OTHER
)	PUNCT	O	B-OTHER
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
no	DET	O	O
gross	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
microscopic	ADJ	O	B-PHYSICAL
evidence	NOUN	O	I-PHYSICAL
of	ADP	O	B-PHYSICAL
residual	ADJ	O	O
tumor	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
response	NOUN	O	O
(	PUNCT	O	B-OTHER
NR	PUNCT	O	I-OTHER

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
sequential	ADJ	O	O
annual	ADJ	O	O
vaccination	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
DHEA	NOUN	O	O
administration	NOUN	O	O
on	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
immune	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
influenza	NOUN	O	O
vaccine	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
repeated	VERB	O	O
vaccination	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
dehydroepiandrosterone	NOUN	O	O
(	PUNCT	O	O
DHEA	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
on	ADP	O	O
the	DET	O	O
immune	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
influenza	NOUN	O	O
vaccine	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Seventy-one	NUM	O	O
elderly	ADJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
aged	ADP	O	O
61-89	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
enrolled	ADV	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
DHEA	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mg	NOUN	O	O
qd	PUNCT	O	O
p.o	NUM	O	O
.	PUNCT	O	O

for	ADP	O	O
4	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
starting	VERB	O	O
2	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
immunization	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Antibody	NOUN	O	O
response	NOUN	O	O
against	ADP	O	O
the	DET	O	O
three	NUM	O	O
strains	NOUN	O	O
of	ADP	O	O
vaccine	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
28	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
vaccination	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
compared	VERB	O	O
between	ADP	O	O
previously	ADV	O	O
vaccinated	DET	O	O
and	CCONJ	O	O
non-vaccinated	VERB	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

DHEA	NOUN	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
enhance	VERB	O	O
established	ADV	O	B-PHYSICAL
immunity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
attainment	NOUN	O	O
of	ADP	O	O
protective	ADJ	O	B-OTHER
antibody	NOUN	O	I-OTHER
titer	NOUN	O	I-OTHER
(	PUNCT	O	O
titer	NOUN	O	O
of	ADP	O	O
1:40	NOUN	O	O
or	CCONJ	O	O
greater	PUNCT	O	O
)	PUNCT	O	O
against	ADP	O	O
A/Texas	NOUN	O	O
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
non-protective	ADJ	O	O
baseline	NOUN	O	O
antibody	NOUN	O	O
titer	NOUN	O	O
was	VERB	O	O
recorded	VERB	O	O
following	VERB	O	O
DHEA	NOUN	O	O
treatment	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
52	ADP	O	O
vs.	CCONJ	O	O
84	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Post-immunization	NOUN	O	B-OTHER
titers	NOUN	O	I-OTHER
against	ADP	O	O
influenza	NOUN	O	O
A	DET	O	O
strains	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
those	PUNCT	O	O
subjects	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
never	ADV	O	O
immunized	PUNCT	O	O
before	PUNCT	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
post-vaccination	NOUN	O	B-OTHER
protective	ADJ	O	I-OTHER
titers	NOUN	O	I-OTHER
against	ADP	O	O
the	DET	O	O
A/Johannesburg	NOUN	O	O
strain	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
prevalent	ADJ	O	O
in	ADP	O	O
those	PUNCT	O	O
subjects	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
never	ADV	O	O
vaccinated	PUNCT	O	O
before	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
were	VERB	O	O
not	ADV	O	O
the	DET	O	O
same	PUNCT	O	O
for	ADP	O	O
anti-B/Harbin	NOUN	O	O
antibodies-repeated	VERB	O	O
vaccination	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
non-significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
HI	NOUN	O	O
titer	NOUN	O	O
in	ADP	O	O
previously	ADV	O	O
vaccinated	ADP	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Levosulpiride	NOUN	O	O
in	ADP	O	O
functional	ADJ	O	O
dyspepsia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
multicentric	ADJ	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Abnormalities	NOUN	O	O
in	ADP	O	O
gastrointestinal	ADJ	O	O
motility	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
in	ADP	O	O
a	DET	O	O
substantial	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
functional	ADJ	O	O
dyspepsia	NOUN	O	O
,	PUNCT	O	O
supporting	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
prokinetic	ADJ	O	O
drugs	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
dyspeptic	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
evaluate	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
levosulpiride	NOUN	O	O
in	ADP	O	O
short-term	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
1298	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
multicentric	ADJ	O	O
study	NOUN	O	O
carried	SYM	O	O
out	ADP	O	O
in	ADP	O	O
45	NUM	O	O
Italian	ADJ	O	O
Gastroenterology	NOUN	O	O
Departments	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
either	PUNCT	O	O
levosulpiride	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
mg	NOUN	O	O
tid	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
domperidone	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
tid	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
metoclopramide	CCONJ	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
tid	ADJ	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
tablet	NOUN	O	O
tid	ADJ	O	O
)	PUNCT	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
selected	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
:	PUNCT	O	O
a	ADP	O	O
)	PUNCT	O	O
occurrence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
last	ADJ	O	O
4	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
at	ADJ	O	O
least	ADV	O	O
5/10	NOUN	O	O
selected	VERB	O	O
symptoms	NOUN	O	O
(	PUNCT	O	O
anorexia	NOUN	O	B-PHYSICAL
,	PUNCT	O	I-PHYSICAL
nausea	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
vomiting	VERB	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
upper	ADJ	O	I-PHYSICAL
abdominal	ADJ	O	I-PHYSICAL
pain	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
postprandial	ADJ	O	I-PHYSICAL
bloating	PUNCT	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
abdominal	ADJ	O	I-PHYSICAL
fullness	ADV	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
early	ADJ	O	I-PHYSICAL
satiety	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
belching	PUNCT	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
heartburn	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
regurgitation	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
severity	NOUN	O	O
of	ADP	O	O
which	ADP	O	O
should	VERB	O	O
reach/exceed	CCONJ	O	O
a	DET	O	O
total	ADJ	O	O
score	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
,	PUNCT	O	O
as	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
a	DET	O	O
specific	ADJ	O	O
scale	NOUN	O	O
ranging	CCONJ	O	O
from	ADP	O	O
0	NUM	O	O
(	PUNCT	O	O
absent	ADJ	O	O
)	PUNCT	O	O
to	ADP	O	O
3	PUNCT	O	O
(	PUNCT	O	O
severe	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
normal	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
routine	ADJ	O	O
biochemical	ADJ	O	O
,	PUNCT	O	O
ultrasound	NOUN	O	O
and	CCONJ	O	O
endoscopic	ADJ	O	O
examinations	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
patient	NOUN	O	O
subjectively	ADV	O	O
evaluated	PUNCT	O	O
efficacy	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
by	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
improvement	NOUN	O	O
was	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
all	PUNCT	O	O
symptoms	NOUN	O	O
at	ADP	O	O
days	NOUN	O	O
10	NUM	O	O
and	CCONJ	O	O
28	NUM	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
levosulpiride	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
superior	ADJ	O	O
to	ADP	O	O
domperidone	NOUN	O	O
,	PUNCT	O	O
metoclopramide	CCONJ	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
both	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
clinical	ADJ	O	O
improvement	NOUN	O	O
scale	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
in	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
(	PUNCT	O	O
postprandial	ADJ	O	B-PHYSICAL
bloating	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
epigastric	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
heartburn	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
.	PUNCT	O	O

Active	ADJ	O	O
treatments	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
as	ADP	O	O
far	PUNCT	O	O
as	PUNCT	O	O
concerns	VERB	O	O
occurrence	NOUN	O	O
of	ADP	O	O
side-effects	NOUN	O	O
(	PUNCT	O	O
12-20	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
including	DET	O	O
galactorrhoea	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
breast	NOUN	O	B-PHYSICAL
tenderness	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
menstrual	ADJ	O	B-PHYSICAL
changes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Testing	VERB	O	O
three	NUM	O	O
different	ADJ	O	O
cancer	NOUN	O	O
genetics	NOUN	O	O
registry	NOUN	O	O
recruitment	NOUN	O	O
methods	NOUN	O	O
with	ADP	O	O
Hispanic	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
family	NOUN	O	O
members	NOUN	O	O
previously	ADV	O	O
registered	PUNCT	O	O
in	ADP	O	O
local	ADJ	O	O
cancer	NOUN	O	O
registries	ADJ	O	O
in	ADP	O	O
Texas	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
increase	VERB	O	O
accrual	ADJ	O	O
among	ADP	O	O
Hispanics	PROPN	O	O
to	ADP	O	O
the	DET	O	O
Cancer	NOUN	O	O
Genetics	PROPN	O	O
Network	ADP	O	O
national	ADJ	O	O
cancer	NOUN	O	O
genetics	NOUN	O	O
registry	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Drawing	PUNCT	O	O
from	ADP	O	O
South	NOUN	O	O
Texas	CCONJ	O	O
cancer	NOUN	O	O
registries	ADJ	O	O
,	PUNCT	O	O
444	NUM	O	O
Hispanic	ADJ	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
:	PUNCT	O	O
standard	PUNCT	O	O
direct-mailed	VERB	O	O
procedures	NOUN	O	O
(	PUNCT	O	O
X1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
X1	NOUN	O	O
plus	CCONJ	O	O
culturally	ADV	O	O
tailored	VERB	O	O
materials	NOUN	O	O
(	PUNCT	O	O
X2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
X2	NOUN	O	O
plus	CCONJ	O	O
interpersonal	ADJ	O	O
phone	NOUN	O	O
contact	NOUN	O	O
(	PUNCT	O	O
X3	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	NUM	O	O
also	ADV	O	O
surveyed	VERB	O	O
about	PUNCT	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
education	NOUN	O	O
materials	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
phone	NOUN	O	O
contact	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
refusal	ADJ	O	O
survey	NOUN	O	O
was	VERB	O	O
provided	VERB	O	O
for	ADP	O	O
those	ADJ	O	O
who	ADP	O	O
declined	VERB	O	O
to	ADP	O	O
join	NOUN	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
154	NUM	O	O
individuals	NOUN	O	O
joined	VERB	O	O
the	DET	O	O
Cancer	NOUN	O	O
Genetics	PROPN	O	O
Network	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
X3	NOUN	O	B-OTHER
condition	NOUN	O	I-OTHER
yielded	VERB	O	I-OTHER
the	DET	O	I-OTHER
greatest	PUNCT	O	I-OTHER
accrual	ADJ	O	I-OTHER
(	PUNCT	O	O
43.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
X1	NOUN	O	O
(	PUNCT	O	O
30.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
X2	NOUN	O	O
(	PUNCT	O	O
29.9	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tailored	VERB	O	O
materials	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
have	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
but	CCONJ	O	O
were	VERB	O	O
highly	ADV	O	O
regarded	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
reasons	NOUN	O	O
for	ADP	O	O
not	ADV	O	O
participating	ADP	O	O
were	ADP	O	O
a	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
interest	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
requirements	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Interpersonal	ADJ	O	O
communication	NOUN	O	O
can	VERB	O	O
have	PUNCT	O	O
a	DET	O	O
powerful	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
recruitment	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
more	DET	O	O
research	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	ADP	O	O
cost-efficacy	NOUN	O	O
of	ADP	O	O
more	DET	O	O
labor-intensive	ADJ	O	O
approaches	NOUN	O	O
to	ADP	O	O
registry	NOUN	O	O
accrual	ADJ	O	O
.	PUNCT	O	O

Dynamic	ADJ	O	O
surface	NOUN	O	B-PHYSICAL
electromyographic	ADJ	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
in	ADP	O	O
chronic	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
treated	VERB	O	O
by	ADP	O	O
traditional	ADJ	O	O
bone	NOUN	O	O
setting	VERB	O	O
and	CCONJ	O	O
conventional	ADJ	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
dynamic	ADJ	O	B-PHYSICAL
surface	NOUN	O	I-PHYSICAL
electromyographic	ADJ	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
EMG	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
activities	NOUN	O	I-PHYSICAL
of	ADP	O	O
back	ADP	O	O
muscles	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
traditional	ADJ	O	O
bone	NOUN	O	O
setting	VERB	O	O
and	CCONJ	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
that	PUNCT	O	O
compared	VERB	O	O
surface	NOUN	O	B-PHYSICAL
EMG	NOUN	O	I-PHYSICAL
dynamic	ADJ	O	I-PHYSICAL
activities	NOUN	O	I-PHYSICAL
after	ADP	O	O
traditional	ADJ	O	O
bone	NOUN	O	O
setting	VERB	O	O
and	CCONJ	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Sixty-one	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
41	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
nonspecific	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
two	NUM	O	O
subgroups	NOUN	O	O
by	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
underwent	VERB	O	O
a	DET	O	O
dynamic	ADJ	O	B-PHYSICAL
EMG	NOUN	O	I-PHYSICAL
evaluation	NOUN	O	I-PHYSICAL
for	ADP	O	O
which	ADP	O	O
they	PUNCT	O	O
were	VERB	O	O
asked	ADV	O	O
to	ADP	O	O
stand	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
bend	PUNCT	O	O
forward	ADV	O	O
as	PUNCT	O	O
far	PUNCT	O	O
as	PUNCT	O	O
possible	ADJ	O	O
,	PUNCT	O	O
stay	NOUN	O	O
fully	ADV	O	O
flexed	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
return	ADJ	O	O
to	ADP	O	O
standing	DET	O	O
.	PUNCT	O	O

A	DET	O	O
flexion-relaxation	NOUN	O	B-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
was	VERB	O	O
calculated	VERB	O	O
by	ADP	O	O
comparing	DET	O	O
maximal	ADJ	O	B-PHYSICAL
EMG	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
while	ADP	O	O
flexing	DET	O	O
with	ADP	O	O
the	DET	O	O
average	ADJ	O	O
EMG	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
full	ADJ	O	O
flexion	NOUN	O	O
.	PUNCT	O	O

Concentric	ADJ	O	O
(	PUNCT	O	O
maximal	ADJ	O	O
EMG	NOUN	O	O
activity	NOUN	O	O
during	ADP	O	O
extension	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
eccentric	ADJ	O	O
(	PUNCT	O	O
maximal	ADJ	O	O
EMG	NOUN	O	O
activity	NOUN	O	O
during	ADP	O	O
flexion	NOUN	O	O
)	PUNCT	O	O
ratios	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Disability	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
depression	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
scores	NOUN	O	O
decreased	VERB	O	O
significantly	ADV	O	O
after	ADP	O	O
both	PUNCT	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
concentric	ADJ	O	B-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
increased	VERB	O	O
statistically	ADV	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
after	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
failed	VERB	O	O
to	ADP	O	O
show	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
experienced	ADP	O	O
back	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
EMG	NOUN	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Both	PUNCT	O	O
treatments	NOUN	O	O
seem	VERB	O	O
to	PART	O	O
have	PUNCT	O	O
a	DET	O	O
positive	ADJ	O	O
influence	NOUN	O	O
on	ADP	O	O
back	ADP	O	O
muscle	NOUN	O	O
function	NOUN	O	O
by	ADP	O	O
improving	VERB	O	O
muscle	NOUN	O	B-PHYSICAL
symmetry	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
treatments	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
flexion-relaxation	NOUN	O	B-PHYSICAL
phenomenon	NOUN	O	I-PHYSICAL
after	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
.	PUNCT	O	O

Active	ADJ	O	O
back	ADP	O	O
exercise	NOUN	O	O
at	ADP	O	O
home	NOUN	O	O
together	ADV	O	O
with	ADP	O	O
rehabilitation	NOUN	O	O
treatments	NOUN	O	O
might	ADJ	O	O
be	NOUN	O	O
effective	ADJ	O	O
and	CCONJ	O	O
improve	ADJ	O	O
function	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
an	DET	O	O
Internet	NOUN	O	O
portal	NOUN	O	O
to	ADV	O	O
improve	NOUN	O	O
community-based	VERB	O	O
pediatric	ADJ	O	O
ADHD	NOUN	O	O
care	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
cluster	NOUN	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
quality	NOUN	O	O
improvement	NOUN	O	O
program	NOUN	O	O
to	PART	O	O
improve	NOUN	O	O
pediatricians	ADP	O	O
'	PUNCT	O	O
adherence	NOUN	O	O
to	ADP	O	O
existing	ADJ	O	O
,	PUNCT	O	O
evidence-based	ADP	O	O
,	PUNCT	O	O
attention-deficit/hyperactivity	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ADHD	NOUN	O	O
)	PUNCT	O	O
practice	NOUN	O	O
guidelines	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty-nine	NUM	O	O
community-based	VERB	O	O
pediatricians	PUNCT	O	O
at	ADP	O	O
8	NUM	O	O
practices	PROPN	O	O
participated	VERB	O	O
in	ADP	O	O
a	DET	O	O
cluster-randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Practices	PROPN	O	O
were	VERB	O	O
matched	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
numbers	NOUN	O	O
of	ADP	O	O
pediatricians	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
proportions	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
Medicaid	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
medical	ADJ	O	O
charts	NOUN	O	O
for	ADP	O	O
a	DET	O	O
random	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ADHD	NOUN	O	O
for	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
participating	ADP	O	O
pediatricians	PUNCT	O	O
were	VERB	O	O
examined	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
practices	PROPN	O	O
participated	VERB	O	O
in	ADP	O	O
4	NUM	O	O
sessions	NOUN	O	O
of	ADP	O	O
training	VERB	O	O
,	PUNCT	O	O
including	CCONJ	O	O
didactic	ADJ	O	O
lectures	NOUN	O	O
and	CCONJ	O	O
office	NOUN	O	O
flow	NOUN	O	O
modification	NOUN	O	O
workshops	NOUN	O	O
.	PUNCT	O	O

Practices	PROPN	O	O
were	ADJ	O	O
then	ADV	O	O
given	VERB	O	O
access	NOUN	O	O
to	ADP	O	O
an	DET	O	O
ADHD	NOUN	O	O
Internet	NOUN	O	O
portal	NOUN	O	O
that	PUNCT	O	O
allowed	VERB	O	O
parents	NOUN	O	O
,	PUNCT	O	O
teachers	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pediatricians	PUNCT	O	O
to	ADP	O	O
input	NOUN	O	O
information	NOUN	O	O
(	PUNCT	O	O
eg	ADP	O	O
,	PUNCT	O	O
rating	ADP	O	O
scales	NOUN	O	O
)	PUNCT	O	O
about	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
which	PUNCT	O	O
information	NOUN	O	O
was	VERB	O	O
scored	VERB	O	O
,	PUNCT	O	O
interpreted	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
formatted	ADP	O	O
in	ADP	O	O
a	DET	O	O
report	ADV	O	O
style	NOUN	O	O
that	PUNCT	O	O
was	VERB	O	O
helpful	ADJ	O	O
for	ADP	O	O
assessment	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ADHD	NOUN	O	O
.	PUNCT	O	O

Physicians	PROPN	O	O
evaluated	VERB	O	O
their	PUNCT	O	O
practice	NOUN	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
quarterly	ADJ	O	O
and	CCONJ	O	O
addressed	PUNCT	O	O
underperforming	PUNCT	O	B-MENTAL
areas	NOUN	O	I-MENTAL
.	PUNCT	O	O

RESULTS	DET	O	O
Pediatricians	ADJ	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
demonstrated	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
rates	NOUN	O	O
of	ADP	O	O
many	CCONJ	O	O
American	ADJ	O	O
Academy	PUNCT	O	O
of	ADP	O	O
Pediatrics-recommended	ADJ	O	O
ADHD	NOUN	O	O
care	NOUN	O	O
practices	PROPN	O	O
,	PUNCT	O	O
including	VERB	O	O
collection	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
parent	NOUN	O	I-MENTAL
(	PUNCT	O	O
Cohen	NOUN	O	O
's	PUNCT	O	O
d	NOUN	O	O
=	SYM	O	O
0.69	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
teacher	NOUN	O	B-MENTAL
(	PUNCT	O	O
d	NOUN	O	O
=	SYM	O	O
0.68	NUM	O	O
)	PUNCT	O	O
rating	ADP	O	B-MENTAL
scales	NOUN	O	I-MENTAL
for	ADP	O	O
assessment	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
ADHD	NOUN	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
Diagnostic	ADJ	O	O
and	CCONJ	O	O
Statistical	ADJ	O	B-MENTAL
Manual	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
Mental	ADJ	O	I-MENTAL
Disorders	NOUN	O	I-MENTAL
,	PUNCT	O	O
Fourth	ADJ	O	O
Edition	NOUN	O	O
,	PUNCT	O	O
criteria	NOUN	O	O
(	PUNCT	O	O
d	NOUN	O	O
=	SYM	O	O
0.85	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
teacher	NOUN	O	B-MENTAL
rating	ADJ	O	I-MENTAL
scales	NOUN	O	I-MENTAL
to	ADJ	O	O
monitor	NOUN	O	O
treatment	NOUN	O	O
responses	NOUN	O	O
(	PUNCT	O	O
d	NOUN	O	O
=	SYM	O	O
1.01	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
A	DET	O	O
quality	NOUN	O	O
improvement	NOUN	O	O
intervention	NOUN	O	O
that	ADP	O	O
can	VERB	O	O
be	VERB	O	O
widely	ADV	O	O
disseminated	VERB	O	O
by	ADP	O	O
using	VERB	O	O
Internet-based	VERB	O	O
information	NOUN	O	O
technology	NOUN	O	O
significantly	ADV	O	O
improved	VERB	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
ADHD	NOUN	O	O
care	NOUN	O	O
in	ADP	O	O
community-based	VERB	O	O
pediatric	ADJ	O	O
settings	NOUN	O	O
.	PUNCT	O	O

Transcutaneous	ADJ	O	O
electrical	ADJ	O	O
nerve	NOUN	O	O
stimulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
myofascial	ADJ	O	O
pain	NOUN	O	O
dysfunction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
transcutaneous	ADJ	O	O
electrical	ADJ	O	O
nerve	NOUN	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
TENS	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
conservative	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ibuprofen	NOUN	O	O
,	PUNCT	O	O
bite	NOUN	O	O
plate	NOUN	O	O
,	PUNCT	O	O
self-physiotherapy	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
myofascial	ADJ	O	O
pain	NOUN	O	O
dysfunction	NOUN	O	O
(	PUNCT	O	O
MPD	CCONJ	O	O
)	PUNCT	O	O
was	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

A	PUNCT	O	O
single-blind	NOUN	O	O
trial	NOUN	O	O
as	PUNCT	O	O
done	PUNCT	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
MPD	CCONJ	O	O
with	ADP	O	O
subthreshold	VERB	O	O
TENS	NOUN	O	O
(	PUNCT	O	O
frequency	NOUN	O	O
35	NUM	O	O
Hz	NOUN	O	O
,	PUNCT	O	O
pulse	NOUN	O	O
width	NOUN	O	O
100	NUM	O	O
milliseconds	NOUN	O	O
,	PUNCT	O	O
modulation	NOUN	O	O
50	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
sham	ADJ	O	O
TENS	NOUN	O	O
at	ADP	O	O
8	NUM	O	O
visits	NOUN	O	O
over	ADP	O	O
14	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
was	VERB	O	O
assessed	VERB	O	O
on	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
TENS	NOUN	O	O
at	ADP	O	O
each	DET	O	O
visit	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
data	NOUN	O	O
were	VERB	O	O
analysed	VERB	O	O
with	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
(	PUNCT	O	O
ANOVA	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
repeated	VERB	O	O
measures	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
highly	ADV	O	O
significant	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
for	ADP	O	O
time	NOUN	O	O
(	PUNCT	O	O
F	NOUN	O	O
=	SYM	O	O
4.80	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0003	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
TENS	NOUN	O	O
.	PUNCT	O	O

Subthreshold	NUM	O	O
TENS	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
increase	VERB	O	O
the	DET	O	O
symptom	NOUN	O	O
relief	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
conservative	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
protocol	NOUN	O	O
used	VERB	O	O
.	PUNCT	O	O

Adenosinergic	ADJ	O	O
mechanisms	NOUN	O	O
contribute	VERB	O	O
to	ADP	O	O
individual	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
sleep	NOUN	O	O
deprivation-induced	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
neurobehavioral	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
rhythmic	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Large	ADJ	O	O
individual	ADJ	O	O
differences	NOUN	O	O
characterize	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
sleep	PUNCT	O	O
deprivation	NOUN	O	O
on	ADP	O	O
neurobehavioral	ADJ	O	O
functions	NOUN	O	O
and	CCONJ	O	O
rhythmic	ADJ	O	O
brain	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	ADV	O	O
adenosinergic	ADJ	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
these	DET	O	O
differences	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
prolonged	VERB	O	O
waking	ADP	O	O
and	CCONJ	O	O
the	DET	O	O
adenosine	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
caffeine	NOUN	O	O
on	ADP	O	O
sustained	VERB	O	O
vigilant	ADJ	O	O
attention	NOUN	O	O
and	CCONJ	O	O
regional	ADJ	O	O
electroencephalogram	NOUN	O	O
(	PUNCT	O	O
EEG	NOUN	O	O
)	PUNCT	O	O
power	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ranges	PUNCT	O	O
of	ADP	O	O
theta	NOUN	O	O
activity	NOUN	O	O
(	PUNCT	O	O
6.25-8.25	NUM	O	O
Hz	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
waking	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
slow	ADJ	O	O
oscillation	NOUN	O	O
(	PUNCT	O	O
<	PROPN	O	O
1	NUM	O	O
Hz	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
sleep	NOUN	O	O
.	PUNCT	O	O

Activity	NOUN	O	O
in	ADP	O	O
these	DET	O	O
frequencies	NOUN	O	O
is	VERB	O	O
functionally	ADV	O	O
related	ADP	O	O
to	PUNCT	O	O
sleep	PUNCT	O	O
deprivation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
12	NUM	O	O
subjectively	ADV	O	O
caffeine-sensitive	ADJ	O	O
and	CCONJ	O	O
10	NUM	O	O
-insensitive	PUNCT	O	O
young	ADJ	O	O
men	NOUN	O	O
,	PUNCT	O	O
psychomotor	NOUN	O	O
vigilance	NOUN	O	O
task	NOUN	O	O
(	PUNCT	O	O
PVT	NOUN	O	O
)	PUNCT	O	O
performance	NOUN	O	O
and	CCONJ	O	O
EEG	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
3	NUM	O	O
h	NOUN	O	O
intervals	NOUN	O	O
before	CCONJ	O	O
,	PUNCT	O	O
during	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
one	NUM	O	O
night	NOUN	O	O
without	ADP	O	O
sleep	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
11	NUM	O	O
and	CCONJ	O	O
23	NUM	O	O
h	NOUN	O	O
waking	PUNCT	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
received	ADJ	O	O
200	NUM	O	O
mg	NOUN	O	O
caffeine	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
manner	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
condition	NOUN	O	O
,	PUNCT	O	O
sleep	ADP	O	O
deprivation	NOUN	O	O
impaired	DET	O	O
PVT	NOUN	O	O
speed	VERB	O	O
more	ADV	O	O
in	ADP	O	O
caffeine-sensitive	ADJ	O	O
than	PUNCT	O	O
in	ADP	O	O
caffeine-insensitive	ADJ	O	O
men	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
counteracted	VERB	O	O
by	ADP	O	O
caffeine	NOUN	O	O
.	PUNCT	O	O

Theta	NOUN	O	B-PHYSICAL
power	NOUN	O	O
in	ADP	O	B-PHYSICAL
waking	ADJ	O	B-PHYSICAL
increased	PUNCT	O	O
more	ADV	O	O
in	ADP	O	O
a	DET	O	O
frontal	ADJ	O	O
EEG	NOUN	O	O
derivation	NOUN	O	O
than	CCONJ	O	O
in	ADP	O	O
a	DET	O	O
posterior	ADJ	O	O
derivation	NOUN	O	O
.	PUNCT	O	O

Caffeine	NOUN	O	O
attenuated	VERB	O	O
this	DET	O	O
power	NOUN	O	O
gradient	NOUN	O	O
in	ADP	O	O
caffeine	NOUN	O	O
sensitive	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Sleep	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
also	ADV	O	O
differently	PUNCT	O	O
affected	ADP	O	O
the	DET	O	O
power	NOUN	O	O
distribution	NOUN	O	O
<	SYM	O	O
1	NUM	O	O
Hz	NOUN	O	O
in	ADP	O	O
non-rapid	NOUN	O	B-PHYSICAL
eye	NOUN	O	I-PHYSICAL
movement	NOUN	O	B-PHYSICAL
sleep	NOUN	O	B-PHYSICAL
between	ADP	O	O
caffeine	NOUN	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
insensitive	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
mirrored	VERB	O	O
by	ADP	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
sleep	NOUN	O	B-PHYSICAL
deprivation	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
caffeine	NOUN	O	O
on	ADP	O	O
sustained	VERB	O	O
attention	NOUN	O	O
and	CCONJ	O	O
regional	ADJ	O	O
EEG	NOUN	O	O
power	NOUN	O	O
in	PUNCT	O	O

Delayed	VERB	O	B-PHYSICAL
alloimmunization	NOUN	O	I-PHYSICAL
using	VERB	O	O
random	ADJ	O	O
single	ADJ	O	O
donor	NOUN	O	O
platelet	NOUN	O	O
transfusions	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
thrombocytopenic	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
54	NUM	O	O
thrombocytopenic	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
leukemia	NOUN	O	O
.	PUNCT	O	O

Alloimmunization	NOUN	O	O
of	ADP	O	O
recipients	NOUN	O	O
of	ADP	O	O
random	ADJ	O	O
multiple-donor	NOUN	O	O
platelet	NOUN	O	O
concentrates	NOUN	O	O
(	PUNCT	O	O
MD	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
random	ADJ	O	O
single-donor	NOUN	O	O
platelets	NOUN	O	O
(	PUNCT	O	O
SD	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
SD	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
formation	NOUN	O	O
of	ADP	O	O
alloantibodies	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
mostly	ADV	O	I-PHYSICAL
anti-HLA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
occurred	VERB	O	O
less	ADV	O	O
frequently	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.002	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
after	ADP	O	O
a	DET	O	O
longer	PUNCT	O	O
time	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.002	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
transfusions	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
0.005	NUM	O	O
)	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
MD	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

SD	NOUN	O	O
patients	NOUN	O	O
also	ADV	O	O
became	VERB	O	O
refractory	ADJ	O	O
to	ADP	O	O
random	ADJ	O	O
platelets	NOUN	O	O
less	ADJ	O	O
frequently	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
0.005	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
after	ADP	O	O
a	DET	O	O
longer	PUNCT	O	O
time	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
transfusions	NOUN	O	B-OTHER
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
SD	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
increments	NOUN	O	B-OTHER
after	ADP	O	O
the	DET	O	O
first	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
last	ADJ	O	I-PHYSICAL
transfusion	NOUN	O	I-PHYSICAL
were	VERB	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
range	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
MD	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
1-hr	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
24-hr	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.025	NUM	O	O
)	PUNCT	O	O
increments	NOUN	O	B-OTHER
decreased	VERB	O	O
from	ADP	O	O
the	DET	O	O
first	ADP	O	O
to	ADP	O	O
the	DET	O	O
last	ADJ	O	O
transfusion	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
random	ADJ	O	O
SD	NOUN	O	O
platelet	NOUN	O	O
transfusions	NOUN	O	O
postponed	VERB	O	O
alloimmunization	NOUN	O	O
.	PUNCT	O	O

Linguistic	ADJ	O	B-MENTAL
alignment	NOUN	O	I-MENTAL
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
Asperger	ADJ	O	O
's	PUNCT	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

Individuals	NOUN	O	O
with	ADP	O	O
Asperger	ADJ	O	O
's	PUNCT	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
AS	ADP	O	O
)	PUNCT	O	O
often	ADV	O	O
have	VERB	O	O
difficulties	NOUN	O	O
with	ADP	O	O
social	ADJ	O	O
interactions	NOUN	O	O
and	CCONJ	O	O
conversations	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
if	PUNCT	O	O
these	DET	O	O
difficulties	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
a	DET	O	O
deficit	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
to	ADP	O	O
linguistically	ADV	O	O
converge	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
interlocutor	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
posited	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
important	ADJ	O	O
for	ADP	O	O
successful	ADJ	O	O
communication	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
that	PUNCT	O	O
end	NOUN	O	O
,	PUNCT	O	O
participants	ADJ	O	O
completed	VERB	O	O
two	NUM	O	O
cooperative	ADJ	O	O
tasks	NOUN	O	O
with	ADP	O	O
a	DET	O	O
confederate	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
allowed	VERB	O	O
us	PROPN	O	O
to	PART	O	O
measure	VERB	O	O
linguistic	ADJ	O	B-MENTAL
alignment	NOUN	O	I-MENTAL
with	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
confederate	ADJ	O	I-MENTAL
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
lexical	ADJ	O	B-MENTAL
choice	NOUN	O	I-MENTAL
,	PUNCT	O	O
syntactic	ADJ	O	B-MENTAL
structure	NOUN	O	O
and	CCONJ	O	O
spatial	ADJ	O	B-MENTAL
frame	NOUN	O	O
of	ADP	O	B-MENTAL
reference	NOUN	O	B-MENTAL
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
AS	ADP	O	O
and	CCONJ	O	O
matched	VERB	O	O
controls	NOUN	O	O
and	CCONJ	O	O
both	CCONJ	O	O
groups	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
alignment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
confederate	ADJ	O	O
at	ADP	O	O
all	DET	O	O
three	NUM	O	O
levels	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	PUNCT	O	O

Effectiveness	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
treprostinil	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
pulmonary	ADJ	O	O
arterial	ADJ	O	O
hypertension	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
prostanoid	NOUN	O	O
therapy	NOUN	O	O
has	PUNCT	O	O
revolutionized	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
pulmonary	ADJ	O	O
arterial	ADJ	O	O
hypertension	NOUN	O	O
(	PUNCT	O	O
PAH	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
prostacyclin	NOUN	O	O
infusion	NOUN	O	O
poses	PUNCT	O	O
significant	ADJ	O	O
risks	NOUN	O	O
and	CCONJ	O	O
challenges	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Inhaled	ADJ	O	O
treprostinil	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	DET	O	O
be	PUNCT	O	O
safe	ADJ	O	O
and	CCONJ	O	O
efficacious	ADJ	O	O
in	ADP	O	O
adults	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
describes	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
treprostinil	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
PAH	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
retrospective	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
29	NUM	O	O
children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
inhaled	VERB	O	O
treprostinil	NOUN	O	O
for	ADP	O	O
?6	PUNCT	O	O
weeks	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
treprostinil	NOUN	O	O
on	ADP	O	O
exercise	NOUN	O	O
capacity	NOUN	O	O
,	PUNCT	O	O
functional	ADJ	O	O
class	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
echocardiographic	ADJ	O	O
and	CCONJ	O	O
hemodynamic	ADJ	O	O
data	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
documented	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
3	NUM	O	O
to	ADP	O	O
9	NUM	O	O
breaths	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
?g/breath	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
inhaled	VERB	O	O
treprostinil	NOUN	O	O
4	NUM	O	O
times/day	NOUN	O	O
.	PUNCT	O	O

All	PUNCT	O	O
were	ADJ	O	O
receiving	ADP	O	O
background	NOUN	O	O
PAH	NOUN	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
12	NUM	O	O
had	PUNCT	O	O
previously	ADV	O	O
received	PUNCT	O	O
parenteral	ADJ	O	O
prostanoid	NOUN	O	O
.	PUNCT	O	O

Inhaled	ADJ	O	O
treprostinil	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
in	ADP	O	O
4	NUM	O	O
patients	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
symptoms	NOUN	O	O
including	ADP	O	O
cough	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
bronchospasm	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
progression	NOUN	O	O
of	ADP	O	O
PAH	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mild	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
including	ADP	O	O
cough	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
sore	DET	O	O
throat	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
did	DET	O	O
not	ADV	O	O
require	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

World	NOUN	O	O
Health	NOUN	O	O
Organization	NOUN	O	O
functional	ADJ	O	O
class	NOUN	O	O
improved	VERB	O	O
in	ADP	O	O
19	NUM	O	O
and	CCONJ	O	O
was	VERB	O	O
unchanged	VERB	O	O
in	ADP	O	O
10	NUM	O	O
;	PUNCT	O	O
exercise	NOUN	O	B-PHYSICAL
capacity	NOUN	O	I-PHYSICAL
significantly	ADV	O	O
improved	VERB	O	O
with	ADP	O	O
the	DET	O	O
6-minute	PUNCT	O	O
walk	NOUN	O	O
distance	NOUN	O	O
,	PUNCT	O	O
improving	VERB	O	O
on	ADP	O	O
follow-up	NOUN	O	O
from	ADP	O	O
455.7	NUM	O	O
?	PUNCT	O	O

71.5	NUM	O	O
to	ADP	O	O
498	PUNCT	O	O
?	PUNCT	O	O

70	NUM	O	O
m	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
peak	ADJ	O	O
oxygen	NOUN	O	B-PHYSICAL
consumption	NOUN	O	I-PHYSICAL
increasing	ADJ	O	O
from	ADP	O	O
25.5	NUM	O	O
?	PUNCT	O	O

10.2	NUM	O	O
to	ADP	O	O
27.4	NUM	O	O
?	PUNCT	O	O

10	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
inhaled	ADJ	O	O
treprostinil	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
improvement	NOUN	O	O
in	ADP	O	O
exercise	NOUN	O	O
capacity	NOUN	O	O
and	CCONJ	O	O
World	NOUN	O	O
Health	NOUN	O	O
Organization	NOUN	O	O
functional	ADJ	O	O
class	NOUN	O	O
when	ADP	O	O
added	VERB	O	O
to	ADP	O	O
background	NOUN	O	O
targeted	VERB	O	O
PAH	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
had	PUNCT	O	O
an	DET	O	O
acceptable	ADJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	ADP	O	O
early	ADJ	O	O
data	NOUN	O	O
,	PUNCT	O	O
further	DET	O	O
study	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
treprostinil	NOUN	O	O
appears	NOUN	O	O
warranted	VERB	O	O
in	ADP	O	O
pediatric	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
PAH	NOUN	O	O
.	PUNCT	O	O

Why	VERB	O	O
distinctive	ADJ	O	O
information	NOUN	O	O
reduces	NOUN	O	O
false	ADJ	O	B-PHYSICAL
memories	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
evidence	NOUN	O	O
for	ADP	O	O
both	CCONJ	O	O
impoverished	PUNCT	O	O
relational-encoding	VERB	O	O
and	CCONJ	O	O
distinctiveness	NOUN	O	O
heuristic	ADJ	O	O
accounts	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
accounts	VERB	O	O
explain	ADP	O	O
why	ADP	O	O
studying	DET	O	O
pictures	NOUN	O	O
reduces	NOUN	O	O
false	ADJ	O	B-PHYSICAL
memories	NOUN	O	I-PHYSICAL
within	ADP	O	O
the	DET	O	O
Deese-Roediger-McDermott	ADJ	O	O
paradigm	NOUN	O	O
(	PUNCT	O	O
J.	NOUN	O	O
Deese	NOUN	O	O
,	PUNCT	O	O
1959	NUM	O	O
;	PUNCT	O	O
H.	ADV	O	O
L.	PUNCT	O	O
Roediger	ADJ	O	O
&	CCONJ	O	O
K.	ADV	O	O
B.	NOUN	O	O
McDermott	NOUN	O	O
,	PUNCT	O	O
1995	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
impoverished	VERB	O	O
relational-encoding	PUNCT	O	O
account	VERB	O	O
suggests	VERB	O	O
that	ADP	O	O
studying	DET	O	B-PHYSICAL
pictures	NOUN	O	I-PHYSICAL
interferes	NOUN	O	O
with	ADP	O	O
the	DET	O	O
encoding	PUNCT	O	O
of	ADP	O	O
relational	ADJ	O	O
information	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
basis	NOUN	O	O
for	ADP	O	O
false	ADJ	O	O
memories	NOUN	O	O
in	ADP	O	O
this	DET	O	O
paradigm	NOUN	O	O
.	PUNCT	O	O

Alternatively	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
distinctiveness	ADV	O	O
heuristic	ADJ	O	O
assumes	PUNCT	O	O
that	ADP	O	O
critical	ADJ	O	B-PHYSICAL
lures	NOUN	O	I-PHYSICAL
are	VERB	O	O
actively	ADV	O	O
withheld	ADJ	O	O
by	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
retrieval	NOUN	O	O
strategy	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
participants	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
inclusion	NOUN	O	O
recall	VERB	O	O
instructions	DET	O	O
to	PUNCT	O	O
report	PUNCT	O	O
studied	NOUN	O	O
items	VERB	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
related	PUNCT	O	O
items	ADP	O	O
,	PUNCT	O	O
they	PRON	O	O
still	ADV	O	O
reported	PUNCT	O	B-PHYSICAL
critical	ADJ	O	I-PHYSICAL
lures	NOUN	O	I-PHYSICAL
less	ADV	O	O
often	ADV	O	O
after	ADP	O	O
picture	NOUN	O	O
encoding	CCONJ	O	O
than	PUNCT	O	O
they	ADP	O	O
did	PUNCT	O	O
after	ADP	O	O
word	NOUN	O	O
encoding	ADJ	O	O
.	PUNCT	O	O

As	ADP	O	O
the	DET	O	O
impoverished	VERB	O	O
relational-encoding	PUNCT	O	O
account	VERB	O	O
suggests	VERB	O	O
,	PUNCT	O	O
critical	ADJ	O	B-PHYSICAL
lures	NOUN	O	I-PHYSICAL
appear	VERB	O	O
less	ADV	O	O
likely	ADJ	O	O
to	ADP	O	O
come	PROPN	O	O
to	PUNCT	O	O
mind	CCONJ	O	O
after	ADP	O	O
picture	NOUN	O	O
encoding	CCONJ	O	O
than	PUNCT	O	O
they	ADV	O	O
do	PUNCT	O	O
after	ADP	O	O
word	NOUN	O	O
encoding	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
results	ADP	O	O
from	ADP	O	O
a	DET	O	O
postrecall	ADJ	O	B-PHYSICAL
recognition	NOUN	O	I-PHYSICAL
test	PUNCT	O	O
provide	PUNCT	O	O
evidence	NOUN	O	O
in	ADP	O	O
favor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
distinctiveness	ADV	O	O
heuristic	ADJ	O	O
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	B-OTHER
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
assessments	NOUN	O	B-PHYSICAL
of	ADP	O	O
galantamine	NOUN	O	O
and	CCONJ	O	O
risperidone	NUM	O	O
after	ADP	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
are	VERB	O	O
administered	VERB	O	O
alone	ADJ	O	O
and	CCONJ	O	O
together	ADV	O	O
.	PUNCT	O	O

To	PART	O	O
explore	CCONJ	O	O
the	DET	O	O
steady-state	NOUN	O	O
pharmacokinetic	ADJ	O	O
profile	NOUN	O	O
after	ADP	O	O
coadministration	NOUN	O	O
of	ADP	O	O
galantamine	NOUN	O	O
and	CCONJ	O	O
risperidone	NUM	O	O
,	PUNCT	O	O
an	DET	O	O
open-label	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
single-center	NOUN	O	O
,	PUNCT	O	O
two-way	NOUN	O	O
crossover	NOUN	O	O
drug-drug	NOUN	O	O
interaction	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
16	NUM	O	O
healthy	ADJ	O	O
elderly	ADJ	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
60	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
risperidone	ADV	O	O
,	PUNCT	O	O
when	ADP	O	O
administered	VERB	O	O
with	ADP	O	O
galantamine	NOUN	O	O
,	PUNCT	O	O
did	PUNCT	O	O
not	ADV	O	O
change	VERB	O	O
the	DET	O	O
bioavailability	NOUN	O	B-OTHER
of	ADP	O	O
galantamine	NOUN	O	O
at	ADP	O	O
steady	ADJ	O	O
state	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
exposure	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
active	ADJ	O	O
moiety	NOUN	O	O
(	PUNCT	O	O
risperidone	ADP	O	O
plus	CCONJ	O	O
9-hydroxyrisperidone	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
most	PUNCT	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
component	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
galantamine	PUNCT	O	O
coadministration	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
systemic	ADJ	O	B-OTHER
exposure	NOUN	O	I-OTHER
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
approximately	ADV	O	O
10	NUM	O	O
%	SYM	O	O
for	ADP	O	O
risperidone	NUM	O	O
and	CCONJ	O	O
decreased	PUNCT	O	O
by	ADP	O	O
about	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
for	ADP	O	O
9-hydroxyrisperidone	NOUN	O	O
(	PUNCT	O	O
active	ADJ	O	O
metabolite	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Galantamine	NOUN	O	O
and	CCONJ	O	O
risperidone	NUM	O	O
were	VERB	O	O
both	CCONJ	O	O
safe	ADJ	O	B-OTHER
and	CCONJ	O	I-OTHER
well	VERB	O	I-OTHER
tolerated	ADP	O	I-OTHER
administered	PUNCT	O	O
either	CCONJ	O	O
alone	ADJ	O	O
or	CCONJ	O	O
together	ADV	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
dose	NOUN	O	O
adjustment	NOUN	O	O
for	ADP	O	O
either	CCONJ	O	O
risperidone	ADP	O	O
orgalantamine	ADP	O	O
is	ADP	O	O
necessary	ADJ	O	O
when	PUNCT	O	O
these	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
are	VERB	O	O
administered	VERB	O	O
together	ADV	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
range	NOUN	O	O
evaluated	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
carbohydrate	NOUN	O	O
meal	NOUN	O	O
attenuates	ADP	O	O
the	DET	O	O
forearm	NOUN	O	O
vasoconstrictor	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
lower	PUNCT	O	O
body	NOUN	O	O
subatmospheric	ADJ	O	O
pressure	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
young	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cardiovascular	ADJ	O	O
(	PUNCT	O	O
CV	NOUN	O	O
)	PUNCT	O	O
responses	NOUN	O	O
to	ADP	O	O
meal	PUNCT	O	O
ingestion	NOUN	O	O
and	CCONJ	O	O
orthostasis	NOUN	O	O
are	VERB	O	O
well	VERB	O	O
established	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
meal	NOUN	O	O
ingestion	NOUN	O	O
and	CCONJ	O	O
meal	NOUN	O	O
composition	NOUN	O	O
on	ADP	O	O
the	DET	O	O
CV	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
orthostasis	NOUN	O	O
are	VERB	O	O
unknown	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
carbohydrate	NOUN	O	O
(	PUNCT	O	O
HC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
high	ADJ	O	O
fat	NOUN	O	O
(	PUNCT	O	O
HF	NOUN	O	O
)	PUNCT	O	O
meal	ADJ	O	O
ingestion	NOUN	O	O
on	ADP	O	O
the	DET	O	O
CV	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
simulated	VERB	O	O
orthostatic	ADJ	O	O
stress	NOUN	O	O
(	PUNCT	O	O
using	PUNCT	O	O
graded	VERB	O	O
lower	PUNCT	O	O
body	NOUN	O	O
subatmospheric	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
LBSP	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
nine	NUM	O	O
healthy	ADJ	O	O
young	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Cardiac	ADJ	O	B-PHYSICAL
output	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
CO	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O

Single-use	PUNCT	O	O
plaque	NOUN	O	O
removal	NOUN	O	O
efficacy	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
power	NOUN	O	O
toothbrushes	ADP	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
plaque	NOUN	O	B-OTHER
removal	NOUN	O	I-OTHER
efficacy	NOUN	O	I-OTHER
of	ADP	O	O
two	NUM	O	O
oscillating/rotating/pulsating	PUNCT	O	O
toothbrushes	PUNCT	O	O
(	PUNCT	O	O
Oral-B	PUNCT	O	O
ProfessionalCare	NOUN	O	O
7000	NUM	O	O
[	PUNCT	O	O
PC	NOUN	O	O
7000	NUM	O	O
]	PUNCT	O	O
and	CCONJ	O	O
Oral-B	ADJ	O	O
3D	NOUN	O	O
Excel	PUNCT	O	O
[	PUNCT	O	O
3DE	PUNCT	O	O
]	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
high-frequency	NOUN	O	O
toothbrush	NOUN	O	O
(	PUNCT	O	O
Sonicare	NOUN	O	O
Advance	NOUN	O	O
,	PUNCT	O	O
Philips	ADV	O	O
Oral	PUNCT	O	O
Healthcare	NOUN	O	O
;	PUNCT	O	O
SA	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
single-use	NOUN	O	O
,	PUNCT	O	O
examiner-blind	PUNCT	O	O
,	PUNCT	O	O
three	NUM	O	O
period	NOUN	O	O
crossover	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
After	ADP	O	O
refraining	ADJ	O	O
from	ADP	O	O
all	DET	O	O
oral	ADJ	O	O
hygiene	NOUN	O	O
procedures	NOUN	O	O
for	ADP	O	O
23-25	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
received	VERB	O	O
an	DET	O	O
oral	ADJ	O	O
tissue	NOUN	O	O
examination	NOUN	O	O
and	CCONJ	O	O
those	PUNCT	O	O
with	ADP	O	O
pre-brushing	PUNCT	O	O
whole	ADJ	O	O
mouth	NOUN	O	O
mean	NOUN	O	O
plaque	NOUN	O	O
scores	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.6	NUM	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
Rustogi	PUNCT	O	O
et	CCONJ	O	O
al	NOUN	O	O
.	PUNCT	O	O

Modified	VERB	O	O
Navy	PUNCT	O	O
Plaque	NOUN	O	O
Index	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
sequence	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
brushing	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
assigned	PUNCT	O	O
toothbrush	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
commercially	ADV	O	O
available	ADJ	O	O
dentifrice	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
oral	ADJ	O	O
tissues	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
re-examined	VERB	O	O
and	CCONJ	O	O
post-brushing	PROPN	O	O
plaque	NOUN	O	O
scores	NOUN	O	O
recorded	PROPN	O	O
.	PUNCT	O	O

Following	VERB	O	O
a	DET	O	O
brief	ADJ	O	O
washout	PUNCT	O	O
period	NOUN	O	O
between	ADP	O	O
two	NUM	O	O
additional	ADJ	O	O
visits	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
above	ADP	O	O
procedures	NOUN	O	O
were	VERB	O	O
repeated	VERB	O	O
with	ADP	O	O
the	DET	O	O
two	NUM	O	O
alternate	PUNCT	O	O
toothbrushes	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
examiner	NOUN	O	O
,	PUNCT	O	O
blinded	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
sequence	NOUN	O	O
,	PUNCT	O	O
performed	VERB	O	O
all	DET	O	O
clinical	ADJ	O	O
measurements	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
79	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
28	NUM	O	O
males	NOUN	O	O
and	CCONJ	O	O
51	NUM	O	O
females	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
enrolled	VERB	O	O
and	CCONJ	O	O
completed	DET	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
toothbrush	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
safe	ADJ	O	B-OTHER
and	CCONJ	O	O
significantly	ADV	O	O
reduced	ADJ	O	O
plaque	NOUN	O	B-OTHER
levels	NOUN	O	I-OTHER
after	ADP	O	O
a	DET	O	O
single	ADJ	O	O
brushing	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
PC	NOUN	O	O
7000	NUM	O	O
and	CCONJ	O	O
3DE	PUNCT	O	O
were	VERB	O	O
equally	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
plaque	NOUN	O	B-PHYSICAL
removal	NOUN	O	I-PHYSICAL
than	ADP	O	O
the	DET	O	O
SA	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
all	DET	O	O
tooth	NOUN	O	O
areas	NOUN	O	O
,	PUNCT	O	O
reducing	PUNCT	O	O
plaque	NOUN	O	B-PHYSICAL
by	ADP	O	O
59.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
59.7	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
51.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
on	ADP	O	O
whole	ADJ	O	O
mouth	NOUN	O	O
surfaces	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
67.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
67.8	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
59.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
on	ADP	O	O
approximal	ADJ	O	O
surfaces	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
action	NOUN	O	O
of	ADP	O	O
the	DET	O	O
oscillating/rotating/pulsating	PUNCT	O	O
toothbrushes	PUNCT	O	O
(	PUNCT	O	O
Oral-B	PUNCT	O	O
ProfessionalCare	NOUN	O	O
7000	NUM	O	O
and	CCONJ	O	O
Oral-B	ADJ	O	O
3D	NOUN	O	O
Excel	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
plaque	NOUN	O	O
removal	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
high-frequency	NOUN	O	O
toothbrush	NOUN	O	O
(	PUNCT	O	O
Sonicare	NOUN	O	O
Advance	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	O
for	ADP	O	O
sleep	ADJ	O	O
problems	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
fragile	PUNCT	O	O
X	NUM	O	O
syndrome	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
autism	NOUN	O	O
and	CCONJ	O	O
fragile	PUNCT	O	O
X	NUM	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	O
on	ADP	O	O
sleep	ADJ	O	O
problems	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autistic	ADJ	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fragile	PUNCT	O	O
X	NUM	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
FXS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
4-week	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
design	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
following	ADJ	O	O
a	DET	O	O
1-week	NOUN	O	O
baseline	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Either	CCONJ	O	O
melatonin	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
participants	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
alternated	VERB	O	O
for	ADP	O	O
another	DET	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Sleep	NOUN	O	B-PHYSICAL
variables	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
including	CCONJ	O	O
sleep	NOUN	O	O
duration	NOUN	O	O
,	PUNCT	O	O
sleep-onset	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
sleep-onset	NOUN	O	O
latency	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
night	NOUN	O	O
awakenings	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
recorded	VERB	O	O
using	VERB	O	O
an	DET	O	O
Actiwatch	NOUN	O	O
and	CCONJ	O	O
from	ADP	O	O
sleep	NOUN	O	O
diaries	NOUN	O	O
completed	VERB	O	O
by	ADP	O	O
parents	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
participants	NOUN	O	O
had	PUNCT	O	O
been	PUNCT	O	O
thoroughly	ADV	O	O
assessed	VERB	O	O
for	ADP	O	O
ASD	NOUN	O	O
and	CCONJ	O	O
also	ADV	O	O
had	PUNCT	O	O
DNA	NOUN	O	O
testing	VERB	O	O
for	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
FXS	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Data	NOUN	O	O
were	VERB	O	O
successfully	ADV	O	O
obtained	VERB	O	O
from	ADP	O	O
the	DET	O	O
12	NUM	O	O
of	ADP	O	O
18	NUM	O	O
subjects	NOUN	O	O
who	ADP	O	O
completed	PROPN	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
males	PROPN	O	O
,	PUNCT	O	O
age	NOUN	O	O
range	NOUN	O	O
2	NUM	O	O
to	ADP	O	O
15.25	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
5.47	NUM	O	O
,	PUNCT	O	O
SD	NOUN	O	O
3.6	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Five	NUM	O	O
participants	NOUN	O	O
met	VERB	O	O
diagnostic	ADJ	O	O
criteria	NOUN	O	O
for	ADP	O	O
ASD	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
for	ADP	O	O
FXS	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
3	NUM	O	O
for	ADP	O	O
FXS	NOUN	O	O
and	CCONJ	O	O
ASD	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
for	ADP	O	O
fragile	ADJ	O	O
X	ADP	O	O
premutation	NUM	O	O
.	PUNCT	O	O

Eight	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
12	NUM	O	O
had	PUNCT	O	O
melatonin	NOUN	O	O
first	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
conclusions	NOUN	O	O
from	ADP	O	O
a	DET	O	O
nonparametric	ADJ	O	O
repeated-measures	NOUN	O	O
technique	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
mean	NOUN	O	O
night	NOUN	O	B-OTHER
sleep	NOUN	O	I-OTHER
duration	NOUN	O	I-OTHER
was	VERB	O	O
longer	PUNCT	O	O
on	ADP	O	O
melatonin	NOUN	O	O
than	PUNCT	O	O
placebo	NOUN	O	O
by	ADP	O	O
21	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mean	VERB	O	O
sleep-onset	NOUN	O	B-OTHER
latency	NOUN	O	I-OTHER
was	VERB	O	O
shorter	PUNCT	O	O
by	ADP	O	O
28	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
sleep-onset	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
was	VERB	O	O
earlier	PUNCT	O	O
by	ADP	O	O
42	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
support	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
sleep	ADJ	O	O
problems	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
and	CCONJ	O	O
FXS	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
The	DET	O	O
chemotherapy	NOUN	O	O
of	ADP	O	O
advanced	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
report	NOUN	O	O
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
600	NUM	O	O
cases	NOUN	O	O
in	ADP	O	O
a	DET	O	O
cooperative	ADJ	O	O
programme	NOUN	O	O
to	VERB	O	O
carry	PUNCT	O	O
out	DET	O	O
a	DET	O	O
systematic	ADJ	O	O
study	NOUN	O	O
(	PUNCT	O	O
1974-1977	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
author	NOUN	O	O
's	PUNCT	O	O
transl	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
explain	VERB	O	O
the	DET	O	O
objectives	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
structure	NOUN	O	O
of	ADP	O	O
a	DET	O	O
programme	NOUN	O	O
evolved	VERB	O	O
for	ADP	O	O
the	DET	O	O
methodic	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
advanced	VERB	O	O
breast	NOUN	O	O
cancers	NOUN	O	O
which	ADP	O	O
they	PRON	O	O
have	VERB	O	O
worked	VERB	O	O
out	PUNCT	O	O
and	CCONJ	O	O
carried	ADP	O	O
out	ADP	O	O
in	ADP	O	O
cooperation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
departments	NOUN	O	O
of	ADP	O	O
medicine	NOUN	O	O
in	ADP	O	O
eight	NUM	O	O
French	ADJ	O	O
anticancer	NOUN	O	O
centres	NOUN	O	O
.	PUNCT	O	O

They	NOUN	O	O
analyse	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
phases	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
correspond	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
three	NUM	O	O
first	ADJ	O	O
years	NOUN	O	O
of	ADP	O	O
work	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
give	VERB	O	O
the	DET	O	O
state	NOUN	O	O
of	ADP	O	O
the	DET	O	O
results	NOUN	O	O
that	ADP	O	O
have	PUNCT	O	O
been	PUNCT	O	O
obtained	VERB	O	O
in	ADP	O	O
603	NUM	O	O
patients	NOUN	O	O
using	VERB	O	O
three	NUM	O	O
protocols	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

These	ADP	O	O
consisted	DET	O	O
of	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
in	ADP	O	O
interrupted	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
which	ADP	O	O
consisted	VERB	O	O
of	ADP	O	O
vincristine	NOUN	O	O
associated	VERB	O	O
for	ADP	O	O
the	DET	O	O
one	NUM	O	O
part	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	O
and	CCONJ	O	O
5-fluoro-uracil	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
with	ADP	O	O
doxorubicine	NOUN	O	O
or/and	PUNCT	O	O
with	ADP	O	O
methotrexate	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
this	DET	O	O
study	NOUN	O	O
there	PUNCT	O	O
emerged	PUNCT	O	O
the	DET	O	O
value	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
therapy	NOUN	O	O
using	VERB	O	O
doxorubicine	NOUN	O	O
as	PUNCT	O	O
much	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
with	ADP	O	O
which	PUNCT	O	B-PHYSICAL
results	PUNCT	O	I-PHYSICAL
better	PUNCT	O	I-PHYSICAL
than	VERB	O	O
50	NUM	O	O
%	SYM	O	O
were	VERB	O	O
obtained	VERB	O	O
(	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
trial	NOUN	O	O
)	PUNCT	O	O
as	VERB	O	O
by	ADP	O	O
their	PUNCT	O	O
quality	NOUN	O	B-OTHER
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
made	SYM	O	O
clear	ADJ	O	O
in	ADP	O	O
an	DET	O	O
important	ADJ	O	O
series	NOUN	O	O
of	ADP	O	O
240	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

They	NUM	O	O
point	PUNCT	O	O
out	ADP	O	O
the	DET	O	O
conditions	NOUN	O	O
required	VERB	O	O
to	PART	O	O
initiate	NOUN	O	O
the	DET	O	O
place	NOUN	O	O
of	ADP	O	O
such	CCONJ	O	O
a	ADP	O	O
scheme	NOUN	O	O
in	ADP	O	O
all	DET	O	O
complex	ADJ	O	O
therapy	NOUN	O	O
which	ADP	O	O
aims	ADP	O	O
as	PUNCT	O	O
much	PUNCT	O	O
at	ADP	O	O
palliation	NOUN	O	O
as	PUNCT	O	O
at	CCONJ	O	O
cure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
point	NOUN	O	O
out	ADJ	O	O
how	PUNCT	O	O
important	ADJ	O	O
it	NOUN	O	O
is	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
methodical	ADP	O	O
in	ADP	O	O
the	DET	O	O
application	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
ensure	NOUN	O	O
its	ADP	O	O
development	NOUN	O	O
as	ADP	O	O
an	DET	O	O
anticancer	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Circadian	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	B-PHYSICAL
of	ADP	O	O
oral	ADJ	O	O
ketoprofen	NOUN	O	O
.	PUNCT	O	O

Several	ADJ	O	O
investigations	NOUN	O	O
which	ADP	O	O
have	PUNCT	O	O
taken	ADP	O	O
treatment	NOUN	O	O
time	NOUN	O	O
into	ADP	O	O
account	PUNCT	O	O
have	PUNCT	O	O
shown	VERB	O	O
that	ADP	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	O
parameters	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
therapeutic	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
and	CCONJ	O	O
even	ADV	O	O
the	ADP	O	O
toxicity	NOUN	O	B-PHYSICAL
of	ADP	O	O
a	DET	O	O
large	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
products	NOUN	O	O
may	VERB	O	O
vary	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
schedule	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
any	DET	O	O
circadian	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
pharmacokinetic	ADJ	O	O
parameters	NOUN	O	O
of	ADP	O	O
ketoprofen	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
non-steroidal	ADJ	O	O
anti-inflammatory	ADJ	O	O
drug	NOUN	O	O
(	PUNCT	O	O
NSAID	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
randomised	VERB	O	O
crossover	NOUN	O	O
study	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ketoprofen	NOUN	O	O
100mg	NOUN	O	O
administered	VERB	O	O
to	ADP	O	O
8	NUM	O	O
healthy	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
27.2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
07.00	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
13.00	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
19.00	NUM	O	O
hours	NOUN	O	O
or	CCONJ	O	O
01.00	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
4	NUM	O	O
study	ADV	O	O
periods	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
the	DET	O	O
year	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
order	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
was	VERB	O	O
randomised	NUM	O	O
,	PUNCT	O	O
with	ADP	O	O
each	DET	O	O
subject	NOUN	O	O
acting	VERB	O	O
as	PUNCT	O	O
his	PUNCT	O	O
own	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
blood	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
urine	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
over	ADP	O	O
a	DET	O	O
12-hour	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
peak	ADJ	O	O
plasma	NOUN	O	B-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
was	VERB	O	O
twice	ADV	O	O
as	VERB	O	O
high	ADJ	O	O
after	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
at	ADP	O	O
07.00	NUM	O	O
hours	NOUN	O	O
(	PUNCT	O	O
13.4	NUM	O	O
+/-	SYM	O	O
1	NUM	O	O
mg/L	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
after	ADP	O	O
other	ADJ	O	O
administration	NOUN	O	O
times	NOUN	O	O
(	PUNCT	O	O
13.00	NUM	O	O
hours	NOUN	O	O
:	PUNCT	O	O
6.9	NUM	O	O
+/-	SYM	O	O
1	NUM	O	O
;	PUNCT	O	O
19.00	NUM	O	O
hours	NOUN	O	O
:	PUNCT	O	O
7.2	NUM	O	O
+/-	SYM	O	O
0.7	NUM	O	O
;	PUNCT	O	O
01.00	NUM	O	O
hours	NOUN	O	O
:	PUNCT	O	O
6.3	NUM	O	O
+/-	SYM	O	O
0.5	NUM	O	O
mg/L	NOUN	O	O
)	PUNCT	O	O
[	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.001	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
reach	NOUN	O	I-PHYSICAL
peak	ADJ	O	O
concentration	NOUN	O	B-PHYSICAL
was	VERB	O	O
much	ADV	O	O
longer	PUNCT	O	O
after	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
at	ADP	O	O
01.00	NUM	O	O
hours	NOUN	O	O
(	PUNCT	O	O
135	NUM	O	O
+/-	SYM	O	O
16.7	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
at	ADP	O	O
07.00	NUM	O	O
(	PUNCT	O	O
73.1	NUM	O	O
+/-	SYM	O	O
14.1	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
13.00	NUM	O	O
(	PUNCT	O	O
75	NUM	O	O
+/-	SYM	O	O
16.5	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
19.00	NUM	O	O
hours	NOUN	O	O
(	PUNCT	O	O
82.5	NUM	O	O
+/-	SYM	O	O
12.7	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
[	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.05	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
lag	NOUN	O	O
time	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
longer	PUNCT	O	O
at	ADP	O	O
01.00	NUM	O	O
hours	NOUN	O	O
than	CCONJ	O	O
at	ADP	O	O
13.00	NUM	O	O
hours	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
absorption	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
constant	ADJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
at	ADP	O	O
01.00	NUM	O	O
hours	NOUN	O	O
was	NUM	O	O
less	ADV	O	O
than	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
other	ADJ	O	O
times	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
bodyweight-corrected	VERB	O	B-PHYSICAL
area	NOUN	O	O
under	ADP	O	B-PHYSICAL
the	DET	O	B-PHYSICAL
curve	NOUN	O	O
(	PUNCT	O	O

Does	PUNCT	O	O
aerobic	ADP	O	O
training	VERB	O	O
lead	NOUN	O	O
to	ADP	O	O
a	DET	O	O
more	DET	O	O
active	ADJ	O	B-MENTAL
lifestyle	NOUN	O	I-MENTAL
and	CCONJ	O	O
improved	VERB	O	B-OTHER
quality	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
life	NOUN	O	I-OTHER
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
?	PUNCT	O	O

BACKGROUND	NOUN	O	O
Due	PUNCT	O	O
to	ADP	O	O
dyspnea	NOUN	O	O
and	CCONJ	O	O
fatigue	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
CHF	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
often	ADV	O	O
restricted	VERB	O	O
in	ADP	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
everyday	NOUN	O	O
activities	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
gradually	ADV	O	O
may	VERB	O	O
lead	PUNCT	O	O
to	ADP	O	O
hypoactivity	NOUN	O	O
.	PUNCT	O	O

AIMS	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
whether	PUNCT	O	O
aerobic	ADJ	O	O
training	ADV	O	O
leads	SYM	O	O
to	ADP	O	O
a	DET	O	O
more	DET	O	O
active	ADJ	O	B-MENTAL
lifestyle	NOUN	O	I-MENTAL
and	CCONJ	O	O
improved	VERB	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
QoL	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
CHF	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
CHF	NOUN	O	O
(	PUNCT	O	O
NYHA	NOUN	O	O
II/III	PUNCT	O	O
;	PUNCT	O	O
59	NUM	O	O
(	PUNCT	O	O
11	NUM	O	O
)	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
a	DET	O	O
training	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=18	NOUN	O	O
;	PUNCT	O	O
3-month	NOUN	O	O
aerobic	ADJ	O	O
program	NOUN	O	O
above	ADP	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=16	NOUN	O	O
;	PUNCT	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
without	ADP	O	O
special	ADJ	O	O
advice	NOUN	O	O
for	ADP	O	O
exercise	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Measurements	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
level	NOUN	O	O
of	ADP	O	O
everyday	NOUN	O	B-MENTAL
physical	ADJ	O	I-MENTAL
activity	NOUN	O	I-MENTAL
(	PUNCT	O	O
PA	NOUN	O	B-MENTAL
,	PUNCT	O	O
novel	ADJ	O	B-MENTAL
accelerometry-based	VERB	O	I-MENTAL
activity	NOUN	O	I-MENTAL
monitor	NOUN	O	I-MENTAL
)	PUNCT	O	O
and	PUNCT	O	O

Human	NOUN	O	O
achaete-scute	ADP	O	O
homologue	NOUN	O	O
(	PUNCT	O	O
hASH1	NOUN	O	O
)	PUNCT	O	O
mRNA	NOUN	O	O
level	NOUN	O	O
as	ADP	O	O
a	DET	O	O
diagnostic	ADJ	O	O
marker	NOUN	O	O
to	ADJ	O	O
distinguish	ADJ	O	O
esthesioneuroblastoma	NOUN	O	O
from	ADP	O	O
poorly	ADV	O	O
differentiated	VERB	O	O
tumors	NOUN	O	O
arising	VERB	O	O
in	ADP	O	O
the	DET	O	O
sinonasal	ADJ	O	O
tract	NOUN	O	O
.	PUNCT	O	O

Distinction	NOUN	O	O
of	ADP	O	O
high-grade	NOUN	O	O
esthesioneuroblastomas	NOUN	O	O
from	ADP	O	O
other	VERB	O	O
poorly	ADV	O	O
differentiated	VERB	O	O
tumors	NOUN	O	O
arising	VERB	O	O
in	ADP	O	O
the	DET	O	O
nasal	ADJ	O	O
cavity	NOUN	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
diagnostic	ADJ	O	O
challenge	NOUN	O	O
because	ADP	O	O
it	ADP	O	O
determines	NOUN	O	O
patient	NOUN	O	O
management	NOUN	O	O
and	CCONJ	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
human	NOUN	O	O
achaete-scute	ADP	O	O
homologue	NOUN	O	O
(	PUNCT	O	O
hASH1	NOUN	O	O
)	PUNCT	O	O
gene	NOUN	O	O
is	VERB	O	O
critical	ADJ	O	O
in	PUNCT	O	O
olfactory	NOUN	O	O
neuronal	ADJ	O	O
differentiation	NOUN	O	O
and	CCONJ	O	O
is	PROPN	O	O
expressed	VERB	O	O
in	ADP	O	O
immature	ADJ	O	O
olfactory	NOUN	O	O
cells	NOUN	O	O
;	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
could	VERB	O	O
have	PUNCT	O	O
potential	ADJ	O	O
use	NOUN	O	O
as	ADP	O	O
a	DET	O	O
diagnostic	ADJ	O	O
marker	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
value	NOUN	O	O
of	ADP	O	O
hASH1	NOUN	O	O
messenger	NOUN	O	O
RNA	NOUN	O	O
(	PUNCT	O	O
mRNA	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
in	ADP	O	O
differentiating	ADJ	O	O
esthesioneuroblastoma	NOUN	O	O
from	ADP	O	O
other	VERB	O	O
poorly	ADV	O	O
differentiated	VERB	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
real-time	NOUN	O	O
polymerase	NOUN	O	O
chain	NOUN	O	O
reaction	NOUN	O	O
assay	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
,	PUNCT	O	O
permitting	VERB	O	O
the	DET	O	O
comparative	ADJ	O	O
determination	NOUN	O	O
of	ADP	O	O
hASH1	NOUN	O	B-PHYSICAL
mRNA	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
triplicate	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
pilot	NOUN	O	O
study	NOUN	O	O
including	ADP	O	O
24	NUM	O	O
frozen	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
esthesioneuroblastoma	NOUN	O	O
and	CCONJ	O	O
poorly	ADV	O	O
differentiated	VERB	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
4	NUM	O	O
positive	ADJ	O	O
cases	NOUN	O	O
were	DET	O	O
esthesioneuroblastomas	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
19	NUM	O	O
poorly	ADV	O	O
differentiated	VERB	O	O
tumors	NOUN	O	O
were	VERB	O	O
negative	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
an	DET	O	O
inverse	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
grade	NOUN	O	O
of	ADP	O	O
esthesioneuroblastomas	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
hASH1	NOUN	O	O
mRNA	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hASH1	NOUN	O	O
mRNA	NOUN	O	O
level	NOUN	O	O
might	VERB	O	O
represent	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
tool	NOUN	O	O
for	ADP	O	O
distinguishing	VERB	O	O
esthesioneuroblastoma	NOUN	O	O
from	ADP	O	O
poorly	ADV	O	O
differentiated	VERB	O	O
tumors	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sinonasal	ADJ	O	O
region	NOUN	O	O
.	PUNCT	O	O

Lack	NOUN	O	O
of	ADP	O	O
benefit	PUNCT	O	O
of	ADP	O	O
an	DET	O	O
active	ADJ	O	O
pectoral	ADJ	O	O
pulse	NOUN	O	O
generator	NOUN	O	O
on	ADP	O	O
atrial	ADJ	O	O
defibrillation	NOUN	O	O
thresholds	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
Atrial	ADJ	O	O
defibrillation	NOUN	O	O
can	PROPN	O	O
be	VERB	O	O
achieved	VERB	O	O
with	ADP	O	O
standard	ADJ	O	O
implantable	ADJ	O	O
cardioverter	ADJ	O	O
defibrillator	NOUN	O	O
leads	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
has	PUNCT	O	O
led	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
atrial	ADJ	O	O
and	CCONJ	O	O
ventricular	ADJ	O	O
devices	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
ventricular	ADJ	O	O
defibrillation	NOUN	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
an	DET	O	O
active	ADJ	O	O
pectoral	ADJ	O	O
electrode	NOUN	O	O
(	PUNCT	O	O
active	ADJ	O	O
can	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
shocking	ADJ	O	O
pathway	NOUN	O	O
markedly	ADV	O	O
reduces	NOUN	O	O
defibrillation	NOUN	O	O
thresholds	NOUN	O	O
(	PUNCT	O	O
DFTs	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
an	DET	O	O
active	ADJ	O	O
pectoral	ADJ	O	O
can	PUNCT	O	O
on	ADP	O	O
atrial	ADJ	O	O
defibrillation	NOUN	O	O
is	VERB	O	O
unknown	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	PUNCT	O	O
This	PUNCT	O	O
study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
paired	ADP	O	O
comparison	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
shock	NOUN	O	O
configurations	NOUN	O	O
on	ADP	O	O
atrial	ADJ	O	O
DFTs	NOUN	O	O
in	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
lead	ADV	O	O
system	NOUN	O	O
evaluated	VERB	O	O
was	VERB	O	O
a	DET	O	O
dual-coil	NOUN	O	O
transvenous	ADJ	O	O
defibrillation	NOUN	O	O
lead	DET	O	O
with	ADP	O	O
a	DET	O	O
left	ADJ	O	O
pectoral	ADJ	O	O
pulse	NOUN	O	O
generator	NOUN	O	O
emulator	NOUN	O	O
.	PUNCT	O	O

Shocks	PUNCT	O	O
were	ADJ	O	O
delivered	ADP	O	O
either	PUNCT	O	O
between	ADP	O	O
the	DET	O	O
right	ADJ	O	O
ventricular	ADJ	O	O
coil	NOUN	O	O
and	CCONJ	O	O
proximal	ADJ	O	O
atrial	ADJ	O	O
coil	NOUN	O	O
(	PUNCT	O	O
lead	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
between	ADP	O	O
the	DET	O	O
right	ADJ	O	O
ventricular	ADJ	O	O
coil	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
active	ADJ	O	O
can	ADP	O	O
in	ADP	O	O
common	ADJ	O	O
with	ADP	O	O
the	DET	O	O
atrial	ADJ	O	O
coil	NOUN	O	O
(	PUNCT	O	O
active	ADJ	O	O
can	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Delivered	VERB	O	B-PHYSICAL
energy	NOUN	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
DFT	NOUN	O	I-PHYSICAL
was	VERB	O	O
4.2	NUM	O	O
+/-	SYM	O	O
4.1	NUM	O	O
J	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lead	ADV	O	O
configuration	NOUN	O	O
and	CCONJ	O	O
5.0	NUM	O	O
+/-	SYM	O	O
3.7	NUM	O	O
J	NOUN	O	O
in	ADP	O	O
the	DET	O	O
active	ADJ	O	O
can	PUNCT	O	O
configuration	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
NS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Peak	ADJ	O	O
current	ADJ	O	B-PHYSICAL
was	VERB	O	O
32	NUM	O	O
%	SYM	O	O
higher	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
active	ADJ	O	O
can	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
shock	NOUN	O	B-PHYSICAL
impedance	NOUN	O	I-PHYSICAL
was	VERB	O	O
18	NUM	O	O
%	SYM	O	O
lower	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
low	ADJ	O	B-PHYSICAL
threshold	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
<	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
3	NUM	O	O
J	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
61	NUM	O	O
%	SYM	O	O
of	ADP	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lead	ADV	O	O
configuration	NOUN	O	O
but	CCONJ	O	O
in	ADP	O	O
only	ADV	O	O
36	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
active	ADJ	O	O
can	PUNCT	O	O
configuration	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
clinical	ADJ	O	B-PHYSICAL
predictors	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
atrial	ADJ	O	O
DFT	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
low	ADJ	O	O
atrial	ADJ	O	O
DFTs	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
using	VERB	O	O
a	DET	O	O
transvenous	ADJ	O	O
ventricular	ADJ	O	O
defibrillation	NOUN	O	O
lead	ADV	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
no	DET	O	O
benefit	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
an	DET	O	O
active	ADJ	O	O
pectoral	ADJ	O	O
electrode	NOUN	O	O
for	ADP	O	O
atrial	ADJ	O	O
defibrillation	NOUN	O	O
,	PUNCT	O	O
programmable	ADJ	O	O
shock	NOUN	O	O
vectors	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
dual-chamber	NOUN	O	O
implantable	ADJ	O	O
cardioverter	ADJ	O	O
defibrillators	NOUN	O	O
.	PUNCT	O	O

Testosterone	NOUN	O	O
and	CCONJ	O	O
gonadotropins	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
estrogen	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
spatial	ADJ	O	B-MENTAL
ability	NOUN	O	I-MENTAL
in	ADP	O	O
women	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
schizophrenia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
estrogen	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
spatial	ADJ	O	B-MENTAL
ability	NOUN	O	I-MENTAL
tasks	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
schizophrenia	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
this	DET	O	O
purpose	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
three-time	NOUN	O	O
cross-over	NOUN	O	O
study	NOUN	O	O
using	VERB	O	O
17beta-estradiol	NOUN	O	O
combined	PUNCT	O	O
with	ADP	O	O
norethisterone	NOUN	O	O
acetate	NOUN	O	O
for	ADP	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
as	VERB	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
a	DET	O	O
naturalistic	ADJ	O	O
maintenance	NOUN	O	O
antipsychotic	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Nineteen	NUM	O	O
women	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age=38.0	PUNCT	O	O
years	NOUN	O	O
,	PUNCT	O	O
SD=9.9	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
hospitalized	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
or	CCONJ	O	O
repeatedly	DET	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Sex	NOUN	O	B-PHYSICAL
hormones	NOUN	O	I-PHYSICAL
-	PUNCT	O	I-PHYSICAL
17beta-estradiol	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
luteinizing	ADP	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
LH	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
follicle-stimulating	VERB	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
FSH	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
prolactin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
testosterone	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
dehydroepiandrosterone	NOUN	O	B-PHYSICAL
sulfate	NOUN	O	I-PHYSICAL
-	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
patients	NOUN	O	O
completed	ADV	O	O
a	DET	O	O
neuropsychological	ADJ	O	O
test	NOUN	O	O
in	ADP	O	O
the	DET	O	O
last	ADJ	O	O
two	NUM	O	O
active	ADJ	O	O
drug	NOUN	O	O
and/or	CCONJ	O	O
placebo	NOUN	O	O
phases	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
different	ADJ	O	O
spatial	ADJ	O	O
ability	NOUN	O	O
tasks	NOUN	O	O
-	PUNCT	O	O
spatial	ADJ	O	B-MENTAL
orientation	NOUN	O	I-MENTAL
,	PUNCT	O	O
spatial	ADJ	O	B-MENTAL
visualization	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
flexibility	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
closure	NOUN	O	I-MENTAL
-	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
a	DET	O	O
paper-and-pencil	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
association	NOUN	O	O
between	ADP	O	O
estrogen	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
spatial	ADJ	O	B-MENTAL
ability	NOUN	O	I-MENTAL
was	VERB	O	O
found	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
exploratory	ADJ	O	O
data	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
testosterone	NOUN	O	O
,	PUNCT	O	O
LH	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
FSH	NOUN	O	B-PHYSICAL
correlated	VERB	O	O
significantly	ADV	O	O
with	ADP	O	O
performance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
flexibility	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
closure	NOUN	O	I-PHYSICAL
task	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
very	ADJ	O	O
first	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
estrogen	NOUN	O	O
intervention	NOUN	O	O
instead	ADJ	O	O
of	ADP	O	O
physiological	ADJ	O	O
hormone	NOUN	O	O
changes	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
estrogen	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
spatial	ADJ	O	B-PHYSICAL
ability	NOUN	O	I-PHYSICAL
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
of	ADP	O	O
hypertensive	ADJ	O	O
and	CCONJ	O	O
hypercholesterolaemic	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
general	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	O
,	PUNCT	O	O
atenolol	NOUN	O	O
and	CCONJ	O	O
pravastatin	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
life	NOUN	O	O
style	ADJ	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
elucidate	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
lipids	NOUN	O	O
of	ADP	O	O
an	DET	O	O
angiotensin	NOUN	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
captopril	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
beta-receptor	NOUN	O	O
blocking	DET	O	O
agent	NOUN	O	O
(	PUNCT	O	O
atenolol	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
given	VERB	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
a	DET	O	O
cholesterol	NOUN	O	O
reducing	ADP	O	O
drug	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
beta-hydroxy-methylglutaryl-coenzyme	NOUN	O	O
A	DET	O	O
reductase	NOUN	O	O
inhibitor	NOUN	O	O
pravastatin	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
also	ADV	O	O
encouraged	VERB	O	O
to	ADP	O	O
improve	ADJ	O	O
their	PUNCT	O	O
lifestyle	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	CCONJ	O	O
longitudinal	ADJ	O	O
study	NOUN	O	O
consisting	DET	O	O
of	ADP	O	O
three	NUM	O	O
phases	NOUN	O	O
.	PUNCT	O	O

I	NUM	O	O
:	PUNCT	O	O
Lifestyle	NOUN	O	O
intervention	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

II	NUM	O	O
:	PUNCT	O	O
Continued	PROPN	O	O
lifestyle	NOUN	O	O
intervention	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
captopril	NOUN	O	O
or	CCONJ	O	O
atenolol	NOUN	O	O
.	PUNCT	O	O

III	NUM	O	O
:	PUNCT	O	O
Continued	PROPN	O	O
lifestyle	NOUN	O	O
intervention	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
the	DET	O	O
same	ADJ	O	O
drugs	NOUN	O	O
as	PUNCT	O	O
in	ADP	O	O
phase	NOUN	O	O
II	NUM	O	O
and	CCONJ	O	O
in	ADP	O	O
addition	NOUN	O	O
pravastatin	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Fifty-four	NUM	O	O
general	ADJ	O	O
practice	NOUN	O	O
surgeries	DET	O	O
in	ADP	O	O
Norway	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
Hypertensive	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
210	NUM	O	O
females	NOUN	O	O
and	CCONJ	O	O
160	NUM	O	O
males	NOUN	O	O
,	PUNCT	O	O
treated	DET	O	O
or	CCONJ	O	O
untreated	VERB	O	O
with	ADP	O	O
antihypertensive	ADJ	O	O
drugs	NOUN	O	O
with	ADP	O	O
a	DET	O	O
sitting	ADP	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
between	ADP	O	O
95	NUM	O	O
and	CCONJ	O	O
115	NUM	O	O
mmHg	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
serum	NOUN	O	O
total	ADJ	O	O
cholesterol	NOUN	O	O
between	ADP	O	O
6.5	NUM	O	O
mmol/l	NOUN	O	O
(	PUNCT	O	O
7.0	NUM	O	O
for	ADP	O	O
those	PUNCT	O	O
age	NOUN	O	O
60-67	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
9.0	NUM	O	O
mmol/l	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
antihypertensive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	O
and	CCONJ	O	O
atenolol	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
concurrent	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
limited	VERB	O	O
by	ADP	O	O
concurrent	ADJ	O	O
medication	NOUN	O	O
with	ADP	O	O
captopril	NOUN	O	O
or	CCONJ	O	O
atenolol	NOUN	O	O
.	PUNCT	O	O

Improvement	NOUN	O	B-MENTAL
in	ADP	O	I-MENTAL
lifestyle	NOUN	O	I-MENTAL
seemed	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
supplementary	ADJ	O	B-PHYSICAL
treatment	NOUN	O	O
with	PUNCT	O	B-PHYSICAL

Long-term	NOUN	O	O
survival	NOUN	O	O
in	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
topotecan	PUNCT	O	O
versus	CCONJ	O	O
paclitaxel	NOUN	O	O
in	ADP	O	O
advanced	VERB	O	O
epithelial	ADJ	O	O
ovarian	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
We	PRON	O	O
have	VERB	O	O
continued	NOUN	O	O
to	ADJ	O	O
monitor	ADP	O	O
the	DET	O	O
survival	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
randomised	ADP	O	O
in	ADP	O	O
a	DET	O	O
previously	ADV	O	O
reported	VERB	O	O
multicentre	NOUN	O	O
phase	NOUN	O	O
III	NUM	O	O
study	NOUN	O	O
of	ADP	O	O
topotecan	PUNCT	O	O
versus	CCONJ	O	O
paclitaxel	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
epithelial	ADJ	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
failed	VERB	O	O
one	NUM	O	O
prior	VERB	O	O
platinum-based	ADP	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
bidimensionally	ADV	O	O
measurable	ADJ	O	O
disease	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
topotecan	PUNCT	O	O
(	PUNCT	O	O
1.5	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
/day	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
paclitaxel	NOUN	O	O
(	PUNCT	O	O
175	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
/day	PUNCT	O	O
as	CCONJ	O	O
a	DET	O	O
3-h	NOUN	O	O
infusion	NOUN	O	O
)	PUNCT	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
eligible	ADJ	O	O
for	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
alternate	NOUN	O	O
therapy	NOUN	O	O
at	ADP	O	O
third	ADJ	O	O
line	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
European	NOUN	O	B-OTHER
Organisation	NOUN	O	I-OTHER
for	ADP	O	I-OTHER
Research	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
Treatment	NOUN	O	O
of	ADP	O	B-OTHER
Cancer	NOUN	O	I-OTHER
Quality	NOUN	O	O
of	ADP	O	B-OTHER
Life	NOUN	O	O
(	PUNCT	O	O
EORTC	NOUN	O	B-OTHER
QOL	NOUN	O	B-OTHER
)	PUNCT	O	O
-C30	PUNCT	O	B-OTHER
questionnaire	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
used	VERB	O	O
to	PART	O	O
measure	PART	O	O
eight	ADJ	O	O
symptoms	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
each	DET	O	O
course	NOUN	O	O
(	PUNCT	O	O
pain	NOUN	O	B-PAIN
,	PUNCT	O	O
anorexia	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
diarrhoea	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
fatigue	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
nausea	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
vomiting	PROPN	O	B-PHYSICAL
,	PUNCT	O	O
dyspnea	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
constipation	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
insomnia	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
226	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluable	ADJ	O	O
for	ADP	O	O
response	NOUN	O	O
.	PUNCT	O	O

Demographic	ADJ	O	O
characteristics	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	PUNCT	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
were	PUNCT	O	O
results	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
EORTC	NOUN	O	O
QOL-30	NOUN	O	O
questionnaire	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
topotecan	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
median	ADJ	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
was	VERB	O	O
18.9	DET	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
<	SYM	O	O
1	NUM	O	O
to	ADP	O	O
92.6+	PUNCT	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
25	NUM	O	O
%	SYM	O	O
censored	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
for	ADP	O	O
paclitaxel	NOUN	O	O
,	PUNCT	O	O
14.7	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
<	SYM	O	O
1	NUM	O	O
to	ADP	O	O
137.3+	NOUN	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
12.3	NUM	O	O
%	SYM	O	O
censored	ADP	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.076	NUM	O	O
.	PUNCT	O	O

At	ADP	O	O
4	NUM	O	O
years	NOUN	O	O
post-randomisation	NOUN	O	O
,	PUNCT	O	O
median	ADJ	O	O
survival	NOUN	O	B-MORTALITY
in	ADP	O	O
the	DET	O	O
topotecan	PUNCT	O	O
group	NOUN	O	O
was	VERB	O	O
63.0	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
<	SYM	O	O
1	NUM	O	O
to	ADP	O	O
238.4+	NOUN	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
20.5	NUM	O	O
%	SYM	O	O
censored	ADP	O	O
)	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
for	ADP	O	O
paclitaxel	NOUN	O	O
,	PUNCT	O	O
53.0	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
<	SYM	O	O
1	NUM	O	O
to	ADP	O	O
226.3+	PUNCT	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
12.3	NUM	O	O
%	SYM	O	O
censored	ADP	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.44	NUM	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Topotecan	NOUN	O	O
continues	PROPN	O	O
to	ADP	O	O
demonstrate	VERB	O	O
comparable	ADJ	O	O
efficacy	NOUN	O	O
and	PUNCT	O	O

[	PUNCT	O	O
Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-PHYSICAL
of	ADP	O	O
extended-release	NOUN	O	O
niacin	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
with	ADP	O	O
atorvastatin	NOUN	O	O
for	ADP	O	O
lipid	NOUN	O	O
profile	NOUN	O	O
modification	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-PHYSICAL
of	ADP	O	O
extended-release	NOUN	O	O
niacin	NOUN	O	O
(	PUNCT	O	O
niacin	NOUN	O	O
ER	NOUN	O	O
)	PUNCT	O	O
either	CCONJ	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
atorvastatin	NOUN	O	O
for	ADP	O	O
the	DET	O	O
lipid	NOUN	O	O
profile	NOUN	O	O
modification	NOUN	O	O
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
(	PUNCT	O	O
CHD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
its	DET	O	O
equivalents	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
ten	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
CHD	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
equivalents	NOUN	O	O
with	ADP	O	O
serum	NOUN	O	O
total	ADJ	O	O
cholesterol	NOUN	O	O
(	PUNCT	O	O
TC	NOUN	O	O
)	PUNCT	O	O
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
3.5	NUM	O	O
mmol/L	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
into	ADP	O	O
three	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
atorvastatin	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
38	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
receiving	VERB	O	O
atorvastatin	NOUN	O	O
10	NUM	O	O
mg/d	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
niacin	NOUN	O	O
ER	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
38	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
given	VERB	O	O
niacin	NOUN	O	O
ER	NOUN	O	O
500	NUM	O	O
mg/d	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
1000	NUM	O	O
mg/d	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
34	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
atorvastatin	NOUN	O	O
(	PUNCT	O	O
10	ADP	O	O
mg/d	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
niacin	NOUN	O	O
ER	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
initiating	ADJ	O	O
from	ADP	O	O
500	ADP	O	O
mg/d	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increasing	VERB	O	O
to	ADP	O	O
1000	NUM	O	O
mg/d	NOUN	O	O
after	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
serums	PUNCT	O	B-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
profiles	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
all	DET	O	O
the	DET	O	O
patients	NOUN	O	O
before	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
After	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
serum	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	O
(	PUNCT	O	O
TG	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
high-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
HDL-C	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
30	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
16	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
in	ADP	O	O
the	DET	O	O
niacin	NOUN	O	O
ER	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
values	NOUN	O	O
(	PUNCT	O	O
both	CCONJ	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
TC	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
low-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
LDL-C	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
TG	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
atorvastatin	NOUN	O	B-PHYSICAL
group	NOUN	O	O
decreased	VERB	O	O
by	ADP	O	O
19	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
26	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
17	NUM	O	O
%	ADJ	O	O
respectively	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
values	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
treatment	NOUN	O	O
decreased	VERB	O	O
the	DET	O	O
TC	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
LDL-C	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
TG	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
by	ADP	O	O
28	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
38	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
39	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
the	DET	O	O
HDL-C	NOUN	O	B-PHYSICAL
level	NOUN	O	I-PHYSICAL
by	ADP	O	O
23	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
TC	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
LDL-C	NOUN	O	B-PHYSICAL
achieved	VERB	O	O
by	ADP	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
atorvastatin	NOUN	O	O
alone	ADJ	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
niacin	NOUN	O	O
ER	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

2	NUM	O	O
)	PUNCT	O	O
The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
achieving	VERB	O	O
the	DET	O	O
LDL-C	NOUN	O	B-PHYSICAL
goal	NOUN	O	O
of	ADP	O	O
The	DET	O	O
National	ADJ	O	O
Cholesterol	NOUN	O	O
Education	NOUN	O	O
Program	NOUN	O	O
(	PUNCT	O	O
NCEP	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
Adult	NOUN	O	O
Treatment	NOUN	O	O
Panel	NOUN	O	O
III	NUM	O	O
(	PUNCT	O	O
ATP	NOUN	O	O
III	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
73.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
those	ADP	O	O
of	ADP	O	O
the	DET	O	O
atorvastatin	NOUN	O	O
and	CCONJ	O	O
niacin	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
47.7	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
42.1	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
,	PUNCT	O	O
both	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

3	NUM	O	O
)	PUNCT	O	O
Adverse	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
flushing	SYM	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
15.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
gastrointestinal	ADJ	O	B-ADVERSE-EFFECTS
symptoms	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
23.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
niacin	NOUN	O	O
ER	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
more	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Niacin	NOUN	O	O
ER	NOUN	O	O
has	PUNCT	O	O
a	DET	O	O
favorable	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
modulating	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
lipid	NOUN	O	O
profile	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
reducing	PROPN	O	B-OTHER
TG	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
elevating	PUNCT	O	B-OTHER
HDL-C	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Combined	VERB	O	O
statin	NOUN	O	O
with	ADP	O	O
niacin	NOUN	O	O
may	VERB	O	O
produce	VERB	O	O
a	DET	O	O
more	ADV	O	O
global	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
effective	ADJ	O	I-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
than	CCONJ	O	O
monotherapy	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
generally	ADV	O	O
safe	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
well	PUNCT	O	B-PHYSICAL
tolerable	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

[	PUNCT	O	O
Local	ADJ	O	O
therapy	NOUN	O	O
of	ADP	O	O
grade	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
hemorrhoids	NOUN	O	O
.	PUNCT	O	O

Effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
preparation	NOUN	O	O
with	ADP	O	O
standardized	VERB	O	O
blood	NOUN	O	O
leech	ADJ	O	O
extract	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

AIMS	NOUN	O	O
Testing	PUNCT	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
topical	ADJ	O	O
combination	NOUN	O	O
preparation	NOUN	O	O
containing	DET	O	O
standardized	VERB	O	O
leech	ADJ	O	O
extract	NOUN	O	O
,	PUNCT	O	O
polidocanol	ADJ	O	O
and	CCONJ	O	O
allantoin	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Placebo-controlled	PROPN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
80	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
first	ADJ	O	O
and	CCONJ	O	O
second	ADP	O	O
degree	NOUN	O	O
hemorrhoids	NOUN	O	O
;	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
one	NUM	O	O
week	NOUN	O	O
;	PUNCT	O	O
examinations	NOUN	O	O
performed	VERB	O	O
on	ADP	O	O
admission	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
days	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Both	CCONJ	O	O
the	PUNCT	O	O
subjective	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
objective	ADJ	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
signs	NOUN	O	I-PHYSICAL
improved	PRON	O	O
during	ADP	O	O
the	DET	O	O
one	NUM	O	O
week	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
statistically	ADJ	O	O
significantly	ADV	O	O
more	ADV	O	O
rapidly	ADV	O	O
under	ADP	O	O
the	DET	O	O
test	ADV	O	O
preparation	NOUN	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Histologically	ADV	O	O
demonstrable	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
inflammation	NOUN	O	B-PHYSICAL
were	VERB	O	O
more	ADV	O	O
clearly	ADV	O	O
improved	VERB	O	O
in	ADP	O	O
the	DET	O	O
preparation	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
good	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
a	DET	O	O
topical	ADJ	O	O
therapeutic	ADJ	O	O
preparation	NOUN	O	O
in	ADP	O	O
first	PUNCT	O	O
and	CCONJ	O	O
second	ADP	O	O
degree	NOUN	O	O
hemorrhoids	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
convincingly	PUNCT	O	O
demonstrated	VERB	O	O
.	PUNCT	O	O

Green	ADJ	O	O
banana-supplemented	VERB	O	O
diet	NOUN	O	O
in	ADP	O	O
the	DET	O	O
home	NOUN	O	O
management	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
prolonged	VERB	O	B-PHYSICAL
diarrhoea	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
children	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
a	DET	O	O
community-based	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
rural	ADJ	O	O
Bangladesh	NOUN	O	O
.	PUNCT	O	O

SUMMARY	NOUN	O	O
OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
green	ADJ	O	O
banana	NOUN	O	O
in	ADP	O	O
the	DET	O	O
home	NOUN	O	O
management	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-OTHER
(	PUNCT	O	O
<	PROPN	O	O
7	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
prolonged	VERB	O	B-MORTALITY
(	PUNCT	O	O
?	PUNCT	O	O

7	DET	O	O
days	NOUN	O	O
)	PUNCT	O	O
diarrhoea	NOUN	O	O
at	ADP	O	O
the	DET	O	O
community	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
cluster	NOUN	O	O
randomized	VERB	O	O
field	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
among	ADP	O	O
2968	NUM	O	O
Bangladeshi	PUNCT	O	O
rural	ADJ	O	O
children	NOUN	O	O
6-36	ADJ	O	O
months	NOUN	O	O
old	ADJ	O	O
.	PUNCT	O	O

Wards	NOUN	O	O
(	PUNCT	O	O
villages	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
standard	ADJ	O	O
care	NOUN	O	O
group	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
standard	ADJ	O	O
care	NOUN	O	O
plus	CCONJ	O	O
green	PUNCT	O	O
banana	NOUN	O	O
group	NOUN	O	O
where	ADP	O	O
mothers	NOUN	O	O
were	VERB	O	O
instructed	VERB	O	O
to	ADP	O	O
add	PUNCT	O	O
cooked	PROPN	O	O
green	ADJ	O	O
banana	NOUN	O	O
to	ADP	O	O
the	DET	O	O
diets	NOUN	O	O
of	ADP	O	O
diarrhoeal	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

Through	ADP	O	O
a	DET	O	O
village-based	ADJ	O	O
surveillance	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
diarrhoeal	ADP	O	O
morbidity	NOUN	O	O
data	NOUN	O	O
(	PUNCT	O	O
severity	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
,	PUNCT	O	O
compliance	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
analysing	VERB	O	O
cumulative	ADJ	O	O
probability	NOUN	O	O
of	ADP	O	O
cure	NOUN	O	O
by	ADP	O	O
testing	VERB	O	O
Cox	NOUN	O	O
proportional	ADJ	O	O
hazards	NOUN	O	O
models	NOUN	O	O
and	CCONJ	O	O
relative	ADJ	O	O
risk	NOUN	O	O
(	PUNCT	O	O
RR	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
cumulative	ADJ	O	O
probability	NOUN	O	O
of	ADP	O	O
cure	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
different	ADJ	O	O
in	ADP	O	O
children	NOUN	O	O
receiving	VERB	O	O
GB	NOUN	O	O
for	ADP	O	O
both	CCONJ	O	O
acute	ADJ	O	O
[	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
=	ADP	O	O
0.63	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.56-0.67	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
and	CCONJ	O	O
prolonged	VERB	O	O
diarrhoea	NOUN	O	O
[	PUNCT	O	O
HR	NOUN	O	O
=	SYM	O	O
0.38	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.26-0.59	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
recovery	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
diarrhoea	NOUN	O	O
receiving	VERB	O	O
GB	NOUN	O	O
(	PUNCT	O	O
vs.	CCONJ	O	O
control	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
more	DET	O	O
by	ADP	O	O
day	NOUN	O	O
3	NUM	O	O
:	PUNCT	O	O
79.9	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
.	PUNCT	O	O

53.3	NUM	O	O
%	ADJ	O	O
[	PUNCT	O	O
(	PUNCT	O	O
RR	NOUN	O	O
)	PUNCT	O	O
=	SYM	O	O
0.47	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.41-0.55	NUM	O	O
]	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
day	NOUN	O	O
7	NUM	O	O
:	PUNCT	O	O
96.6	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
.	PUNCT	O	O

89.1	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
RR	NOUN	O	O
=	SYM	O	O
0.32	NUM	O	O
;	PUNCT	O	O
0.22-0.46	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Children	NOUN	O	O
with	ADP	O	O
prolonged	VERB	O	O
diarrhoea	NOUN	O	O
receiving	VERB	O	O
green	ADJ	O	O
banana	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
recovery	NOUN	O	O
rates	NOUN	O	O
by	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
:	PUNCT	O	O
79.8	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
.	PUNCT	O	O

51.9	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
RR	NOUN	O	O
=	SYM	O	O
0.42	NUM	O	O
;	PUNCT	O	O
0.23-0.73	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
day	NOUN	O	O
14	NUM	O	O
:	PUNCT	O	O
93.6	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
.	PUNCT	O	O

67.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
RR	NOUN	O	O
=	SYM	O	O
0.22	NUM	O	O
;	PUNCT	O	O
0.08-0.54	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
A	PUNCT	O	O
green	ADJ	O	O
banana-supplemented	VERB	O	O
diet	NOUN	O	O
hastened	VERB	O	O
recovery	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
and	CCONJ	O	O
prolonged	VERB	O	O
childhood	NOUN	O	O
diarrhoea	NOUN	O	O
managed	DET	O	O
at	ADP	O	O
home	NOUN	O	O
in	ADP	O	O
rural	ADJ	O	O
Bangladesh	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
glucocorticoids	NOUN	O	O
on	ADP	O	O
energy	NOUN	O	B-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
food	NOUN	O	B-MENTAL
intake	NOUN	O	I-MENTAL
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
glucocorticoid	NOUN	O	O
administration	NOUN	O	O
on	ADP	O	O
energy	NOUN	O	B-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
food	NOUN	O	B-MENTAL
intake	NOUN	O	I-MENTAL
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
20	NUM	O	O
healthy	ADJ	O	O
,	PUNCT	O	O
nondiabetic	ADJ	O	O
Caucasian	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
[	PUNCT	O	O
27	NUM	O	O
+/-	SYM	O	O
5	NUM	O	O
(	PUNCT	O	O
SD	NOUN	O	O
)	PUNCT	O	O
yr	NOUN	O	O
,	PUNCT	O	O
72	NUM	O	O
+/-	SYM	O	O
9	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
+/-	SYM	O	O
7	NUM	O	O
%	SYM	O	O
body	NOUN	O	O
fat	NOUN	O	O
]	PUNCT	O	O
randomly	ADV	O	O
and	CCONJ	O	O
blindly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
glucocorticoid	ADJ	O	O
(	PUNCT	O	O
methylprednisolone	NOUN	O	O
,	PUNCT	O	O
METH	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
PLAC	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
subject	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
twice	ADV	O	O
:	PUNCT	O	O
during	ADP	O	O
a	DET	O	O
weight	NOUN	O	O
maintenance	NOUN	O	O
diet	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
ad	PUNCT	O	O
libitum	PUNCT	O	O
food	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

Energy	NOUN	O	B-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
indirect	ADJ	O	O
calorimetry	NOUN	O	O
and	CCONJ	O	O
food	NOUN	O	B-MENTAL
intake	NOUN	O	I-MENTAL
by	ADP	O	O
an	DET	O	O
automated	VERB	O	O
food-selection	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

Twenty-four-hour	ADV	O	O
urinary	ADJ	O	B-PHYSICAL
norepinephrine	NOUN	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
24-h	NOUN	O	O
NE	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
estimate	NOUN	O	O
of	ADP	O	O
sympathetic	ADJ	O	B-PHYSICAL
nervous	ADJ	O	I-PHYSICAL
system	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

During	ADP	O	O
weight	NOUN	O	O
maintenance	NOUN	O	O
,	PUNCT	O	O
METH	NOUN	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
125	ADP	O	O
mg/30	VERB	O	O
min	NOUN	O	O
)	PUNCT	O	O
increased	ADV	O	O
energy	NOUN	O	B-PHYSICAL
expenditure	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
PLAC	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
METH	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
decreased	PUNCT	O	O
24-h	NOUN	O	B-PHYSICAL
NE	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
increased	VERB	O	O
energy	NOUN	O	B-PHYSICAL
expenditure	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
PLAC	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
ad	PUNCT	O	O
libitum	PUNCT	O	O
food	NOUN	O	O
intake	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
METH	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
PLAC	NOUN	O	O
oral	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
both	PUNCT	O	O
groups	NOUN	O	O
increased	VERB	O	O
their	PUNCT	O	O
energy	NOUN	O	B-PHYSICAL
intake	NOUN	O	I-PHYSICAL
over	ADP	O	O
weight	NOUN	O	O
maintenance	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
larger	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
METH	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
PLAC	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
4,554	NUM	O	O
+/-	SYM	O	O
1,857	NUM	O	O
vs.	CCONJ	O	O
2,867	NUM	O	O
+/-	SYM	O	O
846	NUM	O	O
kcal/day	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
glucocorticoids	NOUN	O	O
induce	VERB	O	O
obesity	NOUN	O	O
mostly	ADV	O	O
by	ADP	O	O
increasing	ADJ	O	O
energy	NOUN	O	B-PHYSICAL
intake	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
an	DET	O	O
effect	NOUN	O	O
which	DET	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
glucocorticoids	NOUN	O	O
to	PART	O	O
act	NOUN	O	O
directly	ADV	O	O
or	CCONJ	O	O
indirectly	ADV	O	O
on	ADP	O	O
the	DET	O	O
central	ADJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
appetite	NOUN	O	O
.	PUNCT	O	O

Preventing	ADV	O	O
disability	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
managing	SYM	O	B-PHYSICAL
chronic	ADJ	O	I-PHYSICAL
illness	NOUN	O	I-PHYSICAL
in	ADP	O	O
frail	NOUN	O	O
older	CCONJ	O	O
adults	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
a	DET	O	O
community-based	VERB	O	O
partnership	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Effective	ADJ	O	O
new	ADJ	O	O
strategies	NOUN	O	O
that	ADP	O	O
complement	NOUN	O	O
primary	ADJ	O	O
care	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
disability	NOUN	O	O
risks	NOUN	O	O
and	CCONJ	O	O
improve	ADJ	O	O
self-management	ADJ	O	O
of	ADP	O	O
chronic	ADJ	O	B-PHYSICAL
illness	NOUN	O	I-PHYSICAL
in	ADP	O	O
frail	NOUN	O	O
older	PUNCT	O	O
people	NOUN	O	O
living	VERB	O	O
in	ADP	O	O
the	DET	O	O
community	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
a	DET	O	O
1-year	NOUN	O	O
,	PUNCT	O	O
senior	ADJ	O	O
center-based	VERB	O	O
chronic	ADJ	O	B-PHYSICAL
illness	NOUN	O	I-PHYSICAL
self-management	ADJ	O	O
and	CCONJ	O	O
disability	NOUN	O	O
prevention	NOUN	O	O
program	NOUN	O	O
on	ADP	O	O
health	NOUN	O	O
,	PUNCT	O	O
functioning	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
healthcare	NOUN	O	B-PHYSICAL
utilization	NOUN	O	I-PHYSICAL
in	ADP	O	O
frail	NOUN	O	O
older	CCONJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
A	PUNCT	O	O
large	ADJ	O	O
senior	ADJ	O	O
center	NOUN	O	O
located	VERB	O	O
in	ADP	O	O
a	DET	O	O
northeast	NOUN	O	O
Seattle	PUNCT	O	O
suburb	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
collaboration	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
providers	ADV	O	O
of	ADP	O	O
two	NUM	O	O
large	ADJ	O	O
managed	VERB	O	O
care	NOUN	O	O
organizations	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
201	NUM	O	O
chronically	ADV	O	O
ill	ADJ	O	O
older	PUNCT	O	O
adults	DET	O	O
seniors	NOUN	O	O
aged	PROPN	O	O
70	NUM	O	O
and	CCONJ	O	O
older	PUNCT	O	O
recruited	VERB	O	O
through	ADP	O	O
medical	ADJ	O	O
practices	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
A	DET	O	O
targeted	VERB	O	O
,	PUNCT	O	O
multi-component	ADJ	O	O
disability	NOUN	O	O
prevention	NOUN	O	O
and	CCONJ	O	O
disease	NOUN	O	O
self-management	ADJ	O	O
program	NOUN	O	O
led	PRON	O	O
by	ADP	O	O
a	DET	O	O
geriatric	ADJ	O	O
nurse	ADJ	O	O
practitioner	NOUN	O	O
(	PUNCT	O	O
GNP	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
Self-reported	PUNCT	O	O
Physical	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
performance	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
health	NOUN	O	B-PHYSICAL
care	NOUN	O	I-PHYSICAL
utilization	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
health	NOUN	O	O
behaviors	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Each	PUNCT	O	O
of	ADP	O	O
101	NUM	O	O
intervention	NOUN	O	O
participants	NOUN	O	O
met	ADJ	O	O
with	ADP	O	O
the	DET	O	O
GNP	NOUN	O	O
from	ADP	O	O
1	NUM	O	O
to	ADP	O	O
8	NUM	O	O
times	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
study	ADJ	O	O
year	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
less	DET	O	O
decline	PUNCT	O	O
in	ADP	O	O
function	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
disability	NOUN	O	O
days	NOUN	O	O
and	CCONJ	O	O
lower	PUNCT	O	O
scores	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Health	NOUN	O	B-PHYSICAL
Assessment	NOUN	O	I-PHYSICAL
Questionnaire	NOUN	O	O
.	PUNCT	O	O

Other	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
function	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
SF-36	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
a	DET	O	O
battery	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
performance	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
did	CCONJ	O	O
not	ADV	O	O
change	VERB	O	O
with	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
hospitalized	VERB	O	B-OTHER
participants	NOUN	O	I-OTHER
increased	VERB	O	O
by	ADP	O	O
69	NUM	O	O
%	SYM	O	O
among	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
and	CCONJ	O	O
decreased	PUNCT	O	O
by	ADP	O	O
38	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.083	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
inpatient	NOUN	O	B-OTHER
hospital	NOUN	O	I-OTHER
days	NOUN	O	I-OTHER
during	ADP	O	O
the	DET	O	O
study	ADJ	O	O
year	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
days	NOUN	O	O
=	SYM	O	O
33	NUM	O	O
vs	CCONJ	O	O
116	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.049	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
senior	ADJ	O	B-MENTAL
center	NOUN	O	I-MENTAL
participation	NOUN	O	I-MENTAL
and	CCONJ	O	O
significant	ADJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
psychoactive	ADJ	O	B-PHYSICAL
medications	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	PUNCT	O	O
project	NOUN	O	O
provides	NOUN	O	O
evidence	NOUN	O	O
that	ADP	O	O
a	DET	O	O
community-based	VERB	O	O
collaboration	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
providers	ADV	O	O
can	VERB	O	O
improve	VERB	O	O
function	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
reduce	VERB	O	O
inpatient	NOUN	O	B-OTHER
utilization	NOUN	O	I-OTHER
in	ADP	O	O
chronically	ADV	O	O
ill	ADJ	O	O
older	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Linking	ADP	O	O
organized	VERB	O	O
medical	ADJ	O	O
care	NOUN	O	O
with	ADP	O	O
complementary	ADJ	O	O
community-based	VERB	O	O
interventions	NOUN	O	O
may	VERB	O	O
be	ADJ	O	O
a	DET	O	O
promising	ADV	O	O
direction	NOUN	O	O
for	ADP	O	O
research	NOUN	O	O
and	CCONJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
I/II	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
granulocyte-macrophage	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
in	ADP	O	O
very	ADJ	O	O
low	ADJ	O	O
birthweight	ADP	O	O
neonates	NOUN	O	O
:	PUNCT	O	O
significant	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
circulatory	ADJ	O	O
neutrophils	NOUN	O	O
,	PUNCT	O	O
monocytes	NOUN	O	O
,	PUNCT	O	O
platelets	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
neutrophils	NOUN	O	O
.	PUNCT	O	O

Neonates	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
those	PUNCT	O	O
of	ADP	O	O
very	ADJ	O	O
low	ADJ	O	O
birthweight	NOUN	O	O
(	PUNCT	O	O
VLBW	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
have	PUNCT	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
nosocomial	ADJ	O	O
infections	NOUN	O	O
secondary	ADJ	O	O
to	ADP	O	O
deficiencies	NOUN	O	O
in	ADP	O	O
development	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
previously	ADV	O	O
demonstrated	PUNCT	O	O
that	ADP	O	O
granulocyte-macrophage	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
(	PUNCT	O	O
GM-CSF	NOUN	O	O
)	PUNCT	O	O
production	NOUN	O	O
and	CCONJ	O	O
mRNA	NOUN	O	O
expression	NOUN	O	O
from	ADP	O	O
stimulated	VERB	O	O
neonatal	ADJ	O	O
mononuclear	ADJ	O	O
cells	NOUN	O	O
are	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
than	PUNCT	O	O
that	PUNCT	O	O
from	ADP	O	O
adult	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Recombinant	ADJ	O	O
murine	ADJ	O	O
GM-CSF	NOUN	O	O
administration	NOUN	O	O
to	ADP	O	O
neonatal	ADJ	O	O
rats	NOUN	O	O
has	PUNCT	O	O
resulted	VERB	O	O
in	PUNCT	O	O
neutrophilia	ADJ	O	O
,	PUNCT	O	O
increased	VERB	O	O
neutrophil	NOUN	O	O
production	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
survival	NOUN	O	O
of	ADP	O	O
pups	NOUN	O	O
during	ADP	O	O
experimental	ADJ	O	O
Staphylococcus	NOUN	O	O
aureus	NOUN	O	O
sepsis	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
biologic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
(	PUNCT	O	O
rhu	PUNCT	O	O
)	PUNCT	O	O
GM-CSF	NOUN	O	O
in	ADP	O	O
VLBW	NOUN	O	O
neonates	NOUN	O	O
.	PUNCT	O	O

Twenty	VERB	O	O
VLBW	NOUN	O	O
neonates	PUNCT	O	O
(	PUNCT	O	O
500	NUM	O	O
to	ADP	O	O
1,500	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
<	ADP	O	O
72	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
rhuGM-CSF	NOUN	O	O
at	ADP	O	O
5.0	NUM	O	O
micrograms/kg	NOUN	O	O
once	PUNCT	O	O
per	PUNCT	O	O
day	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
5.0	NUM	O	O
micrograms/kg	NOUN	O	O
twice	ADV	O	O
per	ADP	O	O
day	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
10	NUM	O	O
micrograms/kg	NOUN	O	O
once	PUNCT	O	O
per	PUNCT	O	O
day	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
given	VERB	O	O
via	ADP	O	O
2-hour	NOUN	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Complete	ADJ	O	O
blood	NOUN	O	O
counts	NOUN	O	O
,	PUNCT	O	O
differential	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
platelet	NOUN	O	O
counts	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tibial	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
aspirate	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
8	NUM	O	O
.	PUNCT	O	O

Neutrophil	NOUN	O	O
C3bi	NOUN	O	O
receptor	NOUN	O	O
expression	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
0	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

GM-CSF	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
a	DET	O	O
sandwich	NOUN	O	O
enzyme-linked	VERB	O	O
immunosorbent	ADJ	O	O
assay	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
rhuGM-CSF	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
all	DET	O	O
doses	NOUN	O	O
,	PUNCT	O	O
rhuGM-CSF	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
grade	NOUN	O	O
III	NUM	O	B-PHYSICAL
or	CCONJ	O	O
IV	NUM	O	B-PHYSICAL
toxicity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Within	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
circulating	VERB	O	B-PHYSICAL
absolute	ADJ	O	I-PHYSICAL
neutrophil	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
ANC	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
at	ADP	O	O
5.0	NUM	O	O
micrograms/kg	NOUN	O	O
twice	ADV	O	O
per	ADP	O	O
day	NOUN	O	O
and	CCONJ	O	O
10.0	NUM	O	O
micrograms/kg	NOUN	O	O
once	PUNCT	O	O
per	PUNCT	O	O
day	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
continued	VERB	O	O
for	ADP	O	O
at	ADJ	O	O
least	ADV	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
rhuGM-CSF	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
the	DET	O	O
ANC	NOUN	O	O
was	VERB	O	O
normalized	VERB	O	O
for	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
's	PUNCT	O	O
first	ADJ	O	O
ANC	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ANC	NOUN	O	B-PHYSICAL
on	ADP	O	O
days	NOUN	O	O
6	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
at	ADP	O	O
each	DET	O	O
dose	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
,	PUNCT	O	O
all	DET	O	O
tested	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
rhuGM-CSF	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absolute	ADJ	O	B-PHYSICAL
monocyte	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
AMC	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
placebo-treated	VERB	O	O
neonates	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
those	PUNCT	O	O
receiving	SYM	O	O
rhuGM-CSF	NOUN	O	O
5.0	NUM	O	O
micrograms/kg	NOUN	O	O
twice	ADV	O	O
per	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
additionally	ADV	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
day	NOUN	O	B-PHYSICAL
7	NUM	O	I-PHYSICAL
and	CCONJ	O	O
8	NUM	O	B-PHYSICAL
platelet	NOUN	O	I-PHYSICAL
count	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Tibial	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
aspirates	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bone	NOUN	O	B-PHYSICAL
marrow	NOUN	O	I-PHYSICAL
neutrophil	NOUN	O	I-PHYSICAL
storage	NOUN	O	I-PHYSICAL
pool	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BM	NOUN	O	I-PHYSICAL
NSP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
at	ADP	O	O
5.0	NUM	O	O
micrograms/kg	NOUN	O	O
twice	ADV	O	O
per	ADP	O	O
day	NOUN	O	O
and	CCONJ	O	O
10.0	NUM	O	O
micrograms/kg	NOUN	O	O
once	PUNCT	O	O
per	PUNCT	O	O
day	NOUN	O	O
.	PUNCT	O	O

Neutrophil	NOUN	O	B-PHYSICAL
C3bi	NOUN	O	I-PHYSICAL
receptor	NOUN	O	I-PHYSICAL
expression	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
rhuGM-CSF	NOUN	O	O
at	ADP	O	O
5.0	NUM	O	O
micrograms/kg	NOUN	O	O
once	PUNCT	O	O
per	PUNCT	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
elimination	NOUN	O	O
half-life	NOUN	O	O
(	PUNCT	O	O
T1/2	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
rhuGM-CSF	NOUN	O	O
was	VERB	O	O
1.4	NUM	O	O
+/-	SYM	O	O
0.8	NUM	O	O
to	ADP	O	O
3.9	NUM	O	O
+/-	SYM	O	O
2.8	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
400	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

Patterns	NOUN	O	O
of	ADP	O	O
management	NOUN	O	O
of	ADP	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
complicating	SYM	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
grafting	VERB	O	O
:	PUNCT	O	O
Results	NOUN	O	O
from	ADP	O	O
the	DET	O	O
PRoject	NOUN	O	O
of	ADP	O	O
Ex-vivo	PUNCT	O	O
Vein	NOUN	O	O
graft	NOUN	O	O
ENgineering	CCONJ	O	O
via	ADP	O	O
Transfection	NOUN	O	O
IV	NUM	O	O
(	PUNCT	O	O
PREVENT-IV	NOUN	O	O
)	PUNCT	O	O
Trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Current	ADJ	O	O
practice	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
AF	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
complicating	CCONJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
grafting	VERB	O	O
(	PUNCT	O	O
CABG	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
uncertain	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
examined	VERB	O	O
management	NOUN	O	O
of	ADP	O	O
post-CABG	NOUN	O	O
AF	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PREVENT-IV	NOUN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
we	NOUN	O	O
explored	PUNCT	O	O
patterns	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
rhythm	NOUN	O	O
versus	CCONJ	O	O
rate	NOUN	O	O
control	NOUN	O	O
and	CCONJ	O	O
anticoagulation	NOUN	O	O
for	ADP	O	O
AF	NOUN	O	B-PHYSICAL
by	ADP	O	O
geographic	ADJ	O	O
region	NOUN	O	O
and	CCONJ	O	O
type	NOUN	O	O
of	ADP	O	O
site	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
compared	PUNCT	O	O
outcomes	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
developed	VERB	O	O
post-CABG	NOUN	O	O
AF	NOUN	O	O
(	PUNCT	O	O
663	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
those	ADP	O	O
who	PROPN	O	O
did	CCONJ	O	O
not	ADV	O	O
(	PUNCT	O	O
2,131	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
AF	NOUN	O	B-PHYSICAL
was	VERB	O	O
24	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

Post-CABG	NOUN	O	B-PHYSICAL
AF	NOUN	O	I-PHYSICAL
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
rhythm	NOUN	O	O
control	NOUN	O	O
strategy	NOUN	O	O
in	ADP	O	O
81	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
warfarin	NOUN	O	O
in	ADP	O	O
23	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
there	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
variations	NOUN	O	O
across	ADP	O	O
sites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
post-CABG	NOUN	O	B-PHYSICAL
AF	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
patterns	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
rhythm	NOUN	O	O
versus	CCONJ	O	O
rate	NOUN	O	O
control	NOUN	O	O
and	CCONJ	O	O
anticoagulation	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
by	ADP	O	O
geographic	ADJ	O	O
region	NOUN	O	O
or	CCONJ	O	O
by	ADP	O	O
whether	PUNCT	O	O
or	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
enrolling	PUNCT	O	O
site	NOUN	O	O
was	VERB	O	O
an	DET	O	O
academic	ADJ	O	O
institution	NOUN	O	O
.	PUNCT	O	O

Mortality	NOUN	O	B-MORTALITY
was	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
post-CABG	NOUN	O	O
AF	NOUN	O	O
than	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
AF	NOUN	O	O
at	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
1.5	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
0.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
at	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
6.9	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
4.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.41	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
mortality	NOUN	O	B-MORTALITY
or	CCONJ	O	O
stroke	NOUN	O	B-PHYSICAL
at	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
AF	NOUN	O	O
(	PUNCT	O	O
2.4	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
1.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.08	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Although	ADP	O	O
a	DET	O	O
rhythm	NOUN	O	O
control	NOUN	O	O
strategy	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
in	ADP	O	O
most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
overall	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	O
was	VERB	O	O
low	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
significance	NOUN	O	O
of	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
is	VERB	O	O
uncertain	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
data	NOUN	O	O
from	ADP	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
substantial	ADJ	O	O
variations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
post-CABG	NOUN	O	O
AF	NOUN	O	O
across	ADP	O	O
sites	NOUN	O	O
are	VERB	O	O
likely	ADJ	O	O
because	PUNCT	O	O
of	ADP	O	O
definitive	ADJ	O	O
data	NOUN	O	O
on	ADP	O	O
the	DET	O	O
most	VERB	O	O
effective	ADJ	O	O
therapies	NOUN	O	O
,	PUNCT	O	O
highlighting	PUNCT	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
on	ADP	O	O
rate	NOUN	O	O
versus	CCONJ	O	O
rhythm	NOUN	O	O
control	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
anticoagulation	NOUN	O	O
for	ADP	O	O
AF	NOUN	O	O
in	ADP	O	O
this	PUNCT	O	O
setting	VERB	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	O
on	ADP	O	O
postoperative	ADJ	O	O
nausea	NOUN	O	O
and	CCONJ	O	O
vomiting	PUNCT	O	O
in	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Postoperative	PUNCT	O	O
nausea	NOUN	O	O
and	CCONJ	O	O
vomiting	PROPN	O	O
(	PUNCT	O	O
PONV	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
still	ADV	O	O
common	ADJ	O	O
,	PUNCT	O	O
especially	ADV	O	O
among	ADP	O	O
female	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Our	VERB	O	O
hypothesis	NOUN	O	O
is	PUNCT	O	O
that	ADP	O	O
coinduction	NOUN	O	O
with	ADP	O	O
clonidine	NOUN	O	O
reduces	NOUN	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
PONV	NOUN	O	O
in	ADP	O	O
adult	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty-eight	PUNCT	O	O
women	NOUN	O	O
premedicated	PRON	O	O
with	ADP	O	O
midazolam	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
coinduction	NOUN	O	O
with	ADP	O	O
intravenous	ADJ	O	O
clonidine	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
P	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Anesthesia	NOUN	O	O
was	VERB	O	O
standardized	VERB	O	O
(	PUNCT	O	O
laryngeal	ADJ	O	O
mask	NOUN	O	O
airway	NOUN	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	O
,	PUNCT	O	O
propofol	NOUN	O	O
,	PUNCT	O	O
sevoflurane	NOUN	O	O
,	PUNCT	O	O
nitrous	ADJ	O	O
oxide	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
oxygen	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Hemodynamic	ADJ	O	O
parameters	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
requirements	NOUN	O	O
for	ADP	O	O
propofol	NOUN	O	O
,	PUNCT	O	O
sevoflurane	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
postoperative	ADJ	O	O
need	NOUN	O	O
for	ADP	O	O
ketobemidone	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoints	NOUN	O	O
studied	VERB	O	O
were	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
PONV-free	ADJ	O	B-PHYSICAL
patients	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
patient	NOUN	O	B-MENTAL
satisfaction	NOUN	O	I-MENTAL
with	ADP	O	I-MENTAL
respect	NOUN	O	I-MENTAL
to	ADP	O	I-MENTAL
PONV	NOUN	O	I-MENTAL
.	PUNCT	O	O

RESULTS	DET	O	O
Patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
C	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
significantly	ADV	O	O
reduced	VERB	O	B-OTHER
need	NOUN	O	I-OTHER
for	ADP	O	I-OTHER
propofol	NOUN	O	I-OTHER
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
sevoflurane	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
reduced	ADJ	O	O
early	ADJ	O	B-OTHER
need	NOUN	O	I-OTHER
for	ADP	O	I-OTHER
ketobemidone	NOUN	O	I-OTHER
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
PONV-free	ADJ	O	B-PHYSICAL
patients	NOUN	O	I-PHYSICAL
in	ADP	O	O
group	NOUN	O	O
C	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
group	NOUN	O	O
P	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
and	CCONJ	O	O
11	NUM	O	O
of	ADP	O	O
30	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
needed	VERB	O	O
to	PART	O	O
treat	PUNCT	O	O
was	VERB	O	O
3.3	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.8	NUM	O	O
,	PUNCT	O	O
16.9	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intraoperative	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
postoperative	ADJ	O	B-PHYSICAL
heart	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
gemcitabine	NOUN	O	O
or	CCONJ	O	O
paclitaxel	NOUN	O	O
plus	CCONJ	O	O
carboplatin	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
paclitaxel	NOUN	O	O
consolidation	NOUN	O	O
in	ADP	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
gemcitabine	NOUN	O	O
plus	CCONJ	O	O
carboplatin	NOUN	O	O
(	PUNCT	O	O
GC	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
paclitaxel	NOUN	O	O
plus	CCONJ	O	O
carboplatin	NOUN	O	O
(	PUNCT	O	O
TC	NOUN	O	O
)	PUNCT	O	O
induction	NOUN	O	O
regimens	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
paclitaxel	NOUN	O	O
consolidation	NOUN	O	O
therapy	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
OC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
IC-IV	NOUN	O	O
OC	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
GC	NOUN	O	O
(	PUNCT	O	O
gemcitabine	NOUN	O	O
1,000	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
,	PUNCT	O	O
plus	CCONJ	O	O
carboplatin	NOUN	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
[	PUNCT	O	O
AUC	NOUN	O	O
]	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
TC	NOUN	O	O
(	PUNCT	O	O
paclitaxel	NOUN	O	O
175	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
carboplatin	NOUN	O	O
AUC	NOUN	O	O
6	NUM	O	O
,	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
up	PUNCT	O	O
to	ADV	O	O
six	NUM	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
complete	ADJ	O	B-PHYSICAL
response	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
CR	PUNCT	O	I-PHYSICAL

Nebulized	VERB	O	O
racemic	ADJ	O	O
epinephrine	NOUN	O	O
by	ADP	O	O
IPPB	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
croup	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Racemic	ADJ	O	O
epinephrine	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
advocated	VERB	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
croup	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
controlled	VERB	O	O
studies	NOUN	O	O
have	ADJ	O	O
not	ADV	O	O
proved	ADP	O	O
it	ADP	O	O
more	PUNCT	O	O
effective	ADJ	O	O
than	PUNCT	O	O
saline	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
aged	DET	O	O
4	NUM	O	O
months	NOUN	O	O
to	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
hospitalized	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
croup	NOUN	O	O
and	CCONJ	O	O
persistent	ADJ	O	O
inspiratory	ADJ	O	O
stridor	NOUN	O	O
at	ADP	O	O
rest	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
saline	ADP	O	O
or	CCONJ	O	O
racemic	ADJ	O	O
epinephrine	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
nebulized	VERB	O	O
and	CCONJ	O	O
delivered	VERB	O	O
by	ADP	O	O
intermittent	ADJ	O	O
positive	ADJ	O	O
pressure	NOUN	O	O
breathing	VERB	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
improved	ADP	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
.01	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
ten	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
minutes	NOUN	O	O
following	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
with	ADP	O	O
racemic	ADJ	O	O
epinephrine	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
at	ADP	O	O
120	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

Racemic	ADJ	O	O
epinephrine	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
saline	NOUN	O	O
at	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
30	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
.05	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
at	ADP	O	O
120	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
nebulized	VERB	O	O
racemic	ADJ	O	O
epinephrine	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
croup	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
exploratory	ADJ	O	O
study	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
paroxetine	NOUN	O	O
for	ADP	O	O
methamphetamine	NOUN	O	B-PHYSICAL
craving	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

Methamphetamine	NOUN	O	O
abuse	NOUN	O	O
and	CCONJ	O	O
dependence	NOUN	O	O
are	CCONJ	O	O
growing	ADP	O	O
problems	NOUN	O	O
nationally	ADV	O	O
and	CCONJ	O	O
worldwide	ADJ	O	O
.	PUNCT	O	O

There	PUNCT	O	O
are	VERB	O	O
currently	ADV	O	O
no	DET	O	O
effective	ADJ	O	O
pharmocologic	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Animal	NOUN	O	O
studies	NOUN	O	O
with	ADP	O	O
SSRI	NOUN	O	O
's	PUNCT	O	O
suggest	VERB	O	O
that	ADP	O	O
serotonergic	ADJ	O	O
modulation	NOUN	O	O
alters	VERB	O	O
methamphetamine	NOUN	O	O
's	PUNCT	O	O
behavioral	ADJ	O	B-MENTAL
effects	NOUN	O	I-MENTAL
.	PUNCT	O	O

This	DET	O	O
exploratory	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
trial	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
SSRI	NOUN	O	O
paroxetine	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
design	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
craving	PUNCT	O	O
and	CCONJ	O	O
use	NOUN	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	O
users	NOUN	O	O
.	PUNCT	O	O

Many	DET	O	O
subjects	NOUN	O	O
dropped	ADP	O	O
out	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
those	PUNCT	O	O
in	ADP	O	O
active	ADJ	O	O
treatment	NOUN	O	O
who	ADP	O	O
completed	PROPN	O	O
the	DET	O	O
eight	NUM	O	O
week	NOUN	O	O
trial	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
methamphetamine	NOUN	O	B-PHYSICAL
craving	PUNCT	O	I-PHYSICAL
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
treatment	NOUN	O	O
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
OCDS	NUM	O	O
modified	VERB	O	O
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
.	PUNCT	O	O

Statistical	ADJ	O	O
analyses	NOUN	O	O
were	NUM	O	O
not	ADV	O	O
performed	VERB	O	O
due	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
low	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
preliminary	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
serotonergic	ADJ	O	O
agents	NOUN	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	B-PHYSICAL
abuse	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
dependence	NOUN	O	B-PHYSICAL
within	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
effective	ADJ	O	O
behavioral	ADJ	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
Duraflo	PUNCT	O	O
II	NUM	O	O
heparin-coated	VERB	O	O
circuits	CCONJ	O	O
in	ADP	O	O
cardiac	ADJ	O	O
reoperations	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Heparin-coated	VERB	O	O
circuits	CCONJ	O	O
in	ADP	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
decrease	NOUN	O	O
the	DET	O	O
systemic	ADJ	O	O
inflammatory	ADJ	O	O
responses	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
on	ADP	O	O
low-risk	NOUN	O	O
patients	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
grafting	VERB	O	O
(	PUNCT	O	O
CABG	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
received	PART	O	O
full-dose	NOUN	O	O
systemic	ADJ	O	O
heparin	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
have	PUNCT	O	O
clearly	ADV	O	O
improved	PUNCT	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin-coated	VERB	O	O
circuits	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
cardiac	ADJ	O	O
reoperations	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Three	NUM	O	O
hundred	NUM	O	O
fifty	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
reoperation	NOUN	O	O
with	ADP	O	O
CABG	NOUN	O	O
only	ADV	O	O
(	PUNCT	O	O
58	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
valve	NOUN	O	O
operations	NOUN	O	O
(	PUNCT	O	O
42	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
a	DET	O	O
heparin-coated	VERB	O	O
(	PUNCT	O	O
Duraflo	PUNCT	O	O
II	NUM	O	O
;	PUNCT	O	O
study	PUNCT	O	O
group	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
uncoated	VERB	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
circuit	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
outcomes	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
variables	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
using	VERB	O	O
the	DET	O	O
following	PUNCT	O	O
three	DET	O	O
groups	NOUN	O	O
:	PUNCT	O	O
entire	ADJ	O	O
populations	NOUN	O	O
of	ADP	O	O
study	ADV	O	O
group	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
CABG	NOUN	O	O
reoperation	NOUN	O	O
only	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
subgroup	NOUN	O	O
who	CCONJ	O	O
had	ADP	O	O
valve	NOUN	O	O
reoperation	NOUN	O	O
or	CCONJ	O	O
combined	VERB	O	O
valve	NOUN	O	O
and	CCONJ	O	O
CABG	NOUN	O	O
reoperation	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Preoperative	ADJ	O	O
variables	NOUN	O	O
were	VERB	O	O
the	DET	O	O
same	ADP	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
demonstrated	VERB	O	O
except	ADP	O	O
that	CCONJ	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-ADVERSE-EFFECTS
with	ADP	O	I-ADVERSE-EFFECTS
major	ADJ	O	I-ADVERSE-EFFECTS
bleeding	VERB	O	I-ADVERSE-EFFECTS
episodes	NOUN	O	I-ADVERSE-EFFECTS
was	NUM	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
1.2	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
5.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.035	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
subgroup	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
valve	NOUN	O	B-PHYSICAL
reoperations	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
lower	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
transfusion	NOUN	O	I-PHYSICAL
requirements	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.013	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
the	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
CABG	NOUN	O	O
reoperations	NOUN	O	O
was	VERB	O	O
analyzed	VERB	O	O
separately	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
less	DET	O	O
reoperation	NOUN	O	B-PHYSICAL
for	ADP	O	I-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
4.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.058	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
heparin-coated	VERB	O	O
circuits	NOUN	O	O
was	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
imparted	PUNCT	O	O
protection	NOUN	O	O
from	ADP	O	O
reoperations	NOUN	O	O
for	ADP	O	O
bleeding	VERB	O	O
and	CCONJ	O	O
major	ADJ	O	O
bleeding	VERB	O	O
episodes	NOUN	O	O
.	PUNCT	O	O

Material-independent	ADJ	O	O
blood	NOUN	O	O
activation	NOUN	O	O
(	PUNCT	O	O
eg	ADP	O	O
,	PUNCT	O	O
blood-air	ADJ	O	O
interface	NOUN	O	O
and	CCONJ	O	O
cardiotomy	NOUN	O	O
suction	NOUN	O	O
)	PUNCT	O	O
blunted	ADP	O	O
the	DET	O	O
total	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
heparin-coated	VERB	O	O
surface	NOUN	O	O
.	PUNCT	O	O

Deliberate	ADP	O	O
mild	ADJ	O	O
intraoperative	ADJ	O	O
hypothermia	NOUN	O	O
for	ADP	O	O
craniotomy	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Despite	ADP	O	O
enthusiasm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
mild	ADJ	O	O
hypothermia	NOUN	O	O
during	ADP	O	O
neurosurgical	ADJ	O	O
procedures	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
therapy	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	PUNCT	O	O
evaluated	VERB	O	O
systematically	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
feasibility	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
deliberate	PUNCT	O	O
mild	ADJ	O	O
hypothermia	NOUN	O	O
and	CCONJ	O	O
rewarming	SYM	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Thirty	NUM	O	O
patients	NOUN	O	O
scheduled	VERB	O	O
for	ADP	O	O
craniotomy	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
normothermic	ADJ	O	O
or	CCONJ	O	O
mildly	ADJ	O	O
hypothermic	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

Tympanic	ADJ	O	O
membrane	NOUN	O	O
temperature	NOUN	O	O
was	VERB	O	O
monitored	VERB	O	O
at	ADP	O	O
anesthetic	ADJ	O	O
induction	NOUN	O	O
,	PUNCT	O	O
throughout	ADP	O	O
the	DET	O	O
isoflurane-fentanyl-N2O-O2	PUNCT	O	O
anesthetic	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
18	NUM	O	O
h	NOUN	O	O
postoperatively	NOUN	O	O
.	PUNCT	O	O

Normothermic	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
warmed	VERB	O	O
to	ADP	O	O
36.5-37.0	ADJ	O	O
degrees	NOUN	O	O
C	NUM	O	O
after	ADP	O	O
an	DET	O	O
initial	ADJ	O	O
temperature	NOUN	O	O
decrease	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hypothermic	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
cooled	VERB	O	O
to	ADP	O	O
35	NUM	O	O
degrees	ADJ	O	O
C.	NUM	O	O
In	ADP	O	O
the	DET	O	O
hypothermic	ADJ	O	O
group	NOUN	O	O
temperatures	NOUN	O	O
were	VERB	O	O
allowed	VERB	O	O
to	PUNCT	O	O
drift	PUNCT	O	O
to	ADP	O	O
34.5	NUM	O	O
degrees	NOUN	O	O
C	NUM	O	O
before	ADP	O	O
rewarming	ADP	O	O
was	VERB	O	O
initiated	VERB	O	O
.	PUNCT	O	O

Water	NOUN	O	O
blankets	NOUN	O	O
and	CCONJ	O	O
convective	ADJ	O	O
heating	ADJ	O	O
devices	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	ADP	O	O
cool	NOUN	O	O
and	CCONJ	O	O
rewarm	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
minimum	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
achieved	VERB	O	O
by	ADP	O	O
the	DET	O	O
hypothermic	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
34.3	NUM	O	O
+/-	SYM	O	O
0.4	NUM	O	O
degrees	ADJ	O	O
C.	NUM	O	O
Cooling	PUNCT	O	B-PHYSICAL
occurred	VERB	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
1.0	NUM	O	O
+/-	SYM	O	O
0.4	NUM	O	O
degrees	ADJ	O	O
C/h	NOUN	O	O
.	PUNCT	O	O

Rewarming	VERB	O	B-OTHER
took	PROPN	O	O
place	NOUN	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
0.7	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
degrees	ADJ	O	O
C/h	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
0.1-1.8	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hypothermic	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Hypothermia	NOUN	O	B-OTHER
did	VERB	O	O
not	ADV	O	O
delay	NUM	O	O
emergence	NOUN	O	O
from	ADP	O	O
anesthesia	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
20	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
normothermia	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.45	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
temperature	NOUN	O	O
upon	ADP	O	O
intensive	ADJ	O	B-OTHER
care	NOUN	O	I-OTHER
unit	NOUN	O	I-OTHER
admission	NOUN	O	I-OTHER
was	VERB	O	O
35.8	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
degrees	NOUN	O	O
C	NUM	O	O
for	ADP	O	O
the	DET	O	O
hypothermic	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
37.1	NUM	O	O
+/-	SYM	O	O
0.5	NUM	O	O
degrees	NOUN	O	O
C	NUM	O	O
for	ADP	O	O
the	DET	O	O
normothermic	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
hypothermic	PUNCT	O	O
patients	NOUN	O	O
had	PUNCT	O	O
more	DET	O	O
postoperative	ADJ	O	B-OTHER
shivering	ADP	O	I-OTHER
.	PUNCT	O	O

From	ADP	O	O
8	NUM	O	O
to	ADP	O	O
18	NUM	O	O
h	NOUN	O	O
postoperatively	ADV	O	O
the	DET	O	O
temperatures	NOUN	O	B-PHYSICAL
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
except	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
slightly	ADV	O	O
greater	PUNCT	O	O
temperature	NOUN	O	B-OTHER
in	ADP	O	O
the	DET	O	O
hypothermic	ADJ	O	O
patients	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
h	NOUN	O	O
(	PUNCT	O	O
37.6	NUM	O	O
+/-	SYM	O	O
0.5	NUM	O	O
vs.	CCONJ	O	O
37.3	NUM	O	O
+/-	SYM	O	O
0.4	NUM	O	O
degrees	NOUN	O	O
C	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.029	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Although	PUNCT	O	O
deliberate	ADP	O	O
mild	ADJ	O	O
hypothermia	NOUN	O	O
is	VERB	O	O
easily	ADV	O	O
achieved	VERB	O	O
intraoperatively	ADV	O	O
,	PUNCT	O	O
complete	ADJ	O	O
rewarming	ADP	O	O
may	ADP	O	O
be	VERB	O	O
difficult	ADJ	O	O
to	ADV	O	O
attain	ADP	O	O
during	ADP	O	O
craniotomy	NOUN	O	O
with	ADP	O	O
current	ADJ	O	O
methods	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
determining	VERB	O	O
whether	PUNCT	O	O
deliberate	ADP	O	O
mild	ADJ	O	O
hypothermia	NOUN	O	O
confers	VERB	O	O
cerebral	ADJ	O	O
protection	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
potential	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
the	DET	O	O
therapy	NOUN	O	O
need	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
further	ADV	O	O
characterized	VERB	O	O
.	PUNCT	O	O

Benefits	NOUN	O	B-OTHER
,	PUNCT	O	O
morbidity	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
associated	VERB	O	O
with	ADP	O	O
long-term	NOUN	O	O
administration	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
anticoagulant	NOUN	O	O
therapy	NOUN	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
peripheral	ADJ	O	O
arterial	ADJ	O	O
bypass	NOUN	O	O
procedures	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
the	DET	O	O
long-term	NOUN	O	O
administration	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
anticoagulant	NOUN	O	O
therapy	NOUN	O	O
remain	VERB	O	O
unclear	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
lower	PUNCT	O	O
extremity	NOUN	O	O
arterial	ADJ	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	O
plus	CCONJ	O	O
aspirin	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
WASA	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
aspirin	NOUN	O	O
therapy	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
ASA	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
patient	NOUN	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
,	PUNCT	O	O
morbidity	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
bypass	NOUN	O	B-PHYSICAL
patency	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
nonmasked	ADP	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
831	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
underwent	VERB	O	O
peripheral	ADJ	O	O
arterial	ADJ	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
a	DET	O	O
long-term	NOUN	O	O
treatment	NOUN	O	O
program	NOUN	O	O
of	ADP	O	O
WASA	NOUN	O	O
(	PUNCT	O	O
target	NOUN	O	O
international	ADJ	O	O
normalized	VERB	O	O
ratio	NOUN	O	O
of	ADP	O	O
1.4	NUM	O	O
to	ADP	O	O
2.8	NUM	O	O
;	PUNCT	O	O
325	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
ASA	NOUN	O	O
(	PUNCT	O	O
325	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
bypass	NUM	O	B-PHYSICAL
patency	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
and	CCONJ	O	O
morbidity	NOUN	O	B-PHYSICAL
were	VERB	O	O
the	DET	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
133	NUM	O	O
deaths	NOUN	O	B-MORTALITY
in	ADP	O	O
the	DET	O	O
WASA	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
31.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
95	NUM	O	O
deaths	NOUN	O	B-MORTALITY
in	ADP	O	O
the	DET	O	O
ASA	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
23.0	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
risk	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
1.41	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.09	NUM	O	O
to	ADP	O	O
1.84	ADJ	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.0001	VERB	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Major	ADJ	O	B-PHYSICAL
hemorrhagic	ADJ	O	I-PHYSICAL
events	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
the	DET	O	O
WASA	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
WASA	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
35	NUM	O	O
;	PUNCT	O	O
ASA	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
15	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.02	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
prosthetic	ADJ	O	O
bypass	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
patency	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
8-mm	PUNCT	O	O
bypass	NOUN	O	O
subgroup	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
patency	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
6-mm	PUNCT	O	O
bypass	NOUN	O	O
subgroup	NOUN	O	O
(	PUNCT	O	O
femoral-popliteal	ADJ	O	O
;	PUNCT	O	O
71.4	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
WASA	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
57.9	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
ASA	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.02	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
vein	NOUN	O	O
bypass	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
patency	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
unaffected	VERB	O	O
(	PUNCT	O	O
75.3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
WASA	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
74.9	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
ASA	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
long-term	NOUN	O	O
administration	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	O
therapy	NOUN	O	O
when	ADP	O	O
combined	PUNCT	O	O
with	ADP	O	O
aspirin	NOUN	O	O
therapy	NOUN	O	O
has	PUNCT	O	O
only	ADV	O	O
a	DET	O	O
few	ADJ	O	O
selected	VERB	O	O
indications	NOUN	O	O
for	ADP	O	O
improvement	NOUN	O	O
of	ADP	O	O
bypass	NOUN	O	B-OTHER
patency	NOUN	O	I-OTHER
and	CCONJ	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
morbidity	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
seven	NUM	O	O
antiarrhythmic	ADJ	O	O
drugs	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ventricular	ADJ	O	O
tachyarrhythmias	NOUN	O	O
.	PUNCT	O	O

Electrophysiologic	ADJ	O	O
Study	NOUN	O	O
versus	CCONJ	O	O
Electrocardiographic	ADJ	O	O
Monitoring	PUNCT	O	O
Investigators	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
relative	ADJ	O	O
efficacies	NOUN	O	O
of	ADP	O	O
various	ADJ	O	O
antiarrhythmic	ADJ	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	O
tachyarrhythmias	NOUN	O	O
are	VERB	O	O
not	VERB	O	O
well	VERB	O	O
known	CCONJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
imipramine	NOUN	O	O
,	PUNCT	O	O
mexiletine	NOUN	O	O
,	PUNCT	O	O
pirmenol	PUNCT	O	O
,	PUNCT	O	O
procainamide	NOUN	O	O
,	PUNCT	O	O
propafenone	NOUN	O	O
,	PUNCT	O	O
quinidine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sotalol	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ventricular	ADJ	O	O
tachyarrhythmias	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
Electrophysiologic	ADJ	O	O
Study	NOUN	O	O
versus	CCONJ	O	O
Electrocardiographic	ADJ	O	O
Monitoring	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADJ	O	O
undergo	VERB	O	O
serial	ADJ	O	O
testing	VERB	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
seven	NUM	O	O
antiarrhythmic	ADJ	O	O
drugs	NOUN	O	O
by	ADP	O	O
one	NUM	O	O
of	ADP	O	O
two	NUM	O	O
strategies	NOUN	O	O
:	PUNCT	O	O
electrophysiologic	ADJ	O	O
study	NOUN	O	O
or	CCONJ	O	O
Holter	NOUN	O	O
monitoring	VERB	O	O
together	ADV	O	O
with	ADP	O	O
exercise	NOUN	O	O
testing	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
seven	NUM	O	O
drugs	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
tested	VERB	O	O
for	ADP	O	O
efficacy	NOUN	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
eligible	ADJ	O	O
to	PART	O	O
receive	PUNCT	O	O
them	PRON	O	O
.	PUNCT	O	O

The	DET	O	O
frequencies	NOUN	O	O
of	ADP	O	O
predictions	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
effects	NOUN	O	O
during	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
drug	NOUN	O	O
titration	NOUN	O	O
were	VERB	O	O
tabulated	VERB	O	O
for	ADP	O	O
all	DET	O	O
486	NUM	O	O
randomized	VERB	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
long-term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
first	ADJ	O	O
antiarrhythmic	ADJ	O	O
drug	NOUN	O	O
that	PUNCT	O	O
was	VERB	O	O
predicted	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
testing	VERB	O	O
.	PUNCT	O	O

Recurrences	NOUN	O	O
of	ADP	O	O
arrhythmia	NOUN	O	O
,	PUNCT	O	O
deaths	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
effects	NOUN	O	O
during	ADP	O	O
long-term	NOUN	O	O
follow-up	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
the	DET	O	O
296	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	ADP	O	O
an	DET	O	O
antiarrhythmic	ADJ	O	O
drug	NOUN	O	O
was	VERB	O	O
predicted	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
the	DET	O	O
electrophysiologic-study	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
predictions	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	B-MENTAL
efficacy	NOUN	O	I-MENTAL
was	VERB	O	O
higher	PUNCT	O	B-MENTAL
with	ADP	O	O
sotalol	NOUN	O	O
(	PUNCT	O	O
35	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
other	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
percent	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	B-MENTAL
difference	NOUN	O	I-MENTAL
among	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Holter-monitoring	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
adverse	ADJ	O	B-MENTAL
drug	NOUN	O	I-MENTAL
effects	NOUN	O	I-MENTAL
was	VERB	O	O
lowest	PUNCT	O	B-MENTAL
among	ADP	O	O
those	PUNCT	O	O
receiving	ADP	O	O
sotalol	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
actuarial	ADJ	O	B-MENTAL
probability	NOUN	O	O
of	ADP	O	B-MENTAL
a	DET	O	I-MENTAL
recurrence	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
arrhythmia	NOUN	O	B-MENTAL
after	ADP	O	O
a	DET	O	O
prediction	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
efficacy	NOUN	O	O
by	ADP	O	O
either	PUNCT	O	O
strategy	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	B-OTHER
lower	PUNCT	O	B-OTHER
for	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
sotalol	NOUN	O	O
than	PUNCT	O	O
for	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
other	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
risk	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
0.43	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.29	NUM	O	O
to	ADP	O	O
0.62	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

With	ADP	O	O
sotalol	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
other	ADJ	O	O
drugs	NOUN	O	O
combined	PROPN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
lower	VERB	O	O
risks	NOUN	O	O
of	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
zonisamide	ADJ	O	O
(	PUNCT	O	O
zonegran	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
essential	ADJ	O	B-PHYSICAL
tremor	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Medical	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
essential	ADJ	O	B-PHYSICAL
tremor	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ET	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
common	ADJ	O	O
movement	NOUN	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
often	ADV	O	O
inadequate	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
randomized	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
zonisamide	PUNCT	O	O
(	PUNCT	O	O
ZNS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
antiepileptic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
treating	VERB	O	O
ET	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Twenty	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
ET	NOUN	O	B-PHYSICAL
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
ZNS	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

ZNS	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
at	ADP	O	O
a	DET	O	O
dosage	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg/day	NOUN	O	O
and	CCONJ	O	O
escalated	VERB	O	O
to	ADP	O	O
200	NUM	O	O
mg/day	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
14	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
accelerometry	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
Fahn-Tolosa-Marin	NOUN	O	B-OTHER
(	PUNCT	O	I-OTHER
FTM	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
rating	ADP	O	I-OTHER
scale	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
days	NOUN	O	O
14	NUM	O	O
and	CCONJ	O	O
28	NUM	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
the	DET	O	O
Clinical	ADJ	O	B-OTHER
Global	ADJ	O	I-OTHER
Impression	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
CGI-C	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
scale	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
28	NUM	O	O
.	PUNCT	O	O

At	ADP	O	O
endpoint	NOUN	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
assigned	VERB	O	O
to	ADP	O	O
ZNS	NOUN	O	O
were	VERB	O	O
taking	CCONJ	O	O
a	DET	O	O
mean	NOUN	O	O
dosage	NOUN	O	O
of	ADP	O	O
160	NUM	O	O
+/-	SYM	O	O
50	NUM	O	O
mg/day	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
the	DET	O	O
FTM	NOUN	O	B-OTHER
total	ADJ	O	O
score	NOUN	O	O
or	CCONJ	O	B-OTHER
its	ADJ	O	B-OTHER
subsections	NOUN	O	I-OTHER
.	PUNCT	O	O

Tremor	NOUN	O	B-PHYSICAL
amplitude	ADJ	O	B-PHYSICAL
as	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
accelerometry	NOUN	O	O
significantly	ADV	O	O
improved	VERB	O	O
in	ADP	O	O
the	DET	O	O
ZNS	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
endpoint	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
-0.50	PUNCT	O	O
+/-	SYM	O	O
0.72	NUM	O	O
vs.	CCONJ	O	O
0.30	NUM	O	O
+/-	SYM	O	O
0.79	NUM	O	O
m/s	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
CGI-C	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ZNS	NOUN	O	O
group	NOUN	O	O
felt	PUNCT	O	O
that	CCONJ	O	O
their	PUNCT	O	O
tremor	NOUN	O	B-PHYSICAL
was	VERB	O	O
unchanged	VERB	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
patients	NOUN	O	O
felt	PUNCT	O	O
that	CCONJ	O	O
their	PUNCT	O	O
tremor	NOUN	O	B-PHYSICAL
was	VERB	O	O
minimally	ADV	O	O
improved	VERB	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
taking	ADJ	O	O
ZNS	NOUN	O	O
discontinued	VERB	O	O
the	DET	O	O
study	ADP	O	O
due	PUNCT	O	O
to	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
(	PUNCT	O	O
fatigue	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
headache	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
paresthesias	ADJ	O	B-ADVERSE-EFFECTS
)	PUNCT	O	O
while	ADP	O	O
taking	ADP	O	O
100	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

ZNS	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
provide	VERB	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	B-OTHER
rating	ADJ	O	B-OTHER
scales	NOUN	O	I-OTHER
at	ADP	O	O
study	NOUN	O	O
endpoint	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
only	ADV	O	O
modestly	VERB	O	O
well	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
soft	ADJ	O	O
tissue	NOUN	O	O
sarcomas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
,	PUNCT	O	O
breast	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
trunk	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
1977	NUM	O	O
,	PUNCT	O	O
31	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
entered	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
study	NOUN	O	O
testing	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
after	ADP	O	O
aggressive	ADJ	O	O
local	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
high-grade	NOUN	O	O
sarcomas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
head	NOUN	O	O
,	PUNCT	O	O
neck	NOUN	O	O
,	PUNCT	O	O
breast	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
trunk	NOUN	O	O
(	PUNCT	O	O
excluding	CCONJ	O	O
retroperitoneal	ADJ	O	O
sarcomas	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	PUNCT	O	O
complete	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
gross	ADJ	O	O
tumor	NOUN	O	O
and	CCONJ	O	O
underwent	PROPN	O	O
postoperative	ADJ	O	O
radiotherapy	NOUN	O	O
(	PUNCT	O	O
6000-6300	NUM	O	O
rads	NOUN	O	O
over	ADP	O	O
7-8	VERB	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Seventeen	PUNCT	O	O
patients	NOUN	O	O
received	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
consisting	VERB	O	O
of	ADP	O	O
doxorubicin	NOUN	O	O
(	PUNCT	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
550	NUM	O	O
mg/m2	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cyclophosphamide	NOUN	O	O
(	PUNCT	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
5500	NUM	O	O
mg/m2	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
methotrexate	NOUN	O	O
(	PUNCT	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
1000	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three-year	PUNCT	O	O
actuarial	ADJ	O	B-MORTALITY
disease-free	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
arm	ADP	O	O
was	VERB	O	O
77	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
49	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
no-chemotherapy	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.075	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three-year	PUNCT	O	O
overall	ADJ	O	B-MORTALITY
actuarial	ADJ	O	I-MORTALITY
survivals	NOUN	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
68	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
58	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.38	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Considering	ADV	O	O
only	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
tumors	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trunk	NOUN	O	O
(	PUNCT	O	O
22	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
3-year	NOUN	O	O
actuarial	ADJ	O	O
disease-free	ADJ	O	O
survival	NOUN	O	O
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
arm	ADP	O	O
was	VERB	O	O
92	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
47	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
no-chemotherapy	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Actuarial	ADJ	O	O
3-year	NOUN	O	O
overall	ADJ	O	O
survival	NOUN	O	O
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
arm	ADP	O	O
was	VERB	O	O
82	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
61	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
no-chemotherapy	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.18	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

An	DET	O	O
additional	ADJ	O	O
26	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
in	ADP	O	O
an	DET	O	O
identical	ADJ	O	O
fashion	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
were	VERB	O	O
not	ADV	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
contraindications	NOUN	O	O
to	ADP	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
refusal	ADJ	O	O
to	PART	O	O
enter	NOUN	O	O
the	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
because	PUNCT	O	O
they	ADP	O	O
were	VERB	O	O
treated	VERB	O	O
before	ADP	O	O
1977	NUM	O	O
in	ADP	O	O
a	DET	O	O
trial	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Considering	ADJ	O	O
the	DET	O	O
entire	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
57	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
follow-up	NOUN	O	O
ranged	VERB	O	O
from	ADP	O	O
10	NUM	O	O
to	ADP	O	O
86	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
35	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Local	ADJ	O	B-OTHER
control	NOUN	O	I-OTHER
was	VERB	O	O
achieved	VERB	O	O
in	ADP	O	O
46	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
81	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
3-year	NOUN	O	O
actuarial	ADJ	O	B-MORTALITY
disease-free	ADJ	O	I-MORTALITY
and	CCONJ	O	I-MORTALITY
overall	ADJ	O	I-MORTALITY
survivals	NOUN	O	I-MORTALITY
were	VERB	O	O
67	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
77	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
tendency	NOUN	O	O
toward	ADP	O	O
improved	CCONJ	O	O
disease-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
apparent	ADJ	O	O
among	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.018	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
overall	PUNCT	O	B-MORTALITY
actuarial	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.46	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
sarcomas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trunk	NOUN	O	O
(	PUNCT	O	O
39	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
demonstrated	VERB	O	O
the	DET	O	O
greatest	PUNCT	O	O
benefit	CCONJ	O	O
from	ADP	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
disease-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
most	VERB	O	O
significant	ADJ	O	O
toxicity	NOUN	O	B-PHYSICAL
associated	VERB	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
doxorubicin-induced	PUNCT	O	B-ADVERSE-EFFECTS
cardiomyopathy	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
which	ADP	O	O
resulted	VERB	O	O
in	ADP	O	O
clinically	ADV	O	O
apparent	ADJ	O	O
congestive	ADJ	O	B-PHYSICAL
heart	NOUN	O	I-PHYSICAL
failure	NOUN	O	I-PHYSICAL
in	ADP	O	O
five	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
when	ADP	O	O
combined	PUNCT	O	O
with	ADP	O	O
aggressive	ADJ	O	O
local	ADJ	O	O
measures	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
improve	PUNCT	O	O
disease-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
,	PUNCT	O	O
but	CCONJ	O	O
additional	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
longer	PUNCT	O	O
follow-up	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
determine	NOUN	O	O
if	PUNCT	O	O
improved	VERB	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
will	ADV	O	O
result	PUNCT	O	O
.	PUNCT	O	O

Changing	PUNCT	O	O
sodium	NOUN	O	O
intake	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Minneapolis	NOUN	O	O
Children	NOUN	O	O
's	PUNCT	O	O
Blood	NOUN	O	O
Pressure	NOUN	O	O
Study	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
modifying	VERB	O	O
dietary	ADJ	O	O
sodium	NOUN	O	O
intake	NOUN	O	O
,	PUNCT	O	O
80	NUM	O	O
school	NOUN	O	O
children	NOUN	O	O
with	ADP	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
above	CCONJ	O	O
the	DET	O	O
95th	ADJ	O	O
percentile	NOUN	O	O
for	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
sex	NOUN	O	O
but	CCONJ	O	O
below	ADP	O	O
130/90	ADJ	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
at	ADP	O	O
school	NOUN	O	O
screening	PUNCT	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
a	DET	O	O
family	NOUN	O	O
intervention	NOUN	O	O
program	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Twenty	VERB	O	O
children	NOUN	O	O
aged	PROPN	O	O
6	NUM	O	O
to	ADP	O	O
9	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
their	ADP	O	O
families	NOUN	O	O
began	VERB	O	O
a	DET	O	O
program	NOUN	O	O
to	DET	O	O
modify	ADP	O	O
the	DET	O	O
family	NOUN	O	O
diet	NOUN	O	O
toward	ADP	O	O
a	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
70	NUM	O	O
mEq	NOUN	O	O
sodium	NOUN	O	O
per	ADP	O	O
person	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

Adherence	NOUN	O	B-MENTAL
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
3-day	NOUN	O	B-OTHER
food	NOUN	O	I-OTHER
records	NOUN	O	I-OTHER
and	CCONJ	O	O
urine	NOUN	O	B-OTHER
collections	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
children	NOUN	O	I-OTHER
and	CCONJ	O	O
adults	NOUN	O	B-OTHER
.	PUNCT	O	O

The	DET	O	O
sodium	NOUN	O	B-MENTAL
intakes	NOUN	O	I-MENTAL
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressures	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
1	NUM	O	O
year	NOUN	O	O
after	ADP	O	O
randomization	NOUN	O	O
.	PUNCT	O	O

Sodium	NOUN	O	B-MENTAL
intake	NOUN	O	I-MENTAL
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
active	ADJ	O	O
participants	NOUN	O	O
as	CCONJ	O	O
compared	VERB	O	O
to	PUNCT	O	O
dropouts	PUNCT	O	O
and	CCONJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
87	NUM	O	O
vs	CCONJ	O	O
130	NUM	O	O
and	CCONJ	O	O
133	ADP	O	O
mmoles/24	PUNCT	O	O
hr	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
in	ADP	O	O
height	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
weight	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Blood	NOUN	O	O
pressure	NOUN	O	O
control	NOUN	O	O
during	ADP	O	O
weight	NOUN	O	O
reduction	NOUN	O	O
in	ADP	O	O
obese	PUNCT	O	O
hypertensive	ADJ	O	O
men	NOUN	O	O
:	PUNCT	O	O
separate	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	O
and	CCONJ	O	O
energy	NOUN	O	O
restriction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
separate	ADJ	O	O
and	CCONJ	O	O
combined	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
energy	NOUN	O	O
and	CCONJ	O	O
sodium	NOUN	O	O
restriction	NOUN	O	O
on	ADP	O	O
regulation	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
30	NUM	O	O
middle	ADJ	O	O
aged	PUNCT	O	O
obese	PUNCT	O	O
men	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
attending	VERB	O	O
the	DET	O	O
outpatient	ADJ	O	O
department	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
basal	ADJ	O	O
period	NOUN	O	O
with	ADP	O	O
no	DET	O	O
dietary	ADJ	O	O
restriction	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
period	NOUN	O	O
taking	PUNCT	O	O
an	DET	O	O
energy	NOUN	O	O
reduced	VERB	O	O
diet	NOUN	O	O
(	PUNCT	O	O
5.1	NUM	O	O
MJ	NOUN	O	O
;	PUNCT	O	O
1230	NUM	O	O
kcal	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
sodium	NOUN	O	O
intake	NOUN	O	O
being	VERB	O	O
supplemented	PUNCT	O	O
and	CCONJ	O	O
hence	ADV	O	O
unchanged	PROPN	O	O
(	PUNCT	O	O
1	NUM	O	O
:	PUNCT	O	O
ErSn	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
basal	ADJ	O	O
period	NOUN	O	O
preceded	VERB	O	O
a	DET	O	O
control	NOUN	O	O
period	NOUN	O	O
with	ADP	O	O
no	DET	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
taking	ADJ	O	O
a	DET	O	O
diet	NOUN	O	O
restricted	PUNCT	O	O
in	ADP	O	O
energy	NOUN	O	O
(	PUNCT	O	O
5.1	NUM	O	O
MJ	NOUN	O	O
;	PUNCT	O	O
1220	NUM	O	O
kcal	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
sodium	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
:	PUNCT	O	O
ErSr	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
period	NOUN	O	O
1	NUM	O	O
:	PUNCT	O	O
ErSn	NOUN	O	O
there	PUNCT	O	O
were	ADP	O	O
reductions	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
urinary	ADJ	O	B-PHYSICAL
noradrenaline	NOUN	O	I-PHYSICAL
output	NOUN	O	I-PHYSICAL
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
systolic	ADJ	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Body	NOUN	O	B-PHYSICAL
weight	NOUN	O	I-PHYSICAL
decreased	PUNCT	O	O
by	ADP	O	O
4.9-11.7	NUM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	B-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
change	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
period	NOUN	O	O
2	NUM	O	O
:	PUNCT	O	O
ErSr	NOUN	O	O
urinary	ADJ	O	B-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
output	NOUN	O	I-PHYSICAL
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
81.4	NUM	O	O
(	PUNCT	O	O
SEM	NOUN	O	O
17.8	NUM	O	O
)	PUNCT	O	O
mmol	NOUN	O	O
(	PUNCT	O	O
mEq	NOUN	O	O
)	PUNCT	O	O
/24	PUNCT	O	O
h	NOUN	O	O
and	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
weight	NOUN	O	O
loss	NOUN	O	B-PHYSICAL
of	ADP	O	O
8.2	NUM	O	O
(	PUNCT	O	O
SEM	NOUN	O	O
0.7	NUM	O	O
)	PUNCT	O	O
kg	NOUN	O	O
.	PUNCT	O	O

Systolic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressures	NOUN	O	I-PHYSICAL
fell	VERB	O	O
significantly	ADV	O	O
,	PUNCT	O	O
as	PUNCT	O	O
did	PUNCT	O	O
the	DET	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
urinary	ADJ	O	B-PHYSICAL
noradrenaline	NOUN	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
in	ADP	O	O
hypertensive	ADJ	O	O
obese	DET	O	O
men	NOUN	O	O
a	DET	O	O
moderate	ADJ	O	O
weight	NOUN	O	O
reducing	PUNCT	O	O
diet	NOUN	O	O
decreases	NOUN	O	O
indices	NOUN	O	O
of	ADP	O	O
sympathetic	ADJ	O	B-PHYSICAL
nervous	ADJ	O	I-PHYSICAL
system	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Reduction	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
normotensive	ADJ	O	O
range	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
only	ADV	O	O
when	ADP	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
concomitant	ADJ	O	O
restriction	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
irrigation	NOUN	O	O
fluid	NOUN	O	O
temperature	NOUN	O	O
on	ADP	O	O
core	NOUN	O	O
body	NOUN	O	O
temperature	NOUN	O	O
during	ADP	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prostate	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
irrigation	NOUN	O	O
fluid	NOUN	O	O
temperature	NOUN	O	O
has	PUNCT	O	O
on	ADV	O	O
core	NOUN	O	O
body	NOUN	O	O
temperature	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prostate	NOUN	O	O
(	PUNCT	O	O
TURP	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Fifty-six	ADJ	O	O
male	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
71.2	NUM	O	O
+/-	SYM	O	O
8.2	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
scheduled	VERB	O	O
for	ADP	O	O
TURP	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
1	NUM	O	O
consisted	PRON	O	O
of	ADP	O	O
27	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
room	NOUN	O	O
temperature	NOUN	O	O
irrigation	NOUN	O	O
fluid	NOUN	O	O
(	PUNCT	O	O
70	NUM	O	O
degrees	NOUN	O	O
F	NOUN	O	O
)	PUNCT	O	O
throughout	ADP	O	O
TURP	NOUN	O	O
;	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
consisted	VERB	O	O
of	ADP	O	O
29	NUM	O	O
patients	NOUN	O	O
whose	DET	O	O
procedure	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
warmed	ADJ	O	O
irrigation	NOUN	O	O
fluid	NOUN	O	O
(	PUNCT	O	O
91.5	NUM	O	O
degrees	NOUN	O	O
F	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
irrigation	NOUN	O	O
fluid	NOUN	O	O
used	VERB	O	O
for	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
was	VERB	O	O
glycine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
baseline	NOUN	O	O
temperature	NOUN	O	O
,	PUNCT	O	O
final	ADJ	O	O
temperature	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
time	NOUN	O	O
in	ADP	O	O
the	DET	O	O
operating	VERB	O	O
room	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
amount	NOUN	O	O
of	ADP	O	O
irrigation	NOUN	O	O
fluid	NOUN	O	O
used	VERB	O	O
during	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
average	ADJ	O	O
time	NOUN	O	B-OTHER
spent	NUM	O	I-OTHER
in	ADP	O	I-OTHER
the	DET	O	I-OTHER
operating	VERB	O	I-OTHER
room	NOUN	O	I-OTHER
or	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
irrigation	NOUN	O	B-OTHER
fluid	NOUN	O	I-OTHER
used	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
27	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
room	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
irrigation	NOUN	O	I-PHYSICAL
fluid	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
15	NUM	O	O
(	PUNCT	O	O
55.6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
body	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
temperature	NOUN	O	B-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
21	NUM	O	O
(	PUNCT	O	O
72.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
29	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
warm	ADP	O	O
irrigation	NOUN	O	B-OTHER
fluid	NOUN	O	I-OTHER
.	PUNCT	O	O

Groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
had	PUNCT	O	O
12	NUM	O	O
(	PUNCT	O	O
44.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
27	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
(	PUNCT	O	O
27.6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
29	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
who	PROPN	O	O
demonstrated	VERB	O	O
an	DET	O	O
elevation	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
core	NOUN	O	B-PHYSICAL
body	NOUN	O	I-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
our	PUNCT	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
irrigation	NOUN	O	O
fluid	NOUN	O	O
temperature	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
factor	NOUN	O	O
responsible	ADJ	O	O
for	ADP	O	O
altering	VERB	O	O
the	DET	O	O
core	NOUN	O	O
body	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
TURP	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
case	NOUN	O	O
management	NOUN	O	O
on	ADP	O	O
the	DET	O	O
costs	NOUN	O	O
of	ADP	O	O
health	NOUN	O	B-OTHER
care	NOUN	O	I-OTHER
for	ADP	O	O
enrollees	NOUN	O	O
in	ADP	O	O
Medicare	NOUN	O	O
Plus	CCONJ	O	O
Choice	NOUN	O	O
plans	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
measure	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
case	NOUN	O	O
management	NOUN	O	O
on	ADP	O	O
an	DET	O	O
older	PUNCT	O	O
population	NOUN	O	O
's	PUNCT	O	O
costs	NOUN	O	O
of	ADP	O	O
health	NOUN	O	B-OTHER
care	NOUN	O	I-OTHER
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	PUNCT	O	O
1-year	NOUN	O	O
randomized	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Multiple	ADJ	O	O
sites	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
in	ADP	O	O
San	ADJ	O	O
Francisco	NOUN	O	O
,	PUNCT	O	O
California	PUNCT	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
Patients	NOUN	O	O
aged	PROPN	O	O
65	NUM	O	O
or	CCONJ	O	O
older	PUNCT	O	O
of	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
physicians	NOUN	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
provider	NOUN	O	O
organization	NOUN	O	O
bearing	SYM	O	O
financial	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
their	PUNCT	O	O
care	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6409	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
Screening	PUNCT	O	O
for	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
and	CCONJ	O	O
provision	NOUN	O	O
of	ADP	O	O
social	ADJ	O	O
work-based	VERB	O	O
case	NOUN	O	O
management	NOUN	O	O
.	PUNCT	O	O

OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Volume	NOUN	O	B-OTHER
and	CCONJ	O	O
cost	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
hospital	NOUN	O	I-OTHER
,	PUNCT	O	O
physician	NOUN	O	B-OTHER
,	PUNCT	O	O
case	NOUN	O	B-OTHER
management	NOUN	O	I-OTHER
,	PUNCT	O	O
and	PUNCT	O	O

Untreated	VERB	O	O
silicone	NOUN	O	O
breast	NOUN	O	O
implant	VERB	O	O
rupture	NOUN	O	O
.	PUNCT	O	O

Implant	NOUN	O	O
rupture	NOUN	O	O
is	ADP	O	O
a	DET	O	O
well-known	VERB	O	O
complication	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	O
implant	VERB	O	O
surgery	NOUN	O	O
that	ADP	O	O
can	PROPN	O	O
pass	VERB	O	O
unnoticed	PROPN	O	O
by	ADP	O	O
both	PUNCT	O	O
patient	NOUN	O	O
and	CCONJ	O	O
physician	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
date	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
has	PUNCT	O	O
addressed	ADJ	O	O
the	DET	O	O
possible	ADJ	O	O
health	NOUN	O	O
implications	NOUN	O	O
of	ADP	O	O
silicone	NUM	O	O
breast	NOUN	O	O
implant	VERB	O	O
rupture	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
whether	ADP	O	O
untreated	VERB	O	O
ruptures	VERB	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
changes	NOUN	O	O
over	PUNCT	O	O
time	NOUN	O	O
in	ADP	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	PROPN	O	O
findings	NOUN	O	O
,	PUNCT	O	O
serologic	ADJ	O	O
markers	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
self-reported	VERB	O	O
breast	NOUN	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
baseline	NOUN	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	ADJ	O	O
examination	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
1999	NUM	O	O
on	ADP	O	O
271	NUM	O	O
women	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
randomly	ADV	O	O
chosen	ADP	O	O
from	ADP	O	O
a	DET	O	O
larger	PUNCT	O	O
cohort	PUNCT	O	O
of	ADP	O	O
women	NOUN	O	O
having	VERB	O	O
cosmetic	ADJ	O	O
breast	NOUN	O	O
implants	NOUN	O	O
for	ADP	O	O
a	DET	O	O
median	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
to	ADP	O	O
25	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
follow-up	NOUN	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	ADJ	O	O
examination	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
in	ADP	O	O
2001	NUM	O	O
,	PUNCT	O	O
excluding	VERB	O	O
women	NOUN	O	O
who	ADP	O	O
underwent	PROPN	O	O
explantation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
period	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	ADJ	O	O
examinations	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
44	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
examinations	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
identified	ADJ	O	O
64	ADP	O	O
women	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
one	NUM	O	O
ruptured	ADJ	O	O
implant	NOUN	O	O
at	ADP	O	O
the	DET	O	O
first	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	PUNCT	O	O
examination	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
for	ADP	O	O
comparison	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
women	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
intact	ADJ	O	O
implants	NOUN	O	O
at	ADP	O	O
both	PUNCT	O	O
examinations	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
98	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Magnetic	ADJ	O	O
resonance	NOUN	O	O
images	NOUN	O	O
from	ADP	O	O
the	DET	O	O
two	NUM	O	O
examinations	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
rupture	NOUN	O	O
configuration	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Comparisons	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
made	VERB	O	O
for	ADP	O	O
self-reported	VERB	O	O
breast	NOUN	O	O
symptoms	NOUN	O	O
occurring	ADJ	O	O
during	ADP	O	O
the	DET	O	O
study	ADV	O	O
period	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
values	NOUN	O	O
of	ADP	O	O
antinuclear	ADP	O	O
antibodies	NOUN	O	O
,	PUNCT	O	O
rheumatoid	ADJ	O	O
factor	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cardiolipin	NOUN	O	O
antibodies	NOUN	O	O
immunoglobulin	NOUN	O	O
G	NOUN	O	O
and	CCONJ	O	O
immunoglobulin	NOUN	O	O
M.	NOUN	O	O
The	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
the	DET	O	O
women	NOUN	O	O
with	ADP	O	O
implant	NOUN	O	O
rupture	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
visible	PUNCT	O	O
magnetic	ADJ	O	B-PHYSICAL
resonance	NOUN	O	I-PHYSICAL
imaging	ADP	O	I-PHYSICAL
changes	NOUN	O	I-PHYSICAL
of	ADP	O	O
their	ADP	O	O
ruptured	ADJ	O	O
implants	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
11	NUM	O	O
implants	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
10	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
observed	VERB	O	O
progression	NOUN	O	O
of	ADP	O	O
silicone	PUNCT	O	B-PHYSICAL
seepage	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
either	PUNCT	O	O
as	VERB	O	O
a	DET	O	O
conversion	NOUN	O	O
from	ADP	O	O
intracapsular	ADJ	O	O
into	ADP	O	O
extracapsular	ADP	O	O
rupture	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	PUNCT	O	O
progression	NOUN	O	O
of	ADP	O	O
extra-capsular	ADJ	O	O
silicone	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
as	VERB	O	O
increasing	ADJ	O	O
herniation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
silicone	NUM	O	O
within	ADP	O	O
the	DET	O	O
fibrous	ADJ	O	O
capsule	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
most	DET	O	O
cases	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
changes	NOUN	O	O
were	VERB	O	O
minor	ADJ	O	O
.	PUNCT	O	O

Some	DET	O	O
changes	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
ascribed	VERB	O	O
to	ADP	O	O
trauma	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
others	NOUN	O	O
seemed	VERB	O	O
spontaneous	ADJ	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
autoantibodies	NOUN	O	I-PHYSICAL
during	ADP	O	O
the	DET	O	O
study	ADV	O	O
period	NOUN	O	O
in	ADP	O	O
either	PUNCT	O	O
study	ADV	O	O
group	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
with	ADP	O	O
untreated	VERB	O	O
implant	NOUN	O	O
ruptures	NOUN	O	O
reported	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
nonspecific	ADJ	O	B-PHYSICAL
breast	NOUN	O	I-PHYSICAL
changes	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
2.1	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.2	NUM	O	O
to	ADP	O	O
3.8	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
women	NOUN	O	O
without	ADP	O	O
ruptures	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
this	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
untreated	VERB	O	O
silicone	NOUN	O	O
breast	NOUN	O	O
implant	VERB	O	O
rupture	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
conclude	VERB	O	O
that	ADP	O	O
implant	VERB	O	O
rupture	NOUN	O	O
is	ADP	O	O
a	DET	O	O
relatively	ADV	O	O
harmless	PUNCT	O	O
condition	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
only	ADV	O	O
rarely	ADV	O	O
progresses	PUNCT	O	O
and	CCONJ	O	O
gives	NOUN	O	O
rise	NOUN	O	O
to	ADP	O	O
notable	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Even	ADV	O	O
so	ADP	O	O
,	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
small	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
silicone	NUM	O	O
spread	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
implant	VERB	O	O
ruptures	NOUN	O	O
be	PUNCT	O	O
followed	ADV	O	O
clinically	ADV	O	O
,	PUNCT	O	O
if	CCONJ	O	O
not	ADV	O	O
operated	VERB	O	O
on	ADP	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
implant	ADP	O	O
ruptures	NOUN	O	O
often	ADV	O	O
occur	VERB	O	O
asymptomatically	ADV	O	O
,	PUNCT	O	O
any	DET	O	O
woman	NOUN	O	O
with	ADP	O	O
silicone	PUNCT	O	O
implants	NOUN	O	O
,	PUNCT	O	O
regardless	VERB	O	O
of	ADP	O	O
rupture	NOUN	O	O
status	NOUN	O	O
,	PUNCT	O	O
should	ADP	O	O
be	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
regular	ADJ	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
atropine	NOUN	O	O
and	CCONJ	O	O
scopolamine	NOUN	O	O
on	ADP	O	O
bradycardia	NUM	O	B-PHYSICAL
and	CCONJ	O	O
emetic	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
in	ADP	O	O
otoplasty	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
unilateral	ADJ	O	O
or	CCONJ	O	O
bilateral	ADJ	O	O
otoplasty	NOUN	O	O
on	ADP	O	O
bradycardia	NUM	O	B-PHYSICAL
and	CCONJ	O	O
postoperative	ADJ	O	B-PHYSICAL
nausea	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
vomiting	PROPN	O	I-PHYSICAL
(	PUNCT	O	O
PONV	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
efficiency	NOUN	O	O
of	ADP	O	O
transdermal	ADJ	O	O
scopolamine	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prophylaxis	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
PONV	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Post	PUNCT	O	O
hoc	CCONJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
data	NOUN	O	O
from	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Fifty	ADJ	O	O
otoplasty	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
;	PUNCT	O	O
half	NOUN	O	O
of	ADP	O	O
them	PRON	O	O
received	VERB	O	O
randomly	ADV	O	O
and	CCONJ	O	O
in	ADP	O	O
double-blind	ADJ	O	O
fashion	NOUN	O	O
a	DET	O	O
transdermal	ADJ	O	O
therapeutic	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
patch	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
scopolamine	NOUN	O	O
(	PUNCT	O	O
TTS-scopolamine	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
prophylaxis	NOUN	O	O
against	ADP	O	O
PONV	NOUN	O	O
before	PUNCT	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
received	ADP	O	O
atropine	PUNCT	O	O
10	NUM	O	O
microg	NOUN	O	O
x	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
intravenously	ADV	O	O
during	ADP	O	O
induction	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
scopolamine-treated	VERB	O	O
patients	NOUN	O	O
suffered	ADJ	O	O
more	ADV	O	O
from	ADP	O	O
moderate	ADJ	O	B-PHYSICAL
peroperative	ADJ	O	I-PHYSICAL
bradycardia	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
8/25	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
atropine-treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
1/25	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
wearing	VERB	O	O
a	DET	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
TTS-scopolamine	NOUN	O	O
patch	NOUN	O	O
needed	PUNCT	O	O
intravenous	ADJ	O	B-PHYSICAL
atropine	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

After	ADP	O	O
unilateral	ADJ	O	O
otoplasty	NOUN	O	O
,	PUNCT	O	O
none	NUM	O	O
of	ADP	O	O
the	DET	O	O
TTS-scopolamine-treated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
atropine-treated	VERB	O	O
patients	NOUN	O	O
suffered	VERB	O	O
from	ADP	O	O
PONV	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

After	ADP	O	O
bilateral	ADJ	O	O
operation	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
respective	ADJ	O	O
incidences	NOUN	O	O
were	VERB	O	O
39	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
81	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
unilateral	ADJ	O	O
otoplasty	NOUN	O	O
no	DET	O	O
patient	NOUN	O	O
needed	PROPN	O	O
droperidol	ADV	O	B-OTHER
,	PUNCT	O	O
but	CCONJ	O	O
after	ADP	O	O
bilateral	ADJ	O	O
otoplasty	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
of	ADP	O	O
19	NUM	O	O
of	ADP	O	O
the	DET	O	O
atropine-treated	VERB	O	O
and	CCONJ	O	O
4	NUM	O	O
of	ADP	O	O
18	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
scopolamine-treated	VERB	O	O
patients	NOUN	O	O
needed	PROPN	O	O
droperidol	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
numbers	NOUN	O	O
of	ADP	O	B-OTHER
doses	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
droperidol	ADV	O	B-OTHER
were	VERB	O	O
0.8+/-0.9	PUNCT	O	O
and	CCONJ	O	O
0.3+/-0.6	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Two	NUM	O	O
additional	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
wearing	CCONJ	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
TTS-scopolamine	NOUN	O	O
patch	NOUN	O	O
,	PUNCT	O	O
suffered	VERB	O	O
from	ADP	O	O
mild	ADJ	O	B-ADVERSE-EFFECTS
central	ADJ	O	B-ADVERSE-EFFECTS
anticholinergic	ADJ	O	I-ADVERSE-EFFECTS
syndrome	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
TTS-scopolamine	NOUN	O	O
offers	ADP	O	O
effective	ADJ	O	O
prophylaxis	NOUN	O	B-OTHER
against	ADP	O	O
PONV	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
auriculoemetic	PUNCT	O	I-PHYSICAL

Randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	O
II-receptor	NOUN	O	O
blocker	NOUN	O	O
vs.	CCONJ	O	O
dihydropiridine	NOUN	O	O
calcium	NOUN	O	O
channel	NOUN	O	O
blocker	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
paroxysmal	ADJ	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
(	PUNCT	O	O
J-RHYTHM	NOUN	O	O
II	NUM	O	O
study	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

AIMS	ADP	O	O
Atrial	ADJ	O	O
fibrillation	NOUN	O	O
(	PUNCT	O	O
AF	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
arrhythmia	NOUN	O	O
frequently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	ADJ	O	O
test	NOUN	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
lowering	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
by	ADP	O	O
angiotensin	NOUN	O	O
II-receptor	NOUN	O	O
blockers	NOUN	O	O
(	PUNCT	O	O
ARB	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
more	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
than	PUNCT	O	O
by	ADP	O	O
conventional	ADJ	O	O
calcium	NOUN	O	O
channel	NOUN	O	O
blockers	NOUN	O	O
(	PUNCT	O	O
CCB	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
paroxysmal	ADJ	O	O
AF	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	PUNCT	O	O
The	DET	O	O
Japanese	ADJ	O	O
Rhythm	NOUN	O	O
Management	NOUN	O	O
Trial	NOUN	O	O
II	NUM	O	O
for	ADP	O	O
Atrial	ADJ	O	O
Fibrillation	NOUN	O	O
(	PUNCT	O	O
J-RHYTHM	NOUN	O	O
II	NUM	O	O
study	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
open-label	NOUN	O	O
randomized	VERB	O	O
comparison	NOUN	O	O
between	ADP	O	O
an	DET	O	O
ARB	NOUN	O	O
(	PUNCT	O	O
candesartan	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
CCB	NOUN	O	O
(	PUNCT	O	O
amlodipine	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
paroxysmal	ADJ	O	O
AF	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
daily	ADJ	O	O
transtelephonic	ADJ	O	O
monitoring	VERB	O	O
,	PUNCT	O	O
we	NOUN	O	O
examined	DET	O	O
asymptomatic	ADJ	O	O
and	CCONJ	O	O
symptomatic	ADJ	O	O
paroxysmal	ADJ	O	B-PHYSICAL
AF	NOUN	O	I-PHYSICAL
episodes	NOUN	O	O
during	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
1	NUM	O	O
year	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
the	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
AF	NOUN	O	B-OTHER
frequency	NOUN	O	I-OTHER
between	ADP	O	O
the	DET	O	O
pre-treatment	NOUN	O	O
period	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
final	ADJ	O	O
month	NOUN	O	O
of	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
secondary	ADJ	O	O
endpoints	NOUN	O	O
included	VERB	O	O
cardiovascular	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
development	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	B-PHYSICAL
AF	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
left	PUNCT	O	B-PHYSICAL
atrial	ADJ	O	I-PHYSICAL
dimension	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
quality-of-life	NOUN	O	B-MENTAL
(	PUNCT	O	I-MENTAL
QOL	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
enrolled	VERB	O	O
318	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
66	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
male/female	NOUN	O	O
219/99	NOUN	O	O
,	PUNCT	O	O
158	NUM	O	O
in	ADP	O	O
the	DET	O	O
ARB	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
160	NUM	O	O
in	ADP	O	O
the	DET	O	O
CCB	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
treated	VERB	O	O
at	ADP	O	O
48	NUM	O	O
sites	NOUN	O	O
throughout	PUNCT	O	O
Japan	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
AF	NOUN	O	B-PHYSICAL
episodes	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
days/month	CCONJ	O	O
)	PUNCT	O	O
was	VERB	O	O
3.8	ADJ	O	O
?	PUNCT	O	O

5.0	NUM	O	O
in	ADP	O	O
the	DET	O	O
ARB	NOUN	O	O
group	NOUN	O	O
vs.	CCONJ	O	O
4.8	NUM	O	O
?	PUNCT	O	O

6.3	NUM	O	O
in	ADP	O	O
the	DET	O	O
CCB	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
not	ADV	O	O
significant	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
CCB	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ARB	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
AF	NOUN	O	O
frequency	NOUN	O	O
decreased	VERB	O	O
similarly	ADV	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
AF	NOUN	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
left	PUNCT	O	O
atrial	ADJ	O	O
dimension	NOUN	O	O
,	PUNCT	O	O
occurrence	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
QOL	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
paroxysmal	ADJ	O	O
AF	NOUN	O	O
and	CCONJ	O	O
hypertension	NOUN	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	O
by	ADP	O	O
candesartan	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
have	PUNCT	O	O
an	DET	O	O
advantage	NOUN	O	O
over	ADP	O	O
amlodipine	NOUN	O	O
in	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
paroxysmal	ADJ	O	O
AF	NOUN	O	O
(	PUNCT	O	O
umin	NOUN	O	O
CTR	NOUN	O	O
C000000427	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
benefit	NOUN	O	O
of	ADP	O	O
low-dose	NOUN	O	O
dopamine	NOUN	O	O
during	ADP	O	O
vigorous	ADJ	O	O
diuresis	NOUN	O	O
for	ADP	O	O
congestive	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
renal	ADJ	O	O
insufficiency	NOUN	O	O
:	PUNCT	O	O
does	PUNCT	O	O
it	ADJ	O	O
protect	VERB	O	O
renal	ADJ	O	O
function	NOUN	O	O
?	PUNCT	O	O

BACKGROUND	NOUN	O	O
Low-dose	NOUN	O	O
dopamine	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
renal	ADJ	O	O
vasodilator	NOUN	O	O
,	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
used	VERB	O	O
empirically	ADV	O	O
to	PART	O	O
improve	PUNCT	O	O
renal	ADJ	O	O
function	NOUN	O	O
or	CCONJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
oliguria	NOUN	O	O
or	CCONJ	O	O
acute	ADJ	O	O
renal	ADJ	O	O
failure	NOUN	O	O
.	PUNCT	O	O

HYPOTHESIS	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
low-dose	NOUN	O	O
dopamine	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
micrograms/kg/min	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
renal-protective	ADJ	O	O
agent	NOUN	O	O
during	ADP	O	O
vigorous	ADJ	O	O
diuresis	NOUN	O	O
for	ADP	O	O
congestive	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
CHF	NOUN	O	O
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
mild	ADJ	O	O
or	CCONJ	O	O
moderate	ADJ	O	O
renal	ADJ	O	O
insufficiency	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Of	ADP	O	O
20	NUM	O	O
study	ADV	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
74.3	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
severe	ADJ	O	O
CHF	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
(	PUNCT	O	O
Group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
strategy	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
bumetanide	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
mg	NOUN	O	O
b.i.d	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O

alone	ADJ	O	O
and	CCONJ	O	O
another	DET	O	O
10	ADP	O	O
(	PUNCT	O	O
Group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
low-dose	NOUN	O	O
dopamine	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
similar	ADJ	O	O
diuretic	NOUN	O	O
regimen	NOUN	O	O
for	ADP	O	O
a	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
or	CCONJ	O	O
less	DET	O	O
if	CCONJ	O	O
clinical	ADJ	O	O
edema	NOUN	O	O
remitted	VERB	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Group	NOUN	O	O
B	NOUN	O	O
patients	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
output	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
urea	NOUN	O	I-PHYSICAL
nitrogen	NOUN	O	B-PHYSICAL
48.9	NUM	O	O
+/-	SYM	O	O
10.3	NUM	O	O
to	ADP	O	O
32.1	NUM	O	O
+/-	SYM	O	O
14.4	NUM	O	O
mg/dl	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
serum	NOUN	O	B-PHYSICAL
creatinine	NOUN	O	I-PHYSICAL
1.97	NUM	O	O
+/-	SYM	O	O
0.24	NUM	O	O
to	ADP	O	O
1.49	NUM	O	O
+/-	SYM	O	O
0.39	NUM	O	O
mg/dl	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
creatinine	NOUN	O	B-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
35.6	NUM	O	O
+/-	SYM	O	O
11.6	NUM	O	O
to	ADP	O	O
48.8	ADV	O	O
+/-	SYM	O	O
12.3	NUM	O	O
ml/min	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
indexed	VERB	O	B-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
output	NOUN	O	I-PHYSICAL
0.56	NUM	O	O
+/-	SYM	O	O
0.16	NUM	O	O
to	ADP	O	O
2.02	NUM	O	O
+/-	SYM	O	O
0.72	NUM	O	O
ml/kg/h	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Group	NOUN	O	O
A	DET	O	O
patients	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	PUNCT	O	O

Short-	PUNCT	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
results	CCONJ	O	O
after	ADP	O	O
thrombolytic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
deep	ADJ	O	O
venous	ADJ	O	O
thrombosis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
assess	NOUN	O	O
the	DET	O	O
short-	ADJ	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
efficacy	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
thrombolytic	ADJ	O	O
therapy	NOUN	O	O
regimens	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
leg	NOUN	O	O
or	CCONJ	O	O
pelvic	ADJ	O	O
deep	ADJ	O	O
venous	ADJ	O	O
thrombosis	NOUN	O	O
(	PUNCT	O	O
DVT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
It	PRON	O	O
is	VERB	O	O
unclear	ADJ	O	O
whether	ADP	O	O
locoregional	ADJ	O	O
or	CCONJ	O	O
systemic	ADJ	O	O
thrombolysis	NOUN	O	O
is	VERB	O	O
superior	ADJ	O	O
in	ADP	O	O
treating	VERB	O	O
acute	ADJ	O	O
leg	NOUN	O	O
DVT	NOUN	O	O
or	CCONJ	O	O
even	ADV	O	O
whether	ADP	O	O
lysis	NOUN	O	O
is	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
anticoagulation	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
postthrombotic	ADJ	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
250	NUM	O	O
patients	NOUN	O	O
averaging	CCONJ	O	O
40	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
DVT	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
five	NUM	O	O
groups	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
full	ADJ	O	O
heparinization	NOUN	O	O
(	PUNCT	O	O
1,000	NUM	O	O
IU/h	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
compression	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
also	ADV	O	O
administered	VERB	O	O
locoregional	ADJ	O	O
tissue	NOUN	O	O
plasminogen	NOUN	O	O
activator	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
urokinase	NOUN	O	O
(	PUNCT	O	O
100,000	NUM	O	O
IU/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
systemic	ADJ	O	O
streptokinase	NOUN	O	O
(	PUNCT	O	O
3,000,000	NUM	O	O
IU	NOUN	O	O
daily	ADJ	O	O
)	PUNCT	O	O
or	CCONJ	O	O
urokinase	NOUN	O	O
(	PUNCT	O	O
5,000,000	ADP	O	O
IU	NOUN	O	O
daily	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
groups	NOUN	O	O
then	ADV	O	O
received	PUNCT	O	O
anticoagulation	NOUN	O	O
and	CCONJ	O	O
compression	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
efficacy	NOUN	O	O
criteria	NOUN	O	O
included	VERB	O	O
the	DET	O	O
change	NOUN	O	O
after	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
closed	VERB	O	B-PHYSICAL
vein	NOUN	O	I-PHYSICAL
segments	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
postthrombotic	ADJ	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Systemic	ADJ	O	O
thrombolytic	ADJ	O	O
therapy	NOUN	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
closed	VERB	O	B-PHYSICAL
vein	NOUN	O	I-PHYSICAL
segments	NOUN	O	I-PHYSICAL
after	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
DVT	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
conventional	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postthrombotic	ADJ	O	B-PHYSICAL
syndrome	NOUN	O	I-PHYSICAL
also	ADV	O	O
occurred	VERB	O	O
with	ADP	O	O
less	DET	O	O
frequency	NOUN	O	O
in	ADP	O	O
systemically	ADV	O	O
treated	DET	O	O
patients	NOUN	O	O
versus	CCONJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

High-dose	NOUN	O	O
thrombolysis	NOUN	O	O
led	VERB	O	O
to	PUNCT	O	O
better	PUNCT	O	O
rates	NOUN	O	O
of	ADP	O	O
complete	ADJ	O	B-PHYSICAL
recanalization	NOUN	O	I-PHYSICAL
after	ADP	O	O
seven	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
locoregional	ADJ	O	O
lysis	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
12	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
thrombolysis	NOUN	O	O
(	PUNCT	O	O
9	NUM	O	O
systemic	ADJ	O	O
,	PUNCT	O	O
3	NUM	O	O
local	ADJ	O	O
)	PUNCT	O	O
suffered	ADP	O	O
major	ADJ	O	B-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
complications	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
9	NUM	O	O
patients	NOUN	O	O
on	ADP	O	O
systemic	ADJ	O	O
treatment	NOUN	O	O
developed	VERB	O	O
pulmonary	ADJ	O	B-ADVERSE-EFFECTS
emboli	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Systemic	ADJ	O	O
thrombolytic	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
DVT	NOUN	O	O
achieved	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
better	PUNCT	O	O
short-	ADJ	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
than	PUNCT	O	O
conventional	ADJ	O	O
heparin/anticoagulation	NOUN	O	O
therapy	NOUN	O	O
but	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
expense	NOUN	O	O
of	ADP	O	O
a	DET	O	O
serious	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
major	ADJ	O	O
bleeding	VERB	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	O
emboli	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
inherent	ADJ	O	O
risks	NOUN	O	O
for	ADP	O	O
such	CCONJ	O	O
serious	ADJ	O	O
complications	NOUN	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
thrombolysis	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
effective	ADJ	O	O
,	PUNCT	O	O
should	ADP	O	O
be	VERB	O	O
used	VERB	O	O
selectively	ADV	O	O
in	ADP	O	O
limb-threatening	ADJ	O	O
thrombotic	ADJ	O	O
situations	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
recovery	NOUN	O	B-OTHER
times	NOUN	O	I-OTHER
of	ADP	O	O
desflurane	NOUN	O	O
and	CCONJ	O	O
isoflurane	ADJ	O	O
in	ADP	O	O
outpatient	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
low	ADJ	O	O
solubility	NOUN	O	O
of	ADP	O	O
desflurane	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
contribute	NOUN	O	O
to	ADP	O	O
faster	PUNCT	O	O
awakening	PUNCT	O	O
from	ADP	O	O
anesthesia	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
anesthetics	NOUN	O	O
in	ADP	O	O
common	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
research	NOUN	O	O
has	PUNCT	O	O
failed	VERB	O	O
to	PUNCT	O	O
consistently	ADV	O	O
demonstrate	ADJ	O	O
faster	PUNCT	O	O
discharge	NOUN	O	O
times	NOUN	O	O
from	ADP	O	O
the	DET	O	O
postanesthesia	NOUN	O	O
care	NOUN	O	O
unit	NOUN	O	O
following	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
desflurane	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
recovery	NOUN	O	B-OTHER
and	CCONJ	O	I-OTHER
discharge	NOUN	O	I-OTHER
times	NOUN	O	I-OTHER
of	ADP	O	O
outpatients	ADJ	O	O
undergoing	PUNCT	O	O
procedures	NOUN	O	O
greater	PUNCT	O	O
than	CCONJ	O	O
2	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
length	NOUN	O	O
.	PUNCT	O	O

Thirty-three	NUM	O	O
patients	NOUN	O	O
aged	PROPN	O	O
18	NUM	O	O
to	ADP	O	O
70	NUM	O	O
years	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
desflurane	NOUN	O	O
or	CCONJ	O	O
isoflurane	NOUN	O	O
following	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
intravenous	ADJ	O	O
induction	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
premedication	NOUN	O	O
and	CCONJ	O	O
opioids	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
institutional	ADJ	O	O
practice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
inhalation	NOUN	O	O
agents	NOUN	O	O
were	VERB	O	O
titrated	VERB	O	O
to	PUNCT	O	O
effect	PUNCT	O	O
during	ADP	O	O
anesthetic	ADJ	O	O
maintenance	NOUN	O	O
.	PUNCT	O	O

Following	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
emergence	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
time	NOUN	O	I-OTHER
to	ADP	O	I-OTHER
meeting	PUNCT	O	I-OTHER
discharge	NOUN	O	I-OTHER
criteria	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
demonstrated	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
emergence	NOUN	O	O
or	CCONJ	O	O
discharge	NOUN	O	O
times	NOUN	O	O
following	VERB	O	O
desflurane	NOUN	O	O
or	CCONJ	O	O
isoflurane	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
measured	PUNCT	O	O
parameters	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
intraoperative	ADJ	O	B-PHYSICAL
vital	ADJ	O	I-PHYSICAL
signs	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
postoperative	ADJ	O	I-PHYSICAL
emesis	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
opioid	NOUN	O	I-PHYSICAL
requirements	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
were	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
desflurane	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
balanced	ADP	O	O
anesthetic	ADJ	O	O
technique	NOUN	O	O
did	PUNCT	O	O
not	PUNCT	O	O
speed	CCONJ	O	O
the	DET	O	O
emergence	NOUN	O	O
or	CCONJ	O	O
discharge	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
isoflurane	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
and	CCONJ	O	O
subchronic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
levocetirizine	ADJ	O	O
and	CCONJ	O	O
diphenhydramine	NOUN	O	O
on	ADP	O	O
memory	NOUN	O	O
functioning	PROPN	O	O
,	PUNCT	O	O
psychomotor	NOUN	O	O
performance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mood	NUM	O	B-MENTAL
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
sedation	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
often	ADV	O	O
accompany	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
first-generation	NOUN	O	O
antihistamines	ADP	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
might	VERB	O	O
interfere	VERB	O	O
with	ADP	O	O
memory	NOUN	O	O
functioning	PROPN	O	O
and	CCONJ	O	O
psychomotor	NOUN	O	O
performance	NOUN	O	O
.	PUNCT	O	O

Levocetirizine	NOUN	O	O
was	VERB	O	O
recently	ADV	O	O
introduced	VERB	O	O
as	ADP	O	O
a	DET	O	O
new	ADJ	O	O
antihistamine	NOUN	O	O
said	PUNCT	O	O
to	ADP	O	O
be	PUNCT	O	O
free	ADJ	O	O
from	ADP	O	O
sedative	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
We	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
levocetirizine	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
diphenhydramine	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
on	ADP	O	O
memory	NOUN	O	B-MENTAL
and	CCONJ	O	O
psychomotor	NOUN	O	B-MENTAL
performance	NOUN	O	I-MENTAL
after	ADP	O	O
acute	ADJ	O	O
(	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
subchronic	ADJ	O	O
(	PUNCT	O	O
day	NOUN	O	O
4	NUM	O	O
)	PUNCT	O	O
daily	ADJ	O	O
administration	NOUN	O	O
in	ADP	O	O
48	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
(	PUNCT	O	O
24	PUNCT	O	O
men	NOUN	O	O
and	CCONJ	O	O
24	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Treatments	NOUN	O	O
were	VERB	O	O
administrated	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
hours	NOUN	O	O
before	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
the	DET	O	O
laboratory	NOUN	O	O
test	ADV	O	O
battery	NOUN	O	O
(	PUNCT	O	O
performed	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
comprising	CCONJ	O	O
a	DET	O	O
word-learning	ADP	O	O
test	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Sternberg	NOUN	O	O
Memory	NOUN	O	O
Scanning	PUNCT	O	O
Test	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
tracking	PUNCT	O	O
test	NOUN	O	O
(	PUNCT	O	O
easy	ADP	O	O
and	CCONJ	O	O
hard	ADJ	O	O
version	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
divided	VERB	O	O
attention	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
tracking	PUNCT	O	O
and	CCONJ	O	O
memory	NOUN	O	O
scanning	VERB	O	O
simultaneously	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Statistical	ADJ	O	O
analyses	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
separately	ADV	O	O
for	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
by	ADP	O	O
using	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
On	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
diphenhydramine	NOUN	O	O
significantly	ADV	O	O
impaired	VERB	O	O
tracking	PROPN	O	B-MENTAL
performance	NOUN	O	I-MENTAL
(	PUNCT	O	O
easy	ADP	O	O
:	PUNCT	O	O
F	NOUN	O	O
(	PUNCT	O	O
1,90	NUM	O	O
)	PUNCT	O	O
=	ADP	O	O
25.9	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0001	NUM	O	O
;	PUNCT	O	O
hard	PUNCT	O	O
:	PUNCT	O	O
F	NOUN	O	O
(	PUNCT	O	O
1,90	NUM	O	O
)	PUNCT	O	O
=	SYM	O	O
20.5	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
divided	VERB	O	B-PHYSICAL
attention	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
tracking	ADP	O	O
:	PUNCT	O	O
F	NOUN	O	O
(	PUNCT	O	O
1,90	NUM	O	O
)	PUNCT	O	O
=	SYM	O	O
23.8	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0001	NUM	O	O
;	PUNCT	O	O
memory	NOUN	O	B-PHYSICAL
scanning	VERB	O	I-PHYSICAL
:	PUNCT	O	O
F	NOUN	O	O
(	PUNCT	O	O
1,90	NUM	O	O
)	PUNCT	O	O
=	SYM	O	O
22.0	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	DET	O	O
on	ADP	O	O
word-learning	PROPN	O	B-MENTAL
tests	NOUN	O	I-MENTAL
and	CCONJ	O	O
Sternberg	NOUN	O	B-MENTAL
Memory	NOUN	O	I-MENTAL
Scanning	DET	O	I-MENTAL
Tests	NOUN	O	I-MENTAL
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
impaired	VERB	O	O
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
diphenhydramine	NOUN	O	O
did	CCONJ	O	O
not	ADV	O	O
reach	ADJ	O	O
significance	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
both	PUNCT	O	O
days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
,	PUNCT	O	O
levocetirizine	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
impair	NUM	O	O
laboratory	NOUN	O	B-OTHER
test	ADV	O	I-OTHER
performance	NOUN	O	I-OTHER
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	ADV	O	O
show	VERB	O	O
that	ADP	O	O
memory	NOUN	O	B-MENTAL
,	PUNCT	O	O
attention	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
tracking	PUNCT	O	B-MENTAL
performance	NOUN	O	I-MENTAL
are	VERB	O	O
unaffected	VERB	O	O
after	ADP	O	O
acute	ADJ	O	O
and	CCONJ	O	O
subchronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
levocetirizine	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
diphenhydramine	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
affected	VERB	O	O
divided	VERB	O	B-MENTAL
attention	NOUN	O	I-MENTAL
and	CCONJ	O	O
tracking	PUNCT	O	B-MENTAL
after	ADP	O	O
acute	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Trial	NOUN	O	O
design	NOUN	O	O
challenges	NOUN	O	O
when	ADP	O	O
combining	ADP	O	O
medication	NOUN	O	O
and	CCONJ	O	O
parent	NOUN	O	O
training	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
paper	NOUN	O	O
presents	NOUN	O	O
the	DET	O	O
rationale	NOUN	O	O
for	ADP	O	O
a	DET	O	O
24-week	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
trial	NOUN	O	O
designed	VERB	O	O
to	PART	O	O
test	VERB	O	O
whether	ADP	O	O
risperidone	NUM	O	O
plus	CCONJ	O	O
structured	VERB	O	O
parent	NOUN	O	O
training	ADP	O	O
would	VERB	O	O
be	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
risperidone	NUM	O	O
only	ADV	O	O
on	ADP	O	O
measures	NOUN	O	O
of	ADP	O	O
noncompliance	NOUN	O	B-MENTAL
,	PUNCT	O	O
irritability	NOUN	O	B-MENTAL
and	CCONJ	O	O
adaptive	ADJ	O	B-MENTAL
functioning	SYM	O	I-MENTAL
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
model	NOUN	O	O
,	PUNCT	O	O
medication	NOUN	O	O
reduces	VERB	O	O
tantrums	ADP	O	B-MENTAL
,	PUNCT	O	O
aggression	NOUN	O	B-MENTAL
and	CCONJ	O	O
self-injury	NOUN	O	B-MENTAL
;	PUNCT	O	O
parent	NOUN	O	O
training	VERB	O	O
promotes	NOUN	O	O
improvement	NOUN	O	O
in	ADP	O	O
noncompliance	NOUN	O	B-MENTAL
and	CCONJ	O	O
adaptive	ADJ	O	B-MENTAL
functioning	SYM	O	I-MENTAL
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
medication	NOUN	O	O
and	CCONJ	O	O
parent	NOUN	O	O
training	PUNCT	O	O
target	NOUN	O	O
related	DET	O	O
,	PUNCT	O	O
but	CCONJ	O	O
separate	PUNCT	O	O
,	PUNCT	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
week	NOUN	O	O
24	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
medication	NOUN	O	O
was	VERB	O	O
gradually	ADV	O	O
withdrawn	PUNCT	O	O
to	PART	O	O
determine	VERB	O	O
whether	VERB	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
combined	VERB	O	O
treatment	NOUN	O	O
group	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
managed	PROPN	O	O
on	ADP	O	O
a	DET	O	O
lower	PUNCT	O	O
dose	NOUN	O	O
or	CCONJ	O	O
off	ADP	O	O
medication	NOUN	O	O
without	ADP	O	O
relapse	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
symptom	NOUN	O	B-OTHER
reduction	NOUN	O	I-OTHER
and	CCONJ	O	O
functional	ADJ	O	B-OTHER
improvement	NOUN	O	I-OTHER
are	VERB	O	O
important	ADJ	O	O
clinical	ADJ	O	O
treatment	NOUN	O	O
targets	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
experimental	ADJ	O	O
evidence	NOUN	O	O
on	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
combining	PUNCT	O	O
pharmacotherapy	NOUN	O	O
and	CCONJ	O	O
exportable	ADJ	O	O
behavioral	ADJ	O	O
interventions	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PART	O	O
guide	NOUN	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

Bacterial	ADJ	O	O
ribosomal	ADJ	O	O
immunostimulants	NOUN	O	O
prime	PROPN	O	O
alveolar	ADJ	O	O
macrophages	NOUN	O	O
in	PUNCT	O	O
vivo	ADV	O	O
to	PART	O	O
produce	ADJ	O	O
interleukin	NOUN	O	O
1	NUM	O	O
in	PUNCT	O	O
vitro	ADV	O	O
.	PUNCT	O	O

Alveolar	ADJ	O	O
macrophages	NOUN	O	O
(	PUNCT	O	O
AMs	ADV	O	O
)	PUNCT	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
key	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
human	NOUN	O	O
respiratory	ADJ	O	O
immune	ADJ	O	O
defenses	NOUN	O	O
,	PUNCT	O	O
partially	ADV	O	O
by	ADP	O	O
synthesizing	ADJ	O	O
and	CCONJ	O	O
releasing	PUNCT	O	O
interleukin	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
IL	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

D53	ADP	O	O
(	PUNCT	O	O
Ribomunyl	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
composite	ADJ	O	O
bacterial	ADJ	O	O
ribosomal	ADJ	O	O
immunostimulant	ADJ	O	O
,	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
recognized	VERB	O	O
as	ADP	O	O
an	DET	O	O
efficient	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	B-PHYSICAL
tract	NOUN	O	I-PHYSICAL
infections	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	PUNCT	O	O
vitro	ADJ	O	O
,	PUNCT	O	O
D53	NOUN	O	O
enhances	ADP	O	O
the	DET	O	O
IL-1	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
by	ADP	O	O
mouse	NOUN	O	O
spleen	NOUN	O	O
adherent	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
thymocyte	NOUN	O	O
proliferative	ADJ	O	O
response	NOUN	O	O
assay	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
in	PUNCT	O	O
vitro	ADJ	O	B-PHYSICAL
IL-1	NOUN	O	I-PHYSICAL
production	NOUN	O	I-PHYSICAL
by	ADP	O	O
AMs	ADV	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
D53	NOUN	O	O
immunostimulant	ADJ	O	O
.	PUNCT	O	O

Twelve	NUM	O	O
nonsmoking	PUNCT	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
took	PROPN	O	O
part	NOUN	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
double-blind	ADJ	O	O
placebo	NOUN	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
first	ADJ	O	O
bronchoalveolar	ADJ	O	O
lavage	NOUN	O	O
(	PUNCT	O	O
BAL	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
IL-1	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
by	ADP	O	O
unstimulated	VERB	O	O
and	CCONJ	O	O
lipopolysaccharide	NOUN	O	O
(	PUNCT	O	O
LPS	NOUN	O	O
)	PUNCT	O	O
stimulated	VERB	O	O
AM	NOUN	O	O
.	PUNCT	O	O

Then	ADV	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
D53	ADP	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
its	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
by	ADP	O	O
both	CCONJ	O	O
oral	ADJ	O	O
and	CCONJ	O	O
subcutaneous	ADJ	O	O
injection	NOUN	O	O
routes	CCONJ	O	O
from	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
to	ADP	O	O
day	NOUN	O	O
15	NUM	O	O
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
15	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
second	ADJ	O	O
BAL	NOUN	O	O
was	VERB	O	O
done	PUNCT	O	O
and	CCONJ	O	O
AM	NOUN	O	O
IL-1	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
was	VERB	O	O
again	ADV	O	O
tested	VERB	O	O
.	PUNCT	O	O

IL-1	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
on	ADP	O	O
day	NOUN	O	O
15	NUM	O	O
did	ADP	O	O
not	ADV	O	O
significantly	ADV	O	O
differ	VERB	O	O
from	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
in	ADP	O	O
both	CCONJ	O	O
D53-treated	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
either	CCONJ	O	O
when	ADP	O	O
AMs	ADV	O	O
were	VERB	O	O
unstimulated	DET	O	O
or	CCONJ	O	O
were	VERB	O	O
stimulated	VERB	O	O
with	ADP	O	O
concentrations	NOUN	O	O
of	ADP	O	O
LPS	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
maximal	ADJ	O	O
IL-1	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
D53-treated	NUM	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
IL-1	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
induced	VERB	O	O
by	ADP	O	O
low	ADJ	O	O
LPS	NOUN	O	B-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
5	NUM	O	O
mg/L	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SEM	NOUN	O	O
:	PUNCT	O	O
1,238	NUM	O	O
+/-	SYM	O	O
287	NUM	O	O
U/10	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
AM	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
15	NUM	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
577	NUM	O	O
+/-	SYM	O	O
113	NUM	O	O
U/10	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
AM	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.05	NUM	O	O
,	PUNCT	O	O
Wilcoxon	NOUN	O	O
W	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
15	NUM	O	O
IL-1	NOUN	O	B-PHYSICAL
production	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
5	NUM	O	O
mg/L	NOUN	O	O
LPS	NOUN	O	O
,	PUNCT	O	O
758	NUM	O	O
+/-	SYM	O	O
175	NUM	O	O
U/10	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
AM	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.05	NUM	O	O
,	PUNCT	O	O
Mann-Whitney	NOUN	O	O
U	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
D53-treated	NUM	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
optimal	ADJ	O	B-PHYSICAL
LPS	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
ie	ADP	O	O
,	PUNCT	O	O
LPS	NOUN	O	O
concentration	NOUN	O	O
that	ADP	O	O
induced	ADJ	O	O
maximal	ADJ	O	O
IL-1	NOUN	O	O
production	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
15	NUM	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
:	PUNCT	O	O
11	NUM	O	O
+/-	SYM	O	O
7	NUM	O	O
mg/L	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
16	NUM	O	O
+/-	SYM	O	O
7	NUM	O	O
mg/L	NOUN	O	O
;	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	CCONJ	O	O
0.05	NUM	O	O
Wilcoxon	NOUN	O	O
W	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
D53	ADP	O	O
immunostimulant	PUNCT	O	O
in	ADP	O	O
vivo	ADJ	O	O
primes	CCONJ	O	O
AM	NOUN	O	O
to	PART	O	O
produce	NOUN	O	O
IL-1	NOUN	O	B-PHYSICAL
following	VERB	O	O
low	ADJ	O	B-PHYSICAL
LPS	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
stimulation	NOUN	O	O
.	PUNCT	O	O

This	PUNCT	O	O
may	PART	O	O
partially	ADV	O	O
explain	VERB	O	O
the	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
D53	NOUN	O	O
immunostimulant	ADJ	O	O
against	ADP	O	O
respiratory	ADJ	O	B-PHYSICAL
tract	NOUN	O	I-PHYSICAL
infection	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Post	PUNCT	O	O
hoc	VERB	O	O
analysis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
IV	NUM	O	O
infusion	NOUN	O	O
of	ADP	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
versus	CCONJ	O	O
daily	ADJ	O	O
oral	ADJ	O	O
risedronate	NOUN	O	O
on	ADP	O	O
lumbar	ADJ	O	O
spine	NOUN	O	O
bone	NOUN	O	O
mineral	NOUN	O	O
density	NOUN	O	O
in	ADP	O	O
different	ADJ	O	O
subgroups	NOUN	O	O
with	ADP	O	O
glucocorticoid-induced	VERB	O	O
osteoporosis	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
summarizes	PUNCT	O	O
the	DET	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
infusion	NOUN	O	O
on	ADP	O	O
lumbar	ADJ	O	B-PHYSICAL
spine	NOUN	O	I-PHYSICAL
bone	NOUN	O	I-PHYSICAL
mineral	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
in	ADP	O	O
different	ADJ	O	O
subgroups	NOUN	O	O
with	ADP	O	O
glucocorticoid-induced	VERB	O	O
osteoporosis	NOUN	O	O
.	PUNCT	O	O

Zoledronic	ADJ	O	O
acid	NOUN	O	O
is	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
than	VERB	O	O
risedronate	NOUN	O	O
in	ADP	O	O
increasing	PUNCT	O	O
lumbar	ADJ	O	B-PHYSICAL
spine	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
LS	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
bone	NOUN	O	I-PHYSICAL
mineral	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
in	ADP	O	O
both	CCONJ	O	O
prevention	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
glucocorticoid-induced	VERB	O	O
osteoporosis	NOUN	O	O
.	PUNCT	O	O

Introduction	NOUN	O	O
In	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
glucocorticoids	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
single	ADJ	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
infusion	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
BMD	NOUN	O	B-PHYSICAL
versus	CCONJ	O	O
daily	ADJ	O	O
oral	ADJ	O	O
risedronate	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
assessed	VERB	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
on	ADP	O	O
LS	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
in	ADP	O	O
different	ADJ	O	O
patient	NOUN	O	O
subgroups	NOUN	O	O
at	ADP	O	O
month	NOUN	O	O
12	NUM	O	O
that	PUNCT	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
osteoporosis	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
glucocorticoids	NOUN	O	O
.	PUNCT	O	O

Methods	NOUN	O	O
Patients	NOUN	O	O
randomized	ADP	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
IV	NUM	O	O
infusion	NOUN	O	O
of	ADP	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
5	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
risedronate	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
stratified	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
glucocorticoids	ADJ	O	O
duration	NOUN	O	O
[	PUNCT	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
>	PROPN	O	O
3	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
(	PUNCT	O	O
?	PUNCT	O	O

3	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
subpopulations	NOUN	O	O
]	PUNCT	O	O
were	VERB	O	O
subgrouped	VERB	O	O
by	ADP	O	O
age	NOUN	O	O
;	PUNCT	O	O
gender	NOUN	O	O
;	PUNCT	O	O
menopausal	ADJ	O	O
status	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
;	PUNCT	O	O
dose	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
prednisone	NOUN	O	O
during	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
baseline	NOUN	O	O
serum	NOUN	O	O
25-OH	NOUN	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
,	PUNCT	O	O
LS	NOUN	O	O
BMD	NOUN	O	O
T-score	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	O
clearance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
concomitant	ADJ	O	O
medication	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

Results	DET	O	O
At	ADP	O	O
month	NOUN	O	O
12	NUM	O	O
,	PUNCT	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
LS	NOUN	O	O
BMD	NOUN	O	O
versus	CCONJ	O	O
risedronate	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
?	PUNCT	O	O

74	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
65-74	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0008	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
subpopulation	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
month	NOUN	O	O
12	NUM	O	O
,	PUNCT	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
LS	NOUN	O	O
BMD	NOUN	O	O
versus	CCONJ	O	O
risedronate	NOUN	O	O
in	ADP	O	O
both	PUNCT	O	O
subpopulations	ADJ	O	O
irrespective	ADJ	O	O
of	ADP	O	O
gender	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cumulative	ADJ	O	O
prednisone	NOUN	O	O
dose	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
postmenopausal	ADJ	O	O
status	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
premenopausal	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
both	PUNCT	O	O
subpopulations	NOUN	O	O
,	PUNCT	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
significantly	ADV	O	O
increased	CCONJ	O	O
total	ADJ	O	O
hip	NOUN	O	O
BMD	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
risedronate	NOUN	O	O
at	ADP	O	O
month	NOUN	O	O
12	NUM	O	O
but	CCONJ	O	O
not	ADV	O	O
LS	NOUN	O	O
BMD	NOUN	O	O
.	PUNCT	O	O

Osteoporotic	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
(	PUNCT	O	O
P=0.0189	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
osteopenic	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
subpopulation	NOUN	O	O
(	PUNCT	O	O
P=0.0305	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
significant	ADJ	O	O
LS	NOUN	O	O
BMD	NOUN	O	O
increases	NOUN	O	O
with	ADP	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
versus	CCONJ	O	O
risedronate	NOUN	O	O
at	ADP	O	O
month	NOUN	O	O
12	NUM	O	O
.	PUNCT	O	O

Conclusions	NOUN	O	O
This	CCONJ	O	O
post	PUNCT	O	O
hoc	ADP	O	O
analysis	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
zoledronic	ADJ	O	O
acid	NOUN	O	O
is	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
than	VERB	O	O
risedronate	NOUN	O	O
in	ADP	O	O
increasing	VERB	O	O
LS	NOUN	O	O
BMD	NOUN	O	O
in	ADP	O	O
prevention	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
glucocorticoid-induced	VERB	O	O
osteoporosis	NOUN	O	O
across	ADP	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
albuterol	NOUN	O	O
powder	NOUN	O	O
and	CCONJ	O	O
aerosol	NOUN	O	O
in	ADP	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
aerosolized	VERB	O	O
albuterol	NOUN	O	O
with	ADP	O	O
the	DET	O	O
dry	ADJ	O	O
powder	NOUN	O	O
formulation	NOUN	O	O
,	PUNCT	O	O
231	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
reversible	ADJ	O	O
obstructive	ADJ	O	O
airway	NOUN	O	O
disease	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
placebo	NOUN	O	O
albuterol	NOUN	O	O
aerosol	NOUN	O	O
followed	VERB	O	O
immediately	ADV	O	O
by	ADP	O	O
active	ADJ	O	O
albuterol	NOUN	O	O
powder	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
active	ADJ	O	O
albuterol	NOUN	O	O
aerosol	NOUN	O	O
(	PUNCT	O	O
two	NUM	O	O
puffs	VERB	O	O
,	PUNCT	O	O
180	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
followed	ADV	O	O
immediately	ADV	O	O
by	ADP	O	O
placebo	NOUN	O	O
lactose	NOUN	O	O
powder	NOUN	O	O
four	NUM	O	O
times	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
powder	NOUN	O	O
and	CCONJ	O	O
aerosol	NOUN	O	O
formulations	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
pulmonary	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
length	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
mean	NOUN	O	O
FEV1	NOUN	O	O
remained	VERB	O	O
greater	PUNCT	O	O
than	VERB	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
15	NUM	O	O
%	SYM	O	O
above	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
physicians	NOUN	O	B-PHYSICAL
'	PUNCT	O	O
assessments	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
patients	NOUN	O	I-PHYSICAL
'	PUNCT	O	O
clinical	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	CCONJ	O	O
patients	NOUN	O	B-OTHER
'	PUNCT	O	O
subjective	ADJ	O	B-OTHER
symptom	NOUN	O	I-OTHER
scores	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
in	ADP	O	O
cardiovascular	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
laboratory	NOUN	O	B-PHYSICAL
values	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	PUNCT	O	O
adverse	PUNCT	O	B-ADVERSE-EFFECTS

Granulocyte-macrophage	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
(	PUNCT	O	O
GM-CSF	NOUN	O	O
)	PUNCT	O	O
as	VERB	O	O
adjunct	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
relapsed	VERB	O	O
Hodgkin	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
economic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
granulocyte	NOUN	O	O
macrophage	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
(	PUNCT	O	O
GM-CSF	NOUN	O	O
)	PUNCT	O	O
as	VERB	O	O
adjunct	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
relapsed	VERB	O	O
or	CCONJ	O	O
refractory	ADJ	O	O
Hodgkin	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
phase	NOUN	O	O
III	NUM	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
A	DET	O	O
tertiary	ADJ	O	O
referral	ADJ	O	O
center	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
Twenty-four	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
twelve	PUNCT	O	O
of	ADP	O	O
whom	ADP	O	O
were	VERB	O	O
controls	NOUN	O	O
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
high-dose	NOUN	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
autologous	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
RESULTS	NOUN	O	O
The	DET	O	O
12	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
GM-CSF	NOUN	O	O
,	PUNCT	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
recipients	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
shorter	PUNCT	O	O
periods	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
neutropenia	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
median	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
an	DET	O	O
absolute	ADJ	O	O
neutrophil	NOUN	O	O
count	NOUN	O	O
of	ADP	O	O
less	ADV	O	O
than	PUNCT	O	O
1000	NUM	O	O
cells/mm3	NOUN	O	O
,	PUNCT	O	O
16	DET	O	O
days	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
27	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
shorter	PUNCT	O	O
periods	NOUN	O	O
of	ADP	O	O
platelet-transfusion	NOUN	O	B-PHYSICAL
dependency	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
median	ADJ	O	O
duration	NOUN	O	O
,	PUNCT	O	O
13.5	NUM	O	O
days	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
shorter	PUNCT	O	B-OTHER
hospitalizations	NOUN	O	I-OTHER
(	PUNCT	O	O
median	ADJ	O	O
hospital	NOUN	O	O
stay	NOUN	O	O
,	PUNCT	O	O
32	NUM	O	O
days	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
40.5	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Other	ADJ	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
toxicities	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
development	NOUN	O	O
of	ADP	O	O
pneumonia	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
infection	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
in-hospital	NOUN	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
,	PUNCT	O	O
and	CCONJ	O	O
response	NOUN	O	O
rate	NOUN	O	B-MENTAL
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Actuarial	ADJ	O	O
long-term	NOUN	O	B-MORTALITY
disease-free	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
64	NUM	O	O
%	SYM	O	O
for	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
GM-CSF	NOUN	O	O
and	CCONJ	O	O
58	NUM	O	O
%	SYM	O	O
for	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
placebo	NOUN	O	O
after	ADP	O	O
32	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.15	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
group	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
GM-CSF	NOUN	O	O
had	PUNCT	O	O
lower	PUNCT	O	O
total	ADJ	O	O
charges	NOUN	O	O
after	ADP	O	O
infusion	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
autologous	ADJ	O	I-PHYSICAL
marrow	NOUN	O	I-PHYSICAL
than	PUNCT	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
in-hospital	NOUN	O	O
charges	NOUN	O	O
,	PUNCT	O	O
$	PUNCT	O	O
39,800	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
$	PROPN	O	O
62,500	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
lower	PUNCT	O	B-PHYSICAL
post-infusion	NOUN	O	I-PHYSICAL
charges	NOUN	O	I-PHYSICAL
for	ADP	O	O
room	NOUN	O	O
and	CCONJ	O	O
board	NOUN	O	O
,	PUNCT	O	O
antibiotic	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
transfusions	NOUN	O	O
,	PUNCT	O	O
laboratory	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
visits	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Administration	NOUN	O	O
of	ADP	O	O
GM-CSF	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
acceleration	NOUN	O	O
of	ADP	O	O
myeloid	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
platelet	NOUN	O	B-PHYSICAL
recovery	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
was	ADP	O	O
cost	NOUN	O	B-OTHER
effective	ADJ	O	I-OTHER
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
relapsed	VERB	O	O
Hodgkin	NOUN	O	O
disease	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
intensive	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Prognostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
CEA	NOUN	O	O
clearance	NOUN	O	O
in	ADP	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
preoperative	ADJ	O	O
CEA	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
We	PRON	O	O
determined	VERB	O	O
the	DET	O	O
prognostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
carcinoembryonic	ADJ	O	O
antigen	NOUN	O	O
(	PUNCT	O	O
CEA	NOUN	O	O
)	PUNCT	O	O
clearance	NOUN	O	O
after	ADP	O	O
tumor	NOUN	O	O
resection	NOUN	O	O
with	ADP	O	O
serial	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
CEA	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Between	ADP	O	O
1994	NUM	O	O
and	CCONJ	O	O
2004	NUM	O	O
,	PUNCT	O	O
we	PRON	O	O
retrospectively	ADP	O	O
reviewed	ADP	O	O
122	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
whose	ADP	O	O
serum	NOUN	O	B-PHYSICAL
CEA	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
on	ADP	O	O
the	DET	O	O
preoperative	ADJ	O	O
day	NOUN	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
days	NOUN	O	O
7	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
preoperative	ADJ	O	O
CEA	NOUN	O	O
levels	NOUN	O	O
<	SYM	O	O
5.0	NUM	O	O
ng/ml	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
exponential	ADJ	O	O
trend	NOUN	O	O
line	NOUN	O	O
was	VERB	O	O
drawn	VERB	O	O
using	VERB	O	O
the	DET	O	O
three	NUM	O	O
CEA	NOUN	O	O
values	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
categorized	VERB	O	O
into	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
R	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
values	NOUN	O	O
calculated	ADP	O	O
through	ADP	O	O
trend	NOUN	O	O
line	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
indicates	NOUN	O	O
the	DET	O	O
correlation	NOUN	O	O
coefficient	NOUN	O	O
between	ADP	O	O
exponential	ADJ	O	O
graph	NOUN	O	O
and	CCONJ	O	O
measured	PUNCT	O	O
CEA	NOUN	O	B-PHYSICAL
values	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
exponential	ADJ	O	O
decrease	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
:	PUNCT	O	O
0.9	NUM	O	O
<	SYM	O	O
R	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
1.0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nearly	PUNCT	O	O
exponential	ADJ	O	O
decrease	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
:	PUNCT	O	O
0.5	NUM	O	O
<	SYM	O	O
R	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.9	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
randomized	VERB	O	O
clearance	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
3	NUM	O	O
:	PUNCT	O	O
0.5	NUM	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
R	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
analyzed	ADP	O	O
the	DET	O	O
CEA	NOUN	O	O
clearance	NOUN	O	O
pattern	NOUN	O	O
as	ADP	O	O
a	DET	O	O
prognostic	ADJ	O	O
indicator	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
With	ADP	O	O
a	DET	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
of	ADP	O	O
57	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
5-year	ADJ	O	B-MORTALITY
overall	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
62.3	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
48.1	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
25	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
the	DET	O	O
5-year	NOUN	O	B-MORTALITY
disease-free	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
58.6	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
52.7	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
25	NUM	O	O
%	SYM	O	O
among	ADP	O	O
groups	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.014	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.027	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
III	NUM	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
stage	NOUN	O	O
II	NUM	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
5-year	ADJ	O	B-MORTALITY
overall	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
rate	NOUN	O	I-MORTALITY
of	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
was	ADJ	O	O
significantly	ADV	O	O
better	PUNCT	O	O
than	VERB	O	O
groups	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
(	PUNCT	O	O
88.8	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
74.1	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.021	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
postoperative	ADJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
CEA	NOUN	O	O
clearance	NOUN	O	O
is	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
prognostic	ADJ	O	O
determinant	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
pattern	NOUN	O	O
of	ADP	O	O
CEA	NOUN	O	B-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
after	ADP	O	O
tumor	NOUN	O	O
resection	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
regarded	VERB	O	O
as	ADP	O	O
having	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
a	DET	O	O
persistent	ADJ	O	O
CEA	NOUN	O	O
source	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
require	VERB	O	O
consideration	NOUN	O	O
of	ADP	O	O
intensive	ADJ	O	O
follow-up	NOUN	O	O
or	CCONJ	O	O
adjuvant	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
antazoline	NOUN	O	O
in	ADP	O	O
rapid	ADJ	O	B-PHYSICAL
cardioversion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
paroxysmal	ADJ	O	I-PHYSICAL
atrial	ADJ	O	I-PHYSICAL
fibrillation	NOUN	O	I-PHYSICAL
--	PUNCT	O	I-PHYSICAL
a	DET	O	O
protocol	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
center	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
AnPAF	NOUN	O	O
Study	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Rapid	ADJ	O	B-PHYSICAL
conversion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
atrial	ADJ	O	I-PHYSICAL
fibrillation	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
AF	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
to	ADP	O	B-PHYSICAL
sinus	NOUN	O	I-PHYSICAL
rhythm	NOUN	O	B-PHYSICAL
may	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
by	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
class	NOUN	O	O
IA	NOUN	O	O
,	PUNCT	O	O
IC	NOUN	O	O
and	CCONJ	O	O
III	NUM	O	O
antiarrhythmic	ADJ	O	O
drugs	NOUN	O	O
or	CCONJ	O	O
vernakalant	ADJ	O	O
hydrochloride	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
that	PUNCT	O	O
treatment	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
potential	CCONJ	O	O
pro-arrhythmia	NOUN	O	O
,	PUNCT	O	O
lack	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
exceptionally	ADJ	O	O
high	ADJ	O	O
cost	NOUN	O	O
of	ADP	O	O
a	DET	O	O
compound	NOUN	O	O
used	VERB	O	O
.	PUNCT	O	O

Antazoline	NOUN	O	O
is	VERB	O	O
a	DET	O	O
first	ADJ	O	O
generation	NOUN	O	O
antihistaminic	ADJ	O	O
agent	NOUN	O	O
with	ADP	O	O
chinidin-like	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
administered	ADP	O	O
intravenously	ADV	O	O
,	PUNCT	O	O
antazoline	NOUN	O	O
exerts	NOUN	O	O
a	DET	O	O
strong	ADJ	O	B-PHYSICAL
antiarrhythmic	ADJ	O	I-PHYSICAL
effect	NOUN	O	O
on	ADP	O	O
supraventricular	VERB	O	B-PHYSICAL
arrhythmia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
especially	ADV	O	O
on	ADP	O	O
AF	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
facilitating	CCONJ	O	O
rapid	ADJ	O	B-PHYSICAL
conversion	NOUN	O	I-PHYSICAL
to	ADP	O	B-PHYSICAL
sinus	NOUN	O	I-PHYSICAL
rhythm	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Despite	ADP	O	O
a	DET	O	O
relative	ADJ	O	O
lack	NOUN	O	O
of	ADP	O	O
published	VERB	O	O
data	NOUN	O	O
antazoline	CCONJ	O	O
has	PUNCT	O	O
been	PUNCT	O	O
marketed	VERB	O	O
in	ADP	O	O
Poland	PUNCT	O	O
and	CCONJ	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
cardiology	NOUN	O	O
wards	NOUN	O	O
and	CCONJ	O	O
emergency	NOUN	O	O
rooms	NOUN	O	O
for	ADP	O	O
many	DET	O	O
years	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
its	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
safety	NOUN	O	O
and	CCONJ	O	O
rapid	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
within	ADP	O	O
minutes	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
.	PUNCT	O	O

METHODS/DESIGN	PUNCT	O	O
A	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
superiority	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
clinical	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
of	ADP	O	O
antazoline	NOUN	O	O
in	ADP	O	O
rapid	ADJ	O	O
conversion	NOUN	O	O
of	ADP	O	O
AF	NOUN	O	O
to	ADP	O	O
sinus	NOUN	O	O
rhythm	NOUN	O	O
.	PUNCT	O	O

Eligible	ADJ	O	O
patients	NOUN	O	O
will	ADP	O	O
present	PUNCT	O	O
AF	NOUN	O	O
lasting	PROPN	O	O
less	ADP	O	O
than	PUNCT	O	O
43	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
will	VERB	O	O
be	ADP	O	O
in	ADP	O	O
stable	ADJ	O	O
cardio-pulmonary	ADJ	O	O
condition	NOUN	O	O
and	CCONJ	O	O
will	PUNCT	O	O
have	CCONJ	O	O
no	DET	O	O
prior	PUNCT	O	O
history	NOUN	O	O
of	ADP	O	O
advanced	VERB	O	O
heart	NOUN	O	O
failure	NOUN	O	O
or	CCONJ	O	O
significant	ADJ	O	O
valvular	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Long-term	NOUN	O	O
antiarrhythmic	ADJ	O	O
therapy	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
considered	PUNCT	O	O
an	DET	O	O
exclusion	NOUN	O	O
criterion	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
who	NUM	O	O
fulfill	PUNCT	O	O
selection	NOUN	O	O
criteria	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	VERB	O	O
intravenously	PUNCT	O	O
either	PUNCT	O	O
antazoline	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
divided	VERB	O	O
doses	NOUN	O	O
and	CCONJ	O	O
observed	VERB	O	O
for	ADP	O	O
1.5	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
conversion	NOUN	O	O
to	ADP	O	O
sinus	NOUN	O	O
rhythm	NOUN	O	O
or	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

bolus	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
the	DET	O	O
conversion	NOUN	O	O
of	PUNCT	O	O

Helicobacter	NOUN	O	O
pylori	NOUN	O	O
and	CCONJ	O	O
gastric	ADJ	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
current	ADJ	O	O
status	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Austrain	NOUN	O	O
Czech	NOUN	O	O
German	PUNCT	O	O
gastric	ADJ	O	O
cancer	NOUN	O	O
prevention	NOUN	O	O
trial	NOUN	O	O
(	PUNCT	O	O
PRISMA	NOUN	O	O
Study	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADJ	O	O
test	NOUN	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
eradication	NOUN	O	O
alone	ADJ	O	O
can	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
gastric	ADJ	O	B-PHYSICAL
cancer	NOUN	O	I-PHYSICAL
in	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
this	CCONJ	O	O
fatal	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
It	ADJ	O	O
is	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
blind	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
multinational	ADJ	O	O
multicenter	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Men	NOUN	O	O
between	ADP	O	O
55	NUM	O	O
and	CCONJ	O	O
65	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
with	ADP	O	O
a	DET	O	O
gastric	ADJ	O	O
cancer	NOUN	O	O
phenotype	NOUN	O	O
of	ADP	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
gastritis	NOUN	O	O
are	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
7	NUM	O	O
day	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
omeprazole	NUM	O	O
2	NUM	O	O
X	ADP	O	O
20mg	NOUN	O	O
,	PUNCT	O	O
clarithromycin	NOUN	O	O
2	NUM	O	O
X	CCONJ	O	O
500mg	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
amoxicillin	NOUN	O	O
2	NUM	O	O
X	PUNCT	O	O
1g	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
omeprazole	NUM	O	O
2	NUM	O	O
X	ADP	O	O
20mg	NOUN	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Follow-up	NOUN	O	O
endoscopy	NOUN	O	O
is	VERB	O	O
scheduled	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thereafter	ADV	O	O
in	ADP	O	O
one-year	NOUN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Predefined	VERB	O	O
study	ADP	O	O
endpoints	NOUN	O	O
are	VERB	O	O
gastric	ADJ	O	B-PHYSICAL
cancer	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
precancerous	ADJ	O	B-PHYSICAL
lesions	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
dysplasia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
adenoma	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O

Potential	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
algorithm	NOUN	O	O
(	PUNCT	O	O
ROCA	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
mortality	NOUN	O	B-MORTALITY
outcome	NOUN	O	I-MORTALITY
of	ADP	O	O
the	DET	O	O
Prostate	NOUN	O	O
,	PUNCT	O	O
Lung	NOUN	O	O
,	PUNCT	O	O
Colorectal	ADJ	O	O
and	CCONJ	O	O
Ovarian	PUNCT	O	O
(	PUNCT	O	O
PLCO	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
Prostate	NOUN	O	O
,	PUNCT	O	O
Lung	NOUN	O	O
,	PUNCT	O	O
Colorectal	ADJ	O	O
and	CCONJ	O	O
Ovarian	PUNCT	O	O
(	PUNCT	O	O
PLCO	NOUN	O	O
)	PUNCT	O	O
Trial	NOUN	O	O
reported	VERB	O	O
no	DET	O	O
mortality	NOUN	O	O
benefit	NOUN	O	O
for	ADP	O	O
annual	ADJ	O	O
screening	VERB	O	O
with	ADP	O	O
CA-125	NOUN	O	O
and	CCONJ	O	O
transvaginal	ADJ	O	O
ultrasound	NOUN	O	O
(	PUNCT	O	O
TVU	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Currently	ADV	O	O
ongoing	PUNCT	O	O
is	ADP	O	O
the	DET	O	O
UK	ADP	O	O
Collaborative	ADJ	O	O
Trial	NOUN	O	O
of	ADP	O	O
Ovarian	ADJ	O	O
Cancer	NOUN	O	O
Screening	PUNCT	O	O
(	PUNCT	O	O
UKCTOCS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADP	O	O
utilizes	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
algorithm	NOUN	O	O
(	PUNCT	O	O
ROCA	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
statistical	ADJ	O	O
tool	NOUN	O	O
that	NUM	O	O
considers	PROPN	O	O
current	PUNCT	O	O
and	CCONJ	O	O
past	ADJ	O	O
CA125	NOUN	O	O
values	NOUN	O	O
to	DET	O	O
determine	VERB	O	O
ovarian	DET	O	O
cancer	NOUN	O	O
risk	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
PLCO	NOUN	O	O
used	VERB	O	O
a	DET	O	O
single	ADJ	O	O
cutoff	NOUN	O	O
for	ADP	O	O
CA125	NOUN	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
current	ADJ	O	O
levels	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
having	VERB	O	O
had	PUNCT	O	O
used	PUNCT	O	O
ROCA	NOUN	O	O
in	ADP	O	O
PLCO	NOUN	O	O
could	VERB	O	O
have	PUNCT	O	O
,	PUNCT	O	O
under	ADP	O	O
optimal	ADJ	O	O
assumptions	NOUN	O	O
,	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
significant	ADJ	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
benefit	NOUN	O	I-MORTALITY
by	ADP	O	O
applying	VERB	O	O
ROCA	NOUN	O	O
to	ADP	O	O
PLCO	ADP	O	O
CA125	NOUN	O	O
screening	VERB	O	O
values	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
best-case	NOUN	O	O
scenario	ADJ	O	O
assumed	ADP	O	O
that	ADP	O	O
all	DET	O	O
cancers	NOUN	O	O
showing	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
screen	NOUN	O	O
result	NOUN	O	O
earlier	PUNCT	O	O
with	ADP	O	O
ROCA	NOUN	O	O
than	PUNCT	O	O
under	ADP	O	O
the	DET	O	O
PLCO	NOUN	O	O
protocol	NOUN	O	O
would	ADJ	O	O
have	PUNCT	O	O
avoided	PUNCT	O	O
mortality	NOUN	O	B-MORTALITY
;	PUNCT	O	O
under	ADP	O	O
a	DET	O	O
stage-shift	PUNCT	O	O
scenario	ADJ	O	O
,	PUNCT	O	O
such	DET	O	O
women	NOUN	O	O
were	VERB	O	O
assigned	PUNCT	O	O
survival	NOUN	O	O
equivalent	ADJ	O	O
to	ADP	O	O
Stage	NOUN	O	O
I/II	NOUN	O	O
screen-detected	VERB	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Updated	ADP	O	O
PLCO	NOUN	O	O
data	NOUN	O	O
show	VERB	O	O
132	NUM	O	O
intervention	NOUN	O	O
arm	NOUN	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
deaths	NOUN	O	O
versus	CCONJ	O	O
119	NUM	O	O
in	ADP	O	O
usual	ADJ	O	O
care	NOUN	O	O
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
,	PUNCT	O	O
RR	NOUN	O	O
=	SYM	O	O
1.11	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Forty-three	ADP	O	O
ovarian	ADJ	O	O
cancer	NOUN	O	O
cases	NOUN	O	O
,	PUNCT	O	O
25	NUM	O	O
fatal	ADJ	O	O
,	PUNCT	O	O
would	PUNCT	O	O
have	PUNCT	O	O
been	PUNCT	O	O
detected	VERB	O	O
earlier	PUNCT	O	O
with	ADP	O	O
ROCA	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
median	ADJ	O	O
(	PUNCT	O	O
minimum	NOUN	O	O
)	PUNCT	O	O
advance	NOUN	O	O
time	NOUN	O	O
for	ADP	O	O
fatal	ADJ	O	B-MORTALITY
cases	NOUN	O	I-MORTALITY
of	ADP	O	O
344	NUM	O	O
(	PUNCT	O	O
147	NUM	O	O
)	PUNCT	O	O
days	NOUN	O	O
.	PUNCT	O	O

Best-case	NOUN	O	O
and	CCONJ	O	O
stage-shift	PUNCT	O	O
scenarios	NOUN	O	O
gave	VERB	O	O
25	NUM	O	O
and	CCONJ	O	O
19	NUM	O	O
deaths	NOUN	O	B-MORTALITY
prevented	ADJ	O	O
with	ADP	O	O
ROCA	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
RRs	NOUN	O	O
of	ADP	O	O
0.90	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.69-1.17	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
0.95	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.74-1.23	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Having	DET	O	O
utilized	PUNCT	O	O
ROCA	NOUN	O	O
in	ADP	O	O
PLCO	NOUN	O	O
would	VERB	O	O
not	ADV	O	O
have	PUNCT	O	O
led	VERB	O	O
to	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
mortality	NOUN	O	B-MORTALITY
benefit	NOUN	O	I-MORTALITY
of	ADP	O	O
screening	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
ROCA	NOUN	O	O
could	SYM	O	O
still	ADV	O	O
show	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
other	ADJ	O	O
screening	ADP	O	O
trials	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
UKCTOCS	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
extradural	ADJ	O	O
analgesia	NOUN	O	O
on	ADP	O	O
stress	NOUN	O	O
responses	NOUN	O	B-PHYSICAL
to	ADP	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
in	ADP	O	O
infants	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
40	NUM	O	O
children	NOUN	O	O
younger	PUNCT	O	O
than	VERB	O	O
4	NUM	O	O
yr	NOUN	O	O
having	ADJ	O	O
elective	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
under	ADP	O	O
general	ADJ	O	O
anaesthesia	NOUN	O	O
supplemented	ADP	O	O
with	ADP	O	O
either	CCONJ	O	O
systemic	ADJ	O	O
opioids	NOUN	O	O
or	CCONJ	O	O
extradural	ADJ	O	O
bupivacaine	NOUN	O	O
.	PUNCT	O	O

Venous	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
samples	NOUN	O	I-PHYSICAL
were	VERB	O	O
obtained	VERB	O	O
before	ADP	O	O
tracheal	ADJ	O	O
intubation	NOUN	O	O
to	PART	O	O
measure	ADJ	O	O
baseline	NOUN	O	O
concentrations	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
adrenaline	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
noradrenaline	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
glucose	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
ACTH	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
cortisol	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Additional	ADJ	O	O
samples	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
45	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-OTHER
concentrations	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
bupivacaine	NOUN	O	I-OTHER
were	VERB	O	O
measured	VERB	O	O
also	ADV	O	O
in	ADP	O	O
the	DET	O	O
extradural	ADJ	O	O
group	NOUN	O	O
at	ADP	O	O
each	DET	O	O
sampling	DET	O	O
time	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
techniques	NOUN	O	O
provided	VERB	O	O
acceptable	ADJ	O	O
analgesia	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
perioperative	ADJ	O	B-PHYSICAL
increases	CCONJ	O	O
in	ADP	O	B-PHYSICAL
adrenaline	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
glucose	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
ACTH	NOUN	O	B-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
opioid	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Noradrenaline	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
decreased	NUM	O	O
to	ADP	O	O
less	ADV	O	O
than	PUNCT	O	O
baseline	NOUN	O	O
values	NOUN	O	O
in	ADP	O	O
the	DET	O	O
extradural	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
opioid	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
perioperative	ADJ	O	B-PHYSICAL
increase	NOUN	O	O
in	ADP	O	B-PHYSICAL
cortisol	NOUN	O	B-PHYSICAL
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
despite	ADP	O	O
the	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
ACTH	NOUN	O	O
responses	NOUN	O	O
.	PUNCT	O	O

Most	PUNCT	O	O
responses	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
values	NOUN	O	O
within	ADP	O	O
24	PUNCT	O	O
h.	PUNCT	O	O

Contribution	NOUN	O	O
of	ADP	O	O
endogenous	ADJ	O	O
bradykinin	NOUN	O	O
to	ADP	O	O
fibrinolysis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
inflammation	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
product	NOUN	O	I-PHYSICAL
transfusion	NOUN	O	I-PHYSICAL
following	SYM	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Bradykinin	NOUN	O	O
increases	ADJ	O	O
during	ADP	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
(	PUNCT	O	O
CPB	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
stimulates	NOUN	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-PHYSICAL
oxide	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
inflammatory	ADJ	O	O
cytokines	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tissue-type	NOUN	O	O
plasminogen	PUNCT	O	O

Clobazam	NOUN	O	O
in	ADP	O	O
catamenial	ADJ	O	O
epilepsy	NOUN	O	O
.	PUNCT	O	O

A	PUNCT	O	O
model	NOUN	O	O
for	ADP	O	O
evaluating	VERB	O	O
anticonvulsants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cyclical	ADJ	O	O
exacerbations	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	O
(	PUNCT	O	O
catamenial	ADJ	O	O
epilepsy	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
antiepileptic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
benzodiazepine	NOUN	O	O
,	PUNCT	O	O
clobazam	ADV	O	O
.	PUNCT	O	O

Doses	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
some	DET	O	O
cases	NOUN	O	O
30	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
per	ADP	O	O
day	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
over	ADP	O	O
predetermined	VERB	O	O
ten-day	NOUN	O	O
periods	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
cross-over	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
preference	NOUN	O	O
in	ADP	O	O
a	DET	O	O
sequential	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
14	NUM	O	O
of	ADP	O	O
18	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
both	PUNCT	O	O
treatments	ADJ	O	O
clobazam	ADV	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
4	NUM	O	O
patients	NOUN	O	O
no	DET	O	O
preference	NOUN	O	O
was	VERB	O	O
established	VERB	O	O
.	PUNCT	O	O

Clobazam	NOUN	O	O
completely	ADV	O	O
prevented	VERB	O	O
seizures	NOUN	O	B-PHYSICAL
in	ADP	O	O
most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
were	ADJ	O	O
of	ADP	O	O
low	ADJ	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	B-OTHER
.	PUNCT	O	O

Diclofenac	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
nonsteroidal	ADJ	O	O
anti-inflammatory	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
decreases	ADJ	O	O
proteinuria	NOUN	O	O
in	ADP	O	O
some	DET	O	O
glomerular	ADJ	O	O
diseases	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
nonsteroidal	ADJ	O	O
anti-inflammatory	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
NSAIDs	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
first	ADJ	O	O
used	VERB	O	O
in	ADP	O	O
glomerulonephritis	NOUN	O	O
(	PUNCT	O	O
GN	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
1966	NUM	O	O
but	CCONJ	O	O
its	PUNCT	O	O
efficiency	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
debated	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
antiproteinuric	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
such	CCONJ	O	O
a	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

29	NUM	O	O
GN	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
(	PUNCT	O	O
17	NUM	O	O
membranoproliferative	ADJ	O	O
GN	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
IgA	NOUN	O	O
GN	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
100	NUM	O	O
mg/day	NOUN	O	O
of	ADP	O	O
diclofenac	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
2	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
antiproteinuric	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
diclofenac	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
with	ADP	O	O
a	DET	O	O
fall	NOUN	O	O
of	ADP	O	O
70	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
diclofenac	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
6	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.001	NUM	O	O
with	ADP	O	O
the	DET	O	O
Mann-Whitney	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADP	O	O
was	ADV	O	O
3	NUM	O	O
mg/min	NOUN	O	O
at	ADP	O	O
onset	NOUN	O	O
and	CCONJ	O	O
2.45	NUM	O	O
mg/min	NOUN	O	O
after	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
diclofenac	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
2.2	NUM	O	O
and	CCONJ	O	O
0.95	NUM	O	O
mg/min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Diclofenac	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
significantly	ADV	O	O
increase	ADV	O	O
creatinine	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Gastric	ADJ	O	B-PHYSICAL
irritation	NOUN	O	I-PHYSICAL
was	VERB	O	O
noted	VERB	O	O
only	ADV	O	O
once	ADP	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
establishes	NOUN	O	O
the	DET	O	O
short-term	NOUN	O	B-PHYSICAL
antiproteinuric	ADJ	O	I-PHYSICAL
action	NOUN	O	I-PHYSICAL
of	ADP	O	O
diclofenac	NOUN	O	O
.	PUNCT	O	O

Whether	ADP	O	O
this	DET	O	O
action	NOUN	O	O
affects	NOUN	O	O
the	DET	O	O
final	ADJ	O	O
outcome	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
yet	ADV	O	O
determined	VERB	O	O
.	PUNCT	O	O

Benefit	NOUN	O	O
of	ADP	O	O
FSH	NOUN	O	O
priming	VERB	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
PCOS	NOUN	O	O
to	ADP	O	O
the	CCONJ	O	O
in	PUNCT	O	O
vitro	ADJ	O	O
maturation	NOUN	O	O
procedure	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
outcome	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
prospective	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
rates	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
in	PUNCT	O	I-PHYSICAL
vitro	ADJ	O	I-PHYSICAL
oocyte	NOUN	O	I-PHYSICAL
maturation	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
fertilization	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
cleavage	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
implantation	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
pregnancy	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
improved	VERB	O	O
by	ADP	O	O
low-dose	NOUN	O	O
priming	VERB	O	O
with	ADP	O	O
FSH	NOUN	O	O
in	VERB	O	O
vivo	ADV	O	O
before	ADP	O	O
retrieval	NOUN	O	O
of	ADP	O	O
immature	ADJ	O	O
oocytes	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
polycystic	ADJ	O	O
ovary	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
PCOS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

From	ADP	O	O
March	NOUN	O	O
1998	NUM	O	O
to	ADP	O	O
June	NOUN	O	O
2000	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
28	NUM	O	O
women	NOUN	O	O
underwent	VERB	O	O
36	NUM	O	O
completed	VERB	O	O
treatment	NOUN	O	O
cycles	NOUN	O	O
,	PUNCT	O	O
randomized	ADP	O	O
sequentially	ADV	O	O
in	ADP	O	O
one	NUM	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
cycles	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
no	DET	O	O
stimulation	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
cycles	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
150	NUM	O	O
iu	PUNCT	O	O
recombinant	ADJ	O	O
FSH	NOUN	O	O
day	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
initiated	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
3	NUM	O	O
after	ADP	O	O
menstruation	NOUN	O	O
.	PUNCT	O	O

Aspiration	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
transvaginally	ADV	O	O
between	ADP	O	O
day	NOUN	O	O
9	NUM	O	O
and	CCONJ	O	O
day	NOUN	O	O
17	NUM	O	O
in	ADP	O	O
the	DET	O	O
unstimulated	VERB	O	O
group	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
day	NOUN	O	O
8	NUM	O	O
or	CCONJ	O	O
day	NOUN	O	O
9	NUM	O	O
in	ADP	O	O
the	DET	O	O
FSH-primed	ADJ	O	O
group	NOUN	O	O
after	ADP	O	O
FSH	NOUN	O	O
deprivation	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
or	CCONJ	O	O
3	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
cumulus-enclosed	VERB	O	O
oocytes	NOUN	O	O
of	ADP	O	O
healthy	ADJ	O	O
appearance	NOUN	O	O
were	VERB	O	O
matured	ADJ	O	O
in	ADP	O	O
culture	NOUN	O	O
medium	NOUN	O	O
(	PUNCT	O	O
TCM-199	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
vitro	ADJ	O	O
for	ADP	O	O
28-36	NUM	O	O
h	NOUN	O	O
before	ADP	O	O
intracytoplasmic	ADJ	O	O
sperm	NOUN	O	O
injection	NOUN	O	O
(	PUNCT	O	O
ICSI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
oocyte	NOUN	O	O
retrieval	NOUN	O	O
the	DET	O	O
women	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
oestradiol	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
mg	NOUN	O	O
day	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
progesterone	NOUN	O	O
administration	NOUN	O	O
(	PUNCT	O	O
300	NUM	O	O
mg	NOUN	O	O
day	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
initiated	VERB	O	O
2	NUM	O	O
days	NOUN	O	O
later	ADJ	O	O
.	PUNCT	O	O

Suitable	ADJ	O	O
embryos	NOUN	O	O
(	PUNCT	O	O
maximum	NOUN	O	O
two	NUM	O	O
embryos	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
transferred	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
3	NUM	O	O
after	ADP	O	O
ICSI	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
oocytes	NOUN	O	B-OTHER
reaching	VERB	O	I-OTHER
metaphase	NOUN	O	I-OTHER
II	NUM	O	I-OTHER
was	ADJ	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
FSH-primed	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
59	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
92/156	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
non-primed	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
44	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
36/81	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rates	NOUN	O	O
of	ADP	O	O
oocyte	NOUN	O	B-OTHER
fertilization	NOUN	O	I-OTHER
and	CCONJ	O	O
cleavage	NOUN	O	B-OTHER
between	ADP	O	O
these	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
pregnancies	NOUN	O	B-PHYSICAL
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
0/12	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
seven	NUM	O	O
clinical	ADJ	O	B-OTHER
pregnancies	NOUN	O	I-OTHER
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
29	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
7/24	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
37	NUM	O	O
embryo	NOUN	O	O
transfers	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
eight	NUM	O	O
implantations	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
21.6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
healthy	ADJ	O	B-PHYSICAL
singleton	NOUN	O	I-PHYSICAL
children	NOUN	O	I-PHYSICAL
have	VERB	O	O
been	PUNCT	O	O
born	VERB	O	B-PHYSICAL
at	ADP	O	O
term	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
remaining	VERB	O	O
pregnancies	NOUN	O	O
ended	PUNCT	O	O
with	ADP	O	O
spontaneous	ADJ	O	B-ADVERSE-EFFECTS
abortions	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
trimester	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
priming	VERB	O	O
with	ADP	O	O
recombinant	ADJ	O	O
FSH	NOUN	O	O
before	ADP	O	O
harvesting	PUNCT	O	O
of	ADP	O	O
immature	ADJ	O	O
oocytes	NOUN	O	O
from	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
PCOS	NOUN	O	O
may	VERB	O	O
improve	VERB	O	O
the	DET	O	O
maturational	ADJ	O	B-OTHER
potential	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
oocytes	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
the	DET	O	I-OTHER
implantation	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
cleaved	VERB	O	I-OTHER
embryos	NOUN	O	I-OTHER
.	PUNCT	O	O

Pentoxifylline	NOUN	O	O
to	PART	O	O
treat	NOUN	O	O
radiation	NOUN	O	O
proctitis	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
small	ADJ	O	O
and	CCONJ	O	O
inconclusive	ADJ	O	O
randomised	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
of	ADP	O	O
40	NUM	O	O
patients	NOUN	O	O
could	ADP	O	O
not	ADV	O	O
show	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
advantage	NOUN	O	O
with	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
pentoxifylline	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
standard	ADJ	O	O
measures	NOUN	O	O
for	ADP	O	O
late	ADJ	O	B-PHYSICAL
radiation-induced	VERB	O	I-PHYSICAL
rectal	ADJ	O	I-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
modest	ADJ	O	O
benefit	NOUN	O	O
can	PRON	O	O
not	ADV	O	O
be	VERB	O	O
excluded	VERB	O	O
and	CCONJ	O	O
larger	PUNCT	O	O
randomised	ADP	O	O
placebo-controlled	VERB	O	O
trials	NOUN	O	O
with	ADP	O	O
longer	PUNCT	O	O
durations	NOUN	O	O
of	ADP	O	O
pentoxifylline	NOUN	O	B-OTHER
treatment	NOUN	O	I-OTHER
may	VERB	O	O
be	VERB	O	O
justified	VERB	O	O
.	PUNCT	O	O

Effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
calculus	NOUN	O	O
scaling	PUNCT	O	O
gel	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
calculus	NOUN	O	O
scaling	PUNCT	O	O
gel	NOUN	O	O
(	PUNCT	O	O
SofScale	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
time	NOUN	O	B-OTHER
and	CCONJ	O	I-OTHER
ease	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
scaling	ADJ	O	I-OTHER
procedure	NOUN	O	I-OTHER
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
split-mouth	NOUN	O	O
clinical	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
32	NUM	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Volpe-Manhold	ADJ	O	B-PHYSICAL
calculus	NOUN	O	I-PHYSICAL
index	NOUN	O	I-PHYSICAL
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
quantify	NOUN	O	O
the	DET	O	O
distribution	NOUN	O	O
and	CCONJ	O	O
amount	NOUN	O	O
of	ADP	O	O
calculus	NOUN	O	O
deposition	NOUN	O	O
on	ADP	O	O
the	DET	O	O
lingual	ADJ	O	O
aspect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mandibular	ADJ	O	O
6	NUM	O	O
anterior	ADJ	O	O
teeth	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
gel	NOUN	O	O
was	VERB	O	O
applied	VERB	O	O
directly	ADV	O	O
to	ADP	O	O
the	DET	O	O
calculus	NOUN	O	O
and	CCONJ	O	O
subgingivally	NOUN	O	O
to	ADP	O	O
the	DET	O	O
area	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
scaled	ADV	O	O
.	PUNCT	O	O

Pre-	PUNCT	O	O
and	CCONJ	O	O
post-treatment	NOUN	O	O
gingival	ADJ	O	O
and	CCONJ	O	O
stain	NOUN	O	O
indices	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
.	PUNCT	O	O

Operator	NOUN	O	B-OTHER
and	CCONJ	O	O
subject	PUNCT	O	B-OTHER
questionnaires	NOUN	O	I-OTHER
were	VERB	O	O
completed	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
treatment	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
ease	NOUN	O	O
of	ADP	O	O
the	DET	O	O
scaling	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
with	ADP	O	O
paired	VERB	O	O
t-tests	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	B-OTHER
difference	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
scaling	DET	O	I-OTHER
between	ADP	O	O
the	DET	O	O
product	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
side	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
found	VERB	O	O
that	ADP	O	O
SofScale	NOUN	O	O
is	VERB	O	O
safe	ADJ	O	O
to	ADP	O	O
gingival	ADJ	O	B-PHYSICAL
tissues	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
promote	VERB	O	O
tooth	NOUN	O	B-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
find	VERB	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
scaling	DET	O	O
time	NOUN	O	O
between	ADP	O	O
product	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
when	ADP	O	O
using	VERB	O	O
a	DET	O	O
2-minute	ADJ	O	O
gel	NOUN	O	O
contact	NOUN	O	O
time	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
pressor	NOUN	O	O
and	CCONJ	O	O
hormonal	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
beta-endorphin	NOUN	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
and	CCONJ	O	O
hypertensive	ADJ	O	O
subjects	NOUN	O	O
:	PUNCT	O	O
role	NOUN	O	O
of	ADP	O	O
opioid	NOUN	O	O
receptor	NOUN	O	O
agonism	NOUN	O	O
.	PUNCT	O	O

CONTEXT	NOUN	O	O
The	DET	O	O
opioid	NOUN	O	O
system	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
regulation	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
normal	ADJ	O	O
humans	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high-dose	NOUN	O	O
infusion	NOUN	O	O
of	ADP	O	O
beta-endorphin	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
opioid	NOUN	O	O
peptide	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
hormonal	ADJ	O	O
profile	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
mediation	NOUN	O	O
played	VERB	O	O
by	ADP	O	O
opioid	NOUN	O	O
receptor	NOUN	O	O
agonism	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
,	PUNCT	O	O
SETTING	VERB	O	O
,	PUNCT	O	O
AND	CCONJ	O	O
PARTICIPANTS	ADP	O	O
According	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
double-blind	ADJ	O	O
design	NOUN	O	O
,	PUNCT	O	O
11	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
controls	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
hypertensive	ADJ	O	O
inpatients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
38.9	NUM	O	O
and	CCONJ	O	O
40.4	NUM	O	O
yr	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
received	VERB	O	O
1-h	NOUN	O	O
iv	PUNCT	O	O
infusion	NOUN	O	O
of	ADP	O	O
beta-endorphin	NOUN	O	O
(	PUNCT	O	O
250	NUM	O	O
mug/h	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
on	ADP	O	O
another	ADP	O	O
occasion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
same	ADJ	O	O
infusion	NOUN	O	O
protocol	NOUN	O	O
preceded	VERB	O	O
by	ADP	O	O
the	DET	O	O
opioid	NOUN	O	O
antagonist	NOUN	O	O
naloxone	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Hemodynamic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
hormonal	ADJ	O	I-PHYSICAL
measurements	NOUN	O	I-PHYSICAL
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
established	VERB	O	O
times	NOUN	O	O
during	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
protocols	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
circulating	VERB	O	O
beta-endorphin	NOUN	O	O
,	PUNCT	O	O
norepinephrine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
endothelin-1	NOUN	O	O
in	ADP	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
higher	PUNCT	O	O
than	CCONJ	O	O
in	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
beta-endorphin	NOUN	O	O
reduced	VERB	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
circulating	VERB	O	B-PHYSICAL
norepinephrine	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
plasma	NOUN	O	O
atrial	ADJ	O	O
natriuretic	ADJ	O	B-PHYSICAL
factor	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
GH	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
beta-endorphin	NOUN	O	O
decreased	VERB	O	O
systemic	ADJ	O	B-PHYSICAL
vascular	ADJ	O	I-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
plasma	NOUN	O	B-PHYSICAL
norepinephrine	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
endothelin-1	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
raised	VERB	O	O
circulating	NUM	O	O
atrial	ADJ	O	O
natriuretic	ADJ	O	B-PHYSICAL
factor	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
GH	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
IGF-I	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
hemodynamic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
hormonal	ADJ	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	O
beta-endorphin	NOUN	O	O
in	ADP	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
greater	PUNCT	O	O
than	CCONJ	O	O
in	ADP	O	O
controls	NOUN	O	O
but	CCONJ	O	O
were	VERB	O	O
annulled	VERB	O	O
in	ADP	O	O
all	DET	O	O
individuals	NOUN	O	O
when	ADP	O	O
naloxone	PUNCT	O	O
preceded	VERB	O	O
beta-endorphin	NOUN	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
High	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
beta-endorphin	NOUN	O	O
induce	VERB	O	O
hypotensive	ADJ	O	O
and	CCONJ	O	O
beneficial	ADJ	O	O
hormonal	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
are	VERB	O	O
enhanced	VERB	O	O
in	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
opioid	NOUN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	O
on	ADP	O	O
kidney	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
protein	NOUN	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
autosomal	ADJ	O	O
dominant	ADJ	O	O
polycystic	ADJ	O	O
kidney	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Autosomal	ADJ	O	O
dominant	ADJ	O	O
polycystic	ADJ	O	O
kidney	NOUN	O	O
disease	NOUN	O	O
(	PUNCT	O	O
ADPKD	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
progressive	ADJ	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
end-stage	NOUN	O	O
kidney	NOUN	O	O
failure	NOUN	O	O
in	ADP	O	O
most	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Experimental	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
have	CCONJ	O	O
suggested	VERB	O	O
that	ADP	O	O
statins	NOUN	O	O
may	DET	O	O
slow	CCONJ	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-PHYSICAL
kidney	NOUN	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
in	ADP	O	O
general	ADJ	O	O
and	CCONJ	O	O
ADPKD	NOUN	O	O
specifically	ADV	O	O
.	PUNCT	O	O

MATERIAL	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
This	PUNCT	O	O
randomized	PUNCT	O	O
open-label	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	O
20	NUM	O	O
mg	NOUN	O	O
on	ADP	O	O
kidney	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
protein	NOUN	O	O
excretion	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ADPKD	NOUN	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
initially	ADV	O	O
recruited	VERB	O	O
but	CCONJ	O	O
49	NUM	O	O
of	ADP	O	O
these	PUNCT	O	O
received	VERB	O	O
either	CCONJ	O	O
pravastatin	NOUN	O	O
20	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
no	DET	O	O
treatment	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Trial	NOUN	O	O
visits	NOUN	O	O
were	VERB	O	O
conducted	ADP	O	O
every	DET	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
assessing	ADP	O	O
kidney	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
by	ADP	O	O
estimated	ADP	O	O
glomerular	ADJ	O	B-OTHER
filtration	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
and	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	B-OTHER
urine	NOUN	O	I-OTHER
creatinine	NOUN	O	I-OTHER
clearance	NOUN	O	I-OTHER
and	CCONJ	O	O
urinary	ADJ	O	B-OTHER
protein	NOUN	O	I-OTHER
excretion	NOUN	O	I-OTHER
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
changes	NOUN	O	B-OTHER
in	ADP	O	O
markers	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
urinary	ADJ	O	B-PHYSICAL
protein	NOUN	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
between	ADP	O	O
groups	NOUN	O	O
over	ADP	O	O
the	DET	O	O
2	NUM	O	O
years	NOUN	O	O
despite	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
serum	NOUN	O	B-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
in	ADP	O	O
pravastatin-treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.029	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
This	DET	O	O
trial	NOUN	O	O
found	VERB	O	O
that	ADP	O	O
taking	PUNCT	O	O
20	NUM	O	O
mg	NOUN	O	O
pravastatin	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
had	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
kidney	NOUN	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
protein	NOUN	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ADPKD	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
statistical	ADJ	O	O
power	NOUN	O	O
limits	NOUN	O	O
the	DET	O	O
external	ADJ	O	O
validity	NOUN	O	O
of	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
larger	PUNCT	O	O
,	PUNCT	O	O
longer	PUNCT	O	O
duration	NOUN	O	O
study	NOUN	O	O
using	VERB	O	O
a	DET	O	O
higher	PUNCT	O	O
dose	NOUN	O	O
of	ADP	O	O
a	DET	O	O
more	ADV	O	O
potent	ADJ	O	O
statin	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
.	PUNCT	O	O

Are	ADJ	O	O
tyrosine	NOUN	O	O
kinase	NOUN	O	O
inhibitors	NOUN	O	O
still	ADV	O	O
active	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
renal	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
tyrosine	NOUN	O	O
kinase	NOUN	O	O
inhibitor	NOUN	O	O
and	CCONJ	O	O
everolimus	NOUN	O	O
?	PUNCT	O	O

Experience	NOUN	O	O
of	ADP	O	O
36	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
in	ADP	O	O
France	NOUN	O	O
in	ADP	O	O
the	DET	O	O
RECORD-1	NOUN	O	O
Trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Because	PUNCT	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
is	VERB	O	O
limited	VERB	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
renal	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
(	PUNCT	O	O
mRCC	NOUN	O	O
)	PUNCT	O	O
typically	ADV	O	O
receive	VERB	O	O
multiple	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Guidelines	PROPN	O	O
recommend	VERB	O	O
everolimus	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
tyrosine	NOUN	O	O
kinase	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
TKI	NOUN	O	O
)	PUNCT	O	O
sunitinib	NOUN	O	O
or	CCONJ	O	O
sorafenib	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
TKI	NOUN	O	O
re-treatment	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
disease	NOUN	O	O
progression	NOUN	O	O
after	ADP	O	O
a	DET	O	O
TKI-everolimus	NOUN	O	O
sequence	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Data	NOUN	O	O
were	VERB	O	O
reviewed	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
RECORD-1	NOUN	O	O
(	PUNCT	O	O
Renal	ADJ	O	O
Cell	NOUN	O	O
Cancer	NOUN	O	O
Treatment	NOUN	O	O
With	ADP	O	O
Oral	ADJ	O	O
RAD001	NOUN	O	O
Given	ADP	O	O
Daily	CCONJ	O	O
)	PUNCT	O	O
at	ADP	O	O
French	ADJ	O	O
sites	NOUN	O	O
.	PUNCT	O	O

Response	NOUN	O	O
,	PUNCT	O	B-MORTALITY
progression-free	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	I-MORTALITY
PFS	NOUN	O	I-MORTALITY
)	PUNCT	O	I-MORTALITY
,	PUNCT	O	I-MORTALITY
and	CCONJ	O	I-MORTALITY
overall	ADJ	O	I-MORTALITY
survival	NOUN	O	B-MORTALITY
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
TKI-everolimus-TKI	NUM	O	O
sequence	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-six	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
TKI	NOUN	O	O
after	ADP	O	O
everolimus	NOUN	O	O
:	PUNCT	O	O
sunitinib	NOUN	O	O
in	ADP	O	O
17	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
sorafenib	NOUN	O	O
in	ADP	O	O
15	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
dovitinib	NOUN	O	O
(	PUNCT	O	O
TKI258	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
4	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
with	ADP	O	O
TKI	NOUN	O	O
re-treatment	NOUN	O	O
was	VERB	O	O
8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
disease-control	NOUN	O	B-PHYSICAL
rate	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
response	NOUN	O	O
plus	CCONJ	O	B-PHYSICAL
stable	PUNCT	O	I-PHYSICAL

Effects	NOUN	O	O
of	ADP	O	O
diet	NOUN	O	O
and	CCONJ	O	O
Aspergillus	NOUN	O	O
oryzae	NOUN	O	O
extract	NOUN	O	O
or	CCONJ	O	O
Saccharomyces	NOUN	O	O
cervisiae	NOUN	O	O
on	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
carcass	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
lambs	NOUN	O	O
and	CCONJ	O	O
steers	ADJ	O	O
fed	VERB	O	O
to	PART	O	O
meet	NOUN	O	O
requirements	NOUN	O	O
of	ADP	O	O
natural	ADJ	O	O
markets	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
studies	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
diet	NOUN	O	O
and	CCONJ	O	O
feed	PUNCT	O	O
additive	ADJ	O	O
on	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
carcass	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
lambs	NOUN	O	O
and	CCONJ	O	O
cattle	NOUN	O	O
destined	VERB	O	O
for	ADP	O	O
all	DET	O	O
natural	ADJ	O	O
markets	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Exp	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
,	PUNCT	O	O
48	NUM	O	O
Dorset	NOUN	O	O
?	PUNCT	O	O

Hampshire	PUNCT	O	O
lambs	NOUN	O	O
(	PUNCT	O	O
initial	ADJ	O	O
BW	NOUN	O	O
29.4	NUM	O	O
?	PUNCT	O	O

0.1	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
complete	ADJ	O	O
block	ADV	O	O
experiment	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
Aspergillus	NOUN	O	O
oryzae	NOUN	O	O
extract	NOUN	O	O
,	PUNCT	O	O
Amaferm	NOUN	O	O
(	PUNCT	O	O
AMF	NOUN	O	O
)	PUNCT	O	O
supplementation	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
g/d	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
an	DET	O	O
85	NUM	O	O
%	SYM	O	O
concentrate	NOUN	O	O
diet	NOUN	O	O
on	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
carcass	NOUN	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

Lambs	ADV	O	O
were	VERB	O	O
allotted	VERB	O	O
to	ADP	O	O
12	NUM	O	O
pens	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
lambs	NOUN	O	O
per	ADP	O	O
pen	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
blocked	VERB	O	O
by	ADP	O	O
sex	NOUN	O	O
and	CCONJ	O	O
BW	NOUN	O	O
.	PUNCT	O	O

Lambs	ADV	O	O
were	VERB	O	O
fed	VERB	O	O
until	ADP	O	O
the	DET	O	O
average	ADJ	O	O
BW	NOUN	O	O
of	ADP	O	O
each	DET	O	O
pen	ADJ	O	O
reached	PRON	O	O
a	DET	O	O
target	NOUN	O	O
BW	NOUN	O	O
(	PUNCT	O	O
55.4	NUM	O	O
kg	NOUN	O	O
for	ADP	O	O
wethers	NOUN	O	O
and	CCONJ	O	O
50.0	NUM	O	O
kg	NOUN	O	O
for	ADP	O	O
ewes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
at	ADP	O	O
which	DET	O	O
time	VERB	O	O
the	DET	O	O
entire	ADJ	O	O
pen	ADJ	O	O
of	ADP	O	O
lambs	NOUN	O	O
was	VERB	O	O
slaughtered	VERB	O	O
.	PUNCT	O	O

Amaferm	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
(	PUNCT	O	O
P=0.07	NOUN	O	O
)	PUNCT	O	O
G	NOUN	O	O
:	PUNCT	O	O
F.	NOUN	O	O
In	ADP	O	O
Exp	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
,	PUNCT	O	O
168	NUM	O	O
crossbred	ADJ	O	O
steers	NOUN	O	O
(	PUNCT	O	O
initial	ADJ	O	O
BW	NOUN	O	O
300	NUM	O	O
?	PUNCT	O	O

0.7	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
in	ADP	O	O
a	DET	O	O
trial	NOUN	O	O
with	ADP	O	O
a	DET	O	O
3	NUM	O	O
?	PUNCT	O	O

2	NUM	O	O
factorial	ADJ	O	O
arrangement	ADJ	O	O
of	ADP	O	O
treatments	NOUN	O	O
to	PART	O	O
examine	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
g/d	NOUN	O	O
of	ADP	O	O
Saccaromyces	PROPN	O	O
cervisiae	VERB	O	O
boulardii	NOUN	O	O
CNCM	NOUN	O	O
1079-Levucell	NOUN	O	O
SB	NOUN	O	O
(	PUNCT	O	O
LEV	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
3	NUM	O	O
g/d	NOUN	O	O
of	ADP	O	O
AMF	NOUN	O	O
with	ADP	O	O
2	NUM	O	O
corn	NOUN	O	O
sources	NOUN	O	O
,	PUNCT	O	O
dry	ADJ	O	O
whole-shelled	ADV	O	O
corn	NOUN	O	O
or	CCONJ	O	O
high	ADJ	O	O
moisture	NOUN	O	O
corn	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
carcass	NOUN	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
LEV	NOUN	O	O
nor	CCONJ	O	O
AMF	NOUN	O	O
improved	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.10	NUM	O	O
)	PUNCT	O	O
carcass	NOUN	O	B-PHYSICAL
characteristics	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
or	CCONJ	O	O
non-feed-supplemented	PRON	O	O
steers	NOUN	O	O
.	PUNCT	O	O

Addition	NOUN	O	O
of	ADP	O	O
LEV	NOUN	O	O
to	ADP	O	O
high-concentrate	ADP	O	O
,	PUNCT	O	O
corn-based	ADJ	O	O
diets	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
improve	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.10	NUM	O	O
)	PUNCT	O	O
growth	NOUN	O	B-PHYSICAL
performance	NOUN	O	I-PHYSICAL
of	ADP	O	O
feedlot	NOUN	O	O
steers	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
addition	NOUN	O	O
of	ADP	O	O
AMF	NOUN	O	O
to	ADP	O	O
a	DET	O	O
diet	NOUN	O	O
composed	VERB	O	O
of	ADP	O	O
dry	ADJ	O	O
whole-shelled	ADV	O	O
corn	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
improvement	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
G	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
F	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
0.208	ADP	O	O
vs.	CCONJ	O	O
0.194	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
at	ADP	O	O
the	DET	O	O
amounts	ADJ	O	O
fed	VERB	O	O
,	PUNCT	O	O
AMF	NOUN	O	O
may	PUNCT	O	O
improve	PUNCT	O	O

Bridge	ADP	O	O
plate	NOUN	O	O
osteosynthesis	NOUN	O	O
using	VERB	O	O
dynamic	ADJ	O	O
condylar	ADJ	O	O
screw	NOUN	O	O
(	PUNCT	O	O
DCS	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
retrograde	ADJ	O	O
intramedullary	ADJ	O	O
supracondylar	ADJ	O	O
nail	NOUN	O	O
(	PUNCT	O	O
RIMSN	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
distal	ADJ	O	O
femoral	ADJ	O	O
fractures	NOUN	O	O
:	PUNCT	O	O
comparison	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
methods	NOUN	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
distal	ADJ	O	O
femoral	ADJ	O	O
fractures	NOUN	O	O
remains	ADJ	O	O
a	DET	O	O
significant	ADJ	O	O
surgical	ADJ	O	O
challenge	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
the	DET	O	O
rigid	ADJ	O	O
fixation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
distal	ADJ	O	O
femoral	ADJ	O	O
fractures	NOUN	O	O
,	PUNCT	O	O
bone	NOUN	O	O
grafting	VERB	O	O
is	VERB	O	O
frequently	ADV	O	O
needed	VERB	O	O
.	PUNCT	O	O

Biological	ADJ	O	O
osteosynthesis	NOUN	O	O
using	VERB	O	O
dynamic	ADJ	O	O
condylar	ADJ	O	O
screw	NOUN	O	O
(	PUNCT	O	O
DCS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
retrograde	ADJ	O	O
intramedullary	ADJ	O	O
supracondylar	ADJ	O	O
nail	NOUN	O	O
(	PUNCT	O	O
RIMSN	NOUN	O	O
)	PUNCT	O	O
preserve	PUNCT	O	O
the	DET	O	O
blood	NOUN	O	O
supply	NOUN	O	O
and	CCONJ	O	O
limit	ADJ	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
bone	NOUN	O	O
grafting	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
From	ADP	O	O
September	NOUN	O	O
2002	NUM	O	O
to	ADP	O	O
December	NOUN	O	O
2004	NUM	O	O
,	PUNCT	O	O
68	NUM	O	O
closed	VERB	O	O
fractures	NOUN	O	O
of	ADP	O	O
the	DET	O	O
distal	ADJ	O	O
femur	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
by	CCONJ	O	O
bridge	ADP	O	O
plate	NOUN	O	O
osteosynthesis	NOUN	O	O
using	VERB	O	O
DCS	NOUN	O	O
in	ADP	O	O
31	NUM	O	O
and	CCONJ	O	O
RIMSN	NOUN	O	O
in	ADP	O	O
37	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
allocated	NUM	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
randomly	ADV	O	O
and	CCONJ	O	O
followed	VERB	O	O
for	ADP	O	O
24-36	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
average	NOUN	O	O
:	PUNCT	O	O
30	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
With	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
operation	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
DCS	NOUN	O	O
group	NOUN	O	O
presented	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
results	PUNCT	O	O
than	VERB	O	O
the	DET	O	O
RIMSN	CCONJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
p=0.000	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
in	ADP	O	O
the	DET	O	O
DCS	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p=0.000	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
cumulative	ADJ	O	B-OTHER
rate	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
union	NOUN	O	I-OTHER
(	PUNCT	O	O
p=0.855	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
range	NOUN	O	O
of	ADP	O	B-PHYSICAL
motion	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
knee	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
p=0.727	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
overall	PUNCT	O	B-PHYSICAL

Dysfunctional	ADJ	O	O
attitudes	ADJ	O	O
as	ADP	O	O
a	DET	O	O
moderator	NOUN	O	O
of	ADP	O	O
pharmacotherapy	NOUN	O	O
and	CCONJ	O	O
psychotherapy	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	O
depression	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Individuals	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
depression	NOUN	O	O
exhibit	VERB	O	O
heterogeneous	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Important	ADJ	O	O
individual	ADJ	O	O
differences	NOUN	O	O
may	ADP	O	O
therefore	ADV	O	O
exist	VERB	O	O
within	ADP	O	O
this	PUNCT	O	O
particularly	ADV	O	O
difficult	ADJ	O	O
to	PART	O	O
treat	NOUN	O	O
population	NOUN	O	O
that	ADP	O	O
act	VERB	O	O
as	ADP	O	O
moderators	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
response	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
whether	ADP	O	O
pretreatment	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
dysfunctional	ADJ	O	O
attitudes	NOUN	O	O
(	PUNCT	O	O
DA	NOUN	O	O
)	PUNCT	O	O
moderated	ADJ	O	O
treatment	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
chronically	ADV	O	O
depressed	VERB	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
from	ADP	O	O
the	DET	O	O
Research	NOUN	O	O
Evaluating	VERB	O	O
the	DET	O	O
Value	NOUN	O	O
of	ADP	O	O
Augmenting	ADP	O	O
Medication	NOUN	O	O
with	ADP	O	O
Psychotherapy	NOUN	O	O
(	PUNCT	O	O
REVAMP	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
study	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
multi-site	ADJ	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
augmentation	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
808	NUM	O	O
chronically	ADV	O	O
depressed	VERB	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

REVAMP	NOUN	O	O
comprised	VERB	O	O
two	NUM	O	O
phases	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
12-week	NOUN	O	O
open-label	NOUN	O	O
antidepressant	NOUN	O	O
trial	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
subsequent	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	PUNCT	O	O
phase	NOUN	O	O
1	NUM	O	O
non-remitters	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
491	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	PUNCT	O	O
receive	ADP	O	O
an	DET	O	O
ongoing	VERB	O	O
medication	NOUN	O	O
algorithm	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
medication	NOUN	O	O
plus	CCONJ	O	O
cognitive	ADJ	O	O
behavioral	ADJ	O	O
analysis	NOUN	O	O
system	NOUN	O	O
of	ADP	O	O
psychotherapy	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
medication	NOUN	O	O
plus	CCONJ	O	O
brief	ADJ	O	O
supportive	ADJ	O	O
psychotherapy	NOUN	O	O
.	PUNCT	O	O

RESULT	NOUN	O	O
In	ADP	O	O
phase	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
pharmacotherapy	NOUN	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
lower	PUNCT	O	O
DA	NOUN	O	O
scores	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
response	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
higher	PUNCT	O	O
DA	NOUN	O	O
scores	NOUN	O	O
was	VERB	O	O
steeper	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
leveled	VERB	O	O
off	ADP	O	O
toward	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
phase	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
phase	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
DA	NOUN	O	O
predicted	VERB	O	O
a	DET	O	O
differential	ADJ	O	O
response	NOUN	O	O
in	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
only	ADV	O	O
arm	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
psychotherapy	NOUN	O	O
+	ADJ	O	O
medication	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Specifically	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
phase	NOUN	O	O
2	NUM	O	O
medication	NOUN	O	O
only	PUNCT	O	O
condition	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
higher	PUNCT	O	O
DA	NOUN	O	O
improved	VERB	O	B-OTHER
while	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
lower	PUNCT	O	O
DA	NOUN	O	O
scores	NOUN	O	O
did	CCONJ	O	O
not	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
DA	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
depression	NOUN	O	O
is	VERB	O	O
complex	CCONJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
greater	PUNCT	O	O
DA	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
steeper	PUNCT	O	O
reduction	NOUN	O	O
and/or	CCONJ	O	O
better	PUNCT	O	O
response	NOUN	O	O
to	ADP	O	O
pharmacotherapy	NOUN	O	O
.	PUNCT	O	O

Sleep	NOUN	O	B-PHYSICAL
patterns	NOUN	O	I-PHYSICAL
in	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

Sleep	NOUN	O	B-PHYSICAL
disturbances	NOUN	O	I-PHYSICAL
are	VERB	O	O
regarded	VERB	O	O
as	ADP	O	O
a	DET	O	O
common	ADJ	O	O
clinical	ADJ	O	O
feature	NOUN	O	O
in	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
concept	NOUN	O	O
is	PUNCT	O	O
based	VERB	O	O
primarily	ADV	O	O
on	ADP	O	O
informal	ADJ	O	O
observations	NOUN	O	O
or	CCONJ	O	O
studies	NOUN	O	O
conducted	VERB	O	O
with	ADP	O	O
questionnaires	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
we	PRON	O	O
compared	PUNCT	O	O
data	NOUN	O	O
obtained	VERB	O	O
by	ADP	O	O
questionnaires	NOUN	O	O
to	ADP	O	O
that	PUNCT	O	O
obtained	VERB	O	O
with	ADP	O	O
actigraphy	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
22	NUM	O	O
autistic	ADJ	O	O
children	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
were	VERB	O	O
reported	VERB	O	O
as	PUNCT	O	O
having	DET	O	O
sleep	ADV	O	O
problems	NOUN	O	O
and	CCONJ	O	O
8	NUM	O	O
patients	NOUN	O	O
completed	VERB	O	O
72	NUM	O	O
hours	ADJ	O	O
actigraphy	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
employment	NOUN	O	O
of	ADP	O	O
questionnaires	NOUN	O	O
disclosed	VERB	O	O
that	PUNCT	O	O
autistic	ADJ	O	O
children	NOUN	O	O
had	PUNCT	O	O
an	DET	O	O
earlier	PUNCT	O	B-PHYSICAL
morning	NOUN	O	I-PHYSICAL
awakening	VERB	O	I-PHYSICAL
time	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
multiple	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
early	ADP	O	I-PHYSICAL
night	NOUN	O	I-PHYSICAL
arousals	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
actigraphic	ADJ	O	O
monitoring	VERB	O	O
showed	VERB	O	O
that	ADP	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
an	DET	O	O
earlier	PUNCT	O	B-PHYSICAL
morning	NOUN	O	I-PHYSICAL
arousal	ADJ	O	I-PHYSICAL
time	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.045	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sleep	ADP	O	B-PHYSICAL
patterns	NOUN	O	I-PHYSICAL
of	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
normal	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

Parental	ADJ	O	O
oversensitivity	NOUN	O	O
to	ADP	O	O
sleep	ADJ	O	B-PHYSICAL
disturbances	ADJ	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
autistic	ADJ	O	O
children	NOUN	O	O
may	VERB	O	O
explain	VERB	O	O
this	DET	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

Exhaled	VERB	O	O
NO	NOUN	O	O
during	ADP	O	O
graded	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
inhaled	VERB	O	O
oxygen	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Nitric	ADJ	O	O
oxide	NOUN	O	O
(	PUNCT	O	O
NO	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
the	DET	O	O
exhaled	VERB	O	O
air	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
and	CCONJ	O	O
humans	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
isolated	VERB	O	O
animal	NOUN	O	O
lungs	CCONJ	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
exhaled	NOUN	O	O
NO	NOUN	O	O
is	VERB	O	O
decreased	VERB	O	O
during	ADP	O	O
hypoxia	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
arterial	ADJ	O	O
oxygen	NOUN	O	O
tension	NOUN	O	O
affect	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
exhaled	NOUN	O	O
NO	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixteen	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
inhale	ADJ	O	O
different	ADJ	O	O
gas	NOUN	O	O
mixtures	NOUN	O	O
of	ADP	O	O
oxygen	NOUN	O	O
and	CCONJ	O	O
nitrogen	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
crossover	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
gas	NOUN	O	O
mixtures	NOUN	O	O
of	ADP	O	O
oxygen	NOUN	O	O
and	CCONJ	O	O
nitrogen	NOUN	O	O
(	PUNCT	O	O
fractional	ADJ	O	O
inspired	PUNCT	O	O
oxygen	NOUN	O	O
concentration	NOUN	O	O
(	PUNCT	O	O
FiO2	NOUN	O	O
)	PUNCT	O	O
0.1	NUM	O	O
to	ADP	O	O
1.0	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Exhaled	VERB	O	B-PHYSICAL
NO	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
a	DET	O	O
chemiluminescence	NOUN	O	O
detector	NOUN	O	O
from	ADP	O	O
end	NOUN	O	O
expiratory	ADJ	O	O
single	ADJ	O	O
breath	NOUN	O	O
exhalation	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
dose-dependent	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
exhaled	NOUN	O	B-PHYSICAL
NO	NOUN	O	O
during	ADP	O	O
graded	VERB	O	B-PHYSICAL
oxygen	NOUN	O	I-PHYSICAL
breathing	VERB	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0012	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
(	PUNCT	O	O
SE	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
exhaled	PUNCT	O	B-PHYSICAL
NO	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
was	VERB	O	O
31	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
ppb	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
39	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
ppb	NOUN	O	O
at	ADP	O	O
an	DET	O	O
FiO2	NOUN	O	O
of	ADP	O	O
1.0	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
26	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
ppb	NOUN	O	O
at	ADP	O	O
an	DET	O	O
FiO2	NOUN	O	O
of	ADP	O	O
0.1	NUM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
NO	NOUN	O	O
concentration	NOUN	O	B-PHYSICAL
in	ADP	O	O
exhaled	ADV	O	O
air	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
humans	NOUN	O	O
is	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
oxygen	NOUN	O	O
tension	NOUN	O	O
.	PUNCT	O	O

Hyperoxia	NOUN	O	O
increases	PUNCT	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
exhaled	NOUN	O	O
NO	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
indicates	ADV	O	O
increased	PUNCT	O	O
NO	NOUN	O	O
production	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
behind	ADP	O	O
this	DET	O	O
phenomenon	NOUN	O	O
remains	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
elucidated	VERB	O	O
.	PUNCT	O	O

Late	ADJ	O	O
miscarriage	NOUN	O	O
and	CCONJ	O	O
preterm	NOUN	O	O
birth	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
clindamycin	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
consent	NOUN	O	O
design	NOUN	O	O
study	ADP	O	O
according	CCONJ	O	O
to	ADP	O	O
Zelen	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PART	O	O
screen	NOUN	O	O
for	ADP	O	O
bacterial	ADJ	O	O
vaginosis	NOUN	O	O
(	PUNCT	O	O
BV	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
vaginal	ADJ	O	O
clindamycin	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
observe	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
late	ADJ	O	B-PHYSICAL
miscarriage	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
delivery	NOUN	O	I-PHYSICAL
prior	PUNCT	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
37	NUM	O	I-PHYSICAL
completed	VERB	O	I-PHYSICAL
weeks	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomised	VERB	O	O
consent	NOUN	O	O
design	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
according	CCONJ	O	O
to	ADP	O	O
Zelen	NOUN	O	O
.	PUNCT	O	O

SETTING	ADJ	O	O
Southeast	NOUN	O	O
region	NOUN	O	O
of	ADP	O	O
Sweden	NUM	O	O
.	PUNCT	O	O

POPULATION	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
9025	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
screened	VERB	O	O
in	ADP	O	O
early	ADJ	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
819	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
a	DET	O	O
Nugent	NOUN	O	O
score	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
above	PUNCT	O	O
were	ADJ	O	O
considered	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
BV	NOUN	O	O
and	CCONJ	O	O
treated	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
Zelen	NOUN	O	O
allocation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
late	ADJ	O	B-PHYSICAL
miscarriage	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
spontaneous	ADJ	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
noniatrogenic	ADP	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
preterm	NOUN	O	I-PHYSICAL
birth	NOUN	O	I-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Late	ADJ	O	B-PHYSICAL
miscarriage	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
spontaneous	ADJ	O	I-PHYSICAL
preterm	NOUN	O	I-PHYSICAL
delivery	NOUN	O	I-PHYSICAL
before	ADP	O	I-PHYSICAL
37	NUM	O	I-PHYSICAL
weeks	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	DET	O	O
Therapy	NOUN	O	O
with	ADP	O	O
vaginal	ADJ	O	O
clindamycin	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
impact	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	B-PHYSICAL
preterm	NOUN	O	I-PHYSICAL
delivery	NOUN	O	I-PHYSICAL
prior	PUNCT	O	O
to	ADP	O	O
37	NUM	O	O
completed	VERB	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
OR	ADV	O	O
0.90	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.40-2.02	NUM	O	O
(	PUNCT	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
variable	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
only	ADV	O	O
1	PUNCT	O	O
of	ADP	O	O
11	NUM	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
5	NUM	O	O
of	ADP	O	O
12	NUM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
delivered	ADP	O	O
prior	PUNCT	O	O
to	ADP	O	O
33	NUM	O	O
completed	VERB	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
OR	ADV	O	O
0.14	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.02-0.95	NUM	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
32	NUM	O	O
days	NOUN	O	O
longer	PUNCT	O	B-PHYSICAL
gestation	NOUN	O	I-PHYSICAL
for	ADP	O	O
the	DET	O	O
23	NUM	O	O
participants	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
late	ADJ	O	B-PHYSICAL
miscarriage	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
spontaneous	ADJ	O	I-PHYSICAL
preterm	NOUN	O	I-PHYSICAL
birth	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P=	NOUN	O	O
0.024	NUM	O	O
,	PUNCT	O	O
Mann-Whitney	NOUN	O	O
U	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
fewer	PUNCT	O	O
infants	NOUN	O	O
had	ADP	O	O
a	DET	O	O
birthweight	NUM	O	O
below	ADP	O	O
2,500	NUM	O	O
g	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
secondary	ADJ	O	O
outcome	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	PUNCT	O	O
follow	PUNCT	O	O
up	CCONJ	O	O
of	ADP	O	O
infants	NOUN	O	O
born	VERB	O	O
preterm	NOUN	O	O
4	NUM	O	O
years	NOUN	O	O
postnatally	ADV	O	O
indicated	PUNCT	O	O
that	ADP	O	O
extending	CCONJ	O	O
gestational	ADJ	O	O
age	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
increase	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
sequelae	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Clindamycin	NOUN	O	O
vaginal	ADJ	O	O
cream	NOUN	O	O
therapy	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significantly	ADV	O	O
prolonged	VERB	O	O
gestation	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
cost	NOUN	O	O
of	ADP	O	O
neonatal	ADJ	O	O
care	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
BV	NOUN	O	O
.	PUNCT	O	O

Early	ADJ	O	O
screening	VERB	O	O
for	ADP	O	O
BV	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
clindamycin	NOUN	O	O
saved	PUNCT	O	O
approximately	ADV	O	O
27	NUM	O	O
euro	PUNCT	O	O
per	ADP	O	O
woman	NOUN	O	O
.	PUNCT	O	O

Double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
dose-ranging	ADV	O	O
study	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
recombinant	ADJ	O	O
hypoallergenic	ADJ	O	O
Bet	ADV	O	O
v	CCONJ	O	O
1	NUM	O	O
in	ADP	O	O
an	DET	O	O
environmental	ADJ	O	O
exposure	NOUN	O	O
chamber	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Recombinant	ADJ	O	O
allergens	NOUN	O	O
offer	VERB	O	O
a	DET	O	O
tool	NOUN	O	O
for	ADP	O	O
improving	VERB	O	O
specific	ADJ	O	O
immunotherapy	NOUN	O	O
(	PUNCT	O	O
SIT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
find	NOUN	O	O
the	DET	O	O
optimal	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
hypoallergenic	ADJ	O	O
folding	VERB	O	O
variant	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
Bet	NOUN	O	O
v	CCONJ	O	O
1	NUM	O	O
(	PUNCT	O	O
rBet	NOUN	O	O
v	NUM	O	O
1-FV	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
SIT	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
birch	NOUN	O	O
pollen	VERB	O	O
allergy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Before	ADP	O	O
SIT	NOUN	O	O
,	PUNCT	O	O
thirty-seven	PUNCT	O	O
adult	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
exposed	VERB	O	O
for	ADP	O	O
eight	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
an	DET	O	O
environmental	ADJ	O	O
exposure	NOUN	O	O
chamber	NOUN	O	O
(	PUNCT	O	O
EEC	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
birch	NOUN	O	O
pollen	ADJ	O	O
at	ADP	O	O
an	DET	O	O
average	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
3500	NUM	O	O
?	PUNCT	O	O

500	NUM	O	O
grains/m	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
then	ADV	O	O
randomized	VERB	O	O
to	ADP	O	O
four	NUM	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
groups	NOUN	O	O
of	ADP	O	O
rBet	NOUN	O	O
v	CCONJ	O	O
1-FV	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
placebo	NOUN	O	O
group	NOUN	O	O
:	PUNCT	O	O
20	NUM	O	O
?g	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
80	NUM	O	O
?g	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
160	NUM	O	O
?g	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
320	NUM	O	O
?g	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
10	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
weekly	ADV	O	O
injections	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
re-exposed	VERB	O	O
in	ADP	O	O
the	DET	O	O
EEC	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
optimal	ADJ	O	O
dose	NOUN	O	O
for	ADP	O	O
SIT	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
using	PUNCT	O	O
efficacy	NOUN	O	O
results	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
EEC	NOUN	O	O
,	PUNCT	O	O
IgG	NOUN	O	O
responses	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-six	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluable	ADJ	O	O
for	ADP	O	O
efficacy	NOUN	O	O
assessment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
symptom	NOUN	O	O
score	NOUN	O	O
significantly	ADV	O	O
decreased	NUM	O	O
in	ADP	O	O
all	DET	O	O
active	ADJ	O	O
groups	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
-18.8	NUM	O	O
%	SYM	O	O
for	ADP	O	O
placebo	NOUN	O	O
patients	NOUN	O	O
;	PUNCT	O	O
-71.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0022	NUM	O	O
for	ADP	O	O
20	NUM	O	O
?g	PUNCT	O	O
;	PUNCT	O	O
-75.6	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	ADP	O	O
0.0007	NUM	O	O
for	ADP	O	O
80	NUM	O	O
?g	PUNCT	O	O
;	PUNCT	O	O
-81.8	ADV	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0009	NUM	O	O
for	ADP	O	O
160	NUM	O	O
?g	PUNCT	O	O
;	PUNCT	O	O
-78.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0003	NUM	O	O
for	ADP	O	O
320	NUM	O	O
?g	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

IgG1	NOUN	O	B-PHYSICAL
increased	PUNCT	O	O
significantly	ADV	O	O
in	ADP	O	O
all	DET	O	O
active	ADJ	O	O
groups	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
four	NUM	O	O
active	ADJ	O	O
doses	NOUN	O	O
were	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	O
,	PUNCT	O	O
no	DET	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
event	NOUN	O	O
occurred	ADJ	O	O
;	PUNCT	O	O
two	NUM	O	O
Grade	NOUN	O	O
II	NUM	O	B-ADVERSE-EFFECTS
reactions	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
according	CCONJ	O	O
to	ADP	O	O
EAACI	NOUN	O	O
classification	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
one	NUM	O	O
in	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
160-	NOUN	O	O
and	CCONJ	O	O
320-?g	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Considering	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
immunological	ADJ	O	O
response	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
80	NUM	O	O
?g	PUNCT	O	O
of	ADP	O	O
rBet	NOUN	O	O
v	NUM	O	O
1-FV	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
the	DET	O	O
ideal	ADJ	O	O
dose	NOUN	O	O
for	ADP	O	O
allergen	NOUN	O	O
immunotherapy	NOUN	O	O
in	ADP	O	O
birch	NOUN	O	O
pollen	ADJ	O	O
allergic	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Prophylaxis	NOUN	O	O
with	ADP	O	O
meropenem	NOUN	O	O
of	ADP	O	O
septic	ADJ	O	B-PHYSICAL
complications	NOUN	O	I-PHYSICAL
in	ADP	O	O
acute	ADJ	O	O
pancreatitis	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
versus	CCONJ	O	O
imipenem	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Prophylactic	ADJ	O	O
antibiotics	NOUN	O	O
are	VERB	O	O
helpful	ADJ	O	O
in	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
septic	ADJ	O	B-PHYSICAL
complications	NOUN	O	I-PHYSICAL
in	ADP	O	O
acute	ADJ	O	O
pancreatitis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
meropenem	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
carbapenem	NOUN	O	O
antibiotic	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
imipenem	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
the	DET	O	O
standard	ADJ	O	O
prophylactic	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
acute	ADJ	O	O
pancreatitis	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
seventy-six	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
necrotizing	ADP	O	O
pancreatitis	NOUN	O	O
were	VERB	O	O
prospectively	ADV	O	O
randomized	PUNCT	O	O
to	PUNCT	O	O
prophylactic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
0.5	NUM	O	O
g	NOUN	O	O
meropenem	NOUN	O	O
t.i.d	ADV	O	O
.	PUNCT	O	O

intravenously	DET	O	O
or	CCONJ	O	O
0.5	NUM	O	O
g	ADP	O	O
imipenem	NOUN	O	O
q.i.d	ADP	O	O
.	PUNCT	O	O

intravenously	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	B-PHYSICAL
infection	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
pancreatic	ADJ	O	I-PHYSICAL
necrosis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
rate	NOUN	O	O
of	ADP	O	O
extrapancreatic	ADJ	O	B-PHYSICAL
infections	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
systemic	ADJ	O	B-ADVERSE-EFFECTS
and	CCONJ	O	B-ADVERSE-EFFECTS
local	ADJ	O	I-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
need	CCONJ	O	B-OTHER
for	ADP	O	I-OTHER
surgery	NOUN	O	B-OTHER
,	PUNCT	O	O
mortality	NOUN	O	B-MORTALITY
rate	NOUN	O	B-MORTALITY
,	PUNCT	O	O
and	CCONJ	O	O
length	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
hospitalization	NOUN	O	B-OTHER
were	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
each	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
a	DET	O	O
septic	ADJ	O	B-PHYSICAL
complication	NOUN	O	I-PHYSICAL
of	ADP	O	O
pancreatic	ADJ	O	O
necrosis	NOUN	O	O
was	VERB	O	O
suspected	VERB	O	O
,	PUNCT	O	O
fine	PUNCT	O	O
needle	NOUN	O	O
aspiration	NOUN	O	O
with	ADP	O	O
cultures	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sample	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

Surgery	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
verified	PUNCT	O	O
infected	PUNCT	O	O
necrosis	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
No	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
meropenem	NOUN	O	O
and	CCONJ	O	O
those	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
imipenem	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
incidence	NOUN	O	O
of	ADP	O	O
pancreatic	ADJ	O	B-PHYSICAL
infection	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
11.4	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
13.6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
preoperative	ADJ	O	O
intentional	ADJ	O	O
hemodilution	NOUN	O	O
on	ADP	O	O
the	DET	O	O
extravasation	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
albumin	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
fluid	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
preoperative	ADJ	O	O
intentional	ADJ	O	O
hemodilution	NOUN	O	O
with	ADP	O	O
4	NUM	O	O
%	SYM	O	O
albumin	NOUN	O	O
solution	NOUN	O	O
on	ADP	O	O
the	DET	O	O
extravasation	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
intravascular	PUNCT	O	O
albumin	NOUN	O	O
and	CCONJ	O	O
fluid	NOUN	O	O
in	ADP	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	CCONJ	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	ADJ	O	O
University	NOUN	O	O
teaching	VERB	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
Two	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
[	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
]	PUNCT	O	O
and	CCONJ	O	O
hemodiluted	VERB	O	O
group	NOUN	O	O
[	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
13	NUM	O	O
healthy	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
during	ADP	O	O
a	DET	O	O
long-term	NOUN	O	O
(	PUNCT	O	O
>	PROPN	O	O
4	NUM	O	O
hrs	NOUN	O	O
)	PUNCT	O	O
surgical	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Autologous	ADJ	O	O
technetium-99m	NOUN	O	O
(	PUNCT	O	O
99mTc	NOUN	O	O
)	PUNCT	O	O
-labeled	PUNCT	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
indium-oxine	NOUN	O	O
(	PUNCT	O	O
(	PUNCT	O	O
111	NUM	O	O
)	PUNCT	O	O
In	PUNCT	O	O
)	PUNCT	O	O
-labeled	NOUN	O	O
human	NOUN	O	O
serum	NOUN	O	O
albumin	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
intravenously	ADV	O	O
during	ADP	O	O
anesthesia	NOUN	O	O
at	ADP	O	O
T	NOUN	O	O
=	SYM	O	O
0	NUM	O	O
min	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
for	ADP	O	O
the	DET	O	O
determination	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
blood	NOUN	O	O
volume	NOUN	O	O
and	CCONJ	O	O
albumin	NOUN	O	O
diffusion	NOUN	O	O
space	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
tetrapolar	ADJ	O	O
electrical	ADJ	O	O
impedance	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
extracellular	ADJ	O	O
fluid	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
hemodiluted	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
15	NUM	O	O
mL/kg	ADJ	O	O
of	ADP	O	O
blood	NOUN	O	O
was	VERB	O	O
withdrawn	CCONJ	O	O
over	ADP	O	O
30	NUM	O	O
mins	NOUN	O	O
(	PUNCT	O	O
T	NOUN	O	O
=	DET	O	O
20	NUM	O	O
mins	NOUN	O	O
to	ADP	O	O
T	NOUN	O	O
=	SYM	O	O
50	NUM	O	O
mins	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
simultaneously	ADV	O	O
replaced	VERB	O	O
by	ADP	O	O
an	DET	O	O
equal	ADJ	O	O
volume	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
%	SYM	O	O
albumin	NOUN	O	O
solution	NOUN	O	O
(	PUNCT	O	O
0.6	NUM	O	O
g/kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
MAIN	ADJ	O	O
RESULTS	NOUN	O	O
The	DET	O	O
albumin	NOUN	O	O
diffusion	NOUN	O	O
space	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
colloid	NOUN	O	O
oncotic	ADJ	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
plasma	NOUN	O	B-PHYSICAL
albumin	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
electrical	ADJ	O	B-PHYSICAL
impedance	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
before	PUNCT	O	O
(	PUNCT	O	O
T	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
mins	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
(	PUNCT	O	O
T	NOUN	O	O
=	SYM	O	O
60	NUM	O	O
,	PUNCT	O	O
120	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
240	NUM	O	O
mins	NOUN	O	O
)	PUNCT	O	O
hemodilution	NOUN	O	O
.	PUNCT	O	O

Urine	NOUN	O	B-PHYSICAL
was	VERB	O	O
collected	VERB	O	O
from	ADP	O	O
T	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
mins	NOUN	O	O
to	VERB	O	O
T	NOUN	O	O
=	SYM	O	O
240	NUM	O	O
mins	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
blood	NOUN	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
was	VERB	O	O
calculated	VERB	O	O
at	ADP	O	O
T	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
mins	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
values	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
hemodilution	NOUN	O	O
(	PUNCT	O	O
hematocrit	NOUN	O	O
30	NUM	O	O
+/-	SYM	O	O
3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
steeper	PUNCT	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
albumin	NOUN	O	B-PHYSICAL
diffusion	NOUN	O	I-PHYSICAL
space	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
progressive	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
body	NOUN	O	B-PHYSICAL
electrical	ADJ	O	I-PHYSICAL
impedance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
extravasation	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
albumin	NOUN	O	I-PHYSICAL
was	VERB	O	O
0.052	NUM	O	O
+/-	SYM	O	O
0.007	NUM	O	O
mL/kg/min	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
vs.	CCONJ	O	O
0.038	NUM	O	O
+/-	SYM	O	O
0.020	NUM	O	O
mL/kg/min	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
value	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
calculated	VERB	O	I-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
at	ADP	O	O
T	NOUN	O	O
=	SYM	O	O
0	NUM	O	O
min	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
shown	VERB	O	O
any	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
value	NOUN	O	O
was	ADJ	O	O
then	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
expected	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
corresponding	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
of	ADP	O	O
>	SYM	O	O
3	NUM	O	O
mL/kg	ADJ	O	O
.	PUNCT	O	O

Urine	NOUN	O	B-PHYSICAL
output	NOUN	O	I-PHYSICAL
was	ADP	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
than	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
0.7	NUM	O	O
+/-	SYM	O	O
0.4	NUM	O	O
vs.	CCONJ	O	O
1.4	NUM	O	O
+/-	SYM	O	O
1.0	NUM	O	O
mL/min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
comparable	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
colloid	NOUN	O	B-PHYSICAL
oncotic	ADJ	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
in	ADP	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
albumin	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
These	PUNCT	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
preoperative	ADJ	O	O
hemodilution	NOUN	O	O
using	VERB	O	O
4	NUM	O	O
%	SYM	O	O
albumin	NOUN	O	O
on	ADP	O	O
a	DET	O	O
1:1	NUM	O	O
volume	NOUN	O	O
basis	NOUN	O	O
for	ADP	O	O
blood	NOUN	O	O
substitution	NOUN	O	O
during	ADP	O	O
a	DET	O	O
prolonged	VERB	O	O
surgical	ADJ	O	O
procedure	NOUN	O	O
with	ADP	O	O
reduced	VERB	O	O
blood	NOUN	O	O
losses	NOUN	O	O
enhances	NOUN	O	O
the	DET	O	O
extravasation	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
albumin	NOUN	O	O
and	CCONJ	O	O
fluid	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
interstitial	ADJ	O	O
tissues	NOUN	O	O
,	PUNCT	O	O
impeding	PUNCT	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
isovolemia	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
volume	NOUN	O	O
of	ADP	O	O
infused	VERB	O	O
colloid	NOUN	O	O
solution	NOUN	O	O
higher	PUNCT	O	O
than	CCONJ	O	O
that	ADP	O	O
of	PUNCT	O	O
withdrawn	PUNCT	O	O
blood	NOUN	O	O
during	ADP	O	O
preoperative	ADJ	O	O
hemodilution	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
eltanolone	NOUN	O	O
and	CCONJ	O	O
thiopental	ADJ	O	O
in	ADP	O	O
anaesthesia	NOUN	O	B-PHYSICAL
for	ADP	O	O
termination	NOUN	O	O
of	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Eltanolone	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
steroid	NOUN	O	O
hypnotic	ADJ	O	O
,	PUNCT	O	O
was	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
thiopental	ADJ	O	O
in	ADP	O	O
short	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
unpremedicated	ADP	O	O
,	PUNCT	O	O
Asa	NOUN	O	O
1-2	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
eltanolone	NOUN	O	O
0.6	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
E1	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
0.8	NUM	O	O
mg.kg-1	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
E2	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
thiopental	ADJ	O	O
4	NUM	O	O
mg.kg-1	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
T	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
minute	ADJ	O	O
before	ADP	O	O
induction	NOUN	O	O
glycopyrrolate	VERB	O	O
0.2	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
alfentanil	NOUN	O	O
15	NUM	O	O
micrograms.kg-1	NOUN	O	O
i.v	NUM	O	O
.	PUNCT	O	O

were	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

If	ADP	O	O
induction	NOUN	O	O
failed	VERB	O	O
,	PUNCT	O	O
additional	ADJ	O	O
boluses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
test	VERB	O	O
drug	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

Anaesthesia	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
with	ADP	O	O
67	NUM	O	O
%	SYM	O	O
nitrous	ADJ	O	O
oxide	NOUN	O	O
in	ADP	O	O
oxygen	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
additional	ADJ	O	O
bolus	NOUN	O	O
doses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
test	VERB	O	O
drug	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
in	ADP	O	O
a	DET	O	O
standardized	VERB	O	O
fashion	NOUN	O	O
,	PUNCT	O	O
if	VERB	O	O
needed	VERB	O	O
.	PUNCT	O	O

Recovery	NOUN	O	B-MENTAL
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
a	DET	O	O
research	NOUN	O	O
nurse	ADJ	O	O
blinded	PRON	O	O
to	ADP	O	O
the	ADP	O	O
agent	NOUN	O	O
used	VERB	O	O
.	PUNCT	O	O

Mean	NOUN	O	O
+/-	SYM	O	B-PHYSICAL
s.d	ADV	O	O
.	PUNCT	O	O

induction	NOUN	O	O
doss	NOUN	O	B-PHYSICAL
were	VERB	O	O
0.7	NUM	O	O
+/-	SYM	O	O
0.1	NUM	O	O
mg.kg-1	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
E1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
0.8	NUM	O	O
+/-	SYM	O	O
0.1	NUM	O	O
mg.kg-1	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
E2	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
4.0	NUM	O	O
+/-	SYM	O	O
0.0	NUM	O	O
mg.kg-1	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
T	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
time	NOUN	O	O
was	VERB	O	O
prolonged	VERB	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
E1	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
other	ADJ	O	O
two	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Side	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
few	ADJ	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
involuntary	ADJ	O	B-PHYSICAL
muscle	NOUN	O	I-PHYSICAL
movements	NOUN	O	I-PHYSICAL
or	CCONJ	O	I-PHYSICAL
hypertonus	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
23	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
eltanolone	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
thiopental	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
n.s	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
thyrotropin	NOUN	O	O
and	CCONJ	O	O
thyroid	NOUN	O	O
hormone	NOUN	O	O
withdrawal	NOUN	O	O
for	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
thyroid	NOUN	O	O
remnant	ADJ	O	O
or	CCONJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
has	VERB	O	O
been	PUNCT	O	O
developed	VERB	O	O
to	PART	O	O
facilitate	NOUN	O	O
monitoring	VERB	O	O
for	ADP	O	O
thyroid	NOUN	O	O
carcinoma	NOUN	O	O
recurrence	NOUN	O	O
or	CCONJ	O	O
persistence	NOUN	O	O
without	ADP	O	O
the	DET	O	O
attendant	PUNCT	O	O
morbidity	NOUN	O	O
of	ADP	O	O
hypothyroidism	NOUN	O	O
seen	VERB	O	O
after	ADP	O	O
thyroid	NOUN	O	O
hormone	NOUN	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objectives	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
administered	VERB	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
with	ADP	O	O
thyroid	NOUN	O	O
hormone	NOUN	O	O
withdrawal	NOUN	O	O
on	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
radioiodine	NOUN	O	O
whole	ADJ	O	O
body	NOUN	O	O
scanning	PUNCT	O	O
(	PUNCT	O	O
WBS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
serum	NOUN	O	O
thyroglobulin	NOUN	O	O
(	PUNCT	O	O
Tg	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
twenty-nine	PUNCT	O	O
adult	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
differentiated	VERB	O	O
thyroid	NOUN	O	O
cancer	NOUN	O	O
requiring	VERB	O	O
radioiodine	NOUN	O	O
WBS	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Radioiodine	NOUN	O	O
WBS	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
Tg	NOUN	O	O
measurements	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
and	CCONJ	O	O
again	ADV	O	O
after	ADP	O	O
thyroid	NOUN	O	O
hormone	NOUN	O	O
withdrawal	NOUN	O	O
in	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Radioiodine	NOUN	O	O
whole	ADJ	O	O
body	NOUN	O	O
scans	PUNCT	O	O
were	VERB	O	O
concordant	ADJ	O	O
between	ADP	O	O
the	DET	O	O
recombinant	ADJ	O	B-PHYSICAL
TSH-stimulated	VERB	O	I-PHYSICAL
and	CCONJ	O	O
thyroid	NOUN	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
withdrawal	NOUN	O	I-PHYSICAL
phases	ADP	O	I-PHYSICAL
in	ADP	O	O
195	ADJ	O	O
of	ADP	O	O
220	NUM	O	O
(	PUNCT	O	O
89	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
discordant	ADJ	O	O
scans	ADJ	O	O
,	PUNCT	O	O
8	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
superior	ADJ	O	O
scans	NOUN	O	O
after	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
17	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
superior	ADJ	O	O
scans	NOUN	O	O
after	ADP	O	O
thyroid	NOUN	O	O
hormone	NOUN	O	O
withdrawal	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.108	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
a	DET	O	O
serum	NOUN	O	B-PHYSICAL
Tg	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
of	ADP	O	O
2	NUM	O	O
ng/mL	NOUN	O	O
or	CCONJ	O	O
more	DET	O	O
,	PUNCT	O	O
thyroid	NOUN	O	O
tissue	NOUN	O	O
or	CCONJ	O	O
cancer	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
during	ADP	O	O
thyroid	NOUN	O	O
hormone	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
22	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
after	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
stimulation	NOUN	O	O
in	ADP	O	O
52	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
thyroid	NOUN	O	O
hormone	NOUN	O	O
withdrawal	NOUN	O	O
in	ADP	O	O
56	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
disease	NOUN	O	O
or	CCONJ	O	O
tissue	NOUN	O	O
limited	VERB	O	O
to	ADP	O	O
the	DET	O	O
thyroid	NOUN	O	O
bed	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
80	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
100	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
metastatic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
radioiodine	NOUN	O	O
WBS	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
Tg	NOUN	O	O
after	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
stimulation	NOUN	O	O
detected	VERB	O	O
thyroid	NOUN	O	B-PHYSICAL
tissue	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
cancer	NOUN	O	B-PHYSICAL
in	ADP	O	O
93	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
disease	NOUN	O	O
or	CCONJ	O	O
tissue	NOUN	O	O
limited	VERB	O	O
to	ADP	O	O
the	DET	O	O
thyroid	NOUN	O	O
bed	PUNCT	O	O
and	CCONJ	O	O
100	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
administration	NOUN	O	O
is	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
means	NOUN	O	O
of	ADP	O	O
stimulating	VERB	O	O
radioiodine	NOUN	O	O
uptake	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
Tg	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	ADP	O	O
evaluation	NOUN	O	O
for	ADP	O	O
thyroid	NOUN	O	O
cancer	NOUN	O	O
persistence	NOUN	O	O
and	CCONJ	O	O
recurrence	NOUN	O	O
.	PUNCT	O	O

Prospective	ADJ	O	O
randomized	VERB	O	O
evaluation	NOUN	O	O
of	ADP	O	O
diode-laser	ADJ	O	O
and	CCONJ	O	O
cryotherapy	NOUN	O	O
in	ADP	O	O
prethreshold	NOUN	O	B-PHYSICAL
retinopathy	NOUN	O	I-PHYSICAL
of	ADP	O	O
prematurity	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADP	O	O
study	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
indirect	ADJ	O	O
diode	NOUN	O	O
laser	NOUN	O	O
photocoagulation	NOUN	O	O
and	CCONJ	O	O
cryotherapy	NOUN	O	O
in	ADP	O	O
prethreshold	NOUN	O	B-PHYSICAL
retinopathy	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
prematurity	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ROP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
Thirty-six	NUM	O	O
eyes	NOUN	O	O
of	ADP	O	O
18	NUM	O	O
premature	ADJ	O	O
infants	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
34	NUM	O	O
weeks	NOUN	O	O
gestational	ADJ	O	O
age	NOUN	O	O
and/or	CCONJ	O	O
less	ADV	O	O
than	ADP	O	O
1600	NUM	O	O
g	NOUN	O	O
birth	NOUN	O	O
weight	NOUN	O	O
with	ADP	O	O
prethreshold	NOUN	O	O
ROP	NOUN	O	O
were	VERB	O	O
prospectively	ADV	O	O
randomized	PUNCT	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
indirect	ADJ	O	O
laser	NOUN	O	O
photocoagulation	NOUN	O	O
or	CCONJ	O	O
cryotherapy	NOUN	O	O
.	PUNCT	O	O

Prethreshold	NOUN	O	O
ROP	NOUN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
any	DET	O	O
stage	NOUN	O	O
of	ADP	O	O
ROP	NOUN	O	O
in	ADP	O	O
zone	NOUN	O	O
I	NUM	O	O
with	ADP	O	O
plus	CCONJ	O	O
disease	NOUN	O	O
;	PUNCT	O	O
or	CCONJ	O	O
stage	NOUN	O	O
3	NUM	O	O
with	ADP	O	O
three	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
contiguous	ADJ	O	O
clock	NOUN	O	O
hours	NOUN	O	O
or	CCONJ	O	O
five	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
total	ADJ	O	O
clock	NOUN	O	O
hours	NOUN	O	O
of	ADP	O	O
involvement	NOUN	O	O
of	ADP	O	O
retina	NOUN	O	O
in	ADP	O	O
zone	NOUN	O	O
II	NUM	O	O
with	ADP	O	O
plus	CCONJ	O	O
disease	NOUN	O	O
but	CCONJ	O	O
less	ADV	O	O
than	CCONJ	O	O
threshold	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Regression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ROP	NOUN	O	B-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Regression	NOUN	O	O
of	ADP	O	O
ROP	NOUN	O	B-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
all	DET	O	O
36	NUM	O	O
eyes	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Excellent	PUNCT	O	O
results	NOUN	O	O
are	VERB	O	O
achieved	VERB	O	O
if	VERB	O	O
ROP	NOUN	O	B-OTHER
is	VERB	O	O
treated	VERB	O	O
at	ADP	O	O
the	DET	O	O
prethreshold	NOUN	O	O
stage	NOUN	O	O
with	ADP	O	O
both	CCONJ	O	O
indirect	ADJ	O	O
laser	NOUN	O	O
photocoagulation	NOUN	O	O
and	CCONJ	O	O
cryotherapy	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
laser	NOUN	O	O
has	VERB	O	O
definite	ADJ	O	O
advantages	NOUN	O	O
,	PUNCT	O	O
cryotherapy	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
an	DET	O	O
alternative	ADJ	O	O
modality	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
developing	VERB	O	O
countries	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
economic	ADJ	O	O
reasons	NOUN	O	O
.	PUNCT	O	O

Association	NOUN	O	O
of	ADP	O	O
efavirenz	ADP	O	O
hypersusceptibility	NOUN	O	O
with	ADP	O	O
virologic	ADJ	O	O
response	NOUN	O	O
in	ADP	O	O
ACTG	NOUN	O	O
368	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
abacavir	NOUN	O	O
(	PUNCT	O	O
ABC	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
efavirenz	NOUN	O	O
(	PUNCT	O	O
EFV	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
indinavir	NOUN	O	O
(	PUNCT	O	O
IDV	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
HIV-infected	VERB	O	O
subjects	NOUN	O	O
with	ADP	O	O
prior	PUNCT	O	O
nucleoside	NOUN	O	O
analog	NOUN	O	O
experience	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
evaluate	NOUN	O	O
the	DET	O	O
association	NOUN	O	O
of	ADP	O	O
efavirenz	ADP	O	O
hypersusceptibility	NOUN	O	O
(	PUNCT	O	O
EFV-HS	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
EFV	NOUN	O	O
plus	CCONJ	O	O
indinavir	NOUN	O	O
(	PUNCT	O	O
EFV+IDV	NOUN	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
EFV+IDV	NOUN	O	O
plus	CCONJ	O	O
abacavir	NOUN	O	O
(	PUNCT	O	O
ABC	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
283	NUM	O	O
nucleoside-experienced	VERB	O	O
HIV-infected	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
AND	CCONJ	O	O
RESULTS	ADJ	O	O
Rates	PUNCT	O	O
of	ADP	O	O
virologic	ADJ	O	B-OTHER
failure	NOUN	O	I-OTHER
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
arms	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
16	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.509	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
discontinuations	NOUN	O	B-OTHER
were	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
the	DET	O	O
ABC	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Using	PROPN	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
association	NOUN	O	O
between	ADP	O	O
virologic	ADJ	O	B-OTHER
failure	NOUN	O	I-OTHER
and	CCONJ	O	O
either	PUNCT	O	O
baseline	NOUN	O	O
ABC	NOUN	O	B-MENTAL
resistance	NOUN	O	I-MENTAL
or	CCONJ	O	O
regimen	NOUN	O	B-OTHER
sensitivity	NOUN	O	I-OTHER
score	NOUN	O	I-OTHER
.	PUNCT	O	O

Using	VERB	O	O
3	NUM	O	O
different	ADJ	O	O
genotypic	ADJ	O	O
scoring	VERB	O	O
systems	NOUN	O	O
,	PUNCT	O	O
EFV-HS	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
reduced	VERB	O	O
virologic	ADJ	O	O
failure	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
16	NUM	O	O
,	PUNCT	O	O
independent	ADJ	O	O
of	ADP	O	O
treatment	NOUN	O	O
assignment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
on	ADP	O	O
the	DET	O	O
nucleoside-sparing	PROPN	O	O
arm	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
nucleoside-resistance	NOUN	O	O
mutation	NOUN	O	O
L74V	NOUN	O	O
was	VERB	O	O
selected	VERB	O	O
for	ADP	O	O
in	PUNCT	O	O
combination	NOUN	O	O
with	ADP	O	O
the	DET	O	O
uncommonly	ADJ	O	O
occurring	VERB	O	O
EFV-resistance	NOUN	O	O
mutations	NOUN	O	O
K103N+L100I	NOUN	O	O
;	PUNCT	O	O
L74V	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
detected	VERB	O	O
as	ADP	O	O
a	DET	O	O
minority	NOUN	O	O
variant	NOUN	O	O
,	PUNCT	O	O
using	SYM	O	O
clonal	ADJ	O	O
sequence	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
when	ADP	O	O
the	DET	O	O
nucleoside-sparing	PROPN	O	O
regimen	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Premature	PUNCT	O	O
treatment	NOUN	O	O
discontinuations	NOUN	O	B-MENTAL
in	ADP	O	O
the	DET	O	O
ABC	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
EFV-HS	NOUN	O	O
HIV	NOUN	O	O
variants	NOUN	O	O
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
population	NOUN	O	O
likely	ADJ	O	O
made	PUNCT	O	O
it	VERB	O	O
difficult	ADJ	O	O
to	ADJ	O	O
detect	NOUN	O	O
a	DET	O	O
benefit	NOUN	O	O
of	ADP	O	O
adding	VERB	O	B-OTHER
ABC	NOUN	O	I-OTHER
to	ADP	O	I-OTHER
EFV+IDV	NOUN	O	I-OTHER
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
L74V	NOUN	O	O
,	PUNCT	O	O
when	ADP	O	O
combined	VERB	O	O
with	ADP	O	O
K103N+L100I	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
confer	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
advantage	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
virus	NOUN	O	O
that	ADP	O	O
is	VERB	O	O
independent	ADJ	O	O
of	ADP	O	O
its	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
nucleoside	NOUN	O	B-ADVERSE-EFFECTS
resistance	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
single-dose	NOUN	O	O
metronidazole	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
their	DET	O	O
partners	NOUN	O	O
with	ADP	O	O
bacterial	ADJ	O	O
vaginosis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	ADJ	O	O
test	NOUN	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
a	DET	O	O
2-g	NOUN	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	O
for	ADP	O	O
male	NOUN	O	O
partners	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
bacterial	ADJ	O	O
vaginosis	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
placebo	NOUN	O	O
in	ADP	O	O
improving	VERB	O	O
cure	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
decreasing	VERB	O	O
recurrence	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
2-g	NOUN	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
seven-day	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
500	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bacterial	ADJ	O	O
vaginosis	NOUN	O	O
.	PUNCT	O	O

Statistically	ADV	O	O
significant	ADJ	O	O
benefits	NOUN	O	O
of	ADP	O	O
partner	NOUN	O	O
treatment	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
cure	NOUN	O	O
rate	NOUN	O	O
by	ADP	O	O
Gram-stained	PUNCT	O	O
smear	NOUN	O	O
criteria	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
percentage	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
symptoms	NOUN	O	O
eight	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
initiating	VERB	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
seven-day	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
the	DET	O	O
single-dose	NOUN	O	O
regimen	NOUN	O	O
in	ADP	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
clue	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
sniff	NOUN	O	O
test	NOUN	O	O
at	ADP	O	O
the	DET	O	O
first	ADJ	O	O
follow-up	NOUN	O	O
visit	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	B-PHYSICAL
cure	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
assessed	VERB	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
clinical	ADJ	O	I-PHYSICAL
criteria	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
Gram-stained	PUNCT	O	B-PHYSICAL
smear	NOUN	O	I-PHYSICAL
criteria	NOUN	O	I-PHYSICAL
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
patient	NOUN	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

Recurrence	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
Gram-stained	PUNCT	O	I-PHYSICAL
smear	NOUN	O	I-PHYSICAL
criteria	NOUN	O	I-PHYSICAL
between	ADP	O	O
patient	NOUN	O	O
and	CCONJ	O	O
partner	NOUN	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
at	ADP	O	O
five	NUM	O	O
and	CCONJ	O	O
eight	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
patient	NOUN	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

Single-dose	PUNCT	O	O
metronidazole	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sexual	ADJ	O	O
partner	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
bacterial	ADJ	O	O
vaginosis	NOUN	O	O
improves	VERB	O	O
initial	ADJ	O	O
bacterial	ADJ	O	B-PHYSICAL
vaginosis	NOUN	O	I-PHYSICAL
cure	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
seven-day	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
found	VERB	O	O
by	ADP	O	O
statistical	ADJ	O	O
analysis	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
significantly	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
single-dose	NOUN	O	O
therapy	NOUN	O	O
when	ADP	O	O
considering	ADV	O	O
initial	ADJ	O	O
cure	NOUN	O	O
rates	NOUN	O	O
by	ADP	O	O
clinical	ADJ	O	O
or	CCONJ	O	O
Gram-stained	PROPN	O	O
smear	NOUN	O	O
criteria	NOUN	O	O
or	CCONJ	O	O
recurrence	NOUN	O	O
rates	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

Long-term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
atomoxetine	NOUN	O	O
for	ADP	O	O
attention-deficit/hyperactivity	NOUN	O	B-MENTAL
disorder	NOUN	O	I-MENTAL
symptoms	NOUN	O	I-MENTAL
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
open-label	NOUN	O	O
extension	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
long-term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
atomoxetine	NOUN	O	O
for	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
attention-deficit/hyperactivity	NOUN	O	B-MENTAL
disorder	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
ADHD	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
established	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
88	NUM	O	O
patients	NOUN	O	O
6-17	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
ADHD	NOUN	O	O
and	CCONJ	O	O
ASD	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
1.2	NUM	O	O
mg/kg/day	PUNCT	O	O
atomoxetine	NOUN	O	O
for	ADP	O	O
20	NUM	O	O
weeks	NOUN	O	O
as	VERB	O	O
follow-up	NOUN	O	O
of	ADP	O	O
an	DET	O	O
8	NUM	O	O
week	NOUN	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
period	NOUN	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
the	DET	O	O
ADHD	NOUN	O	O
Rating	PUNCT	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
ADHD-RS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	ADV	O	O
total	ADJ	O	O
,	PUNCT	O	O
inattention	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
hyperactivity-impulsivity	NOUN	O	B-MENTAL
ADHD-RS	NOUN	O	I-MENTAL
further	NOUN	O	O
decreased	ADV	O	O
significantly	ADV	O	O
from	ADP	O	O
34.9	NUM	O	O
to	ADP	O	O
27.0	NUM	O	O
for	ADP	O	O
the	DET	O	O
total	ADJ	O	O
ADHD-RS	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
18.3	NUM	O	O
to	ADP	O	O
14.5	NUM	O	O
for	ADP	O	O
the	DET	O	O
ADHD-RS	NOUN	O	B-MENTAL
inattention	NOUN	O	I-MENTAL
subscale	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
from	ADP	O	O
16.5	NUM	O	O
to	ADP	O	O
12.6	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
hyperactivity-impulsivity	NOUN	O	B-MENTAL
subscale	NOUN	O	I-MENTAL
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
mild	ADJ	O	O
and	CCONJ	O	O
tended	VERB	O	O
to	ADP	O	O
diminish	NOUN	O	O
over	DET	O	O
time	NOUN	O	O
during	ADP	O	O
continued	VERB	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
regarding	NUM	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
fatigue	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
analysis	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
continued	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
atomoxetine	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
28	NUM	O	O
weeks	NOUN	O	O
further	ADJ	O	O
improve	VERB	O	B-MENTAL
ADHD	NOUN	O	I-MENTAL
symptoms	NOUN	O	I-MENTAL
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
,	PUNCT	O	O
while	CCONJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
tend	ADP	O	O
to	ADP	O	O
subside	NOUN	O	O
.	PUNCT	O	O

Future	ADJ	O	O
studies	NOUN	O	O
investigating	DET	O	O
the	DET	O	O
long-term	NOUN	O	O
efficacy	NOUN	O	O
of	ADP	O	O
atomoxetine	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
randomized	ADP	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
has	VERB	O	O
been	PUNCT	O	O
registered	CCONJ	O	O
in	ADP	O	O
ClinicalTrials.gov	PUNCT	O	O
(	PUNCT	O	O
www.clinicaltrials.gov	NOUN	O	O
)	PUNCT	O	O
under	ADP	O	O
registration	NOUN	O	O
number	NOUN	O	O
NCT00380692	PUNCT	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
selamectin	NOUN	O	O
against	ADP	O	O
fleas	NOUN	O	O
and	CCONJ	O	O
heartworms	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
cats	ADJ	O	O
presented	DET	O	O
as	PUNCT	O	O
veterinary	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
North	NOUN	O	O
America	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
series	NOUN	O	O
of	ADP	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
masked	PUNCT	O	O
field	NOUN	O	O
studies	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
selamectin	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
flea	NOUN	O	O
infestations	NOUN	O	O
on	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
cats	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
heartworm	PUNCT	O	B-PHYSICAL
infection	NOUN	O	I-PHYSICAL
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
observations	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
on	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
selamectin	NOUN	O	O
treatment	NOUN	O	O
on	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
cats	ADJ	O	O
showing	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
flea	NOUN	O	O
allergy	NOUN	O	O
dermatitis	NOUN	O	O
(	PUNCT	O	O
FAD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
studies	NOUN	O	O
selamectin	NOUN	O	O
was	VERB	O	O
applied	VERB	O	O
topically	ADV	O	O
,	PUNCT	O	O
once	PUNCT	O	O
per	PUNCT	O	O
month	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
unit	NOUN	O	O
doses	NOUN	O	O
providing	VERB	O	O
a	DET	O	O
minimum	NOUN	O	O
dosage	NOUN	O	O
of	ADP	O	O
6mgkg	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Dogs	NOUN	O	O
and	CCONJ	O	O
cats	ADJ	O	O
with	ADP	O	O
naturally	ADV	O	O
occurring	DET	O	O
flea	NOUN	O	O
infestations	NOUN	O	O
,	PUNCT	O	O
some	ADP	O	O
of	ADP	O	O
which	ADV	O	O
also	ADV	O	O
had	PUNCT	O	O
signs	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
FAD	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	PART	O	O
receive	NOUN	O	O
three	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
selamectin	NOUN	O	O
(	PUNCT	O	O
220	NUM	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
189	DET	O	O
cats	ADJ	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
positive-control	NOUN	O	O
product	NOUN	O	O
(	PUNCT	O	O
dogs	NOUN	O	O
:	PUNCT	O	O
fenthion	NOUN	O	O
,	PUNCT	O	O
n=81	NOUN	O	O
;	PUNCT	O	O
cats	ADJ	O	O
:	PUNCT	O	O
pyrethrins	NOUN	O	O
,	PUNCT	O	O
n=66	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Selamectin	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
0	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
60	NUM	O	O
.	PUNCT	O	O

Day	NOUN	O	O
0	NUM	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
the	DET	O	O
day	NOUN	O	O
that	ADP	O	O
the	DET	O	O
animal	NOUN	O	O
first	NOUN	O	O
received	PUNCT	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Flea	NOUN	O	B-PHYSICAL
burdens	PUNCT	O	I-PHYSICAL
were	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
flea	NOUN	O	O
comb	NOUN	O	O
counts	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
evaluations	NOUN	O	O
of	ADP	O	O
FAD	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
before	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
days	NOUN	O	O
14	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
60	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
90	NUM	O	O
.	PUNCT	O	O

On	ADP	O	O
days	NOUN	O	O
30	NUM	O	O
,	PUNCT	O	O
60	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
90	NUM	O	O
,	PUNCT	O	O
mean	NOUN	O	O
flea	NOUN	O	B-PHYSICAL
counts	NOUN	O	I-PHYSICAL
in	ADP	O	O
selamectin-treated	VERB	O	O
dogs	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
92.1	NUM	O	O
,	PUNCT	O	O
99.0	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
99.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
flea	NOUN	O	B-PHYSICAL
counts	NOUN	O	I-PHYSICAL
in	ADP	O	O
fenthion-treated	VERB	O	O
dogs	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
81.5	NUM	O	O
,	PUNCT	O	O
86.8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
86.1	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
day	NOUN	O	O
0	NUM	O	O
counts	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
days	NOUN	O	O
30	NUM	O	O
,	PUNCT	O	O
60	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
90	NUM	O	O
,	PUNCT	O	O
mean	NOUN	O	O
flea	NOUN	O	B-PHYSICAL
counts	NOUN	O	I-PHYSICAL
in	ADP	O	O
selamectin-treated	VERB	O	O
cats	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
92.5	NUM	O	O
,	PUNCT	O	O
98.3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
99.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mean	NOUN	O	O
flea	NOUN	O	B-PHYSICAL
counts	NOUN	O	I-PHYSICAL
in	ADP	O	O
pyrethrin-treated	VERB	O	O
cats	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
66.4	NUM	O	O
,	PUNCT	O	O
73.9	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
81.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
day	NOUN	O	O
0	NUM	O	O
counts	NOUN	O	O
.	PUNCT	O	O

Selamectin	NOUN	O	O
also	ADV	O	O
was	VERB	O	O
beneficial	ADJ	O	O
in	ADP	O	O
alleviating	VERB	O	O
signs	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
cats	ADJ	O	O
diagnosed	ADV	O	O
clinically	ADV	O	O
with	ADP	O	O
FAD	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
397	NUM	O	O
dogs	NOUN	O	O
free	ADJ	O	O
of	ADP	O	O
adult	NOUN	O	O
heartworm	ADP	O	O
infection	NOUN	O	O
from	ADP	O	O
four	NUM	O	O
heartworm-endemic	ADJ	O	O
areas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
USA	PUNCT	O	O
were	VERB	O	O
allocated	VERB	O	O
randomly	ADV	O	O
to	PUNCT	O	O
six	PUNCT	O	O
months	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
selamectin	NOUN	O	O
(	PUNCT	O	O
n=298	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ivermectin	NOUN	O	O
(	PUNCT	O	O
n=99	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Selamectin	NOUN	O	O
achieved	VERB	O	O
a	DET	O	O
heartworm	NOUN	O	B-PHYSICAL
prevention	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
100	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
with	ADP	O	O
all	DET	O	O
dogs	NOUN	O	O
testing	VERB	O	O
negative	ADJ	O	O
for	ADP	O	O
microfilariae	ADJ	O	O
and	CCONJ	O	O
adult	NOUN	O	O
heartworm	NOUN	O	O
antigen	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
180	NUM	O	O
and	CCONJ	O	O
300	NUM	O	O
.	PUNCT	O	O

Selamectin	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
673	NUM	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
347	NUM	O	O
cats	ADJ	O	O
having	VERB	O	O
an	DET	O	O
age	NOUN	O	O
range	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
to	ADP	O	O
19	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
3954	NUM	O	O
doses	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
animals	NOUN	O	O
included	VERB	O	O
19	NUM	O	O
purebred	VERB	O	O
or	CCONJ	O	O
crossbred	VERB	O	O
Collies	PUNCT	O	O
(	PUNCT	O	O
Bearded	PUNCT	O	O
,	PUNCT	O	O
Border	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
unspecified	VERB	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Results	NOUN	O	O
of	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
selamectin	NOUN	O	O
was	VERB	O	O
highly	ADV	O	B-OTHER
effective	ADJ	O	I-OTHER
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
of	ADP	O	O
flea	NOUN	O	O
infestations	CCONJ	O	O
in	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
cats	ADJ	O	O
without	ADP	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
simultaneous	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
environment	NOUN	O	O
or	CCONJ	O	O
of	ADP	O	O
in-contact	PUNCT	O	O
animals	NOUN	O	O
and	CCONJ	O	O
also	ADV	O	O
was	VERB	O	O
beneficial	ADJ	O	O
in	ADP	O	O
alleviating	VERB	O	O
signs	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
FAD	NOUN	O	O
.	PUNCT	O	O

Selamectin	NOUN	O	O
also	ADV	O	O
was	ADV	O	O
100	NUM	O	O
%	SYM	O	O
effective	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
canine	ADJ	O	O
heartworms	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
safe	ADJ	O	B-OTHER
for	ADP	O	O
topical	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
cats	NOUN	O	O
.	PUNCT	O	O

Influence	NOUN	O	O
of	ADP	O	O
sentinel	NOUN	O	O
lymph	NOUN	O	O
node	NOUN	O	O
tumor	NOUN	O	O
burden	NOUN	O	O
on	ADP	O	O
survival	NOUN	O	O
in	ADP	O	O
melanoma	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Completion	NOUN	O	O
lymph	NOUN	O	O
node	NOUN	O	O
dissection	NOUN	O	O
(	PUNCT	O	O
CLND	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
standard	ADJ	O	O
procedure	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
positive	ADJ	O	O
sentinel	NOUN	O	O
lymph	NOUN	O	O
nodes	NOUN	O	O
(	PUNCT	O	O
SLN	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

With	ADP	O	O
extensive	ADJ	O	O
pathological	ADJ	O	O
workup	NOUN	O	O
,	PUNCT	O	O
increased	NOUN	O	O
numbers	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
metastatic	ADJ	O	O
deposits	NOUN	O	O
are	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
SLN	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
prognostic	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
SLN	NOUN	O	O
metastatic	ADJ	O	O
deposits	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.2	NUM	O	O
mm	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
in	ADP	O	O
a	DET	O	O
referral	ADJ	O	O
cancer	NOUN	O	O
center	NOUN	O	O
in	ADP	O	O
Brazil	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
I/II	NOUN	O	O
melanoma	NOUN	O	O
,	PUNCT	O	O
consecutively	ADV	O	O
submitted	VERB	O	O
to	ADP	O	O
a	DET	O	O
SLN	NOUN	O	O
procedure	NOUN	O	O
by	ADP	O	O
the	DET	O	O
same	ADJ	O	O
surgeon	NOUN	O	O
from	ADP	O	O
2000	NUM	O	O
to	ADP	O	O
2006	NUM	O	O
,	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
positive	ADJ	O	O
SLN	NOUN	O	O
and	CCONJ	O	O
randomly	ADV	O	O
selected	PUNCT	O	O
negative	ADJ	O	O
cases	NOUN	O	O
were	VERB	O	O
reviewed	VERB	O	O
by	ADP	O	O
two	NUM	O	O
pathologists	NOUN	O	O
.	PUNCT	O	O

Different	ADJ	O	O
prognostic	ADJ	O	O
factors	NOUN	O	O
and	CCONJ	O	O
SLN	NOUN	O	O
tumor	NOUN	O	O
burden	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
positive	ADJ	O	O
non-SLN	NOUN	O	O
after	ADP	O	O
CLND	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
disease	NOUN	O	O
outcome	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
381	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
underwent	VERB	O	O
SLN	NOUN	O	O
biopsy	NOUN	O	O
,	PUNCT	O	O
103	NUM	O	O
(	PUNCT	O	O
27	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
positive	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
mean/median	ADJ	O	O
Breslow	NOUN	O	O
tumor	NOUN	O	B-PHYSICAL
thickness	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
3.4/2.0	PUNCT	O	O
mm	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
SLN	NOUN	O	O
positive	ADJ	O	O
patients	NOUN	O	O
was	ADP	O	O
5.72/4.0	PUNCT	O	O
mm	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
48	NUM	O	O
(	PUNCT	O	O
47	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
metastatic	ADJ	O	O
deposits	NOUN	O	O
>	SYM	O	O
2	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
macrometastasis	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
49	NUM	O	O
(	PUNCT	O	O
47	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
metastatic	ADJ	O	O
deposits	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=2	NUM	O	O
mm	NOUN	O	O
but	CCONJ	O	O
>	SYM	O	O
0.2	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
micrometastasis	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
metastatic	ADJ	O	O
deposits	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=0.2	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
submicrometastasis	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
positive	ADJ	O	O
non-SLN	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
29	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
macrometastasis	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
25	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
micrometastasis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
0	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
submicrometastases	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
of	ADP	O	O
35	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
estimated	VERB	O	O
3-year	NOUN	O	O
overall	ADJ	O	O
survival	NOUN	O	O
was	VERB	O	O
92	NUM	O	O
%	SYM	O	O
for	ADP	O	O
negative	ADJ	O	O
SLN	NOUN	O	O
,	PUNCT	O	O
64	NUM	O	O
%	SYM	O	O
for	ADP	O	O
micrometastases	NOUN	O	O
,	PUNCT	O	O
53	NUM	O	O
%	SYM	O	O
for	ADP	O	O
macrometastases	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
100	NUM	O	O
%	SYM	O	O
for	ADP	O	O
submicrometastases	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
SLN	NOUN	O	O
metastatic	ADJ	O	O
deposits	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=0.2	NUM	O	O
mm	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
additional	ADJ	O	O
positive	ADJ	O	O
non-SLNs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
recurrences	NOUN	O	O
or	CCONJ	O	O
deaths	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
their	PUNCT	O	O
prognosis	NOUN	O	O
is	VERB	O	O
equivalent	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
negative	ADJ	O	O
SLN	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	B-OTHER
effectiveness	NOUN	O	I-OTHER
of	ADP	O	O
acupuncture	ADP	O	O
and	CCONJ	O	O
a	DET	O	O
Western	ADJ	O	O
drug	NOUN	O	O
on	ADP	O	O
allergic	ADJ	O	O
rhinitis	NOUN	O	O
:	PUNCT	O	O
study	ADV	O	O
protocol	NOUN	O	O
for	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
an	DET	O	O
acupuncture	ADP	O	O
regimen	NOUN	O	O
for	ADP	O	O
persistent	ADJ	O	O
allergic	ADJ	O	O
rhinitis	NOUN	O	O
(	PUNCT	O	O
PER	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
aimed	VERB	O	O
at	ADP	O	O
improving	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
's	PUNCT	O	O
mind	NOUN	O	O
or	CCONJ	O	O
Shen	NOUN	O	O
in	ADP	O	O
Traditional	ADJ	O	O
Chinese	NOUN	O	O
Medicine	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
second-generation	NOUN	O	O
Hi-receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
cetirizine	NOUN	O	O
hydrochloride	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
on	ADP	O	O
PER	ADP	O	O
will	PUNCT	O	O
be	VERB	O	O
conducted	VERB	O	O
at	ADP	O	O
three	NUM	O	O
institutions	NOUN	O	O
in	ADP	O	O
China	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
study	NOUN	O	O
period	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
9	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
1-week	NOUN	O	O
preparatory	ADJ	O	O
screening	DET	O	O
period	NOUN	O	O
,	PUNCT	O	O
240	NUM	O	O
eligible	ADJ	O	O
participants	NOUN	O	O
with	ADP	O	O
PER	ADP	O	O
will	PUNCT	O	O
be	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
acupuncture	ADP	O	O
or	CCONJ	O	O
pharmacotherapy	NOUN	O	O
(	PUNCT	O	O
1:1	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
a	DET	O	O
4-week	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
will	PUNCT	O	O
be	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
7-day	NOUN	O	B-OTHER
average	VERB	O	O
total	VERB	O	O
nasal	ADJ	O	B-OTHER
symptom	NOUN	O	I-OTHER
score	NOUN	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
include	VERB	O	O
rhinoconjunctivitis	NOUN	O	B-OTHER
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
questionnaire	PUNCT	O	O

Phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
satraplatin	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
oral	ADJ	O	O
platinum	NOUN	O	O
plus	CCONJ	O	O
prednisone	NOUN	O	O
vs.	CCONJ	O	O
prednisone	NOUN	O	O
alone	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hormone-refractory	ADJ	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Satraplatin	NOUN	O	O
is	VERB	O	O
a	DET	O	O
novel	ADJ	O	O
oral	ADJ	O	O
platinum	NOUN	O	O
(	PUNCT	O	O
IV	NUM	O	O
)	PUNCT	O	O
complex	NOUN	O	O
that	ADP	O	O
shows	ADP	O	O
activity	NOUN	O	O
against	ADP	O	O
hormone-refractory	ADJ	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
HRPC	ADP	O	O
)	PUNCT	O	O
in	ADP	O	O
cisplatin-resistant	ADJ	O	O
human	NOUN	O	O
tumor	NOUN	O	O
lines	NOUN	O	O
in	ADP	O	O
phase	NOUN	O	O
I	NUM	O	O
and	CCONJ	O	O
phase	NOUN	O	O
II	NUM	O	O
trials	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
multicenter	NOUN	O	O
phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
with	ADP	O	O
a	DET	O	O
target	NOUN	O	O
sample	NOUN	O	O
size	NOUN	O	O
of	ADP	O	O
380	NUM	O	O
patients	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
in	ADP	O	O
men	NOUN	O	O
with	ADP	O	O
HRPC	CCONJ	O	O
.	PUNCT	O	O

After	ADP	O	O
50	NUM	O	O
randomized	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
closed	VERB	O	O
to	PUNCT	O	O
further	ADJ	O	O
accrual	ADJ	O	O
by	ADP	O	O
the	DET	O	O
sponsoring	ADJ	O	O
company	ADV	O	O
.	PUNCT	O	O

An	DET	O	O
ad	ADP	O	O
hoc	VERB	O	O
analysis	NOUN	O	O
of	ADP	O	O
all	DET	O	O
available	ADJ	O	O
data	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
here	ADV	O	O
.	PUNCT	O	O

Eligibility	NOUN	O	O
criteria	NOUN	O	O
included	VERB	O	O
pathological	ADJ	O	O
proof	NOUN	O	O
of	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
documented	VERB	O	O
progression	NOUN	O	O
despite	PUNCT	O	O
prior	PUNCT	O	O
hormonal	ADJ	O	O
manipulation	NOUN	O	O
,	PUNCT	O	O
WHO	NOUN	O	O
PS	NOUN	O	O
0-2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
daily	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
narcotic	ADJ	O	O
analgesics	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	PUNCT	O	O
between	ADP	O	O
satraplatin	NOUN	O	O
100	PUNCT	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
plus	CCONJ	O	O
prednisone	NOUN	O	O
10	NUM	O	O
mg	NOUN	O	O
orally	ADV	O	O
BID	NOUN	O	O
or	CCONJ	O	O
prednisone	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Compliance	NOUN	O	O
was	VERB	O	O
excellent	ADJ	O	O
.	PUNCT	O	O

48/50	PUNCT	O	O
patients	NOUN	O	O
have	CCONJ	O	O
progressed	VERB	O	B-PHYSICAL
and	CCONJ	O	O
42	PUNCT	O	O
have	PUNCT	O	O
died	DET	O	B-MORTALITY
,	PUNCT	O	O
mostly	ADV	O	O
due	CCONJ	O	O
to	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
14.9	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
13.7-28.4	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
satraplatin	NOUN	O	O
plus	CCONJ	O	O
prednisone	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
11.9	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
8.4-23.1	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
prednisone	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
HR	NOUN	O	O
=	SYM	O	O
0.84	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.46-1.55	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	PUNCT	O	O
>	PROPN	O	O
50	NUM	O	O
%	SYM	O	O
decrease	NOUN	O	O
in	ADP	O	O
prostrate	PUNCT	O	B-PHYSICAL
specific	ADJ	O	I-PHYSICAL
antigen	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
PSA	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
9/27	NOUN	O	O
(	PUNCT	O	O
33.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
satraplatin	NOUN	O	O
plus	CCONJ	O	O
prednisone	NOUN	O	O
arm	NOUN	O	O
vs.	CCONJ	O	O
2/23	NOUN	O	O
(	PUNCT	O	O
8.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
prednisone	NOUN	O	O
alone	ADJ	O	O
arm	ADP	O	O
.	PUNCT	O	O

Progression-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	ADV	O	O
5.2	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
2.8-13.7	ADV	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
satraplatin	NOUN	O	O
plus	CCONJ	O	O
prednisone	NOUN	O	O
arm	NOUN	O	O
as	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
2.5	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
2.1-	NUM	O	O
4.7	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
prednisone	NOUN	O	O
alone	ADJ	O	O
arm	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
=	SYM	O	O
0.50	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.28-0.92	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
difference	NOUN	O	O
is	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.023	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Toxicity	NOUN	O	B-PHYSICAL
was	VERB	O	O
generally	ADV	O	O
minimal	ADJ	O	O
in	ADP	O	O
both	PUNCT	O	O
arms	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
randomized	VERB	O	O
comparison	NOUN	O	O
of	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
satraplatin	NOUN	O	O
and	CCONJ	O	O
prednisone	NOUN	O	O
versus	CCONJ	O	O
prednisone	NOUN	O	O
alone	ADJ	O	O
supports	NOUN	O	O
the	DET	O	O
antitumor	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
.	PUNCT	O	O

Its	VERB	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
HPRC	NOUN	O	O
remains	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
elucidated	VERB	O	O
in	ADP	O	O
an	DET	O	O
appropriate	ADJ	O	O
phase	NOUN	O	O
III	NUM	O	O
setting	VERB	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
methods	NOUN	O	O
for	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
fat	NOUN	O	O
emulsion	NOUN	O	O
during	ADP	O	O
extracorporeal	ADJ	O	O
membrane	NOUN	O	O
oxygenation	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVES	NOUN	O	O
To	PROPN	O	O
characterize	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
infusing	PROPN	O	O
fat	NOUN	O	O
emulsion	NOUN	O	O
during	ADP	O	O
neonatal	ADJ	O	O
extracorporeal	ADJ	O	O
membrane	NOUN	O	O
oxygenation	NOUN	O	O
(	PUNCT	O	O
ECMO	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
comparing	DET	O	O
results	ADJ	O	O
from	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
fat	NOUN	O	O
emulsion	NOUN	O	O
through	ADP	O	O
the	DET	O	O
ECMO	NOUN	O	O
circuit	NOUN	O	O
with	ADP	O	O
those	PUNCT	O	O
receiving	VERB	O	O
fat	NOUN	O	O
emulsion	NOUN	O	O
through	ADP	O	O
separate	ADJ	O	O
intravenous	ADJ	O	O
access	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
second	ADJ	O	O
goal	NOUN	O	O
was	VERB	O	O
to	PART	O	O
identify	NOUN	O	O
the	DET	O	O
optimal	ADJ	O	O
route	NOUN	O	O
for	ADP	O	O
administration	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
open-label	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Neonatal	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
in	ADP	O	O
a	DET	O	O
106-bed	PUNCT	O	O
quaternary	ADJ	O	O
care	NOUN	O	O
pediatric	ADJ	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
Nine	NUM	O	O
neonates	NOUN	O	O
receiving	VERB	O	O
ECMO	NOUN	O	O
who	ADP	O	O
required	VERB	O	O
intravenous	ADJ	O	O
nutrition	NOUN	O	O
.	PUNCT	O	O

Intervention	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	ADP	O	O
1-3	ADP	O	O
g/kg/day	NOUN	O	O
of	ADP	O	O
fat	NOUN	O	O
emulsion	NOUN	O	O
into	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
ecmo	ADJ	O	O
circuit	NOUN	O	O
or	CCONJ	O	O
separate	ADJ	O	O
intravenous	ADJ	O	O
access	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
MAIN	ADJ	O	O
RESULTS	NOUN	O	O
The	DET	O	O
ECMO	NOUN	O	O
circuit	NOUN	O	O
and	CCONJ	O	O
samples	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
hourly	NOUN	O	O
for	ADP	O	O
phase	NOUN	O	O
separation	NOUN	O	O
,	PUNCT	O	O
layering	ADV	O	O
out	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
emulsion	NOUN	O	O
from	ADP	O	O
blood	NOUN	O	O
,	PUNCT	O	O
agglutination	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
blood	NOUN	O	O
clots	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
completion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
oxygenators	NOUN	O	O
were	VERB	O	O
dissected	VERB	O	O
and	CCONJ	O	O
examined	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
an	DET	O	O
unpaired	VERB	O	O
t	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
characteristics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
mean	NOUN	O	O
weight	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ECMO	NOUN	O	O
circuit	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
3.6	NUM	O	O
+/-	SYM	O	O
0.3	NUM	O	O
kg	NOUN	O	O
vs	CCONJ	O	O
2.8	NUM	O	O
+/-	SYM	O	O
0.4	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
p=0.03	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
+/-	SYM	O	B-PHYSICAL
SD	NOUN	O	I-PHYSICAL
triglyceride	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
during	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	ADV	O	O
87	NUM	O	O
+/-	SYM	O	O
79	NUM	O	O
mg/dl	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
had	PUNCT	O	O
elevated	VERB	O	O
triglyceride	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

No	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
phase	NOUN	O	O
separation	NOUN	O	B-PHYSICAL
occurred	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
five	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
fat	NOUN	O	O
emulsion	NOUN	O	O
into	ADP	O	O
the	DET	O	O
ECMO	NOUN	O	O
circuit	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
had	PUNCT	O	O
layering	ADP	O	O
out	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
emulsion	NOUN	O	O
and	CCONJ	O	O
agglutination	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
developed	PUNCT	O	O
clots	PUNCT	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
circuit	NOUN	O	O
despite	ADP	O	O
adequate	ADJ	O	O
anticoagulation	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
four	ADV	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intravenous-access	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
had	PUNCT	O	O
layering	ADP	O	O
and	CCONJ	O	O
agglutination	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
had	PUNCT	O	O
blood	NOUN	O	O
clots	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Although	ADP	O	O
both	CCONJ	O	O
methods	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
layering	ADP	O	B-PHYSICAL
out	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
agglutination	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Cognitive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
irritable	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
research	NOUN	O	O
was	VERB	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
risperidone	NUM	O	O
on	ADP	O	O
cognitive	ADJ	O	B-MENTAL
processes	NOUN	O	I-MENTAL
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
irritable	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Thirty-eight	PUNCT	O	O
children	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
5-17	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
severe	ADJ	O	O
behavioral	ADJ	O	O
disturbance	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
risperidone	VERB	O	O
(	PUNCT	O	O
0.5	NUM	O	O
to	ADP	O	O
3.5	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
38	NUM	O	O
was	VERB	O	O
a	DET	O	O
subset	NOUN	O	O
of	ADP	O	O
101	ADJ	O	O
subjects	NOUN	O	O
who	PROPN	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
;	PUNCT	O	O
63	NUM	O	O
were	VERB	O	O
unable	ADJ	O	O
to	PART	O	O
perform	NOUN	O	O
the	DET	O	O
cognitive	ADJ	O	O
tasks	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	DET	O	O
parallel	PUNCT	O	O
groups	NOUN	O	O
design	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

Dependent	ADJ	O	O
measures	NOUN	O	O
included	ADV	O	O
tests	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
sustained	VERB	O	I-PHYSICAL
attention	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
verbal	ADJ	O	B-PHYSICAL
learning	PROPN	O	I-PHYSICAL
,	PUNCT	O	O
hand-eye	NOUN	O	B-PHYSICAL
coordination	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
spatial	ADJ	O	B-PHYSICAL
memory	NOUN	O	I-PHYSICAL
assessed	VERB	O	I-PHYSICAL
before	CCONJ	O	O
,	PUNCT	O	O
during	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
8-week	NOUN	O	B-PHYSICAL
treatment	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
performance	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
by	ADP	O	O
repeated	VERB	O	O
measures	NOUN	O	O
ANOVA	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty-nine	NUM	O	O
boys	NOUN	O	O
and	CCONJ	O	O
9	NUM	O	O
girls	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
severe	ADJ	O	O
behavioral	ADJ	O	O
disturbance	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
mental	ADJ	O	O
age	NOUN	O	O
>	SYM	O	O
or=18	NOUN	O	O
months	NOUN	O	O
completed	PUNCT	O	O
the	DET	O	O
cognitive	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
decline	NOUN	O	O
in	ADP	O	O
performance	NOUN	O	O
occurred	VERB	O	O
with	ADP	O	O
risperidone	NUM	O	O
.	PUNCT	O	O

Performance	NOUN	O	O
on	ADP	O	O
a	DET	O	O
cancellation	NOUN	O	B-MENTAL
task	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
number	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
correct	ADJ	O	I-MENTAL
detections	NOUN	O	I-MENTAL
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
verbal	ADJ	O	B-MENTAL
learning	VERB	O	I-MENTAL
task	NOUN	O	I-MENTAL
(	PUNCT	O	O
word	NOUN	O	B-MENTAL
recognition	NOUN	O	I-MENTAL
)	PUNCT	O	O
was	VERB	O	O
better	PUNCT	O	O
on	ADP	O	O
risperidone	NUM	O	O
than	PUNCT	O	O
on	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
without	ADP	O	O
correction	NOUN	O	O
for	ADP	O	O
multiplicity	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Equivocal	ADJ	O	B-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
also	ADV	O	O
occurred	VERB	O	O
on	ADP	O	O
a	DET	O	O
spatial	ADJ	O	B-MENTAL
memory	NOUN	O	I-MENTAL
task	NOUN	O	I-MENTAL
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
treatment	NOUN	O	O
conditions	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Purdue	NOUN	O	B-MENTAL
Pegboard	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
hand-eye	NOUN	O	I-MENTAL
coordination	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
task	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
Analog	NOUN	O	B-MENTAL
Classroom	PUNCT	O	I-MENTAL
Task	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
timed	PUNCT	O	I-MENTAL
math	ADP	O	I-MENTAL
test	NOUN	O	I-MENTAL
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Risperidone	NUM	O	O
given	VERB	O	O
to	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
up	PUNCT	O	O
to	DET	O	O
3.5	NUM	O	O
mg	NOUN	O	O
for	ADP	O	O
up	PUNCT	O	O
to	ADV	O	O
8	NUM	O	O
weeks	NOUN	O	O
appears	NOUN	O	O
to	PUNCT	O	O
have	PUNCT	O	O
no	DET	O	O
detrimental	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
cognitive	ADJ	O	B-MENTAL
performance	NOUN	O	I-MENTAL
.	PUNCT	O	O

Histamine	NOUN	O	O
intolerance-like	ADJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
after	ADP	O	O
oral	ADJ	O	O
provocation	NOUN	O	O
with	ADP	O	O
liquid	ADJ	O	O
histamine	NOUN	O	O
.	PUNCT	O	O

Histamine	NOUN	O	O
in	ADP	O	O
food	NOUN	O	O
at	ADP	O	O
non-toxic	ADJ	O	O
doses	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
proposed	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
major	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
food	NOUN	O	O
intolerance	NOUN	O	O
causing	ADP	O	O
symptoms	NOUN	O	O
like	ADP	O	O
diarrhea	NOUN	O	O
,	PUNCT	O	O
hypotension	NOUN	O	O
,	PUNCT	O	O
headache	NOUN	O	O
,	PUNCT	O	O
pruritus	NOUN	O	O
and	CCONJ	O	O
flush	NOUN	O	O
(	PUNCT	O	O
histamine	NOUN	O	O
intolerance	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Histamine-rich	PUNCT	O	O
foods	ADJ	O	O
such	CCONJ	O	O
as	ADP	O	O
cheese	PUNCT	O	O
,	PUNCT	O	O
sausages	NOUN	O	O
,	PUNCT	O	O
sauerkraut	PUNCT	O	O
,	PUNCT	O	O
tuna	ADP	O	O
,	PUNCT	O	O
tomatoes	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
alcoholic	ADJ	O	O
beverages	NOUN	O	O
may	VERB	O	O
contain	VERB	O	O
histamine	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
500	NUM	O	O
mg/kg	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
cross-over	NOUN	O	O
study	CCONJ	O	O
in	ADP	O	O
10	NUM	O	O
healthy	ADJ	O	O
females	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
range	NOUN	O	O
22-36	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
29.1	NUM	O	O
+/-	SYM	O	O
5.4	NUM	O	O
)	PUNCT	O	O
who	ADP	O	O
were	VERB	O	O
hospitalized	VERB	O	O
and	CCONJ	O	O
challenged	VERB	O	O
on	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
peppermint	NOUN	O	O
tea	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
75	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
pure	ADJ	O	O
histamine	NOUN	O	O
(	PUNCT	O	O
equaling	ADJ	O	O
124	NUM	O	O
mg	NOUN	O	O
histamine	NOUN	O	O
dihydrochloride	NOUN	O	O
,	PUNCT	O	O
dissolved	PUNCT	O	O
in	ADP	O	O
peppermint	NOUN	O	O
tea	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Objective	ADJ	O	O
parameters	NOUN	O	O
(	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
skin	NOUN	O	O
temperature	NOUN	O	O
,	PUNCT	O	O
peak	ADJ	O	O
flow	NOUN	O	O
)	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
a	DET	O	O
total	ADJ	O	O
clinical	ADJ	O	O
symptom	NOUN	O	O
score	NOUN	O	O
using	VERB	O	O
a	DET	O	O
standardized	VERB	O	O
protocol	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
40	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subjects	NOUN	O	O
received	VERB	O	O
a	DET	O	O
histamine-free	VERB	O	O
diet	NOUN	O	O
also	ADV	O	O
low	ADJ	O	O
in	ADP	O	O
allergen	NOUN	O	O
24	NUM	O	O
hours	NOUN	O	O
before	PUNCT	O	O
hospitalization	NOUN	O	O
and	CCONJ	O	O
over	ADP	O	O
the	DET	O	O
whole	ADJ	O	O
observation	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
drawn	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
40	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
80	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
histamine	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
histamine-degrading	ADV	O	O
enzyme	NOUN	O	O
diamine	NOUN	O	O
oxidase	NOUN	O	O
(	PUNCT	O	O
DAO	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
histamine	NOUN	O	O
challenge	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
of	ADP	O	O
10	NUM	O	O
subjects	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
reaction	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

One	NUM	O	O
individual	ADJ	O	O
experienced	VERB	O	O
tachycardia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
mild	ADJ	O	B-PHYSICAL
hypotension	NOUN	O	I-PHYSICAL
after	ADP	O	I-PHYSICAL
20	NUM	O	I-PHYSICAL
minutes	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
sneezing	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
itching	ADJ	O	O
of	ADP	O	O
the	DET	O	O
nose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
rhinorrhea	NOUN	O	O
after	ADP	O	O
60	NUM	O	B-PHYSICAL
minutes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Four	NUM	O	O
subjects	NOUN	O	O
experienced	DET	O	O
delayed	VERB	O	O
symptoms	NOUN	O	O
like	ADP	O	O
diarrhea	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
4x	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
flatulence	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
3x	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
headache	ADJ	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
3x	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
pruritus	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
2x	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
ocular	ADJ	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
1x	NOUN	O	O
)	PUNCT	O	O
starting	ADV	O	O
3	NUM	O	O
to	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
provocation	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
subject	NOUN	O	O
reacted	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
changes	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
histamine	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
DAO	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
80	NUM	O	O
minutes	NOUN	O	O
in	ADP	O	O
non-reactors	NOUN	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
reactors	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
challenge	NOUN	O	O
with	ADP	O	O
histamine	NOUN	O	O
versus	CCONJ	O	O
challenge	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
75	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
pure	ADJ	O	O
liquid	ADJ	O	O
oral	ADJ	O	O
histamine	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
found	VERB	O	O
in	ADP	O	O
normal	ADJ	O	O
meals	NOUN	O	O
--	PUNCT	O	O
can	VERB	O	O
provoke	NOUN	O	O
immediate	ADJ	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
delayed	VERB	O	O
symptoms	NOUN	O	O
in	ADP	O	O
50	NUM	O	O
%	SYM	O	O
of	ADP	O	O
healthy	ADJ	O	O
females	NOUN	O	O
without	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
food	NOUN	O	O
intolerance	NOUN	O	O
.	PUNCT	O	O

Response	NOUN	O	O
prediction	NOUN	O	O
in	ADP	O	O
metastasised	DET	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
using	SYM	O	O
intratumoural	ADJ	O	O
thymidylate	NOUN	O	O
synthase	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
multicentre	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Molecular	ADJ	O	O
markers	NOUN	O	O
to	PART	O	O
predict	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
5-fluorouracil	NOUN	O	O
(	PUNCT	O	O
FU	NOUN	O	O
)	PUNCT	O	O
-based	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	O
or	CCONJ	O	O
metastasised	VERB	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
mCRC	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
not	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
value	NOUN	O	O
of	ADP	O	O
thymidylate	NOUN	O	O
synthase	NOUN	O	O
(	PUNCT	O	O
TS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
key	ADJ	O	O
enzyme	NOUN	O	O
of	ADP	O	O
DNA	NOUN	O	O
synthesis	NOUN	O	O
and	CCONJ	O	O
target	NOUN	O	O
of	ADP	O	O
5-FU	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
predict	NOUN	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	ADP	O	O
chemotherapy	NOUN	O	O
of	ADP	O	O
mCRC	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Tumour	NOUN	O	O
tissue	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
from	ADP	O	O
168	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mCRC	NOUN	O	O
for	ADP	O	O
relative	ADJ	O	O
thymidylate	NOUN	O	O
synthase	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
TS	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
mRNA	NOUN	O	O
quantitation	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
5-FU/folinic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
FA	NOUN	O	O
,	PUNCT	O	O
FUFA	NOUN	O	O
)	PUNCT	O	O
alone	ADJ	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
irinotecan	NOUN	O	O
5-fluorouracil/folinic	PUNCT	O	O
acid	NOUN	O	O
and	CCONJ	O	O
irinotecan	NOUN	O	O
(	PUNCT	O	O
FOLFIRI	NOUN	O	O
)	PUNCT	O	O
stratified	PUNCT	O	O
by	ADP	O	O
TS	NOUN	O	O
(	PUNCT	O	O
low	ADJ	O	O
versus	CCONJ	O	O
high	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Primary	ADJ	O	O
end-point	NOUN	O	O
was	VERB	O	O
overall	ADJ	O	B-PHYSICAL
response	NOUN	O	O
to	ADP	O	B-PHYSICAL
first-line	NOUN	O	I-PHYSICAL
treatment	NOUN	O	B-PHYSICAL
among	ADP	O	O
TS	NOUN	O	O
high	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
parties	ADJ	O	O
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
randomisation	NOUN	O	O
centre	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
blinded	VERB	O	O
for	ADP	O	O
TS	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Biopsies	NOUN	O	O
(	PUNCT	O	O
n=168	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
taken	VERB	O	O
without	ADP	O	O
complications	NOUN	O	O
.	PUNCT	O	O

TS	NOUN	O	B-PHYSICAL
levels	NOUN	O	B-PHYSICAL
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
147	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
87.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Analysing	PROPN	O	O
response	NOUN	O	O
to	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
flurbiprofen	PUNCT	O	O
sodium	NOUN	O	O
on	ADP	O	O
pupillary	ADJ	O	B-PHYSICAL
dilatation	NOUN	O	I-PHYSICAL
during	ADP	O	O
scleral	ADJ	O	O
buckling	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Maintenance	NOUN	O	O
of	ADP	O	O
pupillary	ADJ	O	B-PHYSICAL
dilatation	NOUN	O	I-PHYSICAL
is	VERB	O	O
necessary	ADJ	O	O
for	ADP	O	O
success	NOUN	O	O
of	ADP	O	O
scleral	ADJ	O	O
buckling	ADP	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
0.03	NUM	O	O
%	SYM	O	O
flurbiprofen	PUNCT	O	O
in	ADP	O	O
preventing	VERB	O	O
intraoperative	ADJ	O	O
miosis	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-masked	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
0.03	NUM	O	O
%	SYM	O	O
flurbiprofen	PUNCT	O	O
6	NUM	O	O
times	NOUN	O	O
at	ADP	O	O
15	NUM	O	O
minute	ADJ	O	O
intervals	NOUN	O	O
90	NUM	O	O
minutes	NOUN	O	O
preoperatively	ADV	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
routine	ADJ	O	O
dilation	NOUN	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treated	DET	O	O
group	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
mean	NOUN	O	O
pupillary	ADJ	O	B-PHYSICAL
decrease	NOUN	O	O
of	ADP	O	O
1.88	NUM	O	O
mm	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
had	CCONJ	O	O
a	DET	O	O
decrease	NOUN	O	O
of	ADP	O	O
1.57	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Flurbiprofen	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
pupillary	ADJ	O	B-PHYSICAL
size	NOUN	O	I-PHYSICAL
at	ADP	O	O
any	DET	O	O
step	NOUN	O	O
of	ADP	O	O
the	DET	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Factors	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
age	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	B-MENTAL
,	PUNCT	O	O
lens	NOUN	O	B-PHYSICAL
status	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
cryo	NOUN	O	B-PHYSICAL
applications	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
duration	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
surgery	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
size	NOUN	O	O
and	CCONJ	O	O
extent	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
buckle	NOUN	O	I-OTHER
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
flurbiprofen	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
mean	NOUN	O	O
pupillary	PUNCT	O	B-PHYSICAL
change	NOUN	O	I-PHYSICAL
for	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
these	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Preoperative	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
flurbiprofen	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
significantly	ADV	O	O
decrease	NOUN	O	O
intraoperative	ADJ	O	B-PHYSICAL
miosis	NOUN	O	I-PHYSICAL
during	ADP	O	I-PHYSICAL
scleral	ADJ	O	I-PHYSICAL
buckling	ADP	O	I-PHYSICAL
procedures	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
supports	VERB	O	O
on	ADP	O	O
performance	NOUN	O	B-OTHER
of	ADP	O	O
the	DET	O	O
TGMD-2	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
supports	VERB	O	O
on	ADP	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Test	NOUN	O	O
of	ADP	O	O
Gross	ADJ	O	O
Motor	NOUN	O	O
Development	NOUN	O	O
(	PUNCT	O	O
TGMD-2	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
22	NUM	O	O
)	PUNCT	O	O
performed	VERB	O	O
the	DET	O	O
TGMD-2	NOUN	O	O
under	ADP	O	O
three	NUM	O	O
different	ADJ	O	O
protocols	NOUN	O	O
(	PUNCT	O	O
traditional	ADJ	O	O
protocol	NOUN	O	O
,	PUNCT	O	O
picture	NOUN	O	O
task	NOUN	O	O
card	ADJ	O	O
protocol	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
picture	NOUN	O	O
activity	NOUN	O	O
schedule	NOUN	O	O
protocol	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Gross	ADJ	O	B-PHYSICAL
motor	NOUN	O	I-PHYSICAL
quotient	NOUN	O	I-PHYSICAL
scores	NOUN	O	O
on	ADP	O	O
the	DET	O	O
TGMD-2	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
and	CCONJ	O	O
statistically	ADV	O	O
analyzed	VERB	O	O
using	VERB	O	O
a	DET	O	O
within-subjects	PUNCT	O	O
repeated-measures	VERB	O	O
ANOVA	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
indicated	VERB	O	O
statistically	ADP	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
protocols	NOUN	O	O
,	PUNCT	O	O
while	VERB	O	O
post	PUNCT	O	O
hoc	ADP	O	O
tests	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
the	DET	O	O
picture	NOUN	O	O
task	NOUN	O	O
card	PUNCT	O	O
condition	NOUN	O	O
produced	ADJ	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
gross	ADJ	O	B-PHYSICAL
motor	NOUN	O	I-PHYSICAL
quotient	NOUN	O	I-PHYSICAL
scores	ADJ	O	O
than	VERB	O	O
the	DET	O	O
traditional	ADJ	O	O
protocol	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
picture	NOUN	O	O
activity	NOUN	O	O
schedule	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
more	ADV	O	O
accurate	ADJ	O	O
gross	ADJ	O	O
motor	NOUN	O	O
quotient	NOUN	O	O
scores	NOUN	O	O
on	ADP	O	O
the	DET	O	O
TGMD-2	NOUN	O	B-PHYSICAL
by	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
elicited	VERB	O	O
using	SYM	O	O
the	DET	O	O
picture	NOUN	O	O
task	NOUN	O	O
card	ADJ	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

Hysteroscopic	ADJ	O	O
transcervical	ADJ	O	O
endometrial	ADJ	O	O
resection	NOUN	O	O
versus	CCONJ	O	O
thermal	ADJ	O	O
destruction	NOUN	O	O
for	ADP	O	O
menorrhagia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
on	ADP	O	O
satisfaction	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
satisfaction	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
and	CCONJ	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
transcervical	ADJ	O	O
hysteroscopic	ADJ	O	O
endometrial	ADJ	O	O
resection	NOUN	O	O
and	CCONJ	O	O
thermal	ADJ	O	O
destruction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
endometrium	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
menorrhagia	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
A	CCONJ	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
in	ADP	O	O
the	DET	O	O
Department	NOUN	O	O
of	ADP	O	O
Gynecology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
University	NOUN	O	O
of	ADP	O	O
Naples	NOUN	O	O
.	PUNCT	O	O

Eighty-two	NUM	O	O
patients	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
menorrhagia	NOUN	O	O
that	ADP	O	O
was	VERB	O	O
unresponsive	ADJ	O	O
to	PUNCT	O	O
medical	PUNCT	O	O
treatment	NOUN	O	O
were	VERB	O	O
respectively	ADV	O	O
randomized	VERB	O	O
to	ADP	O	O
transcervical	ADJ	O	O
hysteroscopic	ADJ	O	O
endometrial	ADJ	O	O
resection	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
thermal	ADJ	O	O
destruction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
endometrium	NOUN	O	O
.	PUNCT	O	O

Satisfaction	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
,	PUNCT	O	O
operative	ADJ	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
discharge	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
complication	NOUN	O	B-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
reintervention	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
resumption	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	B-OTHER
activity	NOUN	O	I-OTHER
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
satisfaction	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
thermal	ADJ	O	O
destruction	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Operative	ADJ	O	B-OTHER
time	NOUN	O	I-OTHER
was	VERB	O	O
significantly	ADV	O	O
shorter	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
thermal	ADJ	O	O
destruction	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
24	NUM	O	O
+/-	SYM	O	O
4	NUM	O	O
minutes	NOUN	O	O
vs	CCONJ	O	O
37	NUM	O	O
+/-	SYM	O	O
6	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intraoperative	ADJ	O	B-ADVERSE-EFFECTS
blood	NOUN	O	I-ADVERSE-EFFECTS
loss	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
thermal	ADJ	O	O
destruction	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
7.2	NUM	O	O
+/-	SYM	O	O
2.8	NUM	O	O
mL	NOUN	O	O
vs	CCONJ	O	O
89	NUM	O	O
+/-	SYM	O	O
38	NUM	O	O
mL	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Reintervention	NOUN	O	B-OTHER
rates	NOUN	O	I-OTHER
were	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
transcervical	ADJ	O	O
hysteroscopic	ADJ	O	O
endometrial	ADJ	O	O
resection	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
postoperative	ADJ	O	O
pain	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Discharge	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
complication	NOUN	O	B-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
resumption	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	B-OTHER
activity	NOUN	O	I-OTHER
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Thermal	ADJ	O	O
destruction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
endometrium	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
menorrhagia	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
because	PUNCT	O	O
of	ADP	O	O
its	ADJ	O	O
acceptability	NOUN	O	B-OTHER
among	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
shorter	CCONJ	O	B-OTHER
operative	ADJ	O	I-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
lower	VERB	O	B-OTHER
blood	NOUN	O	I-OTHER
loss	NOUN	O	I-OTHER
.	PUNCT	O	O

Repeatability	NOUN	O	O
and	CCONJ	O	O
protocol	NOUN	O	O
comparability	NOUN	O	O
of	ADP	O	O
presyncopal	ADJ	O	O
symptom	NOUN	O	O
limited	ADP	O	O
lower	PUNCT	O	O
body	NOUN	O	O
negative	ADJ	O	O
pressure	NOUN	O	O
exposures	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
repeatability	NOUN	O	O
and	CCONJ	O	O
comparability	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
presyncopal	ADJ	O	O
symptom-limited	VERB	O	O
lower	PUNCT	O	O
body	NOUN	O	O
negative	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
PSL-LBNP	NOUN	O	O
)	PUNCT	O	O
exposure	NOUN	O	O
protocols	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
scarce	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
critical	ADJ	O	O
to	ADP	O	O
the	DET	O	O
interpretation	NOUN	O	O
of	ADP	O	O
studies	NOUN	O	O
using	VERB	O	O
PSL-LBNP	NOUN	O	O
methods	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	ADP	O	O
if	PUNCT	O	O
PSL-LBNP	NOUN	O	O
tolerance	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
were	VERB	O	O
repeatable	ADJ	O	O
,	PUNCT	O	O
11	NUM	O	O
subjects	NOUN	O	O
were	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
4	NUM	O	O
PSL-LBNP	NOUN	O	O
tests	NOUN	O	O
;	PUNCT	O	O
each	DET	O	O
test	NOUN	O	O
occurring	ADJ	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
of	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
separated	VERB	O	O
by	ADP	O	O
at	ADP	O	O
least	ADV	O	O
72	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
using	VERB	O	O
the	DET	O	O
same	ADJ	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
responses	NOUN	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
PSL-LBNP	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
tolerance	NOUN	O	O
indices	NOUN	O	B-OTHER
(	PUNCT	O	O
cumulative	ADJ	O	O
stress	NOUN	O	O
index	NOUN	O	O
;	PUNCT	O	O
maximum	NOUN	O	O
negative	ADJ	O	O
pressure	NOUN	O	O
tolerated	VERB	O	O
;	PUNCT	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
negative	ADJ	O	O
pressure	NOUN	O	O
exposure	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

To	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
comparability	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
PSL-LBNP	NOUN	O	O
protocols	NOUN	O	O
,	PUNCT	O	O
nine	NUM	O	O
subjects	NOUN	O	O
were	VERB	O	O
exposed	VERB	O	O
randomly	ADV	O	O
to	PUNCT	O	O
five	PUNCT	O	O
PSL-LBNP	NOUN	O	O
tests	NOUN	O	O
using	PROPN	O	O
protocols	NOUN	O	O
that	ADP	O	O
varied	VERB	O	O
in	ADP	O	O
stage	NOUN	O	O
duration	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
pressure	NOUN	O	O
profile	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
protocols	NOUN	O	O
had	PUNCT	O	O
1-	NUM	O	O
,	PUNCT	O	O
3-	NUM	O	O
,	PUNCT	O	O
5-	NUM	O	O
,	PUNCT	O	O
7-	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
9-min	NOUN	O	O
stage	NOUN	O	O
durations	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
PSL-LBNP	NOUN	O	O
exposures	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
of	ADP	O	O
day	NOUN	O	O
and	CCONJ	O	O
separated	VERB	O	O
by	ADP	O	O
at	ADP	O	O
least	ADV	O	O
72	NUM	O	O
h.	NOUN	O	O
While	ADP	O	O
no	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
response	NOUN	O	O
pattern	NOUN	O	O
or	CCONJ	O	O
magnitude	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
differing	VERB	O	O
protocols	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cumulative	ADJ	O	B-OTHER
stress	NOUN	O	O
index	NOUN	O	B-OTHER
and	CCONJ	O	O
the	DET	O	B-PHYSICAL
duration	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
negative	PUNCT	O	O

Helicobacter	NOUN	O	B-PHYSICAL
pylori	NOUN	O	I-PHYSICAL
eradication	NOUN	O	I-PHYSICAL
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
by	ADP	O	O
a	PUNCT	O	O
once	PUNCT	O	O
daily	PUNCT	O	O
6-day	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
a	DET	O	O
proton	NOUN	O	O
pump	NOUN	O	O
inhibitor	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
evaluate	NOUN	O	O
two	NUM	O	O
simplified	VERB	O	O
Helicobacter	NOUN	O	B-PHYSICAL
pylori	NOUN	O	I-PHYSICAL
eradication	NOUN	O	I-PHYSICAL
treatment	NOUN	O	O
alternatives	VERB	O	O
for	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Study	ADP	O	O
subjects	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
by	ADP	O	O
enzyme-linked	VERB	O	O
immunosorbent	ADJ	O	O
assay	NOUN	O	O
and	CCONJ	O	O
immunoblot	NOUN	O	O
in	ADP	O	O
a	DET	O	O
family	NOUN	O	O
screening	ADJ	O	O
project	NOUN	O	O
.	PUNCT	O	O

Helicobacter	NOUN	O	O
pylori	NOUN	O	O
infected	ADP	O	O
10-21	NUM	O	O
year	NOUN	O	O
olds	NUM	O	O
were	VERB	O	O
offered	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
individuals	NOUN	O	O
with	ADP	O	O
abdominal	ADJ	O	O
pain	NOUN	O	O
underwent	VERB	O	O
upper	ADJ	O	O
endoscopy	NOUN	O	O
and	CCONJ	O	O
those	PUNCT	O	O
with	ADP	O	O
peptic	ADJ	O	O
ulcers	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	PUNCT	O	O
azithromycin	NOUN	O	O
500	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
and	CCONJ	O	O
tinidazole	NOUN	O	O
500	NUM	O	O
mg	NOUN	O	O
two	NUM	O	O
tablets	ADV	O	O
daily	ADP	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
lansoprasole	ADJ	O	O
30	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
6	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
ATL-group	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
ATP-group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Urea	NOUN	O	O
Breath	NOUN	O	O
Test	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
inclusion	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
end	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
total	NOUN	O	O
,	PUNCT	O	O
131	NUM	O	O
individuals	NOUN	O	O
were	VERB	O	O
randomized	PROPN	O	O
,	PUNCT	O	O
of	ADP	O	O
whom	ADP	O	O
31	NUM	O	O
(	PUNCT	O	O
24	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
undergone	ADP	O	O
upper	ADJ	O	O
endoscopy	NOUN	O	O
.	PUNCT	O	O

Full	ADJ	O	B-MENTAL
compliance	NOUN	O	I-MENTAL
was	VERB	O	O
achieved	VERB	O	O
in	ADP	O	O
93	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
122	NUM	O	O
of	ADP	O	O
131	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
intention-to-treat	NOUN	O	B-OTHER
eradication	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
67	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
44	NUM	O	O
of	ADP	O	O
66	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
58	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
38	NUM	O	O
of	ADP	O	O
65	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
ATL-	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
ATP-group	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
double-blind	ADJ	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
identify	ADJ	O	O
a	ADP	O	O
simplified	NOUN	O	O
,	PUNCT	O	O
successful	ADJ	O	O
once	PUNCT	O	O
daily	PUNCT	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
twice	ADV	O	O
daily	ADJ	O	O
proton	NOUN	O	O
pump	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
PPI	NOUN	O	O
)	PUNCT	O	O
-based	ADP	O	O
triple	ADJ	O	O
therapies	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
remain	VERB	O	O
as	ADP	O	O
the	DET	O	O
choice	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Further	ADV	O	O
,	PUNCT	O	O
powerful	ADJ	O	O
and	CCONJ	O	O
controlled	VERB	O	O
studies	NOUN	O	O
are	ADV	O	O
needed	VERB	O	O
to	PART	O	O
elucidate	NOUN	O	O
the	DET	O	O
best	PUNCT	O	O
treatment	NOUN	O	O
strategies	NOUN	O	O
for	ADP	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
eradication	NOUN	O	O
in	ADP	O	O
this	DET	O	O
age	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
triggered	ADP	O	O
and	CCONJ	O	O
conventional	ADJ	O	O
fast	ADJ	O	O
rate	NOUN	O	O
ventilation	NOUN	O	O
in	ADP	O	O
neonatal	ADJ	O	O
respiratory	ADJ	O	O
distress	NOUN	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
compare	NOUN	O	O
patient	NOUN	O	O
triggered	ADP	O	O
,	PUNCT	O	O
with	ADP	O	O
conventional	ADJ	O	O
fast	ADJ	O	O
rate	NOUN	O	O
,	PUNCT	O	O
ventilation	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
using	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-PHYSICAL
lung	NOUN	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
as	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Three	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
eighty	PUNCT	O	O
six	PUNCT	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
with	ADP	O	O
birthweights	NOUN	O	O
from	ADP	O	O
1000	NUM	O	O
to	ADP	O	O
2000	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
requiring	PUNCT	O	O
ventilation	NOUN	O	O
for	ADP	O	O
respiratory	ADJ	O	O
distress	NOUN	O	O
syndrome	NOUN	O	O
within	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
birth	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	ADP	O	O
either	PUNCT	O	O
conventional	ADJ	O	O
or	CCONJ	O	O
trigger	PUNCT	O	O
ventilation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
SLE	NOUN	O	O
2000	NUM	O	O
ventilator	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-PHYSICAL
lung	NOUN	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
28	NUM	O	O
day	NOUN	O	O
and	CCONJ	O	O
36	NUM	O	O
week	NOUN	O	O
definitions	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
pneumothorax	NOUN	O	O
,	PUNCT	O	O
intraventricular	ADJ	O	O
haemorrhage	NOUN	O	O
,	PUNCT	O	O
number	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
ventilator	NOUN	O	I-OTHER
days	NOUN	O	I-OTHER
,	PUNCT	O	O
or	PUNCT	O	O

Interventional	ADJ	O	O
study	NOUN	O	O
to	ADP	O	O
strengthen	PUNCT	O	O
the	DET	O	O
health	NOUN	O	O
promoting	PUNCT	O	O
behaviours	NOUN	O	O
of	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
to	PUNCT	O	O
prevent	ADJ	O	O
anaemia	PUNCT	O	O
in	ADP	O	O
southern	PUNCT	O	O
India	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
health	NOUN	O	O
information	NOUN	O	O
package	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
empowering	ADJ	O	O
the	DET	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
to	PUNCT	O	O
modify	ADJ	O	O
their	ADP	O	O
health-care	NOUN	O	O
behaviour	NOUN	O	O
and	CCONJ	O	O
take	ADV	O	O
appropriate	ADJ	O	O
action	NOUN	O	O
to	ADP	O	O
combat	PUNCT	O	O
anaemia	NOUN	O	O
in	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conceptualized	VERB	O	O
based	VERB	O	O
on	ADP	O	O
Rosenstock	NOUN	O	O
and	CCONJ	O	O
Becker	NOUN	O	O
's	PUNCT	O	O
health	NOUN	O	O
belief	ADJ	O	O
model	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
quasi-experimental	ADJ	O	O
pretest-posttest	NOUN	O	O
control	NOUN	O	O
group	NOUN	O	O
design	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
sample	NOUN	O	O
consists	ADP	O	O
of	ADP	O	O
225	NUM	O	O
anaemic	ADJ	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
randomly	ADV	O	O
allocated	VERB	O	O
in	ADP	O	O
experimental	ADJ	O	O
(	PUNCT	O	O
n=75	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
n=75	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
n=75	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
health	NOUN	O	O
seeking	PUNCT	O	O
behaviour	NOUN	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
included	VERB	O	O
knowledge	NOUN	O	O
regarding	VERB	O	O
anaemia	NOUN	O	O
,	PUNCT	O	O
food	NOUN	O	O
selection	NOUN	O	O
ability	NOUN	O	O
,	PUNCT	O	O
increase	CCONJ	O	O
in	ADP	O	O
haemoglobin	NOUN	O	O
level	NOUN	O	O
and	CCONJ	O	O
compliance	NOUN	O	O
to	ADP	O	O
iron	NOUN	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

Intervention	NOUN	O	O
was	VERB	O	O
a	DET	O	O
validated	VERB	O	O
planned	PROPN	O	O
educational	ADJ	O	O
programme	NOUN	O	O
with	ADP	O	O
visual	ADJ	O	O
aids	NOUN	O	O
and	CCONJ	O	O
iron	NOUN	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

FINDINGS	NOUN	O	O
the	DET	O	O
results	CCONJ	O	O
show	VERB	O	O
the	DET	O	O
mean	NOUN	O	O
gain	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
knowledge	NOUN	O	I-OTHER
scores	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
comparatively	ADV	O	O
higher	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
A	DET	O	O
and	CCONJ	O	O
B	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
F	NOUN	O	O
ratio	NOUN	O	O
was	VERB	O	O
(	PUNCT	O	O
F	NOUN	O	O
(	PUNCT	O	O
2,190	ADP	O	O
)	PUNCT	O	O
=11.910	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
learned	VERB	O	O
more	ADV	O	O
about	PUNCT	O	O
anaemia	NOUN	O	O
prevention	NOUN	O	O
than	ADP	O	O
others	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
food	NOUN	O	O
selection	NOUN	O	O
ability	NOUN	O	O
scores	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
,	PUNCT	O	O
control	NOUN	O	O
groups	NOUN	O	O
A	DET	O	O
and	CCONJ	O	O
B	NOUN	O	O
the	DET	O	O
F	NOUN	O	O
ratio	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
F	NOUN	O	O
(	PUNCT	O	O
2,190	ADP	O	O
)	PUNCT	O	O
=20.92	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nearly	ADV	O	O
61.2	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
in	ADP	O	O
experimental	ADJ	O	O
group	NOUN	O	O
became	ADP	O	O
non-anaemic	ADJ	O	B-PHYSICAL
after	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
control	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
indicated	VERB	O	O
that	ADP	O	O
inspite	NOUN	O	O
of	ADP	O	O
iron	NOUN	O	O
supplementation	NOUN	O	O
received	VERB	O	O
by	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
health	NOUN	O	O
education	NOUN	O	O
contributed	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
modifying	VERB	O	O
their	ADP	O	O
health	NOUN	O	O
seeking	PUNCT	O	O
behaviour	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
perception	NOUN	O	O
about	PUNCT	O	O
significance	NOUN	O	O
of	ADP	O	O
anaemia	NOUN	O	O
has	PUNCT	O	O
a	DET	O	O
problem	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
developing	VERB	O	O
countries	NOUN	O	O
still	ADP	O	O
face	ADP	O	O
the	DET	O	O
critical	ADJ	O	O
problem	NOUN	O	O
of	ADP	O	O
anaemia	NOUN	O	O
in	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

These	PUNCT	O	O
are	ADJ	O	O
the	DET	O	O
socio-cultural	PUNCT	O	O
priority	NOUN	O	O
problems	NOUN	O	O
that	PUNCT	O	O
demand	ADJ	O	O
immediate	ADJ	O	O
attention	NOUN	O	O
by	ADP	O	O
the	DET	O	O
policy	NOUN	O	O
makers	NOUN	O	O
and	CCONJ	O	O
health	NOUN	O	O
professionals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
national	ADJ	O	O
anaemia	NOUN	O	O
control	NOUN	O	O
programme	NOUN	O	O
focuses	NOUN	O	O
on	ADP	O	O
iron	NOUN	O	O
supplementation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
nutritional	ADJ	O	O
education	NOUN	O	O
and	CCONJ	O	O
supervision	NOUN	O	O
of	ADP	O	O
iron	NOUN	O	O
supplementation	NOUN	O	O
has	PUNCT	O	O
failed	VERB	O	O
in	ADP	O	O
different	ADJ	O	O
regions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
implies	NOUN	O	O
that	PUNCT	O	O
economic	ADJ	O	O
empowerment	NOUN	O	O
;	PUNCT	O	O
strengthening	NUM	O	O
health	NOUN	O	O
literacy	NOUN	O	O
through	CCONJ	O	O
planned	VERB	O	O
educational	ADJ	O	O
programs	NOUN	O	O
will	ADP	O	O
definitely	ADV	O	O
improve	VERB	O	O
the	DET	O	O
health	NOUN	O	O
behaviour	NOUN	O	O
of	ADP	O	O
individual	ADJ	O	O
and	CCONJ	O	O
community	NOUN	O	O
at	ADP	O	O
large	ADJ	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
thermal	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
restricted	VERB	O	O
feeding	PROPN	O	O
and	CCONJ	O	O
combined	VERB	O	O
stresses	NOUN	O	O
(	PUNCT	O	O
thermal	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
restricted	VERB	O	O
feeding	ADV	O	O
)	PUNCT	O	O
on	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
reproductive	ADJ	O	O
hormone	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
Malpura	PUNCT	O	O
ewes	NOUN	O	O
under	ADP	O	O
semi-arid	ADJ	O	O
tropical	ADJ	O	O
environment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
thermal	ADJ	O	O
,	PUNCT	O	O
nutritional	ADJ	O	O
and	CCONJ	O	O
combined	VERB	O	O
stresses	NOUN	O	O
(	PUNCT	O	O
thermal	ADJ	O	O
and	CCONJ	O	O
nutritional	ADJ	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
growth	NOUN	O	O
,	PUNCT	O	O
oestradiol	NOUN	O	O
and	CCONJ	O	O
progesterone	NOUN	O	O
levels	NOUN	O	O
during	ADP	O	O
oestrus	NOUN	O	O
cycles	NOUN	O	O
in	ADP	O	O
Malpura	PUNCT	O	O
ewes	NOUN	O	O
.	PUNCT	O	O

Twenty-eight	PUNCT	O	O
adult	NOUN	O	O
Malpura	PUNCT	O	O
ewes	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ewes	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
into	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
viz.	NOUN	O	O
,	PUNCT	O	O
GI	NOUN	O	O
(	PUNCT	O	O
n=7	NOUN	O	O
;	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
GII	NOUN	O	O
(	PUNCT	O	O
n=7	NOUN	O	O
;	PUNCT	O	O
thermal	ADJ	O	O
stress	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
GIII	ADJ	O	O
(	PUNCT	O	O
n=7	NOUN	O	O
;	PUNCT	O	O
restricted	VERB	O	O
feeding	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
GIV	NOUN	O	O
(	PUNCT	O	O
n=7	NOUN	O	O
;	PUNCT	O	O
combined	VERB	O	O
stress	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
animals	NOUN	O	O
were	VERB	O	O
stall	NOUN	O	O
fed	ADJ	O	O
with	ADP	O	O
a	DET	O	O
diet	NOUN	O	O
consisting	VERB	O	O
of	ADP	O	O
60	NUM	O	O
%	ADJ	O	O
roughage	NOUN	O	O
and	CCONJ	O	O
40	NUM	O	O
%	SYM	O	O
concentrate	NOUN	O	O
.	PUNCT	O	O

GI	NOUN	O	O
and	CCONJ	O	O
GII	NOUN	O	O
ewes	NOUN	O	O
were	VERB	O	O
provided	VERB	O	O
with	ADP	O	O
ad	PUNCT	O	O
libitum	PUNCT	O	O
feeding	PUNCT	O	O
while	ADP	O	O
GIII	ADJ	O	O
and	CCONJ	O	O
GIV	ADJ	O	O
ewes	NOUN	O	O
were	VERB	O	O
provided	VERB	O	O
with	ADP	O	O
restricted	VERB	O	O
feed	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
intake	NOUN	O	O
of	ADP	O	O
GI	NOUN	O	O
and	CCONJ	O	O
GII	NOUN	O	O
ewes	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
induce	NOUN	O	O
nutritional	ADJ	O	O
insufficiency	NOUN	O	O
.	PUNCT	O	O

GII	NOUN	O	O
and	CCONJ	O	O
GIV	ADJ	O	O
ewes	NOUN	O	O
were	VERB	O	O
kept	PUNCT	O	O
in	ADP	O	O
climatic	ADJ	O	O
chamber	NOUN	O	O
at	ADP	O	O
40?C	NOUN	O	O
and	CCONJ	O	O
55	NUM	O	O
%	SYM	O	O
RH	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
h	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
between	ADP	O	O
10:00	NOUN	O	O
and	CCONJ	O	O
16:00	NOUN	O	O
hours	NOUN	O	O
to	PART	O	O
induce	NOUN	O	O
thermal	ADJ	O	O
stress	NOUN	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
oestrous	ADJ	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

Parameters	NOUN	O	O
studied	VERB	O	O
were	VERB	O	O
body	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
oestrus	NOUN	O	O
incidences	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
oestradiol	NOUN	O	O
17-?	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
progesterone	NOUN	O	O
,	PUNCT	O	O
conception	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
gestation	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
lambing	ADP	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
of	ADP	O	O
lambs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
indicate	VERB	O	O
that	ADP	O	O
combined	VERB	O	O
stress	NOUN	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
reduced	VERB	O	O
body	NOUN	O	B-PHYSICAL
weight	NOUN	O	O
,	PUNCT	O	O
oestrus	NOUN	O	B-PHYSICAL
duration	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
birth	NOUN	O	B-PHYSICAL
weight	NOUN	O	O
of	PUNCT	O	B-PHYSICAL

Erythrocyte	NOUN	O	B-PHYSICAL
deformability	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
endothelin	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
in	ADP	O	O
cyclosporin-treated	VERB	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
:	PUNCT	O	O
effects	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
with	ADP	O	O
fish	NOUN	O	O
oil	NOUN	O	O
and	CCONJ	O	O
corn	NOUN	O	O
oil	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
nine	NUM	O	O
stable	ADJ	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
receiving	VERB	O	O
cyclosporin	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
cyclosporin-prednisolone	NOUN	O	O
and	CCONJ	O	O
nine	NUM	O	O
azathioprine-prednisolone	NOUN	O	O
were	VERB	O	O
supplemented	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADP	O	O
randomization	NOUN	O	O
cross-over	NOUN	O	O
study	CCONJ	O	O
with	ADP	O	O
fish	NOUN	O	O
oil	NOUN	O	O
and	CCONJ	O	O
corn	NOUN	O	O
oil	NOUN	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
each	DET	O	O
.	PUNCT	O	O

Erythrocyte	NOUN	O	B-PHYSICAL
deformability	NOUN	O	I-PHYSICAL
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
the	DET	O	O
cyclosporin-treated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
values	NOUN	O	O
after	ADP	O	O
supplementation	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
oil	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
oil	NOUN	O	O
supplementation	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
increased	VERB	O	O
polyunsaturated	VERB	O	B-PHYSICAL
fatty	ADJ	O	I-PHYSICAL
acid	NOUN	O	I-PHYSICAL
content	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
phospholipids	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
increased	VERB	O	O
erythrocyte	NOUN	O	O
membrane	NOUN	O	O
polyunsaturated	VERB	O	O
fatty	ADJ	O	O
acid	NOUN	O	O
content	NOUN	O	O
might	VERB	O	O
correct	PUNCT	O	O
the	DET	O	O
lower	PUNCT	O	O
erythrocyte	NOUN	O	O
deformability	NOUN	O	O
in	ADP	O	O
cyclosporin	NOUN	O	O
treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
probable	ADJ	O	O
that	ADP	O	O
these	DET	O	O
changes	NOUN	O	O
are	VERB	O	O
membrane-related	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
oil	NOUN	O	O
supplementation	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
effective	ADJ	O	B-PHYSICAL
renal	ADJ	O	I-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
filtration	NOUN	O	B-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
which	DET	O	O
does	PUNCT	O	O
not	ADV	O	O
exclude	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cyclosporin-induced	ADP	O	O
rigidified	VERB	O	O
erythrocytes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Decreased	VERB	O	O
erythrocyte	NOUN	O	B-PHYSICAL
deformability	NOUN	O	I-PHYSICAL
could	VERB	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cyclosporin-induced	VERB	O	O
deterioration	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
haemodynamics	NOUN	O	O
.	PUNCT	O	O

This	PUNCT	O	O
may	VERB	O	O
enhance	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
endothelin	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
also	ADV	O	O
had	PUNCT	O	O
elevated	VERB	O	O
endothelin	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
fasting	ADV	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
omission	NOUN	O	O
on	ADP	O	O
susceptibility	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
hypoglycaemia	NOUN	O	I-PHYSICAL
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
GH	NOUN	O	O
and	CCONJ	O	O
cortisol	NOUN	O	O
insufficiency	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Hypoglycaemia	NOUN	O	O
may	ADP	O	O
be	ADJ	O	O
a	DET	O	O
frequent	ADJ	O	O
occurrence	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
GH	NOUN	O	O
deficient	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
so	ADP	O	O
we	ADP	O	O
studied	VERB	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
fasting	PUNCT	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
with	ADP	O	O
GH	NOUN	O	O
and/or	CCONJ	O	O
cortisol	NOUN	O	O
deficiency	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
2-18	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
fasted	VERB	O	O
for	ADP	O	O
14	NUM	O	O
h	NOUN	O	O
(	PUNCT	O	O
22.00-12.00	PUNCT	O	O
h	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
two	NUM	O	O
occasions	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
cross-over	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
had	PUNCT	O	O
pituitary	NOUN	O	O
hormone	NOUN	O	O
deficiency	NOUN	O	O
(	PUNCT	O	O
PHD	NOUN	O	O
)	PUNCT	O	O
including	VERB	O	O
GH	NOUN	O	O
deficiency	NOUN	O	O
(	PUNCT	O	O
GHD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
14	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
seven	NUM	O	O
were	VERB	O	O
ACTH	NOUN	O	O
sufficient	ADJ	O	O
(	PUNCT	O	O
PHDC+	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
seven	NUM	O	O
ACTH	NOUN	O	O
deficient	ADJ	O	O
(	PUNCT	O	O
PHDC-	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Six	NUM	O	O
had	VERB	O	O
primary	ADJ	O	O
adrenal	ADJ	O	O
failure	NOUN	O	O
(	PUNCT	O	O
PAF	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
administered	ADP	O	O
or	CCONJ	O	O
omitted	PUNCT	O	O
their	PUNCT	O	O
normal	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
evening	PUNCT	O	O
GH	NOUN	O	O
and/or	CCONJ	O	O
morning	NOUN	O	O
hydrocortisone	NOUN	O	O
.	PUNCT	O	O

Glucose	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
insulin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
GH	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
cortisol	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
ketones	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
catecholamines	NOUN	O	B-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
04.00	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
regularly	ADV	O	O
from	ADP	O	O
07.00	NUM	O	O
to	ADP	O	O
12.00	NUM	O	O
h.	NOUN	O	O
Insulin	NOUN	O	B-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
HOMA	NOUN	O	B-OTHER
and	CCONJ	O	O
hypoglycaemia	NOUN	O	B-PHYSICAL
defined	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
blood	NOUN	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
BG	NOUN	O	O
)	PUNCT	O	O
<	SYM	O	O
/=	NUM	O	O
3.3	NUM	O	O
mmol/l	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
BG	NOUN	O	O
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	B-PHYSICAL
mass	NOUN	O	I-PHYSICAL
index	NOUN	O	I-PHYSICAL
on	ADP	O	O
treatment	NOUN	O	O
but	CCONJ	O	O
no	DET	O	O
subject	NOUN	O	O
became	ADP	O	O
hypoglycaemic	ADJ	O	O
on	ADP	O	O
or	CCONJ	O	O
off	ADP	O	O
therapy	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
07.00	NUM	O	O
h.	NOUN	O	O
Five	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
aged	DET	O	O
3	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
and	CCONJ	O	O
11	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
hypoglycaemic	ADJ	O	B-PHYSICAL
between	ADP	O	O
07.00	NUM	O	O
and	CCONJ	O	O
12.00	NUM	O	O
h	NOUN	O	O
off	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
GH	NOUN	O	B-PHYSICAL
AUC	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
minimum	NOUN	O	B-PHYSICAL
BG	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
PHD	NOUN	O	O
on	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
=	SYM	O	O
0.45	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.012	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
increased	VERB	O	O
insulin	NOUN	O	B-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
off	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
cortisol	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
PHDC+	NOUN	O	O
patients	NOUN	O	O
off	ADP	O	O
GH	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
negative	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
minimum	NOUN	O	O
BG	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
adrenaline	ADJ	O	B-PHYSICAL
(	PUNCT	O	O
r	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
=	ADP	O	O
0.37	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ketone	NOUN	O	B-PHYSICAL
bodies	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
r	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
=	ADP	O	O
-0.20	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
NEFA	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
r	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
=	ADP	O	O
-0.35	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Noradrenaline	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
PHDC-	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
BMI	NOUN	O	O
(	PUNCT	O	O
on	ADP	O	O
treatment	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
young	ADJ	O	O
age	NOUN	O	O
(	PUNCT	O	O
off	ADP	O	O
treatment	NOUN	O	O
)	PUNCT	O	O
were	DET	O	O
determinants	NOUN	O	O
of	ADP	O	O
low	ADJ	O	B-PHYSICAL
BG	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
a	DET	O	O
multiple	ADJ	O	O
regression	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Unrecognized	ADJ	O	O
overnight	PROPN	O	O
hypoglycaemia	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
on	ADP	O	O
pituitary	NOUN	O	O
hormone	NOUN	O	O
replacement	NOUN	O	O
is	NUM	O	O
uncommon	ADJ	O	O
but	CCONJ	O	O
BG	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
quickly	PROPN	O	O
become	ADP	O	O
abnormal	ADJ	O	O
when	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
meals	NOUN	O	O
are	VERB	O	O
omitted	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
insulin	NOUN	O	B-PHYSICAL
antagonistic	ADJ	O	I-PHYSICAL
actions	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
GH	NOUN	O	I-PHYSICAL
are	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
hypoglycaemia	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
PHD	NOUN	O	O
have	PUNCT	O	O
altered	VERB	O	O
sympathetic	ADJ	O	B-PHYSICAL
nerve	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Quantifications	NOUN	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
urinary	ADJ	O	B-PHYSICAL
metabolite	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
E	NOUN	O	I-PHYSICAL
prostaglandins	NOUN	O	I-PHYSICAL
by	ADP	O	O
mass	NOUN	O	O
spectrometry	NOUN	O	O
:	PUNCT	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
method	NOUN	O	O
's	PUNCT	O	O
application	NOUN	O	O
to	ADP	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Measurement	NOUN	O	O
of	ADP	O	O
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic	ADJ	O	O
acid	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
PGE-M	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
major	ADJ	O	O
urinary	ADJ	O	O
metabolite	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	O
E1	NOUN	O	O
and	CCONJ	O	O
E2	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
provides	NOUN	O	O
a	DET	O	O
useful	ADJ	O	O
indicator	NOUN	O	O
to	ADP	O	O
monitor	NOUN	O	O
prostaglandin	NOUN	O	O
biosynthesis	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
quantitative	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
this	DET	O	O
prostaglandin	NOUN	O	O
metabolite	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
stable-isotope	PUNCT	O	O
dilution	NOUN	O	O
techniqe	NOUN	O	O
of	ADP	O	O
selected	VERB	O	O
ion	NOUN	O	O
monitoring	VERB	O	O
(	PUNCT	O	O
SIM	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
employed	VERB	O	O
using	VERB	O	O
gas-liquid	NOUN	O	O
chromatography-mass	NOUN	O	O
spectrometry	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
preparation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bis	ADJ	O	O
(	PUNCT	O	O
D3-methyloxime	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bis-methyl	ADP	O	O
ester	NOUN	O	O
of	ADP	O	O
PGE-M	NOUN	O	O
containing	VERB	O	O
a	DET	O	O
tritium	NOUN	O	O
tracer	NOUN	O	O
in	ADP	O	O
position	NOUN	O	O
2	NUM	O	O
which	ADP	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
internal	ADJ	O	O
standard	NOUN	O	O
for	ADP	O	O
the	DET	O	O
SIM	NOUN	O	O
method	NOUN	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
synthesis	NOUN	O	O
of	ADP	O	O
this	DET	O	O
internal	ADJ	O	O
standard	PUNCT	O	O
includes	ADJ	O	O
the	DET	O	O
biosynthetic	ADJ	O	O
conversion	NOUN	O	O
of	ADP	O	O
11-hydroxy-9,15-diketoprostanoic	PUNCT	O	O
acid	NOUN	O	O
to	ADP	O	O
PGE-M	NOUN	O	O
by	ADP	O	O
the	DET	O	O
rabbit	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intra-assay	NOUN	O	O
coefficient	NOUN	O	O
of	ADP	O	O
variation	NOUN	O	O
of	ADP	O	O
this	DET	O	O
SIM	NOUN	O	O
method	NOUN	O	O
ranged	VERB	O	O
between	ADP	O	O
4.0	NUM	O	O
to	ADP	O	O
6.7	NUM	O	O
percent	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
recovery	NOUN	O	O
of	ADP	O	O
authentic	ADJ	O	O
,	PUNCT	O	O
underivatized	VERB	O	O
PGE-M	NOUN	O	O
added	VERB	O	O
to	ADP	O	O
urine	NOUN	O	O
was	VERB	O	O
93	NUM	O	O
+/-	SYM	O	O
3	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SEM	NOUN	O	O
,	PUNCT	O	O
n=17	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
PGE-M	NOUN	O	I-PHYSICAL
excreted	ADJ	O	I-PHYSICAL
in	ADP	O	O
urine	NOUN	O	O
were	VERB	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
males	ADJ	O	O
than	PUNCT	O	O
in	ADP	O	O
females	NOUN	O	O
(	PUNCT	O	O
15.2	NUM	O	O
+/-	SYM	O	O
1.9	ADJ	O	O
mug/24	PUNCT	O	O
hours	NOUN	O	O
(	PUNCT	O	O
n=24	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
3.3	NUM	O	O
+/-	SYM	O	O
0.3	NUM	O	O
mug/24	PUNCT	O	O
hours	NOUN	O	O
(	PUNCT	O	O
n=17	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
levels	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
close	ADJ	O	O
agreement	NOUN	O	O
with	ADP	O	O
values	NOUN	O	O
published	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
excretion	NOUN	O	O
of	ADP	O	O
PGE-M	NOUN	O	O
between	ADP	O	O
the	DET	O	O
sexes	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
pre-pubertal	ADJ	O	O
age-grou	ADJ	O	O
(	PUNCT	O	O
male	NOUN	O	O
:	PUNCT	O	O
2.9	NUM	O	O
+/-	SYM	O	O
0.8	NUM	O	O
mug/24	PUNCT	O	O
hours	NOUN	O	O
,	PUNCT	O	O
n=5	NOUN	O	O
;	PUNCT	O	O
female	NOUN	O	O
:	PUNCT	O	O
3.1	NUM	O	O
+/-	SYM	O	O
0.9	NUM	O	O
mug/24	PUNCT	O	O
hours	NOUN	O	O
,	PUNCT	O	O
n=5	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
age-group	NOUN	O	O
of	ADP	O	O
45-80	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
male	NOUN	O	O
:	PUNCT	O	O
9.3	NUM	O	O
+/-	SYM	O	O
1.1	ADJ	O	O
mug/24	PUNCT	O	O
hours	NOUN	O	O
,	PUNCT	O	O
n=21	NOUN	O	O
;	PUNCT	O	O
female	NOUN	O	O
:	PUNCT	O	O
7.3	NUM	O	O
+/-	SYM	O	O
0.9	NUM	O	O
mug/24	PUNCT	O	O
hours	NOUN	O	O
,	PUNCT	O	O
n=12	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
PGE-M	NOUN	O	O
excreted	ADP	O	O
decreased	VERB	O	O
significantly	ADV	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
indomethacin	NOUN	O	O
or	CCONJ	O	O
acetyl	NOUN	O	O
salicylic	ADJ	O	O
acid	NOUN	O	O
in	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
concomitant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
PGE-M	NOUN	O	O
(	PUNCT	O	O
68	NUM	O	O
to	ADP	O	O
85	NUM	O	O
%	ADV	O	O
decrease	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
prostaglandin	NOUN	O	O
E	NOUN	O	O
(	PUNCT	O	O
73	NUM	O	O
to	ADP	O	O
100	NUM	O	O
%	SYM	O	O
decrease	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
indomethacin	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
each	DET	O	O
case	NOUN	O	O
(	PUNCT	O	O
n=8	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
evidence	NOUN	O	O
that	ADP	O	O
a	DET	O	O
diminished	VERB	O	O
urinary	ADJ	O	O
PGE-M	NOUN	O	O
output	NOUN	O	O
reflects	NOUN	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
prostaglandin	NOUN	O	O
E	NOUN	O	O
biosynthesis	NOUN	O	O
.	PUNCT	O	O

Increasing	ADP	O	O
verbal	ADJ	O	O
responsiveness	NOUN	O	O
in	ADP	O	O
parents	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Correlational	ADJ	O	O
studies	NOUN	O	O
have	ADP	O	O
revealed	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
parent	NOUN	O	O
verbal	ADJ	O	O
responsiveness	NOUN	O	O
and	CCONJ	O	O
language	NOUN	O	O
outcomes	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
parents	NOUN	O	O
of	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
on	ADP	O	O
the	DET	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
could	PUNCT	O	O
learn	VERB	O	O
and	CCONJ	O	O
implement	PUNCT	O	O
the	DET	O	O
specific	ADJ	O	O
categories	NOUN	O	O
of	ADP	O	O
verbal	ADJ	O	O
responsiveness	NOUN	O	O
that	PUNCT	O	O
have	ADP	O	O
been	PUNCT	O	O
suggested	VERB	O	O
to	PART	O	O
facilitate	NOUN	O	O
language	NOUN	O	O
development	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
were	VERB	O	O
taught	NOUN	O	O
to	ADP	O	O
increase	NOUN	O	O
their	PUNCT	O	O
verbal	ADJ	O	O
responsiveness	NOUN	O	O
in	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
a	DET	O	O
short-term	NOUN	O	O
language	NOUN	O	O
intervention	NOUN	O	O
that	PUNCT	O	O
included	DET	O	O
group	NOUN	O	O
parent	NOUN	O	O
education	NOUN	O	O
sessions	NOUN	O	O
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
individual	PUNCT	O	O
and	CCONJ	O	O
small-group	NOUN	O	O
coaching	NUM	O	O
sessions	NOUN	O	O
of	ADP	O	O
parent-child	NOUN	O	O
play	NOUN	O	O
interactions	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
increased	VERB	O	O
their	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
comments	ADJ	O	O
that	ADP	O	O
:	PUNCT	O	O
described	DET	O	O
their	PUNCT	O	O
child	NOUN	O	B-MENTAL
's	PUNCT	O	O
focus	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
attention	NOUN	O	I-MENTAL
;	PUNCT	O	O
interpreted	DET	O	O
or	CCONJ	O	O
expanded	VERB	O	O
child	NOUN	O	B-MENTAL
communication	NOUN	O	I-MENTAL
acts	NOUN	O	I-MENTAL
;	PUNCT	O	O
and	CCONJ	O	O
prompted	PUNCT	O	O
child	NOUN	O	B-MENTAL
communication	NOUN	O	I-MENTAL
.	PUNCT	O	O

Preliminary	ADJ	O	O
treatment	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
noted	NUM	O	O
in	ADP	O	O
children	NOUN	O	B-MENTAL
's	PUNCT	O	O
prompted	VERB	O	B-MENTAL
and	CCONJ	O	O
spontaneous	ADJ	O	B-MENTAL
communication	NOUN	O	I-MENTAL
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
support	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
parent-mediated	NOUN	O	O
interventions	NOUN	O	O
targeting	VERB	O	O
verbal	ADJ	O	B-MENTAL
responsiveness	NOUN	O	I-MENTAL
to	PART	O	O
facilitate	ADP	O	O
language	NOUN	O	B-MENTAL
development	NOUN	O	I-MENTAL
and	CCONJ	O	O
communication	NOUN	O	B-MENTAL
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Prospective	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
value	NOUN	O	O
of	ADP	O	O
brushings	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
biopsy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
endoscopic	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
gastroesophageal	ADJ	O	O
malignancy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
cytodiagnostic	ADJ	O	O
results	CCONJ	O	O
on	ADP	O	O
endoscopic	ADJ	O	O
brushings	NOUN	O	O
obtained	VERB	O	O
before	ADP	O	O
biopsy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
those	PUNCT	O	O
brushings	NOUN	O	O
obtained	VERB	O	O
after	ADP	O	O
biopsy	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
accuracy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
subsequent	ADJ	O	O
biopsy	NOUN	O	O
reduced	VERB	O	O
,	PUNCT	O	O
was	VERB	O	O
examined	VERB	O	O
for	ADP	O	O
300	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
256	NUM	O	O
with	ADP	O	O
esophageal	ADJ	O	O
or	CCONJ	O	O
gastric	ADJ	O	O
carcinomas	NOUN	O	O
.	PUNCT	O	O

Following	ADP	O	O
stratification	NOUN	O	O
by	ADP	O	O
site	NOUN	O	O
and	CCONJ	O	O
endoscopic	ADJ	O	O
appearance	NOUN	O	O
of	ADP	O	O
their	DET	O	O
lesions	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PUNCT	O	O
undergo	NOUN	O	O
brushing	PUNCT	O	O
either	PUNCT	O	O
before	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
forceps	NOUN	O	O
biopsy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
accuracy	NOUN	O	O
of	ADP	O	O
brushing	PUNCT	O	B-OTHER
cytology	NOUN	O	I-OTHER
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
carcinoma	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
when	ADP	O	O
the	DET	O	O
brushing	PUNCT	O	B-OTHER
was	VERB	O	O
performed	VERB	O	O
before	ADP	O	O
biopsy	NOUN	O	O
than	PUNCT	O	O
after	ADP	O	O
biopsy	NOUN	O	O
(	PUNCT	O	O
93.5	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
82.6	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
diagnostic	ADJ	O	B-OTHER
yield	NOUN	O	I-OTHER
of	ADP	O	O
the	DET	O	O
biopsy	NOUN	O	B-OTHER
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
whether	ADP	O	O
the	DET	O	O
lesions	NOUN	O	O
were	VERB	O	O
brushed	PROPN	O	O
before	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
biopsy	NOUN	O	O
(	PUNCT	O	O
92.7	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
93.2	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
.5	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
diagnostic	ADJ	O	B-OTHER
superiority	NOUN	O	I-OTHER
of	ADP	O	O
brushings	NOUN	O	B-OTHER
obtained	VERB	O	O
before	ADP	O	O
biopsy	NOUN	O	O
did	ADP	O	O
not	ADV	O	O
relate	VERB	O	O
to	ADP	O	O
the	DET	O	O
site	NOUN	O	O
or	CCONJ	O	O
endoscopic	ADJ	O	O
appearance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tumor	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
false-positive	ADJ	O	B-OTHER
cytologic	ADJ	O	I-OTHER
or	CCONJ	O	I-OTHER
histologic	ADJ	O	I-OTHER
reports	NOUN	O	I-OTHER
.	PUNCT	O	O

For	ADP	O	O
all	DET	O	O
256	NUM	O	O
carcinomas	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cumulative	ADJ	O	B-OTHER
accuracy	NOUN	O	I-OTHER
(	PUNCT	O	O
brushing	PUNCT	O	B-OTHER
cytology	NOUN	O	I-OTHER
plus	CCONJ	O	I-OTHER
biopsy	NOUN	O	I-OTHER
)	PUNCT	O	O
reached	VERB	O	O
98.8	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
was	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
.001	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
that	PUNCT	O	O
of	ADP	O	O
biopsy	NOUN	O	B-OTHER
alone	ADJ	O	O
(	PUNCT	O	O
93.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
cytology	NOUN	O	B-OTHER
alone	ADJ	O	O
(	PUNCT	O	O
87.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Apart	PUNCT	O	O
from	ADP	O	O
reinforcing	PUNCT	O	O
the	DET	O	O
belief	ADP	O	O
that	PUNCT	O	O
the	DET	O	O
combined	VERB	O	B-OTHER
application	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
brushing	PUNCT	O	I-OTHER
and	CCONJ	O	O
biopsy	NOUN	O	B-OTHER
is	VERB	O	O
mandatory	ADJ	O	O
for	ADP	O	O
achieving	VERB	O	O
optimal	ADJ	O	O
results	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
the	DET	O	O
brushing	PUNCT	O	O
should	PUNCT	O	O
be	VERB	O	O
performed	VERB	O	O
before	ADP	O	O
the	DET	O	O
biopsy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
fluconazole	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
cryptococcal	ADJ	O	O
meningitis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
acquired	VERB	O	O
immunodeficiency	NOUN	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

California	PUNCT	O	O
Collaborative	ADJ	O	O
Treatment	NOUN	O	O
Group	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
acquired	VERB	O	O
immunodeficiency	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
AIDS	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
relapse	NOUN	O	O
after	ADP	O	O
primary	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
cryptococcal	ADJ	O	O
meningitis	NOUN	O	O
remains	NOUN	O	O
high	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
controlled	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
fluconazole	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
entry	NOUN	O	O
into	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
participants	NOUN	O	O
had	PUNCT	O	O
sterile	ADJ	O	O
cultures	NOUN	O	O
of	ADP	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
urine	NOUN	O	O
after	ADP	O	O
following	PUNCT	O	O
a	DET	O	O
standardized	VERB	O	O
course	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
for	ADP	O	O
culture-proved	VERB	O	O
cryptococcal	ADJ	O	O
meningitis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
take	NOUN	O	O
either	PUNCT	O	O
fluconazole	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
as	PUNCT	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	O
was	VERB	O	O
100	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
and	CCONJ	O	O
200	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
phase	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
84	NUM	O	O
patients	NOUN	O	O
initially	ADV	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
16	NUM	O	O
(	PUNCT	O	O
19	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
silent	PUNCT	O	O
,	PUNCT	O	O
persistent	ADJ	O	O
infection	NOUN	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
cultures	NOUN	O	O
that	ADP	O	O
became	VERB	O	O
positive	ADJ	O	O
after	ADP	O	O
entry	NOUN	O	O
into	ADP	O	O
the	DET	O	O
study	NOUN	O	O
;	PUNCT	O	O
7	NUM	O	O
other	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
lost	VERB	O	O
to	ADP	O	O
follow-up	NOUN	O	O
shortly	ADV	O	O
after	ADP	O	O
entry	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
61	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
of	ADP	O	O
27	NUM	O	O
assigned	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
37	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
of	ADP	O	O
34	NUM	O	O
assigned	VERB	O	O
to	PUNCT	O	O
fluconazole	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
had	ADP	O	O
a	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
cryptococcal	ADJ	O	B-PHYSICAL
infection	NOUN	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
any	DET	O	I-PHYSICAL
site	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
difference	NOUN	O	O
in	ADP	O	O
risk	NOUN	O	O
,	PUNCT	O	O
34	NUM	O	O
percent	NOUN	O	O
;	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
15	NUM	O	O
to	ADP	O	O
53	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
11	NUM	O	O
recurrent	ADJ	O	O
infections	NOUN	O	O
,	PUNCT	O	O
7	NUM	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
urine	NOUN	O	O
obtained	VERB	O	O
after	ADP	O	O
prostatic	ADJ	O	O
massage	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
four	NUM	O	O
recurrent	ADJ	O	B-PHYSICAL
meningeal	ADJ	O	I-PHYSICAL
infections	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
taking	ADJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
none	NUM	O	O
in	ADP	O	O
those	PUNCT	O	O
taking	PUNCT	O	O
fluconazole	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
duration	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
164	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
multivariate	ADJ	O	O
analyses	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
best	PUNCT	O	O
predictors	NOUN	O	O
of	ADP	O	O
recurrence-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
were	VERB	O	O
fluconazole	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
;	PUNCT	O	O
relative	ADJ	O	O
hazard	NOUN	O	O
,	PUNCT	O	O
13.2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
lower	PUNCT	O	O
serum	NOUN	O	O
cryptococcal-antigen	NOUN	O	O
titer	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
;	PUNCT	O	O
relative	ADJ	O	O
hazard	NOUN	O	O
,	PUNCT	O	O
1.2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
more	DET	O	O
prolonged	VERB	O	O
primary	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
flucytosine	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.09	NUM	O	O
;	PUNCT	O	O
relative	ADJ	O	O
hazard	NOUN	O	O
,	PUNCT	O	O
1.1	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Survival	NOUN	O	B-MORTALITY
and	CCONJ	O	O
toxicity	NOUN	O	B-OTHER
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
maintenance-treatment	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
AIDS	NOUN	O	O
,	PUNCT	O	O
silent	PUNCT	O	O
persistent	ADJ	O	O
infection	NOUN	O	O
is	ADJ	O	O
common	ADJ	O	O
after	ADP	O	O
clinically	ADV	O	O
successful	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
cryptococcal	ADJ	O	O
meningitis	NOUN	O	O
.	PUNCT	O	O

Maintenance	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
fluconazole	NOUN	O	O
is	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
recurrent	ADJ	O	O
cryptococcal	ADJ	O	O
infection	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
of	ADP	O	O
porcine	ADJ	O	O
secretin	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Secretin	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
gastrointestinal	ADJ	O	O
(	PUNCT	O	O
GI	NOUN	O	O
)	PUNCT	O	O
hormone	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
a	DET	O	O
preliminary	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
improve	PUNCT	O	O
language	NOUN	O	B-MENTAL
and	CCONJ	O	O
behavior	NOUN	O	B-MENTAL
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism/pervasive	ADJ	O	O
developmental	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
PDD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
diarrhea	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
secretin	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
completed	PROPN	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
crossover	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
study	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism/PDD	NUM	O	O
and	CCONJ	O	O
various	ADJ	O	O
GI	NOUN	O	O
conditions	NOUN	O	O
using	VERB	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
porcine	ADJ	O	O
secretin	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
,	PUNCT	O	O
active	ADJ	O	O
diarrhea	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
aberrant	ADJ	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
when	ADP	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
secretin	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
when	ADP	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
with	ADP	O	O
no	DET	O	O
GI	NOUN	O	O
problems	NOUN	O	O
are	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
either	CCONJ	O	O
secretin	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
improvement	NOUN	O	O
seen	VERB	O	O
with	ADP	O	O
secretin	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism/PDD	NUM	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
diarrhea	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
there	PUNCT	O	O
may	VERB	O	O
be	ADJ	O	O
a	DET	O	O
subtype	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism/PDD	NUM	O	O
who	ADP	O	O
respond	PUNCT	O	O
to	ADP	O	O
secretin	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
phase	NOUN	O	O
II	NUM	O	O
study	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
pemetrexed	PUNCT	O	O
as	ADP	O	O
first-line	NOUN	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
advanced	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Pemetrexed	PUNCT	O	O
has	PUNCT	O	O
shown	VERB	O	O
varied	ADV	O	O
response	NOUN	O	O
rates	NOUN	O	O
in	ADP	O	O
advanced	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
phase	NOUN	O	O
II	NUM	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
pemetrexed	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
homogeneous	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

A	CCONJ	O	O
secondary	ADJ	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
identify	NOUN	O	O
molecular	ADJ	O	O
biomarkers	CCONJ	O	O
correlating	CCONJ	O	O
with	ADP	O	O
response	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

EXPERIMENTAL	ADJ	O	O
DESIGN	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
newly	ADJ	O	O
diagnosed	VERB	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
or	CCONJ	O	O
locally	ADV	O	O
recurrent	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
received	VERB	O	O
600	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P600	NOUN	O	O
arm	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
900	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P900	NOUN	O	O
arm	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
pemetrexed	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
21-day	NOUN	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
folic	ADJ	O	O
acid	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
)	PUNCT	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
P600	NOUN	O	O
(	PUNCT	O	O
47	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
P900	NOUN	O	O
(	PUNCT	O	O
45	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
arms	NOUN	O	O
had	PUNCT	O	O
response	NOUN	O	O
rates	NOUN	O	B-OTHER
of	ADP	O	O
17.0	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
7.7-30.8	PUNCT	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
15.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
6.5-29.5	VERB	O	O
%	SYM	O	O
)	PUNCT	O	O
with	ADP	O	O
approximately	ADV	O	O
50	NUM	O	O
%	SYM	O	O
stable	ADJ	O	O
disease	NOUN	O	O
per	ADP	O	O
arm	NOUN	O	O
,	PUNCT	O	O
median	ADJ	O	O
progression-free	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
of	ADP	O	O
4.2	NUM	O	O
and	CCONJ	O	O
4.1	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
median	ADJ	O	O
times	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
tumor	NOUN	O	I-PHYSICAL
progression	NOUN	O	I-PHYSICAL
of	ADP	O	O
4.2	NUM	O	O
and	CCONJ	O	O
4.6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
arms	NOUN	O	O
exhibited	VERB	O	O
minimal	ADJ	O	B-ADVERSE-EFFECTS
toxicity	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
grade	NOUN	O	O
3/4	NUM	O	O
neutropenia	NOUN	O	B-ADVERSE-EFFECTS
<	SYM	O	O
20	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
leukopenia	NOUN	O	B-ADVERSE-EFFECTS
<	SYM	O	O
9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
toxicities	NOUN	O	B-ADVERSE-EFFECTS
<	VERB	O	O
5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tumor	NOUN	O	O
samples	NOUN	O	O
from	ADP	O	O
49	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
pemetrexed-related	VERB	O	O
genes	NOUN	O	O
.	PUNCT	O	O

Folylpolyglutamate	ADV	O	O
synthetase	NOUN	O	O
and	CCONJ	O	O
thymidine	NOUN	O	O
phosphorylase	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

Best	PUNCT	O	B-OTHER
response	NOUN	O	O
rates	NOUN	O	B-OTHER
and	CCONJ	O	O
median	ADJ	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	B-PHYSICAL
tumor	NOUN	O	B-PHYSICAL
progression	NOUN	O	B-PHYSICAL
for	ADP	O	O
high	ADJ	O	O
versus	CCONJ	O	O
low	ADJ	O	O
thymidine	NOUN	O	O
phosphorylase	NOUN	O	O
expression	NOUN	O	O
were	VERB	O	O
27.6	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
6.3	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.023	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
5.4	NUM	O	O
versus	CCONJ	O	O
1.9	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.076	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
folylpolyglutamate	NOUN	O	O
synthetase	NOUN	O	O
were	VERB	O	O
37.5	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
10.0	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.115	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
8.6	NUM	O	O
versus	CCONJ	O	O
3.0	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.019	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

gamma-Glutamyl	ADJ	O	O
hydrolase	NOUN	O	O
expression	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
grade	PUNCT	O	O
3/4	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
acupressure	NOUN	O	O
at	ADP	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
point	NOUN	O	O
on	ADP	O	O
subjective	ADJ	O	O
and	CCONJ	O	O
autonomic	ADJ	O	B-MENTAL
responses	NOUN	O	I-MENTAL
to	ADP	O	O
needle	NOUN	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Premedication	NOUN	O	O
with	ADP	O	O
sedatives	ADV	O	O
can	ADV	O	O
decrease	VERB	O	O
the	DET	O	O
discomfort	NOUN	O	B-MENTAL
associated	VERB	O	O
with	ADP	O	O
invasive	ADJ	O	O
anesthetic	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Some	DET	O	O
researchers	NOUN	O	O
have	CCONJ	O	O
shown	VERB	O	O
that	ADP	O	O
acupressure	NOUN	O	O
on	ADP	O	O
the	DET	O	O
acupuncture	ADP	O	O
extra	ADJ	O	O
1	NUM	O	O
point	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	O
for	ADP	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
acupressure	NOUN	O	O
on	ADP	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
point	NOUN	O	O
could	PUNCT	O	O
alleviate	ADP	O	O
the	DET	O	O
pain	NOUN	O	B-PAIN
of	ADP	O	O
needle	NOUN	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
acupressure	NOUN	O	O
at	ADP	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
point	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
sham	ADJ	O	O
point	NOUN	O	O
on	ADP	O	O
needle	NOUN	O	O
insertion	NOUN	O	O
using	SYM	O	O
verbal	ADJ	O	B-PAIN
rating	VERB	O	I-PAIN
scale	NOUN	O	I-PAIN
(	PUNCT	O	I-PAIN
VRS	NOUN	O	I-PAIN
)	PUNCT	O	I-PAIN
pain	NOUN	O	I-PAIN
scores	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
variability	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
HRV	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
.	PUNCT	O	O

Twenty-two	NUM	O	O
healthy	ADJ	O	O
female	NOUN	O	O
volunteers	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
group	NOUN	O	O
received	VERB	O	O
acupressure	NOUN	O	O
at	ADP	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
point	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
sham	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
acupressure	NOUN	O	O
at	ADP	O	O
a	DET	O	O
sham	ADJ	O	O
point	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
starting	VERB	O	O
the	DET	O	O
electrocardiogram	NOUN	O	O
record	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
27-gauge	NOUN	O	O
needle	NOUN	O	O
was	VERB	O	O
inserted	VERB	O	O
into	ADP	O	O
the	DET	O	O
skin	NOUN	O	O
of	ADP	O	O
a	DET	O	O
forearm	NOUN	O	O
.	PUNCT	O	O

Thereafter	ADV	O	O
,	PUNCT	O	O
another	DET	O	O
needle	NOUN	O	O
was	VERB	O	O
inserted	VERB	O	O
into	ADP	O	O
the	DET	O	O
skin	NOUN	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
forearm	NOUN	O	O
during	ADP	O	O
acupressure	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Acupressure	ADP	O	O
at	ADP	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
point	NOUN	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
VRS	NOUN	O	B-OTHER
,	PUNCT	O	O
but	CCONJ	O	O
acupressure	NOUN	O	O
at	ADP	O	O
the	DET	O	O
sham	ADJ	O	O
increased	VERB	O	O
the	DET	O	O
VRS	NOUN	O	B-OTHER
.	PUNCT	O	O

Acupressure	NOUN	O	O
at	ADP	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
low	ADJ	O	B-PHYSICAL
frequency/high	PUNCT	O	I-PHYSICAL
frequency	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	B-PHYSICAL
HRV	NOUN	O	I-PHYSICAL
responding	PUNCT	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
needle	NOUN	O	B-PHYSICAL
insertion	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Acupressure	NUM	O	O
at	ADP	O	O
the	DET	O	O
extra	ADJ	O	O
1	NUM	O	O
point	NOUN	O	O
significantly	PUNCT	O	O
reduced	PUNCT	O	O

Immunogenicity	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
reactogenicity	NOUN	O	B-PHYSICAL
of	ADP	O	O
a	DET	O	O
group	NOUN	O	O
C	NOUN	O	O
meningococcal	ADJ	O	O
conjugate	ADJ	O	O
vaccine	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
group	NOUN	O	O
A+C	NOUN	O	O
meningococcal	ADJ	O	O
polysaccharide	ADP	O	O
vaccine	NOUN	O	O
in	ADP	O	O
adolescents	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
observer-blind	NOUN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
immunogenicity	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
reactogenicity	NOUN	O	B-PHYSICAL
of	ADP	O	O
a	DET	O	O
group	NOUN	O	O
C	NOUN	O	O
meningococcal	ADJ	O	O
conjugate	ADJ	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
MenC	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
group	NOUN	O	O
A+C	NOUN	O	O
meningococcal	ADJ	O	O
polysaccharide	ADP	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
MenPS	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
healthy	ADJ	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
one	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
MenC	NOUN	O	O
(	PUNCT	O	O
n=92	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
MenPS	NOUN	O	O
(	PUNCT	O	O
n=90	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Group	NOUN	O	O
C	NOUN	O	O
meningococcal	ADJ	O	B-PHYSICAL
IgG	NOUN	O	I-PHYSICAL
antibody	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
bactericidal	ADJ	O	I-PHYSICAL
titres	NOUN	O	I-PHYSICAL
were	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
MenC	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
MenPS	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
(	PUNCT	O	O
22.8	NUM	O	O
U/ml	NOUN	O	O
vs	CCONJ	O	O
4.0	NUM	O	O
U/ml	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
87	NUM	O	O
vs	CCONJ	O	O
20	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
6.1	ADP	O	O
U/ml	NOUN	O	O
vs	CCONJ	O	O
3.0	NUM	O	O
U/ml	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
81.3	NUM	O	O
vs	CCONJ	O	O
20.2	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
post	PUNCT	O	B-PHYSICAL
immunisation	NOUN	O	I-PHYSICAL
reaction	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
were	VERB	O	O
noted	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
vaccinated	VERB	O	O
groups	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrated	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
enhanced	VERB	O	O
immunogenicity	NOUN	O	B-PHYSICAL
of	ADP	O	O
the	DET	O	O
candidate	NOUN	O	O
meningococcal	ADJ	O	O
conjugate	ADJ	O	O
vaccine	NOUN	O	O
as	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
licensed	PUNCT	O	O
polysaccharide	ADP	O	O
vaccine	NOUN	O	O
in	ADP	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
pathway	NOUN	O	O
for	ADP	O	O
fractured	ADV	O	O
neck	NOUN	O	O
of	ADP	O	O
femur	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
outcomes	NOUN	O	O
of	ADP	O	O
using	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
pathway	NOUN	O	O
for	ADP	O	O
managing	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
fractured	PUNCT	O	O
neck	NOUN	O	O
of	ADP	O	O
femur	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
pseudorandomised	PRON	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
St	CCONJ	O	O
Vincent	NOUN	O	O
's	PUNCT	O	O
Hospital	NOUN	O	O
,	PUNCT	O	O
Melbourne	NOUN	O	O
,	PUNCT	O	O
Victoria	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
tertiary	ADJ	O	O
referral	NOUN	O	O
,	PUNCT	O	O
university	NOUN	O	O
teaching	VERB	O	O
hospital	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
1	NUM	O	O
October	NOUN	O	O
1997	NUM	O	O
to	ADP	O	O
30	NUM	O	O
November	NOUN	O	O
1998	NUM	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
111	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
80	NUM	O	O
women	NOUN	O	O
and	CCONJ	O	O
31	NUM	O	O
men	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
81	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
admitted	VERB	O	O
via	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
with	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
fractured	PUNCT	O	O
neck	NOUN	O	O
of	ADP	O	O
femur	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Management	NOUN	O	O
guided	PUNCT	O	O
by	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
pathway	NOUN	O	O
(	PUNCT	O	O
55	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
established	VERB	O	O
standard	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
56	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Timing	ADJ	O	B-OTHER
of	ADP	O	I-OTHER
referrals	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
discharge	NOUN	O	I-OTHER
planning	VERB	O	I-OTHER
;	PUNCT	O	O
total	ADJ	O	O
length	NOUN	O	B-OTHER
of	ADP	O	B-OTHER
stay	NOUN	O	B-OTHER
;	PUNCT	O	O
and	CCONJ	O	O
complication	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
readmission	ADJ	O	B-OTHER
rates	PUNCT	O	I-OTHER

Dose-response	NOUN	O	O
characteristics	NOUN	O	O
during	ADP	O	O
long-term	NOUN	O	O
inhalation	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	O
oxide	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
acute	ADJ	O	O
respiratory	ADJ	O	O
distress	NOUN	O	O
syndrome	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

Inhaled	VERB	O	O
nitric	ADJ	O	O
oxide	NOUN	O	O
(	PUNCT	O	O
NO	NOUN	O	O
)	PUNCT	O	O
improves	NOUN	O	O
systemic	ADJ	O	O
oxygenation	NOUN	O	O
(	PUNCT	O	O
PaO2/FIO2	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
adult	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
respiratory	ADJ	O	O
distress	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
ARDS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
individual	ADJ	O	O
response	NOUN	O	O
varies	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
previous	ADJ	O	O
trials	NOUN	O	O
demonstrated	VERB	O	O
no	DET	O	O
outcome	NOUN	O	O
benefit	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
in	ADP	O	O
40	NUM	O	O
ARDS	NOUN	O	O
patients	NOUN	O	O
analyzed	VERB	O	O
dose-response	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
DR	ADV	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
characteristics	NOUN	O	I-PHYSICAL
during	ADP	O	O
long-term	NOUN	O	O
inhaled	PUNCT	O	O
NO	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
for	ADP	O	O
conventional	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
continuous	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
10	NUM	O	O
parts	NOUN	O	O
per	ADP	O	O
million	NUM	O	O
(	PUNCT	O	O
ppm	NOUN	O	O
)	PUNCT	O	O
inhaled	VERB	O	O
NO	NOUN	O	O
until	ADP	O	O
weaning	VERB	O	O
was	VERB	O	O
initiated	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
measured	VERB	O	O
DR	ADV	O	B-OTHER
curves	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
PaO2/FIO2	NOUN	O	I-OTHER
versus	CCONJ	O	I-OTHER
the	DET	O	I-OTHER
inhaled	VERB	O	I-OTHER
NO	NOUN	O	I-OTHER
dose	NOUN	O	I-OTHER
at	ADP	O	O
regular	ADJ	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
Day	NOUN	O	O
0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
peak	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
PaO2/FIO2	NOUN	O	B-OTHER
was	VERB	O	O
achieved	VERB	O	O
at	ADP	O	O
10	NUM	O	O
ppm	NOUN	O	O
for	ADP	O	O
both	CCONJ	O	O
control	NOUN	O	O
and	CCONJ	O	O
NO-treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
DR	ADV	O	O
curve	NOUN	O	O
of	ADP	O	O
the	DET	O	O
NO-treated	ADJ	O	B-OTHER
patients	NOUN	O	I-OTHER
was	VERB	O	O
left	ADP	O	O
shifted	ADJ	O	O
with	ADP	O	O
a	DET	O	O
peak	ADJ	O	O
response	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
ppm	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
higher	PUNCT	O	O
doses	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
ppm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
oxygenation	NOUN	O	B-PHYSICAL
deteriorated	ADP	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
inhaled	VERB	O	O
NO	NOUN	O	O
disappeared	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
inhaled	VERB	O	O
NO	NOUN	O	O
on	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
mechanical	ADJ	O	B-OTHER
ventilation	NOUN	O	I-OTHER
or	CCONJ	O	O
stay	NOUN	O	B-OTHER
at	ADP	O	I-OTHER
the	DET	O	I-OTHER
intensive	ADJ	O	I-OTHER
care	NOUN	O	I-OTHER
unit	NOUN	O	I-OTHER
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
long-term	NOUN	O	O
inhaled	PUNCT	O	O
NO	NOUN	O	O
with	ADP	O	O
constant	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
ppm	NOUN	O	O
leads	NOUN	O	O
to	ADP	O	O
enhanced	VERB	O	O
sensitivity	NOUN	O	O
after	ADP	O	O
several	ADJ	O	O
days	NOUN	O	O
and	CCONJ	O	O
does	PUNCT	O	O
do	PUNCT	O	O
not	ADV	O	O
allow	VERB	O	O
reduction	NOUN	O	O
of	ADP	O	O
ventilation	NOUN	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

Hence	ADV	O	O
,	PUNCT	O	O
previous	ADJ	O	O
trials	NOUN	O	O
on	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
inhaled	VERB	O	O
NO	NOUN	O	O
in	ADP	O	O
ARDS	NOUN	O	O
should	PUNCT	O	O
be	VERB	O	O
carefully	ADV	O	O
interpreted	VERB	O	O
,	PUNCT	O	O
as	PUNCT	O	O
they	ADV	O	O
used	VERB	O	O
constant	ADJ	O	O
NO	NOUN	O	O
concentrations	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
may	VERB	O	O
have	CCONJ	O	O
become	PUNCT	O	O
overdoses	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
deterioration	NOUN	O	O
of	ADP	O	O
oxygenation	NOUN	O	B-PHYSICAL
after	ADP	O	O
several	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
lunar	ADJ	O	O
stent	NOUN	O	O
characteristics	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

One	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
frequent	ADJ	O	O
long-term	NOUN	O	O
complications	NOUN	O	O
after	ADP	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
is	VERB	O	O
restenosis	NOUN	O	O
due	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
building	ADP	O	O
up	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
neointima	NOUN	O	O
within	ADP	O	O
the	DET	O	O
artery	NOUN	O	O
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
endovascular	ADJ	O	O
hyperplasia	NOUN	O	O
(	PUNCT	O	O
tissue	NOUN	O	O
growth	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
interesting	VERB	O	O
feature	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Lunar	ADJ	O	O
stent	NOUN	O	O
from	ADP	O	O
Inflow	NOUN	O	O
Dynamics	NOUN	O	O
is	VERB	O	O
that	ADP	O	O
it	PRON	O	O
is	VERB	O	O
coated	VERB	O	O
with	ADP	O	O
a	DET	O	O
layer	NOUN	O	O
of	ADP	O	O
iridium	NOUN	O	O
oxide	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
iridium	NOUN	O	O
oxide	NOUN	O	O
coating	PUNCT	O	O
is	VERB	O	O
believed	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
restenosis	NOUN	O	B-PHYSICAL
by	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
inflammatory	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
stent	NOUN	O	O
via	ADP	O	O
its	PUNCT	O	O
antioxidant	NOUN	O	O
action	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
MOONLIGHT	NOUN	O	O
(	PUNCT	O	O
Multicenter	NOUN	O	O
Objective	ADJ	O	O
ObservatioNal	ADV	O	O
Lunar	ADJ	O	O
Iridiumoxide	NOUN	O	O
intimal	ADJ	O	O
GrowtH	NOUN	O	O
Trial	NOUN	O	O
)	PUNCT	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
immediate	ADJ	O	O
outcome	NOUN	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
angiographic	ADJ	O	O
success	NOUN	O	O
after	ADP	O	O
implantation	NOUN	O	O
of	ADP	O	O
Lunar	ADJ	O	O
stents	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
March	NOUN	O	O
2001	NUM	O	O
and	CCONJ	O	O
November	NOUN	O	O
2001	NUM	O	O
,	PUNCT	O	O
87	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
99	NUM	O	O
lesions	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
12	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
mm	NOUN	O	O
long	ADJ	O	O
iridium-oxide	ADJ	O	O
coated	ADP	O	O
Lunar	ADJ	O	O
stents	NOUN	O	O
.	PUNCT	O	O

Delivery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Lunar	ADJ	O	O
stent	NOUN	O	O
was	VERB	O	O
successful	ADJ	O	O
in	ADP	O	O
most	DET	O	O
lesions	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
optimal	ADJ	O	O
radiopacity	NOUN	O	O
facilitated	ADP	O	O
optimal	ADJ	O	O
stent	NOUN	O	B-PHYSICAL
positioning	VERB	O	O
with	ADP	O	O
optimal	ADJ	O	O
immediate	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
angiographic	ADJ	O	O
results	NOUN	O	O
is	VERB	O	O
an	DET	O	O
unselected	VERB	O	O
patient	NOUN	O	O
and	CCONJ	O	O
lesion	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

Preliminary	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
angiographic	ADJ	O	O
follow-up	NOUN	O	O
show	VERB	O	O
a	DET	O	O
low	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
16.1	NUM	O	O
%	SYM	O	O
MACE	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
moderate	ADJ	O	O
hyperplastic	ADJ	O	B-PHYSICAL
response	NOUN	O	O
.	PUNCT	O	O

Noradrenergic	ADJ	O	O
moderation	NOUN	O	B-OTHER
of	ADP	O	O
working	PUNCT	O	O
memory	NOUN	O	O
impairments	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
having	PROPN	O	O
difficulties	NOUN	O	O
with	ADP	O	O
social	ADJ	O	O
communications	NOUN	O	O
,	PUNCT	O	O
individuals	NOUN	O	O
with	ADP	O	O
an	DET	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
often	ADV	O	O
also	ADV	O	O
experience	ADV	O	O
impairment	NOUN	O	O
in	ADP	O	O
higher-order	NOUN	O	B-MENTAL
,	PUNCT	O	I-MENTAL
executive	ADJ	O	I-MENTAL
skills	NOUN	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
pharmacological	ADJ	O	O
modulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
norepinephrine	NOUN	O	O
system	NOUN	O	O
on	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
such	ADP	O	O
impairments	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
high-functioning	PRON	O	O
adults	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
demographically-matched	ADV	O	O
comparison	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
typically	ADV	O	O
developing	NUM	O	O
individuals	NOUN	O	O
participated	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
AX	NOUN	O	O
continuous	ADJ	O	O
performance	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
AX-CPT	ADP	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
working	ADP	O	O
memory	NOUN	O	O
and	CCONJ	O	O
inhibitory	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

AX-CPT	PUNCT	O	B-MENTAL
performance	NOUN	O	I-MENTAL
was	VERB	O	O
assessed	VERB	O	O
following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
beta	NOUN	O	O
adrenergic	ADJ	O	O
antagonist	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
following	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
sugar	NOUN	O	O
pill	ADJ	O	O
)	PUNCT	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Individuals	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
performed	PUNCT	O	B-MENTAL
more	ADV	O	O
poorly	ADV	O	O
than	PUNCT	O	O
non-ASD	NOUN	O	O
individuals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
working	ADJ	O	O
memory	NOUN	O	O
condition	NOUN	O	O
(	PUNCT	O	O
BX	ADJ	O	O
trials	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Importantly	ADV	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	O
attenuated	VERB	O	B-MENTAL
this	DET	O	I-MENTAL
impairment	NOUN	O	I-MENTAL
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
ASD	NOUN	O	O
group	NOUN	O	O
performing	PUNCT	O	B-MENTAL
significantly	ADV	O	O
better	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
propranolol	NOUN	O	O
condition	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
placebo	NOUN	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Working	PUNCT	O	B-MENTAL
memory	NOUN	O	I-MENTAL
performance	NOUN	O	I-MENTAL
of	ADP	O	O
the	DET	O	O
non-ASD	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
propranolol/placebo	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
group	NOUN	O	O
or	CCONJ	O	O
medication	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	B-MENTAL
condition	NOUN	O	I-MENTAL
(	PUNCT	O	O
AY	NUM	O	O
trials	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
norepinephrine	NOUN	O	O
may	PART	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
some	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
necessarily	ADV	O	O
all	PUNCT	O	O
,	PUNCT	O	O
cognitive	ADJ	O	B-MENTAL
impairments	NOUN	O	I-MENTAL
associated	VERB	O	O
with	ADP	O	O
ASD	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
research	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PUNCT	O	O
fully	DET	O	O
understand	VERB	O	O
whether	ADP	O	O
this	DET	O	O
role	NOUN	O	O
is	VERB	O	O
primarily	ADV	O	O
causal	PUNCT	O	O
or	CCONJ	O	O
compensatory	ADJ	O	O
in	ADP	O	O
nature	NOUN	O	O
.	PUNCT	O	O

Exercise	NOUN	O	O
for	ADP	O	O
methamphetamine	NOUN	O	O
dependence	NOUN	O	O
:	PUNCT	O	O
rationale	NOUN	O	O
,	PUNCT	O	O
design	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
methodology	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Effective	ADJ	O	O
pharmacotherapies	NOUN	O	O
to	ADJ	O	O
treat	CCONJ	O	O
methamphetamine	NOUN	O	O
(	PUNCT	O	O
MA	NOUN	O	O
)	PUNCT	O	O
dependence	NOUN	O	O
have	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
identified	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
therapies	NOUN	O	O
are	VERB	O	O
marginally	ADV	O	O
effective	ADJ	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
behavioral	ADJ	O	O
studies	NOUN	O	O
demonstrating	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
for	ADP	O	O
improving	VERB	O	O
depressive	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
,	PUNCT	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O
cognitive	ADJ	O	B-MENTAL
deficits	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	PUNCT	O	O

First-line	NUM	O	O
cisplatin	NOUN	O	O
with	ADP	O	O
docetaxel	PUNCT	O	O
or	CCONJ	O	O
vinorelbine	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
non-small-cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
directed	VERB	O	O
phase	NOUN	O	O
II	NUM	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
Gruppo	NOUN	O	O
Oncologico	NOUN	O	O
Italia	PUNCT	O	O
Meridionale	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
(	PUNCT	O	B-MENTAL
QoL	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
has	PUNCT	O	O
gained	VERB	O	O
greater	PUNCT	O	O
importance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
metastatic	ADJ	O	O
non-small-cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
palliative	ADJ	O	O
nature	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Docetaxel	ADV	O	O
(	PUNCT	O	O
DCT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
cisplatin	NOUN	O	O
(	PUNCT	O	O
CDDP	NOUN	O	O
)	PUNCT	O	O
doublet	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
associated	VERB	O	O
to	ADP	O	O
a	DET	O	O
better	PUNCT	O	O
QoL	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
weekly	PROPN	O	O
vinorelbine	NOUN	O	O
(	PUNCT	O	O
VNR	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
CDDP	NOUN	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
a	DET	O	O
newer	PUNCT	O	O
more	DET	O	O
tolerated	PUNCT	O	O
schedule	NOUN	O	O
of	ADP	O	O
the	DET	O	O
VNR/CDDP	PUNCT	O	O
regimen	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
published	VERB	O	O
and	CCONJ	O	O
is	NOUN	O	O
widely	ADV	O	O
employed	VERB	O	O
in	ADP	O	O
medical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
these	DET	O	O
regimens	NOUN	O	O
on	ADP	O	O
patients	NOUN	O	O
'	PUNCT	O	O
QoL	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
symptoms	CCONJ	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
type	NOUN	O	O
and	CCONJ	O	O
grading	PUNCT	O	O
chemo-related	ADJ	O	O
side-effects	NOUN	O	B-PHYSICAL
has	PUNCT	O	O
been	PUNCT	O	O
compared	VERB	O	O
prospectically	ADV	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
received	VERB	O	O
CDDP	NOUN	O	O
75	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
DCT	NOUN	O	O
75	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
every	DET	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
arm	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
CDDP	NOUN	O	O
80	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
plus	CCONJ	O	O
VNR	NOUN	O	O
30	PUNCT	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
arm	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

G-CSF	NOUN	O	O
and/or	CCONJ	O	O
EPO	NOUN	O	O
were	VERB	O	O
employed	VERB	O	O
as	PUNCT	O	O
needed	PUNCT	O	O
.	PUNCT	O	O

Health-related	VERB	O	B-MENTAL
QoL	NOUN	O	I-MENTAL
was	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
entry	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
every	DET	O	O
cycle	NOUN	O	O
by	ADP	O	O
the	DET	O	O
EORTC-QLQ-C30	ADJ	O	O
and	CCONJ	O	O
LC13	NOUN	O	B-MENTAL
questionnaires	NOUN	O	I-MENTAL
,	PUNCT	O	O
toxicity	NOUN	O	B-PHYSICAL
by	ADP	O	O
the	DET	O	O
NCI-NCCN	NOUN	O	O
CTC	NOUN	O	O
vs	CCONJ	O	O
2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intent-to-treat	NOUN	O	O
objective	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
by	ADP	O	O
the	DET	O	O
Recist	NOUN	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
QoL	NOUN	O	B-PHYSICAL
questionnaires	NOUN	O	I-PHYSICAL
were	VERB	O	O
completed	VERB	O	O
by	ADP	O	O
37	NUM	O	O
pts	NOUN	O	O
(	PUNCT	O	O
88	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
DCT/CDDP	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
39	NUM	O	O
pts	NOUN	O	O
(	PUNCT	O	O
87	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
VNR/CDDP	PUNCT	O	O
one	NUM	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
mean	NOUN	O	O
scores	NOUN	O	O
and	CCONJ	O	O
rates	NOUN	O	O
at	ADP	O	O
which	PUNCT	O	O
pts	NOUN	O	O
failed	VERB	O	O
to	ADP	O	O
complete	ADJ	O	O
QoL	NOUN	O	O
assessment	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
arms	NOUN	O	O
.	PUNCT	O	O

Global	ADJ	O	B-MENTAL
health	NOUN	O	I-MENTAL
status	NOUN	O	I-MENTAL
of	ADP	O	O
the	DET	O	O
EORTC	NOUN	O	B-PHYSICAL
QLQ-C30	NOUN	O	I-PHYSICAL
scale	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
specific	ADJ	O	O
symptoms	NOUN	O	O
control	NOUN	O	O
(	PUNCT	O	O
LC13	NOUN	O	O
module	NOUN	O	O
)	PUNCT	O	O
improved	PRON	O	O
during	ADP	O	O
treatment	NOUN	O	O
without	ADP	O	O
any	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
arms	NOUN	O	O
.	PUNCT	O	O

Emotional	ADJ	O	B-MENTAL
functioning	VERB	O	I-MENTAL
remained	VERB	O	O
stable	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
physical	ADJ	O	B-MENTAL
and	CCONJ	O	O
role	NOUN	O	B-MENTAL
improved	PUNCT	O	O
slightly	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
DCT/CDDP	NOUN	O	O
arm	NOUN	O	O
14	NUM	O	O
pts	NOUN	O	O
(	PUNCT	O	O
33	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CL	NOUN	O	O
24-40	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
PR	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
(	PUNCT	O	O
24	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
SD	NOUN	O	O
for	ADP	O	O
a	DET	O	O
57	NUM	O	O
%	SYM	O	O
TGCR	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
VNR/CDDP	PUNCT	O	O
arm	NOUN	O	O
12	NUM	O	O
pts	NOUN	O	O
(	PUNCT	O	O
27	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
achieved	VERB	O	O
PR	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
18	NUM	O	O
(	PUNCT	O	O
41	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
SD	NOUN	O	O
a	DET	O	O
68	NUM	O	O
%	SYM	O	O
TGCR	NOUN	O	O
.	PUNCT	O	O

Differences	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Median	ADJ	O	O
time-to-progression	NOUN	O	B-PHYSICAL
was	VERB	O	O
4.2	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
DCT/CDDP	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
4.5	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
VNR/CDDP	PUNCT	O	O
one	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
median	ADJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
12.1	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
1-26+	NOUN	O	O
months	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12.5	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
1-28+	NOUN	O	O
months	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
DCT/CDDP	PUNCT	O	O
and	CCONJ	O	O
VNR/CDDP	PUNCT	O	O
arms	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Febrile	ADJ	O	B-PHYSICAL
neutropenia	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
VNR/CDDP	PUNCT	O	O
arm	NOUN	O	O
(	PUNCT	O	O
p=0.02	NOUN	O	O
)	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
G3-4	NOUN	O	O
anemia	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
p=0.005	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
G-CSF/EPO	PUNCT	O	O
use	NOUN	O	O
(	PUNCT	O	O
p=0.019	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Global	PUNCT	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
specific	ADJ	O	I-PHYSICAL
health-related	VERB	O	I-PHYSICAL
QoL	NOUN	O	I-PHYSICAL
data	NOUN	O	O
similar	ADJ	O	O
in	ADP	O	O
both	PUNCT	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
with	ADP	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
measures	NOUN	O	B-OTHER
,	PUNCT	O	O
overall	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
time-to-progression	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
were	VERB	O	O
equivalent	ADJ	O	O
in	ADP	O	O
both	PUNCT	O	O
arms	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
severe	ADJ	O	B-PHYSICAL
anemia	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
febrile	ADJ	O	B-PHYSICAL
neutropenia	NOUN	O	I-PHYSICAL
are	VERB	O	O
statistically	ADV	O	O
more	ADV	O	O
frequent	ADP	O	O
in	ADP	O	O
the	DET	O	O
VNR/CDDP	PUNCT	O	O
arm	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
DCT/CDDP	NOUN	O	O
one	NUM	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
treatment	NOUN	O	O
decision-making	ADJ	O	O
for	ADP	O	O
pts	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
non-small-cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
the	DET	O	O
design	NOUN	O	O
of	ADP	O	O
future	ADJ	O	O
trials	NOUN	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
plus	CCONJ	O	O
biologics	NOUN	O	O
.	PUNCT	O	O

Pharmacogenetic	ADJ	O	O
interaction	NOUN	O	O
analysis	NOUN	O	O
for	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
metastatic	ADJ	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Pharmacogenetic	ADJ	O	O
markers	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
drug	NOUN	O	O
metabolism	NOUN	O	O
and	CCONJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
could	VERB	O	O
help	VERB	O	O
to	PUNCT	O	O
better	PUNCT	O	O
select	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
colorectal	ADJ	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
mCRC	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Genetic	ADJ	O	O
interaction	NOUN	O	O
analysis	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
rational	ADJ	O	O
tool	NOUN	O	O
to	ADP	O	O
study	VERB	O	O
the	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
polygenic	ADJ	O	O
variation	NOUN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
drug	NOUN	O	O
response	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
A	DET	O	O
selection	NOUN	O	O
of	ADP	O	O
17	NUM	O	O
polymorphisms	NOUN	O	O
in	ADP	O	O
genes	NOUN	O	O
encoding	VERB	O	O
drug	NOUN	O	O
targets	NOUN	O	O
,	PUNCT	O	O
pathway	NOUN	O	B-PHYSICAL
molecules	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
detoxification	NOUN	O	B-PHYSICAL
enzymes	NOUN	O	I-PHYSICAL
was	VERB	O	O
analyzed	VERB	O	O
in	ADP	O	O
279	NUM	O	O
previously	ADV	O	O
untreated	VERB	O	O
mCRC	NOUN	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
capecitabine	NOUN	O	O
,	PUNCT	O	O
oxaliplatin	NOUN	O	O
and	CCONJ	O	O
bevacizumab	PUNCT	O	O
(	PUNCT	O	O
CAPOX-B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Multifactor	NOUN	O	O
dimensionality	NOUN	O	O
reduction	NOUN	O	O
analysis	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
identify	NOUN	O	O
a	DET	O	O
genetic	ADJ	O	B-MORTALITY
interaction	NOUN	O	O
profile	NOUN	O	B-MORTALITY
for	ADP	O	I-MORTALITY
progression-free	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	I-MORTALITY
PFS	NOUN	O	I-MORTALITY
)	PUNCT	O	B-MORTALITY
.	PUNCT	O	O

RESULTS	ADJ	O	O
Median	ADJ	O	O
PFS	NOUN	O	B-MORTALITY
was	VERB	O	O
10.9	NUM	O	O
[	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	NOUN	O	O
)	PUNCT	O	O
9.4-12.4	NUM	O	O
]	PUNCT	O	O
months	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
genetic	ADJ	O	B-PHYSICAL
interaction	NOUN	O	O
profile	NOUN	O	B-PHYSICAL
consisting	DET	O	O
of	ADP	O	O
the	DET	O	O
TYMS	NOUN	O	O
enhancer	NOUN	O	O
region	NOUN	O	O
and	CCONJ	O	O
VEGF	NOUN	O	O
+405G	PUNCT	O	O
>	SYM	O	O
C	NOUN	O	O
polymorphisms	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
PFS	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
PFS	NOUN	O	B-MORTALITY
was	VERB	O	O
13.3	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
11.4-15.3	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
9.7	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
7.6-11.8	NUM	O	O
)	PUNCT	O	O
months	NOUN	O	O
for	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
and	CCONJ	O	O
unfavorable	ADJ	O	O
genetic	ADJ	O	B-PHYSICAL
profiles	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
corresponding	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
hazards	ADJ	O	O
ratio	NOUN	O	O
for	PUNCT	O	O

Granulocyte-macrophage	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
treatment	NOUN	O	O
before	ADP	O	O
doxorubicin	NOUN	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	O
chemotherapy	NOUN	O	O
priming	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
early-stage	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
if	PUNCT	O	O
inhibition	NOUN	O	O
of	ADP	O	O
stem-cell	NOUN	O	O
activity	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
granulocyte-macrophage	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
(	PUNCT	O	O
[	PUNCT	O	O
GM-CSF	NOUN	O	O
]	PUNCT	O	O
;	PUNCT	O	O
Sargramostim	NOUN	O	O
;	PUNCT	O	O
Immunex	ADP	O	O
Corporation	NOUN	O	O
,	PUNCT	O	O
Seattle	PUNCT	O	O
,	PUNCT	O	O
WA	NOUN	O	O
)	PUNCT	O	O
withdrawal	NOUN	O	O
or	CCONJ	O	O
priming	PUNCT	O	O
protects	VERB	O	O
hematopoietic	ADJ	O	O
stem	NOUN	O	O
cells	NOUN	O	O
from	ADP	O	O
the	DET	O	O
cytotoxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
early-stage	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Serial	PUNCT	O	O
blood	NOUN	O	O
counts	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
20	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
early-stage	NOUN	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
receiving	VERB	O	O
four	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
balanced	ADP	O	O
randomization	NOUN	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
received	VERB	O	O
GM-CSF	NOUN	O	O
priming	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
5	NUM	O	O
to	ADP	O	O
1	NUM	O	O
for	ADP	O	O
courses	DET	O	O
1	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
or	CCONJ	O	O
courses	ADP	O	O
2	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Compared	VERB	O	O
with	ADP	O	O
before	ADP	O	O
priming	VERB	O	O
,	PUNCT	O	O
after	ADP	O	O
priming	PUNCT	O	O
the	DET	O	O
times	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
neutrophil	NOUN	O	I-PHYSICAL
nadir	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
12.8	NUM	O	O
+/-	SYM	O	O
2.5	NUM	O	O
days	NOUN	O	O
v	NUM	O	O
14.8	NUM	O	O
+/-	SYM	O	O
1.5	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.0001	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
platelet	NOUN	O	B-PHYSICAL
nadir	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
,	PUNCT	O	O
10.1	NUM	O	O
+/-	SYM	O	O
1.9	NUM	O	O
days	NOUN	O	O
v	CCONJ	O	O
11.1	NUM	O	O
+/-	SYM	O	O
2.2	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
shorter	PUNCT	O	O
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
shift	NOUN	O	O
of	ADP	O	O
cytotoxicity	NOUN	O	O
to	ADP	O	O
later	PUNCT	O	O
progenitors	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
neutrophil	NOUN	O	B-PHYSICAL
nadir	NOUN	O	I-PHYSICAL
was	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
priming	VERB	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
,	PUNCT	O	O
490	NUM	O	O
+/-	SYM	O	O
310/microL	NOUN	O	O
v	NUM	O	O
550	NUM	O	O
+/-	SYM	O	O
350/microL	ADP	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.2	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
16	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
neutrophil	NOUN	O	B-PHYSICAL
count	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
,	PUNCT	O	O
1030	NUM	O	O
+/-	SYM	O	O
580/microL	NOUN	O	O
v	NUM	O	O
690	NUM	O	O
+/-	SYM	O	O
370/microL	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=.004	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
neutrophil	NOUN	O	B-PHYSICAL
count	NOUN	O	I-PHYSICAL
less	ADV	O	O
than	PUNCT	O	O
500/microL	ADP	O	O
was	VERB	O	O
lower	PUNCT	O	O
after	ADP	O	O
priming	ADJ	O	O
than	VERB	O	O
before	PUNCT	O	O
(	PUNCT	O	O
six	ADJ	O	O
of	ADP	O	O
35	NUM	O	O
or	CCONJ	O	O
17	NUM	O	O
.	PUNCT	O	O

1	NUM	O	O
%	SYM	O	O
v	NUM	O	O
12	NUM	O	O
of	ADP	O	O
34	NUM	O	O
or	CCONJ	O	O
35.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
=.04	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
platelet	NOUN	O	B-PHYSICAL
nadir	NOUN	O	I-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
SD	NOUN	O	O
,	PUNCT	O	O
166,000	NUM	O	O
+/-	SYM	O	O
51,000/microL	NOUN	O	O
after	ADP	O	O
priming	VERB	O	O
v	NUM	O	O
151,000	NUM	O	O
+/-	SYM	O	O
45,000/microL	NOUN	O	O
before	ADP	O	O
priming	VERB	O	O
,	PUNCT	O	O
P	NOUN	O	O
=.007	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
duration	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
thrombocytopenia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
ie	ADP	O	O
,	PUNCT	O	O
a	DET	O	O
platelet	NOUN	O	O
count	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
150,000/microL	ADP	O	O
,	PUNCT	O	O
was	VERB	O	O
shorter	PUNCT	O	O
(	PUNCT	O	O
1.5	NUM	O	O
+/-	SYM	O	O
2.1	NUM	O	O
days	NOUN	O	O
v	NUM	O	O
2.8	NUM	O	O
+/-	SYM	O	O
2.9	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
P	PUNCT	O	O
=.0025	PUNCT	O	O
)	PUNCT	O	O
after	ADP	O	O
priming	VERB	O	O
.	PUNCT	O	O

Episodes	NOUN	O	O
of	ADP	O	O
fever	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
neutropenia	NOUN	O	B-ADVERSE-EFFECTS
were	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
GM-CSF	NOUN	O	O
priming	VERB	O	O
from	ADP	O	O
days	NOUN	O	O
5	NUM	O	O
to	ADP	O	O
1	NUM	O	O
before	ADP	O	O
doxorubicin	NOUN	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
earlier	PUNCT	O	O
neutrophil	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
platelet	NOUN	O	B-PHYSICAL
nadir	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

On	ADP	O	O
day	NOUN	O	O
16	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
higher	PUNCT	O	O
mean	NOUN	O	O
neutrophil	NOUN	O	B-PHYSICAL
count	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
a	DET	O	O
lower	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
(	PUNCT	O	O
<	ADP	O	O
500/microL	ADP	O	O
)	PUNCT	O	O
neutropenia	NOUN	O	B-ADVERSE-EFFECTS
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Beneficial	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
thrombocytopenia	NOUN	O	B-PHYSICAL
were	VERB	O	O
also	ADV	O	O
noted	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
support	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
GM-CSF	NOUN	O	O
priming	ADP	O	O
protects	NOUN	O	O
hematopoietic	ADJ	O	O
progenitors	NOUN	O	O
from	ADP	O	O
the	DET	O	O
cytotoxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
ORG-2766	NOUN	O	O
on	ADP	O	O
brain	NOUN	O	O
event-related	VERB	O	O
potentials	NOUN	O	O
of	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
adrenocorticotropin4-9	NOUN	O	O
analogue	NOUN	O	O
ORG-2766	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
brain	NOUN	O	O
event-related	VERB	O	O
potentials	NOUN	O	O
(	PUNCT	O	O
ERPs	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
autistic	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
visual	ADJ	O	O
and	CCONJ	O	O
auditory	ADJ	O	O
oddball	DET	O	O
paradigms	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
task	NOUN	O	O
and	CCONJ	O	O
nontask	PUNCT	O	O
conditions	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
standard	ADJ	O	O
(	PUNCT	O	O
80	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
target	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
unexpected	VERB	O	O
novel	ADJ	O	O
stimuli	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

ORG-2766	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
the	DET	O	B-PHYSICAL
occipital	ADJ	O	I-PHYSICAL
P3	NOUN	O	I-PHYSICAL
component	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
ERP	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
visual	ADJ	O	I-PHYSICAL
targets	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
decreased	VERB	O	O
the	DET	O	B-PHYSICAL
occipital	ADJ	O	I-PHYSICAL
P3	NOUN	O	I-PHYSICAL
component	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
ERP	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
auditory	ADJ	O	I-PHYSICAL
targets	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
(	PUNCT	O	B-PHYSICAL
c	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
did	DET	O	I-PHYSICAL
not	ADV	O	I-PHYSICAL
affect	VERB	O	I-PHYSICAL
visual	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
auditory	ADJ	O	I-PHYSICAL
parietal	ADJ	O	I-PHYSICAL
target	NOUN	O	I-PHYSICAL
P3	NOUN	O	B-PHYSICAL
components	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
d	NOUN	O	O
)	PUNCT	O	O
also	ADV	O	O
did	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
A/Pcz/300	NOUN	O	O
to	ADP	O	O
auditory	ADJ	O	O
novel	ADJ	O	O
stimuli	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
ORG-2766	NOUN	O	O
treatment	NOUN	O	O
increased	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
epidermal	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
receptor	NOUN	O	O
and	CCONJ	O	O
tumor	NOUN	O	O
differentiation	NOUN	O	O
on	ADP	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
accelerated	PUNCT	O	O
radiotherapy	NOUN	O	O
of	ADP	O	O
squamous	ADJ	O	O
cell	NOUN	O	O
carcinomas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
in	ADP	O	O
the	DET	O	O
randomized	VERB	O	O
DAHANCA	NOUN	O	O
6	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
PURPOSE	NOUN	O	O
Reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
treatment	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
radiotherapy	NOUN	O	O
has	PUNCT	O	O
increased	PUNCT	O	O
locoregional	ADJ	O	B-PHYSICAL
control	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
disease	NOUN	O	B-PHYSICAL
specific	ADJ	O	I-PHYSICAL
survival	NOUN	O	I-PHYSICAL
in	ADP	O	O
squamous	ADJ	O	O
cell	NOUN	O	O
carcinomas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
(	PUNCT	O	O
HNSCC	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
response	NOUN	O	O
is	VERB	O	O
heterogeneous	ADJ	O	O
.	PUNCT	O	O

EGFr	NOUN	O	O
is	VERB	O	O
often	ADV	O	O
overexpressed	VERB	O	O
in	ADP	O	O
HNSCC	NOUN	O	O
and	CCONJ	O	O
has	PUNCT	O	O
been	PUNCT	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
repopulation	NOUN	O	O
taking	PUNCT	O	O
place	NOUN	O	O
during	ADP	O	O
radiotherapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
address	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
EGFr	NOUN	O	O
and	CCONJ	O	O
histopathological	ADJ	O	B-PHYSICAL
differentiation	NOUN	O	I-PHYSICAL
when	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
treatment	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
radiotherapy	NOUN	O	O
was	VERB	O	O
moderately	ADV	O	O
reduced	VERB	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Eight	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
representative	ADJ	O	O
pretreatment	NOUN	O	O
tissue	NOUN	O	O
samples	NOUN	O	O
from	ADP	O	O
the	DET	O	O
randomized	VERB	O	O
DAHANCA	NOUN	O	O
6	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
study	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
vs.	CCONJ	O	O
6	NUM	O	O
fx/wk	NOUN	O	O
of	ADP	O	O
radiotherapy	NOUN	O	O
.	PUNCT	O	O

EGFr	NOUN	O	O
was	VERB	O	O
visualized	VERB	O	O
using	VERB	O	O
immunohistochemistry	NOUN	O	O
and	CCONJ	O	O
separated	VERB	O	O
into	ADP	O	O
high	ADJ	O	O
and	CCONJ	O	O
low	ADJ	O	O
expression	NOUN	O	O
before	ADP	O	O
correlation	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
data	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Tumors	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
EGFr	NOUN	O	O
(	PUNCT	O	O
84	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
responded	VERB	O	O
better	PUNCT	O	O
to	PUNCT	O	O
moderately	ADV	O	O
accelerated	DET	O	O
radiotherapy	NOUN	O	O
,	PUNCT	O	O
than	PUNCT	O	O
carcinomas	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
EGFr	NOUN	O	O
,	PUNCT	O	O
using	SYM	O	O
locoregional	ADJ	O	O
control	NOUN	O	O
as	PUNCT	O	O
endpoint	ADJ	O	O
and	CCONJ	O	O
a	DET	O	O
similar	ADJ	O	O
pattern	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
,	PUNCT	O	O
stratifying	PUNCT	O	O
by	ADP	O	O
well/moderate	NOUN	O	O
vs.	CCONJ	O	O
poor	ADJ	O	O
tumor	NOUN	O	B-PHYSICAL
differentiation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
combined	VERB	O	O
parameter	NOUN	O	O
was	VERB	O	O
constructed	VERB	O	O
showing	VERB	O	O
a	DET	O	O
more	ADV	O	O
prominent	ADJ	O	B-OTHER
separation	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
response	NOUN	O	I-OTHER
:	PUNCT	O	O
tumors	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
EGFr	NOUN	O	O
and	CCONJ	O	O
well/moderate	NOUN	O	O
differentiation	NOUN	O	O
did	PUNCT	O	O
benefit	CCONJ	O	O
from	ADP	O	O
moderate	ADJ	O	O
acceleration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
regarding	VERB	O	O
locoregional	ADJ	O	O
control	NOUN	O	O
,	PUNCT	O	O
HR	NOUN	O	O
0.54	NUM	O	O
(	PUNCT	O	O
0.37-0.78	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
such	PUNCT	O	O
an	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
seen	VERB	O	O
in	ADP	O	O
tumors	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
EGFr	NOUN	O	O
and/or	CCONJ	O	O
poor	ADJ	O	O
differentiation	NOUN	O	O
,	PUNCT	O	O
HR	NOUN	O	O
0.8	NUM	O	O
(	PUNCT	O	O
0.51-1.25	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	ADP	O	O
reflected	VERB	O	O
the	DET	O	O
disease	NOUN	O	B-MORTALITY
specific	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
as	VERB	O	O
well	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
confirmed	VERB	O	O
in	ADP	O	O
multivariable	ADJ	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Moderately	ADV	O	O
accelerated	VERB	O	O
fractionation	NOUN	O	O
is	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
conventional	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
HNSCC	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
response	NOUN	O	O
is	VERB	O	O
heterogeneous	ADJ	O	O
and	CCONJ	O	O
may	PRON	O	O
be	VERB	O	O
predicted	VERB	O	O
by	ADP	O	O
high	ADJ	O	O
expression	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
EGFr	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
well/moderate	NOUN	O	O
tumor	NOUN	O	B-PHYSICAL
differentiation	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Outcomes	NOUN	O	O
in	ADP	O	O
a	DET	O	O
nursing	VERB	O	O
home	NOUN	O	O
transition	NOUN	O	O
case-management	NOUN	O	O
program	NOUN	O	O
targeting	PUNCT	O	O
new	ADJ	O	O
admissions	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
Providing	PUNCT	O	O
Assistance	NOUN	O	O
to	ADP	O	O
Caregivers	NOUN	O	O
in	ADP	O	O
Transition	NOUN	O	O
(	PUNCT	O	O
PACT	NOUN	O	O
)	PUNCT	O	O
program	NOUN	O	O
offers	NOUN	O	O
nursing	VERB	O	O
home	NOUN	O	O
discharge	NOUN	O	O
planning	PROPN	O	O
and	CCONJ	O	O
case	NOUN	O	O
management	NOUN	O	O
for	ADP	O	O
individuals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
transitional	ADJ	O	O
period	NOUN	O	O
following	VERB	O	O
a	DET	O	O
return	NOUN	O	O
to	ADP	O	O
the	DET	O	O
community	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
PACT	NOUN	O	O
program	NOUN	O	O
targeted	VERB	O	O
individuals	NOUN	O	O
newly	ADV	O	O
admitted	ADP	O	O
to	ADP	O	O
nursing	VERB	O	O
homes	NOUN	O	O
and	CCONJ	O	O
worked	VERB	O	O
with	ADP	O	O
a	DET	O	O
family	NOUN	O	O
caregiver	NOUN	O	O
to	ADJ	O	O
develop	NOUN	O	O
and	CCONJ	O	O
implement	PUNCT	O	O
a	DET	O	O
nursing	VERB	O	O
home	NOUN	O	O
discharge	NOUN	O	O
plan	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHOD	NOUN	O	O
Reported	PUNCT	O	O
are	ADP	O	O
the	DET	O	O
results	CCONJ	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
control	NOUN	O	O
design	NOUN	O	O
evaluating	VERB	O	O
the	DET	O	O
program	NOUN	O	O
's	PUNCT	O	O
effectiveness	NOUN	O	O
.	PUNCT	O	O

Those	ADP	O	O
individuals	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
33	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
PACT	NOUN	O	O
case	NOUN	O	O
management	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
usual	ADJ	O	O
medical	ADJ	O	O
and	CCONJ	O	O
nursing	VERB	O	O
home	NOUN	O	O
care	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
individuals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
29	NUM	O	O
)	PUNCT	O	O
continued	ADP	O	O
their	ADP	O	O
usual	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

RESULT	NOUN	O	O
There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
statistical	ADJ	O	O
differences	NOUN	O	B-OTHER
in	ADP	O	I-OTHER
the	DET	O	I-OTHER
discharge	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
(	PUNCT	O	O
84	NUM	O	O
%	SYM	O	O
treatment	NOUN	O	O
vs	CCONJ	O	O
76	NUM	O	O
%	SYM	O	O
controls	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
in	ADP	O	O
the	DET	O	B-OTHER
median	ADJ	O	O
length	NOUN	O	B-OTHER
of	PUNCT	O	I-OTHER

Effects	NOUN	O	O
of	ADP	O	O
soy	NOUN	O	O
intake	NOUN	O	O
on	ADP	O	O
sex	NOUN	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
in	ADP	O	O
premenopausal	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
phytoestrogens	PUNCT	O	O
in	ADP	O	O
soy	NOUN	O	O
products	NOUN	O	O
may	VERB	O	O
impart	VERB	O	O
hormonal	ADJ	O	O
effects	NOUN	O	O
that	NUM	O	O
protect	DET	O	O
women	NOUN	O	O
against	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Limited	VERB	O	O
research	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
intake	NOUN	O	O
of	ADP	O	O
soy	NOUN	O	O
products	NOUN	O	O
high	ADJ	O	O
in	ADP	O	O
isoflavonoid	NOUN	O	O
phytoestrogens	PUNCT	O	O
affects	NOUN	O	O
sex	NOUN	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
unknown	VERB	O	O
whether	ADP	O	O
phytoestrogens	PUNCT	O	O
in	ADP	O	O
soy	NOUN	O	O
have	PUNCT	O	O
any	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
menstrual	ADJ	O	O
function	NOUN	O	O
or	CCONJ	O	O
serum	NOUN	O	O
sex	NOUN	O	O
hormones	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
on	ADP	O	O
common	ADJ	O	O
hormone	NOUN	O	O
therapies	NOUN	O	O
,	PUNCT	O	O
such	PUNCT	O	O
as	ADP	O	O
oral	ADJ	O	O
contraceptives	NOUN	O	O
(	PUNCT	O	O
OC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
soy	NOUN	O	O
in	ADP	O	O
36	NUM	O	O
premenopausal	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
of	ADP	O	O
whom	ADP	O	O
used	VERB	O	O
OC	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
consumed	PUNCT	O	O
their	PUNCT	O	O
normal	ADJ	O	O
diet	NOUN	O	O
for	ADP	O	O
two	NUM	O	O
menstrual	ADJ	O	O
cycles	NOUN	O	O
and	CCONJ	O	O
added	PUNCT	O	O
a	DET	O	O
soy	NOUN	O	O
beverage	NOUN	O	O
containing	VERB	O	O
20	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
protein	NOUN	O	O
and	CCONJ	O	O
38	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
isoflavones	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
usual	ADJ	O	O
diet	NOUN	O	O
for	ADP	O	O
another	DET	O	O
two	NUM	O	O
menstrual	ADJ	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
serum	NOUN	O	B-PHYSICAL
estrone	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
estradiol	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
sex	NOUN	O	B-PHYSICAL
hormone-binding	VERB	O	I-PHYSICAL
globulin	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
dehydroepiandrosterone	NOUN	O	B-PHYSICAL
sulfate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
prolactin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
or	CCONJ	O	O
progesterone	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
with	ADP	O	O
soy	NOUN	O	O
feeding	ADJ	O	O
in	ADP	O	O
the	DET	O	O
non-OC	CCONJ	O	O
or	CCONJ	O	O
the	DET	O	O
OC	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
menstrual	ADJ	O	B-PHYSICAL
cycle	NOUN	O	O
length	NOUN	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
estrogen	NOUN	O	I-PHYSICAL
metabolite	NOUN	O	I-PHYSICAL
ratio	NOUN	O	O
of	ADP	O	B-PHYSICAL
2-hydroxyestrone	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
16	NUM	O	B-PHYSICAL
alpha-hydroxyestrone	NOUN	O	I-PHYSICAL
were	VERB	O	O
seen	VERB	O	O
with	ADP	O	O
soy	NOUN	O	O
feeding	ADJ	O	O
in	ADP	O	O
the	DET	O	O
non-OC	CCONJ	O	O
or	CCONJ	O	O
the	DET	O	O
OC	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Levels	NOUN	O	B-PHYSICAL
of	ADP	O	B-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
estrogen	PUNCT	O	I-PHYSICAL

Promoting	VERB	O	O
physical	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
colon	NOUN	O	O
adenomas	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
pilot	NOUN	O	O
intervention	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Physical	PUNCT	O	O
activity	NOUN	O	O
decreases	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
colon	NOUN	O	O
polyps	NOUN	O	O
and	CCONJ	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
and	CCONJ	O	O
might	VERB	O	O
reduce	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
recurrence	NOUN	O	O
.	PUNCT	O	O

Focusing	PUNCT	O	O
on	ADP	O	O
recent	ADJ	O	O
calls	ADJ	O	O
for	ADP	O	O
translation	NOUN	O	O
of	ADP	O	O
epidemiologic	ADJ	O	O
evidence	NOUN	O	O
into	ADP	O	O
clinical	ADJ	O	O
care	NOUN	O	O
,	PUNCT	O	O
our	PUNCT	O	O
pilot	NOUN	O	O
study	VERB	O	O
delivered	VERB	O	O
an	DET	O	O
evidence-based	VERB	O	O
physical	ADJ	O	O
activity	NOUN	O	O
intervention	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
polyps	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
are	VERB	O	O
thus	ADV	O	O
at	ADP	O	O
elevated	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	PUNCT	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
change	NOUN	O	O
in	ADP	O	O
physical	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
steps	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
and	CCONJ	O	O
minutes	NOUN	O	O
of	ADP	O	O
moderate/vigorous	ADJ	O	B-MENTAL
physical	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixteen	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
adenomas	NOUN	O	O
detected	ADP	O	O
and	CCONJ	O	O
removed	VERB	O	O
at	ADP	O	O
screening	ADJ	O	O
colonoscopy	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
to	ADP	O	O
a	DET	O	O
12-week	NOUN	O	O
physical	ADJ	O	O
activity	NOUN	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
standard	ADJ	O	O
(	PUNCT	O	O
30	NUM	O	O
minutes/day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
high	ADJ	O	O
(	PUNCT	O	O
60	NUM	O	O
minutes/day	NOUN	O	O
)	PUNCT	O	O
walking	ADP	O	O
program	NOUN	O	O
.	PUNCT	O	O

Physical	ADJ	O	O
activity	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
via	ADP	O	O
blinded	VERB	O	O
pedometer	VERB	O	O
and	CCONJ	O	O
accelerometer	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Intervention	NOUN	O	O
messages	NOUN	O	O
focused	VERB	O	O
on	ADP	O	O
self-monitoring	PUNCT	O	O
using	VERB	O	O
pedometers	NOUN	O	O
and	CCONJ	O	O
overcoming	PROPN	O	O
barriers	NOUN	O	O
to	ADP	O	O
engaging	PUNCT	O	O
in	ADP	O	O
physical	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
Participants	NOUN	O	O
in	ADP	O	O
both	PUNCT	O	O
arms	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
objectively	ADV	O	O
measured	PUNCT	O	O
minutes	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
moderate/vigorous	ADJ	O	I-MENTAL
physical	ADJ	O	I-MENTAL
activity	NOUN	O	I-MENTAL
over	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
arms	NOUN	O	O
exceeded	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
goal	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
arms	NOUN	O	O
at	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
pedometer	ADP	O	B-OTHER
measured	ADP	O	I-OTHER
physical	ADJ	O	I-OTHER
activity	NOUN	O	I-OTHER
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
overall	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
steps/day	NOUN	O	B-MENTAL
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	ADP	O	O
between	ADP	O	O
arm	NOUN	O	O
difference	NOUN	O	O
in	ADP	O	O
change	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Simple	ADJ	O	O
interventions	NOUN	O	O
of	ADP	O	O
minimal	ADJ	O	O
contact	NOUN	O	O
time	NOUN	O	O
focusing	PUNCT	O	O
on	ADP	O	O
walking	PUNCT	O	O
can	PUNCT	O	O
significantly	NOUN	O	O
increase	NOUN	O	O
physical	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
individuals	NOUN	O	O
at	ADP	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	PUNCT	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
ClinicalTrials.gov	PUNCT	O	O
NCT01476631	PUNCT	O	O
.	PUNCT	O	O

Measurement	NOUN	O	O
of	ADP	O	O
health-related	VERB	O	B-PHYSICAL
quality	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
life	NOUN	O	I-PHYSICAL
in	ADP	O	O
multiple	ADJ	O	O
myeloma	NOUN	O	O
.	PUNCT	O	O

Nordic	ADJ	O	O
Myeloma	NOUN	O	O
Study	NOUN	O	O
Group	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
(	PUNCT	O	O
NMSG	NOUN	O	O
4/90	NOUN	O	O
)	PUNCT	O	O
comparing	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
melphalan/prednisone	NOUN	O	O
to	ADP	O	O
melphalan/	NOUN	O	O
prednisone	NOUN	O	O
+	DET	O	O
interferon	NOUN	O	O
alpha-2b	NOUN	O	O
in	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
multiple	ADJ	O	O
myeloma	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
in	ADP	O	O
1990	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
quality-of-life	NOUN	O	B-OTHER
assessment	NOUN	O	B-PHYSICAL
was	VERB	O	O
integrated	VERB	O	O
into	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
the	DET	O	O
questionnaire	NOUN	O	O
(	PUNCT	O	O
QLQ-C30	NOUN	O	O
)	PUNCT	O	O
developed	VERB	O	O
by	ADP	O	O
the	DET	O	O
European	NOUN	O	O
Organization	NOUN	O	O
of	ADP	O	O
Research	NOUN	O	O
and	CCONJ	O	O
Treatment	NOUN	O	O
of	ADP	O	O
Cancer	NOUN	O	O
(	PUNCT	O	O
EORTC	NOUN	O	O
)	PUNCT	O	O
Study	NOUN	O	O
Group	NOUN	O	O
on	ADP	O	O
Quality	NOUN	O	O
of	ADP	O	O
Life	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
QLQ-C30	NOUN	O	O
incorporates	ADJ	O	O
five	NUM	O	O
functional	ADJ	O	O
scales	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
symptom	NOUN	O	O
scales	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
global	ADJ	O	O
health	NOUN	O	O
and	CCONJ	O	O
quality-of	NOUN	O	B-OTHER
life	NOUN	O	I-OTHER
scale	NOUN	O	I-OTHER
and	CCONJ	O	O
some	DET	O	O
single	ADJ	O	O
symptom	NOUN	O	O
measures	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
questionnaire	NOUN	O	O
was	VERB	O	O
completed	VERB	O	O
prior	PUNCT	O	O
to	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
,	PUNCT	O	O
24	NUM	O	O
,	PUNCT	O	O
36	NUM	O	O
and	CCONJ	O	O
48	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

524	NUM	O	O
(	PUNCT	O	O
90.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
581	NUM	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
NMSG	NOUN	O	O
4/90	NOUN	O	O
completed	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
questionnaire	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
484	NUM	O	O
(	PUNCT	O	O
83.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
completed	DET	O	O
all	DET	O	O
questionnaires	NOUN	O	O
given	VERB	O	O
to	ADP	O	O
them	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
but	CCONJ	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
scales	NOUN	O	O
met	VERB	O	O
the	DET	O	O
minimum	NOUN	O	O
criteria	NOUN	O	O
of	ADP	O	O
reliability	NOUN	O	O
(	PUNCT	O	O
Cronbach	NOUN	O	O
's	PUNCT	O	O
alpha	NOUN	O	O
>	SYM	O	O
/	SYM	O	O
0.70	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Validity	NOUN	O	O
was	VERB	O	O
shown	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
scales	NOUN	O	O
to	ADP	O	O
discriminate	NOUN	O	O
clearly	ADV	O	O
between	ADP	O	O
patients	NOUN	O	O
differing	PUNCT	O	O
in	ADP	O	O
clinical	ADJ	O	O
status	NOUN	O	O
as	PUNCT	O	O
defined	VERB	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
W.H.O	NOUN	O	O
.	PUNCT	O	O

performance	NOUN	O	O
index	NOUN	O	O
and	CCONJ	O	O
Durie	NOUN	O	O
&	CCONJ	O	O
Salmon	VERB	O	O
stage	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
objective	ADJ	O	O
disease	NOUN	O	O
status	NOUN	O	O
(	PUNCT	O	O
response	NOUN	O	O
and	CCONJ	O	O
relapse	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
the	DET	O	O
measurement	NOUN	O	O
of	ADP	O	O
health-related	VERB	O	B-OTHER
quality	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
life	NOUN	O	I-OTHER
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
in	ADP	O	O
multiple	ADJ	O	O
myeloma	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	ADV	O	O
demonstrate	VERB	O	O
that	ADP	O	O
the	DET	O	O
QLQ-C30	NOUN	O	B-OTHER
is	VERB	O	O
a	DET	O	O
reliable	ADJ	O	O
and	CCONJ	O	O
valid	PUNCT	O	O
instrument	NOUN	O	O
for	ADP	O	O
the	DET	O	O
measurement	NOUN	O	O
of	ADP	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
used	VERB	O	O
for	ADP	O	O
a	DET	O	O
cost-utility	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
NMSG	NOUN	O	O
4/90	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
cardiac	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
young	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Nicotine	NOUN	O	O
is	VERB	O	O
known	VERB	O	O
to	PUNCT	O	O
have	PUNCT	O	O
many	DET	O	O
physiologic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	O
delivered	VERB	O	O
in	ADP	O	O
chewing	ADP	O	O
gum	NOUN	O	O
upon	ADP	O	O
cardiac	ADJ	O	O
hemodynamics	NOUN	O	O
and	CCONJ	O	O
conduction	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	PUNCT	O	O
well-characterized	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	O
in	ADP	O	O
nonsmoking	ADP	O	O
adults	NOUN	O	O
(	PUNCT	O	O
6	ADP	O	O
male	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
female	NOUN	O	O
;	PUNCT	O	O
ages	NOUN	O	O
23-36	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
chewed	PUNCT	O	O
nicotine	NOUN	O	O
gum	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
20	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
approximate	ADJ	O	O
time	NOUN	O	O
to	ADP	O	O
peak	ADJ	O	O
nicotine	NOUN	O	O
levels	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
echocardiograms	ADJ	O	O
and	CCONJ	O	O
signal-averaged	NOUN	O	O
electrocardiograms	NOUN	O	O
(	PUNCT	O	O
SAECG	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
obtained	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
40	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
were	VERB	O	O
again	ADV	O	O
given	NUM	O	O
nicotine	NOUN	O	O
gum	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
cross-over	NOUN	O	O
fashion	NOUN	O	O
.	PUNCT	O	O

Standard	ADJ	O	O
echocardiographic	ADJ	O	O
measurements	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
from	ADP	O	O
two-dimensional	ADJ	O	O
images	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
calculated	PUNCT	O	O
end-systolic	ADJ	O	B-PHYSICAL
wall	NOUN	O	I-PHYSICAL
stress	NOUN	O	O
(	PUNCT	O	O
ESWS	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
shortening	VERB	O	B-PHYSICAL
fraction	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
SF	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
systemic	ADJ	O	B-PHYSICAL
vascular	ADJ	O	I-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
SVR	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
velocity	NOUN	O	O
for	ADP	O	B-PHYSICAL
circumferential	ADJ	O	B-PHYSICAL
fiber	NOUN	O	I-PHYSICAL
shortening	PUNCT	O	B-PHYSICAL
corrected	VERB	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
heart	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
Vcfc	ADP	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
stroke	NOUN	O	B-PHYSICAL
volume	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	B-PHYSICAL
cardiac	ADJ	O	I-PHYSICAL
output	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

P	NOUN	O	B-PHYSICAL
wave	NOUN	O	I-PHYSICAL
and	CCONJ	O	B-PHYSICAL
QRS	NOUN	O	I-PHYSICAL
duration	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
from	ADP	O	O
SAECG	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Significant	ADJ	O	O
differences	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
from	ADP	O	O
control	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
ESWS	NOUN	O	B-OTHER
,	PUNCT	O	O
mean	VERB	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
cardiac	ADJ	O	B-OTHER
output	NOUN	O	B-OTHER
,	PUNCT	O	O
SVR	NOUN	O	B-OTHER
,	PUNCT	O	O
heart	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
P	NOUN	O	B-OTHER
wave	NOUN	O	I-OTHER
duration	NOUN	O	B-OTHER
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
time	NOUN	O	O
(	PUNCT	O	O
LVET	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
LV	NOUN	O	O
dimensions	NOUN	O	O
,	PUNCT	O	O

A	ADP	O	O
double	ADJ	O	O
blind	ADP	O	O
randomized	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
clodronate	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
metastases	NOUN	O	O
from	ADP	O	O
tumors	NOUN	O	O
poorly	ADV	O	O
responsive	ADJ	O	O
to	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Bisphosphonates	ADP	O	O
are	VERB	O	O
used	VERB	O	O
in	ADP	O	O
oncology	NOUN	O	O
as	ADP	O	O
a	DET	O	O
means	NOUN	O	O
of	ADP	O	O
decreasing	VERB	O	O
complications	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
bone	NOUN	O	O
metastases	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
anticancer	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
and	CCONJ	O	O
myeloma	NOUN	O	O
.	PUNCT	O	O

Little	PUNCT	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
bisphosphonates	ADV	O	O
on	ADP	O	O
bone	NOUN	O	O
metastases	NOUN	O	O
from	ADP	O	O
other	ADJ	O	O
tumors	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
particular	CCONJ	O	O
from	ADP	O	O
tumors	NOUN	O	O
for	ADP	O	O
which	DET	O	O
no	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
is	VERB	O	O
available	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
clodronate	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bone	NOUN	O	O
metastases	NOUN	O	O
from	ADP	O	O
tumors	NOUN	O	O
poorly	ADV	O	O
responsive	ADJ	O	O
to	ADP	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
aims	NOUN	O	O
of	ADP	O	O
evaluating	SYM	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	B-PHYSICAL
on	ADP	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
control	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	B-PHYSICAL
metastases	NOUN	O	I-PHYSICAL
evolution	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Sixty-six	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
poorly	ADV	O	O
responsive	ADJ	O	O
tumors	NOUN	O	O
such	ADP	O	O
as	ADP	O	O
non-small	ADP	O	O
cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
NSCLC	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
gastrointestinal	ADJ	O	O
cancers	NOUN	O	O
,	PUNCT	O	O
kidney	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
melanoma	NOUN	O	O
and	CCONJ	O	O
metastatic	ADJ	O	O
carcinoma	NOUN	O	O
of	ADP	O	O
unknown	VERB	O	O
origin	NOUN	O	O
entered	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	ADP	O	O
either	PUNCT	O	O
clodronate	PUNCT	O	O
1,600	NUM	O	O
mg/day	NOUN	O	O
for	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
or	CCONJ	O	O
identical	ADJ	O	O
placebo-containing	DET	O	O
tablets	ADV	O	O
.	PUNCT	O	O

Various	ADJ	O	O
parameters	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
Karnofsky	NOUN	O	B-PHYSICAL
performance	NOUN	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
pain	NOUN	O	O
score	NOUN	O	O
(	PUNCT	O	O
measured	PROPN	O	O
by	ADP	O	O
a	DET	O	O
visual-analogue	NOUN	O	O
scale	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
analgesic	PUNCT	O	B-PAIN
requirement	NOUN	O	B-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
at	ADP	O	O
monthly	PUNCT	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
66	NUM	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
9	NUM	O	O
were	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
one	NUM	O	O
month	NOUN	O	O
or	CCONJ	O	O
less	DET	O	O
;	PUNCT	O	O
7	NUM	O	O
were	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
two	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
only	ADV	O	O
50	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
more	ADV	O	O
than	CCONJ	O	O
2	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
could	VERB	O	O
be	VERB	O	O
adequately	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

At	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
both	CCONJ	O	O
clodronate	VERB	O	O
and	CCONJ	O	O
placebo-treated	VERB	O	O
patients	NOUN	O	O
had	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
Karnofsky	NOUN	O	B-PHYSICAL
performance	NOUN	O	I-PHYSICAL
status	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
decrease	NOUN	O	O
being	ADP	O	O
more	ADV	O	O
evident	ADJ	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
showed	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PAIN
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
decrease	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	CCONJ	O	O
clodronate	PUNCT	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
difference	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Analgesics	ADJ	O	B-PAIN
requirement	NOUN	O	I-PAIN
increased	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
significantly	ADV	O	O
more	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.042	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
whom	ADP	O	O
increase	CCONJ	O	O
in	ADP	O	O
opioid	NOUN	O	O
requirements	NOUN	O	O
was	VERB	O	O
particularly	ADV	O	O
evident	ADJ	O	O
.	PUNCT	O	O

Toxicity	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	I-ADVERSE-EFFECTS
low	ADJ	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
with	ADP	O	O
occasional	ADJ	O	B-ADVERSE-EFFECTS
gastroenteric	ADJ	O	I-ADVERSE-EFFECTS
discomfort	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
problem	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	ADV	O	O
the	DET	O	O
difficulty	NOUN	O	O
in	ADP	O	O
recruiting	NOUN	O	O
an	DET	O	O
adequate	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
following	VERB	O	O
them	NUM	O	O
for	ADP	O	O
a	DET	O	O
sufficient	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
:	PUNCT	O	O
general	ADJ	O	O
conditions	NOUN	O	O
rapidly	ADV	O	O
deteriorated	VERB	O	O
in	ADP	O	O
many	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
approximately	ADV	O	O
25	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
66	NUM	O	O
enrolled	VERB	O	O
were	VERB	O	O
not	ADV	O	O
considered	PUNCT	O	O
evaluable	ADJ	O	O
;	PUNCT	O	O
few	ADJ	O	O
patients	NOUN	O	O
survived	DET	O	O
for	ADP	O	O
the	DET	O	O
length	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
might	ADP	O	O
partly	ADV	O	O
account	VERB	O	O
for	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
significance	NOUN	O	O
of	ADP	O	O
some	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
parameters	NOUN	O	O
under	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
these	DET	O	O
limits	NOUN	O	O
,	PUNCT	O	O
oral	ADJ	O	O
clodronate	VERB	O	O
demonstrated	VERB	O	O
some	DET	O	O
efficacy	NOUN	O	O
in	ADP	O	O
symptom	NOUN	O	O
control	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
analgesics	NOUN	O	O
.	PUNCT	O	O

Impact	NOUN	O	O
of	ADP	O	O
interviewer	PUNCT	O	O
's	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
on	ADP	O	O
underreporting	PUNCT	O	O
energy	NOUN	O	O
intake	NOUN	O	O
in	ADP	O	O
overweight	ADJ	O	O
and	CCONJ	O	O
obese	PUNCT	O	O
women	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
if	PUNCT	O	O
overweight	VERB	O	O
and	CCONJ	O	O
obese	PUNCT	O	O
women	NOUN	O	O
provide	VERB	O	O
more	ADV	O	O
accurate	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
their	PUNCT	O	O
energy	NOUN	O	O
intake	NOUN	O	O
by	ADP	O	O
1	NUM	O	O
)	PUNCT	O	O
in-person	NOUN	O	O
recall	ADP	O	O
with	ADP	O	O
an	DET	O	O
obese	ADJ	O	O
interviewer	PUNCT	O	O
,	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
in-person	NOUN	O	O
recall	ADP	O	O
with	ADP	O	O
a	DET	O	O
lean	ADJ	O	O
interviewer	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
3	NUM	O	O
)	PUNCT	O	O
telephone	NOUN	O	O
recall	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
unknown	VERB	O	O
interviewer	PUNCT	O	O
.	PUNCT	O	O

RESEARCH	NOUN	O	O
METHODS	NOUN	O	O
AND	CCONJ	O	O
PROCEDURES	NOUN	O	O
Eighty-eight	PUNCT	O	O
overweight	VERB	O	O
and	CCONJ	O	O
obese	PUNCT	O	O
women	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
completed	DET	O	O
one	ADP	O	O
telephone-administered	VERB	O	O
multiple-pass	NOUN	O	O
24-hour	NOUN	O	O
recall	NOUN	O	O
(	PUNCT	O	O
MP24R	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
unknown	VERB	O	O
interviewer	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
then	ADV	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
an	DET	O	O
in-person	NOUN	O	O
MP24R	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
lean	ADJ	O	O
or	CCONJ	O	O
obese	DET	O	O
interviewer	PUNCT	O	O
to	ADP	O	O
gather	ADP	O	O
reported	VERB	O	B-PHYSICAL
energy	NOUN	O	I-PHYSICAL
intake	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
rEI	PUNCT	O	B-PHYSICAL
)	PUNCT	O	O
.	PUNCT	O	O

Basal	ADJ	O	B-PHYSICAL
metabolic	ADJ	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BMR	PUNCT	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
using	SYM	O	O
a	DET	O	O
Deltrac	PUNCT	O	O
monitor	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
EEPA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
was	VERB	O	O
estimated	VERB	O	O
using	VERB	O	O
a	DET	O	O
Caltrac	NOUN	O	O
accelerometer	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
estimated	ADP	O	O
energy	NOUN	O	O
expenditure	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
:	PUNCT	O	O
estTEE	NUM	O	O
=	ADJ	O	O
(	PUNCT	O	O
BMR	PUNCT	O	O
+	ADP	O	O
EEPA	NOUN	O	O
)	PUNCT	O	O
x	SYM	O	O
1.10	NUM	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
in-person	NOUN	O	O
interview	NOUN	O	O
modes	NOUN	O	O
for	ADP	O	O
subject	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
weight	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
percentage	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
fat	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
energy	NOUN	O	O
expenditure	NOUN	O	O
,	PUNCT	O	O
rEI	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
misreporting	PROPN	O	O
of	ADP	O	O
energy	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

In-person	NOUN	O	O
recall	PUNCT	O	O
data	NOUN	O	O
were	VERB	O	O
combined	VERB	O	O
for	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
telephone	NOUN	O	O
recalls	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
in-person	NOUN	O	O
and	CCONJ	O	O
telephone	NOUN	O	O
recalls	CCONJ	O	O
for	ADP	O	O
rEI	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
misreporting	PROPN	O	B-OTHER
.	PUNCT	O	O

Mean	NOUN	O	O
reported	ADV	O	B-PHYSICAL
energy	NOUN	O	I-PHYSICAL
intake	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
estimated	DET	O	O
total	ADJ	O	O
energy	NOUN	O	B-PHYSICAL
expenditure	NOUN	O	I-PHYSICAL
for	ADP	O	O
the	DET	O	O
telephone	NOUN	O	O
recalls	NOUN	O	O
and	CCONJ	O	O
combined	VERB	O	O
(	PUNCT	O	O
lean	ADJ	O	O
and	CCONJ	O	O
obese	DET	O	O
modes	NOUN	O	O
)	PUNCT	O	O
in-person	NOUN	O	O
recalls	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	PUNCT	O	O
study	NOUN	O	O
found	VERB	O	O
that	ADP	O	O
interviewer	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
impact	NOUN	O	O
on	ADP	O	O
self-reported	VERB	O	O
energy	NOUN	O	O
intake	NOUN	O	O
during	ADP	O	O
an	DET	O	O
in-person	NOUN	O	O
MP24R	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
telephone	NOUN	O	O
recall	PUNCT	O	O
data	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
with	ADP	O	O
in-person	NOUN	O	O
recalls	NOUN	O	O
.	PUNCT	O	O

Underreporting	PUNCT	O	O
was	ADP	O	O
a	DET	O	O
widespread	ADJ	O	O
problem	NOUN	O	O
(	PUNCT	O	O
approximately	ADV	O	O
26	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
for	ADP	O	O
all	DET	O	O
modes	NOUN	O	O
in	ADP	O	O
this	DET	O	O
sample	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Postural	ADJ	O	O
biofeedback	NOUN	O	O
and	CCONJ	O	O
locomotion	NOUN	O	O
reeducation	NOUN	O	O
in	ADP	O	O
stroke	NOUN	O	O
patients	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

AIMS	NOUN	O	O
To	PROPN	O	O
compare	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
post-acute	PUNCT	O	O
hemiparetic	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
gait	NOUN	O	B-OTHER
improvement	NOUN	O	I-OTHER
after	ADP	O	O
conventional	ADJ	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
specialised	VERB	O	O
balance	NOUN	O	O
retraining	ADJ	O	O
program	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
Twenty-six	NUM	O	O
patients	NOUN	O	O
within	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	DET	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
retraining	ADJ	O	O
(	PUNCT	O	O
experimental	ADJ	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
with	ADP	O	O
left	ADJ	O	O
hemiplegia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
older	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Thirteen	ADP	O	O
patients	NOUN	O	O
received	ADJ	O	O
early	ADJ	O	O
conventional	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
13	NUM	O	O
received	ADV	O	O
therapy	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
standing	PUNCT	O	O
balance	NOUN	O	O
training	VERB	O	O
by	ADP	O	O
biofeedback	NOUN	O	O
(	PUNCT	O	O
BPM	NOUN	O	O
Monitor	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
measures	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
at	ADP	O	O
entry	NOUN	O	O
(	PUNCT	O	O
J0	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
once	PUNCT	O	O
when	PUNCT	O	O
subjects	NOUN	O	O
began	VERB	O	O
to	ADP	O	O
walk	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
JM	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
30	NUM	O	O
days	NOUN	O	O
later	ADJ	O	O
(	PUNCT	O	O
JM	NOUN	O	O
+	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Gait	NOUN	O	B-OTHER
spatiotemporal	ADJ	O	I-OTHER
parameters	NOUN	O	I-OTHER
were	VERB	O	O
collected	VERB	O	O
by	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Vicon	NOUN	O	B-OTHER
system	NOUN	O	I-OTHER
at	ADP	O	O
JM	NOUN	O	O
and	CCONJ	O	O
JM	NOUN	O	O
+	DET	O	O
30	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Whatever	PUNCT	O	O
the	DET	O	O
method	NOUN	O	O
of	ADP	O	O
rehabilitation	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
clinical	ADJ	O	B-OTHER
scores	NOUN	O	I-OTHER
improved	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
J0	NOUN	O	O
and	CCONJ	O	O
JM	NOUN	O	O
+	SYM	O	O
30	NUM	O	O
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
spasticity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	B-OTHER
between	ADP	O	I-OTHER
stroke	NOUN	O	I-OTHER
and	CCONJ	O	I-OTHER
the	DET	O	I-OTHER
beginning	PUNCT	O	I-OTHER
of	ADP	O	I-OTHER
walking	PUNCT	O	I-OTHER
was	ADV	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Gait	NOUN	O	B-PHYSICAL
velocity	NOUN	O	I-PHYSICAL
increased	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
JM	NOUN	O	O
and	CCONJ	O	O
JM	NOUN	O	O
+	SYM	O	O
30	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
walking	VERB	O	B-PHYSICAL
pattern	NOUN	O	I-PHYSICAL
was	VERB	O	O
improved	VERB	O	O
for	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
paretic	ADJ	O	B-OTHER
limb	NOUN	O	I-OTHER
single	ADJ	O	I-OTHER
stance	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
significantly	ADV	O	O
improved	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	B-OTHER
reception	NOUN	O	I-OTHER
double	ADJ	O	I-OTHER
stance	ADJ	O	I-OTHER
on	ADP	O	I-OTHER
the	DET	O	I-OTHER
paretic	ADJ	O	I-OTHER
limb	NOUN	O	I-OTHER
between	ADP	O	O
JM	NOUN	O	O
and	CCONJ	O	O
JM	NOUN	O	O
+	SYM	O	O
30	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Both	PUNCT	O	O
groups	NOUN	O	O
demonstrated	VERB	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rehabilitation	NOUN	O	O
unit	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
biofeedback	ADP	O	O
by	ADP	O	O
forceplate	NOUN	O	O
system	NOUN	O	O
training	VERB	O	O
suggest	DET	O	O
particular	CCONJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
anticipation	NOUN	O	O
equilibrium	NOUN	O	O
with	ADP	O	O
conventional	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
stretching	PROPN	O	O
durations	NOUN	O	O
on	ADP	O	O
passive	ADJ	O	B-PHYSICAL
torque	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
mobility	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Safety	NOUN	O	B-OTHER
,	PUNCT	O	O
tolerability	NOUN	O	B-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
amyloid	NOUN	O	B-PHYSICAL
beta	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
gamma-secretase	NOUN	O	O
inhibitor	NOUN	O	O
in	ADP	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Amyloid	NOUN	O	O
beta	NOUN	O	O
(	PUNCT	O	O
Abeta	NOUN	O	O
)	PUNCT	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
central	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
Alzheimer	PUNCT	O	O
disease	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
functional	ADJ	O	O
gamma-secretase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
LY450139	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
developed	ADP	O	O
that	ADP	O	O
inhibits	NOUN	O	O
Abeta	NOUN	O	O
formation	NOUN	O	O
in	ADP	O	O
whole	ADJ	O	O
cell	NOUN	O	O
assays	NOUN	O	O
,	PUNCT	O	O
transgenic	ADJ	O	O
mice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
beagle	NOUN	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
wished	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
Abeta	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
(	PUNCT	O	O
CSF	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O

Volunteer	NOUN	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
37	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
using	VERB	O	O
doses	NOUN	O	O
from	ADP	O	O
5	NUM	O	O
to	ADP	O	O
50	NUM	O	O
mg/day	NOUN	O	O
given	VERB	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
CSF	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
LY450139	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
Abeta	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
1-40	NUM	O	B-PHYSICAL
)	PUNCT	O	O
and	CCONJ	O	O
Abeta	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
1-X	ADP	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
Abeta	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
total	NOUN	O	O
)	PUNCT	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
were	VERB	O	O
determined	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
safety	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
plasma	NOUN	O	O
half-life	NOUN	O	O
of	ADP	O	O
LY450139	NOUN	O	O
was	VERB	O	O
approximately	ADV	O	O
2.5	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	O
analyses	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
linear	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
dose	NOUN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
Cmax	NOUN	O	O
of	ADP	O	O
828	NUM	O	O
+/-	SYM	O	O
19.2	NUM	O	O
ng/mL	NOUN	O	O
after	ADP	O	O
a	DET	O	O
50-mg	PUNCT	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
Abeta	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	B-PHYSICAL
decreased	VERB	O	O
in	ADP	O	O
a	DET	O	O
dose-dependent	ADJ	O	O
manner	NOUN	O	O
over	ADP	O	O
a	DET	O	O
6-hour	NOUN	O	O
interval	NOUN	O	O
following	PUNCT	O	O
drug	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
decrease	NOUN	O	O
of	ADP	O	O
approximately	ADV	O	O
40	NUM	O	O
%	ADJ	O	O
relative	ADJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
returning	ADJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
Abeta	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
transiently	ADV	O	O
increased	PUNCT	O	O
.	PUNCT	O	O

CSF	NOUN	O	B-PHYSICAL
Abeta	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	B-PHYSICAL
were	VERB	O	O
unchanged	VERB	O	O
.	PUNCT	O	O

Vitamin	NOUN	O	O
D	NOUN	O	O
supplementation	NOUN	O	O
increases	NOUN	O	O
calcium	NOUN	O	B-PHYSICAL
absorption	NOUN	O	I-PHYSICAL
without	ADP	O	O
a	DET	O	O
threshold	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
maximal	ADJ	O	O
calcium	NOUN	O	O
absorption	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
proposed	VERB	O	O
as	ADP	O	O
a	DET	O	O
biomarker	NOUN	O	O
for	ADP	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
sufficiency	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
there	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
threshold	NOUN	O	O
beyond	ADP	O	O
which	PUNCT	O	O
increasing	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
25-hydroxyvitamin	NOUN	O	O
D	NOUN	O	O
[	PUNCT	O	O
25	NUM	O	O
(	PUNCT	O	O
OH	NOUN	O	O
)	PUNCT	O	O
D	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
no	DET	O	O
longer	PUNCT	O	O
increase	NOUN	O	O
calcium	NOUN	O	B-PHYSICAL
absorption	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

DESIGN	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
dose-response	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
on	ADP	O	O
calcium	NOUN	O	O
absorption	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

Seventy-six	NUM	O	O
healthy	ADJ	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
800	NUM	O	O
IU	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
?g	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2000	NUM	O	O
IU	NOUN	O	O
(	PUNCT	O	O
50	ADP	O	O
?g	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
4000	NUM	O	O
IU	NOUN	O	O
(	PUNCT	O	O
100	ADP	O	O
?g	PUNCT	O	O
)	PUNCT	O	O
vitamin	NOUN	O	O
D?	CCONJ	O	O
for	ADP	O	O
8	NUM	O	O
wk	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
technique	NOUN	O	O
of	ADP	O	O
dual	ADJ	O	O
isotopes	NOUN	O	O
of	ADP	O	O
stable	ADJ	O	O
calcium	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
with	ADP	O	O
a	DET	O	O
calcium	NOUN	O	O
carrier	NOUN	O	O
to	PART	O	O
measure	VERB	O	O
calcium	NOUN	O	O
absorption	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
8	NUM	O	O
wk	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Seventy-one	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
?	PUNCT	O	O

SD	NOUN	O	O
age	NOUN	O	O
of	ADP	O	O
58.8	NUM	O	O
?	PUNCT	O	O

4.9	NUM	O	O
y	NOUN	O	O
completed	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
calcium	NOUN	O	O
intake	NOUN	O	O
was	VERB	O	O
1142	NUM	O	O
?	PUNCT	O	O

509	NUM	O	O
mg/d	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
25	NUM	O	O
(	PUNCT	O	O
OH	NOUN	O	O
)	PUNCT	O	O
D	NOUN	O	O
was	VERB	O	O
63	NUM	O	O
?	PUNCT	O	O

14	NUM	O	O
nmol/L	ADJ	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
linear	ADJ	O	O
trend	NOUN	O	O
of	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
calcium	NOUN	O	O
absorption	NOUN	O	O
adjusted	PUNCT	O	O
for	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
with	ADP	O	O
increasing	ADJ	O	O
vitamin	NOUN	O	O
D?	PUNCT	O	O
dose	NOUN	O	O
or	CCONJ	O	O
serum	NOUN	O	O
25	NUM	O	O
(	PUNCT	O	O
OH	NOUN	O	O
)	PUNCT	O	O
D	NOUN	O	O
concentration	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
6.7	NUM	O	O
%	SYM	O	O
absolute	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
calcium	NOUN	O	O
absorption	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
highest	PUNCT	O	O
vitamin	NOUN	O	O
D?	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
100	ADP	O	O
?g	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
nonlinearity	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
dose-response	NOUN	O	O
curve	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
No	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
threshold	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	O
absorption	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
with	ADP	O	O
a	DET	O	O
serum	NOUN	O	O
25	NUM	O	O
(	PUNCT	O	O
OH	NOUN	O	O
)	PUNCT	O	O
D	NOUN	O	O
range	NOUN	O	O
from	ADP	O	O
40	NUM	O	O
to	ADP	O	O
130	NUM	O	O
nmol/L	ADJ	O	O
.	PUNCT	O	O

Calcium	NOUN	O	O
absorption	NOUN	O	O
in	ADP	O	O
this	DET	O	O
range	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
a	PUNCT	O	O
useful	ADJ	O	O
biomarker	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
nutritional	ADJ	O	O
recommendations	NOUN	O	O
for	ADP	O	O
vitamin	NOUN	O	O
D	NOUN	O	O
.	PUNCT	O	O

Impact	NOUN	O	O
of	ADP	O	O
a	DET	O	O
16-community	NOUN	O	O
trial	NOUN	O	O
to	ADJ	O	O
promote	NOUN	O	O
judicious	ADJ	O	O
antibiotic	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
Massachusetts	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Reducing	PUNCT	O	O
unnecessary	ADJ	O	O
antibiotic	ADJ	O	O
use	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
among	ADP	O	O
children	NOUN	O	O
,	PUNCT	O	O
continues	VERB	O	O
to	DET	O	O
be	PUNCT	O	O
a	DET	O	O
public	ADJ	O	O
health	NOUN	O	O
priority	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
intervention	NOUN	O	O
studies	NOUN	O	O
have	NOUN	O	O
been	PUNCT	O	O
limited	VERB	O	O
by	ADP	O	O
size	NOUN	O	O
or	CCONJ	O	O
design	NOUN	O	O
and	CCONJ	O	O
have	PUNCT	O	O
shown	VERB	O	O
mixed	VERB	O	O
results	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
a	DET	O	O
multifaceted	ADP	O	O
,	PUNCT	O	O
community-wide	NOUN	O	O
intervention	NOUN	O	O
on	ADP	O	O
overall	PUNCT	O	O
antibiotic	ADJ	O	O
use	NOUN	O	O
for	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
broad-spectrum	NOUN	O	O
agents	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
intervention	NOUN	O	O
's	PUNCT	O	O
impact	NOUN	O	O
on	ADP	O	O
commercially	ADV	O	O
and	CCONJ	O	O
Medicaid-insured	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
controlled	VERB	O	O
,	PUNCT	O	O
community-level	PUNCT	O	O
,	PUNCT	O	O
cluster-randomized	ADP	O	O
trial	NOUN	O	O
in	ADP	O	O
16	NUM	O	O
nonoverlapping	ADV	O	O
Massachusetts	NOUN	O	O
communities	NOUN	O	O
,	PUNCT	O	O
studied	VERB	O	O
from	ADP	O	O
1998	NUM	O	O
to	ADP	O	O
2003	NUM	O	O
.	PUNCT	O	O

During	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
implemented	VERB	O	O
a	DET	O	O
physician	NOUN	O	O
behavior-change	NOUN	O	O
strategy	NOUN	O	O
that	ADP	O	O
included	VERB	O	O
guideline	NOUN	O	O
dissemination	NOUN	O	O
,	PUNCT	O	O
small-group	NOUN	O	O
education	NOUN	O	O
,	PUNCT	O	O
frequent	ADJ	O	O
updates	NOUN	O	O
and	CCONJ	O	O
educational	ADJ	O	O
materials	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prescribing	ADJ	O	O
feedback	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
received	VERB	O	O
educational	ADJ	O	O
materials	NOUN	O	O
by	ADP	O	O
mail	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
practices	PROPN	O	O
,	PUNCT	O	O
pharmacies	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
child	NOUN	O	O
care	NOUN	O	O
settings	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
health-plan	NOUN	O	O
data	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
measured	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
antibiotics	NOUN	O	O
dispensed	VERB	O	O
per	ADP	O	O
person-year	ADJ	O	O
of	ADP	O	O
observation	NOUN	O	O
among	ADP	O	O
children	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
aged	VERB	O	O
3	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
72	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
resided	VERB	O	O
in	ADP	O	O
study	VERB	O	O
communities	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
insured	NOUN	O	O
by	ADP	O	O
a	DET	O	O
participating	PUNCT	O	O
commercial	ADJ	O	O
health	NOUN	O	O
plan	NOUN	O	O
or	CCONJ	O	O
Medicaid	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
data	NOUN	O	O
include	VERB	O	O
223,135	NUM	O	O
person-years	NOUN	O	O
of	ADP	O	O
observation	NOUN	O	O
.	PUNCT	O	O

Antibiotic-use	NUM	O	B-MENTAL
rates	NOUN	O	I-MENTAL
at	ADP	O	O
baseline	NOUN	O	O
were	VERB	O	O
2.8	NUM	O	O
,	PUNCT	O	O
1.7	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.4	NUM	O	O
antibiotics	NOUN	O	O
per	ADP	O	O
person-year	ADJ	O	O
among	ADP	O	O
those	PUNCT	O	O
aged	VERB	O	O
3	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
24	NUM	O	O
,	PUNCT	O	O
24	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
48	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
48	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
72	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
a	DET	O	O
substantial	ADJ	O	O
downward	ADJ	O	O
trend	NOUN	O	O
in	ADP	O	O
antibiotic	ADJ	O	B-MENTAL
prescribing	VERB	O	I-MENTAL
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
additional	ADJ	O	O
effect	NOUN	O	O
among	ADP	O	O
children	ADJ	O	O
aged	PROPN	O	O
3	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
but	CCONJ	O	O
was	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
a	DET	O	O
4.2	ADV	O	O
%	ADV	O	O
decrease	NOUN	O	O
among	ADP	O	O
those	PUNCT	O	O
aged	PUNCT	O	O
24	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
48	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
6.7	NUM	O	O
%	ADV	O	O
decrease	NOUN	O	O
among	ADP	O	O
those	PUNCT	O	O
aged	PROPN	O	O
48	NUM	O	O
to	PUNCT	O	O
<	ADP	O	O
72	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
greater	PUNCT	O	O
among	ADP	O	O
Medicaid-insured	VERB	O	O
children	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
broad-spectrum	NOUN	O	O
agents	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
A	CCONJ	O	O
sustained	VERB	O	O
,	PUNCT	O	O
multifaceted	PUNCT	O	O
,	PUNCT	O	O
community-level	PUNCT	O	O
intervention	NOUN	O	O
was	VERB	O	O
only	ADV	O	O
modestly	ADV	O	O
successful	ADJ	O	O
at	ADP	O	O
decreasing	ADP	O	O
overall	ADJ	O	B-MENTAL
antibiotic	ADJ	O	I-MENTAL
use	NOUN	O	I-MENTAL
beyond	ADP	O	O
substantial	ADJ	O	O
secular	ADJ	O	O
trends	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
more	ADV	O	O
robust	ADJ	O	O
impact	NOUN	O	O
among	ADP	O	O
Medicaid-insured	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
specific	ADJ	O	O
medication	NOUN	O	O
classes	NOUN	O	O
provides	NOUN	O	O
an	DET	O	O
argument	NOUN	O	O
for	ADP	O	O
specific	ADJ	O	O
targeting	VERB	O	O
of	ADP	O	O
resources	NOUN	O	O
for	ADP	O	O
patient	NOUN	O	O
and	CCONJ	O	O
physician	NOUN	O	O
behavior	NOUN	O	O
change	NOUN	O	O
.	PUNCT	O	O

Comparative	ADJ	O	B-OTHER
effectiveness	NOUN	O	I-OTHER
of	ADP	O	O
exercise	NOUN	O	O
electrocardiography	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
myocardial	ADJ	O	O
perfusion	NOUN	O	O
single	ADJ	O	O
photon	ADP	O	O
emission	NOUN	O	O
computed	VERB	O	O
tomography	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
:	PUNCT	O	O
results	DET	O	O
from	ADP	O	O
the	DET	O	O
What	PUNCT	O	O
Is	CCONJ	O	O
the	PUNCT	O	O
Optimal	ADJ	O	O
Method	NOUN	O	O
for	ADP	O	O
Ischemia	NOUN	O	O
Evaluation	NOUN	O	O
in	ADP	O	O
Women	NOUN	O	O
(	PUNCT	O	O
WOMEN	PUNCT	O	O
)	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
There	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
paucity	NOUN	O	O
of	ADP	O	O
randomized	VERB	O	O
trials	NOUN	O	O
regarding	VERB	O	O
diagnostic	ADJ	O	O
testing	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
(	PUNCT	O	O
CAD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
remains	NOUN	O	O
unclear	ADJ	O	O
whether	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
perfusion	NOUN	O	O
imaging	VERB	O	O
(	PUNCT	O	O
MPI	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
ECG	NOUN	O	O
exercise	NOUN	O	O
treadmill	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
ETT	NOUN	O	O
)	PUNCT	O	O
provides	NOUN	O	O
incremental	ADJ	O	O
information	NOUN	O	O
to	PART	O	O
improve	ADJ	O	O
clinical	ADJ	O	O
decision	NOUN	O	O
making	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
CAD	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
We	PRON	O	O
randomized	ADV	O	O
symptomatic	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
CAD	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
interpretable	ADJ	O	O
ECG	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
?5	PUNCT	O	O
metabolic	ADJ	O	O
equivalents	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Duke	NOUN	O	O
Activity	NOUN	O	O
Status	NOUN	O	O
Index	NOUN	O	O
to	ADP	O	O
1	PUNCT	O	O
of	ADP	O	O
2	NUM	O	O
diagnostic	ADJ	O	O
strategies	NOUN	O	O
:	PUNCT	O	O
ETT	NOUN	O	O
or	CCONJ	O	O
exercise	NOUN	O	O
MPI	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
2-year	NOUN	O	O
incidence	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
adverse	ADJ	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
CAD	NOUN	O	O
death	NOUN	O	O
or	CCONJ	O	O
hospitalization	NOUN	O	O
for	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
coronary	ADJ	O	O
syndrome	NOUN	O	O
or	CCONJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
824	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
ETT	NOUN	O	O
or	CCONJ	O	O
exercise	NOUN	O	O
MPI	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
women	NOUN	O	O
randomized	ADP	O	O
to	ADP	O	O
ETT	NOUN	O	O
,	PUNCT	O	O
ECG	NOUN	O	O
results	CCONJ	O	O
were	VERB	O	O
normal	ADJ	O	O
in	ADP	O	O
64	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
indeterminate	ADJ	O	O
in	ADP	O	O
16	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
abnormal	ADJ	O	O
in	ADP	O	O
20	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

By	ADP	O	O
comparison	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
exercise	NOUN	O	O
MPI	NOUN	O	O
results	CCONJ	O	O
were	VERB	O	O
normal	ADJ	O	O
in	ADP	O	O
91	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
mildly	ADV	O	O
abnormal	ADJ	O	O
in	ADP	O	O
3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
moderate	ADJ	O	O
to	ADP	O	O
severely	ADV	O	O
abnormal	ADJ	O	O
in	ADP	O	O
6	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

At	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
major	ADJ	O	O
adverse	ADJ	O	O
cardiac	ADJ	O	O
events	NOUN	O	O
(	PUNCT	O	O
98.0	NUM	O	O
%	SYM	O	O
for	ADP	O	O
ETT	NOUN	O	O
and	CCONJ	O	O
97.7	NUM	O	O
%	SYM	O	O
for	ADP	O	O
MPI	NOUN	O	O
;	PUNCT	O	O
P=0.59	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
ETT	NOUN	O	O
,	PUNCT	O	O
index	NOUN	O	O
testing	PUNCT	O	O
costs	NOUN	O	O
were	VERB	O	O
higher	PUNCT	O	O
for	ADP	O	O
exercise	NOUN	O	O
MPI	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
downstream	ADJ	O	O
procedural	ADJ	O	O
costs	NOUN	O	O
were	VERB	O	O
slightly	ADV	O	O
lower	PUNCT	O	O
(	PUNCT	O	O
P=0.0008	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
cumulative	ADJ	O	O
diagnostic	ADJ	O	O
cost	NOUN	O	O
savings	NOUN	O	O
was	VERB	O	O
48	NUM	O	O
%	SYM	O	O
for	ADP	O	O
ETT	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
exercise	NOUN	O	O
MPI	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
low-risk	NOUN	O	O
,	PUNCT	O	O
exercising	PUNCT	O	O
women	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
diagnostic	ADJ	O	O
strategy	NOUN	O	O
that	ADP	O	O
uses	VERB	O	O
ETT	NOUN	O	O
versus	CCONJ	O	O
exercise	NOUN	O	O
MPI	NOUN	O	O
yields	ADJ	O	O
similar	ADJ	O	O
2-year	NOUN	O	O
posttest	ADV	O	O
outcomes	NOUN	O	O
while	ADP	O	O
providing	VERB	O	O
significant	ADJ	O	O
diagnostic	ADJ	O	O
cost	NOUN	O	O
savings	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ETT	NOUN	O	O
with	ADP	O	O
selective	ADJ	O	O
follow-up	NOUN	O	O
testing	VERB	O	O
should	SYM	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
diagnostic	ADJ	O	O
strategy	NOUN	O	O
in	ADP	O	O
symptomatic	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
CAD	NOUN	O	O
.	PUNCT	O	O

CLINICAL	ADJ	O	O
TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
http	PUNCT	O	O
:	PUNCT	O	O
//www.clinicaltrials.gov	PUNCT	O	O
.	PUNCT	O	O

Unique	ADJ	O	O
identifier	NOUN	O	O
:	PUNCT	O	O
NCT00282711	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
lisinopril	NOUN	O	O
and	CCONJ	O	O
nifedipine	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
multicentre	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Lisinopril	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
slow-release	NOUN	O	O
nifedipine	NOUN	O	O
in	ADP	O	O
a	DET	O	O
16-week	NOUN	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
study	NOUN	O	O
involving	VERB	O	O
102	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Sitting	ADP	O	B-PHYSICAL
systolic	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
diastolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressures	NOUN	O	I-PHYSICAL
were	VERB	O	O
reduced	VERB	O	O
6	NUM	O	O
and	CCONJ	O	O
5	NUM	O	O
mmHg	NOUN	O	O
more	ADV	O	O
by	ADP	O	O
lisinopril	NOUN	O	O
than	PUNCT	O	O
by	ADP	O	O
nifedipine	NOUN	O	O
over	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
monotherapy	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
a	DET	O	O
greater	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
taking	PUNCT	O	O
lisinopril	NOUN	O	O
was	VERB	O	O
controlled	VERB	O	O
(	PUNCT	O	O
sitting	PUNCT	O	O
diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
below	ADP	O	O
95	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
those	PUNCT	O	O
taking	ADJ	O	O
nifedipine	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
,	PUNCT	O	O
17	NUM	O	O
%	DET	O	O
of	ADP	O	O
those	PUNCT	O	O
taking	PUNCT	O	O
lisinopril	NOUN	O	O
and	CCONJ	O	O
38	NUM	O	O
%	SYM	O	O
of	ADP	O	O
those	PUNCT	O	O
taking	ADJ	O	O
nifedipine	NOUN	O	O
required	PUNCT	O	O
additional	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
hydrochlorothiazide	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
hydrochlorothiazide	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
similar	ADJ	O	B-OTHER
response	NOUN	O	O
rates	NOUN	O	B-OTHER
in	ADP	O	O
the	DET	O	O
lisinopril	NOUN	O	O
and	CCONJ	O	O
nifedipine	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
89	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
75	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
reporting	VERB	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	B-ADVERSE-EFFECTS
considered	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
drug-related	ADV	O	O
and	CCONJ	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
withdrawals	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
both	PUNCT	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Cough	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
more	ADV	O	O
often	ADV	O	O
reported	VERB	O	O
with	ADP	O	O
lisinopril	NOUN	O	O
and	CCONJ	O	O
headache	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
sweating	VERB	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
and	PUNCT	O	O

A	DET	O	O
good	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
oil	NOUN	O	O
with	ADP	O	O
medium-	NOUN	O	O
and	CCONJ	O	O
long-chain	NOUN	O	O
fatty	ADJ	O	O
acids	NOUN	O	O
in	ADP	O	O
body	NOUN	O	B-PHYSICAL
fat	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
profiles	NOUN	O	I-PHYSICAL
of	ADP	O	O
male	NOUN	O	O
hypertriglyceridemic	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

A	ADP	O	O
double	ADJ	O	O
blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
to	PART	O	O
clarify	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
oil	NOUN	O	O
with	ADP	O	O
medium-	NOUN	O	O
and	CCONJ	O	O
long-chain	NOUN	O	O
triglyceride	NOUN	O	O
(	PUNCT	O	O
MLCT	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
body	NOUN	O	B-PHYSICAL
fat	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
profiles	NOUN	O	I-PHYSICAL
in	ADP	O	O
hypertriglyceridemic	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

One-hundred-and-twelve	PUNCT	O	O
subjects	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
and	CCONJ	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
;	PUNCT	O	O
those	ADP	O	O
that	PUNCT	O	O
consumed	PUNCT	O	O
MLCT	NOUN	O	O
oil	NOUN	O	O
and	CCONJ	O	O
those	PUNCT	O	O
that	PUNCT	O	O
consumed	PUNCT	O	O
long-chain	NOUN	O	O
triglyceride	NOUN	O	O
(	PUNCT	O	O
LCT	NOUN	O	O
)	PUNCT	O	O
oil	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
subjects	NOUN	O	O
were	VERB	O	O
requested	VERB	O	O
to	ADP	O	O
consume	ADJ	O	O
25-30	DET	O	O
g	NOUN	O	O
of	ADP	O	O
the	DET	O	O
oils	NOUN	O	O
daily	ADJ	O	O
and	CCONJ	O	O
maintain	ADJ	O	O
a	DET	O	O
fixed	VERB	O	O
level	NOUN	O	O
of	ADP	O	O
energy	NOUN	O	O
intake	NOUN	O	O
and	CCONJ	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Anthropometric	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
biochemical	ADJ	O	I-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
when	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
and	CCONJ	O	O
completed	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
LCT	NOUN	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
50	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
34	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
16	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
MLCT	NOUN	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
51	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
33	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
18	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
who	ADP	O	O
completed	PROPN	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Larger	PUNCT	O	O
decreases	CCONJ	O	O
in	ADP	O	O
body	NOUN	O	B-PHYSICAL
weight	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	B-PHYSICAL
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
waist	NOUN	O	O
circumference	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	B-PHYSICAL
fat	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
fat	NOUN	O	O
area	NOUN	O	O
and	CCONJ	O	O
subcutaneous	ADJ	O	O
fat	NOUN	O	O
area	NOUN	O	O
in	ADP	O	O
the	DET	O	O
abdomen	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
triglycerides	NOUN	O	O
,	PUNCT	O	O
low-density	NOUN	O	O
lipoprotein	NOUN	O	O
cholesterol	NOUN	O	O
,	PUNCT	O	O
apolipoprotein	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
C2	NOUN	O	O
,	PUNCT	O	O
C3	NOUN	O	O
and	CCONJ	O	O
E	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
male	NOUN	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MLCT	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
LCT	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
these	DET	O	O
parameters	NOUN	O	B-OTHER
between	ADP	O	O
the	DET	O	O
female	NOUN	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
from	ADP	O	O
this	DET	O	O
study	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
consumption	NOUN	O	O
of	ADP	O	O
medium-and	PUNCT	O	O
long-chain	NOUN	O	O
triglycerides	NOUN	O	O
can	VERB	O	O
reduce	VERB	O	O
body	NOUN	O	B-PHYSICAL
weight	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
body	PUNCT	O	B-PHYSICAL

Teaching	ADJ	O	O
young	VERB	O	O
nonverbal	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
useful	ADJ	O	O
speech	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Denver	NOUN	O	O
Model	NOUN	O	O
and	CCONJ	O	O
PROMPT	NOUN	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
single	ADJ	O	O
subject	NOUN	O	O
design	NOUN	O	O
study	NOUN	O	O
examined	VERB	O	O
two	NUM	O	O
models	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
:	PUNCT	O	O
Denver	NOUN	O	O
Model	NOUN	O	O
(	PUNCT	O	O
which	ADP	O	O
merges	PUNCT	O	O
behavioral	ADJ	O	O
,	PUNCT	O	O
developmental	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
relationship-oriented	VERB	O	O
intervention	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
PROMPT	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
neuro-developmental	ADJ	O	O
approach	NOUN	O	O
for	ADP	O	O
speech	NOUN	O	O
production	NOUN	O	O
disorders	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ten	NUM	O	O
young	ADJ	O	O
,	PUNCT	O	O
nonverbal	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
were	VERB	O	O
matched	VERB	O	O
in	ADP	O	O
pairs	NOUN	O	O
and	CCONJ	O	O
randomized	PUNCT	O	O
to	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
received	ADP	O	O
12	NUM	O	O
1-h	NOUN	O	O
weekly	ADV	O	O
sessions	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
daily	ADJ	O	O
1-h	NOUN	O	O
home	NOUN	O	O
intervention	NOUN	O	O
delivered	VERB	O	O
by	ADP	O	O
parents	NOUN	O	O
.	PUNCT	O	O

Fidelity	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
maintained	VERB	O	O
throughout	PUNCT	O	O
.	PUNCT	O	O

Eight	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
ten	NUM	O	O
children	NOUN	O	O
used	ADJ	O	O
five	ADP	O	O
or	CCONJ	O	O
more	DET	O	O
novel	ADJ	O	O
,	PUNCT	O	O
functional	ADJ	O	B-MENTAL
words	NOUN	O	O
spontaneously	ADV	O	O
and	CCONJ	O	O
spoke	PROPN	O	O
multiple	ADJ	O	O
times	NOUN	O	O
per	ADP	O	O
hour	NOUN	O	O
by	ADP	O	O
the	DET	O	O
conclusion	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
acquired	VERB	O	B-MENTAL
language	NOUN	O	I-MENTAL
skills	NOUN	O	I-MENTAL
by	ADP	O	O
intervention	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Initial	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
best	PUNCT	O	O
responders	NOUN	O	O
were	VERB	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
better	PUNCT	O	O
motor	NOUN	O	O
imitation	NOUN	O	O
skills	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
emerging	VERB	O	O
joint	NOUN	O	O
attention	NOUN	O	O
skills	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
imidapril	NOUN	O	O
in	ADP	O	O
congestive	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
EFFIC	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
imidapril	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
dogs	NOUN	O	O
that	PUNCT	O	O
presented	VERB	O	O
with	ADP	O	O
mild	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
congestive	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
New	ADJ	O	O
York	NOUN	O	O
Heart	NOUN	O	O
Association	NOUN	O	O
stage	NOUN	O	O
II	NUM	O	O
to	ADP	O	O
IV	NUM	O	O
)	PUNCT	O	O
by	ADP	O	O
comparing	DET	O	O
the	DET	O	O
success	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
imidapril	NOUN	O	O
with	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
control	NOUN	O	O
by	ADP	O	O
a	DET	O	O
non-inferiority	NOUN	O	O
approach	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	CCONJ	O	O
good	ADJ	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
compliant	NOUN	O	O
,	PUNCT	O	O
multicentre	NOUN	O	O
study	NOUN	O	O
(	PUNCT	O	O
EFFIC	NOUN	O	O
study	NOUN	O	O
)	PUNCT	O	O
enrolled	VERB	O	O
142	NUM	O	O
client-owned	VERB	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
20	NUM	O	O
locations	NOUN	O	O
in	ADP	O	O
France	NOUN	O	O
,	PUNCT	O	O
Belgium	NOUN	O	O
and	CCONJ	O	O
Germany	PUNCT	O	O
.	PUNCT	O	O

Dogs	NOUN	O	O
of	ADP	O	O
various	ADJ	O	O
breed	PUNCT	O	O
,	PUNCT	O	O
age	NOUN	O	O
and	CCONJ	O	O
weight	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
dogs	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
that	NUM	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
84	NUM	O	O
days	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
test	ADV	O	O
product	NOUN	O	O
,	PUNCT	O	O
imidapril	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
positive	ADJ	O	O
control	NOUN	O	O
,	PUNCT	O	O
benazepril	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
followed	VERB	O	O
up	PUNCT	O	O
in	ADP	O	O
parallel	ADJ	O	O
over	ADP	O	O
this	DET	O	O
period	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
treatments	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.25	NUM	O	O
mg/kg	NOUN	O	O
once	PUNCT	O	O
a	DET	O	O
day	NOUN	O	O
with	ADP	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
doubling	PUNCT	O	O
this	DET	O	O
dose	NOUN	O	O
to	ADP	O	O
0.5	NUM	O	O
mg/kg	NOUN	O	O
if	PUNCT	O	O
considered	PUNCT	O	O
necessary	ADJ	O	O
from	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
point	NOUN	O	O
of	ADP	O	O
view	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
concomitant	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
dogs	NOUN	O	O
presenting	VERB	O	O
with	ADP	O	O
pulmonary	ADJ	O	O
oedema	NOUN	O	O
and/or	CCONJ	O	O
ascites	VERB	O	O
,	PUNCT	O	O
supraventricular	ADP	O	O
tachyarrhythmia	NOUN	O	O
and/or	CCONJ	O	O
dilated	VERB	O	O
cardiomyopathy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
evolution	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
New	ADJ	O	I-PHYSICAL
York	NOUN	O	I-PHYSICAL
Heart	NOUN	O	I-PHYSICAL
Association	NOUN	O	O
stage	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
functional	ADJ	O	B-PHYSICAL
signs	NOUN	O	I-PHYSICAL
score	NOUN	O	B-PHYSICAL
were	VERB	O	O
evaluated	VERB	O	O
as	ADP	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
imidapril	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
66	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
68	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
in	ADP	O	O
the	DET	O	O
benazepril	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Regarding	PUNCT	O	O
safety	NOUN	O	O
,	PUNCT	O	O
35	NUM	O	O
dogs	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
experienced	PUNCT	O	O
at	ADP	O	O
least	ADV	O	O
one	NUM	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
event	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
dogs	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
experienced	PUNCT	O	O
at	ADP	O	O
least	ADV	O	O
one	NUM	O	O
serious	PUNCT	O	B-ADVERSE-EFFECTS

Breast	NOUN	O	O
reduction	NOUN	O	O
alleviates	ADJ	O	O
depression	NOUN	O	B-MENTAL
and	CCONJ	O	O
anxiety	NOUN	O	B-MENTAL
and	CCONJ	O	O
restores	VERB	O	O
self-esteem	CCONJ	O	B-MENTAL
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
women	NOUN	O	O
who	ADP	O	O
seek	VERB	O	O
reduction	NOUN	O	O
mammaplasty	NOUN	O	O
,	PUNCT	O	O
up	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
third	PUNCT	O	O
have	PUNCT	O	O
pathological	ADJ	O	O
degrees	PUNCT	O	O
of	ADP	O	O
anxiety	NOUN	O	B-MENTAL
or	CCONJ	O	O
depression	NOUN	O	B-MENTAL
,	PUNCT	O	O
or	CCONJ	O	O
both	CCONJ	O	O
.	PUNCT	O	O

The	DET	O	O
psychological	ADJ	O	B-MENTAL
aspect	NOUN	O	I-MENTAL
of	ADP	O	O
reduction	NOUN	O	O
mammaplasty	NOUN	O	O
is	VERB	O	O
therefore	ADV	O	O
an	DET	O	O
important	ADJ	O	O
consideration	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
did	CCONJ	O	O
a	DET	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
see	NOUN	O	O
how	ADP	O	O
reduction	NOUN	O	O
mammaplasty	NOUN	O	O
affected	VERB	O	O
macromastia	NOUN	O	O
patients	NOUN	O	O
'	PUNCT	O	O
depression	NOUN	O	B-MENTAL
,	PUNCT	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
self-esteem	CCONJ	O	B-MENTAL
.	PUNCT	O	O

Eighty-two	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	NUM	O	O
,	PUNCT	O	O
40	DET	O	O
to	ADP	O	O
have	PUNCT	O	O
the	DET	O	O
operation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
42	NUM	O	O
patients	NOUN	O	O
to	ADP	O	O
conservative	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
completed	VERB	O	O
the	DET	O	O
RBDI	NOUN	O	B-MENTAL
questionnaire	NOUN	O	O
(	PUNCT	O	B-MENTAL
Raitasalo	NOUN	O	I-MENTAL
's	PUNCT	O	O
modification	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
short	ADJ	O	I-MENTAL
form	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
Beck	NOUN	O	I-MENTAL
Depression	NOUN	O	I-MENTAL
Inventory	PUNCT	O	I-MENTAL
)	PUNCT	O	B-MENTAL
.	PUNCT	O	O

Twenty-nine	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
operated	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
35	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
conservative	ADJ	O	O
group	NOUN	O	O
completed	VERB	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
second	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
been	PUNCT	O	O
operated	VERB	O	O
on	ADP	O	O
,	PUNCT	O	O
had	PUNCT	O	O
significantly	ADV	O	O
less	DET	O	O
depression	NOUN	O	B-MENTAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
better	PUNCT	O	B-MENTAL
self-esteem	CCONJ	O	B-MENTAL
(	PUNCT	O	O
p=0.03	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
conservative	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
proportions	NOUN	O	O
of	ADP	O	O
depressed	PUNCT	O	B-MENTAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
anxious	ADJ	O	B-MENTAL
(	PUNCT	O	O
p=0.04	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
smaller	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
operated	VERB	O	O
on	ADP	O	O
.	PUNCT	O	O

There	PUNCT	O	O
is	VERB	O	O
significantly	ADV	O	O
less	DET	O	O
depression	NOUN	O	B-MENTAL
and	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
ketoconazole	NOUN	O	O
and	CCONJ	O	O
griseofulvin	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
tinea	NOUN	O	O
pedis	PUNCT	O	O
.	PUNCT	O	O

Twenty-nine	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mycologically	ADJ	O	O
proven	VERB	O	O
tinea	NOUN	O	O
pedis	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
oral	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
either	PUNCT	O	O
ketoconazole	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
or	CCONJ	O	O
griseofulvin	NOUN	O	O
1	NUM	O	O
g	ADP	O	O
daily	ADJ	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
up	PUNCT	O	O
to	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Mycological	ADJ	O	B-OTHER
cure	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
at	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
33	NUM	O	O
%	SYM	O	O
for	ADP	O	O
ketoconazole	NOUN	O	O
and	CCONJ	O	O
29	NUM	O	O
%	SYM	O	O
for	ADP	O	O
griseofulvin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
53	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
57	NUM	O	O
%	SYM	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
both	PUNCT	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
interdigital	ADJ	O	O
tinea	NOUN	O	O
pedis	ADP	O	O
is	SYM	O	O
similar	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
is	VERB	O	O
considerably	ADV	O	O
lower	PUNCT	O	O
than	CCONJ	O	O
that	PUNCT	O	O
found	VERB	O	O
with	ADP	O	O
topical	ADJ	O	O
imidazole	PUNCT	O	O
preparations	NOUN	O	O
where	ADP	O	O
cure	PUNCT	O	B-OTHER
rates	NOUN	O	I-OTHER
of	ADP	O	O
over	PUNCT	O	O
70	NUM	O	O
%	PUNCT	O	O
are	VERB	O	O
generally	ADV	O	O
expected	VERB	O	O
.	PUNCT	O	O

Bizzy	ADV	O	O
Break	NOUN	O	O
!	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
classroom-based	VERB	O	O
activity	NOUN	O	O
break	NOUN	O	O
on	ADP	O	O
in-school	PUNCT	O	B-MENTAL
physical	ADJ	O	I-MENTAL
activity	NOUN	O	I-MENTAL
levels	NOUN	O	I-MENTAL
of	ADP	O	O
primary	ADJ	O	O
school	NOUN	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
school	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
identified	VERB	O	O
as	ADP	O	O
a	DET	O	O
key	ADJ	O	O
setting	VERB	O	O
to	PART	O	O
promote	PUNCT	O	O
physical	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
classroom-based	VERB	O	O
activity	NOUN	O	O
break	NOUN	O	O
on	ADP	O	O
in-school	PUNCT	O	B-MENTAL
step	NOUN	O	I-MENTAL
counts	NOUN	O	I-MENTAL
of	ADP	O	O
primary	ADJ	O	O
school	NOUN	O	O
children	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
for	ADP	O	O
90	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
49	NUM	O	O
boys	NOUN	O	O
,	PUNCT	O	O
41	NUM	O	O
girls	NOUN	O	O
,	PUNCT	O	O
9.3	NUM	O	O
?	PUNCT	O	O

1.4	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
from	ADP	O	O
three	NUM	O	O
Irish	NOUN	O	O
primary	ADJ	O	O
schools	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
each	DET	O	O
school	NOUN	O	O
one	NUM	O	O
class	NOUN	O	O
was	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
as	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
another	PUNCT	O	O
as	PUNCT	O	O
controls	VERB	O	O
.	PUNCT	O	O

Children	PROPN	O	O
's	PUNCT	O	O
step	NOUN	O	O
counts	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
for	ADP	O	O
five	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
during	ADP	O	O
school	NOUN	O	O
hours	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Teachers	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
classes	NOUN	O	O
led	VERB	O	O
a	DET	O	O
10	NUM	O	O
min	NOUN	O	O
activity	NOUN	O	O
break	NOUN	O	O
in	ADP	O	O
the	DET	O	O
classroom	PUNCT	O	O
each	PUNCT	O	O
day	NOUN	O	O
(	PUNCT	O	O
Bizzy	NOUN	O	O
Break	NOUN	O	O
!	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
daily	ADJ	O	O
in-school	ADJ	O	O
steps	NOUN	O	O
for	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
were	VERB	O	O
5351	NUM	O	O
and	CCONJ	O	O
5054	NUM	O	O
.	PUNCT	O	O

Corresponding	VERB	O	O
values	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
5469	NUM	O	O
and	CCONJ	O	O
4246	NUM	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
daily	ADJ	O	O
steps	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
follow-up	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
girls	NOUN	O	O
and	CCONJ	O	O
boys	NOUN	O	O
responded	VERB	O	O
differently	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Children	NOUN	O	O
participating	VERB	O	O
in	ADP	O	O
a	DET	O	O
daily	ADJ	O	O
10	NUM	O	O
min	NOUN	O	O
classroom-based	NOUN	O	O
activity	NOUN	O	O
break	NOUN	O	O
undertake	VERB	O	O
more	DET	O	O
physical	ADJ	O	O
activity	NOUN	O	O
during	ADP	O	O
school	NOUN	O	O
hours	NOUN	O	O
than	CCONJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Cost-effectiveness	NOUN	O	B-OTHER
of	ADP	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
including	PUNCT	O	O
PST	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
antidepressant	NOUN	O	O
treatment	NOUN	O	O
algorithm	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Depressive	ADJ	O	O
disorder	NOUN	O	O
is	VERB	O	O
currently	ADV	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
burdensome	ADJ	O	O
disorders	NOUN	O	O
worldwide	ADJ	O	O
.	PUNCT	O	O

Evidence-based	ADJ	O	O
treatments	NOUN	O	O
for	ADP	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
are	VERB	O	O
already	ADV	O	O
available	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
these	PUNCT	O	O
are	VERB	O	O
used	VERB	O	O
insufficiently	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
less	ADV	O	O
positive	ADJ	O	O
results	PUNCT	O	O
than	VERB	O	O
possible	ADJ	O	O
.	PUNCT	O	O

Earlier	PUNCT	O	O
research	NOUN	O	O
in	ADP	O	O
the	DET	O	O
USA	PUNCT	O	O
has	PUNCT	O	O
shown	VERB	O	O
good	ADJ	O	O
results	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
a	DET	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
approach	NOUN	O	O
with	ADP	O	O
Problem	NOUN	O	B-PHYSICAL
Solving	PUNCT	O	I-PHYSICAL
Treatment	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
an	DET	O	O
antidepressant	NOUN	O	O
treatment	NOUN	O	O
algorithm	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
research	NOUN	O	O
in	ADP	O	O
the	DET	O	O
UK	NOUN	O	O
has	PUNCT	O	O
also	ADV	O	O
shown	VERB	O	O
good	ADJ	O	O
results	CCONJ	O	O
with	ADP	O	O
Problem	NOUN	O	O
Solving	PUNCT	O	O
Treatment	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
treatment	NOUN	O	O
strategies	NOUN	O	O
may	VERB	O	O
also	NOUN	O	O
work	NOUN	O	O
very	VERB	O	O
well	VERB	O	O
in	PUNCT	O	O
the	DET	O	O
Netherlands	NOUN	O	O
too	ADV	O	O
,	PUNCT	O	O
even	ADV	O	O
though	CCONJ	O	O
health	NOUN	O	O
care	NOUN	O	O
systems	NOUN	O	O
differ	VERB	O	O
between	ADP	O	O
countries	NOUN	O	O
.	PUNCT	O	O

METHODS/DESIGN	PUNCT	O	O
This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
two-armed	NOUN	O	O
randomised	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
randomization	NOUN	O	O
on	ADP	O	O
patient-level	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Netherlands	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
an	DET	O	O
adapted	VERB	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
framework	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
contracting	VERB	O	O
and	CCONJ	O	O
adherence-improving	ADJ	O	O
strategies	NOUN	O	O
,	PUNCT	O	O
combined	PUNCT	O	O
with	ADP	O	O
Problem	NOUN	O	O
Solving	PUNCT	O	O
Treatment	NOUN	O	O
and	CCONJ	O	O
antidepressant	NOUN	O	O
medication	NOUN	O	O
according	ADJ	O	O
to	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
algorithm	NOUN	O	O
.	PUNCT	O	O

Forty	CCONJ	O	O
general	ADJ	O	O
practices	NOUN	O	O
will	ADP	O	O
be	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Included	VERB	O	O
will	ADJ	O	O
be	DET	O	O
patients	NOUN	O	O
who	ADP	O	O
are	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
depression	NOUN	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
DSM-IV	NOUN	O	O
criteria	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
stratified	VERB	O	O
according	ADP	O	O
to	ADP	O	O
comorbid	ADJ	O	O
chronic	ADJ	O	O
physical	ADJ	O	O
illness	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
will	VERB	O	O
receive	VERB	O	O
treatment	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
approach	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
will	VERB	O	O
receive	VERB	O	O
care	NOUN	O	O
as	ADP	O	O
usual	ADJ	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
measurements	NOUN	O	O
and	CCONJ	O	O
follow	VERB	O	O
up	PUNCT	O	O
measures	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
assessed	VERB	O	O
using	PUNCT	O	O
questionnaires	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
interview	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	ADV	O	O
is	VERB	O	O
severity	NOUN	O	O
of	ADP	O	O
depressive	ADJ	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
,	PUNCT	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
PHQ9	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Secondary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
are	VERB	O	O
remission	NOUN	O	B-PHYSICAL
as	PUNCT	O	I-PHYSICAL
measured	VERB	O	I-PHYSICAL
with	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
PHQ9	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
IDS-SR	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
cost-effectiveness	NOUN	O	B-OTHER
measured	VERB	O	O
with	ADP	O	O
the	DET	O	O
TiC-P	NOUN	O	B-OTHER
,	PUNCT	O	O
the	DET	O	O
EQ-5D	NOUN	O	B-OTHER
and	CCONJ	O	O
the	DET	O	O
SF-36	NOUN	O	B-OTHER
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
American	ADJ	O	O
model	NOUN	O	O
to	PART	O	O
enhance	ADJ	O	O
care	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
collaborative	ADJ	O	O
care	NOUN	O	O
model	NOUN	O	O
,	PUNCT	O	O
will	VERB	O	O
be	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
effectiveness	NOUN	O	O
in	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
care	NOUN	O	O
setting	ADV	O	O
.	PUNCT	O	O

If	ADP	O	O
effective	ADJ	O	O
across	ADP	O	O
the	DET	O	O
Atlantic	ADJ	O	O
and	CCONJ	O	O
across	ADP	O	O
different	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
systems	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
also	ADV	O	O
likely	ADV	O	O
to	PART	O	O
be	PUNCT	O	O
an	DET	O	O
effective	ADJ	O	O
strategy	NOUN	O	O
to	VERB	O	O
implement	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Netherlands	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
controlled	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
psychiatric	ADJ	O	O
hospital	NOUN	O	O
versus	CCONJ	O	O
community	NOUN	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
relatives	NOUN	O	B-MENTAL
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
twenty	NUM	O	O
patients	NOUN	O	O
presenting	VERB	O	O
at	ADP	O	O
Macquarie	NOUN	O	O
Hospital	NOUN	O	O
for	ADP	O	O
admission	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
patients	NOUN	O	O
received	VERB	O	O
standard	ADJ	O	O
hospital	NOUN	O	O
care	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
project	NOUN	O	O
group	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
admitted	VERB	O	O
if	PUNCT	O	O
this	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
avoided	VERB	O	O
;	PUNCT	O	O
instead	ADP	O	O
they	PUNCT	O	O
were	VERB	O	O
taken	VERB	O	O
back	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
community	NOUN	O	O
by	ADP	O	O
the	DET	O	O
project	NOUN	O	O
team	NOUN	O	O
who	ADP	O	O
provided	VERB	O	O
them	ADP	O	O
and	CCONJ	O	O
their	ADJ	O	O
relatives	NOUN	O	O
with	ADP	O	O
comprehensive	ADJ	O	O
,	PUNCT	O	O
assertive	ADP	O	O
and	CCONJ	O	O
prolonged	VERB	O	O
follow-up	NOUN	O	O
treatment	NOUN	O	O
backed	PUNCT	O	O
by	ADP	O	O
a	DET	O	O
24-hour	NOUN	O	O
crisis	NOUN	O	O
service	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
majority	NOUN	O	O
(	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
project	NOUN	O	O
group	NOUN	O	O
had	VERB	O	O
no	DET	O	O
admission	NOUN	O	O
during	ADP	O	O
the	DET	O	O
10	NUM	O	O
month	NOUN	O	O
study	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Initially	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
burden	NOUN	O	B-MENTAL
on	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
relatives	NOUN	O	I-MENTAL
of	ADP	O	O
the	DET	O	O
project	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
higher	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
by	ADP	O	O
one	NUM	O	O
month	NOUN	O	O
it	PUNCT	O	O
was	ADP	O	O
somewhat	ADV	O	O
lower	VERB	O	O
and	CCONJ	O	O
by	ADP	O	O
four	NUM	O	O
months	NOUN	O	O
it	PRON	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
burden	NOUN	O	O
on	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
relatives	NOUN	O	O
.	PUNCT	O	O

Relatives	NOUN	O	O
of	ADP	O	O
the	DET	O	O
project	NOUN	O	O
group	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
satisfied	VERB	O	B-MENTAL
with	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
treatment	NOUN	O	I-MENTAL
than	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
relatives	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
clearly	ADV	O	O
feasible	ADJ	O	O
to	PART	O	O
treat	CCONJ	O	O
most	ADP	O	O
psychiatric	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
community	NOUN	O	O
without	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
burden	NOUN	O	B-MENTAL
on	ADP	O	I-MENTAL
their	ADP	O	I-MENTAL
relatives	NOUN	O	I-MENTAL
.	PUNCT	O	O

Tubeless	PUNCT	O	O
percutaneous	ADJ	O	O
nephrolithotomy	NOUN	O	O
:	PUNCT	O	O
safe	ADJ	O	O
even	ADV	O	O
in	ADP	O	O
supracostal	ADJ	O	O
access	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
outcome	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
tubeless	PUNCT	O	O
percutaneous	ADJ	O	O
nephrolithotomy	NOUN	O	O
(	PUNCT	O	O
PCNL	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
calculi	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Between	ADP	O	O
November	NOUN	O	O
2005	NUM	O	O
and	CCONJ	O	O
March	NOUN	O	O
2006	NUM	O	O
,	PUNCT	O	O
48	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
an	DET	O	O
18F	NOUN	O	O
Re-entry	NOUN	O	O
nephrostomy	NOUN	O	O
tube	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
6F	NOUN	O	O
Double-J	PUNCT	O	O
stent	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
well	VERB	O	O
matched	PUNCT	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
stone	NOUN	O	O
size	NOUN	O	O
,	PUNCT	O	O
stone	NOUN	O	O
laterality	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
number	NOUN	O	O
of	ADP	O	O
previous	ADJ	O	O
renal	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
PCNL	NOUN	O	O
procedures	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
by	ADP	O	O
the	DET	O	O
same	ADJ	O	O
surgeon	NOUN	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-PAIN
visual	ADJ	O	I-PAIN
analog	NOUN	O	I-PAIN
pain	NOUN	O	I-PAIN
scale	NOUN	O	I-PAIN
(	PUNCT	O	I-PAIN
VAS	NOUN	O	O
)	PUNCT	O	B-PAIN
scores	NOUN	O	O
at	ADP	O	O
8	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
14	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
in-hospital	NOUN	O	B-OTHER
analgesic	ADJ	O	I-OTHER
use	NOUN	O	B-OTHER
,	PUNCT	O	I-OTHER
length	NOUN	O	I-OTHER
of	ADP	O	B-OTHER
hospital	NOUN	O	I-OTHER
stay	NOUN	O	B-OTHER
,	PUNCT	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
,	PUNCT	O	O
blood	NOUN	O	B-OTHER
transfusion	NOUN	O	I-OTHER
rate	NOUN	O	B-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
postoperative	ADJ	O	B-ADVERSE-EFFECTS
complications	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
compared	VERB	O	O
for	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
mean	NOUN	O	O
hospital	NOUN	O	B-OTHER
stays	NOUN	O	I-OTHER
in	ADP	O	O
groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
were	VERB	O	O
3.1	NUM	O	O
and	CCONJ	O	O
1.6	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
VAS	NOUN	O	O
scores	NOUN	O	O
8	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
than	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
postoperative	ADJ	O	B-PAIN
analgesic	ADP	O	I-PAIN
requirement	NOUN	O	I-PAIN
(	PUNCT	O	O
diclofenac	NOUN	O	O
sodium	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
263	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
120	NUM	O	O
mg	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
transfusion	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
NS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
in	ADP	O	O
VAS	NOUN	O	O
scores	NOUN	O	O
on	ADP	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
14	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
supracostal	ADJ	O	B-PHYSICAL
accesses	NOUN	O	I-PHYSICAL
was	ADJ	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
than	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	PUNCT	O	O

Enhancing	ADP	O	O
attitudes	NOUN	O	B-MENTAL
and	CCONJ	O	O
intentions	NOUN	O	B-MENTAL
in	ADP	O	O
prospective	ADJ	O	O
blood	NOUN	O	O
donors	NOUN	O	O
:	PUNCT	O	O
evaluation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
donor	NOUN	O	O
recruitment	NOUN	O	O
brochure	ADJ	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Although	ADP	O	O
little	DET	O	O
empiric	ADJ	O	O
evidence	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
published	VERB	O	O
concerning	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
donor	NOUN	O	O
recruitment	NOUN	O	O
materials	NOUN	O	O
,	PUNCT	O	O
research	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
simple	ADJ	O	O
attempts	PUNCT	O	O
to	PART	O	O
enhance	ADP	O	O
knowledge	NOUN	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
motivate	ADJ	O	B-MENTAL
donation	NOUN	O	I-MENTAL
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
recent	ADJ	O	O
donor	NOUN	O	O
motivation	NOUN	O	O
studies	NOUN	O	O
highlight	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O
attitudes	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
perceived	VERB	O	B-MENTAL
ability	NOUN	O	I-MENTAL
to	PART	O	I-MENTAL
cope	NOUN	O	I-MENTAL
with	ADP	O	I-MENTAL
donation	NOUN	O	I-MENTAL
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
self-efficacy	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
crucial	ADJ	O	O
determinants	NOUN	O	O
of	ADP	O	O
donation	NOUN	O	O
intention	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
recruitment	NOUN	O	O
materials	NOUN	O	O
that	ADP	O	O
specifically	ADV	O	O
address	VERB	O	O
these	DET	O	O
constructs	DET	O	O
have	PUNCT	O	O
the	DET	O	O
potential	ADJ	O	O
to	ADP	O	O
outperform	PUNCT	O	O
traditional	ADJ	O	O
educational	ADJ	O	O
brochures	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Participants	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PUNCT	O	O
read	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
three	NUM	O	O
brochures	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
brochure	ADJ	O	O
addressing	PUNCT	O	O
common	ADJ	O	O
donor	NOUN	O	O
concerns	NOUN	O	O
and	CCONJ	O	O
suggesting	SYM	O	O
specific	ADJ	O	O
coping	PUNCT	O	O
strategies	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
standard	ADJ	O	O
blood	NOUN	O	O
center	NOUN	O	O
brochure	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
3	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
control	NOUN	O	O
brochure	ADJ	O	O
on	ADP	O	O
healthy	ADJ	O	O
eating	PROPN	O	O
and	CCONJ	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Standardized	VERB	O	O
questionnaires	NOUN	O	O
were	VERB	O	O
completed	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
brochures	PUNCT	O	O
to	PART	O	O
assess	CCONJ	O	O
change	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	B-MENTAL
donation	NOUN	O	I-MENTAL
anxiety	NOUN	O	I-MENTAL
,	PUNCT	O	O
attitude	NOUN	O	B-MENTAL
,	PUNCT	O	O
self-efficacy	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
intention	NOUN	O	B-MENTAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
Although	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
brochure	ADJ	O	O
,	PUNCT	O	O
after	ADP	O	O
reading	PUNCT	O	O
the	DET	O	O
new	ADJ	O	O
brochure	PUNCT	O	O
participants	NOUN	O	O
reported	DET	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
attitude	NOUN	O	B-MENTAL
,	PUNCT	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O
self-efficacy	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
donation	NOUN	O	B-MENTAL
intention	NOUN	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
standard	ADJ	O	O
donation	NOUN	O	O
brochure	ADJ	O	O
had	PUNCT	O	O
an	DET	O	O
intermediate	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Efforts	NOUN	O	O
to	PART	O	O
address	NOUN	O	O
common	ADJ	O	O
donor	NOUN	O	O
fears	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
provide	NOUN	O	O
useful	ADJ	O	O
coping	PUNCT	O	O
suggestions	NOUN	O	O
may	VERB	O	O
improve	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-MENTAL
donation	NOUN	O	I-MENTAL
recruitment	NOUN	O	I-MENTAL
materials	NOUN	O	I-MENTAL
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
cervical	ADJ	O	O
spine	NOUN	O	O
manipulative	ADJ	O	O
therapy	NOUN	O	O
on	ADP	O	O
judo	PUNCT	O	O
athletes	NOUN	O	O
'	PUNCT	O	O
grip	NOUN	O	O
strength	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
perform	NOUN	O	O
an	DET	O	O
investigation	NOUN	O	O
evaluating	PUNCT	O	O
if	PUNCT	O	O
cervical	ADJ	O	O
spinal	ADJ	O	O
manipulative	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
SMT	NOUN	O	O
)	PUNCT	O	O
can	ADJ	O	O
increase	NUM	O	O
grip	NOUN	O	O
strength	NOUN	O	O
on	ADP	O	O
judo	PUNCT	O	O
athletes	NOUN	O	O
in	ADP	O	O
a	DET	O	O
top	ADJ	O	O
10	NUM	O	O
national-ranked	DET	O	O
team	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	NOUN	O	O
single-blinded	PUNCT	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
comparative	ADJ	O	O
,	PUNCT	O	O
pilot	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
18	NUM	O	O
athletes	NOUN	O	O
of	ADP	O	O
both	DET	O	O
sexes	NOUN	O	O
from	ADP	O	O
a	DET	O	O
judo	PUNCT	O	O
team	NOUN	O	O
currently	ADP	O	O
competing	VERB	O	O
on	ADP	O	O
a	DET	O	O
national	ADJ	O	O
level	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
athletes	NOUN	O	O
were	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
2	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
chiropractic	ADJ	O	O
SMT	NOUN	O	O
and	CCONJ	O	O
sham	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
interventions	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
athletes	NOUN	O	O
at	ADP	O	O
different	ADJ	O	O
time	NOUN	O	O
points	NOUN	O	O
.	PUNCT	O	O

Force	NOUN	O	O
measurements	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
by	ADP	O	O
a	DET	O	O
hydraulic	ADJ	O	O
dynamometer	ADJ	O	O
immediately	ADV	O	O
before	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
each	DET	O	O
intervention	NOUN	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
period	NOUN	O	O
before	ADP	O	O
training	VERB	O	O
up	PUNCT	O	O
to	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
at	ADP	O	O
least	ADV	O	O
36	NUM	O	O
hours	NOUN	O	O
between	ADP	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Analysis	NOUN	O	O
of	ADP	O	O
grip	NOUN	O	B-PHYSICAL
strength	NOUN	O	I-PHYSICAL
data	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
strength	NOUN	O	B-OTHER
within	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
6.95	NUM	O	O
%	SYM	O	O
right	NOUN	O	O
,	PUNCT	O	O
12.61	NUM	O	O
%	SYM	O	O
left	NOUN	O	O
)	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
second	ADJ	O	O
(	PUNCT	O	O
11.53	NUM	O	O
%	SYM	O	O
right	NOUN	O	O
,	PUNCT	O	O
17.02	NUM	O	O
%	SYM	O	O
left	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
third	ADJ	O	O
interventions	NOUN	O	O
(	PUNCT	O	O
10.53	NUM	O	O
%	SYM	O	O
right	NOUN	O	O
,	PUNCT	O	O
16.81	NUM	O	O
%	SYM	O	O
left	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
grip	NOUN	O	B-OTHER
strength	NOUN	O	I-OTHER
comparison	NOUN	O	I-OTHER
within	ADP	O	O
the	DET	O	O
sham	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
differences	NOUN	O	B-OTHER
in	ADP	O	O
strength	NOUN	O	B-PHYSICAL
were	VERB	O	O
consistently	ADV	O	O
significant	ADJ	O	O
between	ADP	O	O
the	DET	O	O
study	ADV	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.0025	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
the	DET	O	O
grip	NOUN	O	O
strength	NOUN	O	O
of	ADP	O	O
national	ADJ	O	O
level	NOUN	O	O
judo	ADP	O	O
athletes	NOUN	O	O
receiving	VERB	O	O
chiropractic	ADJ	O	O
SMT	NOUN	O	O
improved	DET	O	O
compared	VERB	O	O
to	ADP	O	O
those	PUNCT	O	O
receiving	SYM	O	O
sham	PUNCT	O	O
.	PUNCT	O	O

Fusidic	ADJ	O	O
acid	NOUN	O	O
prophylaxis	NOUN	O	O
before	ADP	O	O
cataract	NOUN	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
patient	NOUN	O	O
self-administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
randomised	DET	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
patient-administered	ADJ	O	O
1	NUM	O	O
%	ADJ	O	O
fusidic	ADJ	O	O
acid	NOUN	O	O
viscous	ADJ	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
in	ADP	O	O
clearing	PUNCT	O	O
the	DET	O	O
commonest	PUNCT	O	O
organisms	NOUN	O	O
causing	CCONJ	O	O
pseudophakic	NOUN	O	O
endophthalmitis	NOUN	O	O
(	PUNCT	O	O
Staphylococcus	NOUN	O	O
epidermidis	NOUN	O	O
and	CCONJ	O	O
aureus	NOUN	O	O
)	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
lids	NOUN	O	O
and	CCONJ	O	O
conjunctivae	PUNCT	O	O
of	ADP	O	O
79	NUM	O	O
patients	NOUN	O	O
before	PUNCT	O	O
cataract	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
self-administered	ADJ	O	O
fusidic	ADJ	O	O
acid	NOUN	O	O
viscous	ADJ	O	O
eye	NOUN	O	O
drops	ADP	O	O
four	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
seven	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
received	ADP	O	O
inert	PUNCT	O	O
ophthalmic	ADJ	O	O
drops	ADP	O	O
.	PUNCT	O	O

Fellow	ADJ	O	O
eyes	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
remained	VERB	O	O
untreated	VERB	O	O
as	ADP	O	O
a	DET	O	O
natural	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

Lower	PUNCT	O	O
fornix	ADP	O	O
and	CCONJ	O	O
lid	ADJ	O	O
margin	NOUN	O	O
cultures	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
from	ADP	O	O
both	PUNCT	O	O
eyes	NOUN	O	O
before	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
statistical	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
organism	NOUN	O	B-PHYSICAL
counts	NOUN	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
eyes	NOUN	O	O
receiving	VERB	O	O
fusidic	PUNCT	O	O
acid	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
be	PUNCT	O	O
free	ADJ	O	O
of	ADP	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
Staphylococcus	NOUN	O	O
spp	NOUN	O	O
.	PUNCT	O	O

than	PUNCT	O	O
all	DET	O	O
pre-treatment	NOUN	O	O
eyes	NOUN	O	O
(	PUNCT	O	O
for	ADP	O	O
lids	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
;	PUNCT	O	O
conjunctivae	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
highly	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
lid	ADJ	O	B-PHYSICAL
margins	NOUN	O	I-PHYSICAL
were	VERB	O	O
rendered	ADP	O	O
'clinically	PUNCT	O	O
clean	PUNCT	O	O
'	PUNCT	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
0-49	NUM	O	O
organisms/swab	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
fusidic	ADJ	O	O
acid	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
untreated	VERB	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
also	ADV	O	O
effectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
reduced	VERB	O	O
the	DET	O	O
numbers	NOUN	O	O
of	ADP	O	O
bacteria	NOUN	O	B-PHYSICAL
isolated	VERB	O	I-PHYSICAL
from	ADP	O	I-PHYSICAL
conjunctivae	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
indicates	NOUN	O	O
that	ADP	O	O
there	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
highly	ADV	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
Staphylococcus	NOUN	O	O
spp	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
non-Staphylococcus	PUNCT	O	O
spp	NOUN	O	O
.	PUNCT	O	O
(	PUNCT	O	O

P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
attainment	NOUN	O	O
of	ADP	O	O
sterile	ADJ	O	O
eyes	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
operation	NOUN	O	O
gained	VERB	O	O
by	ADP	O	O
patient	NOUN	O	O
self-administration	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
%	ADJ	O	O
fusidic	ADJ	O	O
acid	NOUN	O	O
four	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
seven	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Can	PUNCT	O	O
incentives	PUNCT	O	O
undermine	NOUN	O	O
intrinsic	ADJ	O	B-MENTAL
motivation	NOUN	O	I-MENTAL
to	PART	O	O
participate	NOUN	O	O
in	ADP	O	O
epidemiologic	ADJ	O	O
surveys	NOUN	O	O
?	PUNCT	O	O

Response	NOUN	O	O
rates	NOUN	O	O
to	ADP	O	O
surveys	NOUN	O	O
are	ADP	O	O
decreasing	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
lottery	PUNCT	O	O
tickets	ADP	O	O
as	PUNCT	O	O
incentives	DET	O	O
in	ADP	O	O
an	DET	O	O
epidemiologic	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
self-administered	DET	O	O
questionnaire	NOUN	O	O
was	VERB	O	O
sent	NOUN	O	O
to	ADP	O	O
parents	NOUN	O	O
in	ADP	O	O
the	DET	O	O
municipality	NOUN	O	O
of	ADP	O	O
Stockholm	NOUN	O	O
,	PUNCT	O	O
Sweden	PUNCT	O	O
,	PUNCT	O	O
who	ADP	O	O
were	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
in	ADP	O	O
a	DET	O	O
study	NOUN	O	O
addressing	PUNCT	O	O
stress	NOUN	O	O
in	ADP	O	O
parents	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
stratified	VERB	O	O
random	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
450	NUM	O	O
parents	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
three	NUM	O	O
incentive	ADJ	O	O
groups	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
no	DET	O	O
incentive	ADJ	O	O
;	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
a	DET	O	O
promised	PROPN	O	O
incentive	ADJ	O	O
of	ADP	O	O
one	NUM	O	O
lottery	PUNCT	O	O
ticket	PUNCT	O	O
to	PART	O	O
be	PUNCT	O	O
received	VERB	O	O
upon	ADP	O	O
reply	PUNCT	O	O
;	PUNCT	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
a	DET	O	O
promised	PROPN	O	O
incentive	ADJ	O	O
of	ADP	O	O
one	NUM	O	O
lottery	PUNCT	O	O
ticket	PUNCT	O	O
to	PART	O	O
be	PUNCT	O	O
received	VERB	O	O
upon	ADP	O	O
reply	ADV	O	O
and	CCONJ	O	O
an	DET	O	O
additional	ADJ	O	O
lottery	PUNCT	O	O
ticket	PUNCT	O	O
upon	PUNCT	O	O
reply	PUNCT	O	O
within	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	B-MENTAL
across	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
was	VERB	O	O
65.3	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
rate	NOUN	O	B-MENTAL
was	ADV	O	O
highest	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
no	DET	O	O
incentive	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
69.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
lowest	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
one	NUM	O	O
plus	CCONJ	O	O
one	NUM	O	O
lottery	PUNCT	O	O
ticket	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
62.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
survival	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
response	NOUN	O	O
curves	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
by	ADP	O	O
the	DET	O	O
log-rank	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
no	DET	O	O
incentive	ADJ	O	O
group	NOUN	O	O
having	VERB	O	O
a	DET	O	O
shorter	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
response	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
incentive	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Our	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
lottery	PUNCT	O	O
tickets	ADP	O	O
as	VERB	O	O
incentives	DET	O	O
to	PART	O	O
increase	NOUN	O	O
participation	NOUN	O	B-MENTAL
in	ADP	O	O
a	DET	O	O
mail	NOUN	O	B-OTHER
questionnaire	NOUN	O	O
among	ADP	O	O
parents	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
less	ADV	O	O
valuable	ADJ	O	O
or	CCONJ	O	O
even	ADV	O	O
harmful	ADJ	O	O
.	PUNCT	O	O

Incentives	NOUN	O	O
may	VERB	O	O
undermine	PUNCT	O	O
motivation	NOUN	O	B-MENTAL
in	ADP	O	O
studies	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
the	DET	O	O
intrinsic	ADJ	O	O
motivation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
respondents	NOUN	O	O
is	VERB	O	O
already	ADV	O	O
high	ADJ	O	O
.	PUNCT	O	O

Mending	PUNCT	O	O
the	DET	O	O
rhythm	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
improve	VERB	O	O
prognosis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
persistent	ADJ	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
subanalysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
RACE	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

AIMS	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
outcome	NOUN	O	O
of	ADP	O	O
AF	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
effective	ADJ	O	O
rhythm	NOUN	O	O
control	NOUN	O	O
with	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
rate	NOUN	O	O
control	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	DET	O	O
Out	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
266	NUM	O	O
AF	NOUN	O	O
patients	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
rhythm	NOUN	O	O
control	NOUN	O	O
in	ADP	O	O
the	DET	O	O
RACE	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
49	DET	O	O
patients	NOUN	O	O
turned	ADJ	O	O
to	ADP	O	O
long-term	NOUN	O	O
sinus	NOUN	O	O
rhythm	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
continuously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
anticoagulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
that	PUNCT	O	O
in	ADP	O	O
178	NUM	O	O
patients	NOUN	O	O
out	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
256	NUM	O	O
rate-control	NOUN	O	O
patients	NOUN	O	O
of	ADP	O	O
RACE	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
in	ADP	O	O
AF	NOUN	O	O
and	CCONJ	O	O
using	PROPN	O	O
oral	ADJ	O	O
anticoagulation	NOUN	O	O
continuously	ADV	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
follow-up	NOUN	O	O
of	ADP	O	O
2.3+/-0.6	DET	O	O
years	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
composite	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
cardiovascular	ADJ	O	I-PHYSICAL
mortality	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
heart	NOUN	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
thrombo-embolic	VERB	O	B-PHYSICAL
complications	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
TECs	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
bleeding	VERB	O	B-PHYSICAL
,	PUNCT	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
antiarrhythmic	ADJ	O	I-ADVERSE-EFFECTS
drugs	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
pacemaker	PUNCT	O	B-ADVERSE-EFFECTS
implants	NOUN	O	I-ADVERSE-EFFECTS
)	PUNCT	O	O
was	VERB	O	O
22.4	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
rhythm-control	NOUN	O	O
group	NOUN	O	O
vs.	CCONJ	O	O
15.2	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
rate-control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Multivariable	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
indicated	VERB	O	O
coronary	ADJ	O	B-PHYSICAL
artery	NOUN	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
heart	NOUN	O	O
failure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
digitalis	NOUN	O	B-PHYSICAL
as	PUNCT	O	O
independent	ADJ	O	O
risk	NOUN	O	O
indicators	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	B-PHYSICAL
sinus	NOUN	O	I-PHYSICAL
rhythm	NOUN	O	I-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
matter	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Among	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
remained	VERB	O	O
on	ADP	O	O
warfarin	NOUN	O	O
,	PUNCT	O	O
those	ADP	O	O
who	ADP	O	O
mostly	ADV	O	O
were	VERB	O	O
maintained	VERB	O	O
in	ADP	O	O
sinus	NOUN	O	O
rhythm	NOUN	O	O
under	ADP	O	O
a	DET	O	O
rhythm-control	NOUN	O	O
strategy	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
have	PUNCT	O	O
a	DET	O	O
superior	ADJ	O	O
prognosis	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
those	PUNCT	O	O
who	ADP	O	O
remained	VERB	O	O
in	ADP	O	O
AF	NOUN	O	O
under	ADP	O	O
a	DET	O	O
rate-control	NOUN	O	O
strategy	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
anthelmintic	ADJ	O	O
failure	NOUN	O	O
to	ADP	O	O
control	PUNCT	O	O
nematode	NOUN	O	O
parasites	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
ruminants	NOUN	O	O
on	ADP	O	O
government	NOUN	O	O
breeding	ADJ	O	O
farms	ADP	O	O
in	ADP	O	O
Sabah	NOUN	O	O
,	PUNCT	O	O
East	NOUN	O	O
Malaysia	NOUN	O	O
.	PUNCT	O	O

Government-owned	VERB	O	O
small-ruminant	ADJ	O	O
breeding	SYM	O	O
farms	NOUN	O	O
in	ADP	O	O
Malaysia	NOUN	O	O
provide	VERB	O	O
the	DET	O	O
source	NOUN	O	O
of	ADP	O	O
sheep	NOUN	O	O
and	CCONJ	O	O
goats	NOUN	O	O
to	ADP	O	O
smallholder	ADJ	O	O
farmers	NOUN	O	O
in	ADP	O	O
the	DET	O	O
country	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
eastern	ADJ	O	O
Malaysian	ADJ	O	O
state	NOUN	O	O
of	ADP	O	O
Sabah	NOUN	O	O
,	PUNCT	O	O
high-level	NOUN	O	O
stock	NOUN	O	O
losses	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
recorded	VERB	O	O
on	ADP	O	O
these	DET	O	O
farms	PUNCT	O	O
for	ADP	O	O
several	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
frequently	ADV	O	O
accompanied	VERB	O	O
by	ADP	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
indicating	VERB	O	O
pathogenic	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
infections	NOUN	O	O
with	ADP	O	O
the	DET	O	O
nematode	NOUN	O	O
parasite	NOUN	O	O
Haemonchus	ADV	O	O
contortus	NOUN	O	O
.	PUNCT	O	O

This	ADJ	O	O
suggests	VERB	O	O
that	ADP	O	O
their	ADP	O	O
dependence	NOUN	O	O
on	ADP	O	O
chemotherapy	NOUN	O	O
to	ADP	O	O
control	NOUN	O	O
parasite	NOUN	O	O
infections	NOUN	O	O
had	PUNCT	O	O
failed	VERB	O	O
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
tests	CCONJ	O	O
for	ADP	O	O
anthelmintic	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
using	VERB	O	O
the	DET	O	O
faecal	ADJ	O	O
egg	NOUN	O	O
count	NOUN	O	O
reduction	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
FECRT	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
range	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
used	VERB	O	O
to	PUNCT	O	O
control	PUNCT	O	O
nematode	NOUN	O	O
parasites	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
on	ADP	O	O
the	DET	O	O
five	NUM	O	O
government	NOUN	O	O
small-ruminant	ADJ	O	O
breeding	SYM	O	O
farms	NOUN	O	O
in	ADP	O	O
Sabah	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
tests	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
total	ADJ	O	O
failure	NOUN	O	O
of	ADP	O	B-OTHER
the	DET	O	O
benzimidazole	ADP	O	B-OTHER
,	PUNCT	O	O
imidothiazole	NOUN	O	B-OTHER
,	PUNCT	O	O
macrocyclic	ADJ	O	B-OTHER
lactone	NOUN	O	I-OTHER
and	PUNCT	O	O
salicylanilide	PUNCT	O	B-OTHER

Scaling	ADP	O	O
clinical	ADJ	O	O
judgments	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	O
pathology	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
the	DET	O	O
psychophysiological	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
magnitude	NOUN	O	O
estimation	NOUN	O	O
.	PUNCT	O	O

Summing	PUNCT	O	O
scores	NOUN	O	O
across	ADP	O	O
heterogeneous	ADJ	O	O
symptom	NOUN	O	O
items	ADJ	O	O
without	ADP	O	O
consideration	NOUN	O	O
of	ADP	O	O
their	PUNCT	O	O
differing	ADJ	O	O
psychopathological	ADJ	O	O
significance	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
criticized	VERB	O	O
as	CCONJ	O	O
producing	PUNCT	O	O
an	DET	O	O
inadequate	ADJ	O	O
picture	NOUN	O	O
of	ADP	O	O
an	DET	O	O
individual	ADJ	O	O
's	PUNCT	O	O
clinical	ADJ	O	O
status	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
derive	VERB	O	O
symptom	NOUN	O	O
item	NOUN	O	O
weights	NOUN	O	O
representing	VERB	O	O
clinically	ADV	O	O
judged	PUNCT	O	O
seriousness	NOUN	O	O
of	ADP	O	O
each	ADP	O	O
symptom	NOUN	O	O
through	ADP	O	O
the	DET	O	O
application	NOUN	O	O
of	ADP	O	O
Steven	PUNCT	O	O
's	PUNCT	O	O
psychophysical	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
magnitude	NOUN	O	O
estimation	NOUN	O	O
.	PUNCT	O	O

A	PUNCT	O	O
nationwide	NOUN	O	O
sample	NOUN	O	O
of	ADP	O	O
129	NUM	O	O
clinicians	NOUN	O	O
rated	VERB	O	O
the	DET	O	O
pathological	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
221	NUM	O	O
symptom	NOUN	O	O
items	ADJ	O	O
in	ADP	O	O
a	DET	O	O
design	NOUN	O	O
such	PUNCT	O	O
that	PUNCT	O	O
every	DET	O	O
rater	ADJ	O	O
rated	PUNCT	O	O
121	NUM	O	O
items	ADJ	O	O
,	PUNCT	O	O
21	NUM	O	O
of	ADP	O	O
which	ADP	O	O
were	VERB	O	O
rated	VERB	O	O
by	ADP	O	O
all	DET	O	O
raters	NOUN	O	O
and	CCONJ	O	O
100	NUM	O	O
of	ADP	O	O
which	ADP	O	O
were	VERB	O	O
rated	VERB	O	O
only	ADV	O	O
by	ADP	O	O
the	DET	O	O
A	DET	O	O
or	CCONJ	O	O
B	NOUN	O	O
subgroup	NOUN	O	O
to	ADP	O	O
which	CCONJ	O	O
each	DET	O	O
rater	ADV	O	O
was	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
.	PUNCT	O	O

Each	DET	O	O
item	NOUN	O	O
was	VERB	O	O
rated	VERB	O	O
as	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
seriousness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pathology	NOUN	O	O
it	PRON	O	O
would	VERB	O	O
represent	VERB	O	O
if	PUNCT	O	O
manifested	VERB	O	O
by	ADP	O	O
either	PUNCT	O	O
a	DET	O	O
boy	NOUN	O	O
child	NOUN	O	O
,	PUNCT	O	O
girl	PUNCT	O	O
child	NOUN	O	O
,	PUNCT	O	O
boy	NOUN	O	O
adolescent	NOUN	O	O
,	PUNCT	O	O
or	PUNCT	O	O
girl	NOUN	O	O
adolescent	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
one-fourth	NOUN	O	O
of	ADP	O	O
the	DET	O	O
raters	NOUN	O	O
assigned	NUM	O	O
to	ADP	O	O
each	DET	O	O
condition	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
211	NUM	O	O
two-way	NOUN	O	O
analyses	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
age	NOUN	O	O
and	CCONJ	O	O
sex	NOUN	O	B-MENTAL
in	ADP	O	O
interaction	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
sex	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
significantly	ADV	O	O
influenced	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
ratings	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
resulting	VERB	O	O
magnitude	NOUN	O	B-MENTAL
estimation	NOUN	O	O
ratings	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
symptom	PUNCT	O	I-MENTAL

The	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
response	NOUN	O	O
of	ADP	O	O
Plasmodium	NOUN	O	O
falciparum	NOUN	O	O
malaria	NOUN	O	O
to	ADP	O	O
mefloquine	NOUN	O	O
in	ADP	O	O
African	ADJ	O	O
children	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
sensitivity	NOUN	O	O
in	DET	O	O
vitro	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
mefloquine	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
25	NUM	O	O
mg/kg	NOUN	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
85	NUM	O	O
children	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
acute	ADJ	O	O
symptomatic	ADJ	O	O
falciparum	NOUN	O	O
malaria	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cure	ADV	O	B-OTHER
rate	NOUN	O	I-OTHER
on	ADP	O	O
day	NOUN	O	O
28	NUM	O	O
was	VERB	O	O
100	NUM	O	O
%	SYM	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
mean	NOUN	O	O
parasite	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
fever	NOUN	O	I-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
times	ADP	O	I-PHYSICAL
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
48.5	NUM	O	O
+/-	SYM	O	O
14.6	NUM	O	O
and	CCONJ	O	O
32.0	NUM	O	O
+/-	SYM	O	O
12.7	NUM	O	O
h	NOUN	O	O
respectively	ADV	O	O
for	ADP	O	O
the	DET	O	O
25	NUM	O	O
mg/kg	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
49.0	NUM	O	O
+/-	SYM	O	O
15.1	NUM	O	O
and	CCONJ	O	O
30.0	NUM	O	O
+/-	SYM	O	O
13.3	NUM	O	O
h	NOUN	O	O
respectively	ADV	O	O
for	ADP	O	O
the	DET	O	O
15	NUM	O	O
mg/kg	ADJ	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
these	DET	O	O
values	NOUN	O	O
between	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
hyperparasitaemia	ADJ	O	O
(	PUNCT	O	O
53.6	NUM	O	O
+/-	SYM	O	O
11.1	NUM	O	O
and	CCONJ	O	O
36.0	NUM	O	O
+/-	SYM	O	O
17.0	NUM	O	O
h	NOUN	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
those	PUNCT	O	O
without	ADP	O	O
hyperparasitaemia	ADJ	O	O
(	PUNCT	O	O
49.1	NUM	O	O
+/-	SYM	O	O
13.6	NUM	O	O
and	CCONJ	O	O
31.8	NUM	O	O
+/-	SYM	O	O
14.6	NUM	O	O
h	NOUN	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Recurrence	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
parasitaemia	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	NUM	O	O
after	ADP	O	O
day	NOUN	O	O
30	PUNCT	O	O
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
15	NUM	O	O
mg/kg	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
25	NUM	O	O
mg/kg	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

In	PUNCT	O	O
vitro	ADJ	O	O
,	PUNCT	O	O
3	NUM	O	O
of	ADP	O	O
21	NUM	O	O
isolates	NOUN	O	O
showed	VERB	O	O
reduced	VERB	O	O
susceptibility	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
mefloquine	NOUN	O	I-OTHER
,	PUNCT	O	O
with	ADP	O	O
minimum	NOUN	O	O
inhibitory	ADJ	O	B-OTHER
concentrations	NOUN	O	I-OTHER
(	PUNCT	O	O
MIC	NOUN	O	O
)	PUNCT	O	O
>	SYM	O	O
67	NUM	O	O
nM/litre	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
MIC	NOUN	O	O
and	CCONJ	O	O
50	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
90	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
99	NUM	O	O
%	ADV	O	O
inhibitory	ADJ	O	O
concentrations	NOUN	O	O
were	VERB	O	O
200.8	NUM	O	O
,	PUNCT	O	O
6.27	NUM	O	O
,	PUNCT	O	O
31.7	NUM	O	O
and	CCONJ	O	O
119.6	NUM	O	O
nM/litre	NOUN	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Four	NUM	O	O
of	ADP	O	O
22	NUM	O	O
isolates	NOUN	O	O
were	VERB	O	O
resistant	ADJ	O	B-OTHER
to	ADP	O	O
chloroquine	NOUN	O	O
(	PUNCT	O	O
MIC	NOUN	O	O
>	SYM	O	O
108	NUM	O	O
nM/litre	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Isolates	NOUN	O	O
that	NUM	O	O
showed	VERB	O	O
low	ADJ	O	O
sensitivity	NOUN	O	B-OTHER
to	ADP	O	O
mefloquine	NOUN	O	O
in	DET	O	O
vitro	ADV	O	O
were	VERB	O	O
sensitive	ADJ	O	O
to	ADP	O	O
chloroquine	NOUN	O	O
in	DET	O	O
vitro	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
4	NUM	O	O
that	VERB	O	O
were	VERB	O	O
resistant	ADJ	O	O
to	ADP	O	O
chloroquine	NOUN	O	O
were	VERB	O	O
sensitive	ADJ	O	O
to	ADP	O	O
mefloquine	NOUN	O	O
.	PUNCT	O	O

Irrespective	ADJ	O	O
of	ADP	O	O
MIC	NOUN	O	O
and	CCONJ	O	O
dose	NOUN	O	O
of	ADP	O	O
mefloquine	NOUN	O	O
,	PUNCT	O	O
parasitaemia	NOUN	O	O
cleared	VERB	O	O
in	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
in	ADP	O	O
96	NUM	O	O
h	NOUN	O	O
or	CCONJ	O	O
less	DET	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

D-dimer	NOUN	O	O
predicts	ADV	O	O
outcome	NOUN	O	O
after	ADP	O	O
aneurysmal	ADJ	O	O
subarachnoid	NOUN	O	O
hemorrhage	NOUN	O	O
:	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
thromboprophylaxis	NOUN	O	O
on	ADP	O	O
coagulation	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Approximately	ADV	O	O
one-third	NOUN	O	O
of	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
nontraumatic	ADJ	O	O
subarachnoid	NOUN	O	O
hemorrhage	NOUN	O	O
(	PUNCT	O	O
SAH	NOUN	O	O
)	PUNCT	O	O
experience	DET	O	O
complications	NOUN	O	O
owing	PUNCT	O	O
to	ADP	O	O
delayed	VERB	O	O
ischemic	ADJ	O	O
deficit	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
reported	VERB	O	O
recently	ADV	O	O
that	ADP	O	O
enoxaparin	NOUN	O	O
40	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
seems	NOUN	O	O
safe	ADJ	O	O
and	CCONJ	O	O
demonstrates	NOUN	O	O
thromboprophylactic	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
,	PUNCT	O	O
but	CCONJ	O	O
it	NOUN	O	O
failed	VERB	O	O
to	ADP	O	O
improve	ADP	O	O
outcome	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
SAH	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	NOUN	O	O
assessed	VERB	O	O
hemostatic	ADJ	O	B-PHYSICAL
variables	NOUN	O	I-PHYSICAL
associated	VERB	O	O
with	ADP	O	O
clinical	ADJ	O	O
status	NOUN	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
SAH	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
monitored	PROPN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
enoxaparin	NOUN	O	O
on	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
coagulation	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
fibrinolysis	NOUN	O	B-PHYSICAL
after	ADP	O	O
closure	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ruptured	VERB	O	O
aneurysm	ADV	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Blood	NOUN	O	B-OTHER
samples	NOUN	O	I-OTHER
to	PART	O	O
measure	VERB	O	O
activation	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
coagulation	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
fibrinolysis	NOUN	O	B-PHYSICAL
were	VERB	O	O
collected	VERB	O	O
from	ADP	O	O
42	NUM	O	O
patients	NOUN	O	O
participating	VERB	O	O
in	ADP	O	O
the	DET	O	O
enoxaparin	NOUN	O	O
trial	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
aneurysmal	ADJ	O	O
SAH	NOUN	O	O
at	ADP	O	O
four	NUM	O	O
time	NOUN	O	O
points	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
hospital	NOUN	O	O
admission	NOUN	O	O
;	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
12	NUM	O	O
to	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
aneurysm	NOUN	O	O
surgery	NOUN	O	O
but	CCONJ	O	O
before	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
enoxaparin	NOUN	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
3	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
conclusion	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
several	ADJ	O	O
variables	NOUN	O	O
of	ADP	O	O
coagulation	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
fibrinolysis	NOUN	O	B-PHYSICAL
were	VERB	O	O
elevated	VERB	O	O
and	CCONJ	O	O
correlated	VERB	O	O
well	VERB	O	O
with	CCONJ	O	O
clinical	ADJ	O	O
status	NOUN	O	O
.	PUNCT	O	O

Specifically	ADV	O	O
,	PUNCT	O	O
D-dimer	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
at	ADP	O	O
all	DET	O	O
four	NUM	O	O
time	NOUN	O	O
points	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
patients	NOUN	O	O
'	PUNCT	O	O
long-term	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
enoxaparin	NOUN	O	O
suppressed	VERB	O	O
early	ADJ	O	B-PHYSICAL
coagulation	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
thrombin	NOUN	O	B-PHYSICAL
generation	NOUN	O	I-PHYSICAL
was	VERB	O	O
not	ADV	O	O
inhibited	VERB	O	B-OTHER
during	ADP	O	O
thromboprophylaxis	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
PAI-1	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
was	VERB	O	O
suppressed	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
D-dimer	NOUN	O	O
offers	NOUN	O	O
a	DET	O	O
useful	ADJ	O	O
laboratory	NOUN	O	O
tool	NOUN	O	O
for	ADP	O	O
assessing	VERB	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
clinical	ADJ	O	O
severity	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
SAH	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
thromboprophylactic	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
enoxaparin	NOUN	O	O
inhibited	VERB	O	O
PAI-1	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
but	CCONJ	O	O
failed	VERB	O	O
to	PUNCT	O	O
down-regulate	PUNCT	O	O
coagulation	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
D-dimer	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
are	VERB	O	O
compatible	ADJ	O	O
with	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
of	ADP	O	O
enoxaparin	NOUN	O	O
in	ADP	O	O
reducing	VERB	O	O
ischemic	ADJ	O	O
deficit	NOUN	O	O
after	ADP	O	O
SAH	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
plaque	NOUN	O	O
index	NOUN	O	O
for	ADP	O	O
occlusal	ADJ	O	O
surfaces	NOUN	O	O
and	CCONJ	O	O
fissures	PUNCT	O	O
.	PUNCT	O	O

Measurement	NOUN	O	O
of	ADP	O	O
repeatability	NOUN	O	O
and	CCONJ	O	O
plaque	NOUN	O	O
removal	NOUN	O	O
.	PUNCT	O	O

Plaque	NOUN	O	O
indices	NOUN	O	O
have	ADJ	O	O
largely	ADV	O	O
been	PUNCT	O	O
developed	VERB	O	O
for	ADP	O	O
buccal	ADJ	O	O
and	CCONJ	O	O
lingual	ADJ	O	O
tooth	NOUN	O	O
surfaces	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
has	DET	O	O
been	PUNCT	O	O
minimal	ADJ	O	O
interest	NOUN	O	O
in	ADP	O	O
plaque	NOUN	O	O
accumulation	NOUN	O	O
on	ADP	O	O
occlusal	ADJ	O	O
surfaces	NOUN	O	O
despite	ADP	O	O
the	DET	O	O
predilection	NOUN	O	O
for	ADP	O	O
caries	NOUN	O	O
at	ADP	O	O
these	DET	O	O
sites	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
numerical	ADJ	O	O
plaque	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
0-5	NUM	O	O
)	PUNCT	O	O
is	VERB	O	O
described	VERB	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
and	CCONJ	O	O
distribution	NOUN	O	O
of	ADP	O	O
plaque	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fissures	ADV	O	O
and	CCONJ	O	O
over	ADP	O	O
the	DET	O	O
occlusal	ADJ	O	O
surfaces	NOUN	O	O
of	ADP	O	O
permanent	ADJ	O	O
molar	ADJ	O	O
and	CCONJ	O	O
premolar	ADP	O	O
teeth	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
repeatability	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
examiner	NOUN	O	O
in	ADP	O	O
scoring	ADJ	O	O
the	DET	O	O
index	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
4	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
group	NOUN	O	O
of	ADP	O	O
volunteers	NOUN	O	O
suspended	DET	O	O
tooth	NOUN	O	O
cleaning	PROPN	O	O
for	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
index	NOUN	O	O
scored	PUNCT	O	O
after	ADP	O	O
disclosing	PUNCT	O	O
plaque	NOUN	O	O
deposits	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
index	NOUN	O	O
was	VERB	O	O
rescored	ADP	O	O
60-90	NUM	O	O
min	NOUN	O	O
later	ADJ	O	O
.	PUNCT	O	O

Plaque	NOUN	O	O
area	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
determined	VERB	O	O
by	ADP	O	O
drawing	ADP	O	O
the	DET	O	O
outline	NOUN	O	O
of	ADP	O	O
plaque	NOUN	O	O
onto	ADP	O	O
grids	NOUN	O	O
.	PUNCT	O	O

Except	PUNCT	O	O
for	ADP	O	O
one	NUM	O	O
condition	NOUN	O	O
of	ADP	O	O
repeatability	NOUN	O	O
for	ADP	O	O
one	NUM	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
4	NUM	O	O
conditions	NOUN	O	O
of	ADP	O	O
repeatability	NOUN	O	O
in	ADP	O	O
scoring	ADJ	O	O
the	DET	O	O
index	NOUN	O	O
were	VERB	O	O
met	VERB	O	O
for	ADP	O	O
all	DET	O	O
4	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
index	NOUN	O	O
and	CCONJ	O	O
area	NOUN	O	O
recordings	CCONJ	O	B-OTHER
to	PART	O	O
detect	NOUN	O	O
plaque	NOUN	O	O
removed	VERB	O	O
by	ADP	O	O
brushing	PUNCT	O	O
was	VERB	O	O
then	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
group	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
plaque	NOUN	O	O
scored	VERB	O	O
by	ADP	O	O
index	NOUN	O	O
and	CCONJ	O	O
area	NOUN	O	O
after	ADP	O	O
suspending	ADP	O	O
toothcleaning	DET	O	O
for	ADP	O	O
48	NUM	O	O
h.	NOUN	O	O
Subjects	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
brush	NOUN	O	O
or	CCONJ	O	O
not	ADV	O	O
brush	NOUN	O	O
their	ADP	O	O
teeth	NOUN	O	O
and	CCONJ	O	O
plaque	NOUN	O	O
rescored	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
experiment	NOUN	O	O
was	VERB	O	O
then	ADV	O	O
repeated	VERB	O	O
and	CCONJ	O	O
brushing	PUNCT	O	O
or	CCONJ	O	O
not	ADV	O	O
brushing	PUNCT	O	O
crossed	PUNCT	O	O
over	PUNCT	O	O
.	PUNCT	O	O

Highly	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
brushing	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
brushing	PUNCT	O	O
plaque	NOUN	O	B-OTHER
indices	NOUN	O	I-OTHER
and	CCONJ	O	O
areas	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
occlusal	ADJ	O	B-OTHER
fissure	ADJ	O	I-OTHER
plaque	NOUN	O	I-OTHER
index	NOUN	O	I-OTHER
was	DET	O	O
easy	PUNCT	O	O
to	ADP	O	O
apply	ADP	O	O
,	PUNCT	O	O
repeatable	ADJ	O	O
and	CCONJ	O	O
sufficiently	ADV	O	O
sensitive	ADJ	O	O
to	PART	O	O
detect	NOUN	O	O
plaque	NOUN	O	O
removed	VERB	O	O
by	ADP	O	O
brushing	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
index	NOUN	O	O
could	PUNCT	O	O
find	VERB	O	O
use	ADV	O	O
as	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
measure	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
hygiene	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
on	ADP	O	O
plaque	NOUN	O	O
control	NOUN	O	O
and	CCONJ	O	O
possibly	ADV	O	O
epidemiological	ADJ	O	O
studies	NOUN	O	O
relating	ADJ	O	O
to	PUNCT	O	O
caries	NOUN	O	O
.	PUNCT	O	O

Quitting	ADP	O	O
a	DET	O	O
weight	NOUN	O	O
loss	NOUN	O	O
program	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
anhedonia	NOUN	O	O
:	PUNCT	O	O
preliminary	ADJ	O	O
findings	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Lifestyle	NOUN	O	O
Intervention	NOUN	O	O
Treatment	NOUN	O	O
Evaluation	NOUN	O	O
Study	NOUN	O	O
in	ADP	O	O
northern	ADJ	O	O
Finland	CCONJ	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
examine	NOUN	O	O
whether	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
for	ADP	O	O
major	ADJ	O	O
depression	NOUN	O	O
,	PUNCT	O	O
chronic	ADJ	O	O
depression	NOUN	O	O
or	CCONJ	O	O
specific	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
quitting	NUM	O	O
a	DET	O	O
weight	NOUN	O	O
loss	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
involved	VERB	O	O
82	NUM	O	O
overweight	VERB	O	O
adults	NOUN	O	O
participating	PROPN	O	O
in	ADP	O	O
the	DET	O	O
Lifestyle	NOUN	O	O
Intervention	NOUN	O	O
Treatment	NOUN	O	O
Evaluation	NOUN	O	O
(	PUNCT	O	O
LITE	NOUN	O	O
)	PUNCT	O	O
follow-up	NOUN	O	O
study	NOUN	O	O
at	ADP	O	O
Oulu	NOUN	O	O
University	NOUN	O	O
Hospital	NOUN	O	O
in	ADP	O	O
northern	ADJ	O	O
Finland	CCONJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Psychiatric	ADJ	O	B-MENTAL
diagnostic	ADJ	O	I-MENTAL
assessments	NOUN	O	I-MENTAL
were	VERB	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
Structured	PROPN	O	O
Clinical	ADJ	O	O
Interview	NOUN	O	O
for	ADP	O	O
DSMIV	NOUN	O	B-PHYSICAL
disorders	NOUN	O	O
(	PUNCT	O	O
SCID-I	NOUN	O	O
)	PUNCT	O	O
conducted	VERB	O	O
by	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
psychiatrist	NOUN	O	O
.	PUNCT	O	O

Anhedonia	NOUN	O	B-MENTAL
(	PUNCT	O	I-MENTAL
lack	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
pleasure	ADJ	O	I-MENTAL
)	PUNCT	O	I-MENTAL
was	VERB	O	O
assessed	VERB	O	O
as	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
core	NOUN	O	O
symptoms	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
depression	NOUN	O	O
and	CCONJ	O	O
chronic	ADJ	O	B-PHYSICAL
depression	NOUN	O	O
(	PUNCT	O	O
dysthymia	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Anhedonia	NOUN	O	B-MENTAL
was	VERB	O	O
defined	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
present	ADJ	O	O
if	PUNCT	O	O
the	DET	O	O
participants	NOUN	O	O
reported	PUNCT	O	O
having	SYM	O	O
suffered	VERB	O	O
a	DET	O	O
major	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
interest	NOUN	O	O
during	ADP	O	O
the	DET	O	O
previous	ADJ	O	O
month	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty	PUNCT	O	O
participants	NOUN	O	O
(	PUNCT	O	O
24.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
quit	NOUN	O	O
during	ADP	O	O
the	DET	O	O
6-month	NOUN	O	O
intervention	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Anhedonia	NOUN	O	B-MENTAL
put	PUNCT	O	O
individuals	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
of	ADP	O	O
quitting	PROPN	O	O
the	DET	O	O
weight	NOUN	O	O
loss	NOUN	O	O
program	NOUN	O	O
(	PUNCT	O	O
bivariate	ADJ	O	O
analysis	NOUN	O	O
OR	CCONJ	O	O
3.1	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.8-11.6	PUNCT	O	O
,	PUNCT	O	O
p=0.091	PUNCT	O	O
,	PUNCT	O	O
multivariate	ADJ	O	O
analysis	NOUN	O	O
OR	CCONJ	O	O
6.5	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.1-38.2	PUNCT	O	O
,	PUNCT	O	O
p=0.038	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
diagnosis	NOUN	O	O
for	ADP	O	O
major	ADJ	O	B-MENTAL
depression	NOUN	O	I-MENTAL
or	CCONJ	O	O
chronic	ADJ	O	B-MENTAL
depression	NOUN	O	I-MENTAL
did	ADP	O	O
not	ADV	O	O
predict	VERB	O	O
quitting	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Individual	PUNCT	O	O
assessments	NOUN	O	O
of	ADP	O	O
obesity	NOUN	O	O
and	CCONJ	O	O
overweight	ADV	O	O
should	ADP	O	O
also	ADV	O	O
include	VERB	O	O
an	DET	O	O
assessment	NOUN	O	O
for	ADP	O	O
subthreshold	PUNCT	O	O
depression	NOUN	O	O
,	PUNCT	O	O
mainly	ADV	O	O
anhedonia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Randomised	ADV	O	O
Intervention	NOUN	O	O
Treatment	NOUN	O	O
of	ADP	O	O
Angina	NOUN	O	O
(	PUNCT	O	O
RITA	NOUN	O	O
)	PUNCT	O	O
Trial	NOUN	O	O
protocol	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
long	ADJ	O	O
term	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
and	CCONJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
angina	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Randomised	ADV	O	O
Intervention	NOUN	O	O
Treatment	NOUN	O	O
of	ADP	O	O
Angina	NOUN	O	O
(	PUNCT	O	O
RITA	NOUN	O	O
)	PUNCT	O	O
Trial	NOUN	O	O
is	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	ADP	O	O
study	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
short	ADJ	O	O
term	NOUN	O	O
and	CCONJ	O	O
long	ADJ	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
percutaneous	ADJ	O	O
transluminal	ADJ	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
and	CCONJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
study	ADV	O	O
a	DET	O	O
register	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
coronary	ADJ	O	O
arteriography	NOUN	O	O
at	ADP	O	O
the	DET	O	O
fourteen	ADP	O	O
participating	PUNCT	O	O
centres	NOUN	O	O
is	VERB	O	O
being	VERB	O	O
maintained	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
overall	ADJ	O	O
context	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
recruitment	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
arteriographically	ADV	O	O
proven	VERB	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
are	VERB	O	O
considered	VERB	O	O
for	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
if	ADP	O	O
the	DET	O	O
participating	PUNCT	O	O
cardiologist	NOUN	O	O
and	CCONJ	O	O
surgeon	NOUN	O	O
agree	NOUN	O	O
that	ADP	O	O
equivalent	ADJ	O	O
revascularisation	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
by	ADP	O	O
either	CCONJ	O	O
treatment	NOUN	O	O
method	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	ADV	O	O
satisfy	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
entry	NOUN	O	O
criteria	NOUN	O	O
are	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
by	ADP	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
or	CCONJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
bypass	NOUN	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
prospective	ADJ	O	O
stratification	NOUN	O	O
into	ADP	O	O
groups	NOUN	O	O
with	ADP	O	O
one	NUM	O	O
,	PUNCT	O	O
two	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
three	NUM	O	O
treatment	NOUN	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

Randomisation	NOUN	O	O
implies	NOUN	O	O
an	DET	O	O
intention	NOUN	O	O
to	PART	O	O
treat	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
by	ADP	O	O
the	DET	O	O
assigned	VERB	O	O
procedure	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
term	NOUN	O	O
results	NOUN	O	O
will	VERB	O	O
include	VERB	O	O
all	DET	O	O
randomised	VERB	O	O
cases	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
will	VERB	O	O
recruit	VERB	O	O
at	ADP	O	O
least	ADV	O	O
1000	NUM	O	O
patients	NOUN	O	O
who	DET	O	O
will	ADP	O	O
be	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
five	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
major	ADJ	O	O
trial	NOUN	O	O
end	NOUN	O	O
points	NOUN	O	O
include	VERB	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
new	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
new	ADJ	O	B-PHYSICAL
coronary	ADJ	O	I-PHYSICAL
angioplasty	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
coronary	ADJ	O	B-PHYSICAL
artery	NOUN	O	I-PHYSICAL
bypass	NOUN	O	I-PHYSICAL
procedures	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Other	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
include	VERB	O	O
symptom	NOUN	O	B-OTHER
and	CCONJ	O	O
employment	ADJ	O	B-OTHER
status	NOUN	O	I-OTHER
,	PUNCT	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
,	PUNCT	O	O
exercise	NOUN	O	B-PHYSICAL
tolerance	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
left	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Stapled	ADP	O	B-OTHER
hemorrhoidopexy	NOUN	O	I-OTHER
versus	CCONJ	O	O
milligan-morgan	NOUN	O	B-OTHER
hemorrhoidectomy	NOUN	O	I-OTHER
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
trial	NOUN	O	O
with	ADP	O	O
2-year	NOUN	O	O
postoperative	ADJ	O	O
follow	PUNCT	O	O
up	ADJ	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
stapled	VERB	O	B-OTHER
hemorrhoidopexy	NOUN	O	I-OTHER
(	PUNCT	O	O
SH	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
performed	VERB	O	O
using	VERB	O	O
a	DET	O	O
circular	ADJ	O	O
stapler	PUNCT	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
Milligan-Morgan	NOUN	O	O
technique	NOUN	O	O
(	PUNCT	O	O
MM	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
goals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
reproducibility	NOUN	O	B-OTHER
of	ADP	O	O
stapled	VERB	O	O
hemorrhoidopexy	NOUN	O	O
and	CCONJ	O	O
define	PUNCT	O	O
its	CCONJ	O	O
place	NOUN	O	O
among	ADP	O	O
conventional	ADJ	O	O
techniques	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
series	NOUN	O	O
of	ADP	O	O
134	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
at	ADP	O	O
7	NUM	O	O
hospital	NOUN	O	O
centers	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
randomized	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
single-masked	PUNCT	O	O
design	NOUN	O	O
and	CCONJ	O	O
stratified	VERB	O	O
by	ADP	O	O
center	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
balancing	ADP	O	O
every	DET	O	O
4	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
clinically	ADV	O	O
evaluated	VERB	O	O
preoperatively	ADV	O	O
and	CCONJ	O	O
at	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
completed	ADV	O	O
a	DET	O	O
questionnaire	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
1	NUM	O	O
year	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
to	ADJ	O	O
evaluate	ADP	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
function	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
overall	ADJ	O	O
satisfaction	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
mean	NOUN	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
was	VERB	O	O
2.21	NUM	O	O
years	NOUN	O	O
+/-	SYM	O	O
0.26	NUM	O	O
(	PUNCT	O	O
1.89-3.07	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nine	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
could	VERB	O	O
not	ADV	O	O
be	VERB	O	O
monitored	VERB	O	O
at	ADP	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
4	NUM	O	O
of	ADP	O	O
these	DET	O	O
9	ADP	O	O
nevertheless	ADV	O	O
filled	VERB	O	O
in	ADP	O	O
the	DET	O	O
1-year	ADJ	O	O
questionnaire	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
SH	NOUN	O	O
group	NOUN	O	O
experienced	VERB	O	O
less	ADV	O	O
postoperative	ADJ	O	B-PAIN
pain/discomfort	NOUN	O	I-PAIN
as	PUNCT	O	O
scored	VERB	O	O
by	ADP	O	O
pain	NOUN	O	O
during	ADP	O	O
bowel	NOUN	O	B-PAIN
movement	NOUN	O	I-PAIN
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
analgesic	ADP	O	B-OTHER
requirement	NOUN	O	I-OTHER
over	ADP	O	I-OTHER
the	DET	O	I-OTHER
first	ADJ	O	I-OTHER
3	NUM	O	I-OTHER
days	NOUN	O	I-OTHER
(	PUNCT	O	O
according	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
World	NOUN	O	O
Health	NOUN	O	O
Organization	NOUN	O	O
[	PUNCT	O	O
WHO	NOUN	O	O
]	PUNCT	O	O
class	NOUN	O	O
II	NUM	O	O
analgesics	NOUN	O	O
[	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
]	PUNCT	O	O
;	PUNCT	O	O
class	NOUN	O	O
III	NUM	O	O
[	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.066	PUNCT	O	O
]	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
per-patient	PUNCT	O	O
consumption	NOUN	O	O
frequency	NOUN	O	O
of	ADP	O	O
class	NOUN	O	O
III	NUM	O	O
analgesics	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.089	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
clear	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
morphine	NOUN	O	B-OTHER
requirement	NOUN	O	I-OTHER
became	VERB	O	O
evident	ADJ	O	O
after	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.010	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Hospital	NOUN	O	B-PHYSICAL
stay	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
shorter	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
SH	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
SH	NOUN	O	O
2.2	NUM	O	O
+/-	SYM	O	O
1.2	NUM	O	O
[	PUNCT	O	O
0	NUM	O	O
;	PUNCT	O	O
5.0	NUM	O	O
]	PUNCT	O	O
versus	CCONJ	O	O
MM	NOUN	O	O
3.1	NUM	O	O
+/-	SYM	O	O
1.7	NUM	O	O
[	PUNCT	O	O
1	NUM	O	O
;	PUNCT	O	O
8.0	NUM	O	O
]	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
resolution	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
symptoms	NOUN	O	I-OTHER
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
over	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
overall	ADJ	O	B-ADVERSE-EFFECTS
incidence	NOUN	O	O
of	ADP	O	B-ADVERSE-EFFECTS
complications	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
the	DET	O	O
same	ADJ	O	O
,	PUNCT	O	O
specifically	ADV	O	O
fecaloma	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
MM	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
external	ADJ	O	B-ADVERSE-EFFECTS
hemorrhoidal	ADJ	O	I-ADVERSE-EFFECTS
thrombosis	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
SH	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Impaired	VERB	O	B-ADVERSE-EFFECTS
sphincter	NOUN	O	I-ADVERSE-EFFECTS
function	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
with	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
for	ADP	O	O
urgency	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
continence	ADV	O	O
problems	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
tenesmus	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
patient	NOUN	O	O
needed	VERB	O	O
a	DET	O	O
second	ADJ	O	O
procedure	NOUN	O	O
for	ADP	O	O
recurrence	NOUN	O	O
within	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
partial	ADJ	O	B-ADVERSE-EFFECTS
residual	ADJ	O	O
prolapse	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
4	NUM	O	O
SH	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
7.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
1	NUM	O	O
MM	NOUN	O	O
patient	NOUN	O	O
(	PUNCT	O	O
1.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.194	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Stapled	PUNCT	O	O
hemorrhoidopexy	NOUN	O	O
causes	ADV	O	O
significantly	ADV	O	O
less	PUNCT	O	O

Assisted	VERB	O	O
exercise	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
strength	NOUN	O	O
in	ADP	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
have	ADP	O	O
previously	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
brief	ADJ	O	O
(	PUNCT	O	O
4	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
passive	ADJ	O	O
range-of-motion	NOUN	O	O
exercise	NOUN	O	O
is	VERB	O	O
beneficial	ADJ	O	O
for	ADP	O	O
bone	NOUN	O	O
development	NOUN	O	O
in	ADP	O	O
very	ADV	O	O
low	ADJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
(	PUNCT	O	O
VLBW	NOUN	O	O
)	PUNCT	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
optimal	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
for	ADP	O	O
bone	NOUN	O	O
development	NOUN	O	O
in	ADP	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
is	ADP	O	O
yet	ADV	O	O
unknown	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
examine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
assisted	VERB	O	O
exercise	NOUN	O	O
on	ADP	O	O
bone	NOUN	O	O
strength	NOUN	O	O
and	CCONJ	O	O
metabolism	NOUN	O	O
in	ADP	O	O
VLBW	NOUN	O	O
premature	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Sixteen	NUM	O	O
infants	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
+/-	SYM	O	O
standard	ADJ	O	O
error	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mean	NOUN	O	O
birth	NOUN	O	O
weight	NOUN	O	O
1,009	NUM	O	O
+/-	SYM	O	O
55	NUM	O	O
g	NOUN	O	O
and	CCONJ	O	O
gestational	ADJ	O	O
age	NOUN	O	O
27.3	NUM	O	O
+/-	SYM	O	O
0.3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
into	ADP	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
8	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
8	NUM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
started	VERB	O	O
at	ADP	O	O
the	DET	O	O
first	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
and	CCONJ	O	O
involved	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
daily	PUNCT	O	O
passive	ADJ	O	O
extension	NOUN	O	O
and	CCONJ	O	O
flexion	NOUN	O	O
range-of-motion	NOUN	O	O
exercise	NOUN	O	O
of	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
and	CCONJ	O	O
lower	PUNCT	O	O
extremities	NOUN	O	O
.	PUNCT	O	O

Biochemical	ADJ	O	B-PHYSICAL
markers	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
bone	NOUN	O	I-PHYSICAL
turnover	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
enrollment	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Bone	NOUN	O	B-PHYSICAL
strength	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
weekly	ADV	O	O
by	ADP	O	O
quantitative	ADJ	O	O
ultrasound	NOUN	O	O
measurement	NOUN	O	O
of	ADP	O	O
tibial	ADJ	O	B-PHYSICAL
bone	NOUN	O	I-PHYSICAL
speed	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
sound	ADJ	O	I-PHYSICAL
(	PUNCT	O	O
SOS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Bone	NOUN	O	B-PHYSICAL
SOS	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
-108.1	ADJ	O	O
+/-	SYM	O	O
33.7	NUM	O	O
m/second	ADJ	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
study	ADV	O	O
period	NOUN	O	O
,	PUNCT	O	O
while	CCONJ	O	O
remaining	PUNCT	O	O
stable	ADJ	O	O
in	ADP	O	O
the	DET	O	O
exercise	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
11.3	NUM	O	O
+/-	SYM	O	O
22.8	NUM	O	O
m/second	CCONJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	B-PHYSICAL
beneficial	ADJ	O	I-PHYSICAL
effect	NOUN	O	O
of	ADP	O	B-PHYSICAL
exercise	NOUN	O	B-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
4	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bone	NOUN	O	B-PHYSICAL
turnover	NOUN	O	I-PHYSICAL
marker	NOUN	O	I-PHYSICAL
changes	NOUN	O	I-PHYSICAL
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
postnatal	ADJ	O	B-PHYSICAL
decrease	NOUN	O	O
in	PUNCT	O	B-PHYSICAL

Investigations	NOUN	O	O
into	ADP	O	O
the	DET	O	O
potential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
multiple	ADJ	O	O
dose	NOUN	O	O
ketorolac	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
pharmacodynamics	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
racemic	ADJ	O	I-PHYSICAL
warfarin	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

1	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
potential	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
racemic	ADJ	O	O
warfarin	NOUN	O	O
given	VERB	O	O
as	ADP	O	O
a	DET	O	O
25	NUM	O	O
mg	NOUN	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
and	CCONJ	O	O
chronically	ADV	O	O
administered	ADP	O	O
ketorolac	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
12	NUM	O	O
young	ADJ	O	O
healthy	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

2	NUM	O	O
.	PUNCT	O	O

Ketorolac	PUNCT	O	O
produced	PUNCT	O	O
no	DET	O	O
major	ADJ	O	B-PHYSICAL
change	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
pharmacokinetics	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
(	PUNCT	O	O
R	NOUN	O	O
)	PUNCT	O	O
-	PUNCT	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
(	PUNCT	O	O
S	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
-warfarin	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

3	NUM	O	O
.	PUNCT	O	O

Ketorolac	CCONJ	O	O
did	PUNCT	O	O
not	ADV	O	B-PHYSICAL
alter	VERB	O	I-PHYSICAL
the	PUNCT	O	I-PHYSICAL

Patient-reported	VERB	O	O
outcomes	NOUN	O	O
after	ADP	O	O
inguinal	ADJ	O	O
herniorrhaphy	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Patient-reported	VERB	O	O
outcomes	NOUN	O	O
(	PUNCT	O	O
PRO	NOUN	O	O
)	PUNCT	O	O
reflect	VERB	O	O
the	DET	O	O
functional	ADJ	O	O
outcomes	NOUN	O	O
of	ADP	O	O
inguinal	ADJ	O	O
herniorrhaphy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
hernia	NOUN	O	O
recurrence	NOUN	O	O
and	CCONJ	O	O
complications	NOUN	O	O
on	ADP	O	O
PRO	NOUN	O	O
for	ADP	O	O
participants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Veterans	PUNCT	O	O
Affairs	PUNCT	O	O
trial	NOUN	O	O
of	ADP	O	O
Open	ADJ	O	O
or	CCONJ	O	O
Laparoscopic	ADJ	O	O
Repair	NOUN	O	O
of	ADP	O	O
Inguinal	ADJ	O	O
Hernia	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Analyzed	PUNCT	O	O
PRO	NOUN	O	O
included	VERB	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
Medical	ADJ	O	O
Outcomes	NOUN	O	O
Study	PUNCT	O	O
Short	ADJ	O	O
Form	NOUN	O	O
36	NUM	O	O
,	PUNCT	O	O
version	ADJ	O	O
2	NUM	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
Surgical	ADJ	O	O
Pain	NOUN	O	O
Scale	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
Activities	PUNCT	O	O
Assessment	NOUN	O	O
Scale	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
patient	NOUN	O	O
satisfaction	NOUN	O	O
.	PUNCT	O	O

Recurrences	NOUN	O	O
and	CCONJ	O	O
complications	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
at	ADP	O	O
follow-up	NOUN	O	O
visits	NOUN	O	O
.	PUNCT	O	O

Complications	NOUN	O	O
were	VERB	O	O
categorized	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
hematoma/seroma	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
orchitis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
neuralgia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
other	PUNCT	O	O
.	PUNCT	O	O

Univariate	ADJ	O	O
and	CCONJ	O	O
multivariable	ADJ	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
identified	PUNCT	O	O
variables	NOUN	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
postoperative	ADJ	O	O
PRO	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
1603	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
PRO	NOUN	O	O
data	NOUN	O	O
,	PUNCT	O	O
105	NUM	O	O
had	PUNCT	O	O
a	DET	O	O
recurrence	NOUN	O	O
and	CCONJ	O	O
342	NUM	O	O
had	VERB	O	O
a	DET	O	O
complication	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Multivariable	ADJ	O	O
analyses	NOUN	O	O
showed	VERB	O	O
neuralgia	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.0005	NUM	O	O
)	PUNCT	O	O
adversely	ADV	O	O
affected	VERB	O	O
all	DET	O	O
PRO	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
recurrence	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
affected	VERB	O	O
patient-reported	VERB	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
activity	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
satisfaction	NOUN	O	B-OTHER
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	PUNCT	O	O
score	NOUN	O	O
for	ADP	O	O
the	DET	O	O
Medical	ADJ	O	B-OTHER
Outcomes	NOUN	O	I-OTHER
Study	PUNCT	O	I-OTHER
Short	ADJ	O	I-OTHER
Form	NOUN	O	I-OTHER
3	NUM	O	I-OTHER
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
recurrence	NOUN	O	O
after	ADP	O	O
open	ADJ	O	O
repair	NOUN	O	O
had	PUNCT	O	O
more	DET	O	O
pain	NOUN	O	B-PAIN
than	PUNCT	O	O
those	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
recurrence	NOUN	O	O
after	ADP	O	O
laparoscopic	ADJ	O	O
repair	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
complications	NOUN	O	O
after	ADP	O	O
laparoscopic	ADJ	O	O
repair	NOUN	O	O
reported	DET	O	O
more	DET	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
less	DET	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
than	PUNCT	O	O
those	PUNCT	O	O
with	ADP	O	O
other	ADJ	O	O
complications	NOUN	O	O
after	ADP	O	O
open	ADJ	O	O
repair	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.003	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O
=	SYM	O	O
.009	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
inguinal	ADJ	O	O
herniorrhaphy	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
recurrence	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
neuralgia	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Postoperative	ADJ	O	O
neuralgias	PROPN	O	O
have	ADP	O	O
a	DET	O	O
deleterious	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
all	ADP	O	O
patient-reported	VERB	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Reduced	VERB	O	O
cardiotoxicity	NOUN	O	O
and	CCONJ	O	O
comparable	ADJ	O	O
efficacy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
pegylated	VERB	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	O
HCl	NOUN	O	O
(	PUNCT	O	O
CAELYX/Doxil	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
conventional	ADJ	O	O
doxorubicin	NOUN	O	O
for	ADP	O	O
first-line	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
demonstrate	NOUN	O	O
that	ADP	O	O
efficacy	NOUN	O	O
[	PUNCT	O	O
progression-free	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	I-MORTALITY
PFS	NOUN	O	I-MORTALITY
)	PUNCT	O	I-MORTALITY
]	PUNCT	O	O
of	ADP	O	O
CAELYX	NOUN	O	O
[	PUNCT	O	O
pegylated	PROPN	O	O
liposomal	ADJ	O	O
doxorubicin	NOUN	O	O
HCl	VERB	O	O
(	PUNCT	O	O
PLD	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
is	VERB	O	O
non-inferior	ADJ	O	O
to	ADP	O	O
doxorubicin	NOUN	O	O
with	ADP	O	O
significantly	ADV	O	O
less	DET	O	O
cardiotoxicity	NOUN	O	O
in	ADP	O	O
first-line	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
MBC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Women	NOUN	O	O
(	PUNCT	O	O
n=509	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
MBC	NOUN	O	O
and	CCONJ	O	O
normal	ADJ	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
PLD	NOUN	O	O
50	NUM	O	O
mg/m2	NOUN	O	O
(	PUNCT	O	O
every	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
doxorubicin	NOUN	O	O
60	PUNCT	O	O
mg/m2	NOUN	O	O
(	PUNCT	O	O
every	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cardiac	ADJ	O	B-ADVERSE-EFFECTS
event	NOUN	O	O
rates	NOUN	O	B-ADVERSE-EFFECTS
were	VERB	O	O
based	VERB	O	O
on	ADP	O	O
reductions	NOUN	O	O
in	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
as	ADP	O	O
a	DET	O	O
function	NOUN	O	O
of	ADP	O	O
cumulative	ADJ	O	O
anthracycline	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
PLD	NOUN	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
PFS	NOUN	O	B-MORTALITY
[	PUNCT	O	O
6.9	ADJ	O	O
versus	CCONJ	O	O
7.8	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
=1.00	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	NOUN	O	O
)	PUNCT	O	O
0.82-1.22	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Subgroup	NOUN	O	O
results	NOUN	O	O
were	VERB	O	O
consistent	ADJ	O	O
.	PUNCT	O	O

Overall	PUNCT	O	B-ADVERSE-EFFECTS
risk	NOUN	O	O
of	ADP	O	B-ADVERSE-EFFECTS
cardiotoxicity	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
with	ADP	O	O
doxorubicin	NOUN	O	O
than	PUNCT	O	O
PLD	NOUN	O	O
(	PUNCT	O	O
HR=3.16	NOUN	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.58-6.31	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	B-MORTALITY
survival	NOUN	O	B-MORTALITY
was	VERB	O	O
similar	ADJ	O	O
(	PUNCT	O	O
21	NUM	O	O
and	CCONJ	O	O
22	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
PLD	NOUN	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
HR=0.94	NOUN	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.74-1.19	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Alopecia	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
overall	ADJ	O	O
,	PUNCT	O	O
66	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
20	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
pronounced	VERB	O	O
,	PUNCT	O	O
54	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
53	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
37	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
vomiting	ADP	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
31	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
19	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
neutropenia	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
more	ADV	O	O
often	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
doxorubicin	NOUN	O	O
than	PUNCT	O	O
PLD	NOUN	O	O
.	PUNCT	O	O

Palmar-plantar	NOUN	O	B-ADVERSE-EFFECTS
erythrodysesthesia	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
48	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
stomatitis	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
22	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
15	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	PUNCT	O	O

[	PUNCT	O	O
Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy/tolerability	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
cibenzoline	NOUN	O	O
and	CCONJ	O	O
propafenone	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	O
arrhythmia	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Cibenzoline	NOUN	O	O
(	PUNCT	O	O
C	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
propafenone	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
18	NUM	O	O
adult	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
7	NUM	O	O
women	NOUN	O	O
and	CCONJ	O	O
11	NUM	O	O
men	NOUN	O	O
)	PUNCT	O	O
aged	PUNCT	O	O
50	NUM	O	O
+/-	SYM	O	O
7	NUM	O	O
in	ADP	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
wash-out	PUNCT	O	O
period	NOUN	O	O
corresponding	PUNCT	O	O
to	ADP	O	O
5	NUM	O	O
times	NOUN	O	O
the	DET	O	O
half-life	NOUN	O	O
of	ADP	O	O
previous	ADJ	O	O
anti-arrhythmic	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
more	ADV	O	O
than	CCONJ	O	O
100	NUM	O	O
premature	ADJ	O	O
ventricular	ADJ	O	O
contractions	NOUN	O	O
(	PUNCT	O	O
PVC	NOUN	O	O
)	PUNCT	O	O
per	ADP	O	O
hour	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
24	NUM	O	O
hour	NOUN	O	O
Holter	NOUN	O	O
records	NOUN	O	O
obtained	VERB	O	O
at	ADP	O	O
an	DET	O	O
interval	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
in	ADP	O	O
succession	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
randomised	PUNCT	O	O
by	ADP	O	O
C	NOUN	O	O
(	PUNCT	O	O
390	NUM	O	O
mg/day	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
divided	VERB	O	O
doses	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
P	NOUN	O	O
(	PUNCT	O	O
900	NUM	O	O
mg/day	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
divided	VERB	O	O
doses	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
active	ADJ	O	O
sequence	NOUN	O	O
being	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
two	NUM	O	O
week	NOUN	O	O
wash-out	PUNCT	O	O
period	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
(	PUNCT	O	O
based	ADP	O	O
upon	ADP	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
PVC/hour	NOUN	O	O
in	ADP	O	O
a	DET	O	O
24	NUM	O	O
hour	NOUN	O	O
Holter	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
each	DET	O	O
sequence	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
samples	NOUN	O	O
drawn	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
times	NOUN	O	O
for	ADP	O	O
assay	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
dropped	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
with	ADP	O	O
each	DET	O	O
active	ADJ	O	O
drug	NOUN	O	O
(	PUNCT	O	O
for	ADP	O	O
epigastric	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
)	PUNCT	O	I-PAIN
and	CCONJ	O	O
1	NUM	O	O
with	ADP	O	O
dummy	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
regarding	DET	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
number	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
PVC/hour	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
15	NUM	O	O
patients	NOUN	O	O
completing	VERB	O	O
the	DET	O	O
cross-over	NOUN	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
reduction	NOUN	O	B-OTHER
in	ADP	O	I-OTHER
PVC/hour	NOUN	O	I-OTHER
of	ADP	O	O
more	ADV	O	O
than	PUNCT	O	O
70	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
7	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
C	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
9	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
P.	NOUN	O	O
C	NOUN	O	B-OTHER
was	VERB	O	I-OTHER
better	PUNCT	O	I-OTHER
tolerated	ADP	O	I-OTHER
than	PUNCT	O	O
P	NOUN	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
both	CCONJ	O	I-PHYSICAL
clinical	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
electrocardiographic	ADJ	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
developed	VERB	O	O
troublesome	PUNCT	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
reactions	NOUN	O	I-ADVERSE-EFFECTS
with	ADP	O	O
C	NOUN	O	O
as	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
4	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
P.	NOUN	O	O
A	NOUN	O	O
more	ADV	O	O
than	ADP	O	O
20	NUM	O	O
per	ADP	O	B-PHYSICAL
cent	NUM	O	I-PHYSICAL
increase	NOUN	O	O
in	ADP	O	B-PHYSICAL
QRS	NOUN	O	B-PHYSICAL
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
7	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
C	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
P	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
figures	NOUN	O	O
for	ADP	O	O
PR	NOUN	O	O
being	ADV	O	O
2	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
patients	NOUN	O	O
respectively	ADV	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
proarrhythmic	ADJ	O	O
effect	NOUN	O	O
with	ADP	O	O
P.	NOUN	O	O
Plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
C	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
responders	NOUN	O	O
(	PUNCT	O	O
328	NUM	O	O
+/-	SYM	O	O
149	NUM	O	O
ng/ml	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
non-responders	NOUN	O	O
(	PUNCT	O	O
137	NUM	O	O
+/-	SYM	O	O
41	NUM	O	O
ng/ml	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
concerning	ADP	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
P	NOUN	O	O
(	PUNCT	O	O
578	NUM	O	O
+/-	SYM	O	O
477	NUM	O	O
ng/ml	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
646	NUM	O	O
+/-	SYM	O	O
457	NUM	O	O
ng/ml	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	PUNCT	O	O

Retrograde	ADJ	O	O
tracing	ADP	O	O
and	CCONJ	O	O
electrophysiological	ADJ	O	O
findings	NOUN	O	O
of	ADP	O	O
collateral	ADJ	O	O
sprouting	PUNCT	O	O
after	PUNCT	O	O
end-to-side	NUM	O	O
neurorrhaphy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
seek	PROPN	O	O
more	DET	O	O
potent	ADJ	O	O
evidences	NOUN	O	O
of	ADP	O	O
collateral	ADJ	O	O
sprouting	PUNCT	O	O
for	ADP	O	O
both	PUNCT	O	O
motor	NOUN	O	O
and	CCONJ	O	O
sensory	ADJ	O	O
nerve	NOUN	O	O
fibres	NOUN	O	O
after	ADP	O	O
end-to-side	NUM	O	O
neurorrhaphy	NOUN	O	O
using	VERB	O	O
a	DET	O	O
modified	VERB	O	O
double-labelling	VERB	O	O
retrograde	ADJ	O	O
tracing	ADP	O	O
method	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
function	NOUN	O	O
of	ADP	O	O
regenerated	PUNCT	O	O
motor	NOUN	O	O
axons	NOUN	O	O
with	ADP	O	O
electrophysiological	ADJ	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

Four	PUNCT	O	O
groups	NOUN	O	O
(	PUNCT	O	O
n=4	NOUN	O	O
for	ADP	O	O
each	DET	O	O
group	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
:	PUNCT	O	O
end-to-end	NOUN	O	O
coaptation	NOUN	O	O
(	PUNCT	O	O
six	NUM	O	O
months	NOUN	O	O
postoperatively	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
end-to-side	ADV	O	O
coaptation	NOUN	O	O
(	PUNCT	O	O
four	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
six	NUM	O	O
months	NOUN	O	O
postoperatively	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
normal	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
fluorescent	ADJ	O	O
tracers	NOUN	O	O
(	PUNCT	O	O
true	ADJ	O	O
blue	ADJ	O	O
and	CCONJ	O	O
diamidino	PUNCT	O	O
yellow	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
applied	VERB	O	O
to	ADP	O	O
the	DET	O	O
proximal	ADJ	O	O
ends	NOUN	O	O
of	ADP	O	O
tibial	ADJ	O	O
and	CCONJ	O	O
common	ADJ	O	O
peroneal	NOUN	O	O
nerves	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
after	ADP	O	O
four	NUM	O	O
or	CCONJ	O	O
six	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
nerve	NOUN	O	O
coaptation	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
days	NOUN	O	O
later	ADJ	O	O
,	PUNCT	O	O
we	ADP	O	O
only	ADV	O	O
found	PUNCT	O	O
single-labelled	ADJ	O	B-PHYSICAL
motor	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
sensory	ADJ	O	I-PHYSICAL
neurons	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
and	CCONJ	O	O
end-to-end	NOUN	O	O
coaptation	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
some	DET	O	O
dual-labelled	ADV	O	O
neurons	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
end-to-side	NUM	O	O
coaptation	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
motor	NOUN	O	B-PHYSICAL
nerve	NOUN	O	I-PHYSICAL
conduction	NOUN	O	I-PHYSICAL
velocity	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
end-to-side	NOUN	O	I-PHYSICAL
coaptation	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
slower	PUNCT	O	O
than	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

But	CCONJ	O	O
no	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
sixth	ADJ	O	O
month	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
end-to-side	NUM	O	O
neurorrhaphy	NOUN	O	O
can	VERB	O	O
induce	VERB	O	O
the	DET	O	O
functional	ADJ	O	O
collateral	ADJ	O	O
sprouting	PUNCT	O	O
of	ADP	O	O
both	PUNCT	O	O
motor	NOUN	O	O
and	CCONJ	O	O
sensory	ADJ	O	O
axons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nerve	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	O
II	NUM	O	O
receptor	NOUN	O	O
blockade	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
DASH	NOUN	O	O
diet	NOUN	O	O
on	ADP	O	O
markers	NOUN	O	B-PHYSICAL
of	ADP	O	O
endogenous	ADJ	O	O
fibrinolysis	NOUN	O	O
.	PUNCT	O	O

Hypertension	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
impaired	VERB	O	O
fibrinolysis	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
angiotensin	NOUN	O	O
receptor	NOUN	O	O
blockers	NOUN	O	O
(	PUNCT	O	O
ARB	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
DASH	NOUN	O	O
(	PUNCT	O	O
Dietary	ADJ	O	O
Approaches	PROPN	O	O
to	VERB	O	O
Stop	PUNCT	O	O
Hypertension	NOUN	O	O
)	PUNCT	O	O
diet	NOUN	O	O
effectively	ADV	O	O
lower	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Some	DET	O	O
evidence	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
ARBs	NOUN	O	O
could	VERB	O	O
increase	VERB	O	O
fibrinolysis	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
data	NOUN	O	O
is	VERB	O	O
conflicting	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DASH	NOUN	O	O
diet	NOUN	O	O
on	ADP	O	O
fibrinolytic	ADJ	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
.	PUNCT	O	O

Fifty-five	ADJ	O	O
hypertensive	ADJ	O	O
participants	NOUN	O	O
(	PUNCT	O	O
35	NUM	O	O
African-American	ADJ	O	O
,	PUNCT	O	O
20	NUM	O	O
white	ADJ	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
diet	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
DASH	NOUN	O	O
diet	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
diets	NOUN	O	O
did	CCONJ	O	O
not	ADV	O	O
differ	VERB	O	O
in	ADP	O	O
sodium	NOUN	O	O
content	NOUN	O	O
(	PUNCT	O	O
approximately	ADV	O	O
3	NUM	O	O
g/day	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Within	ADP	O	O
each	DET	O	O
diet	NOUN	O	O
,	PUNCT	O	O
individuals	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
losartan	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
cross-over	NOUN	O	O
fashion	NOUN	O	O
.	PUNCT	O	O

Tissue	NOUN	O	B-PHYSICAL
plasminogen	NOUN	O	I-PHYSICAL
activator	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
t-PA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
antigen	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
t-PA	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
plasminogen	NOUN	O	B-PHYSICAL
activator	NOUN	O	I-PHYSICAL
inhibitor-1	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
PAI-1	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
plasma	NOUN	O	B-PHYSICAL
renin	NOUN	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
PRA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
a	DET	O	O
2-week	NOUN	O	O
run-in	NOUN	O	O
period	NOUN	O	O
on	ADP	O	O
the	DET	O	O
control	NOUN	O	O
diet	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
DASH	NOUN	O	O
diet	NOUN	O	O
did	DET	O	O
not	ADV	O	O
affect	VERB	O	O
markers	NOUN	O	O
of	ADP	O	O
fibrinolysis	NOUN	O	O
.	PUNCT	O	O

Losartan	NOUN	O	O
significantly	ADV	O	O
lowered	ADJ	O	O
t-PA	NOUN	O	B-PHYSICAL
antigen	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
-1.8	ADP	O	O
ng/mL	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.045	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
t-PA	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
PAI-1	NOUN	O	B-PHYSICAL
activities	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

This	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
pronounced	VERB	O	O
in	ADP	O	O
whites	PUNCT	O	O
(	PUNCT	O	O
-4.1	PUNCT	O	O
ng/mL	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
African-Americans	VERB	O	O
(	PUNCT	O	O
-0.3	PUNCT	O	O
ng/mL	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
P-interaction	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
materially	PUNCT	O	O
affected	VERB	O	O
by	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
basline	NOUN	O	O
values	NOUN	O	O
or	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrates	NOUN	O	O
that	ADP	O	O
losartan	NOUN	O	O
reduces	NOUN	O	O
t-PA	NOUN	O	B-PHYSICAL
antigen	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
white	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
African-American	ADJ	O	O
hypertensive	ADJ	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
DASH	NOUN	O	O
diet	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
markers	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
fibrinolysis	NOUN	O	I-PHYSICAL
in	ADP	O	O
whites	PUNCT	O	O
or	CCONJ	O	O
African-Americans	PUNCT	O	O
.	PUNCT	O	O

Influence	NOUN	O	O
of	ADP	O	O
phase-related	VERB	O	O
variability	NOUN	O	O
in	ADP	O	O
premenstrual	ADJ	O	B-PHYSICAL
symptomatology	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
mood	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
smoking	PUNCT	O	B-PHYSICAL
withdrawal	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	O
plus	CCONJ	O	O
sequential	ADJ	O	O
CMF	NOUN	O	O
chemotherapy	NOUN	O	O
versus	CCONJ	O	O
tamoxifen	NOUN	O	O
alone	ADJ	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Eighty-eight	PUNCT	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
whom	ADP	O	O
estrogen	NOUN	O	O
receptors	NOUN	O	O
(	PUNCT	O	O
ER	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
positive	ADJ	O	O
or	CCONJ	O	O
unknown	VERB	O	O
,	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
on	ADP	O	O
a	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
therapeutic	ADJ	O	B-OTHER
advantage	NOUN	O	I-OTHER
of	ADP	O	O
sequentially	ADV	O	O
adding	VERB	O	O
low-dose	NOUN	O	O
cyclophosphamide-methotrexate-5-fluorouracil	NOUN	O	O
(	PUNCT	O	O
CMF	NOUN	O	O
)	PUNCT	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
tamoxifen	NOUN	O	O
responders	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
known	PUNCT	O	O
ER	NOUN	O	O
negative	ADJ	O	O
status	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
12-week	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
tamoxifen	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
60	NUM	O	O
%	SYM	O	O
of	ADP	O	O
ER	NOUN	O	O
positive	ADJ	O	O
patients	NOUN	O	O
achieved	ADP	O	O
complete	ADJ	O	B-OTHER
or	CCONJ	O	I-OTHER
partial	ADJ	O	I-OTHER
response	NOUN	O	I-OTHER
as	PUNCT	O	O
did	PUNCT	O	O
35	NUM	O	O
%	SYM	O	O
in	ADP	O	O
whom	ADP	O	O
ER	NOUN	O	O
were	VERB	O	O
unknown	VERB	O	O
.	PUNCT	O	O

Response	NOUN	O	O
status	NOUN	O	O
further	ADV	O	O
improved	VERB	O	O
in	ADP	O	O
18	NUM	O	O
%	SYM	O	O
randomized	VERB	O	O
to	PART	O	O
continue	PROPN	O	O
tamoxifen	NOUN	O	O
alone	ADJ	O	O
vs	CCONJ	O	O
31	NUM	O	O
%	SYM	O	O
in	ADP	O	O
whom	ADP	O	O
CMF	NOUN	O	O
was	VERB	O	O
added	VERB	O	O
to	ADP	O	O
tamoxifen	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
time	NOUN	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	B-PHYSICAL
disease	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
survival	NOUN	O	B-MORTALITY
between	ADP	O	O
the	DET	O	O
ER	NOUN	O	O
positive	ADJ	O	O
and	CCONJ	O	O
ER	NOUN	O	O
unknown	ADJ	O	O
patients	NOUN	O	O
or	CCONJ	O	O
between	ADP	O	O
the	DET	O	O
tamoxifen	NOUN	O	O
and	CCONJ	O	O
tamoxifen	NOUN	O	O
plus	CCONJ	O	O
CMF	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
inability	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
ER	NOUN	O	O
status	NOUN	O	O
should	VERB	O	O
not	PUNCT	O	O
prejudice	PUNCT	O	O
against	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
benefit	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
demonstrated	VERB	O	O
from	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
CMF	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
tamoxifen	NOUN	O	O
responders	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
surveillance	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
pedunculated	VERB	O	O
and	CCONJ	O	O
small	ADJ	O	O
sessile	ADJ	O	O
tubular	ADJ	O	O
and	CCONJ	O	O
tubulovillous	ADJ	O	O
adenomas	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Funen	NOUN	O	O
Adenoma	NOUN	O	O
Follow-up	NOUN	O	O
Study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
We	PRON	O	O
wanted	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
various	ADJ	O	O
surveillance	NOUN	O	O
intervals	NOUN	O	O
on	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
new	ADJ	O	B-PHYSICAL
neoplasia	NOUN	O	I-PHYSICAL
after	ADP	O	O
removal	NOUN	O	O
of	ADP	O	O
pedunculated	ADP	O	O
and	CCONJ	O	O
small	ADJ	O	O
sessile	ADJ	O	O
tubular	ADJ	O	O
and	CCONJ	O	O
tubulovillous	ADJ	O	O
adenomas	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
After	ADP	O	O
initial	ADJ	O	O
colonoscopic	PUNCT	O	O
polypectomy	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
surveillance	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
2	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
4	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
between	ADP	O	O
colorectal	ADJ	O	O
examinations	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
cumulated	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
a	DET	O	B-PHYSICAL
patient	NOUN	O	I-PHYSICAL
having	PUNCT	O	I-PHYSICAL
new	ADJ	O	I-PHYSICAL
adenomas	NOUN	O	I-PHYSICAL
was	VERB	O	O
35.0	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
28.7-41.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
35.5	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
28.4-42.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
after	ADP	O	O
48	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
increased	VERB	O	O
to	ADP	O	O
44.9	ADV	O	O
%	ADJ	O	O
(	PUNCT	O	O
36.0-53.9	NUM	O	O
%	ADP	O	O
)	PUNCT	O	O
and	CCONJ	O	O
60.1	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
48.5-71.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
after	ADP	O	O
96	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
significant	ADJ	O	B-PHYSICAL
neoplasia	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
carcinoma	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
adenoma	NOUN	O	B-PHYSICAL
with	ADP	O	I-PHYSICAL
villous	ADJ	O	I-PHYSICAL
structure	NOUN	O	O
,	PUNCT	O	O
severe	ADJ	O	B-PHYSICAL
dysplasia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	CCONJ	O	O
diameter	NOUN	O	O
>	SYM	O	O
10	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
5.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
2.3-8.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
8.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
3.8-13.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
after	ADP	O	O
48	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
8.6	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
4.2-13.0	ADV	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
17.4	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
7.6-27.2	ADP	O	O
%	SYM	O	O
)	PUNCT	O	O
after	ADP	O	O
96	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

More	DET	O	O
than	ADP	O	O
one	NUM	O	O
adenoma	NOUN	O	O
at	ADP	O	O
first	ADJ	O	O
examination	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
higher	PUNCT	O	O
risk	PUNCT	O	O

Cost-effectiveness	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	O
coronary	ADJ	O	O
syndromes	NOUN	O	O
in	ADP	O	O
Canada	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
long-term	NOUN	O	O
analysis	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
CURE	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Cardiovascular	ADJ	O	O
diseases	NOUN	O	O
account	VERB	O	O
for	ADP	O	O
nearly	ADV	O	O
20	NUM	O	O
%	SYM	O	O
of	ADP	O	O
all	DET	O	O
hospitalizations	NOUN	O	O
in	ADP	O	O
Canada	PUNCT	O	O
and	CCONJ	O	O
consume	PUNCT	O	O
12	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
cost	NOUN	O	O
of	ADP	O	O
all	DET	O	O
illnesses	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
increasing	ADJ	O	O
trends	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
and	CCONJ	O	O
increasing	PUNCT	O	O
costs	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
,	PUNCT	O	O
development	NOUN	O	O
of	ADP	O	O
cost-effective	ADJ	O	O
strategies	NOUN	O	O
is	VERB	O	O
vital	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
Clopidogrel	NOUN	O	O
in	ADP	O	O
Unstable	ADJ	O	O
angina	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
Recurrent	ADJ	O	O
Events	NOUN	O	O
(	PUNCT	O	O
CURE	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
demonstrated	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	O
plus	CCONJ	O	O
acetylsalicylic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
ASA	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
ASA	NOUN	O	O
alone	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
coronary	ADJ	O	O
syndromes	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Percutaneous	ADJ	O	O
Coronary	ADJ	O	O
Intervention	NOUN	O	O
in	ADP	O	O
CURE	NOUN	O	O
(	PUNCT	O	O
PCI-CURE	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
the	DET	O	O
cost-effectiveness	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Canadian	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Estimates	NOUN	O	O
of	ADP	O	O
hospitalization	NOUN	O	O
costs	NOUN	O	O
were	VERB	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
2003	NUM	O	O
cost	NOUN	O	O
schedules	NOUN	O	O
released	VERB	O	O
by	ADP	O	O
the	DET	O	O
Health	NOUN	O	O
Funding	PUNCT	O	O
and	CCONJ	O	O
Costing	PUNCT	O	O
Branch	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Alberta	PUNCT	O	O
Health	NOUN	O	O
and	CCONJ	O	O
Wellness	PUNCT	O	O
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
Case	NOUN	O	O
Mix	NOUN	O	O
Group	NOUN	O	O
classification	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

Life	NOUN	O	O
expectancy	NOUN	O	O
beyond	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
estimated	VERB	O	O
from	ADP	O	O
the	DET	O	O
Saskatchewan	NOUN	O	O
Health	NOUN	O	O
Database	NOUN	O	O
.	PUNCT	O	O

Cost-effectiveness	NOUN	O	O
was	VERB	O	O
expressed	VERB	O	O
as	ADP	O	O
the	DET	O	O
incremental	ADJ	O	O
cost-effectiveness	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bootstrap	NOUN	O	O
methods	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
estimate	NOUN	O	O
the	DET	O	O
joint	NOUN	O	O
distribution	NOUN	O	O
of	ADP	O	O
costs	NOUN	O	O
and	CCONJ	O	O
effectiveness	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Clopidogrel	NOUN	O	O
was	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
cost-effective	ADJ	O	B-OTHER
,	PUNCT	O	O
with	ADP	O	O
incremental	ADJ	O	O
cost-effectiveness	NOUN	O	B-OTHER
ratios	NOUN	O	I-OTHER
less	ADV	O	O
than	VERB	O	O
$	SYM	O	O
10,000	NUM	O	O
per	ADP	O	O
event	NOUN	O	O
prevented	ADP	O	B-OTHER
and	CCONJ	O	O
less	ADV	O	O
than	VERB	O	O
$	SYM	O	O
4,000	NUM	O	O
per	ADP	O	O
life-year	NOUN	O	O
gained	VERB	O	B-OTHER
.	PUNCT	O	O

The	DET	O	O
probability	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
cost	NOUN	O	O
per	ADP	O	O
life-year	NOUN	O	B-OTHER
gained	VERB	O	I-OTHER
of	ADP	O	O
less	ADV	O	O
than	PUNCT	O	O
$	ADV	O	O
20,000	NUM	O	O
was	VERB	O	O
0.975	PUNCT	O	O
for	ADP	O	O
CURE	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
0.904	NUM	O	O
for	ADP	O	O
PCI-CURE	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
economic	ADJ	O	O
analysis	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
clopidogrel	NOUN	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
only	ADV	O	O
cost-effective	ADJ	O	O
as	ADP	O	O
antiplatelet	NOUN	O	O
therapy	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
ASA	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
also	ADV	O	O
cost-effective	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
commonly	ADV	O	O
used	DET	O	O
and	CCONJ	O	O
openly	ADV	O	O
reimbursed	PUNCT	O	O
cardiovascular	ADJ	O	O
therapies	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Canadian	ADJ	O	O
health	NOUN	O	O
care	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

Strategies	NOUN	O	O
for	ADP	O	O
dietary	ADJ	O	O
and	CCONJ	O	O
anti-smoking	VERB	O	O
advice	NOUN	O	O
.	PUNCT	O	O

Practical	ADJ	O	O
experiences	ADJ	O	O
from	ADP	O	O
the	DET	O	O
Oslo	NOUN	O	O
Study	NOUN	O	O
.	PUNCT	O	O

One	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
2	NUM	O	O
controlled	VERB	O	O
preventive	ADJ	O	O
trials	NOUN	O	O
within	ADP	O	O
the	DET	O	O
Oslo	NOUN	O	O
Study	NOUN	O	O
was	VERB	O	O
a	DET	O	O
non-drug	NOUN	O	O
trial	NOUN	O	O
on	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
diet	NOUN	O	B-OTHER
and	CCONJ	O	O
smoking	VERB	O	B-OTHER
intervention	NOUN	O	I-OTHER
on	ADP	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
in	ADP	O	O
1232	NUM	O	O
middleaged	PROPN	O	O
,	PUNCT	O	O
normotensive	ADJ	O	O
,	PUNCT	O	O
healthy	ADJ	O	O
men	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
had	PUNCT	O	O
elevated	VERB	O	O
serum	NOUN	O	O
cholesterol	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
5	NUM	O	O
smoked	PUNCT	O	O
every	DET	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
participants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
met	VERB	O	O
every	DET	O	O
6	NUM	O	O
months	NOUN	O	O
during	ADP	O	O
the	DET	O	O
5-year	ADJ	O	O
study	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
examination	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
dietary	ADJ	O	O
and	CCONJ	O	O
smoking	VERB	O	B-OTHER
counselling	PROPN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
serum	NOUN	O	B-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
was	VERB	O	O
a	DET	O	O
13	NUM	O	O
%	SYM	O	O
lowering	SYM	O	O
(	PUNCT	O	O
i.e	ADV	O	O
.	PUNCT	O	O

10	NUM	O	O
%	SYM	O	O
net	ADJ	O	O
reduction	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
about	ADP	O	O
a	DET	O	O
50	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
in	ADP	O	O
cigarette	NOUN	O	B-MENTAL
consumption	NOUN	O	I-MENTAL
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
coronary	ADJ	O	B-PHYSICAL
heart	NOUN	O	I-PHYSICAL
disease	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
fatal	ADJ	O	O
and	CCONJ	O	O
non-fatal	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
or	CCONJ	O	O
sudden	ADJ	O	O
death	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
47	NUM	O	O
%	SYM	O	O
lowering	DET	O	O
of	ADP	O	O
the	DET	O	O
5-year	ADJ	O	O
incidence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
,	PUNCT	O	O
2-sided	VERB	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
intervention	NOUN	O	O
strategies	NOUN	O	O
were	ADJ	O	O
:	PUNCT	O	O
information	NOUN	O	O
about	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
concept	NOUN	O	O
to	ADP	O	O
participant	PUNCT	O	O
and	CCONJ	O	O
spouse	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
groups	NOUN	O	O
)	PUNCT	O	O
individual	ADJ	O	O
diet	NOUN	O	O
and	CCONJ	O	O
anti-smoking	VERB	O	O
counselling	VERB	O	O
after	ADP	O	O
finishing	DET	O	O
an	DET	O	O
extensive	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
electrocardiographic	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
exercise-ECG	NOUN	O	O
basis	NOUN	O	O
and	CCONJ	O	O
background	NOUN	O	O
for	ADP	O	O
the	DET	O	O
counselling	DET	O	O
strategy	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
total	ADJ	O	O
situation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
participant	NOUN	O	O
.	PUNCT	O	O

Some	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
most	VERB	O	O
important	ADJ	O	O
items	NOUN	O	O
:	PUNCT	O	O
personality	NOUN	O	O
,	PUNCT	O	O
motivation	NOUN	O	O
,	PUNCT	O	O
diet	NOUN	O	O
history	NOUN	O	O
,	PUNCT	O	O
bodyweight	ADJ	O	O
,	PUNCT	O	O
blood	NOUN	O	O
lipids	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
sugar	NOUN	O	O
anti-smoking	DET	O	O
advice	NOUN	O	O
given	VERB	O	O
individually	ADV	O	O
to	ADP	O	O
all	DET	O	O
smokers	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
advice	NOUN	O	O
that	ADP	O	O
smoking	ADJ	O	O
cessation	NOUN	O	O
was	VERB	O	O
expected	VERB	O	O
to	DET	O	O
be	PUNCT	O	O
of	ADP	O	O
special	ADJ	O	O
importance	NOUN	O	O
for	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
elevated	VERB	O	O
blood	NOUN	O	O
lipids	NOUN	O	O
.	PUNCT	O	O

Preventing	ADV	O	O
disability	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
falls	ADJ	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
older	PUNCT	O	O
adults	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
a	DET	O	O
population-based	VERB	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
Because	PUNCT	O	O
preventing	ADP	O	O
disability	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
falls	ADJ	O	B-PHYSICAL
in	ADP	O	B-PHYSICAL
older	PUNCT	O	O
adults	NOUN	O	B-PHYSICAL
is	VERB	O	O
a	DET	O	O
national	ADJ	O	O
priority	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
test	NOUN	O	O
a	DET	O	O
multicomponent	ADJ	O	O
intervention	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
From	ADP	O	O
a	DET	O	O
random	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
health	NOUN	O	O
maintenance	NOUN	O	O
organization	NOUN	O	O
(	PUNCT	O	O
HMO	NOUN	O	O
)	PUNCT	O	O
enrollees	NOUN	O	O
65	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
,	PUNCT	O	O
1559	NUM	O	O
ambulatory	ADJ	O	O
seniors	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
nurse	ADJ	O	O
assessment	NOUN	O	O
visit	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
interventions	NOUN	O	O
targeting	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
disability	NOUN	O	O
and	CCONJ	O	O
falls	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
635	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
a	DET	O	O
general	ADJ	O	O
health	NOUN	O	O
promotion	NOUN	O	O
nurse	ADJ	O	O
visit	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
317	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
usual	ADJ	O	O
care	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
607	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Data	NOUN	O	O
collection	NOUN	O	O
consisted	ADJ	O	O
of	ADP	O	O
a	DET	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
two	NUM	O	O
annual	ADJ	O	O
follow-up	NOUN	O	O
surveys	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
subjects	NOUN	O	O
reported	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
declining	NUM	O	B-PHYSICAL
functional	ADJ	O	B-PHYSICAL
status	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
a	DET	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
falls	CCONJ	O	B-PHYSICAL
than	PUNCT	O	O
group	NOUN	O	O
3	NUM	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
2	NUM	O	O
subjects	NOUN	O	O
had	VERB	O	O
intermediate	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
most	DET	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
differences	NOUN	O	O
narrowed	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
modest	ADJ	O	O
,	PUNCT	O	O
one-time	ADJ	O	O
prevention	NOUN	O	O
program	NOUN	O	O
appeared	VERB	O	O
to	PUNCT	O	O
confer	PUNCT	O	O

A	DET	O	O
comparative	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
fixed	VERB	O	O
ratio	NOUN	O	O
beta-adrenoceptor	NOUN	O	O
blocker	NOUN	O	O
and	CCONJ	O	O
diuretic	NOUN	O	O
combination	NOUN	O	O
products	NOUN	O	O
in	ADP	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
fixed	VERB	O	O
ratio	NOUN	O	O
combination	NOUN	O	O
tablets	ADV	O	O
,	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
pindolol	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
5	NUM	O	O
mg	NOUN	O	O
clopamide	NOUN	O	O
and	CCONJ	O	O
100	NUM	O	O
mg	NOUN	O	O
metoprolol	NOUN	O	O
combined	PROPN	O	O
with	ADP	O	O
12.5	NUM	O	O
mg	NOUN	O	O
hydrochlorothiazide	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
at	ADP	O	O
two	NUM	O	O
dose	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
crossover	ADP	O	O
trial	NOUN	O	O
in	ADP	O	O
10	NUM	O	O
previously	ADV	O	O
untreated	PUNCT	O	O
hypertensive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
resting	VERB	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
on	ADP	O	O
the	DET	O	O
two	NUM	O	O
combinations	NOUN	O	O
at	ADP	O	O
either	PUNCT	O	O
dose	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

Exercise	NOUN	O	B-PHYSICAL
systolic	ADJ	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
was	VERB	O	O
lower	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
pindolol/clopamide	NOUN	O	O
combination	NOUN	O	O
at	ADP	O	O
low	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
side-effects	NOUN	O	B-ADVERSE-EFFECTS
in	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
high	ADJ	O	O
but	CCONJ	O	O
proper	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
products	NOUN	O	O
could	VERB	O	O
not	ADV	O	O
be	VERB	O	O
made	VERB	O	O
because	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
small	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	VERB	O	O
combination	NOUN	O	O
products	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
only	ADV	O	O
after	ADP	O	O
patients	NOUN	O	O
have	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
respond	NOUN	O	O
adequately	ADV	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Elevated	ADP	O	O
concentration	NOUN	O	O
of	ADP	O	O
placental	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
PlGF	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
long	ADJ	O	O
term	NOUN	O	O
risk	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
coronary	ADJ	O	O
syndrome	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PROVE	NOUN	O	O
IT-TIMI	NOUN	O	O
22	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Placental	ADJ	O	B-PHYSICAL
growth	NOUN	O	I-PHYSICAL
factor	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
PlGF	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
member	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
VEGF	NOUN	O	O
)	PUNCT	O	O
family	NOUN	O	O
,	PUNCT	O	O
acts	NOUN	O	O
via	ADP	O	O
the	DET	O	O
flt-1	NOUN	O	O
receptor	NOUN	O	O
and	CCONJ	O	O
promotes	ADV	O	O
endothelial	ADJ	O	O
activation	NOUN	O	O
and	CCONJ	O	O
macrophage	NOUN	O	O
recruitment	NOUN	O	O
into	ADP	O	O
atherosclerotic	ADJ	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
of	ADP	O	O
PlGF	NOUN	O	O
with	ADP	O	O
cardiovascular	ADJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
cohort	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
presenting	ADJ	O	O
across	ADP	O	O
the	DET	O	O
spectrum	NOUN	O	O
of	ADP	O	O
ACS	NOUN	O	O
.	PUNCT	O	O

PlGF	NOUN	O	B-MENTAL
was	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3,761	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
four-months	ADP	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3,369	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
atorvastatin	NOUN	O	O
80	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
pravastatin	NOUN	O	O
40	NUM	O	O
mg	NOUN	O	O
after	ADP	O	O
ACS	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PROVE	NOUN	O	O
IT-TIMI	NOUN	O	O
22	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
myocardial	PUNCT	O	B-PHYSICAL

EEG	NOUN	O	O
mapping	PUNCT	O	O
and	CCONJ	O	O
psychopharmacological	ADJ	O	O
studies	NOUN	O	O
with	ADP	O	O
denbufylline	NOUN	O	O
in	ADP	O	O
SDAT	NOUN	O	O
and	CCONJ	O	O
MID	NOUN	O	O
.	PUNCT	O	O

Computed	VERB	O	O
tomography	NOUN	O	O
(	PUNCT	O	O
CT	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
electroencephalograms	NOUN	O	O
(	PUNCT	O	O
EEG	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
psychometric	ADJ	O	O
data	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
96	NUM	O	O
mildly	ADJ	O	O
to	PUNCT	O	O
moderately	ADV	O	O
demented	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
72	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
24	NUM	O	O
men	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
61-96	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
82	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
diagnosed	VERB	O	O
according	CCONJ	O	O
to	ADP	O	O
DSM-III	NUM	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
off	ADP	O	O
drugs	NOUN	O	O
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
2	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
subdiagnosed	ADP	O	O
according	ADP	O	O
to	ADP	O	O
the	DET	O	O
modified	VERB	O	O
Marshall-Hachinski	PUNCT	O	O
ischemic	ADJ	O	O
score	NOUN	O	O
and	CCONJ	O	O
CT	NOUN	O	O
in	ADP	O	O
45	NUM	O	O
senile	ADJ	O	O
dementia	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Alzheimer	PUNCT	O	O
type	NOUN	O	O
(	PUNCT	O	O
SDAT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
51	NUM	O	O
multiinfarct	NOUN	O	O
dementia	NOUN	O	O
(	PUNCT	O	O
MID	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Evaluations	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
before	ADP	O	O
and	CCONJ	O	O
12	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
100	PUNCT	O	O
mg	NOUN	O	O
denbufylline	NOUN	O	O
BID	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
included	VERB	O	O
EEG	NOUN	O	O
mapping	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
Sandoz	NOUN	O	O
Clinical	ADJ	O	O
Assessment	NOUN	O	O
Geriatric	ADJ	O	O
(	PUNCT	O	O
SCAG	NOUN	O	O
)	PUNCT	O	O
score/factors	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Clinical	ADJ	O	O
Global	ADJ	O	O
Impression	NOUN	O	O
(	PUNCT	O	O
CGI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
Digit	NOUN	O	O
Symbol	NOUN	O	O
Substitution	NOUN	O	O
Test	NOUN	O	O
(	PUNCT	O	O
DSST	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
Trail-Making	PUNCT	O	O
Test	NOUN	O	O
(	PUNCT	O	O
TMT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Digit	NOUN	O	O
Span	NOUN	O	O
Test	NOUN	O	O
(	PUNCT	O	O
DS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Descriptive	ADJ	O	O
data	NOUN	O	O
analysis	NOUN	O	O
including	VERB	O	O
confirmatory	ADJ	O	O
statements	NOUN	O	O
found	VERB	O	O
delta/theta	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
enhanced	VERB	O	O
,	PUNCT	O	O
alpha	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
beta	NOUN	O	B-PHYSICAL
activity	NOUN	O	I-PHYSICAL
reduced	VERB	O	O
,	PUNCT	O	O
total	ADJ	O	O
power	NOUN	O	B-PHYSICAL
augmented	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
centroid	NOUN	O	B-PHYSICAL
slowed	DET	O	O
down	ADJ	O	O
over	ADP	O	O
various	ADJ	O	O
brain	NOUN	O	O
regions	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
subtypes	NOUN	O	O
of	ADP	O	O
dementia	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
differentiated	VERB	O	O
in	ADP	O	O
some	DET	O	O
conventional	ADJ	O	O
EEG	NOUN	O	O
variables	NOUN	O	O
but	CCONJ	O	O
mostly	ADV	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
power	NOUN	O	O
asymmetry	NOUN	O	O
indices	NOUN	O	O
.	PUNCT	O	O

Denbufylline	NOUN	O	O
induced	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
and	CCONJ	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
both	PUNCT	O	O
SDAT	NOUN	O	B-OTHER
and	CCONJ	O	O
MID	NOUN	O	B-OTHER
patients	NOUN	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
after	ADP	O	O
placebo	NOUN	O	O
this	VERB	O	O
was	NUM	O	O
not	ADV	O	O
the	DET	O	O
case	NOUN	O	O
in	ADP	O	O
CGI	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
TMT	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
DS	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
interdrug	NOUN	O	O
differences	NOUN	O	O
being	VERB	O	O
significant	ADJ	O	O
in	ADP	O	O
all	DET	O	O
primary	ADJ	O	O
target	NOUN	O	O
variables	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
the	DET	O	O
CGI	NOUN	O	O
,	PUNCT	O	O
MMS	NOUN	O	O
,	PUNCT	O	O
SCAG	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
DSST	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
both	PUNCT	O	O
the	DET	O	O
degenerative	ADJ	O	O
and	CCONJ	O	O
vascular	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
dementia	NOUN	O	O
exhibited	VERB	O	O
a	DET	O	O
therapeutic	ADJ	O	O
benefit	NOUN	O	O
that	ADP	O	O
could	ADP	O	O
be	ADP	O	O
objectified	VERB	O	O
at	ADP	O	O
the	DET	O	O
neurophysiological	ADJ	O	O
level	NOUN	O	O
by	ADP	O	O
EEG	NOUN	O	O
mapping	PUNCT	O	O
in	ADP	O	O
an	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
vigilance	NOUN	O	O
.	PUNCT	O	O

Alendronate	NOUN	O	O
daily	ADJ	O	O
,	PUNCT	O	O
weekly	ADV	O	O
in	ADP	O	O
conventional	ADJ	O	O
tablets	ADV	O	O
and	CCONJ	O	O
weekly	ADV	O	O
in	ADP	O	O
enteric	ADJ	O	O
tablets	ADV	O	O
:	PUNCT	O	O
preliminary	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
in	ADP	O	O
bone	NOUN	O	B-PHYSICAL
turnover	NOUN	O	I-PHYSICAL
markers	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
side	NOUN	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Bisphosphonates	ADP	O	O
are	NOUN	O	O
now	ADV	O	O
in	ADP	O	O
the	DET	O	O
vanguard	PUNCT	O	O
of	ADP	O	O
osteoporosis	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Frequently	ADV	O	O
,	PUNCT	O	O
gastro-oesophageal	ADJ	O	O
symptoms	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
turnover	NOUN	O	O
markers	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
received	SYM	O	O
alendronate	NOUN	O	O
daily	ADJ	O	O
or	CCONJ	O	O
weekly	ADV	O	O
in	ADP	O	O
tablets	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
enteric	ADJ	O	O
coating	SYM	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
3-month	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
involved	VERB	O	O
75	NUM	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
45-58	PUNCT	O	O
with	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	CCONJ	O	O
osteopenia	NOUN	O	O
(	PUNCT	O	O
T-score	NOUN	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
-2	NUM	O	O
SD	NOUN	O	O
)	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
quantitative	ADJ	O	O
ultrasound	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	PART	O	O
receive	ADP	O	O
:	PUNCT	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
alendronate	NOUN	O	O
10mg/day	NUM	O	O
:	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
alendronate	NOUN	O	O
70	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
a	DET	O	O
week	NOUN	O	O
:	PUNCT	O	O
or	CCONJ	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
enteric	ADJ	O	O
alendronate	NOUN	O	O
70	NUM	O	O
mg	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
recorded	PROPN	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
C-telopeptide	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
osteocalcin	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
urine	NOUN	O	B-PHYSICAL
hydroxyproline	NOUN	O	I-PHYSICAL
at	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
pyrosis	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
heartburn	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
was	VERB	O	O
noted	VERB	O	O
by	ADP	O	O
seven	NUM	O	O
women	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
28	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
three	NUM	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
in	ADP	O	O
group	NOUN	O	O
C	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
nausea	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
by	ADP	O	O
one	NUM	O	O
woman	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	B-PHYSICAL
by	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

C-telopeptide	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
A	NOUN	O	O
:	PUNCT	O	O
40.7	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
B	NOUN	O	O
:	PUNCT	O	O
34.1	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
C	NOUN	O	O
:	PUNCT	O	O
38.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
hydroxyproline	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
A	NOUN	O	O
:	PUNCT	O	O
31.1	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
B	NOUN	O	O
:	PUNCT	O	O
25.3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
C	NOUN	O	O
:	PUNCT	O	O
31.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
osteocalcin	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
A	NOUN	O	O
:	PUNCT	O	O
27.0	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
B	NOUN	O	O
:	PUNCT	O	O
25.4	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
C	NOUN	O	O
:	PUNCT	O	O
25.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
decreased	VERB	O	O
similarly	ADV	O	O
in	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Weekly	ADV	O	O
intake	NOUN	O	O
of	ADP	O	O
alendronate	NOUN	O	O
,	PUNCT	O	O
whether	ADP	O	O
conventional	ADJ	O	O
or	CCONJ	O	O
enteric-coated	VERB	O	O
;	PUNCT	O	O
is	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
less	DET	O	O
heartburn	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
nausea	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Enteric	ADJ	O	O
alendronate	NOUN	O	O
has	PUNCT	O	O
a	DET	O	O
similar	ADJ	O	O
action	NOUN	O	O
to	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
tablets	ADV	O	O
on	ADP	O	O
biochemical	ADJ	O	B-PHYSICAL
markers	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Impact	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
platelet	NOUN	O	O
glycoprotein	NOUN	O	O
IIb/IIIa	NOUN	O	O
receptor	NOUN	O	O
inhibitors	NOUN	O	O
among	ADP	O	O
diabetic	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
:	PUNCT	O	O
:	PUNCT	O	O
Do	PUNCT	O	O
Tirofiban	NOUN	O	O
and	CCONJ	O	O
ReoPro	NOUN	O	O
Give	VERB	O	O
Similar	ADJ	O	O
Efficacy	NOUN	O	O
Outcomes	NOUN	O	O
Trial	NOUN	O	O
(	PUNCT	O	O
TARGET	NOUN	O	O
)	PUNCT	O	O
1-year	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
platelet	NOUN	O	O
glycoprotein	NOUN	O	O
IIb/IIIa	NOUN	O	O
receptor	NOUN	O	O
inhibitor	NOUN	O	O
abciximab	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
monoclonal	ADJ	O	O
antibody	NOUN	O	O
,	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
improve	PUNCT	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
outcomes	NOUN	O	O
among	ADP	O	O
diabetic	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
PCI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
unknown	VERB	O	O
whether	ADP	O	O
small-molecule	NOUN	O	O
agents	NOUN	O	O
confer	VERB	O	O
similar	ADJ	O	O
benefits	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
In	ADP	O	O
18	NUM	O	O
countries	NOUN	O	O
,	PUNCT	O	O
4809	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
PCI	NOUN	O	O
with	ADP	O	O
stent	NOUN	O	O
implantation	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
tirofiban	NOUN	O	O
or	CCONJ	O	O
abciximab	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
enrollment	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
stratified	VERB	O	O
according	ADP	O	O
to	ADP	O	O
diabetes	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

As	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
non-diabetic	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
(	PUNCT	O	O
n=1117	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
similar	ADJ	O	O
30-day	NOUN	O	O
ischemic	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
any	DET	O	B-PHYSICAL
target	NOUN	O	I-PHYSICAL
vessel	NOUN	O	I-PHYSICAL
revascularization	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
TVR	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
10.3	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
7.8	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P=	NOUN	O	O
0.008	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
higher	PUNCT	O	B-MORTALITY
1-year	NOUN	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
(	PUNCT	O	O
2.5	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
1.6	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P=0.056	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
diabetic	ADJ	O	O
patients	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
tirofiban	NOUN	O	O
(	PUNCT	O	O
n=560	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
death	NOUN	O	B-MORTALITY
,	PUNCT	O	O
myocardial	ADJ	O	B-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
MI	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
or	PUNCT	O	O

[	PUNCT	O	O
Bupivacaine-CO2	NOUN	O	O
and	CCONJ	O	O
bupivacaine-HCl	NOUN	O	O
at	ADP	O	O
various	ADJ	O	O
injection	NOUN	O	O
temperatures	NOUN	O	O
in	ADP	O	O
peridural	ADJ	O	O
anesthesia	NOUN	O	O
for	ADP	O	O
extracorporeal	ADJ	O	O
shock	NOUN	O	O
wave	NOUN	O	O
lithotripsy	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
injection	NOUN	O	O
temperatures	NOUN	O	O
on	ADP	O	O
carbonated	VERB	O	O
anesthetics	NOUN	O	O
has	PUNCT	O	O
been	ADP	O	O
controversial	ADJ	O	O
since	ADP	O	O
1965	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
onset	NOUN	O	O
times	NOUN	O	O
of	ADP	O	O
sensory	ADJ	O	O
and	CCONJ	O	O
motor	NOUN	O	O
blockade	NOUN	O	O
after	ADP	O	O
epidural	ADJ	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
0.5	NUM	O	O
%	SYM	O	O
bupivacaine-CO2	NOUN	O	O
and	CCONJ	O	O
0.5	NUM	O	O
%	SYM	O	O
bupivacaine-HCl	NOUN	O	O
at	ADP	O	O
various	ADJ	O	O
injection	NOUN	O	O
temperatures	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
90	NUM	O	O
ASA	NOUN	O	O
class	NOUN	O	O
I-II	ADV	O	O
urologic	ADJ	O	O
patients	NOUN	O	O
during	ADP	O	O
extracorporeal	ADJ	O	O
shock	NOUN	O	O
wave	NOUN	O	O
lithotripsy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
in	ADP	O	O
six	DET	O	O
groups	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
0.5	NUM	O	O
%	SYM	O	O
bupivacaine-CO2	NOUN	O	O
or	CCONJ	O	O
0.5	NUM	O	O
%	SYM	O	O
bupivacaine-HCl	NOUN	O	O
at	ADP	O	O
temperatures	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
degrees	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
degrees	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
36	NUM	O	O
degrees	ADJ	O	O
C.	PUNCT	O	O
The	DET	O	O
six	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
height	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
weight	NOUN	O	O
.	PUNCT	O	O

Epidural	ADJ	O	O
anesthesia	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
the	DET	O	O
L2-3	NOUN	O	O
interspace	NOUN	O	O
with	ADP	O	O
an	DET	O	O
18-gauge	NOUN	O	O
Tuohy	NOUN	O	O
needle	NOUN	O	O
using	VERB	O	O
loss	NOUN	O	O
of	ADP	O	O
resistance	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
catheter	NOUN	O	O
was	VERB	O	O
advanced	VERB	O	O
4	NUM	O	O
cm	NOUN	O	O
in	ADP	O	O
the	DET	O	O
epidural	ADJ	O	O
space	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
ml	NOUN	O	O
0.5	NUM	O	O
%	SYM	O	O
bupivacaine	NOUN	O	O
with	ADP	O	O
adrenaline	PUNCT	O	O
1:200,000	ADV	O	O
was	VERB	O	O
given	VERB	O	O
as	ADP	O	O
a	DET	O	O
test	PUNCT	O	O
dose	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
4	NUM	O	O
min	NOUN	O	O
the	DET	O	O
full	ADJ	O	O
anesthetic	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
body	NOUN	O	O
size	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
supine	NOUN	O	O
.	PUNCT	O	O

Sensory	ADJ	O	B-OTHER
blockade	NOUN	O	I-OTHER
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
the	DET	O	O
pinprick	NOUN	O	O
method	NOUN	O	O
and	CCONJ	O	O
motor	NOUN	O	B-OTHER
blockade	NOUN	O	I-OTHER
by	ADP	O	O
the	DET	O	O
Bromage	NOUN	O	O
method	NOUN	O	O
at	ADP	O	O
2-min	NOUN	O	O
intervals	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
20	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
5-min	NOUN	O	O
intervals	NOUN	O	O
for	ADP	O	O
the	DET	O	O
next	ADJ	O	O
10	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
then	ADP	O	O
every	DET	O	O
15	NUM	O	O
min	NOUN	O	O
to	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
240	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Statistical	ADJ	O	O
analysis	NOUN	O	O
was	VERB	O	O
done	PUNCT	O	O
by	ADP	O	O
the	DET	O	O
Mann-Whitney	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.05	NUM	O	O
considered	PUNCT	O	O
significant	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Spread	NUM	O	O
of	ADP	O	O
sensory	ADJ	O	B-OTHER
blockade	NOUN	O	I-OTHER
was	VERB	O	O
significantly	ADV	O	O
faster	PUNCT	O	O
with	ADP	O	O
bupivacaine-CO2	NOUN	O	O
and	CCONJ	O	O
-HCl	NOUN	O	O
at	ADP	O	O
a	DET	O	O
temperature	NOUN	O	O
of	ADP	O	O
36	NUM	O	O
degrees	NOUN	O	O
C	NUM	O	O
as	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
4	NUM	O	O
degrees	NOUN	O	O
or	CCONJ	O	O
20	NUM	O	O
degrees	ADJ	O	O
C	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
Figs	NOUN	O	O
.	PUNCT	O	O

1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
and	CCONJ	O	O
Table	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

ABSTRACT	ADP	O	O
TRUNCATED	PUNCT	O	O
AT	ADP	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O

Risk	NOUN	O	O
of	ADP	O	O
infection	NOUN	O	O
after	ADP	O	O
penetrating	VERB	O	O
abdominal	ADJ	O	O
trauma	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
identify	NOUN	O	O
the	DET	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
septic	ADJ	O	O
complications	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
intestinal	ADJ	O	O
perforation	NOUN	O	O
after	ADP	O	O
abdominal	ADJ	O	O
trauma	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
efficacies	NOUN	O	O
of	ADP	O	O
single-drug	NOUN	O	O
and	CCONJ	O	O
dual-drug	NOUN	O	O
prophylactic	ADJ	O	O
antibiotic	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
145	NUM	O	O
patients	NOUN	O	O
who	PROPN	O	O
presented	VERB	O	O
with	ADP	O	O
abdominal	ADJ	O	O
trauma	NOUN	O	O
and	CCONJ	O	O
intestinal	ADJ	O	O
perforation	NOUN	O	O
at	ADP	O	O
two	NUM	O	O
hospitals	PROPN	O	O
between	ADP	O	O
July	NOUN	O	O
1979	NUM	O	O
and	CCONJ	O	O
June	NOUN	O	O
1982	NUM	O	O
.	PUNCT	O	O

Logistic-regression	NOUN	O	O
analysis	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
infection	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
age	NOUN	O	O
,	PUNCT	O	O
injury	NOUN	O	O
to	ADP	O	O
the	DET	O	O
left	ADJ	O	O
colon	NOUN	O	O
necessitating	NUM	O	O
colostomy	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
larger	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
units	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
or	CCONJ	O	O
blood	NOUN	O	O
products	NOUN	O	O
administered	VERB	O	O
at	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
larger	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
injured	VERB	O	O
organs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
shock	NOUN	O	O
on	ADP	O	O
arrival	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
increase	NOUN	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
infection	NOUN	O	B-PHYSICAL
when	ADP	O	O
this	DET	O	O
factor	NOUN	O	O
was	VERB	O	O
analyzed	VERB	O	O
individually	ADV	O	O
,	PUNCT	O	O
did	PUNCT	O	O
not	ADV	O	O
add	PUNCT	O	O
predictive	ADJ	O	O
power	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
postoperative	ADJ	O	O
sepsis	NOUN	O	O
were	VERB	O	O
hospitalized	VERB	O	B-OTHER
significantly	ADV	O	I-OTHER
longer	PUNCT	O	O
than	PUNCT	O	O
were	DET	O	O
patients	NOUN	O	O
without	ADP	O	O
infection	NOUN	O	O
(	PUNCT	O	O
13.8	NUM	O	O
vs.	CCONJ	O	O
7.7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
--	PUNCT	O	O
cefoxitin	NOUN	O	O
given	VERB	O	O
alone	ADJ	O	O
and	CCONJ	O	O
clindamycin	NOUN	O	O
and	CCONJ	O	O
gentamicin	NOUN	O	O
given	VERB	O	O
together	ADV	O	O
--	PUNCT	O	O
resulted	CCONJ	O	O
in	ADP	O	O
similar	ADJ	O	O
infection	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
drug	NOUN	O	B-PHYSICAL
toxicity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
duration	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
hospitalization	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
costs	NOUN	O	O
.	PUNCT	O	O

Immediately	ADV	O	O
restored	VERB	O	O
,	PUNCT	O	O
single-tapered	ADJ	O	O
implants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
maxilla	NOUN	O	O
:	PUNCT	O	O
prosthodontic	ADJ	O	O
and	CCONJ	O	O
aesthetic	ADJ	O	O
outcomes	NOUN	O	O
after	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Conventional	ADJ	O	O
implant	NOUN	O	O
protocols	NOUN	O	O
advocate	NOUN	O	O
a	DET	O	O
two-stage	ADJ	O	O
technique	NOUN	O	O
with	ADP	O	O
a	DET	O	O
load-free	ADP	O	O
,	PUNCT	O	O
submerged	PUNCT	O	O
healing	PROPN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
immediate	ADJ	O	O
restoration	NOUN	O	O
of	ADP	O	O
single	ADJ	O	O
implants	NOUN	O	O
may	VERB	O	O
be	ADJ	O	O
a	DET	O	O
viable	ADJ	O	O
treatment	NOUN	O	O
option	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
prosthodontic	ADJ	O	O
and	CCONJ	O	O
aesthetic	ADJ	O	O
peri-implant	PUNCT	O	O
mucosal	ADJ	O	O
outcomes	NOUN	O	O
of	ADP	O	O
immediately	ADV	O	O
restored	VERB	O	O
,	PUNCT	O	O
Southern	NOUN	O	O
single-tapered	ADJ	O	O
implants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
maxilla	NOUN	O	O
after	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	PROPN	O	O
Participants	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
:	PUNCT	O	O
43.25	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
:	PUNCT	O	O
23-71	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
satisfying	PUNCT	O	O
specified	PUNCT	O	O
inclusion	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
conventional	ADJ	O	O
two-stage	ADJ	O	O
restoration	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
n=14	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
immediate	ADJ	O	O
restoration	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
test	ADV	O	O
group	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=14	ADP	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Tapered	VERB	O	O
,	PUNCT	O	O
roughened-surface	NOUN	O	O
Southern	ADJ	O	O
implants	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
using	VERB	O	O
a	DET	O	O
standardized	VERB	O	O
technique	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
implant	NOUN	O	O
level	NOUN	O	O
bone	NOUN	O	O
impressions	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
.	PUNCT	O	O

Provisional	ADJ	O	O
screw-retained	VERB	O	O
crowns	NOUN	O	O
,	PUNCT	O	O
out	PUNCT	O	O
of	ADP	O	O
occlusion	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
placed	VERB	O	O
at	ADP	O	O
second-stage	NOUN	O	O
surgery	NOUN	O	O
after	ADP	O	O
26	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
restoration	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
within	ADP	O	O
4	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
implant	NOUN	O	O
placement	NOUN	O	O
for	ADP	O	O
the	DET	O	O
immediate	ADJ	O	O
restoration	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
had	PUNCT	O	O
definitive	ADJ	O	O
screw-retained	VERB	O	O
metal-ceramic	ADJ	O	O
crowns	NOUN	O	O
placed	VERB	O	O
in	ADP	O	O
occlusion	NOUN	O	O
8	NUM	O	O
weeks	NOUN	O	O
later	ADJ	O	O
.	PUNCT	O	O

Peri-implant	ADJ	O	B-PHYSICAL
mucosal	ADJ	O	I-PHYSICAL
response	NOUN	O	O
and	CCONJ	O	B-PHYSICAL
papilla	NOUN	O	I-PHYSICAL
index	NOUN	O	B-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
4	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
definitive	ADJ	O	O
crown	PUNCT	O	O
placement	NOUN	O	O
to	PART	O	O
allow	VERB	O	O
for	ADP	O	O
mucosal	ADJ	O	O
maturation	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

Prosthodontic	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
aesthetic	ADJ	O	B-PHYSICAL
outcomes	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
using	VERB	O	O
established	VERB	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
within	ADP	O	O
,	PUNCT	O	O
or	CCONJ	O	O
between	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
and	CCONJ	O	O
test	ADV	O	O
groups	NOUN	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
gender	NOUN	O	O
,	PUNCT	O	O
bone	NOUN	O	B-OTHER
quality	NOUN	O	B-OTHER
or	CCONJ	O	O
quantity	NOUN	O	B-OTHER
,	PUNCT	O	O
implant	VERB	O	O
stability	NOUN	O	B-OTHER
measurements	NOUN	O	I-OTHER
at	ADP	O	B-OTHER
surgery	NOUN	O	I-OTHER
,	PUNCT	O	O
or	CCONJ	O	O
implant	PUNCT	O	B-OTHER
length	NOUN	O	I-OTHER
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
implant	NOUN	O	B-OTHER
success	NOUN	O	I-OTHER
rate	NOUN	O	B-OTHER
as	PUNCT	O	O
determined	VERB	O	O
by	ADP	O	O
radiographic	PUNCT	O	O

Nitrous	ADJ	O	O
oxide	NOUN	O	O
diffusion	NOUN	O	O
into	ADP	O	O
tracheal	ADJ	O	O
tube	NOUN	O	O
cuffs	ADP	O	B-PHYSICAL
--	PUNCT	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
prototype	NOUN	O	O
cuff	ADJ	O	O
pressure	NOUN	O	O
release	NOUN	O	O
valve	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
performance	NOUN	O	B-OTHER
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
cuff	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
release	NOUN	O	O
valve	NOUN	O	O
(	PUNCT	O	O
CPRV	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADP	O	O
the	DET	O	O
release	NOUN	O	O
pressure	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
adjusted	VERB	O	O
from	ADP	O	O
10	NUM	O	O
to	ADP	O	O
25	NUM	O	O
cmH2O	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
intended	VERB	O	O
to	ADP	O	O
control	ADP	O	O
pressure	NOUN	O	O
in	ADP	O	O
paediatric	ADJ	O	O
cuffed	PUNCT	O	O
tracheal	ADJ	O	O
tubes	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
avoid	NOUN	O	O
cuff	ADJ	O	O
hyperinflation	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
N2O	NOUN	O	O
diffusion	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	PUNCT	O	O
vitro	ADJ	O	O
:	PUNCT	O	O
the	DET	O	O
PRV	NOUN	O	O
was	VERB	O	O
set	PUNCT	O	O
to	ADP	O	O
10	NUM	O	O
,	PUNCT	O	O
15	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
or	CCONJ	O	O
25	NUM	O	O
cmH2O	NOUN	O	O
release	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
connected	VERB	O	O
to	ADP	O	O
a	DET	O	O
cuffed	ADJ	O	O
tube	NOUN	O	O
placed	VERB	O	O
into	ADP	O	O
a	DET	O	O
box	NOUN	O	O
flushed	PUNCT	O	O
with	ADP	O	O
66	NUM	O	O
%	SYM	O	O
N2O	NOUN	O	O
in	ADP	O	O
O2	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cuff	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
was	VERB	O	O
monitored	VERB	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
CPRV	NOUN	O	O
for	ADP	O	O
60	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Experiments	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
four	NUM	O	O
times	NOUN	O	O
using	VERB	O	O
two	NUM	O	O
different	ADJ	O	O
CPRVs	NOUN	O	O
.	PUNCT	O	O

In	ADJ	O	O
vivo	ADJ	O	O
:	PUNCT	O	O
with	ADP	O	O
Institutional	ADJ	O	O
Review	NOUN	O	O
Board	NOUN	O	O
approval	PUNCT	O	O
,	PUNCT	O	O
CPRV	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
50	NUM	O	O
children	NOUN	O	O
undergoing	SYM	O	O
general	ADJ	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
tracheal	ADJ	O	O
intubation	NOUN	O	O
and	CCONJ	O	O
standardized	VERB	O	O
anaesthesia	NOUN	O	O
technique	NOUN	O	O
(	PUNCT	O	O
including	PROPN	O	O
66	NUM	O	O
%	SYM	O	O
N2O	NOUN	O	O
in	ADP	O	O
O2	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
ventilator	NOUN	O	O
settings	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
CPRV	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
cuff	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
baseline	NOUN	O	O
was	VERB	O	O
20	NUM	O	O
cmH2O	NOUN	O	O
and	CCONJ	O	O
CPRV	NOUN	O	O
was	VERB	O	O
set	PUNCT	O	O
to	ADP	O	O
25	NUM	O	O
cmH2O	NOUN	O	O
.	PUNCT	O	O

If	PUNCT	O	O
the	DET	O	O
cuff	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
exceeded	VERB	O	O
25	NUM	O	O
cmH2O	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
manually	ADV	O	O
released	VERB	O	O
to	ADP	O	O
20	NUM	O	O
cmH2O	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
numbers	NOUN	O	O
of	ADP	O	O
deflations	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
and	CCONJ	O	O
compared	VERB	O	O
by	ADP	O	O
Mann-Whitney	NOUN	O	O
U-test	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
In	PUNCT	O	O
vitro	ADJ	O	O
:	PUNCT	O	O
the	DET	O	O
cuff	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
exceeded	ADP	O	O
50	NUM	O	O
cmH2O	NOUN	O	O
after	ADP	O	O
60	NUM	O	O
min	NOUN	O	O
without	ADP	O	O
CPRV	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	PUNCT	O	O
not	ADV	O	O
exceed	PUNCT	O	O
the	DET	O	O
settings	NOUN	O	O
with	ADP	O	O
CPRV	NOUN	O	O
.	PUNCT	O	O

In	ADJ	O	O
vivo	ADJ	O	O
:	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
need	ADP	O	O
to	PUNCT	O	O
manually	ADV	O	O
deflate	PUNCT	O	O
the	DET	O	O
cuff	ADJ	O	O
in	ADP	O	O
the	DET	O	O
CPRV	NOUN	O	O
group	NOUN	O	O
but	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
every	DET	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
(	PUNCT	O	O
two	NUM	O	O
to	ADP	O	O
seven	NUM	O	O
)	PUNCT	O	O
deflating	VERB	O	O
manoeuvres	NOUN	O	O
were	VERB	O	O
required	VERB	O	O
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
hour	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
CPRV	NOUN	O	O
allows	NOUN	O	O
reliable	ADJ	O	B-PHYSICAL
cuff	ADJ	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
release	NOUN	O	I-PHYSICAL
at	ADP	O	O
various	ADJ	O	O
pressure	NOUN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
reliably	ADV	O	O
prevents	NOUN	O	O
cuff	ADJ	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
increases	CCONJ	O	O
caused	VERB	O	O
by	ADP	O	O
N2O	NOUN	O	O
.	PUNCT	O	O

Cigarette	NOUN	O	O
smoking	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
circulating	VERB	O	O
proinflammatory	ADJ	O	O
and	CCONJ	O	O
procoagulant	NOUN	O	O
markers	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
:	PUNCT	O	O
effects	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Smoking	PROPN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
endothelial	ADJ	O	O
dysfunction	NOUN	O	O
.	PUNCT	O	O

Cytokines	NOUN	O	O
released	VERB	O	O
by	ADP	O	O
injured	ADV	O	O
endothelium	NOUN	O	O
promote	NOUN	O	O
vascular	ADJ	O	O
interactions	NOUN	O	O
with	ADP	O	O
leukocytes	NOUN	O	O
and	CCONJ	O	O
platelets	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
cigarette	NOUN	O	O
smoking	PUNCT	O	O
is	VERB	O	O
linked	VERB	O	O
to	ADP	O	O
increased	VERB	O	O
cytokine	NOUN	O	O
production	NOUN	O	O
,	PUNCT	O	O
which	DET	O	O
may	VERB	O	O
mediate	VERB	O	O
platelet	NOUN	O	O
activation	NOUN	O	O
and	CCONJ	O	O
thrombin	NOUN	O	O
generation	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
(	PUNCT	O	O
CAD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
aspirin	NOUN	O	O
treatment	NOUN	O	O
inhibits	NOUN	O	O
smoking-related	VERB	O	O
changes	NOUN	O	O
on	ADP	O	O
cytokines	NOUN	O	O
,	PUNCT	O	O
platelets	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thrombin	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	PROPN	O	O
Plasma	NOUN	O	O
macrophage-colony-stimulating	ADJ	O	O
factor	NOUN	O	O
(	PUNCT	O	O
M-CSF	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
C-reactive	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
CRP	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
100	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
CAD	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
of	ADP	O	O
whom	ADP	O	O
were	VERB	O	O
chronic	ADJ	O	O
smokers	NOUN	O	O
.	PUNCT	O	O

Prothrombin	NOUN	O	O
fragments	NOUN	O	O
1+2	ADJ	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
11-dehydro-thromboxane	ADJ	O	O
B2	NOUN	O	O
(	PUNCT	O	O
TXB2	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
additionally	ADV	O	O
measured	VERB	O	O
in	ADP	O	O
60	NUM	O	O
of	ADP	O	O
100	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
of	ADP	O	O
whom	ADP	O	O
were	VERB	O	O
smokers	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
24	NUM	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Smokers	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
matched	PROPN	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
myocardial	ADJ	O	O
ischemia	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
with	ADP	O	O
20	NUM	O	O
nonsmokers	NOUN	O	O
entered	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
crossover	ADP	O	O
trial	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	O
(	PUNCT	O	O
300	ADP	O	O
mg/d	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
measurements	NOUN	O	O
were	VERB	O	O
repeated	VERB	O	O
after	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
nonsmokers	NOUN	O	O
,	PUNCT	O	O
smokers	NOUN	O	O
had	PUNCT	O	O
3-fold	NOUN	O	B-PHYSICAL
median	ADJ	O	O
M-CSF	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
1499	NUM	O	O
vs	CCONJ	O	O
476	NUM	O	O
pg/mL	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2-fold	ADP	O	B-PHYSICAL
CRP	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
1.5	NUM	O	O
vs	CCONJ	O	O
0.8	NUM	O	O
mg/L	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
higher	PUNCT	O	O
11-dehydro-TXB	NUM	O	B-PHYSICAL
2	NUM	O	O
(	PUNCT	O	O
3.6	NUM	O	O
vs	CCONJ	O	O
2.1	NUM	O	O
ng/mg	NOUN	O	O
creatinine	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.01	PUNCT	O	O
for	ADP	O	O
all	DET	O	O
comparisons	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
aspirin	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
M-CSF	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
CRP	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
11-dehydro-TXB	NOUN	O	B-PHYSICAL
2	NUM	O	I-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Conjugated	VERB	O	O
equine	ADJ	O	O
estrogen	NOUN	O	O
influence	NOUN	O	O
on	ADP	O	O
mammographic	ADJ	O	B-PHYSICAL
density	NOUN	O	I-PHYSICAL
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
in	ADP	O	O
a	DET	O	O
substudy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
women	NOUN	O	O
's	PUNCT	O	O
health	NOUN	O	O
initiative	NOUN	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Increased	PUNCT	O	O
mammographic	ADJ	O	B-PHYSICAL
density	NOUN	O	I-PHYSICAL
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
risk	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
screening	VERB	O	O
mammography	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
hormone	NOUN	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
conjugated	PUNCT	O	O
equine	ADJ	O	O
estrogens	NOUN	O	O
(	PUNCT	O	O
CEEs	NOUN	O	O
)	PUNCT	O	O
alone	ADJ	O	O
on	ADP	O	O
mammographic	ADJ	O	B-PHYSICAL
density	NOUN	O	I-PHYSICAL
in	ADP	O	O
diverse	ADJ	O	O
racial/ethnic	ADJ	O	O
populations	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
CEE	NOUN	O	O
alone	ADJ	O	O
on	ADP	O	O
mammographic	ADJ	O	B-PHYSICAL
density	NOUN	O	I-PHYSICAL
in	ADP	O	O
a	DET	O	O
subsample	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Women	NOUN	O	O
's	PUNCT	O	O
Health	NOUN	O	O
Initiative	NOUN	O	O
(	PUNCT	O	O
WHI	NOUN	O	O
)	PUNCT	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
participants	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
In	ADP	O	O
the	DET	O	O
WHI	PUNCT	O	O
trial	NOUN	O	O
,	PUNCT	O	O
women	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
daily	ADJ	O	O
CEE	NOUN	O	O
0.625	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
CEE	NOUN	O	O
on	ADP	O	O
mammographic	ADJ	O	B-PHYSICAL
percent	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
over	ADP	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
years	NOUN	O	O
in	ADP	O	O
a	DET	O	O
stratified	VERB	O	O
random	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
435	NUM	O	O
racially	ADV	O	O
and	CCONJ	O	O
ethnically	NUM	O	O
diverse	ADJ	O	O
participants	NOUN	O	O
from	ADP	O	O
15	NUM	O	O
of	ADP	O	O
40	NUM	O	O
WHI	NOUN	O	O
clinics	PROPN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Use	NOUN	O	O
of	ADP	O	O
CEE	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
mean	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
mammographic	ADJ	O	B-PHYSICAL
percent	NOUN	O	I-PHYSICAL
density	NOUN	O	I-PHYSICAL
of	ADP	O	O
1.6	NUM	O	O
percentage	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
0.8	NUM	O	O
to	ADP	O	O
2.4	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
year	NOUN	O	O
1	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
decrease	NOUN	O	O
of	ADP	O	O
1.0	NUM	O	O
percentage	NOUN	O	O
point	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
-1.7	DET	O	O
to	ADP	O	O
-0.4	ADP	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
persisted	VERB	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
increase	NOUN	O	O
of	ADP	O	O
1.7	NUM	O	O
percentage	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
0.7	NUM	O	O
to	ADP	O	O
2.7	NUM	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
a	DET	O	O
mean	NOUN	O	O
decrease	NOUN	O	O
of	ADP	O	O
1.2	NUM	O	O
percentage	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
-1.8	ADJ	O	O
to	ADP	O	O
-0.5	ADJ	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hormone	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
women	NOUN	O	O
age	NOUN	O	O
60	NUM	O	O
to	ADP	O	O
79	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
for	ADP	O	O
interaction	NOUN	O	O
across	ADP	O	O
age	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Use	NOUN	O	O
of	ADP	O	O
CEE	NOUN	O	O
results	ADP	O	O
in	ADP	O	O
a	DET	O	O
modest	ADJ	O	O
but	CCONJ	O	O
statistically	ADV	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
mammographic	ADJ	O	B-PHYSICAL
density	NOUN	O	I-PHYSICAL
that	ADP	O	O
is	VERB	O	O
sustained	VERB	O	O
over	ADP	O	O
at	VERB	O	O
least	ADV	O	O
a	DET	O	O
2-year	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
CEE	NOUN	O	O
effect	NOUN	O	O
on	ADP	O	O
mammographic	ADJ	O	B-PHYSICAL
density	NOUN	O	I-PHYSICAL
remains	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
determined	VERB	O	O
.	PUNCT	O	O

Low-dose	NOUN	O	O
,	PUNCT	O	O
vaginally	ADV	O	O
administered	ADJ	O	O
estrogens	NOUN	O	O
may	VERB	O	O
enhance	VERB	O	O
local	ADJ	O	O
benefits	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
urogenital	ADJ	O	O
atrophy	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
on	ADP	O	O
hormone	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
When	ADP	O	O
genital	ADJ	O	O
atrophy	NOUN	O	O
exists	NOUN	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
hormone	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
HT	NOUN	O	O
)	PUNCT	O	O
has	CCONJ	O	O
a	DET	O	O
timing	VERB	O	O
until	ADP	O	O
to	PUNCT	O	O
induce	NOUN	O	O
vaginal	ADJ	O	O
proliferation	NOUN	O	O
and	CCONJ	O	O
symptomatic	ADJ	O	O
relieve	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
obtain	NOUN	O	O
a	DET	O	O
prompt	NOUN	O	O
improvement	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
association	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
therapy	NOUN	O	O
acting	VERB	O	O
on	ADP	O	O
the	DET	O	O
genital	ADJ	O	O
epithelium	NOUN	O	O
to	ADP	O	O
the	DET	O	O
systemic	ADJ	O	O
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
combined	VERB	O	O
therapy	NOUN	O	O
consisting	VERB	O	O
of	ADP	O	O
vaginal	ADJ	O	O
estriol	NOUN	O	O
with	ADP	O	O
transdermal	ADJ	O	O
17-beta-estradiol	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
microg/day	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
medroxyprogesterone	NOUN	O	O
acetate	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg/day	NOUN	O	O
)	PUNCT	O	O
per	ADP	O	O
os	PUNCT	O	O
in	ADP	O	O
shortening	ADV	O	O
the	DET	O	O
period	NOUN	O	O
of	ADP	O	O
uro-genital	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
blind	ADJ	O	O
,	PUNCT	O	O
controlled	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
27	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
climacteric	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
atrophic	ADJ	O	O
vaginitis	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
with	ADP	O	O
HT	NOUN	O	O
plus	CCONJ	O	O
vaginal	ADJ	O	O
estriol	NOUN	O	O
0.5	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
E	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
P	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
use	NUM	O	O
the	DET	O	O
local	ADJ	O	O
medication	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
3	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
twice-weekly	ADP	O	O
thereafter	ADV	O	O
.	PUNCT	O	O

Before	ADP	O	O
entering	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
asked	VERB	O	O
about	PUNCT	O	O
HT	NOUN	O	O
and	CCONJ	O	O
selected	VERB	O	O
for	ADP	O	O
inclusion	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
first	ADJ	O	O
visit	NOUN	O	O
,	PUNCT	O	O
electible	ADJ	O	O
patients	NOUN	O	O
after	PUNCT	O	O
written	PUNCT	O	O
informed	VERB	O	O
consent	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
HT	NOUN	O	O
plus	CCONJ	O	O
local	ADJ	O	O
estriol	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
the	DET	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
baseline	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
including	PUNCT	O	O
medical	ADJ	O	O
history	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
treatment	NOUN	O	O
on	ADP	O	O
urinary	ADJ	O	O
and	CCONJ	O	O
genital	ADJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
score	NOUN	O	O
for	ADP	O	O
genital	ADJ	O	O
,	PUNCT	O	O
urinary	ADJ	O	O
and	CCONJ	O	O
colposcopic	ADJ	O	O
complaints	NOUN	O	O
(	PUNCT	O	O
0	NUM	O	O
minimum-100	NOUN	O	O
maximum	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
developed	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
score	NOUN	O	O
and	CCONJ	O	O
Blatt-Kuperman	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
and	CCONJ	O	O
performed	VERB	O	O
in	ADP	O	O
every	DET	O	O
control	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
on	ADP	O	O
climacteric	ADJ	O	B-OTHER
symptoms	NOUN	O	I-OTHER
relief	NOUN	O	I-OTHER
between	ADP	O	I-OTHER
the	DET	O	I-OTHER
two	NUM	O	I-OTHER
groups	NOUN	O	I-OTHER
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	B-OTHER
symptoms	NOUN	O	I-OTHER
at	ADP	O	I-OTHER
the	DET	O	I-OTHER
end	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
study	NOUN	O	I-OTHER
was	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
from	ADP	O	O
16.5	NUM	O	O
+/-	SYM	O	O
6.1	NUM	O	O
to	ADP	O	O
8.5	NUM	O	O
+/-	SYM	O	O
2.4	NUM	O	O
for	ADP	O	O
E	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
from	ADP	O	O
15.8	NUM	O	O
+/-	SYM	O	O
7.8	NUM	O	O
to	ADP	O	O
8.8	NUM	O	O
+/-	SYM	O	O
2.7	NUM	O	O
for	ADP	O	O
P	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
versus	CCONJ	O	O
basal	ADJ	O	O
)	PUNCT	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
those	ADP	O	O
women	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
E	NOUN	O	O
reached	ADP	O	O
significant	ADJ	O	B-OTHER
improvement	NOUN	O	I-OTHER
on	ADP	O	I-OTHER
urinary	ADJ	O	I-OTHER
complaints	NOUN	O	I-OTHER
since	ADP	O	O
the	DET	O	O
first	ADJ	O	O
month	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
E	NOUN	O	O
and	CCONJ	O	O
P	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
months	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
,	PUNCT	O	O
although	ADP	O	O
no	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Papanicolaou	NOUN	O	O
smear	NOUN	O	O
showed	VERB	O	O
reactive	ADJ	O	B-OTHER
or	CCONJ	O	O
reparative	ADJ	O	B-OTHER
changes	NOUN	O	I-OTHER
and	CCONJ	O	O
karyopyknotic	ADJ	O	B-OTHER
index	NOUN	O	O
exhibited	VERB	O	B-OTHER
a	DET	O	I-OTHER
significant	ADJ	O	B-OTHER
increase	NOUN	O	O
in	ADP	O	O
superficial	ADJ	O	B-PHYSICAL
cells	NOUN	O	I-PHYSICAL
in	ADP	O	O
both	CCONJ	O	B-OTHER
groups	NOUN	O	I-OTHER
and	CCONJ	O	O
at	ADP	O	B-OTHER
the	DET	O	I-OTHER
end	PUNCT	O	I-OTHER

Effect	NOUN	O	O
of	ADP	O	O
ibuprofen	NOUN	O	O
on	ADP	O	O
cyclooxygenase	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
nitric	ADJ	O	B-PHYSICAL
oxide	NOUN	O	I-PHYSICAL
synthase	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
gastric	ADJ	O	I-PHYSICAL
mucosa	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
correlation	NOUN	O	O
with	ADP	O	O
endoscopic	ADJ	O	B-PHYSICAL
lesions	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
reactions	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
ibuprofen	NOUN	O	O
on	ADP	O	O
gastric	ADJ	O	B-PHYSICAL
mucosa	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
enzymes	NOUN	O	B-PHYSICAL
involved	VERB	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
gastroprotection	NOUN	O	I-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Twenty-four	PUNCT	O	O
Helicobacter	NOUN	O	O
pylori-negative	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
ibuprofen	NOUN	O	O
or	CCONJ	O	O
ibuprofen-arginate	NOUN	O	O
(	PUNCT	O	O
each	CCONJ	O	O
600	NUM	O	O
mg/6	NOUN	O	O
hr	NOUN	O	O
during	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Endoscopies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
1	NUM	O	O
week	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Biopsies	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
from	ADP	O	O
the	DET	O	O
gastric	ADJ	O	O
antrum	NOUN	O	O
and	CCONJ	O	O
corpus	NOUN	O	O
for	ADP	O	O
determination	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	O
E2	NOUN	O	O
(	PUNCT	O	O
PGE2	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
ELISA	NOUN	O	O
and	CCONJ	O	O
cyclooxygenase	NOUN	O	O
(	PUNCT	O	O
COX-1	NOUN	O	O
and	CCONJ	O	O
COX-2	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nitric	ADJ	O	O
oxide	NOUN	O	O
synthase	NOUN	O	O
(	PUNCT	O	O
eNOS	NOUN	O	O
and	CCONJ	O	O
iNOS	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
western	NOUN	O	O
blot	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
one	NUM	O	O
gastric	ADJ	O	O
lesion	NOUN	O	O
except	PUNCT	O	O
for	ADP	O	O
two	NUM	O	O
individuals	NOUN	O	O
taking	PUNCT	O	O
ibuprofen-arginate	NOUN	O	O
.	PUNCT	O	O

Ibuprofen-arginate	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
lower	PUNCT	O	O
rate	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	B-PHYSICAL
adverse	ADJ	O	I-PHYSICAL
reactions	ADJ	O	I-PHYSICAL
than	ADP	O	O
ibuprofen	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
with	ADP	O	O
gastric	ADJ	O	B-PHYSICAL
lesions	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
had	VERB	O	O
lower	PUNCT	O	O
PGE2	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

COX-1	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
COX-2	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
eNOS	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
iNOS	NOUN	O	B-PHYSICAL
were	VERB	O	O
detectable	ADJ	O	O
in	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
constitutive	ADJ	O	O
enzymes	NOUN	O	O
(	PUNCT	O	O
COX-1	NOUN	O	O
and	CCONJ	O	O
eNOS	NOUN	O	O
)	PUNCT	O	O
did	DET	O	O
not	ADV	O	O
change	VERB	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

COX-2	NOUN	O	O
was	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
corpus	NOUN	O	O
than	PUNCT	O	O
antrum	NOUN	O	O
and	CCONJ	O	O
it	PRON	O	O
increased	VERB	O	O
after	ADP	O	O
ibuprofen	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

iNOS	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
increase	VERB	O	O
mildly	ADV	O	O
in	ADP	O	O
the	DET	O	O
corpus	NOUN	O	O
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
or	CCONJ	O	O
endoscopic	ADJ	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
ibuprofen	NOUN	O	O
and	CCONJ	O	O
ibuprofen-arginate	NOUN	O	O
in	ADP	O	O
PGE2	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
enzymes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
experience	NOUN	O	O
of	ADP	O	O
community	NOUN	O	O
hospital	NOUN	O	O
--	PUNCT	O	O
the	DET	O	O
process	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
as	ADP	O	O
a	DET	O	O
determinant	NOUN	O	O
of	ADP	O	O
satisfaction	NOUN	O	O
.	PUNCT	O	O

AIMS	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVES	NOUN	O	O
We	PRON	O	O
report	VERB	O	O
findings	NOUN	O	O
from	ADP	O	O
a	DET	O	O
qualitative	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
identify	NOUN	O	O
patient	NOUN	O	O
views	CCONJ	O	O
of	ADP	O	O
community	NOUN	O	O
hospital	NOUN	O	O
care	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
consider	VERB	O	O
how	ADP	O	O
far	ADV	O	O
these	ADP	O	O
were	VERB	O	O
in	ADP	O	O
accord	NOUN	O	O
with	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
staffs	ADV	O	O
'	PUNCT	O	O
views	DET	O	O
.	PUNCT	O	O

This	DET	O	O
constituted	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
wider	PUNCT	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
(	PUNCT	O	O
RCT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
methodological	ADJ	O	O
challenges	NOUN	O	O
in	ADP	O	O
seeking	SYM	O	O
to	PART	O	O
identify	ADJ	O	O
patient	NOUN	O	O
satisfaction	NOUN	O	B-OTHER
and	CCONJ	O	O
in	ADP	O	O
linking	VERB	O	O
qualitative	ADJ	O	B-OTHER
findings	NOUN	O	I-OTHER
with	ADP	O	O
trial	NOUN	O	O
results	CCONJ	O	O
are	VERB	O	O
explored	VERB	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	CCONJ	O	O
sample	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
randomized	VERB	O	O
to	ADP	O	O
the	DET	O	O
community	NOUN	O	O
hospital	NOUN	O	O
arm	NOUN	O	O
of	ADP	O	O
the	DET	O	O
RCT	NOUN	O	O
joined	VERB	O	O
the	DET	O	O
qualitative	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Official	ADJ	O	O
documentation	NOUN	O	O
from	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
were	VERB	O	O
accessed	VERB	O	O
and	CCONJ	O	O
six	NUM	O	O
staff	NOUN	O	O
interviewed	PUNCT	O	O
to	PART	O	O
identify	NOUN	O	O
assumptions	NOUN	O	O
underlying	ADV	O	O
practice	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Analysis	NOUN	O	O
of	ADP	O	O
interviews	NOUN	O	O
identified	VERB	O	O
a	DET	O	O
complex	ADJ	O	O
picture	NOUN	O	O
concerning	ADV	O	O
expectations	PROPN	O	O
These	ADV	O	O
could	ADJ	O	O
be	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
ideal	ADJ	O	O
,	PUNCT	O	O
realistic	ADJ	O	O
,	PUNCT	O	O
normative	ADJ	O	O
and	CCONJ	O	O
unformed	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
hospital	NOUN	O	O
philosophy	NOUN	O	O
and	CCONJ	O	O
staff	NOUN	O	B-OTHER
views	DET	O	I-OTHER
about	PUNCT	O	O
service	NOUN	O	O
delivery	NOUN	O	O
were	VERB	O	O
closely	ADV	O	O
in	ADP	O	O
harmony	PUNCT	O	O
,	PUNCT	O	O
they	ADV	O	O
delivered	PART	O	O
rehabilitation	NOUN	O	O
in	ADP	O	O
a	DET	O	O
home-based	VERB	O	O
atmosphere	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
formal	ADJ	O	B-MENTAL
,	PUNCT	O	I-MENTAL
or	CCONJ	O	I-MENTAL
'hard	PUNCT	O	O
'	PUNCT	O	O
,	PUNCT	O	B-MENTAL
process	NOUN	O	I-MENTAL
of	PUNCT	O	I-MENTAL

The	DET	O	O
A-V	NOUN	O	O
Impulse	NOUN	O	O
System	NOUN	O	O
reduces	NOUN	O	O
deep-vein	NOUN	O	O
thrombosis	NOUN	O	O
and	CCONJ	O	O
swelling	VERB	O	O
after	ADP	O	O
hemiarthroplasty	NOUN	O	O
for	ADP	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
the	DET	O	O
A-V	NOUN	O	O
Impulse	NOUN	O	O
System	NOUN	O	O
in	ADP	O	O
82	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
by	ADP	O	O
hemiarthroplasty	NOUN	O	O
for	ADP	O	O
subcapital	ADJ	O	O
fracture	NOUN	O	O
of	ADP	O	O
the	DET	O	O
femoral	ADJ	O	O
neck	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
proximal	ADJ	O	O
deep-vein	NOUN	O	O
thrombosis	NOUN	O	O
as	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
Doppler	NOUN	O	O
ultrasonography	NOUN	O	O
was	VERB	O	O
23	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
0	NUM	O	O
%	SYM	O	O
in	ADP	O	O
those	PUNCT	O	O
using	VERB	O	O
the	DET	O	O
device	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Calf	NOUN	O	O
and	CCONJ	O	O
thigh	DET	O	O
circumferences	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
at	ADP	O	O
seven	NUM	O	O
to	ADP	O	O
ten	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
operation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
mean	NOUN	O	O
relative	ADJ	O	B-OTHER
reduction	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
postoperative	ADJ	O	I-OTHER
swelling	DET	O	I-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
thigh	DET	O	I-OTHER
by	ADP	O	O
3.27	NUM	O	O
cm	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
calf	NOUN	O	O
by	ADP	O	O
1.55	NUM	O	O
cm	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
A-V	NOUN	O	O
Impulse	NOUN	O	O
System	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
safe	ADJ	O	B-OTHER
and	CCONJ	O	O
effective	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
proximal	ADJ	O	B-PHYSICAL
deep-vein	NOUN	O	I-PHYSICAL
thrombosis	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
postoperative	ADJ	O	B-ADVERSE-EFFECTS
swelling	VERB	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Uterine	ADJ	O	O
incision	NOUN	O	O
closure	NOUN	O	O
at	ADP	O	O
caesarean	NOUN	O	O
section	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
comparative	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
intraperitoneal	ADJ	O	O
closure	NOUN	O	O
and	CCONJ	O	O
closure	NOUN	O	O
after	ADP	O	O
temporary	ADJ	O	O
exteriorisation	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
the	DET	O	O
technique	NOUN	O	O
of	ADP	O	O
uterine	ADJ	O	O
exteriorization	NOUN	O	O
at	ADP	O	O
caesarean	NOUN	O	O
section	NOUN	O	O
though	ADP	O	O
popular	ADJ	O	O
among	ADP	O	O
obstetricians	NOUN	O	O
,	PUNCT	O	O
remains	NOUN	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
exteriorization	NOUN	O	O
of	ADP	O	O
uterus	NOUN	O	O
during	ADP	O	O
uterine	ADJ	O	O
repair	NOUN	O	O
on	ADP	O	O
caesarean	NOUN	O	O
morbidity	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	CCONJ	O	O
randomized	VERB	O	O
comparative	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
136	NUM	O	O
women	NOUN	O	O
undergoing	VERB	O	O
primary	ADJ	O	O
caesarean	NOUN	O	O
delivery	NOUN	O	O
at	ADP	O	O
Havana	NOUN	O	O
Specialist	NOUN	O	O
Hospital	NOUN	O	O
Lagos	NOUN	O	O
Nigeria	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
operation	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
estimated	ADP	O	O
blood	NOUN	O	O
loss	NOUN	O	O
,	PUNCT	O	O
postoperative	ADJ	O	O
morbidities	PUNCT	O	O
were	VERB	O	O
collected	ADV	O	O
and	CCONJ	O	O
analysed	VERB	O	O
with	ADP	O	O
comparison	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
using	SYM	O	O
chi	NOUN	O	O
square	PUNCT	O	O
,	PUNCT	O	O
Fischer	NOUN	O	O
's	PUNCT	O	O
exact	ADJ	O	O
test	NOUN	O	O
and	CCONJ	O	O
t-test	NOUN	O	O
as	PUNCT	O	O
appropriate	ADJ	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
mean	NOUN	O	O
operative	ADJ	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
estimated	ADP	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
transfusion	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
postoperative	ADJ	O	B-PHYSICAL
anemia	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
in	ADP	O	O
the	DET	O	O
exteriorized	VERB	O	O
group	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
intraperitoneal	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.000	NUM	O	O
,	PUNCT	O	O
0.009,0.048	PUNCT	O	O
0.038	NUM	O	O
and	CCONJ	O	O
0.028	NUM	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
other	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
With	ADP	O	O
shorter	PUNCT	O	O
operative	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
less	DET	O	O
blood	NOUN	O	O
loss	NOUN	O	O
and	CCONJ	O	O
similar	ADJ	O	O
morbidity	NOUN	O	O
profile	ADJ	O	O
exteriorization	NOUN	O	O
of	ADP	O	O
uterus	NOUN	O	O
during	ADP	O	O
caesarean	NOUN	O	O
section	NOUN	O	O
seems	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
preferred	VERB	O	O
except	ADP	O	O
where	ADP	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
possible	ADJ	O	O
because	PUNCT	O	O
of	ADP	O	O
adhesions	NOUN	O	O
and	CCONJ	O	O
surgeons	ADJ	O	O
inexperience	NOUN	O	O
.	PUNCT	O	O

Double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	O
in	ADP	O	O
restricting-	ADJ	O	O
and	CCONJ	O	O
restricting-purging-type	NOUN	O	O
anorexia	PUNCT	O	O
nervosa	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Anorexia	NOUN	O	O
nervosa	NOUN	O	O
is	VERB	O	O
an	DET	O	O
often	ADV	O	O
chronic	ADJ	O	O
disorder	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Many	DET	O	O
people	NOUN	O	O
relapse	NOUN	O	O
after	ADP	O	O
weight	NOUN	O	O
restoration	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
a	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	O
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
would	VERB	O	O
improve	VERB	O	O
outcome	NOUN	O	O
and	CCONJ	O	O
reduce	VERB	O	O
relapse	NOUN	O	O
after	ADP	O	O
weight	NOUN	O	B-PHYSICAL
restoration	NOUN	O	I-PHYSICAL
by	ADP	O	I-PHYSICAL
contributing	SYM	O	I-PHYSICAL
to	PUNCT	O	I-PHYSICAL
maintenance	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
healthy	ADJ	O	I-PHYSICAL
normal	ADJ	O	I-PHYSICAL
weight	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
reduction	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
symptoms	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
administered	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	O
to	ADP	O	O
35	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
restricting-type	NOUN	O	O
anorexia	PUNCT	O	O
nervosa	NOUN	O	O
.	PUNCT	O	O

Anorexics	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
fluoxetine	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
16	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
19	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
inpatient	NOUN	O	O
weight	NOUN	O	O
gain	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
were	ADJ	O	O
observed	VERB	O	O
as	ADP	O	O
outpatients	VERB	O	O
for	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Ten	NUM	O	O
of	ADP	O	O
16	NUM	O	O
(	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
subjects	NOUN	O	O
remained	VERB	O	O
on	ADP	O	O
fluoxetine	NOUN	O	O
for	ADP	O	O
a	DET	O	O
year	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
only	ADV	O	O
three	PUNCT	O	O
of	ADP	O	O
19	NUM	O	O
(	PUNCT	O	O
16	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
remained	VERB	O	O
on	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
for	ADP	O	O
a	DET	O	O
year	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=.006	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Those	PUNCT	O	O
subjects	NOUN	O	O
remaining	CCONJ	O	O
on	ADP	O	O
fluoxetine	NOUN	O	O
for	ADP	O	O
a	DET	O	O
year	NOUN	O	O
had	PUNCT	O	O
reduced	CCONJ	O	B-MENTAL
relapse	NOUN	O	I-MENTAL
as	PUNCT	O	O
determined	VERB	O	O
by	ADP	O	O
a	DET	O	O
significant	ADJ	O	B-PHYSICAL
increase	NOUN	O	O
in	ADP	O	B-PHYSICAL
weight	NOUN	O	O
and	CCONJ	O	O
reduction	PUNCT	O	B-PHYSICAL

Long-term	NOUN	O	O
follow-up	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Stockholm	NOUN	O	O
randomized	VERB	O	O
trials	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
versus	CCONJ	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
among	ADP	O	O
'high	PUNCT	O	O
risk	NOUN	O	O
'	PUNCT	O	O
pre-	ADJ	O	O
and	CCONJ	O	O
postmenopausal	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
many	DET	O	O
years	NOUN	O	O
,	PUNCT	O	O
loco-regional	ADJ	O	O
radiotherapy	NOUN	O	O
was	VERB	O	O
the	DET	O	O
standard	ADJ	O	O
postoperative	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
node	NOUN	O	O
positive	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
in	ADP	O	O
Sweden	NUM	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
of	ADP	O	O
encouraging	VERB	O	O
results	CCONJ	O	O
from	ADP	O	O
trials	NOUN	O	O
of	ADP	O	O
adjuvant	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mid	NOUN	O	O
1970s	ADP	O	O
,	PUNCT	O	O
the	DET	O	O
Stockholm	NOUN	O	O
Breast	NOUN	O	O
Cancer	NOUN	O	O
Study	NOUN	O	O
Group	NOUN	O	O
decided	VERB	O	O
to	PUNCT	O	O
directly	ADV	O	O
compare	PUNCT	O	O
postoperative	ADJ	O	O
radiation	NOUN	O	O
(	PUNCT	O	O
RT	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
adjuvant	NOUN	O	O
CMF-type	NOUN	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
CT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Long-term	NOUN	O	O
results	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
from	ADP	O	O
two	NUM	O	O
randomized	VERB	O	O
trials	NOUN	O	O
of	ADP	O	O
RT	NOUN	O	O
versus	CCONJ	O	O
CT	NOUN	O	O
in	ADP	O	O
pre-	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
547	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
postmenopausal	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
679	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
node	NOUN	O	O
positive	ADJ	O	O
disease	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
tumour	NOUN	O	O
diameter	NOUN	O	O
>	SYM	O	O
30	NUM	O	O
mm	NOUN	O	O
.	PUNCT	O	O

RT	NOUN	O	O
substantially	ADV	O	O
reduced	VERB	O	O
loco-regional	ADJ	O	B-PHYSICAL
recurrences	NOUN	O	I-PHYSICAL
among	ADP	O	O
both	CCONJ	O	O
pre-	ADJ	O	O
and	CCONJ	O	O
postmenopausal	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
relative	ADJ	O	O
hazard	NOUN	O	O
RT	NOUN	O	O
versus	CCONJ	O	O
CT	NOUN	O	O
:	PUNCT	O	O
0.67	NUM	O	O
and	CCONJ	O	O
0.43	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
premenopausal	ADJ	O	O
patients	NOUN	O	O
distant	ADJ	O	B-PHYSICAL
metastases	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
less	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
the	DET	O	O
CT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
relative	ADJ	O	O
hazard	NOUN	O	O
:	PUNCT	O	O
1.68	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
an	DET	O	O
improved	VERB	O	O
recurrence-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
also	ADV	O	O
better	PUNCT	O	O
with	ADP	O	O
CT	NOUN	O	O
(	PUNCT	O	O
cumulative	ADJ	O	O
survival	NOUN	O	O
at	ADP	O	O
15	NUM	O	O
years	NOUN	O	O
:	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
44	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
CT	NOUN	O	O
and	CCONJ	O	O
RT	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
postmenopausal	ADJ	O	O
patients	NOUN	O	O
there	ADJ	O	O
were	VERB	O	O
no	DET	O	O
substantial	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
recurrence-free	ADJ	O	B-MORTALITY
or	CCONJ	O	I-MORTALITY
overall	ADJ	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
between	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
a	DET	O	O
second	ADJ	O	O
primary	ADJ	O	O
malignancy	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
was	VERB	O	O
doubled	VERB	O	O
in	ADP	O	O
the	DET	O	O
RT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
most	CCONJ	O	O
pronounced	VERB	O	O
excess	ADJ	O	O
concerned	VERB	O	O
second	ADJ	O	B-PHYSICAL
lung	NOUN	O	I-PHYSICAL
cancers	NOUN	O	I-PHYSICAL
occurring	VERB	O	O
after	ADP	O	O
10	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	B-PHYSICAL
incidence	NOUN	O	O
at	ADP	O	B-PHYSICAL
20	NUM	O	I-PHYSICAL
years	NOUN	O	B-PHYSICAL
was	VERB	O	O
estimated	VERB	O	O
at	ADP	O	O
0.3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
3.7	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
CT	NOUN	O	O
and	CCONJ	O	O
RT	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
trials	NOUN	O	O
illustrate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
radiotherapy	NOUN	O	O
in	PUNCT	O	O
preventing	PUNCT	O	O

Strength	NOUN	O	O
of	ADP	O	O
vital	ADJ	O	O
force	NOUN	O	O
in	ADP	O	O
classical	ADJ	O	O
homeopathy	NOUN	O	O
:	PUNCT	O	O
bio-psycho-social-spiritual	ADJ	O	O
correlates	SYM	O	O
within	ADP	O	O
a	DET	O	O
complex	ADJ	O	O
systems	NOUN	O	O
context	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	ADJ	O	O
explore	NOUN	O	O
associations	NOUN	O	O
between	ADP	O	O
a	DET	O	O
global	ADJ	O	O
rating	NOUN	O	O
for	ADP	O	O
the	DET	O	O
classical	ADJ	O	O
homeopathic	ADJ	O	O
construct	NOUN	O	O
of	ADP	O	O
vital	ADJ	O	O
force	NOUN	O	O
and	CCONJ	O	O
clinician	NOUN	O	O
and	CCONJ	O	O
patient	NOUN	O	O
ratings	NOUN	O	O
on	ADP	O	O
previously	ADV	O	O
validated	PUNCT	O	O
bio-psycho-social-spiritual	ADJ	O	O
questionnaires	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty-two	NUM	O	O
(	PUNCT	O	O
62	NUM	O	O
)	PUNCT	O	O
community-recruited	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
fibromyalgia	NOUN	O	O
(	PUNCT	O	O
FM	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
individualized	VERB	O	O
homeopathy	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
homeopaths	VERB	O	O
jointly	ADV	O	O
performed	PUNCT	O	O
case-taking	ADJ	O	O
interviews	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
conventional	ADJ	O	O
medical	ADJ	O	O
provider	NOUN	O	O
independently	ADV	O	O
evaluated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
standardized	VERB	O	O
history	NOUN	O	O
and	CCONJ	O	O
physical	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

Homeopaths	ADJ	O	O
rated	DET	O	O
each	DET	O	O
patient	NOUN	O	O
's	PUNCT	O	O
vital	ADJ	O	O
force	NOUN	O	O
(	PUNCT	O	O
five-point	NOUN	O	O
Likert	PUNCT	O	O
scale	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
1	NUM	O	O
=	SYM	O	O
very	ADV	O	O
weak	ADJ	O	O
to	ADP	O	O
5	NUM	O	O
=	SYM	O	O
very	ADV	O	O
strong	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Homeopaths	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
conventional	ADJ	O	O
medical	ADJ	O	O
provider	NOUN	O	O
rated	VERB	O	O
their	ADP	O	O
Clinical	ADJ	O	B-PHYSICAL
Global	ADJ	O	I-PHYSICAL
Impression	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
CGI	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
of	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
severity	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
illness	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
1	NUM	O	O
=	SYM	O	O
normal	ADJ	O	O
;	PUNCT	O	O
7	NUM	O	O
=	SYM	O	O
among	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
extremely	ADV	O	O
ill	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
completed	ADJ	O	O
self-rating	ADJ	O	O
scales	NOUN	O	O
on	ADP	O	O
pain	NOUN	O	O
,	PUNCT	O	O
global	ADJ	O	B-PHYSICAL
health	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
mood	PUNCT	O	B-MENTAL
,	PUNCT	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
,	PUNCT	O	O
coping	ADP	O	B-MENTAL
style	NOUN	O	I-MENTAL
,	PUNCT	O	O
health	NOUN	O	B-MENTAL
locus	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
control	NOUN	O	I-MENTAL
,	PUNCT	O	O
multidimensional	ADJ	O	B-MENTAL
well-being	DET	O	I-MENTAL
,	PUNCT	O	O
spirituality	NOUN	O	B-MENTAL
,	PUNCT	O	O
sense	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
coherence	NOUN	O	I-MENTAL
,	PUNCT	O	O
positive	ADJ	O	O
states	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
mind	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
social	ADJ	O	B-MENTAL
desirability	NOUN	O	B-MENTAL
.	PUNCT	O	O

RESULTS	PUNCT	O	O
Greater	PUNCT	O	O
vital	ADJ	O	B-PHYSICAL
force	NOUN	O	I-PHYSICAL
ratings	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
mean	NOUN	O	O
2.9	NUM	O	O
standard	ADJ	O	O
deviation	NOUN	O	O
[	PUNCT	O	O
SD	NOUN	O	O
]	PUNCT	O	O
0.6	NUM	O	O
)	PUNCT	O	O
correlated	VERB	O	O
moderately	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
less	ADV	O	O
severe	ADJ	O	O
CGI	NOUN	O	B-PHYSICAL
illness	NOUN	O	I-PHYSICAL
ratings	NOUN	O	O
by	ADP	O	O
the	DET	O	O
homeopaths	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=-0.59	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
decreased	DET	O	O
patient-rated	VERB	O	B-MENTAL
mental	ADJ	O	B-MENTAL
confusion	NOUN	O	I-MENTAL
(	PUNCT	O	O
r	NOUN	O	O
=-0.43	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
higher	PUNCT	O	O
vigor	NOUN	O	B-MENTAL
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.38	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
greater	PUNCT	O	O
positive	ADJ	O	O
states	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
mind	NOUN	O	I-MENTAL
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.36	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Vital	ADJ	O	O
force	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
correlations	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
with	PUNCT	O	O
lower	PUNCT	O	O

Cyclosporine	NOUN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
P-glycoprotein	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
blast	NOUN	O	O
phase	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
blast	NOUN	O	O
phase	NOUN	O	O
(	PUNCT	O	O
CML-BP	NOUN	O	O
)	PUNCT	O	O
cells	NOUN	O	O
commonly	ADV	O	O
express	VERB	O	O
the	DET	O	O
multidrug	NOUN	O	O
transporter	NOUN	O	O
,	PUNCT	O	O
P-glycoprotein	NOUN	O	O
(	PUNCT	O	O
Pgp	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

To	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
Pgp	NOUN	O	O
inhibition	NOUN	O	O
improves	NOUN	O	O
treatment	NOUN	O	O
outcome	NOUN	O	O
in	ADP	O	O
CML-BP	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Southwest	ADV	O	O
Oncology	NOUN	O	O
Group	NOUN	O	O
performed	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
testing	PUNCT	O	O
the	DET	O	O
benefit	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Pgp	NOUN	O	O
modulator	NOUN	O	O
,	PUNCT	O	O
cyclosporin	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Seventy-three	NUM	O	O
eligible	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
cytarabine	NOUN	O	O
and	CCONJ	O	O
infusional	ADJ	O	O
daunorubicin	ADV	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
intravenous	ADJ	O	O
CsA	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
CsA	NOUN	O	O
yielded	VERB	O	O
no	DET	O	O
improvement	NOUN	O	B-OTHER
in	ADP	O	O
treatment	NOUN	O	O
outcome	NOUN	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
resistance	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
68	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
53	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rate	NOUN	O	O
of	ADP	O	O
complete	ADJ	O	B-PHYSICAL
remission	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
restored	PUNCT	O	B-PHYSICAL
chronic	ADJ	O	I-PHYSICAL
phase	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
CR/CP	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
30	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
survival	NOUN	O	B-MORTALITY
(	PUNCT	O	O
3	NUM	O	O
vs	CCONJ	O	O
5	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blast	NOUN	O	B-PHYSICAL
expression	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
Pgp	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
LRP	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
71	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
was	VERB	O	O
common	ADJ	O	O
,	PUNCT	O	O
whereas	ADP	O	O
only	DET	O	O
Pgp	NOUN	O	O
adversely	ADV	O	O
impacted	PROPN	O	O
the	DET	O	O
rate	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
CR/CP	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=.025	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
Pgp	NOUN	O	O
has	PUNCT	O	O
prognostic	ADJ	O	O
relevance	NOUN	O	O
in	ADP	O	O
CML-BP	NOUN	O	O
but	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
modulation	NOUN	O	O
of	ADP	O	O
Pgp	NOUN	O	O
function	NOUN	O	O
with	ADP	O	O
CsA	NOUN	O	O
as	ADP	O	O
applied	VERB	O	O
in	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
halothane	NOUN	O	O
and	CCONJ	O	O
isoflurane	NOUN	O	O
on	ADP	O	O
transient	ADJ	O	B-PHYSICAL
renal	ADJ	O	I-PHYSICAL
dysfunction	NOUN	O	I-PHYSICAL
associated	VERB	O	O
with	ADP	O	O
infrarenal	ADJ	O	O
aortic	ADJ	O	O
cross-clamping	PUNCT	O	O
.	PUNCT	O	O

Aortic	ADJ	O	O
cross-clamping	PUNCT	O	O
for	ADP	O	O
reconstructive	ADJ	O	O
aortic	ADJ	O	O
surgery	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
impairment	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Halothane	NOUN	O	O
or	CCONJ	O	O
isoflurane	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
volatile	ADJ	O	O
anesthesia	NOUN	O	O
on	ADP	O	O
renal	ADJ	O	B-PHYSICAL
hemodynamics	NOUN	O	I-PHYSICAL
during	ADP	O	O
aortic	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Nineteen	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
preoperative	ADJ	O	O
creatinine	NOUN	O	O
clearances	ADP	O	O
who	ADP	O	O
were	VERB	O	O
scheduled	VERB	O	O
for	ADP	O	O
reconstructive	ADJ	O	O
aortic	ADJ	O	O
surgery	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
halothane	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
isoflurane	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
midazolam	NOUN	O	O
,	PUNCT	O	O
fentanyl	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pancuronium	NOUN	O	O
.	PUNCT	O	O

Anesthesia	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
with	ADP	O	O
fentanyl	NOUN	O	O
and	CCONJ	O	O
halothane	NOUN	O	O
or	CCONJ	O	O
isoflurane	NOUN	O	O
in	ADP	O	O
nitrous	ADJ	O	O
oxide	NOUN	O	O
and	CCONJ	O	O
oxygen	NOUN	O	O
(	PUNCT	O	O
50/50	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Systemic	ADJ	O	B-PHYSICAL
hemodynamics	NOUN	O	I-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
throughout	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Before	PUNCT	O	O
aortic	ADJ	O	O
cross-clamping	PUNCT	O	O
,	PUNCT	O	O
effective	ADJ	O	B-PHYSICAL
renal	ADJ	O	I-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ERPF	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
131I-hippuran	NOUN	O	I-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
glomerular	ADJ	O	B-PHYSICAL
filtration	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
GFR	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
99Tc-DTPA	PUNCT	O	I-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
halothane	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
118.4	NUM	O	O
+/-	SYM	O	O
25.6	NUM	O	O
and	CCONJ	O	O
19.7	NUM	O	O
+/-	SYM	O	O
5.2	NUM	O	O
mL/min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
isoflurane	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
253.4	NUM	O	O
+/-	SYM	O	O
51.5	NUM	O	O
and	CCONJ	O	O
44.9	NUM	O	O
+/-	SYM	O	O
8.4	NUM	O	O
mL/min	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.05	NUM	O	O
for	ADP	O	O
both	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
cross-clamping	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
renal	ADJ	O	B-PHYSICAL
variables	NOUN	O	I-PHYSICAL
were	VERB	O	O
not	ADV	O	O
markedly	ADV	O	O
affected	VERB	O	O
in	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
remained	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
isoflurane-anesthetized	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
232.9	NUM	O	O
+/-	SYM	O	O
47.1	NUM	O	O
and	CCONJ	O	O
49.5	NUM	O	O
+/-	SYM	O	O
1.2	NUM	O	O
mL/min	NOUN	O	O
for	ADP	O	O
ERPF	NOUN	O	O
and	CCONJ	O	O
GFR	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
halothane-anesthetized	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
132.4	NUM	O	O
+/-	SYM	O	O
31.6	NUM	O	O
and	CCONJ	O	O
14.8	NUM	O	O
+/-	SYM	O	O
3.7	NUM	O	O
mL/min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
aortic	ADJ	O	O
unclamping	VERB	O	O
,	PUNCT	O	O
ERPF	NOUN	O	B-PHYSICAL
increased	VERB	O	O
markedly	ADV	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
467.8	NUM	O	O
+/-	SYM	O	O
122	NUM	O	O
and	CCONJ	O	O
362.5	NUM	O	O
+/-	SYM	O	O
57.7	NUM	O	O
mL/min	NOUN	O	O
in	ADP	O	O
the	DET	O	O
halothane	NOUN	O	O
and	CCONJ	O	O
isoflurane	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	PUNCT	O	O
did	PUNCT	O	O
GFR	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
74.8	NUM	O	O
+/-	SYM	O	O
22	NUM	O	O
and	CCONJ	O	O
71.8	NUM	O	O
+/-	SYM	O	O
13.1	NUM	O	O
mL/min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
halothane	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
transient	ADJ	O	B-PHYSICAL
renal	ADJ	O	I-PHYSICAL
vasoconstriction	NOUN	O	I-PHYSICAL
during	ADP	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
aortic	ADJ	O	O
cross-clamping	PUNCT	O	O
during	ADP	O	O
isoflurane	NOUN	O	O
anesthesia	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
renal	ADJ	O	B-PHYSICAL
hemodynamic	ADJ	O	I-PHYSICAL
impairment	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Lessons	ADJ	O	O
learnt	NOUN	O	O
in	ADP	O	O
conducting	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
drug	NOUN	O	O
trial	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
Asperger	ADJ	O	O
Syndrome	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	ADJ	O	O
describe	PROPN	O	O
the	DET	O	O
authors	NOUN	O	O
'	PUNCT	O	O
experience	NOUN	O	O
of	ADP	O	O
conducting	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
drug	NOUN	O	O
trial	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
Asperger	ADJ	O	O
Syndrome	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
pitfalls	ADV	O	O
encountered	ADP	O	O
and	CCONJ	O	O
lessons	ADJ	O	O
learnt	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
main	ADJ	O	O
barrier	NOUN	O	O
encountered	PUNCT	O	O
was	VERB	O	O
in	ADP	O	O
the	DET	O	O
recruitment	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
children	NOUN	O	I-OTHER
:	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
not	ADV	O	O
possible	ADJ	O	O
to	PART	O	O
recruit	NOUN	O	O
the	DET	O	O
target	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
recruitment	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
children	NOUN	O	I-OTHER
is	VERB	O	O
often	ADV	O	O
the	DET	O	O
major	ADJ	O	O
barrier	NOUN	O	O
to	ADP	O	O
the	DET	O	O
progress	NOUN	O	O
of	ADP	O	O
a	DET	O	O
successful	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Conducting	PUNCT	O	O
the	DET	O	O
clinical	ADJ	O	O
drug	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
greatly	ADV	O	O
facilitated	VERB	O	O
by	ADP	O	O
the	DET	O	O
appropriate	ADJ	O	O
setting	ADP	O	O
and	CCONJ	O	O
experienced	VERB	O	O
clinical	ADJ	O	O
pharmacology	NOUN	O	O
staff	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
tension-free	ADJ	O	O
hernioplasty	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
tension-free	ADJ	O	O
hernioplasty	NOUN	O	O
as	VERB	O	O
introduced	PUNCT	O	O
by	ADP	O	O
Lichtenstein	NOUN	O	O
has	PUNCT	O	O
gained	VERB	O	O
increasing	ADP	O	O
acceptance	NOUN	O	O
during	ADP	O	O
the	DET	O	O
last	ADJ	O	O
decade	NOUN	O	O
although	ADP	O	O
the	DET	O	O
technique	NOUN	O	O
has	PUNCT	O	O
not	ADV	O	O
been	PUNCT	O	O
evaluated	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
randomized	NOUN	O	O
study	NOUN	O	O
compares	PUNCT	O	O
the	DET	O	O
2-year	NOUN	O	O
follow-up	NOUN	O	O
results	PUNCT	O	O
after	ADP	O	O
102	NUM	O	O
tension-free	ADJ	O	O
hernioplasties	CCONJ	O	O
with	ADP	O	O
implantation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
prolene	ADJ	O	O
mesh	NOUN	O	O
in	ADP	O	O
all	DET	O	O
groin	NOUN	O	O
hernias	ADV	O	O
to	ADP	O	O
53	NUM	O	O
Cooper	PUNCT	O	O
ligament	NOUN	O	O
repairs	VERB	O	O
in	ADP	O	O
direct	ADJ	O	O
hernias	ADV	O	O
and	CCONJ	O	O
53	NUM	O	O
abdominal	ADJ	O	O
ring	NOUN	O	O
repairs	NOUN	O	O
in	ADP	O	O
indirect	ADJ	O	O
hernias	ADV	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
tension-free	VERB	O	O
repairs	NOUN	O	O
five	NUM	O	O
hernias	ADJ	O	B-PHYSICAL
recurred	ADP	O	I-PHYSICAL
(	PUNCT	O	O
5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
either	CCONJ	O	O
Cooper	PUNCT	O	O
ligament	NOUN	O	O
or	CCONJ	O	O
abdominal	ADJ	O	O
ring	NOUN	O	O
repair	NOUN	O	O
,	PUNCT	O	O
16	NUM	O	O
recurrences	NOUN	O	B-PHYSICAL
were	VERB	O	O
found	VERB	O	O
(	PUNCT	O	O
15	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.025	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
indirect	ADJ	O	B-PHYSICAL
hernias	ADJ	O	I-PHYSICAL
recurred	DET	O	I-PHYSICAL
after	ADP	O	O
a	DET	O	O
tension-free	ADJ	O	O
repair	NOUN	O	O
;	PUNCT	O	O
2	NUM	O	O
recurred	PUNCT	O	O
after	ADP	O	O
abdominal	ADJ	O	O
ring	NOUN	O	O
repair	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
NS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
recurrence	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
after	ADP	O	I-PHYSICAL
tension-free	VERB	O	I-PHYSICAL
repairs	VERB	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
primary	ADJ	O	I-PHYSICAL
direct	ADJ	O	I-PHYSICAL
inguinal	ADJ	O	I-PHYSICAL
hernias	ADV	O	I-PHYSICAL
was	VERB	O	O
7	NUM	O	O
%	SYM	O	O
as	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
30	NUM	O	O
%	SYM	O	O
after	ADP	O	O
Cooper	PUNCT	O	O
ligament	NOUN	O	O
repair	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0081	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
complication	NOUN	O	B-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
between	ADP	O	O
the	DET	O	O
tested	ADJ	O	O
methods	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Recurrence	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
is	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
one-third	NOUN	O	O
after	ADP	O	O
tension-free	VERB	O	O
herniotomies	NOUN	O	O
as	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
conventionel	NOUN	O	O
herniotomies	NOUN	O	O
without	ADP	O	O
increase	NOUN	O	O
in	ADP	O	O
complication	NOUN	O	B-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Comparing	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
copper	NOUN	O	O
intrauterine	ADJ	O	O
devices	NOUN	O	O
available	ADJ	O	O
in	ADP	O	O
Canada	PUNCT	O	O
.	PUNCT	O	O

Is	PUNCT	O	O
FlexiT	PUNCT	O	O
non-inferior	ADP	O	O
to	ADP	O	O
NovaT	NOUN	O	O
when	ADP	O	O
inserted	ADP	O	O
immediately	ADV	O	O
after	ADP	O	O
first-trimester	NOUN	O	O
abortion	NOUN	O	O
?	PUNCT	O	O

Study	NOUN	O	O
protocol	NOUN	O	O
for	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
rationale	NOUN	O	O
and	CCONJ	O	O
protocol	NOUN	O	O
for	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
noninferiority	NOUN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
(	PUNCT	O	O
RCT	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
determine	VERB	O	O
if	PUNCT	O	O
the	DET	O	O
Flexi-T380	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
copper	NOUN	O	O
intrauterine	ADJ	O	O
contraceptive	ADJ	O	O
device	NOUN	O	O
(	PUNCT	O	O
IUD	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
effectiveness	NOUN	O	O
and	CCONJ	O	O
expulsion	NOUN	O	O
rates	NOUN	O	O
to	ADP	O	O
the	DET	O	O
most	CCONJ	O	O
common	ADJ	O	O
Canadian	ADJ	O	O
IUD	NOUN	O	O
currently	ADV	O	O
in	ADP	O	O
use	NOUN	O	O
,	PUNCT	O	O
NovaT-200	NOUN	O	O
,	PUNCT	O	O
when	ADP	O	O
placed	ADP	O	O
immediately	ADV	O	O
after	ADP	O	O
a	DET	O	O
first-trimester	NOUN	O	O
abortion	NOUN	O	O
.	PUNCT	O	O

METHODS/DESIGN	PUNCT	O	O
Consenting	PUNCT	O	O
women	VERB	O	O
choosing	ADV	O	O
to	ADV	O	O
use	VERB	O	O
an	DET	O	O
IUD	NOUN	O	O
after	ADP	O	O
an	DET	O	O
abortion	NOUN	O	O
for	ADP	O	O
a	DET	O	O
pregnancy	NOUN	O	O
of	ADP	O	O
less	ADV	O	O
than	CCONJ	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
gestation	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
device-type	NOUN	O	O
groups	NOUN	O	O
to	PART	O	O
receive	NOUN	O	O
immediate	ADJ	O	O
post-abortion	NOUN	O	O
placement	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
a	DET	O	O
Flexi-T380	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
IUD	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
device	NOUN	O	O
for	ADP	O	O
which	DET	O	O
no	DET	O	O
current	ADJ	O	O
evidence	NOUN	O	O
on	ADP	O	O
expulsion	NOUN	O	O
or	CCONJ	O	O
effectiveness	NOUN	O	O
rates	NOUN	O	O
is	VERB	O	O
available	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
Nova-T200	PUNCT	O	O
IUD	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
only	ADJ	O	O
other	ADJ	O	O
brand	NOUN	O	O
of	ADP	O	O
copper	NOUN	O	O
IUD	NOUN	O	O
available	ADJ	O	O
in	ADP	O	O
Canada	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
initiation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	ADV	O	O
is	VERB	O	O
IUD	NOUN	O	B-MENTAL
expulsion	NOUN	O	I-MENTAL
rate	NOUN	O	I-MENTAL
at	ADP	O	I-MENTAL
1	NUM	O	I-MENTAL
year	NOUN	O	I-MENTAL
.	PUNCT	O	O

Secondary	ADJ	O	O
outcomes	NOUN	O	O
include	VERB	O	O
:	PUNCT	O	O
pregnancy	NOUN	O	B-MENTAL
rate	NOUN	O	I-MENTAL
,	PUNCT	O	O
method	NOUN	O	B-MENTAL
continuation	NOUN	O	I-MENTAL
rate	NOUN	O	I-MENTAL
,	PUNCT	O	O
complication	NOUN	O	O
rates	NOUN	O	O
(	PUNCT	O	O
infection	NOUN	O	O
,	PUNCT	O	O
perforation	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
satisfaction	NOUN	O	B-OTHER
with	ADP	O	O
contraceptive	ADJ	O	B-PHYSICAL
method	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
non-intervention	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
consenting	PUNCT	O	O
women	NOUN	O	O
choosing	PUNCT	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
post-abortion	NOUN	O	O
contraception	NOUN	O	O
methods	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
no	DET	O	O
contraception	NOUN	O	O
,	PUNCT	O	O
will	VERB	O	O
be	VERB	O	O
included	VERB	O	O
for	ADP	O	O
comparison	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Web-based	VERB	O	O
contraception	NOUN	O	O
satisfaction	NOUN	O	O
questionnaires	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
records	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
government-linked	VERB	O	O
health	NOUN	O	O
administrative	ADJ	O	O
databases	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
primary	ADJ	O	O
and	CCONJ	O	O
secondary	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
The	DET	O	O
RCT	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
combined	PUNCT	O	O
with	ADP	O	O
access	NOUN	O	O
to	ADP	O	O
clinical	ADJ	O	O
records	NOUN	O	O
at	ADP	O	O
all	DET	O	O
provincial	ADJ	O	O
abortion	NOUN	O	O
clinics	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	ADP	O	O
information	NOUN	O	O
in	ADP	O	O
provincial	ADJ	O	O
single-payer	NOUN	O	O
linked	ADJ	O	O
administrative	ADJ	O	O
health	NOUN	O	O
databases	NOUN	O	O
,	PUNCT	O	O
birth	NOUN	O	O
registry	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hospital	NOUN	O	O
records	NOUN	O	O
,	PUNCT	O	O
offers	NOUN	O	O
a	DET	O	O
unique	ADJ	O	O
opportunity	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
if	PUNCT	O	O
a	DET	O	O
novel	ADJ	O	O
IUD	NOUN	O	O
has	VERB	O	O
a	DET	O	O
comparable	ADJ	O	O
expulsion	NOUN	O	B-MENTAL
rate	NOUN	O	I-MENTAL
to	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
current	ADJ	O	O
standard	ADJ	O	O
IUD	NOUN	O	O
in	ADP	O	O
Canada	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
first	ADJ	O	O
opportunity	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
pregnancy	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
and	CCONJ	O	O
method	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
post-abortion	NOUN	O	O
for	ADP	O	O
women	NOUN	O	O
choosing	PUNCT	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
post-abortion	NOUN	O	O
contraceptive	ADJ	O	O
options	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
highlight	PUNCT	O	O
considerations	NOUN	O	O
of	ADP	O	O
design	NOUN	O	O
,	PUNCT	O	O
implementation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
first	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
provide	VERB	O	O
rigorous	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
current	ADJ	O	O
Canadian	ADJ	O	O
IUDs	NOUN	O	O
when	ADP	O	O
inserted	VERB	O	O
after	ADP	O	O
first-trimester	NOUN	O	O
abortion	NOUN	O	O
.	PUNCT	O	O

TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
ClinicalTrials.gov	PUNCT	O	O
Identifier	NOUN	O	O
NCT01174225	NOUN	O	O
.	PUNCT	O	O

Equivalence	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
a	DET	O	O
topical	ADJ	O	O
diclofenac	NOUN	O	O
solution	NOUN	O	O
(	PUNCT	O	O
pennsaid	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
diclofenac	NOUN	O	O
in	ADP	O	O
symptomatic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
osteoarthritis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
compare	NOUN	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
topical	ADJ	O	O
diclofenac	NOUN	O	O
solution	NOUN	O	O
versus	CCONJ	O	O
oral	ADJ	O	O
diclofenac	NOUN	O	O
in	ADP	O	O
relieving	NUM	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
osteoarthritis	NOUN	O	O
(	PUNCT	O	O
OA	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
double-dummy	NOUN	O	O
equivalence	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
622	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
with	ADP	O	O
radiological	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
knee	NOUN	O	O
OA	NOUN	O	O
and	CCONJ	O	O
mild	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
symptoms	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
topical	ADJ	O	O
diclofenac	NOUN	O	O
solution	NOUN	O	O
plus	CCONJ	O	O
placebo	NOUN	O	O
oral	ADJ	O	O
capsules	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
topical	ADJ	O	O
solution	NOUN	O	O
plus	CCONJ	O	O
oral	ADJ	O	O
diclofenac	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
capsules	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
applied	DET	O	O
50	NUM	O	O
drops	ADP	O	O
of	ADP	O	O
study	PUNCT	O	O
solution	NOUN	O	O
and	CCONJ	O	O
took	PROPN	O	O
1	NUM	O	O
study	ADV	O	O
capsule	NOUN	O	O
3	NUM	O	O
times	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
variables	NOUN	O	O
were	VERB	O	O
pain	NOUN	O	O
and	CCONJ	O	O
physical	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
Western	NOUN	O	O
Ontario	NOUN	O	O
and	CCONJ	O	O
McMaster	ADJ	O	O
Universities	NOUN	O	O
(	PUNCT	O	O
WOMAC	NOUN	O	O
)	PUNCT	O	O
VA	NOUN	O	O
3.1	NUM	O	O
OA	NOUN	O	O
Index	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
patient	NOUN	O	O
global	ADJ	O	O
assessment	NOUN	O	O
(	PUNCT	O	O
PGA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Equivalence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
per-protocol	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
based	VERB	O	O
on	ADP	O	O
previously	ADV	O	O
defined	PUNCT	O	O
ranges	PUNCT	O	O
of	ADP	O	O
clinically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
.	PUNCT	O	O

Safety	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
evaluation	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
vital	ADJ	O	O
signs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
data	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
)	PUNCT	O	O
change	DET	O	O
scores	NOUN	O	O
(	PUNCT	O	O
final	ADJ	O	O
minus	NOUN	O	O
baseline	NOUN	O	O
)	PUNCT	O	O
between	ADP	O	O
treatments	NOUN	O	O
was	VERB	O	O
13.3	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
-8.6	PUNCT	O	O
to	ADP	O	O
35.2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
pain	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
scale	NOUN	O	O
500	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
71.0	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
-2.4	NUM	O	O
to	ADP	O	O
144.5	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
physical	ADJ	O	O
function	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
scale	NOUN	O	O
1700	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4.3	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
-1.2	ADP	O	O
to	ADP	O	O
9.8	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
PGA	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
scale	NOUN	O	O
100	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
CI	NOUN	O	O
for	ADP	O	O
each	DET	O	O
efficacy	NOUN	O	O
variable	CCONJ	O	O
fell	VERB	O	O
within	ADP	O	O
the	DET	O	O
predefined	ADP	O	O
equivalence	NOUN	O	O
ranges	ADJ	O	O
(	PUNCT	O	O
pain	NOUN	O	O
,	PUNCT	O	O
+/-	ADP	O	O
75	NUM	O	O
mm	NOUN	O	O
;	PUNCT	O	O
physical	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
+/-	SYM	O	O
255	NUM	O	O
mm	NOUN	O	O
;	PUNCT	O	O
PGA	NOUN	O	O
,	PUNCT	O	O
+/-	ADP	O	O
20	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
no	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
.	PUNCT	O	O

Safety	NOUN	O	B-OTHER
analyses	NOUN	O	I-OTHER
of	ADP	O	O
patients	NOUN	O	O
applying	VERB	O	O
topical	ADJ	O	O
diclofenac	NOUN	O	O
solution	NOUN	O	O
revealed	VERB	O	O
some	DET	O	O
minor	ADJ	O	B-ADVERSE-EFFECTS
skin	NOUN	O	I-ADVERSE-EFFECTS
irritation	NOUN	O	I-ADVERSE-EFFECTS
at	ADP	O	I-ADVERSE-EFFECTS
the	DET	O	I-ADVERSE-EFFECTS
application	NOUN	O	I-ADVERSE-EFFECTS
site	NOUN	O	I-ADVERSE-EFFECTS
--	PUNCT	O	I-ADVERSE-EFFECTS
mostly	ADV	O	I-ADVERSE-EFFECTS
skin	NOUN	O	O
dryness	NOUN	O	O
in	ADP	O	O
83/311	NOUN	O	O
(	PUNCT	O	O
27	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
--	PUNCT	O	O
but	CCONJ	O	O
a	DET	O	O
significantly	ADV	O	O
reduced	DET	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
relative	ADJ	O	O
to	ADP	O	O
oral	ADJ	O	O
diclofenac	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
total	ADJ	O	O
and	CCONJ	O	O
severe	ADJ	O	B-ADVERSE-EFFECTS
gastrointestinal	ADJ	O	I-ADVERSE-EFFECTS
(	PUNCT	O	I-ADVERSE-EFFECTS
GI	NOUN	O	I-ADVERSE-EFFECTS
)	PUNCT	O	I-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
including	VERB	O	O
dyspepsia	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
abdominal	ADJ	O	B-PHYSICAL
pain	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
diarrhea	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
developing	PUNCT	O	O
abnormal	ADJ	O	O
liver	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
(	PUNCT	O	O
including	PROPN	O	O
clinically	ADV	O	O
significant	ADJ	O	O
elevation	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hemoglobin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
creatinine	NOUN	O	O
clearance	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
diclofenac	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Application	NOUN	O	O
of	ADP	O	O
this	DET	O	O
topical	ADJ	O	O
diclofenac	NOUN	O	O
solution	NOUN	O	O
to	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
OA	NOUN	O	O
produced	ADP	O	O
relief	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
equivalent	ADJ	O	O
to	ADP	O	O
oral	ADJ	O	O
diclofenac	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
minor	ADJ	O	O
local	ADJ	O	O
skin	NOUN	O	O
irritation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
significantly	ADV	O	O
reduced	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
diclofenac-related	VERB	O	B-PHYSICAL
GI	NOUN	O	I-PHYSICAL
complaints	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
abnormal	ADJ	O	B-PHYSICAL
laboratory	NOUN	O	I-PHYSICAL
values	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
sublingual	ADJ	O	O
immunotherapy	NOUN	O	O
for	ADP	O	O
respiratory	ADJ	O	O
allergy	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
different	ADJ	O	O
dosage	NOUN	O	O
regimens	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
phase	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Sublingual	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
allergens	NOUN	O	O
is	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
alternative	ADJ	O	O
to	ADP	O	O
subcutaneous	ADJ	O	O
immunotherapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
respiratory	ADJ	O	O
allergies	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
drawback	NOUN	O	O
to	ADP	O	O
this	DET	O	O
therapeutic	ADJ	O	O
approach	NOUN	O	O
is	VERB	O	O
the	DET	O	O
relatively	ADV	O	O
long	ADJ	O	O
and	CCONJ	O	O
complex	ADJ	O	O
management	NOUN	O	O
of	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
phase	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
OF	ADP	O	O
THE	DET	O	O
STUDY	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
whether	ADP	O	O
different	ADJ	O	O
induction	NOUN	O	O
regimens	NOUN	O	O
affect	VERB	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
sublingual	ADJ	O	O
immunotherapy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
Adult	ADJ	O	O
and	CCONJ	O	O
pediatric	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
allergic	ADJ	O	O
rhinoconjunctivitis	NOUN	O	O
and/or	CCONJ	O	O
asthma	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
subjects	NOUN	O	O
served	PART	O	O
as	ADP	O	O
controls	VERB	O	O
and	CCONJ	O	O
received	VERB	O	O
symptomatic	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Forty-three	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
allocated	NUM	O	O
to	ADP	O	O
sublingual	ADJ	O	O
immunotherapy	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
three	NUM	O	O
different	ADJ	O	O
induction	NOUN	O	O
protocols	NOUN	O	O
(	PUNCT	O	O
8-	NUM	O	O
,	PUNCT	O	O
15-	NUM	O	O
and	CCONJ	O	O
20-day	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Symptom	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
medication	NOUN	O	I-PHYSICAL
scores	NOUN	O	O
,	PUNCT	O	O
skin	NOUN	O	B-PHYSICAL
test	NOUN	O	I-PHYSICAL
results	DET	O	I-PHYSICAL
and	CCONJ	O	O
(	PUNCT	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
asthmatic	ADJ	O	I-PHYSICAL
patients	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
FEV1	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
for	ADP	O	O
two	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
induction	NOUN	O	O
regimens	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
significant	ADJ	O	B-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
symptom	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
medication	NOUN	O	B-PHYSICAL
usage	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
skin	NOUN	O	B-PHYSICAL
test	NOUN	O	I-PHYSICAL
scores	NOUN	O	I-PHYSICAL
decreased	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
FEV1	NOUN	O	B-PHYSICAL
improved	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
symptom	NOUN	O	O
and	CCONJ	O	O
skin	NOUN	O	O
test	NOUN	O	O
scores	NOUN	O	O
did	CCONJ	O	O
not	ADV	O	O
significantly	ADV	O	O
change	NUM	O	B-OTHER
in	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
relevant	ADJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
For	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
respiratory	ADJ	O	O
allergies	NOUN	O	O
,	PUNCT	O	O
sublingual	ADP	O	O
immunotherapy	NOUN	O	O
with	ADP	O	O
an	DET	O	O
8-day	NOUN	O	O
induction	NOUN	O	O
protocol	NOUN	O	O
is	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
encourage	PUNCT	O	O
the	DET	O	O
usage	NOUN	O	O
of	ADP	O	O
shorter	PUNCT	O	O
induction	NOUN	O	O
regimens	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
produce	VERB	O	O
better	CCONJ	O	O
compliance	NOUN	O	O
with	ADP	O	O
this	DET	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomised	VERB	O	O
comparison	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
drainage	NOUN	O	O
systems	NOUN	O	O
following	VERB	O	O
cholecystectomy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
passive	ADJ	O	O
drainage	NOUN	O	O
systems	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
compared	VERB	O	O
after	ADP	O	O
cholecystectomy	NOUN	O	O
.	PUNCT	O	O

Symptoms	NOUN	O	B-PAIN
of	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
discomfort	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
were	VERB	O	O
compared	VERB	O	O
using	SYM	O	O
linear	ADJ	O	O
analogue	NOUN	O	O
scales	NOUN	O	O
and	CCONJ	O	O
spirometry	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
pre-operative	ADJ	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
respiratory	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
low	ADJ	O	O
pressure	NOUN	O	O
suction	NOUN	O	O
drain	NOUN	O	O
removed	VERB	O	O
an	DET	O	O
intraperitoneal	ADJ	O	O
marker	NOUN	O	O
,	PUNCT	O	O
gentamicin	NOUN	O	O
,	PUNCT	O	O
more	ADV	O	O
effectively	ADV	O	O
than	PUNCT	O	O
the	DET	O	O
high	ADJ	O	O
pressure	NOUN	O	O
suction	NOUN	O	O
drain	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
more	ADV	O	O
effectively	ADV	O	O
than	PUNCT	O	O
the	DET	O	O
passive	ADJ	O	O
drain	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
postoperative	ADJ	O	B-PHYSICAL
respiratory	ADJ	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
nor	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PAIN
or	CCONJ	O	O
discomfort	NOUN	O	B-PAIN
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
passive	ADJ	O	O
drain	NOUN	O	O
group	NOUN	O	O
reported	VERB	O	O
less	ADV	O	O
nausea	NOUN	O	B-PHYSICAL
than	PUNCT	O	O
the	DET	O	O
suction	NOUN	O	O
drain	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

If	PUNCT	O	O
a	DET	O	O
negative	ADJ	O	O
pressure	NOUN	O	O
drainage	NOUN	O	O
system	NOUN	O	O
is	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
used	VERB	O	O
,	PUNCT	O	O
a	DET	O	O
low	ADJ	O	O
pressure	NOUN	O	O
suction	NOUN	O	O
drain	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
in	ADP	O	O
preference	NOUN	O	O
to	ADP	O	O
a	DET	O	O
high	ADJ	O	O
pressure	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
versus	CCONJ	O	O
atenolol	NOUN	O	O
on	ADP	O	O
cardiovascular	ADJ	O	B-MORTALITY
morbidity	NOUN	O	I-MORTALITY
and	CCONJ	O	I-MORTALITY
mortality	NOUN	O	I-MORTALITY
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
in	ADP	O	O
the	DET	O	O
LIFE-study	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
The	DET	O	O
most	PUNCT	O	O
suitable	ADJ	O	O
antihypertensive	ADJ	O	O
drug	NOUN	O	O
to	ADJ	O	O
reduce	NOUN	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
diabetes	NOUN	O	O
is	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
prespecified	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
LIFE-study	NOUN	O	O
we	ADJ	O	O
compared	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
and	CCONJ	O	O
atenolol	NOUN	O	O
on	ADP	O	O
cardiovascular	ADJ	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
in	ADP	O	O
diabetic	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

MATERIAL	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
1195	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
LIFE-study	NOUN	O	O
had	PUNCT	O	O
diabetes	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
the	DET	O	O
randomisation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
for	ADP	O	O
double-blind	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
losartan	NOUN	O	O
versus	CCONJ	O	O
atenolol	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
had	CCONJ	O	O
ECG-verified	VERB	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
hypertrophy	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
67	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
177/96	NOUN	O	O
mmHg	NOUN	O	O
after	ADP	O	O
two	NUM	O	O
weeks	NOUN	O	O
placebo	NOUN	O	O
run-in	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
at	ADP	O	O
least	ADV	O	O
four	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
4.7	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
composite	ADJ	O	O
endpoint	NOUN	O	O
was	VERB	O	O
cardiovascular	ADJ	O	B-PHYSICAL
death	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
stroke	NOUN	O	B-PHYSICAL
or	CCONJ	O	O
myocardial	ADJ	O	B-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	ADJ	O	O
Blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
was	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
146/79	NOUN	O	O
and	CCONJ	O	O
148/79	NOUN	O	O
in	ADP	O	O
losartan-treated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
atenolol-treated	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
103	NUM	O	O
patients	NOUN	O	O
assigned	DET	O	O
losartan	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
586	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
139	NUM	O	O
assigned	PUNCT	O	O
atenolol	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
609	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Relative	ADJ	O	O
risk	NOUN	O	O
reduction	NOUN	O	B-PHYSICAL
24	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.031	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cardiovascular	ADJ	O	B-PHYSICAL
mortality	NOUN	O	I-PHYSICAL
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
37	NUM	O	O
%	SYM	O	O
in	ADP	O	O
favour	NOUN	O	O
of	ADP	O	O
losartan	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.028	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
cause	PUNCT	O	O
mortality	NOUN	O	B-MORTALITY
by	ADP	O	O
39	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
Losartan	NOUN	O	O
was	VERB	O	O
very	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
cardiovascular	ADJ	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
as	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
atenolol	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
will	VERB	O	O
have	CCONJ	O	O
a	DET	O	O
major	ADJ	O	O
impact	NOUN	O	O
on	ADP	O	O
the	DET	O	O
choice	NOUN	O	O
of	ADP	O	O
anti-hypertensive	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
interleukin-1	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
on	ADP	O	O
the	DET	O	O
inflamed	ADP	O	O
synovial	ADJ	O	O
membrane	NOUN	O	O
in	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
interleukin-1	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
(	PUNCT	O	O
IL-1Ra	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
synovial	ADJ	O	O
tissue	NOUN	O	O
in	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
(	PUNCT	O	O
RA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Twelve	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
RA	NOUN	O	O
entering	CCONJ	O	O
a	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
recombinant	ADJ	O	O
IL-1Ra	NOUN	O	O
underwent	VERB	O	O
synovial	ADJ	O	O
biopsies	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Cellular	ADJ	O	B-PHYSICAL
infiltration	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
adhesion	NOUN	O	I-PHYSICAL
molecule	NOUN	O	I-PHYSICAL
expression	NOUN	O	I-PHYSICAL
were	VERB	O	O
evaluated	VERB	O	O
after	ADP	O	O
immunohistochemical	ADJ	O	O
staining	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
was	VERB	O	O
a	DET	O	O
notable	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
intimal	ADJ	O	B-PHYSICAL
layer	NOUN	O	I-PHYSICAL
macrophages	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
subintimal	ADJ	O	B-PHYSICAL
macrophages	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
lymphocytes	NOUN	O	B-PHYSICAL
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
IL-1Ra	NOUN	O	O
at	ADP	O	O
150	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
n=3	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Increased	VERB	O	O
cellular	ADJ	O	B-PHYSICAL
infiltration	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
receiving	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n=3	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
variable	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
observed	NUM	O	O
after	ADP	O	O
IL-1Ra	NOUN	O	O
30	PUNCT	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
n=6	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
limited	PUNCT	O	O
study	NOUN	O	O
of	ADP	O	O
adhesion	NOUN	O	O
molecule	NOUN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
down-regulation	NOUN	O	O
of	ADP	O	O
E-selectin	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
vascular	ADJ	O	B-PHYSICAL
cell	NOUN	O	I-PHYSICAL
adhesion	NOUN	O	I-PHYSICAL
molecule-1	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	NUM	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
IL-1Ra	NOUN	O	O
150	NUM	O	O
mg/day	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
after	ADP	O	O
IL-1Ra	NOUN	O	O
30	PUNCT	O	O
mg/day	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
apparent	ADJ	O	O
arrest	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	B-PHYSICAL
joint	NOUN	O	I-PHYSICAL
damage	NOUN	O	I-PHYSICAL
seen	VERB	O	O
in	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
IL-1Ra	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
reduced	ADP	O	O
intimal	ADJ	O	O
layer	NOUN	O	O
macrophage	NOUN	O	O
accumulation	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Treatment	NOUN	O	O
of	ADP	O	O
RA	NOUN	O	O
with	ADP	O	O
IL-1Ra	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
reduced	ADP	O	O
mononuclear	ADJ	O	O
cell	NOUN	O	O
infiltration	NOUN	O	O
of	ADP	O	O
synovial	ADJ	O	O
membrane	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
may	VERB	O	O
represent	VERB	O	O
the	DET	O	O
in	PUNCT	O	O
vivo	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
biologically	ADV	O	O
relevant	ADJ	O	O
IL-1ss-mediated	ADJ	O	O
pathogenic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
hypnosis	NOUN	O	O
versus	CCONJ	O	O
cognitive	ADJ	O	O
behavioral	ADJ	O	O
training	VERB	O	O
for	ADP	O	O
pain	NOUN	O	B-PAIN
management	NOUN	O	I-PAIN
with	ADP	O	O
pediatric	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
aspirations	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
hypnosis	NOUN	O	O
versus	CCONJ	O	O
cognitive	ADJ	O	O
behavioral	ADJ	O	O
(	PUNCT	O	O
CB	NOUN	O	O
)	PUNCT	O	O
coping	ADJ	O	O
skills	NOUN	O	O
training	VERB	O	O
in	ADP	O	O
alleviating	VERB	O	O
the	DET	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
distress	NOUN	O	B-PAIN
of	ADP	O	O
30	NUM	O	O
pediatric	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
5	NUM	O	O
to	ADP	O	O
15	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
undergoing	VERB	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
aspirations	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
hypnosis	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
package	NOUN	O	O
of	ADP	O	O
CB	NOUN	O	O
coping	PROPN	O	O
skills	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
either	PUNCT	O	O
hypnosis	NOUN	O	O
or	CCONJ	O	O
CB	NOUN	O	O
reported	PUNCT	O	O
less	DET	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
pain-related	VERB	O	B-MENTAL
anxiety	ADJ	O	I-MENTAL
than	PUNCT	O	O
did	PUNCT	O	O
control	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
less	DET	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
anxiety	NOUN	O	B-MENTAL
than	PUNCT	O	O
at	ADP	O	O
their	PUNCT	O	O
own	ADJ	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Hypnosis	NOUN	O	O
and	CCONJ	O	O
CB	NOUN	O	O
were	VERB	O	O
similarly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
relief	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
pain	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Results	NOUN	O	O
also	ADV	O	O
indicated	VERB	O	O
that	ADP	O	O
children	NOUN	O	O
reported	VERB	O	O
more	DET	O	O
anxiety	NOUN	O	B-MENTAL
and	CCONJ	O	O
exhibited	VERB	O	O
more	DET	O	O
behavioral	ADJ	O	B-MENTAL
distress	NOUN	O	I-MENTAL
in	ADP	O	O
the	DET	O	O
CB	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hypnosis	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	NOUN	O	O
that	ADP	O	O
hypnosis	NOUN	O	O
and	CCONJ	O	O
CB	NOUN	O	O
coping	PUNCT	O	O
skills	NOUN	O	O
are	PROPN	O	O
effective	ADJ	O	O
in	ADP	O	O
preparing	VERB	O	O
pediatric	ADJ	O	O
oncology	NOUN	O	O
patients	NOUN	O	O
for	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
aspiration	NOUN	O	O
.	PUNCT	O	O

Perioperative	PUNCT	O	O
blood	NOUN	O	O
transfusions	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
allogeneic	ADJ	O	O
leucocytes	NOUN	O	O
,	PUNCT	O	O
relate	VERB	O	O
to	ADP	O	O
survival	NOUN	O	B-MORTALITY
,	PUNCT	O	O
not	ADV	O	O
to	ADP	O	O
cancer	NOUN	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Perioperative	PUNCT	O	O
blood	NOUN	O	O
transfusions	NOUN	O	O
are	VERB	O	O
reported	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
related	VERB	O	O
to	ADP	O	O
cancer	NOUN	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
reduced	VERB	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
.	PUNCT	O	O

Different	ADJ	O	O
underlying	ADP	O	O
mechanisms	NOUN	O	O
have	ADP	O	O
been	PUNCT	O	O
proposed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
allogeneic	ADJ	O	O
leucocytes	NOUN	O	O
in	ADP	O	O
transfused	DET	O	O
blood	NOUN	O	O
have	PUNCT	O	O
been	PUNCT	O	O
suggested	VERB	O	O
to	PART	O	O
contribute	NOUN	O	O
to	ADP	O	O
this	DET	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Packed	PUNCT	O	O
red	ADJ	O	O
cells	NOUN	O	O
without	ADP	O	O
buffy	ADJ	O	O
coat	NOUN	O	O
(	PUNCT	O	O
PC	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
filtered	ADP	O	O
,	PUNCT	O	O
leucoreduced	PUNCT	O	O
,	PUNCT	O	O
red	ADJ	O	O
cells	NOUN	O	O
(	PUNCT	O	O
LD	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
697	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
colorectal	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

Five-year	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
and	CCONJ	O	O
cancer	NOUN	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
were	VERB	O	O
determined	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
special	ADJ	O	O
emphasis	NOUN	O	O
on	ADP	O	O
the	DET	O	O
location	NOUN	O	O
of	ADP	O	O
recurrence	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
intention-to-treat	NOUN	O	O
analysis	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
survival	NOUN	O	B-MORTALITY
rate	NOUN	O	I-MORTALITY
of	ADP	O	O
63.6	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
in	ADP	O	O
the	DET	O	O
PC	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
65.3	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
in	ADP	O	O
the	DET	O	O
LD	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.69	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
recurrence	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
of	ADP	O	O
27.8	NUM	O	O
and	CCONJ	O	O
27.9	NUM	O	O
per	ADP	O	O
cent	ADP	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
observational	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	B-MORTALITY
in	ADP	O	I-MORTALITY
survival	NOUN	O	I-MORTALITY
between	ADP	O	O
transfused	VERB	O	O
and	CCONJ	O	O
non-transfused	ADV	O	O
patients	NOUN	O	O
(	PUNCT	O	O
59.6	ADP	O	O
versus	CCONJ	O	O
72.9	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
between	ADP	O	O
transfused	VERB	O	O
and	CCONJ	O	O
non-transfused	ADV	O	O
patients	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
29.8	NUM	O	O
versus	CCONJ	O	O
24.3	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.13	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Local	ADJ	O	B-PHYSICAL
recurrences	NOUN	O	I-PHYSICAL
were	VERB	O	O
more	ADV	O	O
frequent	ADP	O	O
in	ADP	O	O
transfused	ADP	O	O
than	PUNCT	O	O
non-transfused	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
11.9	ADP	O	O
versus	CCONJ	O	O
7.6	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.09	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Leucocyte	NOUN	O	O
depletion	NOUN	O	O
of	ADP	O	O
perioperative	ADJ	O	O
transfused	VERB	O	O
blood	NOUN	O	O
has	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
long-term	NOUN	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
and/or	CCONJ	O	O
cancer	NOUN	O	B-PHYSICAL
recurrence	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Perioperative	PUNCT	O	O
blood	NOUN	O	O
transfusions	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
impaired	VERB	O	O
survival	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
cancer	NOUN	O	O
recurrence	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
slight	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
local	ADJ	O	O
recurrence	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
in	ADP	O	O
transfused	VERB	O	O
patients	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
related	VERB	O	O
to	ADP	O	O
complicated	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
particular	PUNCT	O	O
rectal	ADJ	O	O
,	PUNCT	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Controlled-release	NOUN	O	O
melatonin	NOUN	O	O
,	PUNCT	O	O
singly	ADV	O	O
and	CCONJ	O	O
combined	VERB	O	O
with	ADP	O	O
cognitive	ADJ	O	O
behavioural	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
persistent	ADJ	O	O
insomnia	NOUN	O	B-PHYSICAL
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
melatonin	NOUN	O	O
and	CCONJ	O	O
cognitive-behavioural	ADJ	O	O
therapy	NOUN	O	O
have	PUNCT	O	O
shown	PUNCT	O	O
efficacy	NOUN	O	O
in	ADP	O	O
treating	VERB	O	O
sleep	NOUN	O	O
disorders	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
little	PUNCT	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
their	PUNCT	O	O
relative	ADJ	O	O
or	CCONJ	O	O
combined	VERB	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
sixty	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
4-10	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
suffering	ADP	O	O
from	ADP	O	O
sleep	NOUN	O	O
onset	NOUN	O	O
insomnia	ADV	O	O
and	CCONJ	O	O
impaired	VERB	O	O
sleep	NOUN	O	O
maintenance	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	ADP	O	O
either	CCONJ	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
combination	NOUN	O	O
of	ADP	O	O
controlled-release	NOUN	O	O
melatonin	NOUN	O	O
and	CCONJ	O	O
cognitive-behavioural	ADJ	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
controlled-release	NOUN	O	O
melatonin	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
four	NUM	O	O
sessions	NOUN	O	O
of	ADP	O	O
cognitive-behavioural	ADJ	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
or	CCONJ	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
placebo	NOUN	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
condition	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
a	DET	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
ratio	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
response	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
1-week	NOUN	O	O
actigraphic	ADJ	O	O
monitoring	VERB	O	O
,	PUNCT	O	O
sleep	ADP	O	O
diary	PUNCT	O	O
and	CCONJ	O	O
sleep	NOUN	O	O
questionnaire	NOUN	O	O
.	PUNCT	O	O

Main	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
,	PUNCT	O	O
derived	VERB	O	O
actigraphically	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
sleep	NOUN	O	O
latency	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
sleep	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
wake	NOUN	O	O
after	ADP	O	O
sleep	NOUN	O	O
onset	NOUN	O	O
and	CCONJ	O	O
number	NOUN	O	O
of	ADP	O	O
awakenings	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
active	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
all	DET	O	O
resulted	PUNCT	O	O
in	ADP	O	O
improvements	NOUN	O	O
across	ADP	O	O
all	DET	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
moderate-to-large	PUNCT	O	O
effect	NOUN	O	O
sizes	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
a	DET	O	O
12-week	NOUN	O	O
assessment	NOUN	O	O
.	PUNCT	O	O

Melatonin	NOUN	O	O
treatment	NOUN	O	O
was	VERB	O	O
mainly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
insomnia	NOUN	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
while	ADP	O	O
cognitive-behavioural	ADJ	O	O
therapy	NOUN	O	O
had	VERB	O	O
a	DET	O	O
light	ADJ	O	O
positive	ADJ	O	O
impact	NOUN	O	O
mainly	ADV	O	O
on	ADP	O	O
sleep	NOUN	O	B-PHYSICAL
latency	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
some	DET	O	O
behavioural	ADJ	O	O
aspects	NOUN	O	O
might	VERB	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
determining	VERB	O	O
initial	ADJ	O	B-PHYSICAL
insomnia	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
to	ADP	O	O
outperform	PUNCT	O	O
other	ADJ	O	O
active	ADJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
fewer	PUNCT	O	O
dropouts	ADP	O	O
and	CCONJ	O	O
a	DET	O	O
greater	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
responders	NOUN	O	O
achieving	PUNCT	O	O
clinically	ADV	O	O
significant	ADJ	O	O
changes	NOUN	O	O
(	PUNCT	O	O
63.38	NUM	O	O
%	SYM	O	O
normative	ADJ	O	O
sleep	NOUN	O	O
efficiency	NOUN	O	O
criterion	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
85	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
84.62	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
sleep	ADP	O	O
onset	NOUN	O	O
latency	NOUN	O	O
<	SYM	O	O
30	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
adding	VERB	O	O
behavioural	ADJ	O	O
intervention	NOUN	O	O
to	ADP	O	O
melatonin	NOUN	O	O
treatment	NOUN	O	O
seems	NOUN	O	O
to	PART	O	O
result	NOUN	O	O
in	ADP	O	O
a	DET	O	O
better	PUNCT	O	O
treatment	NOUN	O	O
response	NOUN	O	O
,	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
in	ADP	O	O
the	DET	O	O
short	ADJ	O	O
term	NOUN	O	O
.	PUNCT	O	O

Phase	NOUN	O	O
II	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
nab-paclitaxel	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
docetaxel	PUNCT	O	O
as	ADP	O	O
first-line	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
final	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
overall	ADJ	O	O
survival	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
phase	NOUN	O	O
II	NUM	O	O
study	NOUN	O	O
in	ADP	O	O
first-line	NOUN	O	O
MBC	NOUN	O	O
demonstrated	VERB	O	O
superior	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
weekly	ADV	O	O
nab-paclitaxel	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
docetaxel	NOUN	O	O
.	PUNCT	O	O

Final	ADJ	O	O
survival	NOUN	O	B-MORTALITY
analyses	NOUN	O	O
and	CCONJ	O	O
updated	ADP	O	O
safety	NOUN	O	B-OTHER
results	ADJ	O	O
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Three	NUM	O	O
hundred	NUM	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
previous	ADJ	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
MBC	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
nab-paclitaxel	NOUN	O	O
300	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
q3w	NOUN	O	O
,	PUNCT	O	O
nab-paclitaxel	NOUN	O	O
100	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
150	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
3	NUM	O	O
of	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
qw	NOUN	O	O
3/4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
docetaxel	VERB	O	O
100	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
q3w	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
powered	VERB	O	O
for	ADP	O	O
analyses	NOUN	O	O
of	ADP	O	O
antitumor	NOUN	O	B-OTHER
activity	NOUN	O	I-OTHER
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
.	PUNCT	O	O

RESULTS	NOUN	O	O
Treatment	NOUN	O	O
with	ADP	O	O
nab-paclitaxel	NOUN	O	O
150	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
qw	NOUN	O	O
3/4	NUM	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
median	ADJ	O	O
overall	ADJ	O	O
survival	NOUN	O	B-MORTALITY
(	PUNCT	O	O
OS	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
33.8	NUM	O	O
months	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
22.2	NUM	O	O
,	PUNCT	O	O
27.7	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
26.6	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
nab-paclitaxel	NOUN	O	O
100	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
qw	NOUN	O	O
3/4	NUM	O	O
,	PUNCT	O	O
nab-paclitaxel	NOUN	O	O
300	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
q3w	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
docetaxel	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
overall	ADJ	O	O
P	NOUN	O	O
=	SYM	O	O
.047	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
receiving	VERB	O	O
150	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
nab-paclitaxel	NOUN	O	O
had	PUNCT	O	O
prolonged	PUNCT	O	O
median	ADJ	O	O
OS	NOUN	O	B-MORTALITY
compared	VERB	O	O
with	ADP	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
100	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
nab-paclitaxel	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
0.575	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.008	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
a	DET	O	O
longer	PUNCT	O	O
OS	PUNCT	O	B-MORTALITY
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
150	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
nab-paclitaxel	NOUN	O	O
arm	NOUN	O	O
versus	CCONJ	O	O
docetaxel	DET	O	O
arm	NOUN	O	O
(	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
0.688	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
4	NUM	O	B-PHYSICAL
fatigue	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
neutropenia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
febrile	ADJ	O	B-PHYSICAL
neutropenia	NOUN	O	I-PHYSICAL
were	VERB	O	O
less	ADV	O	O
frequent	ADP	O	O
in	ADP	O	O
all	DET	O	O
nab-paclitaxel	NOUN	O	O
arms	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
docetaxel	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Consistent	ADJ	O	O
with	ADP	O	O
previously	ADV	O	O
published	PUNCT	O	O
efficacy	NOUN	O	O
results	ADJ	O	O
,	PUNCT	O	O
these	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
150	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
qw	NOUN	O	O
3/4	NUM	O	O
may	VERB	O	O
represent	VERB	O	O
the	ADP	O	O
most	PUNCT	O	O
clinically	ADV	O	O
efficacious	ADJ	O	O
nab-paclitaxel	NOUN	O	O
dosing	PUNCT	O	O
regimen	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
previous	ADJ	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
MBC	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
confirming	VERB	O	O
these	DET	O	O
results	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
necessary	ADJ	O	O
and	CCONJ	O	O
prudent	ADJ	O	O
before	ADP	O	O
widespread	ADJ	O	O
adoption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
150	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
dose	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

Laser-aided	ADJ	O	O
external	ADJ	O	O
drainage	NOUN	O	O
of	ADP	O	O
subretinal	ADJ	O	O
fluid	NOUN	O	O
:	PUNCT	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
comparison	NOUN	O	O
with	ADP	O	O
needle	NOUN	O	O
drainage	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
consecutive	ADJ	O	O
eyes	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
compared	VERB	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
draining	ADP	O	O
subretinal	ADJ	O	O
fluid	NOUN	O	O
transchoroidally	ADV	O	O
in	ADP	O	O
primary	ADJ	O	O
scleral	ADJ	O	O
buckling	PUNCT	O	O
for	ADP	O	O
rhegmatogenous	ADJ	O	O
retinal	ADJ	O	O
detachment	NOUN	O	O
using	VERB	O	O
a	DET	O	O
needle	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
safety	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
procedure	NOUN	O	O
using	VERB	O	O
an	DET	O	O
angulated	VERB	O	O
endolaser	ADJ	O	O
probe	NOUN	O	O
set	ADP	O	O
at	ADP	O	O
1	NUM	O	O
W	NOUN	O	O
for	ADP	O	O
0.2	NUM	O	O
seconds	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
2.4	NUM	O	O
laser	NOUN	O	O
burns	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
complications	NOUN	O	B-ADVERSE-EFFECTS
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
laser-aided	VERB	O	O
drainage	NOUN	O	O
procedures	NOUN	O	O
(	PUNCT	O	O
25	PUNCT	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
transchoroidal	ADJ	O	O
needle	NOUN	O	O
drainage	NOUN	O	O
procedures	NOUN	O	O
(	PUNCT	O	O
25	PUNCT	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
subretinal	ADJ	O	B-PHYSICAL
hemorrhage	NOUN	O	I-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
three	NUM	O	O
eyes	NOUN	O	O
and	CCONJ	O	O
retinal	ADJ	O	O
incarceration	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
though	ADP	O	O
our	ADP	O	O
numbers	NOUN	O	O
are	VERB	O	O
small	ADJ	O	O
,	PUNCT	O	O
there	PUNCT	O	O
appears	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
some	CCONJ	O	O
advantage	NOUN	O	O
of	ADP	O	O
laser-assisted	VERB	O	O
drainage	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
a	DET	O	O
lower	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
complications	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
anesthesia	NOUN	O	O
and	CCONJ	O	O
age	NOUN	O	O
on	ADP	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
during	ADP	O	O
retinopathy	NOUN	O	O
of	ADP	O	O
prematurity	NOUN	O	O
screening	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
anesthesia	NOUN	O	O
during	ADP	O	O
retinopathy	NOUN	O	O
of	ADP	O	O
prematurity	NOUN	O	O
(	PUNCT	O	O
ROP	NOUN	O	O
)	PUNCT	O	O
screening	ADP	O	O
has	PUNCT	O	O
been	PUNCT	O	O
a	DET	O	O
controversial	ADJ	O	O
issue	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
proparacaine	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
(	PUNCT	O	O
0.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
compared	VERB	O	O
the	DET	O	O
Premature	ADJ	O	B-PAIN
Infant	NOUN	O	I-PAIN
Pain	NOUN	O	I-PAIN
Profile	NOUN	O	I-PAIN
(	PUNCT	O	O
PIPP	NOUN	O	B-PAIN
)	PUNCT	O	O
scores	NOUN	O	O
in	ADP	O	O
40	NUM	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
undergoing	VERB	O	O
ROP	NOUN	O	O
screening	VERB	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Prospective	ADJ	O	O
randomized	VERB	O	O
double	PUNCT	O	O
masked	CCONJ	O	O
cross-over	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
the	DET	O	O
neonatal	ADJ	O	O
intensive	ADJ	O	O
units	NOUN	O	O
for	ADP	O	O
infants	NOUN	O	O
undergoing	VERB	O	O
routine	ADJ	O	O
ROP	NOUN	O	O
screening	VERB	O	O
exams	NOUN	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
PIPP	NOUN	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
post-examination	NOUN	O	B-PHYSICAL
PIPP	NOUN	O	I-PHYSICAL
scores	NOUN	O	I-PHYSICAL
at	ADP	O	O
1	NUM	O	O
and	CCONJ	O	O
5	NUM	O	O
min	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
for	ADP	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
those	PUNCT	O	O
receiving	VERB	O	O
saline	NOUN	O	O
vs	CCONJ	O	O
proparacaine	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
first	ADJ	O	O
ROP	NOUN	O	O
screening	VERB	O	O
vs	CCONJ	O	O
second	ADJ	O	O
ROP	NOUN	O	O
screening	VERB	O	O
,	PUNCT	O	O
regardless	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
used	VERB	O	O
.	PUNCT	O	O

Wilcoxon	NOUN	O	O
signed-ranks	NOUN	O	O
test	ADV	O	O
was	VERB	O	O
used	VERB	O	O
to	ADP	O	O
pair	PUNCT	O	O
pain	NOUN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

RESULT	NOUN	O	O
Forty	CCONJ	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Mean	DET	O	O
gestational	ADJ	O	O
age	NOUN	O	O
(	PUNCT	O	O
GA	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
first	PUNCT	O	O
and	CCONJ	O	O
second	ADP	O	O
examinations	NOUN	O	O
was	VERB	O	O
33.3	NUM	O	O
and	CCONJ	O	O
35.3	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Proparacaine	ADJ	O	O
use	ADP	O	O
significantly	ADV	O	O
lowered	CCONJ	O	O
mean	NOUN	O	O
PIPP	NOUN	O	O
scores	NOUN	O	O
(	PUNCT	O	O
P=0.027	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
delta	NOUN	O	O
scores	NOUN	O	O
(	PUNCT	O	O
P=0.013	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
1	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
examination	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
at	ADP	O	O
5	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
examination	NOUN	O	O
.	PUNCT	O	O

Second	ADJ	O	O
examinations	NOUN	O	O
showed	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
mean	NOUN	O	O
PIPP	NOUN	O	O
scores	NOUN	O	O
after	ADP	O	O
examination	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
P=0.003	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
P=0.025	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
regardless	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
drop	PUNCT	O	O
used	PRON	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Proparacaine	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
offer	VERB	O	O
significant	ADJ	O	O
relief	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	O
that	ADP	O	O
is	VERB	O	O
apparently	ADV	O	O
short	ADJ	O	O
lived	PRON	O	O
.	PUNCT	O	O

Significantly	ADV	O	O
lower	PUNCT	O	O
PIPP	NOUN	O	O
scores	NOUN	O	O
at	ADP	O	O
second	ADJ	O	O
ROP	NOUN	O	O
examinations	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
infants	NOUN	O	O
of	ADP	O	O
older	PUNCT	O	O
GA	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
a	DET	O	O
greater	PUNCT	O	O
ability	NOUN	O	O
to	VERB	O	O
tolerate	NOUN	O	O
ROP	NOUN	O	O
screening	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
recommend	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
proparacaine	NOUN	O	O
eye	NOUN	O	O
drops	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
short	ADJ	O	O
term	NOUN	O	O
,	PUNCT	O	O
immediate	ADJ	O	O
relief	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	O
during	ADP	O	O
ROP	NOUN	O	O
screening	NUM	O	O
in	ADP	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
of	ADP	O	O
lesser	PUNCT	O	O
GA	NOUN	O	O
.	PUNCT	O	O

Iontophoretic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	O
sodium	NOUN	O	O
phosphate	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
epicondylitis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blinded	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
A	DET	O	O
better	PUNCT	O	O
treatment	NOUN	O	O
modality	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	ADP	O	O
control	ADP	O	O
the	DET	O	O
pain	NOUN	O	B-PAIN
of	ADP	O	O
medial	ADJ	O	B-PHYSICAL
or	CCONJ	O	O
lateral	ADJ	O	B-PHYSICAL
epicondylitis	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
tennis	NOUN	O	I-PHYSICAL
elbow	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

HYPOTHESIS	ADJ	O	O
Dermal	ADJ	O	O
iontophoretic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	O
sodium	NOUN	O	O
phosphate	NOUN	O	O
will	PUNCT	O	O
be	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
controlling	PUNCT	O	O
pain	NOUN	O	B-PAIN
than	PUNCT	O	O
a	DET	O	O
placebo	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
medial	ADJ	O	O
or	CCONJ	O	O
lateral	ADJ	O	O
elbow	NOUN	O	O
epicondylitis	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
double-blinded	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
On	ADP	O	O
six	NUM	O	O
occasions	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
to	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
apart	PUNCT	O	O
within	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
199	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
elbow	NOUN	O	O
epicondylitis	NOUN	O	O
received	VERB	O	O
40	NUM	O	O
mA-minutes	ADP	O	O
of	ADP	O	O
either	CCONJ	O	O
active	ADJ	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Dexamethasone	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
23-mm	PUNCT	O	O
improvement	NOUN	O	O
on	ADP	O	O
the	DET	O	O
100-mm	ADJ	O	B-PAIN
patient	NOUN	O	I-PAIN
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
ratings	NOUN	O	B-PAIN
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
14	NUM	O	O
mm	NOUN	O	O
for	ADP	O	O
placebo	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
24	NUM	O	O
mm	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
19	NUM	O	O
mm	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
.	PUNCT	O	O

More	DET	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
dexamethasone	NOUN	O	O
than	PUNCT	O	O
those	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
scored	VERB	O	O
moderate	ADJ	O	O
or	CCONJ	O	O
better	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
investigator	NOUN	O	B-PHYSICAL
's	PUNCT	O	O
global	ADJ	O	B-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
scale	NOUN	O	O
(	PUNCT	O	O
52	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
33	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
at	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
at	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
(	PUNCT	O	O
54	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
49	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Investigator-rated	PUNCT	O	B-PAIN
pain	NOUN	O	B-PAIN
and	CCONJ	O	I-PAIN
tenderness	NOUN	O	I-PAIN
scores	NOUN	O	O
favored	VERB	O	O
dexamethasone	NOUN	O	O
over	ADP	O	O
placebo	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
completing	VERB	O	O
six	NUM	O	O
treatments	NOUN	O	O
in	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
or	CCONJ	O	O
less	DET	O	O
had	PUNCT	O	O
better	PUNCT	O	O
results	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
treated	VERB	O	O
over	ADP	O	O
a	DET	O	O
longer	PUNCT	O	O
period	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Iontophoresis	NOUN	O	O
treatment	NOUN	O	O
was	PUNCT	O	O
well	PUNCT	O	O

Long-term	NOUN	O	O
retention	NOUN	O	O
on	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
lumiracoxib	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
or	CCONJ	O	O
twice	PUNCT	O	O
daily	ADJ	O	O
compared	VERB	O	O
with	ADP	O	O
celecoxib	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	ADJ	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
osteoarthritis	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
safety	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
lumiracoxib	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
novel	ADJ	O	O
selective	ADJ	O	O
cyclooxygenase-2	NOUN	O	O
(	PUNCT	O	O
COX-2	NOUN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
demonstrated	VERB	O	O
in	ADP	O	O
previous	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
osteoarthritis	NOUN	O	O
(	PUNCT	O	O
OA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

As	PUNCT	O	O
it	DET	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
establish	ADJ	O	O
the	DET	O	O
long-term	NOUN	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
treatments	NOUN	O	O
for	ADP	O	O
a	DET	O	O
chronic	ADJ	O	O
disease	NOUN	O	O
such	PUNCT	O	O
as	ADP	O	O
OA	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
lumiracoxib	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	DET	O	O
(	PUNCT	O	O
o.d	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O

and	CCONJ	O	O
100	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
(	PUNCT	O	O
b.i.d	ADP	O	O
.	PUNCT	O	O
)	PUNCT	O	O

with	ADP	O	O
those	PUNCT	O	O
of	ADP	O	O
celecoxib	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
o.d	PUNCT	O	O
.	PUNCT	O	O

on	ADP	O	O
retention	NOUN	O	O
on	ADP	O	O
treatment	NOUN	O	O
over	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
52-week	NOUN	O	O
,	PUNCT	O	O
multicentre	NOUN	O	O
,	PUNCT	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
male	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
aged	PROPN	O	O
at	DET	O	O
least	ADV	O	O
40	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
symptomatic	ADJ	O	O
primary	ADJ	O	O
OA	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
,	PUNCT	O	O
knee	NOUN	O	O
,	PUNCT	O	O
hand	NOUN	O	O
or	CCONJ	O	O
spine	NOUN	O	O
were	VERB	O	O
randomised	NUM	O	O
(	PUNCT	O	O
1:2:1	ADV	O	O
)	PUNCT	O	O
to	ADP	O	O
lumiracoxib	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
o.d	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

n	NOUN	O	O
=	SYM	O	O
755	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
lumiracoxib	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
b.i.d	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

n	NOUN	O	O
=	SYM	O	O
1,519	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
celecoxib	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
o.d	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

n	NOUN	O	O
=	SYM	O	O
758	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
objective	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
demonstrate	NOUN	O	O
non-inferiority	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
lumiracoxib	NOUN	O	I-PHYSICAL
at	ADP	O	O
either	PUNCT	O	O
dose	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
celecoxib	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
o.d	PUNCT	O	O
.	PUNCT	O	O

with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
1-year	NOUN	O	B-MENTAL
retention	NOUN	O	I-MENTAL
on	ADP	O	I-MENTAL
treatment	NOUN	O	O
rate	NOUN	O	B-MENTAL
.	PUNCT	O	O

Secondary	ADJ	O	O
outcome	NOUN	O	O
variables	NOUN	O	O
included	ADP	O	O
OA	NOUN	O	O
pain	NOUN	O	O
in	ADP	O	O
the	DET	O	O
target	NOUN	O	O
joint	NOUN	O	O
,	PUNCT	O	O
patient	NOUN	O	O
's	PUNCT	O	O
and	CCONJ	O	O
physician	NOUN	O	O
's	PUNCT	O	O
global	ADJ	O	O
assessments	NOUN	O	O
of	ADP	O	O
disease	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
Short	ADJ	O	O
Arthritis	NOUN	O	O
assessment	NOUN	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
SAS	NOUN	O	O
)	PUNCT	O	O
total	ADP	O	O
score	NOUN	O	O
,	PUNCT	O	O
rescue	VERB	O	O
medication	NOUN	O	O
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
safety	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Retention	NOUN	O	B-PHYSICAL
rates	NOUN	O	B-PHYSICAL
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
the	DET	O	O
lumiracoxib	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
o.d.	NOUN	O	O
,	PUNCT	O	O
lumiracoxib	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
b.i.d	ADV	O	O
.	PUNCT	O	O

and	CCONJ	O	O
celecoxib	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
o.d	PUNCT	O	O
.	PUNCT	O	O

groups	NOUN	O	O
(	PUNCT	O	O
46.9	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
47.5	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
45.3	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
retention	NOUN	O	B-OTHER
on	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
lumiracoxib	NOUN	O	O
at	ADP	O	O
either	PUNCT	O	O
dose	NOUN	O	O
was	ADP	O	O
non-inferior	ADJ	O	O
to	ADP	O	O
celecoxib	NOUN	O	O
200	NUM	O	O
mg	NOUN	O	O
o.d	PUNCT	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
Kaplan-Meier	PUNCT	O	O
curves	NOUN	O	O
for	ADP	O	O
the	DET	O	O
probability	NOUN	O	O
of	ADP	O	O
premature	ADJ	O	O
discontinuation	NOUN	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
for	ADP	O	O
any	DET	O	O
reason	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
across	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
three	NUM	O	O
treatments	NOUN	O	O
generally	ADV	O	O
yielded	ADV	O	O
comparable	ADJ	O	O
results	NOUN	O	O
for	ADP	O	O
the	DET	O	O
secondary	ADJ	O	O
efficacy	NOUN	O	O
variables	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
treatments	NOUN	O	O
were	PUNCT	O	O
well	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
knee	NOUN	O	O
position	NOUN	O	O
on	ADP	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
range	NOUN	O	O
of	ADP	O	O
motion	NOUN	O	B-PHYSICAL
following	SYM	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
prospectively	ADV	O	O
assessed	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
knee	NOUN	O	O
position	NOUN	O	O
on	ADP	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
range	NOUN	O	O
of	ADP	O	O
motion	NOUN	O	B-PHYSICAL
after	ADP	O	O
primary	ADJ	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
(	PUNCT	O	O
TKA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
ten	NUM	O	O
consecutive	ADJ	O	O
TKA	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
flexion	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
extension	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
had	PUNCT	O	O
the	DET	O	O
leg	NOUN	O	O
elevated	ADJ	O	O
30?	NOUN	O	O
at	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
over	ADP	O	O
an	DET	O	O
inactive	ADJ	O	O
CPM	NOUN	O	O
for	ADP	O	O
72	NUM	O	O
h	NOUN	O	O
postoperatively	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
flexion	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
the	DET	O	O
knee	NOUN	O	O
flexed	VERB	O	O
to	ADP	O	O
30?	NUM	O	O
during	ADP	O	O
this	DET	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
extension	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
the	DET	O	O
knee	NOUN	O	O
extended	VERB	O	O
fully	ADV	O	O
.	PUNCT	O	O

Perioperative	PUNCT	O	O
blood	NOUN	O	O
loss	NOUN	O	O
,	PUNCT	O	O
hidden	PUNCT	O	O
blood	NOUN	O	O
loss	NOUN	O	O
,	PUNCT	O	O
knee	NOUN	O	O
swelling	VERB	O	O
,	PUNCT	O	O
ecchymosis	NOUN	O	O
,	PUNCT	O	O
analgesia	NOUN	O	O
requirements	NOUN	O	O
,	PUNCT	O	O
range	NOUN	O	O
of	ADP	O	O
motion	NOUN	O	O
(	PUNCT	O	O
ROM	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fixed	VERB	O	O
flexion	NOUN	O	O
deformity	NOUN	O	O
(	PUNCT	O	O
FFD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
straight-leg	NOUN	O	O
raising	SYM	O	O
action	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
complications	NOUN	O	O
within	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
for	ADP	O	O
evaluation	NOUN	O	O
and	CCONJ	O	O
comparison	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
postoperative	ADJ	O	O
hidden	PUNCT	O	O
blood	NOUN	O	O
loss	NOUN	O	O
,	PUNCT	O	O
knee	NOUN	O	O
swelling	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
scope	NOUN	O	O
of	ADP	O	O
ecchymosis	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
flexion	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
extension	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
ROM	NOUN	O	O
and	CCONJ	O	O
straight-leg	NOUN	O	O
raising	SYM	O	O
action	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
early	ADJ	O	O
period	NOUN	O	O
after	ADP	O	O
operation	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
perioperative	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	O
used	ADP	O	O
,	PUNCT	O	O
or	CCONJ	O	O
FFD	NOUN	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
postoperative	ADJ	O	O
period	NOUN	O	O
or	CCONJ	O	O
in	ADP	O	O
ROM	NOUN	O	O
and	CCONJ	O	O
FFD	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
postoperatively	ADV	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
findings	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
flexion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
to	ADP	O	O
30?	NUM	O	O
with	ADP	O	O
the	DET	O	O
leg	NOUN	O	O
elevated	ADJ	O	O
30?	NOUN	O	O
at	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
after	ADP	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
may	NOUN	O	O
mitigate	PUNCT	O	O
knee	NOUN	O	O
swelling	VERB	O	O
and	CCONJ	O	O
provide	PUNCT	O	O
other	ADJ	O	O
beneficial	ADJ	O	O
results	DET	O	O
during	ADP	O	O
the	DET	O	O
early	ADJ	O	O
rehabilitation	NOUN	O	O
following	VERB	O	O
TKA	NOUN	O	O
.	PUNCT	O	O

LEVEL	NOUN	O	O
OF	ADP	O	O
EVIDENCE	NOUN	O	O
Prospective	ADJ	O	O
comparative	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
Level	NOUN	O	O
I	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
on	ADP	O	O
academic	ADJ	O	O
engagement	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
whether	VERB	O	O
participation	NOUN	O	O
in	ADP	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
before	PUNCT	O	O
classroom	PUNCT	O	O
activities	NOUN	O	O
improves	NOUN	O	O
academic	ADJ	O	O
engagement	NOUN	O	O
and	CCONJ	O	O
reduces	VERB	O	O
stereotypic	ADJ	O	O
behaviors	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
study	NOUN	O	O
employed	VERB	O	O
a	DET	O	O
within-subjects	VERB	O	O
crossover	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
treatment	NOUN	O	O
condition	NOUN	O	O
(	PUNCT	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
condition	NOUN	O	O
,	PUNCT	O	O
across	ADP	O	O
4	NUM	O	O
classrooms	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
condition	NOUN	O	O
included	VERB	O	O
15	NUM	O	O
minutes	NOUN	O	O
of	ADP	O	O
running/jogging	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
classroom	PUNCT	O	O
task	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
condition	NOUN	O	O
included	VERB	O	O
a	DET	O	O
classroom	PUNCT	O	O
task	NOUN	O	O
not	ADV	O	O
preceded	VERB	O	O
by	ADP	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
stereotypic	ADJ	O	I-MENTAL
behaviors	NOUN	O	I-MENTAL
,	PUNCT	O	O
percentage	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
on-task	PUNCT	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
pre-	ADJ	O	O
and	CCONJ	O	O
intraoperative	ADJ	O	O
positioning	VERB	O	O
of	ADP	O	O
the	DET	O	O
condyle	ADJ	O	O
in	ADP	O	O
the	DET	O	O
centre	NOUN	O	O
of	ADP	O	O
the	DET	O	O
articular	ADJ	O	O
fossa	NOUN	O	O
on	ADP	O	O
the	DET	O	O
position	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disc	NOUN	O	O
in	ADP	O	O
orthognathic	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
temporomandibular	ADJ	O	O
joint	NOUN	O	O
(	PUNCT	O	O
TMJ	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
bilateral	ADJ	O	O
sagittal	ADJ	O	O
split	ADJ	O	O
osteotomy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mandible	ADJ	O	O
for	ADP	O	O
orthognathic	ADJ	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
positioning	VERB	O	O
of	ADP	O	O
the	DET	O	O
condylar	ADJ	O	O
process	NOUN	O	O
in	ADP	O	O
the	DET	O	O
centre	NOUN	O	O
of	ADP	O	O
the	DET	O	O
articular	ADJ	O	O
fossa	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
operation	NOUN	O	O
for	ADP	O	O
preventing	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
TMJ	NOUN	O	O
postoperatively	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
28	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
mandibular	ADJ	O	O
retrognathism	NOUN	O	O
had	PUNCT	O	O
bilateral	ADJ	O	O
sagittal	ADJ	O	O
split	ADJ	O	O
osteotomies	NOUN	O	O
for	ADP	O	O
mandibular	ADJ	O	O
advancement	ADP	O	O
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
group	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
28	NUM	O	O
TMJ	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
condyles	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
in	ADP	O	O
the	DET	O	O
centre	NOUN	O	O
of	ADP	O	O
the	DET	O	O
articular	ADJ	O	O
fossa	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
operation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
group	NOUN	O	O
they	PUNCT	O	O
were	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

Differences	NOUN	O	B-OTHER
on	ADP	O	I-OTHER
magnetic	ADJ	O	I-OTHER
resonance	NOUN	O	I-OTHER
imaging	VERB	O	I-OTHER
(	PUNCT	O	I-OTHER
MRI	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
were	VERB	O	O
calculated	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
results	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
main	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
at	ADP	O	O
maximal	ADJ	O	B-PHYSICAL
mouth	NOUN	O	I-PHYSICAL
opening	ADJ	O	I-PHYSICAL
.	PUNCT	O	O

15/28	PUNCT	O	O
TMJs	NOUN	O	O
(	PUNCT	O	O
54	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
that	ADP	O	O
had	ADP	O	O
not	ADV	O	O
been	PUNCT	O	O
positioned	VERB	O	O
changed	VERB	O	O
the	DET	O	O
position	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disc	NOUN	O	O
from	ADP	O	O
physiological	ADJ	O	O
to	ADP	O	O
anterior	ADJ	O	O
disc	NOUN	O	O
derangement	VERB	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
reduction	NOUN	O	O
postoperatively	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
28	NUM	O	O
that	PUNCT	O	O
had	VERB	O	O
been	PUNCT	O	O
positioned	VERB	O	O
,	PUNCT	O	O
changes	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
only	ADV	O	O
3	NUM	O	O
TMJs	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
11	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
postoperatively	ADV	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Fixing	PUNCT	O	O
the	DET	O	O
condylar	ADJ	O	O
process	NOUN	O	O
in	ADP	O	O
the	DET	O	O
centre	NOUN	O	O
of	ADP	O	O
the	DET	O	O
articular	ADJ	O	O
fossa	ADV	O	O
intraoperatively	ADV	O	O
before	ADP	O	O
bilateral	ADJ	O	O
sagittal	ADJ	O	O
split	ADJ	O	O
osteotomy	NOUN	O	O
is	VERB	O	O
a	DET	O	O
factor	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
postoperative	ADJ	O	O
structural	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
temporomandibular	ADJ	O	O
joint	NOUN	O	O
.	PUNCT	O	O

Recombinant	ADJ	O	O
human	NOUN	O	O
thyrotropin-stimulated	VERB	O	O
radioiodine	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
nodular	ADJ	O	O
goiter	ADJ	O	O
allows	ADV	O	O
major	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
radiation	NOUN	O	B-OTHER
burden	NOUN	O	I-OTHER
with	ADP	O	O
retained	VERB	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

CONTEXT	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVE	NOUN	O	O
Stimulation	NOUN	O	O
with	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
TSH	NOUN	O	O
(	PUNCT	O	O
rhTSH	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
radioiodine	NOUN	O	O
(	PUNCT	O	O
131I	NOUN	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
augments	NOUN	O	O
goiter	ADJ	O	B-PHYSICAL
volume	NOUN	O	I-PHYSICAL
reduction	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
GVR	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

Observations	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
rhTSH	NOUN	O	O
has	ADP	O	O
a	DET	O	O
preconditioning	ADV	O	O
effect	NOUN	O	O
beyond	ADP	O	O
increasing	PUNCT	O	O
thyroid	NOUN	O	O
(	PUNCT	O	O
131	NUM	O	O
)	PUNCT	O	O
I	NUM	O	O
uptake	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
test	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
an	DET	O	O
equivalent	ADJ	O	O
GVR	NOUN	O	O
might	VERB	O	O
be	NOUN	O	O
obtained	VERB	O	O
by	ADP	O	O
an	DET	O	O
absorbed	VERB	O	O
thyroid	NOUN	O	O
dose	VERB	O	O
well	VERB	O	O
below	PUNCT	O	O
what	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
used	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
DESIGN	NOUN	O	O
In	ADP	O	O
a	DET	O	O
double-blinded	ADV	O	O
setup	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
78	NUM	O	O
women	NOUN	O	O
;	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
52	NUM	O	O
yr	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
22-83	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
nontoxic	ADJ	O	O
nodular	ADJ	O	O
goiter	ADJ	O	O
(	PUNCT	O	O
median	ADJ	O	O
size	NOUN	O	O
,	PUNCT	O	O
63	NUM	O	O
ml	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
25-379	NUM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
0.1	NUM	O	O
mg	NOUN	O	O
rhTSH	NOUN	O	O
(	PUNCT	O	O
n=60	NOUN	O	O
)	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
thyroid	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
Gy	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
100	NUM	O	O
Gy	NOUN	O	O
(	PUNCT	O	O
n=30	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
relative	ADJ	O	B-PHYSICAL
GVR	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
rhTSH	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
identical	ADJ	O	O
(	PUNCT	O	O
35+/-3	NOUN	O	O
%	SYM	O	O
;	PUNCT	O	O
P=0.81	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
administered	VERB	O	O
131I-activity	NOUN	O	B-PHYSICAL
was	VERB	O	O
170	NUM	O	O
MBq	NOUN	O	O
(	PUNCT	O	O
45-1269	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
rhTSH	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
559	NUM	O	O
MBq	NOUN	O	O
(	PUNCT	O	O
245-3530	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
70	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

According	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
official	ADJ	O	O
radiation	NOUN	O	O
regulation	NOUN	O	O
,	PUNCT	O	O
hospitalization	NOUN	O	B-OTHER
was	VERB	O	O
required	VERB	O	O
in	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
vs.	CCONJ	O	O
one	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rhTSH	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
goiter-related	VERB	O	B-PHYSICAL
symptoms	NOUN	O	I-PHYSICAL
were	VERB	O	O
effectively	ADV	O	O
relieved	VERB	O	O
in	ADP	O	O
the	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
myxedema	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
did	DET	O	O
not	ADV	O	O
differ	VERB	O	O
among	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
to	DET	O	O
demonstrate	NOUN	O	O
that	ADP	O	O
rhTSH	NOUN	O	O
not	ADV	O	O
only	ADV	O	O
increases	NOUN	O	O
the	DET	O	O
thyroid	NOUN	O	B-PHYSICAL
131I	NOUN	O	I-PHYSICAL
uptake	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
per	PUNCT	O	O
se	ADV	O	O
potentiates	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
131I-therapy	NOUN	O	O
,	PUNCT	O	O
allowing	VERB	O	O
a	DET	O	O
major	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
131I-activity	NOUN	O	B-PHYSICAL
without	ADP	O	O
compromising	PUNCT	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
approach	NOUN	O	O
is	VERB	O	O
attractive	ADJ	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
minimizing	VERB	O	O
posttherapeutic	ADJ	O	B-OTHER
restrictions	NOUN	O	I-OTHER
and	CCONJ	O	O
in	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
radiation-induced	VERB	O	B-PHYSICAL
malignancy	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
active-learning	PROPN	O	O
strategies	NOUN	O	O
for	ADP	O	O
motivational	ADJ	O	B-MENTAL
interviewing	PUNCT	O	I-MENTAL
skills	NOUN	O	I-MENTAL
,	PUNCT	O	O
knowledge	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	PUNCT	O	O

Intestinal	ADJ	O	O
absorption	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
fat	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
.	PUNCT	O	O

Fat	NOUN	O	B-PHYSICAL
absorption	NOUN	O	I-PHYSICAL
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
clinically	ADV	O	O
definite	ADJ	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
36	NUM	O	O
healthy	ADJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Beta-carotene	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
vitamin	NOUN	O	I-PHYSICAL
A	PUNCT	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
their	ADJ	O	I-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
were	VERB	O	O
also	ADV	O	O
measured	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
double-blind	ADJ	O	O
and	CCONJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
these	DET	O	O
two	NUM	O	O
populations	NOUN	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
three	NUM	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
did	CCONJ	O	O
not	ADV	O	O
find	VERB	O	O
evidence	NOUN	O	O
for	ADP	O	O
fat	NOUN	O	O
malabsorption	NOUN	O	O
in	ADP	O	O
multiple	ADJ	O	O
sclerosis	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
power	NOUN	O	O
Ga-Al-As	NOUN	O	O
laser	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
painful	ADJ	O	B-PAIN
osteoarthritis	NOUN	O	I-PAIN
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
power	NOUN	O	O
Ga-Al-As	NOUN	O	O
laser	NOUN	O	O
treatment	NOUN	O	O
on	ADP	O	O
chronic	ADJ	O	B-PAIN
pain	NOUN	O	I-PAIN
related	VERB	O	O
to	ADP	O	O
osteoarthritis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
with	ADP	O	O
periarticular	ADJ	O	O
tender	ADP	O	O
points	NOUN	O	O
.	PUNCT	O	O

Twenty-nine	NUM	O	O
out-patients	NOUN	O	O
with	ADP	O	O
uni-	PUNCT	O	O
or	CCONJ	O	O
bilateral	ADJ	O	O
osteoarthritis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
and	CCONJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
laser	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
laser	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
active	ADJ	O	O
laser	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
patients	NOUN	O	O
included	DET	O	O
completed	PUNCT	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
variables	ADP	O	O
were	VERB	O	O
daily	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	O
,	PUNCT	O	O
analgesic	ADP	O	B-PAIN
requirements	NOUN	O	I-PAIN
,	PUNCT	O	O
palpation	NOUN	O	B-PHYSICAL
tenderness	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
isokinetic	ADJ	O	I-PHYSICAL
quadriceps	NOUN	O	I-PHYSICAL
strength	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Each	DET	O	O
patient	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
for	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
registered	CCONJ	O	O
daily	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
consumption	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
analgesics	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
weeks	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
the	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
nine	NUM	O	O
treatments	NOUN	O	O
,	PUNCT	O	O
each	ADP	O	O
of	ADP	O	O
15	NUM	O	O
min	NOUN	O	O
and	CCONJ	O	O
administered	VERB	O	O
to	ADP	O	O
periarticular	ADJ	O	O
tender	ADP	O	O
points	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
per	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
22.5	NUM	O	O
joule	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
variables	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
before	CCONJ	O	O
,	PUNCT	O	O
during	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
'	PUNCT	O	O
overall	ADJ	O	O
assessment	NOUN	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
clearly	ADV	O	O
demonstrable	VERB	O	O
positive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
be	PUNCT	O	O
due	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
pioglitazone	ADJ	O	O
and	CCONJ	O	O
glimepiride	NOUN	O	O
on	ADP	O	O
glycemic	ADJ	O	O
control	NOUN	O	O
and	CCONJ	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
Mexican	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Pioglitazone	NOUN	O	O
and	CCONJ	O	O
glimepiride	NOUN	O	O
improve	ADV	O	O
glycemic	ADJ	O	O
control	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
by	ADP	O	O
different	ADJ	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

Pioglitazone	NOUN	O	O
is	VERB	O	O
a	DET	O	O
thiazolidinedione	NOUN	O	O
that	NUM	O	O
reduces	VERB	O	O
insulin	NOUN	O	O
resistance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
glimepiride	NOUN	O	O
is	VERB	O	O
a	DET	O	O
sulfonylurea	NOUN	O	O
insulin	NOUN	O	O
secretagogue	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
goals	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
measures	NOUN	O	O
of	ADP	O	O
glycemic	ADJ	O	O
control	NOUN	O	O
and	CCONJ	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
Mexican	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
pioglitazone	ADJ	O	O
or	CCONJ	O	O
glimepiride	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
52-week	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
monotherapy	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
glimepiride	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
mg	NOUN	O	O
QD	NOUN	O	O
initially	ADV	O	O
)	PUNCT	O	O
or	CCONJ	O	O
pioglitazone	ADJ	O	O
(	PUNCT	O	O
15	NUM	O	O
mg	NOUN	O	O
QD	NOUN	O	O
initially	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Doses	NOUN	O	O
were	VERB	O	O
titrated	NOUN	O	O
(	PUNCT	O	O
maximal	ADJ	O	O
doses	NOUN	O	O
:	PUNCT	O	O
pioglitazone	ADJ	O	O
45	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
glimepiride	NOUN	O	O
8	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
achieve	VERB	O	O
glycemic	ADJ	O	O
targets	NOUN	O	O
(	PUNCT	O	O
fasting	PROPN	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=7	NUM	O	O
mmol/L	NOUN	O	O
and	CCONJ	O	O
1-hour	NOUN	O	O
postprandial	ADJ	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=10	NUM	O	O
mmol/L	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Insulin	NOUN	O	O
sensitivity	NOUN	O	O
(	PUNCT	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Homeostasis	NOUN	O	O
Model	NOUN	O	O
Assessment	NOUN	O	O
for	ADP	O	O
Insulin	NOUN	O	O
Sensitivity	NOUN	O	O
(	PUNCT	O	O
HOMA-S	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
Quantitative	ADJ	O	O
Insulin	NOUN	O	O
Sensitivity	NOUN	O	O
Check	NOUN	O	O
Index	NOUN	O	O
(	PUNCT	O	O
QUICKI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fasting	VERB	O	O
serum	NOUN	O	O
insulin	NOUN	O	O
(	PUNCT	O	O
FSI	NOUN	O	O
)	PUNCT	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

Glycemic	ADJ	O	O
control	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
glycosylated	VERB	O	O
hemoglobin	NOUN	O	O
(	PUNCT	O	O
HbA	NOUN	O	O
(	PUNCT	O	O
1c	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
values	NOUN	O	O
and	CCONJ	O	O
fasting	VERB	O	O
plasma	NOUN	O	O
glucose	NOUN	O	O
(	PUNCT	O	O
FPG	NOUN	O	O
)	PUNCT	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
encouraged	VERB	O	O
to	ADJ	O	O
maintain	NOUN	O	O
their	DET	O	O
individual	ADJ	O	O
diet	NOUN	O	O
and	CCONJ	O	O
exercise	NOUN	O	O
regimens	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Two	NUM	O	O
hundred	NUM	O	O
forty-four	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
125	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
119	NUM	O	O
men	NOUN	O	O
;	PUNCT	O	O
all	ADP	O	O
but	CCONJ	O	O
1	NUM	O	O
Hispanic	ADJ	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
pioglitazone	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
121	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
glimepiride	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
123	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
intent-to-treat	NOUN	O	O
sample	NOUN	O	O
,	PUNCT	O	O
pioglitazone	ADJ	O	O
and	CCONJ	O	O
glimepirede	NOUN	O	O
produced	PRON	O	O
comparable	ADJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
HbA	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
1c	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
-0.78	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
-0.68	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
pioglitazone	ADJ	O	O
group	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
HbA	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
1c	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
values	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
glimepiride	NOUN	O	O
group	NOUN	O	O
after	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
8.66	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
7.80	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.007	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
had	PUNCT	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
values	NOUN	O	O
after	ADP	O	O
52	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
7.46	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
7.77	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.027	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pioglitazone	ADJ	O	O
significantly	ADV	O	O
reduced	VERB	O	O
FPG	NOUN	O	B-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
glimepiride	NOUN	O	O
(	PUNCT	O	O
-0.6	ADJ	O	O
vs	CCONJ	O	O
0.6	NUM	O	O
mmol/L	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pioglitazone	ADJ	O	O
therapy	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
insulin	NOUN	O	B-PHYSICAL
sensitivity	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
reduced	PUNCT	O	B-PHYSICAL
insulin	NOUN	O	I-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
glimepiride	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

HOMA-S	NOUN	O	B-PHYSICAL
values	NOUN	O	I-PHYSICAL
changed	VERB	O	O
18.0	NUM	O	O
%	SYM	O	O
for	ADP	O	O
pioglitazone	ADJ	O	O
and	CCONJ	O	O
-7.9	PUNCT	O	O
%	SYM	O	O
for	ADP	O	O
glimepiride	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
QUICKI	ADJ	O	O
values	NOUN	O	O
changed	PRON	O	O
a	DET	O	O
respective	ADJ	O	O
0.013	NUM	O	O
and	CCONJ	O	O
-0.007	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
FSI	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
-21.1	ADJ	O	O
and	CCONJ	O	O
15.1	NUM	O	O
pmol/L	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
drugs	NOUN	O	O
were	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	B-OTHER
,	PUNCT	O	O
with	ADP	O	O
pioglitazone	ADJ	O	O
associated	VERB	O	O
with	ADP	O	O
more	DET	O	O
peripheral	ADJ	O	B-PHYSICAL
edema	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
treatment-emergent	ADJ	O	O
cases	NOUN	O	O
:	PUNCT	O	O
35/121	NOUN	O	O
[	PUNCT	O	O
28.9	NUM	O	O
%	SYM	O	O
]	PUNCT	O	O
vs	CCONJ	O	O
17/123	NOUN	O	O
[	PUNCT	O	O
13.8	NUM	O	O
%	SYM	O	O
]	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fewer	PUNCT	O	O
hypoglycemic	ADJ	O	B-PHYSICAL
episodes	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
19	NUM	O	O
[	PUNCT	O	O
15.7	NUM	O	O
%	SYM	O	O
]	PUNCT	O	O
vs	CCONJ	O	O
38	NUM	O	O
[	PUNCT	O	O
30.9	NUM	O	O
%	SYM	O	O
]	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.024	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
weight	NOUN	O	O
gain	NOUN	O	B-PHYSICAL
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
long-term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
pioglitazone	ADJ	O	O
enhances	VERB	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
glimepiride	NOUN	O	O
in	ADP	O	O
Mexican	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
and	CCONJ	O	O
that	VERB	O	O
pioglitazone	NOUN	O	O
may	PUNCT	O	O
have	PUNCT	O	O
a	DET	O	O
more	ADV	O	O
sustained	ADP	O	O
antihyperglycemic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
Cys	NOUN	O	O
LT1	NOUN	O	O
receptor	NOUN	O	O
blockade	NOUN	O	O
on	ADP	O	O
airway	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
allergen	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
potent	ADJ	O	O
experimental	ADJ	O	O
leukotriene	NOUN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
MK-571	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
airway	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
inhaled	NOUN	O	O
allergen	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
crossover	ADP	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Clinical	ADJ	O	O
research	NOUN	O	O
center	NOUN	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
Eight	NUM	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
with	ADP	O	O
allergic	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	CCONJ	O	O
An	DET	O	O
intravenous	ADJ	O	O
loading	VERB	O	O
dose	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
8-hour	NOUN	O	O
infusion	NOUN	O	O
of	ADP	O	O
MK-571	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
7-	NUM	O	O
to	ADP	O	O
14-day	NOUN	O	O
washout	PUNCT	O	O
between	ADP	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Allergen	NOUN	O	O
challenge	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
after	ADP	O	O
the	DET	O	O
loading	VERB	O	O
dose	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
histamine	NOUN	O	O
challenge	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
allergen	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
MAIN	ADJ	O	O
RESULTS	NOUN	O	O
Forced	PROPN	O	B-PHYSICAL
expiratory	ADJ	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
in	ADP	O	O
1	NUM	O	O
second	ADJ	O	O
was	VERB	O	O
measured	VERB	O	O
serially	ADV	O	O
.	PUNCT	O	O

MK-571	NOUN	O	O
provided	VERB	O	O
about	PUNCT	O	O
50	NUM	O	O
%	ADV	O	O
protection	NOUN	O	O
during	ADP	O	O
maximum	NOUN	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
responses	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
p=0.005	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
airway	NOUN	O	B-PHYSICAL
obstruction	NOUN	O	I-PHYSICAL
persisted	DET	O	O
8-24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
allergen	NOUN	O	O
on	ADP	O	O
both	PUNCT	O	O
treatment	NOUN	O	O
days	NOUN	O	O
.	PUNCT	O	O

Airway	NOUN	O	B-OTHER
responsiveness	NOUN	O	I-OTHER
to	ADP	O	O
histamine	NOUN	O	B-OTHER
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Blocking	PUNCT	O	O
Cys	NOUN	O	O
LT1	NOUN	O	O
receptors	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
hours	NOUN	O	O
attenuated	VERB	O	O
the	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
responses	NOUN	O	O
but	CCONJ	O	O
did	PUNCT	O	O
not	DET	O	O
interrupt	PUNCT	O	O
the	DET	O	O
cascade	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
subsequent	ADJ	O	O
allergen-induced	ADJ	O	O
airway	NOUN	O	O
obstruction	NOUN	O	O
and	CCONJ	O	O
hyperreactivity	NOUN	O	O
.	PUNCT	O	O

Rituximab	NOUN	O	O
plus	CCONJ	O	O
concurrent	ADJ	O	O
infusional	ADJ	O	O
EPOCH	NOUN	O	O
chemotherapy	NOUN	O	O
is	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
HIV-associated	VERB	O	O
B-cell	NOUN	O	O
non-Hodgkin	NOUN	O	O
lymphoma	NOUN	O	O
.	PUNCT	O	O

Rituximab	NOUN	O	O
plus	CCONJ	O	O
intravenous	ADJ	O	O
bolus	NOUN	O	O
chemotherapy	NOUN	O	O
is	VERB	O	O
a	DET	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
immunocompetent	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
B-cell	NOUN	O	O
non-Hodgkin	NOUN	O	O
lymphoma	NOUN	O	O
(	PUNCT	O	O
NHL	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Some	DET	O	O
studies	NOUN	O	O
have	ADP	O	O
suggested	VERB	O	O
that	ADP	O	O
rituximab	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
excessive	ADJ	O	B-PHYSICAL
toxicity	NOUN	O	I-PHYSICAL
in	ADP	O	O
HIV-associated	VERB	O	O
NHL	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
infusional	ADJ	O	O
chemotherapy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
phase	NOUN	O	O
2	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
rituximab	NOUN	O	O
(	PUNCT	O	O
375	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
given	VERB	O	O
either	PUNCT	O	O
concurrently	ADV	O	O
before	ADP	O	O
each	DET	O	O
infusional	ADJ	O	O
etoposide	NOUN	O	O
,	PUNCT	O	O
vincristine	NOUN	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	O
,	PUNCT	O	O
cyclophosphamide	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prednisone	NOUN	O	O
(	PUNCT	O	O
EPOCH	NOUN	O	O
)	PUNCT	O	O
chemotherapy	NOUN	O	O
cycle	NOUN	O	O
or	CCONJ	O	O
sequentially	ADV	O	O
(	PUNCT	O	O
weekly	ADV	O	O
for	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
completion	NOUN	O	O
of	ADP	O	O
all	DET	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
HIV-associated	VERB	O	O
NHL	NOUN	O	O
.	PUNCT	O	O

EPOCH	NOUN	O	O
consisted	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
96-hour	NOUN	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
etoposide	NOUN	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
vincristine	NOUN	O	O
plus	CCONJ	O	O
oral	ADJ	O	O
prednisone	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
intravenous	ADJ	O	O
bolus	NOUN	O	O
cyclophosphamide	NOUN	O	O
given	ADP	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
to	ADP	O	O
6	NUM	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
concurrent	ADJ	O	O
arm	NOUN	O	O
,	PUNCT	O	O
35	NUM	O	O
of	ADP	O	O
48	NUM	O	O
evaluable	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
73	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
58	NUM	O	O
%	SYM	O	O
-85	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
a	DET	O	O
complete	ADJ	O	B-OTHER
response	NOUN	O	I-OTHER
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
sequential	ADJ	O	O
arm	NOUN	O	O
,	PUNCT	O	O
29	NUM	O	O
of	ADP	O	O
53	NUM	O	O
evaluable	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
55	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
41	NUM	O	O
%	SYM	O	O
-68	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
a	DET	O	O
complete	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
endpoint	NOUN	O	O
was	VERB	O	O
met	VERB	O	O
for	ADP	O	O
the	DET	O	O
concurrent	ADJ	O	O
arm	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Toxicity	NOUN	O	B-PHYSICAL
was	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
arms	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
baseline	NOUN	O	O
CD4	NOUN	O	B-PHYSICAL
count	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
50/microL	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
high	ADJ	O	O
infectious	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
rate	NOUN	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
concurrent	ADJ	O	O
arm	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
concurrent	ADJ	O	O
rituximab	NOUN	O	O
plus	CCONJ	O	O
infusional	ADJ	O	O
EPOCH	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
regimen	NOUN	O	O
for	ADP	O	O
HIV-associated	VERB	O	O
lymphoma	NOUN	O	O
.	PUNCT	O	O

Randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
:	PUNCT	O	O
Multimodal	ADJ	O	O
Anxiety	NOUN	O	O
and	CCONJ	O	O
Social	ADJ	O	O
Skill	NOUN	O	O
Intervention	NOUN	O	O
for	ADP	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Anxiety	NOUN	O	O
is	VERB	O	O
common	ADJ	O	O
among	ADP	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
amplify	ADP	O	O
the	DET	O	O
core	NOUN	O	O
social	ADJ	O	O
disability	NOUN	O	O
,	PUNCT	O	O
thus	ADV	O	O
necessitating	PUNCT	O	O
combined	VERB	O	O
treatment	NOUN	O	O
approaches	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
pilot	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
feasibility	NOUN	O	B-OTHER
and	CCONJ	O	O
preliminary	ADJ	O	B-OTHER
outcomes	NOUN	O	I-OTHER
of	ADP	O	O
the	DET	O	O
Multimodal	ADJ	O	O
Anxiety	NOUN	O	O
and	CCONJ	O	O
Social	ADJ	O	O
Skills	NOUN	O	O
Intervention	NOUN	O	O
(	PUNCT	O	O
MASSI	NOUN	O	O
)	PUNCT	O	O
program	NOUN	O	O
in	ADP	O	O
a	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
adolescents	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
and	CCONJ	O	O
anxiety	NOUN	O	O
symptoms	NOUN	O	O
of	ADP	O	O
moderate	ADJ	O	O
or	CCONJ	O	O
greater	PUNCT	O	O
severity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
was	VERB	O	O
acceptable	ADJ	O	O
to	ADP	O	O
families	NOUN	O	O
,	PUNCT	O	O
subject	PUNCT	O	B-OTHER
adherence	NOUN	O	I-OTHER
was	VERB	O	O
high	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
therapist	NOUN	O	B-OTHER
fidelity	NOUN	O	I-OTHER
was	VERB	O	O
high	ADJ	O	O
.	PUNCT	O	O

A	PUNCT	O	O
16	NUM	O	O
%	SYM	O	O
improvement	NOUN	O	O
in	ADP	O	O
ASD	NOUN	O	B-MENTAL
social	ADJ	O	I-MENTAL
impairment	NOUN	O	I-MENTAL
(	PUNCT	O	O
within-group	NOUN	O	O
effect	NOUN	O	O
size	NOUN	O	O
=	SYM	O	O
1.18	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
on	ADP	O	O
a	DET	O	O
parent-reported	VERB	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
anxiety	NOUN	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
declined	VERB	O	O
by	ADP	O	O
26	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
the	DET	O	O
change	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
MASSI	NOUN	O	O
is	VERB	O	O
a	DET	O	O
feasible	ADJ	O	B-OTHER
treatment	NOUN	O	O
program	NOUN	O	O
and	CCONJ	O	O
further	ADJ	O	O
evaluation	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
of	ADP	O	O
anal	ADJ	O	O
fissures	NOUN	O	O
using	SYM	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
minoxidil	NOUN	O	O
and	CCONJ	O	O
lignocaine	ADP	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
Anal	ADJ	O	O
fissures	ADV	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
hypertonia	NOUN	O	O
of	ADP	O	O
the	DET	O	O
internal	ADJ	O	O
anal	ADJ	O	O
sphincter	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
minoxidil	NOUN	O	O
and	CCONJ	O	O
lignocaine	ADP	O	O
in	ADP	O	O
healing	VERB	O	O
anal	ADJ	O	O
fissures	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
anal	ADJ	O	O
fissure	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	PUNCT	O	O
local	ADJ	O	O
applications	NOUN	O	O
of	ADP	O	O
ointments	NOUN	O	O
containing	VERB	O	O
5	NUM	O	O
%	SYM	O	O
lignocaine	ADP	O	O
(	PUNCT	O	O
n=28	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
0.5	NUM	O	O
%	ADV	O	O
minoxidil	CCONJ	O	O
(	PUNCT	O	O
n=36	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	PUNCT	O	O
(	PUNCT	O	O
n=26	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Healing	VERB	O	O
of	ADP	O	O
anal	ADJ	O	B-PHYSICAL
fissure	NOUN	O	I-PHYSICAL
at	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
end-point	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Rates	PUNCT	O	O
of	ADP	O	B-PHYSICAL
complete	ADJ	O	I-PHYSICAL
healing	VERB	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
fissure	ADJ	O	B-PHYSICAL
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
lignocaine	ADP	O	O
alone	ADJ	O	O
8/27	NOUN	O	O
,	PUNCT	O	O
minoxidil	PUNCT	O	O
alone	ADJ	O	O
10/34	PUNCT	O	O
,	PUNCT	O	O
combination	NOUN	O	O
7/22	NOUN	O	O
;	PUNCT	O	O
p=ns	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	NOUN	O	O
(	PUNCT	O	O
SD	NOUN	O	O
)	PUNCT	O	O
time	NOUN	O	O
taken	PRON	O	O
for	ADP	O	O
complete	ADJ	O	O
healing	VERB	O	O
with	ADP	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
[	PUNCT	O	O
1.9	NUM	O	O
(	PUNCT	O	O
0.6	NUM	O	O
)	PUNCT	O	O
weeks	NOUN	O	O
]	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
shorter	PUNCT	O	O
than	VERB	O	O
that	PUNCT	O	O
with	ADP	O	O
minoxidil	PUNCT	O	O
alone	ADJ	O	O
(	PUNCT	O	O
3.1	NUM	O	O
[	PUNCT	O	O
1.7	PUNCT	O	O
]	PUNCT	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
p=0.001	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
lignocaine	ADP	O	O
alone	ADJ	O	O
(	PUNCT	O	O
3.3	NUM	O	O
[	PUNCT	O	O
0.8	ADP	O	O
]	PUNCT	O	O
weeks	NOUN	O	O
;	PUNCT	O	O
p=0.002	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Rates	NOUN	O	B-PHYSICAL
of	ADP	O	O
pain	NOUN	O	B-PAIN
relief	NOUN	O	I-PAIN
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Stoppage	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
bleeding	PUNCT	O	I-PHYSICAL
occurred	VERB	O	O
more	ADV	O	O
often	ADV	O	O
with	ADP	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
than	PUNCT	O	O
with	ADP	O	O
lignocaine	ADP	O	O
alone	ADJ	O	O
.	PUNCT	O	O

No	DET	O	O
patient	NOUN	O	O
had	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
ketoprofen	NOUN	O	O
'controlled	PUNCT	O	O
release	NOUN	O	O
'	PUNCT	O	O
and	CCONJ	O	O
indomethacin	NOUN	O	O
suppository	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
with	ADP	O	O
special	ADJ	O	O
regard	NOUN	O	O
to	ADP	O	O
morning	NOUN	O	O
stiffness	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	O
on	ADP	O	O
awakening	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
double-dummy	NOUN	O	O
,	PUNCT	O	O
crossover	ADP	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
in	ADP	O	O
8	NUM	O	O
centres	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
'controlled-release	PUNCT	O	O
'	PUNCT	O	O
ketoprofen	NOUN	O	O
tablets	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
indomethacin	NOUN	O	O
suppositories	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
out-patients	NOUN	O	O
with	ADP	O	O
definite	ADJ	O	O
or	CCONJ	O	O
classical	ADJ	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
allocated	VERB	O	O
at	ADP	O	O
random	PUNCT	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
daily	ADJ	O	O
bedtime	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
1	NUM	O	O
ketoprofen	NOUN	O	O
tablet	NOUN	O	O
or	CCONJ	O	O
1	NUM	O	O
indomethacin	NOUN	O	O
suppository	ADJ	O	O
plus	CCONJ	O	O
the	DET	O	O
dummy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
formulation	NOUN	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
then	ADV	O	O
crossed	VERB	O	O
over	PUNCT	O	O
to	PUNCT	O	O
the	DET	O	O
alternative	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
a	DET	O	O
further	ADJ	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Daily	ADJ	O	O
diary	ADJ	O	O
records	NOUN	O	O
were	VERB	O	O
kept	PUNCT	O	O
by	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
night-time	NOUN	O	O
awakenings	NOUN	O	O
due	VERB	O	O
to	ADP	O	O
pain	NOUN	O	O
,	PUNCT	O	O
pain	NOUN	O	O
severity	NOUN	O	O
at	ADP	O	O
awakening	ADJ	O	O
in	ADP	O	O
the	DET	O	O
morning	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
morning	NOUN	O	O
stiffness	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
efficacy	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
each	DET	O	O
trial	NOUN	O	O
period	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
an	DET	O	O
articular	ADJ	O	O
index	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
physician	NOUN	O	O
's	PUNCT	O	O
and	CCONJ	O	O
patient	NOUN	O	O
's	PUNCT	O	O
overall	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
effects	NOUN	O	O
spontaneously	ADV	O	O
mentioned	PROPN	O	O
by	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
or	CCONJ	O	O
elicited	VERB	O	O
by	ADP	O	O
direct	ADJ	O	O
questioning	PUNCT	O	O
using	ADP	O	O
a	DET	O	O
symptom	NOUN	O	O
check-list	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Statistical	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
results	ADP	O	O
from	ADP	O	O
83	NUM	O	O
evaluable	ADJ	O	O
patients	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
'controlled-release	PUNCT	O	O
'	PUNCT	O	O
tablet	NOUN	O	B-OTHER
formulation	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
200	NUM	O	I-OTHER
mg	NOUN	O	I-OTHER
ketoprofen	NOUN	O	O
was	VERB	O	O
equally	ADV	O	O
as	PUNCT	O	O
effective	ADJ	O	O
as	CCONJ	O	O
the	DET	O	O
100	NUM	O	O
mg	NOUN	O	O
indomethacin	NOUN	O	B-OTHER
suppository	ADJ	O	I-OTHER
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
pain	NOUN	O	B-PAIN
at	ADP	O	I-PAIN
awakening	PROPN	O	I-PAIN
and	CCONJ	O	O
morning	NOUN	O	B-PAIN
stiffness	NOUN	O	I-PAIN
.	PUNCT	O	O

Side-effects	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
were	VERB	O	O
those	PUNCT	O	O
commonly	ADV	O	O
seen	VERB	O	O
with	ADP	O	O
non-steroidal	ADJ	O	O
anti-inflammatory	ADJ	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
as	CCONJ	O	O
expected	VERB	O	O
,	PUNCT	O	O
gastro-intestinal	ADJ	O	B-ADVERSE-EFFECTS
and	CCONJ	O	I-ADVERSE-EFFECTS
CNS	NOUN	O	I-ADVERSE-EFFECTS
disturbances	NOUN	O	I-ADVERSE-EFFECTS
predominated	VERB	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
side-effects	NOUN	O	B-ADVERSE-EFFECTS
were	VERB	O	O
fewer	PUNCT	O	O
with	ADP	O	O
ketoprofen	NOUN	O	B-OTHER
than	PUNCT	O	O
with	ADP	O	O
indomethacin	NOUN	O	B-OTHER
.	PUNCT	O	O

Genetic	ADJ	O	O
polymorphisms	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
flavin	NOUN	O	O
monooxygenase	NOUN	O	O
3	NUM	O	O
in	ADP	O	O
sulindac-mediated	VERB	O	O
primary	ADJ	O	O
chemoprevention	NOUN	O	O
of	ADP	O	O
familial	ADJ	O	O
adenomatous	ADJ	O	O
polyposis	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Sulindac	NOUN	O	O
is	VERB	O	O
a	DET	O	O
nonsteroidal	ADJ	O	O
anti-inflammatory	ADJ	O	O
drug	NOUN	O	O
(	PUNCT	O	O
NSAID	NOUN	O	O
)	PUNCT	O	O
effective	ADJ	O	O
in	ADP	O	O
regressing	ADJ	O	O
adenomas	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
familial	ADJ	O	O
adenomatous	ADJ	O	O
polyposis	NOUN	O	O
(	PUNCT	O	O
FAP	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
recent	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
sulindac	NOUN	O	O
,	PUNCT	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
prevent	ADJ	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
adenomatous	ADJ	O	O
polyps	NOUN	O	O
in	ADP	O	O
genotypically	ADV	O	O
positive	ADJ	O	O
but	CCONJ	O	O
phenotypically	ADV	O	O
negative	ADJ	O	O
FAP	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
determined	VERB	O	O
whether	ADP	O	O
polymorphisms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
gene	NOUN	O	O
encoding	VERB	O	O
flavin	NOUN	O	O
monooxygenase	NOUN	O	O
3	NUM	O	O
(	PUNCT	O	O
FMO3	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
hepatic	ADJ	O	O
microsomal	ADJ	O	O
enzyme	NOUN	O	O
that	PUNCT	O	O
inactivates	NOUN	O	O
sulindac	NOUN	O	O
,	PUNCT	O	O
played	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
determining	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
sulindac	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
polyposis	NOUN	O	O
in	ADP	O	O
this	DET	O	O
cohort	NOUN	O	O
of	ADP	O	O
FAP	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

EXPERIMENTAL	ADJ	O	O
DESIGN	NOUN	O	O
Genotyping	PROPN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
seven	NUM	O	O
established	ADP	O	O
FMO3	NOUN	O	O
polymorphisms	NOUN	O	O
previously	ADV	O	O
shown	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
functional	ADJ	O	O
relevance-M66I	NOUN	O	O
,	PUNCT	O	O
P153L	NOUN	O	O
,	PUNCT	O	O
E158K	NOUN	O	O
,	PUNCT	O	O
V257M	NOUN	O	O
,	PUNCT	O	O
E305X	NOUN	O	O
,	PUNCT	O	O
E308G	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
R492W-in	ADJ	O	O
21	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
FAP	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
who	PROPN	O	O
received	VERB	O	O
sulindac	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
None	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
41	NUM	O	O
patients	NOUN	O	O
exhibited	VERB	O	O
heterozygous	ADJ	O	B-PHYSICAL
or	CCONJ	O	O
homozygous	ADJ	O	B-PHYSICAL
M66I	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
R492W	NOUN	O	B-PHYSICAL
variant	ADJ	O	I-PHYSICAL
alleles	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	PUNCT	O	O

Determinants	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	O
on	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
subclinical	ADJ	O	B-PHYSICAL
atherosclerosis	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
Estrogen	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Prevention	NOUN	O	O
of	ADP	O	O
Atherosclerosis	NOUN	O	O
Trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
extent	NOUN	O	O
to	ADP	O	O
which	VERB	O	O
the	DET	O	O
estrogen-induced	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
lipids	NOUN	O	O
and	CCONJ	O	O
markers	NOUN	O	O
of	ADP	O	O
carbohydrate	NOUN	O	O
metabolism	NOUN	O	O
explain	VERB	O	O
the	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
carotid	ADJ	O	B-PHYSICAL
artery	NOUN	O	I-PHYSICAL
intima-media	ADP	O	I-PHYSICAL
thickness	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
single-center	ADP	O	O
trial	NOUN	O	O
enrolling	CCONJ	O	O
222	NUM	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
45	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
without	ADP	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
low-density	NOUN	O	O
lipoprotein	NOUN	O	O
(	PUNCT	O	O
LDL	NOUN	O	O
)	PUNCT	O	O
cholesterol	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
3.37	NUM	O	O
mmol/L	NOUN	O	O
or	CCONJ	O	O
greater	PUNCT	O	O
(	PUNCT	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
130	NUM	O	O
mg/dL	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intervention	NOUN	O	O
was	VERB	O	O
unopposed	VERB	O	O
micronized	VERB	O	O
17beta-estradiol	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Measurements	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
using	ADP	O	O
high-resolution	NOUN	O	O
B-mode	NOUN	O	O
ultrasonography	NOUN	O	O
to	PART	O	O
measure	ADJ	O	O
carotid	ADJ	O	B-PHYSICAL
artery	NOUN	O	I-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
every	DET	O	O
6	NUM	O	O
months	NOUN	O	O
on-trial	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Progression	NOUN	O	O
of	ADP	O	O
carotid	ADJ	O	B-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
was	ADJ	O	O
inversely	ADV	O	O
related	ADP	O	O
to	ADP	O	O
on-trial	ADJ	O	O
high-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
HDL	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
directly	ADV	O	O
related	VERB	O	O
to	ADP	O	O
on-trial	ADJ	O	O
LDL-cholesterol	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
women	NOUN	O	O
randomized	ADP	O	O
to	ADP	O	O
estradiol	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
higher	PUNCT	O	O
mean	NOUN	O	O
on-trial	ADJ	O	O
HDL-cholesterol	NOUN	O	B-PHYSICAL
level	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
a	DET	O	O
lower	PUNCT	O	O
mean	NOUN	O	O
on-trial	ADJ	O	O
LDL-cholesterol	NOUN	O	B-PHYSICAL
level	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
fasting	VERB	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
insulin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
hemoglobin	NOUN	O	B-PHYSICAL
A1C	NOUN	O	I-PHYSICAL
were	VERB	O	O
lowered	VERB	O	O
and	CCONJ	O	O
insulin	NOUN	O	O
sensitivity	NOUN	O	O
increased	VERB	O	O
with	ADP	O	O
estradiol	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
changes	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
related	PUNCT	O	O
to	ADP	O	O
carotid	CCONJ	O	O
IMT	NOUN	O	O
progression	NOUN	O	O
.	PUNCT	O	O

On-trial	ADJ	O	O
HDL-cholesterol	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
LDL-cholesterol	NOUN	O	B-PHYSICAL
were	VERB	O	O
significant	ADJ	O	O
independent	ADJ	O	O
determinants	NOUN	O	O
of	ADP	O	O
carotid	ADJ	O	B-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
progression	NOUN	O	O
,	PUNCT	O	O
jointly	ADV	O	O
explaining	VERB	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
unopposed	VERB	O	O
estrogen	NOUN	O	O
on	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
carotid	ADJ	O	B-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Unopposed	NOUN	O	O
17beta-estradiol	NOUN	O	O
reduced	VERB	O	O
carotid	ADJ	O	B-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
progression	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
in	ADP	O	O
part	NOUN	O	O
by	ADP	O	O
increasing	VERB	O	O
HDL-cholesterol	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
decreasing	ADJ	O	O
LDL-cholesterol	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Although	ADP	O	O
women	NOUN	O	O
randomized	ADP	O	O
to	ADP	O	O
estradiol	NOUN	O	O
showed	VERB	O	O
improvement	NOUN	O	O
in	ADP	O	O
all	DET	O	O
the	DET	O	O
markers	NOUN	O	O
of	ADP	O	O
carbohydrate	NOUN	O	O
metabolism	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
factors	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
play	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
carotid	ADJ	O	B-PHYSICAL
IMT	NOUN	O	I-PHYSICAL
progression	NOUN	O	O
.	PUNCT	O	O

Skin	NOUN	O	B-PHYSICAL
manifestations	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
inhaled	VERB	O	I-PHYSICAL
corticosteroids	NOUN	O	I-PHYSICAL
in	ADP	O	O
COPD	NOUN	O	O
patients	NOUN	O	O
:	PUNCT	O	O
results	DET	O	O
from	ADP	O	O
Lung	NOUN	O	O
Health	NOUN	O	O
Study	NOUN	O	O
II	NUM	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	ADJ	O	O
define	NOUN	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
skin	NOUN	O	B-ADVERSE-EFFECTS
bruising	ADJ	O	I-ADVERSE-EFFECTS
(	PUNCT	O	B-PHYSICAL
as	PUNCT	O	I-PHYSICAL
well	PUNCT	O	I-PHYSICAL
as	CCONJ	O	I-PHYSICAL
other	ADJ	O	O
cutaneous	ADJ	O	B-ADVERSE-EFFECTS
manifestations	NOUN	O	I-ADVERSE-EFFECTS
)	PUNCT	O	O
and	CCONJ	O	O
inhaled	DET	O	O
corticosteroid	NOUN	O	O
(	PUNCT	O	O
ICS	NOUN	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
vs	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
COPD	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
participating	VERB	O	O
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
explore	CCONJ	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
easy	CCONJ	O	B-PHYSICAL
skin	NOUN	O	I-PHYSICAL
bruising	ADP	O	I-PHYSICAL
and	CCONJ	O	O
other	ADJ	O	O
systemic	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
ICS	NOUN	O	I-PHYSICAL
therapy	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
including	CCONJ	O	O
adrenal	ADJ	O	B-ADVERSE-EFFECTS
suppression	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
loss	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	B-ADVERSE-EFFECTS
mineral	NOUN	O	I-ADVERSE-EFFECTS
density	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	I-ADVERSE-EFFECTS
BMD	NOUN	O	I-ADVERSE-EFFECTS
)	PUNCT	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Double-blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
triamcinolone	ADV	O	O
acetonide	NOUN	O	O
(	PUNCT	O	O
1200	NUM	O	O
microg	NOUN	O	O
daily	ADJ	O	O
)	PUNCT	O	O
vs	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
mild-to-moderate	ADJ	O	O
COPD	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Lung	NOUN	O	O
Health	NOUN	O	O
Study	NOUN	O	O
II	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
ICS	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
1,116	NUM	O	O
participants	NOUN	O	O
in	ADP	O	O
10	NUM	O	O
centers	NOUN	O	O
over	ADP	O	O
>	ADP	O	O
3.5	NUM	O	O
to	ADP	O	O
4.5	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
1,116	NUM	O	O
smokers	NOUN	O	O
or	CCONJ	O	O
recent	ADJ	O	O
ex-smokers	NOUN	O	O
with	ADP	O	O
mild-to-moderate	ADJ	O	O
COPD	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
range	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
to	ADP	O	O
69	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
56.3	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
37.2	NUM	O	O
%	SYM	O	O
female	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MEASUREMENTS	ADP	O	O
AND	CCONJ	O	O
RESULTS	PUNCT	O	O
Every	DET	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
structured	VERB	O	O
questionnaire	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	PUNCT	O	O
elicit	ADP	O	O
reports	NOUN	O	O
of	ADP	O	O
any	DET	O	O
bruising	PUNCT	O	B-ADVERSE-EFFECTS
and/or	CCONJ	O	I-ADVERSE-EFFECTS
skin	NOUN	O	I-ADVERSE-EFFECTS
rashes	PUNCT	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
slow	ADJ	O	B-ADVERSE-EFFECTS
healing	DET	O	I-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
cuts	ADJ	O	I-ADVERSE-EFFECTS
or	CCONJ	O	O
sores	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
or	CCONJ	O	B-PHYSICAL
other	ADJ	O	O
skin	NOUN	O	B-ADVERSE-EFFECTS
changes	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Compliance	NOUN	O	O
with	ADP	O	O
inhaler	ADJ	O	O
use	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
canister	PUNCT	O	O
weighing	CCONJ	O	O
.	PUNCT	O	O

A	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	O
ICS	NOUN	O	O
than	PUNCT	O	O
placebo	NOUN	O	O
participants	NOUN	O	O
who	ADP	O	O
complied	PUNCT	O	O
with	ADP	O	O
using	ADP	O	O
their	NOUN	O	O
inhaler	ADJ	O	O
reported	PUNCT	O	O
easy	PUNCT	O	B-ADVERSE-EFFECTS
bruising	ADJ	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
11.2	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
3.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
slow	ADJ	O	B-ADVERSE-EFFECTS
healing	VERB	O	I-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
skin	NOUN	O	I-ADVERSE-EFFECTS
cuts	PROPN	O	I-ADVERSE-EFFECTS
or	CCONJ	O	O
sores	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
2.4	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
0.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Older	PUNCT	O	O
men	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ICS	NOUN	O	O
group	NOUN	O	O
with	ADP	O	O
good	ADJ	O	O
inhaler	ADJ	O	O
compliance	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
greatest	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
bruising	SYM	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

In	ADP	O	O
those	PUNCT	O	O
participants	NOUN	O	O
undergoing	VERB	O	O
serial	ADJ	O	O
measurements	NOUN	O	O
of	ADP	O	O
adrenal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
BMD	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
association	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
between	ADP	O	O
skin	NOUN	O	B-ADVERSE-EFFECTS
bruising	ADP	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
either	CCONJ	O	O
the	DET	O	O
suppression	NOUN	O	O
of	ADP	O	O
adrenal	ADJ	O	B-ADVERSE-EFFECTS
function	NOUN	O	I-ADVERSE-EFFECTS
or	CCONJ	O	O
the	DET	O	O
loss	NOUN	O	B-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
BMD	NOUN	O	I-ADVERSE-EFFECTS
as	PUNCT	O	O
systemic	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
ICS	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
moderate-to-high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ICSs	NOUN	O	O
result	VERB	O	O
in	ADP	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
easy	ADP	O	B-ADVERSE-EFFECTS
bruising	DET	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
impairment	NOUN	O	O
in	ADP	O	O
skin	NOUN	O	B-ADVERSE-EFFECTS
healing	VERB	O	I-ADVERSE-EFFECTS
in	ADP	O	O
middle-aged	NOUN	O	O
to	ADP	O	O
elderly	ADP	O	O
persons	NOUN	O	O
with	ADP	O	O
COPD	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
association	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
between	ADP	O	O
skin	NOUN	O	B-ADVERSE-EFFECTS
bruising	ADP	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
other	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	B-ADVERSE-EFFECTS
toxicity	NOUN	O	I-ADVERSE-EFFECTS
from	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
ICSs	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
antithrombin	NOUN	O	O
in	ADP	O	O
heparin-resistant	ADJ	O	O
patients	NOUN	O	O
scheduled	DET	O	O
to	PART	O	O
undergo	VERB	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
necessitating	PUNCT	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
human	NOUN	O	O
antithrombin	NOUN	O	O
(	PUNCT	O	O
rhAT	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
restoring	ADV	O	O
heparin	NOUN	O	B-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
in	ADP	O	O
heparin	NOUN	O	O
resistant	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
in	ADP	O	O
heparin-resistant	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
with	ADP	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
.	PUNCT	O	O

Heparin	NOUN	O	O
resistance	NOUN	O	O
was	VERB	O	O
diagnosed	VERB	O	O
when	ADP	O	O
the	DET	O	O
activated	VERB	O	O
clotting	DET	O	O
time	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
than	PUNCT	O	O
480	NUM	O	O
s	NOUN	O	O
after	ADP	O	O
400	NUM	O	O
U/kg	ADV	O	O
heparin	NOUN	O	O
.	PUNCT	O	O

Fifty-four	NUM	O	O
heparin-resistant	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
cohort	NOUN	O	O
received	VERB	O	O
75	NUM	O	O
U/kg	NOUN	O	O
rhAT	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
received	VERB	O	O
normal	ADJ	O	O
saline	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
the	DET	O	O
activated	VERB	O	O
clotting	DET	O	O
time	NOUN	O	O
remained	VERB	O	O
less	ADV	O	O
than	ADP	O	O
480	NUM	O	O
s	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
was	NUM	O	O
considered	PUNCT	O	O
treatment	NOUN	O	O
failure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
units	NOUN	O	O
fresh	ADJ	O	O
frozen	VERB	O	O
plasma	NOUN	O	O
was	VERB	O	O
transfused	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
for	ADP	O	O
adverse	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Only	ADJ	O	O
19	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rhAT	NOUN	O	O
group	NOUN	O	O
received	ADP	O	O
fresh	ADJ	O	O
frozen	VERB	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
81	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
their	PUNCT	O	O
hospitalization	NOUN	O	O
,	PUNCT	O	O
48	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rhAT	NOUN	O	O
group	NOUN	O	O
received	ADP	O	O
fresh	ADJ	O	O
frozen	VERB	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
85	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.009	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
required	VERB	O	O
higher	PUNCT	O	O
heparin	NOUN	O	O
doses	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
anticoagulation	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
rhAT	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
increased	VERB	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
12	NUM	O	O
h	NOUN	O	O
postoperatively	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
increased	NOUN	O	O
24-h	NOUN	O	B-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
rhAT	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.06	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
and	CCONJ	O	O
platelet	NOUN	O	O
transfusions	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Treatment	NOUN	O	O
with	ADP	O	O
75	NUM	O	O
U/kg	NOUN	O	O
rhAT	NOUN	O	O
is	VERB	O	O
effective	ADJ	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
restoring	ADV	O	I-PHYSICAL
heparin	NOUN	O	I-PHYSICAL
responsiveness	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
promoting	VERB	O	O
therapeutic	ADJ	O	B-PHYSICAL
anticoagulation	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
heparin-resistant	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Treating	VERB	O	O
heparin-resistant	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
rhAT	NOUN	O	O
may	ADP	O	O
decrease	VERB	O	O
the	DET	O	B-PHYSICAL
requirement	NOUN	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
heparin	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
fresh	ADJ	O	O
frozen	VERB	O	O
plasma	NOUN	O	O
.	PUNCT	O	O

